

# **Dossier zur Nutzenbewertung gemäß § 35a SGB V**

*Tezepelumab (Tezspire®)*

AstraZeneca GmbH

## **Modul 4 A – Anhang 4-G-1**

*Add-on-Erhaltungstherapie bei Erwachsenen und Jugendlichen ab 12 Jahren mit schwerem Asthma, das trotz hochdosierter inhalativer Kortikosteroide plus eines weiteren Arzneimittels zur Erhaltungstherapie unzureichend kontrolliert ist*

Werte im Studienverlauf

mITT-Population

RCT mit dem zu bewertenden Arzneimittel

Stand: 11.11.2022

MT1FAC_ILMH0: Course of FEV1 Pre-BD - pooled NP set, DITTL _____	10
MT1FAC_ILMC0: Change from baseline in FEV1 Pre-BD - MMRM results - pooled NP set, DITTL _____	12
NT1FAC_ILMH0: Course of FEV1 Pre-BD - NAVIGATOR, DITTL, DCO 1 _____	13
NT1FAC_ILMC0: Change from baseline in FEV1 Pre-BD - MMRM results - NAVIGATOR, DITTL, DCO 1 _____	15
PT3FAC_ILMH0: Course of FEV1 Pre-BD - PATHWAY, DITTL, DCO 3 _____	16
PT3FAC_PLMH0: Course of FEV1 Pre-BD - PATHWAY, DPPSL, DCO 3 _____	18
PT3FAC_ILMC0: Change from baseline in FEV1 Pre-BD - MMRM results - PATHWAY, DITTL, DCO 3 _____	20
PT3FAC_PLMC0: Change from baseline in FEV1 Pre-BD - MMRM results - PATHWAY, DPPSL, DCO 3 _____	21
ST1FAC_ILMH0: Course of FEV1 Pre-BD - SOURCE, DITTL _____	22
ST1FAC_ILMC0: Change from baseline in FEV1 Pre-BD - MMRM results - SOURCE, DITTL _____	24
DT1FAC_BLMH0: Course of FEV1 Pre-BD - DESTINATION, DITTNL - LTE _____	25
DT1FAC_BLMC0: Change from baseline in FEV1 Pre-BD - MMRM results - DESTINATION, DITTNL - LTE _____	27
CT1FAC_ILMH0: Course of FEV1 Pre-BD - CASCADE, DITTL _____	29
CT1FAC_ILMC0: Change from baseline in FEV1 Pre-BD - MMRM results - CASCADE, DITTL _____	31
NT1FAC_KLMH0: Course of FEV1 Pre-BD - NAVIGATOR, DITTL-adolescent, DCO 1 _____	32
NT1FAC_KLMC0: Change from baseline in FEV1 Pre-BD - MMRM results - NAVIGATOR, DITTL-adolescent, DCO 1 _____	34
DT1FAC_MLMH0: Course of FEV1 Pre-BD - DESTINATION, DITTNL - LTE - adolescents _____	35
DT1FAC_MLMC0: Change from baseline in FEV1 Pre-BD - MMRM results - DESTINATION, DITTNL - LTE - adolescents _____	37
NT1FAC_ALMH0: Course of FEV1 Pre-BD - NAVIGATOR, DITTL-adult , DCO 1 _____	39
NT1FAC_ALMC0: Change from baseline in FEV1 Pre-BD - MMRM results - NAVIGATOR, DITTL-adult , DCO 1 _____	41
DT1FAC_HLMH0: Course of FEV1 Pre-BD - DESTINATION, DITTNL - LTE - adult _____	42
DT1FAC_HLMC0: Change from baseline in FEV1 Pre-BD - MMRM results - DESTINATION, DITTNL - LTE - adult _____	44
MT1H5C_ILMH0: Course of ACQ-5 score - pooled NP set, DITTL _____	46
MT1H5C_ILMC0: Change from baseline in ACQ-5 score - MMRM results - pooled NP set, DITTL _____	48
NT1H5C_ILMH0: Course of ACQ-5 score - NAVIGATOR, DITTL, DCO 1 _____	50
NT1H5C_ILMC0: Change from baseline in ACQ-5 score - MMRM results - NAVIGATOR, DITTL, DCO 1 _____	52
PT3H5C_ILMH0: Course of ACQ-5 score - PATHWAY, DITTL, DCO 3 _____	54
PT3H5C_ILMC0: Change from baseline in ACQ-5 score - MMRM results - PATHWAY, DITTL, DCO 3 _____	58
DT1H5C_BLMH0: Course of ACQ-5 score - DESTINATION, DITTNL - LTE _____	61
DT1H5C_BLMC0: Change from baseline in ACQ-5 score - MMRM results - DESTINATION, DITTNL - LTE _____	63

CT1H5C_ILMH0: Course of ACQ-5 score - CASCADE, DITTL _____	65
CT1H5C_ILMC0: Change from baseline in ACQ-5 score - MMRM results - CASCADE, DITTL _____	67
MT1H6C_ILMH0: Course of ACQ-6 score - pooled NP set, DITTL _____	68
MT1H6C_ILMC0: Change from baseline in ACQ-6 score - MMRM results - pooled NP set, DITTL _____	70
NT1H6C_ILMH0: Course of ACQ-6 score - NAVIGATOR, DITTL, DCO 1 _____	72
NT1H6C_ILMC0: Change from baseline in ACQ-6 score - MMRM results - NAVIGATOR, DITTL, DCO 1 _____	74
PT3H6C_ILMH0: Course of ACQ-6 score - PATHWAY, DITTL, DCO 3 _____	76
PT3H6C_ILMC0: Change from baseline in ACQ-6 score - MMRM results - PATHWAY, DITTL, DCO 3 _____	80
ST1H6C_ILMH0: Course of ACQ-6 score - SOURCE, DITTL _____	83
ST1H6C_ILMC0: Change from baseline in ACQ-6 score - MMRM results - SOURCE, DITTL _____	85
DT1H6C_BLMH0: Course of ACQ-6 score - DESTINATION, DITTNL - LTE _____	87
DT1H6C_BLMC0: Change from baseline in ACQ-6 score - MMRM results - DESTINATION, DITTNL - LTE _____	89
CT1H6C_ILMH0: Course of ACQ-6 score - CASCADE, DITTL _____	91
CT1H6C_ILMC0: Change from baseline in ACQ-6 score - MMRM results - CASCADE, DITTL _____	93
NT1H5C_KLMH0: Course of ACQ-5 score - NAVIGATOR, DITTL-adolescent, DCO 1 _____	94
NT1H5C_KLMC0: Change from baseline in ACQ-5 score - MMRM results - NAVIGATOR, DITTL-adolescent, DCO 1 _____	96
DT1H5C_MLMH0: Course of ACQ-5 score - DESTINATION, DITTNL - LTE - adolescents _____	98
DT1H5C_MLMC0: Change from baseline in ACQ-5 score - MMRM results - DESTINATION, DITTNL - LTE - adolescents _____	100
NT1H6C_KLMH0: Course of ACQ-6 score - NAVIGATOR, DITTL-adolescent, DCO 1 _____	102
NT1H6C_KLMC0: Change from baseline in ACQ-6 score - MMRM results - NAVIGATOR, DITTL-adolescent, DCO 1 _____	104
DT1H6C_MLMH0: Course of ACQ-6 score - DESTINATION, DITTNL - LTE - adolescents _____	106
DT1H6C_MLMC0: Change from baseline in ACQ-6 score - MMRM results - DESTINATION, DITTNL - LTE - adolescents _____	108
NT1H5C_ALMH0: Course of ACQ-5 score - NAVIGATOR, DITTL-adult , DCO 1 _____	110
NT1H5C_ALMC0: Change from baseline in ACQ-5 score - MMRM results - NAVIGATOR, DITTL-adult , DCO 1 _____	112
DT1H5C_HLMH0: Course of ACQ-5 score - DESTINATION, DITTNL - LTE - adult _____	114
DT1H5C_HLMC0: Change from baseline in ACQ-5 score - MMRM results - DESTINATION, DITTNL - LTE - adult _____	116
NT1H6C_ALMH0: Course of ACQ-6 score - NAVIGATOR, DITTL-adult , DCO 1 _____	118
NT1H6C_ALMC0: Change from baseline in ACQ-6 score - MMRM results - NAVIGATOR, DITTL-adult , DCO 1 _____	120
DT1H6C_HLMH0: Course of ACQ-6 score - DESTINATION, DITTNL - LTE - adult _____	122
DT1H6C_HLMC0: Change from baseline in ACQ-6 score - MMRM results - DESTINATION, DITTNL - LTE - adult _____	124

NT1WTC_ILMH0: Course of ASD weekly total score - NAVIGATOR, DITTL, DCO 1 _____	126
NT1WTC_ILMC0: Change from baseline in ASD weekly total score - MMRM results - NAVIGATOR, DITTL, DCO 1 _____	132
ST1WTC_ILMH0: Course of ASD weekly total score - SOURCE, DITTL _____	138
ST1WTC_ILMC0: Change from baseline in ASD weekly total score - MMRM results - SOURCE, DITTL _____	144
NT1WDC_ILMH0: Course of ASD weekly daytime score - NAVIGATOR, DITTL, DCO 1 _____	149
NT1WDC_ILMC0: Change from baseline in ASD weekly daytime score - MMRM results - NAVIGATOR, DITTL, DCO 1 _____	155
ST1WDC_ILMH0: Course of ASD weekly daytime score - SOURCE, DITTL _____	161
ST1WDC_ILMC0: Change from baseline in ASD weekly daytime score - MMRM results - SOURCE, DITTL _____	167
NT1WNC_ILMH0: Course of ASD weekly night-time score - NAVIGATOR, DITTL, DCO 1 _____	172
NT1WNC_ILMC0: Change from baseline in ASD weekly night-time score - MMRM results - NAVIGATOR, DITTL, DCO 1 _____	178
ST1WNC_ILMH0: Course of ASD weekly night-time score - SOURCE, DITTL _____	184
ST1WNC_ILMC0: Change from baseline in ASD weekly night-time score - MMRM results - SOURCE, DITTL _____	190
NT1WWC_ILMH0: Course of ASD weekly wheezing score - NAVIGATOR, DITTL, DCO 1 _____	195
NT1WWC_ILMC0: Change from baseline in ASD weekly wheezing score - MMRM results - NAVIGATOR, DITTL, DCO 1 _____	201
ST1WWC_ILMH0: Course of ASD weekly wheezing score - SOURCE, DITTL _____	207
ST1WWC_ILMC0: Change from baseline in ASD weekly wheezing score - MMRM results - SOURCE, DITTL _____	213
NT1WBC_ILMH0: Course of ASD weekly shortness of breath score - NAVIGATOR, DITTL, DCO 1 _____	218
NT1WBC_ILMC0: Change from baseline in ASD weekly shortness of breath score - MMRM results - NAVIGATOR, DITTL, DCO 1 _____	224
ST1WBC_ILMH0: Course of ASD weekly shortness of breath score - SOURCE, DITTL _____	230
ST1WBC_ILMC0: Change from baseline in ASD weekly shortness of breath score - MMRM results - SOURCE, DITTL _____	236
NT1WHC_ILMH0: Course of ASD weekly cough score - NAVIGATOR, DITTL, DCO 1 _____	241
NT1WHC_ILMC0: Change from baseline in ASD weekly cough score - MMRM results - NAVIGATOR, DITTL, DCO 1 _____	247
ST1WHC_ILMH0: Course of ASD weekly cough score - SOURCE, DITTL _____	253
ST1WHC_ILMC0: Change from baseline in ASD weekly cough score - MMRM results - SOURCE, DITTL _____	259
NT1WEC_ILMH0: Course of ASD weekly chest tightness score - NAVIGATOR, DITTL, DCO 1 _____	264
NT1WEC_ILMC0: Change from baseline in ASD weekly chest tightness score - MMRM results - NAVIGATOR, DITTL, DCO 1 _____	270
ST1WEC_ILMH0: Course of ASD weekly chest tightness score - SOURCE, DITTL _____	276
ST1WEC_ILMC0: Change from baseline in ASD weekly chest tightness score - MMRM results - SOURCE, DITTL _____	282
NT1WAC_ILMH0: Course of ASD weekly waking score - NAVIGATOR, DITTL, DCO 1 _____	287
NT1WAC_ILMC0: Change from baseline in ASD weekly waking score - MMRM results - NAVIGATOR, DITTL, DCO 1 _____	293

ST1WAC_ILMH0: Course of ASD weekly waking score - SOURCE, DITTL _____	299
ST1WAC_ILMC0: Change from baseline in ASD weekly waking score - MMRM results - SOURCE, DITTL _____	305
NT1WLC_ILMH0: Course of ASD weekly limiting activity score - NAVIGATOR, DITTL, DCO 1 _____	310
NT1WLC_ILMC0: Change from baseline in ASD weekly limiting activity score - MMRM results - NAVIGATOR, DITTL, DCO 1 _____	316
ST1WLC_ILMH0: Course of ASD weekly limiting activity score - SOURCE, DITTL _____	322
ST1WLC_ILMC0: Change from baseline in ASD weekly limiting activity score - MMRM results - SOURCE, DITTL _____	328
NT1WTC_KLMH0: Course of ASD weekly total score - NAVIGATOR, DITTL-adolescent, DCO 1 _____	333
NT1WTC_KLMC0: Change from baseline in ASD weekly total score - MMRM results - NAVIGATOR, DITTL-adolescent, DCO 1 _____	339
NT1WDC_KLMH0: Course of ASD weekly daytime score - NAVIGATOR, DITTL-adolescent, DCO 1 _____	345
NT1WDC_KLMC0: Change from baseline in ASD weekly daytime score - MMRM results - NAVIGATOR, DITTL-adolescent, DCO 1 _____	351
NT1WNC_KLMH0: Course of ASD weekly night-time score - NAVIGATOR, DITTL-adolescent, DCO 1 _____	357
NT1WNC_KLMC0: Change from baseline in ASD weekly night-time score - MMRM results - NAVIGATOR, DITTL-adolescent, DCO 1 _____	363
NT1WWC_KLMH0: Course of ASD weekly wheezing score - NAVIGATOR, DITTL-adolescent, DCO 1 _____	369
NT1WWC_KLMC0: Change from baseline in ASD weekly wheezing score - MMRM results - NAVIGATOR, DITTL-adolescent, DCO 1 _____	375
NT1WBC_KLMH0: Course of ASD weekly shortness of breath score - NAVIGATOR, DITTL-adolescent, DCO 1 _____	381
NT1WBC_KLMC0: Change from baseline in ASD weekly shortness of breath score - MMRM results - NAVIGATOR, DITTL-adolescent, DCO 1 _____	387
NT1WHC_KLMH0: Course of ASD weekly cough score - NAVIGATOR, DITTL-adolescent, DCO 1 _____	393
NT1WHC_KLMC0: Change from baseline in ASD weekly cough score - MMRM results - NAVIGATOR, DITTL-adolescent, DCO 1 _____	399
NT1WEC_KLMH0: Course of ASD weekly chest tightness score - NAVIGATOR, DITTL-adolescent, DCO 1 _____	405
NT1WEC_KLMC0: Change from baseline in ASD weekly chest tightness score - MMRM results - NAVIGATOR, DITTL-adolescent, DCO 1 _____	411
NT1WAC_KLMH0: Course of ASD weekly waking score - NAVIGATOR, DITTL-adolescent, DCO 1 _____	417
NT1WAC_KLMC0: Change from baseline in ASD weekly waking score - MMRM results - NAVIGATOR, DITTL-adolescent, DCO 1 _____	423
NT1WLC_KLMH0: Course of ASD weekly limiting activity score - NAVIGATOR, DITTL-adolescent, DCO 1 _____	429
NT1WLC_KLMC0: Change from baseline in ASD weekly limiting activity score - MMRM results - NAVIGATOR, DITTL-adolescent, DCO 1 _____	435
NT1WTC_ALMH0: Course of ASD weekly total score - NAVIGATOR, DITTL-adult , DCO 1 _____	441
NT1WTC_ALMC0: Change from baseline in ASD weekly total score - MMRM results - NAVIGATOR, DITTL-adult , DCO 1 _____	447
NT1WDC_ALMH0: Course of ASD weekly daytime score - NAVIGATOR, DITTL-adult , DCO 1 _____	453
NT1WDC_ALMC0: Change from baseline in ASD weekly daytime score - MMRM results - NAVIGATOR, DITTL-adult , DCO 1 _____	459
NT1WNC_ALMH0: Course of ASD weekly night-time score - NAVIGATOR, DITTL-adult , DCO 1 _____	465
NT1WNC_ALMC0: Change from baseline in ASD weekly night-time score - MMRM results - NAVIGATOR, DITTL-adult , DCO 1 _____	471

NT1WWC_ALMH0: Course of ASD weekly wheezing score - NAVIGATOR, DITTL-adult , DCO 1 _____	477
NT1WWC_ALMC0: Change from baseline in ASD weekly wheezing score - MMRM results - NAVIGATOR, DITTL-adult , DCO 1 _____	483
NT1WBC_ALMH0: Course of ASD weekly shortness of breath score - NAVIGATOR, DITTL-adult , DCO 1 _____	489
NT1WBC_ALMC0: Change from baseline in ASD weekly shortness of breath score - MMRM results - NAVIGATOR, DITTL-adult , DCO 1 _____	495
NT1WHC_ALMH0: Course of ASD weekly cough score - NAVIGATOR, DITTL-adult , DCO 1 _____	501
NT1WHC_ALMC0: Change from baseline in ASD weekly cough score - MMRM results - NAVIGATOR, DITTL-adult , DCO 1 _____	507
NT1WEC_ALMH0: Course of ASD weekly chest tightness score - NAVIGATOR, DITTL-adult , DCO 1 _____	513
NT1WEC_ALMC0: Change from baseline in ASD weekly chest tightness score - MMRM results - NAVIGATOR, DITTL-adult , DCO 1 _____	519
NT1WAC_ALMH0: Course of ASD weekly waking score - NAVIGATOR, DITTL-adult , DCO 1 _____	525
NT1WAC_ALMC0: Change from baseline in ASD weekly waking score - MMRM results - NAVIGATOR, DITTL-adult , DCO 1 _____	531
NT1WLC_ALMH0: Course of ASD weekly limiting activity score - NAVIGATOR, DITTL-adult , DCO 1 _____	537
NT1WLC_ALMC0: Change from baseline in ASD weekly limiting activity score - MMRM results - NAVIGATOR, DITTL-adult , DCO 1 _____	543
MT1VSC_ILMH0: Course of EQ-5D-VAS - pooled NP set, DITTL _____	549
MT1VSC_ILMC0: Change from baseline in EQ-5D-VAS - MMRM results - pooled NP set, DITTL _____	553
NT1VSC_ILMH0: Course of EQ-5D-VAS - NAVIGATOR, DITTL, DCO 1 _____	556
NT1VSC_ILMC0: Change from baseline in EQ-5D-VAS - MMRM results - NAVIGATOR, DITTL, DCO 1 _____	560
PT3VSC_ILMH0: Course of EQ-5D-VAS - PATHWAY, DITTL, DCO 3 _____	563
PT3VSC_ILMC0: Change from baseline in EQ-5D-VAS - MMRM results - PATHWAY, DITTL, DCO 3 _____	569
ST1VSC_ILMH0: Course of EQ-5D-VAS - SOURCE, DITTL _____	575
ST1VSC_ILMC0: Change from baseline in EQ-5D-VAS - MMRM results - SOURCE, DITTL _____	579
NT1VSC_KLMH0: Course of EQ-5D-VAS - NAVIGATOR, DITTL-adolescent, DCO 1 _____	582
NT1VSC_KLMC0: Change from baseline in EQ-5D-VAS - MMRM results - NAVIGATOR, DITTL-adolescent, DCO 1 _____	586
NT1VSC_ALMH0: Course of EQ-5D-VAS - NAVIGATOR, DITTL-adult , DCO 1 _____	589
NT1VSC_ALMC0: Change from baseline in EQ-5D-VAS - MMRM results - NAVIGATOR, DITTL-adult , DCO 1 _____	593
NT1SNC_RLMH0: Course of in SNOT-22 total score - NAVIGATOR, DITTRL, DCO 1 _____	596
NT1SNC_NLMH0: Course of in SNOT-22 total score - NAVIGATOR, DITTRL-adult, DCO 1 _____	598
NT1SNC_RLMC0: Change from baseline in in SNOT-22 total score - MMRM results - NAVIGATOR, DITTRL, DCO 1 _____	600
NT1SNC_NLMC0: Change from baseline in in SNOT-22 total score - MMRM results - NAVIGATOR, DITTRL-adult, DCO 1 _____	601
MT1QTC_ILMH0: Course of AQLQ+12 total score - pooled NP set, DITTL _____	602
MT1QTC_ILMC0: Change from baseline in AQLQ+12 total score - MMRM results - pooled NP set, DITTL _____	604

NT1QTC_ILMH0: Course of AQLQ+12 total score - NAVIGATOR, DITTL, DCO 1	605
NT1QTC_ILMC0: Change from baseline in AQLQ+12 total score - MMRM results - NAVIGATOR, DITTL, DCO 1	607
PT3QTC_ILMH0: Course of AQLQ+12 total score - PATHWAY, DITTL, DCO 3	608
PT3QTC_ILMC0: Change from baseline in AQLQ+12 total score - MMRM results - PATHWAY, DITTL, DCO 3	610
ST1QTC_ILMH0: Course of AQLQ+12 total score - SOURCE, DITTL	612
ST1QTC_ILMC0: Change from baseline in AQLQ+12 total score - MMRM results - SOURCE, DITTL	614
MT1QAC_ILMH0: Course of AQLQ+12 activity limitations score - pooled NP set, DITTL	615
MT1QAC_ILMC0: Change from baseline in AQLQ+12 activity limitations score - MMRM results - pooled NP set, DITTL	617
NT1QAC_ILMH0: Course of AQLQ+12 activity limitations score - NAVIGATOR, DITTL, DCO 1	618
NT1QAC_ILMC0: Change from baseline in AQLQ+12 activity limitations score - MMRM results - NAVIGATOR, DITTL, DCO 1	620
PT3QAC_ILMH0: Course of AQLQ+12 activity limitations score - PATHWAY, DITTL, DCO 3	621
PT3QAC_ILMC0: Change from baseline in AQLQ+12 activity limitations score - MMRM results - PATHWAY, DITTL, DCO 3	623
ST1QAC_ILMH0: Course of AQLQ+12 activity limitations score - SOURCE, DITTL	625
ST1QAC_ILMC0: Change from baseline in AQLQ+12 activity limitations score - MMRM results - SOURCE, DITTL	627
MT1QEC_ILMH0: Course of AQLQ+12 environmental stimuli score - pooled NP set, DITTL	628
MT1QEC_ILMC0: Change from baseline in AQLQ+12 environmental stimuli score - MMRM results - pooled NP set, DITTL	630
NT1QEC_ILMH0: Course of AQLQ+12 environmental stimuli score - NAVIGATOR, DITTL, DCO 1	631
NT1QEC_ILMC0: Change from baseline in AQLQ+12 environmental stimuli score - MMRM results - NAVIGATOR, DITTL, DCO 1	633
PT3QEC_ILMH0: Course of AQLQ+12 environmental stimuli score - PATHWAY, DITTL, DCO 3	634
PT3QEC_ILMC0: Change from baseline in AQLQ+12 environmental stimuli score - MMRM results - PATHWAY, DITTL, DCO 3	636
ST1QEC_ILMH0: Course of AQLQ+12 environmental stimuli score - SOURCE, DITTL	638
ST1QEC_ILMC0: Change from baseline in AQLQ+12 environmental stimuli score - MMRM results - SOURCE, DITTL	640
MT1QGC_ILMH0: Course of AQLQ+12 emotional function score - pooled NP set, DITTL	641
MT1QGC_ILMC0: Change from baseline in AQLQ+12 emotional function score - MMRM results - pooled NP set, DITTL	643
NT1QGC_ILMH0: Course of AQLQ+12 emotional function score - NAVIGATOR, DITTL, DCO 1	644
NT1QGC_ILMC0: Change from baseline in AQLQ+12 emotional function score - MMRM results - NAVIGATOR, DITTL, DCO 1	646
PT3QGC_ILMH0: Course of AQLQ+12 emotional function score - PATHWAY, DITTL, DCO 3	647
PT3QGC_ILMC0: Change from baseline in AQLQ+12 emotional function score - MMRM results - PATHWAY, DITTL, DCO 3	649
ST1QGC_ILMH0: Course of AQLQ+12 emotional function score - SOURCE, DITTL	651
ST1QGC_ILMC0: Change from baseline in AQLQ+12 emotional function score - MMRM results - SOURCE, DITTL	653

MT1QMC_ILMH0: Course of AQLQ+12 symptom score - pooled NP set, DITTL _____	654
MT1QMC_ILMC0: Change from baseline in AQLQ+12 symptom score - MMRM results - pooled NP set, DITTL _____	656
NT1QMC_ILMH0: Course of AQLQ+12 symptom score - NAVIGATOR, DITTL, DCO 1 _____	657
NT1QMC_ILMC0: Change from baseline in AQLQ+12 symptom score - MMRM results - NAVIGATOR, DITTL, DCO 1 _____	659
PT3QMC_ILMH0: Course of AQLQ+12 symptom score - PATHWAY, DITTL, DCO 3 _____	660
PT3QMC_ILMC0: Change from baseline in AQLQ+12 symptom score - MMRM results - PATHWAY, DITTL, DCO 3 _____	662
ST1QMC_ILMH0: Course of AQLQ+12 symptom score - SOURCE, DITTL _____	664
ST1QMC_ILMC0: Change from baseline in AQLQ+12 symptom score - MMRM results - SOURCE, DITTL _____	666
NT1QTC_KLMH0: Course of AQLQ+12 total score - NAVIGATOR, DITTL-adolescent, DCO 1 _____	667
NT1QTC_KLMC0: Change from baseline in AQLQ+12 total score - MMRM results - NAVIGATOR, DITTL-adolescent, DCO 1 _____	669
NT1QAC_KLMH0: Course of AQLQ+12 activity limitations score - NAVIGATOR, DITTL-adolescent, DCO 1 _____	670
NT1QAC_KLMC0: Change from baseline in AQLQ+12 activity limitations score - MMRM results - NAVIGATOR, DITTL-adolescent, DCO 1 _____	672
NT1QEC_KLMH0: Course of AQLQ+12 environmental stimuli score - NAVIGATOR, DITTL-adolescent, DCO 1 _____	673
NT1QEC_KLMC0: Change from baseline in AQLQ+12 environmental stimuli score - MMRM results - NAVIGATOR, DITTL-adolescent, DCO 1 _____	675
NT1QGC_KLMH0: Course of AQLQ+12 emotional function score - NAVIGATOR, DITTL-adolescent, DCO 1 _____	676
NT1QGC_KLMC0: Change from baseline in AQLQ+12 emotional function score - MMRM results - NAVIGATOR, DITTL-adolescent, DCO 1 _____	678
NT1QMC_KLMH0: Course of AQLQ+12 symptom score - NAVIGATOR, DITTL-adolescent, DCO 1 _____	679
NT1QMC_KLMC0: Change from baseline in AQLQ+12 symptom score - MMRM results - NAVIGATOR, DITTL-adolescent, DCO 1 _____	681
NT1QTC_ALMH0: Course of AQLQ+12 total score - NAVIGATOR, DITTL-adult , DCO 1 _____	682
NT1QTC_ALMC0: Change from baseline in AQLQ+12 total score - MMRM results - NAVIGATOR, DITTL-adult , DCO 1 _____	684
NT1QAC_ALMH0: Course of AQLQ+12 activity limitations score - NAVIGATOR, DITTL-adult , DCO 1 _____	685
NT1QAC_ALMC0: Change from baseline in AQLQ+12 activity limitations score - MMRM results - NAVIGATOR, DITTL-adult , DCO 1 _____	687
NT1QEC_ALMH0: Course of AQLQ+12 environmental stimuli score - NAVIGATOR, DITTL-adult , DCO 1 _____	688
NT1QEC_ALMC0: Change from baseline in AQLQ+12 environmental stimuli score - MMRM results - NAVIGATOR, DITTL-adult , DCO 1 _____	690
NT1QGC_ALMH0: Course of AQLQ+12 emotional function score - NAVIGATOR, DITTL-adult , DCO 1 _____	691
NT1QGC_ALMC0: Change from baseline in AQLQ+12 emotional function score - MMRM results - NAVIGATOR, DITTL-adult , DCO 1 _____	693
NT1QMC_ALMH0: Course of AQLQ+12 symptom score - NAVIGATOR, DITTL-adult , DCO 1 _____	694
NT1QMC_ALMC0: Change from baseline in AQLQ+12 symptom score - MMRM results - NAVIGATOR, DITTL-adult , DCO 1 _____	696
NT1GTC_ILMH0: Course of SGRQ total score - NAVIGATOR, DITTL, DCO 1 _____	697
NT1GTC_ILMC0: Change from baseline in SGRQ total score - MMRM results - NAVIGATOR, DITTL, DCO 1 _____	699



ST1GTC_ILMH0: Course of SGRQ total score - SOURCE, DITTL _____	700
ST1GTC_ILMC0: Change from baseline in SGRQ total score - MMRM results - SOURCE, DITTL _____	702
DT1GTC_BLMH0: Course of SGRQ total score - DESTINATION, DITTNL - LTE _____	703
DT1GTC_BLMC0: Change from baseline in SGRQ total score - MMRM results - DESTINATION, DITTNL - LTE _____	705
NT1GMC_ILMH0: Course of SGRQ symptom score - NAVIGATOR, DITTL, DCO 1 _____	706
NT1GMC_ILMC0: Change from baseline in SGRQ symptom score - MMRM results - NAVIGATOR, DITTL, DCO 1 _____	708
ST1GMC_ILMH0: Course of SGRQ symptom score - SOURCE, DITTL _____	709
ST1GMC_ILMC0: Change from baseline in SGRQ symptom score - MMRM results - SOURCE, DITTL _____	711
DT1GMC_BLMH0: Course of SGRQ symptom score - DESTINATION, DITTNL - LTE _____	712
DT1GMC_BLMC0: Change from baseline in SGRQ symptom score - MMRM results - DESTINATION, DITTNL - LTE _____	714
NT1GAC_ILMH0: Course of SGRQ activities score - NAVIGATOR, DITTL, DCO 1 _____	715
NT1GAC_ILMC0: Change from baseline in SGRQ activities score - MMRM results - NAVIGATOR, DITTL, DCO 1 _____	717
ST1GAC_ILMH0: Course of SGRQ activities score - SOURCE, DITTL _____	718
ST1GAC_ILMC0: Change from baseline in SGRQ activities score - MMRM results - SOURCE, DITTL _____	720
DT1GAC_BLMH0: Course of SGRQ activities score - DESTINATION, DITTNL - LTE _____	721
DT1GAC_BLMC0: Change from baseline in SGRQ activities score - MMRM results - DESTINATION, DITTNL - LTE _____	723
NT1GRC_ILMH0: Course of SGRQ impact score - NAVIGATOR, DITTL, DCO 1 _____	724
NT1GRC_ILMC0: Change from baseline in SGRQ impact score - MMRM results - NAVIGATOR, DITTL, DCO 1 _____	726
ST1GRC_ILMH0: Course of SGRQ impact score - SOURCE, DITTL _____	727
ST1GRC_ILMC0: Change from baseline in SGRQ impact score - MMRM results - SOURCE, DITTL _____	729
DT1GRC_BLMH0: Course of SGRQ impact score - DESTINATION, DITTNL - LTE _____	730
DT1GRC_BLMC0: Change from baseline in SGRQ impact score - MMRM results - DESTINATION, DITTNL - LTE _____	732
NT1GTC_KLMH0: Course of SGRQ total score - NAVIGATOR, DITTL-adolescent, DCO 1 _____	733
NT1GTC_KLMC0: Change from baseline in SGRQ total score - MMRM results - NAVIGATOR, DITTL-adolescent, DCO 1 _____	735
DT1GTC_MLMH0: Course of SGRQ total score - DESTINATION, DITTNL - LTE - adolescents _____	736
DT1GTC_MLMC0: Change from baseline in SGRQ total score - MMRM results - DESTINATION, DITTNL - LTE - adolescents _____	738
NT1GMC_KLMH0: Course of SGRQ symptom score - NAVIGATOR, DITTL-adolescent, DCO 1 _____	739
NT1GMC_KLMC0: Change from baseline in SGRQ symptom score - MMRM results - NAVIGATOR, DITTL-adolescent, DCO 1 _____	741
DT1GMC_MLMH0: Course of SGRQ symptom score - DESTINATION, DITTNL - LTE - adolescents _____	742
DT1GMC_MLMC0: Change from baseline in SGRQ symptom score - MMRM results - DESTINATION, DITTNL - LTE - adolescents _____	744

NT1GAC_KLMH0: Course of SGRQ activities score - NAVIGATOR, DITTTL-adolescent, DCO 1 _____	745
NT1GAC_KLMC0: Change from baseline in SGRQ activities score - MMRM results - NAVIGATOR, DITTTL-adolescent, DCO 1 _____	747
DT1GAC_MLMH0: Course of SGRQ activities score - DESTINATION, DITTNL - LTE - adolescents _____	748
DT1GAC_MLMC0: Change from baseline in SGRQ activities score - MMRM results - DESTINATION, DITTNL - LTE - adolescents _____	750
NT1GRC_KLMH0: Course of SGRQ impact score - NAVIGATOR, DITTTL-adolescent, DCO 1 _____	751
NT1GRC_KLMC0: Change from baseline in SGRQ impact score - MMRM results - NAVIGATOR, DITTTL-adolescent, DCO 1 _____	753
DT1GRC_MLMH0: Course of SGRQ impact score - DESTINATION, DITTNL - LTE - adolescents _____	754
DT1GRC_MLMC0: Change from baseline in SGRQ impact score - MMRM results - DESTINATION, DITTNL - LTE - adolescents _____	756
NT1GTC_ALMH0: Course of SGRQ total score - NAVIGATOR, DITTTL-adult , DCO 1 _____	757
NT1GTC_ALMC0: Change from baseline in SGRQ total score - MMRM results - NAVIGATOR, DITTTL-adult , DCO 1 _____	759
DT1GTC_HLMH0: Course of SGRQ total score - DESTINATION, DITTNL - LTE - adult _____	760
DT1GTC_HLMC0: Change from baseline in SGRQ total score - MMRM results - DESTINATION, DITTNL - LTE - adult _____	762
NT1GMC_ALMH0: Course of SGRQ symptom score - NAVIGATOR, DITTTL-adult , DCO 1 _____	763
NT1GMC_ALMC0: Change from baseline in SGRQ symptom score - MMRM results - NAVIGATOR, DITTTL-adult , DCO 1 _____	765
DT1GMC_HLMH0: Course of SGRQ symptom score - DESTINATION, DITTNL - LTE - adult _____	766
DT1GMC_HLMC0: Change from baseline in SGRQ symptom score - MMRM results - DESTINATION, DITTNL - LTE - adult _____	768
NT1GAC_ALMH0: Course of SGRQ activities score - NAVIGATOR, DITTTL-adult , DCO 1 _____	769
NT1GAC_ALMC0: Change from baseline in SGRQ activities score - MMRM results - NAVIGATOR, DITTTL-adult , DCO 1 _____	771
DT1GAC_HLMH0: Course of SGRQ activities score - DESTINATION, DITTNL - LTE - adult _____	772
DT1GAC_HLMC0: Change from baseline in SGRQ activities score - MMRM results - DESTINATION, DITTNL - LTE - adult _____	774
NT1GRC_ALMH0: Course of SGRQ impact score - NAVIGATOR, DITTTL-adult , DCO 1 _____	775
NT1GRC_ALMC0: Change from baseline in SGRQ impact score - MMRM results - NAVIGATOR, DITTTL-adult , DCO 1 _____	777
DT1GRC_HLMH0: Course of SGRQ impact score - DESTINATION, DITTNL - LTE - adult _____	778
DT1GRC_HLMC0: Change from baseline in SGRQ impact score - MMRM results - DESTINATION, DITTNL - LTE - adult _____	780
NT1PSC_ILMH0: Course of PGI-S - NAVIGATOR, DITTTL, DCO 1 _____	781
NT1PSC_ILMC0: Change from baseline in PGI-S - MMRM results - NAVIGATOR, DITTTL, DCO 1 _____	783
NT1PSC_KLMH0: Course of PGI-S - NAVIGATOR, DITTTL-adolescent, DCO 1 _____	784
NT1PSC_KLMC0: Change from baseline in PGI-S - MMRM results - NAVIGATOR, DITTTL-adolescent, DCO 1 _____	786
NT1PSC_ALMH0: Course of PGI-S - NAVIGATOR, DITTTL-adult , DCO 1 _____	787
NT1PSC_ALMC0: Change from baseline in PGI-S - MMRM results - NAVIGATOR, DITTTL-adult , DCO 1 _____	789

Table MT1FAC\_ILMH0: Course of FEV1 Pre-BD  
 DITTL

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
FEV1 Pre-BD	Baseline	Tezepelumab	446	446 (100.0)	1.74 (0.66)	0.4	1.27	1.62	2.12	4.1
		Placebo	436	436 (100.0)	1.80 (0.66)	0.4	1.35	1.69	2.19	4.5
	Week 4	Tezepelumab	446	441 (98.9)	1.95 (0.73)	0.6	1.41	1.83	2.41	4.5
		Placebo	436	428 (98.2)	1.86 (0.67)	0.4	1.42	1.79	2.25	4.8
	Week 8	Tezepelumab	446	434 (97.3)	1.96 (0.71)	0.6	1.41	1.85	2.40	4.7
		Placebo	436	422 (96.8)	1.89 (0.71)	0.4	1.40	1.82	2.28	4.6
	Week 12	Tezepelumab	446	431 (96.6)	1.98 (0.73)	0.6	1.48	1.87	2.42	4.7
		Placebo	436	420 (96.3)	1.89 (0.71)	0.5	1.39	1.76	2.30	4.6
	Week 52	Tezepelumab	446	396 (88.8)	1.95 (0.72)	0.6	1.43	1.83	2.38	4.3
		Placebo	436	368 (84.4)	1.87 (0.74)	0.6	1.32	1.73	2.29	4.5

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G.

FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.

Source Data: afev, created on: 15MAR2022

Table MT1FAC\_ILMH0: Course of FEV1 Pre-BD  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in FEV1 Pre-BD	Week 4	Tezepelumab	446	441 (98.9)	0.22 (0.38)	-0.9	0.00	0.13	0.36	2.4	0.40 [0.26, 0.53]
		Placebo	436	428 (98.2)	0.07 (0.37)	-1.8	-0.12	0.04	0.22	1.6	
	Week 8	Tezepelumab	446	434 (97.3)	0.24 (0.40)	-0.8	-0.03	0.16	0.44	2.2	0.41 [0.27, 0.54]
		Placebo	436	422 (96.8)	0.08 (0.35)	-1.5	-0.11	0.06	0.25	1.6	
	Week 12	Tezepelumab	446	431 (96.6)	0.25 (0.41)	-0.8	-0.01	0.18	0.44	2.1	0.42 [0.29, 0.56]
		Placebo	436	420 (96.3)	0.08 (0.39)	-1.5	-0.10	0.05	0.26	1.7	
	Week 52	Tezepelumab	446	396 (88.8)	0.23 (0.42)	-1.0	-0.02	0.16	0.47	2.3	0.44 [0.29, 0.58]
		Placebo	436	368 (84.4)	0.06 (0.36)	-1.0	-0.15	0.04	0.23	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G.

FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.

Source Data: afev, created on: 15MAR2022

Table MT1FAC\_ILMC0: Change from baseline in FEV1 Pre-BD - MMRM results  
DITTL

Change from baseline in FEV1 Pre-BD				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	446	441 (98.9)	0.21 (0.02)	(0.18, 0.25)	0.14 (0.03)	(0.09, 0.19)	<0.001 *
	Placebo	436	428 (98.2)	0.07 (0.02)	(0.03, 0.10)			
Week 8	Tezepelumab	446	434 (97.3)	0.24 (0.02)	(0.20, 0.27)	0.15 (0.03)	(0.10, 0.20)	<0.001 *
	Placebo	436	422 (96.8)	0.09 (0.02)	(0.05, 0.12)			
Week 12	Tezepelumab	446	431 (96.6)	0.25 (0.02)	(0.21, 0.28)	0.16 (0.03)	(0.11, 0.21)	<0.001 *
	Placebo	436	420 (96.3)	0.09 (0.02)	(0.05, 0.13)			
Week 52	Tezepelumab	446	396 (88.8)	0.23 (0.02)	(0.20, 0.27)	0.17 (0.03)	(0.11, 0.22)	<0.001 *
	Placebo	436	368 (84.4)	0.07 (0.02)	(0.03, 0.10)			

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.

Source Data: afev, created on: 15MAR2022

Table NT1FAC\_ILMH0: Course of FEV1 Pre-BD  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
FEV1 Pre-BD	Baseline	Tezepelumab	395	395 (100.0)	1.77 (0.69)	0.4	1.27	1.64	2.14	4.1	
		Placebo	391	391 (100.0)	1.84 (0.71)	0.4	1.34	1.71	2.22	4.9	
	Week 2	Tezepelumab	395	384 (97.2)	1.95 (0.72)	0.6	1.40	1.83	2.43	4.3	
		Placebo	391	373 (95.4)	1.91 (0.72)	0.4	1.38	1.80	2.33	4.7	
	Week 4	Tezepelumab	395	391 (99.0)	1.97 (0.73)	0.6	1.42	1.86	2.48	4.3	
		Placebo	391	382 (97.7)	1.90 (0.69)	0.4	1.43	1.82	2.28	4.8	
	Week 8	Tezepelumab	395	388 (98.2)	1.98 (0.74)	0.6	1.41	1.87	2.44	4.7	
		Placebo	391	380 (97.2)	1.93 (0.74)	0.4	1.40	1.83	2.35	4.9	
	Week 12	Tezepelumab	395	382 (96.7)	1.99 (0.74)	0.6	1.49	1.89	2.44	4.7	
		Placebo	391	377 (96.4)	1.94 (0.74)	0.5	1.40	1.81	2.38	5.0	
	Week 16	Tezepelumab	395	380 (96.2)	2.02 (0.75)	0.6	1.48	1.90	2.48	4.9	
		Placebo	391	370 (94.6)	1.93 (0.74)	0.5	1.36	1.80	2.32	5.2	
	Week 24	Tezepelumab	395	368 (93.2)	1.98 (0.72)	0.6	1.49	1.85	2.43	4.4	
		Placebo	391	356 (91.0)	1.93 (0.74)	0.6	1.41	1.81	2.25	5.1	
	Week 36	Tezepelumab	395	356 (90.1)	2.00 (0.75)	0.5	1.43	1.90	2.45	4.5	
		Placebo	391	346 (88.5)	1.96 (0.76)	0.6	1.42	1.83	2.33	5.3	
	Week 52	Tezepelumab	395	349 (88.4)	2.00 (0.76)	0.6	1.48	1.87	2.45	4.3	
		Placebo	391	326 (83.4)	1.92 (0.78)	0.6	1.34	1.77	2.32	5.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G.

FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.

Source Data: afev, created on: 15MAR2022

Table NT1FAC\_ILMH0: Course of FEV1 Pre-BD  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in FEV1 Pre-BD	Week 2	Tezepelumab	395	384 (97.2)	0.18 (0.33)	-0.7	-0.00	0.13	0.32	1.5	0.37 [0.23, 0.51]
		Placebo	391	373 (95.4)	0.05 (0.37)	-1.8	-0.11	0.01	0.18	1.7	
	Week 4	Tezepelumab	395	391 (99.0)	0.21 (0.36)	-0.9	-0.01	0.14	0.35	1.8	0.33 [0.19, 0.47]
		Placebo	391	382 (97.7)	0.08 (0.39)	-1.8	-0.11	0.04	0.25	1.7	
	Week 8	Tezepelumab	395	388 (98.2)	0.23 (0.42)	-1.1	-0.04	0.15	0.44	1.8	0.37 [0.23, 0.51]
		Placebo	391	380 (97.2)	0.09 (0.37)	-1.7	-0.12	0.05	0.25	2.0	
	Week 12	Tezepelumab	395	382 (96.7)	0.24 (0.42)	-1.5	-0.03	0.17	0.43	2.0	0.34 [0.20, 0.49]
		Placebo	391	377 (96.4)	0.09 (0.40)	-1.5	-0.10	0.05	0.26	1.7	
	Week 16	Tezepelumab	395	380 (96.2)	0.25 (0.41)	-0.8	0.00	0.17	0.42	2.0	0.43 [0.29, 0.58]
		Placebo	391	370 (94.6)	0.08 (0.39)	-1.6	-0.11	0.03	0.26	1.8	
	Week 24	Tezepelumab	395	368 (93.2)	0.23 (0.41)	-1.0	-0.05	0.18	0.43	1.8	0.39 [0.25, 0.54]
		Placebo	391	356 (91.0)	0.07 (0.40)	-1.4	-0.13	0.04	0.27	1.7	
	Week 36	Tezepelumab	395	356 (90.1)	0.24 (0.42)	-1.0	-0.04	0.17	0.46	1.7	0.34 [0.19, 0.49]
		Placebo	391	346 (88.5)	0.10 (0.42)	-1.7	-0.16	0.06	0.29	2.2	
	Week 52	Tezepelumab	395	349 (88.4)	0.25 (0.42)	-1.0	-0.02	0.18	0.49	1.7	0.44 [0.28, 0.59]
		Placebo	391	326 (83.4)	0.07 (0.37)	-1.4	-0.14	0.06	0.23	1.9	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G.

FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.

Source Data: afev, created on: 15MAR2022

Table NT1FAC\_ILMC0: Change from baseline in FEV1 Pre-BD - MMRM results  
 DITTTL

Change from baseline in FEV1 Pre-BD				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 2	Tezepelumab	395	384 (97.2)	0.18 (0.02)	(0.15, 0.21)	0.12 (0.02)	(0.08, 0.17)	<0.001 *
	Placebo	391	373 (95.4)	0.05 (0.02)	(0.02, 0.09)			
Week 4	Tezepelumab	395	391 (99.0)	0.20 (0.02)	(0.17, 0.24)	0.12 (0.03)	(0.07, 0.17)	<0.001 *
	Placebo	391	382 (97.7)	0.08 (0.02)	(0.05, 0.12)			
Week 8	Tezepelumab	395	388 (98.2)	0.23 (0.02)	(0.19, 0.27)	0.14 (0.03)	(0.08, 0.19)	<0.001 *
	Placebo	391	380 (97.2)	0.09 (0.02)	(0.05, 0.13)			
Week 12	Tezepelumab	395	382 (96.7)	0.23 (0.02)	(0.19, 0.27)	0.13 (0.03)	(0.08, 0.19)	<0.001 *
	Placebo	391	377 (96.4)	0.10 (0.02)	(0.06, 0.14)			
Week 16	Tezepelumab	395	380 (96.2)	0.25 (0.02)	(0.21, 0.29)	0.17 (0.03)	(0.11, 0.22)	<0.001 *
	Placebo	391	370 (94.6)	0.08 (0.02)	(0.04, 0.12)			
Week 24	Tezepelumab	395	368 (93.2)	0.22 (0.02)	(0.19, 0.26)	0.14 (0.03)	(0.09, 0.20)	<0.001 *
	Placebo	391	356 (91.0)	0.08 (0.02)	(0.04, 0.12)			
Week 36	Tezepelumab	395	356 (90.1)	0.24 (0.02)	(0.20, 0.28)	0.14 (0.03)	(0.08, 0.20)	<0.001 *
	Placebo	391	346 (88.5)	0.10 (0.02)	(0.06, 0.14)			
Week 52	Tezepelumab	395	349 (88.4)	0.25 (0.02)	(0.21, 0.29)	0.17 (0.03)	(0.11, 0.23)	<0.001 *
	Placebo	391	326 (83.4)	0.08 (0.02)	(0.04, 0.12)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.

Source Data: afev, created on: 15MAR2022



Table PT3FAC\_ILMH0: Course of FEV1 Pre-BD  
 DITTLL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
FEV1 Pre-BD	Baseline	Tezepelumab	66	66 (100.0)	1.75 (0.59)	0.7	1.34	1.66	2.12	3.1	
		Placebo	65	65 (100.0)	1.82 (0.56)	0.9	1.43	1.71	2.21	3.2	
	Week 4	Tezepelumab	66	64 (97.0)	1.99 (0.78)	0.9	1.45	1.82	2.34	4.5	
		Placebo	65	65 (100.0)	1.85 (0.61)	0.7	1.52	1.76	2.34	3.2	
	Week 8	Tezepelumab	66	60 (90.9)	1.94 (0.62)	0.7	1.47	1.88	2.37	3.4	
		Placebo	65	61 (93.8)	1.90 (0.64)	0.8	1.54	1.93	2.29	3.6	
	Week 12	Tezepelumab	66	62 (93.9)	2.04 (0.75)	0.9	1.48	1.89	2.55	4.6	
		Placebo	65	63 (96.9)	1.88 (0.70)	0.5	1.41	1.79	2.40	4.1	
	Week 20	Tezepelumab	66	57 (86.4)	1.91 (0.69)	1.0	1.39	1.71	2.37	4.1	
		Placebo	65	60 (92.3)	1.87 (0.65)	0.5	1.45	1.74	2.33	3.3	
	Week 28	Tezepelumab	66	60 (90.9)	1.93 (0.71)	0.9	1.41	1.76	2.29	4.6	
		Placebo	65	59 (90.8)	1.82 (0.65)	0.7	1.42	1.72	2.24	3.4	
	Week 40	Tezepelumab	66	58 (87.9)	1.93 (0.64)	0.9	1.34	1.91	2.33	3.5	
		Placebo	65	57 (87.7)	1.91 (0.74)	0.6	1.43	1.71	2.29	4.0	
	Week 52	Tezepelumab	66	59 (89.4)	1.86 (0.60)	0.9	1.34	1.80	2.27	3.4	
		Placebo	65	60 (92.3)	1.85 (0.73)	0.6	1.35	1.71	2.31	3.7	

Note: DITTLL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G.

FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.

Source Data: afev, created on: 14MAR2022

Table PT3FAC\_ILMH0: Course of FEV1 Pre-BD  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in FEV1 Pre-BD	Week 4	Tezepelumab	66	64 (97.0)	0.26 (0.49)	-0.6	-0.01	0.12	0.42	2.4	0.55 [0.20, 0.90]
		Placebo	65	65 (100.0)	0.03 (0.36)	-1.1	-0.15	0.03	0.16	1.1	
	Week 8	Tezepelumab	66	60 (90.9)	0.21 (0.38)	-0.5	-0.02	0.17	0.36	2.2	0.35 [-0.01, 0.71]
		Placebo	65	61 (93.8)	0.07 (0.41)	-1.5	-0.06	0.13	0.24	1.0	
	Week 12	Tezepelumab	66	62 (93.9)	0.31 (0.45)	-0.5	-0.01	0.21	0.47	2.1	0.58 [0.22, 0.93]
		Placebo	65	63 (96.9)	0.06 (0.43)	-1.2	-0.12	0.04	0.28	1.3	
	Week 20	Tezepelumab	66	57 (86.4)	0.21 (0.45)	-0.6	-0.07	0.12	0.39	2.2	0.41 [0.04, 0.77]
		Placebo	65	60 (92.3)	0.05 (0.31)	-1.0	-0.04	0.07	0.23	0.8	
	Week 28	Tezepelumab	66	60 (90.9)	0.23 (0.48)	-1.0	-0.04	0.19	0.50	2.2	0.51 [0.14, 0.87]
		Placebo	65	59 (90.8)	0.01 (0.36)	-1.1	-0.17	0.05	0.23	0.9	
	Week 40	Tezepelumab	66	58 (87.9)	0.24 (0.46)	-0.7	-0.05	0.24	0.44	2.3	0.34 [-0.03, 0.71]
		Placebo	65	57 (87.7)	0.09 (0.39)	-1.1	-0.12	0.06	0.23	1.1	
	Week 52	Tezepelumab	66	59 (89.4)	0.18 (0.44)	-0.8	-0.04	0.11	0.40	2.3	0.31 [-0.05, 0.67]
		Placebo	65	60 (92.3)	0.04 (0.43)	-1.0	-0.16	0.04	0.18	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G.

FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.

Source Data: afev, created on: 14MAR2022

Table PT3FAC\_PLMH0: Course of FEV1 Pre-BD  
 DPPSL

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
FEV1 Pre-BD	Baseline	Tezepelumab	52	52 (100.0)	1.72 (0.53)	0.7	1.35	1.66	2.08	3.1
		Placebo	53	53 (100.0)	1.79 (0.56)	0.9	1.41	1.67	2.21	3.2
	Week 4	Tezepelumab	52	52 (100.0)	1.98 (0.68)	0.9	1.49	1.86	2.28	3.8
		Placebo	53	53 (100.0)	1.84 (0.65)	0.7	1.45	1.76	2.37	3.2
	Week 8	Tezepelumab	52	50 (96.2)	1.94 (0.58)	0.7	1.51	1.92	2.36	3.2
		Placebo	53	51 (96.2)	1.91 (0.68)	0.8	1.48	1.93	2.35	3.6
	Week 12	Tezepelumab	52	51 (98.1)	2.01 (0.64)	1.0	1.48	2.00	2.55	3.3
		Placebo	53	53 (100.0)	1.85 (0.68)	0.5	1.25	1.81	2.40	3.3
	Week 20	Tezepelumab	52	49 (94.2)	1.90 (0.61)	1.0	1.46	1.74	2.37	3.3
		Placebo	53	52 (98.1)	1.85 (0.67)	0.5	1.36	1.72	2.33	3.3
	Week 28	Tezepelumab	52	52 (100.0)	1.91 (0.61)	0.9	1.41	1.84	2.29	3.5
		Placebo	53	51 (96.2)	1.83 (0.69)	0.7	1.40	1.72	2.27	3.4
	Week 40	Tezepelumab	52	51 (98.1)	1.96 (0.61)	0.9	1.36	1.94	2.36	3.3
		Placebo	53	50 (94.3)	1.88 (0.72)	0.6	1.39	1.71	2.29	3.5
	Week 52	Tezepelumab	52	52 (100.0)	1.88 (0.58)	0.9	1.36	1.82	2.31	3.2
		Placebo	53	53 (100.0)	1.82 (0.73)	0.6	1.30	1.70	2.31	3.7

Note: DPPSL = Dossier Label Per-Protocol Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G.

FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.

Source Data: afev, created on: 14MAR2022

Table PT3FAC\_PLMH0: Course of FEV1 Pre-BD  
 DPPSL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in FEV1 Pre-BD	Week 4	Tezepelumab	52	52 (100.0)	0.25 (0.39)	-0.6	0.03	0.13	0.44	1.7	0.53 [0.14, 0.92]
		Placebo	53	53 (100.0)	0.06 (0.36)	-1.1	-0.15	0.05	0.17	1.1	
	Week 8	Tezepelumab	52	50 (96.2)	0.21 (0.29)	-0.5	0.02	0.20	0.40	0.8	0.28 [-0.11, 0.67]
		Placebo	53	51 (96.2)	0.12 (0.36)	-0.9	-0.06	0.13	0.27	1.0	
	Week 12	Tezepelumab	52	51 (98.1)	0.30 (0.35)	-0.5	0.06	0.23	0.49	1.3	0.61 [0.22, 1.01]
		Placebo	53	53 (100.0)	0.06 (0.43)	-1.2	-0.12	0.05	0.29	1.3	
	Week 20	Tezepelumab	52	49 (94.2)	0.17 (0.36)	-0.6	-0.08	0.17	0.39	0.9	0.34 [-0.05, 0.74]
		Placebo	53	52 (98.1)	0.06 (0.31)	-1.0	-0.04	0.07	0.23	0.8	
	Week 28	Tezepelumab	52	52 (100.0)	0.19 (0.38)	-1.0	-0.04	0.17	0.50	0.9	0.42 [0.03, 0.81]
		Placebo	53	51 (96.2)	0.03 (0.35)	-1.1	-0.12	0.07	0.23	0.9	
	Week 40	Tezepelumab	52	51 (98.1)	0.23 (0.38)	-0.7	-0.05	0.26	0.48	1.1	0.37 [-0.02, 0.77]
		Placebo	53	50 (94.3)	0.08 (0.40)	-1.1	-0.14	0.05	0.23	1.1	
	Week 52	Tezepelumab	52	52 (100.0)	0.15 (0.35)	-0.8	-0.03	0.11	0.42	0.8	0.28 [-0.10, 0.67]
		Placebo	53	53 (100.0)	0.04 (0.46)	-1.0	-0.16	0.01	0.17	1.5	

Note: DPPSL = Dossier Label Per-Protocol Set.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G.  
 FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.  
 Source Data: afev, created on: 14MAR2022

Table PT3FAC\_ILMC0: Change from baseline in FEV1 Pre-BD - MMRM results  
 DITTTL

Change from baseline in FEV1 Pre-BD				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	66	64 (97.0)	0.26 (0.05)	(0.15, 0.36)	0.23 (0.08)	(0.08, 0.38)	0.003 *
	Placebo	65	65 (100.0)	0.03 (0.05)	(-0.08, 0.14)			
Week 8	Tezepelumab	66	60 (90.9)	0.23 (0.05)	(0.13, 0.33)	0.15 (0.07)	(0.01, 0.29)	0.038 *
	Placebo	65	61 (93.8)	0.08 (0.05)	(-0.02, 0.18)			
Week 12	Tezepelumab	66	62 (93.9)	0.29 (0.06)	(0.18, 0.40)	0.23 (0.08)	(0.08, 0.38)	0.004 *
	Placebo	65	63 (96.9)	0.06 (0.06)	(-0.05, 0.17)			
Week 20	Tezepelumab	66	57 (86.4)	0.20 (0.05)	(0.10, 0.30)	0.16 (0.07)	(0.02, 0.30)	0.030 *
	Placebo	65	60 (92.3)	0.04 (0.05)	(-0.06, 0.14)			
Week 28	Tezepelumab	66	60 (90.9)	0.21 (0.06)	(0.10, 0.32)	0.20 (0.08)	(0.05, 0.36)	0.012 *
	Placebo	65	59 (90.8)	0.01 (0.06)	(-0.10, 0.12)			
Week 40	Tezepelumab	66	58 (87.9)	0.23 (0.06)	(0.12, 0.35)	0.14 (0.08)	(-0.01, 0.30)	0.075
	Placebo	65	57 (87.7)	0.09 (0.06)	(-0.02, 0.20)			
Week 52	Tezepelumab	66	59 (89.4)	0.18 (0.06)	(0.06, 0.29)	0.15 (0.08)	(-0.01, 0.31)	0.066
	Placebo	65	60 (92.3)	0.03 (0.06)	(-0.09, 0.14)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.

Source Data: afev, created on: 14MAR2022

Table PT3FAC\_PLMC0: Change from baseline in FEV1 Pre-BD - MMRM results  
 DPPSL

Change from baseline in FEV1 Pre-BD				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	52	52 (100.0)	0.25 (0.05)	(0.15, 0.36)	0.20 (0.07)	(0.05, 0.34)	0.009 *
	Placebo	53	53 (100.0)	0.06 (0.05)	(-0.04, 0.16)			
Week 8	Tezepelumab	52	50 (96.2)	0.22 (0.05)	(0.13, 0.31)	0.09 (0.06)	(-0.03, 0.22)	0.152
	Placebo	53	51 (96.2)	0.12 (0.05)	(0.03, 0.21)			
Week 12	Tezepelumab	52	51 (98.1)	0.29 (0.06)	(0.18, 0.40)	0.23 (0.08)	(0.07, 0.38)	0.004 *
	Placebo	53	53 (100.0)	0.06 (0.05)	(-0.05, 0.17)			
Week 20	Tezepelumab	52	49 (94.2)	0.19 (0.05)	(0.09, 0.28)	0.12 (0.07)	(-0.02, 0.25)	0.087
	Placebo	53	52 (98.1)	0.07 (0.05)	(-0.02, 0.16)			
Week 28	Tezepelumab	52	52 (100.0)	0.19 (0.05)	(0.08, 0.29)	0.15 (0.07)	(0.01, 0.29)	0.042 *
	Placebo	53	51 (96.2)	0.04 (0.05)	(-0.06, 0.14)			
Week 40	Tezepelumab	52	51 (98.1)	0.22 (0.05)	(0.12, 0.33)	0.13 (0.08)	(-0.02, 0.28)	0.096
	Placebo	53	50 (94.3)	0.10 (0.05)	(-0.01, 0.20)			
Week 52	Tezepelumab	52	52 (100.0)	0.15 (0.06)	(0.04, 0.26)	0.11 (0.08)	(-0.04, 0.27)	0.156
	Placebo	53	53 (100.0)	0.04 (0.06)	(-0.07, 0.15)			

Note: DPPSL = Dossier Label Per-Protocol Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.

Source Data: afev, created on: 14MAR2022

Table ST1FAC\_ILMH0: Course of FEV1 Pre-BD  
 DITTL

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
FEV1 Pre-BD	Baseline	Tezepelumab	73	73 (100.0)	1.55 (0.51)	0.7	1.20	1.55	1.93	2.7
		Placebo	76	76 (100.0)	1.59 (0.64)	0.7	1.11	1.48	1.89	3.3
	Week 4	Tezepelumab	73	72 (98.6)	1.83 (0.66)	0.9	1.40	1.71	2.15	4.7
		Placebo	76	76 (100.0)	1.56 (0.66)	0.7	1.07	1.35	1.94	3.6
	Week 12	Tezepelumab	73	69 (94.5)	1.73 (0.61)	0.8	1.26	1.71	2.13	3.6
		Placebo	76	73 (96.1)	1.59 (0.60)	0.6	1.07	1.54	2.01	3.6
	Week 24	Tezepelumab	73	66 (90.4)	1.76 (0.65)	0.6	1.32	1.74	2.11	4.5
		Placebo	76	69 (90.8)	1.55 (0.68)	0.8	1.05	1.32	1.78	3.5
	Week 40	Tezepelumab	73	60 (82.2)	1.87 (0.63)	0.7	1.46	1.88	2.15	4.3
		Placebo	76	68 (89.5)	1.56 (0.72)	0.7	1.01	1.41	1.94	3.7
	Week 48	Tezepelumab	73	64 (87.7)	1.83 (0.61)	0.6	1.40	1.82	2.13	3.8
		Placebo	76	64 (84.2)	1.56 (0.65)	0.5	1.09	1.46	1.94	3.6

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G.

FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.

Source Data: afev, created on: 15MAR2022

Table ST1FAC\_ILMH0: Course of FEV1 Pre-BD  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in FEV1 Pre-BD	Week 4	Tezepelumab	73	72 (98.6)	0.27 (0.43)	-0.3	0.06	0.16	0.38	2.1	0.77 [0.44, 1.11]
		Placebo	76	76 (100.0)	-0.03 (0.33)	-1.4	-0.18	0.01	0.16	0.8	
	Week 12	Tezepelumab	73	69 (94.5)	0.18 (0.39)	-1.1	-0.04	0.19	0.35	1.2	0.44 [0.11, 0.77]
		Placebo	76	73 (96.1)	0.03 (0.31)	-1.1	-0.13	0.04	0.19	0.8	
	Week 24	Tezepelumab	73	66 (90.4)	0.20 (0.46)	-0.7	-0.06	0.11	0.33	1.9	0.57 [0.23, 0.92]
		Placebo	76	69 (90.8)	-0.03 (0.36)	-0.9	-0.21	-0.04	0.17	1.3	
	Week 40	Tezepelumab	73	60 (82.2)	0.27 (0.47)	-0.7	0.01	0.16	0.46	1.7	0.60 [0.24, 0.95]
		Placebo	76	68 (89.5)	0.01 (0.40)	-0.8	-0.23	-0.04	0.14	1.7	
	Week 48	Tezepelumab	73	64 (87.7)	0.24 (0.43)	-0.6	-0.04	0.17	0.43	1.6	0.71 [0.35, 1.06]
		Placebo	76	64 (84.2)	-0.04 (0.36)	-1.1	-0.26	-0.06	0.16	1.1	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G.

FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.

Source Data: afev, created on: 15MAR2022



Table ST1FAC\_ILMC0: Change from baseline in FEV1 Pre-BD - MMRM results  
 DITTTL

Change from baseline in FEV1 Pre-BD				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	73	72 (98.6)	0.26 (0.05)	(0.18, 0.35)	0.29 (0.06)	(0.17, 0.42)	<0.001 *
	Placebo	76	76 (100.0)	-0.03 (0.04)	(-0.12, 0.06)			
Week 12	Tezepelumab	73	69 (94.5)	0.18 (0.04)	(0.09, 0.26)	0.14 (0.06)	(0.03, 0.25)	0.015 *
	Placebo	76	73 (96.1)	0.03 (0.04)	(-0.04, 0.11)			
Week 24	Tezepelumab	73	66 (90.4)	0.19 (0.05)	(0.09, 0.29)	0.21 (0.07)	(0.07, 0.34)	0.003 *
	Placebo	76	69 (90.8)	-0.02 (0.05)	(-0.11, 0.08)			
Week 40	Tezepelumab	73	60 (82.2)	0.23 (0.05)	(0.13, 0.33)	0.21 (0.07)	(0.07, 0.35)	0.004 *
	Placebo	76	68 (89.5)	0.02 (0.05)	(-0.08, 0.12)			
Week 48	Tezepelumab	73	64 (87.7)	0.22 (0.05)	(0.13, 0.31)	0.26 (0.07)	(0.13, 0.39)	<0.001 *
	Placebo	76	64 (84.2)	-0.04 (0.05)	(-0.13, 0.05)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.

Source Data: afev, created on: 15MAR2022

Table DT1FAC\_BLMH0: Course of FEV1 Pre-BD  
 DITTNL - LTE

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
FEV1 Pre-BD	Baseline	Teze+Teze	310	310 (100.0)	1.76 (0.66)	0.5	1.28	1.64	2.12	4.0	
		Pbo+Pbo	149	149 (100.0)	1.80 (0.69)	0.7	1.34	1.67	2.22	4.2	
	Week 2	Teze+Teze	310	303 (97.7)	1.93 (0.69)	0.6	1.42	1.80	2.41	4.1	
		Pbo+Pbo	149	144 (96.6)	1.85 (0.69)	0.7	1.38	1.75	2.28	4.0	
	Week 4	Teze+Teze	310	308 (99.4)	1.95 (0.73)	0.6	1.43	1.84	2.43	4.3	
		Pbo+Pbo	149	147 (98.7)	1.90 (0.66)	0.7	1.42	1.82	2.28	4.2	
	Week 8	Teze+Teze	310	307 (99.0)	1.97 (0.73)	0.6	1.40	1.84	2.41	4.7	
		Pbo+Pbo	149	146 (98.0)	1.90 (0.69)	0.7	1.41	1.81	2.30	4.3	
	Week 12	Teze+Teze	310	304 (98.1)	1.98 (0.74)	0.6	1.50	1.84	2.41	4.7	
		Pbo+Pbo	149	148 (99.3)	1.92 (0.68)	0.7	1.42	1.79	2.37	4.3	
	Week 16	Teze+Teze	310	305 (98.4)	2.00 (0.73)	0.6	1.48	1.86	2.42	4.9	
		Pbo+Pbo	149	146 (98.0)	1.89 (0.69)	0.8	1.35	1.81	2.31	4.1	
	Week 24	Teze+Teze	310	299 (96.5)	1.97 (0.72)	0.6	1.48	1.83	2.41	4.4	
		Pbo+Pbo	149	145 (97.3)	1.87 (0.69)	0.6	1.40	1.76	2.22	4.8	
	Week 36	Teze+Teze	310	291 (93.9)	1.98 (0.75)	0.5	1.43	1.89	2.41	4.5	
		Pbo+Pbo	149	145 (97.3)	1.90 (0.74)	0.8	1.41	1.71	2.31	4.6	
	Week 52	Teze+Teze	310	291 (93.9)	1.99 (0.76)	0.6	1.44	1.87	2.43	4.3	
		Pbo+Pbo	149	139 (93.3)	1.86 (0.76)	0.7	1.27	1.68	2.30	4.4	
	Week 64	Teze+Teze	310	267 (86.1)	2.01 (0.78)	0.6	1.44	1.87	2.47	4.4	
		Pbo+Pbo	149	132 (88.6)	1.87 (0.73)	0.8	1.34	1.74	2.23	4.2	
	Week 76	Teze+Teze	310	255 (82.3)	1.98 (0.75)	0.5	1.42	1.90	2.44	4.3	
		Pbo+Pbo	149	124 (83.2)	1.91 (0.77)	0.5	1.37	1.73	2.30	4.4	
	Week 88	Teze+Teze	310	244 (78.7)	1.95 (0.72)	0.6	1.46	1.86	2.44	4.4	
		Pbo+Pbo	149	119 (79.9)	1.92 (0.75)	0.6	1.39	1.77	2.39	4.6	
	Week 104	Teze+Teze	310	261 (84.2)	1.97 (0.73)	0.5	1.43	1.86	2.46	4.1	
		Pbo+Pbo	149	126 (84.6)	1.87 (0.74)	0.7	1.37	1.71	2.25	4.5	

Note: DITTNL - LTE = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G.  
 FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.  
 Source Data: afev, created on: 28JUL2022

Table DT1FAC\_BLMH0: Course of FEV1 Pre-BD  
 DITTNL - LTE

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in FEV1 Pre-BD	Week 2	Teze+Teze	310	303 (97.7)	0.18 (0.33)	-0.7	-0.01	0.13	0.32	1.5	0.35 [0.15, 0.55]
		Pbo+Pbo	149	144 (96.6)	0.05 (0.40)	-1.8	-0.10	0.00	0.16	1.7	
	Week 4	Teze+Teze	310	308 (99.4)	0.20 (0.36)	-0.7	-0.04	0.13	0.33	1.8	0.25 [0.06, 0.45]
		Pbo+Pbo	149	147 (98.7)	0.10 (0.41)	-1.0	-0.10	0.05	0.28	1.7	
	Week 8	Teze+Teze	310	307 (99.0)	0.22 (0.41)	-1.1	-0.04	0.14	0.44	1.8	0.31 [0.11, 0.51]
		Pbo+Pbo	149	146 (98.0)	0.10 (0.41)	-1.7	-0.12	0.08	0.28	2.0	
	Week 12	Teze+Teze	310	304 (98.1)	0.22 (0.42)	-1.5	-0.04	0.16	0.41	2.0	0.23 [0.03, 0.42]
		Pbo+Pbo	149	148 (99.3)	0.13 (0.41)	-1.2	-0.07	0.06	0.26	1.6	
	Week 16	Teze+Teze	310	305 (98.4)	0.25 (0.41)	-0.8	0.00	0.15	0.40	2.0	0.36 [0.16, 0.56]
		Pbo+Pbo	149	146 (98.0)	0.10 (0.40)	-1.6	-0.09	0.04	0.25	1.6	
	Week 24	Teze+Teze	310	299 (96.5)	0.23 (0.41)	-1.0	-0.06	0.16	0.43	1.8	0.39 [0.19, 0.59]
		Pbo+Pbo	149	145 (97.3)	0.07 (0.40)	-1.4	-0.14	0.03	0.22	1.5	
	Week 36	Teze+Teze	310	291 (93.9)	0.23 (0.42)	-0.8	-0.06	0.12	0.46	1.7	0.33 [0.13, 0.53]
		Pbo+Pbo	149	145 (97.3)	0.10 (0.44)	-1.7	-0.11	0.06	0.27	2.2	
	Week 52	Teze+Teze	310	291 (93.9)	0.24 (0.41)	-0.8	-0.03	0.16	0.47	1.7	0.41 [0.20, 0.61]
		Pbo+Pbo	149	139 (93.3)	0.07 (0.42)	-1.4	-0.17	0.06	0.23	1.9	
	Week 64	Teze+Teze	310	267 (86.1)	0.24 (0.45)	-0.9	-0.05	0.16	0.42	1.9	0.37 [0.16, 0.58]
		Pbo+Pbo	149	132 (88.6)	0.08 (0.38)	-0.8	-0.13	0.06	0.26	1.5	
	Week 76	Teze+Teze	310	255 (82.3)	0.22 (0.44)	-0.9	-0.06	0.14	0.43	1.9	0.20 [-0.02, 0.41]
		Pbo+Pbo	149	124 (83.2)	0.14 (0.42)	-1.1	-0.14	0.06	0.32	2.1	
	Week 88	Teze+Teze	310	244 (78.7)	0.23 (0.43)	-0.8	-0.05	0.17	0.43	1.9	0.21 [-0.01, 0.43]
		Pbo+Pbo	149	119 (79.9)	0.13 (0.44)	-1.1	-0.09	0.07	0.28	2.0	
	Week 104	Teze+Teze	310	261 (84.2)	0.21 (0.42)	-1.3	-0.05	0.16	0.40	1.7	0.29 [0.08, 0.51]
		Pbo+Pbo	149	126 (84.6)	0.09 (0.46)	-1.1	-0.15	0.05	0.22	2.1	

Note: DITTNL - LTE = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G.  
 FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.  
 Source Data: afev, created on: 28JUL2022

Table DT1FAC\_BLMC0: Change from baseline in FEV1 Pre-BD - MMRM results  
 DITTNL - LTE

Change from baseline in FEV1 Pre-BD				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 2	Teze+Teze	310	303 (97.7)	0.18 (0.02)	(0.14, 0.22)	0.12 (0.03)	(0.05, 0.19)	<0.001 *	
	Pbo+Pbo	149	144 (96.6)	0.06 (0.03)	(-0.00, 0.11)				
Week 4	Teze+Teze	310	308 (99.4)	0.20 (0.02)	(0.16, 0.24)	0.09 (0.04)	(0.02, 0.17)	0.012 *	
	Pbo+Pbo	149	147 (98.7)	0.11 (0.03)	(0.05, 0.17)				
Week 8	Teze+Teze	310	307 (99.0)	0.22 (0.02)	(0.18, 0.27)	0.12 (0.04)	(0.04, 0.20)	0.003 *	
	Pbo+Pbo	149	146 (98.0)	0.10 (0.03)	(0.03, 0.16)				
Week 12	Teze+Teze	310	304 (98.1)	0.22 (0.02)	(0.18, 0.27)	0.09 (0.04)	(0.01, 0.17)	0.023 *	
	Pbo+Pbo	149	148 (99.3)	0.13 (0.03)	(0.07, 0.20)				
Week 16	Teze+Teze	310	305 (98.4)	0.24 (0.02)	(0.20, 0.29)	0.14 (0.04)	(0.06, 0.22)	<0.001 *	
	Pbo+Pbo	149	146 (98.0)	0.10 (0.03)	(0.04, 0.17)				
Week 24	Teze+Teze	310	299 (96.5)	0.22 (0.02)	(0.18, 0.27)	0.14 (0.04)	(0.06, 0.22)	<0.001 *	
	Pbo+Pbo	149	145 (97.3)	0.08 (0.03)	(0.02, 0.15)				
Week 36	Teze+Teze	310	291 (93.9)	0.24 (0.02)	(0.19, 0.29)	0.14 (0.04)	(0.06, 0.22)	<0.001 *	
	Pbo+Pbo	149	145 (97.3)	0.10 (0.03)	(0.03, 0.17)				
Week 52	Teze+Teze	310	291 (93.9)	0.25 (0.02)	(0.20, 0.29)	0.16 (0.04)	(0.08, 0.24)	<0.001 *	
	Pbo+Pbo	149	139 (93.3)	0.08 (0.03)	(0.02, 0.15)				
Week 64	Teze+Teze	310	267 (86.1)	0.24 (0.03)	(0.19, 0.29)	0.14 (0.04)	(0.05, 0.23)	0.002 *	
	Pbo+Pbo	149	132 (88.6)	0.10 (0.04)	(0.03, 0.17)				
Week 76	Teze+Teze	310	255 (82.3)	0.22 (0.03)	(0.17, 0.27)	0.09 (0.04)	(0.00, 0.17)	0.045 *	
	Pbo+Pbo	149	124 (83.2)	0.13 (0.04)	(0.06, 0.20)				

Note: DITTNL - LTE = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.  
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.  
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.  
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.  
 FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.  
 Source Data: afev, created on: 28JUL2022

Table DT1FAC\_BLMC0: Change from baseline in FEV1 Pre-BD - MMRM results  
 DITTNL - LTE

Change from baseline in FEV1 Pre-BD				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 88	Teze+Teze	310	244 (78.7)	0.23 (0.03)	(0.18, 0.28)	0.08 (0.04)	(-0.01, 0.17)	0.073
	Pbo+Pbo	149	119 (79.9)	0.15 (0.04)	(0.08, 0.22)			
Week 104	Teze+Teze	310	261 (84.2)	0.21 (0.03)	(0.16, 0.25)	0.09 (0.04)	(0.01, 0.18)	0.037 *
	Pbo+Pbo	149	126 (84.6)	0.11 (0.04)	(0.04, 0.18)			

Note: DITTNL - LTE = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.  
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.  
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.  
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.  
 FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.  
 Source Data: afev, created on: 28JUL2022

Table CT1FAC\_ILMH0: Course of FEV1 Pre-BD  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
FEV1 Pre-BD	Baseline	Tezepelumab	31	31 (100.0)	2.23 (0.67)	1.2	1.62	2.29	2.63	3.5	
		Placebo	34	34 (100.0)	2.30 (0.55)	1.2	1.81	2.29	2.65	3.6	
	Week 12	Tezepelumab	31	31 (100.0)	2.42 (0.72)	1.0	1.76	2.48	2.89	4.0	
		Placebo	34	33 (97.1)	2.49 (0.66)	1.3	1.97	2.52	3.01	4.0	
	Week 28	Tezepelumab	31	29 (93.5)	2.37 (0.73)	1.1	1.96	2.36	2.82	4.2	
		Placebo	34	30 (88.2)	2.52 (0.69)	1.4	2.00	2.51	3.02	4.1	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G.

FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.

Source Data: afev, created on: 15MAR2022

Table CT1FAC\_ILMH0: Course of FEV1 Pre-BD  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in FEV1 Pre-BD	Week 12	Tezepelumab	31	31 (100.0)	0.19 (0.36)	-0.4	-0.06	0.14	0.35	1.3	0.07 [-0.42, 0.56]
	Week 28	Placebo	34	33 (97.1)	0.17 (0.21)	-0.4	0.07	0.16	0.32	0.5	
		Tezepelumab	31	29 (93.5)	0.16 (0.38)	-1.0	-0.08	0.13	0.41	0.9	-0.04 [-0.55, 0.47]
		Placebo	34	30 (88.2)	0.17 (0.34)	-0.7	0.08	0.16	0.25	1.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G.

FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.

Source Data: afev, created on: 15MAR2022

Table CT1FAC\_ILMC0: Change from baseline in FEV1 Pre-BD - MMRM results  
 DITTTL

Change from baseline in FEV1 Pre-BD				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 12	Tezepelumab	31	31 (100.0)	0.19 (0.05)	(0.09, 0.30)	0.02 (0.07)	(-0.13, 0.16)	0.814
	Placebo	34	33 (97.1)	0.18 (0.05)	(0.08, 0.28)			
Week 28	Tezepelumab	31	29 (93.5)	0.16 (0.07)	(0.03, 0.29)	-0.02 (0.09)	(-0.20, 0.17)	0.843
	Placebo	34	30 (88.2)	0.18 (0.06)	(0.05, 0.30)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.

Source Data: afev, created on: 15MAR2022



Table NT1FAC\_KLMH0: Course of FEV1 Pre-BD  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
FEV1 Pre-BD	Baseline	Tezepelumab	15	15 (100.0)	2.59 (0.68)	1.4	2.12	2.69	3.18	3.7	
		Placebo	20	20 (100.0)	2.53 (0.93)	1.0	2.07	2.34	3.00	4.9	
	Week 2	Tezepelumab	15	14 (93.3)	2.80 (0.70)	1.7	2.41	2.67	3.36	4.0	
		Placebo	20	20 (100.0)	2.67 (0.68)	1.3	2.31	2.66	2.98	4.7	
	Week 4	Tezepelumab	15	14 (93.3)	2.68 (0.68)	1.3	2.47	2.64	3.18	3.8	
		Placebo	20	19 (95.0)	2.62 (0.50)	1.4	2.39	2.59	2.86	3.7	
	Week 8	Tezepelumab	15	14 (93.3)	2.58 (0.95)	1.0	2.15	2.65	3.43	3.7	
		Placebo	20	19 (95.0)	2.67 (0.75)	1.4	2.30	2.69	2.99	4.9	
	Week 12	Tezepelumab	15	13 (86.7)	2.58 (0.89)	0.8	2.07	2.64	3.37	3.6	
		Placebo	20	20 (100.0)	2.71 (0.77)	1.4	2.39	2.55	3.02	5.0	
	Week 16	Tezepelumab	15	13 (86.7)	2.68 (0.64)	1.5	2.22	2.50	3.31	3.8	
		Placebo	20	20 (100.0)	2.69 (0.75)	1.5	2.39	2.51	2.98	5.2	
	Week 24	Tezepelumab	15	13 (86.7)	2.65 (0.71)	1.6	2.20	2.88	3.16	3.7	
		Placebo	20	18 (90.0)	2.79 (0.77)	1.5	2.52	2.69	3.11	5.1	
	Week 36	Tezepelumab	15	13 (86.7)	2.88 (0.67)	1.4	2.56	2.93	3.30	4.0	
		Placebo	20	18 (90.0)	2.83 (0.96)	1.4	2.34	2.92	3.33	5.3	
	Week 52	Tezepelumab	15	12 (80.0)	2.94 (0.68)	1.9	2.45	2.94	3.38	4.2	
		Placebo	20	18 (90.0)	2.77 (0.95)	1.2	2.14	2.64	3.22	5.3	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G.

FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.

Source Data: afev, created on: 15MAR2022

Table NT1FAC\_KLMH0: Course of FEV1 Pre-BD  
 DITTLL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in FEV1 Pre-BD	Week 2	Tezepelumab	15	14 (93.3)	0.23 (0.49)	-0.5	-0.04	0.23	0.47	1.4	0.15 [-0.54, 0.83]
		Placebo	20	20 (100.0)	0.15 (0.59)	-1.3	-0.08	0.01	0.25	1.7	
	Week 4	Tezepelumab	15	14 (93.3)	0.13 (0.48)	-0.3	-0.18	-0.11	0.39	1.2	-0.14 [-0.83, 0.55]
		Placebo	20	19 (95.0)	0.21 (0.64)	-1.0	-0.11	0.02	0.40	1.7	
	Week 8	Tezepelumab	15	14 (93.3)	0.03 (0.66)	-1.1	-0.40	0.03	0.42	1.6	-0.13 [-0.82, 0.56]
		Placebo	20	19 (95.0)	0.13 (0.79)	-1.7	-0.22	0.05	0.49	2.0	
	Week 12	Tezepelumab	15	13 (86.7)	-0.00 (0.73)	-1.5	-0.30	-0.09	0.30	1.5	-0.26 [-0.96, 0.44]
		Placebo	20	20 (100.0)	0.18 (0.70)	-1.2	-0.19	0.07	0.40	1.6	
	Week 16	Tezepelumab	15	13 (86.7)	0.19 (0.47)	-0.5	0.00	0.10	0.36	1.4	0.05 [-0.65, 0.74]
		Placebo	20	20 (100.0)	0.16 (0.72)	-1.6	-0.18	0.08	0.35	1.6	
	Week 24	Tezepelumab	15	13 (86.7)	0.15 (0.62)	-0.8	-0.16	0.18	0.27	1.8	-0.01 [-0.72, 0.70]
		Placebo	20	18 (90.0)	0.16 (0.68)	-1.4	-0.06	0.20	0.54	1.5	
	Week 36	Tezepelumab	15	13 (86.7)	0.38 (0.50)	-0.1	-0.01	0.32	0.57	1.7	0.16 [-0.55, 0.88]
		Placebo	20	18 (90.0)	0.26 (0.87)	-1.7	0.03	0.22	0.47	2.2	
	Week 52	Tezepelumab	15	12 (80.0)	0.42 (0.49)	-0.6	0.20	0.47	0.70	1.3	0.31 [-0.42, 1.05]
		Placebo	20	18 (90.0)	0.22 (0.72)	-1.4	-0.02	0.24	0.53	1.9	

Note: DITTLL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G.

FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.

Source Data: afev, created on: 15MAR2022

Table NT1FAC\_KLMC0: Change from baseline in FEV1 Pre-BD - MMRM results  
 DITTL - adolescents

Change from baseline in FEV1 Pre-BD				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 2	Tezepelumab	15	14 (93.3)	0.26 (0.12)	(0.02, 0.50)	0.12 (0.15)	(-0.20, 0.43)	0.446
	Placebo	20	20 (100.0)	0.14 (0.10)	(-0.06, 0.35)			
Week 4	Tezepelumab	15	14 (93.3)	0.16 (0.12)	(-0.09, 0.41)	-0.02 (0.16)	(-0.35, 0.31)	0.895
	Placebo	20	19 (95.0)	0.18 (0.11)	(-0.03, 0.40)			
Week 8	Tezepelumab	15	14 (93.3)	0.08 (0.17)	(-0.27, 0.43)	-0.03 (0.23)	(-0.50, 0.43)	0.880
	Placebo	20	19 (95.0)	0.11 (0.15)	(-0.19, 0.41)			
Week 12	Tezepelumab	15	13 (86.7)	0.08 (0.17)	(-0.27, 0.42)	-0.10 (0.22)	(-0.55, 0.34)	0.636
	Placebo	20	20 (100.0)	0.18 (0.14)	(-0.11, 0.47)			
Week 16	Tezepelumab	15	13 (86.7)	0.23 (0.14)	(-0.05, 0.51)	0.07 (0.18)	(-0.30, 0.44)	0.692
	Placebo	20	20 (100.0)	0.16 (0.12)	(-0.08, 0.40)			
Week 24	Tezepelumab	15	13 (86.7)	0.21 (0.15)	(-0.11, 0.52)	-0.03 (0.20)	(-0.45, 0.38)	0.871
	Placebo	20	18 (90.0)	0.24 (0.13)	(-0.03, 0.51)			
Week 36	Tezepelumab	15	13 (86.7)	0.44 (0.17)	(0.08, 0.79)	0.17 (0.23)	(-0.29, 0.63)	0.464
	Placebo	20	18 (90.0)	0.27 (0.15)	(-0.03, 0.57)			
Week 52	Tezepelumab	15	12 (80.0)	0.41 (0.16)	(0.09, 0.73)	0.20 (0.21)	(-0.22, 0.62)	0.339
	Placebo	20	18 (90.0)	0.21 (0.13)	(-0.06, 0.48)			

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.

Source Data: afev, created on: 15MAR2022

Table DT1FAC\_MLMH0: Course of FEV1 Pre-BD  
 DITTNL - LTE - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
FEV1 Pre-BD	Baseline	Teze+Teze	14	14 (100.0)	2.55 (0.69)	1.4	2.12	2.69	2.98	3.7	
		Pbo+Pbo	12	12 (100.0)	2.58 (0.89)	1.0	2.03	2.86	3.05	4.0	
	Week 2	Teze+Teze	14	13 (92.9)	2.73 (0.67)	1.7	2.41	2.59	3.26	4.0	
		Pbo+Pbo	12	12 (100.0)	2.73 (0.47)	1.7	2.50	2.75	3.01	3.5	
	Week 4	Teze+Teze	14	14 (100.0)	2.68 (0.68)	1.3	2.47	2.64	3.18	3.8	
		Pbo+Pbo	12	12 (100.0)	2.75 (0.39)	2.3	2.54	2.63	2.95	3.7	
	Week 8	Teze+Teze	14	14 (100.0)	2.58 (0.95)	1.0	2.15	2.65	3.43	3.7	
		Pbo+Pbo	12	11 (91.7)	2.61 (0.55)	1.4	2.30	2.69	2.99	3.3	
	Week 12	Teze+Teze	14	13 (92.9)	2.58 (0.89)	0.8	2.07	2.64	3.37	3.6	
		Pbo+Pbo	12	12 (100.0)	2.68 (0.55)	1.7	2.47	2.58	3.02	3.5	
	Week 16	Teze+Teze	14	13 (92.9)	2.68 (0.64)	1.5	2.22	2.50	3.31	3.8	
		Pbo+Pbo	12	12 (100.0)	2.65 (0.46)	1.9	2.43	2.56	2.98	3.5	
	Week 24	Teze+Teze	14	13 (92.9)	2.65 (0.71)	1.6	2.20	2.88	3.16	3.7	
		Pbo+Pbo	12	11 (91.7)	2.68 (0.51)	2.0	2.15	2.66	3.14	3.4	
	Week 36	Teze+Teze	14	13 (92.9)	2.88 (0.67)	1.4	2.56	2.93	3.30	4.0	
		Pbo+Pbo	12	12 (100.0)	2.77 (0.80)	1.4	2.31	2.95	3.42	3.7	
	Week 52	Teze+Teze	14	12 (85.7)	2.94 (0.68)	1.9	2.45	2.94	3.38	4.2	
		Pbo+Pbo	12	11 (91.7)	2.79 (0.81)	1.2	2.27	2.67	3.65	3.8	
	Week 64	Teze+Teze	14	10 (71.4)	3.12 (0.60)	1.8	2.83	3.23	3.60	3.8	
		Pbo+Pbo	12	9 (75.0)	2.91 (0.75)	1.7	2.37	2.96	3.61	3.7	
	Week 76	Teze+Teze	14	9 (64.3)	3.04 (0.65)	1.8	2.91	3.17	3.34	4.0	
		Pbo+Pbo	12	9 (75.0)	3.07 (0.83)	1.8	2.59	3.04	3.72	4.2	
	Week 88	Teze+Teze	14	9 (64.3)	3.09 (0.68)	2.2	2.68	3.22	3.38	4.4	
		Pbo+Pbo	12	10 (83.3)	3.23 (0.66)	2.6	2.71	2.98	3.64	4.6	
	Week 104	Teze+Teze	14	9 (64.3)	2.92 (0.51)	2.2	2.50	3.04	3.25	3.7	
		Pbo+Pbo	12	9 (75.0)	3.25 (0.72)	2.4	2.82	3.19	3.56	4.5	

Note: DITTNL - LTE - adolescents = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G.  
 FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.  
 Source Data: afev, created on: 28JUL2022

Table DT1FAC\_MLMH0: Course of FEV1 Pre-BD  
 DITTNL - LTE - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in FEV1 Pre-BD	Week 2	Teze+Teze	14	13 (92.9)	0.21 (0.51)	-0.5	-0.04	0.19	0.36	1.4	0.09 [-0.69, 0.88]
		Pbo+Pbo	12	12 (100.0)	0.15 (0.74)	-1.3	-0.08	-0.02	0.27	1.7	
	Week 4	Teze+Teze	14	14 (100.0)	0.13 (0.48)	-0.3	-0.18	-0.11	0.39	1.2	-0.06 [-0.84, 0.71]
		Pbo+Pbo	12	12 (100.0)	0.17 (0.72)	-1.0	-0.27	0.08	0.56	1.7	
	Week 8	Teze+Teze	14	14 (100.0)	0.03 (0.66)	-1.1	-0.40	0.03	0.42	1.6	0.05 [-0.74, 0.84]
		Pbo+Pbo	12	11 (91.7)	-0.01 (0.98)	-1.7	-0.45	-0.13	0.09	2.0	
	Week 12	Teze+Teze	14	13 (92.9)	-0.00 (0.73)	-1.5	-0.30	-0.09	0.30	1.5	-0.13 [-0.92, 0.65]
		Pbo+Pbo	12	12 (100.0)	0.10 (0.84)	-1.2	-0.30	0.01	0.40	1.6	
	Week 16	Teze+Teze	14	13 (92.9)	0.19 (0.47)	-0.5	0.00	0.10	0.36	1.4	0.17 [-0.62, 0.95]
		Pbo+Pbo	12	12 (100.0)	0.07 (0.89)	-1.6	-0.34	-0.04	0.36	1.6	
	Week 24	Teze+Teze	14	13 (92.9)	0.15 (0.62)	-0.8	-0.16	0.18	0.27	1.8	0.28 [-0.52, 1.09]
		Pbo+Pbo	12	11 (91.7)	-0.05 (0.78)	-1.4	-0.26	-0.01	0.23	1.5	
	Week 36	Teze+Teze	14	13 (92.9)	0.38 (0.50)	-0.1	-0.01	0.32	0.57	1.7	0.24 [-0.55, 1.03]
		Pbo+Pbo	12	12 (100.0)	0.19 (1.04)	-1.7	-0.13	0.18	0.45	2.2	
	Week 52	Teze+Teze	14	12 (85.7)	0.42 (0.49)	-0.6	0.20	0.47	0.70	1.3	0.31 [-0.51, 1.14]
		Pbo+Pbo	12	11 (91.7)	0.19 (0.92)	-1.4	-0.57	0.25	0.63	1.9	
	Week 64	Teze+Teze	14	10 (71.4)	0.45 (0.62)	-0.2	-0.15	0.34	0.82	1.8	0.16 [-0.74, 1.06]
		Pbo+Pbo	12	9 (75.0)	0.35 (0.66)	-0.7	-0.01	0.53	0.66	1.5	
	Week 76	Teze+Teze	14	9 (64.3)	0.39 (0.67)	-0.7	0.22	0.36	0.54	1.5	-0.23 [-1.16, 0.69]
		Pbo+Pbo	12	9 (75.0)	0.59 (1.02)	-1.1	-0.14	0.58	1.18	2.1	
Week 88	Teze+Teze	14	9 (64.3)	0.36 (0.59)	-0.4	0.06	0.28	0.77	1.4	-0.41 [-1.32, 0.50]	
	Pbo+Pbo	12	10 (83.3)	0.66 (0.84)	-0.2	-0.11	0.52	1.65	2.0		
Week 104	Teze+Teze	14	9 (64.3)	0.26 (0.59)	-0.5	-0.04	0.02	0.73	1.3	-0.41 [-1.34, 0.53]	
	Pbo+Pbo	12	9 (75.0)	0.56 (0.87)	-0.7	0.10	0.41	1.17	2.1		

Note: DITTNL - LTE - adolescents = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G.  
 FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.  
 Source Data: afev, created on: 28JUL2022

Table DT1FAC\_MLMC0: Change from baseline in FEV1 Pre-BD - MMRM results  
 DITTNL - LTE - adolescents

Change from baseline in FEV1 Pre-BD				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 2	Teze+Teze	14	13 (92.9)	NE		NE		
	Pbo+Pbo	12	12 (100.0)					
Week 4	Teze+Teze	14	14 (100.0)	NE		NE		
	Pbo+Pbo	12	12 (100.0)					
Week 8	Teze+Teze	14	14 (100.0)	NE		NE		
	Pbo+Pbo	12	11 (91.7)					
Week 12	Teze+Teze	14	13 (92.9)	NE		NE		
	Pbo+Pbo	12	12 (100.0)					
Week 16	Teze+Teze	14	13 (92.9)	NE		NE		
	Pbo+Pbo	12	12 (100.0)					
Week 24	Teze+Teze	14	13 (92.9)	NE		NE		
	Pbo+Pbo	12	11 (91.7)					
Week 36	Teze+Teze	14	13 (92.9)	NE		NE		
	Pbo+Pbo	12	12 (100.0)					
Week 52	Teze+Teze	14	12 (85.7)	NE		NE		
	Pbo+Pbo	12	11 (91.7)					
Week 64	Teze+Teze	14	10 (71.4)	NE		NE		
	Pbo+Pbo	12	9 (75.0)					
Week 76	Teze+Teze	14	9 (64.3)	NE		NE		
	Pbo+Pbo	12	9 (75.0)					

Note: DITTNL - LTE - adolescents = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adolescents.  
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.  
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.  
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.  
 FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.  
 Source Data: afev, created on: 28JUL2022

Table DT1FAC\_MLMC0: Change from baseline in FEV1 Pre-BD - MMRM results  
 DITTNL - LTE - adolescents

Change from baseline in FEV1 Pre-BD				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 88	Teze+Teze	14	9 (64.3)	NE		NE		
	Pbo+Pbo	12	10 (83.3)					
Week 104	Teze+Teze	14	9 (64.3)	NE		NE		
	Pbo+Pbo	12	9 (75.0)					

Note: DITTNL - LTE - adolescents = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adolescents.  
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.  
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.  
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.  
 FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.  
 Source Data: afev, created on: 28JUL2022

Table NT1FAC\_ALMH0: Course of FEV1 Pre-BD  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
FEV1 Pre-BD	Baseline	Tezepelumab	380	380 (100.0)	1.74 (0.67)	0.4	1.26	1.62	2.12	4.1	
		Placebo	371	371 (100.0)	1.80 (0.68)	0.4	1.33	1.69	2.18	4.5	
	Week 2	Tezepelumab	380	370 (97.4)	1.92 (0.70)	0.6	1.39	1.80	2.39	4.3	
		Placebo	371	353 (95.1)	1.86 (0.70)	0.4	1.38	1.75	2.28	4.1	
	Week 4	Tezepelumab	380	377 (99.2)	1.94 (0.72)	0.6	1.41	1.84	2.42	4.3	
		Placebo	371	363 (97.8)	1.86 (0.68)	0.4	1.40	1.79	2.22	4.8	
	Week 8	Tezepelumab	380	374 (98.4)	1.96 (0.72)	0.6	1.41	1.85	2.41	4.7	
		Placebo	371	361 (97.3)	1.89 (0.72)	0.4	1.39	1.79	2.27	4.6	
	Week 12	Tezepelumab	380	369 (97.1)	1.97 (0.72)	0.6	1.48	1.87	2.41	4.7	
		Placebo	371	357 (96.2)	1.89 (0.72)	0.5	1.38	1.76	2.29	4.6	
	Week 16	Tezepelumab	380	367 (96.6)	1.99 (0.74)	0.6	1.45	1.87	2.42	4.9	
		Placebo	371	350 (94.3)	1.88 (0.72)	0.5	1.35	1.77	2.23	4.7	
	Week 24	Tezepelumab	380	355 (93.4)	1.96 (0.71)	0.6	1.47	1.82	2.40	4.4	
		Placebo	371	338 (91.1)	1.88 (0.71)	0.6	1.40	1.77	2.22	4.8	
	Week 36	Tezepelumab	380	343 (90.3)	1.96 (0.74)	0.5	1.42	1.86	2.39	4.5	
		Placebo	371	328 (88.4)	1.91 (0.72)	0.6	1.41	1.80	2.28	4.6	
	Week 52	Tezepelumab	380	337 (88.7)	1.97 (0.74)	0.6	1.44	1.84	2.40	4.3	
		Placebo	371	308 (83.0)	1.87 (0.74)	0.6	1.32	1.73	2.29	4.5	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G.

FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.

Source Data: afev, created on: 15MAR2022



Table NT1FAC\_ALMH0: Course of FEV1 Pre-BD  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in FEV1 Pre-BD	Week 2	Tezepelumab	380	370 (97.4)	0.18 (0.33)	-0.7	0.00	0.13	0.31	1.5	0.39 [0.25, 0.54]
		Placebo	371	353 (95.1)	0.05 (0.35)	-1.8	-0.12	0.01	0.18	1.2	
	Week 4	Tezepelumab	380	377 (99.2)	0.21 (0.36)	-0.9	0.00	0.14	0.34	1.8	0.37 [0.22, 0.51]
		Placebo	371	363 (97.8)	0.07 (0.38)	-1.8	-0.11	0.04	0.24	1.6	
	Week 8	Tezepelumab	380	374 (98.4)	0.24 (0.40)	-0.8	-0.04	0.16	0.44	1.8	0.42 [0.27, 0.56]
		Placebo	371	361 (97.3)	0.08 (0.34)	-0.9	-0.11	0.05	0.25	1.6	
	Week 12	Tezepelumab	380	369 (97.1)	0.24 (0.40)	-0.8	-0.01	0.18	0.43	2.0	0.39 [0.25, 0.54]
		Placebo	371	357 (96.2)	0.09 (0.38)	-1.5	-0.10	0.05	0.26	1.7	
	Week 16	Tezepelumab	380	367 (96.6)	0.26 (0.41)	-0.8	0.00	0.17	0.42	2.0	0.47 [0.32, 0.62]
		Placebo	371	350 (94.3)	0.08 (0.36)	-1.2	-0.11	0.02	0.24	1.8	
	Week 24	Tezepelumab	380	355 (93.4)	0.24 (0.41)	-1.0	-0.04	0.18	0.43	1.7	0.43 [0.27, 0.58]
		Placebo	371	338 (91.1)	0.07 (0.38)	-1.1	-0.13	0.03	0.25	1.7	
	Week 36	Tezepelumab	380	343 (90.3)	0.23 (0.41)	-1.0	-0.04	0.16	0.46	1.7	0.36 [0.21, 0.52]
		Placebo	371	328 (88.4)	0.09 (0.38)	-1.1	-0.16	0.04	0.29	1.7	
	Week 52	Tezepelumab	380	337 (88.7)	0.24 (0.41)	-1.0	-0.02	0.17	0.47	1.7	0.46 [0.30, 0.62]
		Placebo	371	308 (83.0)	0.06 (0.34)	-1.0	-0.15	0.05	0.23	1.2	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G.

FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.

Source Data: afev, created on: 15MAR2022

Table NT1FAC\_ALMC0: Change from baseline in FEV1 Pre-BD - MMRM results  
DITTL - adult

Change from baseline in FEV1 Pre-BD				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 2	Tezepelumab	380	370 (97.4)	0.18 (0.02)	(0.14, 0.21)	0.13 (0.02)	(0.08, 0.18)	<0.001 *
	Placebo	371	353 (95.1)	0.05 (0.02)	(0.01, 0.08)			
Week 4	Tezepelumab	380	377 (99.2)	0.20 (0.02)	(0.17, 0.24)	0.13 (0.03)	(0.08, 0.18)	<0.001 *
	Placebo	371	363 (97.8)	0.08 (0.02)	(0.04, 0.11)			
Week 8	Tezepelumab	380	374 (98.4)	0.24 (0.02)	(0.20, 0.27)	0.15 (0.03)	(0.10, 0.20)	<0.001 *
	Placebo	371	361 (97.3)	0.09 (0.02)	(0.05, 0.13)			
Week 12	Tezepelumab	380	369 (97.1)	0.24 (0.02)	(0.20, 0.28)	0.15 (0.03)	(0.09, 0.20)	<0.001 *
	Placebo	371	357 (96.2)	0.09 (0.02)	(0.05, 0.13)			
Week 16	Tezepelumab	380	367 (96.6)	0.25 (0.02)	(0.21, 0.29)	0.17 (0.03)	(0.12, 0.23)	<0.001 *
	Placebo	371	350 (94.3)	0.08 (0.02)	(0.04, 0.12)			
Week 24	Tezepelumab	380	355 (93.4)	0.23 (0.02)	(0.19, 0.27)	0.15 (0.03)	(0.10, 0.21)	<0.001 *
	Placebo	371	338 (91.1)	0.07 (0.02)	(0.03, 0.11)			
Week 36	Tezepelumab	380	343 (90.3)	0.24 (0.02)	(0.20, 0.28)	0.14 (0.03)	(0.08, 0.20)	<0.001 *
	Placebo	371	328 (88.4)	0.09 (0.02)	(0.05, 0.13)			
Week 52	Tezepelumab	380	337 (88.7)	0.24 (0.02)	(0.20, 0.28)	0.17 (0.03)	(0.11, 0.23)	<0.001 *
	Placebo	371	308 (83.0)	0.07 (0.02)	(0.03, 0.11)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.

Source Data: afev, created on: 15MAR2022

Table DT1FAC\_HLMH0: Course of FEV1 Pre-BD  
 DITTNL - LTE - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
FEV1 Pre-BD	Baseline	Teze+Teze	296	296 (100.0)	1.72 (0.64)	0.5	1.28	1.62	2.05	4.0	
		Pbo+Pbo	137	137 (100.0)	1.73 (0.63)	0.7	1.31	1.64	2.10	4.2	
	Week 2	Teze+Teze	296	290 (98.0)	1.90 (0.67)	0.6	1.40	1.79	2.33	4.1	
		Pbo+Pbo	137	132 (96.4)	1.77 (0.66)	0.7	1.36	1.65	2.16	4.0	
	Week 4	Teze+Teze	296	294 (99.3)	1.92 (0.71)	0.6	1.41	1.82	2.38	4.3	
		Pbo+Pbo	137	135 (98.5)	1.83 (0.62)	0.7	1.38	1.74	2.18	4.2	
	Week 8	Teze+Teze	296	293 (99.0)	1.94 (0.71)	0.6	1.40	1.82	2.38	4.7	
		Pbo+Pbo	137	135 (98.5)	1.84 (0.67)	0.7	1.38	1.76	2.20	4.3	
	Week 12	Teze+Teze	296	291 (98.3)	1.95 (0.72)	0.6	1.48	1.83	2.35	4.7	
		Pbo+Pbo	137	136 (99.3)	1.86 (0.66)	0.7	1.39	1.73	2.24	4.3	
	Week 16	Teze+Teze	296	292 (98.6)	1.97 (0.72)	0.6	1.46	1.84	2.38	4.9	
		Pbo+Pbo	137	134 (97.8)	1.82 (0.66)	0.8	1.33	1.73	2.16	4.1	
	Week 24	Teze+Teze	296	286 (96.6)	1.94 (0.70)	0.6	1.44	1.81	2.38	4.4	
		Pbo+Pbo	137	134 (97.8)	1.81 (0.67)	0.6	1.36	1.72	2.18	4.8	
	Week 36	Teze+Teze	296	278 (93.9)	1.94 (0.73)	0.5	1.42	1.85	2.37	4.5	
		Pbo+Pbo	137	133 (97.1)	1.82 (0.68)	0.8	1.41	1.69	2.23	4.6	
	Week 52	Teze+Teze	296	279 (94.3)	1.95 (0.73)	0.6	1.43	1.83	2.39	4.3	
		Pbo+Pbo	137	128 (93.4)	1.79 (0.71)	0.7	1.26	1.63	2.24	4.4	
	Week 64	Teze+Teze	296	257 (86.8)	1.96 (0.75)	0.6	1.42	1.81	2.41	4.4	
		Pbo+Pbo	137	123 (89.8)	1.79 (0.68)	0.8	1.32	1.67	2.19	4.2	
	Week 76	Teze+Teze	296	246 (83.1)	1.94 (0.72)	0.5	1.41	1.86	2.39	4.3	
		Pbo+Pbo	137	115 (83.9)	1.82 (0.69)	0.5	1.34	1.67	2.23	4.4	
	Week 88	Teze+Teze	296	235 (79.4)	1.91 (0.69)	0.6	1.44	1.82	2.41	4.0	
		Pbo+Pbo	137	109 (79.6)	1.80 (0.64)	0.6	1.37	1.72	2.14	3.6	
	Week 104	Teze+Teze	296	252 (85.1)	1.94 (0.72)	0.5	1.40	1.81	2.43	4.1	
		Pbo+Pbo	137	117 (85.4)	1.76 (0.62)	0.7	1.32	1.64	2.16	3.4	

Note: DITTNL - LTE - adult = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G.  
 FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.  
 Source Data: afev, created on: 28JUL2022

Table DT1FAC\_HLMH0: Course of FEV1 Pre-BD  
 DITTNL - LTE - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in FEV1 Pre-BD	Week 2	Teze+Teze	296	290 (98.0)	0.18 (0.32)	-0.7	-0.01	0.13	0.32	1.5	0.40 [0.19, 0.61]
		Pbo+Pbo	137	132 (96.4)	0.04 (0.36)	-1.8	-0.11	0.00	0.16	1.1	
	Week 4	Teze+Teze	296	294 (99.3)	0.20 (0.36)	-0.7	-0.03	0.13	0.33	1.8	0.29 [0.09, 0.50]
		Pbo+Pbo	137	135 (98.5)	0.10 (0.37)	-1.0	-0.09	0.05	0.26	1.2	
	Week 8	Teze+Teze	296	293 (99.0)	0.23 (0.40)	-0.8	-0.04	0.14	0.44	1.8	0.34 [0.13, 0.54]
		Pbo+Pbo	137	135 (98.5)	0.10 (0.33)	-0.8	-0.10	0.08	0.29	1.2	
	Week 12	Teze+Teze	296	291 (98.3)	0.23 (0.40)	-0.8	-0.03	0.17	0.41	2.0	0.26 [0.06, 0.47]
		Pbo+Pbo	137	136 (99.3)	0.13 (0.35)	-1.2	-0.06	0.07	0.25	1.3	
	Week 16	Teze+Teze	296	292 (98.6)	0.25 (0.41)	-0.8	0.00	0.15	0.40	2.0	0.38 [0.17, 0.58]
		Pbo+Pbo	137	134 (97.8)	0.10 (0.33)	-0.8	-0.07	0.05	0.25	1.5	
	Week 24	Teze+Teze	296	286 (96.6)	0.23 (0.40)	-1.0	-0.05	0.16	0.43	1.7	0.40 [0.19, 0.60]
		Pbo+Pbo	137	134 (97.8)	0.08 (0.36)	-0.9	-0.13	0.04	0.22	1.4	
	Week 36	Teze+Teze	296	278 (93.9)	0.23 (0.41)	-0.8	-0.06	0.12	0.46	1.7	0.36 [0.15, 0.57]
		Pbo+Pbo	137	133 (97.1)	0.09 (0.34)	-0.9	-0.11	0.04	0.27	1.3	
	Week 52	Teze+Teze	296	279 (94.3)	0.23 (0.41)	-0.8	-0.03	0.15	0.44	1.7	0.44 [0.23, 0.65]
		Pbo+Pbo	137	128 (93.4)	0.06 (0.35)	-0.9	-0.17	0.05	0.22	1.2	
	Week 64	Teze+Teze	296	257 (86.8)	0.23 (0.44)	-0.9	-0.05	0.16	0.40	1.9	0.41 [0.20, 0.63]
		Pbo+Pbo	137	123 (89.8)	0.06 (0.34)	-0.8	-0.13	0.06	0.22	1.4	
	Week 76	Teze+Teze	296	246 (83.1)	0.22 (0.43)	-0.9	-0.06	0.13	0.42	1.9	0.29 [0.07, 0.51]
		Pbo+Pbo	137	115 (83.9)	0.10 (0.32)	-0.7	-0.13	0.06	0.27	1.1	
	Week 88	Teze+Teze	296	235 (79.4)	0.22 (0.42)	-0.8	-0.05	0.16	0.42	1.9	0.34 [0.11, 0.57]
		Pbo+Pbo	137	109 (79.6)	0.09 (0.35)	-1.1	-0.08	0.06	0.24	1.0	
	Week 104	Teze+Teze	296	252 (85.1)	0.21 (0.41)	-1.3	-0.05	0.17	0.40	1.7	0.40 [0.18, 0.62]
		Pbo+Pbo	137	117 (85.4)	0.05 (0.40)	-1.1	-0.17	0.05	0.20	1.3	

Note: DITTNL - LTE - adult = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G.  
 FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.  
 Source Data: afev, created on: 28JUL2022

Table DT1FAC\_HLMC0: Change from baseline in FEV1 Pre-BD - MMRM results  
 DITTNL - LTE - adult

Change from baseline in FEV1 Pre-BD				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 2	Teze+Teze	296	290 (98.0)	0.18 (0.02)	(0.14, 0.21)	0.13 (0.03)	(0.06, 0.20)	<0.001 *
	Pbo+Pbo	137	132 (96.4)	0.04 (0.03)	(-0.01, 0.10)			
Week 4	Teze+Teze	296	294 (99.3)	0.20 (0.02)	(0.16, 0.24)	0.11 (0.04)	(0.03, 0.18)	0.004 *
	Pbo+Pbo	137	135 (98.5)	0.10 (0.03)	(0.04, 0.16)			
Week 8	Teze+Teze	296	293 (99.0)	0.23 (0.02)	(0.19, 0.27)	0.13 (0.04)	(0.05, 0.20)	0.001 *
	Pbo+Pbo	137	135 (98.5)	0.11 (0.03)	(0.04, 0.17)			
Week 12	Teze+Teze	296	291 (98.3)	0.24 (0.02)	(0.19, 0.28)	0.10 (0.04)	(0.03, 0.18)	0.009 *
	Pbo+Pbo	137	136 (99.3)	0.13 (0.03)	(0.07, 0.20)			
Week 16	Teze+Teze	296	292 (98.6)	0.25 (0.02)	(0.20, 0.29)	0.14 (0.04)	(0.07, 0.22)	<0.001 *
	Pbo+Pbo	137	134 (97.8)	0.10 (0.03)	(0.04, 0.17)			
Week 24	Teze+Teze	296	286 (96.6)	0.23 (0.02)	(0.18, 0.27)	0.15 (0.04)	(0.07, 0.23)	<0.001 *
	Pbo+Pbo	137	134 (97.8)	0.08 (0.03)	(0.01, 0.14)			
Week 36	Teze+Teze	296	278 (93.9)	0.23 (0.02)	(0.19, 0.28)	0.15 (0.04)	(0.07, 0.23)	<0.001 *
	Pbo+Pbo	137	133 (97.1)	0.09 (0.03)	(0.02, 0.15)			
Week 52	Teze+Teze	296	279 (94.3)	0.24 (0.02)	(0.19, 0.29)	0.17 (0.04)	(0.09, 0.25)	<0.001 *
	Pbo+Pbo	137	128 (93.4)	0.07 (0.03)	(0.00, 0.14)			
Week 64	Teze+Teze	296	257 (86.8)	0.23 (0.02)	(0.18, 0.28)	0.16 (0.04)	(0.07, 0.24)	<0.001 *
	Pbo+Pbo	137	123 (89.8)	0.08 (0.04)	(0.00, 0.15)			
Week 76	Teze+Teze	296	246 (83.1)	0.22 (0.02)	(0.17, 0.26)	0.11 (0.04)	(0.03, 0.19)	0.008 *
	Pbo+Pbo	137	115 (83.9)	0.10 (0.03)	(0.04, 0.17)			

Note: DITTNL - LTE - adult = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.  
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.  
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.  
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.  
 FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.  
 Source Data: afev, created on: 28JUL2022

Table DT1FAC\_HLMC0: Change from baseline in FEV1 Pre-BD - MMRM results  
 DITTNL - LTE - adult

Change from baseline in FEV1 Pre-BD				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 88	Teze+Teze	296	235 (79.4)	0.22 (0.02)	(0.17, 0.27)	0.12 (0.04)	(0.03, 0.20)	0.007 *
	Pbo+Pbo	137	109 (79.6)	0.10 (0.04)	(0.04, 0.17)			
Week 104	Teze+Teze	296	252 (85.1)	0.20 (0.02)	(0.16, 0.25)	0.13 (0.04)	(0.05, 0.22)	0.002 *
	Pbo+Pbo	137	117 (85.4)	0.07 (0.04)	(-0.00, 0.14)			

Note: DITTNL - LTE - adult = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.  
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.  
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.  
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.  
 FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.  
 Source Data: afev, created on: 28JUL2022

Table MT1H5C\_ILMH0: Course of ACQ-5 score  
 DITTTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-5 score	Baseline	Tezepelumab	446	446 (100.0)	3.06 (0.90)	0.0	2.40	3.00	3.60	5.8	
		Placebo	436	436 (100.0)	2.98 (0.84)	0.4	2.40	3.00	3.40	5.8	
	Week 2	Tezepelumab	446	426 (95.5)	2.22 (1.04)	0.0	1.60	2.20	2.80	5.8	
		Placebo	436	402 (92.2)	2.38 (1.08)	0.0	1.60	2.40	3.00	5.8	
	Week 4	Tezepelumab	446	435 (97.5)	2.00 (1.04)	0.0	1.20	2.00	2.80	5.6	
		Placebo	436	418 (95.9)	2.15 (1.05)	0.0	1.40	2.20	2.80	5.6	
	Week 8	Tezepelumab	446	435 (97.5)	1.75 (1.10)	0.0	1.00	1.60	2.60	5.4	
		Placebo	436	419 (96.1)	2.02 (1.12)	0.0	1.20	2.00	2.80	5.8	
	Week 12	Tezepelumab	446	428 (96.0)	1.69 (1.19)	0.0	0.80	1.60	2.40	6.0	
		Placebo	436	414 (95.0)	1.89 (1.14)	0.0	1.00	1.80	2.60	5.8	
	Week 16	Tezepelumab	446	430 (96.4)	1.58 (1.12)	0.0	0.80	1.40	2.40	5.8	
		Placebo	436	410 (94.0)	1.87 (1.20)	0.0	1.00	1.80	2.60	5.8	
	Week 20	Tezepelumab	446	421 (94.4)	1.54 (1.15)	0.0	0.60	1.40	2.20	5.8	
		Placebo	436	403 (92.4)	1.79 (1.16)	0.0	1.00	1.80	2.60	5.6	
	Week 24	Tezepelumab	446	421 (94.4)	1.54 (1.12)	0.0	0.60	1.40	2.40	5.4	
		Placebo	436	398 (91.3)	1.82 (1.14)	0.0	1.00	1.80	2.60	5.8	
	Week 28	Tezepelumab	446	420 (94.2)	1.52 (1.15)	0.0	0.60	1.40	2.40	5.2	
		Placebo	436	398 (91.3)	1.79 (1.23)	0.0	0.80	1.60	2.60	5.6	
	Week 32	Tezepelumab	446	418 (93.7)	1.54 (1.17)	0.0	0.60	1.40	2.40	5.0	
		Placebo	436	397 (91.1)	1.81 (1.15)	0.0	1.00	1.80	2.60	5.4	
	Week 36	Tezepelumab	446	425 (95.3)	1.52 (1.16)	0.0	0.60	1.40	2.20	5.0	
		Placebo	436	394 (90.4)	1.79 (1.17)	0.0	0.80	1.80	2.60	5.6	
	Week 40	Tezepelumab	446	420 (94.2)	1.52 (1.16)	0.0	0.50	1.40	2.40	4.8	
		Placebo	436	393 (90.1)	1.79 (1.21)	0.0	0.80	1.80	2.60	5.4	
	Week 44	Tezepelumab	446	417 (93.5)	1.47 (1.15)	0.0	0.60	1.20	2.20	5.0	
		Placebo	436	389 (89.2)	1.76 (1.19)	0.0	0.80	1.60	2.60	5.2	
	Week 48	Tezepelumab	446	418 (93.7)	1.48 (1.20)	0.0	0.60	1.20	2.20	5.4	
		Placebo	436	387 (88.8)	1.74 (1.17)	0.0	0.80	1.80	2.40	5.6	
	Week 52	Tezepelumab	446	412 (92.4)	1.43 (1.15)	0.0	0.50	1.20	2.20	5.2	
		Placebo	436	384 (88.1)	1.71 (1.19)	0.0	0.80	1.60	2.60	5.4	

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Last observation carried forward is applied in case of missing values.

Source Data: aacq, created on: 21FEB2022

Table MT1H5C\_ILMH0: Course of ACQ-5 score  
 DITTTL

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-5 Week 2 score	Tezepelumab	446	426 (95.5)	-0.84 (0.98)	-5.0	-1.40	-0.80	-0.20	1.6	-0.24 [-0.37, -0.10]
	Placebo	436	402 (92.2)	-0.62 (0.94)	-4.2	-1.00	-0.60	0.00	3.4	
Week 4	Tezepelumab	446	435 (97.5)	-1.06 (1.05)	-5.6	-1.60	-1.00	-0.40	2.6	-0.23 [-0.36, -0.09]
	Placebo	436	418 (95.9)	-0.83 (0.97)	-4.2	-1.40	-0.80	-0.20	2.4	
Week 8	Tezepelumab	446	435 (97.5)	-1.32 (1.19)	-5.6	-2.20	-1.20	-0.40	2.6	-0.31 [-0.45, -0.18]
	Placebo	436	419 (96.1)	-0.97 (1.08)	-4.6	-1.60	-1.00	-0.20	2.8	
Week 12	Tezepelumab	446	428 (96.0)	-1.36 (1.22)	-5.6	-2.20	-1.20	-0.60	2.6	-0.22 [-0.35, -0.08]
	Placebo	436	414 (95.0)	-1.11 (1.11)	-5.2	-1.80	-1.00	-0.40	2.4	
Week 16	Tezepelumab	446	430 (96.4)	-1.47 (1.17)	-5.4	-2.20	-1.40	-0.80	2.6	-0.32 [-0.45, -0.18]
	Placebo	436	410 (94.0)	-1.11 (1.14)	-5.2	-1.80	-1.00	-0.40	2.6	
Week 20	Tezepelumab	446	421 (94.4)	-1.49 (1.22)	-5.4	-2.40	-1.40	-0.60	3.8	-0.27 [-0.40, -0.13]
	Placebo	436	403 (92.4)	-1.18 (1.15)	-5.6	-1.80	-1.20	-0.40	2.6	
Week 24	Tezepelumab	446	421 (94.4)	-1.50 (1.21)	-5.4	-2.20	-1.40	-0.60	2.8	-0.30 [-0.44, -0.16]
	Placebo	436	398 (91.3)	-1.15 (1.12)	-5.2	-1.80	-1.20	-0.40	2.6	
Week 28	Tezepelumab	446	420 (94.2)	-1.51 (1.21)	-5.6	-2.40	-1.40	-0.80	2.6	-0.29 [-0.42, -0.15]
	Placebo	436	398 (91.3)	-1.17 (1.20)	-5.4	-2.00	-1.20	-0.40	2.6	
Week 32	Tezepelumab	446	418 (93.7)	-1.49 (1.26)	-5.6	-2.20	-1.40	-0.60	3.0	-0.27 [-0.41, -0.14]
	Placebo	436	397 (91.1)	-1.16 (1.16)	-4.2	-2.00	-1.00	-0.40	2.6	
Week 36	Tezepelumab	446	425 (95.3)	-1.52 (1.27)	-5.6	-2.40	-1.40	-0.80	2.8	-0.29 [-0.42, -0.15]
	Placebo	436	394 (90.4)	-1.17 (1.19)	-5.6	-2.00	-1.20	-0.20	2.6	
Week 40	Tezepelumab	446	420 (94.2)	-1.53 (1.27)	-5.6	-2.40	-1.60	-0.60	3.0	-0.30 [-0.43, -0.16]
	Placebo	436	393 (90.1)	-1.16 (1.20)	-5.2	-2.00	-1.00	-0.40	2.6	
Week 44	Tezepelumab	446	417 (93.5)	-1.57 (1.24)	-5.6	-2.40	-1.60	-0.80	2.6	-0.31 [-0.45, -0.17]
	Placebo	436	389 (89.2)	-1.20 (1.21)	-5.4	-2.00	-1.20	-0.40	2.6	
Week 48	Tezepelumab	446	418 (93.7)	-1.56 (1.29)	-5.6	-2.40	-1.60	-0.80	2.6	-0.27 [-0.41, -0.13]
	Placebo	436	387 (88.8)	-1.23 (1.17)	-5.8	-2.00	-1.20	-0.40	2.6	
Week 52	Tezepelumab	446	412 (92.4)	-1.60 (1.28)	-5.6	-2.40	-1.60	-0.80	3.6	-0.28 [-0.42, -0.14]
	Placebo	436	384 (88.1)	-1.26 (1.21)	-4.4	-2.00	-1.20	-0.40	2.6	

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Last observation carried forward is applied in case of missing values.

Source Data: aacq, created on: 21FEB2022



Table MT1H5C\_ILMC0: Change from baseline in ACQ-5 score - MMRM results  
DITTL

Change from baseline in ACQ-5 score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 2	Tezepelumab	446	426 (95.5)	-0.82 (0.04)	(-0.91, -0.74)	-0.21 (0.06)	(-0.34, -0.09)	<0.001 *	
	Placebo	436	402 (92.2)	-0.61 (0.04)	(-0.70, -0.52)				
Week 4	Tezepelumab	446	432 (96.9)	-1.04 (0.04)	(-1.13, -0.95)	-0.19 (0.06)	(-0.31, -0.06)	0.003 *	
	Placebo	436	417 (95.6)	-0.85 (0.05)	(-0.94, -0.77)				
Week 8	Tezepelumab	446	432 (96.9)	-1.29 (0.05)	(-1.39, -1.20)	-0.33 (0.07)	(-0.46, -0.19)	<0.001 *	
	Placebo	436	418 (95.9)	-0.97 (0.05)	(-1.07, -0.87)				
Week 12	Tezepelumab	446	424 (95.1)	-1.34 (0.05)	(-1.45, -1.24)	-0.24 (0.07)	(-0.39, -0.10)	0.001 *	
	Placebo	436	410 (94.0)	-1.10 (0.05)	(-1.21, -1.00)				
Week 16	Tezepelumab	446	424 (95.1)	-1.44 (0.05)	(-1.54, -1.34)	-0.33 (0.07)	(-0.47, -0.19)	<0.001 *	
	Placebo	436	404 (92.7)	-1.11 (0.05)	(-1.22, -1.01)				
Week 20	Tezepelumab	446	412 (92.4)	-1.48 (0.05)	(-1.59, -1.38)	-0.32 (0.07)	(-0.46, -0.17)	<0.001 *	
	Placebo	436	393 (90.1)	-1.17 (0.05)	(-1.27, -1.06)				
Week 24	Tezepelumab	446	412 (92.4)	-1.49 (0.05)	(-1.59, -1.39)	-0.34 (0.07)	(-0.48, -0.19)	<0.001 *	
	Placebo	436	387 (88.8)	-1.15 (0.05)	(-1.26, -1.05)				
Week 28	Tezepelumab	446	409 (91.7)	-1.50 (0.05)	(-1.60, -1.39)	-0.33 (0.08)	(-0.48, -0.18)	<0.001 *	
	Placebo	436	386 (88.5)	-1.17 (0.05)	(-1.28, -1.06)				
Week 32	Tezepelumab	446	409 (91.7)	-1.48 (0.05)	(-1.59, -1.38)	-0.34 (0.08)	(-0.49, -0.19)	<0.001 *	
	Placebo	436	385 (88.3)	-1.15 (0.05)	(-1.25, -1.04)				
Week 36	Tezepelumab	446	416 (93.3)	-1.50 (0.05)	(-1.61, -1.39)	-0.33 (0.08)	(-0.49, -0.18)	<0.001 *	
	Placebo	436	382 (87.6)	-1.17 (0.06)	(-1.28, -1.06)				

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 21FEB2022

Table MT1H5C\_ILMC0: Change from baseline in ACQ-5 score - MMRM results  
 DITTTL

Change from baseline in ACQ-5 score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 40	Tezepelumab	446	408 (91.5)	-1.51 (0.05)	(-1.62, -1.40)	-0.35 (0.08)	(-0.50, -0.19)	<0.001 *	
	Placebo	436	383 (87.8)	-1.16 (0.06)	(-1.27, -1.05)				
Week 44	Tezepelumab	446	405 (90.8)	-1.56 (0.05)	(-1.66, -1.45)	-0.36 (0.08)	(-0.51, -0.20)	<0.001 *	
	Placebo	436	377 (86.5)	-1.20 (0.06)	(-1.31, -1.09)				
Week 48	Tezepelumab	446	405 (90.8)	-1.55 (0.06)	(-1.66, -1.45)	-0.36 (0.08)	(-0.52, -0.21)	<0.001 *	
	Placebo	436	375 (86.0)	-1.19 (0.06)	(-1.30, -1.08)				
Week 52	Tezepelumab	446	364 (81.6)	-1.60 (0.06)	(-1.71, -1.48)	-0.36 (0.08)	(-0.51, -0.20)	<0.001 *	
	Placebo	436	344 (78.9)	-1.24 (0.06)	(-1.35, -1.13)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 21FEB2022

Table NT1H5C\_ILMH0: Course of ACQ-5 score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-5 score	Baseline	Tezepelumab	395	395 (100.0)	3.09 (0.89)	1.4	2.40	3.00	3.60	5.8	
		Placebo	391	391 (100.0)	3.01 (0.85)	1.6	2.40	2.80	3.40	5.8	
Week 2		Tezepelumab	395	376 (95.2)	2.19 (1.05)	0.0	1.40	2.20	2.80	5.8	
		Placebo	391	363 (92.8)	2.35 (1.11)	0.0	1.60	2.40	3.00	5.8	
Week 4		Tezepelumab	395	386 (97.7)	1.97 (1.04)	0.0	1.20	2.00	2.60	5.6	
		Placebo	391	378 (96.7)	2.11 (1.08)	0.0	1.40	2.00	2.80	5.6	
Week 8		Tezepelumab	395	385 (97.5)	1.73 (1.08)	0.0	1.00	1.60	2.40	5.4	
		Placebo	391	377 (96.4)	2.00 (1.12)	0.0	1.20	2.00	2.60	5.8	
Week 12		Tezepelumab	395	378 (95.7)	1.69 (1.19)	0.0	0.80	1.40	2.40	6.0	
		Placebo	391	375 (95.9)	1.86 (1.17)	0.0	1.00	1.80	2.60	5.8	
Week 16		Tezepelumab	395	381 (96.5)	1.55 (1.10)	0.0	0.80	1.40	2.20	5.8	
		Placebo	391	370 (94.6)	1.83 (1.20)	0.0	1.00	1.80	2.40	5.8	
Week 20		Tezepelumab	395	371 (93.9)	1.51 (1.15)	0.0	0.60	1.40	2.20	5.8	
		Placebo	391	363 (92.8)	1.74 (1.18)	0.0	0.80	1.60	2.60	5.6	
Week 24		Tezepelumab	395	370 (93.7)	1.49 (1.10)	0.0	0.60	1.40	2.20	5.4	
		Placebo	391	356 (91.0)	1.78 (1.16)	0.0	0.80	1.60	2.60	5.8	
Week 28		Tezepelumab	395	368 (93.2)	1.46 (1.14)	0.0	0.60	1.20	2.20	5.2	
		Placebo	391	358 (91.6)	1.75 (1.24)	0.0	0.80	1.60	2.40	5.6	
Week 32		Tezepelumab	395	366 (92.7)	1.50 (1.17)	0.0	0.60	1.40	2.40	5.0	
		Placebo	391	357 (91.3)	1.78 (1.17)	0.0	0.80	1.60	2.60	5.4	
Week 36		Tezepelumab	395	373 (94.4)	1.48 (1.16)	0.0	0.60	1.40	2.20	5.0	
		Placebo	391	352 (90.0)	1.72 (1.18)	0.0	0.80	1.80	2.60	5.6	
Week 40		Tezepelumab	395	368 (93.2)	1.47 (1.15)	0.0	0.40	1.20	2.40	4.6	
		Placebo	391	352 (90.0)	1.73 (1.22)	0.0	0.80	1.60	2.60	5.4	
Week 44		Tezepelumab	395	363 (91.9)	1.42 (1.14)	0.0	0.60	1.20	2.20	5.0	
		Placebo	391	347 (88.7)	1.71 (1.21)	0.0	0.80	1.60	2.60	5.2	
Week 48		Tezepelumab	395	366 (92.7)	1.42 (1.19)	0.0	0.40	1.20	2.20	5.4	
		Placebo	391	345 (88.2)	1.69 (1.18)	0.0	0.80	1.60	2.40	5.6	
Week 52		Tezepelumab	395	359 (90.9)	1.37 (1.13)	0.0	0.40	1.20	2.00	5.2	
		Placebo	391	344 (88.0)	1.65 (1.20)	0.0	0.80	1.60	2.40	5.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Source Data: aacq, created on: 20FEB2022

Table NT1H5C\_ILMH0: Course of ACQ-5 score  
 DITTL

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-5 Week 2 score	Tezepelumab	395	376 (95.2)	-0.90 (1.00)	-5.0	-1.60	-0.80	-0.20	1.6	-0.24 [-0.38, -0.10]
	Placebo	391	363 (92.8)	-0.66 (0.98)	-4.2	-1.20	-0.60	-0.20	3.4	
Week 4	Tezepelumab	395	386 (97.7)	-1.12 (1.06)	-5.6	-1.80	-1.00	-0.40	1.8	-0.22 [-0.36, -0.08]
	Placebo	391	378 (96.7)	-0.89 (0.98)	-4.2	-1.40	-0.80	-0.20	2.4	
Week 8	Tezepelumab	395	385 (97.5)	-1.36 (1.19)	-5.6	-2.20	-1.40	-0.60	2.4	-0.32 [-0.46, -0.17]
	Placebo	391	377 (96.4)	-1.00 (1.07)	-4.6	-1.60	-1.00	-0.20	2.8	
Week 12	Tezepelumab	395	378 (95.7)	-1.39 (1.23)	-5.6	-2.20	-1.20	-0.60	2.6	-0.20 [-0.34, -0.06]
	Placebo	391	375 (95.9)	-1.15 (1.12)	-5.2	-1.80	-1.20	-0.40	2.4	
Week 16	Tezepelumab	395	381 (96.5)	-1.53 (1.16)	-5.4	-2.20	-1.40	-0.80	2.0	-0.32 [-0.47, -0.18]
	Placebo	391	370 (94.6)	-1.16 (1.14)	-5.2	-1.80	-1.10	-0.40	2.4	
Week 20	Tezepelumab	395	371 (93.9)	-1.55 (1.24)	-5.4	-2.40	-1.60	-0.80	3.8	-0.26 [-0.40, -0.11]
	Placebo	391	363 (92.8)	-1.24 (1.16)	-5.6	-2.00	-1.20	-0.40	1.4	
Week 24	Tezepelumab	395	370 (93.7)	-1.58 (1.21)	-5.4	-2.40	-1.40	-0.80	2.8	-0.32 [-0.46, -0.17]
	Placebo	391	356 (91.0)	-1.21 (1.13)	-5.2	-2.00	-1.20	-0.40	1.8	
Week 28	Tezepelumab	395	368 (93.2)	-1.60 (1.19)	-5.6	-2.40	-1.60	-0.80	1.8	-0.30 [-0.45, -0.15]
	Placebo	391	358 (91.6)	-1.24 (1.19)	-5.4	-2.00	-1.20	-0.40	2.0	
Week 32	Tezepelumab	395	366 (92.7)	-1.56 (1.28)	-5.6	-2.40	-1.40	-0.80	3.0	-0.28 [-0.43, -0.14]
	Placebo	391	357 (91.3)	-1.21 (1.17)	-4.6	-2.00	-1.00	-0.40	2.4	
Week 36	Tezepelumab	395	373 (94.4)	-1.60 (1.28)	-5.6	-2.40	-1.60	-0.80	2.8	-0.28 [-0.43, -0.13]
	Placebo	391	352 (90.0)	-1.25 (1.19)	-5.6	-2.20	-1.20	-0.40	2.4	
Week 40	Tezepelumab	395	368 (93.2)	-1.60 (1.28)	-5.6	-2.40	-1.60	-0.80	3.0	-0.30 [-0.44, -0.15]
	Placebo	391	352 (90.0)	-1.24 (1.20)	-5.2	-2.00	-1.20	-0.40	2.2	
Week 44	Tezepelumab	395	363 (91.9)	-1.65 (1.22)	-5.6	-2.40	-1.60	-0.80	2.0	-0.31 [-0.46, -0.16]
	Placebo	391	347 (88.7)	-1.27 (1.22)	-5.4	-2.00	-1.20	-0.40	2.6	
Week 48	Tezepelumab	395	366 (92.7)	-1.64 (1.29)	-5.6	-2.40	-1.60	-0.80	2.2	-0.28 [-0.43, -0.14]
	Placebo	391	345 (88.2)	-1.29 (1.16)	-5.8	-2.20	-1.20	-0.40	2.4	
Week 52	Tezepelumab	395	359 (90.9)	-1.70 (1.27)	-5.6	-2.60	-1.80	-1.00	3.6	-0.29 [-0.44, -0.14]
	Placebo	391	344 (88.0)	-1.34 (1.21)	-4.6	-2.10	-1.40	-0.40	1.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Source Data: aacq, created on: 20FEB2022

Table NT1H5C\_ILMC0: Change from baseline in ACQ-5 score - MMRM results  
 DITTTL

Change from baseline in ACQ-5 score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 2	Tezepelumab	395	376 (95.2)	-0.88 (0.05)	(-0.97, -0.79)	-0.23 (0.07)	(-0.36, -0.09)	<0.001 *	
	Placebo	391	363 (92.8)	-0.66 (0.05)	(-0.75, -0.56)				
Week 4	Tezepelumab	395	386 (97.7)	-1.09 (0.05)	(-1.19, -1.00)	-0.18 (0.07)	(-0.31, -0.04)	0.010 *	
	Placebo	391	378 (96.7)	-0.92 (0.05)	(-1.01, -0.82)				
Week 8	Tezepelumab	395	385 (97.5)	-1.33 (0.05)	(-1.43, -1.23)	-0.33 (0.07)	(-0.47, -0.18)	<0.001 *	
	Placebo	391	377 (96.4)	-1.01 (0.05)	(-1.11, -0.90)				
Week 12	Tezepelumab	395	378 (95.7)	-1.36 (0.06)	(-1.47, -1.25)	-0.22 (0.08)	(-0.37, -0.06)	0.006 *	
	Placebo	391	375 (95.9)	-1.15 (0.06)	(-1.26, -1.04)				
Week 16	Tezepelumab	395	381 (96.5)	-1.50 (0.05)	(-1.60, -1.39)	-0.33 (0.08)	(-0.48, -0.18)	<0.001 *	
	Placebo	391	370 (94.6)	-1.16 (0.05)	(-1.27, -1.06)				
Week 20	Tezepelumab	395	371 (93.9)	-1.53 (0.06)	(-1.64, -1.42)	-0.31 (0.08)	(-0.47, -0.16)	<0.001 *	
	Placebo	391	363 (92.8)	-1.22 (0.06)	(-1.33, -1.10)				
Week 24	Tezepelumab	395	370 (93.7)	-1.56 (0.06)	(-1.66, -1.45)	-0.35 (0.08)	(-0.50, -0.20)	<0.001 *	
	Placebo	391	356 (91.0)	-1.21 (0.06)	(-1.32, -1.10)				
Week 28	Tezepelumab	395	368 (93.2)	-1.56 (0.06)	(-1.67, -1.45)	-0.33 (0.08)	(-0.49, -0.17)	<0.001 *	
	Placebo	391	358 (91.6)	-1.23 (0.06)	(-1.34, -1.11)				
Week 32	Tezepelumab	395	366 (92.7)	-1.53 (0.06)	(-1.65, -1.42)	-0.35 (0.08)	(-0.51, -0.19)	<0.001 *	
	Placebo	391	357 (91.3)	-1.19 (0.06)	(-1.30, -1.07)				
Week 36	Tezepelumab	395	373 (94.4)	-1.56 (0.06)	(-1.67, -1.44)	-0.32 (0.08)	(-0.49, -0.16)	<0.001 *	
	Placebo	391	352 (90.0)	-1.23 (0.06)	(-1.35, -1.12)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 20FEB2022

Table NT1H5C\_ILMC0: Change from baseline in ACQ-5 score - MMRM results  
 DITTTL

Change from baseline in ACQ-5 score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 40	Tezepelumab	395	368 (93.2)	-1.57 (0.06)	(-1.68, -1.45)	-0.34 (0.08)	(-0.51, -0.18)	<0.001 *	
	Placebo	391	352 (90.0)	-1.23 (0.06)	(-1.34, -1.11)				
Week 44	Tezepelumab	395	363 (91.9)	-1.62 (0.06)	(-1.73, -1.50)	-0.35 (0.08)	(-0.51, -0.19)	<0.001 *	
	Placebo	391	347 (88.7)	-1.27 (0.06)	(-1.38, -1.15)				
Week 48	Tezepelumab	395	366 (92.7)	-1.62 (0.06)	(-1.74, -1.51)	-0.36 (0.08)	(-0.53, -0.20)	<0.001 *	
	Placebo	391	345 (88.2)	-1.26 (0.06)	(-1.38, -1.14)				
Week 52	Tezepelumab	395	359 (90.9)	-1.66 (0.06)	(-1.78, -1.55)	-0.36 (0.08)	(-0.52, -0.19)	<0.001 *	
	Placebo	391	344 (88.0)	-1.31 (0.06)	(-1.42, -1.19)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 20FEB2022

Table PT3H5C\_ILMH0: Course of ACQ-5 score  
 DITTTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-5 score	Baseline	Tezepelumab	66	66 (100.0)	2.87 (0.88)	0.0	2.40	2.80	3.20	5.2	
		Placebo	65	65 (100.0)	2.86 (0.77)	0.4	2.60	3.00	3.20	5.0	
	Week 2	Tezepelumab	66	63 (95.5)	2.34 (1.02)	0.0	1.60	2.60	3.00	4.4	
		Placebo	65	58 (89.2)	2.40 (0.80)	0.4	2.00	2.40	2.80	5.0	
	Week 4	Tezepelumab	66	63 (95.5)	2.08 (1.00)	0.2	1.20	2.20	3.00	3.6	
		Placebo	65	58 (89.2)	2.25 (0.92)	0.2	1.80	2.50	2.80	4.2	
	Week 6	Tezepelumab	66	63 (95.5)	1.97 (1.04)	0.0	1.20	1.80	2.80	4.0	
		Placebo	65	58 (89.2)	2.21 (1.16)	0.2	1.40	2.20	3.00	6.0	
	Week 8	Tezepelumab	66	63 (95.5)	1.82 (1.18)	0.0	1.00	1.80	2.80	5.2	
		Placebo	65	59 (90.8)	2.13 (1.14)	0.0	1.20	2.40	3.00	5.0	
	Week 10	Tezepelumab	66	63 (95.5)	1.72 (1.14)	0.0	0.80	1.60	2.60	4.8	
		Placebo	65	59 (90.8)	2.15 (1.08)	0.0	1.60	2.20	3.00	5.2	
	Week 12	Tezepelumab	66	63 (95.5)	1.61 (1.10)	0.0	0.60	1.60	2.60	4.8	
		Placebo	65	59 (90.8)	1.94 (1.06)	0.0	1.00	2.00	2.60	4.4	
	Week 14	Tezepelumab	66	63 (95.5)	1.56 (1.12)	0.0	0.60	1.40	2.20	4.8	
		Placebo	65	59 (90.8)	1.87 (1.00)	0.0	1.20	2.00	2.40	5.0	
	Week 16	Tezepelumab	66	63 (95.5)	1.71 (1.18)	0.0	0.80	1.60	2.60	4.8	
		Placebo	65	59 (90.8)	2.03 (1.21)	0.0	1.00	2.00	2.80	5.0	
	Week 18	Tezepelumab	66	64 (97.0)	1.67 (1.08)	0.0	0.80	1.60	2.40	4.8	
		Placebo	65	59 (90.8)	1.93 (1.18)	0.0	1.00	2.00	2.60	5.0	
	Week 20	Tezepelumab	66	64 (97.0)	1.68 (1.14)	0.0	0.80	1.70	2.60	5.0	
		Placebo	65	59 (90.8)	2.03 (1.11)	0.0	1.20	2.00	2.80	5.0	
	Week 22	Tezepelumab	66	64 (97.0)	1.78 (1.03)	0.0	1.00	2.00	2.50	4.8	
		Placebo	65	59 (90.8)	1.98 (1.16)	0.0	1.00	2.00	2.60	5.0	
	Week 24	Tezepelumab	66	64 (97.0)	1.74 (1.11)	0.0	0.90	1.70	2.60	4.8	
		Placebo	65	59 (90.8)	2.05 (1.07)	0.0	1.40	2.20	2.80	4.4	
	Week 26	Tezepelumab	66	65 (98.5)	1.79 (1.12)	0.0	1.00	1.80	2.60	4.8	
		Placebo	65	59 (90.8)	1.98 (1.14)	0.0	1.00	1.80	3.00	4.4	
	Week 28	Tezepelumab	66	66 (100.0)	1.73 (1.16)	0.0	1.00	1.80	2.40	4.8	
		Placebo	65	60 (92.3)	1.96 (1.23)	0.0	1.00	2.00	2.80	4.4	
	Week 30	Tezepelumab	66	66 (100.0)	1.70 (1.10)	0.0	0.80	1.60	2.40	4.8	
		Placebo	65	60 (92.3)	1.94 (1.18)	0.0	1.00	2.00	2.90	4.4	
	Week 32	Tezepelumab	66	66 (100.0)	1.63 (1.12)	0.0	0.80	1.60	2.40	4.8	
		Placebo	65	60 (92.3)	1.90 (1.14)	0.0	1.00	1.80	2.80	4.8	
Week 34	Tezepelumab	66	66 (100.0)	1.71 (1.19)	0.0	0.80	1.50	2.80	4.8		
	Placebo	65	60 (92.3)	1.88 (1.14)	0.0	0.90	1.80	2.60	4.8		

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Last observation carried forward is applied in case of missing values.

Source Data: aacq, created on: 21FEB2022

Table PT3H5C\_ILMH0: Course of ACQ-5 score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-5 score	Week 36	Tezepelumab	66	66 (100.0)	1.67 (1.11)	0.0	1.00	1.50	2.40	4.8	
		Placebo	65	60 (92.3)	2.05 (1.19)	0.0	1.20	2.10	2.80	4.8	
	Week 38	Tezepelumab	66	66 (100.0)	1.72 (1.23)	0.0	0.80	1.70	2.60	4.8	
		Placebo	65	60 (92.3)	1.92 (1.13)	0.0	1.00	1.80	2.70	4.8	
	Week 40	Tezepelumab	66	66 (100.0)	1.70 (1.18)	0.0	0.80	1.80	2.60	4.8	
		Placebo	65	60 (92.3)	2.06 (1.19)	0.0	1.10	2.10	3.00	4.4	
	Week 42	Tezepelumab	66	66 (100.0)	1.64 (1.15)	0.0	0.80	1.60	2.40	4.8	
		Placebo	65	60 (92.3)	1.92 (1.06)	0.0	1.10	2.00	2.60	4.6	
	Week 44	Tezepelumab	66	66 (100.0)	1.68 (1.14)	0.0	0.80	1.70	2.60	4.8	
		Placebo	65	60 (92.3)	2.01 (1.12)	0.0	1.20	2.00	2.80	4.4	
	Week 46	Tezepelumab	66	66 (100.0)	1.71 (1.19)	0.0	0.80	1.80	2.60	4.8	
		Placebo	65	60 (92.3)	1.88 (1.01)	0.0	1.20	2.00	2.40	4.4	
	Week 48	Tezepelumab	66	66 (100.0)	1.71 (1.19)	0.0	0.80	1.80	2.60	4.8	
		Placebo	65	60 (92.3)	1.94 (1.10)	0.0	1.00	2.00	2.60	4.6	
	Week 50	Tezepelumab	66	66 (100.0)	1.65 (1.20)	0.0	0.80	1.40	2.60	4.8	
		Placebo	65	60 (92.3)	1.82 (1.03)	0.0	1.00	1.80	2.40	4.4	
	Week 52	Tezepelumab	66	66 (100.0)	1.68 (1.18)	0.0	0.80	1.60	2.60	4.8	
		Placebo	65	60 (92.3)	1.89 (1.09)	0.0	1.00	2.00	2.70	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Last observation carried forward is applied in case of missing values.

Source Data: aacq, created on: 21FEB2022



Table PT3H5C\_ILMH0: Course of ACQ-5 score  
 DITTL

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-5 Week 2 score	Tezepelumab	66	63 (95.5)	-0.56 (0.79)	-3.2	-1.20	-0.40	0.20	0.8	-0.08 [-0.43, 0.28]
	Placebo	65	58 (89.2)	-0.50 (0.72)	-2.8	-1.00	-0.40	0.00	1.2	
Week 4	Tezepelumab	66	63 (95.5)	-0.83 (0.93)	-2.6	-1.40	-0.80	-0.20	2.6	-0.19 [-0.54, 0.17]
	Placebo	65	58 (89.2)	-0.65 (0.97)	-3.0	-1.40	-0.40	0.00	1.2	
Week 6	Tezepelumab	66	63 (95.5)	-0.93 (1.02)	-2.8	-1.60	-1.00	-0.20	2.6	-0.24 [-0.60, 0.12]
	Placebo	65	58 (89.2)	-0.69 (1.05)	-3.4	-1.40	-0.60	0.00	1.6	
Week 8	Tezepelumab	66	63 (95.5)	-1.09 (1.15)	-3.2	-1.80	-1.00	-0.40	2.6	-0.28 [-0.64, 0.08]
	Placebo	65	59 (90.8)	-0.78 (1.06)	-3.6	-1.40	-0.60	0.00	1.0	
Week 10	Tezepelumab	66	63 (95.5)	-1.18 (1.12)	-3.4	-2.00	-1.20	-0.60	2.6	-0.38 [-0.73, -0.02]
	Placebo	65	59 (90.8)	-0.76 (1.16)	-3.8	-1.40	-0.60	0.00	2.6	
Week 12	Tezepelumab	66	63 (95.5)	-1.29 (1.10)	-3.2	-2.20	-1.40	-0.60	2.6	-0.30 [-0.66, 0.06]
	Placebo	65	59 (90.8)	-0.97 (1.08)	-3.8	-1.60	-0.80	-0.20	1.6	
Week 14	Tezepelumab	66	63 (95.5)	-1.35 (1.11)	-4.0	-2.20	-1.40	-0.60	2.6	-0.28 [-0.64, 0.07]
	Placebo	65	59 (90.8)	-1.04 (1.08)	-3.4	-1.60	-1.20	-0.40	2.4	
Week 16	Tezepelumab	66	63 (95.5)	-1.20 (1.15)	-3.2	-2.20	-1.20	-0.60	2.6	-0.28 [-0.63, 0.08]
	Placebo	65	59 (90.8)	-0.87 (1.18)	-3.6	-1.40	-1.00	-0.20	2.6	
Week 18	Tezepelumab	66	64 (97.0)	-1.22 (1.10)	-3.8	-1.90	-1.00	-0.60	2.6	-0.21 [-0.56, 0.15]
	Placebo	65	59 (90.8)	-0.98 (1.23)	-3.6	-2.00	-1.00	-0.20	2.6	
Week 20	Tezepelumab	66	64 (97.0)	-1.21 (1.10)	-3.4	-2.20	-1.20	-0.50	2.6	-0.30 [-0.65, 0.06]
	Placebo	65	59 (90.8)	-0.87 (1.18)	-3.6	-1.60	-0.80	-0.20	2.6	
Week 22	Tezepelumab	66	64 (97.0)	-1.12 (1.13)	-3.2	-2.00	-1.00	-0.60	2.6	-0.16 [-0.52, 0.19]
	Placebo	65	59 (90.8)	-0.93 (1.18)	-3.8	-1.60	-1.00	-0.20	2.6	
Week 24	Tezepelumab	66	64 (97.0)	-1.15 (1.09)	-3.4	-2.00	-1.20	-0.40	2.6	-0.26 [-0.62, 0.10]
	Placebo	65	59 (90.8)	-0.86 (1.13)	-3.6	-1.60	-0.80	0.00	2.6	
Week 26	Tezepelumab	66	65 (98.5)	-1.08 (1.13)	-3.0	-2.20	-1.00	-0.20	2.6	-0.13 [-0.49, 0.22]
	Placebo	65	59 (90.8)	-0.93 (1.20)	-3.4	-1.80	-1.20	0.00	2.6	
Week 28	Tezepelumab	66	66 (100.0)	-1.14 (1.21)	-3.4	-2.20	-1.20	-0.20	2.6	-0.19 [-0.54, 0.16]
	Placebo	65	60 (92.3)	-0.91 (1.23)	-3.4	-1.80	-1.10	0.00	2.6	
Week 30	Tezepelumab	66	66 (100.0)	-1.17 (1.18)	-3.8	-2.20	-1.20	-0.40	2.6	-0.20 [-0.55, 0.15]
	Placebo	65	60 (92.3)	-0.93 (1.23)	-3.4	-1.60	-1.10	-0.20	2.6	
Week 32	Tezepelumab	66	66 (100.0)	-1.24 (1.11)	-3.2	-2.20	-1.20	-0.60	2.6	-0.24 [-0.59, 0.11]
	Placebo	65	60 (92.3)	-0.96 (1.17)	-3.2	-1.60	-1.20	-0.20	2.6	
Week 34	Tezepelumab	66	66 (100.0)	-1.16 (1.20)	-3.0	-2.20	-1.40	-0.40	2.6	-0.14 [-0.49, 0.21]
	Placebo	65	60 (92.3)	-0.99 (1.16)	-3.2	-1.70	-1.20	-0.20	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Last observation carried forward is applied in case of missing values.

Source Data: aacq, created on: 21FEB2022

Table PT3H5C\_ILMH0: Course of ACQ-5 score  
 DITTL

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-5 Week 36 score	Tezepelumab	66	66 (100.0)	-1.20 (1.18)	-3.2	-2.20	-1.20	-0.20	2.6	-0.33 [-0.68, 0.03]
	Placebo	65	60 (92.3)	-0.81 (1.22)	-3.6	-1.40	-1.00	-0.10	2.6	
Week 38	Tezepelumab	66	66 (100.0)	-1.15 (1.23)	-3.2	-2.20	-1.30	-0.40	2.6	-0.18 [-0.53, 0.17]
	Placebo	65	60 (92.3)	-0.94 (1.15)	-3.2	-1.60	-1.00	-0.40	2.6	
Week 40	Tezepelumab	66	66 (100.0)	-1.17 (1.21)	-3.4	-2.20	-1.20	-0.40	2.6	-0.30 [-0.66, 0.05]
	Placebo	65	60 (92.3)	-0.80 (1.22)	-3.2	-1.60	-0.80	0.00	2.6	
Week 42	Tezepelumab	66	66 (100.0)	-1.23 (1.21)	-3.6	-2.20	-1.30	-0.40	2.6	-0.25 [-0.60, 0.11]
	Placebo	65	60 (92.3)	-0.94 (1.10)	-2.8	-1.60	-1.00	-0.30	2.6	
Week 44	Tezepelumab	66	66 (100.0)	-1.19 (1.20)	-3.8	-2.20	-1.20	-0.40	2.6	-0.28 [-0.63, 0.07]
	Placebo	65	60 (92.3)	-0.86 (1.15)	-3.4	-1.60	-1.00	-0.10	2.6	
Week 46	Tezepelumab	66	66 (100.0)	-1.16 (1.21)	-3.6	-2.20	-1.20	-0.20	2.6	-0.16 [-0.51, 0.19]
	Placebo	65	60 (92.3)	-0.98 (1.06)	-3.2	-1.60	-1.00	-0.50	2.6	
Week 48	Tezepelumab	66	66 (100.0)	-1.16 (1.19)	-3.0	-2.20	-1.00	-0.40	2.6	-0.20 [-0.55, 0.15]
	Placebo	65	60 (92.3)	-0.92 (1.13)	-3.4	-1.60	-1.00	-0.30	2.6	
Week 50	Tezepelumab	66	66 (100.0)	-1.22 (1.22)	-3.2	-2.20	-1.30	-0.40	2.6	-0.16 [-0.51, 0.19]
	Placebo	65	60 (92.3)	-1.04 (1.06)	-3.6	-1.60	-1.00	-0.40	2.6	
Week 52	Tezepelumab	66	66 (100.0)	-1.19 (1.20)	-3.2	-2.20	-1.20	-0.40	2.6	-0.19 [-0.54, 0.16]
	Placebo	65	60 (92.3)	-0.97 (1.11)	-3.6	-1.60	-0.90	-0.40	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Last observation carried forward is applied in case of missing values.

Source Data: aacq, created on: 21FEB2022

Table PT3H5C\_ILMC0: Change from baseline in ACQ-5 score - MMRM results  
 DITTTL

Change from baseline in ACQ-5 score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 2	Tezepelumab	66	63 (95.5)	NE		NE			
	Placebo	65	58 (89.2)						
Week 4	Tezepelumab	66	60 (90.9)	NE		NE			
	Placebo	65	57 (87.7)						
Week 6	Tezepelumab	66	59 (89.4)	NE		NE			
	Placebo	65	57 (87.7)						
Week 8	Tezepelumab	66	60 (90.9)	NE		NE			
	Placebo	65	58 (89.2)						
Week 10	Tezepelumab	66	59 (89.4)	NE		NE			
	Placebo	65	56 (86.2)						
Week 12	Tezepelumab	66	59 (89.4)	NE		NE			
	Placebo	65	55 (84.6)						
Week 14	Tezepelumab	66	59 (89.4)	NE		NE			
	Placebo	65	54 (83.1)						
Week 16	Tezepelumab	66	57 (86.4)	NE		NE			
	Placebo	65	53 (81.5)						
Week 18	Tezepelumab	66	59 (89.4)	NE		NE			
	Placebo	65	50 (76.9)						
Week 20	Tezepelumab	66	55 (83.3)	NE		NE			
	Placebo	65	49 (75.4)						

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 21FEB2022

Table PT3H5C\_ILMC0: Change from baseline in ACQ-5 score - MMRM results  
 DITTTL

Change from baseline in ACQ-5 score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 22	Tezepelumab	66	55 (83.3)	NE		NE			
	Placebo	65	50 (76.9)						
Week 24	Tezepelumab	66	55 (83.3)	NE		NE			
	Placebo	65	48 (73.8)						
Week 26	Tezepelumab	66	56 (84.8)	NE		NE			
	Placebo	65	47 (72.3)						
Week 28	Tezepelumab	66	55 (83.3)	NE		NE			
	Placebo	65	48 (73.8)						
Week 30	Tezepelumab	66	56 (84.8)	NE		NE			
	Placebo	65	46 (70.8)						
Week 32	Tezepelumab	66	57 (86.4)	NE		NE			
	Placebo	65	48 (73.8)						
Week 34	Tezepelumab	66	57 (86.4)	NE		NE			
	Placebo	65	46 (70.8)						
Week 36	Tezepelumab	66	57 (86.4)	NE		NE			
	Placebo	65	48 (73.8)						
Week 38	Tezepelumab	66	56 (84.8)	NE		NE			
	Placebo	65	48 (73.8)						
Week 40	Tezepelumab	66	54 (81.8)	NE		NE			
	Placebo	65	50 (76.9)						

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 21FEB2022

Table PT3H5C\_ILMC0: Change from baseline in ACQ-5 score - MMRM results  
 DITTTL

Change from baseline in ACQ-5 score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Time	Treatment	N	n (%)					
Week 42	Tezepelumab	66	54 (81.8)	NE		NE		
	Placebo	65	47 (72.3)					
Week 44	Tezepelumab	66	54 (81.8)	NE		NE		
	Placebo	65	48 (73.8)					
Week 46	Tezepelumab	66	54 (81.8)	NE		NE		
	Placebo	65	48 (73.8)					
Week 48	Tezepelumab	66	53 (80.3)	NE		NE		
	Placebo	65	48 (73.8)					
Week 50	Tezepelumab	66	54 (81.8)	NE		NE		
	Placebo	65	49 (75.4)					
Week 52	Tezepelumab	66	18 (27.3)	NE		NE		
	Placebo	65	20 (30.8)					

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 21FEB2022

Table DT1H5C\_BLMH0: Course of ACQ-5 score  
 DITTNL - LTE

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-5 score	Baseline	Teze+Teze	310	310 (100.0)	3.12 (0.85)	1.4	2.60	3.00	3.60	5.8	
		Pbo+Pbo	149	149 (100.0)	3.08 (0.87)	1.6	2.40	3.00	3.40	5.6	
Week 2		Teze+Teze	310	296 (95.5)	2.19 (1.04)	0.0	1.40	2.20	2.80	5.8	
		Pbo+Pbo	149	138 (92.6)	2.40 (1.05)	0.2	1.60	2.40	3.00	5.6	
Week 4		Teze+Teze	310	304 (98.1)	1.97 (1.02)	0.0	1.20	2.00	2.80	5.0	
		Pbo+Pbo	149	146 (98.0)	2.11 (1.14)	0.0	1.20	2.20	2.80	5.6	
Week 8		Teze+Teze	310	303 (97.7)	1.70 (1.06)	0.0	0.80	1.60	2.40	4.8	
		Pbo+Pbo	149	146 (98.0)	2.10 (1.19)	0.0	1.20	2.00	2.80	5.8	
Week 12		Teze+Teze	310	299 (96.5)	1.67 (1.19)	0.0	0.80	1.40	2.40	5.6	
		Pbo+Pbo	149	148 (99.3)	1.88 (1.25)	0.0	0.90	1.80	2.80	5.8	
Week 16		Teze+Teze	310	306 (98.7)	1.53 (1.10)	0.0	0.60	1.40	2.20	5.2	
		Pbo+Pbo	149	146 (98.0)	1.84 (1.31)	0.0	1.00	1.70	2.60	5.8	
Week 20		Teze+Teze	310	300 (96.8)	1.54 (1.14)	0.0	0.60	1.40	2.40	4.8	
		Pbo+Pbo	149	145 (97.3)	1.84 (1.27)	0.0	1.00	1.60	2.60	5.6	
Week 24		Teze+Teze	310	300 (96.8)	1.49 (1.09)	0.0	0.60	1.40	2.20	5.0	
		Pbo+Pbo	149	144 (96.6)	1.87 (1.28)	0.0	0.90	1.70	2.80	5.8	
Week 28		Teze+Teze	310	300 (96.8)	1.49 (1.16)	0.0	0.60	1.40	2.20	5.2	
		Pbo+Pbo	149	144 (96.6)	1.75 (1.30)	0.0	0.60	1.60	2.60	5.6	
Week 32		Teze+Teze	310	299 (96.5)	1.50 (1.17)	0.0	0.60	1.40	2.40	5.0	
		Pbo+Pbo	149	145 (97.3)	1.85 (1.23)	0.0	1.00	1.60	2.80	5.4	
Week 36		Teze+Teze	310	308 (99.4)	1.48 (1.17)	0.0	0.40	1.40	2.20	5.0	
		Pbo+Pbo	149	146 (98.0)	1.86 (1.26)	0.0	0.80	1.80	2.80	5.6	
Week 40		Teze+Teze	310	303 (97.7)	1.48 (1.14)	0.0	0.60	1.20	2.40	4.6	
		Pbo+Pbo	149	147 (98.7)	1.89 (1.29)	0.0	0.80	1.80	2.80	5.4	
Week 44		Teze+Teze	310	300 (96.8)	1.45 (1.16)	0.0	0.50	1.20	2.20	5.0	
		Pbo+Pbo	149	145 (97.3)	1.85 (1.30)	0.0	0.80	1.60	2.80	5.2	
Week 48		Teze+Teze	310	303 (97.7)	1.43 (1.19)	0.0	0.40	1.20	2.20	5.4	
		Pbo+Pbo	149	143 (96.0)	1.83 (1.24)	0.0	1.00	1.60	2.60	5.6	
Week 52		Teze+Teze	310	301 (97.1)	1.37 (1.11)	0.0	0.40	1.20	2.20	4.4	
		Pbo+Pbo	149	145 (97.3)	1.73 (1.25)	0.0	0.80	1.60	2.60	5.4	
Week 64		Teze+Teze	310	306 (98.7)	1.38 (1.11)	0.0	0.40	1.20	2.20	5.0	
		Pbo+Pbo	149	144 (96.6)	1.76 (1.25)	0.0	0.80	1.60	2.40	5.6	
Week 76		Teze+Teze	310	301 (97.1)	1.45 (1.18)	0.0	0.40	1.20	2.20	5.4	
		Pbo+Pbo	149	147 (98.7)	1.82 (1.30)	0.0	0.80	1.80	2.80	5.6	
Week 88		Teze+Teze	310	297 (95.8)	1.38 (1.13)	0.0	0.40	1.20	2.20	5.4	
		Pbo+Pbo	149	142 (95.3)	1.74 (1.28)	0.0	0.80	1.60	2.60	5.8	
Week 104		Teze+Teze	310	291 (93.9)	1.27 (1.11)	0.0	0.40	1.00	2.00	5.0	
		Pbo+Pbo	149	142 (95.3)	1.69 (1.23)	0.0	0.60	1.70	2.40	5.6	

Note: DITTNL - LTE = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.  
 Source Data: aacq, created on: 20JUL2022

Table DT1H5C\_BLMH0: Course of ACQ-5 score  
 DITTNL - LTE

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-5 Week 2 score	Teze+Teze	310	296 (95.5)	-0.93 (0.97)	-5.0	-1.60	-0.80	-0.30	1.2	-0.23 [-0.43, -0.02]
	Pbo+Pbo	149	138 (92.6)	-0.71 (0.98)	-4.2	-1.20	-0.60	-0.20	2.2	
Week 4	Teze+Teze	310	304 (98.1)	-1.13 (1.02)	-5.6	-1.80	-1.00	-0.40	1.8	-0.17 [-0.37, 0.03]
	Pbo+Pbo	149	146 (98.0)	-0.96 (1.04)	-4.2	-1.60	-0.80	-0.20	1.8	
Week 8	Teze+Teze	310	303 (97.7)	-1.41 (1.13)	-5.6	-2.20	-1.40	-0.60	2.0	-0.37 [-0.57, -0.17]
	Pbo+Pbo	149	146 (98.0)	-0.99 (1.15)	-4.6	-1.80	-1.00	-0.20	2.8	
Week 12	Teze+Teze	310	299 (96.5)	-1.43 (1.21)	-5.6	-2.20	-1.40	-0.60	2.4	-0.19 [-0.39, 0.01]
	Pbo+Pbo	149	148 (99.3)	-1.20 (1.18)	-4.6	-2.00	-1.20	-0.40	2.0	
Week 16	Teze+Teze	310	306 (98.7)	-1.59 (1.12)	-5.4	-2.40	-1.60	-0.80	2.0	-0.32 [-0.51, -0.12]
	Pbo+Pbo	149	146 (98.0)	-1.23 (1.20)	-5.0	-2.00	-1.20	-0.60	2.4	
Week 20	Teze+Teze	310	300 (96.8)	-1.57 (1.18)	-5.4	-2.40	-1.60	-0.80	1.8	-0.28 [-0.48, -0.08]
	Pbo+Pbo	149	145 (97.3)	-1.23 (1.25)	-4.6	-2.00	-1.20	-0.40	1.4	
Week 24	Teze+Teze	310	300 (96.8)	-1.62 (1.18)	-5.4	-2.40	-1.50	-0.80	1.4	-0.36 [-0.56, -0.15]
	Pbo+Pbo	149	144 (96.6)	-1.20 (1.20)	-4.0	-2.00	-1.20	-0.40	1.8	
Week 28	Teze+Teze	310	300 (96.8)	-1.60 (1.17)	-5.6	-2.40	-1.60	-0.80	1.6	-0.23 [-0.43, -0.03]
	Pbo+Pbo	149	144 (96.6)	-1.33 (1.22)	-4.6	-2.20	-1.20	-0.60	1.6	
Week 32	Teze+Teze	310	299 (96.5)	-1.60 (1.26)	-5.6	-2.40	-1.60	-0.80	3.0	-0.30 [-0.49, -0.10]
	Pbo+Pbo	149	145 (97.3)	-1.24 (1.22)	-4.6	-2.20	-1.20	-0.20	2.4	
Week 36	Teze+Teze	310	308 (99.4)	-1.63 (1.24)	-5.6	-2.60	-1.60	-0.80	2.4	-0.33 [-0.52, -0.13]
	Pbo+Pbo	149	146 (98.0)	-1.22 (1.26)	-4.6	-2.20	-1.20	-0.20	2.4	
Week 40	Teze+Teze	310	303 (97.7)	-1.63 (1.23)	-5.6	-2.40	-1.60	-0.80	2.0	-0.37 [-0.57, -0.17]
	Pbo+Pbo	149	147 (98.7)	-1.18 (1.24)	-4.0	-2.00	-1.00	-0.20	2.2	
Week 44	Teze+Teze	310	300 (96.8)	-1.66 (1.21)	-5.6	-2.60	-1.60	-0.80	1.6	-0.35 [-0.55, -0.15]
	Pbo+Pbo	149	145 (97.3)	-1.23 (1.29)	-4.6	-2.00	-1.20	-0.40	2.6	
Week 48	Teze+Teze	310	303 (97.7)	-1.68 (1.28)	-5.6	-2.60	-1.60	-0.80	2.2	-0.35 [-0.55, -0.15]
	Pbo+Pbo	149	143 (96.0)	-1.25 (1.19)	-4.0	-2.20	-1.20	-0.40	1.4	
Week 52	Teze+Teze	310	301 (97.1)	-1.75 (1.19)	-5.6	-2.60	-1.80	-1.00	1.4	-0.31 [-0.51, -0.12]
	Pbo+Pbo	149	145 (97.3)	-1.37 (1.23)	-4.6	-2.20	-1.40	-0.40	1.2	
Week 64	Teze+Teze	310	306 (98.7)	-1.75 (1.17)	-5.6	-2.60	-1.80	-1.00	1.8	-0.35 [-0.55, -0.15]
	Pbo+Pbo	149	144 (96.6)	-1.33 (1.25)	-4.6	-2.20	-1.20	-0.30	2.2	
Week 76	Teze+Teze	310	301 (97.1)	-1.68 (1.21)	-5.6	-2.60	-1.80	-1.00	2.4	-0.34 [-0.54, -0.14]
	Pbo+Pbo	149	147 (98.7)	-1.27 (1.18)	-4.2	-2.00	-1.20	-0.40	1.6	
Week 88	Teze+Teze	310	297 (95.8)	-1.75 (1.19)	-5.6	-2.60	-1.80	-1.00	1.4	-0.34 [-0.54, -0.14]
	Pbo+Pbo	149	142 (95.3)	-1.35 (1.19)	-4.8	-2.20	-1.20	-0.60	1.2	
Week 104	Teze+Teze	310	291 (93.9)	-1.83 (1.14)	-5.6	-2.60	-1.80	-1.00	1.4	-0.36 [-0.57, -0.16]
	Pbo+Pbo	149	142 (95.3)	-1.40 (1.25)	-4.8	-2.20	-1.20	-0.60	2.0	

Note: DITTNL - LTE = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.  
 Source Data: aacq, created on: 20JUL2022

Table DT1H5C\_BLMC0: Change from baseline in ACQ-5 score - MMRM results  
 DITTNL - LTE

Change from baseline in ACQ-5 score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 2	Teze+Teze	310	296 (95.5)	-0.92 (0.05)	(-1.02, -0.82)	-0.23 (0.09)	(-0.41, -0.05)	0.012	*
	Pbo+Pbo	149	138 (92.6)	-0.69 (0.08)	(-0.84, -0.54)				
Week 4	Teze+Teze	310	304 (98.1)	-1.14 (0.05)	(-1.24, -1.03)	-0.16 (0.10)	(-0.35, 0.03)	0.093	
	Pbo+Pbo	149	146 (98.0)	-0.97 (0.08)	(-1.13, -0.82)				
Week 8	Teze+Teze	310	303 (97.7)	-1.41 (0.06)	(-1.52, -1.29)	-0.40 (0.10)	(-0.61, -0.20)	<0.001	*
	Pbo+Pbo	149	146 (98.0)	-1.01 (0.08)	(-1.17, -0.84)				
Week 12	Teze+Teze	310	299 (96.5)	-1.43 (0.06)	(-1.56, -1.31)	-0.23 (0.11)	(-0.45, -0.00)	0.046	*
	Pbo+Pbo	149	148 (99.3)	-1.21 (0.09)	(-1.39, -1.03)				
Week 16	Teze+Teze	310	306 (98.7)	-1.58 (0.06)	(-1.70, -1.46)	-0.33 (0.11)	(-0.55, -0.12)	0.002	*
	Pbo+Pbo	149	146 (98.0)	-1.25 (0.09)	(-1.42, -1.07)				
Week 20	Teze+Teze	310	300 (96.8)	-1.57 (0.06)	(-1.70, -1.45)	-0.35 (0.11)	(-0.57, -0.13)	0.002	*
	Pbo+Pbo	149	145 (97.3)	-1.22 (0.09)	(-1.40, -1.05)				
Week 24	Teze+Teze	310	300 (96.8)	-1.61 (0.06)	(-1.74, -1.49)	-0.39 (0.11)	(-0.61, -0.18)	<0.001	*
	Pbo+Pbo	149	144 (96.6)	-1.22 (0.09)	(-1.40, -1.05)				
Week 28	Teze+Teze	310	300 (96.8)	-1.60 (0.06)	(-1.73, -1.48)	-0.27 (0.11)	(-0.49, -0.05)	0.016	*
	Pbo+Pbo	149	144 (96.6)	-1.33 (0.09)	(-1.51, -1.15)				
Week 32	Teze+Teze	310	299 (96.5)	-1.61 (0.07)	(-1.74, -1.48)	-0.37 (0.11)	(-0.60, -0.15)	0.001	*
	Pbo+Pbo	149	145 (97.3)	-1.24 (0.09)	(-1.42, -1.05)				
Week 36	Teze+Teze	310	308 (99.4)	-1.63 (0.07)	(-1.76, -1.50)	-0.41 (0.11)	(-0.64, -0.18)	<0.001	*
	Pbo+Pbo	149	146 (98.0)	-1.22 (0.09)	(-1.40, -1.03)				

Note: DITTNL - LTE = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.  
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.  
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.  
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.  
 ACQ = asthma control questionnaire.  
 Source Data: aacq, created on: 20JUL2022



Table DT1H5C\_BLMC0: Change from baseline in ACQ-5 score - MMRM results  
 DITTNL - LTE

Change from baseline in ACQ-5 score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 40	Teze+Teze	310	303 (97.7)	-1.63 (0.06)	(-1.75, -1.50)	-0.44 (0.11)	(-0.66, -0.22)	<0.001 *	
	Pbo+Pbo	149	147 (98.7)	-1.19 (0.09)	(-1.37, -1.01)				
Week 44	Teze+Teze	310	300 (96.8)	-1.66 (0.07)	(-1.79, -1.53)	-0.41 (0.11)	(-0.63, -0.18)	<0.001 *	
	Pbo+Pbo	149	145 (97.3)	-1.25 (0.09)	(-1.44, -1.07)				
Week 48	Teze+Teze	310	303 (97.7)	-1.68 (0.07)	(-1.81, -1.55)	-0.42 (0.12)	(-0.65, -0.20)	<0.001 *	
	Pbo+Pbo	149	143 (96.0)	-1.26 (0.10)	(-1.45, -1.07)				
Week 52	Teze+Teze	310	301 (97.1)	-1.76 (0.06)	(-1.88, -1.63)	-0.40 (0.11)	(-0.61, -0.18)	<0.001 *	
	Pbo+Pbo	149	145 (97.3)	-1.36 (0.09)	(-1.54, -1.18)				
Week 64	Teze+Teze	310	306 (98.7)	-1.74 (0.06)	(-1.86, -1.61)	-0.39 (0.11)	(-0.61, -0.18)	<0.001 *	
	Pbo+Pbo	149	144 (96.6)	-1.34 (0.09)	(-1.52, -1.17)				
Week 76	Teze+Teze	310	301 (97.1)	-1.65 (0.06)	(-1.78, -1.52)	-0.37 (0.11)	(-0.59, -0.14)	0.001 *	
	Pbo+Pbo	149	147 (98.7)	-1.28 (0.09)	(-1.47, -1.10)				
Week 88	Teze+Teze	310	297 (95.8)	-1.71 (0.06)	(-1.84, -1.59)	-0.36 (0.11)	(-0.58, -0.14)	0.002 *	
	Pbo+Pbo	149	142 (95.3)	-1.35 (0.09)	(-1.54, -1.17)				
Week 104	Teze+Teze	310	291 (93.9)	-1.81 (0.06)	(-1.93, -1.68)	-0.41 (0.11)	(-0.63, -0.20)	<0.001 *	
	Pbo+Pbo	149	142 (95.3)	-1.39 (0.09)	(-1.57, -1.21)				

Note: DITTNL - LTE = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.  
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.  
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.  
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.  
 ACQ = asthma control questionnaire.  
 Source Data: aacq, created on: 20JUL2022

Table CT1H5C\_ILMH0: Course of ACQ-5 score  
 DITTLL

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]	
ACQ-5 score	Baseline	Tezepelumab	31	31 (100.0)	2.50 (0.79)	0.0	2.00	2.60	3.00	3.6	
		Placebo	34	34 (100.0)	2.11 (0.76)	0.8	1.60	2.00	2.40	3.6	
	Week 12	Tezepelumab	31	31 (100.0)	1.77 (1.04)	0.0	1.00	1.60	2.60	4.2	
		Placebo	34	34 (100.0)	1.35 (0.68)	0.0	1.00	1.40	1.60	2.8	
	Week 28	Tezepelumab	31	24 (77.4)	1.73 (0.89)	0.4	1.00	1.80	2.20	3.6	
		Placebo	34	24 (70.6)	1.48 (0.92)	0.4	0.80	1.40	1.70	3.4	
	End of treatment	Tezepelumab	31	29 (93.5)	1.61 (0.90)	0.4	0.80	1.40	2.20	3.6	
		Placebo	34	34 (100.0)	1.42 (0.91)	0.4	0.80	1.20	1.60	3.4	

Note: DITTLL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Source Data: aacq, created on: 21FEB2022

Table CT1H5C\_ILMH0: Course of ACQ-5 score  
 DITTLL

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-5 Week 12 score	Tezepelumab	31	31 (100.0)	-0.73 (0.92)	-3.2	-1.40	-0.60	0.00	0.8	0.03 [-0.45, 0.52]
	Placebo	34	34 (100.0)	-0.76 (0.95)	-3.4	-1.20	-0.60	-0.20	1.2	
Week 28	Tezepelumab	31	24 (77.4)	-0.78 (0.84)	-2.4	-1.40	-1.00	0.00	0.6	-0.05 [-0.62, 0.51]
	Placebo	34	24 (70.6)	-0.73 (1.00)	-3.0	-1.10	-0.60	-0.30	1.8	
End of treatment	Tezepelumab	31	29 (93.5)	-0.90 (0.91)	-3.2	-1.40	-1.00	-0.20	0.6	-0.22 [-0.72, 0.27]
	Placebo	34	34 (100.0)	-0.69 (0.90)	-3.0	-1.00	-0.60	-0.20	1.8	

Note: DITTLL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Source Data: aacq, created on: 21FEB2022

Table CT1H5C\_ILMC0: Change from baseline in ACQ-5 score - MMRM results  
 DITTTL

Change from baseline in ACQ-5 score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 12	Tezepelumab	31	31 (100.0)	-0.63 (0.15)	(-0.93, -0.33)	0.25 (0.21)	(-0.17, 0.67)	0.237
	Placebo	34	34 (100.0)	-0.88 (0.14)	(-1.17, -0.59)			
Week 28	Tezepelumab	31	24 (77.4)	-0.66 (0.17)	(-1.00, -0.33)	0.14 (0.24)	(-0.33, 0.62)	0.548
	Placebo	34	24 (70.6)	-0.81 (0.17)	(-1.14, -0.47)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 21FEB2022

Table MT1H6C\_ILMH0: Course of ACQ-6 score  
 DITTTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-6 score	Baseline	Tezepelumab	446	446 (100.0)	2.88 (0.86)	0.0	2.33	2.75	3.33	5.3	
		Placebo	436	436 (100.0)	2.80 (0.81)	0.3	2.25	2.67	3.25	5.7	
	Week 2	Tezepelumab	446	426 (95.5)	2.09 (0.99)	0.0	1.50	2.00	2.67	5.3	
		Placebo	436	402 (92.2)	2.26 (1.02)	0.0	1.50	2.17	2.83	5.5	
	Week 4	Tezepelumab	446	435 (97.5)	1.89 (1.00)	0.0	1.17	1.83	2.67	5.7	
		Placebo	436	418 (95.9)	2.05 (1.02)	0.0	1.33	2.00	2.67	5.3	
	Week 8	Tezepelumab	446	435 (97.5)	1.66 (1.05)	0.0	0.83	1.67	2.33	5.5	
		Placebo	436	419 (96.1)	1.92 (1.06)	0.0	1.17	1.83	2.50	5.5	
	Week 12	Tezepelumab	446	428 (96.0)	1.60 (1.12)	0.0	0.83	1.50	2.33	6.0	
		Placebo	436	414 (95.0)	1.80 (1.09)	0.0	1.00	1.83	2.50	5.7	
	Week 16	Tezepelumab	446	430 (96.4)	1.51 (1.06)	0.0	0.67	1.33	2.17	5.7	
		Placebo	436	410 (94.0)	1.78 (1.15)	0.0	1.00	1.67	2.50	5.7	
	Week 20	Tezepelumab	446	421 (94.4)	1.47 (1.09)	0.0	0.67	1.33	2.17	5.5	
		Placebo	436	403 (92.4)	1.71 (1.11)	0.0	0.83	1.67	2.50	5.3	
	Week 24	Tezepelumab	446	421 (94.4)	1.47 (1.06)	0.0	0.67	1.33	2.17	5.3	
		Placebo	436	398 (91.3)	1.73 (1.10)	0.0	0.83	1.67	2.50	5.5	
	Week 28	Tezepelumab	446	420 (94.2)	1.44 (1.09)	0.0	0.50	1.33	2.17	5.0	
		Placebo	436	398 (91.3)	1.72 (1.18)	0.0	0.83	1.50	2.50	5.3	
	Week 32	Tezepelumab	446	418 (93.7)	1.48 (1.12)	0.0	0.50	1.33	2.33	5.0	
		Placebo	436	397 (91.1)	1.74 (1.10)	0.0	0.83	1.67	2.50	5.2	
	Week 36	Tezepelumab	446	425 (95.3)	1.45 (1.10)	0.0	0.50	1.33	2.17	5.2	
		Placebo	436	394 (90.4)	1.71 (1.11)	0.0	0.83	1.67	2.50	5.5	
	Week 40	Tezepelumab	446	420 (94.2)	1.45 (1.11)	0.0	0.50	1.33	2.33	4.8	
		Placebo	436	393 (90.1)	1.70 (1.14)	0.0	0.83	1.67	2.50	5.3	
	Week 44	Tezepelumab	446	417 (93.5)	1.40 (1.09)	0.0	0.50	1.17	2.17	4.7	
		Placebo	436	389 (89.2)	1.68 (1.14)	0.0	0.83	1.50	2.50	5.0	
	Week 48	Tezepelumab	446	418 (93.7)	1.41 (1.13)	0.0	0.50	1.17	2.17	5.2	
		Placebo	436	387 (88.8)	1.66 (1.11)	0.0	0.83	1.67	2.33	5.5	
	Week 52	Tezepelumab	446	412 (92.4)	1.37 (1.10)	0.0	0.50	1.17	2.17	5.0	
		Placebo	436	384 (88.1)	1.64 (1.12)	0.0	0.83	1.50	2.33	5.5	

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Last observation carried forward is applied in case of missing values.

Source Data: aacq, created on: 21FEB2022

Table MT1H6C\_ILMH0: Course of ACQ-6 score  
 DITTTL

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-6 Week 2 score	Tezepelumab	446	426 (95.5)	-0.79 (0.91)	-4.5	-1.33	-0.67	-0.17	1.7	-0.26 [-0.40, -0.12]
	Placebo	436	402 (92.2)	-0.55 (0.88)	-4.0	-1.00	-0.50	0.00	3.2	
Week 4	Tezepelumab	446	435 (97.5)	-0.99 (0.98)	-5.0	-1.50	-0.83	-0.33	2.3	-0.25 [-0.38, -0.11]
	Placebo	436	418 (95.9)	-0.76 (0.92)	-4.0	-1.33	-0.67	-0.17	2.2	
Week 8	Tezepelumab	446	435 (97.5)	-1.23 (1.10)	-5.0	-2.00	-1.17	-0.50	2.3	-0.33 [-0.46, -0.19]
	Placebo	436	419 (96.1)	-0.88 (1.01)	-4.2	-1.50	-0.83	-0.17	2.7	
Week 12	Tezepelumab	446	428 (96.0)	-1.27 (1.13)	-5.0	-2.00	-1.17	-0.50	2.3	-0.24 [-0.37, -0.10]
	Placebo	436	414 (95.0)	-1.01 (1.04)	-4.5	-1.67	-1.00	-0.33	2.3	
Week 16	Tezepelumab	446	430 (96.4)	-1.37 (1.08)	-4.8	-2.17	-1.33	-0.67	2.3	-0.33 [-0.46, -0.19]
	Placebo	436	410 (94.0)	-1.02 (1.09)	-4.7	-1.67	-1.00	-0.33	2.5	
Week 20	Tezepelumab	446	421 (94.4)	-1.39 (1.12)	-4.8	-2.17	-1.33	-0.67	3.2	-0.28 [-0.41, -0.14]
	Placebo	436	403 (92.4)	-1.08 (1.08)	-4.8	-1.67	-1.00	-0.33	2.3	
Week 24	Tezepelumab	446	421 (94.4)	-1.39 (1.12)	-4.8	-2.17	-1.33	-0.67	2.3	-0.31 [-0.44, -0.17]
	Placebo	436	398 (91.3)	-1.06 (1.07)	-4.7	-1.83	-1.00	-0.33	2.3	
Week 28	Tezepelumab	446	420 (94.2)	-1.40 (1.11)	-5.0	-2.17	-1.33	-0.67	2.3	-0.31 [-0.45, -0.17]
	Placebo	436	398 (91.3)	-1.06 (1.13)	-4.8	-1.83	-1.00	-0.33	2.3	
Week 32	Tezepelumab	446	418 (93.7)	-1.37 (1.16)	-5.0	-2.17	-1.33	-0.67	2.5	-0.29 [-0.43, -0.15]
	Placebo	436	397 (91.1)	-1.04 (1.09)	-4.0	-1.83	-1.00	-0.33	2.3	
Week 36	Tezepelumab	446	425 (95.3)	-1.41 (1.18)	-5.0	-2.17	-1.33	-0.67	2.3	-0.29 [-0.43, -0.15]
	Placebo	436	394 (90.4)	-1.07 (1.11)	-5.0	-1.83	-1.00	-0.33	2.3	
Week 40	Tezepelumab	446	420 (94.2)	-1.41 (1.18)	-5.0	-2.17	-1.42	-0.67	2.7	-0.30 [-0.44, -0.16]
	Placebo	436	393 (90.1)	-1.07 (1.12)	-4.5	-1.83	-1.00	-0.33	2.3	
Week 44	Tezepelumab	446	417 (93.5)	-1.46 (1.14)	-5.0	-2.17	-1.50	-0.67	2.3	-0.31 [-0.45, -0.17]
	Placebo	436	389 (89.2)	-1.10 (1.14)	-4.8	-1.83	-1.00	-0.33	2.5	
Week 48	Tezepelumab	446	418 (93.7)	-1.45 (1.19)	-5.0	-2.17	-1.50	-0.67	2.3	-0.28 [-0.42, -0.14]
	Placebo	436	387 (88.8)	-1.12 (1.10)	-5.2	-1.83	-1.17	-0.33	2.3	
Week 52	Tezepelumab	446	412 (92.4)	-1.49 (1.19)	-5.2	-2.33	-1.50	-0.83	3.2	-0.29 [-0.43, -0.15]
	Placebo	436	384 (88.1)	-1.14 (1.15)	-4.3	-2.00	-1.00	-0.33	2.3	

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Last observation carried forward is applied in case of missing values.

Source Data: aacq, created on: 21FEB2022

Table MT1H6C\_ILMC0: Change from baseline in ACQ-6 score - MMRM results  
 DITTL

Change from baseline in ACQ-6 score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 2	Tezepelumab	446	426 (95.5)	-0.77 (0.04)	(-0.85, -0.69)	-0.22 (0.06)	(-0.34, -0.11)	<0.001	*
	Placebo	436	402 (92.2)	-0.55 (0.04)	(-0.63, -0.47)				
Week 4	Tezepelumab	446	432 (96.9)	-0.97 (0.04)	(-1.06, -0.89)	-0.20 (0.06)	(-0.31, -0.08)	0.001	*
	Placebo	436	417 (95.6)	-0.78 (0.04)	(-0.86, -0.69)				
Week 8	Tezepelumab	446	432 (96.9)	-1.20 (0.05)	(-1.29, -1.11)	-0.32 (0.07)	(-0.45, -0.19)	<0.001	*
	Placebo	436	418 (95.9)	-0.89 (0.05)	(-0.98, -0.79)				
Week 12	Tezepelumab	446	424 (95.1)	-1.25 (0.05)	(-1.35, -1.16)	-0.25 (0.07)	(-0.38, -0.11)	<0.001	*
	Placebo	436	410 (94.0)	-1.01 (0.05)	(-1.10, -0.91)				
Week 16	Tezepelumab	446	424 (95.1)	-1.34 (0.05)	(-1.43, -1.24)	-0.32 (0.07)	(-0.46, -0.18)	<0.001	*
	Placebo	436	404 (92.7)	-1.02 (0.05)	(-1.11, -0.92)				
Week 20	Tezepelumab	446	412 (92.4)	-1.38 (0.05)	(-1.47, -1.28)	-0.30 (0.07)	(-0.44, -0.17)	<0.001	*
	Placebo	436	393 (90.1)	-1.07 (0.05)	(-1.17, -0.97)				
Week 24	Tezepelumab	446	412 (92.4)	-1.38 (0.05)	(-1.48, -1.29)	-0.33 (0.07)	(-0.46, -0.19)	<0.001	*
	Placebo	436	387 (88.8)	-1.06 (0.05)	(-1.16, -0.96)				
Week 28	Tezepelumab	446	409 (91.7)	-1.39 (0.05)	(-1.49, -1.29)	-0.33 (0.07)	(-0.47, -0.19)	<0.001	*
	Placebo	436	386 (88.5)	-1.06 (0.05)	(-1.16, -0.96)				
Week 32	Tezepelumab	446	409 (91.7)	-1.37 (0.05)	(-1.47, -1.27)	-0.34 (0.07)	(-0.48, -0.20)	<0.001	*
	Placebo	436	385 (88.3)	-1.03 (0.05)	(-1.14, -0.93)				
Week 36	Tezepelumab	446	416 (93.3)	-1.39 (0.05)	(-1.49, -1.29)	-0.32 (0.07)	(-0.46, -0.18)	<0.001	*
	Placebo	436	382 (87.6)	-1.07 (0.05)	(-1.17, -0.97)				

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 21FEB2022

Table MT1H6C\_ILMC0: Change from baseline in ACQ-6 score - MMRM results  
 DITTTL

Change from baseline in ACQ-6 score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 40	Tezepelumab	446	408 (91.5)	-1.40 (0.05)	(-1.50, -1.30)	-0.33 (0.07)	(-0.48, -0.19)	<0.001 *	
	Placebo	436	383 (87.8)	-1.07 (0.05)	(-1.18, -0.97)				
Week 44	Tezepelumab	446	405 (90.8)	-1.45 (0.05)	(-1.55, -1.34)	-0.34 (0.07)	(-0.48, -0.19)	<0.001 *	
	Placebo	436	377 (86.5)	-1.11 (0.05)	(-1.21, -1.01)				
Week 48	Tezepelumab	446	405 (90.8)	-1.44 (0.05)	(-1.54, -1.34)	-0.35 (0.07)	(-0.49, -0.20)	<0.001 *	
	Placebo	436	375 (86.0)	-1.09 (0.05)	(-1.20, -0.99)				
Week 52	Tezepelumab	446	364 (81.6)	-1.48 (0.05)	(-1.59, -1.38)	-0.35 (0.08)	(-0.50, -0.20)	<0.001 *	
	Placebo	436	344 (78.9)	-1.13 (0.05)	(-1.24, -1.03)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 21FEB2022



Table NT1H6C\_ILMH0: Course of ACQ-6 score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-6 score	Baseline	Tezepelumab	395	395 (100.0)	2.91 (0.86)	1.3	2.33	2.83	3.33	5.3	
		Placebo	391	391 (100.0)	2.83 (0.84)	1.5	2.17	2.67	3.33	5.7	
	Week 2	Tezepelumab	395	376 (95.2)	2.06 (0.99)	0.0	1.33	2.00	2.67	5.3	
		Placebo	391	363 (92.8)	2.23 (1.05)	0.0	1.50	2.17	2.83	5.5	
	Week 4	Tezepelumab	395	386 (97.7)	1.86 (1.00)	0.0	1.00	1.83	2.50	5.7	
		Placebo	391	378 (96.7)	2.01 (1.03)	0.0	1.33	1.83	2.67	5.3	
	Week 8	Tezepelumab	395	385 (97.5)	1.64 (1.03)	0.0	0.83	1.50	2.33	5.5	
		Placebo	391	377 (96.4)	1.89 (1.05)	0.0	1.17	1.83	2.50	5.5	
	Week 12	Tezepelumab	395	378 (95.7)	1.60 (1.12)	0.0	0.83	1.50	2.33	6.0	
		Placebo	391	375 (95.9)	1.77 (1.12)	0.0	1.00	1.67	2.33	5.7	
	Week 16	Tezepelumab	395	381 (96.5)	1.48 (1.05)	0.0	0.67	1.33	2.17	5.7	
		Placebo	391	370 (94.6)	1.74 (1.15)	0.0	1.00	1.67	2.33	5.7	
	Week 20	Tezepelumab	395	371 (93.9)	1.44 (1.08)	0.0	0.67	1.33	2.17	5.5	
		Placebo	391	363 (92.8)	1.65 (1.12)	0.0	0.83	1.50	2.50	5.3	
	Week 24	Tezepelumab	395	370 (93.7)	1.42 (1.05)	0.0	0.67	1.33	2.00	5.3	
		Placebo	391	356 (91.0)	1.69 (1.11)	0.0	0.83	1.50	2.50	5.5	
	Week 28	Tezepelumab	395	368 (93.2)	1.39 (1.07)	0.0	0.50	1.17	2.00	5.0	
		Placebo	391	358 (91.6)	1.68 (1.19)	0.0	0.67	1.50	2.33	5.3	
	Week 32	Tezepelumab	395	366 (92.7)	1.43 (1.12)	0.0	0.50	1.33	2.17	5.0	
		Placebo	391	357 (91.3)	1.70 (1.11)	0.0	0.83	1.50	2.50	5.2	
	Week 36	Tezepelumab	395	373 (94.4)	1.40 (1.10)	0.0	0.50	1.33	2.17	5.2	
		Placebo	391	352 (90.0)	1.63 (1.11)	0.0	0.67	1.67	2.33	5.5	
	Week 40	Tezepelumab	395	368 (93.2)	1.40 (1.10)	0.0	0.50	1.17	2.17	4.8	
		Placebo	391	352 (90.0)	1.64 (1.14)	0.0	0.83	1.50	2.50	5.3	
	Week 44	Tezepelumab	395	363 (91.9)	1.35 (1.08)	0.0	0.50	1.17	2.00	4.7	
		Placebo	391	347 (88.7)	1.63 (1.15)	0.0	0.67	1.50	2.50	5.0	
	Week 48	Tezepelumab	395	366 (92.7)	1.35 (1.13)	0.0	0.50	1.17	2.00	5.2	
		Placebo	391	345 (88.2)	1.60 (1.12)	0.0	0.83	1.50	2.33	5.5	
	Week 52	Tezepelumab	395	359 (90.9)	1.30 (1.08)	0.0	0.50	1.00	2.00	5.0	
		Placebo	391	344 (88.0)	1.57 (1.13)	0.0	0.67	1.50	2.33	5.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Source Data: aacq, created on: 20FEB2022

Table NT1H6C\_ILMH0: Course of ACQ-6 score  
 DITTLL

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-6 Week 2 score	Tezepelumab	395	376 (95.2)	-0.84 (0.93)	-4.5	-1.42	-0.67	-0.17	1.7	-0.26 [-0.40, -0.11]
	Placebo	391	363 (92.8)	-0.60 (0.92)	-4.0	-1.00	-0.50	-0.17	3.2	
Week 4	Tezepelumab	395	386 (97.7)	-1.04 (1.00)	-5.0	-1.67	-1.00	-0.33	1.8	-0.23 [-0.37, -0.09]
	Placebo	391	378 (96.7)	-0.82 (0.94)	-4.0	-1.33	-0.67	-0.17	2.2	
Week 8	Tezepelumab	395	385 (97.5)	-1.27 (1.10)	-5.0	-2.00	-1.17	-0.50	2.3	-0.32 [-0.47, -0.18]
	Placebo	391	377 (96.4)	-0.93 (1.01)	-4.2	-1.50	-0.83	-0.33	2.7	
Week 12	Tezepelumab	395	378 (95.7)	-1.29 (1.15)	-5.0	-2.00	-1.17	-0.50	2.3	-0.21 [-0.36, -0.07]
	Placebo	391	375 (95.9)	-1.06 (1.05)	-4.5	-1.67	-1.00	-0.33	2.3	
Week 16	Tezepelumab	395	381 (96.5)	-1.42 (1.08)	-4.8	-2.17	-1.33	-0.67	1.7	-0.32 [-0.47, -0.18]
	Placebo	391	370 (94.6)	-1.07 (1.09)	-4.7	-1.67	-1.00	-0.33	2.5	
Week 20	Tezepelumab	395	371 (93.9)	-1.44 (1.14)	-4.8	-2.17	-1.33	-0.67	3.2	-0.26 [-0.40, -0.11]
	Placebo	391	363 (92.8)	-1.15 (1.09)	-4.8	-1.83	-1.17	-0.50	1.3	
Week 24	Tezepelumab	395	370 (93.7)	-1.46 (1.12)	-4.8	-2.17	-1.33	-0.67	2.3	-0.32 [-0.46, -0.17]
	Placebo	391	356 (91.0)	-1.12 (1.07)	-4.7	-1.83	-1.17	-0.50	2.0	
Week 28	Tezepelumab	395	368 (93.2)	-1.48 (1.11)	-5.0	-2.17	-1.42	-0.83	1.8	-0.31 [-0.46, -0.17]
	Placebo	391	358 (91.6)	-1.13 (1.13)	-4.8	-1.83	-1.08	-0.50	1.8	
Week 32	Tezepelumab	395	366 (92.7)	-1.44 (1.18)	-5.0	-2.17	-1.33	-0.67	2.5	-0.29 [-0.44, -0.15]
	Placebo	391	357 (91.3)	-1.10 (1.11)	-4.8	-1.83	-1.00	-0.33	2.0	
Week 36	Tezepelumab	395	373 (94.4)	-1.48 (1.20)	-5.0	-2.33	-1.50	-0.67	2.3	-0.28 [-0.42, -0.13]
	Placebo	391	352 (90.0)	-1.16 (1.11)	-5.0	-2.00	-1.08	-0.33	2.0	
Week 40	Tezepelumab	395	368 (93.2)	-1.48 (1.19)	-5.0	-2.33	-1.50	-0.67	2.7	-0.29 [-0.44, -0.14]
	Placebo	391	352 (90.0)	-1.15 (1.12)	-4.5	-2.00	-1.00	-0.33	1.8	
Week 44	Tezepelumab	395	363 (91.9)	-1.53 (1.13)	-5.0	-2.33	-1.50	-0.83	2.0	-0.31 [-0.46, -0.16]
	Placebo	391	347 (88.7)	-1.17 (1.15)	-4.8	-2.00	-1.17	-0.33	2.5	
Week 48	Tezepelumab	395	366 (92.7)	-1.53 (1.21)	-5.0	-2.33	-1.50	-0.83	2.2	-0.29 [-0.44, -0.14]
	Placebo	391	345 (88.2)	-1.19 (1.09)	-5.2	-2.00	-1.17	-0.50	2.2	
Week 52	Tezepelumab	395	359 (90.9)	-1.58 (1.19)	-5.2	-2.33	-1.67	-0.83	3.2	-0.29 [-0.44, -0.15]
	Placebo	391	344 (88.0)	-1.23 (1.16)	-4.8	-2.00	-1.17	-0.33	1.7	

Note: DITTLL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Source Data: aacq, created on: 20FEB2022

Table NT1H6C\_ILMC0: Change from baseline in ACQ-6 score - MMRM results  
 DITTTL

Change from baseline in ACQ-6 score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 2	Tezepelumab	395	376 (95.2)	-0.82 (0.04)	(-0.91, -0.74)	-0.23 (0.06)	(-0.35, -0.10)	<0.001 *	
	Placebo	391	363 (92.8)	-0.60 (0.04)	(-0.68, -0.51)				
Week 4	Tezepelumab	395	386 (97.7)	-1.02 (0.05)	(-1.11, -0.93)	-0.18 (0.06)	(-0.31, -0.05)	0.005 *	
	Placebo	391	378 (96.7)	-0.84 (0.05)	(-0.93, -0.75)				
Week 8	Tezepelumab	395	385 (97.5)	-1.24 (0.05)	(-1.34, -1.15)	-0.31 (0.07)	(-0.45, -0.18)	<0.001 *	
	Placebo	391	377 (96.4)	-0.93 (0.05)	(-1.03, -0.83)				
Week 12	Tezepelumab	395	378 (95.7)	-1.27 (0.05)	(-1.38, -1.17)	-0.23 (0.07)	(-0.37, -0.08)	0.003 *	
	Placebo	391	375 (95.9)	-1.05 (0.05)	(-1.15, -0.95)				
Week 16	Tezepelumab	395	381 (96.5)	-1.39 (0.05)	(-1.49, -1.28)	-0.32 (0.07)	(-0.46, -0.17)	<0.001 *	
	Placebo	391	370 (94.6)	-1.07 (0.05)	(-1.17, -0.97)				
Week 20	Tezepelumab	395	371 (93.9)	-1.42 (0.05)	(-1.52, -1.32)	-0.29 (0.07)	(-0.44, -0.15)	<0.001 *	
	Placebo	391	363 (92.8)	-1.13 (0.05)	(-1.23, -1.02)				
Week 24	Tezepelumab	395	370 (93.7)	-1.44 (0.05)	(-1.55, -1.34)	-0.33 (0.07)	(-0.47, -0.18)	<0.001 *	
	Placebo	391	356 (91.0)	-1.12 (0.05)	(-1.22, -1.01)				
Week 28	Tezepelumab	395	368 (93.2)	-1.45 (0.05)	(-1.55, -1.34)	-0.33 (0.08)	(-0.48, -0.18)	<0.001 *	
	Placebo	391	358 (91.6)	-1.11 (0.05)	(-1.22, -1.01)				
Week 32	Tezepelumab	395	366 (92.7)	-1.42 (0.05)	(-1.53, -1.31)	-0.34 (0.08)	(-0.49, -0.19)	<0.001 *	
	Placebo	391	357 (91.3)	-1.08 (0.06)	(-1.19, -0.97)				
Week 36	Tezepelumab	395	373 (94.4)	-1.45 (0.05)	(-1.55, -1.34)	-0.30 (0.08)	(-0.46, -0.15)	<0.001 *	
	Placebo	391	352 (90.0)	-1.14 (0.06)	(-1.25, -1.03)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 20FEB2022

Table NT1H6C\_ILMC0: Change from baseline in ACQ-6 score - MMRM results  
 DITTL

Change from baseline in ACQ-6 score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 40	Tezepelumab	395	368 (93.2)	-1.45 (0.05)	(-1.56, -1.35)	-0.32 (0.08)	(-0.47, -0.16)	<0.001 *	
	Placebo	391	352 (90.0)	-1.14 (0.06)	(-1.25, -1.03)				
Week 44	Tezepelumab	395	363 (91.9)	-1.51 (0.05)	(-1.61, -1.40)	-0.33 (0.08)	(-0.48, -0.18)	<0.001 *	
	Placebo	391	347 (88.7)	-1.17 (0.06)	(-1.28, -1.07)				
Week 48	Tezepelumab	395	366 (92.7)	-1.50 (0.06)	(-1.61, -1.40)	-0.34 (0.08)	(-0.50, -0.19)	<0.001 *	
	Placebo	391	345 (88.2)	-1.16 (0.06)	(-1.27, -1.05)				
Week 52	Tezepelumab	395	359 (90.9)	-1.55 (0.06)	(-1.66, -1.44)	-0.34 (0.08)	(-0.50, -0.19)	<0.001 *	
	Placebo	391	344 (88.0)	-1.20 (0.06)	(-1.31, -1.09)				

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 20FEB2022

Table PT3H6C\_ILMH0: Course of ACQ-6 score  
DITTTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-6 score	Baseline	Tezepelumab	66	66 (100.0)	2.71 (0.83)	0.0	2.17	2.67	3.17	4.8	
		Placebo	65	65 (100.0)	2.71 (0.72)	0.3	2.33	2.67	3.17	4.7	
	Week 2	Tezepelumab	66	63 (95.5)	2.23 (0.96)	0.0	1.50	2.33	3.00	4.2	
		Placebo	65	58 (89.2)	2.29 (0.77)	0.3	2.00	2.33	2.67	4.8	
	Week 4	Tezepelumab	66	63 (95.5)	1.98 (0.95)	0.2	1.33	2.17	2.67	3.5	
		Placebo	65	58 (89.2)	2.15 (0.91)	0.2	1.50	2.33	2.67	4.2	
	Week 6	Tezepelumab	66	63 (95.5)	1.88 (1.00)	0.0	1.00	1.83	2.67	4.0	
		Placebo	65	58 (89.2)	2.10 (1.10)	0.2	1.17	2.17	2.67	5.5	
	Week 8	Tezepelumab	66	63 (95.5)	1.74 (1.11)	0.0	0.83	1.67	2.67	4.8	
		Placebo	65	59 (90.8)	2.06 (1.08)	0.0	1.17	2.17	2.83	4.7	
	Week 10	Tezepelumab	66	63 (95.5)	1.66 (1.08)	0.0	0.83	1.67	2.67	4.3	
		Placebo	65	59 (90.8)	2.07 (1.05)	0.0	1.50	2.17	2.67	5.3	
	Week 12	Tezepelumab	66	63 (95.5)	1.56 (1.05)	0.0	0.50	1.50	2.50	4.3	
		Placebo	65	59 (90.8)	1.86 (0.99)	0.0	1.00	2.00	2.50	4.3	
	Week 14	Tezepelumab	66	63 (95.5)	1.49 (1.05)	0.0	0.67	1.50	2.17	4.3	
		Placebo	65	59 (90.8)	1.79 (0.97)	0.0	1.17	1.83	2.17	5.0	
	Week 16	Tezepelumab	66	63 (95.5)	1.63 (1.12)	0.0	0.67	1.50	2.50	4.3	
		Placebo	65	59 (90.8)	1.96 (1.15)	0.0	1.00	2.00	2.67	5.0	
	Week 18	Tezepelumab	66	64 (97.0)	1.60 (1.02)	0.0	0.75	1.58	2.33	4.3	
		Placebo	65	59 (90.8)	1.87 (1.13)	0.0	1.00	1.83	2.50	5.0	
	Week 20	Tezepelumab	66	64 (97.0)	1.62 (1.09)	0.0	0.83	1.67	2.33	5.0	
		Placebo	65	59 (90.8)	1.97 (1.08)	0.0	1.17	2.17	2.67	5.0	
	Week 22	Tezepelumab	66	64 (97.0)	1.68 (0.97)	0.0	0.92	1.83	2.33	4.3	
		Placebo	65	59 (90.8)	1.93 (1.13)	0.0	1.00	2.00	2.67	5.0	
	Week 24	Tezepelumab	66	64 (97.0)	1.67 (1.05)	0.0	0.83	1.75	2.42	4.3	
		Placebo	65	59 (90.8)	1.99 (1.04)	0.0	1.33	2.00	2.67	4.5	
	Week 26	Tezepelumab	66	65 (98.5)	1.71 (1.07)	0.0	0.83	1.83	2.50	4.3	
		Placebo	65	59 (90.8)	1.92 (1.11)	0.0	1.00	1.83	2.83	4.5	
	Week 28	Tezepelumab	66	66 (100.0)	1.66 (1.09)	0.0	0.83	1.67	2.50	4.3	
		Placebo	65	60 (92.3)	1.91 (1.18)	0.0	1.00	2.00	2.67	4.5	
	Week 30	Tezepelumab	66	66 (100.0)	1.63 (1.06)	0.0	0.83	1.67	2.33	4.3	
		Placebo	65	60 (92.3)	1.89 (1.14)	0.0	1.00	1.83	2.67	4.5	
	Week 32	Tezepelumab	66	66 (100.0)	1.58 (1.06)	0.0	0.67	1.67	2.33	4.3	
		Placebo	65	60 (92.3)	1.86 (1.09)	0.0	1.17	1.83	2.50	4.5	
	Week 34	Tezepelumab	66	66 (100.0)	1.64 (1.12)	0.0	0.67	1.50	2.50	4.3	
		Placebo	65	60 (92.3)	1.82 (1.09)	0.0	1.00	1.83	2.42	4.5	

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Last observation carried forward is applied in case of missing values.

Source Data: aacq, created on: 21FEB2022

Table PT3H6C\_ILMH0: Course of ACQ-6 score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-6 score	Week 36	Tezepelumab	66	66 (100.0)	1.61 (1.05)	0.0	0.83	1.58	2.33	4.3	
		Placebo	65	60 (92.3)	1.99 (1.13)	0.0	1.17	1.92	2.75	4.5	
	Week 38	Tezepelumab	66	66 (100.0)	1.63 (1.15)	0.0	0.83	1.67	2.50	4.5	
		Placebo	65	60 (92.3)	1.86 (1.09)	0.0	1.08	1.83	2.50	4.5	
	Week 40	Tezepelumab	66	66 (100.0)	1.61 (1.11)	0.0	0.67	1.75	2.50	4.3	
		Placebo	65	60 (92.3)	2.00 (1.13)	0.0	1.25	2.00	2.67	4.5	
	Week 42	Tezepelumab	66	66 (100.0)	1.58 (1.09)	0.0	0.83	1.67	2.33	4.3	
		Placebo	65	60 (92.3)	1.86 (1.02)	0.0	1.17	1.83	2.50	4.5	
	Week 44	Tezepelumab	66	66 (100.0)	1.61 (1.08)	0.0	0.67	1.58	2.50	4.3	
		Placebo	65	60 (92.3)	1.94 (1.06)	0.0	1.17	2.00	2.58	4.5	
	Week 46	Tezepelumab	66	66 (100.0)	1.63 (1.12)	0.0	0.83	1.83	2.50	4.3	
		Placebo	65	60 (92.3)	1.84 (0.98)	0.0	1.17	1.83	2.33	4.5	
	Week 48	Tezepelumab	66	66 (100.0)	1.63 (1.11)	0.0	0.67	1.67	2.33	4.3	
		Placebo	65	60 (92.3)	1.88 (1.05)	0.0	1.00	2.08	2.50	4.5	
	Week 50	Tezepelumab	66	66 (100.0)	1.57 (1.13)	0.0	0.67	1.50	2.33	4.3	
		Placebo	65	60 (92.3)	1.78 (0.99)	0.0	1.00	1.83	2.33	4.5	
	Week 52	Tezepelumab	66	66 (100.0)	1.60 (1.12)	0.0	0.67	1.50	2.33	4.3	
		Placebo	65	60 (92.3)	1.85 (1.04)	0.0	1.08	1.92	2.50	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Last observation carried forward is applied in case of missing values.

Source Data: aacq, created on: 21FEB2022

Table PT3H6C\_ILMH0: Course of ACQ-6 score  
 DITTL

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-6 Week 2 score	Tezepelumab	66	63 (95.5)	-0.52 (0.71)	-2.8	-1.00	-0.33	0.00	0.7	-0.11 [-0.47, 0.24]
	Placebo	65	58 (89.2)	-0.45 (0.68)	-2.8	-0.83	-0.33	0.00	1.0	
Week 4	Tezepelumab	66	63 (95.5)	-0.78 (0.83)	-2.5	-1.33	-0.83	-0.17	2.3	-0.22 [-0.58, 0.14]
	Placebo	65	58 (89.2)	-0.59 (0.90)	-3.0	-1.17	-0.33	0.00	1.2	
Week 6	Tezepelumab	66	63 (95.5)	-0.87 (0.94)	-2.7	-1.50	-1.00	-0.17	2.3	-0.24 [-0.60, 0.12]
	Placebo	65	58 (89.2)	-0.64 (0.98)	-3.3	-1.17	-0.50	0.00	1.5	
Week 8	Tezepelumab	66	63 (95.5)	-1.01 (1.04)	-3.0	-1.67	-1.00	-0.33	2.3	-0.32 [-0.67, 0.04]
	Placebo	65	59 (90.8)	-0.69 (1.00)	-3.2	-1.17	-0.67	0.00	1.0	
Week 10	Tezepelumab	66	63 (95.5)	-1.09 (1.02)	-3.2	-1.83	-1.17	-0.50	2.3	-0.39 [-0.75, -0.03]
	Placebo	65	59 (90.8)	-0.68 (1.11)	-3.3	-1.33	-0.50	-0.17	2.7	
Week 12	Tezepelumab	66	63 (95.5)	-1.19 (1.00)	-3.0	-2.00	-1.17	-0.67	2.3	-0.31 [-0.66, 0.05]
	Placebo	65	59 (90.8)	-0.89 (0.99)	-3.3	-1.33	-0.83	-0.33	1.3	
Week 14	Tezepelumab	66	63 (95.5)	-1.26 (1.01)	-3.7	-2.00	-1.17	-0.67	2.3	-0.31 [-0.66, 0.05]
	Placebo	65	59 (90.8)	-0.95 (1.02)	-3.2	-1.50	-1.00	-0.33	2.3	
Week 16	Tezepelumab	66	63 (95.5)	-1.12 (1.04)	-3.0	-2.00	-1.00	-0.50	2.3	-0.31 [-0.67, 0.05]
	Placebo	65	59 (90.8)	-0.79 (1.11)	-3.2	-1.33	-0.83	0.00	2.3	
Week 18	Tezepelumab	66	64 (97.0)	-1.14 (0.99)	-3.5	-1.83	-1.00	-0.67	2.3	-0.25 [-0.60, 0.11]
	Placebo	65	59 (90.8)	-0.87 (1.16)	-3.2	-1.67	-0.83	-0.17	2.3	
Week 20	Tezepelumab	66	64 (97.0)	-1.12 (1.00)	-3.2	-2.00	-1.08	-0.50	2.3	-0.32 [-0.68, 0.03]
	Placebo	65	59 (90.8)	-0.78 (1.11)	-3.2	-1.50	-0.83	-0.17	2.3	
Week 22	Tezepelumab	66	64 (97.0)	-1.06 (1.02)	-3.0	-1.83	-1.00	-0.67	2.3	-0.22 [-0.58, 0.13]
	Placebo	65	59 (90.8)	-0.82 (1.12)	-3.3	-1.50	-0.83	-0.33	2.3	
Week 24	Tezepelumab	66	64 (97.0)	-1.07 (0.98)	-3.2	-1.83	-1.08	-0.42	2.3	-0.30 [-0.66, 0.05]
	Placebo	65	59 (90.8)	-0.76 (1.09)	-3.2	-1.50	-0.67	0.00	2.3	
Week 26	Tezepelumab	66	65 (98.5)	-1.01 (1.03)	-2.8	-2.00	-1.00	-0.33	2.3	-0.17 [-0.53, 0.18]
	Placebo	65	59 (90.8)	-0.82 (1.13)	-3.2	-1.50	-1.00	0.17	2.3	
Week 28	Tezepelumab	66	66 (100.0)	-1.06 (1.09)	-3.2	-2.00	-1.00	-0.17	2.3	-0.23 [-0.58, 0.12]
	Placebo	65	60 (92.3)	-0.80 (1.16)	-3.2	-1.67	-0.83	-0.17	2.3	
Week 30	Tezepelumab	66	66 (100.0)	-1.08 (1.07)	-3.5	-2.00	-1.00	-0.33	2.3	-0.24 [-0.59, 0.11]
	Placebo	65	60 (92.3)	-0.81 (1.14)	-3.2	-1.50	-0.92	-0.17	2.3	
Week 32	Tezepelumab	66	66 (100.0)	-1.14 (1.00)	-3.0	-2.00	-1.00	-0.50	2.3	-0.28 [-0.63, 0.07]
	Placebo	65	60 (92.3)	-0.85 (1.09)	-3.0	-1.50	-1.00	-0.33	2.3	
Week 34	Tezepelumab	66	66 (100.0)	-1.08 (1.09)	-2.8	-2.00	-1.17	-0.33	2.3	-0.18 [-0.53, 0.17]
	Placebo	65	60 (92.3)	-0.88 (1.08)	-3.2	-1.50	-1.00	-0.17	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Last observation carried forward is applied in case of missing values.

Source Data: aacq, created on: 21FEB2022

Table PT3H6C\_ILMH0: Course of ACQ-6 score  
 DITTL

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-6 Week 36 score	Tezepelumab	66	66 (100.0)	-1.11 (1.07)	-3.0	-2.00	-1.17	-0.33	2.3	-0.36 [-0.71, -0.01]
	Placebo	65	60 (92.3)	-0.71 (1.13)	-3.5	-1.33	-0.83	-0.08	2.3	
Week 38	Tezepelumab	66	66 (100.0)	-1.08 (1.11)	-3.0	-2.00	-1.17	-0.33	2.3	-0.22 [-0.57, 0.13]
	Placebo	65	60 (92.3)	-0.85 (1.08)	-3.2	-1.33	-0.92	-0.08	2.3	
Week 40	Tezepelumab	66	66 (100.0)	-1.11 (1.09)	-3.2	-2.00	-1.08	-0.33	2.3	-0.36 [-0.71, -0.01]
	Placebo	65	60 (92.3)	-0.70 (1.15)	-3.2	-1.33	-0.75	0.17	2.3	
Week 42	Tezepelumab	66	66 (100.0)	-1.13 (1.09)	-3.3	-2.00	-1.17	-0.50	2.3	-0.27 [-0.62, 0.09]
	Placebo	65	60 (92.3)	-0.85 (1.03)	-2.8	-1.33	-1.00	-0.17	2.3	
Week 44	Tezepelumab	66	66 (100.0)	-1.10 (1.09)	-3.5	-2.00	-1.08	-0.50	2.3	-0.31 [-0.66, 0.04]
	Placebo	65	60 (92.3)	-0.77 (1.09)	-3.3	-1.50	-0.83	0.00	2.3	
Week 46	Tezepelumab	66	66 (100.0)	-1.09 (1.08)	-3.3	-2.00	-1.00	-0.17	2.3	-0.21 [-0.56, 0.14]
	Placebo	65	60 (92.3)	-0.87 (1.00)	-3.2	-1.42	-1.00	-0.33	2.3	
Week 48	Tezepelumab	66	66 (100.0)	-1.08 (1.07)	-2.7	-2.00	-1.00	-0.50	2.3	-0.24 [-0.59, 0.11]
	Placebo	65	60 (92.3)	-0.82 (1.07)	-3.3	-1.42	-0.83	-0.33	2.3	
Week 50	Tezepelumab	66	66 (100.0)	-1.14 (1.09)	-2.7	-2.00	-1.17	-0.50	2.3	-0.20 [-0.55, 0.15]
	Placebo	65	60 (92.3)	-0.93 (1.01)	-3.5	-1.42	-1.00	-0.42	2.3	
Week 52	Tezepelumab	66	66 (100.0)	-1.11 (1.08)	-2.7	-2.00	-1.08	-0.50	2.3	-0.24 [-0.59, 0.11]
	Placebo	65	60 (92.3)	-0.86 (1.06)	-3.5	-1.42	-0.83	-0.25	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Last observation carried forward is applied in case of missing values.

Source Data: aacq, created on: 21FEB2022



Table PT3H6C\_ILMC0: Change from baseline in ACQ-6 score - MMRM results  
 DITTTL

Change from baseline in ACQ-6 score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 2	Tezepelumab	66	63 (95.5)	NE		NE			
	Placebo	65	58 (89.2)						
Week 4	Tezepelumab	66	60 (90.9)	NE		NE			
	Placebo	65	57 (87.7)						
Week 6	Tezepelumab	66	59 (89.4)	NE		NE			
	Placebo	65	57 (87.7)						
Week 8	Tezepelumab	66	60 (90.9)	NE		NE			
	Placebo	65	58 (89.2)						
Week 10	Tezepelumab	66	59 (89.4)	NE		NE			
	Placebo	65	56 (86.2)						
Week 12	Tezepelumab	66	59 (89.4)	NE		NE			
	Placebo	65	55 (84.6)						
Week 14	Tezepelumab	66	59 (89.4)	NE		NE			
	Placebo	65	54 (83.1)						
Week 16	Tezepelumab	66	57 (86.4)	NE		NE			
	Placebo	65	53 (81.5)						
Week 18	Tezepelumab	66	59 (89.4)	NE		NE			
	Placebo	65	50 (76.9)						
Week 20	Tezepelumab	66	55 (83.3)	NE		NE			
	Placebo	65	49 (75.4)						

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 21FEB2022

Table PT3H6C\_ILMC0: Change from baseline in ACQ-6 score - MMRM results  
DITTTL

Change from baseline in ACQ-6 score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 22	Tezepelumab	66	55 (83.3)	NE		NE			
	Placebo	65	50 (76.9)						
Week 24	Tezepelumab	66	55 (83.3)	NE		NE			
	Placebo	65	48 (73.8)						
Week 26	Tezepelumab	66	56 (84.8)	NE		NE			
	Placebo	65	47 (72.3)						
Week 28	Tezepelumab	66	55 (83.3)	NE		NE			
	Placebo	65	48 (73.8)						
Week 30	Tezepelumab	66	56 (84.8)	NE		NE			
	Placebo	65	46 (70.8)						
Week 32	Tezepelumab	66	57 (86.4)	NE		NE			
	Placebo	65	48 (73.8)						
Week 34	Tezepelumab	66	57 (86.4)	NE		NE			
	Placebo	65	46 (70.8)						
Week 36	Tezepelumab	66	57 (86.4)	NE		NE			
	Placebo	65	48 (73.8)						
Week 38	Tezepelumab	66	56 (84.8)	NE		NE			
	Placebo	65	48 (73.8)						
Week 40	Tezepelumab	66	54 (81.8)	NE		NE			
	Placebo	65	50 (76.9)						

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 21FEB2022

Table PT3H6C\_ILMC0: Change from baseline in ACQ-6 score - MMRM results  
 DITTTL

Change from baseline in ACQ-6 score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 42	Tezepelumab	66	54 (81.8)	NE		NE			
	Placebo	65	47 (72.3)						
Week 44	Tezepelumab	66	54 (81.8)	NE		NE			
	Placebo	65	48 (73.8)						
Week 46	Tezepelumab	66	54 (81.8)	NE		NE			
	Placebo	65	48 (73.8)						
Week 48	Tezepelumab	66	53 (80.3)	NE		NE			
	Placebo	65	48 (73.8)						
Week 50	Tezepelumab	66	54 (81.8)	NE		NE			
	Placebo	65	49 (75.4)						
Week 52	Tezepelumab	66	18 (27.3)	NE		NE			
	Placebo	65	20 (30.8)						

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 21FEB2022

Table ST1H6C\_ILMH0: Course of ACQ-6 score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-6 score	Baseline	Tezepelumab	73	73 (100.0)	2.46 (1.06)	0.0	1.83	2.50	3.00	5.2	
		Placebo	76	76 (100.0)	2.46 (1.03)	0.2	1.83	2.50	3.25	4.8	
	Week 4	Tezepelumab	73	71 (97.3)	1.77 (1.11)	0.0	0.83	1.67	2.50	5.0	
		Placebo	76	76 (100.0)	2.16 (0.94)	0.0	1.50	2.08	3.00	3.7	
	Week 8	Tezepelumab	73	70 (95.9)	1.60 (1.14)	0.0	0.67	1.50	2.33	5.3	
		Placebo	76	70 (92.1)	2.14 (1.10)	0.0	1.50	2.17	2.83	4.5	
	Week 12	Tezepelumab	73	70 (95.9)	1.82 (1.17)	0.0	1.00	1.75	2.50	5.7	
		Placebo	76	74 (97.4)	2.17 (1.11)	0.0	1.33	2.17	2.83	5.7	
	Week 16	Tezepelumab	73	69 (94.5)	1.77 (1.20)	0.0	1.00	1.83	2.50	5.8	
		Placebo	76	70 (92.1)	1.94 (1.09)	0.0	1.00	2.08	2.67	4.3	
	Week 20	Tezepelumab	73	69 (94.5)	1.63 (1.18)	0.0	0.83	1.50	2.33	5.3	
		Placebo	76	71 (93.4)	1.94 (1.14)	0.0	1.17	2.00	2.83	4.2	
	Week 24	Tezepelumab	73	68 (93.2)	1.64 (1.27)	0.0	0.58	1.50	2.67	5.5	
		Placebo	76	73 (96.1)	2.06 (1.18)	0.0	1.33	2.00	2.83	5.2	
	Week 28	Tezepelumab	73	66 (90.4)	1.54 (1.16)	0.0	0.83	1.33	2.17	5.5	
		Placebo	76	70 (92.1)	1.94 (1.28)	0.0	1.00	1.75	3.00	4.8	
	Week 32	Tezepelumab	73	66 (90.4)	1.51 (1.20)	0.0	0.67	1.33	2.17	5.7	
		Placebo	76	72 (94.7)	1.93 (1.19)	0.0	0.83	2.00	2.83	4.5	
	Week 36	Tezepelumab	73	64 (87.7)	1.50 (1.19)	0.0	0.50	1.33	2.17	5.7	
		Placebo	76	70 (92.1)	1.90 (1.15)	0.0	1.17	2.00	2.67	5.3	
	Week 40	Tezepelumab	73	62 (84.9)	1.43 (1.22)	0.0	0.33	1.33	2.33	5.7	
		Placebo	76	68 (89.5)	1.89 (1.28)	0.0	0.75	1.92	2.83	5.2	
	Week 44	Tezepelumab	73	64 (87.7)	1.48 (1.16)	0.0	0.50	1.33	2.42	5.0	
		Placebo	76	72 (94.7)	1.97 (1.21)	0.0	1.00	1.92	2.67	5.2	
	Week 48	Tezepelumab	73	65 (89.0)	1.52 (1.26)	0.0	0.67	1.17	2.33	5.8	
		Placebo	76	68 (89.5)	1.95 (1.16)	0.0	1.00	1.83	2.83	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Source Data: aacq, created on: 23FEB2022

Table ST1H6C\_ILMH0: Course of ACQ-6 score  
 DITTLL

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-6 Week 4 score	Tezepelumab	73	71 (97.3)	-0.71 (1.04)	-3.0	-1.17	-0.50	-0.17	3.5	-0.46 [-0.78, -0.13]
	Placebo	76	76 (100.0)	-0.31 (0.68)	-2.5	-0.58	-0.33	0.17	1.0	
Week 8	Tezepelumab	73	70 (95.9)	-0.87 (1.00)	-3.3	-1.50	-0.67	-0.17	0.8	-0.60 [-0.94, -0.26]
	Placebo	76	70 (92.1)	-0.30 (0.89)	-2.5	-0.83	-0.33	0.17	1.7	
Week 12	Tezepelumab	73	70 (95.9)	-0.66 (1.26)	-3.5	-1.50	-0.67	0.00	4.3	-0.33 [-0.66, -0.00]
	Placebo	76	74 (97.4)	-0.30 (0.96)	-2.7	-0.83	-0.33	0.17	2.8	
Week 16	Tezepelumab	73	69 (94.5)	-0.71 (1.23)	-3.3	-1.67	-0.50	0.17	2.7	-0.14 [-0.48, 0.19]
	Placebo	76	70 (92.1)	-0.55 (0.97)	-3.5	-1.17	-0.50	0.00	2.0	
Week 20	Tezepelumab	73	69 (94.5)	-0.86 (1.13)	-3.7	-1.67	-0.83	0.00	1.8	-0.32 [-0.66, 0.01]
	Placebo	76	71 (93.4)	-0.52 (0.95)	-2.8	-1.33	-0.33	0.17	1.3	
Week 24	Tezepelumab	73	68 (93.2)	-0.81 (1.18)	-3.0	-1.50	-0.67	0.00	3.3	-0.38 [-0.71, -0.05]
	Placebo	76	73 (96.1)	-0.41 (0.93)	-2.7	-1.00	-0.33	0.33	1.8	
Week 28	Tezepelumab	73	66 (90.4)	-0.88 (1.19)	-3.7	-1.67	-0.92	-0.17	2.3	-0.37 [-0.71, -0.03]
	Placebo	76	70 (92.1)	-0.46 (1.03)	-3.3	-1.00	-0.50	0.17	2.0	
Week 32	Tezepelumab	73	66 (90.4)	-0.90 (1.22)	-3.7	-1.83	-0.83	0.00	2.3	-0.38 [-0.72, -0.04]
	Placebo	76	72 (94.7)	-0.49 (0.93)	-3.0	-1.17	-0.42	0.17	1.3	
Week 36	Tezepelumab	73	64 (87.7)	-0.89 (1.22)	-3.8	-1.83	-0.83	0.00	2.0	-0.31 [-0.65, 0.03]
	Placebo	76	70 (92.1)	-0.54 (1.01)	-3.2	-1.17	-0.50	0.00	1.7	
Week 40	Tezepelumab	73	62 (84.9)	-0.99 (1.22)	-3.2	-1.83	-1.17	-0.17	2.2	-0.35 [-0.70, -0.01]
	Placebo	76	68 (89.5)	-0.57 (1.20)	-3.7	-1.33	-0.50	0.17	2.8	
Week 44	Tezepelumab	73	64 (87.7)	-0.94 (1.24)	-3.7	-1.92	-1.00	0.00	2.5	-0.42 [-0.76, -0.07]
	Placebo	76	72 (94.7)	-0.45 (1.11)	-3.0	-1.17	-0.33	0.42	2.8	
Week 48	Tezepelumab	73	65 (89.0)	-0.92 (1.26)	-3.7	-2.00	-1.17	0.00	2.2	-0.36 [-0.70, -0.01]
	Placebo	76	68 (89.5)	-0.52 (1.02)	-3.0	-1.33	-0.33	0.17	1.7	

Note: DITTLL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Source Data: aacq, created on: 23FEB2022

Table ST1H6C\_ILMC0: Change from baseline in ACQ-6 score - MMRM results  
DITTL

Change from baseline in ACQ-6 score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	73	71 (97.3)	-0.69 (0.09)	(-0.88, -0.51)	-0.39 (0.13)	(-0.65, -0.14)	0.003 *
	Placebo	76	76 (100.0)	-0.30 (0.09)	(-0.48, -0.12)			
Week 8	Tezepelumab	73	70 (95.9)	-0.86 (0.10)	(-1.07, -0.66)	-0.56 (0.15)	(-0.85, -0.27)	<0.001 *
	Placebo	76	70 (92.1)	-0.30 (0.10)	(-0.51, -0.10)			
Week 12	Tezepelumab	73	70 (95.9)	-0.66 (0.12)	(-0.90, -0.42)	-0.36 (0.17)	(-0.69, -0.03)	0.033 *
	Placebo	76	74 (97.4)	-0.30 (0.12)	(-0.53, -0.07)			
Week 16	Tezepelumab	73	69 (94.5)	-0.70 (0.12)	(-0.94, -0.47)	-0.18 (0.17)	(-0.50, 0.15)	0.294
	Placebo	76	70 (92.1)	-0.53 (0.12)	(-0.76, -0.30)			
Week 20	Tezepelumab	73	69 (94.5)	-0.85 (0.11)	(-1.08, -0.63)	-0.30 (0.16)	(-0.62, 0.02)	0.062
	Placebo	76	71 (93.4)	-0.55 (0.11)	(-0.77, -0.33)			
Week 24	Tezepelumab	73	68 (93.2)	-0.80 (0.12)	(-1.04, -0.56)	-0.37 (0.17)	(-0.70, -0.04)	0.029 *
	Placebo	76	73 (96.1)	-0.43 (0.12)	(-0.66, -0.20)			
Week 28	Tezepelumab	73	66 (90.4)	-0.84 (0.13)	(-1.09, -0.59)	-0.32 (0.18)	(-0.67, 0.03)	0.073
	Placebo	76	70 (92.1)	-0.52 (0.12)	(-0.76, -0.27)			
Week 32	Tezepelumab	73	66 (90.4)	-0.91 (0.12)	(-1.15, -0.67)	-0.42 (0.17)	(-0.76, -0.09)	0.014 *
	Placebo	76	72 (94.7)	-0.49 (0.12)	(-0.72, -0.25)			
Week 36	Tezepelumab	73	64 (87.7)	-0.89 (0.12)	(-1.14, -0.65)	-0.34 (0.17)	(-0.68, -0.00)	0.047 *
	Placebo	76	70 (92.1)	-0.55 (0.12)	(-0.78, -0.32)			
Week 40	Tezepelumab	73	62 (84.9)	-0.92 (0.14)	(-1.19, -0.65)	-0.33 (0.19)	(-0.70, 0.05)	0.085
	Placebo	76	68 (89.5)	-0.59 (0.13)	(-0.85, -0.33)			

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 23FEB2022

Table ST1H6C\_ILMC0: Change from baseline in ACQ-6 score - MMRM results  
 DITTTL

Change from baseline in ACQ-6 score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 44	Tezepelumab	73	64 (87.7)	-0.86 (0.13)	(-1.13, -0.60)	-0.41 (0.18)	(-0.77, -0.04)	0.028 *
	Placebo	76	72 (94.7)	-0.46 (0.13)	(-0.71, -0.21)			
Week 48	Tezepelumab	73	65 (89.0)	-0.88 (0.13)	(-1.13, -0.62)	-0.38 (0.18)	(-0.74, -0.03)	0.035 *
	Placebo	76	68 (89.5)	-0.50 (0.12)	(-0.74, -0.25)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 23FEB2022

Table DT1H6C\_BLMH0: Course of ACQ-6 score  
 DITTNL - LTE

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-6 score	Baseline	Teze+Teze	310	310 (100.0)	2.94 (0.82)	1.3	2.33	2.83	3.33	5.3	
		Pbo+Pbo	149	149 (100.0)	2.91 (0.85)	1.7	2.33	2.83	3.33	5.7	
	Week 2	Teze+Teze	310	296 (95.5)	2.07 (0.98)	0.0	1.42	2.00	2.67	5.3	
		Pbo+Pbo	149	138 (92.6)	2.27 (0.99)	0.3	1.50	2.17	2.83	5.2	
	Week 4	Teze+Teze	310	304 (98.1)	1.87 (0.98)	0.0	1.17	1.83	2.50	5.0	
		Pbo+Pbo	149	146 (98.0)	2.00 (1.08)	0.0	1.17	2.00	2.67	5.3	
	Week 8	Teze+Teze	310	303 (97.7)	1.61 (0.99)	0.0	0.83	1.50	2.33	4.5	
		Pbo+Pbo	149	146 (98.0)	1.99 (1.11)	0.0	1.17	2.00	2.67	5.5	
	Week 12	Teze+Teze	310	299 (96.5)	1.59 (1.12)	0.0	0.83	1.50	2.33	5.5	
		Pbo+Pbo	149	148 (99.3)	1.79 (1.17)	0.0	1.00	1.67	2.50	5.5	
	Week 16	Teze+Teze	310	306 (98.7)	1.46 (1.04)	0.0	0.67	1.33	2.17	5.0	
		Pbo+Pbo	149	146 (98.0)	1.74 (1.26)	0.0	0.83	1.58	2.33	5.7	
	Week 20	Teze+Teze	310	300 (96.8)	1.47 (1.08)	0.0	0.67	1.33	2.17	4.7	
		Pbo+Pbo	149	145 (97.3)	1.74 (1.21)	0.0	0.83	1.50	2.50	5.3	
	Week 24	Teze+Teze	310	300 (96.8)	1.43 (1.03)	0.0	0.50	1.33	2.17	5.0	
		Pbo+Pbo	149	144 (96.6)	1.78 (1.22)	0.0	0.92	1.67	2.58	5.5	
	Week 28	Teze+Teze	310	300 (96.8)	1.42 (1.09)	0.0	0.50	1.17	2.17	5.0	
		Pbo+Pbo	149	144 (96.6)	1.68 (1.25)	0.0	0.67	1.50	2.50	5.3	
	Week 32	Teze+Teze	310	299 (96.5)	1.44 (1.11)	0.0	0.50	1.33	2.17	5.0	
		Pbo+Pbo	149	145 (97.3)	1.77 (1.18)	0.0	0.83	1.50	2.50	5.2	
	Week 36	Teze+Teze	310	308 (99.4)	1.41 (1.11)	0.0	0.50	1.33	2.17	5.2	
		Pbo+Pbo	149	146 (98.0)	1.75 (1.20)	0.0	0.83	1.67	2.50	5.5	
	Week 40	Teze+Teze	310	303 (97.7)	1.41 (1.09)	0.0	0.50	1.17	2.33	4.8	
		Pbo+Pbo	149	147 (98.7)	1.79 (1.21)	0.0	0.83	1.67	2.50	5.3	
	Week 44	Teze+Teze	310	300 (96.8)	1.38 (1.09)	0.0	0.50	1.17	2.00	4.7	
		Pbo+Pbo	149	145 (97.3)	1.75 (1.23)	0.0	0.67	1.50	2.67	5.0	
	Week 48	Teze+Teze	310	303 (97.7)	1.37 (1.13)	0.0	0.50	1.17	2.00	5.2	
		Pbo+Pbo	149	143 (96.0)	1.74 (1.16)	0.0	0.83	1.50	2.50	5.2	
	Week 52	Teze+Teze	310	301 (97.1)	1.31 (1.07)	0.0	0.33	1.17	2.00	4.7	
		Pbo+Pbo	149	145 (97.3)	1.64 (1.18)	0.0	0.83	1.50	2.33	5.2	
	Week 64	Teze+Teze	310	306 (98.7)	1.31 (1.06)	0.0	0.50	1.17	2.17	5.2	
		Pbo+Pbo	149	144 (96.6)	1.68 (1.19)	0.0	0.67	1.58	2.33	5.5	
	Week 76	Teze+Teze	310	301 (97.1)	1.39 (1.12)	0.0	0.50	1.17	2.17	4.8	
		Pbo+Pbo	149	147 (98.7)	1.74 (1.22)	0.0	0.67	1.67	2.50	5.2	
	Week 88	Teze+Teze	310	297 (95.8)	1.32 (1.08)	0.0	0.50	1.17	2.17	5.0	
		Pbo+Pbo	149	142 (95.3)	1.67 (1.23)	0.0	0.67	1.50	2.50	5.7	
	Week 104	Teze+Teze	310	291 (93.9)	1.23 (1.06)	0.0	0.33	1.00	2.00	4.8	
		Pbo+Pbo	149	142 (95.3)	1.61 (1.16)	0.0	0.67	1.67	2.33	5.5	

Note: DITTNL - LTE = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.  
 Source Data: aacq, created on: 20JUL2022



Table DT1H6C\_BLMH0: Course of ACQ-6 score  
 DITTNL - LTE

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-6 Week 2 score	Teze+Teze	310	296 (95.5)	-0.88 (0.90)	-4.5	-1.50	-0.75	-0.33	1.3	-0.24 [-0.45, -0.04]
	Pbo+Pbo	149	138 (92.6)	-0.65 (0.92)	-3.8	-1.00	-0.50	-0.17	1.8	
Week 4	Teze+Teze	310	304 (98.1)	-1.07 (0.96)	-5.0	-1.67	-1.00	-0.33	1.8	-0.18 [-0.38, 0.02]
	Pbo+Pbo	149	146 (98.0)	-0.89 (0.98)	-3.8	-1.50	-0.67	-0.17	2.0	
Week 8	Teze+Teze	310	303 (97.7)	-1.33 (1.06)	-5.0	-2.00	-1.33	-0.50	1.8	-0.38 [-0.58, -0.18]
	Pbo+Pbo	149	146 (98.0)	-0.92 (1.08)	-4.2	-1.67	-0.83	-0.17	2.7	
Week 12	Teze+Teze	310	299 (96.5)	-1.33 (1.13)	-5.0	-2.00	-1.33	-0.50	2.3	-0.19 [-0.39, 0.00]
	Pbo+Pbo	149	148 (99.3)	-1.12 (1.12)	-4.2	-1.92	-1.17	-0.33	2.0	
Week 16	Teze+Teze	310	306 (98.7)	-1.48 (1.04)	-4.8	-2.17	-1.42	-0.83	1.7	-0.30 [-0.50, -0.11]
	Pbo+Pbo	149	146 (98.0)	-1.15 (1.16)	-4.5	-2.00	-1.17	-0.50	2.5	
Week 20	Teze+Teze	310	300 (96.8)	-1.46 (1.10)	-4.8	-2.17	-1.50	-0.67	1.3	-0.28 [-0.48, -0.08]
	Pbo+Pbo	149	145 (97.3)	-1.15 (1.18)	-4.2	-2.00	-1.17	-0.33	1.3	
Week 24	Teze+Teze	310	300 (96.8)	-1.50 (1.10)	-4.8	-2.17	-1.33	-0.67	1.7	-0.35 [-0.55, -0.15]
	Pbo+Pbo	149	144 (96.6)	-1.11 (1.15)	-4.3	-1.83	-1.17	-0.33	2.0	
Week 28	Teze+Teze	310	300 (96.8)	-1.50 (1.09)	-5.0	-2.33	-1.50	-0.83	1.8	-0.24 [-0.44, -0.04]
	Pbo+Pbo	149	144 (96.6)	-1.23 (1.17)	-4.2	-2.00	-1.17	-0.50	1.5	
Week 32	Teze+Teze	310	299 (96.5)	-1.49 (1.16)	-5.0	-2.17	-1.50	-0.67	2.5	-0.30 [-0.50, -0.10]
	Pbo+Pbo	149	145 (97.3)	-1.15 (1.16)	-4.8	-2.00	-1.17	-0.33	2.0	
Week 36	Teze+Teze	310	308 (99.4)	-1.52 (1.17)	-5.0	-2.33	-1.50	-0.67	2.3	-0.31 [-0.51, -0.12]
	Pbo+Pbo	149	146 (98.0)	-1.15 (1.20)	-4.8	-2.00	-1.17	-0.17	2.0	
Week 40	Teze+Teze	310	303 (97.7)	-1.52 (1.15)	-5.0	-2.33	-1.50	-0.67	2.0	-0.36 [-0.55, -0.16]
	Pbo+Pbo	149	147 (98.7)	-1.11 (1.17)	-4.0	-2.00	-1.00	-0.17	1.8	
Week 44	Teze+Teze	310	300 (96.8)	-1.55 (1.11)	-5.0	-2.33	-1.50	-0.83	1.8	-0.34 [-0.54, -0.14]
	Pbo+Pbo	149	145 (97.3)	-1.16 (1.24)	-4.8	-2.00	-1.17	-0.33	2.5	
Week 48	Teze+Teze	310	303 (97.7)	-1.57 (1.18)	-5.0	-2.33	-1.50	-0.83	2.0	-0.34 [-0.55, -0.14]
	Pbo+Pbo	149	143 (96.0)	-1.16 (1.13)	-3.8	-2.00	-1.17	-0.33	1.5	
Week 52	Teze+Teze	310	301 (97.1)	-1.63 (1.13)	-5.2	-2.33	-1.67	-0.83	1.7	-0.31 [-0.50, -0.11]
	Pbo+Pbo	149	145 (97.3)	-1.28 (1.19)	-4.8	-2.17	-1.17	-0.33	1.0	
Week 64	Teze+Teze	310	306 (98.7)	-1.63 (1.09)	-5.0	-2.33	-1.67	-1.00	1.7	-0.35 [-0.55, -0.15]
	Pbo+Pbo	149	144 (96.6)	-1.24 (1.21)	-4.2	-2.00	-1.17	-0.33	2.2	
Week 76	Teze+Teze	310	301 (97.1)	-1.56 (1.12)	-5.0	-2.33	-1.67	-0.83	1.8	-0.35 [-0.55, -0.15]
	Pbo+Pbo	149	147 (98.7)	-1.17 (1.12)	-4.3	-1.83	-1.17	-0.33	1.7	
Week 88	Teze+Teze	310	297 (95.8)	-1.63 (1.10)	-5.2	-2.33	-1.67	-0.83	1.5	-0.35 [-0.55, -0.15]
	Pbo+Pbo	149	142 (95.3)	-1.24 (1.17)	-4.5	-2.00	-1.17	-0.50	1.3	
Week 104	Teze+Teze	310	291 (93.9)	-1.70 (1.08)	-5.0	-2.33	-1.83	-1.00	1.8	-0.35 [-0.55, -0.15]
	Pbo+Pbo	149	142 (95.3)	-1.31 (1.21)	-4.8	-2.17	-1.17	-0.50	2.0	

Note: DITTNL - LTE = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.  
 Source Data: aacq, created on: 20JUL2022

Table DT1H6C\_BLMC0: Change from baseline in ACQ-6 score - MMRM results  
 DITTNL - LTE

Change from baseline in ACQ-6 score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 2	Teze+Teze	310	296 (95.5)	-0.87 (0.05)	(-0.96, -0.77)	-0.23 (0.09)	(-0.40, -0.06)	0.008	*
	Pbo+Pbo	149	138 (92.6)	-0.64 (0.07)	(-0.78, -0.50)				
Week 4	Teze+Teze	310	304 (98.1)	-1.07 (0.05)	(-1.17, -0.97)	-0.16 (0.09)	(-0.34, 0.01)	0.072	
	Pbo+Pbo	149	146 (98.0)	-0.91 (0.07)	(-1.05, -0.76)				
Week 8	Teze+Teze	310	303 (97.7)	-1.32 (0.05)	(-1.43, -1.22)	-0.38 (0.10)	(-0.57, -0.19)	<0.001	*
	Pbo+Pbo	149	146 (98.0)	-0.94 (0.08)	(-1.10, -0.78)				
Week 12	Teze+Teze	310	299 (96.5)	-1.34 (0.06)	(-1.46, -1.22)	-0.22 (0.11)	(-0.42, -0.01)	0.041	*
	Pbo+Pbo	149	148 (99.3)	-1.12 (0.09)	(-1.29, -0.96)				
Week 16	Teze+Teze	310	306 (98.7)	-1.47 (0.06)	(-1.58, -1.36)	-0.31 (0.10)	(-0.51, -0.11)	0.003	*
	Pbo+Pbo	149	146 (98.0)	-1.17 (0.08)	(-1.33, -1.00)				
Week 20	Teze+Teze	310	300 (96.8)	-1.46 (0.06)	(-1.58, -1.35)	-0.31 (0.10)	(-0.52, -0.11)	0.003	*
	Pbo+Pbo	149	145 (97.3)	-1.15 (0.09)	(-1.32, -0.98)				
Week 24	Teze+Teze	310	300 (96.8)	-1.50 (0.06)	(-1.62, -1.39)	-0.37 (0.10)	(-0.57, -0.17)	<0.001	*
	Pbo+Pbo	149	144 (96.6)	-1.14 (0.08)	(-1.30, -0.97)				
Week 28	Teze+Teze	310	300 (96.8)	-1.50 (0.06)	(-1.61, -1.38)	-0.26 (0.11)	(-0.47, -0.06)	0.012	*
	Pbo+Pbo	149	144 (96.6)	-1.23 (0.09)	(-1.40, -1.06)				
Week 32	Teze+Teze	310	299 (96.5)	-1.50 (0.06)	(-1.62, -1.38)	-0.35 (0.11)	(-0.56, -0.14)	0.001	*
	Pbo+Pbo	149	145 (97.3)	-1.15 (0.09)	(-1.32, -0.97)				
Week 36	Teze+Teze	310	308 (99.4)	-1.52 (0.06)	(-1.64, -1.40)	-0.37 (0.11)	(-0.58, -0.16)	<0.001	*
	Pbo+Pbo	149	146 (98.0)	-1.15 (0.09)	(-1.32, -0.97)				

Note: DITTNL - LTE = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.  
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.  
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.  
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.  
 ACQ = asthma control questionnaire.  
 Source Data: aacq, created on: 20JUL2022

Table DT1H6C\_BLMC0: Change from baseline in ACQ-6 score - MMRM results  
DITTNL - LTE

Change from baseline in ACQ-6 score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 40	Teze+Teze	310	303 (97.7)	-1.52 (0.06)	(-1.63, -1.40)	-0.40 (0.11)	(-0.61, -0.19)	<0.001 *	
	Pbo+Pbo	149	147 (98.7)	-1.12 (0.09)	(-1.29, -0.94)				
Week 44	Teze+Teze	310	300 (96.8)	-1.55 (0.06)	(-1.67, -1.43)	-0.37 (0.11)	(-0.58, -0.16)	<0.001 *	
	Pbo+Pbo	149	145 (97.3)	-1.18 (0.09)	(-1.35, -1.00)				
Week 48	Teze+Teze	310	303 (97.7)	-1.57 (0.06)	(-1.69, -1.45)	-0.39 (0.11)	(-0.60, -0.17)	<0.001 *	
	Pbo+Pbo	149	143 (96.0)	-1.18 (0.09)	(-1.35, -1.00)				
Week 52	Teze+Teze	310	301 (97.1)	-1.64 (0.06)	(-1.75, -1.52)	-0.36 (0.10)	(-0.57, -0.16)	<0.001 *	
	Pbo+Pbo	149	145 (97.3)	-1.27 (0.09)	(-1.44, -1.10)				
Week 64	Teze+Teze	310	306 (98.7)	-1.62 (0.06)	(-1.74, -1.51)	-0.37 (0.10)	(-0.58, -0.17)	<0.001 *	
	Pbo+Pbo	149	144 (96.6)	-1.25 (0.09)	(-1.42, -1.08)				
Week 76	Teze+Teze	310	301 (97.1)	-1.53 (0.06)	(-1.65, -1.41)	-0.35 (0.11)	(-0.55, -0.14)	0.001 *	
	Pbo+Pbo	149	147 (98.7)	-1.19 (0.09)	(-1.36, -1.01)				
Week 88	Teze+Teze	310	297 (95.8)	-1.59 (0.06)	(-1.71, -1.47)	-0.35 (0.11)	(-0.56, -0.14)	0.001 *	
	Pbo+Pbo	149	142 (95.3)	-1.25 (0.09)	(-1.42, -1.08)				
Week 104	Teze+Teze	310	291 (93.9)	-1.67 (0.06)	(-1.79, -1.55)	-0.38 (0.10)	(-0.58, -0.17)	<0.001 *	
	Pbo+Pbo	149	142 (95.3)	-1.29 (0.09)	(-1.46, -1.13)				

Note: DITTNL - LTE = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.  
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.  
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.  
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.  
ACQ = asthma control questionnaire.  
Source Data: aacq, created on: 20JUL2022

Table CT1H6C\_ILMH0: Course of ACQ-6 score  
 DITTLL

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-6 score	Baseline	Tezepelumab	31	31 (100.0)	2.35 (0.79)	0.0	2.00	2.33	3.00	3.7
		Placebo	34	34 (100.0)	1.99 (0.71)	0.8	1.50	1.83	2.33	3.5
	Week 12	Tezepelumab	31	31 (100.0)	1.68 (1.02)	0.0	0.83	1.50	2.50	3.7
		Placebo	34	34 (100.0)	1.26 (0.65)	0.0	0.83	1.33	1.50	2.8
	Week 28	Tezepelumab	31	24 (77.4)	1.67 (0.90)	0.3	0.92	1.58	2.33	3.3
		Placebo	34	24 (70.6)	1.42 (0.87)	0.3	0.75	1.25	1.58	3.3
	End of treatment	Tezepelumab	31	29 (93.5)	1.54 (0.90)	0.3	0.83	1.33	2.17	3.3
		Placebo	34	34 (100.0)	1.33 (0.85)	0.3	0.67	1.17	1.50	3.3

Note: DITTLL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Source Data: aacq, created on: 21FEB2022

Table CT1H6C\_ILMH0: Course of ACQ-6 score  
 DITTL

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-6 Week 12 score	Tezepelumab	31	31 (100.0)	-0.67 (0.88)	-3.3	-1.33	-0.50	0.00	0.5	0.06 [-0.42, 0.55]
	Placebo	34	34 (100.0)	-0.73 (0.94)	-3.3	-1.17	-0.58	-0.17	1.3	
Week 28	Tezepelumab	31	24 (77.4)	-0.69 (0.77)	-2.5	-1.17	-0.92	-0.08	0.7	-0.02 [-0.59, 0.54]
	Placebo	34	24 (70.6)	-0.67 (0.97)	-2.8	-1.00	-0.42	-0.33	1.8	
End of treatment	Tezepelumab	31	29 (93.5)	-0.81 (0.88)	-3.3	-1.17	-1.00	-0.17	0.7	-0.18 [-0.67, 0.32]
	Placebo	34	34 (100.0)	-0.66 (0.86)	-2.8	-1.00	-0.50	-0.33	1.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Source Data: aacq, created on: 21FEB2022

Table CT1H6C\_ILMC0: Change from baseline in ACQ-6 score - MMRM results  
 DITTTL

Change from baseline in ACQ-6 score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 12	Tezepelumab	31	31 (100.0)	-0.58 (0.14)	(-0.87, -0.29)	0.26 (0.20)	(-0.15, 0.67)	0.209
	Placebo	34	34 (100.0)	-0.84 (0.14)	(-1.12, -0.56)			
Week 28	Tezepelumab	31	24 (77.4)	-0.60 (0.16)	(-0.92, -0.29)	0.14 (0.22)	(-0.31, 0.59)	0.539
	Placebo	34	24 (70.6)	-0.74 (0.16)	(-1.06, -0.43)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 21FEB2022

Table NT1H5C\_KLMH0: Course of ACQ-5 score  
 DITTLL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-5 score	Baseline	Tezepelumab	15	15 (100.0)	3.00 (0.56)	2.2	2.60	2.80	3.20	4.4	
		Placebo	20	20 (100.0)	3.07 (1.00)	2.0	2.30	2.60	3.70	5.0	
	Week 2	Tezepelumab	15	13 (86.7)	1.89 (1.10)	0.2	1.40	2.00	2.60	4.0	
		Placebo	20	19 (95.0)	1.94 (0.86)	0.4	1.20	2.00	2.80	3.2	
	Week 4	Tezepelumab	15	14 (93.3)	1.61 (0.80)	0.4	1.00	1.80	2.40	2.6	
		Placebo	20	18 (90.0)	1.62 (1.07)	0.0	1.00	1.70	2.20	4.0	
	Week 8	Tezepelumab	15	13 (86.7)	1.49 (0.85)	0.2	1.20	1.20	2.20	3.4	
		Placebo	20	17 (85.0)	1.88 (1.13)	0.0	1.40	2.00	2.40	4.0	
	Week 12	Tezepelumab	15	13 (86.7)	1.34 (0.91)	0.2	0.60	1.00	2.00	3.2	
		Placebo	20	20 (100.0)	1.52 (1.39)	0.0	0.40	1.20	2.20	5.2	
	Week 16	Tezepelumab	15	14 (93.3)	1.19 (0.79)	0.2	0.60	0.90	2.00	2.4	
		Placebo	20	19 (95.0)	1.62 (1.32)	0.0	0.80	1.40	2.00	4.6	
	Week 20	Tezepelumab	15	14 (93.3)	1.33 (0.92)	0.2	0.40	1.30	2.20	3.2	
		Placebo	20	19 (95.0)	1.54 (1.49)	0.0	0.00	1.00	3.00	4.2	
	Week 24	Tezepelumab	15	13 (86.7)	1.06 (0.63)	0.2	0.60	1.00	1.40	2.4	
		Placebo	20	17 (85.0)	1.72 (1.40)	0.0	1.00	1.20	2.00	4.8	
	Week 28	Tezepelumab	15	14 (93.3)	1.07 (0.78)	0.0	0.40	1.00	1.60	2.6	
		Placebo	20	20 (100.0)	1.47 (1.44)	0.0	0.60	1.10	1.70	4.8	
	Week 32	Tezepelumab	15	14 (93.3)	0.89 (0.65)	0.0	0.40	0.60	1.40	2.0	
		Placebo	20	20 (100.0)	1.56 (1.46)	0.0	0.80	1.00	1.80	5.4	
	Week 36	Tezepelumab	15	14 (93.3)	0.93 (0.79)	0.0	0.40	0.60	1.60	2.6	
		Placebo	20	18 (90.0)	1.30 (1.41)	0.0	0.40	1.10	1.80	5.4	
	Week 40	Tezepelumab	15	14 (93.3)	1.09 (0.88)	0.0	0.40	0.80	2.00	2.6	
		Placebo	20	19 (95.0)	1.53 (1.44)	0.0	0.60	1.20	2.00	5.2	
	Week 44	Tezepelumab	15	12 (80.0)	1.10 (0.81)	0.0	0.30	1.20	1.80	2.2	
		Placebo	20	18 (90.0)	1.62 (1.40)	0.0	0.60	1.20	2.20	4.2	
	Week 48	Tezepelumab	15	14 (93.3)	1.04 (0.87)	0.0	0.20	0.80	2.00	2.2	
		Placebo	20	18 (90.0)	1.42 (1.20)	0.0	0.40	1.30	2.00	4.4	
	Week 52	Tezepelumab	15	13 (86.7)	0.86 (0.71)	0.0	0.40	0.80	1.00	2.2	
		Placebo	20	20 (100.0)	1.26 (0.97)	0.0	0.50	1.10	1.90	3.2	

Note: DITTLL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Source Data: aacq, created on: 20FEB2022

Table NT1H5C\_KLMH0: Course of ACQ-5 score  
 DITTL - adolescents

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-5 Week 2 score	Tezepelumab	15	13 (86.7)	-1.14 (0.97)	-3.2	-1.80	-1.20	-0.40	0.2	0.04 [-0.66, 0.75]
	Placebo	20	19 (95.0)	-1.18 (0.91)	-3.0	-1.80	-1.20	-0.60	0.8	
Week 4	Tezepelumab	15	14 (93.3)	-1.40 (0.87)	-3.0	-1.60	-1.30	-0.60	-0.4	0.07 [-0.63, 0.77]
	Placebo	20	18 (90.0)	-1.47 (1.03)	-2.8	-2.20	-1.60	-1.00	1.0	
Week 8	Tezepelumab	15	13 (86.7)	-1.52 (1.18)	-3.6	-2.00	-1.40	-0.60	0.6	-0.35 [-1.07, 0.38]
	Placebo	20	17 (85.0)	-1.15 (0.97)	-2.4	-2.00	-1.00	-0.60	1.0	
Week 12	Tezepelumab	15	13 (86.7)	-1.74 (1.19)	-4.0	-2.20	-1.60	-1.00	0.0	-0.17 [-0.87, 0.53]
	Placebo	20	20 (100.0)	-1.55 (1.05)	-4.0	-2.30	-1.60	-1.00	0.8	
Week 16	Tezepelumab	15	14 (93.3)	-1.83 (1.14)	-4.2	-2.60	-1.50	-0.80	-0.4	-0.34 [-1.03, 0.36]
	Placebo	20	19 (95.0)	-1.42 (1.25)	-3.8	-2.00	-1.40	-0.60	1.6	
Week 20	Tezepelumab	15	14 (93.3)	-1.69 (1.21)	-4.0	-2.40	-1.40	-0.80	0.0	-0.18 [-0.88, 0.51]
	Placebo	20	19 (95.0)	-1.43 (1.49)	-3.8	-2.40	-1.40	-0.40	1.2	
Week 24	Tezepelumab	15	13 (86.7)	-1.95 (0.86)	-3.6	-2.80	-1.80	-1.60	-0.6	-0.57 [-1.31, 0.17]
	Placebo	20	17 (85.0)	-1.26 (1.43)	-4.0	-2.00	-1.20	-0.80	1.8	
Week 28	Tezepelumab	15	14 (93.3)	-1.94 (1.09)	-4.4	-2.20	-1.70	-1.20	-0.6	-0.29 [-0.97, 0.40]
	Placebo	20	20 (100.0)	-1.60 (1.25)	-4.0	-2.30	-1.40	-0.90	1.4	
Week 32	Tezepelumab	15	14 (93.3)	-2.13 (1.01)	-4.4	-2.80	-2.00	-1.40	-0.8	-0.49 [-1.19, 0.20]
	Placebo	20	20 (100.0)	-1.51 (1.39)	-4.6	-2.10	-1.20	-0.90	2.4	
Week 36	Tezepelumab	15	14 (93.3)	-2.09 (1.14)	-4.4	-2.80	-2.00	-1.20	-0.4	-0.34 [-1.04, 0.36]
	Placebo	20	18 (90.0)	-1.63 (1.46)	-4.6	-2.20	-1.80	-0.80	2.4	
Week 40	Tezepelumab	15	14 (93.3)	-1.93 (1.27)	-4.4	-2.80	-1.90	-1.00	0.0	-0.37 [-1.07, 0.32]
	Placebo	20	19 (95.0)	-1.44 (1.33)	-3.8	-2.20	-1.60	-0.80	2.2	
Week 44	Tezepelumab	15	12 (80.0)	-1.80 (0.95)	-3.4	-2.30	-1.80	-1.20	-0.2	-0.28 [-1.01, 0.45]
	Placebo	20	18 (90.0)	-1.47 (1.32)	-4.6	-2.00	-1.40	-0.60	1.2	
Week 48	Tezepelumab	15	14 (93.3)	-1.97 (1.26)	-4.4	-2.80	-1.90	-0.80	-0.4	-0.37 [-1.07, 0.33]
	Placebo	20	18 (90.0)	-1.53 (1.12)	-3.8	-2.20	-1.70	-1.00	1.4	
Week 52	Tezepelumab	15	13 (86.7)	-2.17 (0.93)	-3.6	-2.80	-2.20	-1.40	-0.6	-0.36 [-1.06, 0.34]
	Placebo	20	20 (100.0)	-1.81 (1.03)	-4.6	-2.10	-1.80	-1.30	0.2	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Source Data: aacq, created on: 20FEB2022



Table NT1H5C\_KLMC0: Change from baseline in ACQ-5 score - MMRM results  
DITTL - adolescents

Change from baseline in ACQ-5 score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 2	Tezepelumab	15	13 (86.7)	-1.04 (0.24)	(-1.54, -0.54)	0.16 (0.32)	(-0.49, 0.82)	0.620
	Placebo	20	19 (95.0)	-1.20 (0.21)	(-1.63, -0.78)			
Week 4	Tezepelumab	15	14 (93.3)	-1.37 (0.24)	(-1.85, -0.88)	0.02 (0.31)	(-0.61, 0.66)	0.941
	Placebo	20	18 (90.0)	-1.39 (0.20)	(-1.80, -0.97)			
Week 8	Tezepelumab	15	13 (86.7)	-1.57 (0.28)	(-2.14, -1.00)	-0.35 (0.36)	(-1.10, 0.40)	0.352
	Placebo	20	17 (85.0)	-1.22 (0.24)	(-1.71, -0.74)			
Week 12	Tezepelumab	15	13 (86.7)	-1.70 (0.30)	(-2.31, -1.09)	-0.18 (0.39)	(-0.97, 0.62)	0.651
	Placebo	20	20 (100.0)	-1.52 (0.25)	(-2.03, -1.01)			
Week 16	Tezepelumab	15	14 (93.3)	-1.82 (0.29)	(-2.40, -1.23)	-0.39 (0.38)	(-1.15, 0.38)	0.311
	Placebo	20	19 (95.0)	-1.43 (0.24)	(-1.92, -0.94)			
Week 20	Tezepelumab	15	14 (93.3)	-1.68 (0.36)	(-2.40, -0.95)	-0.34 (0.47)	(-1.29, 0.61)	0.470
	Placebo	20	19 (95.0)	-1.33 (0.30)	(-1.95, -0.72)			
Week 24	Tezepelumab	15	13 (86.7)	-1.92 (0.33)	(-2.59, -1.26)	-0.56 (0.43)	(-1.44, 0.32)	0.201
	Placebo	20	17 (85.0)	-1.36 (0.28)	(-1.93, -0.80)			
Week 28	Tezepelumab	15	14 (93.3)	-1.94 (0.31)	(-2.56, -1.32)	-0.37 (0.40)	(-1.18, 0.44)	0.360
	Placebo	20	20 (100.0)	-1.57 (0.26)	(-2.09, -1.05)			
Week 32	Tezepelumab	15	14 (93.3)	-2.11 (0.31)	(-2.74, -1.49)	-0.63 (0.40)	(-1.45, 0.19)	0.125
	Placebo	20	20 (100.0)	-1.48 (0.26)	(-2.00, -0.95)			
Week 36	Tezepelumab	15	14 (93.3)	-2.07 (0.31)	(-2.70, -1.43)	-0.37 (0.41)	(-1.20, 0.46)	0.372
	Placebo	20	18 (90.0)	-1.70 (0.26)	(-2.23, -1.16)			

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 20FEB2022

Table NT1H5C\_KLMC0: Change from baseline in ACQ-5 score - MMRM results  
 DITTL - adolescents

Change from baseline in ACQ-5 score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 40	Tezepelumab	15	14 (93.3)	-1.92 (0.32)	(-2.58, -1.25)	-0.51 (0.42)	(-1.37, 0.36)	0.242
	Placebo	20	19 (95.0)	-1.41 (0.27)	(-1.97, -0.85)			
Week 44	Tezepelumab	15	12 (80.0)	-2.05 (0.31)	(-2.68, -1.41)	-0.49 (0.41)	(-1.32, 0.34)	0.240
	Placebo	20	18 (90.0)	-1.56 (0.26)	(-2.09, -1.03)			
Week 48	Tezepelumab	15	14 (93.3)	-1.96 (0.28)	(-2.53, -1.40)	-0.31 (0.36)	(-1.05, 0.43)	0.404
	Placebo	20	18 (90.0)	-1.66 (0.23)	(-2.13, -1.18)			
Week 52	Tezepelumab	15	13 (86.7)	-2.17 (0.22)	(-2.63, -1.72)	-0.39 (0.29)	(-0.98, 0.20)	0.184
	Placebo	20	20 (100.0)	-1.78 (0.18)	(-2.15, -1.41)			

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 20FEB2022

Table DT1H5C\_MLMH0: Course of ACQ-5 score  
 DITTNL - LTE - adolescents

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-5 score	Baseline	Teze+Teze	14	14 (100.0)	3.01 (0.57)	2.2	2.60	2.90	3.20	4.4
		Pbo+Pbo	12	12 (100.0)	2.98 (1.05)	2.0	2.30	2.50	3.80	4.8
Week 2	Teze+Teze	Teze+Teze	14	12 (85.7)	1.82 (1.11)	0.2	1.00	1.80	2.50	4.0
		Pbo+Pbo	12	11 (91.7)	1.91 (0.89)	0.4	1.20	2.00	2.80	3.2
Week 4	Teze+Teze	Teze+Teze	14	14 (100.0)	1.61 (0.80)	0.4	1.00	1.80	2.40	2.6
		Pbo+Pbo	12	12 (100.0)	1.55 (1.27)	0.0	0.60	1.40	2.10	4.0
Week 8	Teze+Teze	Teze+Teze	14	13 (92.9)	1.49 (0.85)	0.2	1.20	1.20	2.20	3.4
		Pbo+Pbo	12	10 (83.3)	1.94 (1.27)	0.0	1.40	2.00	2.40	4.0
Week 12	Teze+Teze	Teze+Teze	14	13 (92.9)	1.34 (0.91)	0.2	0.60	1.00	2.00	3.2
		Pbo+Pbo	12	12 (100.0)	1.20 (1.24)	0.0	0.00	0.90	1.80	3.8
Week 16	Teze+Teze	Teze+Teze	14	14 (100.0)	1.19 (0.79)	0.2	0.60	0.90	2.00	2.4
		Pbo+Pbo	12	12 (100.0)	1.47 (1.25)	0.0	0.80	1.20	1.90	4.6
Week 20	Teze+Teze	Teze+Teze	14	14 (100.0)	1.33 (0.92)	0.2	0.40	1.30	2.20	3.2
		Pbo+Pbo	12	12 (100.0)	1.63 (1.58)	0.0	0.20	1.10	2.90	4.2
Week 24	Teze+Teze	Teze+Teze	14	13 (92.9)	1.06 (0.63)	0.2	0.60	1.00	1.40	2.4
		Pbo+Pbo	12	11 (91.7)	1.76 (1.53)	0.0	0.60	1.20	2.60	4.8
Week 28	Teze+Teze	Teze+Teze	14	14 (100.0)	1.07 (0.78)	0.0	0.40	1.00	1.60	2.6
		Pbo+Pbo	12	12 (100.0)	1.38 (1.44)	0.0	0.30	1.10	1.60	4.4
Week 32	Teze+Teze	Teze+Teze	14	14 (100.0)	0.89 (0.65)	0.0	0.40	0.60	1.40	2.0
		Pbo+Pbo	12	12 (100.0)	1.48 (1.64)	0.0	0.40	1.00	1.70	5.4
Week 36	Teze+Teze	Teze+Teze	14	14 (100.0)	0.93 (0.79)	0.0	0.40	0.60	1.60	2.6
		Pbo+Pbo	12	12 (100.0)	1.40 (1.66)	0.0	0.20	1.10	1.70	5.4
Week 40	Teze+Teze	Teze+Teze	14	14 (100.0)	1.09 (0.88)	0.0	0.40	0.80	2.00	2.6
		Pbo+Pbo	12	12 (100.0)	1.53 (1.70)	0.0	0.30	1.10	1.80	5.2
Week 44	Teze+Teze	Teze+Teze	14	12 (85.7)	1.10 (0.81)	0.0	0.30	1.20	1.80	2.2
		Pbo+Pbo	12	11 (91.7)	1.49 (1.44)	0.0	0.60	1.00	2.20	4.2
Week 48	Teze+Teze	Teze+Teze	14	14 (100.0)	1.04 (0.87)	0.0	0.20	0.80	2.00	2.2
		Pbo+Pbo	12	11 (91.7)	1.36 (1.27)	0.0	0.40	1.00	1.80	4.4
Week 52	Teze+Teze	Teze+Teze	14	13 (92.9)	0.86 (0.71)	0.0	0.40	0.80	1.00	2.2
		Pbo+Pbo	12	12 (100.0)	1.03 (0.95)	0.0	0.10	1.00	1.60	2.8
Week 64	Teze+Teze	Teze+Teze	14	14 (100.0)	0.93 (0.88)	0.0	0.20	0.60	1.60	2.6
		Pbo+Pbo	12	12 (100.0)	0.95 (1.01)	0.0	0.20	0.50	1.60	3.0
Week 76	Teze+Teze	Teze+Teze	14	13 (92.9)	0.97 (0.79)	0.0	0.40	1.00	1.60	2.2
		Pbo+Pbo	12	12 (100.0)	1.27 (1.54)	0.0	0.10	0.80	1.80	4.8
Week 88	Teze+Teze	Teze+Teze	14	14 (100.0)	0.86 (0.77)	0.0	0.40	0.50	1.60	2.6
		Pbo+Pbo	12	12 (100.0)	0.90 (1.10)	0.0	0.10	0.50	1.10	3.2
Week 104	Teze+Teze	Teze+Teze	14	13 (92.9)	0.63 (0.48)	0.0	0.40	0.60	1.00	1.6
		Pbo+Pbo	12	12 (100.0)	0.95 (1.13)	0.0	0.20	0.50	1.50	3.6

Note: DITTNL - LTE - adolescents = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.  
 Source Data: aacq, created on: 20JUL2022

Table DT1H5C\_MLMH0: Course of ACQ-5 score  
 DITTNL - LTE - adolescents

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-5 Week 2 score	Teze+Teze	14	12 (85.7)	-1.23 (0.95)	-3.2	-1.80	-1.40	-0.40	0.2	-0.09 [-0.91, 0.73]
	Pbo+Pbo	12	11 (91.7)	-1.15 (0.96)	-2.6	-2.00	-1.20	-0.60	0.8	
Week 4	Teze+Teze	14	14 (100.0)	-1.40 (0.87)	-3.0	-1.60	-1.30	-0.60	-0.4	0.03 [-0.74, 0.80]
	Pbo+Pbo	12	12 (100.0)	-1.43 (1.16)	-2.8	-2.30	-1.60	-0.80	1.0	
Week 8	Teze+Teze	14	13 (92.9)	-1.52 (1.18)	-3.6	-2.00	-1.40	-0.60	0.6	-0.31 [-1.14, 0.52]
	Pbo+Pbo	12	10 (83.3)	-1.16 (1.19)	-2.4	-2.40	-1.00	-0.20	1.0	
Week 12	Teze+Teze	14	13 (92.9)	-1.74 (1.19)	-4.0	-2.20	-1.60	-1.00	0.0	0.04 [-0.75, 0.82]
	Pbo+Pbo	12	12 (100.0)	-1.78 (1.20)	-4.0	-2.50	-1.90	-1.10	0.8	
Week 16	Teze+Teze	14	14 (100.0)	-1.83 (1.14)	-4.2	-2.60	-1.50	-0.80	-0.4	-0.24 [-1.01, 0.54]
	Pbo+Pbo	12	12 (100.0)	-1.52 (1.51)	-3.8	-2.30	-1.70	-0.60	1.6	
Week 20	Teze+Teze	14	14 (100.0)	-1.69 (1.21)	-4.0	-2.40	-1.40	-0.80	0.0	-0.23 [-1.01, 0.54]
	Pbo+Pbo	12	12 (100.0)	-1.35 (1.70)	-3.8	-2.40	-1.80	0.00	1.2	
Week 24	Teze+Teze	14	13 (92.9)	-1.95 (0.86)	-3.6	-2.80	-1.80	-1.60	-0.6	-0.50 [-1.31, 0.32]
	Pbo+Pbo	12	11 (91.7)	-1.29 (1.74)	-4.0	-2.40	-1.00	-0.40	1.8	
Week 28	Teze+Teze	14	14 (100.0)	-1.94 (1.09)	-4.4	-2.20	-1.70	-1.20	-0.6	-0.27 [-1.05, 0.50]
	Pbo+Pbo	12	12 (100.0)	-1.60 (1.45)	-4.0	-2.50	-1.40	-0.80	1.4	
Week 32	Teze+Teze	14	14 (100.0)	-2.13 (1.01)	-4.4	-2.80	-2.00	-1.40	-0.8	-0.45 [-1.23, 0.33]
	Pbo+Pbo	12	12 (100.0)	-1.50 (1.76)	-4.6	-2.40	-1.20	-0.80	2.4	
Week 36	Teze+Teze	14	14 (100.0)	-2.09 (1.14)	-4.4	-2.80	-2.00	-1.20	-0.4	-0.34 [-1.12, 0.43]
	Pbo+Pbo	12	12 (100.0)	-1.58 (1.77)	-4.6	-2.30	-1.60	-0.80	2.4	
Week 40	Teze+Teze	14	14 (100.0)	-1.93 (1.27)	-4.4	-2.80	-1.90	-1.00	0.0	-0.33 [-1.11, 0.45]
	Pbo+Pbo	12	12 (100.0)	-1.45 (1.64)	-3.8	-2.50	-1.50	-0.60	2.2	
Week 44	Teze+Teze	14	12 (85.7)	-1.80 (0.95)	-3.4	-2.30	-1.80	-1.20	-0.2	-0.18 [-1.00, 0.64]
	Pbo+Pbo	12	11 (91.7)	-1.56 (1.63)	-4.6	-2.40	-1.40	-0.60	1.2	
Week 48	Teze+Teze	14	14 (100.0)	-1.97 (1.26)	-4.4	-2.80	-1.90	-0.80	-0.4	-0.38 [-1.18, 0.42]
	Pbo+Pbo	12	11 (91.7)	-1.47 (1.38)	-3.8	-2.20	-1.60	-0.40	1.4	
Week 52	Teze+Teze	14	13 (92.9)	-2.17 (0.93)	-3.6	-2.80	-2.20	-1.40	-0.6	-0.20 [-0.98, 0.59]
	Pbo+Pbo	12	12 (100.0)	-1.95 (1.28)	-4.6	-2.30	-1.80	-1.30	0.2	
Week 64	Teze+Teze	14	14 (100.0)	-2.09 (0.92)	-3.8	-2.80	-2.00	-1.40	-0.8	-0.05 [-0.82, 0.72]
	Pbo+Pbo	12	12 (100.0)	-2.03 (1.23)	-4.6	-2.40	-2.20	-1.40	0.0	
Week 76	Teze+Teze	14	13 (92.9)	-2.06 (1.07)	-4.0	-2.40	-2.00	-1.40	-0.2	-0.27 [-1.06, 0.52]
	Pbo+Pbo	12	12 (100.0)	-1.72 (1.44)	-4.2	-2.60	-1.70	-0.70	0.6	
Week 88	Teze+Teze	14	14 (100.0)	-2.16 (1.01)	-4.0	-2.80	-2.10	-1.40	-0.4	-0.06 [-0.83, 0.71]
	Pbo+Pbo	12	12 (100.0)	-2.08 (1.32)	-4.8	-2.50	-1.90	-1.30	0.2	
Week 104	Teze+Teze	14	13 (92.9)	-2.40 (0.83)	-3.8	-3.00	-2.40	-1.60	-1.2	-0.32 [-1.11, 0.47]
	Pbo+Pbo	12	12 (100.0)	-2.03 (1.43)	-4.8	-2.50	-2.00	-1.40	0.6	

Note: DITTNL - LTE - adolescents = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.  
 Source Data: aacq, created on: 20JUL2022

Table DT1H5C\_MLMC0: Change from baseline in ACQ-5 score - MMRM results  
 DITTNL - LTE - adolescents

Change from baseline in ACQ-5 score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 2	Teze+Teze	14	12 (85.7)	NE		NE			
	Pbo+Pbo	12	11 (91.7)						
Week 4	Teze+Teze	14	14 (100.0)	NE		NE			
	Pbo+Pbo	12	12 (100.0)						
Week 8	Teze+Teze	14	13 (92.9)	NE		NE			
	Pbo+Pbo	12	10 (83.3)						
Week 12	Teze+Teze	14	13 (92.9)	NE		NE			
	Pbo+Pbo	12	12 (100.0)						
Week 16	Teze+Teze	14	14 (100.0)	NE		NE			
	Pbo+Pbo	12	12 (100.0)						
Week 20	Teze+Teze	14	14 (100.0)	NE		NE			
	Pbo+Pbo	12	12 (100.0)						
Week 24	Teze+Teze	14	13 (92.9)	NE		NE			
	Pbo+Pbo	12	11 (91.7)						
Week 28	Teze+Teze	14	14 (100.0)	NE		NE			
	Pbo+Pbo	12	12 (100.0)						
Week 32	Teze+Teze	14	14 (100.0)	NE		NE			
	Pbo+Pbo	12	12 (100.0)						
Week 36	Teze+Teze	14	14 (100.0)	NE		NE			
	Pbo+Pbo	12	12 (100.0)						

Note: DITTNL - LTE - adolescents = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adolescents.  
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.  
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.  
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.  
 ACQ = asthma control questionnaire.  
 Source Data: aacq, created on: 20JUL2022

Table DT1H5C\_MLMC0: Change from baseline in ACQ-5 score - MMRM results  
 DITTNL - LTE - adolescents

Change from baseline in ACQ-5 score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 40	Teze+Teze	14	14 (100.0)	NE		NE		
	Pbo+Pbo	12	12 (100.0)					
Week 44	Teze+Teze	14	12 (85.7)	NE		NE		
	Pbo+Pbo	12	11 (91.7)					
Week 48	Teze+Teze	14	14 (100.0)	NE		NE		
	Pbo+Pbo	12	11 (91.7)					
Week 52	Teze+Teze	14	13 (92.9)	NE		NE		
	Pbo+Pbo	12	12 (100.0)					
Week 64	Teze+Teze	14	14 (100.0)	NE		NE		
	Pbo+Pbo	12	12 (100.0)					
Week 76	Teze+Teze	14	13 (92.9)	NE		NE		
	Pbo+Pbo	12	12 (100.0)					
Week 88	Teze+Teze	14	14 (100.0)	NE		NE		
	Pbo+Pbo	12	12 (100.0)					
Week 104	Teze+Teze	14	13 (92.9)	NE		NE		
	Pbo+Pbo	12	12 (100.0)					

Note: DITTNL - LTE - adolescents = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adolescents.  
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.  
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.  
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.  
 ACQ = asthma control questionnaire.  
 Source Data: aacq, created on: 20JUL2022

Table NT1H6C\_KLMH0: Course of ACQ-6 score  
DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-6 score	Baseline	Tezepelumab	15	15 (100.0)	2.78 (0.60)	2.0	2.33	2.67	3.00	4.3	
		Placebo	20	20 (100.0)	2.96 (1.05)	2.0	2.17	2.42	3.67	4.8	
	Week 2	Tezepelumab	15	13 (86.7)	1.79 (1.01)	0.3	1.17	2.00	2.33	3.8	
		Placebo	20	19 (95.0)	1.83 (0.78)	0.3	1.17	1.83	2.50	3.0	
	Week 4	Tezepelumab	15	14 (93.3)	1.51 (0.75)	0.3	0.83	1.67	2.17	2.5	
		Placebo	20	18 (90.0)	1.55 (1.00)	0.0	0.83	1.67	2.00	3.7	
	Week 8	Tezepelumab	15	13 (86.7)	1.38 (0.82)	0.2	1.00	1.17	2.17	3.2	
		Placebo	20	17 (85.0)	1.76 (1.00)	0.0	1.17	2.00	2.17	3.7	
	Week 12	Tezepelumab	15	13 (86.7)	1.28 (0.86)	0.2	0.67	1.00	1.67	3.2	
		Placebo	20	20 (100.0)	1.47 (1.32)	0.0	0.42	1.25	2.17	5.0	
	Week 16	Tezepelumab	15	14 (93.3)	1.10 (0.72)	0.2	0.50	0.92	1.83	2.2	
		Placebo	20	19 (95.0)	1.54 (1.24)	0.0	0.83	1.17	2.00	4.5	
	Week 20	Tezepelumab	15	14 (93.3)	1.27 (0.89)	0.2	0.50	1.17	1.83	3.2	
		Placebo	20	19 (95.0)	1.43 (1.35)	0.0	0.00	1.00	2.83	3.8	
	Week 24	Tezepelumab	15	13 (86.7)	1.00 (0.59)	0.2	0.50	1.00	1.50	2.0	
		Placebo	20	17 (85.0)	1.62 (1.28)	0.0	1.00	1.33	2.00	4.3	
	Week 28	Tezepelumab	15	14 (93.3)	0.99 (0.71)	0.2	0.33	0.92	1.50	2.3	
		Placebo	20	20 (100.0)	1.42 (1.41)	0.0	0.50	1.00	1.75	4.8	
	Week 32	Tezepelumab	15	14 (93.3)	0.86 (0.60)	0.2	0.33	0.58	1.33	2.0	
		Placebo	20	20 (100.0)	1.46 (1.36)	0.0	0.75	1.00	1.75	4.8	
	Week 36	Tezepelumab	15	14 (93.3)	0.83 (0.72)	0.0	0.33	0.50	1.50	2.2	
		Placebo	20	18 (90.0)	1.21 (1.28)	0.0	0.33	1.08	1.67	4.8	
	Week 40	Tezepelumab	15	14 (93.3)	0.99 (0.81)	0.0	0.33	0.67	1.67	2.3	
		Placebo	20	19 (95.0)	1.42 (1.30)	0.0	0.50	1.17	1.83	4.7	
	Week 44	Tezepelumab	15	12 (80.0)	1.00 (0.76)	0.0	0.25	1.08	1.75	2.0	
		Placebo	20	18 (90.0)	1.56 (1.33)	0.0	0.50	1.17	2.17	3.8	
	Week 48	Tezepelumab	15	14 (93.3)	0.98 (0.81)	0.0	0.17	0.75	1.83	2.0	
		Placebo	20	18 (90.0)	1.36 (1.11)	0.0	0.50	1.25	1.83	4.0	
	Week 52	Tezepelumab	15	13 (86.7)	0.81 (0.68)	0.0	0.33	0.67	1.00	2.0	
		Placebo	20	20 (100.0)	1.21 (0.91)	0.0	0.50	1.00	1.75	3.0	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Source Data: aacq, created on: 20FEB2022

Table NT1H6C\_KLMH0: Course of ACQ-6 score  
 DITTLL - adolescents

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-6 Week 2 score	Tezepelumab	15	13 (86.7)	-1.03 (0.84)	-2.8	-1.50	-1.17	-0.33	0.2	0.16 [-0.55, 0.87]
	Placebo	20	19 (95.0)	-1.17 (0.90)	-3.0	-1.83	-1.00	-0.50	0.7	
Week 4	Tezepelumab	15	14 (93.3)	-1.29 (0.79)	-2.8	-1.50	-1.17	-0.67	-0.3	0.15 [-0.55, 0.85]
	Placebo	20	18 (90.0)	-1.43 (1.01)	-3.0	-2.33	-1.50	-0.83	0.8	
Week 8	Tezepelumab	15	13 (86.7)	-1.42 (1.15)	-3.5	-1.83	-1.33	-0.67	0.7	-0.25 [-0.98, 0.47]
	Placebo	20	17 (85.0)	-1.16 (0.96)	-2.8	-1.83	-1.00	-0.83	0.8	
Week 12	Tezepelumab	15	13 (86.7)	-1.58 (1.12)	-3.7	-2.00	-1.50	-0.83	0.2	-0.08 [-0.78, 0.62]
	Placebo	20	20 (100.0)	-1.49 (1.03)	-3.7	-2.17	-1.50	-0.92	0.7	
Week 16	Tezepelumab	15	14 (93.3)	-1.70 (1.06)	-4.0	-2.33	-1.42	-0.67	-0.3	-0.26 [-0.96, 0.43]
	Placebo	20	19 (95.0)	-1.39 (1.23)	-3.8	-2.17	-1.33	-0.50	1.3	
Week 20	Tezepelumab	15	14 (93.3)	-1.52 (1.18)	-3.8	-2.17	-1.25	-0.67	0.2	-0.07 [-0.76, 0.62]
	Placebo	20	19 (95.0)	-1.43 (1.40)	-3.8	-2.17	-1.50	-0.17	0.8	
Week 24	Tezepelumab	15	13 (86.7)	-1.81 (0.84)	-3.5	-2.50	-1.67	-1.50	-0.5	-0.48 [-1.22, 0.25]
	Placebo	20	17 (85.0)	-1.25 (1.36)	-4.3	-2.00	-1.00	-0.67	1.5	
Week 28	Tezepelumab	15	14 (93.3)	-1.81 (1.06)	-4.2	-2.00	-1.67	-1.00	-0.7	-0.23 [-0.92, 0.45]
	Placebo	20	20 (100.0)	-1.54 (1.23)	-3.8	-2.25	-1.42	-0.92	1.2	
Week 32	Tezepelumab	15	14 (93.3)	-1.94 (0.97)	-4.2	-2.33	-1.75	-1.17	-0.8	-0.37 [-1.05, 0.32]
	Placebo	20	20 (100.0)	-1.50 (1.34)	-4.8	-2.08	-1.17	-0.92	2.0	
Week 36	Tezepelumab	15	14 (93.3)	-1.96 (1.14)	-4.3	-2.67	-1.83	-1.17	-0.3	-0.27 [-0.98, 0.43]
	Placebo	20	18 (90.0)	-1.61 (1.39)	-4.8	-2.17	-1.58	-0.83	2.0	
Week 40	Tezepelumab	15	14 (93.3)	-1.81 (1.23)	-4.3	-2.50	-1.83	-0.83	0.0	-0.30 [-0.99, 0.40]
	Placebo	20	19 (95.0)	-1.44 (1.27)	-3.8	-2.17	-1.50	-0.83	1.8	
Week 44	Tezepelumab	15	12 (80.0)	-1.68 (0.92)	-3.3	-2.08	-1.75	-1.17	-0.2	-0.23 [-0.97, 0.50]
	Placebo	20	18 (90.0)	-1.41 (1.31)	-4.8	-1.83	-1.17	-0.83	1.0	
Week 48	Tezepelumab	15	14 (93.3)	-1.82 (1.22)	-4.3	-2.50	-1.83	-0.83	-0.3	-0.32 [-1.02, 0.39]
	Placebo	20	18 (90.0)	-1.46 (1.05)	-3.5	-2.17	-1.58	-1.00	1.2	
Week 52	Tezepelumab	15	13 (86.7)	-1.99 (0.89)	-3.5	-2.50	-1.83	-1.17	-0.5	-0.24 [-0.94, 0.46]
	Placebo	20	20 (100.0)	-1.75 (1.07)	-4.8	-2.08	-1.75	-1.17	0.3	

Note: DITTLL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Source Data: aacq, created on: 20FEB2022



Table NT1H6C\_KLMC0: Change from baseline in ACQ-6 score - MMRM results  
 DITTL - adolescents

Change from baseline in ACQ-6 score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 2	Tezepelumab	15	13 (86.7)	-0.99 (0.23)	(-1.46, -0.53)	0.15 (0.30)	(-0.46, 0.76)	0.616
	Placebo	20	19 (95.0)	-1.15 (0.19)	(-1.54, -0.75)			
Week 4	Tezepelumab	15	14 (93.3)	-1.32 (0.22)	(-1.77, -0.86)	-0.00 (0.29)	(-0.61, 0.60)	0.995
	Placebo	20	18 (90.0)	-1.31 (0.19)	(-1.71, -0.92)			
Week 8	Tezepelumab	15	13 (86.7)	-1.51 (0.27)	(-2.06, -0.96)	-0.36 (0.35)	(-1.08, 0.37)	0.319
	Placebo	20	17 (85.0)	-1.15 (0.23)	(-1.62, -0.69)			
Week 12	Tezepelumab	15	13 (86.7)	-1.60 (0.29)	(-2.19, -1.01)	-0.18 (0.38)	(-0.95, 0.59)	0.630
	Placebo	20	20 (100.0)	-1.42 (0.24)	(-1.91, -0.93)			
Week 16	Tezepelumab	15	14 (93.3)	-1.74 (0.27)	(-2.29, -1.20)	-0.40 (0.35)	(-1.11, 0.32)	0.264
	Placebo	20	19 (95.0)	-1.35 (0.23)	(-1.81, -0.89)			
Week 20	Tezepelumab	15	14 (93.3)	-1.56 (0.33)	(-2.24, -0.89)	-0.26 (0.43)	(-1.15, 0.62)	0.551
	Placebo	20	19 (95.0)	-1.30 (0.28)	(-1.87, -0.73)			
Week 24	Tezepelumab	15	13 (86.7)	-1.84 (0.31)	(-2.49, -1.20)	-0.56 (0.41)	(-1.40, 0.29)	0.187
	Placebo	20	17 (85.0)	-1.29 (0.26)	(-1.83, -0.74)			
Week 28	Tezepelumab	15	14 (93.3)	-1.85 (0.30)	(-2.46, -1.25)	-0.38 (0.39)	(-1.18, 0.41)	0.332
	Placebo	20	20 (100.0)	-1.47 (0.25)	(-1.98, -0.96)			
Week 32	Tezepelumab	15	14 (93.3)	-1.98 (0.29)	(-2.56, -1.40)	-0.55 (0.37)	(-1.31, 0.21)	0.151
	Placebo	20	20 (100.0)	-1.43 (0.24)	(-1.92, -0.94)			
Week 36	Tezepelumab	15	14 (93.3)	-2.00 (0.29)	(-2.59, -1.42)	-0.37 (0.38)	(-1.14, 0.40)	0.333
	Placebo	20	18 (90.0)	-1.63 (0.24)	(-2.13, -1.13)			

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 20FEB2022

Table NT1H6C\_KLMC0: Change from baseline in ACQ-6 score - MMRM results  
 DITTL - adolescents

Change from baseline in ACQ-6 score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 40	Tezepelumab	15	14 (93.3)	-1.85 (0.30)	(-2.47, -1.23)	-0.50 (0.40)	(-1.32, 0.31)	0.215
	Placebo	20	19 (95.0)	-1.35 (0.26)	(-1.87, -0.82)			
Week 44	Tezepelumab	15	12 (80.0)	-1.96 (0.30)	(-2.57, -1.35)	-0.51 (0.39)	(-1.30, 0.28)	0.200
	Placebo	20	18 (90.0)	-1.45 (0.25)	(-1.96, -0.95)			
Week 48	Tezepelumab	15	14 (93.3)	-1.87 (0.25)	(-2.38, -1.35)	-0.32 (0.33)	(-1.00, 0.36)	0.342
	Placebo	20	18 (90.0)	-1.55 (0.21)	(-1.98, -1.11)			
Week 52	Tezepelumab	15	13 (86.7)	-2.03 (0.21)	(-2.46, -1.60)	-0.35 (0.28)	(-0.91, 0.21)	0.212
	Placebo	20	20 (100.0)	-1.68 (0.18)	(-2.04, -1.32)			

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 20FEB2022

Table DT1H6C\_MLMH0: Course of ACQ-6 score  
 DITTNL - LTE - adolescents

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-6 score	Baseline	Teze+Teze	14	14 (100.0)	2.80 (0.62)	2.0	2.33	2.75	3.00	4.3
		Pbo+Pbo	12	12 (100.0)	2.92 (1.12)	2.0	2.17	2.42	3.67	4.8
Week 2	Teze+Teze	Teze+Teze	14	12 (85.7)	1.75 (1.05)	0.3	0.92	1.83	2.42	3.8
		Pbo+Pbo	12	11 (91.7)	1.83 (0.81)	0.3	1.17	1.83	2.67	3.0
Week 4	Teze+Teze	Teze+Teze	14	14 (100.0)	1.51 (0.75)	0.3	0.83	1.67	2.17	2.5
		Pbo+Pbo	12	12 (100.0)	1.49 (1.16)	0.0	0.58	1.50	2.00	3.7
Week 8	Teze+Teze	Teze+Teze	14	13 (92.9)	1.38 (0.82)	0.2	1.00	1.17	2.17	3.2
		Pbo+Pbo	12	10 (83.3)	1.83 (1.13)	0.0	1.17	2.00	2.17	3.7
Week 12	Teze+Teze	Teze+Teze	14	13 (92.9)	1.28 (0.86)	0.2	0.67	1.00	1.67	3.2
		Pbo+Pbo	12	12 (100.0)	1.17 (1.17)	0.0	0.00	0.92	1.67	3.5
Week 16	Teze+Teze	Teze+Teze	14	14 (100.0)	1.10 (0.72)	0.2	0.50	0.92	1.83	2.2
		Pbo+Pbo	12	12 (100.0)	1.38 (1.14)	0.0	0.75	1.08	1.92	4.2
Week 20	Teze+Teze	Teze+Teze	14	14 (100.0)	1.27 (0.89)	0.2	0.50	1.17	1.83	3.2
		Pbo+Pbo	12	12 (100.0)	1.51 (1.43)	0.0	0.17	1.00	2.75	3.8
Week 24	Teze+Teze	Teze+Teze	14	13 (92.9)	1.00 (0.59)	0.2	0.50	1.00	1.50	2.0
		Pbo+Pbo	12	11 (91.7)	1.67 (1.41)	0.0	0.50	1.33	2.50	4.3
Week 28	Teze+Teze	Teze+Teze	14	14 (100.0)	0.99 (0.71)	0.2	0.33	0.92	1.50	2.3
		Pbo+Pbo	12	12 (100.0)	1.32 (1.38)	0.0	0.25	1.00	1.58	4.0
Week 32	Teze+Teze	Teze+Teze	14	14 (100.0)	0.86 (0.60)	0.2	0.33	0.58	1.33	2.0
		Pbo+Pbo	12	12 (100.0)	1.36 (1.48)	0.0	0.33	1.00	1.58	4.8
Week 36	Teze+Teze	Teze+Teze	14	14 (100.0)	0.83 (0.72)	0.0	0.33	0.50	1.50	2.2
		Pbo+Pbo	12	12 (100.0)	1.29 (1.50)	0.0	0.17	1.08	1.58	4.8
Week 40	Teze+Teze	Teze+Teze	14	14 (100.0)	0.99 (0.81)	0.0	0.33	0.67	1.67	2.3
		Pbo+Pbo	12	12 (100.0)	1.44 (1.53)	0.0	0.25	1.00	1.75	4.7
Week 44	Teze+Teze	Teze+Teze	14	12 (85.7)	1.00 (0.76)	0.0	0.25	1.08	1.75	2.0
		Pbo+Pbo	12	11 (91.7)	1.44 (1.34)	0.0	0.50	1.00	2.17	3.8
Week 48	Teze+Teze	Teze+Teze	14	14 (100.0)	0.98 (0.81)	0.0	0.17	0.75	1.83	2.0
		Pbo+Pbo	12	11 (91.7)	1.32 (1.16)	0.0	0.50	1.00	1.83	4.0
Week 52	Teze+Teze	Teze+Teze	14	13 (92.9)	0.81 (0.68)	0.0	0.33	0.67	1.00	2.0
		Pbo+Pbo	12	12 (100.0)	0.99 (0.89)	0.0	0.17	0.92	1.42	2.7
Week 64	Teze+Teze	Teze+Teze	14	14 (100.0)	0.88 (0.84)	0.0	0.17	0.58	1.50	2.5
		Pbo+Pbo	12	12 (100.0)	0.96 (0.99)	0.0	0.25	0.50	1.67	2.8
Week 76	Teze+Teze	Teze+Teze	14	13 (92.9)	0.92 (0.75)	0.0	0.33	1.00	1.67	2.0
		Pbo+Pbo	12	12 (100.0)	1.25 (1.47)	0.0	0.17	0.75	1.83	4.7
Week 88	Teze+Teze	Teze+Teze	14	14 (100.0)	0.83 (0.72)	0.0	0.33	0.58	1.50	2.5
		Pbo+Pbo	12	12 (100.0)	0.89 (1.07)	0.0	0.08	0.50	1.17	3.0
Week 104	Teze+Teze	Teze+Teze	14	13 (92.9)	0.63 (0.48)	0.0	0.33	0.50	1.00	1.5
		Pbo+Pbo	12	12 (100.0)	0.93 (1.05)	0.0	0.17	0.58	1.42	3.3

Note: DITTNL - LTE - adolescents = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.  
 Source Data: aacq, created on: 20JUL2022

Table DT1H6C\_MLMH0: Course of ACQ-6 score  
 DITTNL - LTE - adolescents

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-6 Week 2 score	Teze+Teze	14	12 (85.7)	-1.10 (0.84)	-2.8	-1.58	-1.25	-0.33	0.2	0.06 [-0.76, 0.88]
	Pbo+Pbo	12	11 (91.7)	-1.15 (0.98)	-3.0	-1.83	-1.00	-0.67	0.7	
Week 4	Teze+Teze	14	14 (100.0)	-1.29 (0.79)	-2.8	-1.50	-1.17	-0.67	-0.3	0.15 [-0.62, 0.92]
	Pbo+Pbo	12	12 (100.0)	-1.43 (1.13)	-3.0	-2.25	-1.58	-0.67	0.8	
Week 8	Teze+Teze	14	13 (92.9)	-1.42 (1.15)	-3.5	-1.83	-1.33	-0.67	0.7	-0.19 [-1.02, 0.64]
	Pbo+Pbo	12	10 (83.3)	-1.20 (1.19)	-2.8	-2.17	-1.25	0.00	0.8	
Week 12	Teze+Teze	14	13 (92.9)	-1.58 (1.12)	-3.7	-2.00	-1.50	-0.83	0.2	0.15 [-0.63, 0.94]
	Pbo+Pbo	12	12 (100.0)	-1.75 (1.17)	-3.7	-2.42	-2.00	-1.08	0.7	
Week 16	Teze+Teze	14	14 (100.0)	-1.70 (1.06)	-4.0	-2.33	-1.42	-0.67	-0.3	-0.13 [-0.90, 0.65]
	Pbo+Pbo	12	12 (100.0)	-1.54 (1.49)	-3.8	-2.42	-1.67	-0.58	1.3	
Week 20	Teze+Teze	14	14 (100.0)	-1.52 (1.18)	-3.8	-2.17	-1.25	-0.67	0.2	-0.09 [-0.86, 0.68]
	Pbo+Pbo	12	12 (100.0)	-1.40 (1.59)	-3.8	-2.25	-1.83	0.08	0.8	
Week 24	Teze+Teze	14	13 (92.9)	-1.81 (0.84)	-3.5	-2.50	-1.67	-1.50	-0.5	-0.38 [-1.19, 0.43]
	Pbo+Pbo	12	11 (91.7)	-1.32 (1.67)	-4.3	-2.33	-1.00	-0.67	1.5	
Week 28	Teze+Teze	14	14 (100.0)	-1.81 (1.06)	-4.2	-2.00	-1.67	-1.00	-0.7	-0.17 [-0.95, 0.60]
	Pbo+Pbo	12	12 (100.0)	-1.60 (1.40)	-3.8	-2.42	-1.33	-0.75	1.2	
Week 32	Teze+Teze	14	14 (100.0)	-1.94 (0.97)	-4.2	-2.33	-1.75	-1.17	-0.8	-0.29 [-1.06, 0.49]
	Pbo+Pbo	12	12 (100.0)	-1.56 (1.68)	-4.8	-2.33	-1.17	-0.92	2.0	
Week 36	Teze+Teze	14	14 (100.0)	-1.96 (1.14)	-4.3	-2.67	-1.83	-1.17	-0.3	-0.24 [-1.01, 0.53]
	Pbo+Pbo	12	12 (100.0)	-1.62 (1.68)	-4.8	-2.25	-1.58	-0.83	2.0	
Week 40	Teze+Teze	14	14 (100.0)	-1.81 (1.23)	-4.3	-2.50	-1.83	-0.83	0.0	-0.24 [-1.02, 0.53]
	Pbo+Pbo	12	12 (100.0)	-1.47 (1.56)	-3.8	-2.42	-1.33	-0.75	1.8	
Week 44	Teze+Teze	14	12 (85.7)	-1.68 (0.92)	-3.3	-2.08	-1.75	-1.17	-0.2	-0.10 [-0.92, 0.71]
	Pbo+Pbo	12	11 (91.7)	-1.55 (1.61)	-4.8	-2.33	-1.17	-0.83	1.0	
Week 48	Teze+Teze	14	14 (100.0)	-1.82 (1.22)	-4.3	-2.50	-1.83	-0.83	-0.3	-0.32 [-1.11, 0.48]
	Pbo+Pbo	12	11 (91.7)	-1.42 (1.30)	-3.5	-2.33	-1.50	-0.33	1.2	
Week 52	Teze+Teze	14	13 (92.9)	-1.99 (0.89)	-3.5	-2.50	-1.83	-1.17	-0.5	-0.05 [-0.84, 0.73]
	Pbo+Pbo	12	12 (100.0)	-1.93 (1.31)	-4.8	-2.25	-1.92	-1.25	0.3	
Week 64	Teze+Teze	14	14 (100.0)	-1.92 (0.89)	-3.7	-2.50	-1.92	-1.50	-0.3	0.04 [-0.73, 0.81]
	Pbo+Pbo	12	12 (100.0)	-1.96 (1.18)	-4.2	-2.33	-2.08	-1.33	0.0	
Week 76	Teze+Teze	14	13 (92.9)	-1.90 (1.04)	-3.8	-2.33	-2.00	-1.00	-0.2	-0.19 [-0.97, 0.60]
	Pbo+Pbo	12	12 (100.0)	-1.67 (1.40)	-4.3	-2.50	-1.58	-0.58	0.5	
Week 88	Teze+Teze	14	14 (100.0)	-1.96 (1.01)	-3.8	-2.50	-1.83	-1.33	0.0	0.05 [-0.72, 0.83]
	Pbo+Pbo	12	12 (100.0)	-2.03 (1.33)	-4.5	-2.42	-1.92	-1.17	0.2	
Week 104	Teze+Teze	14	13 (92.9)	-2.19 (0.84)	-3.5	-2.67	-2.33	-1.50	-1.0	-0.18 [-0.97, 0.61]
	Pbo+Pbo	12	12 (100.0)	-1.99 (1.41)	-4.5	-2.50	-1.83	-1.33	0.5	

Note: DITTNL - LTE - adolescents = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.  
 Source Data: aacq, created on: 20JUL2022

Table DT1H6C\_MLMC0: Change from baseline in ACQ-6 score - MMRM results  
DITTNL - LTE - adolescents

Change from baseline in ACQ-6 score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 2	Teze+Teze	14	12 (85.7)	NE		NE			
	Pbo+Pbo	12	11 (91.7)						
Week 4	Teze+Teze	14	14 (100.0)	NE		NE			
	Pbo+Pbo	12	12 (100.0)						
Week 8	Teze+Teze	14	13 (92.9)	NE		NE			
	Pbo+Pbo	12	10 (83.3)						
Week 12	Teze+Teze	14	13 (92.9)	NE		NE			
	Pbo+Pbo	12	12 (100.0)						
Week 16	Teze+Teze	14	14 (100.0)	NE		NE			
	Pbo+Pbo	12	12 (100.0)						
Week 20	Teze+Teze	14	14 (100.0)	NE		NE			
	Pbo+Pbo	12	12 (100.0)						
Week 24	Teze+Teze	14	13 (92.9)	NE		NE			
	Pbo+Pbo	12	11 (91.7)						
Week 28	Teze+Teze	14	14 (100.0)	NE		NE			
	Pbo+Pbo	12	12 (100.0)						
Week 32	Teze+Teze	14	14 (100.0)	NE		NE			
	Pbo+Pbo	12	12 (100.0)						
Week 36	Teze+Teze	14	14 (100.0)	NE		NE			
	Pbo+Pbo	12	12 (100.0)						

Note: DITTNL - LTE - adolescents = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adolescents.  
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.  
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.  
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.  
ACQ = asthma control questionnaire.  
Source Data: aacq, created on: 20JUL2022

Table DT1H6C\_MLMC0: Change from baseline in ACQ-6 score - MMRM results  
 DITTNL - LTE - adolescents

Change from baseline in ACQ-6 score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 40	Teze+Teze	14	14 (100.0)	NE		NE		
	Pbo+Pbo	12	12 (100.0)					
Week 44	Teze+Teze	14	12 (85.7)	NE		NE		
	Pbo+Pbo	12	11 (91.7)					
Week 48	Teze+Teze	14	14 (100.0)	NE		NE		
	Pbo+Pbo	12	11 (91.7)					
Week 52	Teze+Teze	14	13 (92.9)	NE		NE		
	Pbo+Pbo	12	12 (100.0)					
Week 64	Teze+Teze	14	14 (100.0)	NE		NE		
	Pbo+Pbo	12	12 (100.0)					
Week 76	Teze+Teze	14	13 (92.9)	NE		NE		
	Pbo+Pbo	12	12 (100.0)					
Week 88	Teze+Teze	14	14 (100.0)	NE		NE		
	Pbo+Pbo	12	12 (100.0)					
Week 104	Teze+Teze	14	13 (92.9)	NE		NE		
	Pbo+Pbo	12	12 (100.0)					

Note: DITTNL - LTE - adolescents = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adolescents.  
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.  
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.  
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.  
 ACQ = asthma control questionnaire.  
 Source Data: aacq, created on: 20JUL2022

Table NT1H5C\_ALMH0: Course of ACQ-5 score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-5 score	Baseline	Tezepelumab	380	380 (100.0)	3.10 (0.90)	1.4	2.40	3.00	3.60	5.8	
		Placebo	371	371 (100.0)	3.01 (0.85)	1.6	2.40	2.80	3.40	5.8	
	Week 2	Tezepelumab	380	363 (95.5)	2.20 (1.05)	0.0	1.40	2.20	2.80	5.8	
		Placebo	371	344 (92.7)	2.37 (1.12)	0.0	1.60	2.40	3.00	5.8	
	Week 4	Tezepelumab	380	372 (97.9)	1.98 (1.05)	0.0	1.20	2.00	2.70	5.6	
		Placebo	371	360 (97.0)	2.14 (1.07)	0.0	1.40	2.00	2.80	5.6	
	Week 8	Tezepelumab	380	372 (97.9)	1.74 (1.09)	0.0	1.00	1.60	2.40	5.4	
		Placebo	371	360 (97.0)	2.00 (1.12)	0.0	1.20	2.00	2.60	5.8	
	Week 12	Tezepelumab	380	365 (96.1)	1.70 (1.20)	0.0	0.80	1.60	2.40	6.0	
		Placebo	371	355 (95.7)	1.88 (1.16)	0.0	1.00	1.80	2.60	5.8	
	Week 16	Tezepelumab	380	367 (96.6)	1.56 (1.11)	0.0	0.80	1.40	2.20	5.8	
		Placebo	371	351 (94.6)	1.84 (1.20)	0.0	1.00	1.80	2.40	5.8	
	Week 20	Tezepelumab	380	357 (93.9)	1.52 (1.16)	0.0	0.60	1.40	2.20	5.8	
		Placebo	371	344 (92.7)	1.75 (1.16)	0.0	0.80	1.60	2.60	5.6	
	Week 24	Tezepelumab	380	357 (93.9)	1.50 (1.12)	0.0	0.60	1.40	2.20	5.4	
		Placebo	371	339 (91.4)	1.78 (1.15)	0.0	0.80	1.60	2.60	5.8	
	Week 28	Tezepelumab	380	354 (93.2)	1.48 (1.15)	0.0	0.60	1.40	2.20	5.2	
		Placebo	371	338 (91.1)	1.76 (1.23)	0.0	0.80	1.60	2.60	5.6	
	Week 32	Tezepelumab	380	352 (92.6)	1.53 (1.18)	0.0	0.60	1.40	2.40	5.0	
		Placebo	371	337 (90.8)	1.79 (1.15)	0.0	0.80	1.60	2.60	5.4	
	Week 36	Tezepelumab	380	359 (94.5)	1.50 (1.17)	0.0	0.60	1.40	2.20	5.0	
		Placebo	371	334 (90.0)	1.74 (1.16)	0.0	0.80	1.80	2.60	5.6	
	Week 40	Tezepelumab	380	354 (93.2)	1.48 (1.15)	0.0	0.40	1.20	2.40	4.6	
		Placebo	371	333 (89.8)	1.74 (1.21)	0.0	0.80	1.60	2.60	5.4	
	Week 44	Tezepelumab	380	351 (92.4)	1.44 (1.15)	0.0	0.60	1.20	2.20	5.0	
		Placebo	371	329 (88.7)	1.72 (1.21)	0.0	0.80	1.60	2.60	5.2	
	Week 48	Tezepelumab	380	352 (92.6)	1.44 (1.20)	0.0	0.40	1.20	2.20	5.4	
		Placebo	371	327 (88.1)	1.70 (1.18)	0.0	0.80	1.60	2.40	5.6	
	Week 52	Tezepelumab	380	346 (91.1)	1.39 (1.14)	0.0	0.40	1.20	2.20	5.2	
		Placebo	371	324 (87.3)	1.67 (1.21)	0.0	0.80	1.60	2.40	5.4	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Source Data: aacq, created on: 20FEB2022

Table NT1H5C\_ALMH0: Course of ACQ-5 score  
 DITTL - adult

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-5 Week 2 score	Tezepelumab	380	363 (95.5)	-0.89 (1.01)	-5.0	-1.60	-0.80	-0.20	1.6	-0.26 [-0.41, -0.11]
	Placebo	371	344 (92.7)	-0.63 (0.97)	-4.2	-1.20	-0.60	0.00	3.4	
Week 4	Tezepelumab	380	372 (97.9)	-1.10 (1.07)	-5.6	-1.80	-1.00	-0.40	1.8	-0.24 [-0.38, -0.09]
	Placebo	371	360 (97.0)	-0.86 (0.97)	-4.2	-1.40	-0.80	-0.20	2.4	
Week 8	Tezepelumab	380	372 (97.9)	-1.36 (1.19)	-5.6	-2.20	-1.30	-0.40	2.4	-0.32 [-0.46, -0.17]
	Placebo	371	360 (97.0)	-1.00 (1.08)	-4.6	-1.60	-1.00	-0.20	2.8	
Week 12	Tezepelumab	380	365 (96.1)	-1.37 (1.24)	-5.6	-2.20	-1.20	-0.40	2.6	-0.21 [-0.35, -0.06]
	Placebo	371	355 (95.7)	-1.13 (1.12)	-5.2	-1.80	-1.20	-0.40	2.4	
Week 16	Tezepelumab	380	367 (96.6)	-1.52 (1.16)	-5.4	-2.20	-1.40	-0.80	2.0	-0.32 [-0.47, -0.18]
	Placebo	371	351 (94.6)	-1.15 (1.13)	-5.2	-1.80	-1.00	-0.40	2.4	
Week 20	Tezepelumab	380	357 (93.9)	-1.54 (1.24)	-5.4	-2.40	-1.60	-0.80	3.8	-0.26 [-0.41, -0.12]
	Placebo	371	344 (92.7)	-1.23 (1.14)	-5.6	-1.80	-1.20	-0.50	1.4	
Week 24	Tezepelumab	380	357 (93.9)	-1.57 (1.22)	-5.4	-2.40	-1.40	-0.80	2.8	-0.31 [-0.46, -0.16]
	Placebo	371	339 (91.4)	-1.21 (1.11)	-5.2	-2.00	-1.20	-0.40	1.8	
Week 28	Tezepelumab	380	354 (93.2)	-1.58 (1.19)	-5.6	-2.40	-1.60	-0.80	1.8	-0.31 [-0.46, -0.16]
	Placebo	371	338 (91.1)	-1.22 (1.19)	-5.4	-2.00	-1.20	-0.40	2.0	
Week 32	Tezepelumab	380	352 (92.6)	-1.53 (1.28)	-5.6	-2.30	-1.40	-0.80	3.0	-0.28 [-0.43, -0.13]
	Placebo	371	337 (90.8)	-1.19 (1.15)	-4.2	-2.00	-1.00	-0.40	2.0	
Week 36	Tezepelumab	380	359 (94.5)	-1.58 (1.28)	-5.6	-2.40	-1.60	-0.80	2.8	-0.28 [-0.43, -0.13]
	Placebo	371	334 (90.0)	-1.23 (1.17)	-5.6	-2.00	-1.20	-0.40	2.2	
Week 40	Tezepelumab	380	354 (93.2)	-1.59 (1.28)	-5.6	-2.40	-1.60	-0.80	3.0	-0.30 [-0.45, -0.15]
	Placebo	371	333 (89.8)	-1.22 (1.19)	-5.2	-2.00	-1.20	-0.40	1.8	
Week 44	Tezepelumab	380	351 (92.4)	-1.64 (1.23)	-5.6	-2.40	-1.60	-0.80	2.0	-0.31 [-0.47, -0.16]
	Placebo	371	329 (88.7)	-1.26 (1.21)	-5.4	-2.00	-1.20	-0.40	2.6	
Week 48	Tezepelumab	380	352 (92.6)	-1.63 (1.30)	-5.6	-2.40	-1.60	-0.80	2.2	-0.28 [-0.44, -0.13]
	Placebo	371	327 (88.1)	-1.28 (1.16)	-5.8	-2.00	-1.20	-0.40	2.4	
Week 52	Tezepelumab	380	346 (91.1)	-1.68 (1.28)	-5.6	-2.60	-1.80	-1.00	3.6	-0.30 [-0.45, -0.15]
	Placebo	371	324 (87.3)	-1.31 (1.22)	-4.4	-2.10	-1.20	-0.40	1.8	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Source Data: aacq, created on: 20FEB2022



Table NT1H5C\_ALMC0: Change from baseline in ACQ-5 score - MMRM results  
DITTL - adult

Change from baseline in ACQ-5 score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 2	Tezepelumab	380	363 (95.5)	-0.87 (0.05)	(-0.97, -0.78)	-0.25 (0.07)	(-0.38, -0.11)	<0.001 *	
	Placebo	371	344 (92.7)	-0.63 (0.05)	(-0.72, -0.53)				
Week 4	Tezepelumab	380	372 (97.9)	-1.08 (0.05)	(-1.18, -0.99)	-0.20 (0.07)	(-0.33, -0.06)	0.005 *	
	Placebo	371	360 (97.0)	-0.89 (0.05)	(-0.98, -0.79)				
Week 8	Tezepelumab	380	372 (97.9)	-1.33 (0.05)	(-1.43, -1.22)	-0.33 (0.08)	(-0.48, -0.18)	<0.001 *	
	Placebo	371	360 (97.0)	-1.00 (0.05)	(-1.10, -0.89)				
Week 12	Tezepelumab	380	365 (96.1)	-1.35 (0.06)	(-1.47, -1.24)	-0.23 (0.08)	(-0.39, -0.07)	0.005 *	
	Placebo	371	355 (95.7)	-1.12 (0.06)	(-1.24, -1.01)				
Week 16	Tezepelumab	380	367 (96.6)	-1.48 (0.06)	(-1.59, -1.38)	-0.34 (0.08)	(-0.49, -0.18)	<0.001 *	
	Placebo	371	351 (94.6)	-1.15 (0.06)	(-1.26, -1.04)				
Week 20	Tezepelumab	380	357 (93.9)	-1.53 (0.06)	(-1.64, -1.41)	-0.32 (0.08)	(-0.48, -0.16)	<0.001 *	
	Placebo	371	344 (92.7)	-1.21 (0.06)	(-1.32, -1.09)				
Week 24	Tezepelumab	380	357 (93.9)	-1.54 (0.06)	(-1.65, -1.43)	-0.34 (0.08)	(-0.50, -0.19)	<0.001 *	
	Placebo	371	339 (91.4)	-1.20 (0.06)	(-1.31, -1.09)				
Week 28	Tezepelumab	380	354 (93.2)	-1.55 (0.06)	(-1.66, -1.43)	-0.34 (0.08)	(-0.50, -0.18)	<0.001 *	
	Placebo	371	338 (91.1)	-1.21 (0.06)	(-1.32, -1.09)				
Week 32	Tezepelumab	380	352 (92.6)	-1.51 (0.06)	(-1.63, -1.40)	-0.34 (0.08)	(-0.51, -0.18)	<0.001 *	
	Placebo	371	337 (90.8)	-1.17 (0.06)	(-1.29, -1.05)				
Week 36	Tezepelumab	380	359 (94.5)	-1.54 (0.06)	(-1.66, -1.42)	-0.33 (0.08)	(-0.49, -0.16)	<0.001 *	
	Placebo	371	334 (90.0)	-1.21 (0.06)	(-1.33, -1.09)				

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 20FEB2022

Table NT1H5C\_ALMC0: Change from baseline in ACQ-5 score - MMRM results  
DITTL - adult

Change from baseline in ACQ-5 score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 40	Tezepelumab	380	354 (93.2)	-1.56 (0.06)	(-1.67, -1.44)	-0.34 (0.09)	(-0.51, -0.17)	<0.001 *	
	Placebo	371	333 (89.8)	-1.22 (0.06)	(-1.34, -1.10)				
Week 44	Tezepelumab	380	351 (92.4)	-1.61 (0.06)	(-1.72, -1.49)	-0.35 (0.08)	(-0.52, -0.19)	<0.001 *	
	Placebo	371	329 (88.7)	-1.25 (0.06)	(-1.37, -1.13)				
Week 48	Tezepelumab	380	352 (92.6)	-1.61 (0.06)	(-1.73, -1.49)	-0.37 (0.09)	(-0.54, -0.20)	<0.001 *	
	Placebo	371	327 (88.1)	-1.24 (0.06)	(-1.36, -1.12)				
Week 52	Tezepelumab	380	346 (91.1)	-1.65 (0.06)	(-1.77, -1.53)	-0.37 (0.09)	(-0.54, -0.20)	<0.001 *	
	Placebo	371	324 (87.3)	-1.28 (0.06)	(-1.40, -1.16)				

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 20FEB2022

Table DT1H5C\_HLMH0: Course of ACQ-5 score  
 DITTNL - LTE - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-5 score	Baseline	Teze+Teze	296	296 (100.0)	3.12 (0.87)	1.4	2.60	3.00	3.60	5.8	
		Pbo+Pbo	137	137 (100.0)	3.09 (0.85)	1.6	2.60	3.00	3.40	5.6	
Week 2		Teze+Teze	296	284 (95.9)	2.21 (1.04)	0.0	1.60	2.20	2.80	5.8	
		Pbo+Pbo	137	127 (92.7)	2.44 (1.05)	0.2	1.60	2.40	3.00	5.6	
Week 4		Teze+Teze	296	290 (98.0)	1.99 (1.03)	0.0	1.20	2.00	2.80	5.0	
		Pbo+Pbo	137	134 (97.8)	2.16 (1.12)	0.0	1.40	2.20	2.80	5.6	
Week 8		Teze+Teze	296	290 (98.0)	1.71 (1.06)	0.0	0.80	1.60	2.40	4.8	
		Pbo+Pbo	137	136 (99.3)	2.11 (1.19)	0.0	1.10	2.00	2.80	5.8	
Week 12		Teze+Teze	296	286 (96.6)	1.69 (1.21)	0.0	0.80	1.40	2.40	5.6	
		Pbo+Pbo	137	136 (99.3)	1.94 (1.23)	0.0	1.00	1.80	2.80	5.8	
Week 16		Teze+Teze	296	292 (98.6)	1.55 (1.11)	0.0	0.60	1.40	2.20	5.2	
		Pbo+Pbo	137	134 (97.8)	1.87 (1.32)	0.0	1.00	1.80	2.60	5.8	
Week 20		Teze+Teze	296	286 (96.6)	1.55 (1.15)	0.0	0.60	1.40	2.40	4.8	
		Pbo+Pbo	137	133 (97.1)	1.86 (1.25)	0.0	1.00	1.60	2.60	5.6	
Week 24		Teze+Teze	296	287 (97.0)	1.51 (1.10)	0.0	0.60	1.40	2.40	5.0	
		Pbo+Pbo	137	133 (97.1)	1.88 (1.26)	0.0	1.00	1.80	2.80	5.8	
Week 28		Teze+Teze	296	286 (96.6)	1.51 (1.17)	0.0	0.60	1.40	2.20	5.2	
		Pbo+Pbo	137	132 (96.4)	1.79 (1.28)	0.0	0.60	1.70	2.60	5.6	
Week 32		Teze+Teze	296	285 (96.3)	1.53 (1.18)	0.0	0.60	1.40	2.40	5.0	
		Pbo+Pbo	137	133 (97.1)	1.88 (1.19)	0.0	1.00	1.80	2.80	5.4	
Week 36		Teze+Teze	296	294 (99.3)	1.51 (1.18)	0.0	0.40	1.40	2.20	5.0	
		Pbo+Pbo	137	134 (97.8)	1.90 (1.21)	0.0	1.00	2.00	2.80	5.6	
Week 40		Teze+Teze	296	289 (97.6)	1.49 (1.15)	0.0	0.60	1.40	2.40	4.6	
		Pbo+Pbo	137	135 (98.5)	1.92 (1.25)	0.0	0.80	1.80	2.80	5.4	
Week 44		Teze+Teze	296	288 (97.3)	1.46 (1.17)	0.0	0.60	1.20	2.20	5.0	
		Pbo+Pbo	137	134 (97.8)	1.88 (1.29)	0.0	0.80	1.80	2.80	5.2	
Week 48		Teze+Teze	296	289 (97.6)	1.45 (1.21)	0.0	0.40	1.20	2.20	5.4	
		Pbo+Pbo	137	132 (96.4)	1.87 (1.23)	0.0	1.00	1.80	2.80	5.6	
Week 52		Teze+Teze	296	288 (97.3)	1.39 (1.12)	0.0	0.40	1.20	2.20	4.4	
		Pbo+Pbo	137	133 (97.1)	1.79 (1.25)	0.0	1.00	1.60	2.60	5.4	
Week 64		Teze+Teze	296	292 (98.6)	1.40 (1.12)	0.0	0.40	1.20	2.20	5.0	
		Pbo+Pbo	137	132 (96.4)	1.84 (1.25)	0.0	1.00	1.80	2.50	5.6	
Week 76		Teze+Teze	296	288 (97.3)	1.47 (1.19)	0.0	0.60	1.20	2.20	5.4	
		Pbo+Pbo	137	135 (98.5)	1.87 (1.27)	0.0	0.80	1.80	2.80	5.6	
Week 88		Teze+Teze	296	283 (95.6)	1.40 (1.14)	0.0	0.40	1.20	2.20	5.4	
		Pbo+Pbo	137	130 (94.9)	1.82 (1.27)	0.0	0.80	1.60	2.60	5.8	
Week 104		Teze+Teze	296	278 (93.9)	1.30 (1.12)	0.0	0.40	1.00	2.00	5.0	
		Pbo+Pbo	137	130 (94.9)	1.76 (1.22)	0.0	0.80	1.80	2.60	5.6	

Note: DITTNL - LTE - adult = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.  
 Source Data: aacq, created on: 20JUL2022

Table DT1H5C\_HLMH0: Course of ACQ-5 score  
 DITTNL - LTE - adult

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-5 Week 2 score	Teze+Teze	296	284 (95.9)	-0.91 (0.97)	-5.0	-1.60	-0.80	-0.20	1.2	-0.25 [-0.46, -0.04]
	Pbo+Pbo	137	127 (92.7)	-0.67 (0.97)	-4.2	-1.20	-0.60	0.00	2.2	
Week 4	Teze+Teze	296	290 (98.0)	-1.12 (1.02)	-5.6	-1.80	-1.00	-0.40	1.8	-0.20 [-0.40, 0.01]
	Pbo+Pbo	137	134 (97.8)	-0.92 (1.02)	-4.2	-1.60	-0.80	-0.20	1.8	
Week 8	Teze+Teze	296	290 (98.0)	-1.41 (1.13)	-5.6	-2.20	-1.40	-0.60	2.0	-0.38 [-0.58, -0.17]
	Pbo+Pbo	137	136 (99.3)	-0.98 (1.15)	-4.6	-1.80	-1.00	-0.20	2.8	
Week 12	Teze+Teze	296	286 (96.6)	-1.41 (1.21)	-5.6	-2.20	-1.40	-0.60	2.4	-0.22 [-0.43, -0.02]
	Pbo+Pbo	137	136 (99.3)	-1.15 (1.17)	-4.6	-1.90	-1.20	-0.40	2.0	
Week 16	Teze+Teze	296	292 (98.6)	-1.58 (1.12)	-5.4	-2.30	-1.60	-0.80	2.0	-0.33 [-0.54, -0.12]
	Pbo+Pbo	137	134 (97.8)	-1.20 (1.17)	-5.0	-2.00	-1.20	-0.60	2.4	
Week 20	Teze+Teze	296	286 (96.6)	-1.57 (1.18)	-5.4	-2.40	-1.60	-0.80	1.8	-0.29 [-0.50, -0.08]
	Pbo+Pbo	137	133 (97.1)	-1.22 (1.20)	-4.6	-2.00	-1.20	-0.40	1.4	
Week 24	Teze+Teze	296	287 (97.0)	-1.60 (1.19)	-5.4	-2.40	-1.40	-0.80	1.4	-0.35 [-0.56, -0.14]
	Pbo+Pbo	137	133 (97.1)	-1.19 (1.15)	-3.8	-2.00	-1.20	-0.40	1.8	
Week 28	Teze+Teze	296	286 (96.6)	-1.59 (1.18)	-5.6	-2.40	-1.60	-0.80	1.6	-0.24 [-0.44, -0.03]
	Pbo+Pbo	137	132 (96.4)	-1.31 (1.20)	-4.6	-2.00	-1.20	-0.40	1.6	
Week 32	Teze+Teze	296	285 (96.3)	-1.58 (1.26)	-5.6	-2.40	-1.60	-0.80	3.0	-0.30 [-0.50, -0.09]
	Pbo+Pbo	137	133 (97.1)	-1.21 (1.17)	-3.8	-2.00	-1.20	-0.20	1.4	
Week 36	Teze+Teze	296	294 (99.3)	-1.61 (1.24)	-5.6	-2.40	-1.60	-0.80	2.4	-0.34 [-0.54, -0.13]
	Pbo+Pbo	137	134 (97.8)	-1.19 (1.21)	-4.4	-2.00	-1.20	-0.20	1.6	
Week 40	Teze+Teze	296	289 (97.6)	-1.62 (1.23)	-5.6	-2.40	-1.60	-0.80	2.0	-0.38 [-0.59, -0.17]
	Pbo+Pbo	137	135 (98.5)	-1.16 (1.20)	-4.0	-2.00	-1.00	-0.20	1.8	
Week 44	Teze+Teze	296	288 (97.3)	-1.66 (1.22)	-5.6	-2.60	-1.60	-0.80	1.6	-0.37 [-0.57, -0.16]
	Pbo+Pbo	137	134 (97.8)	-1.21 (1.27)	-4.2	-2.00	-1.20	-0.40	2.6	
Week 48	Teze+Teze	296	289 (97.6)	-1.67 (1.28)	-5.6	-2.40	-1.60	-0.80	2.2	-0.35 [-0.56, -0.14]
	Pbo+Pbo	137	132 (96.4)	-1.23 (1.18)	-4.0	-2.00	-1.20	-0.30	1.2	
Week 52	Teze+Teze	296	288 (97.3)	-1.73 (1.20)	-5.6	-2.60	-1.80	-1.00	1.4	-0.34 [-0.55, -0.14]
	Pbo+Pbo	137	133 (97.1)	-1.31 (1.22)	-4.4	-2.20	-1.20	-0.40	1.2	
Week 64	Teze+Teze	296	292 (98.6)	-1.73 (1.18)	-5.6	-2.60	-1.80	-1.00	1.8	-0.39 [-0.60, -0.18]
	Pbo+Pbo	137	132 (96.4)	-1.27 (1.23)	-4.2	-2.10	-1.20	-0.20	2.2	
Week 76	Teze+Teze	296	288 (97.3)	-1.66 (1.22)	-5.6	-2.60	-1.70	-1.00	2.4	-0.36 [-0.57, -0.16]
	Pbo+Pbo	137	135 (98.5)	-1.23 (1.15)	-4.0	-2.00	-1.20	-0.40	1.6	
Week 88	Teze+Teze	296	283 (95.6)	-1.73 (1.19)	-5.6	-2.60	-1.80	-1.00	1.4	-0.38 [-0.59, -0.17]
	Pbo+Pbo	137	130 (94.9)	-1.28 (1.16)	-4.2	-2.20	-1.20	-0.40	1.2	
Week 104	Teze+Teze	296	278 (93.9)	-1.81 (1.15)	-5.6	-2.60	-1.80	-1.00	1.4	-0.39 [-0.60, -0.18]
	Pbo+Pbo	137	130 (94.9)	-1.35 (1.22)	-4.8	-2.20	-1.20	-0.60	2.0	

Note: DITTNL - LTE - adult = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.  
 Source Data: aacq, created on: 20JUL2022

Table DT1H5C\_HLMC0: Change from baseline in ACQ-5 score - MMRM results  
 DITTNL - LTE - adult

Change from baseline in ACQ-5 score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 2	Teze+Teze	296	284 (95.9)	-0.91 (0.05)	(-1.01, -0.81)	-0.27 (0.09)	(-0.45, -0.08)	0.005 *	
	Pbo+Pbo	137	127 (92.7)	-0.64 (0.08)	(-0.80, -0.49)				
Week 4	Teze+Teze	296	290 (98.0)	-1.12 (0.06)	(-1.23, -1.01)	-0.19 (0.10)	(-0.38, 0.00)	0.053	
	Pbo+Pbo	137	134 (97.8)	-0.93 (0.08)	(-1.09, -0.77)				
Week 8	Teze+Teze	296	290 (98.0)	-1.40 (0.06)	(-1.52, -1.29)	-0.42 (0.11)	(-0.63, -0.21)	<0.001 *	
	Pbo+Pbo	137	136 (99.3)	-0.99 (0.09)	(-1.16, -0.81)				
Week 12	Teze+Teze	296	286 (96.6)	-1.42 (0.07)	(-1.55, -1.29)	-0.27 (0.12)	(-0.50, -0.04)	0.023 *	
	Pbo+Pbo	137	136 (99.3)	-1.15 (0.10)	(-1.34, -0.96)				
Week 16	Teze+Teze	296	292 (98.6)	-1.57 (0.06)	(-1.69, -1.45)	-0.35 (0.11)	(-0.57, -0.13)	0.002 *	
	Pbo+Pbo	137	134 (97.8)	-1.22 (0.09)	(-1.40, -1.04)				
Week 20	Teze+Teze	296	286 (96.6)	-1.57 (0.06)	(-1.70, -1.44)	-0.36 (0.11)	(-0.58, -0.13)	0.002 *	
	Pbo+Pbo	137	133 (97.1)	-1.21 (0.09)	(-1.40, -1.03)				
Week 24	Teze+Teze	296	287 (97.0)	-1.60 (0.06)	(-1.72, -1.48)	-0.39 (0.11)	(-0.61, -0.17)	<0.001 *	
	Pbo+Pbo	137	133 (97.1)	-1.21 (0.09)	(-1.39, -1.03)				
Week 28	Teze+Teze	296	286 (96.6)	-1.59 (0.06)	(-1.71, -1.46)	-0.28 (0.12)	(-0.51, -0.05)	0.015 *	
	Pbo+Pbo	137	132 (96.4)	-1.31 (0.10)	(-1.49, -1.12)				
Week 32	Teze+Teze	296	285 (96.3)	-1.59 (0.07)	(-1.72, -1.46)	-0.37 (0.12)	(-0.60, -0.14)	0.002 *	
	Pbo+Pbo	137	133 (97.1)	-1.21 (0.10)	(-1.40, -1.02)				
Week 36	Teze+Teze	296	294 (99.3)	-1.61 (0.07)	(-1.74, -1.48)	-0.42 (0.12)	(-0.65, -0.19)	<0.001 *	
	Pbo+Pbo	137	134 (97.8)	-1.19 (0.10)	(-1.38, -0.99)				

Note: DITTNL - LTE - adult = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.  
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.  
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.  
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.  
 ACQ = asthma control questionnaire.  
 Source Data: aacq, created on: 20JUL2022

Table DT1H5C\_HLMC0: Change from baseline in ACQ-5 score - MMRM results  
 DITTNL - LTE - adult

Change from baseline in ACQ-5 score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 40	Teze+Teze	296	289 (97.6)	-1.62 (0.07)	(-1.74, -1.49)	-0.45 (0.12)	(-0.68, -0.22)	<0.001 *	
	Pbo+Pbo	137	135 (98.5)	-1.16 (0.10)	(-1.35, -0.97)				
Week 44	Teze+Teze	296	288 (97.3)	-1.64 (0.07)	(-1.77, -1.51)	-0.43 (0.12)	(-0.66, -0.19)	<0.001 *	
	Pbo+Pbo	137	134 (97.8)	-1.22 (0.10)	(-1.41, -1.03)				
Week 48	Teze+Teze	296	289 (97.6)	-1.67 (0.07)	(-1.80, -1.54)	-0.45 (0.12)	(-0.69, -0.22)	<0.001 *	
	Pbo+Pbo	137	132 (96.4)	-1.22 (0.10)	(-1.41, -1.02)				
Week 52	Teze+Teze	296	288 (97.3)	-1.74 (0.06)	(-1.87, -1.61)	-0.43 (0.11)	(-0.66, -0.21)	<0.001 *	
	Pbo+Pbo	137	133 (97.1)	-1.31 (0.09)	(-1.49, -1.12)				
Week 64	Teze+Teze	296	292 (98.6)	-1.72 (0.06)	(-1.85, -1.59)	-0.44 (0.11)	(-0.66, -0.22)	<0.001 *	
	Pbo+Pbo	137	132 (96.4)	-1.28 (0.09)	(-1.47, -1.09)				
Week 76	Teze+Teze	296	288 (97.3)	-1.63 (0.07)	(-1.76, -1.50)	-0.39 (0.12)	(-0.62, -0.16)	<0.001 *	
	Pbo+Pbo	137	135 (98.5)	-1.24 (0.10)	(-1.43, -1.05)				
Week 88	Teze+Teze	296	283 (95.6)	-1.69 (0.07)	(-1.82, -1.56)	-0.40 (0.12)	(-0.63, -0.18)	<0.001 *	
	Pbo+Pbo	137	130 (94.9)	-1.29 (0.10)	(-1.48, -1.10)				
Week 104	Teze+Teze	296	278 (93.9)	-1.78 (0.06)	(-1.91, -1.66)	-0.45 (0.11)	(-0.68, -0.23)	<0.001 *	
	Pbo+Pbo	137	130 (94.9)	-1.33 (0.09)	(-1.52, -1.15)				

Note: DITTNL - LTE - adult = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.  
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.  
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.  
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.  
 ACQ = asthma control questionnaire.  
 Source Data: aacq, created on: 20JUL2022

Table NT1H6C\_ALMH0: Course of ACQ-6 score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-6 score	Baseline	Tezepelumab	380	380 (100.0)	2.91 (0.87)	1.3	2.33	2.83	3.33	5.3	
		Placebo	371	371 (100.0)	2.82 (0.82)	1.5	2.17	2.67	3.33	5.7	
	Week 2	Tezepelumab	380	363 (95.5)	2.07 (0.99)	0.0	1.50	2.00	2.67	5.3	
		Placebo	371	344 (92.7)	2.25 (1.06)	0.0	1.50	2.17	2.83	5.5	
	Week 4	Tezepelumab	380	372 (97.9)	1.87 (1.01)	0.0	1.00	1.83	2.50	5.7	
		Placebo	371	360 (97.0)	2.03 (1.03)	0.0	1.33	2.00	2.67	5.3	
	Week 8	Tezepelumab	380	372 (97.9)	1.64 (1.04)	0.0	0.83	1.50	2.33	5.5	
		Placebo	371	360 (97.0)	1.90 (1.06)	0.0	1.17	1.83	2.50	5.5	
	Week 12	Tezepelumab	380	365 (96.1)	1.61 (1.13)	0.0	0.83	1.50	2.33	6.0	
		Placebo	371	355 (95.7)	1.79 (1.11)	0.0	1.00	1.67	2.50	5.7	
	Week 16	Tezepelumab	380	367 (96.6)	1.49 (1.05)	0.0	0.67	1.33	2.17	5.7	
		Placebo	371	351 (94.6)	1.75 (1.15)	0.0	1.00	1.67	2.33	5.7	
	Week 20	Tezepelumab	380	357 (93.9)	1.45 (1.09)	0.0	0.67	1.33	2.17	5.5	
		Placebo	371	344 (92.7)	1.66 (1.11)	0.0	0.83	1.50	2.50	5.3	
	Week 24	Tezepelumab	380	357 (93.9)	1.43 (1.06)	0.0	0.67	1.33	2.17	5.3	
		Placebo	371	339 (91.4)	1.69 (1.10)	0.0	0.83	1.50	2.50	5.5	
	Week 28	Tezepelumab	380	354 (93.2)	1.40 (1.08)	0.0	0.50	1.17	2.00	5.0	
		Placebo	371	338 (91.1)	1.69 (1.18)	0.0	0.83	1.50	2.50	5.3	
	Week 32	Tezepelumab	380	352 (92.6)	1.46 (1.13)	0.0	0.50	1.33	2.25	5.0	
		Placebo	371	337 (90.8)	1.72 (1.10)	0.0	0.83	1.50	2.50	5.2	
	Week 36	Tezepelumab	380	359 (94.5)	1.42 (1.11)	0.0	0.50	1.33	2.17	5.2	
		Placebo	371	334 (90.0)	1.65 (1.10)	0.0	0.83	1.67	2.33	5.5	
	Week 40	Tezepelumab	380	354 (93.2)	1.42 (1.11)	0.0	0.50	1.17	2.17	4.8	
		Placebo	371	333 (89.8)	1.65 (1.13)	0.0	0.83	1.50	2.50	5.3	
	Week 44	Tezepelumab	380	351 (92.4)	1.36 (1.09)	0.0	0.50	1.17	2.00	4.7	
		Placebo	371	329 (88.7)	1.63 (1.14)	0.0	0.67	1.50	2.50	5.0	
	Week 48	Tezepelumab	380	352 (92.6)	1.37 (1.14)	0.0	0.50	1.17	2.00	5.2	
		Placebo	371	327 (88.1)	1.62 (1.12)	0.0	0.83	1.50	2.33	5.5	
	Week 52	Tezepelumab	380	346 (91.1)	1.32 (1.09)	0.0	0.50	1.17	2.00	5.0	
		Placebo	371	324 (87.3)	1.60 (1.14)	0.0	0.67	1.50	2.33	5.5	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Source Data: aacq, created on: 20FEB2022

Table NT1H6C\_ALMH0: Course of ACQ-6 score  
 DITTL - adult

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-6 Week 2 score	Tezepelumab	380	363 (95.5)	-0.84 (0.94)	-4.5	-1.33	-0.67	-0.17	1.7	-0.28 [-0.43, -0.14]
	Placebo	371	344 (92.7)	-0.57 (0.91)	-4.0	-1.00	-0.50	0.00	3.2	
Week 4	Tezepelumab	380	372 (97.9)	-1.03 (1.00)	-5.0	-1.67	-0.92	-0.33	1.8	-0.25 [-0.40, -0.11]
	Placebo	371	360 (97.0)	-0.79 (0.92)	-4.0	-1.33	-0.67	-0.17	2.2	
Week 8	Tezepelumab	380	372 (97.9)	-1.27 (1.10)	-5.0	-2.00	-1.17	-0.50	2.3	-0.33 [-0.48, -0.18]
	Placebo	371	360 (97.0)	-0.92 (1.01)	-4.2	-1.50	-0.83	-0.33	2.7	
Week 12	Tezepelumab	380	365 (96.1)	-1.28 (1.15)	-5.0	-2.00	-1.17	-0.50	2.3	-0.23 [-0.37, -0.08]
	Placebo	371	355 (95.7)	-1.03 (1.05)	-4.5	-1.67	-1.00	-0.33	2.3	
Week 16	Tezepelumab	380	367 (96.6)	-1.41 (1.08)	-4.8	-2.17	-1.33	-0.67	1.7	-0.33 [-0.48, -0.18]
	Placebo	371	351 (94.6)	-1.05 (1.08)	-4.7	-1.67	-1.00	-0.33	2.5	
Week 20	Tezepelumab	380	357 (93.9)	-1.43 (1.14)	-4.8	-2.17	-1.50	-0.67	3.2	-0.27 [-0.42, -0.12]
	Placebo	371	344 (92.7)	-1.13 (1.07)	-4.8	-1.67	-1.17	-0.50	1.3	
Week 24	Tezepelumab	380	357 (93.9)	-1.45 (1.13)	-4.8	-2.17	-1.33	-0.67	2.3	-0.31 [-0.46, -0.16]
	Placebo	371	339 (91.4)	-1.11 (1.05)	-4.7	-1.83	-1.17	-0.50	2.0	
Week 28	Tezepelumab	380	354 (93.2)	-1.47 (1.11)	-5.0	-2.17	-1.33	-0.83	1.8	-0.33 [-0.48, -0.18]
	Placebo	371	338 (91.1)	-1.10 (1.12)	-4.8	-1.83	-1.00	-0.33	1.8	
Week 32	Tezepelumab	380	352 (92.6)	-1.42 (1.19)	-5.0	-2.17	-1.33	-0.67	2.5	-0.30 [-0.45, -0.15]
	Placebo	371	337 (90.8)	-1.08 (1.09)	-4.0	-1.83	-1.00	-0.33	2.0	
Week 36	Tezepelumab	380	359 (94.5)	-1.46 (1.20)	-5.0	-2.33	-1.50	-0.67	2.3	-0.28 [-0.43, -0.13]
	Placebo	371	334 (90.0)	-1.14 (1.09)	-5.0	-1.83	-1.00	-0.33	1.8	
Week 40	Tezepelumab	380	354 (93.2)	-1.47 (1.19)	-5.0	-2.33	-1.50	-0.67	2.7	-0.30 [-0.45, -0.15]
	Placebo	371	333 (89.8)	-1.13 (1.11)	-4.5	-1.83	-1.00	-0.33	1.8	
Week 44	Tezepelumab	380	351 (92.4)	-1.52 (1.13)	-5.0	-2.33	-1.50	-0.83	2.0	-0.32 [-0.47, -0.17]
	Placebo	371	329 (88.7)	-1.16 (1.14)	-4.8	-2.00	-1.00	-0.33	2.5	
Week 48	Tezepelumab	380	352 (92.6)	-1.51 (1.21)	-5.0	-2.33	-1.50	-0.83	2.2	-0.29 [-0.44, -0.14]
	Placebo	371	327 (88.1)	-1.18 (1.10)	-5.2	-2.00	-1.17	-0.50	2.2	
Week 52	Tezepelumab	380	346 (91.1)	-1.56 (1.20)	-5.2	-2.33	-1.67	-0.83	3.2	-0.31 [-0.46, -0.16]
	Placebo	371	324 (87.3)	-1.20 (1.15)	-4.3	-2.00	-1.17	-0.33	1.7	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.

Source Data: aacq, created on: 20FEB2022



Table NT1H6C\_ALMC0: Change from baseline in ACQ-6 score - MMRM results  
 DITTl - adult

Change from baseline in ACQ-6 score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 2	Tezepelumab	380	363 (95.5)	-0.81 (0.05)	(-0.90, -0.73)	-0.25 (0.06)	(-0.38, -0.12)	<0.001 *	
	Placebo	371	344 (92.7)	-0.56 (0.05)	(-0.66, -0.47)				
Week 4	Tezepelumab	380	372 (97.9)	-1.01 (0.05)	(-1.10, -0.92)	-0.20 (0.07)	(-0.33, -0.07)	0.002 *	
	Placebo	371	360 (97.0)	-0.81 (0.05)	(-0.90, -0.71)				
Week 8	Tezepelumab	380	372 (97.9)	-1.24 (0.05)	(-1.33, -1.14)	-0.32 (0.07)	(-0.46, -0.18)	<0.001 *	
	Placebo	371	360 (97.0)	-0.92 (0.05)	(-1.02, -0.82)				
Week 12	Tezepelumab	380	365 (96.1)	-1.26 (0.05)	(-1.37, -1.16)	-0.24 (0.08)	(-0.39, -0.09)	0.002 *	
	Placebo	371	355 (95.7)	-1.03 (0.05)	(-1.13, -0.92)				
Week 16	Tezepelumab	380	367 (96.6)	-1.37 (0.05)	(-1.48, -1.27)	-0.32 (0.07)	(-0.47, -0.18)	<0.001 *	
	Placebo	371	351 (94.6)	-1.05 (0.05)	(-1.16, -0.95)				
Week 20	Tezepelumab	380	357 (93.9)	-1.42 (0.05)	(-1.52, -1.31)	-0.30 (0.08)	(-0.45, -0.15)	<0.001 *	
	Placebo	371	344 (92.7)	-1.11 (0.05)	(-1.22, -1.01)				
Week 24	Tezepelumab	380	357 (93.9)	-1.43 (0.05)	(-1.53, -1.33)	-0.32 (0.08)	(-0.47, -0.18)	<0.001 *	
	Placebo	371	339 (91.4)	-1.11 (0.05)	(-1.21, -1.00)				
Week 28	Tezepelumab	380	354 (93.2)	-1.44 (0.05)	(-1.54, -1.33)	-0.34 (0.08)	(-0.50, -0.19)	<0.001 *	
	Placebo	371	338 (91.1)	-1.09 (0.06)	(-1.20, -0.98)				
Week 32	Tezepelumab	380	352 (92.6)	-1.40 (0.06)	(-1.51, -1.29)	-0.34 (0.08)	(-0.50, -0.19)	<0.001 *	
	Placebo	371	337 (90.8)	-1.06 (0.06)	(-1.17, -0.95)				
Week 36	Tezepelumab	380	359 (94.5)	-1.43 (0.06)	(-1.54, -1.32)	-0.31 (0.08)	(-0.47, -0.15)	<0.001 *	
	Placebo	371	334 (90.0)	-1.12 (0.06)	(-1.23, -1.01)				

Note: DITTl - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 20FEB2022

Table NT1H6C\_ALMC0: Change from baseline in ACQ-6 score - MMRM results  
DITTL - adult

Change from baseline in ACQ-6 score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 40	Tezepelumab	380	354 (93.2)	-1.44 (0.06)	(-1.55, -1.33)	-0.32 (0.08)	(-0.47, -0.16)	<0.001 *	
	Placebo	371	333 (89.8)	-1.12 (0.06)	(-1.24, -1.01)				
Week 44	Tezepelumab	380	351 (92.4)	-1.49 (0.06)	(-1.60, -1.38)	-0.33 (0.08)	(-0.49, -0.18)	<0.001 *	
	Placebo	371	329 (88.7)	-1.16 (0.06)	(-1.27, -1.05)				
Week 48	Tezepelumab	380	352 (92.6)	-1.49 (0.06)	(-1.60, -1.38)	-0.36 (0.08)	(-0.52, -0.20)	<0.001 *	
	Placebo	371	327 (88.1)	-1.14 (0.06)	(-1.25, -1.02)				
Week 52	Tezepelumab	380	346 (91.1)	-1.53 (0.06)	(-1.64, -1.42)	-0.36 (0.08)	(-0.52, -0.20)	<0.001 *	
	Placebo	371	324 (87.3)	-1.17 (0.06)	(-1.29, -1.06)				

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

ACQ = asthma control questionnaire.

Source Data: aacq, created on: 20FEB2022

Table DT1H6C\_HLMH0: Course of ACQ-6 score  
 DITTNL - LTE - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-6 score	Baseline	Teze+Teze	296	296 (100.0)	2.95 (0.83)	1.3	2.33	2.83	3.33	5.3	
		Pbo+Pbo	137	137 (100.0)	2.91 (0.83)	1.7	2.33	2.83	3.33	5.7	
Week 2		Teze+Teze	296	284 (95.9)	2.08 (0.98)	0.0	1.50	2.00	2.67	5.3	
		Pbo+Pbo	137	127 (92.7)	2.31 (1.00)	0.3	1.50	2.33	2.83	5.2	
Week 4		Teze+Teze	296	290 (98.0)	1.88 (0.99)	0.0	1.17	1.83	2.50	5.0	
		Pbo+Pbo	137	134 (97.8)	2.05 (1.06)	0.0	1.33	2.00	2.67	5.3	
Week 8		Teze+Teze	296	290 (98.0)	1.62 (1.00)	0.0	0.83	1.50	2.33	4.5	
		Pbo+Pbo	137	136 (99.3)	2.00 (1.11)	0.0	1.17	1.92	2.67	5.5	
Week 12		Teze+Teze	296	286 (96.6)	1.60 (1.13)	0.0	0.83	1.50	2.33	5.5	
		Pbo+Pbo	137	136 (99.3)	1.84 (1.16)	0.0	1.00	1.75	2.58	5.5	
Week 16		Teze+Teze	296	292 (98.6)	1.48 (1.05)	0.0	0.67	1.33	2.17	5.0	
		Pbo+Pbo	137	134 (97.8)	1.78 (1.26)	0.0	0.83	1.67	2.50	5.7	
Week 20		Teze+Teze	296	286 (96.6)	1.48 (1.09)	0.0	0.67	1.33	2.33	4.7	
		Pbo+Pbo	137	133 (97.1)	1.76 (1.19)	0.0	0.83	1.50	2.50	5.3	
Week 24		Teze+Teze	296	287 (97.0)	1.45 (1.04)	0.0	0.67	1.33	2.17	5.0	
		Pbo+Pbo	137	133 (97.1)	1.79 (1.21)	0.0	1.00	1.67	2.67	5.5	
Week 28		Teze+Teze	296	286 (96.6)	1.44 (1.10)	0.0	0.50	1.33	2.17	5.0	
		Pbo+Pbo	137	132 (96.4)	1.71 (1.23)	0.0	0.67	1.67	2.50	5.3	
Week 32		Teze+Teze	296	285 (96.3)	1.46 (1.12)	0.0	0.50	1.33	2.33	5.0	
		Pbo+Pbo	137	133 (97.1)	1.80 (1.15)	0.0	1.00	1.67	2.50	5.2	
Week 36		Teze+Teze	296	294 (99.3)	1.44 (1.12)	0.0	0.50	1.33	2.17	5.2	
		Pbo+Pbo	137	134 (97.8)	1.80 (1.16)	0.0	0.83	1.83	2.50	5.5	
Week 40		Teze+Teze	296	289 (97.6)	1.43 (1.10)	0.0	0.50	1.17	2.33	4.8	
		Pbo+Pbo	137	135 (98.5)	1.82 (1.18)	0.0	0.83	1.83	2.67	5.3	
Week 44		Teze+Teze	296	288 (97.3)	1.40 (1.10)	0.0	0.50	1.17	2.00	4.7	
		Pbo+Pbo	137	134 (97.8)	1.78 (1.22)	0.0	0.67	1.58	2.67	5.0	
Week 48		Teze+Teze	296	289 (97.6)	1.39 (1.14)	0.0	0.50	1.17	2.17	5.2	
		Pbo+Pbo	137	132 (96.4)	1.77 (1.16)	0.0	0.92	1.58	2.50	5.2	
Week 52		Teze+Teze	296	288 (97.3)	1.34 (1.08)	0.0	0.50	1.17	2.17	4.7	
		Pbo+Pbo	137	133 (97.1)	1.70 (1.19)	0.0	0.83	1.50	2.50	5.2	
Week 64		Teze+Teze	296	292 (98.6)	1.33 (1.07)	0.0	0.50	1.17	2.17	5.2	
		Pbo+Pbo	137	132 (96.4)	1.74 (1.19)	0.0	0.83	1.67	2.42	5.5	
Week 76		Teze+Teze	296	288 (97.3)	1.41 (1.13)	0.0	0.50	1.17	2.17	4.8	
		Pbo+Pbo	137	135 (98.5)	1.78 (1.19)	0.0	0.83	1.83	2.50	5.2	
Week 88		Teze+Teze	296	283 (95.6)	1.34 (1.09)	0.0	0.50	1.17	2.17	5.0	
		Pbo+Pbo	137	130 (94.9)	1.74 (1.22)	0.0	0.83	1.50	2.50	5.7	
Week 104		Teze+Teze	296	278 (93.9)	1.26 (1.07)	0.0	0.33	1.00	2.00	4.8	
		Pbo+Pbo	137	130 (94.9)	1.67 (1.15)	0.0	0.67	1.67	2.33	5.5	

Note: DITTNL - LTE - adult = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.  
 Source Data: aacq, created on: 20JUL2022

Table DT1H6C\_HLMH0: Course of ACQ-6 score  
 DITTNL - LTE - adult

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-6 Week 2 score	Teze+Teze	296	284 (95.9)	-0.87 (0.90)	-4.5	-1.42	-0.67	-0.33	1.3	-0.28 [-0.49, -0.07]
	Pbo+Pbo	137	127 (92.7)	-0.61 (0.91)	-3.8	-1.00	-0.50	-0.17	1.8	
Week 4	Teze+Teze	296	290 (98.0)	-1.06 (0.96)	-5.0	-1.67	-1.00	-0.33	1.8	-0.22 [-0.42, -0.01]
	Pbo+Pbo	137	134 (97.8)	-0.84 (0.96)	-3.8	-1.50	-0.67	-0.17	2.0	
Week 8	Teze+Teze	296	290 (98.0)	-1.32 (1.05)	-5.0	-2.00	-1.33	-0.50	1.8	-0.40 [-0.60, -0.19]
	Pbo+Pbo	137	136 (99.3)	-0.90 (1.07)	-4.2	-1.67	-0.83	-0.25	2.7	
Week 12	Teze+Teze	296	286 (96.6)	-1.32 (1.13)	-5.0	-2.00	-1.33	-0.50	2.3	-0.23 [-0.44, -0.03]
	Pbo+Pbo	137	136 (99.3)	-1.06 (1.10)	-4.2	-1.75	-1.08	-0.33	2.0	
Week 16	Teze+Teze	296	292 (98.6)	-1.47 (1.04)	-4.8	-2.17	-1.42	-0.83	1.7	-0.33 [-0.54, -0.13]
	Pbo+Pbo	137	134 (97.8)	-1.12 (1.13)	-4.5	-1.83	-1.08	-0.50	2.5	
Week 20	Teze+Teze	296	286 (96.6)	-1.46 (1.09)	-4.8	-2.17	-1.50	-0.67	1.3	-0.30 [-0.50, -0.09]
	Pbo+Pbo	137	133 (97.1)	-1.13 (1.14)	-4.2	-2.00	-1.00	-0.33	1.3	
Week 24	Teze+Teze	296	287 (97.0)	-1.49 (1.11)	-4.8	-2.17	-1.33	-0.67	1.7	-0.36 [-0.57, -0.15]
	Pbo+Pbo	137	133 (97.1)	-1.09 (1.11)	-3.8	-1.83	-1.17	-0.33	2.0	
Week 28	Teze+Teze	296	286 (96.6)	-1.48 (1.10)	-5.0	-2.33	-1.50	-0.83	1.8	-0.25 [-0.46, -0.05]
	Pbo+Pbo	137	132 (96.4)	-1.20 (1.15)	-4.2	-2.00	-1.17	-0.33	1.5	
Week 32	Teze+Teze	296	285 (96.3)	-1.47 (1.17)	-5.0	-2.17	-1.50	-0.67	2.5	-0.31 [-0.52, -0.11]
	Pbo+Pbo	137	133 (97.1)	-1.11 (1.11)	-3.7	-2.00	-1.17	-0.33	1.3	
Week 36	Teze+Teze	296	294 (99.3)	-1.50 (1.17)	-5.0	-2.33	-1.50	-0.67	2.3	-0.34 [-0.54, -0.13]
	Pbo+Pbo	137	134 (97.8)	-1.11 (1.14)	-4.0	-2.00	-1.00	-0.17	1.5	
Week 40	Teze+Teze	296	289 (97.6)	-1.50 (1.14)	-5.0	-2.33	-1.50	-0.67	2.0	-0.38 [-0.58, -0.17]
	Pbo+Pbo	137	135 (98.5)	-1.08 (1.13)	-4.0	-1.83	-1.00	-0.17	1.8	
Week 44	Teze+Teze	296	288 (97.3)	-1.55 (1.12)	-5.0	-2.33	-1.50	-0.83	1.8	-0.37 [-0.57, -0.16]
	Pbo+Pbo	137	134 (97.8)	-1.13 (1.20)	-3.8	-2.00	-1.17	-0.33	2.5	
Week 48	Teze+Teze	296	289 (97.6)	-1.55 (1.18)	-5.0	-2.33	-1.50	-0.83	2.0	-0.35 [-0.56, -0.15]
	Pbo+Pbo	137	132 (96.4)	-1.14 (1.11)	-3.8	-2.00	-1.17	-0.33	1.5	
Week 52	Teze+Teze	296	288 (97.3)	-1.61 (1.13)	-5.2	-2.33	-1.67	-0.83	1.7	-0.34 [-0.55, -0.14]
	Pbo+Pbo	137	133 (97.1)	-1.22 (1.17)	-4.0	-2.00	-1.17	-0.33	1.0	
Week 64	Teze+Teze	296	292 (98.6)	-1.62 (1.09)	-5.0	-2.33	-1.67	-1.00	1.7	-0.40 [-0.61, -0.19]
	Pbo+Pbo	137	132 (96.4)	-1.17 (1.20)	-4.0	-2.00	-1.17	-0.17	2.2	
Week 76	Teze+Teze	296	288 (97.3)	-1.55 (1.12)	-5.0	-2.33	-1.67	-0.83	1.8	-0.38 [-0.58, -0.17]
	Pbo+Pbo	137	135 (98.5)	-1.13 (1.08)	-3.8	-1.83	-1.00	-0.33	1.7	
Week 88	Teze+Teze	296	283 (95.6)	-1.62 (1.11)	-5.2	-2.33	-1.67	-0.83	1.5	-0.41 [-0.61, -0.20]
	Pbo+Pbo	137	130 (94.9)	-1.17 (1.13)	-4.0	-1.83	-1.08	-0.33	1.3	
Week 104	Teze+Teze	296	278 (93.9)	-1.68 (1.09)	-5.0	-2.33	-1.67	-0.83	1.8	-0.39 [-0.60, -0.18]
	Pbo+Pbo	137	130 (94.9)	-1.24 (1.17)	-4.8	-2.00	-1.17	-0.50	2.0	

Note: DITTNL - LTE - adult = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.  
 Source Data: aacq, created on: 20JUL2022

Table DT1H6C\_HLMC0: Change from baseline in ACQ-6 score - MMRM results  
 DITTNL - LTE - adult

Change from baseline in ACQ-6 score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 2	Teze+Teze	296	284 (95.9)	-0.86 (0.05)	(-0.95, -0.76)	-0.27 (0.09)	(-0.44, -0.09)	0.003 *	
	Pbo+Pbo	137	127 (92.7)	-0.59 (0.07)	(-0.73, -0.45)				
Week 4	Teze+Teze	296	290 (98.0)	-1.06 (0.05)	(-1.16, -0.95)	-0.20 (0.09)	(-0.38, -0.01)	0.035 *	
	Pbo+Pbo	137	134 (97.8)	-0.86 (0.08)	(-1.01, -0.71)				
Week 8	Teze+Teze	296	290 (98.0)	-1.32 (0.06)	(-1.43, -1.21)	-0.40 (0.10)	(-0.60, -0.21)	<0.001 *	
	Pbo+Pbo	137	136 (99.3)	-0.92 (0.08)	(-1.08, -0.75)				
Week 12	Teze+Teze	296	286 (96.6)	-1.33 (0.06)	(-1.45, -1.21)	-0.26 (0.11)	(-0.47, -0.04)	0.018 *	
	Pbo+Pbo	137	136 (99.3)	-1.07 (0.09)	(-1.25, -0.89)				
Week 16	Teze+Teze	296	292 (98.6)	-1.46 (0.06)	(-1.57, -1.34)	-0.33 (0.10)	(-0.53, -0.12)	0.002 *	
	Pbo+Pbo	137	134 (97.8)	-1.13 (0.09)	(-1.30, -0.96)				
Week 20	Teze+Teze	296	286 (96.6)	-1.46 (0.06)	(-1.58, -1.34)	-0.33 (0.11)	(-0.54, -0.12)	0.002 *	
	Pbo+Pbo	137	133 (97.1)	-1.13 (0.09)	(-1.30, -0.96)				
Week 24	Teze+Teze	296	287 (97.0)	-1.49 (0.06)	(-1.60, -1.37)	-0.37 (0.11)	(-0.58, -0.16)	<0.001 *	
	Pbo+Pbo	137	133 (97.1)	-1.12 (0.09)	(-1.29, -0.95)				
Week 28	Teze+Teze	296	286 (96.6)	-1.48 (0.06)	(-1.60, -1.36)	-0.28 (0.11)	(-0.49, -0.07)	0.010 *	
	Pbo+Pbo	137	132 (96.4)	-1.20 (0.09)	(-1.38, -1.02)				
Week 32	Teze+Teze	296	285 (96.3)	-1.47 (0.06)	(-1.60, -1.35)	-0.36 (0.11)	(-0.58, -0.14)	0.001 *	
	Pbo+Pbo	137	133 (97.1)	-1.11 (0.09)	(-1.29, -0.93)				
Week 36	Teze+Teze	296	294 (99.3)	-1.50 (0.06)	(-1.62, -1.38)	-0.39 (0.11)	(-0.61, -0.17)	<0.001 *	
	Pbo+Pbo	137	134 (97.8)	-1.11 (0.09)	(-1.29, -0.93)				

Note: DITTNL - LTE - adult = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.  
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.  
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.  
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.  
 ACQ = asthma control questionnaire.  
 Source Data: aacq, created on: 20JUL2022

Table DT1H6C\_HLMC0: Change from baseline in ACQ-6 score - MMRM results  
 DITTNL - LTE - adult

Change from baseline in ACQ-6 score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 40	Teze+Teze	296	289 (97.6)	-1.50 (0.06)	(-1.62, -1.38)	-0.42 (0.11)	(-0.63, -0.20)	<0.001 *	
	Pbo+Pbo	137	135 (98.5)	-1.09 (0.09)	(-1.26, -0.91)				
Week 44	Teze+Teze	296	288 (97.3)	-1.53 (0.06)	(-1.65, -1.41)	-0.39 (0.11)	(-0.61, -0.18)	<0.001 *	
	Pbo+Pbo	137	134 (97.8)	-1.14 (0.09)	(-1.32, -0.96)				
Week 48	Teze+Teze	296	289 (97.6)	-1.55 (0.06)	(-1.68, -1.43)	-0.42 (0.11)	(-0.64, -0.20)	<0.001 *	
	Pbo+Pbo	137	132 (96.4)	-1.14 (0.09)	(-1.32, -0.95)				
Week 52	Teze+Teze	296	288 (97.3)	-1.62 (0.06)	(-1.74, -1.50)	-0.40 (0.11)	(-0.61, -0.19)	<0.001 *	
	Pbo+Pbo	137	133 (97.1)	-1.22 (0.09)	(-1.39, -1.04)				
Week 64	Teze+Teze	296	292 (98.6)	-1.61 (0.06)	(-1.73, -1.49)	-0.42 (0.11)	(-0.63, -0.21)	<0.001 *	
	Pbo+Pbo	137	132 (96.4)	-1.19 (0.09)	(-1.37, -1.02)				
Week 76	Teze+Teze	296	288 (97.3)	-1.52 (0.06)	(-1.64, -1.40)	-0.37 (0.11)	(-0.59, -0.16)	<0.001 *	
	Pbo+Pbo	137	135 (98.5)	-1.15 (0.09)	(-1.32, -0.97)				
Week 88	Teze+Teze	296	283 (95.6)	-1.58 (0.06)	(-1.70, -1.45)	-0.40 (0.11)	(-0.61, -0.18)	<0.001 *	
	Pbo+Pbo	137	130 (94.9)	-1.18 (0.09)	(-1.36, -1.00)				
Week 104	Teze+Teze	296	278 (93.9)	-1.65 (0.06)	(-1.77, -1.53)	-0.41 (0.11)	(-0.63, -0.20)	<0.001 *	
	Pbo+Pbo	137	130 (94.9)	-1.23 (0.09)	(-1.41, -1.06)				

Note: DITTNL - LTE - adult = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.  
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.  
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.  
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.  
 ACQ = asthma control questionnaire.  
 Source Data: aacq, created on: 20JUL2022

Table NT1WTC\_ILMH0: Course of ASD weekly total score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly total score	Baseline	Tezepelumab	395	395 (100.0)	1.44 (0.72)	0.0	0.96	1.39	1.89	4.0	
		Placebo	391	391 (100.0)	1.40 (0.71)	0.1	0.89	1.30	1.89	3.9	
	Week 1	Tezepelumab	395	386 (97.7)	1.22 (0.67)	0.0	0.80	1.11	1.62	3.8	
		Placebo	391	382 (97.7)	1.28 (0.70)	0.0	0.76	1.21	1.70	3.7	
	Week 2	Tezepelumab	395	384 (97.2)	1.11 (0.68)	0.0	0.65	1.00	1.49	3.4	
		Placebo	391	379 (96.9)	1.22 (0.70)	0.0	0.69	1.16	1.74	3.7	
	Week 3	Tezepelumab	395	379 (95.9)	1.05 (0.67)	0.0	0.57	0.99	1.42	3.2	
		Placebo	391	371 (94.9)	1.11 (0.69)	0.0	0.59	1.03	1.59	3.9	
	Week 4	Tezepelumab	395	375 (94.9)	1.01 (0.69)	0.0	0.50	0.94	1.45	3.4	
		Placebo	391	370 (94.6)	1.09 (0.68)	0.0	0.57	1.02	1.51	3.7	
	Week 5	Tezepelumab	395	375 (94.9)	0.95 (0.68)	0.0	0.46	0.88	1.37	3.5	
		Placebo	391	360 (92.1)	1.02 (0.67)	0.0	0.49	0.95	1.45	3.8	
	Week 6	Tezepelumab	395	368 (93.2)	0.92 (0.68)	0.0	0.38	0.85	1.34	3.7	
		Placebo	391	365 (93.4)	1.02 (0.70)	0.0	0.49	0.94	1.50	3.9	
	Week 7	Tezepelumab	395	366 (92.7)	0.91 (0.70)	0.0	0.31	0.86	1.31	3.8	
		Placebo	391	365 (93.4)	1.00 (0.70)	0.0	0.44	0.91	1.45	3.9	
	Week 8	Tezepelumab	395	368 (93.2)	0.88 (0.68)	0.0	0.31	0.80	1.31	3.8	
		Placebo	391	356 (91.0)	0.98 (0.68)	0.0	0.45	0.91	1.39	3.9	
	Week 9	Tezepelumab	395	370 (93.7)	0.84 (0.67)	0.0	0.30	0.77	1.23	3.7	
		Placebo	391	357 (91.3)	0.95 (0.68)	0.0	0.40	0.92	1.34	4.0	
	Week 10	Tezepelumab	395	368 (93.2)	0.85 (0.68)	0.0	0.27	0.80	1.21	3.7	
		Placebo	391	353 (90.3)	0.95 (0.68)	0.0	0.37	0.93	1.40	3.8	
	Week 11	Tezepelumab	395	359 (90.9)	0.85 (0.69)	0.0	0.23	0.84	1.27	3.6	
		Placebo	391	351 (89.8)	0.93 (0.69)	0.0	0.34	0.90	1.36	3.7	
	Week 12	Tezepelumab	395	360 (91.1)	0.85 (0.69)	0.0	0.26	0.81	1.20	3.6	
		Placebo	391	347 (88.7)	0.91 (0.68)	0.0	0.32	0.87	1.33	3.8	
	Week 13	Tezepelumab	395	353 (89.4)	0.82 (0.68)	0.0	0.26	0.74	1.18	3.2	
		Placebo	391	345 (88.2)	0.89 (0.67)	0.0	0.32	0.90	1.27	3.7	
	Week 14	Tezepelumab	395	350 (88.6)	0.79 (0.66)	0.0	0.20	0.70	1.13	3.1	
		Placebo	391	343 (87.7)	0.90 (0.67)	0.0	0.35	0.87	1.30	3.8	
	Week 15	Tezepelumab	395	348 (88.1)	0.79 (0.66)	0.0	0.22	0.72	1.12	3.2	
		Placebo	391	335 (85.7)	0.90 (0.70)	0.0	0.30	0.87	1.31	4.0	
	Week 16	Tezepelumab	395	352 (89.1)	0.78 (0.67)	0.0	0.18	0.68	1.12	3.2	
		Placebo	391	333 (85.2)	0.92 (0.71)	0.0	0.30	0.88	1.42	3.9	
Week 17	Tezepelumab	395	347 (87.8)	0.74 (0.66)	0.0	0.16	0.66	1.10	3.2		
	Placebo	391	327 (83.6)	0.88 (0.67)	0.0	0.32	0.84	1.33	3.9		

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WTC\_ILMH0: Course of ASD weekly total score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly total score	Week 18	Tezepelumab	395	346 (87.6)	0.77 (0.67)	0.0	0.18	0.70	1.10	3.4	
		Placebo	391	322 (82.4)	0.89 (0.71)	0.0	0.26	0.81	1.34	3.9	
	Week 19	Tezepelumab	395	343 (86.8)	0.76 (0.67)	0.0	0.14	0.63	1.10	3.3	
		Placebo	391	332 (84.9)	0.90 (0.73)	0.0	0.25	0.87	1.40	3.7	
	Week 20	Tezepelumab	395	335 (84.8)	0.76 (0.68)	0.0	0.14	0.66	1.10	3.2	
		Placebo	391	324 (82.9)	0.90 (0.72)	0.0	0.28	0.83	1.46	3.9	
	Week 21	Tezepelumab	395	334 (84.6)	0.74 (0.68)	0.0	0.12	0.65	1.07	3.3	
		Placebo	391	319 (81.6)	0.85 (0.72)	0.0	0.20	0.80	1.29	4.0	
	Week 22	Tezepelumab	395	333 (84.3)	0.78 (0.69)	0.0	0.14	0.71	1.15	3.3	
		Placebo	391	312 (79.8)	0.88 (0.72)	0.0	0.22	0.87	1.34	3.9	
	Week 23	Tezepelumab	395	328 (83.0)	0.77 (0.70)	0.0	0.11	0.69	1.20	3.3	
		Placebo	391	310 (79.3)	0.87 (0.72)	0.0	0.21	0.84	1.33	3.8	
	Week 24	Tezepelumab	395	337 (85.3)	0.76 (0.69)	0.0	0.13	0.67	1.13	3.2	
		Placebo	391	310 (79.3)	0.84 (0.71)	0.0	0.21	0.77	1.30	3.8	
	Week 25	Tezepelumab	395	323 (81.8)	0.77 (0.67)	0.0	0.14	0.70	1.13	3.2	
		Placebo	391	308 (78.8)	0.84 (0.72)	0.0	0.20	0.78	1.30	3.9	
	Week 26	Tezepelumab	395	327 (82.8)	0.77 (0.68)	0.0	0.17	0.70	1.14	3.2	
		Placebo	391	303 (77.5)	0.86 (0.71)	0.0	0.20	0.82	1.32	3.9	
	Week 27	Tezepelumab	395	317 (80.3)	0.75 (0.70)	0.0	0.13	0.63	1.10	3.3	
		Placebo	391	313 (80.1)	0.86 (0.73)	0.0	0.20	0.76	1.30	3.8	
	Week 28	Tezepelumab	395	325 (82.3)	0.73 (0.70)	0.0	0.06	0.60	1.14	3.4	
		Placebo	391	314 (80.3)	0.85 (0.72)	0.0	0.20	0.74	1.36	3.7	
	Week 29	Tezepelumab	395	317 (80.3)	0.73 (0.69)	0.0	0.10	0.60	1.10	3.4	
		Placebo	391	312 (79.8)	0.86 (0.74)	0.0	0.21	0.72	1.33	3.7	
	Week 30	Tezepelumab	395	322 (81.5)	0.74 (0.67)	0.0	0.16	0.62	1.11	3.9	
		Placebo	391	303 (77.5)	0.86 (0.72)	0.0	0.20	0.77	1.38	3.7	
	Week 31	Tezepelumab	395	322 (81.5)	0.73 (0.69)	0.0	0.10	0.63	1.09	4.0	
		Placebo	391	308 (78.8)	0.85 (0.69)	0.0	0.25	0.76	1.29	3.7	
	Week 32	Tezepelumab	395	324 (82.0)	0.74 (0.68)	0.0	0.14	0.66	1.10	3.8	
		Placebo	391	308 (78.8)	0.85 (0.69)	0.0	0.26	0.76	1.35	3.7	
	Week 33	Tezepelumab	395	321 (81.3)	0.72 (0.68)	0.0	0.10	0.59	1.08	3.5	
		Placebo	391	304 (77.7)	0.87 (0.71)	0.0	0.22	0.78	1.41	3.7	
	Week 34	Tezepelumab	395	319 (80.8)	0.72 (0.69)	0.0	0.05	0.61	1.11	3.5	
		Placebo	391	303 (77.5)	0.85 (0.72)	0.0	0.20	0.79	1.37	3.7	
	Week 35	Tezepelumab	395	320 (81.0)	0.74 (0.70)	0.0	0.08	0.59	1.09	3.6	
		Placebo	391	295 (75.4)	0.83 (0.71)	0.0	0.20	0.74	1.36	3.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table NT1WTC\_ILMH0: Course of ASD weekly total score  
 DITTLL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly total score	Week 36	Tezepelumab	395	317 (80.3)	0.75 (0.70)	0.0	0.09	0.67	1.11	3.5	
		Placebo	391	299 (76.5)	0.84 (0.68)	0.0	0.22	0.79	1.30	3.7	
	Week 37	Tezepelumab	395	320 (81.0)	0.73 (0.70)	0.0	0.10	0.59	1.10	3.4	
		Placebo	391	298 (76.2)	0.82 (0.67)	0.0	0.20	0.76	1.21	3.7	
	Week 38	Tezepelumab	395	317 (80.3)	0.75 (0.72)	0.0	0.10	0.60	1.17	3.4	
		Placebo	391	299 (76.5)	0.80 (0.68)	0.0	0.20	0.71	1.17	3.7	
	Week 39	Tezepelumab	395	325 (82.3)	0.76 (0.74)	0.0	0.09	0.60	1.20	3.9	
		Placebo	391	292 (74.7)	0.82 (0.71)	0.0	0.20	0.73	1.28	3.7	
	Week 40	Tezepelumab	395	321 (81.3)	0.75 (0.71)	0.0	0.10	0.61	1.20	3.4	
		Placebo	391	297 (76.0)	0.84 (0.71)	0.0	0.20	0.75	1.30	3.7	
	Week 41	Tezepelumab	395	324 (82.0)	0.71 (0.69)	0.0	0.09	0.57	1.12	3.1	
		Placebo	391	297 (76.0)	0.85 (0.69)	0.0	0.21	0.80	1.38	3.7	
	Week 42	Tezepelumab	395	316 (80.0)	0.72 (0.70)	0.0	0.10	0.55	1.11	3.1	
		Placebo	391	298 (76.2)	0.86 (0.73)	0.0	0.20	0.78	1.30	3.8	
	Week 43	Tezepelumab	395	319 (80.8)	0.72 (0.71)	0.0	0.06	0.53	1.13	3.1	
		Placebo	391	296 (75.7)	0.83 (0.71)	0.0	0.20	0.76	1.30	3.7	
	Week 44	Tezepelumab	395	316 (80.0)	0.71 (0.71)	0.0	0.07	0.54	1.08	3.1	
		Placebo	391	294 (75.2)	0.84 (0.71)	0.0	0.20	0.76	1.34	3.7	
	Week 45	Tezepelumab	395	319 (80.8)	0.71 (0.70)	0.0	0.09	0.52	1.10	3.2	
		Placebo	391	296 (75.7)	0.83 (0.71)	0.0	0.20	0.75	1.32	3.7	
	Week 46	Tezepelumab	395	314 (79.5)	0.73 (0.71)	0.0	0.09	0.50	1.15	3.2	
		Placebo	391	287 (73.4)	0.81 (0.69)	0.0	0.21	0.72	1.20	3.7	
	Week 47	Tezepelumab	395	302 (76.5)	0.72 (0.71)	0.0	0.09	0.49	1.12	3.0	
		Placebo	391	291 (74.4)	0.79 (0.67)	0.0	0.20	0.70	1.19	3.7	
	Week 48	Tezepelumab	395	323 (81.8)	0.72 (0.70)	0.0	0.08	0.51	1.09	3.0	
		Placebo	391	301 (77.0)	0.81 (0.69)	0.0	0.20	0.73	1.20	3.7	
	Week 49	Tezepelumab	395	315 (79.7)	0.71 (0.70)	0.0	0.06	0.55	1.10	3.0	
		Placebo	391	290 (74.2)	0.82 (0.67)	0.0	0.21	0.76	1.22	3.7	
	Week 50	Tezepelumab	395	312 (79.0)	0.71 (0.69)	0.0	0.05	0.52	1.12	3.0	
		Placebo	391	288 (73.7)	0.83 (0.69)	0.0	0.20	0.76	1.30	3.7	
	Week 51	Tezepelumab	395	307 (77.7)	0.73 (0.70)	0.0	0.07	0.56	1.10	3.0	
		Placebo	391	282 (72.1)	0.82 (0.70)	0.0	0.22	0.74	1.17	3.7	
	Week 52	Tezepelumab	395	276 (69.9)	0.74 (0.72)	0.0	0.08	0.60	1.14	3.0	
		Placebo	391	257 (65.7)	0.82 (0.73)	0.0	0.19	0.74	1.27	3.7	

Note: DITTLL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WTC\_ILMH0: Course of ASD weekly total score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly total score	Week 1	Tezepelumab	395	386 (97.7)	-0.21 (0.36)	-2.2	-0.36	-0.13	0.00	1.0	-0.26 [-0.40, -0.11]
		Placebo	391	382 (97.7)	-0.12 (0.35)	-2.0	-0.29	-0.09	0.06	1.2	
	Week 2	Tezepelumab	395	384 (97.2)	-0.32 (0.48)	-2.7	-0.56	-0.19	0.00	0.8	-0.30 [-0.44, -0.15]
		Placebo	391	379 (96.9)	-0.18 (0.49)	-2.5	-0.35	-0.10	0.05	1.4	
	Week 3	Tezepelumab	395	379 (95.9)	-0.38 (0.54)	-3.4	-0.64	-0.26	-0.02	0.7	-0.19 [-0.33, -0.05]
		Placebo	391	371 (94.9)	-0.28 (0.54)	-2.4	-0.52	-0.19	0.00	1.8	
	Week 4	Tezepelumab	395	375 (94.9)	-0.42 (0.56)	-3.4	-0.69	-0.26	-0.01	0.7	-0.19 [-0.33, -0.05]
		Placebo	391	370 (94.6)	-0.31 (0.56)	-2.5	-0.61	-0.19	0.02	1.6	
	Week 5	Tezepelumab	395	375 (94.9)	-0.48 (0.59)	-3.5	-0.79	-0.34	-0.06	0.8	-0.18 [-0.32, -0.03]
		Placebo	391	360 (92.1)	-0.38 (0.56)	-2.7	-0.68	-0.27	-0.03	1.4	
	Week 6	Tezepelumab	395	368 (93.2)	-0.51 (0.62)	-3.5	-0.79	-0.39	-0.09	0.8	-0.21 [-0.36, -0.07]
		Placebo	391	365 (93.4)	-0.38 (0.61)	-3.0	-0.67	-0.28	0.00	1.5	
	Week 7	Tezepelumab	395	366 (92.7)	-0.53 (0.66)	-3.5	-0.83	-0.42	-0.07	1.2	-0.20 [-0.35, -0.06]
		Placebo	391	365 (93.4)	-0.40 (0.62)	-3.1	-0.71	-0.27	0.00	1.5	
	Week 8	Tezepelumab	395	368 (93.2)	-0.55 (0.65)	-3.4	-0.88	-0.41	-0.09	1.2	-0.22 [-0.37, -0.07]
		Placebo	391	356 (91.0)	-0.42 (0.61)	-3.0	-0.78	-0.32	-0.00	1.5	
	Week 9	Tezepelumab	395	370 (93.7)	-0.59 (0.65)	-3.5	-1.00	-0.49	-0.09	1.3	-0.22 [-0.37, -0.07]
		Placebo	391	357 (91.3)	-0.45 (0.61)	-3.1	-0.81	-0.38	-0.04	1.6	
	Week 10	Tezepelumab	395	368 (93.2)	-0.58 (0.64)	-3.4	-0.97	-0.44	-0.09	0.8	-0.19 [-0.34, -0.04]
		Placebo	391	353 (90.3)	-0.45 (0.63)	-3.2	-0.81	-0.34	-0.06	1.5	
	Week 11	Tezepelumab	395	359 (90.9)	-0.58 (0.66)	-3.4	-0.98	-0.47	-0.09	0.9	-0.17 [-0.32, -0.03]
		Placebo	391	351 (89.8)	-0.47 (0.64)	-3.1	-0.81	-0.38	-0.07	1.5	
	Week 12	Tezepelumab	395	360 (91.1)	-0.57 (0.68)	-3.5	-0.94	-0.45	-0.08	1.0	-0.14 [-0.28, 0.01]
		Placebo	391	347 (88.7)	-0.48 (0.61)	-3.1	-0.83	-0.38	-0.10	1.5	
	Week 13	Tezepelumab	395	353 (89.4)	-0.59 (0.67)	-3.4	-1.00	-0.49	-0.09	1.1	-0.13 [-0.28, 0.02]
		Placebo	391	345 (88.2)	-0.51 (0.63)	-3.1	-0.89	-0.43	-0.09	1.4	
	Week 14	Tezepelumab	395	350 (88.6)	-0.65 (0.67)	-3.4	-1.04	-0.51	-0.11	0.8	-0.22 [-0.37, -0.07]
		Placebo	391	343 (87.7)	-0.51 (0.64)	-3.1	-0.89	-0.41	-0.07	1.4	
	Week 15	Tezepelumab	395	348 (88.1)	-0.62 (0.66)	-3.0	-1.06	-0.50	-0.10	0.8	-0.19 [-0.34, -0.04]
		Placebo	391	335 (85.7)	-0.49 (0.64)	-3.1	-0.86	-0.46	-0.08	1.4	
	Week 16	Tezepelumab	395	352 (89.1)	-0.64 (0.69)	-3.4	-1.06	-0.49	-0.10	1.4	-0.22 [-0.37, -0.07]
		Placebo	391	333 (85.2)	-0.49 (0.65)	-3.0	-0.90	-0.40	-0.05	1.5	
	Week 17	Tezepelumab	395	347 (87.8)	-0.68 (0.68)	-3.5	-1.09	-0.57	-0.13	0.8	-0.25 [-0.40, -0.10]
		Placebo	391	327 (83.6)	-0.51 (0.63)	-3.1	-0.91	-0.44	-0.06	1.4	
	Week 18	Tezepelumab	395	346 (87.6)	-0.65 (0.69)	-3.4	-1.04	-0.53	-0.13	0.8	-0.21 [-0.36, -0.06]
		Placebo	391	322 (82.4)	-0.51 (0.66)	-3.1	-0.90	-0.43	-0.07	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WTC\_ILMH0: Course of ASD weekly total score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly total score	Week 19	Tezepelumab	395	343 (86.8)	-0.66 (0.70)	-3.5	-1.05	-0.57	-0.12	1.2	-0.23 [-0.38, -0.07]
		Placebo	391	332 (84.9)	-0.50 (0.68)	-3.1	-0.89	-0.41	-0.07	2.0	
	Week 20	Tezepelumab	395	335 (84.8)	-0.65 (0.69)	-3.5	-1.08	-0.50	-0.11	0.8	-0.21 [-0.36, -0.06]
		Placebo	391	324 (82.9)	-0.51 (0.70)	-3.1	-0.89	-0.44	-0.07	1.5	
	Week 21	Tezepelumab	395	334 (84.6)	-0.66 (0.68)	-3.4	-1.02	-0.61	-0.13	1.8	-0.18 [-0.34, -0.03]
		Placebo	391	319 (81.6)	-0.54 (0.69)	-3.2	-0.89	-0.44	-0.06	1.4	
	Week 22	Tezepelumab	395	333 (84.3)	-0.63 (0.69)	-3.2	-1.03	-0.53	-0.11	1.0	-0.17 [-0.33, -0.02]
		Placebo	391	312 (79.8)	-0.52 (0.66)	-2.9	-0.82	-0.47	-0.07	1.4	
	Week 23	Tezepelumab	395	328 (83.0)	-0.64 (0.69)	-3.2	-1.03	-0.54	-0.16	1.0	-0.16 [-0.31, -0.00]
		Placebo	391	310 (79.3)	-0.54 (0.68)	-3.1	-0.91	-0.45	-0.12	1.5	
	Week 24	Tezepelumab	395	337 (85.3)	-0.66 (0.69)	-3.4	-1.11	-0.59	-0.17	1.2	-0.18 [-0.33, -0.02]
		Placebo	391	310 (79.3)	-0.54 (0.68)	-3.1	-0.90	-0.50	-0.08	1.5	
	Week 25	Tezepelumab	395	323 (81.8)	-0.66 (0.68)	-3.4	-1.07	-0.61	-0.17	1.2	-0.16 [-0.32, -0.00]
		Placebo	391	308 (78.8)	-0.55 (0.71)	-3.4	-0.97	-0.47	-0.14	1.7	
	Week 26	Tezepelumab	395	327 (82.8)	-0.65 (0.70)	-3.3	-1.04	-0.59	-0.10	1.6	-0.16 [-0.32, -0.00]
		Placebo	391	303 (77.5)	-0.53 (0.69)	-3.1	-0.96	-0.43	-0.09	1.4	
	Week 27	Tezepelumab	395	317 (80.3)	-0.67 (0.71)	-3.5	-1.07	-0.61	-0.13	1.0	-0.22 [-0.37, -0.06]
		Placebo	391	313 (80.1)	-0.52 (0.71)	-3.1	-0.93	-0.47	-0.09	2.0	
	Week 28	Tezepelumab	395	325 (82.3)	-0.68 (0.70)	-3.5	-1.10	-0.60	-0.16	0.9	-0.22 [-0.38, -0.07]
		Placebo	391	314 (80.3)	-0.53 (0.69)	-3.1	-0.96	-0.44	-0.09	1.7	
	Week 29	Tezepelumab	395	317 (80.3)	-0.70 (0.70)	-3.5	-1.12	-0.64	-0.15	0.9	-0.24 [-0.40, -0.08]
		Placebo	391	312 (79.8)	-0.53 (0.71)	-3.1	-0.95	-0.44	-0.08	1.4	
	Week 30	Tezepelumab	395	322 (81.5)	-0.67 (0.70)	-3.5	-1.09	-0.64	-0.13	0.9	-0.21 [-0.36, -0.05]
		Placebo	391	303 (77.5)	-0.53 (0.70)	-3.1	-0.96	-0.47	-0.08	1.4	
	Week 31	Tezepelumab	395	322 (81.5)	-0.70 (0.72)	-3.5	-1.13	-0.61	-0.13	1.4	-0.23 [-0.39, -0.08]
		Placebo	391	308 (78.8)	-0.53 (0.66)	-2.8	-0.99	-0.46	-0.10	1.4	
	Week 32	Tezepelumab	395	324 (82.0)	-0.67 (0.69)	-3.5	-1.08	-0.61	-0.14	1.8	-0.18 [-0.34, -0.02]
		Placebo	391	308 (78.8)	-0.54 (0.71)	-3.3	-1.00	-0.46	-0.06	1.4	
	Week 33	Tezepelumab	395	321 (81.3)	-0.69 (0.71)	-3.5	-1.11	-0.64	-0.14	1.7	-0.23 [-0.38, -0.07]
		Placebo	391	304 (77.7)	-0.53 (0.71)	-3.3	-0.96	-0.42	-0.09	1.5	
	Week 34	Tezepelumab	395	319 (80.8)	-0.70 (0.70)	-3.5	-1.09	-0.64	-0.16	1.7	-0.23 [-0.39, -0.08]
		Placebo	391	303 (77.5)	-0.54 (0.69)	-3.1	-0.93	-0.45	-0.13	1.4	
	Week 35	Tezepelumab	395	320 (81.0)	-0.68 (0.71)	-3.5	-1.09	-0.61	-0.16	1.6	-0.19 [-0.35, -0.04]
		Placebo	391	295 (75.4)	-0.54 (0.69)	-3.1	-0.96	-0.45	-0.13	1.4	
	Week 36	Tezepelumab	395	317 (80.3)	-0.67 (0.72)	-3.5	-1.09	-0.57	-0.13	1.6	-0.18 [-0.34, -0.03]
		Placebo	391	299 (76.5)	-0.54 (0.68)	-3.4	-0.96	-0.43	-0.10	1.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WTC\_ILMH0: Course of ASD weekly total score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly total score	Week 37	Tezepelumab	395	320 (81.0)	-0.68 (0.73)	-3.5	-1.11	-0.62	-0.13	1.6	-0.20 [-0.35, -0.04]
		Placebo	391	298 (76.2)	-0.54 (0.67)	-3.1	-0.96	-0.46	-0.12	1.4	
	Week 38	Tezepelumab	395	317 (80.3)	-0.68 (0.73)	-3.5	-1.09	-0.59	-0.16	1.6	-0.17 [-0.33, -0.01]
		Placebo	391	299 (76.5)	-0.56 (0.65)	-3.1	-1.01	-0.50	-0.10	1.4	
	Week 39	Tezepelumab	395	325 (82.3)	-0.68 (0.74)	-3.5	-1.13	-0.61	-0.15	1.6	-0.18 [-0.34, -0.02]
		Placebo	391	292 (74.7)	-0.55 (0.69)	-3.4	-1.01	-0.47	-0.08	1.6	
	Week 40	Tezepelumab	395	321 (81.3)	-0.68 (0.72)	-3.5	-1.11	-0.62	-0.13	1.6	-0.22 [-0.38, -0.06]
		Placebo	391	297 (76.0)	-0.52 (0.68)	-3.5	-0.96	-0.43	-0.08	1.5	
	Week 41	Tezepelumab	395	324 (82.0)	-0.71 (0.72)	-3.5	-1.14	-0.64	-0.17	1.6	-0.22 [-0.38, -0.06]
		Placebo	391	297 (76.0)	-0.56 (0.67)	-3.3	-0.96	-0.47	-0.11	1.5	
	Week 42	Tezepelumab	395	316 (80.0)	-0.71 (0.71)	-3.4	-1.10	-0.64	-0.18	1.6	-0.27 [-0.43, -0.11]
		Placebo	391	298 (76.2)	-0.52 (0.68)	-3.4	-0.89	-0.44	-0.10	1.4	
	Week 43	Tezepelumab	395	319 (80.8)	-0.72 (0.72)	-3.5	-1.13	-0.62	-0.17	1.5	-0.23 [-0.39, -0.07]
		Placebo	391	296 (75.7)	-0.56 (0.68)	-3.1	-0.98	-0.47	-0.11	1.4	
	Week 44	Tezepelumab	395	316 (80.0)	-0.72 (0.72)	-3.5	-1.11	-0.64	-0.17	1.6	-0.25 [-0.41, -0.09]
		Placebo	391	294 (75.2)	-0.55 (0.70)	-3.3	-0.93	-0.46	-0.09	1.4	
	Week 45	Tezepelumab	395	319 (80.8)	-0.73 (0.71)	-3.5	-1.11	-0.67	-0.22	1.6	-0.21 [-0.37, -0.06]
		Placebo	391	296 (75.7)	-0.57 (0.72)	-3.4	-1.04	-0.47	-0.08	1.4	
	Week 46	Tezepelumab	395	314 (79.5)	-0.72 (0.73)	-3.5	-1.11	-0.64	-0.19	1.6	-0.22 [-0.38, -0.06]
		Placebo	391	287 (73.4)	-0.56 (0.70)	-3.3	-1.01	-0.48	-0.07	1.4	
	Week 47	Tezepelumab	395	302 (76.5)	-0.71 (0.70)	-3.5	-1.13	-0.64	-0.17	1.5	-0.19 [-0.35, -0.02]
		Placebo	391	291 (74.4)	-0.58 (0.66)	-3.1	-0.97	-0.48	-0.15	1.2	
	Week 48	Tezepelumab	395	323 (81.8)	-0.70 (0.72)	-3.5	-1.11	-0.65	-0.17	1.6	-0.17 [-0.32, -0.01]
		Placebo	391	301 (77.0)	-0.58 (0.66)	-3.1	-0.99	-0.48	-0.14	1.3	
	Week 49	Tezepelumab	395	315 (79.7)	-0.71 (0.71)	-3.5	-1.11	-0.63	-0.18	1.6	-0.19 [-0.35, -0.03]
		Placebo	391	290 (74.2)	-0.58 (0.66)	-3.1	-0.95	-0.50	-0.10	1.2	
	Week 50	Tezepelumab	395	312 (79.0)	-0.71 (0.71)	-3.5	-1.14	-0.64	-0.17	1.5	-0.21 [-0.37, -0.05]
		Placebo	391	288 (73.7)	-0.56 (0.68)	-3.1	-0.99	-0.47	-0.11	1.5	
	Week 51	Tezepelumab	395	307 (77.7)	-0.70 (0.74)	-3.5	-1.11	-0.64	-0.14	1.6	-0.18 [-0.34, -0.02]
		Placebo	391	282 (72.1)	-0.57 (0.70)	-3.5	-1.01	-0.48	-0.11	1.5	
	Week 52	Tezepelumab	395	276 (69.9)	-0.69 (0.76)	-3.5	-1.15	-0.64	-0.11	1.6	-0.15 [-0.32, 0.02]
		Placebo	391	257 (65.7)	-0.58 (0.70)	-3.6	-0.98	-0.49	-0.13	1.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WTC\_ILMC0: Change from baseline in ASD weekly total score - MMRM results  
 DITTTL

Change from baseline in ASD weekly total score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 1	Tezepelumab	395	386 (97.7)	-0.20 (0.03)	(-0.26, -0.14)	-0.08 (0.04)	(-0.16, 0.01)	0.069	
	Placebo	391	382 (97.7)	-0.13 (0.03)	(-0.18, -0.07)				
Week 2	Tezepelumab	395	384 (97.2)	-0.32 (0.03)	(-0.37, -0.26)	-0.13 (0.04)	(-0.21, -0.05)	0.002 *	
	Placebo	391	379 (96.9)	-0.18 (0.03)	(-0.24, -0.13)				
Week 3	Tezepelumab	395	379 (95.9)	-0.38 (0.03)	(-0.44, -0.32)	-0.11 (0.04)	(-0.19, -0.02)	0.012 *	
	Placebo	391	371 (94.9)	-0.28 (0.03)	(-0.33, -0.22)				
Week 4	Tezepelumab	395	375 (94.9)	-0.42 (0.03)	(-0.48, -0.36)	-0.10 (0.04)	(-0.18, -0.02)	0.015 *	
	Placebo	391	370 (94.6)	-0.32 (0.03)	(-0.37, -0.26)				
Week 5	Tezepelumab	395	375 (94.9)	-0.47 (0.03)	(-0.53, -0.41)	-0.10 (0.04)	(-0.18, -0.01)	0.023 *	
	Placebo	391	360 (92.1)	-0.38 (0.03)	(-0.44, -0.32)				
Week 6	Tezepelumab	395	368 (93.2)	-0.51 (0.03)	(-0.56, -0.45)	-0.13 (0.04)	(-0.21, -0.04)	0.003 *	
	Placebo	391	365 (93.4)	-0.38 (0.03)	(-0.44, -0.32)				
Week 7	Tezepelumab	395	366 (92.7)	-0.52 (0.03)	(-0.58, -0.46)	-0.12 (0.04)	(-0.20, -0.04)	0.004 *	
	Placebo	391	365 (93.4)	-0.40 (0.03)	(-0.46, -0.34)				
Week 8	Tezepelumab	395	368 (93.2)	-0.55 (0.03)	(-0.60, -0.49)	-0.14 (0.04)	(-0.22, -0.06)	<0.001 *	
	Placebo	391	356 (91.0)	-0.41 (0.03)	(-0.47, -0.35)				
Week 9	Tezepelumab	395	370 (93.7)	-0.58 (0.03)	(-0.64, -0.52)	-0.14 (0.04)	(-0.22, -0.05)	0.001 *	
	Placebo	391	357 (91.3)	-0.45 (0.03)	(-0.50, -0.39)				
Week 10	Tezepelumab	395	368 (93.2)	-0.58 (0.03)	(-0.64, -0.52)	-0.13 (0.04)	(-0.22, -0.05)	0.001 *	
	Placebo	391	353 (90.3)	-0.45 (0.03)	(-0.50, -0.39)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WTC\_ILMC0: Change from baseline in ASD weekly total score - MMRM results  
 DITTTL

Change from baseline in ASD weekly total score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 11	Tezepelumab	395	359 (90.9)	-0.58 (0.03)	(-0.64, -0.52)	-0.12 (0.04)	(-0.21, -0.04)	0.003 *	
	Placebo	391	351 (89.8)	-0.46 (0.03)	(-0.51, -0.40)				
Week 12	Tezepelumab	395	360 (91.1)	-0.57 (0.03)	(-0.63, -0.51)	-0.11 (0.04)	(-0.19, -0.02)	0.012 *	
	Placebo	391	347 (88.7)	-0.46 (0.03)	(-0.52, -0.40)				
Week 13	Tezepelumab	395	353 (89.4)	-0.60 (0.03)	(-0.66, -0.54)	-0.12 (0.04)	(-0.20, -0.04)	0.004 *	
	Placebo	391	345 (88.2)	-0.48 (0.03)	(-0.54, -0.42)				
Week 14	Tezepelumab	395	350 (88.6)	-0.63 (0.03)	(-0.68, -0.57)	-0.14 (0.04)	(-0.23, -0.06)	<0.001 *	
	Placebo	391	343 (87.7)	-0.48 (0.03)	(-0.54, -0.42)				
Week 15	Tezepelumab	395	348 (88.1)	-0.62 (0.03)	(-0.68, -0.57)	-0.14 (0.04)	(-0.22, -0.05)	0.001 *	
	Placebo	391	335 (85.7)	-0.49 (0.03)	(-0.55, -0.43)				
Week 16	Tezepelumab	395	352 (89.1)	-0.65 (0.03)	(-0.71, -0.59)	-0.18 (0.04)	(-0.26, -0.10)	<0.001 *	
	Placebo	391	333 (85.2)	-0.47 (0.03)	(-0.53, -0.41)				
Week 17	Tezepelumab	395	347 (87.8)	-0.66 (0.03)	(-0.72, -0.60)	-0.16 (0.04)	(-0.24, -0.08)	<0.001 *	
	Placebo	391	327 (83.6)	-0.50 (0.03)	(-0.56, -0.44)				
Week 18	Tezepelumab	395	346 (87.6)	-0.64 (0.03)	(-0.70, -0.58)	-0.14 (0.04)	(-0.23, -0.06)	<0.001 *	
	Placebo	391	322 (82.4)	-0.49 (0.03)	(-0.55, -0.43)				
Week 19	Tezepelumab	395	343 (86.8)	-0.65 (0.03)	(-0.71, -0.60)	-0.16 (0.04)	(-0.24, -0.07)	<0.001 *	
	Placebo	391	332 (84.9)	-0.50 (0.03)	(-0.56, -0.44)				
Week 20	Tezepelumab	395	335 (84.8)	-0.66 (0.03)	(-0.72, -0.60)	-0.16 (0.04)	(-0.24, -0.08)	<0.001 *	
	Placebo	391	324 (82.9)	-0.50 (0.03)	(-0.56, -0.44)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WTC\_ILMC0: Change from baseline in ASD weekly total score - MMRM results  
 DITTTL

Change from baseline in ASD weekly total score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 21	Tezepelumab	395	334 (84.6)	-0.66 (0.03)	(-0.72, -0.60)	-0.15 (0.04)	(-0.23, -0.06)	<0.001 *	
	Placebo	391	319 (81.6)	-0.51 (0.03)	(-0.57, -0.45)				
Week 22	Tezepelumab	395	333 (84.3)	-0.65 (0.03)	(-0.71, -0.59)	-0.14 (0.04)	(-0.22, -0.05)	0.001 *	
	Placebo	391	312 (79.8)	-0.52 (0.03)	(-0.58, -0.46)				
Week 23	Tezepelumab	395	328 (83.0)	-0.66 (0.03)	(-0.72, -0.60)	-0.16 (0.04)	(-0.24, -0.07)	<0.001 *	
	Placebo	391	310 (79.3)	-0.50 (0.03)	(-0.56, -0.44)				
Week 24	Tezepelumab	395	337 (85.3)	-0.66 (0.03)	(-0.72, -0.60)	-0.14 (0.04)	(-0.23, -0.06)	<0.001 *	
	Placebo	391	310 (79.3)	-0.52 (0.03)	(-0.58, -0.46)				
Week 25	Tezepelumab	395	323 (81.8)	-0.66 (0.03)	(-0.72, -0.60)	-0.14 (0.04)	(-0.22, -0.05)	0.002 *	
	Placebo	391	308 (78.8)	-0.52 (0.03)	(-0.58, -0.46)				
Week 26	Tezepelumab	395	327 (82.8)	-0.65 (0.03)	(-0.71, -0.60)	-0.14 (0.04)	(-0.23, -0.06)	0.001 *	
	Placebo	391	303 (77.5)	-0.51 (0.03)	(-0.57, -0.45)				
Week 27	Tezepelumab	395	317 (80.3)	-0.66 (0.03)	(-0.72, -0.60)	-0.15 (0.04)	(-0.24, -0.07)	<0.001 *	
	Placebo	391	313 (80.1)	-0.51 (0.03)	(-0.57, -0.45)				
Week 28	Tezepelumab	395	325 (82.3)	-0.68 (0.03)	(-0.74, -0.62)	-0.15 (0.04)	(-0.24, -0.07)	<0.001 *	
	Placebo	391	314 (80.3)	-0.53 (0.03)	(-0.59, -0.47)				
Week 29	Tezepelumab	395	317 (80.3)	-0.68 (0.03)	(-0.74, -0.62)	-0.16 (0.04)	(-0.24, -0.07)	<0.001 *	
	Placebo	391	312 (79.8)	-0.52 (0.03)	(-0.58, -0.46)				
Week 30	Tezepelumab	395	322 (81.5)	-0.67 (0.03)	(-0.73, -0.61)	-0.15 (0.04)	(-0.24, -0.07)	<0.001 *	
	Placebo	391	303 (77.5)	-0.52 (0.03)	(-0.58, -0.46)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WTC\_ILMC0: Change from baseline in ASD weekly total score - MMRM results  
 DITTTL

Change from baseline in ASD weekly total score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 31	Tezepelumab	395	322 (81.5)	-0.67 (0.03)	(-0.73, -0.61)	-0.14 (0.04)	(-0.23, -0.06)	0.001 *	
	Placebo	391	308 (78.8)	-0.53 (0.03)	(-0.59, -0.47)				
Week 32	Tezepelumab	395	324 (82.0)	-0.67 (0.03)	(-0.73, -0.61)	-0.14 (0.04)	(-0.23, -0.06)	<0.001 *	
	Placebo	391	308 (78.8)	-0.53 (0.03)	(-0.59, -0.47)				
Week 33	Tezepelumab	395	321 (81.3)	-0.69 (0.03)	(-0.75, -0.63)	-0.16 (0.04)	(-0.25, -0.08)	<0.001 *	
	Placebo	391	304 (77.7)	-0.53 (0.03)	(-0.59, -0.47)				
Week 34	Tezepelumab	395	319 (80.8)	-0.70 (0.03)	(-0.76, -0.64)	-0.17 (0.04)	(-0.26, -0.09)	<0.001 *	
	Placebo	391	303 (77.5)	-0.53 (0.03)	(-0.59, -0.47)				
Week 35	Tezepelumab	395	320 (81.0)	-0.69 (0.03)	(-0.75, -0.62)	-0.15 (0.04)	(-0.24, -0.07)	<0.001 *	
	Placebo	391	295 (75.4)	-0.53 (0.03)	(-0.59, -0.47)				
Week 36	Tezepelumab	395	317 (80.3)	-0.67 (0.03)	(-0.73, -0.61)	-0.14 (0.04)	(-0.23, -0.06)	0.001 *	
	Placebo	391	299 (76.5)	-0.53 (0.03)	(-0.59, -0.47)				
Week 37	Tezepelumab	395	320 (81.0)	-0.68 (0.03)	(-0.74, -0.62)	-0.13 (0.04)	(-0.22, -0.05)	0.003 *	
	Placebo	391	298 (76.2)	-0.55 (0.03)	(-0.61, -0.48)				
Week 38	Tezepelumab	395	317 (80.3)	-0.67 (0.03)	(-0.73, -0.61)	-0.12 (0.04)	(-0.21, -0.04)	0.005 *	
	Placebo	391	299 (76.5)	-0.55 (0.03)	(-0.61, -0.48)				
Week 39	Tezepelumab	395	325 (82.3)	-0.66 (0.03)	(-0.72, -0.60)	-0.11 (0.04)	(-0.20, -0.02)	0.013 *	
	Placebo	391	292 (74.7)	-0.56 (0.03)	(-0.62, -0.49)				
Week 40	Tezepelumab	395	321 (81.3)	-0.68 (0.03)	(-0.74, -0.62)	-0.15 (0.04)	(-0.23, -0.06)	<0.001 *	
	Placebo	391	297 (76.0)	-0.53 (0.03)	(-0.60, -0.47)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table NT1WTC\_ILMC0: Change from baseline in ASD weekly total score - MMRM results  
 DITTTL

Change from baseline in ASD weekly total score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 41	Tezepelumab	395	324 (82.0)	-0.70 (0.03)	(-0.76, -0.64)	-0.16 (0.04)	(-0.25, -0.07)	<0.001 *	
	Placebo	391	297 (76.0)	-0.54 (0.03)	(-0.61, -0.48)				
Week 42	Tezepelumab	395	316 (80.0)	-0.70 (0.03)	(-0.76, -0.64)	-0.16 (0.04)	(-0.25, -0.08)	<0.001 *	
	Placebo	391	298 (76.2)	-0.54 (0.03)	(-0.60, -0.47)				
Week 43	Tezepelumab	395	319 (80.8)	-0.71 (0.03)	(-0.77, -0.64)	-0.15 (0.04)	(-0.24, -0.06)	<0.001 *	
	Placebo	391	296 (75.7)	-0.56 (0.03)	(-0.62, -0.49)				
Week 44	Tezepelumab	395	316 (80.0)	-0.71 (0.03)	(-0.77, -0.65)	-0.16 (0.04)	(-0.25, -0.08)	<0.001 *	
	Placebo	391	294 (75.2)	-0.55 (0.03)	(-0.61, -0.48)				
Week 45	Tezepelumab	395	319 (80.8)	-0.72 (0.03)	(-0.78, -0.66)	-0.16 (0.04)	(-0.25, -0.08)	<0.001 *	
	Placebo	391	296 (75.7)	-0.56 (0.03)	(-0.62, -0.49)				
Week 46	Tezepelumab	395	314 (79.5)	-0.72 (0.03)	(-0.78, -0.66)	-0.15 (0.04)	(-0.24, -0.07)	<0.001 *	
	Placebo	391	287 (73.4)	-0.57 (0.03)	(-0.63, -0.50)				
Week 47	Tezepelumab	395	302 (76.5)	-0.71 (0.03)	(-0.78, -0.65)	-0.14 (0.04)	(-0.23, -0.05)	0.002 *	
	Placebo	391	291 (74.4)	-0.57 (0.03)	(-0.64, -0.51)				
Week 48	Tezepelumab	395	323 (81.8)	-0.70 (0.03)	(-0.76, -0.64)	-0.13 (0.04)	(-0.21, -0.04)	0.004 *	
	Placebo	391	301 (77.0)	-0.58 (0.03)	(-0.64, -0.51)				
Week 49	Tezepelumab	395	315 (79.7)	-0.71 (0.03)	(-0.77, -0.65)	-0.13 (0.04)	(-0.22, -0.05)	0.003 *	
	Placebo	391	290 (74.2)	-0.58 (0.03)	(-0.64, -0.51)				
Week 50	Tezepelumab	395	312 (79.0)	-0.71 (0.03)	(-0.77, -0.65)	-0.14 (0.04)	(-0.23, -0.05)	0.001 *	
	Placebo	391	288 (73.7)	-0.57 (0.03)	(-0.63, -0.51)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WTC\_ILMC0: Change from baseline in ASD weekly total score - MMRM results  
 DITTTL

Change from baseline in ASD weekly total score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 51	Tezepelumab	395	307 (77.7)	-0.70 (0.03)	(-0.76, -0.64)	-0.14 (0.04)	(-0.22, -0.05)	0.002 *
	Placebo	391	282 (72.1)	-0.57 (0.03)	(-0.63, -0.50)			
Week 52	Tezepelumab	395	276 (69.9)	-0.70 (0.03)	(-0.76, -0.63)	-0.13 (0.05)	(-0.22, -0.04)	0.004 *
	Placebo	391	257 (65.7)	-0.56 (0.03)	(-0.63, -0.50)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WTC\_ILMH0: Course of ASD weekly total score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly total score	Baseline	Tezepelumab	73	73 (100.0)	1.31 (0.70)	0.0	0.84	1.37	1.80	2.9	
		Placebo	76	76 (100.0)	1.25 (0.75)	0.0	0.74	1.06	1.81	3.7	
	Week 1	Tezepelumab	73	71 (97.3)	1.18 (0.68)	0.0	0.70	1.08	1.74	2.9	
		Placebo	76	76 (100.0)	1.22 (0.66)	0.0	0.75	1.13	1.77	2.7	
	Week 2	Tezepelumab	73	73 (100.0)	1.08 (0.70)	0.0	0.54	0.99	1.66	3.1	
		Placebo	76	74 (97.4)	1.19 (0.65)	0.0	0.76	1.15	1.74	2.6	
	Week 3	Tezepelumab	73	73 (100.0)	1.05 (0.68)	0.0	0.53	1.00	1.63	3.0	
		Placebo	76	73 (96.1)	1.16 (0.62)	0.0	0.79	1.13	1.63	2.5	
	Week 4	Tezepelumab	73	71 (97.3)	1.02 (0.70)	0.0	0.40	0.93	1.54	3.0	
		Placebo	76	76 (100.0)	1.16 (0.63)	0.0	0.79	1.14	1.66	2.7	
	Week 5	Tezepelumab	73	71 (97.3)	0.99 (0.73)	0.0	0.26	0.93	1.65	3.0	
		Placebo	76	74 (97.4)	1.10 (0.63)	0.0	0.69	1.08	1.64	2.5	
	Week 6	Tezepelumab	73	69 (94.5)	0.99 (0.76)	0.0	0.24	0.90	1.70	3.0	
		Placebo	76	72 (94.7)	1.15 (0.66)	0.0	0.71	1.08	1.68	2.4	
	Week 7	Tezepelumab	73	69 (94.5)	0.98 (0.77)	0.0	0.31	0.85	1.68	3.1	
		Placebo	76	75 (98.7)	1.14 (0.64)	0.0	0.66	1.16	1.66	2.3	
	Week 8	Tezepelumab	73	68 (93.2)	1.01 (0.77)	0.0	0.39	0.96	1.76	3.2	
		Placebo	76	75 (98.7)	1.15 (0.67)	0.0	0.70	1.10	1.69	2.6	
	Week 9	Tezepelumab	73	69 (94.5)	0.98 (0.78)	0.0	0.29	0.91	1.80	3.1	
		Placebo	76	73 (96.1)	1.13 (0.70)	0.0	0.63	1.04	1.70	2.9	
	Week 10	Tezepelumab	73	70 (95.9)	1.03 (0.76)	0.0	0.40	0.97	1.72	3.2	
		Placebo	76	74 (97.4)	1.12 (0.65)	0.0	0.66	1.06	1.57	2.6	
	Week 11	Tezepelumab	73	70 (95.9)	1.01 (0.76)	0.0	0.39	0.91	1.70	3.2	
		Placebo	76	74 (97.4)	1.10 (0.66)	0.0	0.70	1.06	1.63	3.0	
	Week 12	Tezepelumab	73	70 (95.9)	0.98 (0.76)	0.0	0.40	0.87	1.72	3.4	
		Placebo	76	75 (98.7)	1.12 (0.63)	0.0	0.64	1.13	1.61	2.7	
	Week 13	Tezepelumab	73	68 (93.2)	0.99 (0.80)	0.0	0.31	0.86	1.77	3.3	
		Placebo	76	71 (93.4)	1.05 (0.66)	0.0	0.56	1.04	1.56	2.6	
	Week 14	Tezepelumab	73	69 (94.5)	1.01 (0.77)	0.0	0.35	0.93	1.80	3.2	
		Placebo	76	73 (96.1)	1.07 (0.66)	0.0	0.50	1.04	1.50	2.5	
	Week 15	Tezepelumab	73	69 (94.5)	1.03 (0.77)	0.0	0.33	0.95	1.80	3.4	
		Placebo	76	72 (94.7)	1.03 (0.66)	0.0	0.48	1.01	1.47	2.7	
	Week 16	Tezepelumab	73	69 (94.5)	1.03 (0.78)	0.0	0.37	0.95	1.73	3.5	
		Placebo	76	74 (97.4)	1.02 (0.63)	0.0	0.54	0.99	1.50	2.4	
Week 17	Tezepelumab	73	68 (93.2)	1.02 (0.77)	0.0	0.34	0.90	1.74	3.4		
	Placebo	76	74 (97.4)	1.01 (0.64)	0.0	0.55	0.96	1.44	2.5		

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WTC\_ILMH0: Course of ASD weekly total score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly total score	Week 18	Tezepelumab	73	68 (93.2)	0.99 (0.79)	0.0	0.36	0.85	1.71	3.4	
		Placebo	76	72 (94.7)	1.03 (0.66)	0.0	0.66	0.95	1.49	2.6	
	Week 19	Tezepelumab	73	67 (91.8)	0.96 (0.78)	0.0	0.28	0.80	1.69	3.1	
		Placebo	76	72 (94.7)	1.03 (0.67)	0.0	0.57	0.93	1.56	2.6	
	Week 20	Tezepelumab	73	70 (95.9)	0.98 (0.80)	0.0	0.29	0.83	1.73	3.1	
		Placebo	76	72 (94.7)	1.04 (0.65)	0.0	0.64	0.99	1.47	2.5	
	Week 21	Tezepelumab	73	67 (91.8)	0.98 (0.79)	0.0	0.28	0.96	1.67	3.3	
		Placebo	76	73 (96.1)	1.06 (0.69)	0.0	0.68	1.00	1.55	2.9	
	Week 22	Tezepelumab	73	69 (94.5)	1.00 (0.79)	0.0	0.36	0.89	1.62	3.3	
		Placebo	76	74 (97.4)	1.12 (0.77)	0.0	0.67	1.06	1.57	3.9	
	Week 23	Tezepelumab	73	69 (94.5)	0.99 (0.83)	0.0	0.23	0.78	1.73	3.4	
		Placebo	76	74 (97.4)	1.10 (0.73)	0.0	0.60	1.09	1.59	3.4	
	Week 24	Tezepelumab	73	69 (94.5)	1.00 (0.82)	0.0	0.30	0.86	1.76	3.3	
		Placebo	76	75 (98.7)	1.09 (0.71)	0.0	0.61	1.03	1.56	2.8	
	Week 25	Tezepelumab	73	68 (93.2)	0.98 (0.85)	0.0	0.26	0.76	1.80	3.5	
		Placebo	76	74 (97.4)	1.06 (0.69)	0.0	0.59	1.00	1.53	2.8	
	Week 26	Tezepelumab	73	67 (91.8)	0.96 (0.83)	0.0	0.25	0.80	1.80	3.3	
		Placebo	76	73 (96.1)	1.06 (0.73)	0.0	0.50	1.03	1.48	3.2	
	Week 27	Tezepelumab	73	68 (93.2)	0.98 (0.84)	0.0	0.28	0.86	1.76	3.5	
		Placebo	76	71 (93.4)	1.05 (0.73)	0.0	0.52	1.00	1.60	2.6	
	Week 28	Tezepelumab	73	67 (91.8)	1.00 (0.84)	0.0	0.28	0.90	1.80	3.2	
		Placebo	76	71 (93.4)	1.05 (0.73)	0.0	0.47	0.97	1.60	2.8	
	Week 29	Tezepelumab	73	64 (87.7)	0.90 (0.82)	0.0	0.19	0.71	1.50	3.2	
		Placebo	76	74 (97.4)	1.07 (0.73)	0.0	0.41	1.00	1.54	2.7	
	Week 30	Tezepelumab	73	66 (90.4)	0.92 (0.85)	0.0	0.20	0.70	1.72	3.3	
		Placebo	76	74 (97.4)	1.06 (0.71)	0.0	0.49	1.00	1.60	2.6	
	Week 31	Tezepelumab	73	66 (90.4)	0.88 (0.85)	0.0	0.09	0.72	1.43	3.4	
		Placebo	76	72 (94.7)	1.04 (0.72)	0.0	0.45	1.00	1.50	2.9	
	Week 32	Tezepelumab	73	64 (87.7)	0.95 (0.87)	0.0	0.20	0.75	1.68	3.5	
		Placebo	76	73 (96.1)	1.02 (0.67)	0.0	0.43	1.02	1.47	2.6	
	Week 33	Tezepelumab	73	67 (91.8)	0.90 (0.81)	0.0	0.16	0.75	1.70	3.4	
		Placebo	76	72 (94.7)	1.00 (0.65)	0.0	0.47	1.01	1.41	2.6	
	Week 34	Tezepelumab	73	67 (91.8)	0.87 (0.80)	0.0	0.17	0.70	1.52	3.3	
		Placebo	76	71 (93.4)	0.99 (0.69)	0.0	0.50	0.91	1.48	2.7	
	Week 35	Tezepelumab	73	65 (89.0)	0.87 (0.79)	0.0	0.21	0.70	1.28	3.3	
		Placebo	76	74 (97.4)	0.98 (0.71)	0.0	0.40	0.95	1.54	2.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WTC\_ILMH0: Course of ASD weekly total score  
 DITTLL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly total score	Week 36	Tezepelumab	73	69 (94.5)	0.94 (0.84)	0.0	0.20	0.81	1.68	3.4	
		Placebo	76	71 (93.4)	0.98 (0.70)	0.0	0.34	0.95	1.43	2.8	
	Week 37	Tezepelumab	73	66 (90.4)	0.91 (0.85)	0.0	0.13	0.76	1.70	3.4	
		Placebo	76	72 (94.7)	1.00 (0.67)	0.0	0.54	0.98	1.34	2.9	
	Week 38	Tezepelumab	73	64 (87.7)	0.86 (0.84)	0.0	0.09	0.73	1.64	3.4	
		Placebo	76	72 (94.7)	1.05 (0.71)	0.0	0.54	0.99	1.52	3.1	
	Week 39	Tezepelumab	73	64 (87.7)	0.87 (0.83)	0.0	0.07	0.81	1.57	3.4	
		Placebo	76	71 (93.4)	1.00 (0.72)	0.0	0.43	0.97	1.43	3.1	
	Week 40	Tezepelumab	73	64 (87.7)	0.89 (0.85)	0.0	0.07	0.69	1.70	3.5	
		Placebo	76	71 (93.4)	1.02 (0.73)	0.0	0.40	1.00	1.44	3.2	
	Week 41	Tezepelumab	73	63 (86.3)	0.85 (0.85)	0.0	0.06	0.71	1.51	3.5	
		Placebo	76	70 (92.1)	0.94 (0.65)	0.0	0.53	0.90	1.38	2.9	
	Week 42	Tezepelumab	73	63 (86.3)	0.86 (0.81)	0.0	0.06	0.71	1.49	3.5	
		Placebo	76	72 (94.7)	0.97 (0.63)	0.0	0.55	0.96	1.34	2.8	
	Week 43	Tezepelumab	73	63 (86.3)	0.87 (0.84)	0.0	0.11	0.81	1.37	3.7	
		Placebo	76	72 (94.7)	1.01 (0.70)	0.0	0.47	0.93	1.54	2.9	
	Week 44	Tezepelumab	73	63 (86.3)	0.85 (0.84)	0.0	0.10	0.63	1.53	3.4	
		Placebo	76	73 (96.1)	0.99 (0.67)	0.0	0.50	0.90	1.41	2.9	
	Week 45	Tezepelumab	73	62 (84.9)	0.84 (0.82)	0.0	0.07	0.63	1.47	3.2	
		Placebo	76	70 (92.1)	0.95 (0.66)	0.0	0.43	0.91	1.34	2.6	
	Week 46	Tezepelumab	73	62 (84.9)	0.85 (0.84)	0.0	0.02	0.65	1.53	3.2	
		Placebo	76	68 (89.5)	0.96 (0.68)	0.0	0.48	0.91	1.36	2.8	
	Week 47	Tezepelumab	73	62 (84.9)	0.84 (0.82)	0.0	0.06	0.60	1.50	3.2	
		Placebo	76	70 (92.1)	0.99 (0.64)	0.0	0.66	0.94	1.26	2.9	
	Week 48	Tezepelumab	73	57 (78.1)	0.94 (0.82)	0.0	0.06	0.83	1.56	3.2	
		Placebo	76	68 (89.5)	1.00 (0.67)	0.0	0.61	0.98	1.29	2.9	

Note: DITTLL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WTC\_ILMH0: Course of ASD weekly total score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly total score	Week 1	Tezepelumab	73	71 (97.3)	-0.12 (0.35)	-1.5	-0.31	-0.03	0.04	0.9	-0.29 [-0.61, 0.04]
		Placebo	76	76 (100.0)	-0.03 (0.32)	-1.7	-0.07	0.00	0.13	0.6	
	Week 2	Tezepelumab	73	73 (100.0)	-0.23 (0.39)	-1.6	-0.47	-0.09	0.00	0.5	-0.51 [-0.84, -0.19]
		Placebo	76	74 (97.4)	-0.03 (0.38)	-1.6	-0.13	0.00	0.12	0.9	
	Week 3	Tezepelumab	73	73 (100.0)	-0.26 (0.45)	-1.4	-0.57	-0.15	0.01	0.9	-0.51 [-0.84, -0.18]
		Placebo	76	73 (96.1)	-0.05 (0.38)	-1.0	-0.23	0.00	0.11	1.0	
	Week 4	Tezepelumab	73	71 (97.3)	-0.32 (0.47)	-1.4	-0.66	-0.20	0.00	0.9	-0.49 [-0.82, -0.16]
		Placebo	76	76 (100.0)	-0.09 (0.46)	-2.0	-0.16	0.00	0.13	0.9	
	Week 5	Tezepelumab	73	71 (97.3)	-0.33 (0.48)	-1.6	-0.67	-0.19	0.00	0.6	-0.39 [-0.72, -0.06]
		Placebo	76	74 (97.4)	-0.14 (0.52)	-2.6	-0.30	-0.04	0.09	0.8	
	Week 6	Tezepelumab	73	69 (94.5)	-0.33 (0.53)	-1.7	-0.61	-0.14	0.03	0.7	-0.44 [-0.77, -0.10]
		Placebo	76	72 (94.7)	-0.09 (0.55)	-2.6	-0.25	0.00	0.16	1.2	
	Week 7	Tezepelumab	73	69 (94.5)	-0.33 (0.55)	-1.6	-0.71	-0.13	0.03	0.9	-0.39 [-0.72, -0.06]
		Placebo	76	75 (98.7)	-0.11 (0.59)	-2.4	-0.39	0.00	0.17	1.2	
	Week 8	Tezepelumab	73	68 (93.2)	-0.33 (0.58)	-1.7	-0.68	-0.19	0.01	1.1	-0.42 [-0.75, -0.08]
		Placebo	76	75 (98.7)	-0.09 (0.55)	-1.9	-0.29	0.00	0.21	0.9	
	Week 9	Tezepelumab	73	69 (94.5)	-0.33 (0.62)	-1.7	-0.80	-0.17	0.00	1.2	-0.35 [-0.68, -0.01]
		Placebo	76	73 (96.1)	-0.12 (0.58)	-2.2	-0.43	-0.03	0.24	0.9	
	Week 10	Tezepelumab	73	70 (95.9)	-0.28 (0.64)	-1.7	-0.76	-0.17	0.06	1.9	-0.26 [-0.58, 0.07]
		Placebo	76	74 (97.4)	-0.12 (0.61)	-1.9	-0.50	-0.06	0.17	2.3	
	Week 11	Tezepelumab	73	70 (95.9)	-0.30 (0.64)	-1.7	-0.73	-0.18	0.03	1.9	-0.26 [-0.58, 0.07]
		Placebo	76	74 (97.4)	-0.14 (0.64)	-1.9	-0.52	-0.05	0.16	2.8	
	Week 12	Tezepelumab	73	70 (95.9)	-0.35 (0.65)	-1.6	-0.79	-0.28	0.00	1.9	-0.36 [-0.69, -0.03]
		Placebo	76	75 (98.7)	-0.13 (0.60)	-2.0	-0.49	-0.07	0.19	2.1	
	Week 13	Tezepelumab	73	68 (93.2)	-0.34 (0.69)	-2.1	-0.80	-0.24	0.02	1.9	-0.23 [-0.57, 0.10]
		Placebo	76	71 (93.4)	-0.18 (0.63)	-2.4	-0.61	-0.10	0.18	1.2	
	Week 14	Tezepelumab	73	69 (94.5)	-0.32 (0.65)	-1.7	-0.76	-0.23	0.03	1.9	-0.25 [-0.58, 0.08]
		Placebo	76	73 (96.1)	-0.17 (0.54)	-1.8	-0.47	-0.06	0.12	1.4	
	Week 15	Tezepelumab	73	69 (94.5)	-0.31 (0.64)	-1.7	-0.76	-0.14	0.00	1.9	-0.14 [-0.47, 0.19]
		Placebo	76	72 (94.7)	-0.23 (0.57)	-2.6	-0.50	-0.04	0.13	0.7	
	Week 16	Tezepelumab	73	69 (94.5)	-0.31 (0.64)	-1.7	-0.73	-0.19	0.00	1.7	-0.13 [-0.46, 0.20]
		Placebo	76	74 (97.4)	-0.23 (0.60)	-2.1	-0.56	-0.03	0.16	1.2	
	Week 17	Tezepelumab	73	68 (93.2)	-0.32 (0.60)	-1.7	-0.71	-0.22	0.05	0.9	-0.14 [-0.47, 0.19]
		Placebo	76	74 (97.4)	-0.24 (0.61)	-2.3	-0.61	-0.10	0.13	1.1	
	Week 18	Tezepelumab	73	68 (93.2)	-0.32 (0.63)	-1.6	-0.77	-0.18	0.01	1.6	-0.16 [-0.49, 0.17]
		Placebo	76	72 (94.7)	-0.22 (0.62)	-2.1	-0.64	-0.10	0.14	1.1	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WTC\_ILMH0: Course of ASD weekly total score  
 DITTLL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly total score	Week 19	Tezepelumab	73	67 (91.8)	-0.37 (0.67)	-1.6	-0.93	-0.28	0.00	1.8	-0.22 [-0.56, 0.11]
		Placebo	76	72 (94.7)	-0.23 (0.57)	-1.9	-0.53	-0.09	0.04	0.9	
	Week 20	Tezepelumab	73	70 (95.9)	-0.35 (0.67)	-1.6	-0.96	-0.33	0.03	1.5	-0.25 [-0.58, 0.08]
		Placebo	76	72 (94.7)	-0.20 (0.56)	-1.9	-0.44	-0.05	0.13	0.8	
	Week 21	Tezepelumab	73	67 (91.8)	-0.36 (0.66)	-1.7	-0.90	-0.28	0.03	1.7	-0.27 [-0.60, 0.07]
		Placebo	76	73 (96.1)	-0.20 (0.61)	-1.9	-0.54	-0.08	0.11	0.9	
	Week 22	Tezepelumab	73	69 (94.5)	-0.34 (0.61)	-1.7	-0.73	-0.28	0.00	1.0	-0.34 [-0.67, -0.00]
		Placebo	76	74 (97.4)	-0.13 (0.67)	-1.9	-0.51	-0.07	0.21	1.8	
	Week 23	Tezepelumab	73	69 (94.5)	-0.34 (0.66)	-2.3	-0.79	-0.20	0.03	1.5	-0.30 [-0.63, 0.03]
		Placebo	76	74 (97.4)	-0.15 (0.62)	-1.9	-0.47	-0.04	0.20	1.0	
	Week 24	Tezepelumab	73	69 (94.5)	-0.34 (0.67)	-2.2	-0.80	-0.30	0.00	1.2	-0.29 [-0.62, 0.04]
		Placebo	76	75 (98.7)	-0.16 (0.59)	-1.9	-0.49	-0.03	0.19	0.9	
	Week 25	Tezepelumab	73	68 (93.2)	-0.35 (0.74)	-2.3	-0.78	-0.16	0.01	2.2	-0.22 [-0.55, 0.11]
		Placebo	76	74 (97.4)	-0.19 (0.65)	-2.6	-0.49	-0.06	0.10	1.7	
	Week 26	Tezepelumab	73	67 (91.8)	-0.37 (0.71)	-2.4	-0.84	-0.27	0.00	1.5	-0.26 [-0.60, 0.07]
		Placebo	76	73 (96.1)	-0.18 (0.74)	-2.3	-0.54	-0.10	0.17	3.1	
	Week 27	Tezepelumab	73	68 (93.2)	-0.34 (0.74)	-2.4	-0.76	-0.25	0.00	1.8	-0.26 [-0.59, 0.08]
		Placebo	76	71 (93.4)	-0.17 (0.62)	-1.9	-0.46	-0.07	0.11	1.4	
	Week 28	Tezepelumab	73	67 (91.8)	-0.32 (0.74)	-2.4	-0.80	-0.16	0.00	1.7	-0.21 [-0.55, 0.12]
		Placebo	76	71 (93.4)	-0.17 (0.60)	-1.8	-0.43	-0.09	0.13	1.3	
	Week 29	Tezepelumab	73	64 (87.7)	-0.42 (0.71)	-2.4	-0.89	-0.31	0.00	1.9	-0.38 [-0.72, -0.05]
		Placebo	76	74 (97.4)	-0.16 (0.63)	-2.0	-0.47	-0.05	0.12	1.1	
	Week 30	Tezepelumab	73	66 (90.4)	-0.39 (0.78)	-2.4	-0.84	-0.27	0.00	2.0	-0.33 [-0.66, 0.01]
		Placebo	76	74 (97.4)	-0.17 (0.56)	-1.8	-0.49	-0.09	0.19	0.9	
	Week 31	Tezepelumab	73	66 (90.4)	-0.42 (0.79)	-2.4	-0.98	-0.34	0.01	2.2	-0.32 [-0.65, 0.02]
		Placebo	76	72 (94.7)	-0.20 (0.58)	-1.8	-0.59	-0.12	0.13	1.2	
	Week 32	Tezepelumab	73	64 (87.7)	-0.40 (0.78)	-2.4	-0.87	-0.36	0.00	2.2	-0.27 [-0.61, 0.07]
		Placebo	76	73 (96.1)	-0.22 (0.56)	-1.8	-0.61	-0.14	0.07	1.1	
	Week 33	Tezepelumab	73	67 (91.8)	-0.41 (0.71)	-2.4	-0.84	-0.31	0.00	2.1	-0.26 [-0.59, 0.08]
		Placebo	76	72 (94.7)	-0.24 (0.61)	-2.3	-0.61	-0.14	0.05	1.1	
	Week 34	Tezepelumab	73	67 (91.8)	-0.44 (0.71)	-2.4	-0.90	-0.37	0.00	2.1	-0.29 [-0.63, 0.04]
		Placebo	76	71 (93.4)	-0.25 (0.53)	-1.8	-0.57	-0.14	0.07	0.9	
	Week 35	Tezepelumab	73	65 (89.0)	-0.44 (0.73)	-2.4	-0.83	-0.36	0.00	1.9	-0.30 [-0.63, 0.04]
		Placebo	76	74 (97.4)	-0.24 (0.56)	-1.8	-0.54	-0.14	0.04	1.0	
	Week 36	Tezepelumab	73	69 (94.5)	-0.38 (0.75)	-2.4	-0.83	-0.33	0.03	1.9	-0.18 [-0.51, 0.15]
		Placebo	76	71 (93.4)	-0.26 (0.58)	-1.8	-0.67	-0.14	0.07	1.1	

Note: DITTLL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WTC\_ILMH0: Course of ASD weekly total score  
 DITTLL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly total score	Week 37	Tezepelumab	73	66 (90.4)	-0.41 (0.78)	-2.4	-0.84	-0.37	0.03	1.8	-0.26 [-0.60, 0.08]
		Placebo	76	72 (94.7)	-0.24 (0.58)	-1.8	-0.55	-0.13	0.10	0.9	
	Week 38	Tezepelumab	73	64 (87.7)	-0.44 (0.77)	-2.4	-0.86	-0.40	0.01	2.0	-0.36 [-0.70, -0.02]
		Placebo	76	72 (94.7)	-0.19 (0.62)	-2.0	-0.48	-0.06	0.11	1.2	
	Week 39	Tezepelumab	73	64 (87.7)	-0.43 (0.78)	-2.4	-0.85	-0.37	0.00	2.0	-0.34 [-0.68, -0.00]
		Placebo	76	71 (93.4)	-0.20 (0.59)	-1.8	-0.59	-0.13	0.10	1.0	
	Week 40	Tezepelumab	73	64 (87.7)	-0.42 (0.78)	-2.3	-0.87	-0.31	0.01	2.0	-0.29 [-0.63, 0.05]
		Placebo	76	71 (93.4)	-0.22 (0.58)	-1.8	-0.61	-0.11	0.13	1.1	
	Week 41	Tezepelumab	73	63 (86.3)	-0.45 (0.79)	-2.3	-0.93	-0.40	0.00	1.9	-0.25 [-0.59, 0.09]
		Placebo	76	70 (92.1)	-0.28 (0.59)	-2.2	-0.61	-0.19	0.07	0.9	
	Week 42	Tezepelumab	73	63 (86.3)	-0.43 (0.76)	-2.2	-0.93	-0.34	0.00	1.7	-0.24 [-0.58, 0.10]
		Placebo	76	72 (94.7)	-0.27 (0.56)	-1.8	-0.61	-0.22	0.11	0.8	
	Week 43	Tezepelumab	73	63 (86.3)	-0.42 (0.79)	-2.2	-0.89	-0.37	0.00	1.8	-0.29 [-0.63, 0.05]
		Placebo	76	72 (94.7)	-0.22 (0.64)	-1.9	-0.63	-0.11	0.24	1.1	
	Week 44	Tezepelumab	73	63 (86.3)	-0.44 (0.78)	-2.2	-0.91	-0.36	0.00	1.7	-0.30 [-0.63, 0.04]
		Placebo	76	73 (96.1)	-0.24 (0.60)	-1.9	-0.60	-0.10	0.11	0.9	
	Week 45	Tezepelumab	73	62 (84.9)	-0.45 (0.78)	-2.3	-0.87	-0.42	0.00	1.7	-0.26 [-0.60, 0.08]
		Placebo	76	70 (92.1)	-0.27 (0.63)	-2.6	-0.61	-0.16	0.10	1.0	
	Week 46	Tezepelumab	73	62 (84.9)	-0.44 (0.77)	-2.4	-0.87	-0.37	0.00	1.6	-0.22 [-0.56, 0.13]
		Placebo	76	68 (89.5)	-0.29 (0.59)	-2.0	-0.64	-0.18	0.02	1.0	
	Week 47	Tezepelumab	73	62 (84.9)	-0.44 (0.80)	-2.3	-0.94	-0.37	0.00	1.6	-0.24 [-0.59, 0.10]
		Placebo	76	70 (92.1)	-0.27 (0.57)	-1.8	-0.60	-0.16	0.09	0.9	
	Week 48	Tezepelumab	73	57 (78.1)	-0.37 (0.80)	-2.4	-0.79	-0.33	0.01	1.5	-0.16 [-0.51, 0.19]
		Placebo	76	68 (89.5)	-0.26 (0.58)	-1.8	-0.61	-0.18	0.12	0.9	

Note: DITTLL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table ST1WTC\_ILMC0: Change from baseline in ASD weekly total score - MMRM results  
 DITTTL

Change from baseline in ASD weekly total score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 1	Tezepelumab	73	71 (97.3)	-0.11 (0.07)	(-0.24, 0.02)	-0.07 (0.09)	(-0.25, 0.11)	0.439
	Placebo	76	76 (100.0)	-0.04 (0.06)	(-0.16, 0.09)			
Week 2	Tezepelumab	73	73 (100.0)	-0.22 (0.07)	(-0.34, -0.09)	-0.15 (0.09)	(-0.33, 0.03)	0.094
	Placebo	76	74 (97.4)	-0.06 (0.06)	(-0.19, 0.06)			
Week 3	Tezepelumab	73	73 (100.0)	-0.25 (0.07)	(-0.38, -0.12)	-0.16 (0.09)	(-0.34, 0.02)	0.082
	Placebo	76	73 (96.1)	-0.09 (0.06)	(-0.22, 0.04)			
Week 4	Tezepelumab	73	71 (97.3)	-0.30 (0.07)	(-0.42, -0.17)	-0.20 (0.09)	(-0.38, -0.02)	0.032 *
	Placebo	76	76 (100.0)	-0.10 (0.06)	(-0.22, 0.03)			
Week 5	Tezepelumab	73	71 (97.3)	-0.32 (0.07)	(-0.45, -0.19)	-0.16 (0.09)	(-0.34, 0.02)	0.077
	Placebo	76	74 (97.4)	-0.16 (0.06)	(-0.29, -0.04)			
Week 6	Tezepelumab	73	69 (94.5)	-0.31 (0.07)	(-0.44, -0.18)	-0.18 (0.09)	(-0.36, 0.00)	0.052
	Placebo	76	72 (94.7)	-0.13 (0.06)	(-0.26, -0.01)			
Week 7	Tezepelumab	73	69 (94.5)	-0.31 (0.07)	(-0.44, -0.19)	-0.19 (0.09)	(-0.37, -0.01)	0.038 *
	Placebo	76	75 (98.7)	-0.12 (0.06)	(-0.25, 0.00)			
Week 8	Tezepelumab	73	68 (93.2)	-0.30 (0.07)	(-0.43, -0.17)	-0.19 (0.09)	(-0.37, -0.01)	0.036 *
	Placebo	76	75 (98.7)	-0.11 (0.06)	(-0.24, 0.02)			
Week 9	Tezepelumab	73	69 (94.5)	-0.32 (0.07)	(-0.45, -0.19)	-0.18 (0.09)	(-0.36, -0.00)	0.046 *
	Placebo	76	73 (96.1)	-0.13 (0.06)	(-0.26, -0.01)			
Week 10	Tezepelumab	73	70 (95.9)	-0.27 (0.07)	(-0.40, -0.14)	-0.14 (0.09)	(-0.32, 0.04)	0.131
	Placebo	76	74 (97.4)	-0.13 (0.06)	(-0.25, -0.00)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WTC\_ILMC0: Change from baseline in ASD weekly total score - MMRM results  
 DITTTL

Change from baseline in ASD weekly total score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 11	Tezepelumab	73	70 (95.9)	-0.29 (0.07)	(-0.42, -0.16)	-0.14 (0.09)	(-0.33, 0.04)	0.118
	Placebo	76	74 (97.4)	-0.14 (0.06)	(-0.27, -0.02)			
Week 12	Tezepelumab	73	70 (95.9)	-0.33 (0.07)	(-0.46, -0.20)	-0.19 (0.09)	(-0.37, -0.01)	0.037 *
	Placebo	76	75 (98.7)	-0.14 (0.06)	(-0.27, -0.01)			
Week 13	Tezepelumab	73	68 (93.2)	-0.32 (0.07)	(-0.45, -0.19)	-0.11 (0.09)	(-0.29, 0.08)	0.253
	Placebo	76	71 (93.4)	-0.21 (0.06)	(-0.34, -0.08)			
Week 14	Tezepelumab	73	69 (94.5)	-0.29 (0.07)	(-0.42, -0.16)	-0.09 (0.09)	(-0.27, 0.09)	0.340
	Placebo	76	73 (96.1)	-0.21 (0.06)	(-0.33, -0.08)			
Week 15	Tezepelumab	73	69 (94.5)	-0.30 (0.07)	(-0.43, -0.17)	-0.07 (0.09)	(-0.25, 0.12)	0.482
	Placebo	76	72 (94.7)	-0.23 (0.06)	(-0.36, -0.10)			
Week 16	Tezepelumab	73	69 (94.5)	-0.29 (0.07)	(-0.42, -0.16)	-0.05 (0.09)	(-0.23, 0.13)	0.579
	Placebo	76	74 (97.4)	-0.24 (0.06)	(-0.36, -0.11)			
Week 17	Tezepelumab	73	68 (93.2)	-0.32 (0.07)	(-0.45, -0.19)	-0.07 (0.09)	(-0.25, 0.11)	0.450
	Placebo	76	74 (97.4)	-0.25 (0.06)	(-0.37, -0.12)			
Week 18	Tezepelumab	73	68 (93.2)	-0.32 (0.07)	(-0.45, -0.19)	-0.09 (0.09)	(-0.27, 0.09)	0.329
	Placebo	76	72 (94.7)	-0.23 (0.06)	(-0.36, -0.10)			
Week 19	Tezepelumab	73	67 (91.8)	-0.35 (0.07)	(-0.48, -0.22)	-0.12 (0.09)	(-0.30, 0.06)	0.188
	Placebo	76	72 (94.7)	-0.22 (0.06)	(-0.35, -0.10)			
Week 20	Tezepelumab	73	70 (95.9)	-0.34 (0.07)	(-0.47, -0.20)	-0.13 (0.09)	(-0.31, 0.05)	0.156
	Placebo	76	72 (94.7)	-0.20 (0.06)	(-0.33, -0.08)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WTC\_ILMC0: Change from baseline in ASD weekly total score - MMRM results  
 DITTTL

Change from baseline in ASD weekly total score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 21	Tezepelumab	73	67 (91.8)	-0.34 (0.07)	(-0.47, -0.21)	-0.13 (0.09)	(-0.32, 0.05)	0.150
	Placebo	76	73 (96.1)	-0.20 (0.06)	(-0.33, -0.08)			
Week 22	Tezepelumab	73	69 (94.5)	-0.33 (0.07)	(-0.46, -0.20)	-0.20 (0.09)	(-0.38, -0.02)	0.034 *
	Placebo	76	74 (97.4)	-0.13 (0.06)	(-0.26, -0.01)			
Week 23	Tezepelumab	73	69 (94.5)	-0.34 (0.07)	(-0.47, -0.20)	-0.17 (0.09)	(-0.35, 0.01)	0.068
	Placebo	76	74 (97.4)	-0.17 (0.06)	(-0.29, -0.04)			
Week 24	Tezepelumab	73	69 (94.5)	-0.33 (0.07)	(-0.46, -0.20)	-0.16 (0.09)	(-0.34, 0.02)	0.080
	Placebo	76	75 (98.7)	-0.17 (0.06)	(-0.30, -0.04)			
Week 25	Tezepelumab	73	68 (93.2)	-0.32 (0.07)	(-0.45, -0.19)	-0.12 (0.09)	(-0.30, 0.07)	0.212
	Placebo	76	74 (97.4)	-0.21 (0.06)	(-0.33, -0.08)			
Week 26	Tezepelumab	73	67 (91.8)	-0.34 (0.07)	(-0.47, -0.21)	-0.16 (0.09)	(-0.34, 0.03)	0.094
	Placebo	76	73 (96.1)	-0.18 (0.06)	(-0.31, -0.06)			
Week 27	Tezepelumab	73	68 (93.2)	-0.33 (0.07)	(-0.46, -0.20)	-0.14 (0.09)	(-0.32, 0.05)	0.140
	Placebo	76	71 (93.4)	-0.20 (0.06)	(-0.32, -0.07)			
Week 28	Tezepelumab	73	67 (91.8)	-0.31 (0.07)	(-0.44, -0.18)	-0.13 (0.09)	(-0.31, 0.06)	0.178
	Placebo	76	71 (93.4)	-0.18 (0.06)	(-0.31, -0.06)			
Week 29	Tezepelumab	73	64 (87.7)	-0.37 (0.07)	(-0.50, -0.24)	-0.20 (0.09)	(-0.38, -0.01)	0.036 *
	Placebo	76	74 (97.4)	-0.17 (0.06)	(-0.30, -0.04)			
Week 30	Tezepelumab	73	66 (90.4)	-0.38 (0.07)	(-0.51, -0.25)	-0.20 (0.09)	(-0.38, -0.02)	0.032 *
	Placebo	76	74 (97.4)	-0.18 (0.06)	(-0.31, -0.06)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WTC\_ILMC0: Change from baseline in ASD weekly total score - MMRM results  
DITTTL

Change from baseline in ASD weekly total score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 31	Tezepelumab	73	66 (90.4)	-0.39 (0.07)	(-0.52, -0.26)	-0.20 (0.09)	(-0.38, -0.01)	0.035 *
	Placebo	76	72 (94.7)	-0.19 (0.06)	(-0.32, -0.07)			
Week 32	Tezepelumab	73	64 (87.7)	-0.37 (0.07)	(-0.51, -0.24)	-0.16 (0.09)	(-0.34, 0.03)	0.095
	Placebo	76	73 (96.1)	-0.22 (0.06)	(-0.34, -0.09)			
Week 33	Tezepelumab	73	67 (91.8)	-0.37 (0.07)	(-0.51, -0.24)	-0.12 (0.09)	(-0.30, 0.06)	0.195
	Placebo	76	72 (94.7)	-0.25 (0.06)	(-0.38, -0.13)			
Week 34	Tezepelumab	73	67 (91.8)	-0.40 (0.07)	(-0.53, -0.27)	-0.14 (0.09)	(-0.33, 0.04)	0.126
	Placebo	76	71 (93.4)	-0.26 (0.06)	(-0.38, -0.13)			
Week 35	Tezepelumab	73	65 (89.0)	-0.39 (0.07)	(-0.52, -0.26)	-0.14 (0.09)	(-0.32, 0.05)	0.147
	Placebo	76	74 (97.4)	-0.26 (0.06)	(-0.38, -0.13)			
Week 36	Tezepelumab	73	69 (94.5)	-0.36 (0.07)	(-0.49, -0.23)	-0.10 (0.09)	(-0.28, 0.08)	0.284
	Placebo	76	71 (93.4)	-0.26 (0.06)	(-0.39, -0.14)			
Week 37	Tezepelumab	73	66 (90.4)	-0.39 (0.07)	(-0.52, -0.26)	-0.14 (0.09)	(-0.33, 0.04)	0.132
	Placebo	76	72 (94.7)	-0.25 (0.07)	(-0.37, -0.12)			
Week 38	Tezepelumab	73	64 (87.7)	-0.41 (0.07)	(-0.54, -0.27)	-0.21 (0.09)	(-0.39, -0.03)	0.025 *
	Placebo	76	72 (94.7)	-0.20 (0.07)	(-0.32, -0.07)			
Week 39	Tezepelumab	73	64 (87.7)	-0.40 (0.07)	(-0.53, -0.26)	-0.16 (0.09)	(-0.35, 0.02)	0.080
	Placebo	76	71 (93.4)	-0.23 (0.07)	(-0.36, -0.10)			
Week 40	Tezepelumab	73	64 (87.7)	-0.38 (0.07)	(-0.51, -0.24)	-0.15 (0.09)	(-0.33, 0.04)	0.114
	Placebo	76	71 (93.4)	-0.23 (0.07)	(-0.35, -0.10)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WTC\_ILMC0: Change from baseline in ASD weekly total score - MMRM results  
 DITTTL

Change from baseline in ASD weekly total score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 41	Tezepelumab	73	63 (86.3)	-0.40 (0.07)	(-0.53, -0.27)	-0.11 (0.09)	(-0.30, 0.07)	0.235
	Placebo	76	70 (92.1)	-0.29 (0.07)	(-0.42, -0.16)			
Week 42	Tezepelumab	73	63 (86.3)	-0.38 (0.07)	(-0.51, -0.24)	-0.10 (0.09)	(-0.29, 0.08)	0.283
	Placebo	76	72 (94.7)	-0.28 (0.07)	(-0.40, -0.15)			
Week 43	Tezepelumab	73	63 (86.3)	-0.37 (0.07)	(-0.51, -0.24)	-0.14 (0.09)	(-0.33, 0.04)	0.128
	Placebo	76	72 (94.7)	-0.23 (0.07)	(-0.36, -0.10)			
Week 44	Tezepelumab	73	63 (86.3)	-0.40 (0.07)	(-0.53, -0.26)	-0.15 (0.09)	(-0.33, 0.04)	0.121
	Placebo	76	73 (96.1)	-0.25 (0.07)	(-0.38, -0.12)			
Week 45	Tezepelumab	73	62 (84.9)	-0.41 (0.07)	(-0.55, -0.28)	-0.12 (0.09)	(-0.31, 0.07)	0.210
	Placebo	76	70 (92.1)	-0.29 (0.07)	(-0.42, -0.17)			
Week 46	Tezepelumab	73	62 (84.9)	-0.42 (0.07)	(-0.55, -0.28)	-0.15 (0.10)	(-0.33, 0.04)	0.125
	Placebo	76	68 (89.5)	-0.27 (0.07)	(-0.40, -0.14)			
Week 47	Tezepelumab	73	62 (84.9)	-0.39 (0.07)	(-0.53, -0.26)	-0.13 (0.10)	(-0.31, 0.06)	0.180
	Placebo	76	70 (92.1)	-0.27 (0.07)	(-0.39, -0.14)			
Week 48	Tezepelumab	73	57 (78.1)	-0.37 (0.07)	(-0.50, -0.23)	-0.13 (0.10)	(-0.31, 0.06)	0.189
	Placebo	76	68 (89.5)	-0.24 (0.07)	(-0.37, -0.11)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WDC\_ILMH0: Course of ASD weekly daytime score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly daytime score	Baseline	Tezepelumab	395	395 (100.0)	1.53 (0.76)	0.0	1.00	1.49	2.00	4.0	
		Placebo	391	391 (100.0)	1.49 (0.75)	0.0	0.97	1.43	2.03	4.0	
	Week 1	Tezepelumab	395	388 (98.2)	1.32 (0.69)	0.0	0.89	1.21	1.77	3.8	
		Placebo	391	385 (98.5)	1.39 (0.74)	0.0	0.89	1.30	1.86	3.9	
	Week 2	Tezepelumab	395	387 (98.0)	1.19 (0.71)	0.0	0.71	1.06	1.60	3.4	
		Placebo	391	385 (98.5)	1.32 (0.74)	0.0	0.80	1.23	1.89	3.9	
	Week 3	Tezepelumab	395	385 (97.5)	1.12 (0.70)	0.0	0.66	1.03	1.54	3.2	
		Placebo	391	377 (96.4)	1.20 (0.74)	0.0	0.66	1.11	1.71	4.0	
	Week 4	Tezepelumab	395	382 (96.7)	1.09 (0.72)	0.0	0.57	1.00	1.52	3.4	
		Placebo	391	382 (97.7)	1.16 (0.73)	0.0	0.60	1.08	1.70	3.9	
	Week 5	Tezepelumab	395	385 (97.5)	1.04 (0.71)	0.0	0.54	1.00	1.49	3.6	
		Placebo	391	373 (95.4)	1.11 (0.71)	0.0	0.57	1.03	1.60	3.9	
	Week 6	Tezepelumab	395	378 (95.7)	1.00 (0.72)	0.0	0.43	0.94	1.46	3.8	
		Placebo	391	378 (96.7)	1.11 (0.74)	0.0	0.54	1.03	1.66	4.0	
	Week 7	Tezepelumab	395	381 (96.5)	0.98 (0.74)	0.0	0.37	0.94	1.43	3.8	
		Placebo	391	376 (96.2)	1.09 (0.75)	0.0	0.51	1.00	1.57	4.0	
	Week 8	Tezepelumab	395	380 (96.2)	0.96 (0.72)	0.0	0.37	0.90	1.43	3.7	
		Placebo	391	372 (95.1)	1.07 (0.74)	0.0	0.50	1.00	1.57	3.9	
	Week 9	Tezepelumab	395	381 (96.5)	0.91 (0.71)	0.0	0.34	0.88	1.37	3.8	
		Placebo	391	370 (94.6)	1.03 (0.73)	0.0	0.46	1.00	1.49	4.0	
	Week 10	Tezepelumab	395	385 (97.5)	0.90 (0.71)	0.0	0.27	0.87	1.34	3.7	
		Placebo	391	365 (93.4)	1.02 (0.74)	0.0	0.40	1.00	1.50	4.0	
	Week 11	Tezepelumab	395	375 (94.9)	0.90 (0.73)	0.0	0.24	0.90	1.37	3.6	
		Placebo	391	365 (93.4)	1.01 (0.74)	0.0	0.40	1.00	1.49	3.8	
	Week 12	Tezepelumab	395	377 (95.4)	0.91 (0.72)	0.0	0.30	0.90	1.30	3.6	
		Placebo	391	362 (92.6)	0.99 (0.74)	0.0	0.40	0.97	1.43	3.8	
	Week 13	Tezepelumab	395	369 (93.4)	0.88 (0.71)	0.0	0.30	0.83	1.31	3.3	
		Placebo	391	357 (91.3)	0.99 (0.73)	0.0	0.40	1.00	1.40	3.8	
	Week 14	Tezepelumab	395	366 (92.7)	0.85 (0.70)	0.0	0.20	0.80	1.29	3.3	
		Placebo	391	364 (93.1)	0.98 (0.72)	0.0	0.40	0.97	1.49	3.8	
	Week 15	Tezepelumab	395	370 (93.7)	0.86 (0.70)	0.0	0.23	0.83	1.23	3.3	
		Placebo	391	354 (90.5)	0.98 (0.76)	0.0	0.30	0.99	1.43	4.0	
	Week 16	Tezepelumab	395	365 (92.4)	0.84 (0.70)	0.0	0.20	0.80	1.20	3.2	
		Placebo	391	355 (90.8)	1.00 (0.77)	0.0	0.29	0.94	1.57	4.0	
Week 17	Tezepelumab	395	366 (92.7)	0.79 (0.70)	0.0	0.16	0.71	1.20	3.1		
	Placebo	391	351 (89.8)	0.96 (0.75)	0.0	0.29	0.94	1.43	3.9		

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WDC\_ILMH0: Course of ASD weekly daytime score  
 DITTLL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly daytime score	Week 18	Tezepelumab	395	365 (92.4)	0.82 (0.71)	0.0	0.17	0.77	1.17	3.4	
		Placebo	391	351 (89.8)	0.96 (0.75)	0.0	0.29	0.91	1.43	4.0	
	Week 19	Tezepelumab	395	356 (90.1)	0.81 (0.72)	0.0	0.17	0.74	1.17	3.4	
		Placebo	391	350 (89.5)	0.97 (0.78)	0.0	0.26	0.94	1.53	3.8	
	Week 20	Tezepelumab	395	354 (89.6)	0.81 (0.72)	0.0	0.14	0.77	1.20	3.2	
		Placebo	391	346 (88.5)	0.96 (0.77)	0.0	0.26	0.86	1.57	3.9	
	Week 21	Tezepelumab	395	357 (90.4)	0.80 (0.71)	0.0	0.11	0.72	1.17	3.3	
		Placebo	391	341 (87.2)	0.94 (0.79)	0.0	0.20	0.90	1.46	4.0	
	Week 22	Tezepelumab	395	353 (89.4)	0.83 (0.73)	0.0	0.12	0.80	1.20	3.4	
		Placebo	391	338 (86.4)	0.93 (0.78)	0.0	0.20	0.93	1.49	4.0	
	Week 23	Tezepelumab	395	356 (90.1)	0.81 (0.73)	0.0	0.13	0.73	1.26	3.3	
		Placebo	391	339 (86.7)	0.94 (0.77)	0.0	0.20	0.94	1.46	3.9	
	Week 24	Tezepelumab	395	356 (90.1)	0.82 (0.74)	0.0	0.14	0.77	1.24	3.2	
		Placebo	391	336 (85.9)	0.92 (0.77)	0.0	0.26	0.83	1.43	3.9	
	Week 25	Tezepelumab	395	351 (88.9)	0.82 (0.71)	0.0	0.13	0.77	1.20	3.3	
		Placebo	391	328 (83.9)	0.92 (0.77)	0.0	0.21	0.86	1.41	4.0	
	Week 26	Tezepelumab	395	348 (88.1)	0.81 (0.72)	0.0	0.14	0.73	1.20	3.2	
		Placebo	391	329 (84.1)	0.93 (0.77)	0.0	0.20	0.86	1.46	4.0	
	Week 27	Tezepelumab	395	347 (87.8)	0.79 (0.72)	0.0	0.10	0.70	1.20	3.5	
		Placebo	391	334 (85.4)	0.93 (0.80)	0.0	0.20	0.83	1.40	3.9	
	Week 28	Tezepelumab	395	349 (88.4)	0.78 (0.73)	0.0	0.06	0.70	1.17	3.5	
		Placebo	391	339 (86.7)	0.94 (0.80)	0.0	0.20	0.83	1.49	3.8	
	Week 29	Tezepelumab	395	348 (88.1)	0.77 (0.72)	0.0	0.09	0.66	1.16	3.5	
		Placebo	391	330 (84.4)	0.93 (0.79)	0.0	0.20	0.80	1.47	3.8	
	Week 30	Tezepelumab	395	344 (87.1)	0.80 (0.71)	0.0	0.15	0.71	1.20	3.9	
		Placebo	391	321 (82.1)	0.93 (0.78)	0.0	0.20	0.86	1.49	3.8	
	Week 31	Tezepelumab	395	354 (89.6)	0.79 (0.73)	0.0	0.10	0.73	1.20	4.0	
		Placebo	391	333 (85.2)	0.92 (0.75)	0.0	0.23	0.86	1.34	3.8	
	Week 32	Tezepelumab	395	345 (87.3)	0.79 (0.71)	0.0	0.11	0.75	1.23	3.9	
		Placebo	391	328 (83.9)	0.95 (0.76)	0.0	0.29	0.83	1.46	3.8	
	Week 33	Tezepelumab	395	342 (86.6)	0.78 (0.71)	0.0	0.09	0.69	1.17	3.5	
		Placebo	391	330 (84.4)	0.93 (0.77)	0.0	0.20	0.85	1.54	3.8	
	Week 34	Tezepelumab	395	347 (87.8)	0.76 (0.74)	0.0	0.03	0.66	1.17	3.5	
		Placebo	391	328 (83.9)	0.91 (0.77)	0.0	0.20	0.83	1.44	3.8	
	Week 35	Tezepelumab	395	342 (86.6)	0.78 (0.74)	0.0	0.09	0.68	1.20	3.6	
		Placebo	391	320 (81.8)	0.92 (0.76)	0.0	0.23	0.84	1.44	3.8	

Note: DITTLL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WDC\_ILMH0: Course of ASD weekly daytime score  
 DITTTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly daytime score	Week 36	Tezepelumab	395	345 (87.3)	0.79 (0.74)	0.0	0.06	0.69	1.20	3.5	
		Placebo	391	317 (81.1)	0.92 (0.75)	0.0	0.23	0.89	1.43	3.8	
	Week 37	Tezepelumab	395	338 (85.6)	0.79 (0.73)	0.0	0.09	0.70	1.20	3.4	
		Placebo	391	328 (83.9)	0.91 (0.75)	0.0	0.20	0.83	1.37	3.8	
	Week 38	Tezepelumab	395	343 (86.8)	0.79 (0.75)	0.0	0.09	0.69	1.27	3.4	
		Placebo	391	323 (82.6)	0.90 (0.74)	0.0	0.23	0.86	1.40	3.8	
	Week 39	Tezepelumab	395	345 (87.3)	0.81 (0.78)	0.0	0.07	0.69	1.23	3.9	
		Placebo	391	318 (81.3)	0.92 (0.76)	0.0	0.23	0.86	1.46	3.8	
	Week 40	Tezepelumab	395	344 (87.1)	0.79 (0.75)	0.0	0.05	0.66	1.23	3.4	
		Placebo	391	322 (82.4)	0.92 (0.77)	0.0	0.20	0.86	1.54	3.8	
	Week 41	Tezepelumab	395	342 (86.6)	0.77 (0.72)	0.0	0.03	0.66	1.17	3.0	
		Placebo	391	322 (82.4)	0.92 (0.76)	0.0	0.23	0.89	1.47	3.8	
	Week 42	Tezepelumab	395	340 (86.1)	0.77 (0.74)	0.0	0.03	0.61	1.19	3.2	
		Placebo	391	323 (82.6)	0.91 (0.79)	0.0	0.20	0.80	1.40	3.8	
	Week 43	Tezepelumab	395	342 (86.6)	0.78 (0.75)	0.0	0.06	0.63	1.20	3.1	
		Placebo	391	323 (82.6)	0.91 (0.78)	0.0	0.17	0.83	1.44	3.8	
	Week 44	Tezepelumab	395	339 (85.8)	0.77 (0.74)	0.0	0.04	0.63	1.17	3.1	
		Placebo	391	325 (83.1)	0.92 (0.77)	0.0	0.20	0.84	1.43	3.8	
	Week 45	Tezepelumab	395	341 (86.3)	0.75 (0.72)	0.0	0.06	0.60	1.20	3.1	
		Placebo	391	322 (82.4)	0.91 (0.77)	0.0	0.20	0.80	1.40	3.8	
	Week 46	Tezepelumab	395	339 (85.8)	0.77 (0.73)	0.0	0.06	0.60	1.20	3.3	
		Placebo	391	314 (80.3)	0.89 (0.75)	0.0	0.20	0.83	1.46	3.8	
	Week 47	Tezepelumab	395	337 (85.3)	0.76 (0.73)	0.0	0.07	0.60	1.20	3.0	
		Placebo	391	312 (79.8)	0.87 (0.73)	0.0	0.20	0.79	1.43	3.8	
	Week 48	Tezepelumab	395	339 (85.8)	0.77 (0.74)	0.0	0.04	0.60	1.20	3.0	
		Placebo	391	316 (80.8)	0.88 (0.73)	0.0	0.20	0.83	1.37	3.8	
	Week 49	Tezepelumab	395	336 (85.1)	0.76 (0.74)	0.0	0.03	0.60	1.20	3.0	
		Placebo	391	315 (80.6)	0.89 (0.72)	0.0	0.20	0.83	1.29	3.8	
	Week 50	Tezepelumab	395	336 (85.1)	0.76 (0.72)	0.0	0.03	0.60	1.20	3.0	
		Placebo	391	313 (80.1)	0.88 (0.74)	0.0	0.20	0.83	1.32	3.8	
	Week 51	Tezepelumab	395	330 (83.5)	0.77 (0.73)	0.0	0.00	0.63	1.20	3.0	
		Placebo	391	306 (78.3)	0.89 (0.75)	0.0	0.20	0.83	1.36	3.8	
	Week 52	Tezepelumab	395	303 (76.7)	0.78 (0.75)	0.0	0.03	0.60	1.20	3.0	
		Placebo	391	286 (73.1)	0.88 (0.79)	0.0	0.20	0.80	1.35	3.8	

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table NT1WDC\_ILMH0: Course of ASD weekly daytime score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly daytime score	Week 1	Tezepelumab	395	388 (98.2)	-0.20 (0.38)	-1.7	-0.37	-0.11	0.03	0.8	-0.24 [-0.38, -0.10]
		Placebo	391	385 (98.5)	-0.11 (0.37)	-1.8	-0.27	-0.07	0.09	1.5	
	Week 2	Tezepelumab	395	387 (98.0)	-0.34 (0.52)	-2.9	-0.63	-0.19	0.00	0.7	-0.32 [-0.46, -0.18]
		Placebo	391	385 (98.5)	-0.17 (0.53)	-2.7	-0.37	-0.11	0.09	1.5	
	Week 3	Tezepelumab	395	385 (97.5)	-0.41 (0.59)	-3.6	-0.71	-0.26	0.00	0.7	-0.20 [-0.34, -0.05]
		Placebo	391	377 (96.4)	-0.29 (0.58)	-2.6	-0.54	-0.20	0.02	1.6	
	Week 4	Tezepelumab	395	382 (96.7)	-0.44 (0.61)	-3.6	-0.74	-0.26	0.00	0.8	-0.18 [-0.32, -0.04]
		Placebo	391	382 (97.7)	-0.33 (0.61)	-2.7	-0.63	-0.23	0.03	2.1	
	Week 5	Tezepelumab	395	385 (97.5)	-0.49 (0.64)	-3.7	-0.87	-0.33	-0.02	0.8	-0.18 [-0.32, -0.04]
		Placebo	391	373 (95.4)	-0.38 (0.60)	-2.8	-0.70	-0.27	-0.03	1.6	
	Week 6	Tezepelumab	395	378 (95.7)	-0.53 (0.68)	-3.7	-0.91	-0.37	-0.04	0.9	-0.21 [-0.35, -0.07]
		Placebo	391	378 (96.7)	-0.39 (0.67)	-3.1	-0.74	-0.29	0.00	1.9	
	Week 7	Tezepelumab	395	381 (96.5)	-0.55 (0.72)	-3.7	-0.94	-0.43	-0.03	1.2	-0.20 [-0.34, -0.05]
		Placebo	391	376 (96.2)	-0.41 (0.68)	-3.1	-0.76	-0.31	0.00	1.7	
	Week 8	Tezepelumab	395	380 (96.2)	-0.56 (0.71)	-3.7	-0.97	-0.40	-0.03	1.3	-0.19 [-0.34, -0.05]
		Placebo	391	372 (95.1)	-0.43 (0.66)	-3.0	-0.83	-0.31	0.00	1.7	
	Week 9	Tezepelumab	395	381 (96.5)	-0.60 (0.72)	-3.7	-1.03	-0.48	-0.06	1.5	-0.20 [-0.34, -0.06]
		Placebo	391	370 (94.6)	-0.47 (0.66)	-3.1	-0.86	-0.39	-0.03	1.7	
	Week 10	Tezepelumab	395	385 (97.5)	-0.62 (0.72)	-3.6	-1.06	-0.46	-0.06	1.1	-0.22 [-0.37, -0.08]
		Placebo	391	365 (93.4)	-0.46 (0.68)	-3.1	-0.87	-0.34	-0.03	1.8	
	Week 11	Tezepelumab	395	375 (94.9)	-0.60 (0.72)	-3.6	-1.03	-0.47	-0.07	1.0	-0.18 [-0.32, -0.04]
		Placebo	391	365 (93.4)	-0.48 (0.68)	-3.1	-0.86	-0.37	-0.04	1.7	
	Week 12	Tezepelumab	395	377 (95.4)	-0.60 (0.74)	-3.7	-1.06	-0.46	-0.06	1.2	-0.14 [-0.29, 0.00]
		Placebo	391	362 (92.6)	-0.50 (0.68)	-3.1	-0.86	-0.38	-0.06	1.7	
	Week 13	Tezepelumab	395	369 (93.4)	-0.63 (0.75)	-3.7	-1.09	-0.51	-0.07	1.3	-0.17 [-0.31, -0.02]
		Placebo	391	357 (91.3)	-0.51 (0.68)	-3.1	-0.91	-0.40	-0.04	1.7	
	Week 14	Tezepelumab	395	366 (92.7)	-0.66 (0.74)	-3.7	-1.14	-0.54	-0.09	1.0	-0.21 [-0.35, -0.06]
		Placebo	391	364 (93.1)	-0.52 (0.69)	-3.1	-0.86	-0.40	-0.06	1.7	
	Week 15	Tezepelumab	395	370 (93.7)	-0.66 (0.73)	-3.0	-1.17	-0.53	-0.06	1.1	-0.20 [-0.35, -0.06]
		Placebo	391	354 (90.5)	-0.51 (0.69)	-3.1	-0.89	-0.43	-0.06	1.7	
	Week 16	Tezepelumab	395	365 (92.4)	-0.68 (0.74)	-3.7	-1.17	-0.53	-0.11	1.5	-0.24 [-0.38, -0.09]
		Placebo	391	355 (90.8)	-0.51 (0.70)	-2.9	-0.89	-0.43	-0.06	1.7	
	Week 17	Tezepelumab	395	366 (92.7)	-0.71 (0.75)	-3.7	-1.20	-0.62	-0.11	1.4	-0.25 [-0.39, -0.10]
		Placebo	391	351 (89.8)	-0.53 (0.69)	-3.1	-0.97	-0.43	-0.06	1.7	
	Week 18	Tezepelumab	395	365 (92.4)	-0.69 (0.77)	-3.7	-1.17	-0.60	-0.11	1.2	-0.21 [-0.36, -0.07]
		Placebo	391	351 (89.8)	-0.53 (0.72)	-3.3	-0.95	-0.43	-0.05	1.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WDC\_ILMH0: Course of ASD weekly daytime score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly daytime score	Week 19	Tezepelumab	395	356 (90.1)	-0.70 (0.77)	-3.7	-1.17	-0.60	-0.09	1.6	-0.22 [-0.37, -0.07]
		Placebo	391	350 (89.5)	-0.53 (0.74)	-3.2	-0.94	-0.40	-0.04	2.0	
	Week 20	Tezepelumab	395	354 (89.6)	-0.69 (0.76)	-3.7	-1.20	-0.63	-0.11	1.1	-0.21 [-0.36, -0.06]
		Placebo	391	346 (88.5)	-0.53 (0.76)	-3.3	-0.94	-0.45	-0.06	1.7	
	Week 21	Tezepelumab	395	357 (90.4)	-0.71 (0.75)	-3.7	-1.17	-0.63	-0.11	1.7	-0.21 [-0.36, -0.06]
		Placebo	391	341 (87.2)	-0.55 (0.74)	-3.2	-0.94	-0.49	-0.03	1.7	
	Week 22	Tezepelumab	395	353 (89.4)	-0.67 (0.76)	-3.4	-1.17	-0.60	-0.10	1.1	-0.17 [-0.32, -0.02]
		Placebo	391	338 (86.4)	-0.55 (0.73)	-3.5	-0.93	-0.46	-0.06	1.7	
	Week 23	Tezepelumab	395	356 (90.1)	-0.69 (0.78)	-3.5	-1.17	-0.62	-0.11	1.3	-0.18 [-0.33, -0.03]
		Placebo	391	339 (86.7)	-0.55 (0.76)	-3.4	-0.97	-0.46	-0.07	1.7	
	Week 24	Tezepelumab	395	356 (90.1)	-0.68 (0.76)	-3.7	-1.17	-0.60	-0.12	1.4	-0.15 [-0.30, -0.00]
		Placebo	391	336 (85.9)	-0.57 (0.76)	-3.4	-1.01	-0.51	-0.08	1.7	
	Week 25	Tezepelumab	395	351 (88.9)	-0.69 (0.75)	-3.7	-1.16	-0.60	-0.14	1.3	-0.17 [-0.32, -0.02]
		Placebo	391	328 (83.9)	-0.56 (0.76)	-3.3	-0.97	-0.48	-0.12	1.7	
	Week 26	Tezepelumab	395	348 (88.1)	-0.69 (0.76)	-3.6	-1.17	-0.63	-0.14	1.4	-0.17 [-0.32, -0.02]
		Placebo	391	329 (84.1)	-0.56 (0.78)	-3.2	-0.97	-0.44	-0.04	1.7	
	Week 27	Tezepelumab	395	347 (87.8)	-0.71 (0.77)	-3.7	-1.19	-0.63	-0.11	1.2	-0.21 [-0.36, -0.06]
		Placebo	391	334 (85.4)	-0.54 (0.79)	-3.2	-1.01	-0.45	-0.03	2.2	
	Week 28	Tezepelumab	395	349 (88.4)	-0.72 (0.77)	-3.7	-1.20	-0.63	-0.11	1.3	-0.23 [-0.38, -0.08]
		Placebo	391	339 (86.7)	-0.54 (0.75)	-3.2	-1.03	-0.43	-0.03	1.7	
	Week 29	Tezepelumab	395	348 (88.1)	-0.73 (0.77)	-3.7	-1.20	-0.63	-0.14	1.1	-0.24 [-0.39, -0.09]
		Placebo	391	330 (84.4)	-0.54 (0.76)	-3.2	-0.97	-0.46	-0.06	1.7	
	Week 30	Tezepelumab	395	344 (87.1)	-0.71 (0.75)	-3.7	-1.20	-0.69	-0.11	1.3	-0.22 [-0.37, -0.06]
		Placebo	391	321 (82.1)	-0.54 (0.77)	-3.2	-1.00	-0.47	-0.06	1.7	
	Week 31	Tezepelumab	395	354 (89.6)	-0.72 (0.79)	-3.7	-1.20	-0.65	-0.11	1.6	-0.20 [-0.35, -0.05]
		Placebo	391	333 (85.2)	-0.56 (0.75)	-3.2	-1.03	-0.46	-0.03	1.7	
	Week 32	Tezepelumab	395	345 (87.3)	-0.71 (0.76)	-3.7	-1.18	-0.63	-0.14	2.0	-0.21 [-0.36, -0.06]
		Placebo	391	328 (83.9)	-0.55 (0.77)	-3.3	-1.02	-0.46	-0.03	1.7	
	Week 33	Tezepelumab	395	342 (86.6)	-0.72 (0.78)	-3.7	-1.20	-0.63	-0.14	2.1	-0.20 [-0.36, -0.05]
		Placebo	391	330 (84.4)	-0.56 (0.78)	-3.3	-1.00	-0.43	-0.08	1.7	
	Week 34	Tezepelumab	395	347 (87.8)	-0.73 (0.77)	-3.7	-1.20	-0.69	-0.15	2.0	-0.20 [-0.35, -0.05]
		Placebo	391	328 (83.9)	-0.58 (0.79)	-3.4	-0.98	-0.46	-0.09	1.7	
	Week 35	Tezepelumab	395	342 (86.6)	-0.71 (0.78)	-3.7	-1.20	-0.66	-0.14	1.8	-0.21 [-0.36, -0.06]
		Placebo	391	320 (81.8)	-0.55 (0.76)	-3.2	-1.02	-0.43	-0.05	1.7	
	Week 36	Tezepelumab	395	345 (87.3)	-0.72 (0.78)	-3.7	-1.19	-0.63	-0.14	1.8	-0.22 [-0.37, -0.07]
		Placebo	391	317 (81.1)	-0.55 (0.75)	-3.3	-1.03	-0.43	-0.06	1.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WDC\_ILMH0: Course of ASD weekly daytime score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly daytime score	Week 37	Tezepelumab	395	338 (85.6)	-0.71 (0.78)	-3.7	-1.23	-0.64	-0.11	1.8	-0.18 [-0.33, -0.02]
		Placebo	391	328 (83.9)	-0.57 (0.76)	-3.4	-1.03	-0.43	-0.07	1.7	
	Week 38	Tezepelumab	395	343 (86.8)	-0.71 (0.79)	-3.7	-1.20	-0.60	-0.14	1.8	-0.18 [-0.33, -0.03]
		Placebo	391	323 (82.6)	-0.57 (0.74)	-3.5	-1.06	-0.43	-0.06	1.7	
	Week 39	Tezepelumab	395	345 (87.3)	-0.70 (0.81)	-3.7	-1.20	-0.63	-0.10	1.8	-0.18 [-0.33, -0.02]
		Placebo	391	318 (81.3)	-0.56 (0.74)	-3.3	-1.06	-0.45	-0.03	1.7	
	Week 40	Tezepelumab	395	344 (87.1)	-0.72 (0.78)	-3.7	-1.20	-0.69	-0.14	1.8	-0.22 [-0.37, -0.07]
		Placebo	391	322 (82.4)	-0.55 (0.75)	-3.5	-1.00	-0.40	-0.06	1.7	
	Week 41	Tezepelumab	395	342 (86.6)	-0.74 (0.78)	-3.7	-1.26	-0.67	-0.14	1.8	-0.25 [-0.40, -0.09]
		Placebo	391	322 (82.4)	-0.56 (0.73)	-3.1	-1.05	-0.46	-0.06	1.7	
	Week 42	Tezepelumab	395	340 (86.1)	-0.75 (0.79)	-3.7	-1.22	-0.68	-0.14	1.8	-0.25 [-0.40, -0.09]
		Placebo	391	323 (82.6)	-0.55 (0.75)	-3.2	-0.99	-0.43	-0.06	1.7	
	Week 43	Tezepelumab	395	342 (86.6)	-0.72 (0.79)	-3.7	-1.24	-0.68	-0.17	1.8	-0.18 [-0.33, -0.03]
		Placebo	391	323 (82.6)	-0.58 (0.76)	-3.2	-1.06	-0.49	-0.06	1.7	
	Week 44	Tezepelumab	395	339 (85.8)	-0.74 (0.78)	-3.7	-1.20	-0.67	-0.17	1.8	-0.24 [-0.39, -0.09]
		Placebo	391	325 (83.1)	-0.56 (0.75)	-3.2	-1.01	-0.40	-0.06	1.7	
	Week 45	Tezepelumab	395	341 (86.3)	-0.76 (0.76)	-3.7	-1.21	-0.71	-0.20	1.8	-0.23 [-0.39, -0.08]
		Placebo	391	322 (82.4)	-0.58 (0.75)	-3.3	-1.10	-0.43	-0.05	1.7	
	Week 46	Tezepelumab	395	339 (85.8)	-0.75 (0.79)	-3.7	-1.26	-0.70	-0.17	1.8	-0.21 [-0.37, -0.06]
		Placebo	391	314 (80.3)	-0.59 (0.76)	-3.2	-1.09	-0.49	-0.06	1.7	
	Week 47	Tezepelumab	395	337 (85.3)	-0.75 (0.78)	-3.7	-1.23	-0.71	-0.14	1.8	-0.20 [-0.35, -0.04]
		Placebo	391	312 (79.8)	-0.61 (0.73)	-3.2	-1.03	-0.49	-0.12	1.3	
	Week 48	Tezepelumab	395	339 (85.8)	-0.73 (0.78)	-3.7	-1.20	-0.71	-0.17	1.8	-0.17 [-0.32, -0.01]
		Placebo	391	316 (80.8)	-0.61 (0.73)	-3.2	-1.07	-0.51	-0.11	1.3	
	Week 49	Tezepelumab	395	336 (85.1)	-0.75 (0.78)	-3.7	-1.23	-0.69	-0.20	1.8	-0.21 [-0.36, -0.05]
		Placebo	391	315 (80.6)	-0.60 (0.74)	-3.4	-1.01	-0.50	-0.06	1.3	
	Week 50	Tezepelumab	395	336 (85.1)	-0.76 (0.78)	-3.7	-1.20	-0.71	-0.20	1.8	-0.19 [-0.35, -0.04]
		Placebo	391	313 (80.1)	-0.61 (0.75)	-3.7	-1.07	-0.50	-0.06	1.3	
	Week 51	Tezepelumab	395	330 (83.5)	-0.73 (0.79)	-3.7	-1.20	-0.69	-0.17	1.8	-0.16 [-0.32, -0.01]
		Placebo	391	306 (78.3)	-0.60 (0.75)	-3.3	-1.09	-0.51	-0.09	1.3	
	Week 52	Tezepelumab	395	303 (76.7)	-0.73 (0.82)	-3.7	-1.26	-0.69	-0.15	1.8	-0.18 [-0.34, -0.01]
		Placebo	391	286 (73.1)	-0.59 (0.76)	-3.5	-1.03	-0.51	-0.06	1.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WDC\_ILMC0: Change from baseline in ASD weekly daytime score - MMRM results  
 DITTTL

Change from baseline in ASD weekly daytime score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 1	Tezepelumab	395	388 (98.2)	-0.19 (0.03)	(-0.25, -0.13)	-0.08 (0.05)	(-0.17, 0.01)	0.075	
	Placebo	391	385 (98.5)	-0.11 (0.03)	(-0.17, -0.05)				
Week 2	Tezepelumab	395	387 (98.0)	-0.33 (0.03)	(-0.40, -0.27)	-0.16 (0.04)	(-0.25, -0.07)	<0.001 *	
	Placebo	391	385 (98.5)	-0.17 (0.03)	(-0.24, -0.11)				
Week 3	Tezepelumab	395	385 (97.5)	-0.40 (0.03)	(-0.46, -0.34)	-0.11 (0.05)	(-0.20, -0.02)	0.013 *	
	Placebo	391	377 (96.4)	-0.29 (0.03)	(-0.35, -0.22)				
Week 4	Tezepelumab	395	382 (96.7)	-0.43 (0.03)	(-0.49, -0.37)	-0.11 (0.04)	(-0.20, -0.02)	0.017 *	
	Placebo	391	382 (97.7)	-0.32 (0.03)	(-0.38, -0.26)				
Week 5	Tezepelumab	395	385 (97.5)	-0.48 (0.03)	(-0.54, -0.42)	-0.09 (0.05)	(-0.18, -0.01)	0.036 *	
	Placebo	391	373 (95.4)	-0.39 (0.03)	(-0.45, -0.32)				
Week 6	Tezepelumab	395	378 (95.7)	-0.52 (0.03)	(-0.58, -0.45)	-0.13 (0.05)	(-0.22, -0.05)	0.003 *	
	Placebo	391	378 (96.7)	-0.38 (0.03)	(-0.44, -0.32)				
Week 7	Tezepelumab	395	381 (96.5)	-0.53 (0.03)	(-0.59, -0.47)	-0.13 (0.05)	(-0.22, -0.04)	0.004 *	
	Placebo	391	376 (96.2)	-0.40 (0.03)	(-0.47, -0.34)				
Week 8	Tezepelumab	395	380 (96.2)	-0.56 (0.03)	(-0.62, -0.49)	-0.14 (0.05)	(-0.22, -0.05)	0.003 *	
	Placebo	391	372 (95.1)	-0.42 (0.03)	(-0.48, -0.36)				
Week 9	Tezepelumab	395	381 (96.5)	-0.61 (0.03)	(-0.67, -0.54)	-0.15 (0.05)	(-0.24, -0.06)	<0.001 *	
	Placebo	391	370 (94.6)	-0.45 (0.03)	(-0.52, -0.39)				
Week 10	Tezepelumab	395	385 (97.5)	-0.61 (0.03)	(-0.67, -0.55)	-0.16 (0.05)	(-0.24, -0.07)	<0.001 *	
	Placebo	391	365 (93.4)	-0.45 (0.03)	(-0.52, -0.39)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WDC\_ILMC0: Change from baseline in ASD weekly daytime score - MMRM results  
 DITTTL

Change from baseline in ASD weekly daytime score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 11	Tezepelumab	395	375 (94.9)	-0.61 (0.03)	(-0.67, -0.55)	-0.14 (0.05)	(-0.23, -0.05)	0.002 *	
	Placebo	391	365 (93.4)	-0.47 (0.03)	(-0.53, -0.41)				
Week 12	Tezepelumab	395	377 (95.4)	-0.59 (0.03)	(-0.65, -0.53)	-0.12 (0.05)	(-0.21, -0.03)	0.009 *	
	Placebo	391	362 (92.6)	-0.47 (0.03)	(-0.54, -0.41)				
Week 13	Tezepelumab	395	369 (93.4)	-0.62 (0.03)	(-0.69, -0.56)	-0.14 (0.05)	(-0.23, -0.05)	0.002 *	
	Placebo	391	357 (91.3)	-0.49 (0.03)	(-0.55, -0.42)				
Week 14	Tezepelumab	395	366 (92.7)	-0.65 (0.03)	(-0.72, -0.59)	-0.15 (0.05)	(-0.24, -0.07)	<0.001 *	
	Placebo	391	364 (93.1)	-0.50 (0.03)	(-0.56, -0.43)				
Week 15	Tezepelumab	395	370 (93.7)	-0.65 (0.03)	(-0.71, -0.59)	-0.15 (0.05)	(-0.24, -0.06)	<0.001 *	
	Placebo	391	354 (90.5)	-0.50 (0.03)	(-0.56, -0.44)				
Week 16	Tezepelumab	395	365 (92.4)	-0.68 (0.03)	(-0.74, -0.62)	-0.20 (0.05)	(-0.29, -0.11)	<0.001 *	
	Placebo	391	355 (90.8)	-0.48 (0.03)	(-0.55, -0.42)				
Week 17	Tezepelumab	395	366 (92.7)	-0.70 (0.03)	(-0.77, -0.64)	-0.19 (0.05)	(-0.28, -0.10)	<0.001 *	
	Placebo	391	351 (89.8)	-0.51 (0.03)	(-0.58, -0.45)				
Week 18	Tezepelumab	395	365 (92.4)	-0.68 (0.03)	(-0.74, -0.61)	-0.17 (0.05)	(-0.26, -0.08)	<0.001 *	
	Placebo	391	351 (89.8)	-0.51 (0.03)	(-0.57, -0.44)				
Week 19	Tezepelumab	395	356 (90.1)	-0.69 (0.03)	(-0.75, -0.62)	-0.17 (0.05)	(-0.26, -0.08)	<0.001 *	
	Placebo	391	350 (89.5)	-0.51 (0.03)	(-0.58, -0.45)				
Week 20	Tezepelumab	395	354 (89.6)	-0.69 (0.03)	(-0.76, -0.63)	-0.17 (0.05)	(-0.26, -0.08)	<0.001 *	
	Placebo	391	346 (88.5)	-0.52 (0.03)	(-0.58, -0.46)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WDC\_ILMC0: Change from baseline in ASD weekly daytime score - MMRM results  
 DITTTL

Change from baseline in ASD weekly daytime score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 21	Tezepelumab	395	357 (90.4)	-0.70 (0.03)	(-0.76, -0.64)	-0.17 (0.05)	(-0.26, -0.08)	<0.001 *	
	Placebo	391	341 (87.2)	-0.53 (0.03)	(-0.59, -0.47)				
Week 22	Tezepelumab	395	353 (89.4)	-0.70 (0.03)	(-0.76, -0.63)	-0.16 (0.05)	(-0.25, -0.07)	<0.001 *	
	Placebo	391	338 (86.4)	-0.54 (0.03)	(-0.60, -0.47)				
Week 23	Tezepelumab	395	356 (90.1)	-0.69 (0.03)	(-0.76, -0.63)	-0.17 (0.05)	(-0.26, -0.08)	<0.001 *	
	Placebo	391	339 (86.7)	-0.53 (0.03)	(-0.59, -0.46)				
Week 24	Tezepelumab	395	356 (90.1)	-0.68 (0.03)	(-0.75, -0.62)	-0.15 (0.05)	(-0.24, -0.06)	<0.001 *	
	Placebo	391	336 (85.9)	-0.53 (0.03)	(-0.60, -0.47)				
Week 25	Tezepelumab	395	351 (88.9)	-0.69 (0.03)	(-0.76, -0.63)	-0.14 (0.05)	(-0.23, -0.05)	0.002 *	
	Placebo	391	328 (83.9)	-0.55 (0.03)	(-0.62, -0.49)				
Week 26	Tezepelumab	395	348 (88.1)	-0.69 (0.03)	(-0.76, -0.63)	-0.15 (0.05)	(-0.24, -0.06)	<0.001 *	
	Placebo	391	329 (84.1)	-0.54 (0.03)	(-0.60, -0.47)				
Week 27	Tezepelumab	395	347 (87.8)	-0.70 (0.03)	(-0.77, -0.64)	-0.17 (0.05)	(-0.26, -0.08)	<0.001 *	
	Placebo	391	334 (85.4)	-0.53 (0.03)	(-0.60, -0.47)				
Week 28	Tezepelumab	395	349 (88.4)	-0.72 (0.03)	(-0.78, -0.66)	-0.18 (0.05)	(-0.27, -0.08)	<0.001 *	
	Placebo	391	339 (86.7)	-0.55 (0.03)	(-0.61, -0.48)				
Week 29	Tezepelumab	395	348 (88.1)	-0.73 (0.03)	(-0.79, -0.66)	-0.17 (0.05)	(-0.27, -0.08)	<0.001 *	
	Placebo	391	330 (84.4)	-0.55 (0.03)	(-0.62, -0.49)				
Week 30	Tezepelumab	395	344 (87.1)	-0.71 (0.03)	(-0.78, -0.65)	-0.17 (0.05)	(-0.26, -0.08)	<0.001 *	
	Placebo	391	321 (82.1)	-0.54 (0.03)	(-0.61, -0.48)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WDC\_ILMC0: Change from baseline in ASD weekly daytime score - MMRM results  
 DITTTL

Change from baseline in ASD weekly daytime score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 31	Tezepelumab	395	354 (89.6)	-0.71 (0.03)	(-0.78, -0.65)	-0.15 (0.05)	(-0.24, -0.06)	0.001 *	
	Placebo	391	333 (85.2)	-0.56 (0.03)	(-0.63, -0.50)				
Week 32	Tezepelumab	395	345 (87.3)	-0.71 (0.03)	(-0.78, -0.65)	-0.16 (0.05)	(-0.26, -0.07)	<0.001 *	
	Placebo	391	328 (83.9)	-0.55 (0.03)	(-0.61, -0.48)				
Week 33	Tezepelumab	395	342 (86.6)	-0.73 (0.03)	(-0.79, -0.67)	-0.17 (0.05)	(-0.26, -0.08)	<0.001 *	
	Placebo	391	330 (84.4)	-0.56 (0.03)	(-0.62, -0.49)				
Week 34	Tezepelumab	395	347 (87.8)	-0.74 (0.03)	(-0.81, -0.68)	-0.19 (0.05)	(-0.28, -0.09)	<0.001 *	
	Placebo	391	328 (83.9)	-0.56 (0.03)	(-0.62, -0.49)				
Week 35	Tezepelumab	395	342 (86.6)	-0.72 (0.03)	(-0.79, -0.66)	-0.17 (0.05)	(-0.26, -0.08)	<0.001 *	
	Placebo	391	320 (81.8)	-0.55 (0.03)	(-0.62, -0.49)				
Week 36	Tezepelumab	395	345 (87.3)	-0.71 (0.03)	(-0.78, -0.65)	-0.16 (0.05)	(-0.25, -0.07)	<0.001 *	
	Placebo	391	317 (81.1)	-0.55 (0.03)	(-0.62, -0.49)				
Week 37	Tezepelumab	395	338 (85.6)	-0.72 (0.03)	(-0.78, -0.65)	-0.15 (0.05)	(-0.24, -0.06)	0.001 *	
	Placebo	391	328 (83.9)	-0.57 (0.03)	(-0.63, -0.50)				
Week 38	Tezepelumab	395	343 (86.8)	-0.71 (0.03)	(-0.77, -0.65)	-0.14 (0.05)	(-0.23, -0.05)	0.002 *	
	Placebo	391	323 (82.6)	-0.57 (0.03)	(-0.63, -0.50)				
Week 39	Tezepelumab	395	345 (87.3)	-0.71 (0.03)	(-0.77, -0.64)	-0.13 (0.05)	(-0.22, -0.04)	0.005 *	
	Placebo	391	318 (81.3)	-0.57 (0.03)	(-0.64, -0.51)				
Week 40	Tezepelumab	395	344 (87.1)	-0.72 (0.03)	(-0.79, -0.66)	-0.16 (0.05)	(-0.26, -0.07)	<0.001 *	
	Placebo	391	322 (82.4)	-0.56 (0.03)	(-0.62, -0.49)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WDC\_ILMC0: Change from baseline in ASD weekly daytime score - MMRM results  
DITTTL

Change from baseline in ASD weekly daytime score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 41	Tezepelumab	395	342 (86.6)	-0.74 (0.03)	(-0.81, -0.68)	-0.18 (0.05)	(-0.27, -0.09)	<0.001 *	
	Placebo	391	322 (82.4)	-0.56 (0.03)	(-0.63, -0.50)				
Week 42	Tezepelumab	395	340 (86.1)	-0.74 (0.03)	(-0.81, -0.68)	-0.18 (0.05)	(-0.27, -0.09)	<0.001 *	
	Placebo	391	323 (82.6)	-0.56 (0.03)	(-0.63, -0.50)				
Week 43	Tezepelumab	395	342 (86.6)	-0.73 (0.03)	(-0.80, -0.67)	-0.16 (0.05)	(-0.25, -0.06)	<0.001 *	
	Placebo	391	323 (82.6)	-0.58 (0.03)	(-0.64, -0.51)				
Week 44	Tezepelumab	395	339 (85.8)	-0.75 (0.03)	(-0.81, -0.68)	-0.18 (0.05)	(-0.27, -0.09)	<0.001 *	
	Placebo	391	325 (83.1)	-0.57 (0.03)	(-0.63, -0.50)				
Week 45	Tezepelumab	395	341 (86.3)	-0.76 (0.03)	(-0.82, -0.69)	-0.19 (0.05)	(-0.28, -0.09)	<0.001 *	
	Placebo	391	322 (82.4)	-0.57 (0.03)	(-0.64, -0.51)				
Week 46	Tezepelumab	395	339 (85.8)	-0.76 (0.03)	(-0.82, -0.69)	-0.17 (0.05)	(-0.26, -0.08)	<0.001 *	
	Placebo	391	314 (80.3)	-0.59 (0.03)	(-0.65, -0.52)				
Week 47	Tezepelumab	395	337 (85.3)	-0.74 (0.03)	(-0.81, -0.68)	-0.15 (0.05)	(-0.24, -0.05)	0.002 *	
	Placebo	391	312 (79.8)	-0.60 (0.03)	(-0.67, -0.53)				
Week 48	Tezepelumab	395	339 (85.8)	-0.74 (0.03)	(-0.80, -0.67)	-0.14 (0.05)	(-0.23, -0.04)	0.004 *	
	Placebo	391	316 (80.8)	-0.60 (0.03)	(-0.67, -0.53)				
Week 49	Tezepelumab	395	336 (85.1)	-0.75 (0.03)	(-0.81, -0.68)	-0.15 (0.05)	(-0.25, -0.06)	0.001 *	
	Placebo	391	315 (80.6)	-0.60 (0.03)	(-0.66, -0.53)				
Week 50	Tezepelumab	395	336 (85.1)	-0.76 (0.03)	(-0.82, -0.69)	-0.16 (0.05)	(-0.26, -0.07)	<0.001 *	
	Placebo	391	313 (80.1)	-0.59 (0.03)	(-0.66, -0.53)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table NT1WDC\_ILMC0: Change from baseline in ASD weekly daytime score - MMRM results  
 DITTLL

Change from baseline in ASD weekly daytime score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 51	Tezepelumab	395	330 (83.5)	-0.74 (0.03)	(-0.80, -0.67)	-0.15 (0.05)	(-0.24, -0.05)	0.002 *
	Placebo	391	306 (78.3)	-0.59 (0.03)	(-0.66, -0.53)			
Week 52	Tezepelumab	395	303 (76.7)	-0.73 (0.03)	(-0.80, -0.67)	-0.15 (0.05)	(-0.24, -0.05)	0.003 *
	Placebo	391	286 (73.1)	-0.59 (0.03)	(-0.65, -0.52)			

Note: DITTLL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WDC\_ILMH0: Course of ASD weekly daytime score  
 DITTTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly daytime score	Baseline	Tezepelumab	73	73 (100.0)	1.42 (0.74)	0.0	1.00	1.46	2.00	3.0	
		Placebo	76	76 (100.0)	1.33 (0.78)	0.0	0.80	1.14	1.92	3.6	
	Week 1	Tezepelumab	73	72 (98.6)	1.30 (0.72)	0.0	0.83	1.14	1.93	3.0	
		Placebo	76	76 (100.0)	1.31 (0.70)	0.0	0.79	1.20	1.90	2.9	
	Week 2	Tezepelumab	73	73 (100.0)	1.17 (0.74)	0.0	0.66	1.00	1.77	3.2	
		Placebo	76	76 (100.0)	1.33 (0.73)	0.0	0.83	1.26	1.95	3.7	
	Week 3	Tezepelumab	73	73 (100.0)	1.13 (0.72)	0.0	0.60	1.00	1.57	3.1	
		Placebo	76	76 (100.0)	1.28 (0.65)	0.0	0.90	1.32	1.84	2.5	
	Week 4	Tezepelumab	73	72 (98.6)	1.09 (0.74)	0.0	0.50	1.00	1.64	3.1	
		Placebo	76	76 (100.0)	1.26 (0.66)	0.0	0.85	1.33	1.70	3.0	
	Week 5	Tezepelumab	73	72 (98.6)	1.06 (0.78)	0.0	0.31	1.00	1.74	3.1	
		Placebo	76	74 (97.4)	1.20 (0.67)	0.0	0.77	1.26	1.73	2.8	
	Week 6	Tezepelumab	73	70 (95.9)	1.09 (0.79)	0.0	0.29	1.00	1.83	3.1	
		Placebo	76	74 (97.4)	1.23 (0.70)	0.0	0.80	1.20	1.74	2.7	
	Week 7	Tezepelumab	73	71 (97.3)	1.09 (0.80)	0.0	0.49	1.00	1.80	3.1	
		Placebo	76	75 (98.7)	1.26 (0.68)	0.0	0.86	1.29	1.77	2.6	
	Week 8	Tezepelumab	73	71 (97.3)	1.09 (0.80)	0.0	0.46	1.00	1.83	3.2	
		Placebo	76	75 (98.7)	1.25 (0.71)	0.0	0.80	1.26	1.77	2.9	
	Week 9	Tezepelumab	73	72 (98.6)	1.07 (0.82)	0.0	0.27	1.00	1.89	3.1	
		Placebo	76	75 (98.7)	1.23 (0.72)	0.0	0.74	1.23	1.80	2.7	
	Week 10	Tezepelumab	73	71 (97.3)	1.13 (0.81)	0.0	0.46	1.00	1.86	3.4	
		Placebo	76	74 (97.4)	1.21 (0.69)	0.0	0.80	1.17	1.63	2.8	
	Week 11	Tezepelumab	73	70 (95.9)	1.08 (0.81)	0.0	0.43	1.00	1.80	3.4	
		Placebo	76	74 (97.4)	1.20 (0.69)	0.0	0.71	1.15	1.77	3.0	
	Week 12	Tezepelumab	73	70 (95.9)	1.07 (0.80)	0.0	0.49	0.99	1.80	3.6	
		Placebo	76	75 (98.7)	1.24 (0.67)	0.0	0.83	1.33	1.74	3.0	
	Week 13	Tezepelumab	73	68 (93.2)	1.07 (0.84)	0.0	0.40	0.93	1.90	3.3	
		Placebo	76	74 (97.4)	1.16 (0.71)	0.0	0.57	1.20	1.69	2.9	
	Week 14	Tezepelumab	73	70 (95.9)	1.11 (0.81)	0.0	0.43	1.00	1.94	3.2	
		Placebo	76	74 (97.4)	1.15 (0.72)	0.0	0.60	1.21	1.71	2.8	
	Week 15	Tezepelumab	73	69 (94.5)	1.12 (0.82)	0.0	0.43	1.00	1.89	3.5	
		Placebo	76	73 (96.1)	1.13 (0.71)	0.0	0.51	1.09	1.67	3.0	
	Week 16	Tezepelumab	73	69 (94.5)	1.13 (0.81)	0.0	0.54	1.00	1.89	3.6	
		Placebo	76	74 (97.4)	1.11 (0.67)	0.0	0.57	1.16	1.60	2.7	
	Week 17	Tezepelumab	73	70 (95.9)	1.09 (0.82)	0.0	0.40	0.97	1.83	3.5	
		Placebo	76	74 (97.4)	1.10 (0.66)	0.0	0.69	1.01	1.60	2.7	

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WDC\_ILMH0: Course of ASD weekly daytime score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly daytime score	Week 18	Tezepelumab	73	70 (95.9)	1.09 (0.81)	0.0	0.43	1.00	1.80	3.3	
		Placebo	76	73 (96.1)	1.12 (0.70)	0.0	0.74	1.06	1.60	2.7	
	Week 19	Tezepelumab	73	69 (94.5)	1.07 (0.83)	0.0	0.40	0.97	1.80	3.3	
		Placebo	76	74 (97.4)	1.14 (0.71)	0.0	0.67	1.00	1.74	2.9	
	Week 20	Tezepelumab	73	70 (95.9)	1.08 (0.86)	0.0	0.37	0.95	1.83	3.2	
		Placebo	76	74 (97.4)	1.16 (0.71)	0.0	0.71	1.01	1.69	2.9	
	Week 21	Tezepelumab	73	69 (94.5)	1.08 (0.83)	0.0	0.40	1.00	1.71	3.2	
		Placebo	76	73 (96.1)	1.16 (0.72)	0.0	0.77	1.09	1.70	2.9	
	Week 22	Tezepelumab	73	69 (94.5)	1.09 (0.84)	0.0	0.46	1.00	1.83	3.5	
		Placebo	76	75 (98.7)	1.21 (0.79)	0.0	0.73	1.20	1.69	4.0	
	Week 23	Tezepelumab	73	69 (94.5)	1.10 (0.87)	0.0	0.40	0.94	1.83	3.5	
		Placebo	76	74 (97.4)	1.20 (0.78)	0.0	0.63	1.11	1.70	3.7	
	Week 24	Tezepelumab	73	70 (95.9)	1.06 (0.86)	0.0	0.31	0.99	1.90	3.4	
		Placebo	76	75 (98.7)	1.20 (0.75)	0.0	0.69	1.20	1.69	3.2	
	Week 25	Tezepelumab	73	69 (94.5)	1.07 (0.89)	0.0	0.40	1.00	1.94	3.5	
		Placebo	76	74 (97.4)	1.16 (0.74)	0.0	0.71	1.09	1.69	3.1	
	Week 26	Tezepelumab	73	68 (93.2)	1.07 (0.87)	0.0	0.37	1.00	1.95	3.3	
		Placebo	76	73 (96.1)	1.16 (0.77)	0.0	0.66	1.11	1.60	3.3	
	Week 27	Tezepelumab	73	69 (94.5)	1.06 (0.89)	0.0	0.31	1.00	1.83	3.5	
		Placebo	76	73 (96.1)	1.15 (0.77)	0.0	0.57	1.09	1.80	2.9	
	Week 28	Tezepelumab	73	67 (91.8)	1.11 (0.90)	0.0	0.40	1.00	2.00	3.3	
		Placebo	76	74 (97.4)	1.15 (0.77)	0.0	0.54	1.04	1.71	2.9	
	Week 29	Tezepelumab	73	66 (90.4)	1.02 (0.88)	0.0	0.20	0.97	1.74	3.4	
		Placebo	76	74 (97.4)	1.17 (0.77)	0.0	0.63	1.15	1.80	2.9	
	Week 30	Tezepelumab	73	69 (94.5)	1.00 (0.90)	0.0	0.20	0.86	1.80	3.4	
		Placebo	76	74 (97.4)	1.17 (0.74)	0.0	0.69	1.16	1.74	2.8	
	Week 31	Tezepelumab	73	67 (91.8)	0.99 (0.90)	0.0	0.17	0.80	1.80	3.5	
		Placebo	76	73 (96.1)	1.14 (0.75)	0.0	0.66	1.20	1.69	2.9	
	Week 32	Tezepelumab	73	66 (90.4)	1.03 (0.91)	0.0	0.20	0.97	1.80	3.6	
		Placebo	76	73 (96.1)	1.12 (0.73)	0.0	0.60	1.11	1.71	2.9	
	Week 33	Tezepelumab	73	67 (91.8)	0.99 (0.86)	0.0	0.20	0.83	1.80	3.5	
		Placebo	76	74 (97.4)	1.09 (0.70)	0.0	0.57	1.03	1.63	2.9	
	Week 34	Tezepelumab	73	67 (91.8)	0.96 (0.84)	0.0	0.20	0.80	1.70	3.4	
		Placebo	76	72 (94.7)	1.08 (0.73)	0.0	0.49	1.00	1.60	2.9	
	Week 35	Tezepelumab	73	67 (91.8)	1.01 (0.87)	0.0	0.20	0.94	1.63	3.4	
		Placebo	76	74 (97.4)	1.08 (0.77)	0.0	0.40	1.03	1.63	2.9	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WDC\_ILMH0: Course of ASD weekly daytime score  
 DITTLL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly daytime score	Week 36	Tezepelumab	73	69 (94.5)	1.02 (0.88)	0.0	0.26	0.89	1.80	3.4	
		Placebo	76	73 (96.1)	1.08 (0.72)	0.0	0.43	1.00	1.60	3.0	
	Week 37	Tezepelumab	73	68 (93.2)	0.98 (0.89)	0.0	0.21	0.81	1.81	3.5	
		Placebo	76	73 (96.1)	1.10 (0.71)	0.0	0.64	1.06	1.57	3.0	
	Week 38	Tezepelumab	73	67 (91.8)	0.97 (0.89)	0.0	0.14	0.86	1.80	3.6	
		Placebo	76	72 (94.7)	1.14 (0.73)	0.0	0.62	1.09	1.63	3.0	
	Week 39	Tezepelumab	73	65 (89.0)	0.97 (0.89)	0.0	0.13	0.89	1.80	3.4	
		Placebo	76	73 (96.1)	1.12 (0.76)	0.0	0.60	1.00	1.67	3.0	
	Week 40	Tezepelumab	73	65 (89.0)	0.97 (0.91)	0.0	0.09	0.77	1.80	3.5	
		Placebo	76	72 (94.7)	1.13 (0.76)	0.0	0.56	1.13	1.60	3.2	
	Week 41	Tezepelumab	73	63 (86.3)	0.92 (0.90)	0.0	0.09	0.74	1.53	3.6	
		Placebo	76	72 (94.7)	1.05 (0.70)	0.0	0.67	1.00	1.54	3.0	
	Week 42	Tezepelumab	73	64 (87.7)	0.96 (0.86)	0.0	0.13	0.84	1.60	3.4	
		Placebo	76	73 (96.1)	1.07 (0.67)	0.0	0.60	1.09	1.50	3.0	
	Week 43	Tezepelumab	73	64 (87.7)	0.96 (0.89)	0.0	0.14	0.90	1.59	3.9	
		Placebo	76	74 (97.4)	1.11 (0.74)	0.0	0.54	1.00	1.69	3.0	
	Week 44	Tezepelumab	73	63 (86.3)	0.92 (0.89)	0.0	0.11	0.74	1.51	3.7	
		Placebo	76	73 (96.1)	1.09 (0.71)	0.0	0.57	1.00	1.60	3.0	
	Week 45	Tezepelumab	73	63 (86.3)	0.90 (0.87)	0.0	0.03	0.69	1.49	3.1	
		Placebo	76	73 (96.1)	1.05 (0.71)	0.0	0.46	1.00	1.51	2.9	
	Week 46	Tezepelumab	73	64 (87.7)	0.94 (0.88)	0.0	0.03	0.83	1.49	3.4	
		Placebo	76	70 (92.1)	1.06 (0.72)	0.0	0.49	1.00	1.57	3.0	
	Week 47	Tezepelumab	73	63 (86.3)	0.93 (0.87)	0.0	0.03	0.77	1.60	3.2	
		Placebo	76	71 (93.4)	1.07 (0.69)	0.0	0.60	1.00	1.48	3.0	
	Week 48	Tezepelumab	73	58 (79.5)	1.06 (0.89)	0.0	0.03	0.99	1.70	3.3	
		Placebo	76	69 (90.8)	1.09 (0.70)	0.0	0.71	1.04	1.43	3.0	

Note: DITTLL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WDC\_ILMH0: Course of ASD weekly daytime score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly daytime score	Week 1	Tezepelumab	73	72 (98.6)	-0.11 (0.38)	-1.7	-0.26	-0.05	0.03	0.9	-0.27 [-0.60, 0.05]
		Placebo	76	76 (100.0)	-0.02 (0.32)	-1.4	-0.07	0.00	0.17	0.6	
	Week 2	Tezepelumab	73	73 (100.0)	-0.24 (0.41)	-1.7	-0.51	-0.09	0.00	0.6	-0.60 [-0.93, -0.27]
		Placebo	76	76 (100.0)	-0.00 (0.39)	-1.7	-0.16	0.00	0.23	1.0	
	Week 3	Tezepelumab	73	73 (100.0)	-0.28 (0.48)	-1.6	-0.63	-0.15	0.03	1.1	-0.49 [-0.82, -0.17]
		Placebo	76	76 (100.0)	-0.05 (0.46)	-1.9	-0.31	0.00	0.18	1.1	
	Week 4	Tezepelumab	73	72 (98.6)	-0.32 (0.51)	-1.5	-0.67	-0.19	0.00	0.9	-0.54 [-0.87, -0.21]
		Placebo	76	76 (100.0)	-0.07 (0.44)	-1.6	-0.24	0.00	0.18	1.0	
	Week 5	Tezepelumab	73	72 (98.6)	-0.35 (0.52)	-2.0	-0.72	-0.21	0.00	0.5	-0.46 [-0.79, -0.13]
		Placebo	76	74 (97.4)	-0.12 (0.51)	-2.3	-0.26	-0.01	0.11	1.0	
	Week 6	Tezepelumab	73	70 (95.9)	-0.34 (0.57)	-2.0	-0.69	-0.17	0.03	1.1	-0.42 [-0.75, -0.09]
		Placebo	76	74 (97.4)	-0.10 (0.58)	-2.4	-0.29	0.00	0.14	1.4	
	Week 7	Tezepelumab	73	71 (97.3)	-0.33 (0.61)	-2.0	-0.83	-0.11	0.00	0.9	-0.43 [-0.76, -0.10]
		Placebo	76	75 (98.7)	-0.07 (0.61)	-2.2	-0.32	0.00	0.17	1.2	
	Week 8	Tezepelumab	73	71 (97.3)	-0.33 (0.63)	-2.0	-0.77	-0.17	0.00	1.1	-0.43 [-0.75, -0.10]
		Placebo	76	75 (98.7)	-0.08 (0.55)	-2.0	-0.31	0.00	0.22	0.9	
	Week 9	Tezepelumab	73	72 (98.6)	-0.35 (0.64)	-1.9	-0.80	-0.19	0.00	1.1	-0.39 [-0.72, -0.06]
		Placebo	76	75 (98.7)	-0.10 (0.59)	-2.0	-0.37	-0.03	0.29	1.0	
	Week 10	Tezepelumab	73	71 (97.3)	-0.29 (0.69)	-1.8	-0.80	-0.20	0.09	2.0	-0.28 [-0.61, 0.04]
		Placebo	76	74 (97.4)	-0.11 (0.60)	-2.0	-0.53	-0.04	0.14	2.1	
	Week 11	Tezepelumab	73	70 (95.9)	-0.33 (0.70)	-1.9	-0.80	-0.21	0.00	2.0	-0.31 [-0.64, 0.02]
		Placebo	76	74 (97.4)	-0.12 (0.65)	-2.0	-0.51	-0.04	0.11	2.9	
	Week 12	Tezepelumab	73	70 (95.9)	-0.37 (0.69)	-1.9	-0.86	-0.31	0.00	2.0	-0.43 [-0.76, -0.10]
		Placebo	76	75 (98.7)	-0.09 (0.62)	-2.0	-0.37	-0.08	0.24	2.3	
	Week 13	Tezepelumab	73	68 (93.2)	-0.36 (0.74)	-2.3	-0.88	-0.27	0.01	2.0	-0.27 [-0.61, 0.06]
		Placebo	76	74 (97.4)	-0.16 (0.69)	-2.4	-0.63	-0.03	0.17	1.4	
	Week 14	Tezepelumab	73	70 (95.9)	-0.33 (0.70)	-1.8	-0.83	-0.21	0.04	2.0	-0.21 [-0.54, 0.12]
		Placebo	76	74 (97.4)	-0.19 (0.66)	-2.7	-0.49	-0.05	0.09	1.7	
	Week 15	Tezepelumab	73	69 (94.5)	-0.32 (0.69)	-1.9	-0.80	-0.20	0.00	2.0	-0.17 [-0.50, 0.16]
		Placebo	76	73 (96.1)	-0.21 (0.61)	-2.8	-0.57	-0.03	0.09	0.9	
	Week 16	Tezepelumab	73	69 (94.5)	-0.31 (0.67)	-1.9	-0.74	-0.20	0.00	1.9	-0.14 [-0.47, 0.19]
		Placebo	76	74 (97.4)	-0.22 (0.64)	-2.0	-0.60	-0.04	0.11	1.1	
	Week 17	Tezepelumab	73	70 (95.9)	-0.34 (0.65)	-1.8	-0.71	-0.20	0.07	1.1	-0.18 [-0.50, 0.15]
		Placebo	76	74 (97.4)	-0.23 (0.63)	-2.2	-0.66	-0.11	0.09	1.1	
	Week 18	Tezepelumab	73	70 (95.9)	-0.35 (0.68)	-1.8	-0.89	-0.26	0.00	1.6	-0.21 [-0.54, 0.12]
		Placebo	76	73 (96.1)	-0.21 (0.63)	-1.9	-0.61	-0.10	0.09	1.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WDC\_ILMH0: Course of ASD weekly daytime score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly daytime score	Week 19	Tezepelumab	73	69 (94.5)	-0.37 (0.72)	-1.9	-0.94	-0.20	0.00	2.1	-0.26 [-0.59, 0.07]
		Placebo	76	74 (97.4)	-0.20 (0.62)	-2.0	-0.63	-0.07	0.09	1.3	
	Week 20	Tezepelumab	73	70 (95.9)	-0.36 (0.73)	-1.8	-0.94	-0.33	0.06	1.8	-0.28 [-0.61, 0.05]
		Placebo	76	74 (97.4)	-0.17 (0.58)	-2.0	-0.40	-0.06	0.09	1.0	
	Week 21	Tezepelumab	73	69 (94.5)	-0.36 (0.71)	-1.9	-0.89	-0.29	0.00	1.9	-0.27 [-0.60, 0.06]
		Placebo	76	73 (96.1)	-0.18 (0.63)	-1.9	-0.47	-0.09	0.11	1.0	
	Week 22	Tezepelumab	73	69 (94.5)	-0.36 (0.66)	-1.8	-0.86	-0.33	0.00	1.2	-0.35 [-0.68, -0.02]
		Placebo	76	75 (98.7)	-0.12 (0.69)	-2.0	-0.54	-0.09	0.23	2.0	
	Week 23	Tezepelumab	73	69 (94.5)	-0.35 (0.71)	-2.1	-0.89	-0.23	0.10	1.6	-0.30 [-0.63, 0.03]
		Placebo	76	74 (97.4)	-0.14 (0.66)	-2.0	-0.49	-0.11	0.20	1.3	
	Week 24	Tezepelumab	73	70 (95.9)	-0.38 (0.72)	-2.1	-0.89	-0.31	0.00	1.2	-0.36 [-0.69, -0.03]
		Placebo	76	75 (98.7)	-0.14 (0.63)	-2.0	-0.43	-0.03	0.20	1.2	
	Week 25	Tezepelumab	73	69 (94.5)	-0.36 (0.78)	-2.2	-0.93	-0.20	0.00	2.2	-0.24 [-0.57, 0.09]
		Placebo	76	74 (97.4)	-0.18 (0.68)	-2.5	-0.51	-0.06	0.12	1.6	
	Week 26	Tezepelumab	73	68 (93.2)	-0.38 (0.75)	-2.3	-0.96	-0.20	0.00	1.8	-0.29 [-0.63, 0.04]
		Placebo	76	73 (96.1)	-0.16 (0.76)	-2.1	-0.54	-0.06	0.16	3.1	
	Week 27	Tezepelumab	73	69 (94.5)	-0.36 (0.79)	-2.3	-0.89	-0.23	0.00	1.9	-0.28 [-0.61, 0.05]
		Placebo	76	73 (96.1)	-0.16 (0.66)	-2.0	-0.42	-0.03	0.17	1.8	
	Week 28	Tezepelumab	73	67 (91.8)	-0.32 (0.79)	-2.3	-0.89	-0.20	0.00	1.8	-0.22 [-0.55, 0.11]
		Placebo	76	74 (97.4)	-0.16 (0.64)	-1.9	-0.51	-0.05	0.14	1.6	
	Week 29	Tezepelumab	73	66 (90.4)	-0.42 (0.75)	-2.3	-0.90	-0.30	0.00	2.1	-0.38 [-0.72, -0.05]
		Placebo	76	74 (97.4)	-0.14 (0.68)	-2.0	-0.50	-0.05	0.19	1.3	
	Week 30	Tezepelumab	73	69 (94.5)	-0.42 (0.81)	-2.3	-0.95	-0.31	0.00	2.1	-0.39 [-0.73, -0.06]
		Placebo	76	74 (97.4)	-0.14 (0.58)	-1.8	-0.53	-0.06	0.20	1.1	
	Week 31	Tezepelumab	73	67 (91.8)	-0.43 (0.84)	-2.3	-1.00	-0.31	0.00	2.2	-0.34 [-0.68, -0.01]
		Placebo	76	73 (96.1)	-0.18 (0.58)	-1.8	-0.60	-0.13	0.17	1.1	
	Week 32	Tezepelumab	73	66 (90.4)	-0.40 (0.82)	-2.3	-0.95	-0.26	0.00	2.3	-0.28 [-0.61, 0.06]
		Placebo	76	73 (96.1)	-0.21 (0.58)	-1.8	-0.60	-0.10	0.11	1.1	
	Week 33	Tezepelumab	73	67 (91.8)	-0.42 (0.74)	-2.3	-1.00	-0.33	0.00	2.2	-0.29 [-0.62, 0.04]
		Placebo	76	74 (97.4)	-0.22 (0.63)	-1.9	-0.57	-0.12	0.06	1.2	
	Week 34	Tezepelumab	73	67 (91.8)	-0.45 (0.74)	-2.3	-1.00	-0.34	0.00	2.1	-0.33 [-0.66, 0.01]
		Placebo	76	72 (94.7)	-0.24 (0.56)	-2.1	-0.57	-0.14	0.08	0.9	
	Week 35	Tezepelumab	73	67 (91.8)	-0.42 (0.79)	-2.3	-0.97	-0.31	0.08	2.1	-0.27 [-0.60, 0.06]
		Placebo	76	74 (97.4)	-0.23 (0.58)	-1.8	-0.60	-0.17	0.03	1.1	
	Week 36	Tezepelumab	73	69 (94.5)	-0.40 (0.79)	-2.3	-0.96	-0.34	0.00	1.9	-0.23 [-0.56, 0.10]
		Placebo	76	73 (96.1)	-0.24 (0.61)	-1.9	-0.66	-0.09	0.11	1.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WDC\_ILMH0: Course of ASD weekly daytime score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly daytime score	Week 37	Tezepelumab	73	68 (93.2)	-0.43 (0.83)	-2.3	-0.91	-0.39	0.08	2.0	-0.29 [-0.62, 0.04]
		Placebo	76	73 (96.1)	-0.22 (0.59)	-1.8	-0.57	-0.10	0.23	1.0	
	Week 38	Tezepelumab	73	67 (91.8)	-0.45 (0.82)	-2.3	-1.03	-0.40	0.02	2.3	-0.37 [-0.71, -0.03]
		Placebo	76	72 (94.7)	-0.18 (0.61)	-1.9	-0.55	-0.06	0.18	1.3	
	Week 39	Tezepelumab	73	65 (89.0)	-0.46 (0.83)	-2.3	-1.03	-0.37	0.00	2.1	-0.36 [-0.70, -0.03]
		Placebo	76	73 (96.1)	-0.20 (0.61)	-1.8	-0.60	-0.09	0.17	1.1	
	Week 40	Tezepelumab	73	65 (89.0)	-0.44 (0.83)	-2.2	-1.03	-0.40	0.00	2.0	-0.34 [-0.68, -0.00]
		Placebo	76	72 (94.7)	-0.19 (0.59)	-1.8	-0.66	-0.09	0.24	0.9	
	Week 41	Tezepelumab	73	63 (86.3)	-0.49 (0.84)	-2.3	-1.03	-0.40	0.00	1.9	-0.30 [-0.64, 0.04]
		Placebo	76	72 (94.7)	-0.27 (0.60)	-2.1	-0.64	-0.16	0.09	1.0	
	Week 42	Tezepelumab	73	64 (87.7)	-0.44 (0.82)	-2.1	-1.00	-0.30	0.00	1.8	-0.27 [-0.61, 0.06]
		Placebo	76	73 (96.1)	-0.25 (0.56)	-1.8	-0.63	-0.14	0.14	0.9	
	Week 43	Tezepelumab	73	64 (87.7)	-0.44 (0.84)	-2.1	-1.00	-0.35	0.00	1.9	-0.32 [-0.66, 0.02]
		Placebo	76	74 (97.4)	-0.20 (0.65)	-1.8	-0.63	-0.17	0.33	1.3	
	Week 44	Tezepelumab	73	63 (86.3)	-0.47 (0.84)	-2.2	-1.03	-0.40	0.00	1.8	-0.33 [-0.67, 0.00]
		Placebo	76	73 (96.1)	-0.23 (0.64)	-1.8	-0.68	-0.11	0.17	1.4	
	Week 45	Tezepelumab	73	63 (86.3)	-0.49 (0.83)	-2.3	-1.03	-0.43	0.00	1.7	-0.31 [-0.65, 0.03]
		Placebo	76	73 (96.1)	-0.26 (0.64)	-2.4	-0.66	-0.23	0.09	1.1	
	Week 46	Tezepelumab	73	64 (87.7)	-0.47 (0.82)	-2.3	-0.99	-0.37	0.00	1.7	-0.26 [-0.61, 0.08]
		Placebo	76	70 (92.1)	-0.28 (0.60)	-1.9	-0.63	-0.15	0.06	1.1	
	Week 47	Tezepelumab	73	63 (86.3)	-0.46 (0.86)	-2.3	-1.03	-0.34	0.00	1.7	-0.28 [-0.62, 0.06]
		Placebo	76	71 (93.4)	-0.26 (0.57)	-1.8	-0.71	-0.11	0.11	1.0	
	Week 48	Tezepelumab	73	58 (79.5)	-0.36 (0.85)	-2.3	-0.89	-0.29	0.11	1.7	-0.14 [-0.49, 0.21]
		Placebo	76	69 (90.8)	-0.26 (0.59)	-1.8	-0.67	-0.11	0.16	1.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WDC\_ILMC0: Change from baseline in ASD weekly daytime score - MMRM results  
 DITTTL

Change from baseline in ASD weekly daytime score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 1	Tezepelumab	73	72 (98.6)	-0.09 (0.07)	(-0.23, 0.04)	-0.06 (0.10)	(-0.25, 0.13)	0.518
	Placebo	76	76 (100.0)	-0.03 (0.07)	(-0.16, 0.10)			
Week 2	Tezepelumab	73	73 (100.0)	-0.23 (0.07)	(-0.37, -0.09)	-0.21 (0.10)	(-0.40, -0.02)	0.028 *
	Placebo	76	76 (100.0)	-0.02 (0.07)	(-0.15, 0.12)			
Week 3	Tezepelumab	73	73 (100.0)	-0.27 (0.07)	(-0.41, -0.13)	-0.20 (0.10)	(-0.40, -0.01)	0.037 *
	Placebo	76	76 (100.0)	-0.07 (0.07)	(-0.20, 0.07)			
Week 4	Tezepelumab	73	72 (98.6)	-0.31 (0.07)	(-0.45, -0.17)	-0.23 (0.10)	(-0.42, -0.04)	0.019 *
	Placebo	76	76 (100.0)	-0.08 (0.07)	(-0.21, 0.05)			
Week 5	Tezepelumab	73	72 (98.6)	-0.34 (0.07)	(-0.48, -0.20)	-0.19 (0.10)	(-0.38, -0.00)	0.049 *
	Placebo	76	74 (97.4)	-0.15 (0.07)	(-0.28, -0.01)			
Week 6	Tezepelumab	73	70 (95.9)	-0.33 (0.07)	(-0.47, -0.19)	-0.20 (0.10)	(-0.39, -0.01)	0.040 *
	Placebo	76	74 (97.4)	-0.13 (0.07)	(-0.26, 0.00)			
Week 7	Tezepelumab	73	71 (97.3)	-0.33 (0.07)	(-0.46, -0.19)	-0.23 (0.10)	(-0.42, -0.04)	0.019 *
	Placebo	76	75 (98.7)	-0.10 (0.07)	(-0.23, 0.04)			
Week 8	Tezepelumab	73	71 (97.3)	-0.33 (0.07)	(-0.46, -0.19)	-0.22 (0.10)	(-0.41, -0.03)	0.024 *
	Placebo	76	75 (98.7)	-0.11 (0.07)	(-0.24, 0.03)			
Week 9	Tezepelumab	73	72 (98.6)	-0.33 (0.07)	(-0.47, -0.19)	-0.21 (0.10)	(-0.40, -0.01)	0.036 *
	Placebo	76	75 (98.7)	-0.13 (0.07)	(-0.26, 0.01)			
Week 10	Tezepelumab	73	71 (97.3)	-0.28 (0.07)	(-0.41, -0.14)	-0.15 (0.10)	(-0.35, 0.04)	0.117
	Placebo	76	74 (97.4)	-0.12 (0.07)	(-0.26, 0.01)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table ST1WDC\_ILMC0: Change from baseline in ASD weekly daytime score - MMRM results  
 DITTTL

Change from baseline in ASD weekly daytime score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Time	Treatment	N	n (%)					
Week 11	Tezepelumab	73	70 (95.9)	-0.31 (0.07)	(-0.45, -0.18)	-0.18 (0.10)	(-0.37, 0.01)	0.070
	Placebo	76	74 (97.4)	-0.14 (0.07)	(-0.27, -0.00)			
Week 12	Tezepelumab	73	70 (95.9)	-0.35 (0.07)	(-0.49, -0.21)	-0.24 (0.10)	(-0.43, -0.05)	0.014 *
	Placebo	76	75 (98.7)	-0.11 (0.07)	(-0.25, 0.02)			
Week 13	Tezepelumab	73	68 (93.2)	-0.34 (0.07)	(-0.48, -0.20)	-0.16 (0.10)	(-0.35, 0.04)	0.114
	Placebo	76	74 (97.4)	-0.18 (0.07)	(-0.32, -0.05)			
Week 14	Tezepelumab	73	70 (95.9)	-0.31 (0.07)	(-0.45, -0.17)	-0.11 (0.10)	(-0.31, 0.08)	0.252
	Placebo	76	74 (97.4)	-0.20 (0.07)	(-0.33, -0.06)			
Week 15	Tezepelumab	73	69 (94.5)	-0.30 (0.07)	(-0.44, -0.16)	-0.08 (0.10)	(-0.27, 0.11)	0.411
	Placebo	76	73 (96.1)	-0.22 (0.07)	(-0.36, -0.09)			
Week 16	Tezepelumab	73	69 (94.5)	-0.29 (0.07)	(-0.43, -0.15)	-0.06 (0.10)	(-0.25, 0.14)	0.568
	Placebo	76	74 (97.4)	-0.24 (0.07)	(-0.37, -0.10)			
Week 17	Tezepelumab	73	70 (95.9)	-0.32 (0.07)	(-0.46, -0.18)	-0.08 (0.10)	(-0.27, 0.12)	0.436
	Placebo	76	74 (97.4)	-0.25 (0.07)	(-0.38, -0.11)			
Week 18	Tezepelumab	73	70 (95.9)	-0.33 (0.07)	(-0.46, -0.19)	-0.11 (0.10)	(-0.30, 0.09)	0.282
	Placebo	76	73 (96.1)	-0.22 (0.07)	(-0.35, -0.09)			
Week 19	Tezepelumab	73	69 (94.5)	-0.36 (0.07)	(-0.50, -0.22)	-0.15 (0.10)	(-0.34, 0.05)	0.138
	Placebo	76	74 (97.4)	-0.21 (0.07)	(-0.35, -0.08)			
Week 20	Tezepelumab	73	70 (95.9)	-0.34 (0.07)	(-0.47, -0.20)	-0.14 (0.10)	(-0.34, 0.05)	0.143
	Placebo	76	74 (97.4)	-0.19 (0.07)	(-0.33, -0.06)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WDC\_ILMC0: Change from baseline in ASD weekly daytime score - MMRM results  
 DITTLL

Change from baseline in ASD weekly daytime score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 21	Tezepelumab	73	69 (94.5)	-0.34 (0.07)	(-0.48, -0.20)	-0.15 (0.10)	(-0.34, 0.05)	0.135
	Placebo	76	73 (96.1)	-0.20 (0.07)	(-0.33, -0.06)			
Week 22	Tezepelumab	73	69 (94.5)	-0.34 (0.07)	(-0.48, -0.21)	-0.21 (0.10)	(-0.40, -0.01)	0.035 *
	Placebo	76	75 (98.7)	-0.14 (0.07)	(-0.27, -0.00)			
Week 23	Tezepelumab	73	69 (94.5)	-0.33 (0.07)	(-0.47, -0.19)	-0.18 (0.10)	(-0.37, 0.01)	0.069
	Placebo	76	74 (97.4)	-0.15 (0.07)	(-0.29, -0.02)			
Week 24	Tezepelumab	73	70 (95.9)	-0.36 (0.07)	(-0.49, -0.22)	-0.20 (0.10)	(-0.40, -0.01)	0.039 *
	Placebo	76	75 (98.7)	-0.15 (0.07)	(-0.29, -0.02)			
Week 25	Tezepelumab	73	69 (94.5)	-0.33 (0.07)	(-0.47, -0.19)	-0.13 (0.10)	(-0.32, 0.06)	0.185
	Placebo	76	74 (97.4)	-0.20 (0.07)	(-0.34, -0.07)			
Week 26	Tezepelumab	73	68 (93.2)	-0.35 (0.07)	(-0.49, -0.21)	-0.17 (0.10)	(-0.37, 0.02)	0.077
	Placebo	76	73 (96.1)	-0.17 (0.07)	(-0.31, -0.04)			
Week 27	Tezepelumab	73	69 (94.5)	-0.34 (0.07)	(-0.48, -0.20)	-0.16 (0.10)	(-0.35, 0.04)	0.108
	Placebo	76	73 (96.1)	-0.18 (0.07)	(-0.31, -0.04)			
Week 28	Tezepelumab	73	67 (91.8)	-0.30 (0.07)	(-0.44, -0.16)	-0.13 (0.10)	(-0.33, 0.06)	0.180
	Placebo	76	74 (97.4)	-0.17 (0.07)	(-0.31, -0.04)			
Week 29	Tezepelumab	73	66 (90.4)	-0.37 (0.07)	(-0.51, -0.23)	-0.22 (0.10)	(-0.41, -0.02)	0.030 *
	Placebo	76	74 (97.4)	-0.15 (0.07)	(-0.29, -0.02)			
Week 30	Tezepelumab	73	69 (94.5)	-0.40 (0.07)	(-0.54, -0.26)	-0.24 (0.10)	(-0.44, -0.05)	0.015 *
	Placebo	76	74 (97.4)	-0.16 (0.07)	(-0.29, -0.02)			

Note: DITTLL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WDC\_ILMC0: Change from baseline in ASD weekly daytime score - MMRM results  
 DITTTL

Change from baseline in ASD weekly daytime score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 31	Tezepelumab	73	67 (91.8)	-0.40 (0.07)	(-0.54, -0.26)	-0.22 (0.10)	(-0.41, -0.02)	0.029 *
	Placebo	76	73 (96.1)	-0.18 (0.07)	(-0.32, -0.05)			
Week 32	Tezepelumab	73	66 (90.4)	-0.38 (0.07)	(-0.52, -0.24)	-0.18 (0.10)	(-0.37, 0.02)	0.072
	Placebo	76	73 (96.1)	-0.21 (0.07)	(-0.34, -0.07)			
Week 33	Tezepelumab	73	67 (91.8)	-0.39 (0.07)	(-0.53, -0.25)	-0.15 (0.10)	(-0.35, 0.04)	0.131
	Placebo	76	74 (97.4)	-0.24 (0.07)	(-0.37, -0.10)			
Week 34	Tezepelumab	73	67 (91.8)	-0.42 (0.07)	(-0.56, -0.28)	-0.16 (0.10)	(-0.36, 0.03)	0.104
	Placebo	76	72 (94.7)	-0.25 (0.07)	(-0.39, -0.12)			
Week 35	Tezepelumab	73	67 (91.8)	-0.39 (0.07)	(-0.53, -0.25)	-0.15 (0.10)	(-0.34, 0.05)	0.145
	Placebo	76	74 (97.4)	-0.25 (0.07)	(-0.38, -0.11)			
Week 36	Tezepelumab	73	69 (94.5)	-0.38 (0.07)	(-0.52, -0.24)	-0.13 (0.10)	(-0.33, 0.06)	0.185
	Placebo	76	73 (96.1)	-0.25 (0.07)	(-0.39, -0.11)			
Week 37	Tezepelumab	73	68 (93.2)	-0.40 (0.07)	(-0.54, -0.26)	-0.17 (0.10)	(-0.36, 0.03)	0.097
	Placebo	76	73 (96.1)	-0.23 (0.07)	(-0.37, -0.10)			
Week 38	Tezepelumab	73	67 (91.8)	-0.42 (0.07)	(-0.56, -0.28)	-0.23 (0.10)	(-0.43, -0.04)	0.019 *
	Placebo	76	72 (94.7)	-0.19 (0.07)	(-0.32, -0.05)			
Week 39	Tezepelumab	73	65 (89.0)	-0.42 (0.07)	(-0.56, -0.28)	-0.21 (0.10)	(-0.41, -0.02)	0.032 *
	Placebo	76	73 (96.1)	-0.21 (0.07)	(-0.34, -0.07)			
Week 40	Tezepelumab	73	65 (89.0)	-0.40 (0.07)	(-0.54, -0.26)	-0.19 (0.10)	(-0.39, 0.01)	0.057
	Placebo	76	72 (94.7)	-0.21 (0.07)	(-0.34, -0.07)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WDC\_ILMC0: Change from baseline in ASD weekly daytime score - MMRM results  
DITTLL

Change from baseline in ASD weekly daytime score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 41	Tezepelumab	73	63 (86.3)	-0.43 (0.07)	(-0.58, -0.29)	-0.16 (0.10)	(-0.36, 0.04)	0.107
	Placebo	76	72 (94.7)	-0.27 (0.07)	(-0.41, -0.14)			
Week 42	Tezepelumab	73	64 (87.7)	-0.39 (0.07)	(-0.54, -0.25)	-0.13 (0.10)	(-0.33, 0.06)	0.184
	Placebo	76	73 (96.1)	-0.26 (0.07)	(-0.40, -0.13)			
Week 43	Tezepelumab	73	64 (87.7)	-0.40 (0.07)	(-0.54, -0.25)	-0.18 (0.10)	(-0.38, 0.02)	0.077
	Placebo	76	74 (97.4)	-0.22 (0.07)	(-0.35, -0.08)			
Week 44	Tezepelumab	73	63 (86.3)	-0.42 (0.07)	(-0.57, -0.28)	-0.18 (0.10)	(-0.38, 0.01)	0.070
	Placebo	76	73 (96.1)	-0.24 (0.07)	(-0.38, -0.11)			
Week 45	Tezepelumab	73	63 (86.3)	-0.44 (0.07)	(-0.59, -0.30)	-0.16 (0.10)	(-0.36, 0.03)	0.106
	Placebo	76	73 (96.1)	-0.28 (0.07)	(-0.41, -0.14)			
Week 46	Tezepelumab	73	64 (87.7)	-0.43 (0.07)	(-0.57, -0.28)	-0.17 (0.10)	(-0.36, 0.03)	0.102
	Placebo	76	70 (92.1)	-0.26 (0.07)	(-0.40, -0.13)			
Week 47	Tezepelumab	73	63 (86.3)	-0.42 (0.07)	(-0.56, -0.27)	-0.16 (0.10)	(-0.36, 0.04)	0.108
	Placebo	76	71 (93.4)	-0.25 (0.07)	(-0.39, -0.12)			
Week 48	Tezepelumab	73	58 (79.5)	-0.37 (0.07)	(-0.52, -0.22)	-0.13 (0.10)	(-0.33, 0.07)	0.204
	Placebo	76	69 (90.8)	-0.24 (0.07)	(-0.38, -0.10)			

Note: DITTLL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WNC\_ILMH0: Course of ASD weekly night-time score  
 DITTTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly night-time score	Baseline	Tezepelumab	395	395 (100.0)	1.35 (0.71)	0.0	0.86	1.29	1.77	4.0	
		Placebo	391	391 (100.0)	1.30 (0.69)	0.1	0.80	1.20	1.74	3.8	
	Week 1	Tezepelumab	395	391 (99.0)	1.13 (0.68)	0.0	0.69	1.00	1.54	3.7	
		Placebo	391	385 (98.5)	1.17 (0.68)	0.0	0.66	1.09	1.60	3.5	
	Week 2	Tezepelumab	395	387 (98.0)	1.03 (0.68)	0.0	0.54	0.94	1.40	3.5	
		Placebo	391	387 (99.0)	1.11 (0.68)	0.0	0.60	1.06	1.60	3.6	
	Week 3	Tezepelumab	395	387 (98.0)	0.98 (0.66)	0.0	0.51	0.90	1.31	3.3	
		Placebo	391	385 (98.5)	1.02 (0.68)	0.0	0.51	0.94	1.46	3.9	
	Week 4	Tezepelumab	395	387 (98.0)	0.94 (0.67)	0.0	0.43	0.86	1.29	3.5	
		Placebo	391	379 (96.9)	0.99 (0.65)	0.0	0.47	0.89	1.43	3.6	
	Week 5	Tezepelumab	395	382 (96.7)	0.87 (0.67)	0.0	0.34	0.80	1.26	3.6	
		Placebo	391	377 (96.4)	0.94 (0.65)	0.0	0.40	0.86	1.33	3.7	
	Week 6	Tezepelumab	395	386 (97.7)	0.84 (0.67)	0.0	0.29	0.77	1.27	3.7	
		Placebo	391	379 (96.9)	0.93 (0.67)	0.0	0.40	0.86	1.33	3.8	
	Week 7	Tezepelumab	395	378 (95.7)	0.83 (0.68)	0.0	0.26	0.74	1.20	3.8	
		Placebo	391	378 (96.7)	0.92 (0.68)	0.0	0.40	0.81	1.37	3.8	
	Week 8	Tezepelumab	395	378 (95.7)	0.80 (0.66)	0.0	0.26	0.71	1.20	3.8	
		Placebo	391	377 (96.4)	0.91 (0.66)	0.0	0.40	0.83	1.23	3.8	
	Week 9	Tezepelumab	395	385 (97.5)	0.77 (0.65)	0.0	0.23	0.69	1.11	3.7	
		Placebo	391	374 (95.7)	0.86 (0.66)	0.0	0.31	0.80	1.23	3.9	
	Week 10	Tezepelumab	395	379 (95.9)	0.77 (0.66)	0.0	0.23	0.69	1.14	3.7	
		Placebo	391	366 (93.6)	0.87 (0.65)	0.0	0.31	0.86	1.23	3.8	
	Week 11	Tezepelumab	395	376 (95.2)	0.78 (0.67)	0.0	0.20	0.75	1.19	3.5	
		Placebo	391	373 (95.4)	0.85 (0.67)	0.0	0.26	0.80	1.23	3.6	
	Week 12	Tezepelumab	395	373 (94.4)	0.78 (0.67)	0.0	0.20	0.77	1.13	3.6	
		Placebo	391	367 (93.9)	0.85 (0.67)	0.0	0.26	0.80	1.20	3.7	
	Week 13	Tezepelumab	395	375 (94.9)	0.74 (0.65)	0.0	0.20	0.65	1.11	3.1	
		Placebo	391	369 (94.4)	0.82 (0.64)	0.0	0.30	0.77	1.20	3.7	
	Week 14	Tezepelumab	395	370 (93.7)	0.71 (0.64)	0.0	0.15	0.60	1.07	3.0	
		Placebo	391	368 (94.1)	0.80 (0.64)	0.0	0.27	0.77	1.11	3.7	
	Week 15	Tezepelumab	395	367 (92.9)	0.72 (0.64)	0.0	0.17	0.64	1.11	3.2	
		Placebo	391	351 (89.8)	0.82 (0.67)	0.0	0.20	0.77	1.20	3.9	
	Week 16	Tezepelumab	395	370 (93.7)	0.70 (0.65)	0.0	0.14	0.59	1.03	3.3	
		Placebo	391	357 (91.3)	0.82 (0.67)	0.0	0.20	0.80	1.20	3.9	
	Week 17	Tezepelumab	395	366 (92.7)	0.70 (0.65)	0.0	0.17	0.57	1.03	3.2	
		Placebo	391	352 (90.0)	0.80 (0.65)	0.0	0.23	0.74	1.14	3.8	

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WNC\_ILMH0: Course of ASD weekly night-time score  
 DITTTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly night-time score	Week 18	Tezepelumab	395	362 (91.6)	0.71 (0.64)	0.0	0.20	0.60	1.03	3.4	
		Placebo	391	352 (90.0)	0.82 (0.69)	0.0	0.20	0.74	1.23	3.7	
	Week 19	Tezepelumab	395	366 (92.7)	0.70 (0.64)	0.0	0.12	0.60	1.03	3.3	
		Placebo	391	354 (90.5)	0.81 (0.69)	0.0	0.20	0.77	1.23	3.6	
	Week 20	Tezepelumab	395	358 (90.6)	0.69 (0.66)	0.0	0.11	0.59	1.00	3.2	
		Placebo	391	353 (90.3)	0.83 (0.69)	0.0	0.20	0.80	1.29	3.8	
	Week 21	Tezepelumab	395	360 (91.1)	0.70 (0.67)	0.0	0.09	0.60	1.04	3.3	
		Placebo	391	350 (89.5)	0.80 (0.69)	0.0	0.20	0.76	1.24	4.0	
	Week 22	Tezepelumab	395	360 (91.1)	0.71 (0.66)	0.0	0.10	0.60	1.09	3.3	
		Placebo	391	343 (87.7)	0.81 (0.68)	0.0	0.20	0.77	1.23	3.8	
	Week 23	Tezepelumab	395	355 (89.9)	0.69 (0.66)	0.0	0.07	0.60	1.09	3.4	
		Placebo	391	335 (85.7)	0.80 (0.69)	0.0	0.20	0.80	1.20	3.8	
	Week 24	Tezepelumab	395	354 (89.6)	0.69 (0.66)	0.0	0.10	0.60	1.06	3.2	
		Placebo	391	338 (86.4)	0.78 (0.69)	0.0	0.20	0.69	1.20	3.8	
	Week 25	Tezepelumab	395	358 (90.6)	0.70 (0.65)	0.0	0.11	0.60	1.00	3.1	
		Placebo	391	336 (85.9)	0.76 (0.67)	0.0	0.20	0.71	1.16	3.9	
	Week 26	Tezepelumab	395	352 (89.1)	0.70 (0.65)	0.0	0.15	0.60	1.05	3.3	
		Placebo	391	333 (85.2)	0.76 (0.67)	0.0	0.17	0.71	1.11	3.8	
	Week 27	Tezepelumab	395	358 (90.6)	0.69 (0.67)	0.0	0.10	0.57	1.06	3.3	
		Placebo	391	330 (84.4)	0.78 (0.69)	0.0	0.17	0.66	1.20	3.7	
	Week 28	Tezepelumab	395	356 (90.1)	0.68 (0.67)	0.0	0.04	0.57	1.05	3.4	
		Placebo	391	341 (87.2)	0.78 (0.69)	0.0	0.20	0.66	1.20	3.6	
	Week 29	Tezepelumab	395	352 (89.1)	0.66 (0.65)	0.0	0.11	0.51	1.00	3.4	
		Placebo	391	340 (87.0)	0.77 (0.69)	0.0	0.20	0.66	1.17	3.6	
	Week 30	Tezepelumab	395	352 (89.1)	0.68 (0.65)	0.0	0.13	0.54	1.03	3.8	
		Placebo	391	332 (84.9)	0.79 (0.69)	0.0	0.17	0.70	1.20	3.6	
	Week 31	Tezepelumab	395	354 (89.6)	0.69 (0.67)	0.0	0.13	0.55	1.08	4.0	
		Placebo	391	326 (83.4)	0.78 (0.66)	0.0	0.20	0.69	1.23	3.6	
	Week 32	Tezepelumab	395	356 (90.1)	0.68 (0.65)	0.0	0.14	0.56	1.00	3.8	
		Placebo	391	340 (87.0)	0.78 (0.66)	0.0	0.23	0.63	1.17	3.7	
	Week 33	Tezepelumab	395	352 (89.1)	0.66 (0.66)	0.0	0.09	0.50	1.00	3.4	
		Placebo	391	331 (84.7)	0.77 (0.67)	0.0	0.20	0.70	1.29	3.6	
	Week 34	Tezepelumab	395	354 (89.6)	0.66 (0.66)	0.0	0.03	0.53	1.03	3.4	
		Placebo	391	334 (85.4)	0.77 (0.67)	0.0	0.17	0.68	1.20	3.6	
	Week 35	Tezepelumab	395	349 (88.4)	0.68 (0.67)	0.0	0.07	0.54	1.03	3.5	
		Placebo	391	325 (83.1)	0.76 (0.67)	0.0	0.17	0.66	1.17	3.7	

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WNC\_ILMH0: Course of ASD weekly night-time score  
 DITTLL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly night-time score	Week 36	Tezepelumab	395	350 (88.6)	0.69 (0.68)	0.0	0.07	0.57	1.08	3.4	
		Placebo	391	329 (84.1)	0.77 (0.64)	0.0	0.20	0.71	1.14	3.6	
	Week 37	Tezepelumab	395	345 (87.3)	0.66 (0.68)	0.0	0.06	0.53	1.03	3.5	
		Placebo	391	331 (84.7)	0.75 (0.65)	0.0	0.20	0.67	1.14	3.6	
	Week 38	Tezepelumab	395	343 (86.8)	0.68 (0.69)	0.0	0.06	0.49	1.13	3.4	
		Placebo	391	329 (84.1)	0.75 (0.65)	0.0	0.20	0.71	1.11	3.7	
	Week 39	Tezepelumab	395	349 (88.4)	0.69 (0.72)	0.0	0.06	0.49	1.06	4.0	
		Placebo	391	331 (84.7)	0.75 (0.66)	0.0	0.16	0.68	1.16	3.6	
	Week 40	Tezepelumab	395	351 (88.9)	0.67 (0.68)	0.0	0.06	0.49	1.00	3.4	
		Placebo	391	329 (84.1)	0.78 (0.68)	0.0	0.20	0.69	1.20	3.6	
	Week 41	Tezepelumab	395	351 (88.9)	0.65 (0.67)	0.0	0.04	0.43	1.00	3.2	
		Placebo	391	328 (83.9)	0.77 (0.67)	0.0	0.17	0.70	1.25	3.7	
	Week 42	Tezepelumab	395	344 (87.1)	0.65 (0.68)	0.0	0.05	0.40	1.03	3.2	
		Placebo	391	328 (83.9)	0.78 (0.71)	0.0	0.17	0.71	1.19	3.7	
	Week 43	Tezepelumab	395	343 (86.8)	0.66 (0.69)	0.0	0.03	0.46	1.03	3.2	
		Placebo	391	325 (83.1)	0.77 (0.68)	0.0	0.16	0.66	1.20	3.7	
	Week 44	Tezepelumab	395	340 (86.1)	0.65 (0.68)	0.0	0.03	0.43	1.04	3.2	
		Placebo	391	323 (82.6)	0.77 (0.67)	0.0	0.20	0.69	1.20	3.7	
	Week 45	Tezepelumab	395	348 (88.1)	0.65 (0.68)	0.0	0.05	0.43	1.03	3.3	
		Placebo	391	327 (83.6)	0.75 (0.67)	0.0	0.20	0.65	1.17	3.6	
	Week 46	Tezepelumab	395	343 (86.8)	0.66 (0.69)	0.0	0.03	0.43	1.09	3.2	
		Placebo	391	320 (81.8)	0.74 (0.65)	0.0	0.19	0.65	1.12	3.7	
	Week 47	Tezepelumab	395	334 (84.6)	0.65 (0.68)	0.0	0.03	0.40	1.03	3.2	
		Placebo	391	319 (81.6)	0.73 (0.64)	0.0	0.20	0.60	1.07	3.6	
	Week 48	Tezepelumab	395	348 (88.1)	0.66 (0.68)	0.0	0.06	0.43	1.01	3.2	
		Placebo	391	323 (82.6)	0.74 (0.66)	0.0	0.17	0.68	1.14	3.7	
	Week 49	Tezepelumab	395	351 (88.9)	0.64 (0.67)	0.0	0.03	0.43	1.00	3.1	
		Placebo	391	320 (81.8)	0.74 (0.64)	0.0	0.16	0.67	1.10	3.6	
	Week 50	Tezepelumab	395	342 (86.6)	0.65 (0.67)	0.0	0.03	0.44	1.03	3.0	
		Placebo	391	314 (80.3)	0.74 (0.66)	0.0	0.14	0.65	1.11	3.6	
	Week 51	Tezepelumab	395	331 (83.8)	0.66 (0.69)	0.0	0.00	0.43	1.00	3.0	
		Placebo	391	314 (80.3)	0.75 (0.67)	0.0	0.17	0.69	1.09	3.6	
	Week 52	Tezepelumab	395	309 (78.2)	0.64 (0.68)	0.0	0.00	0.43	1.00	3.0	
		Placebo	391	286 (73.1)	0.74 (0.67)	0.0	0.14	0.61	1.12	3.6	

Note: DITTLL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WNC\_ILMH0: Course of ASD weekly night-time score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly night-time score	Week 1	Tezepelumab	395	391 (99.0)	-0.22 (0.37)	-2.5	-0.40	-0.14	0.00	1.1	-0.23 [-0.37, -0.09]
		Placebo	391	385 (98.5)	-0.14 (0.37)	-2.1	-0.30	-0.09	0.06	1.1	
	Week 2	Tezepelumab	395	387 (98.0)	-0.31 (0.48)	-2.8	-0.54	-0.20	0.00	0.9	-0.26 [-0.40, -0.12]
		Placebo	391	387 (99.0)	-0.19 (0.49)	-2.3	-0.38	-0.11	0.05	1.3	
	Week 3	Tezepelumab	395	387 (98.0)	-0.37 (0.53)	-3.1	-0.60	-0.23	-0.03	0.9	-0.16 [-0.30, -0.02]
		Placebo	391	385 (98.5)	-0.28 (0.55)	-2.4	-0.53	-0.20	0.00	2.0	
	Week 4	Tezepelumab	395	387 (98.0)	-0.41 (0.56)	-3.2	-0.66	-0.26	0.00	0.7	-0.18 [-0.32, -0.04]
		Placebo	391	379 (96.9)	-0.31 (0.54)	-2.5	-0.60	-0.20	0.03	1.4	
	Week 5	Tezepelumab	395	382 (96.7)	-0.48 (0.58)	-3.2	-0.79	-0.36	-0.05	0.8	-0.20 [-0.35, -0.06]
		Placebo	391	377 (96.4)	-0.36 (0.55)	-2.7	-0.67	-0.29	0.00	1.4	
	Week 6	Tezepelumab	395	386 (97.7)	-0.51 (0.60)	-3.3	-0.81	-0.40	-0.09	0.8	-0.25 [-0.39, -0.10]
		Placebo	391	379 (96.9)	-0.37 (0.59)	-3.0	-0.66	-0.27	0.00	1.5	
	Week 7	Tezepelumab	395	378 (95.7)	-0.51 (0.63)	-3.2	-0.81	-0.39	-0.09	1.1	-0.21 [-0.35, -0.06]
		Placebo	391	378 (96.7)	-0.39 (0.60)	-3.1	-0.69	-0.28	0.00	1.3	
	Week 8	Tezepelumab	395	378 (95.7)	-0.54 (0.63)	-3.1	-0.89	-0.40	-0.09	1.2	-0.23 [-0.38, -0.09]
		Placebo	391	377 (96.4)	-0.40 (0.59)	-3.1	-0.74	-0.30	-0.03	1.9	
	Week 9	Tezepelumab	395	385 (97.5)	-0.57 (0.64)	-3.3	-0.91	-0.44	-0.09	0.9	-0.21 [-0.35, -0.07]
		Placebo	391	374 (95.7)	-0.44 (0.60)	-3.1	-0.77	-0.37	-0.09	1.8	
	Week 10	Tezepelumab	395	379 (95.9)	-0.57 (0.64)	-3.2	-0.94	-0.46	-0.11	0.8	-0.22 [-0.36, -0.08]
		Placebo	391	366 (93.6)	-0.43 (0.60)	-3.2	-0.76	-0.32	-0.06	1.3	
	Week 11	Tezepelumab	395	376 (95.2)	-0.56 (0.65)	-3.1	-0.94	-0.43	-0.11	1.0	-0.19 [-0.33, -0.04]
		Placebo	391	373 (95.4)	-0.44 (0.61)	-3.1	-0.77	-0.39	-0.09	1.4	
	Week 12	Tezepelumab	395	373 (94.4)	-0.56 (0.66)	-3.3	-0.91	-0.47	-0.09	0.9	-0.17 [-0.31, -0.03]
		Placebo	391	367 (93.9)	-0.45 (0.61)	-3.3	-0.80	-0.37	-0.06	1.7	
	Week 13	Tezepelumab	395	375 (94.9)	-0.59 (0.65)	-3.1	-0.97	-0.51	-0.11	0.7	-0.19 [-0.34, -0.05]
		Placebo	391	369 (94.4)	-0.47 (0.60)	-3.1	-0.80	-0.35	-0.07	1.3	
	Week 14	Tezepelumab	395	370 (93.7)	-0.62 (0.64)	-3.0	-1.00	-0.49	-0.14	0.8	-0.22 [-0.37, -0.08]
		Placebo	391	368 (94.1)	-0.48 (0.62)	-3.2	-0.80	-0.40	-0.06	1.2	
	Week 15	Tezepelumab	395	367 (92.9)	-0.61 (0.65)	-3.0	-1.00	-0.51	-0.12	0.7	-0.22 [-0.37, -0.07]
		Placebo	391	351 (89.8)	-0.47 (0.63)	-3.2	-0.80	-0.43	-0.06	1.5	
	Week 16	Tezepelumab	395	370 (93.7)	-0.63 (0.66)	-3.0	-1.00	-0.51	-0.14	1.5	-0.25 [-0.39, -0.10]
		Placebo	391	357 (91.3)	-0.47 (0.62)	-3.1	-0.83	-0.40	-0.06	1.2	
	Week 17	Tezepelumab	395	366 (92.7)	-0.62 (0.65)	-3.3	-1.00	-0.56	-0.17	1.0	-0.20 [-0.35, -0.06]
		Placebo	391	352 (90.0)	-0.49 (0.62)	-3.1	-0.86	-0.40	-0.06	1.1	
Week 18	Tezepelumab	395	362 (91.6)	-0.62 (0.66)	-3.2	-1.00	-0.54	-0.14	0.9	-0.23 [-0.38, -0.08]	
	Placebo	391	352 (90.0)	-0.47 (0.64)	-3.0	-0.83	-0.34	-0.07	1.6		

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table NT1WNC\_ILMH0: Course of ASD weekly night-time score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly night-time score	Week 19	Tezepelumab	395	366 (92.7)	-0.64 (0.66)	-3.2	-1.01	-0.57	-0.14	0.9	-0.24 [-0.39, -0.09]
		Placebo	391	354 (90.5)	-0.48 (0.66)	-3.3	-0.82	-0.37	-0.09	1.9	
	Week 20	Tezepelumab	395	358 (90.6)	-0.65 (0.67)	-3.2	-1.06	-0.57	-0.14	0.9	-0.28 [-0.42, -0.13]
		Placebo	391	353 (90.3)	-0.47 (0.66)	-3.1	-0.80	-0.40	-0.08	1.3	
	Week 21	Tezepelumab	395	360 (91.1)	-0.63 (0.67)	-3.2	-1.00	-0.56	-0.16	1.9	-0.22 [-0.36, -0.07]
		Placebo	391	350 (89.5)	-0.49 (0.65)	-3.3	-0.80	-0.40	-0.09	1.5	
	Week 22	Tezepelumab	395	360 (91.1)	-0.62 (0.67)	-3.3	-1.00	-0.52	-0.14	1.1	-0.21 [-0.36, -0.06]
		Placebo	391	343 (87.7)	-0.49 (0.63)	-2.9	-0.78	-0.43	-0.09	1.3	
	Week 23	Tezepelumab	395	355 (89.9)	-0.64 (0.68)	-3.3	-1.00	-0.56	-0.15	1.0	-0.22 [-0.37, -0.07]
		Placebo	391	335 (85.7)	-0.49 (0.64)	-3.1	-0.86	-0.40	-0.10	1.3	
	Week 24	Tezepelumab	395	354 (89.6)	-0.63 (0.68)	-3.3	-1.00	-0.59	-0.17	1.3	-0.21 [-0.36, -0.06]
		Placebo	391	338 (86.4)	-0.49 (0.64)	-3.1	-0.86	-0.43	-0.13	1.6	
	Week 25	Tezepelumab	395	358 (90.6)	-0.63 (0.66)	-3.3	-1.00	-0.60	-0.14	1.2	-0.18 [-0.32, -0.03]
		Placebo	391	336 (85.9)	-0.51 (0.66)	-3.5	-0.86	-0.43	-0.14	1.6	
	Week 26	Tezepelumab	395	352 (89.1)	-0.63 (0.68)	-3.3	-1.00	-0.57	-0.11	1.6	-0.16 [-0.31, -0.01]
		Placebo	391	333 (85.2)	-0.52 (0.65)	-3.1	-0.91	-0.43	-0.11	1.3	
	Week 27	Tezepelumab	395	358 (90.6)	-0.64 (0.67)	-3.2	-1.03	-0.57	-0.13	0.8	-0.22 [-0.37, -0.07]
		Placebo	391	330 (84.4)	-0.50 (0.68)	-3.1	-0.91	-0.43	-0.11	1.8	
	Week 28	Tezepelumab	395	356 (90.1)	-0.64 (0.67)	-3.3	-1.03	-0.57	-0.16	1.0	-0.20 [-0.35, -0.05]
		Placebo	391	341 (87.2)	-0.51 (0.68)	-3.3	-0.89	-0.43	-0.11	2.1	
	Week 29	Tezepelumab	395	352 (89.1)	-0.66 (0.67)	-3.3	-1.09	-0.57	-0.17	0.8	-0.22 [-0.37, -0.07]
		Placebo	391	340 (87.0)	-0.52 (0.68)	-3.1	-0.89	-0.41	-0.10	1.3	
	Week 30	Tezepelumab	395	352 (89.1)	-0.65 (0.66)	-3.3	-1.00	-0.57	-0.17	0.8	-0.22 [-0.37, -0.07]
		Placebo	391	332 (84.9)	-0.50 (0.71)	-3.1	-0.90	-0.45	-0.08	2.0	
	Week 31	Tezepelumab	395	354 (89.6)	-0.65 (0.68)	-3.3	-1.03	-0.57	-0.17	1.1	-0.22 [-0.37, -0.07]
		Placebo	391	326 (83.4)	-0.50 (0.64)	-2.7	-0.89	-0.44	-0.09	1.2	
	Week 32	Tezepelumab	395	356 (90.1)	-0.64 (0.68)	-3.3	-1.03	-0.57	-0.17	1.5	-0.19 [-0.34, -0.04]
		Placebo	391	340 (87.0)	-0.52 (0.68)	-3.4	-0.89	-0.46	-0.09	1.8	
	Week 33	Tezepelumab	395	352 (89.1)	-0.67 (0.70)	-3.3	-1.06	-0.60	-0.20	1.3	-0.22 [-0.37, -0.07]
		Placebo	391	331 (84.7)	-0.52 (0.69)	-3.4	-0.91	-0.43	-0.11	1.2	
	Week 34	Tezepelumab	395	354 (89.6)	-0.68 (0.68)	-3.3	-1.06	-0.59	-0.20	1.4	-0.23 [-0.38, -0.08]
		Placebo	391	334 (85.4)	-0.52 (0.67)	-3.1	-0.91	-0.43	-0.11	1.1	
	Week 35	Tezepelumab	395	349 (88.4)	-0.66 (0.69)	-3.3	-1.03	-0.57	-0.20	1.4	-0.20 [-0.36, -0.05]
		Placebo	391	325 (83.1)	-0.52 (0.67)	-3.1	-0.93	-0.46	-0.14	1.7	
	Week 36	Tezepelumab	395	350 (88.6)	-0.65 (0.70)	-3.3	-1.06	-0.57	-0.19	1.5	-0.20 [-0.35, -0.05]
		Placebo	391	329 (84.1)	-0.52 (0.67)	-3.4	-0.91	-0.40	-0.11	1.1	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WNC\_ILMH0: Course of ASD weekly night-time score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly night-time score	Week 37	Tezepelumab	395	345 (87.3)	-0.67 (0.70)	-3.3	-1.06	-0.60	-0.17	1.6	-0.20 [-0.35, -0.05]
		Placebo	391	331 (84.7)	-0.53 (0.67)	-3.5	-0.91	-0.43	-0.11	1.1	
	Week 38	Tezepelumab	395	343 (86.8)	-0.66 (0.71)	-3.3	-1.00	-0.60	-0.20	1.7	-0.17 [-0.33, -0.02]
		Placebo	391	329 (84.1)	-0.54 (0.65)	-3.6	-0.94	-0.43	-0.11	1.2	
	Week 39	Tezepelumab	395	349 (88.4)	-0.65 (0.71)	-3.3	-1.03	-0.54	-0.17	1.8	-0.15 [-0.30, -0.00]
		Placebo	391	331 (84.7)	-0.54 (0.69)	-3.5	-0.94	-0.46	-0.10	1.4	
	Week 40	Tezepelumab	395	351 (88.9)	-0.68 (0.69)	-3.3	-1.11	-0.60	-0.14	1.4	-0.25 [-0.40, -0.10]
		Placebo	391	329 (84.1)	-0.51 (0.67)	-3.5	-0.91	-0.43	-0.09	1.7	
	Week 41	Tezepelumab	395	351 (88.9)	-0.68 (0.70)	-3.3	-1.06	-0.60	-0.14	1.4	-0.23 [-0.39, -0.08]
		Placebo	391	328 (83.9)	-0.53 (0.64)	-3.5	-0.91	-0.43	-0.13	1.4	
	Week 42	Tezepelumab	395	344 (87.1)	-0.67 (0.67)	-3.1	-1.06	-0.57	-0.20	1.4	-0.24 [-0.39, -0.09]
		Placebo	391	328 (83.9)	-0.50 (0.67)	-3.5	-0.89	-0.43	-0.11	1.8	
	Week 43	Tezepelumab	395	343 (86.8)	-0.68 (0.69)	-3.3	-1.09	-0.60	-0.17	1.3	-0.24 [-0.39, -0.09]
		Placebo	391	325 (83.1)	-0.52 (0.66)	-3.3	-0.91	-0.43	-0.11	1.3	
	Week 44	Tezepelumab	395	340 (86.1)	-0.69 (0.68)	-3.3	-1.09	-0.63	-0.20	1.4	-0.25 [-0.41, -0.10]
		Placebo	391	323 (82.6)	-0.52 (0.67)	-3.5	-0.90	-0.43	-0.11	1.1	
	Week 45	Tezepelumab	395	348 (88.1)	-0.69 (0.69)	-3.3	-1.08	-0.62	-0.20	1.4	-0.22 [-0.37, -0.07]
		Placebo	391	327 (83.6)	-0.54 (0.68)	-3.5	-0.94	-0.49	-0.07	1.1	
	Week 46	Tezepelumab	395	343 (86.8)	-0.69 (0.70)	-3.3	-1.09	-0.60	-0.20	1.4	-0.20 [-0.35, -0.05]
		Placebo	391	320 (81.8)	-0.55 (0.68)	-3.5	-0.96	-0.46	-0.11	1.1	
	Week 47	Tezepelumab	395	334 (84.6)	-0.70 (0.70)	-3.3	-1.09	-0.60	-0.17	1.3	-0.22 [-0.37, -0.07]
		Placebo	391	319 (81.6)	-0.55 (0.66)	-3.2	-0.91	-0.46	-0.14	1.1	
	Week 48	Tezepelumab	395	348 (88.1)	-0.67 (0.69)	-3.3	-1.09	-0.61	-0.20	1.4	-0.19 [-0.34, -0.04]
		Placebo	391	323 (82.6)	-0.55 (0.67)	-3.4	-0.89	-0.46	-0.17	1.5	
	Week 49	Tezepelumab	395	351 (88.9)	-0.70 (0.70)	-3.3	-1.10	-0.60	-0.20	1.4	-0.21 [-0.36, -0.06]
		Placebo	391	320 (81.8)	-0.55 (0.66)	-3.5	-0.89	-0.46	-0.14	1.1	
	Week 50	Tezepelumab	395	342 (86.6)	-0.67 (0.68)	-3.3	-1.09	-0.60	-0.17	1.3	-0.16 [-0.31, -0.00]
		Placebo	391	314 (80.3)	-0.57 (0.70)	-3.7	-0.94	-0.46	-0.14	1.8	
	Week 51	Tezepelumab	395	331 (83.8)	-0.67 (0.71)	-3.3	-1.06	-0.60	-0.17	1.4	-0.18 [-0.33, -0.02]
		Placebo	391	314 (80.3)	-0.55 (0.70)	-3.7	-0.96	-0.46	-0.11	1.8	
	Week 52	Tezepelumab	395	309 (78.2)	-0.68 (0.73)	-3.3	-1.11	-0.60	-0.17	1.3	-0.16 [-0.32, -0.00]
		Placebo	391	286 (73.1)	-0.57 (0.70)	-3.7	-0.91	-0.47	-0.14	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WNC\_ILMC0: Change from baseline in ASD weekly night-time score - MMRM results  
 DITTTL

Change from baseline in ASD weekly night-time score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 1	Tezepelumab	395	391 (99.0)	-0.20 (0.03)	(-0.26, -0.15)	-0.06 (0.04)	(-0.14, 0.01)	0.104	
	Placebo	391	385 (98.5)	-0.14 (0.03)	(-0.19, -0.08)				
Week 2	Tezepelumab	395	387 (98.0)	-0.30 (0.03)	(-0.35, -0.24)	-0.10 (0.04)	(-0.18, -0.03)	0.009 *	
	Placebo	391	387 (99.0)	-0.19 (0.03)	(-0.25, -0.14)				
Week 3	Tezepelumab	395	387 (98.0)	-0.36 (0.03)	(-0.41, -0.30)	-0.08 (0.04)	(-0.16, -0.00)	0.048 *	
	Placebo	391	385 (98.5)	-0.28 (0.03)	(-0.33, -0.22)				
Week 4	Tezepelumab	395	387 (98.0)	-0.39 (0.03)	(-0.45, -0.34)	-0.08 (0.04)	(-0.16, -0.00)	0.046 *	
	Placebo	391	379 (96.9)	-0.31 (0.03)	(-0.37, -0.26)				
Week 5	Tezepelumab	395	382 (96.7)	-0.46 (0.03)	(-0.52, -0.41)	-0.10 (0.04)	(-0.18, -0.02)	0.011 *	
	Placebo	391	377 (96.4)	-0.36 (0.03)	(-0.42, -0.31)				
Week 6	Tezepelumab	395	386 (97.7)	-0.49 (0.03)	(-0.55, -0.44)	-0.12 (0.04)	(-0.20, -0.04)	0.003 *	
	Placebo	391	379 (96.9)	-0.37 (0.03)	(-0.43, -0.32)				
Week 7	Tezepelumab	395	378 (95.7)	-0.50 (0.03)	(-0.55, -0.44)	-0.11 (0.04)	(-0.19, -0.04)	0.004 *	
	Placebo	391	378 (96.7)	-0.39 (0.03)	(-0.44, -0.33)				
Week 8	Tezepelumab	395	378 (95.7)	-0.53 (0.03)	(-0.58, -0.47)	-0.14 (0.04)	(-0.22, -0.06)	<0.001 *	
	Placebo	391	377 (96.4)	-0.39 (0.03)	(-0.44, -0.33)				
Week 9	Tezepelumab	395	385 (97.5)	-0.56 (0.03)	(-0.61, -0.50)	-0.13 (0.04)	(-0.20, -0.05)	0.002 *	
	Placebo	391	374 (95.7)	-0.43 (0.03)	(-0.49, -0.38)				
Week 10	Tezepelumab	395	379 (95.9)	-0.55 (0.03)	(-0.61, -0.50)	-0.13 (0.04)	(-0.20, -0.05)	0.002 *	
	Placebo	391	366 (93.6)	-0.43 (0.03)	(-0.48, -0.37)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WNC\_ILMC0: Change from baseline in ASD weekly night-time score - MMRM results  
 DITTTL

Change from baseline in ASD weekly night-time score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Time	Treatment	N	n (%)						
Week 11	Tezepelumab	395	376 (95.2)	-0.55 (0.03)	(-0.60, -0.49)	-0.10 (0.04)	(-0.18, -0.02)	0.010	*
	Placebo	391	373 (95.4)	-0.44 (0.03)	(-0.50, -0.39)				
Week 12	Tezepelumab	395	373 (94.4)	-0.55 (0.03)	(-0.60, -0.49)	-0.10 (0.04)	(-0.17, -0.02)	0.017	*
	Placebo	391	367 (93.9)	-0.45 (0.03)	(-0.51, -0.39)				
Week 13	Tezepelumab	395	375 (94.9)	-0.57 (0.03)	(-0.63, -0.52)	-0.11 (0.04)	(-0.19, -0.03)	0.007	*
	Placebo	391	369 (94.4)	-0.46 (0.03)	(-0.52, -0.41)				
Week 14	Tezepelumab	395	370 (93.7)	-0.60 (0.03)	(-0.65, -0.54)	-0.12 (0.04)	(-0.20, -0.04)	0.002	*
	Placebo	391	368 (94.1)	-0.48 (0.03)	(-0.53, -0.42)				
Week 15	Tezepelumab	395	367 (92.9)	-0.59 (0.03)	(-0.65, -0.54)	-0.12 (0.04)	(-0.20, -0.04)	0.002	*
	Placebo	391	351 (89.8)	-0.47 (0.03)	(-0.53, -0.42)				
Week 16	Tezepelumab	395	370 (93.7)	-0.62 (0.03)	(-0.67, -0.56)	-0.15 (0.04)	(-0.23, -0.07)	<0.001	*
	Placebo	391	357 (91.3)	-0.47 (0.03)	(-0.52, -0.41)				
Week 17	Tezepelumab	395	366 (92.7)	-0.62 (0.03)	(-0.68, -0.56)	-0.14 (0.04)	(-0.22, -0.06)	<0.001	*
	Placebo	391	352 (90.0)	-0.48 (0.03)	(-0.54, -0.43)				
Week 18	Tezepelumab	395	362 (91.6)	-0.61 (0.03)	(-0.66, -0.55)	-0.13 (0.04)	(-0.21, -0.06)	<0.001	*
	Placebo	391	352 (90.0)	-0.47 (0.03)	(-0.53, -0.42)				
Week 19	Tezepelumab	395	366 (92.7)	-0.63 (0.03)	(-0.68, -0.57)	-0.14 (0.04)	(-0.22, -0.06)	<0.001	*
	Placebo	391	354 (90.5)	-0.48 (0.03)	(-0.54, -0.43)				
Week 20	Tezepelumab	395	358 (90.6)	-0.63 (0.03)	(-0.69, -0.57)	-0.16 (0.04)	(-0.23, -0.08)	<0.001	*
	Placebo	391	353 (90.3)	-0.47 (0.03)	(-0.53, -0.42)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WNC\_ILMC0: Change from baseline in ASD weekly night-time score - MMRM results  
 DITTTL

Change from baseline in ASD weekly night-time score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 21	Tezepelumab	395	360 (91.1)	-0.63 (0.03)	(-0.68, -0.57)	-0.14 (0.04)	(-0.22, -0.06)	<0.001 *	
	Placebo	391	350 (89.5)	-0.49 (0.03)	(-0.55, -0.44)				
Week 22	Tezepelumab	395	360 (91.1)	-0.62 (0.03)	(-0.68, -0.57)	-0.13 (0.04)	(-0.21, -0.05)	0.002 *	
	Placebo	391	343 (87.7)	-0.50 (0.03)	(-0.55, -0.44)				
Week 23	Tezepelumab	395	355 (89.9)	-0.63 (0.03)	(-0.69, -0.58)	-0.15 (0.04)	(-0.23, -0.07)	<0.001 *	
	Placebo	391	335 (85.7)	-0.48 (0.03)	(-0.54, -0.42)				
Week 24	Tezepelumab	395	354 (89.6)	-0.63 (0.03)	(-0.69, -0.58)	-0.14 (0.04)	(-0.22, -0.06)	<0.001 *	
	Placebo	391	338 (86.4)	-0.50 (0.03)	(-0.55, -0.44)				
Week 25	Tezepelumab	395	358 (90.6)	-0.63 (0.03)	(-0.69, -0.57)	-0.12 (0.04)	(-0.20, -0.04)	0.003 *	
	Placebo	391	336 (85.9)	-0.51 (0.03)	(-0.57, -0.45)				
Week 26	Tezepelumab	395	352 (89.1)	-0.63 (0.03)	(-0.68, -0.57)	-0.12 (0.04)	(-0.20, -0.04)	0.003 *	
	Placebo	391	333 (85.2)	-0.50 (0.03)	(-0.56, -0.45)				
Week 27	Tezepelumab	395	358 (90.6)	-0.64 (0.03)	(-0.70, -0.58)	-0.14 (0.04)	(-0.22, -0.06)	<0.001 *	
	Placebo	391	330 (84.4)	-0.50 (0.03)	(-0.55, -0.44)				
Week 28	Tezepelumab	395	356 (90.1)	-0.65 (0.03)	(-0.70, -0.59)	-0.15 (0.04)	(-0.23, -0.07)	<0.001 *	
	Placebo	391	341 (87.2)	-0.50 (0.03)	(-0.55, -0.44)				
Week 29	Tezepelumab	395	352 (89.1)	-0.65 (0.03)	(-0.71, -0.59)	-0.15 (0.04)	(-0.23, -0.07)	<0.001 *	
	Placebo	391	340 (87.0)	-0.51 (0.03)	(-0.56, -0.45)				
Week 30	Tezepelumab	395	352 (89.1)	-0.64 (0.03)	(-0.70, -0.59)	-0.14 (0.04)	(-0.22, -0.06)	<0.001 *	
	Placebo	391	332 (84.9)	-0.50 (0.03)	(-0.56, -0.45)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WNC\_ILMC0: Change from baseline in ASD weekly night-time score - MMRM results  
 DITTTL

Change from baseline in ASD weekly night-time score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 31	Tezepelumab	395	354 (89.6)	-0.64 (0.03)	(-0.70, -0.59)	-0.13 (0.04)	(-0.21, -0.05)	0.002 *	
	Placebo	391	326 (83.4)	-0.52 (0.03)	(-0.58, -0.46)				
Week 32	Tezepelumab	395	356 (90.1)	-0.64 (0.03)	(-0.70, -0.59)	-0.12 (0.04)	(-0.20, -0.04)	0.003 *	
	Placebo	391	340 (87.0)	-0.52 (0.03)	(-0.58, -0.46)				
Week 33	Tezepelumab	395	352 (89.1)	-0.66 (0.03)	(-0.72, -0.60)	-0.15 (0.04)	(-0.23, -0.06)	<0.001 *	
	Placebo	391	331 (84.7)	-0.52 (0.03)	(-0.57, -0.46)				
Week 34	Tezepelumab	395	354 (89.6)	-0.67 (0.03)	(-0.72, -0.61)	-0.15 (0.04)	(-0.23, -0.07)	<0.001 *	
	Placebo	391	334 (85.4)	-0.52 (0.03)	(-0.58, -0.46)				
Week 35	Tezepelumab	395	349 (88.4)	-0.65 (0.03)	(-0.71, -0.60)	-0.13 (0.04)	(-0.21, -0.05)	0.002 *	
	Placebo	391	325 (83.1)	-0.52 (0.03)	(-0.58, -0.46)				
Week 36	Tezepelumab	395	350 (88.6)	-0.65 (0.03)	(-0.70, -0.59)	-0.13 (0.04)	(-0.21, -0.05)	0.001 *	
	Placebo	391	329 (84.1)	-0.51 (0.03)	(-0.57, -0.46)				
Week 37	Tezepelumab	395	345 (87.3)	-0.65 (0.03)	(-0.71, -0.60)	-0.12 (0.04)	(-0.20, -0.04)	0.003 *	
	Placebo	391	331 (84.7)	-0.53 (0.03)	(-0.59, -0.47)				
Week 38	Tezepelumab	395	343 (86.8)	-0.64 (0.03)	(-0.70, -0.59)	-0.11 (0.04)	(-0.20, -0.03)	0.006 *	
	Placebo	391	329 (84.1)	-0.53 (0.03)	(-0.59, -0.47)				
Week 39	Tezepelumab	395	349 (88.4)	-0.64 (0.03)	(-0.70, -0.59)	-0.10 (0.04)	(-0.18, -0.02)	0.013 *	
	Placebo	391	331 (84.7)	-0.54 (0.03)	(-0.60, -0.48)				
Week 40	Tezepelumab	395	351 (88.9)	-0.66 (0.03)	(-0.71, -0.60)	-0.14 (0.04)	(-0.22, -0.06)	<0.001 *	
	Placebo	391	329 (84.1)	-0.51 (0.03)	(-0.57, -0.45)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WNC\_ILMC0: Change from baseline in ASD weekly night-time score - MMRM results  
 DITTTL

Change from baseline in ASD weekly night-time score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 41	Tezepelumab	395	351 (88.9)	-0.68 (0.03)	(-0.73, -0.62)	-0.14 (0.04)	(-0.23, -0.06)	<0.001 *	
	Placebo	391	328 (83.9)	-0.53 (0.03)	(-0.59, -0.47)				
Week 42	Tezepelumab	395	344 (87.1)	-0.67 (0.03)	(-0.72, -0.61)	-0.15 (0.04)	(-0.23, -0.07)	<0.001 *	
	Placebo	391	328 (83.9)	-0.51 (0.03)	(-0.57, -0.46)				
Week 43	Tezepelumab	395	343 (86.8)	-0.67 (0.03)	(-0.73, -0.62)	-0.14 (0.04)	(-0.22, -0.06)	<0.001 *	
	Placebo	391	325 (83.1)	-0.54 (0.03)	(-0.59, -0.48)				
Week 44	Tezepelumab	395	340 (86.1)	-0.68 (0.03)	(-0.74, -0.62)	-0.15 (0.04)	(-0.24, -0.07)	<0.001 *	
	Placebo	391	323 (82.6)	-0.53 (0.03)	(-0.58, -0.47)				
Week 45	Tezepelumab	395	348 (88.1)	-0.69 (0.03)	(-0.74, -0.63)	-0.14 (0.04)	(-0.23, -0.06)	<0.001 *	
	Placebo	391	327 (83.6)	-0.54 (0.03)	(-0.60, -0.48)				
Week 46	Tezepelumab	395	343 (86.8)	-0.68 (0.03)	(-0.74, -0.63)	-0.14 (0.04)	(-0.22, -0.05)	0.001 *	
	Placebo	391	320 (81.8)	-0.55 (0.03)	(-0.61, -0.49)				
Week 47	Tezepelumab	395	334 (84.6)	-0.67 (0.03)	(-0.73, -0.62)	-0.12 (0.04)	(-0.21, -0.04)	0.003 *	
	Placebo	391	319 (81.6)	-0.55 (0.03)	(-0.61, -0.49)				
Week 48	Tezepelumab	395	348 (88.1)	-0.67 (0.03)	(-0.73, -0.61)	-0.12 (0.04)	(-0.20, -0.04)	0.004 *	
	Placebo	391	323 (82.6)	-0.55 (0.03)	(-0.61, -0.49)				
Week 49	Tezepelumab	395	351 (88.9)	-0.68 (0.03)	(-0.74, -0.62)	-0.13 (0.04)	(-0.21, -0.05)	0.002 *	
	Placebo	391	320 (81.8)	-0.55 (0.03)	(-0.61, -0.49)				
Week 50	Tezepelumab	395	342 (86.6)	-0.68 (0.03)	(-0.74, -0.62)	-0.12 (0.04)	(-0.20, -0.03)	0.005 *	
	Placebo	391	314 (80.3)	-0.56 (0.03)	(-0.62, -0.50)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WNC\_ILMC0: Change from baseline in ASD weekly night-time score - MMRM results  
 DITTTL

Change from baseline in ASD weekly night-time score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 51	Tezepelumab	395	331 (83.8)	-0.67 (0.03)	(-0.73, -0.61)	-0.12 (0.04)	(-0.21, -0.04)	0.003 *	
	Placebo	391	314 (80.3)	-0.55 (0.03)	(-0.61, -0.49)				
Week 52	Tezepelumab	395	309 (78.2)	-0.67 (0.03)	(-0.73, -0.62)	-0.12 (0.04)	(-0.20, -0.04)	0.005 *	
	Placebo	391	286 (73.1)	-0.55 (0.03)	(-0.61, -0.49)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table ST1WNC\_ILMH0: Course of ASD weekly night-time score  
 DITTTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly night-time score	Baseline	Tezepelumab	73	73 (100.0)	1.21 (0.68)	0.0	0.66	1.23	1.63	2.9	
		Placebo	76	76 (100.0)	1.16 (0.75)	0.0	0.67	0.96	1.69	3.7	
	Week 1	Tezepelumab	73	73 (100.0)	1.08 (0.65)	0.0	0.60	1.03	1.60	2.7	
		Placebo	76	76 (100.0)	1.13 (0.65)	0.0	0.68	1.00	1.63	2.8	
	Week 2	Tezepelumab	73	73 (100.0)	1.00 (0.67)	0.0	0.47	0.94	1.44	3.0	
		Placebo	76	75 (98.7)	1.11 (0.69)	0.0	0.63	0.97	1.63	3.4	
	Week 3	Tezepelumab	73	73 (100.0)	0.97 (0.67)	0.0	0.46	0.89	1.43	2.9	
		Placebo	76	75 (98.7)	1.05 (0.60)	0.0	0.71	0.94	1.57	2.4	
	Week 4	Tezepelumab	73	71 (97.3)	0.93 (0.69)	0.0	0.29	0.83	1.46	2.9	
		Placebo	76	76 (100.0)	1.06 (0.64)	0.0	0.70	1.00	1.50	2.5	
	Week 5	Tezepelumab	73	72 (98.6)	0.89 (0.71)	0.0	0.20	0.81	1.56	2.9	
		Placebo	76	75 (98.7)	1.00 (0.62)	0.0	0.60	0.91	1.46	2.4	
	Week 6	Tezepelumab	73	71 (97.3)	0.91 (0.72)	0.0	0.17	0.83	1.60	2.9	
		Placebo	76	73 (96.1)	1.05 (0.64)	0.0	0.63	0.97	1.57	2.4	
	Week 7	Tezepelumab	73	70 (95.9)	0.90 (0.75)	0.0	0.23	0.77	1.60	3.0	
		Placebo	76	76 (100.0)	1.01 (0.63)	0.0	0.57	1.01	1.47	2.3	
	Week 8	Tezepelumab	73	71 (97.3)	0.92 (0.73)	0.0	0.31	0.80	1.60	3.1	
		Placebo	76	76 (100.0)	1.05 (0.65)	0.0	0.55	0.97	1.57	2.4	
	Week 9	Tezepelumab	73	71 (97.3)	0.90 (0.74)	0.0	0.17	0.80	1.60	3.0	
		Placebo	76	73 (96.1)	1.03 (0.68)	0.0	0.60	0.91	1.51	2.8	
	Week 10	Tezepelumab	73	70 (95.9)	0.94 (0.73)	0.0	0.29	0.86	1.60	3.0	
		Placebo	76	74 (97.4)	1.02 (0.64)	0.0	0.60	0.93	1.34	2.5	
	Week 11	Tezepelumab	73	72 (98.6)	0.93 (0.73)	0.0	0.33	0.80	1.60	3.1	
		Placebo	76	75 (98.7)	1.02 (0.68)	0.0	0.60	0.91	1.37	3.0	
	Week 12	Tezepelumab	73	70 (95.9)	0.91 (0.73)	0.0	0.34	0.80	1.60	3.3	
		Placebo	76	75 (98.7)	1.00 (0.61)	0.0	0.60	0.94	1.40	2.5	
	Week 13	Tezepelumab	73	69 (94.5)	0.90 (0.77)	0.0	0.23	0.80	1.60	3.3	
		Placebo	76	74 (97.4)	0.95 (0.65)	0.0	0.49	0.94	1.43	2.5	
	Week 14	Tezepelumab	73	70 (95.9)	0.94 (0.74)	0.0	0.31	0.89	1.60	3.3	
		Placebo	76	75 (98.7)	0.95 (0.64)	0.0	0.40	0.91	1.31	2.3	
	Week 15	Tezepelumab	73	70 (95.9)	0.91 (0.75)	0.0	0.20	0.87	1.60	3.4	
		Placebo	76	72 (94.7)	0.92 (0.63)	0.0	0.53	0.83	1.37	2.5	
	Week 16	Tezepelumab	73	70 (95.9)	0.92 (0.76)	0.0	0.26	0.79	1.60	3.5	
		Placebo	76	74 (97.4)	0.94 (0.61)	0.0	0.52	0.89	1.40	2.4	
	Week 17	Tezepelumab	73	70 (95.9)	0.91 (0.74)	0.0	0.23	0.81	1.60	3.4	
		Placebo	76	74 (97.4)	0.92 (0.63)	0.0	0.51	0.84	1.29	2.4	

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WNC\_ILMH0: Course of ASD weekly night-time score  
 DITTTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly night-time score	Week 18	Tezepelumab	73	69 (94.5)	0.90 (0.77)	0.0	0.26	0.77	1.49	3.4	
		Placebo	76	74 (97.4)	0.93 (0.65)	0.0	0.51	0.84	1.31	2.5	
	Week 19	Tezepelumab	73	70 (95.9)	0.88 (0.76)	0.0	0.20	0.70	1.57	3.1	
		Placebo	76	73 (96.1)	0.94 (0.64)	0.0	0.53	0.83	1.43	2.3	
	Week 20	Tezepelumab	73	70 (95.9)	0.88 (0.75)	0.0	0.20	0.69	1.57	3.1	
		Placebo	76	75 (98.7)	0.97 (0.65)	0.0	0.57	0.91	1.49	2.5	
	Week 21	Tezepelumab	73	69 (94.5)	0.89 (0.76)	0.0	0.20	0.89	1.40	3.4	
		Placebo	76	74 (97.4)	0.97 (0.67)	0.0	0.49	0.89	1.40	2.9	
	Week 22	Tezepelumab	73	70 (95.9)	0.90 (0.76)	0.0	0.20	0.80	1.51	3.1	
		Placebo	76	75 (98.7)	1.04 (0.75)	0.0	0.57	1.00	1.47	3.7	
	Week 23	Tezepelumab	73	70 (95.9)	0.88 (0.80)	0.0	0.13	0.67	1.60	3.3	
		Placebo	76	74 (97.4)	0.99 (0.70)	0.0	0.50	0.99	1.46	3.1	
	Week 24	Tezepelumab	73	70 (95.9)	0.90 (0.79)	0.0	0.13	0.70	1.60	3.3	
		Placebo	76	75 (98.7)	0.98 (0.68)	0.0	0.48	0.89	1.53	2.5	
	Week 25	Tezepelumab	73	68 (93.2)	0.88 (0.82)	0.0	0.11	0.65	1.60	3.5	
		Placebo	76	74 (97.4)	0.97 (0.67)	0.0	0.46	0.90	1.43	2.9	
	Week 26	Tezepelumab	73	69 (94.5)	0.88 (0.79)	0.0	0.14	0.74	1.60	3.4	
		Placebo	76	73 (96.1)	0.96 (0.71)	0.0	0.34	0.94	1.43	3.1	
	Week 27	Tezepelumab	73	69 (94.5)	0.86 (0.81)	0.0	0.11	0.66	1.60	3.4	
		Placebo	76	73 (96.1)	0.95 (0.70)	0.0	0.40	0.80	1.44	2.5	
	Week 28	Tezepelumab	73	67 (91.8)	0.89 (0.80)	0.0	0.16	0.80	1.60	3.2	
		Placebo	76	74 (97.4)	0.96 (0.69)	0.0	0.43	0.85	1.48	2.7	
	Week 29	Tezepelumab	73	66 (90.4)	0.83 (0.79)	0.0	0.14	0.60	1.46	3.1	
		Placebo	76	74 (97.4)	0.96 (0.72)	0.0	0.40	0.89	1.37	2.6	
	Week 30	Tezepelumab	73	68 (93.2)	0.81 (0.80)	0.0	0.07	0.60	1.51	3.2	
		Placebo	76	74 (97.4)	0.94 (0.70)	0.0	0.32	0.87	1.43	2.5	
	Week 31	Tezepelumab	73	67 (91.8)	0.81 (0.82)	0.0	0.03	0.60	1.54	3.4	
		Placebo	76	73 (96.1)	0.95 (0.70)	0.0	0.40	0.89	1.33	2.8	
	Week 32	Tezepelumab	73	67 (91.8)	0.83 (0.83)	0.0	0.03	0.60	1.44	3.3	
		Placebo	76	74 (97.4)	0.93 (0.64)	0.0	0.49	0.95	1.29	2.5	
	Week 33	Tezepelumab	73	68 (93.2)	0.82 (0.77)	0.0	0.06	0.70	1.49	3.2	
		Placebo	76	74 (97.4)	0.89 (0.63)	0.0	0.40	0.83	1.23	2.4	
	Week 34	Tezepelumab	73	68 (93.2)	0.80 (0.78)	0.0	0.10	0.60	1.38	3.3	
		Placebo	76	73 (96.1)	0.91 (0.66)	0.0	0.40	0.80	1.40	2.5	
	Week 35	Tezepelumab	73	66 (90.4)	0.79 (0.76)	0.0	0.11	0.63	1.20	3.2	
		Placebo	76	74 (97.4)	0.89 (0.67)	0.0	0.40	0.80	1.31	2.6	

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WNC\_ILMH0: Course of ASD weekly night-time score  
 DITTLL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly night-time score	Week 36	Tezepelumab	73	69 (94.5)	0.85 (0.81)	0.0	0.11	0.80	1.51	3.3	
		Placebo	76	73 (96.1)	0.88 (0.67)	0.0	0.34	0.83	1.14	2.7	
	Week 37	Tezepelumab	73	68 (93.2)	0.80 (0.80)	0.0	0.10	0.61	1.51	3.4	
		Placebo	76	72 (94.7)	0.91 (0.66)	0.0	0.44	0.81	1.25	2.9	
	Week 38	Tezepelumab	73	67 (91.8)	0.80 (0.81)	0.0	0.03	0.63	1.57	3.4	
		Placebo	76	73 (96.1)	0.95 (0.71)	0.0	0.43	0.83	1.46	3.2	
	Week 39	Tezepelumab	73	66 (90.4)	0.80 (0.80)	0.0	0.00	0.70	1.46	3.5	
		Placebo	76	72 (94.7)	0.90 (0.71)	0.0	0.39	0.81	1.21	3.2	
	Week 40	Tezepelumab	73	66 (90.4)	0.80 (0.82)	0.0	0.03	0.60	1.60	3.5	
		Placebo	76	72 (94.7)	0.92 (0.71)	0.0	0.40	0.81	1.23	3.2	
	Week 41	Tezepelumab	73	64 (87.7)	0.79 (0.82)	0.0	0.00	0.61	1.51	3.4	
		Placebo	76	73 (96.1)	0.87 (0.64)	0.0	0.43	0.80	1.20	2.7	
	Week 42	Tezepelumab	73	65 (89.0)	0.81 (0.78)	0.0	0.03	0.60	1.49	3.5	
		Placebo	76	72 (94.7)	0.87 (0.62)	0.0	0.46	0.83	1.26	2.7	
	Week 43	Tezepelumab	73	64 (87.7)	0.81 (0.80)	0.0	0.03	0.63	1.41	3.5	
		Placebo	76	73 (96.1)	0.91 (0.68)	0.0	0.40	0.83	1.34	2.7	
	Week 44	Tezepelumab	73	65 (89.0)	0.80 (0.81)	0.0	0.06	0.60	1.54	3.2	
		Placebo	76	73 (96.1)	0.90 (0.66)	0.0	0.43	0.80	1.28	2.8	
	Week 45	Tezepelumab	73	64 (87.7)	0.77 (0.81)	0.0	0.01	0.57	1.41	3.3	
		Placebo	76	72 (94.7)	0.87 (0.63)	0.0	0.39	0.82	1.17	2.4	
	Week 46	Tezepelumab	73	65 (89.0)	0.78 (0.79)	0.0	0.03	0.60	1.49	3.0	
		Placebo	76	71 (93.4)	0.85 (0.66)	0.0	0.34	0.80	1.27	2.5	
	Week 47	Tezepelumab	73	65 (89.0)	0.79 (0.78)	0.0	0.04	0.60	1.53	3.2	
		Placebo	76	71 (93.4)	0.88 (0.63)	0.0	0.54	0.80	1.20	2.8	
	Week 48	Tezepelumab	73	58 (79.5)	0.83 (0.77)	0.0	0.06	0.69	1.51	3.1	
		Placebo	76	70 (92.1)	0.91 (0.65)	0.0	0.54	0.82	1.24	2.8	

Note: DITTLL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WNC\_ILMH0: Course of ASD weekly night-time score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly night-time score	Week 1	Tezepelumab	73	73 (100.0)	-0.13 (0.35)	-1.3	-0.23	-0.03	0.04	0.8	-0.26 [-0.58, 0.06]
		Placebo	76	76 (100.0)	-0.04 (0.36)	-1.9	-0.13	0.00	0.11	0.7	
	Week 2	Tezepelumab	73	73 (100.0)	-0.21 (0.37)	-1.4	-0.46	-0.09	0.00	0.5	-0.40 [-0.73, -0.08]
		Placebo	76	75 (98.7)	-0.06 (0.40)	-1.5	-0.22	0.00	0.06	1.2	
	Week 3	Tezepelumab	73	73 (100.0)	-0.24 (0.45)	-1.3	-0.46	-0.14	0.00	1.3	-0.28 [-0.60, 0.04]
		Placebo	76	75 (98.7)	-0.11 (0.47)	-2.4	-0.26	-0.03	0.06	1.3	
	Week 4	Tezepelumab	73	71 (97.3)	-0.30 (0.46)	-1.4	-0.57	-0.20	0.00	1.1	-0.42 [-0.75, -0.09]
		Placebo	76	76 (100.0)	-0.10 (0.50)	-2.4	-0.23	0.00	0.11	1.2	
	Week 5	Tezepelumab	73	72 (98.6)	-0.32 (0.45)	-1.5	-0.59	-0.14	0.00	0.7	-0.33 [-0.66, -0.01]
		Placebo	76	75 (98.7)	-0.15 (0.55)	-2.9	-0.31	-0.03	0.09	1.2	
	Week 6	Tezepelumab	73	71 (97.3)	-0.31 (0.50)	-1.5	-0.66	-0.09	0.00	0.7	-0.38 [-0.71, -0.05]
		Placebo	76	73 (96.1)	-0.10 (0.57)	-2.9	-0.29	-0.03	0.17	1.3	
	Week 7	Tezepelumab	73	70 (95.9)	-0.31 (0.51)	-1.5	-0.66	-0.15	0.00	0.9	-0.28 [-0.60, 0.05]
		Placebo	76	76 (100.0)	-0.15 (0.62)	-2.7	-0.31	-0.04	0.13	1.3	
	Week 8	Tezepelumab	73	71 (97.3)	-0.29 (0.55)	-1.5	-0.60	-0.14	0.03	1.1	-0.31 [-0.64, 0.01]
		Placebo	76	76 (100.0)	-0.11 (0.58)	-2.1	-0.23	0.00	0.14	1.1	
	Week 9	Tezepelumab	73	71 (97.3)	-0.31 (0.58)	-1.5	-0.66	-0.21	0.00	1.2	-0.29 [-0.62, 0.04]
		Placebo	76	73 (96.1)	-0.14 (0.61)	-2.5	-0.36	0.00	0.17	0.9	
	Week 10	Tezepelumab	73	70 (95.9)	-0.27 (0.61)	-1.5	-0.69	-0.09	0.03	1.8	-0.21 [-0.54, 0.12]
		Placebo	76	74 (97.4)	-0.13 (0.66)	-2.4	-0.43	-0.03	0.17	2.5	
	Week 11	Tezepelumab	73	72 (98.6)	-0.28 (0.59)	-1.5	-0.66	-0.14	0.00	1.8	-0.22 [-0.54, 0.11]
		Placebo	76	75 (98.7)	-0.14 (0.66)	-2.4	-0.54	-0.04	0.20	2.7	
	Week 12	Tezepelumab	73	70 (95.9)	-0.32 (0.62)	-1.6	-0.69	-0.21	0.00	1.8	-0.25 [-0.58, 0.07]
		Placebo	76	75 (98.7)	-0.16 (0.62)	-2.5	-0.54	-0.05	0.23	1.9	
	Week 13	Tezepelumab	73	69 (94.5)	-0.32 (0.65)	-1.8	-0.74	-0.20	0.00	1.8	-0.16 [-0.49, 0.17]
		Placebo	76	74 (97.4)	-0.21 (0.65)	-2.3	-0.60	-0.03	0.14	1.1	
	Week 14	Tezepelumab	73	70 (95.9)	-0.29 (0.60)	-1.6	-0.77	-0.11	0.00	1.8	-0.13 [-0.46, 0.19]
		Placebo	76	75 (98.7)	-0.21 (0.58)	-2.4	-0.51	-0.06	0.06	1.1	
	Week 15	Tezepelumab	73	70 (95.9)	-0.32 (0.60)	-1.6	-0.76	-0.15	0.00	1.8	-0.13 [-0.46, 0.20]
		Placebo	76	72 (94.7)	-0.25 (0.58)	-2.4	-0.53	-0.07	0.07	0.7	
	Week 16	Tezepelumab	73	70 (95.9)	-0.32 (0.62)	-1.6	-0.71	-0.20	0.00	1.6	-0.15 [-0.48, 0.18]
		Placebo	76	74 (97.4)	-0.22 (0.61)	-2.3	-0.60	-0.03	0.14	1.2	
	Week 17	Tezepelumab	73	70 (95.9)	-0.32 (0.56)	-1.5	-0.74	-0.19	0.00	0.8	-0.14 [-0.47, 0.19]
		Placebo	76	74 (97.4)	-0.24 (0.61)	-2.4	-0.66	-0.10	0.11	1.0	
	Week 18	Tezepelumab	73	69 (94.5)	-0.31 (0.59)	-1.5	-0.74	-0.17	0.00	1.6	-0.13 [-0.46, 0.20]
		Placebo	76	74 (97.4)	-0.24 (0.61)	-2.3	-0.69	-0.04	0.19	0.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WNC\_ILMH0: Course of ASD weekly night-time score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly night-time score	Week 19	Tezepelumab	73	70 (95.9)	-0.34 (0.62)	-1.5	-0.82	-0.26	0.00	1.6	-0.20 [-0.53, 0.13]
		Placebo	76	73 (96.1)	-0.23 (0.56)	-2.0	-0.54	-0.09	0.06	0.7	
	Week 20	Tezepelumab	73	70 (95.9)	-0.35 (0.61)	-1.5	-0.83	-0.27	0.00	1.2	-0.28 [-0.60, 0.05]
		Placebo	76	75 (98.7)	-0.19 (0.56)	-1.9	-0.54	0.00	0.17	0.9	
	Week 21	Tezepelumab	73	69 (94.5)	-0.34 (0.63)	-1.5	-0.82	-0.20	0.00	1.5	-0.23 [-0.56, 0.10]
		Placebo	76	74 (97.4)	-0.20 (0.63)	-2.2	-0.58	-0.04	0.20	0.8	
	Week 22	Tezepelumab	73	70 (95.9)	-0.33 (0.57)	-1.6	-0.71	-0.16	0.00	0.9	-0.33 [-0.66, -0.00]
		Placebo	76	75 (98.7)	-0.12 (0.67)	-1.9	-0.54	-0.03	0.20	1.7	
	Week 23	Tezepelumab	73	70 (95.9)	-0.35 (0.62)	-2.4	-0.74	-0.20	0.00	1.2	-0.29 [-0.62, 0.04]
		Placebo	76	74 (97.4)	-0.17 (0.61)	-2.0	-0.52	-0.06	0.20	0.9	
	Week 24	Tezepelumab	73	70 (95.9)	-0.33 (0.64)	-2.3	-0.71	-0.14	0.00	1.3	-0.24 [-0.56, 0.09]
		Placebo	76	75 (98.7)	-0.18 (0.59)	-1.9	-0.43	-0.06	0.20	0.9	
	Week 25	Tezepelumab	73	68 (93.2)	-0.34 (0.71)	-2.4	-0.75	-0.19	0.00	2.2	-0.21 [-0.54, 0.12]
		Placebo	76	74 (97.4)	-0.19 (0.66)	-2.7	-0.51	-0.04	0.20	1.7	
	Week 26	Tezepelumab	73	69 (94.5)	-0.35 (0.67)	-2.4	-0.71	-0.20	0.00	1.5	-0.23 [-0.56, 0.10]
		Placebo	76	73 (96.1)	-0.19 (0.74)	-2.5	-0.51	-0.11	0.17	3.1	
	Week 27	Tezepelumab	73	69 (94.5)	-0.35 (0.70)	-2.4	-0.71	-0.23	0.00	1.7	-0.24 [-0.57, 0.09]
		Placebo	76	73 (96.1)	-0.19 (0.62)	-2.2	-0.46	-0.08	0.07	1.3	
	Week 28	Tezepelumab	73	67 (91.8)	-0.32 (0.70)	-2.4	-0.71	-0.17	0.00	1.6	-0.21 [-0.54, 0.13]
		Placebo	76	74 (97.4)	-0.19 (0.59)	-2.0	-0.42	-0.09	0.11	1.0	
	Week 29	Tezepelumab	73	66 (90.4)	-0.37 (0.70)	-2.4	-0.83	-0.24	0.00	1.8	-0.28 [-0.62, 0.05]
		Placebo	76	74 (97.4)	-0.18 (0.62)	-2.3	-0.46	-0.05	0.20	0.9	
	Week 30	Tezepelumab	73	68 (93.2)	-0.39 (0.73)	-2.4	-0.86	-0.25	0.00	1.8	-0.28 [-0.61, 0.05]
		Placebo	76	74 (97.4)	-0.20 (0.58)	-2.1	-0.54	-0.11	0.17	1.0	
	Week 31	Tezepelumab	73	67 (91.8)	-0.39 (0.74)	-2.3	-0.89	-0.34	0.00	2.1	-0.29 [-0.62, 0.05]
		Placebo	76	73 (96.1)	-0.20 (0.61)	-2.5	-0.54	-0.11	0.11	1.1	
	Week 32	Tezepelumab	73	67 (91.8)	-0.39 (0.72)	-2.4	-0.80	-0.29	0.00	2.1	-0.26 [-0.59, 0.08]
		Placebo	76	74 (97.4)	-0.22 (0.58)	-2.1	-0.54	-0.12	0.06	1.0	
	Week 33	Tezepelumab	73	68 (93.2)	-0.39 (0.68)	-2.4	-0.79	-0.30	0.00	1.9	-0.22 [-0.55, 0.11]
		Placebo	76	74 (97.4)	-0.25 (0.60)	-2.6	-0.60	-0.11	0.06	1.1	
	Week 34	Tezepelumab	73	68 (93.2)	-0.41 (0.69)	-2.4	-0.83	-0.34	0.00	2.0	-0.27 [-0.60, 0.07]
		Placebo	76	73 (96.1)	-0.25 (0.53)	-2.0	-0.57	-0.14	0.06	0.9	
	Week 35	Tezepelumab	73	66 (90.4)	-0.41 (0.69)	-2.4	-0.74	-0.34	0.00	1.7	-0.26 [-0.60, 0.07]
		Placebo	76	74 (97.4)	-0.25 (0.56)	-2.0	-0.60	-0.14	0.09	1.0	
	Week 36	Tezepelumab	73	69 (94.5)	-0.36 (0.74)	-2.4	-0.83	-0.31	0.00	1.8	-0.14 [-0.47, 0.19]
		Placebo	76	73 (96.1)	-0.27 (0.57)	-2.0	-0.66	-0.14	0.06	1.1	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WNC\_ILMH0: Course of ASD weekly night-time score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly night-time score	Week 37	Tezepelumab	73	68 (93.2)	-0.40 (0.73)	-2.4	-0.83	-0.34	0.00	1.6	-0.22 [-0.55, 0.11]
		Placebo	76	72 (94.7)	-0.25 (0.60)	-2.1	-0.60	-0.14	0.05	1.0	
	Week 38	Tezepelumab	73	67 (91.8)	-0.40 (0.72)	-2.4	-0.83	-0.34	0.00	1.7	-0.31 [-0.64, 0.02]
		Placebo	76	73 (96.1)	-0.19 (0.64)	-2.3	-0.54	-0.12	0.06	1.4	
	Week 39	Tezepelumab	73	66 (90.4)	-0.40 (0.72)	-2.4	-0.76	-0.30	0.00	1.9	-0.30 [-0.63, 0.04]
		Placebo	76	72 (94.7)	-0.21 (0.58)	-2.0	-0.60	-0.11	0.06	1.3	
	Week 40	Tezepelumab	73	66 (90.4)	-0.40 (0.72)	-2.3	-0.82	-0.29	0.00	1.9	-0.25 [-0.59, 0.08]
		Placebo	76	72 (94.7)	-0.24 (0.60)	-2.0	-0.60	-0.06	0.06	1.4	
	Week 41	Tezepelumab	73	64 (87.7)	-0.42 (0.74)	-2.3	-0.84	-0.36	0.00	1.9	-0.20 [-0.54, 0.13]
		Placebo	76	73 (96.1)	-0.28 (0.59)	-2.4	-0.54	-0.17	0.08	0.8	
	Week 42	Tezepelumab	73	65 (89.0)	-0.40 (0.70)	-2.1	-0.83	-0.29	0.00	1.5	-0.17 [-0.51, 0.16]
		Placebo	76	72 (94.7)	-0.29 (0.59)	-2.3	-0.60	-0.21	0.09	0.8	
	Week 43	Tezepelumab	73	64 (87.7)	-0.39 (0.75)	-2.2	-0.84	-0.33	0.00	1.6	-0.22 [-0.56, 0.11]
		Placebo	76	73 (96.1)	-0.23 (0.64)	-2.4	-0.61	-0.14	0.20	1.0	
	Week 44	Tezepelumab	73	65 (89.0)	-0.40 (0.71)	-2.1	-0.83	-0.31	0.00	1.6	-0.23 [-0.57, 0.10]
		Placebo	76	73 (96.1)	-0.25 (0.60)	-2.2	-0.62	-0.10	0.06	0.8	
	Week 45	Tezepelumab	73	64 (87.7)	-0.43 (0.73)	-2.1	-0.83	-0.36	0.00	1.6	-0.21 [-0.55, 0.12]
		Placebo	76	72 (94.7)	-0.28 (0.63)	-2.8	-0.60	-0.10	0.04	1.0	
	Week 46	Tezepelumab	73	65 (89.0)	-0.43 (0.72)	-2.4	-0.79	-0.29	0.00	1.6	-0.21 [-0.54, 0.13]
		Placebo	76	71 (93.4)	-0.29 (0.60)	-2.4	-0.60	-0.19	0.06	1.0	
	Week 47	Tezepelumab	73	65 (89.0)	-0.40 (0.72)	-2.2	-0.83	-0.29	0.00	1.4	-0.18 [-0.52, 0.16]
		Placebo	76	71 (93.4)	-0.29 (0.59)	-2.3	-0.60	-0.11	0.03	0.8	
	Week 48	Tezepelumab	73	58 (79.5)	-0.37 (0.73)	-2.3	-0.83	-0.26	0.00	1.4	-0.16 [-0.51, 0.18]
		Placebo	76	70 (92.1)	-0.26 (0.59)	-2.1	-0.65	-0.07	0.09	0.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WNC\_ILMC0: Change from baseline in ASD weekly night-time score - MMRM results  
 DITTTL

Change from baseline in ASD weekly night-time score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 1	Tezepelumab	73	73 (100.0)	-0.12 (0.06)	(-0.25, 0.00)	-0.08 (0.09)	(-0.25, 0.10)	0.395
	Placebo	76	76 (100.0)	-0.04 (0.06)	(-0.17, 0.08)			
Week 2	Tezepelumab	73	73 (100.0)	-0.20 (0.06)	(-0.33, -0.08)	-0.14 (0.09)	(-0.31, 0.04)	0.118
	Placebo	76	75 (98.7)	-0.06 (0.06)	(-0.19, 0.06)			
Week 3	Tezepelumab	73	73 (100.0)	-0.23 (0.06)	(-0.36, -0.11)	-0.11 (0.09)	(-0.29, 0.06)	0.203
	Placebo	76	75 (98.7)	-0.12 (0.06)	(-0.24, 0.00)			
Week 4	Tezepelumab	73	71 (97.3)	-0.28 (0.06)	(-0.40, -0.15)	-0.17 (0.09)	(-0.35, 0.00)	0.053
	Placebo	76	76 (100.0)	-0.11 (0.06)	(-0.23, 0.02)			
Week 5	Tezepelumab	73	72 (98.6)	-0.31 (0.06)	(-0.44, -0.19)	-0.14 (0.09)	(-0.32, 0.03)	0.108
	Placebo	76	75 (98.7)	-0.17 (0.06)	(-0.29, -0.05)			
Week 6	Tezepelumab	73	71 (97.3)	-0.30 (0.06)	(-0.43, -0.18)	-0.17 (0.09)	(-0.35, 0.00)	0.056
	Placebo	76	73 (96.1)	-0.13 (0.06)	(-0.26, -0.01)			
Week 7	Tezepelumab	73	70 (95.9)	-0.30 (0.06)	(-0.43, -0.18)	-0.15 (0.09)	(-0.32, 0.03)	0.105
	Placebo	76	76 (100.0)	-0.16 (0.06)	(-0.28, -0.03)			
Week 8	Tezepelumab	73	71 (97.3)	-0.29 (0.06)	(-0.42, -0.17)	-0.17 (0.09)	(-0.35, 0.01)	0.058
	Placebo	76	76 (100.0)	-0.12 (0.06)	(-0.24, 0.00)			
Week 9	Tezepelumab	73	71 (97.3)	-0.30 (0.06)	(-0.42, -0.17)	-0.15 (0.09)	(-0.33, 0.02)	0.092
	Placebo	76	73 (96.1)	-0.15 (0.06)	(-0.27, -0.02)			
Week 10	Tezepelumab	73	70 (95.9)	-0.26 (0.06)	(-0.39, -0.14)	-0.12 (0.09)	(-0.30, 0.05)	0.175
	Placebo	76	74 (97.4)	-0.14 (0.06)	(-0.26, -0.02)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WNC\_ILMC0: Change from baseline in ASD weekly night-time score - MMRM results  
 DITTTL

Change from baseline in ASD weekly night-time score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 11	Tezepelumab	73	72 (98.6)	-0.27 (0.06)	(-0.39, -0.14)	-0.11 (0.09)	(-0.29, 0.06)	0.212	
	Placebo	76	75 (98.7)	-0.15 (0.06)	(-0.28, -0.03)				
Week 12	Tezepelumab	73	70 (95.9)	-0.32 (0.06)	(-0.45, -0.19)	-0.14 (0.09)	(-0.32, 0.03)	0.112	
	Placebo	76	75 (98.7)	-0.18 (0.06)	(-0.30, -0.05)				
Week 13	Tezepelumab	73	69 (94.5)	-0.31 (0.06)	(-0.44, -0.19)	-0.09 (0.09)	(-0.26, 0.09)	0.329	
	Placebo	76	74 (97.4)	-0.23 (0.06)	(-0.35, -0.10)				
Week 14	Tezepelumab	73	70 (95.9)	-0.29 (0.06)	(-0.42, -0.16)	-0.06 (0.09)	(-0.24, 0.11)	0.476	
	Placebo	76	75 (98.7)	-0.23 (0.06)	(-0.35, -0.10)				
Week 15	Tezepelumab	73	70 (95.9)	-0.31 (0.06)	(-0.43, -0.18)	-0.06 (0.09)	(-0.24, 0.12)	0.505	
	Placebo	76	72 (94.7)	-0.25 (0.06)	(-0.37, -0.12)				
Week 16	Tezepelumab	73	70 (95.9)	-0.30 (0.06)	(-0.42, -0.17)	-0.06 (0.09)	(-0.24, 0.11)	0.483	
	Placebo	76	74 (97.4)	-0.23 (0.06)	(-0.36, -0.11)				
Week 17	Tezepelumab	73	70 (95.9)	-0.32 (0.06)	(-0.45, -0.19)	-0.07 (0.09)	(-0.25, 0.11)	0.435	
	Placebo	76	74 (97.4)	-0.25 (0.06)	(-0.37, -0.13)				
Week 18	Tezepelumab	73	69 (94.5)	-0.33 (0.06)	(-0.45, -0.20)	-0.08 (0.09)	(-0.26, 0.10)	0.373	
	Placebo	76	74 (97.4)	-0.24 (0.06)	(-0.37, -0.12)				
Week 19	Tezepelumab	73	70 (95.9)	-0.34 (0.06)	(-0.47, -0.21)	-0.11 (0.09)	(-0.29, 0.07)	0.221	
	Placebo	76	73 (96.1)	-0.23 (0.06)	(-0.35, -0.11)				
Week 20	Tezepelumab	73	70 (95.9)	-0.35 (0.06)	(-0.47, -0.22)	-0.15 (0.09)	(-0.33, 0.03)	0.101	
	Placebo	76	75 (98.7)	-0.20 (0.06)	(-0.32, -0.08)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table ST1WNC\_ILMC0: Change from baseline in ASD weekly night-time score - MMRM results  
 DITTTL

Change from baseline in ASD weekly night-time score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 21	Tezepelumab	73	69 (94.5)	-0.34 (0.06)	(-0.47, -0.22)	-0.13 (0.09)	(-0.31, 0.05)	0.144
	Placebo	76	74 (97.4)	-0.21 (0.06)	(-0.33, -0.09)			
Week 22	Tezepelumab	73	70 (95.9)	-0.32 (0.06)	(-0.45, -0.20)	-0.19 (0.09)	(-0.37, -0.01)	0.036 *
	Placebo	76	75 (98.7)	-0.13 (0.06)	(-0.26, -0.01)			
Week 23	Tezepelumab	73	70 (95.9)	-0.34 (0.06)	(-0.47, -0.22)	-0.16 (0.09)	(-0.34, 0.01)	0.070
	Placebo	76	74 (97.4)	-0.18 (0.06)	(-0.30, -0.06)			
Week 24	Tezepelumab	73	70 (95.9)	-0.32 (0.06)	(-0.45, -0.19)	-0.13 (0.09)	(-0.31, 0.05)	0.156
	Placebo	76	75 (98.7)	-0.19 (0.06)	(-0.31, -0.07)			
Week 25	Tezepelumab	73	68 (93.2)	-0.32 (0.06)	(-0.45, -0.20)	-0.12 (0.09)	(-0.29, 0.06)	0.198
	Placebo	76	74 (97.4)	-0.21 (0.06)	(-0.33, -0.08)			
Week 26	Tezepelumab	73	69 (94.5)	-0.35 (0.06)	(-0.48, -0.22)	-0.16 (0.09)	(-0.34, 0.02)	0.080
	Placebo	76	73 (96.1)	-0.19 (0.06)	(-0.31, -0.07)			
Week 27	Tezepelumab	73	69 (94.5)	-0.34 (0.07)	(-0.47, -0.21)	-0.13 (0.09)	(-0.31, 0.04)	0.138
	Placebo	76	73 (96.1)	-0.20 (0.06)	(-0.33, -0.08)			
Week 28	Tezepelumab	73	67 (91.8)	-0.32 (0.07)	(-0.45, -0.19)	-0.13 (0.09)	(-0.31, 0.05)	0.157
	Placebo	76	74 (97.4)	-0.19 (0.06)	(-0.32, -0.07)			
Week 29	Tezepelumab	73	66 (90.4)	-0.37 (0.07)	(-0.50, -0.24)	-0.18 (0.09)	(-0.36, -0.00)	0.047 *
	Placebo	76	74 (97.4)	-0.19 (0.06)	(-0.31, -0.06)			
Week 30	Tezepelumab	73	68 (93.2)	-0.37 (0.07)	(-0.50, -0.25)	-0.17 (0.09)	(-0.34, 0.01)	0.069
	Placebo	76	74 (97.4)	-0.21 (0.06)	(-0.33, -0.08)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WNC\_ILMC0: Change from baseline in ASD weekly night-time score - MMRM results  
 DITTTL

Change from baseline in ASD weekly night-time score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 31	Tezepelumab	73	67 (91.8)	-0.38 (0.07)	(-0.51, -0.25)	-0.17 (0.09)	(-0.35, 0.01)	0.058
	Placebo	76	73 (96.1)	-0.21 (0.06)	(-0.33, -0.08)			
Week 32	Tezepelumab	73	67 (91.8)	-0.38 (0.07)	(-0.50, -0.25)	-0.15 (0.09)	(-0.33, 0.03)	0.098
	Placebo	76	74 (97.4)	-0.23 (0.06)	(-0.35, -0.10)			
Week 33	Tezepelumab	73	68 (93.2)	-0.37 (0.07)	(-0.50, -0.24)	-0.11 (0.09)	(-0.29, 0.07)	0.215
	Placebo	76	74 (97.4)	-0.26 (0.06)	(-0.38, -0.13)			
Week 34	Tezepelumab	73	68 (93.2)	-0.39 (0.07)	(-0.52, -0.26)	-0.14 (0.09)	(-0.31, 0.04)	0.137
	Placebo	76	73 (96.1)	-0.25 (0.06)	(-0.38, -0.13)			
Week 35	Tezepelumab	73	66 (90.4)	-0.39 (0.07)	(-0.52, -0.26)	-0.13 (0.09)	(-0.31, 0.05)	0.158
	Placebo	76	74 (97.4)	-0.26 (0.06)	(-0.38, -0.13)			
Week 36	Tezepelumab	73	69 (94.5)	-0.35 (0.07)	(-0.48, -0.22)	-0.08 (0.09)	(-0.26, 0.10)	0.395
	Placebo	76	73 (96.1)	-0.27 (0.06)	(-0.40, -0.15)			
Week 37	Tezepelumab	73	68 (93.2)	-0.38 (0.07)	(-0.50, -0.25)	-0.12 (0.09)	(-0.30, 0.06)	0.195
	Placebo	76	72 (94.7)	-0.26 (0.06)	(-0.38, -0.13)			
Week 38	Tezepelumab	73	67 (91.8)	-0.39 (0.07)	(-0.52, -0.26)	-0.19 (0.09)	(-0.37, -0.01)	0.037 *
	Placebo	76	73 (96.1)	-0.20 (0.06)	(-0.33, -0.08)			
Week 39	Tezepelumab	73	66 (90.4)	-0.37 (0.07)	(-0.50, -0.24)	-0.13 (0.09)	(-0.31, 0.05)	0.148
	Placebo	76	72 (94.7)	-0.24 (0.06)	(-0.36, -0.12)			
Week 40	Tezepelumab	73	66 (90.4)	-0.38 (0.07)	(-0.51, -0.25)	-0.14 (0.09)	(-0.32, 0.04)	0.131
	Placebo	76	72 (94.7)	-0.24 (0.06)	(-0.36, -0.11)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WNC\_ILMC0: Change from baseline in ASD weekly night-time score - MMRM results  
 DITTTL

Change from baseline in ASD weekly night-time score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 41	Tezepelumab	73	64 (87.7)	-0.38 (0.07)	(-0.51, -0.25)	-0.10 (0.09)	(-0.28, 0.08)	0.295
	Placebo	76	73 (96.1)	-0.29 (0.06)	(-0.41, -0.16)			
Week 42	Tezepelumab	73	65 (89.0)	-0.37 (0.07)	(-0.50, -0.24)	-0.08 (0.09)	(-0.26, 0.10)	0.384
	Placebo	76	72 (94.7)	-0.29 (0.06)	(-0.41, -0.16)			
Week 43	Tezepelumab	73	64 (87.7)	-0.36 (0.07)	(-0.49, -0.23)	-0.11 (0.09)	(-0.29, 0.07)	0.215
	Placebo	76	73 (96.1)	-0.24 (0.06)	(-0.37, -0.12)			
Week 44	Tezepelumab	73	65 (89.0)	-0.38 (0.07)	(-0.51, -0.25)	-0.12 (0.09)	(-0.30, 0.06)	0.199
	Placebo	76	73 (96.1)	-0.26 (0.06)	(-0.39, -0.14)			
Week 45	Tezepelumab	73	64 (87.7)	-0.40 (0.07)	(-0.53, -0.27)	-0.10 (0.09)	(-0.28, 0.08)	0.281
	Placebo	76	72 (94.7)	-0.30 (0.06)	(-0.43, -0.18)			
Week 46	Tezepelumab	73	65 (89.0)	-0.41 (0.07)	(-0.54, -0.28)	-0.12 (0.09)	(-0.31, 0.06)	0.177
	Placebo	76	71 (93.4)	-0.29 (0.06)	(-0.41, -0.16)			
Week 47	Tezepelumab	73	65 (89.0)	-0.38 (0.07)	(-0.51, -0.25)	-0.10 (0.09)	(-0.28, 0.08)	0.274
	Placebo	76	71 (93.4)	-0.28 (0.06)	(-0.40, -0.15)			
Week 48	Tezepelumab	73	58 (79.5)	-0.37 (0.07)	(-0.51, -0.24)	-0.13 (0.09)	(-0.31, 0.05)	0.170
	Placebo	76	70 (92.1)	-0.25 (0.06)	(-0.37, -0.12)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WWC\_ILMH0: Course of ASD weekly wheezing score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly wheezing score	Baseline	Tezepelumab	395	395 (100.0)	1.49 (0.81)	0.0	1.00	1.43	2.00	4.0	
		Placebo	391	391 (100.0)	1.46 (0.80)	0.0	1.00	1.43	2.00	4.0	
Week 1		Tezepelumab	395	386 (97.7)	1.25 (0.75)	0.0	0.75	1.14	1.79	3.8	
		Placebo	391	382 (97.7)	1.32 (0.81)	0.0	0.79	1.21	1.93	3.6	
Week 2		Tezepelumab	395	384 (97.2)	1.11 (0.76)	0.0	0.57	1.00	1.50	3.4	
		Placebo	391	379 (96.9)	1.26 (0.81)	0.0	0.75	1.14	1.93	3.7	
Week 3		Tezepelumab	395	379 (95.9)	1.04 (0.75)	0.0	0.50	1.00	1.50	3.1	
		Placebo	391	371 (94.9)	1.16 (0.80)	0.0	0.58	1.00	1.75	4.0	
Week 4		Tezepelumab	395	375 (94.9)	1.00 (0.76)	0.0	0.36	1.00	1.50	3.4	
		Placebo	391	370 (94.6)	1.12 (0.78)	0.0	0.57	1.00	1.67	4.0	
Week 5		Tezepelumab	395	375 (94.9)	0.94 (0.78)	0.0	0.21	0.93	1.36	3.8	
		Placebo	391	360 (92.1)	1.05 (0.79)	0.0	0.36	1.00	1.61	3.6	
Week 6		Tezepelumab	395	368 (93.2)	0.90 (0.77)	0.0	0.14	0.93	1.32	4.0	
		Placebo	391	365 (93.4)	1.05 (0.81)	0.0	0.30	1.00	1.64	4.0	
Week 7		Tezepelumab	395	366 (92.7)	0.89 (0.78)	0.0	0.10	0.93	1.33	4.0	
		Placebo	391	365 (93.4)	1.05 (0.81)	0.0	0.30	1.00	1.57	4.0	
Week 8		Tezepelumab	395	368 (93.2)	0.86 (0.76)	0.0	0.08	0.92	1.33	4.0	
		Placebo	391	356 (91.0)	1.02 (0.79)	0.0	0.29	1.00	1.43	3.9	
Week 9		Tezepelumab	395	370 (93.7)	0.82 (0.74)	0.0	0.07	0.83	1.14	4.0	
		Placebo	391	357 (91.3)	0.98 (0.78)	0.0	0.25	1.00	1.40	4.0	
Week 10		Tezepelumab	395	368 (93.2)	0.83 (0.77)	0.0	0.00	0.91	1.21	4.0	
		Placebo	391	353 (90.3)	0.99 (0.79)	0.0	0.21	1.00	1.50	4.0	
Week 11		Tezepelumab	395	359 (90.9)	0.84 (0.79)	0.0	0.00	0.92	1.21	4.0	
		Placebo	391	351 (89.8)	0.96 (0.81)	0.0	0.13	1.00	1.36	4.0	
Week 12		Tezepelumab	395	360 (91.1)	0.84 (0.78)	0.0	0.04	0.83	1.14	4.0	
		Placebo	391	347 (88.7)	0.95 (0.81)	0.0	0.14	1.00	1.36	4.0	
Week 13		Tezepelumab	395	353 (89.4)	0.80 (0.76)	0.0	0.00	0.86	1.10	3.5	
		Placebo	391	345 (88.2)	0.92 (0.80)	0.0	0.14	1.00	1.25	4.0	
Week 14		Tezepelumab	395	350 (88.6)	0.77 (0.75)	0.0	0.00	0.79	1.13	3.3	
		Placebo	391	343 (87.7)	0.92 (0.80)	0.0	0.10	1.00	1.33	4.0	
Week 15		Tezepelumab	395	348 (88.1)	0.78 (0.77)	0.0	0.00	0.79	1.10	3.6	
		Placebo	391	335 (85.7)	0.91 (0.82)	0.0	0.08	1.00	1.29	4.0	
Week 16		Tezepelumab	395	352 (89.1)	0.76 (0.77)	0.0	0.00	0.71	1.04	3.8	
		Placebo	391	333 (85.2)	0.94 (0.83)	0.0	0.10	1.00	1.42	4.0	
Week 17		Tezepelumab	395	347 (87.8)	0.72 (0.76)	0.0	0.00	0.60	1.07	3.1	
		Placebo	391	327 (83.6)	0.90 (0.81)	0.0	0.08	1.00	1.42	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WWC\_ILMH0: Course of ASD weekly wheezing score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly wheezing score	Week 18	Tezepelumab	395	346 (87.6)	0.76 (0.77)	0.0	0.00	0.70	1.07	3.1	
		Placebo	391	322 (82.4)	0.91 (0.85)	0.0	0.07	1.00	1.43	4.0	
	Week 19	Tezepelumab	395	343 (86.8)	0.75 (0.78)	0.0	0.00	0.79	1.07	3.9	
		Placebo	391	332 (84.9)	0.93 (0.86)	0.0	0.07	1.00	1.50	4.0	
	Week 20	Tezepelumab	395	335 (84.8)	0.75 (0.78)	0.0	0.00	0.71	1.00	3.0	
		Placebo	391	324 (82.9)	0.92 (0.85)	0.0	0.00	1.00	1.58	4.0	
	Week 21	Tezepelumab	395	334 (84.6)	0.71 (0.76)	0.0	0.00	0.58	1.00	3.1	
		Placebo	391	319 (81.6)	0.87 (0.84)	0.0	0.00	0.93	1.36	4.0	
	Week 22	Tezepelumab	395	333 (84.3)	0.78 (0.80)	0.0	0.00	0.79	1.07	3.8	
		Placebo	391	312 (79.8)	0.90 (0.85)	0.0	0.07	1.00	1.38	4.0	
	Week 23	Tezepelumab	395	328 (83.0)	0.78 (0.81)	0.0	0.00	0.86	1.09	3.9	
		Placebo	391	310 (79.3)	0.91 (0.85)	0.0	0.00	1.00	1.50	4.0	
	Week 24	Tezepelumab	395	337 (85.3)	0.76 (0.80)	0.0	0.00	0.67	1.00	3.2	
		Placebo	391	310 (79.3)	0.87 (0.84)	0.0	0.00	1.00	1.36	4.0	
	Week 25	Tezepelumab	395	323 (81.8)	0.76 (0.78)	0.0	0.00	0.75	1.07	3.3	
		Placebo	391	308 (78.8)	0.87 (0.84)	0.0	0.07	0.92	1.29	4.0	
	Week 26	Tezepelumab	395	327 (82.8)	0.77 (0.77)	0.0	0.00	0.79	1.07	3.1	
		Placebo	391	303 (77.5)	0.88 (0.85)	0.0	0.00	0.88	1.50	4.0	
	Week 27	Tezepelumab	395	317 (80.3)	0.74 (0.80)	0.0	0.00	0.64	1.07	4.0	
		Placebo	391	313 (80.1)	0.89 (0.86)	0.0	0.07	0.90	1.50	4.0	
	Week 28	Tezepelumab	395	325 (82.3)	0.74 (0.80)	0.0	0.00	0.58	1.00	3.9	
		Placebo	391	314 (80.3)	0.88 (0.85)	0.0	0.00	0.93	1.42	4.0	
	Week 29	Tezepelumab	395	317 (80.3)	0.73 (0.80)	0.0	0.00	0.67	1.00	3.9	
		Placebo	391	312 (79.8)	0.88 (0.86)	0.0	0.00	0.93	1.42	4.0	
	Week 30	Tezepelumab	395	322 (81.5)	0.73 (0.75)	0.0	0.00	0.70	1.00	3.7	
		Placebo	391	303 (77.5)	0.89 (0.84)	0.0	0.00	1.00	1.40	4.0	
	Week 31	Tezepelumab	395	322 (81.5)	0.73 (0.78)	0.0	0.00	0.65	1.00	4.0	
		Placebo	391	308 (78.8)	0.89 (0.83)	0.0	0.00	1.00	1.33	4.0	
	Week 32	Tezepelumab	395	324 (82.0)	0.76 (0.79)	0.0	0.00	0.73	1.07	3.8	
		Placebo	391	308 (78.8)	0.89 (0.82)	0.0	0.00	0.92	1.36	4.0	
	Week 33	Tezepelumab	395	321 (81.3)	0.72 (0.78)	0.0	0.00	0.50	1.07	3.1	
		Placebo	391	304 (77.7)	0.90 (0.83)	0.0	0.00	1.00	1.50	4.0	
	Week 34	Tezepelumab	395	319 (80.8)	0.72 (0.79)	0.0	0.00	0.50	1.07	3.4	
		Placebo	391	303 (77.5)	0.89 (0.84)	0.0	0.00	1.00	1.50	4.0	
	Week 35	Tezepelumab	395	320 (81.0)	0.73 (0.80)	0.0	0.00	0.50	1.04	4.0	
		Placebo	391	295 (75.4)	0.86 (0.84)	0.0	0.00	0.92	1.33	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WWC\_ILMH0: Course of ASD weekly wheezing score  
 DITTTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly wheezing score	Week 36	Tezepelumab	395	317 (80.3)	0.75 (0.79)	0.0	0.00	0.75	1.07	3.9	
		Placebo	391	299 (76.5)	0.88 (0.82)	0.0	0.00	1.00	1.33	4.0	
	Week 37	Tezepelumab	395	320 (81.0)	0.72 (0.79)	0.0	0.00	0.60	1.00	4.0	
		Placebo	391	298 (76.2)	0.86 (0.81)	0.0	0.00	1.00	1.29	4.0	
	Week 38	Tezepelumab	395	317 (80.3)	0.75 (0.82)	0.0	0.00	0.57	1.00	4.0	
		Placebo	391	299 (76.5)	0.83 (0.81)	0.0	0.00	0.92	1.25	4.0	
	Week 39	Tezepelumab	395	325 (82.3)	0.75 (0.84)	0.0	0.00	0.43	1.07	3.9	
		Placebo	391	292 (74.7)	0.84 (0.84)	0.0	0.00	0.90	1.29	4.0	
	Week 40	Tezepelumab	395	321 (81.3)	0.76 (0.82)	0.0	0.00	0.71	1.07	3.9	
		Placebo	391	297 (76.0)	0.89 (0.84)	0.0	0.00	1.00	1.50	4.0	
	Week 41	Tezepelumab	395	324 (82.0)	0.71 (0.81)	0.0	0.00	0.37	1.00	4.0	
		Placebo	391	297 (76.0)	0.88 (0.83)	0.0	0.00	1.00	1.43	4.0	
	Week 42	Tezepelumab	395	316 (80.0)	0.72 (0.81)	0.0	0.00	0.43	1.00	4.0	
		Placebo	391	298 (76.2)	0.88 (0.86)	0.0	0.00	1.00	1.43	4.0	
	Week 43	Tezepelumab	395	319 (80.8)	0.70 (0.81)	0.0	0.00	0.38	1.00	4.0	
		Placebo	391	296 (75.7)	0.86 (0.85)	0.0	0.00	1.00	1.50	4.0	
	Week 44	Tezepelumab	395	316 (80.0)	0.69 (0.80)	0.0	0.00	0.32	1.00	4.0	
		Placebo	391	294 (75.2)	0.87 (0.84)	0.0	0.00	0.93	1.43	4.0	
	Week 45	Tezepelumab	395	319 (80.8)	0.70 (0.79)	0.0	0.00	0.38	1.00	3.9	
		Placebo	391	296 (75.7)	0.86 (0.84)	0.0	0.00	1.00	1.30	4.0	
	Week 46	Tezepelumab	395	314 (79.5)	0.72 (0.81)	0.0	0.00	0.58	1.00	4.0	
		Placebo	391	287 (73.4)	0.84 (0.83)	0.0	0.00	0.83	1.33	4.0	
	Week 47	Tezepelumab	395	302 (76.5)	0.70 (0.81)	0.0	0.00	0.42	1.00	3.8	
		Placebo	391	291 (74.4)	0.83 (0.81)	0.0	0.00	0.88	1.25	4.0	
	Week 48	Tezepelumab	395	323 (81.8)	0.70 (0.81)	0.0	0.00	0.36	1.00	3.6	
		Placebo	391	301 (77.0)	0.85 (0.82)	0.0	0.00	0.93	1.25	4.0	
	Week 49	Tezepelumab	395	315 (79.7)	0.70 (0.81)	0.0	0.00	0.36	1.00	4.0	
		Placebo	391	290 (74.2)	0.85 (0.82)	0.0	0.00	0.93	1.33	4.0	
	Week 50	Tezepelumab	395	312 (79.0)	0.70 (0.81)	0.0	0.00	0.42	1.00	4.0	
		Placebo	391	288 (73.7)	0.86 (0.83)	0.0	0.00	0.91	1.43	4.0	
	Week 51	Tezepelumab	395	307 (77.7)	0.72 (0.81)	0.0	0.00	0.43	1.00	3.9	
		Placebo	391	282 (72.1)	0.86 (0.83)	0.0	0.00	1.00	1.21	4.0	
	Week 52	Tezepelumab	395	276 (69.9)	0.73 (0.83)	0.0	0.00	0.50	1.00	4.0	
		Placebo	391	257 (65.7)	0.84 (0.85)	0.0	0.00	0.90	1.25	4.0	

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WWC\_ILMH0: Course of ASD weekly wheezing score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly wheezing score	Week 1	Tezepelumab	395	386 (97.7)	-0.22 (0.41)	-2.1	-0.42	-0.14	0.00	1.3	-0.20 [-0.34, -0.05]
		Placebo	391	382 (97.7)	-0.15 (0.40)	-2.1	-0.36	-0.08	0.07	1.1	
	Week 2	Tezepelumab	395	384 (97.2)	-0.37 (0.57)	-2.7	-0.71	-0.21	0.00	1.1	-0.32 [-0.46, -0.18]
		Placebo	391	379 (96.9)	-0.20 (0.54)	-3.1	-0.41	-0.08	0.02	1.4	
	Week 3	Tezepelumab	395	379 (95.9)	-0.44 (0.63)	-3.6	-0.86	-0.29	0.00	0.9	-0.24 [-0.38, -0.09]
		Placebo	391	371 (94.9)	-0.30 (0.60)	-2.4	-0.61	-0.17	0.00	1.4	
	Week 4	Tezepelumab	395	375 (94.9)	-0.47 (0.65)	-3.6	-0.86	-0.29	0.00	0.9	-0.21 [-0.36, -0.07]
		Placebo	391	370 (94.6)	-0.34 (0.64)	-2.7	-0.64	-0.21	0.00	2.2	
	Week 5	Tezepelumab	395	375 (94.9)	-0.54 (0.69)	-3.6	-1.00	-0.43	0.00	1.1	-0.18 [-0.33, -0.04]
		Placebo	391	360 (92.1)	-0.42 (0.64)	-2.7	-0.76	-0.30	0.00	1.9	
	Week 6	Tezepelumab	395	368 (93.2)	-0.58 (0.72)	-3.6	-0.96	-0.45	-0.06	1.1	-0.23 [-0.38, -0.09]
		Placebo	391	365 (93.4)	-0.41 (0.69)	-3.1	-0.77	-0.29	0.00	2.0	
	Week 7	Tezepelumab	395	366 (92.7)	-0.59 (0.77)	-3.5	-1.00	-0.43	0.00	1.2	-0.24 [-0.38, -0.09]
		Placebo	391	365 (93.4)	-0.42 (0.69)	-3.2	-0.82	-0.29	0.00	1.9	
	Week 8	Tezepelumab	395	368 (93.2)	-0.61 (0.76)	-3.5	-1.03	-0.50	-0.01	1.4	-0.24 [-0.39, -0.10]
		Placebo	391	356 (91.0)	-0.44 (0.68)	-3.1	-0.86	-0.36	0.00	1.9	
	Week 9	Tezepelumab	395	370 (93.7)	-0.65 (0.75)	-3.6	-1.06	-0.58	-0.07	1.4	-0.25 [-0.39, -0.10]
		Placebo	391	357 (91.3)	-0.48 (0.68)	-3.2	-0.92	-0.40	0.00	1.9	
	Week 10	Tezepelumab	395	368 (93.2)	-0.63 (0.75)	-3.6	-1.04	-0.50	-0.07	1.0	-0.23 [-0.37, -0.08]
		Placebo	391	353 (90.3)	-0.47 (0.70)	-3.2	-0.87	-0.36	0.00	1.8	
	Week 11	Tezepelumab	395	359 (90.9)	-0.64 (0.77)	-3.3	-1.07	-0.57	0.00	1.3	-0.18 [-0.33, -0.04]
		Placebo	391	351 (89.8)	-0.50 (0.72)	-3.2	-0.93	-0.43	0.00	1.9	
	Week 12	Tezepelumab	395	360 (91.1)	-0.62 (0.79)	-3.6	-1.00	-0.50	0.00	1.6	-0.15 [-0.30, -0.00]
		Placebo	391	347 (88.7)	-0.51 (0.70)	-3.2	-0.92	-0.42	0.00	1.9	
	Week 13	Tezepelumab	395	353 (89.4)	-0.65 (0.78)	-3.4	-1.07	-0.56	-0.07	1.9	-0.14 [-0.29, 0.01]
		Placebo	391	345 (88.2)	-0.55 (0.71)	-3.2	-1.00	-0.48	-0.05	1.9	
	Week 14	Tezepelumab	395	350 (88.6)	-0.71 (0.77)	-3.3	-1.14	-0.64	-0.08	1.0	-0.21 [-0.36, -0.06]
		Placebo	391	343 (87.7)	-0.55 (0.73)	-3.2	-1.00	-0.48	0.00	1.9	
	Week 15	Tezepelumab	395	348 (88.1)	-0.67 (0.77)	-3.1	-1.10	-0.57	-0.04	1.9	-0.18 [-0.33, -0.03]
		Placebo	391	335 (85.7)	-0.54 (0.74)	-3.2	-1.00	-0.50	0.00	1.9	
	Week 16	Tezepelumab	395	352 (89.1)	-0.70 (0.80)	-3.5	-1.14	-0.57	-0.07	2.1	-0.22 [-0.37, -0.07]
		Placebo	391	333 (85.2)	-0.53 (0.74)	-3.0	-1.00	-0.43	0.00	1.9	
	Week 17	Tezepelumab	395	347 (87.8)	-0.74 (0.79)	-3.6	-1.14	-0.67	-0.07	1.0	-0.25 [-0.40, -0.10]
		Placebo	391	327 (83.6)	-0.55 (0.74)	-3.2	-1.00	-0.50	0.00	1.9	
	Week 18	Tezepelumab	395	346 (87.6)	-0.70 (0.81)	-3.4	-1.14	-0.58	-0.07	1.0	-0.20 [-0.35, -0.05]
		Placebo	391	322 (82.4)	-0.54 (0.77)	-3.1	-1.00	-0.42	0.00	1.9	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WWC\_ILMH0: Course of ASD weekly wheezing score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly wheezing score	Week 19	Tezepelumab	395	343 (86.8)	-0.71 (0.83)	-3.6	-1.14	-0.64	-0.04	2.3	-0.22 [-0.37, -0.07]
		Placebo	391	332 (84.9)	-0.53 (0.78)	-3.2	-1.00	-0.42	0.00	2.0	
	Week 20	Tezepelumab	395	335 (84.8)	-0.71 (0.82)	-3.6	-1.14	-0.64	-0.07	1.5	-0.21 [-0.36, -0.05]
		Placebo	391	324 (82.9)	-0.54 (0.78)	-3.2	-1.00	-0.47	0.00	1.9	
	Week 21	Tezepelumab	395	334 (84.6)	-0.72 (0.78)	-3.4	-1.14	-0.64	-0.08	1.0	-0.19 [-0.35, -0.04]
		Placebo	391	319 (81.6)	-0.57 (0.77)	-3.2	-1.00	-0.50	0.00	1.9	
	Week 22	Tezepelumab	395	333 (84.3)	-0.67 (0.82)	-3.2	-1.10	-0.64	-0.07	2.2	-0.16 [-0.32, -0.01]
		Placebo	391	312 (79.8)	-0.55 (0.76)	-3.2	-1.00	-0.44	0.00	1.9	
	Week 23	Tezepelumab	395	328 (83.0)	-0.68 (0.82)	-3.3	-1.14	-0.64	-0.06	2.3	-0.16 [-0.31, -0.00]
		Placebo	391	310 (79.3)	-0.56 (0.77)	-3.2	-1.00	-0.44	0.00	1.9	
	Week 24	Tezepelumab	395	337 (85.3)	-0.71 (0.82)	-3.4	-1.15	-0.64	-0.07	1.8	-0.17 [-0.32, -0.01]
		Placebo	391	310 (79.3)	-0.57 (0.77)	-3.2	-1.00	-0.50	-0.02	1.9	
	Week 25	Tezepelumab	395	323 (81.8)	-0.71 (0.78)	-3.5	-1.14	-0.67	-0.07	1.4	-0.16 [-0.31, -0.00]
		Placebo	391	308 (78.8)	-0.58 (0.79)	-3.2	-1.01	-0.50	-0.07	1.9	
	Week 26	Tezepelumab	395	327 (82.8)	-0.69 (0.81)	-3.5	-1.13	-0.64	0.00	1.4	-0.14 [-0.30, 0.01]
		Placebo	391	303 (77.5)	-0.57 (0.78)	-3.1	-1.06	-0.50	0.00	1.9	
	Week 27	Tezepelumab	395	317 (80.3)	-0.73 (0.82)	-3.6	-1.20	-0.64	-0.08	2.3	-0.21 [-0.37, -0.05]
		Placebo	391	313 (80.1)	-0.56 (0.81)	-3.1	-1.03	-0.50	0.00	1.9	
	Week 28	Tezepelumab	395	325 (82.3)	-0.72 (0.81)	-3.6	-1.14	-0.64	-0.07	1.0	-0.18 [-0.34, -0.03]
		Placebo	391	314 (80.3)	-0.57 (0.78)	-3.2	-1.00	-0.51	0.00	1.9	
	Week 29	Tezepelumab	395	317 (80.3)	-0.73 (0.82)	-3.4	-1.25	-0.64	-0.07	1.0	-0.20 [-0.36, -0.05]
		Placebo	391	312 (79.8)	-0.57 (0.81)	-3.2	-1.00	-0.50	0.00	1.9	
	Week 30	Tezepelumab	395	322 (81.5)	-0.73 (0.82)	-3.6	-1.21	-0.64	-0.07	1.0	-0.20 [-0.36, -0.05]
		Placebo	391	303 (77.5)	-0.56 (0.80)	-3.2	-1.07	-0.50	0.00	1.9	
	Week 31	Tezepelumab	395	322 (81.5)	-0.73 (0.83)	-3.6	-1.21	-0.64	-0.07	1.2	-0.22 [-0.37, -0.06]
		Placebo	391	308 (78.8)	-0.56 (0.75)	-3.0	-1.06	-0.50	0.00	2.0	
	Week 32	Tezepelumab	395	324 (82.0)	-0.70 (0.82)	-3.6	-1.14	-0.62	-0.07	1.9	-0.16 [-0.31, -0.00]
		Placebo	391	308 (78.8)	-0.57 (0.80)	-3.0	-1.01	-0.50	0.00	1.9	
	Week 33	Tezepelumab	395	321 (81.3)	-0.74 (0.84)	-3.6	-1.21	-0.71	-0.07	1.8	-0.21 [-0.37, -0.06]
		Placebo	391	304 (77.7)	-0.56 (0.79)	-3.2	-1.00	-0.50	0.00	1.9	
	Week 34	Tezepelumab	395	319 (80.8)	-0.74 (0.83)	-3.6	-1.21	-0.71	-0.07	1.7	-0.22 [-0.38, -0.06]
		Placebo	391	303 (77.5)	-0.57 (0.79)	-3.2	-1.07	-0.50	0.00	1.9	
	Week 35	Tezepelumab	395	320 (81.0)	-0.72 (0.83)	-3.6	-1.18	-0.64	-0.08	1.9	-0.19 [-0.34, -0.03]
		Placebo	391	295 (75.4)	-0.57 (0.80)	-3.2	-1.01	-0.50	0.00	1.9	
	Week 36	Tezepelumab	395	317 (80.3)	-0.70 (0.83)	-3.6	-1.14	-0.64	-0.07	1.8	-0.19 [-0.35, -0.03]
		Placebo	391	299 (76.5)	-0.55 (0.79)	-3.2	-1.00	-0.50	0.00	1.9	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table NT1WWC\_ILMH0: Course of ASD weekly wheezing score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly wheezing score	Week 37	Tezepelumab	395	320 (81.0)	-0.73 (0.86)	-3.6	-1.21	-0.71	-0.07	1.9	-0.20 [-0.36, -0.04]
		Placebo	391	298 (76.2)	-0.56 (0.77)	-3.2	-1.00	-0.50	0.00	1.9	
	Week 38	Tezepelumab	395	317 (80.3)	-0.72 (0.85)	-3.6	-1.14	-0.66	-0.07	1.9	-0.18 [-0.33, -0.02]
		Placebo	391	299 (76.5)	-0.58 (0.76)	-3.2	-1.07	-0.54	0.00	1.9	
	Week 39	Tezepelumab	395	325 (82.3)	-0.73 (0.85)	-3.6	-1.21	-0.71	-0.07	1.9	-0.18 [-0.34, -0.02]
		Placebo	391	292 (74.7)	-0.58 (0.78)	-3.2	-1.07	-0.50	-0.03	1.9	
	Week 40	Tezepelumab	395	321 (81.3)	-0.71 (0.84)	-3.6	-1.14	-0.64	-0.07	1.9	-0.19 [-0.35, -0.03]
		Placebo	391	297 (76.0)	-0.55 (0.77)	-3.0	-1.00	-0.50	0.00	1.9	
	Week 41	Tezepelumab	395	324 (82.0)	-0.76 (0.84)	-3.5	-1.29	-0.71	-0.08	1.9	-0.23 [-0.39, -0.07]
		Placebo	391	297 (76.0)	-0.58 (0.75)	-3.0	-1.00	-0.50	-0.07	1.9	
	Week 42	Tezepelumab	395	316 (80.0)	-0.76 (0.83)	-3.5	-1.21	-0.73	-0.09	1.9	-0.25 [-0.41, -0.09]
		Placebo	391	298 (76.2)	-0.56 (0.76)	-3.0	-1.00	-0.50	-0.02	1.9	
	Week 43	Tezepelumab	395	319 (80.8)	-0.77 (0.84)	-3.6	-1.21	-0.75	-0.08	1.9	-0.23 [-0.39, -0.07]
		Placebo	391	296 (75.7)	-0.58 (0.77)	-3.2	-1.02	-0.57	0.00	1.9	
	Week 44	Tezepelumab	395	316 (80.0)	-0.78 (0.84)	-3.4	-1.23	-0.72	-0.14	1.9	-0.26 [-0.42, -0.10]
		Placebo	391	294 (75.2)	-0.57 (0.78)	-3.2	-1.00	-0.50	0.00	1.9	
	Week 45	Tezepelumab	395	319 (80.8)	-0.78 (0.84)	-3.6	-1.21	-0.75	-0.14	1.8	-0.22 [-0.38, -0.06]
		Placebo	391	296 (75.7)	-0.60 (0.79)	-3.2	-1.07	-0.54	0.00	1.9	
	Week 46	Tezepelumab	395	314 (79.5)	-0.77 (0.86)	-3.6	-1.29	-0.79	-0.08	2.4	-0.23 [-0.39, -0.07]
		Placebo	391	287 (73.4)	-0.58 (0.80)	-3.2	-1.07	-0.50	-0.05	1.9	
	Week 47	Tezepelumab	395	302 (76.5)	-0.77 (0.83)	-3.6	-1.23	-0.76	-0.08	1.7	-0.22 [-0.38, -0.05]
		Placebo	391	291 (74.4)	-0.59 (0.75)	-3.2	-1.07	-0.57	0.00	1.6	
	Week 48	Tezepelumab	395	323 (81.8)	-0.76 (0.84)	-3.6	-1.29	-0.71	-0.08	1.7	-0.21 [-0.37, -0.05]
		Placebo	391	301 (77.0)	-0.59 (0.75)	-3.2	-1.04	-0.55	-0.07	1.6	
	Week 49	Tezepelumab	395	315 (79.7)	-0.76 (0.84)	-3.6	-1.29	-0.75	-0.08	1.9	-0.21 [-0.37, -0.05]
		Placebo	391	290 (74.2)	-0.59 (0.77)	-3.2	-1.00	-0.54	-0.07	1.6	
	Week 50	Tezepelumab	395	312 (79.0)	-0.76 (0.84)	-3.6	-1.29	-0.69	-0.14	1.9	-0.22 [-0.38, -0.06]
		Placebo	391	288 (73.7)	-0.59 (0.76)	-3.2	-1.01	-0.50	0.00	1.6	
	Week 51	Tezepelumab	395	307 (77.7)	-0.74 (0.85)	-3.6	-1.21	-0.67	-0.07	1.9	-0.19 [-0.35, -0.03]
		Placebo	391	282 (72.1)	-0.59 (0.78)	-3.2	-1.07	-0.50	-0.07	1.6	
	Week 52	Tezepelumab	395	276 (69.9)	-0.74 (0.89)	-3.6	-1.29	-0.68	-0.07	1.9	-0.15 [-0.32, 0.02]
		Placebo	391	257 (65.7)	-0.61 (0.77)	-3.5	-1.04	-0.57	-0.07	1.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WWC\_ILMC0: Change from baseline in ASD weekly wheezing score - MMRM results  
 DITTTL

Change from baseline in ASD weekly wheezing score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 1	Tezepelumab	395	386 (97.7)	-0.22 (0.03)	(-0.28, -0.15)	-0.07 (0.05)	(-0.17, 0.02)	0.124	
	Placebo	391	382 (97.7)	-0.14 (0.03)	(-0.21, -0.08)				
Week 2	Tezepelumab	395	384 (97.2)	-0.37 (0.03)	(-0.44, -0.30)	-0.17 (0.05)	(-0.26, -0.08)	<0.001 *	
	Placebo	391	379 (96.9)	-0.20 (0.03)	(-0.26, -0.13)				
Week 3	Tezepelumab	395	379 (95.9)	-0.44 (0.03)	(-0.51, -0.37)	-0.16 (0.05)	(-0.25, -0.06)	0.001 *	
	Placebo	391	371 (94.9)	-0.28 (0.03)	(-0.35, -0.22)				
Week 4	Tezepelumab	395	375 (94.9)	-0.48 (0.03)	(-0.54, -0.41)	-0.15 (0.05)	(-0.24, -0.05)	0.002 *	
	Placebo	391	370 (94.6)	-0.33 (0.03)	(-0.40, -0.26)				
Week 5	Tezepelumab	395	375 (94.9)	-0.53 (0.03)	(-0.60, -0.47)	-0.12 (0.05)	(-0.22, -0.03)	0.010 *	
	Placebo	391	360 (92.1)	-0.41 (0.03)	(-0.48, -0.34)				
Week 6	Tezepelumab	395	368 (93.2)	-0.57 (0.03)	(-0.64, -0.51)	-0.17 (0.05)	(-0.26, -0.07)	<0.001 *	
	Placebo	391	365 (93.4)	-0.41 (0.03)	(-0.47, -0.34)				
Week 7	Tezepelumab	395	366 (92.7)	-0.58 (0.03)	(-0.65, -0.52)	-0.17 (0.05)	(-0.27, -0.08)	<0.001 *	
	Placebo	391	365 (93.4)	-0.41 (0.03)	(-0.47, -0.34)				
Week 8	Tezepelumab	395	368 (93.2)	-0.61 (0.03)	(-0.68, -0.54)	-0.18 (0.05)	(-0.28, -0.09)	<0.001 *	
	Placebo	391	356 (91.0)	-0.43 (0.03)	(-0.49, -0.36)				
Week 9	Tezepelumab	395	370 (93.7)	-0.65 (0.03)	(-0.71, -0.58)	-0.18 (0.05)	(-0.28, -0.09)	<0.001 *	
	Placebo	391	357 (91.3)	-0.46 (0.03)	(-0.53, -0.40)				
Week 10	Tezepelumab	395	368 (93.2)	-0.64 (0.03)	(-0.70, -0.57)	-0.18 (0.05)	(-0.28, -0.09)	<0.001 *	
	Placebo	391	353 (90.3)	-0.46 (0.03)	(-0.52, -0.39)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WWC\_ILMC0: Change from baseline in ASD weekly wheezing score - MMRM results  
 DITTTL

Change from baseline in ASD weekly wheezing score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 11	Tezepelumab	395	359 (90.9)	-0.64 (0.03)	(-0.71, -0.57)	-0.15 (0.05)	(-0.25, -0.06)	0.001 *	
	Placebo	391	351 (89.8)	-0.48 (0.03)	(-0.55, -0.42)				
Week 12	Tezepelumab	395	360 (91.1)	-0.63 (0.03)	(-0.70, -0.56)	-0.14 (0.05)	(-0.24, -0.05)	0.004 *	
	Placebo	391	347 (88.7)	-0.49 (0.03)	(-0.56, -0.42)				
Week 13	Tezepelumab	395	353 (89.4)	-0.66 (0.03)	(-0.73, -0.60)	-0.15 (0.05)	(-0.25, -0.06)	0.002 *	
	Placebo	391	345 (88.2)	-0.51 (0.03)	(-0.58, -0.44)				
Week 14	Tezepelumab	395	350 (88.6)	-0.69 (0.03)	(-0.76, -0.62)	-0.17 (0.05)	(-0.27, -0.08)	<0.001 *	
	Placebo	391	343 (87.7)	-0.52 (0.03)	(-0.59, -0.45)				
Week 15	Tezepelumab	395	348 (88.1)	-0.68 (0.03)	(-0.75, -0.61)	-0.15 (0.05)	(-0.25, -0.06)	0.002 *	
	Placebo	391	335 (85.7)	-0.53 (0.03)	(-0.59, -0.46)				
Week 16	Tezepelumab	395	352 (89.1)	-0.72 (0.03)	(-0.78, -0.65)	-0.21 (0.05)	(-0.31, -0.12)	<0.001 *	
	Placebo	391	333 (85.2)	-0.50 (0.03)	(-0.57, -0.43)				
Week 17	Tezepelumab	395	347 (87.8)	-0.73 (0.03)	(-0.79, -0.66)	-0.20 (0.05)	(-0.30, -0.10)	<0.001 *	
	Placebo	391	327 (83.6)	-0.53 (0.03)	(-0.59, -0.46)				
Week 18	Tezepelumab	395	346 (87.6)	-0.69 (0.03)	(-0.76, -0.63)	-0.18 (0.05)	(-0.28, -0.08)	<0.001 *	
	Placebo	391	322 (82.4)	-0.51 (0.04)	(-0.58, -0.45)				
Week 19	Tezepelumab	395	343 (86.8)	-0.71 (0.03)	(-0.78, -0.64)	-0.20 (0.05)	(-0.29, -0.10)	<0.001 *	
	Placebo	391	332 (84.9)	-0.52 (0.04)	(-0.58, -0.45)				
Week 20	Tezepelumab	395	335 (84.8)	-0.72 (0.03)	(-0.78, -0.65)	-0.19 (0.05)	(-0.29, -0.10)	<0.001 *	
	Placebo	391	324 (82.9)	-0.52 (0.04)	(-0.59, -0.45)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WWC\_ILMC0: Change from baseline in ASD weekly wheezing score - MMRM results  
 DITTTL

Change from baseline in ASD weekly wheezing score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 21	Tezepelumab	395	334 (84.6)	-0.72 (0.03)	(-0.79, -0.66)	-0.19 (0.05)	(-0.28, -0.09)	<0.001 *	
	Placebo	391	319 (81.6)	-0.54 (0.04)	(-0.61, -0.47)				
Week 22	Tezepelumab	395	333 (84.3)	-0.70 (0.03)	(-0.77, -0.64)	-0.17 (0.05)	(-0.27, -0.07)	<0.001 *	
	Placebo	391	312 (79.8)	-0.54 (0.04)	(-0.60, -0.47)				
Week 23	Tezepelumab	395	328 (83.0)	-0.70 (0.03)	(-0.77, -0.63)	-0.19 (0.05)	(-0.28, -0.09)	<0.001 *	
	Placebo	391	310 (79.3)	-0.51 (0.04)	(-0.58, -0.45)				
Week 24	Tezepelumab	395	337 (85.3)	-0.70 (0.03)	(-0.77, -0.63)	-0.17 (0.05)	(-0.27, -0.07)	<0.001 *	
	Placebo	391	310 (79.3)	-0.53 (0.04)	(-0.60, -0.47)				
Week 25	Tezepelumab	395	323 (81.8)	-0.71 (0.04)	(-0.78, -0.64)	-0.16 (0.05)	(-0.26, -0.06)	0.001 *	
	Placebo	391	308 (78.8)	-0.55 (0.04)	(-0.62, -0.48)				
Week 26	Tezepelumab	395	327 (82.8)	-0.69 (0.04)	(-0.76, -0.63)	-0.15 (0.05)	(-0.25, -0.05)	0.003 *	
	Placebo	391	303 (77.5)	-0.55 (0.04)	(-0.62, -0.48)				
Week 27	Tezepelumab	395	317 (80.3)	-0.71 (0.04)	(-0.78, -0.64)	-0.17 (0.05)	(-0.27, -0.07)	<0.001 *	
	Placebo	391	313 (80.1)	-0.54 (0.04)	(-0.61, -0.47)				
Week 28	Tezepelumab	395	325 (82.3)	-0.71 (0.04)	(-0.78, -0.64)	-0.15 (0.05)	(-0.25, -0.05)	0.003 *	
	Placebo	391	314 (80.3)	-0.56 (0.04)	(-0.63, -0.49)				
Week 29	Tezepelumab	395	317 (80.3)	-0.71 (0.04)	(-0.78, -0.64)	-0.16 (0.05)	(-0.26, -0.06)	0.002 *	
	Placebo	391	312 (79.8)	-0.55 (0.04)	(-0.62, -0.48)				
Week 30	Tezepelumab	395	322 (81.5)	-0.71 (0.04)	(-0.78, -0.64)	-0.17 (0.05)	(-0.27, -0.07)	<0.001 *	
	Placebo	391	303 (77.5)	-0.54 (0.04)	(-0.61, -0.47)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WWC\_ILMC0: Change from baseline in ASD weekly wheezing score - MMRM results  
 DITTTL

Change from baseline in ASD weekly wheezing score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 31	Tezepelumab	395	322 (81.5)	-0.71 (0.04)	(-0.78, -0.64)	-0.17 (0.05)	(-0.26, -0.07)	0.001 *	
	Placebo	391	308 (78.8)	-0.55 (0.04)	(-0.62, -0.47)				
Week 32	Tezepelumab	395	324 (82.0)	-0.70 (0.04)	(-0.77, -0.63)	-0.15 (0.05)	(-0.25, -0.06)	0.002 *	
	Placebo	391	308 (78.8)	-0.55 (0.04)	(-0.62, -0.48)				
Week 33	Tezepelumab	395	321 (81.3)	-0.74 (0.04)	(-0.81, -0.67)	-0.19 (0.05)	(-0.29, -0.09)	<0.001 *	
	Placebo	391	304 (77.7)	-0.55 (0.04)	(-0.62, -0.48)				
Week 34	Tezepelumab	395	319 (80.8)	-0.75 (0.04)	(-0.82, -0.68)	-0.21 (0.05)	(-0.31, -0.11)	<0.001 *	
	Placebo	391	303 (77.5)	-0.54 (0.04)	(-0.61, -0.47)				
Week 35	Tezepelumab	395	320 (81.0)	-0.73 (0.04)	(-0.80, -0.66)	-0.18 (0.05)	(-0.28, -0.08)	<0.001 *	
	Placebo	391	295 (75.4)	-0.55 (0.04)	(-0.62, -0.48)				
Week 36	Tezepelumab	395	317 (80.3)	-0.71 (0.04)	(-0.78, -0.64)	-0.18 (0.05)	(-0.28, -0.08)	<0.001 *	
	Placebo	391	299 (76.5)	-0.53 (0.04)	(-0.60, -0.46)				
Week 37	Tezepelumab	395	320 (81.0)	-0.72 (0.04)	(-0.79, -0.65)	-0.17 (0.05)	(-0.27, -0.07)	0.001 *	
	Placebo	391	298 (76.2)	-0.56 (0.04)	(-0.63, -0.48)				
Week 38	Tezepelumab	395	317 (80.3)	-0.72 (0.04)	(-0.79, -0.65)	-0.16 (0.05)	(-0.26, -0.06)	0.002 *	
	Placebo	391	299 (76.5)	-0.56 (0.04)	(-0.63, -0.49)				
Week 39	Tezepelumab	395	325 (82.3)	-0.72 (0.04)	(-0.79, -0.65)	-0.15 (0.05)	(-0.25, -0.05)	0.004 *	
	Placebo	391	292 (74.7)	-0.57 (0.04)	(-0.64, -0.50)				
Week 40	Tezepelumab	395	321 (81.3)	-0.72 (0.04)	(-0.79, -0.65)	-0.18 (0.05)	(-0.28, -0.08)	<0.001 *	
	Placebo	391	297 (76.0)	-0.54 (0.04)	(-0.61, -0.47)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WWC\_ILMC0: Change from baseline in ASD weekly wheezing score - MMRM results  
 DITTTL

Change from baseline in ASD weekly wheezing score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 41	Tezepelumab	395	324 (82.0)	-0.75 (0.04)	(-0.82, -0.68)	-0.19 (0.05)	(-0.30, -0.09)	<0.001 *	
	Placebo	391	297 (76.0)	-0.55 (0.04)	(-0.63, -0.48)				
Week 42	Tezepelumab	395	316 (80.0)	-0.75 (0.04)	(-0.82, -0.68)	-0.20 (0.05)	(-0.30, -0.10)	<0.001 *	
	Placebo	391	298 (76.2)	-0.56 (0.04)	(-0.63, -0.49)				
Week 43	Tezepelumab	395	319 (80.8)	-0.76 (0.04)	(-0.83, -0.69)	-0.19 (0.05)	(-0.29, -0.09)	<0.001 *	
	Placebo	391	296 (75.7)	-0.57 (0.04)	(-0.64, -0.50)				
Week 44	Tezepelumab	395	316 (80.0)	-0.77 (0.04)	(-0.84, -0.70)	-0.21 (0.05)	(-0.31, -0.11)	<0.001 *	
	Placebo	391	294 (75.2)	-0.56 (0.04)	(-0.63, -0.49)				
Week 45	Tezepelumab	395	319 (80.8)	-0.78 (0.04)	(-0.85, -0.71)	-0.20 (0.05)	(-0.30, -0.10)	<0.001 *	
	Placebo	391	296 (75.7)	-0.58 (0.04)	(-0.65, -0.51)				
Week 46	Tezepelumab	395	314 (79.5)	-0.78 (0.04)	(-0.85, -0.71)	-0.20 (0.05)	(-0.30, -0.10)	<0.001 *	
	Placebo	391	287 (73.4)	-0.58 (0.04)	(-0.65, -0.50)				
Week 47	Tezepelumab	395	302 (76.5)	-0.77 (0.04)	(-0.84, -0.70)	-0.18 (0.05)	(-0.29, -0.08)	<0.001 *	
	Placebo	391	291 (74.4)	-0.59 (0.04)	(-0.66, -0.51)				
Week 48	Tezepelumab	395	323 (81.8)	-0.76 (0.04)	(-0.83, -0.69)	-0.17 (0.05)	(-0.27, -0.07)	<0.001 *	
	Placebo	391	301 (77.0)	-0.59 (0.04)	(-0.66, -0.52)				
Week 49	Tezepelumab	395	315 (79.7)	-0.76 (0.04)	(-0.83, -0.69)	-0.17 (0.05)	(-0.27, -0.07)	<0.001 *	
	Placebo	391	290 (74.2)	-0.59 (0.04)	(-0.66, -0.51)				
Week 50	Tezepelumab	395	312 (79.0)	-0.76 (0.04)	(-0.83, -0.69)	-0.18 (0.05)	(-0.28, -0.08)	<0.001 *	
	Placebo	391	288 (73.7)	-0.58 (0.04)	(-0.66, -0.51)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WWC\_ILMC0: Change from baseline in ASD weekly wheezing score - MMRM results  
 DITTTL

Change from baseline in ASD weekly wheezing score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 51	Tezepelumab	395	307 (77.7)	-0.75 (0.04)	(-0.83, -0.68)	-0.17 (0.05)	(-0.28, -0.07)	<0.001 *	
	Placebo	391	282 (72.1)	-0.58 (0.04)	(-0.65, -0.51)				
Week 52	Tezepelumab	395	276 (69.9)	-0.74 (0.04)	(-0.81, -0.67)	-0.15 (0.05)	(-0.25, -0.05)	0.005 *	
	Placebo	391	257 (65.7)	-0.59 (0.04)	(-0.66, -0.51)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WWC\_ILMH0: Course of ASD weekly wheezing score  
DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly wheezing score	Baseline	Tezepelumab	73	73 (100.0)	1.40 (0.84)	0.0	1.00	1.57	2.00	3.1	
		Placebo	76	76 (100.0)	1.33 (0.87)	0.0	0.68	1.14	2.00	3.8	
	Week 1	Tezepelumab	73	71 (97.3)	1.24 (0.79)	0.0	0.75	1.14	2.00	3.1	
		Placebo	76	76 (100.0)	1.26 (0.82)	0.0	0.79	1.07	2.00	3.1	
	Week 2	Tezepelumab	73	73 (100.0)	1.15 (0.80)	0.0	0.64	1.00	1.86	3.3	
		Placebo	76	74 (97.4)	1.25 (0.83)	0.0	0.58	1.07	2.00	3.1	
	Week 3	Tezepelumab	73	73 (100.0)	1.10 (0.79)	0.0	0.50	1.00	1.75	3.2	
		Placebo	76	73 (96.1)	1.25 (0.74)	0.0	0.86	1.07	2.00	2.8	
	Week 4	Tezepelumab	73	71 (97.3)	1.07 (0.81)	0.0	0.36	1.00	1.90	3.1	
		Placebo	76	76 (100.0)	1.24 (0.75)	0.0	0.89	1.08	2.00	3.6	
	Week 5	Tezepelumab	73	71 (97.3)	1.04 (0.86)	0.0	0.14	1.00	2.00	3.3	
		Placebo	76	74 (97.4)	1.17 (0.77)	0.0	0.71	1.00	1.86	3.3	
	Week 6	Tezepelumab	73	69 (94.5)	1.03 (0.87)	0.0	0.14	1.00	2.00	3.4	
		Placebo	76	72 (94.7)	1.23 (0.80)	0.0	0.75	1.07	2.00	3.4	
	Week 7	Tezepelumab	73	69 (94.5)	1.01 (0.90)	0.0	0.14	0.93	2.00	3.5	
		Placebo	76	75 (98.7)	1.21 (0.79)	0.0	0.57	1.08	2.00	2.8	
	Week 8	Tezepelumab	73	68 (93.2)	1.03 (0.88)	0.0	0.17	1.00	2.00	3.3	
		Placebo	76	75 (98.7)	1.21 (0.83)	0.0	0.60	1.08	2.00	3.2	
	Week 9	Tezepelumab	73	69 (94.5)	1.00 (0.87)	0.0	0.07	1.00	1.93	3.4	
		Placebo	76	73 (96.1)	1.19 (0.86)	0.0	0.71	1.00	2.00	3.0	
	Week 10	Tezepelumab	73	70 (95.9)	1.03 (0.89)	0.0	0.07	1.00	2.00	3.9	
		Placebo	76	74 (97.4)	1.17 (0.83)	0.0	0.50	1.00	2.00	3.1	
	Week 11	Tezepelumab	73	70 (95.9)	1.02 (0.88)	0.0	0.13	1.00	1.92	3.6	
		Placebo	76	74 (97.4)	1.16 (0.83)	0.0	0.58	1.00	2.00	3.1	
	Week 12	Tezepelumab	73	70 (95.9)	1.01 (0.88)	0.0	0.08	1.00	2.00	4.0	
		Placebo	76	75 (98.7)	1.18 (0.81)	0.0	0.57	1.00	1.93	3.0	
	Week 13	Tezepelumab	73	68 (93.2)	1.02 (0.90)	0.0	0.11	1.00	2.00	3.6	
		Placebo	76	71 (93.4)	1.10 (0.84)	0.0	0.36	1.00	1.86	3.0	
	Week 14	Tezepelumab	73	69 (94.5)	1.06 (0.87)	0.0	0.14	1.00	2.00	3.6	
		Placebo	76	73 (96.1)	1.09 (0.85)	0.0	0.36	1.00	1.90	3.0	
	Week 15	Tezepelumab	73	69 (94.5)	1.05 (0.87)	0.0	0.08	1.00	2.00	4.0	
		Placebo	76	72 (94.7)	1.06 (0.84)	0.0	0.21	1.00	2.00	3.0	
	Week 16	Tezepelumab	73	69 (94.5)	1.07 (0.87)	0.0	0.29	1.00	2.00	4.0	
		Placebo	76	74 (97.4)	1.05 (0.82)	0.0	0.21	1.00	1.64	3.0	
	Week 17	Tezepelumab	73	68 (93.2)	1.07 (0.89)	0.0	0.21	1.00	2.00	3.7	
		Placebo	76	74 (97.4)	1.02 (0.80)	0.0	0.17	1.00	1.71	3.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table ST1WWC\_ILMH0: Course of ASD weekly wheezing score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly wheezing score	Week 18	Tezepelumab	73	68 (93.2)	1.03 (0.88)	0.0	0.04	1.00	2.00	3.7	
		Placebo	76	72 (94.7)	1.08 (0.82)	0.0	0.32	1.00	1.88	3.0	
	Week 19	Tezepelumab	73	67 (91.8)	1.01 (0.91)	0.0	0.00	1.00	1.86	3.8	
		Placebo	76	72 (94.7)	1.06 (0.84)	0.0	0.12	1.00	1.88	3.2	
	Week 20	Tezepelumab	73	70 (95.9)	1.03 (0.92)	0.0	0.07	1.00	1.93	3.4	
		Placebo	76	72 (94.7)	1.06 (0.81)	0.0	0.30	1.00	2.00	3.0	
	Week 21	Tezepelumab	73	67 (91.8)	1.03 (0.89)	0.0	0.00	1.00	1.86	3.6	
		Placebo	76	73 (96.1)	1.12 (0.84)	0.0	0.36	1.00	2.00	3.4	
	Week 22	Tezepelumab	73	69 (94.5)	1.05 (0.88)	0.0	0.07	1.00	1.83	3.8	
		Placebo	76	74 (97.4)	1.15 (0.92)	0.0	0.36	1.00	2.00	4.0	
	Week 23	Tezepelumab	73	69 (94.5)	1.04 (0.92)	0.0	0.07	1.00	1.86	3.7	
		Placebo	76	74 (97.4)	1.11 (0.91)	0.0	0.08	1.00	2.00	3.7	
	Week 24	Tezepelumab	73	69 (94.5)	1.05 (0.90)	0.0	0.07	1.00	1.93	3.6	
		Placebo	76	75 (98.7)	1.14 (0.86)	0.0	0.36	1.00	2.00	3.4	
	Week 25	Tezepelumab	73	68 (93.2)	1.04 (0.96)	0.0	0.00	1.00	2.00	3.8	
		Placebo	76	74 (97.4)	1.10 (0.84)	0.0	0.29	1.00	1.92	3.0	
	Week 26	Tezepelumab	73	67 (91.8)	1.03 (0.94)	0.0	0.07	1.00	2.00	3.5	
		Placebo	76	73 (96.1)	1.12 (0.90)	0.0	0.21	1.00	1.93	3.2	
	Week 27	Tezepelumab	73	68 (93.2)	1.04 (0.97)	0.0	0.00	1.00	1.96	3.9	
		Placebo	76	71 (93.4)	1.09 (0.88)	0.0	0.07	1.00	1.93	3.0	
	Week 28	Tezepelumab	73	67 (91.8)	1.08 (0.96)	0.0	0.00	1.00	2.00	3.6	
		Placebo	76	71 (93.4)	1.07 (0.87)	0.0	0.17	1.00	2.00	3.1	
	Week 29	Tezepelumab	73	64 (87.7)	0.95 (0.95)	0.0	0.00	1.00	1.86	3.9	
		Placebo	76	74 (97.4)	1.11 (0.87)	0.0	0.21	1.00	2.00	3.0	
	Week 30	Tezepelumab	73	66 (90.4)	1.00 (0.97)	0.0	0.00	1.00	2.00	3.9	
		Placebo	76	74 (97.4)	1.10 (0.85)	0.0	0.08	1.00	1.80	3.0	
	Week 31	Tezepelumab	73	66 (90.4)	0.95 (0.94)	0.0	0.00	0.88	2.00	4.0	
		Placebo	76	72 (94.7)	1.11 (0.87)	0.0	0.09	1.00	1.96	3.0	
	Week 32	Tezepelumab	73	64 (87.7)	1.00 (0.99)	0.0	0.00	1.00	2.00	3.9	
		Placebo	76	73 (96.1)	1.10 (0.82)	0.0	0.14	1.00	1.86	3.0	
	Week 33	Tezepelumab	73	67 (91.8)	1.00 (0.95)	0.0	0.00	1.00	2.00	3.9	
		Placebo	76	72 (94.7)	1.06 (0.81)	0.0	0.21	1.00	1.82	3.1	
	Week 34	Tezepelumab	73	67 (91.8)	0.96 (0.95)	0.0	0.00	1.00	1.90	3.9	
		Placebo	76	71 (93.4)	1.04 (0.87)	0.0	0.00	1.00	1.93	3.0	
	Week 35	Tezepelumab	73	65 (89.0)	0.94 (0.95)	0.0	0.07	1.00	1.43	3.9	
		Placebo	76	74 (97.4)	1.03 (0.89)	0.0	0.07	1.00	1.83	3.1	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WWC\_ILMH0: Course of ASD weekly wheezing score  
 DITTLL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly wheezing score	Week 36	Tezepelumab	73	69 (94.5)	1.01 (1.00)	0.0	0.00	1.00	2.00	4.0	
		Placebo	76	71 (93.4)	1.01 (0.86)	0.0	0.07	1.00	1.71	3.0	
	Week 37	Tezepelumab	73	66 (90.4)	0.94 (0.97)	0.0	0.00	1.00	1.86	3.9	
		Placebo	76	72 (94.7)	1.04 (0.82)	0.0	0.18	1.00	1.65	3.0	
	Week 38	Tezepelumab	73	64 (87.7)	0.92 (0.97)	0.0	0.00	1.00	1.83	4.0	
		Placebo	76	72 (94.7)	1.08 (0.84)	0.0	0.25	1.00	1.89	3.3	
	Week 39	Tezepelumab	73	64 (87.7)	0.92 (0.95)	0.0	0.00	1.00	1.67	4.0	
		Placebo	76	71 (93.4)	1.02 (0.85)	0.0	0.00	1.00	1.67	3.1	
	Week 40	Tezepelumab	73	64 (87.7)	0.95 (0.98)	0.0	0.00	1.00	1.93	4.0	
		Placebo	76	71 (93.4)	1.06 (0.88)	0.0	0.17	1.00	1.88	3.6	
	Week 41	Tezepelumab	73	63 (86.3)	0.91 (0.96)	0.0	0.00	1.00	1.50	4.0	
		Placebo	76	70 (92.1)	0.97 (0.80)	0.0	0.07	1.00	1.50	3.0	
	Week 42	Tezepelumab	73	63 (86.3)	0.93 (0.93)	0.0	0.00	1.00	1.50	4.0	
		Placebo	76	72 (94.7)	1.00 (0.80)	0.0	0.14	1.00	1.54	3.0	
	Week 43	Tezepelumab	73	63 (86.3)	0.91 (0.94)	0.0	0.00	0.93	1.50	3.9	
		Placebo	76	72 (94.7)	1.02 (0.85)	0.0	0.10	1.00	1.59	3.0	
	Week 44	Tezepelumab	73	63 (86.3)	0.89 (0.95)	0.0	0.00	0.88	1.57	3.9	
		Placebo	76	73 (96.1)	1.03 (0.81)	0.0	0.29	1.00	1.50	3.0	
	Week 45	Tezepelumab	73	62 (84.9)	0.87 (0.92)	0.0	0.00	0.96	1.50	3.5	
		Placebo	76	70 (92.1)	1.01 (0.81)	0.0	0.14	1.00	1.50	3.0	
	Week 46	Tezepelumab	73	62 (84.9)	0.89 (0.95)	0.0	0.00	0.93	1.50	3.7	
		Placebo	76	68 (89.5)	1.02 (0.84)	0.0	0.11	1.00	1.58	3.0	
	Week 47	Tezepelumab	73	62 (84.9)	0.88 (0.94)	0.0	0.00	0.96	1.50	4.0	
		Placebo	76	70 (92.1)	1.04 (0.82)	0.0	0.21	1.00	1.75	3.0	
	Week 48	Tezepelumab	73	57 (78.1)	1.01 (0.97)	0.0	0.00	1.00	2.00	4.0	
		Placebo	76	68 (89.5)	1.07 (0.86)	0.0	0.08	1.00	1.86	3.0	

Note: DITTLL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WWC\_ILMH0: Course of ASD weekly wheezing score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly wheezing score	Week 1	Tezepelumab	73	71 (97.3)	-0.14 (0.42)	-1.3	-0.32	0.00	0.00	1.0	-0.18 [-0.50, 0.15]
		Placebo	76	76 (100.0)	-0.07 (0.39)	-1.6	-0.11	0.00	0.09	0.8	
	Week 2	Tezepelumab	73	73 (100.0)	-0.25 (0.47)	-1.6	-0.57	0.00	0.00	0.6	-0.38 [-0.70, -0.05]
		Placebo	76	74 (97.4)	-0.06 (0.51)	-1.8	-0.21	0.00	0.07	1.4	
	Week 3	Tezepelumab	73	73 (100.0)	-0.30 (0.55)	-1.5	-0.71	-0.07	0.00	0.9	-0.46 [-0.79, -0.14]
		Placebo	76	73 (96.1)	-0.06 (0.51)	-1.4	-0.29	0.00	0.14	1.5	
	Week 4	Tezepelumab	73	71 (97.3)	-0.37 (0.60)	-1.9	-0.71	-0.17	0.00	1.1	-0.48 [-0.81, -0.16]
		Placebo	76	76 (100.0)	-0.08 (0.58)	-2.1	-0.21	0.00	0.18	1.4	
	Week 5	Tezepelumab	73	71 (97.3)	-0.38 (0.59)	-1.9	-0.79	-0.14	0.00	0.9	-0.37 [-0.70, -0.04]
		Placebo	76	74 (97.4)	-0.15 (0.67)	-2.9	-0.43	0.00	0.14	1.4	
	Week 6	Tezepelumab	73	69 (94.5)	-0.40 (0.63)	-2.0	-0.73	-0.14	0.00	0.9	-0.44 [-0.78, -0.11]
		Placebo	76	72 (94.7)	-0.10 (0.69)	-2.7	-0.36	0.00	0.21	1.6	
	Week 7	Tezepelumab	73	69 (94.5)	-0.41 (0.64)	-1.9	-1.00	-0.14	0.00	0.9	-0.41 [-0.74, -0.08]
		Placebo	76	75 (98.7)	-0.12 (0.75)	-2.7	-0.36	0.00	0.21	2.3	
	Week 8	Tezepelumab	73	68 (93.2)	-0.41 (0.67)	-2.0	-0.87	-0.18	0.00	0.8	-0.43 [-0.76, -0.10]
		Placebo	76	75 (98.7)	-0.12 (0.71)	-2.1	-0.43	0.00	0.21	1.9	
	Week 9	Tezepelumab	73	69 (94.5)	-0.42 (0.71)	-2.0	-1.00	-0.14	0.00	1.1	-0.36 [-0.69, -0.03]
		Placebo	76	73 (96.1)	-0.15 (0.74)	-2.1	-0.50	0.00	0.21	1.6	
	Week 10	Tezepelumab	73	70 (95.9)	-0.39 (0.76)	-2.0	-1.00	-0.13	0.00	2.0	-0.31 [-0.64, 0.02]
		Placebo	76	74 (97.4)	-0.15 (0.79)	-2.0	-0.50	0.00	0.20	2.4	
	Week 11	Tezepelumab	73	70 (95.9)	-0.40 (0.78)	-2.0	-1.00	-0.17	0.00	2.0	-0.30 [-0.63, 0.03]
		Placebo	76	74 (97.4)	-0.16 (0.77)	-1.9	-0.62	0.00	0.21	3.0	
	Week 12	Tezepelumab	73	70 (95.9)	-0.43 (0.81)	-1.9	-1.00	-0.25	0.00	2.0	-0.37 [-0.70, -0.04]
		Placebo	76	75 (98.7)	-0.15 (0.73)	-2.2	-0.49	0.00	0.17	2.2	
	Week 13	Tezepelumab	73	68 (93.2)	-0.42 (0.83)	-2.3	-1.00	-0.16	0.00	2.0	-0.24 [-0.57, 0.09]
		Placebo	76	71 (93.4)	-0.23 (0.78)	-2.8	-0.64	0.00	0.14	1.4	
	Week 14	Tezepelumab	73	69 (94.5)	-0.38 (0.77)	-2.0	-1.00	-0.20	0.00	2.0	-0.22 [-0.55, 0.11]
		Placebo	76	73 (96.1)	-0.23 (0.65)	-2.0	-0.56	-0.07	0.00	1.1	
	Week 15	Tezepelumab	73	69 (94.5)	-0.40 (0.77)	-2.0	-1.00	-0.21	0.00	2.0	-0.16 [-0.49, 0.17]
		Placebo	76	72 (94.7)	-0.28 (0.71)	-3.0	-0.63	-0.14	0.13	1.0	
	Week 16	Tezepelumab	73	69 (94.5)	-0.39 (0.76)	-2.0	-1.00	-0.21	0.00	1.8	-0.13 [-0.46, 0.19]
		Placebo	76	74 (97.4)	-0.29 (0.72)	-2.0	-0.64	-0.11	0.07	1.3	
	Week 17	Tezepelumab	73	68 (93.2)	-0.39 (0.70)	-2.0	-0.96	-0.14	0.00	1.0	-0.10 [-0.43, 0.23]
		Placebo	76	74 (97.4)	-0.31 (0.75)	-2.2	-0.90	-0.07	0.07	1.0	
	Week 18	Tezepelumab	73	68 (93.2)	-0.40 (0.75)	-2.0	-0.96	-0.21	0.00	1.8	-0.19 [-0.52, 0.14]
		Placebo	76	72 (94.7)	-0.26 (0.75)	-2.1	-0.79	-0.01	0.09	1.1	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WWC\_ILMH0: Course of ASD weekly wheezing score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly wheezing score	Week 19	Tezepelumab	73	67 (91.8)	-0.43 (0.83)	-2.1	-1.00	-0.30	0.00	2.6	-0.19 [-0.52, 0.14]
		Placebo	76	72 (94.7)	-0.29 (0.73)	-2.0	-0.84	-0.07	0.11	1.0	
	Week 20	Tezepelumab	73	70 (95.9)	-0.41 (0.79)	-2.0	-1.00	-0.21	0.00	2.2	-0.21 [-0.54, 0.12]
		Placebo	76	72 (94.7)	-0.26 (0.72)	-2.0	-0.81	-0.03	0.07	1.0	
	Week 21	Tezepelumab	73	67 (91.8)	-0.43 (0.78)	-2.0	-1.00	-0.30	0.00	2.2	-0.27 [-0.60, 0.06]
		Placebo	76	73 (96.1)	-0.23 (0.73)	-2.0	-0.64	-0.07	0.17	1.2	
	Week 22	Tezepelumab	73	69 (94.5)	-0.40 (0.74)	-2.0	-0.93	-0.29	0.00	1.6	-0.29 [-0.62, 0.04]
		Placebo	76	74 (97.4)	-0.18 (0.77)	-2.0	-0.64	-0.07	0.14	1.7	
	Week 23	Tezepelumab	73	69 (94.5)	-0.41 (0.79)	-2.5	-1.00	-0.21	0.00	2.0	-0.24 [-0.57, 0.09]
		Placebo	76	74 (97.4)	-0.23 (0.74)	-2.0	-0.67	-0.11	0.17	1.1	
	Week 24	Tezepelumab	73	69 (94.5)	-0.40 (0.79)	-2.4	-1.00	-0.29	0.00	1.6	-0.29 [-0.62, 0.04]
		Placebo	76	75 (98.7)	-0.19 (0.71)	-2.0	-0.57	0.00	0.14	1.0	
	Week 25	Tezepelumab	73	68 (93.2)	-0.40 (0.86)	-2.5	-1.00	-0.08	0.00	2.4	-0.21 [-0.54, 0.12]
		Placebo	76	74 (97.4)	-0.23 (0.76)	-2.4	-0.67	-0.04	0.10	1.6	
	Week 26	Tezepelumab	73	67 (91.8)	-0.41 (0.84)	-2.6	-1.00	-0.14	0.00	2.1	-0.26 [-0.59, 0.07]
		Placebo	76	73 (96.1)	-0.19 (0.84)	-2.2	-0.64	-0.07	0.13	3.1	
	Week 27	Tezepelumab	73	68 (93.2)	-0.40 (0.89)	-2.7	-1.00	-0.17	0.00	2.6	-0.24 [-0.58, 0.09]
		Placebo	76	71 (93.4)	-0.20 (0.73)	-2.0	-0.57	0.00	0.07	1.3	
	Week 28	Tezepelumab	73	67 (91.8)	-0.36 (0.90)	-2.7	-1.00	-0.14	0.00	2.4	-0.16 [-0.49, 0.17]
		Placebo	76	71 (93.4)	-0.23 (0.73)	-2.0	-0.71	-0.07	0.14	1.6	
	Week 29	Tezepelumab	73	64 (87.7)	-0.49 (0.87)	-2.6	-1.00	-0.29	0.00	2.7	-0.36 [-0.70, -0.03]
		Placebo	76	74 (97.4)	-0.19 (0.74)	-2.0	-0.64	0.00	0.14	1.1	
	Week 30	Tezepelumab	73	66 (90.4)	-0.44 (0.91)	-2.7	-1.00	-0.21	0.00	2.7	-0.29 [-0.63, 0.04]
		Placebo	76	74 (97.4)	-0.21 (0.69)	-2.0	-0.54	-0.07	0.19	1.3	
	Week 31	Tezepelumab	73	66 (90.4)	-0.47 (0.91)	-2.7	-1.00	-0.29	0.00	2.8	-0.31 [-0.64, 0.03]
		Placebo	76	72 (94.7)	-0.22 (0.72)	-2.0	-0.78	-0.04	0.05	1.4	
	Week 32	Tezepelumab	73	64 (87.7)	-0.48 (0.91)	-2.7	-1.07	-0.32	0.00	2.7	-0.32 [-0.66, 0.02]
		Placebo	76	73 (96.1)	-0.22 (0.70)	-2.0	-0.71	-0.07	0.07	1.3	
	Week 33	Tezepelumab	73	67 (91.8)	-0.43 (0.87)	-2.7	-1.00	-0.29	0.00	2.7	-0.21 [-0.55, 0.12]
		Placebo	76	72 (94.7)	-0.26 (0.74)	-2.2	-0.69	-0.07	0.07	1.4	
	Week 34	Tezepelumab	73	67 (91.8)	-0.47 (0.86)	-2.6	-1.00	-0.29	0.00	2.6	-0.24 [-0.57, 0.10]
		Placebo	76	71 (93.4)	-0.28 (0.70)	-2.1	-0.72	-0.07	0.00	1.4	
	Week 35	Tezepelumab	73	65 (89.0)	-0.48 (0.89)	-2.7	-1.00	-0.36	0.00	2.7	-0.25 [-0.59, 0.08]
		Placebo	76	74 (97.4)	-0.28 (0.72)	-2.0	-0.90	-0.14	0.07	1.4	
	Week 36	Tezepelumab	73	69 (94.5)	-0.43 (0.92)	-2.7	-1.00	-0.29	0.00	2.8	-0.12 [-0.45, 0.21]
		Placebo	76	71 (93.4)	-0.33 (0.71)	-2.0	-0.93	-0.14	0.07	1.1	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WWC\_ILMH0: Course of ASD weekly wheezing score  
 DITTLL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly wheezing score	Week 37	Tezepelumab	73	66 (90.4)	-0.50 (0.93)	-2.7	-1.07	-0.36	0.00	2.7	-0.24 [-0.58, 0.09]
		Placebo	76	72 (94.7)	-0.30 (0.71)	-2.0	-0.82	-0.11	0.07	1.1	
	Week 38	Tezepelumab	73	64 (87.7)	-0.51 (0.94)	-2.7	-1.18	-0.32	0.00	2.6	-0.30 [-0.64, 0.03]
		Placebo	76	72 (94.7)	-0.25 (0.77)	-2.0	-0.75	0.00	0.20	1.5	
	Week 39	Tezepelumab	73	64 (87.7)	-0.51 (0.94)	-2.7	-1.18	-0.29	0.00	2.8	-0.29 [-0.63, 0.05]
		Placebo	76	71 (93.4)	-0.27 (0.72)	-2.0	-0.85	-0.07	0.05	1.4	
	Week 40	Tezepelumab	73	64 (87.7)	-0.49 (0.95)	-2.7	-1.18	-0.25	0.00	2.8	-0.25 [-0.59, 0.09]
		Placebo	76	71 (93.4)	-0.28 (0.70)	-2.0	-0.79	-0.13	0.07	1.4	
	Week 41	Tezepelumab	73	63 (86.3)	-0.51 (0.94)	-2.6	-1.07	-0.29	0.00	2.8	-0.21 [-0.55, 0.13]
		Placebo	76	70 (92.1)	-0.33 (0.75)	-2.2	-0.93	-0.04	0.02	1.0	
	Week 42	Tezepelumab	73	63 (86.3)	-0.47 (0.91)	-2.4	-1.00	-0.29	0.00	2.8	-0.17 [-0.51, 0.16]
		Placebo	76	72 (94.7)	-0.33 (0.74)	-2.0	-0.93	-0.13	0.07	1.3	
	Week 43	Tezepelumab	73	63 (86.3)	-0.49 (0.92)	-2.5	-1.00	-0.29	0.00	2.7	-0.22 [-0.56, 0.11]
		Placebo	76	72 (94.7)	-0.30 (0.78)	-2.0	-0.93	-0.17	0.23	1.6	
	Week 44	Tezepelumab	73	63 (86.3)	-0.52 (0.92)	-2.5	-1.29	-0.21	0.00	2.7	-0.27 [-0.61, 0.07]
		Placebo	76	73 (96.1)	-0.29 (0.76)	-2.0	-0.88	-0.14	0.17	1.4	
	Week 45	Tezepelumab	73	62 (84.9)	-0.54 (0.90)	-2.5	-1.13	-0.39	0.00	2.3	-0.29 [-0.64, 0.05]
		Placebo	76	70 (92.1)	-0.29 (0.80)	-2.7	-0.79	-0.11	0.07	1.1	
	Week 46	Tezepelumab	73	62 (84.9)	-0.50 (0.90)	-2.7	-1.07	-0.25	0.00	2.5	-0.21 [-0.56, 0.13]
		Placebo	76	68 (89.5)	-0.32 (0.79)	-2.0	-0.92	-0.14	0.00	1.1	
	Week 47	Tezepelumab	73	62 (84.9)	-0.52 (0.96)	-2.5	-1.25	-0.32	0.00	2.8	-0.25 [-0.60, 0.09]
		Placebo	76	70 (92.1)	-0.30 (0.75)	-2.0	-0.90	-0.06	0.07	1.1	
	Week 48	Tezepelumab	73	57 (78.1)	-0.42 (0.97)	-2.6	-1.00	-0.21	0.00	2.8	-0.15 [-0.51, 0.20]
		Placebo	76	68 (89.5)	-0.29 (0.77)	-2.0	-0.92	-0.10	0.19	1.4	

Note: DITTLL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WWC\_ILMC0: Change from baseline in ASD weekly wheezing score - MMRM results  
 DITTTL

Change from baseline in ASD weekly wheezing score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 1	Tezepelumab	73	71 (97.3)	-0.13 (0.08)	(-0.29, 0.03)	-0.04 (0.11)	(-0.26, 0.18)	0.698
	Placebo	76	76 (100.0)	-0.09 (0.08)	(-0.24, 0.07)			
Week 2	Tezepelumab	73	73 (100.0)	-0.24 (0.08)	(-0.39, -0.08)	-0.13 (0.11)	(-0.35, 0.08)	0.228
	Placebo	76	74 (97.4)	-0.10 (0.08)	(-0.26, 0.05)			
Week 3	Tezepelumab	73	73 (100.0)	-0.29 (0.08)	(-0.45, -0.14)	-0.19 (0.11)	(-0.41, 0.03)	0.093
	Placebo	76	73 (96.1)	-0.11 (0.08)	(-0.26, 0.05)			
Week 4	Tezepelumab	73	71 (97.3)	-0.35 (0.08)	(-0.50, -0.19)	-0.25 (0.11)	(-0.47, -0.03)	0.027 *
	Placebo	76	76 (100.0)	-0.10 (0.08)	(-0.25, 0.05)			
Week 5	Tezepelumab	73	71 (97.3)	-0.37 (0.08)	(-0.53, -0.21)	-0.19 (0.11)	(-0.41, 0.02)	0.081
	Placebo	76	74 (97.4)	-0.18 (0.08)	(-0.33, -0.02)			
Week 6	Tezepelumab	73	69 (94.5)	-0.38 (0.08)	(-0.53, -0.22)	-0.23 (0.11)	(-0.45, -0.01)	0.043 *
	Placebo	76	72 (94.7)	-0.15 (0.08)	(-0.30, 0.00)			
Week 7	Tezepelumab	73	69 (94.5)	-0.39 (0.08)	(-0.54, -0.23)	-0.25 (0.11)	(-0.47, -0.03)	0.028 *
	Placebo	76	75 (98.7)	-0.14 (0.08)	(-0.29, 0.01)			
Week 8	Tezepelumab	73	68 (93.2)	-0.38 (0.08)	(-0.54, -0.23)	-0.24 (0.11)	(-0.46, -0.02)	0.030 *
	Placebo	76	75 (98.7)	-0.14 (0.08)	(-0.29, 0.01)			
Week 9	Tezepelumab	73	69 (94.5)	-0.40 (0.08)	(-0.56, -0.25)	-0.23 (0.11)	(-0.45, -0.01)	0.037 *
	Placebo	76	73 (96.1)	-0.17 (0.08)	(-0.32, -0.02)			
Week 10	Tezepelumab	73	70 (95.9)	-0.38 (0.08)	(-0.53, -0.22)	-0.22 (0.11)	(-0.43, 0.00)	0.055
	Placebo	76	74 (97.4)	-0.16 (0.08)	(-0.31, -0.01)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WWC\_ILMC0: Change from baseline in ASD weekly wheezing score - MMRM results  
 DITTTL

Change from baseline in ASD weekly wheezing score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 11	Tezepelumab	73	70 (95.9)	-0.38 (0.08)	(-0.54, -0.22)	-0.21 (0.11)	(-0.43, 0.01)	0.057
	Placebo	76	74 (97.4)	-0.17 (0.08)	(-0.32, -0.02)			
Week 12	Tezepelumab	73	70 (95.9)	-0.42 (0.08)	(-0.57, -0.26)	-0.25 (0.11)	(-0.47, -0.03)	0.026 *
	Placebo	76	75 (98.7)	-0.17 (0.08)	(-0.32, -0.01)			
Week 13	Tezepelumab	73	68 (93.2)	-0.40 (0.08)	(-0.56, -0.24)	-0.13 (0.11)	(-0.35, 0.09)	0.241
	Placebo	76	71 (93.4)	-0.27 (0.08)	(-0.42, -0.11)			
Week 14	Tezepelumab	73	69 (94.5)	-0.35 (0.08)	(-0.51, -0.19)	-0.08 (0.11)	(-0.30, 0.14)	0.476
	Placebo	76	73 (96.1)	-0.27 (0.08)	(-0.43, -0.12)			
Week 15	Tezepelumab	73	69 (94.5)	-0.38 (0.08)	(-0.54, -0.22)	-0.08 (0.11)	(-0.31, 0.14)	0.452
	Placebo	76	72 (94.7)	-0.30 (0.08)	(-0.45, -0.14)			
Week 16	Tezepelumab	73	69 (94.5)	-0.37 (0.08)	(-0.52, -0.21)	-0.06 (0.11)	(-0.28, 0.16)	0.584
	Placebo	76	74 (97.4)	-0.30 (0.08)	(-0.46, -0.15)			
Week 17	Tezepelumab	73	68 (93.2)	-0.37 (0.08)	(-0.53, -0.21)	-0.04 (0.11)	(-0.27, 0.18)	0.695
	Placebo	76	74 (97.4)	-0.33 (0.08)	(-0.48, -0.17)			
Week 18	Tezepelumab	73	68 (93.2)	-0.40 (0.08)	(-0.56, -0.24)	-0.12 (0.11)	(-0.34, 0.10)	0.275
	Placebo	76	72 (94.7)	-0.27 (0.08)	(-0.43, -0.12)			
Week 19	Tezepelumab	73	67 (91.8)	-0.41 (0.08)	(-0.56, -0.25)	-0.12 (0.11)	(-0.34, 0.10)	0.297
	Placebo	76	72 (94.7)	-0.29 (0.08)	(-0.44, -0.13)			
Week 20	Tezepelumab	73	70 (95.9)	-0.39 (0.08)	(-0.55, -0.24)	-0.12 (0.11)	(-0.35, 0.10)	0.272
	Placebo	76	72 (94.7)	-0.27 (0.08)	(-0.42, -0.12)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WWC\_ILMC0: Change from baseline in ASD weekly wheezing score - MMRM results  
DITTL

Change from baseline in ASD weekly wheezing score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 21	Tezepelumab	73	67 (91.8)	-0.40 (0.08)	(-0.56, -0.24)	-0.16 (0.11)	(-0.38, 0.06)	0.159
	Placebo	76	73 (96.1)	-0.24 (0.08)	(-0.39, -0.09)			
Week 22	Tezepelumab	73	69 (94.5)	-0.39 (0.08)	(-0.55, -0.23)	-0.19 (0.11)	(-0.42, 0.03)	0.086
	Placebo	76	74 (97.4)	-0.19 (0.08)	(-0.35, -0.04)			
Week 23	Tezepelumab	73	69 (94.5)	-0.40 (0.08)	(-0.55, -0.24)	-0.16 (0.11)	(-0.38, 0.06)	0.161
	Placebo	76	74 (97.4)	-0.24 (0.08)	(-0.39, -0.08)			
Week 24	Tezepelumab	73	69 (94.5)	-0.39 (0.08)	(-0.55, -0.23)	-0.19 (0.11)	(-0.41, 0.03)	0.095
	Placebo	76	75 (98.7)	-0.20 (0.08)	(-0.36, -0.05)			
Week 25	Tezepelumab	73	68 (93.2)	-0.37 (0.08)	(-0.53, -0.21)	-0.13 (0.11)	(-0.35, 0.09)	0.260
	Placebo	76	74 (97.4)	-0.25 (0.08)	(-0.40, -0.09)			
Week 26	Tezepelumab	73	67 (91.8)	-0.38 (0.08)	(-0.54, -0.22)	-0.18 (0.11)	(-0.40, 0.05)	0.120
	Placebo	76	73 (96.1)	-0.21 (0.08)	(-0.36, -0.05)			
Week 27	Tezepelumab	73	68 (93.2)	-0.38 (0.08)	(-0.54, -0.22)	-0.14 (0.11)	(-0.36, 0.08)	0.216
	Placebo	76	71 (93.4)	-0.24 (0.08)	(-0.39, -0.08)			
Week 28	Tezepelumab	73	67 (91.8)	-0.34 (0.08)	(-0.50, -0.18)	-0.09 (0.11)	(-0.32, 0.13)	0.409
	Placebo	76	71 (93.4)	-0.24 (0.08)	(-0.40, -0.09)			
Week 29	Tezepelumab	73	64 (87.7)	-0.43 (0.08)	(-0.59, -0.26)	-0.21 (0.11)	(-0.44, 0.01)	0.059
	Placebo	76	74 (97.4)	-0.21 (0.08)	(-0.37, -0.06)			
Week 30	Tezepelumab	73	66 (90.4)	-0.42 (0.08)	(-0.58, -0.26)	-0.20 (0.11)	(-0.42, 0.03)	0.084
	Placebo	76	74 (97.4)	-0.23 (0.08)	(-0.38, -0.07)			

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table ST1WWC\_ILMC0: Change from baseline in ASD weekly wheezing score - MMRM results  
DITTL

Change from baseline in ASD weekly wheezing score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 31	Tezepelumab	73	66 (90.4)	-0.43 (0.08)	(-0.59, -0.27)	-0.21 (0.11)	(-0.43, 0.01)	0.066
	Placebo	76	72 (94.7)	-0.22 (0.08)	(-0.38, -0.07)			
Week 32	Tezepelumab	73	64 (87.7)	-0.44 (0.08)	(-0.60, -0.28)	-0.21 (0.11)	(-0.44, 0.01)	0.061
	Placebo	76	73 (96.1)	-0.23 (0.08)	(-0.38, -0.07)			
Week 33	Tezepelumab	73	67 (91.8)	-0.39 (0.08)	(-0.55, -0.23)	-0.10 (0.11)	(-0.33, 0.12)	0.357
	Placebo	76	72 (94.7)	-0.28 (0.08)	(-0.44, -0.13)			
Week 34	Tezepelumab	73	67 (91.8)	-0.42 (0.08)	(-0.58, -0.26)	-0.13 (0.11)	(-0.36, 0.09)	0.244
	Placebo	76	71 (93.4)	-0.29 (0.08)	(-0.45, -0.14)			
Week 35	Tezepelumab	73	65 (89.0)	-0.43 (0.08)	(-0.59, -0.27)	-0.13 (0.11)	(-0.35, 0.10)	0.265
	Placebo	76	74 (97.4)	-0.30 (0.08)	(-0.46, -0.15)			
Week 36	Tezepelumab	73	69 (94.5)	-0.40 (0.08)	(-0.56, -0.24)	-0.07 (0.11)	(-0.29, 0.16)	0.562
	Placebo	76	71 (93.4)	-0.34 (0.08)	(-0.49, -0.18)			
Week 37	Tezepelumab	73	66 (90.4)	-0.46 (0.08)	(-0.62, -0.30)	-0.14 (0.11)	(-0.36, 0.08)	0.215
	Placebo	76	72 (94.7)	-0.32 (0.08)	(-0.47, -0.16)			
Week 38	Tezepelumab	73	64 (87.7)	-0.46 (0.08)	(-0.62, -0.30)	-0.20 (0.11)	(-0.42, 0.02)	0.081
	Placebo	76	72 (94.7)	-0.26 (0.08)	(-0.42, -0.11)			
Week 39	Tezepelumab	73	64 (87.7)	-0.46 (0.08)	(-0.62, -0.30)	-0.16 (0.11)	(-0.38, 0.07)	0.171
	Placebo	76	71 (93.4)	-0.30 (0.08)	(-0.46, -0.15)			
Week 40	Tezepelumab	73	64 (87.7)	-0.43 (0.08)	(-0.60, -0.27)	-0.15 (0.11)	(-0.37, 0.08)	0.194
	Placebo	76	71 (93.4)	-0.29 (0.08)	(-0.44, -0.13)			

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WWC\_ILMC0: Change from baseline in ASD weekly wheezing score - MMRM results  
DITTL

Change from baseline in ASD weekly wheezing score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 41	Tezepelumab	73	63 (86.3)	-0.45 (0.08)	(-0.62, -0.29)	-0.11 (0.11)	(-0.33, 0.12)	0.348
	Placebo	76	70 (92.1)	-0.35 (0.08)	(-0.50, -0.19)			
Week 42	Tezepelumab	73	63 (86.3)	-0.41 (0.08)	(-0.58, -0.25)	-0.08 (0.11)	(-0.30, 0.15)	0.507
	Placebo	76	72 (94.7)	-0.34 (0.08)	(-0.49, -0.18)			
Week 43	Tezepelumab	73	63 (86.3)	-0.43 (0.08)	(-0.60, -0.27)	-0.11 (0.12)	(-0.34, 0.11)	0.330
	Placebo	76	72 (94.7)	-0.32 (0.08)	(-0.47, -0.16)			
Week 44	Tezepelumab	73	63 (86.3)	-0.46 (0.08)	(-0.63, -0.30)	-0.15 (0.12)	(-0.38, 0.07)	0.187
	Placebo	76	73 (96.1)	-0.31 (0.08)	(-0.47, -0.16)			
Week 45	Tezepelumab	73	62 (84.9)	-0.49 (0.08)	(-0.65, -0.32)	-0.16 (0.12)	(-0.38, 0.07)	0.172
	Placebo	76	70 (92.1)	-0.33 (0.08)	(-0.49, -0.18)			
Week 46	Tezepelumab	73	62 (84.9)	-0.48 (0.08)	(-0.64, -0.31)	-0.16 (0.12)	(-0.39, 0.06)	0.156
	Placebo	76	68 (89.5)	-0.31 (0.08)	(-0.47, -0.16)			
Week 47	Tezepelumab	73	62 (84.9)	-0.46 (0.08)	(-0.63, -0.30)	-0.15 (0.12)	(-0.38, 0.07)	0.185
	Placebo	76	70 (92.1)	-0.31 (0.08)	(-0.46, -0.15)			
Week 48	Tezepelumab	73	57 (78.1)	-0.41 (0.09)	(-0.58, -0.24)	-0.13 (0.12)	(-0.36, 0.10)	0.261
	Placebo	76	68 (89.5)	-0.28 (0.08)	(-0.43, -0.12)			

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC\_ILMH0: Course of ASD weekly shortness of breath score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly shortness of breath score	Baseline	Tezepelumab	395	395 (100.0)	1.62 (0.78)	0.0	1.00	1.57	2.07	4.0	
		Placebo	391	391 (100.0)	1.58 (0.78)	0.0	1.00	1.50	2.07	3.9	
	Week 1	Tezepelumab	395	386 (97.7)	1.38 (0.74)	0.0	1.00	1.21	1.93	4.0	
		Placebo	391	382 (97.7)	1.45 (0.78)	0.0	0.93	1.36	2.00	3.8	
	Week 2	Tezepelumab	395	384 (97.2)	1.26 (0.75)	0.0	0.85	1.14	1.86	3.9	
		Placebo	391	379 (96.9)	1.38 (0.78)	0.0	0.86	1.29	2.00	3.9	
	Week 3	Tezepelumab	395	379 (95.9)	1.19 (0.76)	0.0	0.71	1.07	1.79	3.9	
		Placebo	391	371 (94.9)	1.26 (0.79)	0.0	0.71	1.14	1.93	4.0	
	Week 4	Tezepelumab	395	375 (94.9)	1.16 (0.78)	0.0	0.50	1.00	1.79	3.9	
		Placebo	391	370 (94.6)	1.25 (0.78)	0.0	0.70	1.14	1.90	3.9	
	Week 5	Tezepelumab	395	375 (94.9)	1.10 (0.79)	0.0	0.50	1.00	1.70	4.0	
		Placebo	391	360 (92.1)	1.19 (0.78)	0.0	0.57	1.08	1.83	4.0	
	Week 6	Tezepelumab	395	368 (93.2)	1.06 (0.81)	0.0	0.33	1.00	1.71	4.0	
		Placebo	391	365 (93.4)	1.15 (0.80)	0.0	0.60	1.00	1.80	4.0	
	Week 7	Tezepelumab	395	366 (92.7)	1.03 (0.82)	0.0	0.21	1.00	1.63	4.0	
		Placebo	391	365 (93.4)	1.14 (0.82)	0.0	0.50	1.00	1.75	4.0	
	Week 8	Tezepelumab	395	368 (93.2)	1.02 (0.81)	0.0	0.23	1.00	1.64	4.0	
		Placebo	391	356 (91.0)	1.12 (0.79)	0.0	0.50	1.00	1.71	4.0	
	Week 9	Tezepelumab	395	370 (93.7)	0.97 (0.79)	0.0	0.17	1.00	1.50	4.0	
		Placebo	391	357 (91.3)	1.08 (0.79)	0.0	0.40	1.00	1.57	4.0	
	Week 10	Tezepelumab	395	368 (93.2)	0.99 (0.80)	0.0	0.21	1.00	1.50	4.0	
		Placebo	391	353 (90.3)	1.07 (0.78)	0.0	0.36	1.00	1.57	4.0	
	Week 11	Tezepelumab	395	359 (90.9)	0.98 (0.82)	0.0	0.14	1.00	1.50	4.0	
		Placebo	391	351 (89.8)	1.05 (0.80)	0.0	0.30	1.00	1.58	4.0	
	Week 12	Tezepelumab	395	360 (91.1)	0.98 (0.81)	0.0	0.21	1.00	1.50	4.0	
		Placebo	391	347 (88.7)	1.05 (0.81)	0.0	0.29	1.00	1.57	4.0	
	Week 13	Tezepelumab	395	353 (89.4)	0.94 (0.80)	0.0	0.14	1.00	1.50	4.0	
		Placebo	391	345 (88.2)	1.04 (0.80)	0.0	0.29	1.00	1.50	4.0	
	Week 14	Tezepelumab	395	350 (88.6)	0.91 (0.80)	0.0	0.08	1.00	1.38	4.0	
		Placebo	391	343 (87.7)	1.03 (0.78)	0.0	0.29	1.00	1.50	4.0	
	Week 15	Tezepelumab	395	348 (88.1)	0.91 (0.80)	0.0	0.08	1.00	1.42	4.0	
		Placebo	391	335 (85.7)	1.03 (0.82)	0.0	0.25	1.00	1.58	4.0	
	Week 16	Tezepelumab	395	352 (89.1)	0.91 (0.80)	0.0	0.08	1.00	1.38	4.0	
		Placebo	391	333 (85.2)	1.06 (0.82)	0.0	0.25	1.00	1.79	4.0	
Week 17	Tezepelumab	395	347 (87.8)	0.88 (0.79)	0.0	0.00	1.00	1.25	4.0		
	Placebo	391	327 (83.6)	1.03 (0.81)	0.0	0.21	1.00	1.64	4.0		

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC\_ILMH0: Course of ASD weekly shortness of breath score  
 DITTLL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly shortness of breath score	Week 18	Tezepelumab	395	346 (87.6)	0.90 (0.80)	0.0	0.07	1.00	1.36	4.0	
		Placebo	391	322 (82.4)	1.02 (0.84)	0.0	0.14	1.00	1.63	4.0	
	Week 19	Tezepelumab	395	343 (86.8)	0.88 (0.81)	0.0	0.00	1.00	1.29	4.0	
		Placebo	391	332 (84.9)	1.03 (0.85)	0.0	0.17	1.00	1.71	4.0	
	Week 20	Tezepelumab	395	335 (84.8)	0.90 (0.82)	0.0	0.00	1.00	1.43	4.0	
		Placebo	391	324 (82.9)	1.03 (0.84)	0.0	0.15	1.00	1.82	4.0	
	Week 21	Tezepelumab	395	334 (84.6)	0.86 (0.81)	0.0	0.00	1.00	1.25	4.0	
		Placebo	391	319 (81.6)	0.98 (0.83)	0.0	0.13	1.00	1.64	4.0	
	Week 22	Tezepelumab	395	333 (84.3)	0.91 (0.84)	0.0	0.00	1.00	1.43	4.0	
		Placebo	391	312 (79.8)	0.99 (0.83)	0.0	0.14	1.00	1.61	4.0	
	Week 23	Tezepelumab	395	328 (83.0)	0.89 (0.84)	0.0	0.00	1.00	1.38	4.0	
		Placebo	391	310 (79.3)	0.99 (0.83)	0.0	0.10	1.00	1.67	4.0	
	Week 24	Tezepelumab	395	337 (85.3)	0.88 (0.83)	0.0	0.00	1.00	1.40	4.0	
		Placebo	391	310 (79.3)	0.96 (0.82)	0.0	0.08	1.00	1.57	4.0	
	Week 25	Tezepelumab	395	323 (81.8)	0.90 (0.81)	0.0	0.00	1.00	1.38	4.0	
		Placebo	391	308 (78.8)	0.97 (0.84)	0.0	0.11	1.00	1.58	4.0	
	Week 26	Tezepelumab	395	327 (82.8)	0.89 (0.82)	0.0	0.00	1.00	1.36	4.0	
		Placebo	391	303 (77.5)	1.00 (0.84)	0.0	0.13	1.00	1.71	4.0	
	Week 27	Tezepelumab	395	317 (80.3)	0.87 (0.84)	0.0	0.00	1.00	1.29	4.0	
		Placebo	391	313 (80.1)	0.98 (0.85)	0.0	0.13	1.00	1.71	4.0	
	Week 28	Tezepelumab	395	325 (82.3)	0.84 (0.83)	0.0	0.00	1.00	1.21	4.0	
		Placebo	391	314 (80.3)	0.99 (0.85)	0.0	0.13	1.00	1.67	4.0	
	Week 29	Tezepelumab	395	317 (80.3)	0.85 (0.84)	0.0	0.00	1.00	1.21	4.0	
		Placebo	391	312 (79.8)	0.98 (0.86)	0.0	0.08	1.00	1.80	4.0	
	Week 30	Tezepelumab	395	322 (81.5)	0.86 (0.80)	0.0	0.00	1.00	1.21	3.9	
		Placebo	391	303 (77.5)	0.98 (0.85)	0.0	0.08	1.00	1.83	4.0	
	Week 31	Tezepelumab	395	322 (81.5)	0.84 (0.81)	0.0	0.00	1.00	1.29	4.0	
		Placebo	391	308 (78.8)	0.98 (0.83)	0.0	0.14	1.00	1.63	4.0	
	Week 32	Tezepelumab	395	324 (82.0)	0.85 (0.80)	0.0	0.00	1.00	1.25	3.9	
		Placebo	391	308 (78.8)	0.98 (0.82)	0.0	0.13	1.00	1.68	4.0	
	Week 33	Tezepelumab	395	321 (81.3)	0.83 (0.81)	0.0	0.00	0.93	1.20	3.9	
		Placebo	391	304 (77.7)	1.00 (0.83)	0.0	0.14	1.00	1.75	4.0	
	Week 34	Tezepelumab	395	319 (80.8)	0.82 (0.82)	0.0	0.00	1.00	1.25	4.0	
		Placebo	391	303 (77.5)	0.98 (0.84)	0.0	0.10	1.00	1.71	4.0	
	Week 35	Tezepelumab	395	320 (81.0)	0.82 (0.82)	0.0	0.00	0.90	1.17	4.0	
		Placebo	391	295 (75.4)	0.96 (0.83)	0.0	0.10	1.00	1.63	4.0	

Note: DITTLL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC\_ILMH0: Course of ASD weekly shortness of breath score  
 DITTLL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly shortness of breath score	Week 36	Tezepelumab	395	317 (80.3)	0.83 (0.82)	0.0	0.00	1.00	1.17	3.9	
		Placebo	391	299 (76.5)	0.95 (0.82)	0.0	0.08	1.00	1.50	4.0	
	Week 37	Tezepelumab	395	320 (81.0)	0.82 (0.82)	0.0	0.00	1.00	1.13	3.9	
		Placebo	391	298 (76.2)	0.93 (0.80)	0.0	0.08	1.00	1.50	4.0	
	Week 38	Tezepelumab	395	317 (80.3)	0.85 (0.84)	0.0	0.00	1.00	1.21	3.9	
		Placebo	391	299 (76.5)	0.92 (0.81)	0.0	0.00	1.00	1.43	4.0	
	Week 39	Tezepelumab	395	325 (82.3)	0.85 (0.86)	0.0	0.00	1.00	1.29	4.0	
		Placebo	391	292 (74.7)	0.93 (0.84)	0.0	0.00	1.00	1.57	4.0	
	Week 40	Tezepelumab	395	321 (81.3)	0.86 (0.84)	0.0	0.00	1.00	1.36	4.0	
		Placebo	391	297 (76.0)	0.95 (0.83)	0.0	0.07	1.00	1.64	4.0	
	Week 41	Tezepelumab	395	324 (82.0)	0.81 (0.82)	0.0	0.00	0.92	1.21	3.5	
		Placebo	391	297 (76.0)	0.96 (0.81)	0.0	0.10	1.00	1.63	4.0	
	Week 42	Tezepelumab	395	316 (80.0)	0.83 (0.83)	0.0	0.00	1.00	1.21	4.0	
		Placebo	391	298 (76.2)	0.97 (0.85)	0.0	0.13	1.00	1.64	4.0	
	Week 43	Tezepelumab	395	319 (80.8)	0.83 (0.83)	0.0	0.00	0.92	1.14	3.6	
		Placebo	391	296 (75.7)	0.94 (0.84)	0.0	0.07	1.00	1.54	4.0	
	Week 44	Tezepelumab	395	316 (80.0)	0.83 (0.83)	0.0	0.00	0.93	1.18	3.6	
		Placebo	391	294 (75.2)	0.95 (0.84)	0.0	0.10	1.00	1.58	4.0	
	Week 45	Tezepelumab	395	319 (80.8)	0.81 (0.83)	0.0	0.00	0.90	1.21	3.7	
		Placebo	391	296 (75.7)	0.96 (0.84)	0.0	0.10	1.00	1.57	4.0	
	Week 46	Tezepelumab	395	314 (79.5)	0.83 (0.85)	0.0	0.00	0.92	1.29	3.9	
		Placebo	391	287 (73.4)	0.93 (0.83)	0.0	0.08	1.00	1.50	4.0	
	Week 47	Tezepelumab	395	302 (76.5)	0.84 (0.85)	0.0	0.00	0.93	1.29	3.2	
		Placebo	391	291 (74.4)	0.90 (0.80)	0.0	0.08	1.00	1.43	4.0	
	Week 48	Tezepelumab	395	323 (81.8)	0.83 (0.85)	0.0	0.00	1.00	1.25	3.4	
		Placebo	391	301 (77.0)	0.92 (0.81)	0.0	0.08	1.00	1.42	4.0	
	Week 49	Tezepelumab	395	315 (79.7)	0.83 (0.85)	0.0	0.00	1.00	1.21	3.2	
		Placebo	391	290 (74.2)	0.94 (0.81)	0.0	0.08	1.00	1.38	4.0	
	Week 50	Tezepelumab	395	312 (79.0)	0.83 (0.85)	0.0	0.00	0.92	1.14	3.2	
		Placebo	391	288 (73.7)	0.93 (0.81)	0.0	0.10	1.00	1.50	4.0	
	Week 51	Tezepelumab	395	307 (77.7)	0.85 (0.85)	0.0	0.00	1.00	1.20	3.1	
		Placebo	391	282 (72.1)	0.95 (0.83)	0.0	0.08	1.00	1.40	4.0	
	Week 52	Tezepelumab	395	276 (69.9)	0.87 (0.86)	0.0	0.00	1.00	1.15	3.2	
		Placebo	391	257 (65.7)	0.94 (0.86)	0.0	0.00	1.00	1.50	4.0	

Note: DITTLL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC\_ILMH0: Course of ASD weekly shortness of breath score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly shortness of breath score	Week 1	Tezepelumab	395	386 (97.7)	-0.23 (0.40)	-2.1	-0.43	-0.14	0.00	0.9	-0.24 [-0.38, -0.10]
		Placebo	391	382 (97.7)	-0.13 (0.42)	-2.0	-0.36	-0.08	0.07	1.4	
	Week 2	Tezepelumab	395	384 (97.2)	-0.35 (0.55)	-3.2	-0.64	-0.21	0.00	0.9	-0.28 [-0.42, -0.13]
		Placebo	391	379 (96.9)	-0.20 (0.55)	-3.1	-0.43	-0.11	0.07	1.5	
	Week 3	Tezepelumab	395	379 (95.9)	-0.42 (0.60)	-3.8	-0.74	-0.29	0.00	0.9	-0.17 [-0.32, -0.03]
		Placebo	391	371 (94.9)	-0.31 (0.63)	-2.7	-0.57	-0.21	0.00	1.6	
	Week 4	Tezepelumab	395	375 (94.9)	-0.46 (0.63)	-3.8	-0.79	-0.29	0.00	0.9	-0.18 [-0.33, -0.04]
		Placebo	391	370 (94.6)	-0.34 (0.66)	-2.9	-0.65	-0.21	0.00	1.8	
	Week 5	Tezepelumab	395	375 (94.9)	-0.51 (0.66)	-3.8	-0.93	-0.36	-0.05	0.9	-0.18 [-0.32, -0.03]
		Placebo	391	360 (92.1)	-0.40 (0.66)	-2.7	-0.75	-0.30	0.00	1.8	
	Week 6	Tezepelumab	395	368 (93.2)	-0.55 (0.70)	-3.8	-0.93	-0.44	-0.04	1.1	-0.18 [-0.33, -0.04]
		Placebo	391	365 (93.4)	-0.42 (0.70)	-3.0	-0.79	-0.33	0.00	1.8	
	Week 7	Tezepelumab	395	366 (92.7)	-0.58 (0.73)	-3.8	-1.00	-0.42	-0.07	1.6	-0.19 [-0.34, -0.05]
		Placebo	391	365 (93.4)	-0.44 (0.72)	-3.2	-0.86	-0.29	0.00	1.9	
	Week 8	Tezepelumab	395	368 (93.2)	-0.59 (0.72)	-3.8	-1.00	-0.45	-0.07	1.6	-0.19 [-0.34, -0.05]
		Placebo	391	356 (91.0)	-0.46 (0.71)	-3.1	-0.92	-0.35	0.00	1.9	
	Week 9	Tezepelumab	395	370 (93.7)	-0.63 (0.72)	-3.8	-1.00	-0.53	-0.07	1.7	-0.17 [-0.32, -0.03]
		Placebo	391	357 (91.3)	-0.50 (0.72)	-3.2	-0.98	-0.43	0.00	1.9	
	Week 10	Tezepelumab	395	368 (93.2)	-0.61 (0.72)	-3.8	-1.00	-0.50	-0.06	1.0	-0.13 [-0.28, 0.02]
		Placebo	391	353 (90.3)	-0.51 (0.73)	-3.1	-0.95	-0.37	0.00	1.7	
	Week 11	Tezepelumab	395	359 (90.9)	-0.62 (0.73)	-3.8	-1.00	-0.50	-0.07	1.1	-0.13 [-0.28, 0.01]
		Placebo	391	351 (89.8)	-0.53 (0.74)	-3.2	-0.93	-0.49	0.00	1.9	
	Week 12	Tezepelumab	395	360 (91.1)	-0.61 (0.75)	-3.8	-1.00	-0.50	-0.07	1.3	-0.12 [-0.26, 0.03]
		Placebo	391	347 (88.7)	-0.52 (0.72)	-3.1	-0.93	-0.43	-0.07	1.9	
	Week 13	Tezepelumab	395	353 (89.4)	-0.64 (0.74)	-3.8	-1.00	-0.50	-0.07	1.0	-0.14 [-0.29, 0.01]
		Placebo	391	345 (88.2)	-0.54 (0.74)	-3.2	-1.00	-0.43	-0.06	1.9	
	Week 14	Tezepelumab	395	350 (88.6)	-0.70 (0.75)	-3.8	-1.07	-0.58	-0.12	0.9	-0.19 [-0.34, -0.04]
		Placebo	391	343 (87.7)	-0.55 (0.74)	-3.1	-1.00	-0.44	-0.02	1.9	
	Week 15	Tezepelumab	395	348 (88.1)	-0.67 (0.75)	-3.3	-1.11	-0.54	-0.07	1.1	-0.17 [-0.32, -0.02]
		Placebo	391	335 (85.7)	-0.54 (0.74)	-3.2	-1.00	-0.50	0.00	1.9	
	Week 16	Tezepelumab	395	352 (89.1)	-0.69 (0.77)	-3.8	-1.13	-0.50	-0.07	1.4	-0.21 [-0.36, -0.06]
		Placebo	391	333 (85.2)	-0.53 (0.75)	-3.1	-1.00	-0.43	0.00	1.9	
	Week 17	Tezepelumab	395	347 (87.8)	-0.72 (0.77)	-3.8	-1.14	-0.58	-0.10	0.9	-0.22 [-0.37, -0.07]
		Placebo	391	327 (83.6)	-0.55 (0.73)	-3.2	-1.00	-0.50	0.00	1.9	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC\_ILMH0: Course of ASD weekly shortness of breath score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly shortness of breath score	Week 18	Tezepelumab	395	346 (87.6)	-0.69 (0.77)	-3.8	-1.14	-0.57	-0.07	1.0	-0.19 [-0.34, -0.03]
		Placebo	391	322 (82.4)	-0.55 (0.77)	-3.1	-1.00	-0.44	0.00	1.9	
	Week 19	Tezepelumab	395	343 (86.8)	-0.70 (0.78)	-3.8	-1.07	-0.63	-0.07	1.4	-0.19 [-0.34, -0.04]
		Placebo	391	332 (84.9)	-0.55 (0.78)	-3.2	-1.00	-0.43	0.00	2.0	
	Week 20	Tezepelumab	395	335 (84.8)	-0.69 (0.78)	-3.8	-1.08	-0.57	-0.07	1.2	-0.16 [-0.31, -0.01]
		Placebo	391	324 (82.9)	-0.56 (0.80)	-3.2	-1.00	-0.50	0.00	1.9	
	Week 21	Tezepelumab	395	334 (84.6)	-0.70 (0.76)	-3.8	-1.14	-0.64	-0.14	2.2	-0.15 [-0.30, 0.01]
		Placebo	391	319 (81.6)	-0.59 (0.79)	-3.2	-1.00	-0.50	-0.07	1.9	
	Week 22	Tezepelumab	395	333 (84.3)	-0.68 (0.78)	-3.4	-1.07	-0.57	-0.11	1.3	-0.13 [-0.28, 0.03]
		Placebo	391	312 (79.8)	-0.58 (0.76)	-3.2	-1.00	-0.51	-0.07	1.9	
	Week 23	Tezepelumab	395	328 (83.0)	-0.70 (0.78)	-3.6	-1.14	-0.64	-0.07	1.2	-0.13 [-0.29, 0.02]
		Placebo	391	310 (79.3)	-0.59 (0.79)	-3.3	-1.07	-0.50	-0.07	1.9	
	Week 24	Tezepelumab	395	337 (85.3)	-0.71 (0.78)	-3.7	-1.14	-0.63	-0.13	1.3	-0.14 [-0.29, 0.02]
		Placebo	391	310 (79.3)	-0.60 (0.78)	-3.2	-1.07	-0.57	-0.07	1.9	
	Week 25	Tezepelumab	395	323 (81.8)	-0.70 (0.77)	-3.8	-1.14	-0.64	-0.07	1.0	-0.13 [-0.29, 0.03]
		Placebo	391	308 (78.8)	-0.60 (0.82)	-3.2	-1.08	-0.55	-0.08	2.0	
	Week 26	Tezepelumab	395	327 (82.8)	-0.70 (0.79)	-3.8	-1.12	-0.63	-0.07	1.8	-0.16 [-0.31, 0.00]
		Placebo	391	303 (77.5)	-0.57 (0.82)	-3.1	-1.07	-0.48	-0.06	1.9	
	Week 27	Tezepelumab	395	317 (80.3)	-0.73 (0.80)	-3.8	-1.17	-0.64	-0.14	1.2	-0.19 [-0.34, -0.03]
		Placebo	391	313 (80.1)	-0.57 (0.83)	-3.1	-1.07	-0.55	0.00	2.4	
	Week 28	Tezepelumab	395	325 (82.3)	-0.75 (0.79)	-3.8	-1.24	-0.64	-0.14	0.9	-0.22 [-0.37, -0.06]
		Placebo	391	314 (80.3)	-0.57 (0.82)	-3.2	-1.07	-0.44	-0.02	1.9	
	Week 29	Tezepelumab	395	317 (80.3)	-0.76 (0.80)	-3.8	-1.29	-0.71	-0.07	1.0	-0.21 [-0.37, -0.05]
		Placebo	391	312 (79.8)	-0.59 (0.82)	-3.2	-1.08	-0.44	-0.02	1.9	
	Week 30	Tezepelumab	395	322 (81.5)	-0.73 (0.79)	-3.8	-1.21	-0.64	-0.14	1.0	-0.18 [-0.34, -0.03]
		Placebo	391	303 (77.5)	-0.58 (0.82)	-3.2	-1.14	-0.50	0.00	1.9	
	Week 31	Tezepelumab	395	322 (81.5)	-0.75 (0.80)	-3.8	-1.21	-0.64	-0.14	1.1	-0.22 [-0.37, -0.06]
		Placebo	391	308 (78.8)	-0.58 (0.76)	-3.0	-1.08	-0.43	-0.04	1.9	
	Week 32	Tezepelumab	395	324 (82.0)	-0.74 (0.77)	-3.8	-1.17	-0.64	-0.14	1.7	-0.19 [-0.35, -0.04]
		Placebo	391	308 (78.8)	-0.59 (0.81)	-3.4	-1.07	-0.47	0.00	1.9	
	Week 33	Tezepelumab	395	321 (81.3)	-0.76 (0.80)	-3.8	-1.21	-0.71	-0.14	1.6	-0.22 [-0.38, -0.06]
		Placebo	391	304 (77.7)	-0.58 (0.81)	-3.5	-1.07	-0.50	0.00	1.9	
	Week 34	Tezepelumab	395	319 (80.8)	-0.77 (0.79)	-3.8	-1.21	-0.75	-0.14	1.6	-0.22 [-0.38, -0.06]
		Placebo	391	303 (77.5)	-0.59 (0.81)	-3.2	-1.07	-0.57	0.00	1.9	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC\_ILMH0: Course of ASD weekly shortness of breath score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly shortness of breath score	Week 35	Tezepelumab	395	320 (81.0)	-0.76 (0.80)	-3.8	-1.21	-0.71	-0.14	1.6	-0.22 [-0.38, -0.06]
		Placebo	391	295 (75.4)	-0.59 (0.80)	-3.2	-1.07	-0.50	0.00	1.9	
	Week 36	Tezepelumab	395	317 (80.3)	-0.75 (0.80)	-3.8	-1.14	-0.75	-0.14	1.8	-0.20 [-0.36, -0.04]
		Placebo	391	299 (76.5)	-0.59 (0.81)	-3.9	-1.07	-0.50	0.00	1.9	
	Week 37	Tezepelumab	395	320 (81.0)	-0.76 (0.81)	-3.8	-1.29	-0.71	-0.14	1.6	-0.20 [-0.36, -0.04]
		Placebo	391	298 (76.2)	-0.60 (0.78)	-3.2	-1.03	-0.50	0.00	1.9	
	Week 38	Tezepelumab	395	317 (80.3)	-0.75 (0.82)	-3.8	-1.21	-0.71	-0.14	1.6	-0.15 [-0.31, 0.01]
		Placebo	391	299 (76.5)	-0.63 (0.77)	-3.2	-1.14	-0.57	-0.07	1.9	
	Week 39	Tezepelumab	395	325 (82.3)	-0.75 (0.82)	-3.8	-1.14	-0.67	-0.14	1.7	-0.17 [-0.33, -0.02]
		Placebo	391	292 (74.7)	-0.61 (0.81)	-3.3	-1.10	-0.56	-0.07	1.9	
	Week 40	Tezepelumab	395	321 (81.3)	-0.75 (0.81)	-3.8	-1.21	-0.71	-0.14	1.6	-0.19 [-0.35, -0.04]
		Placebo	391	297 (76.0)	-0.59 (0.80)	-3.9	-1.08	-0.50	0.00	1.9	
	Week 41	Tezepelumab	395	324 (82.0)	-0.78 (0.80)	-3.8	-1.30	-0.73	-0.14	1.6	-0.20 [-0.36, -0.04]
		Placebo	391	297 (76.0)	-0.62 (0.79)	-3.5	-1.07	-0.56	-0.06	1.9	
	Week 42	Tezepelumab	395	316 (80.0)	-0.78 (0.80)	-3.8	-1.29	-0.71	-0.14	1.6	-0.23 [-0.39, -0.07]
		Placebo	391	298 (76.2)	-0.60 (0.79)	-3.4	-1.07	-0.49	-0.07	1.9	
	Week 43	Tezepelumab	395	319 (80.8)	-0.79 (0.81)	-3.8	-1.25	-0.75	-0.14	1.6	-0.19 [-0.35, -0.04]
		Placebo	391	296 (75.7)	-0.63 (0.80)	-3.2	-1.08	-0.58	-0.07	1.9	
	Week 44	Tezepelumab	395	316 (80.0)	-0.78 (0.81)	-3.8	-1.23	-0.74	-0.16	1.6	-0.20 [-0.36, -0.04]
		Placebo	391	294 (75.2)	-0.62 (0.82)	-3.6	-1.07	-0.50	0.00	1.9	
	Week 45	Tezepelumab	395	319 (80.8)	-0.80 (0.80)	-3.8	-1.25	-0.79	-0.14	1.6	-0.20 [-0.36, -0.04]
		Placebo	391	296 (75.7)	-0.63 (0.84)	-3.6	-1.14	-0.58	0.00	1.9	
	Week 46	Tezepelumab	395	314 (79.5)	-0.79 (0.83)	-3.8	-1.29	-0.71	-0.17	1.7	-0.20 [-0.36, -0.04]
		Placebo	391	287 (73.4)	-0.62 (0.81)	-3.8	-1.07	-0.57	-0.07	1.9	
	Week 47	Tezepelumab	395	302 (76.5)	-0.77 (0.80)	-3.8	-1.29	-0.76	-0.14	1.6	-0.15 [-0.31, 0.01]
		Placebo	391	291 (74.4)	-0.65 (0.78)	-3.4	-1.10	-0.57	-0.08	1.4	
	Week 48	Tezepelumab	395	323 (81.8)	-0.76 (0.82)	-3.8	-1.29	-0.71	-0.14	2.0	-0.14 [-0.29, 0.02]
		Placebo	391	301 (77.0)	-0.65 (0.77)	-3.2	-1.07	-0.62	-0.08	1.4	
	Week 49	Tezepelumab	395	315 (79.7)	-0.76 (0.81)	-3.8	-1.29	-0.64	-0.14	1.6	-0.15 [-0.31, 0.01]
		Placebo	391	290 (74.2)	-0.64 (0.78)	-3.2	-1.07	-0.58	-0.07	1.4	
	Week 50	Tezepelumab	395	312 (79.0)	-0.76 (0.82)	-3.8	-1.24	-0.68	-0.14	1.6	-0.15 [-0.31, 0.01]
		Placebo	391	288 (73.7)	-0.64 (0.79)	-3.2	-1.08	-0.59	-0.10	1.6	
	Week 51	Tezepelumab	395	307 (77.7)	-0.75 (0.83)	-3.8	-1.29	-0.64	-0.14	1.6	-0.16 [-0.32, 0.00]
		Placebo	391	282 (72.1)	-0.62 (0.82)	-3.5	-1.07	-0.57	-0.05	1.6	
	Week 52	Tezepelumab	395	276 (69.9)	-0.75 (0.86)	-3.8	-1.29	-0.64	-0.14	1.7	-0.14 [-0.31, 0.04]
		Placebo	391	257 (65.7)	-0.64 (0.83)	-3.7	-1.07	-0.58	-0.07	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table NT1WBC\_ILMC0: Change from baseline in ASD weekly shortness of breath score - MMRM results  
 DITTTL

Change from baseline in ASD weekly shortness of breath score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 1	Tezepelumab	395	386 (97.7)	-0.22 (0.03)	(-0.29, -0.15)	-0.09 (0.05)	(-0.18, 0.01)	0.070	
	Placebo	391	382 (97.7)	-0.13 (0.03)	(-0.20, -0.07)				
Week 2	Tezepelumab	395	384 (97.2)	-0.35 (0.03)	(-0.41, -0.28)	-0.14 (0.05)	(-0.24, -0.05)	0.003 *	
	Placebo	391	379 (96.9)	-0.20 (0.03)	(-0.27, -0.14)				
Week 3	Tezepelumab	395	379 (95.9)	-0.42 (0.03)	(-0.49, -0.35)	-0.11 (0.05)	(-0.21, -0.01)	0.025 *	
	Placebo	391	371 (94.9)	-0.31 (0.03)	(-0.38, -0.24)				
Week 4	Tezepelumab	395	375 (94.9)	-0.45 (0.03)	(-0.52, -0.38)	-0.11 (0.05)	(-0.21, -0.02)	0.020 *	
	Placebo	391	370 (94.6)	-0.34 (0.03)	(-0.41, -0.27)				
Week 5	Tezepelumab	395	375 (94.9)	-0.51 (0.03)	(-0.57, -0.44)	-0.11 (0.05)	(-0.21, -0.02)	0.023 *	
	Placebo	391	360 (92.1)	-0.40 (0.03)	(-0.46, -0.33)				
Week 6	Tezepelumab	395	368 (93.2)	-0.54 (0.03)	(-0.61, -0.47)	-0.11 (0.05)	(-0.21, -0.02)	0.019 *	
	Placebo	391	365 (93.4)	-0.42 (0.03)	(-0.49, -0.36)				
Week 7	Tezepelumab	395	366 (92.7)	-0.57 (0.03)	(-0.64, -0.50)	-0.13 (0.05)	(-0.23, -0.04)	0.007 *	
	Placebo	391	365 (93.4)	-0.44 (0.03)	(-0.50, -0.37)				
Week 8	Tezepelumab	395	368 (93.2)	-0.59 (0.03)	(-0.65, -0.52)	-0.14 (0.05)	(-0.24, -0.04)	0.004 *	
	Placebo	391	356 (91.0)	-0.45 (0.03)	(-0.51, -0.38)				
Week 9	Tezepelumab	395	370 (93.7)	-0.62 (0.03)	(-0.69, -0.55)	-0.12 (0.05)	(-0.22, -0.03)	0.012 *	
	Placebo	391	357 (91.3)	-0.50 (0.03)	(-0.57, -0.43)				
Week 10	Tezepelumab	395	368 (93.2)	-0.61 (0.03)	(-0.68, -0.55)	-0.11 (0.05)	(-0.21, -0.01)	0.024 *	
	Placebo	391	353 (90.3)	-0.50 (0.03)	(-0.57, -0.44)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC\_ILMC0: Change from baseline in ASD weekly shortness of breath score - MMRM results  
 DITTTL

Change from baseline in ASD weekly shortness of breath score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 11	Tezepelumab	395	359 (90.9)	-0.63 (0.03)	(-0.70, -0.56)	-0.11 (0.05)	(-0.21, -0.01)	0.024 *	
	Placebo	391	351 (89.8)	-0.52 (0.03)	(-0.59, -0.45)				
Week 12	Tezepelumab	395	360 (91.1)	-0.61 (0.03)	(-0.68, -0.54)	-0.10 (0.05)	(-0.20, -0.01)	0.034 *	
	Placebo	391	347 (88.7)	-0.51 (0.04)	(-0.58, -0.44)				
Week 13	Tezepelumab	395	353 (89.4)	-0.65 (0.03)	(-0.72, -0.58)	-0.14 (0.05)	(-0.24, -0.04)	0.004 *	
	Placebo	391	345 (88.2)	-0.51 (0.04)	(-0.58, -0.44)				
Week 14	Tezepelumab	395	350 (88.6)	-0.68 (0.03)	(-0.75, -0.61)	-0.15 (0.05)	(-0.24, -0.05)	0.003 *	
	Placebo	391	343 (87.7)	-0.53 (0.04)	(-0.60, -0.46)				
Week 15	Tezepelumab	395	348 (88.1)	-0.68 (0.03)	(-0.75, -0.61)	-0.14 (0.05)	(-0.24, -0.04)	0.004 *	
	Placebo	391	335 (85.7)	-0.53 (0.04)	(-0.60, -0.47)				
Week 16	Tezepelumab	395	352 (89.1)	-0.70 (0.03)	(-0.77, -0.63)	-0.19 (0.05)	(-0.29, -0.10)	<0.001 *	
	Placebo	391	333 (85.2)	-0.50 (0.04)	(-0.57, -0.44)				
Week 17	Tezepelumab	395	347 (87.8)	-0.70 (0.04)	(-0.77, -0.64)	-0.17 (0.05)	(-0.26, -0.07)	<0.001 *	
	Placebo	391	327 (83.6)	-0.54 (0.04)	(-0.61, -0.47)				
Week 18	Tezepelumab	395	346 (87.6)	-0.69 (0.04)	(-0.76, -0.62)	-0.15 (0.05)	(-0.25, -0.05)	0.002 *	
	Placebo	391	322 (82.4)	-0.54 (0.04)	(-0.61, -0.47)				
Week 19	Tezepelumab	395	343 (86.8)	-0.71 (0.04)	(-0.77, -0.64)	-0.16 (0.05)	(-0.26, -0.06)	0.001 *	
	Placebo	391	332 (84.9)	-0.55 (0.04)	(-0.62, -0.48)				
Week 20	Tezepelumab	395	335 (84.8)	-0.70 (0.04)	(-0.77, -0.63)	-0.15 (0.05)	(-0.25, -0.05)	0.003 *	
	Placebo	391	324 (82.9)	-0.55 (0.04)	(-0.62, -0.48)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC\_ILMC0: Change from baseline in ASD weekly shortness of breath score - MMRM results  
 DITTTL

Change from baseline in ASD weekly shortness of breath score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 21	Tezepelumab	395	334 (84.6)	-0.71 (0.04)	(-0.78, -0.64)	-0.14 (0.05)	(-0.24, -0.04)	0.006 *	
	Placebo	391	319 (81.6)	-0.57 (0.04)	(-0.64, -0.50)				
Week 22	Tezepelumab	395	333 (84.3)	-0.71 (0.04)	(-0.77, -0.64)	-0.12 (0.05)	(-0.22, -0.02)	0.017 *	
	Placebo	391	312 (79.8)	-0.58 (0.04)	(-0.66, -0.51)				
Week 23	Tezepelumab	395	328 (83.0)	-0.72 (0.04)	(-0.79, -0.65)	-0.16 (0.05)	(-0.26, -0.06)	0.002 *	
	Placebo	391	310 (79.3)	-0.56 (0.04)	(-0.63, -0.49)				
Week 24	Tezepelumab	395	337 (85.3)	-0.71 (0.04)	(-0.78, -0.64)	-0.13 (0.05)	(-0.23, -0.04)	0.008 *	
	Placebo	391	310 (79.3)	-0.58 (0.04)	(-0.65, -0.51)				
Week 25	Tezepelumab	395	323 (81.8)	-0.70 (0.04)	(-0.77, -0.63)	-0.13 (0.05)	(-0.22, -0.03)	0.013 *	
	Placebo	391	308 (78.8)	-0.58 (0.04)	(-0.65, -0.51)				
Week 26	Tezepelumab	395	327 (82.8)	-0.71 (0.04)	(-0.78, -0.64)	-0.15 (0.05)	(-0.25, -0.05)	0.003 *	
	Placebo	391	303 (77.5)	-0.56 (0.04)	(-0.63, -0.49)				
Week 27	Tezepelumab	395	317 (80.3)	-0.72 (0.04)	(-0.79, -0.65)	-0.15 (0.05)	(-0.25, -0.05)	0.003 *	
	Placebo	391	313 (80.1)	-0.57 (0.04)	(-0.64, -0.50)				
Week 28	Tezepelumab	395	325 (82.3)	-0.74 (0.04)	(-0.81, -0.67)	-0.17 (0.05)	(-0.27, -0.07)	0.001 *	
	Placebo	391	314 (80.3)	-0.58 (0.04)	(-0.65, -0.51)				
Week 29	Tezepelumab	395	317 (80.3)	-0.74 (0.04)	(-0.81, -0.67)	-0.16 (0.05)	(-0.26, -0.06)	0.002 *	
	Placebo	391	312 (79.8)	-0.58 (0.04)	(-0.65, -0.51)				
Week 30	Tezepelumab	395	322 (81.5)	-0.73 (0.04)	(-0.80, -0.66)	-0.16 (0.05)	(-0.26, -0.06)	0.002 *	
	Placebo	391	303 (77.5)	-0.57 (0.04)	(-0.64, -0.50)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC\_ILMC0: Change from baseline in ASD weekly shortness of breath score - MMRM results  
 DITTTL

Change from baseline in ASD weekly shortness of breath score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 31	Tezepelumab	395	322 (81.5)	-0.74 (0.04)	(-0.81, -0.67)	-0.16 (0.05)	(-0.26, -0.06)	0.001 *	
	Placebo	391	308 (78.8)	-0.58 (0.04)	(-0.65, -0.51)				
Week 32	Tezepelumab	395	324 (82.0)	-0.75 (0.04)	(-0.82, -0.68)	-0.17 (0.05)	(-0.27, -0.07)	<0.001 *	
	Placebo	391	308 (78.8)	-0.58 (0.04)	(-0.65, -0.51)				
Week 33	Tezepelumab	395	321 (81.3)	-0.76 (0.04)	(-0.83, -0.69)	-0.18 (0.05)	(-0.28, -0.08)	<0.001 *	
	Placebo	391	304 (77.7)	-0.58 (0.04)	(-0.65, -0.51)				
Week 34	Tezepelumab	395	319 (80.8)	-0.77 (0.04)	(-0.84, -0.70)	-0.19 (0.05)	(-0.29, -0.09)	<0.001 *	
	Placebo	391	303 (77.5)	-0.58 (0.04)	(-0.65, -0.51)				
Week 35	Tezepelumab	395	320 (81.0)	-0.77 (0.04)	(-0.84, -0.70)	-0.19 (0.05)	(-0.29, -0.09)	<0.001 *	
	Placebo	391	295 (75.4)	-0.58 (0.04)	(-0.65, -0.51)				
Week 36	Tezepelumab	395	317 (80.3)	-0.76 (0.04)	(-0.84, -0.69)	-0.18 (0.05)	(-0.28, -0.08)	<0.001 *	
	Placebo	391	299 (76.5)	-0.59 (0.04)	(-0.66, -0.51)				
Week 37	Tezepelumab	395	320 (81.0)	-0.77 (0.04)	(-0.84, -0.69)	-0.16 (0.05)	(-0.26, -0.05)	0.003 *	
	Placebo	391	298 (76.2)	-0.61 (0.04)	(-0.68, -0.54)				
Week 38	Tezepelumab	395	317 (80.3)	-0.74 (0.04)	(-0.81, -0.67)	-0.14 (0.05)	(-0.24, -0.03)	0.009 *	
	Placebo	391	299 (76.5)	-0.61 (0.04)	(-0.68, -0.53)				
Week 39	Tezepelumab	395	325 (82.3)	-0.74 (0.04)	(-0.81, -0.67)	-0.13 (0.05)	(-0.23, -0.02)	0.015 *	
	Placebo	391	292 (74.7)	-0.62 (0.04)	(-0.69, -0.54)				
Week 40	Tezepelumab	395	321 (81.3)	-0.75 (0.04)	(-0.82, -0.68)	-0.15 (0.05)	(-0.25, -0.05)	0.005 *	
	Placebo	391	297 (76.0)	-0.60 (0.04)	(-0.67, -0.53)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC\_ILMC0: Change from baseline in ASD weekly shortness of breath score - MMRM results  
 DITTTL

Change from baseline in ASD weekly shortness of breath score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 41	Tezepelumab	395	324 (82.0)	-0.78 (0.04)	(-0.85, -0.71)	-0.17 (0.05)	(-0.27, -0.07)	<0.001 *	
	Placebo	391	297 (76.0)	-0.61 (0.04)	(-0.68, -0.53)				
Week 42	Tezepelumab	395	316 (80.0)	-0.77 (0.04)	(-0.85, -0.70)	-0.16 (0.05)	(-0.27, -0.06)	0.002 *	
	Placebo	391	298 (76.2)	-0.61 (0.04)	(-0.68, -0.54)				
Week 43	Tezepelumab	395	319 (80.8)	-0.78 (0.04)	(-0.85, -0.70)	-0.15 (0.05)	(-0.25, -0.04)	0.005 *	
	Placebo	391	296 (75.7)	-0.63 (0.04)	(-0.70, -0.56)				
Week 44	Tezepelumab	395	316 (80.0)	-0.78 (0.04)	(-0.85, -0.71)	-0.16 (0.05)	(-0.27, -0.06)	0.002 *	
	Placebo	391	294 (75.2)	-0.61 (0.04)	(-0.69, -0.54)				
Week 45	Tezepelumab	395	319 (80.8)	-0.79 (0.04)	(-0.86, -0.72)	-0.18 (0.05)	(-0.28, -0.08)	<0.001 *	
	Placebo	391	296 (75.7)	-0.61 (0.04)	(-0.69, -0.54)				
Week 46	Tezepelumab	395	314 (79.5)	-0.80 (0.04)	(-0.87, -0.73)	-0.17 (0.05)	(-0.27, -0.07)	0.001 *	
	Placebo	391	287 (73.4)	-0.63 (0.04)	(-0.70, -0.55)				
Week 47	Tezepelumab	395	302 (76.5)	-0.78 (0.04)	(-0.85, -0.71)	-0.13 (0.05)	(-0.24, -0.03)	0.010 *	
	Placebo	391	291 (74.4)	-0.64 (0.04)	(-0.72, -0.57)				
Week 48	Tezepelumab	395	323 (81.8)	-0.76 (0.04)	(-0.83, -0.69)	-0.12 (0.05)	(-0.22, -0.01)	0.025 *	
	Placebo	391	301 (77.0)	-0.64 (0.04)	(-0.72, -0.57)				
Week 49	Tezepelumab	395	315 (79.7)	-0.76 (0.04)	(-0.83, -0.69)	-0.12 (0.05)	(-0.22, -0.02)	0.020 *	
	Placebo	391	290 (74.2)	-0.64 (0.04)	(-0.71, -0.57)				
Week 50	Tezepelumab	395	312 (79.0)	-0.78 (0.04)	(-0.85, -0.70)	-0.13 (0.05)	(-0.23, -0.03)	0.014 *	
	Placebo	391	288 (73.7)	-0.65 (0.04)	(-0.72, -0.57)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC\_ILMC0: Change from baseline in ASD weekly shortness of breath score - MMRM results  
 DITTTL

Change from baseline in ASD weekly shortness of breath score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 51	Tezepelumab	395	307 (77.7)	-0.76 (0.04)	(-0.84, -0.69)	-0.14 (0.05)	(-0.24, -0.04)	0.007 *	
	Placebo	391	282 (72.1)	-0.62 (0.04)	(-0.70, -0.55)				
Week 52	Tezepelumab	395	276 (69.9)	-0.76 (0.04)	(-0.83, -0.68)	-0.13 (0.05)	(-0.24, -0.03)	0.012 *	
	Placebo	391	257 (65.7)	-0.62 (0.04)	(-0.70, -0.55)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WBC\_ILMH0: Course of ASD weekly shortness of breath score  
 DITTLL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly shortness of breath score	Baseline	Tezepelumab	73	73 (100.0)	1.51 (0.75)	0.0	1.00	1.64	2.00	3.1	
		Placebo	76	76 (100.0)	1.43 (0.84)	0.0	0.93	1.31	2.00	3.9	
	Week 1	Tezepelumab	73	71 (97.3)	1.37 (0.70)	0.0	1.00	1.21	1.93	3.1	
		Placebo	76	76 (100.0)	1.43 (0.79)	0.0	0.89	1.61	2.00	3.0	
	Week 2	Tezepelumab	73	73 (100.0)	1.25 (0.73)	0.0	0.90	1.00	1.86	3.3	
		Placebo	76	74 (97.4)	1.43 (0.79)	0.0	0.92	1.57	2.00	3.0	
	Week 3	Tezepelumab	73	73 (100.0)	1.24 (0.73)	0.0	0.83	1.00	1.83	3.5	
		Placebo	76	73 (96.1)	1.41 (0.72)	0.0	1.00	1.50	2.00	2.7	
	Week 4	Tezepelumab	73	71 (97.3)	1.21 (0.73)	0.0	0.79	1.00	1.90	3.1	
		Placebo	76	76 (100.0)	1.40 (0.74)	0.0	1.00	1.45	2.00	3.1	
	Week 5	Tezepelumab	73	71 (97.3)	1.17 (0.81)	0.0	0.43	1.07	2.00	3.3	
		Placebo	76	74 (97.4)	1.33 (0.75)	0.0	1.00	1.29	2.00	3.0	
	Week 6	Tezepelumab	73	69 (94.5)	1.18 (0.84)	0.0	0.50	1.00	1.93	3.9	
		Placebo	76	72 (94.7)	1.38 (0.77)	0.0	1.00	1.46	2.00	2.9	
	Week 7	Tezepelumab	73	69 (94.5)	1.17 (0.86)	0.0	0.57	1.00	1.93	4.0	
		Placebo	76	75 (98.7)	1.38 (0.75)	0.0	1.00	1.42	2.00	3.0	
	Week 8	Tezepelumab	73	68 (93.2)	1.21 (0.89)	0.0	0.46	1.00	1.96	4.0	
		Placebo	76	75 (98.7)	1.40 (0.76)	0.0	1.00	1.50	2.00	3.2	
	Week 9	Tezepelumab	73	69 (94.5)	1.15 (0.92)	0.0	0.36	1.00	2.00	4.0	
		Placebo	76	73 (96.1)	1.36 (0.81)	0.0	1.00	1.29	2.00	3.0	
	Week 10	Tezepelumab	73	70 (95.9)	1.22 (0.89)	0.0	0.57	1.00	2.00	4.0	
		Placebo	76	74 (97.4)	1.33 (0.76)	0.0	1.00	1.25	2.00	2.9	
	Week 11	Tezepelumab	73	70 (95.9)	1.19 (0.89)	0.0	0.58	1.00	2.00	4.0	
		Placebo	76	74 (97.4)	1.31 (0.76)	0.0	1.00	1.23	2.00	3.1	
	Week 12	Tezepelumab	73	70 (95.9)	1.16 (0.89)	0.0	0.43	1.00	2.00	4.0	
		Placebo	76	75 (98.7)	1.35 (0.76)	0.0	1.00	1.43	2.00	2.9	
	Week 13	Tezepelumab	73	68 (93.2)	1.15 (0.93)	0.0	0.35	1.00	2.00	4.0	
		Placebo	76	71 (93.4)	1.27 (0.81)	0.0	0.71	1.21	2.00	3.0	
	Week 14	Tezepelumab	73	69 (94.5)	1.17 (0.89)	0.0	0.50	1.00	2.00	4.0	
		Placebo	76	73 (96.1)	1.31 (0.83)	0.0	0.86	1.40	2.00	3.4	
	Week 15	Tezepelumab	73	69 (94.5)	1.21 (0.90)	0.0	0.50	1.00	2.00	4.0	
		Placebo	76	72 (94.7)	1.27 (0.82)	0.0	0.65	1.36	2.00	3.0	
	Week 16	Tezepelumab	73	69 (94.5)	1.20 (0.90)	0.0	0.50	1.00	2.00	4.0	
		Placebo	76	74 (97.4)	1.23 (0.76)	0.0	1.00	1.21	2.00	3.0	
Week 17	Tezepelumab	73	68 (93.2)	1.18 (0.87)	0.0	0.61	1.00	1.92	4.0		
	Placebo	76	74 (97.4)	1.23 (0.76)	0.0	1.00	1.08	2.00	2.9		

Note: DITTLL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WBC\_ILMH0: Course of ASD weekly shortness of breath score  
 DITTTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly shortness of breath score	Week 18	Tezepelumab	73	68 (93.2)	1.17 (0.89)	0.0	0.61	1.00	2.00	4.0	
		Placebo	76	72 (94.7)	1.25 (0.79)	0.0	1.00	1.11	2.00	3.0	
	Week 19	Tezepelumab	73	67 (91.8)	1.12 (0.89)	0.0	0.36	1.00	1.83	4.0	
		Placebo	76	72 (94.7)	1.23 (0.79)	0.0	0.81	1.00	2.00	3.0	
	Week 20	Tezepelumab	73	70 (95.9)	1.14 (0.91)	0.0	0.29	1.00	2.00	4.0	
		Placebo	76	72 (94.7)	1.24 (0.78)	0.0	0.82	1.08	2.00	3.0	
	Week 21	Tezepelumab	73	67 (91.8)	1.13 (0.93)	0.0	0.14	1.00	1.86	4.0	
		Placebo	76	73 (96.1)	1.27 (0.80)	0.0	0.93	1.14	2.00	3.1	
	Week 22	Tezepelumab	73	69 (94.5)	1.17 (0.93)	0.0	0.57	1.00	1.88	4.0	
		Placebo	76	74 (97.4)	1.31 (0.87)	0.0	1.00	1.21	2.00	4.0	
	Week 23	Tezepelumab	73	69 (94.5)	1.14 (0.98)	0.0	0.14	1.00	2.00	4.0	
		Placebo	76	74 (97.4)	1.29 (0.86)	0.0	0.88	1.08	2.00	3.6	
	Week 24	Tezepelumab	73	69 (94.5)	1.14 (0.94)	0.0	0.14	1.00	2.00	3.9	
		Placebo	76	75 (98.7)	1.29 (0.84)	0.0	0.93	1.08	2.00	3.1	
	Week 25	Tezepelumab	73	68 (93.2)	1.13 (0.96)	0.0	0.08	1.00	2.00	4.0	
		Placebo	76	74 (97.4)	1.24 (0.79)	0.0	0.86	1.14	2.00	3.0	
	Week 26	Tezepelumab	73	67 (91.8)	1.12 (0.94)	0.0	0.14	1.00	1.93	4.0	
		Placebo	76	73 (96.1)	1.22 (0.82)	0.0	0.64	1.00	2.00	3.2	
	Week 27	Tezepelumab	73	68 (93.2)	1.13 (0.89)	0.0	0.25	1.00	1.93	3.9	
		Placebo	76	71 (93.4)	1.25 (0.84)	0.0	0.71	1.07	2.00	2.9	
	Week 28	Tezepelumab	73	67 (91.8)	1.13 (0.89)	0.0	0.14	1.00	2.00	3.5	
		Placebo	76	71 (93.4)	1.24 (0.85)	0.0	0.71	1.00	2.00	3.0	
	Week 29	Tezepelumab	73	64 (87.7)	1.04 (0.86)	0.0	0.11	1.00	1.78	3.3	
		Placebo	76	74 (97.4)	1.24 (0.83)	0.0	0.64	1.18	2.00	2.9	
	Week 30	Tezepelumab	73	66 (90.4)	1.06 (0.89)	0.0	0.20	1.00	1.86	3.7	
		Placebo	76	74 (97.4)	1.25 (0.83)	0.0	0.79	1.23	2.00	2.9	
	Week 31	Tezepelumab	73	66 (90.4)	1.00 (0.93)	0.0	0.07	1.00	1.50	3.7	
		Placebo	76	72 (94.7)	1.23 (0.84)	0.0	0.64	1.04	2.00	3.0	
	Week 32	Tezepelumab	73	64 (87.7)	1.08 (0.94)	0.0	0.14	1.00	1.86	3.9	
		Placebo	76	73 (96.1)	1.18 (0.79)	0.0	0.50	1.07	1.93	2.9	
	Week 33	Tezepelumab	73	67 (91.8)	1.01 (0.89)	0.0	0.00	1.00	1.71	3.9	
		Placebo	76	72 (94.7)	1.18 (0.80)	0.0	0.59	1.00	2.00	3.0	
	Week 34	Tezepelumab	73	67 (91.8)	0.98 (0.87)	0.0	0.08	1.00	1.43	3.6	
		Placebo	76	71 (93.4)	1.15 (0.80)	0.0	0.29	1.00	2.00	3.0	
	Week 35	Tezepelumab	73	65 (89.0)	1.00 (0.87)	0.0	0.07	1.00	1.50	3.9	
		Placebo	76	74 (97.4)	1.14 (0.81)	0.0	0.30	1.00	2.00	3.0	

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table ST1WBC\_ILMH0: Course of ASD weekly shortness of breath score  
 DITTTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly shortness of breath score	Week 36	Tezepelumab	73	69 (94.5)	1.06 (0.92)	0.0	0.07	1.00	2.00	4.0	
		Placebo	76	71 (93.4)	1.15 (0.80)	0.0	0.30	1.07	2.00	3.0	
	Week 37	Tezepelumab	73	66 (90.4)	1.02 (0.91)	0.0	0.07	1.00	2.00	3.9	
		Placebo	76	72 (94.7)	1.20 (0.80)	0.0	0.62	1.13	2.00	3.0	
	Week 38	Tezepelumab	73	64 (87.7)	0.98 (0.92)	0.0	0.07	1.00	1.79	4.0	
		Placebo	76	72 (94.7)	1.24 (0.80)	0.0	0.81	1.20	2.00	3.0	
	Week 39	Tezepelumab	73	64 (87.7)	0.99 (0.93)	0.0	0.00	1.00	1.69	3.9	
		Placebo	76	71 (93.4)	1.19 (0.83)	0.0	0.50	1.00	2.00	3.0	
	Week 40	Tezepelumab	73	64 (87.7)	1.01 (0.94)	0.0	0.00	1.00	1.96	3.9	
		Placebo	76	71 (93.4)	1.18 (0.84)	0.0	0.57	1.07	2.00	3.0	
	Week 41	Tezepelumab	73	63 (86.3)	0.97 (0.94)	0.0	0.00	1.00	1.71	3.9	
		Placebo	76	70 (92.1)	1.10 (0.81)	0.0	0.21	1.00	1.92	3.0	
	Week 42	Tezepelumab	73	63 (86.3)	0.99 (0.89)	0.0	0.00	1.00	1.64	3.8	
		Placebo	76	72 (94.7)	1.15 (0.77)	0.0	0.50	1.00	1.81	3.0	
	Week 43	Tezepelumab	73	63 (86.3)	1.01 (0.92)	0.0	0.00	1.00	1.50	3.9	
		Placebo	76	72 (94.7)	1.18 (0.82)	0.0	0.29	1.08	1.91	3.0	
	Week 44	Tezepelumab	73	63 (86.3)	0.98 (0.94)	0.0	0.07	1.00	1.50	3.7	
		Placebo	76	73 (96.1)	1.17 (0.79)	0.0	0.64	1.08	1.93	3.0	
	Week 45	Tezepelumab	73	62 (84.9)	0.97 (0.92)	0.0	0.07	1.00	1.50	3.3	
		Placebo	76	70 (92.1)	1.12 (0.79)	0.0	0.50	1.00	2.00	2.7	
	Week 46	Tezepelumab	73	62 (84.9)	0.97 (0.93)	0.0	0.00	1.00	1.50	3.4	
		Placebo	76	68 (89.5)	1.11 (0.80)	0.0	0.36	1.00	1.91	2.8	
	Week 47	Tezepelumab	73	62 (84.9)	0.96 (0.91)	0.0	0.00	1.00	1.50	3.4	
		Placebo	76	70 (92.1)	1.18 (0.77)	0.0	0.67	1.04	2.00	3.0	
	Week 48	Tezepelumab	73	57 (78.1)	1.06 (0.93)	0.0	0.00	1.00	1.58	3.6	
		Placebo	76	68 (89.5)	1.19 (0.79)	0.0	0.50	1.04	2.00	3.0	

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WBC\_ILMH0: Course of ASD weekly shortness of breath score  
 DITTTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly shortness of breath score	Week 1	Tezepelumab	73	71 (97.3)	-0.12 (0.37)	-1.3	-0.26	0.00	0.00	1.0	-0.33 [-0.65, -0.00]
		Placebo	76	76 (100.0)	0.00 (0.40)	-1.8	-0.07	0.00	0.14	0.9	
	Week 2	Tezepelumab	73	73 (100.0)	-0.26 (0.44)	-1.6	-0.43	-0.07	0.00	0.6	-0.64 [-0.97, -0.30]
		Placebo	76	74 (97.4)	0.03 (0.47)	-1.9	-0.10	0.00	0.18	1.3	
	Week 3	Tezepelumab	73	73 (100.0)	-0.27 (0.50)	-1.4	-0.68	-0.07	0.00	0.8	-0.58 [-0.91, -0.25]
		Placebo	76	73 (96.1)	0.02 (0.49)	-1.2	-0.21	0.00	0.21	1.4	
	Week 4	Tezepelumab	73	71 (97.3)	-0.33 (0.56)	-1.7	-0.71	-0.07	0.00	1.2	-0.53 [-0.86, -0.20]
		Placebo	76	76 (100.0)	-0.03 (0.55)	-2.0	-0.19	0.00	0.15	1.3	
	Week 5	Tezepelumab	73	71 (97.3)	-0.35 (0.58)	-2.1	-0.64	-0.14	0.00	0.6	-0.45 [-0.78, -0.12]
		Placebo	76	74 (97.4)	-0.08 (0.60)	-2.2	-0.30	0.00	0.15	1.4	
	Week 6	Tezepelumab	73	69 (94.5)	-0.34 (0.63)	-2.0	-0.71	-0.14	0.00	0.9	-0.49 [-0.83, -0.16]
		Placebo	76	72 (94.7)	-0.04 (0.63)	-2.3	-0.25	0.00	0.25	1.7	
	Week 7	Tezepelumab	73	69 (94.5)	-0.34 (0.65)	-2.0	-0.71	-0.14	0.00	1.0	-0.43 [-0.76, -0.10]
		Placebo	76	75 (98.7)	-0.05 (0.67)	-2.3	-0.35	0.00	0.29	1.5	
	Week 8	Tezepelumab	73	68 (93.2)	-0.34 (0.70)	-2.1	-0.75	-0.14	0.00	1.0	-0.45 [-0.78, -0.12]
		Placebo	76	75 (98.7)	-0.04 (0.65)	-2.3	-0.35	0.00	0.29	1.5	
	Week 9	Tezepelumab	73	69 (94.5)	-0.37 (0.76)	-2.0	-0.86	-0.07	0.00	1.1	-0.41 [-0.74, -0.07]
		Placebo	76	73 (96.1)	-0.07 (0.69)	-2.3	-0.29	0.00	0.29	1.6	
	Week 10	Tezepelumab	73	70 (95.9)	-0.28 (0.78)	-2.0	-0.86	-0.06	0.13	2.0	-0.25 [-0.58, 0.08]
		Placebo	76	74 (97.4)	-0.10 (0.71)	-2.3	-0.45	-0.07	0.14	2.4	
	Week 11	Tezepelumab	73	70 (95.9)	-0.32 (0.76)	-2.1	-0.79	-0.13	0.00	2.0	-0.28 [-0.61, 0.05]
		Placebo	76	74 (97.4)	-0.11 (0.71)	-2.3	-0.43	-0.04	0.07	3.0	
	Week 12	Tezepelumab	73	70 (95.9)	-0.38 (0.79)	-2.1	-0.93	-0.14	0.00	2.0	-0.38 [-0.71, -0.06]
		Placebo	76	75 (98.7)	-0.09 (0.72)	-2.3	-0.49	-0.04	0.21	2.2	
	Week 13	Tezepelumab	73	68 (93.2)	-0.38 (0.83)	-2.1	-0.90	-0.18	0.03	2.0	-0.29 [-0.63, 0.04]
		Placebo	76	71 (93.4)	-0.15 (0.76)	-2.8	-0.50	-0.07	0.16	1.4	
	Week 14	Tezepelumab	73	69 (94.5)	-0.36 (0.77)	-2.1	-0.86	-0.14	0.00	2.0	-0.34 [-0.67, -0.01]
		Placebo	76	73 (96.1)	-0.11 (0.67)	-2.0	-0.49	0.00	0.07	1.8	
	Week 15	Tezepelumab	73	69 (94.5)	-0.33 (0.75)	-2.1	-0.86	-0.14	0.00	2.0	-0.23 [-0.56, 0.10]
		Placebo	76	72 (94.7)	-0.16 (0.73)	-2.9	-0.55	-0.04	0.21	1.4	
	Week 16	Tezepelumab	73	69 (94.5)	-0.34 (0.74)	-2.1	-0.79	-0.10	0.00	1.8	-0.20 [-0.53, 0.13]
		Placebo	76	74 (97.4)	-0.19 (0.71)	-2.3	-0.50	-0.12	0.14	1.4	
	Week 17	Tezepelumab	73	68 (93.2)	-0.37 (0.68)	-2.0	-0.82	-0.17	0.00	1.0	-0.24 [-0.57, 0.09]
		Placebo	76	74 (97.4)	-0.20 (0.74)	-2.0	-0.57	-0.04	0.14	1.3	

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WBC\_ILMH0: Course of ASD weekly shortness of breath score  
 DITTLL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly shortness of breath score	Week 18	Tezepelumab	73	68 (93.2)	-0.35 (0.74)	-2.0	-0.88	-0.21	0.00	1.9	-0.22 [-0.55, 0.11]
		Placebo	76	72 (94.7)	-0.19 (0.77)	-2.3	-0.57	-0.07	0.14	1.4	
	Week 19	Tezepelumab	73	67 (91.8)	-0.41 (0.77)	-2.0	-1.00	-0.21	0.00	1.9	-0.27 [-0.60, 0.07]
		Placebo	76	72 (94.7)	-0.21 (0.72)	-2.3	-0.60	-0.07	0.04	1.5	
	Week 20	Tezepelumab	73	70 (95.9)	-0.39 (0.78)	-2.0	-0.93	-0.25	0.07	1.7	-0.28 [-0.61, 0.05]
		Placebo	76	72 (94.7)	-0.19 (0.71)	-2.3	-0.55	0.00	0.14	1.4	
	Week 21	Tezepelumab	73	67 (91.8)	-0.42 (0.78)	-2.1	-1.00	-0.30	0.00	2.1	-0.31 [-0.64, 0.03]
		Placebo	76	73 (96.1)	-0.18 (0.75)	-2.3	-0.57	-0.07	0.14	1.3	
	Week 22	Tezepelumab	73	69 (94.5)	-0.37 (0.73)	-2.0	-0.86	-0.18	0.00	1.3	-0.33 [-0.66, 0.00]
		Placebo	76	74 (97.4)	-0.12 (0.78)	-2.3	-0.50	0.00	0.21	1.8	
	Week 23	Tezepelumab	73	69 (94.5)	-0.40 (0.82)	-2.2	-1.00	-0.14	0.00	2.0	-0.31 [-0.64, 0.02]
		Placebo	76	74 (97.4)	-0.16 (0.75)	-2.3	-0.57	-0.03	0.29	1.1	
	Week 24	Tezepelumab	73	69 (94.5)	-0.40 (0.81)	-2.2	-0.86	-0.21	0.00	1.1	-0.33 [-0.66, -0.00]
		Placebo	76	75 (98.7)	-0.15 (0.72)	-2.3	-0.50	-0.07	0.21	1.2	
	Week 25	Tezepelumab	73	68 (93.2)	-0.40 (0.85)	-2.3	-1.00	-0.18	0.04	2.1	-0.24 [-0.57, 0.09]
		Placebo	76	74 (97.4)	-0.20 (0.78)	-2.7	-0.57	-0.10	0.14	1.6	
	Week 26	Tezepelumab	73	67 (91.8)	-0.41 (0.83)	-2.3	-1.00	-0.14	0.00	1.7	-0.25 [-0.59, 0.08]
		Placebo	76	73 (96.1)	-0.19 (0.84)	-2.2	-0.57	-0.07	0.14	3.1	
	Week 27	Tezepelumab	73	68 (93.2)	-0.39 (0.83)	-2.4	-0.93	-0.21	0.00	1.9	-0.31 [-0.64, 0.03]
		Placebo	76	71 (93.4)	-0.15 (0.73)	-2.3	-0.42	-0.02	0.21	1.6	
	Week 28	Tezepelumab	73	67 (91.8)	-0.38 (0.84)	-2.4	-0.86	-0.14	0.00	1.8	-0.28 [-0.62, 0.05]
		Placebo	76	71 (93.4)	-0.17 (0.70)	-2.0	-0.50	-0.07	0.12	1.2	
	Week 29	Tezepelumab	73	64 (87.7)	-0.47 (0.78)	-2.4	-1.00	-0.23	0.00	2.0	-0.40 [-0.73, -0.06]
		Placebo	76	74 (97.4)	-0.17 (0.74)	-2.3	-0.50	0.00	0.14	1.4	
	Week 30	Tezepelumab	73	66 (90.4)	-0.46 (0.88)	-2.4	-1.00	-0.25	0.00	2.0	-0.38 [-0.71, -0.04]
		Placebo	76	74 (97.4)	-0.16 (0.68)	-2.0	-0.55	-0.04	0.14	1.4	
	Week 31	Tezepelumab	73	66 (90.4)	-0.50 (0.92)	-2.4	-1.00	-0.39	0.00	2.4	-0.39 [-0.73, -0.05]
		Placebo	76	72 (94.7)	-0.19 (0.69)	-2.0	-0.61	-0.07	0.07	1.4	
	Week 32	Tezepelumab	73	64 (87.7)	-0.47 (0.92)	-2.4	-1.00	-0.32	0.00	2.6	-0.28 [-0.62, 0.06]
		Placebo	76	73 (96.1)	-0.24 (0.68)	-2.0	-0.57	-0.14	0.00	1.3	
	Week 33	Tezepelumab	73	67 (91.8)	-0.49 (0.86)	-2.4	-1.00	-0.29	0.00	2.6	-0.31 [-0.64, 0.03]
		Placebo	76	72 (94.7)	-0.25 (0.75)	-2.3	-0.61	-0.08	0.00	1.7	
	Week 34	Tezepelumab	73	67 (91.8)	-0.53 (0.83)	-2.4	-1.00	-0.57	0.00	2.2	-0.33 [-0.67, 0.00]
		Placebo	76	71 (93.4)	-0.28 (0.66)	-2.0	-0.72	-0.14	0.08	1.1	

Note: DITTLL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WBC\_ILMH0: Course of ASD weekly shortness of breath score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly shortness of breath score	Week 35	Tezepelumab	73	65 (89.0)	-0.50 (0.86)	-2.4	-1.00	-0.40	0.00	2.0	-0.30 [-0.64, 0.03]
		Placebo	76	74 (97.4)	-0.27 (0.67)	-2.0	-0.75	-0.09	0.00	1.2	
	Week 36	Tezepelumab	73	69 (94.5)	-0.45 (0.87)	-2.4	-0.93	-0.21	0.00	2.0	-0.23 [-0.56, 0.11]
		Placebo	76	71 (93.4)	-0.27 (0.70)	-2.0	-0.79	-0.07	0.14	1.4	
	Week 37	Tezepelumab	73	66 (90.4)	-0.50 (0.90)	-2.4	-1.00	-0.39	0.00	1.9	-0.35 [-0.68, -0.01]
		Placebo	76	72 (94.7)	-0.22 (0.72)	-2.0	-0.59	-0.06	0.21	1.3	
	Week 38	Tezepelumab	73	64 (87.7)	-0.52 (0.90)	-2.4	-1.00	-0.50	0.00	2.5	-0.43 [-0.77, -0.09]
		Placebo	76	72 (94.7)	-0.17 (0.73)	-2.0	-0.57	0.00	0.19	1.3	
	Week 39	Tezepelumab	73	64 (87.7)	-0.52 (0.91)	-2.4	-1.04	-0.29	0.00	2.2	-0.41 [-0.75, -0.07]
		Placebo	76	71 (93.4)	-0.19 (0.71)	-2.0	-0.57	0.00	0.20	1.5	
	Week 40	Tezepelumab	73	64 (87.7)	-0.51 (0.91)	-2.3	-1.04	-0.29	0.00	2.0	-0.33 [-0.67, 0.01]
		Placebo	76	71 (93.4)	-0.24 (0.67)	-2.0	-0.72	-0.05	0.17	1.0	
	Week 41	Tezepelumab	73	63 (86.3)	-0.54 (0.93)	-2.3	-1.07	-0.64	0.00	2.3	-0.30 [-0.64, 0.04]
		Placebo	76	70 (92.1)	-0.29 (0.72)	-2.6	-0.67	-0.10	0.00	1.0	
	Week 42	Tezepelumab	73	63 (86.3)	-0.51 (0.89)	-2.2	-1.00	-0.64	0.00	1.8	-0.31 [-0.65, 0.04]
		Placebo	76	72 (94.7)	-0.27 (0.68)	-2.0	-0.71	-0.11	0.11	1.0	
	Week 43	Tezepelumab	73	63 (86.3)	-0.49 (0.91)	-2.2	-1.00	-0.57	0.00	1.9	-0.32 [-0.66, 0.02]
		Placebo	76	72 (94.7)	-0.22 (0.77)	-2.2	-0.74	-0.07	0.25	1.3	
	Week 44	Tezepelumab	73	63 (86.3)	-0.51 (0.92)	-2.2	-1.00	-0.64	0.00	2.0	-0.34 [-0.68, 0.00]
		Placebo	76	73 (96.1)	-0.24 (0.73)	-2.0	-0.64	0.00	0.21	1.0	
	Week 45	Tezepelumab	73	62 (84.9)	-0.53 (0.91)	-2.2	-1.00	-0.56	0.00	2.0	-0.31 [-0.66, 0.03]
		Placebo	76	70 (92.1)	-0.27 (0.74)	-2.7	-0.64	-0.07	0.14	1.2	
	Week 46	Tezepelumab	73	62 (84.9)	-0.52 (0.88)	-2.4	-1.00	-0.61	0.00	2.0	-0.27 [-0.61, 0.08]
		Placebo	76	68 (89.5)	-0.30 (0.74)	-2.0	-0.80	-0.07	0.00	1.3	
	Week 47	Tezepelumab	73	62 (84.9)	-0.53 (0.93)	-2.3	-1.00	-0.61	0.00	2.0	-0.33 [-0.67, 0.02]
		Placebo	76	70 (92.1)	-0.26 (0.71)	-2.0	-0.85	-0.11	0.21	1.3	
	Week 48	Tezepelumab	73	57 (78.1)	-0.46 (0.93)	-2.4	-1.00	-0.57	0.00	2.0	-0.24 [-0.59, 0.11]
		Placebo	76	68 (89.5)	-0.26 (0.71)	-2.0	-0.85	-0.09	0.23	1.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WBC\_ILMC0: Change from baseline in ASD weekly shortness of breath score - MMRM results  
DITTTL

Change from baseline in ASD weekly shortness of breath score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Time	Treatment	N	n (%)					
Week 1	Tezepelumab	73	71 (97.3)	-0.11 (0.08)	(-0.26, 0.05)	-0.09 (0.11)	(-0.31, 0.12)	0.389
	Placebo	76	76 (100.0)	-0.01 (0.08)	(-0.16, 0.14)			
Week 2	Tezepelumab	73	73 (100.0)	-0.24 (0.08)	(-0.40, -0.09)	-0.24 (0.11)	(-0.45, -0.03)	0.029 *
	Placebo	76	74 (97.4)	-0.00 (0.08)	(-0.15, 0.15)			
Week 3	Tezepelumab	73	73 (100.0)	-0.25 (0.08)	(-0.41, -0.10)	-0.22 (0.11)	(-0.44, -0.01)	0.041 *
	Placebo	76	73 (96.1)	-0.03 (0.08)	(-0.18, 0.12)			
Week 4	Tezepelumab	73	71 (97.3)	-0.30 (0.08)	(-0.45, -0.15)	-0.25 (0.11)	(-0.47, -0.04)	0.021 *
	Placebo	76	76 (100.0)	-0.05 (0.08)	(-0.20, 0.10)			
Week 5	Tezepelumab	73	71 (97.3)	-0.33 (0.08)	(-0.49, -0.18)	-0.22 (0.11)	(-0.43, -0.00)	0.049 *
	Placebo	76	74 (97.4)	-0.12 (0.08)	(-0.27, 0.03)			
Week 6	Tezepelumab	73	69 (94.5)	-0.32 (0.08)	(-0.47, -0.17)	-0.23 (0.11)	(-0.44, -0.01)	0.040 *
	Placebo	76	72 (94.7)	-0.09 (0.08)	(-0.25, 0.06)			
Week 7	Tezepelumab	73	69 (94.5)	-0.32 (0.08)	(-0.47, -0.16)	-0.24 (0.11)	(-0.46, -0.03)	0.027 *
	Placebo	76	75 (98.7)	-0.07 (0.08)	(-0.22, 0.08)			
Week 8	Tezepelumab	73	68 (93.2)	-0.31 (0.08)	(-0.46, -0.15)	-0.25 (0.11)	(-0.47, -0.04)	0.022 *
	Placebo	76	75 (98.7)	-0.06 (0.08)	(-0.21, 0.09)			
Week 9	Tezepelumab	73	69 (94.5)	-0.35 (0.08)	(-0.51, -0.20)	-0.26 (0.11)	(-0.48, -0.05)	0.018 *
	Placebo	76	73 (96.1)	-0.09 (0.08)	(-0.24, 0.06)			
Week 10	Tezepelumab	73	70 (95.9)	-0.27 (0.08)	(-0.42, -0.11)	-0.16 (0.11)	(-0.38, 0.06)	0.147
	Placebo	76	74 (97.4)	-0.11 (0.08)	(-0.26, 0.04)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WBC\_ILMC0: Change from baseline in ASD weekly shortness of breath score - MMRM results  
 DITTTL

Change from baseline in ASD weekly shortness of breath score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Time	Treatment	N	n (%)					
Week 11	Tezepelumab	73	70 (95.9)	-0.30 (0.08)	(-0.46, -0.15)	-0.18 (0.11)	(-0.40, 0.03)	0.096
	Placebo	76	74 (97.4)	-0.12 (0.08)	(-0.27, 0.03)			
Week 12	Tezepelumab	73	70 (95.9)	-0.36 (0.08)	(-0.51, -0.20)	-0.26 (0.11)	(-0.47, -0.04)	0.021 *
	Placebo	76	75 (98.7)	-0.10 (0.08)	(-0.25, 0.05)			
Week 13	Tezepelumab	73	68 (93.2)	-0.36 (0.08)	(-0.52, -0.20)	-0.18 (0.11)	(-0.39, 0.04)	0.113
	Placebo	76	71 (93.4)	-0.18 (0.08)	(-0.34, -0.03)			
Week 14	Tezepelumab	73	69 (94.5)	-0.33 (0.08)	(-0.48, -0.17)	-0.18 (0.11)	(-0.40, 0.04)	0.104
	Placebo	76	73 (96.1)	-0.15 (0.08)	(-0.30, 0.00)			
Week 15	Tezepelumab	73	69 (94.5)	-0.31 (0.08)	(-0.47, -0.16)	-0.14 (0.11)	(-0.35, 0.08)	0.214
	Placebo	76	72 (94.7)	-0.18 (0.08)	(-0.33, -0.03)			
Week 16	Tezepelumab	73	69 (94.5)	-0.32 (0.08)	(-0.48, -0.17)	-0.11 (0.11)	(-0.33, 0.10)	0.300
	Placebo	76	74 (97.4)	-0.21 (0.08)	(-0.36, -0.06)			
Week 17	Tezepelumab	73	68 (93.2)	-0.36 (0.08)	(-0.52, -0.21)	-0.15 (0.11)	(-0.36, 0.07)	0.187
	Placebo	76	74 (97.4)	-0.22 (0.08)	(-0.37, -0.06)			
Week 18	Tezepelumab	73	68 (93.2)	-0.34 (0.08)	(-0.50, -0.19)	-0.14 (0.11)	(-0.36, 0.07)	0.196
	Placebo	76	72 (94.7)	-0.20 (0.08)	(-0.35, -0.05)			
Week 19	Tezepelumab	73	67 (91.8)	-0.38 (0.08)	(-0.54, -0.22)	-0.18 (0.11)	(-0.39, 0.04)	0.113
	Placebo	76	72 (94.7)	-0.20 (0.08)	(-0.35, -0.05)			
Week 20	Tezepelumab	73	70 (95.9)	-0.37 (0.08)	(-0.53, -0.22)	-0.18 (0.11)	(-0.40, 0.03)	0.100
	Placebo	76	72 (94.7)	-0.19 (0.08)	(-0.34, -0.04)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WBC\_ILMC0: Change from baseline in ASD weekly shortness of breath score - MMRM results  
 DITTTL

Change from baseline in ASD weekly shortness of breath score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 21	Tezepelumab	73	67 (91.8)	-0.38 (0.08)	(-0.54, -0.23)	-0.19 (0.11)	(-0.41, 0.03)	0.085
	Placebo	76	73 (96.1)	-0.19 (0.08)	(-0.34, -0.04)			
Week 22	Tezepelumab	73	69 (94.5)	-0.35 (0.08)	(-0.51, -0.20)	-0.22 (0.11)	(-0.44, -0.01)	0.044 *
	Placebo	76	74 (97.4)	-0.13 (0.08)	(-0.28, 0.02)			
Week 23	Tezepelumab	73	69 (94.5)	-0.39 (0.08)	(-0.54, -0.23)	-0.21 (0.11)	(-0.43, 0.00)	0.055
	Placebo	76	74 (97.4)	-0.17 (0.08)	(-0.32, -0.02)			
Week 24	Tezepelumab	73	69 (94.5)	-0.39 (0.08)	(-0.55, -0.24)	-0.23 (0.11)	(-0.45, -0.01)	0.039 *
	Placebo	76	75 (98.7)	-0.16 (0.08)	(-0.31, -0.01)			
Week 25	Tezepelumab	73	68 (93.2)	-0.37 (0.08)	(-0.53, -0.21)	-0.14 (0.11)	(-0.36, 0.07)	0.195
	Placebo	76	74 (97.4)	-0.23 (0.08)	(-0.38, -0.08)			
Week 26	Tezepelumab	73	67 (91.8)	-0.37 (0.08)	(-0.53, -0.21)	-0.16 (0.11)	(-0.38, 0.05)	0.141
	Placebo	76	73 (96.1)	-0.21 (0.08)	(-0.36, -0.05)			
Week 27	Tezepelumab	73	68 (93.2)	-0.36 (0.08)	(-0.52, -0.20)	-0.17 (0.11)	(-0.39, 0.04)	0.118
	Placebo	76	71 (93.4)	-0.19 (0.08)	(-0.34, -0.04)			
Week 28	Tezepelumab	73	67 (91.8)	-0.35 (0.08)	(-0.51, -0.19)	-0.17 (0.11)	(-0.39, 0.05)	0.131
	Placebo	76	71 (93.4)	-0.18 (0.08)	(-0.34, -0.03)			
Week 29	Tezepelumab	73	64 (87.7)	-0.40 (0.08)	(-0.55, -0.24)	-0.21 (0.11)	(-0.43, 0.01)	0.057
	Placebo	76	74 (97.4)	-0.18 (0.08)	(-0.33, -0.03)			
Week 30	Tezepelumab	73	66 (90.4)	-0.42 (0.08)	(-0.58, -0.27)	-0.25 (0.11)	(-0.47, -0.03)	0.026 *
	Placebo	76	74 (97.4)	-0.18 (0.08)	(-0.33, -0.02)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WBC\_ILMC0: Change from baseline in ASD weekly shortness of breath score - MMRM results  
 DITTTL

Change from baseline in ASD weekly shortness of breath score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 31	Tezepelumab	73	66 (90.4)	-0.45 (0.08)	(-0.61, -0.30)	-0.27 (0.11)	(-0.49, -0.05)	0.017 *	
	Placebo	76	72 (94.7)	-0.19 (0.08)	(-0.34, -0.04)				
Week 32	Tezepelumab	73	64 (87.7)	-0.43 (0.08)	(-0.59, -0.28)	-0.19 (0.11)	(-0.41, 0.03)	0.088	
	Placebo	76	73 (96.1)	-0.24 (0.08)	(-0.39, -0.09)				
Week 33	Tezepelumab	73	67 (91.8)	-0.45 (0.08)	(-0.60, -0.29)	-0.18 (0.11)	(-0.40, 0.04)	0.101	
	Placebo	76	72 (94.7)	-0.26 (0.08)	(-0.42, -0.11)				
Week 34	Tezepelumab	73	67 (91.8)	-0.48 (0.08)	(-0.64, -0.32)	-0.18 (0.11)	(-0.40, 0.04)	0.103	
	Placebo	76	71 (93.4)	-0.30 (0.08)	(-0.45, -0.14)				
Week 35	Tezepelumab	73	65 (89.0)	-0.44 (0.08)	(-0.60, -0.29)	-0.16 (0.11)	(-0.38, 0.06)	0.161	
	Placebo	76	74 (97.4)	-0.29 (0.08)	(-0.44, -0.13)				
Week 36	Tezepelumab	73	69 (94.5)	-0.42 (0.08)	(-0.58, -0.27)	-0.13 (0.11)	(-0.35, 0.09)	0.233	
	Placebo	76	71 (93.4)	-0.29 (0.08)	(-0.44, -0.14)				
Week 37	Tezepelumab	73	66 (90.4)	-0.46 (0.08)	(-0.62, -0.30)	-0.22 (0.11)	(-0.44, -0.00)	0.045 *	
	Placebo	76	72 (94.7)	-0.23 (0.08)	(-0.39, -0.08)				
Week 38	Tezepelumab	73	64 (87.7)	-0.48 (0.08)	(-0.64, -0.32)	-0.28 (0.11)	(-0.50, -0.06)	0.013 *	
	Placebo	76	72 (94.7)	-0.20 (0.08)	(-0.35, -0.05)				
Week 39	Tezepelumab	73	64 (87.7)	-0.47 (0.08)	(-0.63, -0.31)	-0.24 (0.11)	(-0.46, -0.02)	0.035 *	
	Placebo	76	71 (93.4)	-0.23 (0.08)	(-0.38, -0.08)				
Week 40	Tezepelumab	73	64 (87.7)	-0.46 (0.08)	(-0.61, -0.30)	-0.20 (0.11)	(-0.42, 0.02)	0.077	
	Placebo	76	71 (93.4)	-0.26 (0.08)	(-0.41, -0.10)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table ST1WBC\_ILMC0: Change from baseline in ASD weekly shortness of breath score - MMRM results  
 DITTTL

Change from baseline in ASD weekly shortness of breath score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 41	Tezepelumab	73	63 (86.3)	-0.47 (0.08)	(-0.63, -0.31)	-0.16 (0.11)	(-0.38, 0.07)	0.166	
	Placebo	76	70 (92.1)	-0.32 (0.08)	(-0.47, -0.16)				
Week 42	Tezepelumab	73	63 (86.3)	-0.44 (0.08)	(-0.60, -0.28)	-0.16 (0.11)	(-0.38, 0.06)	0.156	
	Placebo	76	72 (94.7)	-0.28 (0.08)	(-0.43, -0.12)				
Week 43	Tezepelumab	73	63 (86.3)	-0.42 (0.08)	(-0.59, -0.26)	-0.18 (0.11)	(-0.40, 0.05)	0.119	
	Placebo	76	72 (94.7)	-0.25 (0.08)	(-0.40, -0.10)				
Week 44	Tezepelumab	73	63 (86.3)	-0.45 (0.08)	(-0.61, -0.29)	-0.19 (0.11)	(-0.42, 0.03)	0.088	
	Placebo	76	73 (96.1)	-0.26 (0.08)	(-0.41, -0.11)				
Week 45	Tezepelumab	73	62 (84.9)	-0.47 (0.08)	(-0.63, -0.31)	-0.16 (0.11)	(-0.38, 0.06)	0.160	
	Placebo	76	70 (92.1)	-0.31 (0.08)	(-0.46, -0.16)				
Week 46	Tezepelumab	73	62 (84.9)	-0.49 (0.08)	(-0.65, -0.33)	-0.20 (0.11)	(-0.42, 0.03)	0.086	
	Placebo	76	68 (89.5)	-0.29 (0.08)	(-0.45, -0.14)				
Week 47	Tezepelumab	73	62 (84.9)	-0.47 (0.08)	(-0.63, -0.30)	-0.21 (0.11)	(-0.43, 0.02)	0.072	
	Placebo	76	70 (92.1)	-0.26 (0.08)	(-0.41, -0.11)				
Week 48	Tezepelumab	73	57 (78.1)	-0.44 (0.08)	(-0.60, -0.27)	-0.20 (0.11)	(-0.42, 0.03)	0.085	
	Placebo	76	68 (89.5)	-0.24 (0.08)	(-0.39, -0.09)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WHC\_ILMH0: Course of ASD weekly cough score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly cough score	Baseline	Tezepelumab	395	395 (100.0)	1.40 (0.82)	0.0	0.93	1.36	2.00	4.0	
		Placebo	391	391 (100.0)	1.36 (0.83)	0.0	0.79	1.29	2.00	3.9	
	Week 1	Tezepelumab	395	386 (97.7)	1.20 (0.79)	0.0	0.64	1.14	1.71	3.8	
		Placebo	391	382 (97.7)	1.27 (0.81)	0.0	0.71	1.17	1.92	4.0	
	Week 2	Tezepelumab	395	384 (97.2)	1.07 (0.80)	0.0	0.42	1.00	1.61	3.9	
		Placebo	391	379 (96.9)	1.22 (0.82)	0.0	0.64	1.08	1.92	4.0	
	Week 3	Tezepelumab	395	379 (95.9)	1.01 (0.79)	0.0	0.25	1.00	1.50	3.9	
		Placebo	391	371 (94.9)	1.11 (0.80)	0.0	0.43	1.00	1.71	4.0	
	Week 4	Tezepelumab	395	375 (94.9)	0.98 (0.80)	0.0	0.21	1.00	1.43	4.0	
		Placebo	391	370 (94.6)	1.07 (0.78)	0.0	0.36	1.00	1.70	4.0	
	Week 5	Tezepelumab	395	375 (94.9)	0.91 (0.80)	0.0	0.14	0.92	1.36	4.0	
		Placebo	391	360 (92.1)	1.01 (0.79)	0.0	0.27	1.00	1.50	4.0	
	Week 6	Tezepelumab	395	368 (93.2)	0.88 (0.78)	0.0	0.13	0.87	1.36	3.9	
		Placebo	391	365 (93.4)	1.02 (0.82)	0.0	0.25	1.00	1.64	4.0	
	Week 7	Tezepelumab	395	366 (92.7)	0.86 (0.78)	0.0	0.08	0.92	1.33	4.0	
		Placebo	391	365 (93.4)	0.96 (0.80)	0.0	0.17	1.00	1.50	4.0	
	Week 8	Tezepelumab	395	368 (93.2)	0.83 (0.77)	0.0	0.07	0.79	1.32	3.9	
		Placebo	391	356 (91.0)	0.96 (0.80)	0.0	0.17	1.00	1.43	4.0	
	Week 9	Tezepelumab	395	370 (93.7)	0.80 (0.76)	0.0	0.00	0.77	1.17	3.1	
		Placebo	391	357 (91.3)	0.94 (0.81)	0.0	0.14	1.00	1.43	4.0	
	Week 10	Tezepelumab	395	368 (93.2)	0.81 (0.77)	0.0	0.00	0.92	1.18	3.0	
		Placebo	391	353 (90.3)	0.96 (0.79)	0.0	0.17	1.00	1.50	4.0	
	Week 11	Tezepelumab	395	359 (90.9)	0.83 (0.78)	0.0	0.00	0.86	1.33	3.0	
		Placebo	391	351 (89.8)	0.94 (0.79)	0.0	0.17	1.00	1.43	4.0	
	Week 12	Tezepelumab	395	360 (91.1)	0.83 (0.77)	0.0	0.00	0.96	1.21	3.1	
		Placebo	391	347 (88.7)	0.90 (0.79)	0.0	0.14	0.93	1.30	4.0	
	Week 13	Tezepelumab	395	353 (89.4)	0.80 (0.78)	0.0	0.00	0.79	1.21	3.5	
		Placebo	391	345 (88.2)	0.88 (0.79)	0.0	0.08	0.93	1.33	4.0	
	Week 14	Tezepelumab	395	350 (88.6)	0.76 (0.74)	0.0	0.00	0.75	1.08	3.1	
		Placebo	391	343 (87.7)	0.88 (0.79)	0.0	0.07	1.00	1.36	4.0	
	Week 15	Tezepelumab	395	348 (88.1)	0.77 (0.73)	0.0	0.00	0.77	1.14	3.0	
		Placebo	391	335 (85.7)	0.87 (0.80)	0.0	0.07	0.93	1.29	4.0	
	Week 16	Tezepelumab	395	352 (89.1)	0.75 (0.76)	0.0	0.00	0.65	1.07	3.1	
		Placebo	391	333 (85.2)	0.90 (0.81)	0.0	0.08	0.93	1.29	4.0	
Week 17	Tezepelumab	395	347 (87.8)	0.71 (0.74)	0.0	0.00	0.57	1.07	3.1		
	Placebo	391	327 (83.6)	0.88 (0.76)	0.0	0.08	1.00	1.29	4.0		

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WHC\_ILMH0: Course of ASD weekly cough score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly cough score	Week 18	Tezepelumab	395	346 (87.6)	0.74 (0.76)	0.0	0.00	0.58	1.14	3.4	
		Placebo	391	322 (82.4)	0.88 (0.78)	0.0	0.08	0.92	1.29	4.0	
	Week 19	Tezepelumab	395	343 (86.8)	0.72 (0.75)	0.0	0.00	0.64	1.08	3.1	
		Placebo	391	332 (84.9)	0.89 (0.82)	0.0	0.07	1.00	1.33	4.0	
	Week 20	Tezepelumab	395	335 (84.8)	0.72 (0.76)	0.0	0.00	0.57	1.00	3.1	
		Placebo	391	324 (82.9)	0.89 (0.80)	0.0	0.08	1.00	1.37	4.0	
	Week 21	Tezepelumab	395	334 (84.6)	0.69 (0.74)	0.0	0.00	0.50	1.00	3.4	
		Placebo	391	319 (81.6)	0.85 (0.79)	0.0	0.00	0.93	1.20	4.0	
	Week 22	Tezepelumab	395	333 (84.3)	0.72 (0.74)	0.0	0.00	0.63	1.07	3.1	
		Placebo	391	312 (79.8)	0.87 (0.79)	0.0	0.07	1.00	1.31	4.0	
	Week 23	Tezepelumab	395	328 (83.0)	0.73 (0.75)	0.0	0.00	0.71	1.04	3.1	
		Placebo	391	310 (79.3)	0.87 (0.78)	0.0	0.07	1.00	1.25	4.0	
	Week 24	Tezepelumab	395	337 (85.3)	0.72 (0.75)	0.0	0.00	0.67	1.00	3.3	
		Placebo	391	310 (79.3)	0.86 (0.79)	0.0	0.07	1.00	1.20	4.0	
	Week 25	Tezepelumab	395	323 (81.8)	0.73 (0.73)	0.0	0.00	0.64	1.07	3.6	
		Placebo	391	308 (78.8)	0.85 (0.80)	0.0	0.07	0.93	1.21	4.0	
	Week 26	Tezepelumab	395	327 (82.8)	0.74 (0.74)	0.0	0.00	0.71	1.07	3.0	
		Placebo	391	303 (77.5)	0.86 (0.79)	0.0	0.07	0.93	1.21	4.0	
	Week 27	Tezepelumab	395	317 (80.3)	0.71 (0.75)	0.0	0.00	0.57	1.00	3.1	
		Placebo	391	313 (80.1)	0.87 (0.83)	0.0	0.00	1.00	1.29	4.0	
	Week 28	Tezepelumab	395	325 (82.3)	0.69 (0.76)	0.0	0.00	0.43	1.00	3.1	
		Placebo	391	314 (80.3)	0.86 (0.79)	0.0	0.00	1.00	1.25	4.0	
	Week 29	Tezepelumab	395	317 (80.3)	0.70 (0.76)	0.0	0.00	0.43	1.00	3.4	
		Placebo	391	312 (79.8)	0.86 (0.81)	0.0	0.07	0.89	1.29	4.0	
	Week 30	Tezepelumab	395	322 (81.5)	0.71 (0.75)	0.0	0.00	0.60	1.00	3.8	
		Placebo	391	303 (77.5)	0.85 (0.79)	0.0	0.07	1.00	1.25	4.0	
	Week 31	Tezepelumab	395	322 (81.5)	0.70 (0.76)	0.0	0.00	0.50	1.07	4.0	
		Placebo	391	308 (78.8)	0.83 (0.76)	0.0	0.07	0.87	1.14	4.0	
	Week 32	Tezepelumab	395	324 (82.0)	0.73 (0.76)	0.0	0.00	0.59	1.07	3.8	
		Placebo	391	308 (78.8)	0.85 (0.77)	0.0	0.07	0.93	1.14	4.0	
	Week 33	Tezepelumab	395	321 (81.3)	0.71 (0.76)	0.0	0.00	0.58	1.07	3.2	
		Placebo	391	304 (77.7)	0.85 (0.80)	0.0	0.07	0.90	1.21	4.0	
	Week 34	Tezepelumab	395	319 (80.8)	0.70 (0.77)	0.0	0.00	0.42	1.08	3.5	
		Placebo	391	303 (77.5)	0.84 (0.79)	0.0	0.07	0.86	1.21	4.0	
	Week 35	Tezepelumab	395	320 (81.0)	0.74 (0.80)	0.0	0.00	0.50	1.11	4.0	
		Placebo	391	295 (75.4)	0.82 (0.78)	0.0	0.00	0.93	1.14	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WHC\_ILMH0: Course of ASD weekly cough score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly cough score	Week 36	Tezepelumab	395	317 (80.3)	0.78 (0.81)	0.0	0.00	0.64	1.07	4.0	
		Placebo	391	299 (76.5)	0.84 (0.76)	0.0	0.07	1.00	1.20	4.0	
	Week 37	Tezepelumab	395	320 (81.0)	0.74 (0.81)	0.0	0.00	0.61	1.07	4.0	
		Placebo	391	298 (76.2)	0.82 (0.77)	0.0	0.00	0.93	1.14	4.0	
	Week 38	Tezepelumab	395	317 (80.3)	0.75 (0.80)	0.0	0.00	0.58	1.00	4.0	
		Placebo	391	299 (76.5)	0.78 (0.72)	0.0	0.07	0.88	1.08	4.0	
	Week 39	Tezepelumab	395	325 (82.3)	0.78 (0.83)	0.0	0.00	0.63	1.13	3.9	
		Placebo	391	292 (74.7)	0.81 (0.77)	0.0	0.07	0.87	1.13	4.0	
	Week 40	Tezepelumab	395	321 (81.3)	0.75 (0.79)	0.0	0.00	0.50	1.08	3.7	
		Placebo	391	297 (76.0)	0.84 (0.78)	0.0	0.08	0.88	1.13	4.0	
	Week 41	Tezepelumab	395	324 (82.0)	0.70 (0.79)	0.0	0.00	0.50	1.00	4.0	
		Placebo	391	297 (76.0)	0.84 (0.75)	0.0	0.07	1.00	1.21	4.0	
	Week 42	Tezepelumab	395	316 (80.0)	0.72 (0.80)	0.0	0.00	0.50	1.07	4.0	
		Placebo	391	298 (76.2)	0.88 (0.79)	0.0	0.07	1.00	1.20	4.0	
	Week 43	Tezepelumab	395	319 (80.8)	0.71 (0.80)	0.0	0.00	0.43	1.00	4.0	
		Placebo	391	296 (75.7)	0.83 (0.77)	0.0	0.07	1.00	1.18	4.0	
	Week 44	Tezepelumab	395	316 (80.0)	0.68 (0.79)	0.0	0.00	0.36	1.00	4.0	
		Placebo	391	294 (75.2)	0.84 (0.77)	0.0	0.07	0.96	1.17	4.0	
	Week 45	Tezepelumab	395	319 (80.8)	0.69 (0.78)	0.0	0.00	0.42	1.00	3.9	
		Placebo	391	296 (75.7)	0.83 (0.78)	0.0	0.08	0.88	1.15	4.0	
	Week 46	Tezepelumab	395	314 (79.5)	0.70 (0.78)	0.0	0.00	0.41	1.00	3.9	
		Placebo	391	287 (73.4)	0.79 (0.74)	0.0	0.00	0.93	1.07	4.0	
	Week 47	Tezepelumab	395	302 (76.5)	0.69 (0.78)	0.0	0.00	0.42	1.00	3.8	
		Placebo	391	291 (74.4)	0.78 (0.71)	0.0	0.08	0.92	1.00	4.0	
	Week 48	Tezepelumab	395	323 (81.8)	0.68 (0.78)	0.0	0.00	0.36	1.00	3.6	
		Placebo	391	301 (77.0)	0.81 (0.73)	0.0	0.07	1.00	1.10	4.0	
	Week 49	Tezepelumab	395	315 (79.7)	0.67 (0.78)	0.0	0.00	0.42	1.00	4.0	
		Placebo	391	290 (74.2)	0.82 (0.73)	0.0	0.07	1.00	1.07	4.0	
	Week 50	Tezepelumab	395	312 (79.0)	0.67 (0.77)	0.0	0.00	0.41	1.00	4.0	
		Placebo	391	288 (73.7)	0.82 (0.76)	0.0	0.00	1.00	1.13	4.0	
	Week 51	Tezepelumab	395	307 (77.7)	0.68 (0.77)	0.0	0.00	0.38	1.00	3.9	
		Placebo	391	282 (72.1)	0.81 (0.77)	0.0	0.00	1.00	1.08	4.0	
	Week 52	Tezepelumab	395	276 (69.9)	0.70 (0.80)	0.0	0.00	0.46	1.00	4.0	
		Placebo	391	257 (65.7)	0.80 (0.79)	0.0	0.00	0.90	1.07	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WHC\_ILMH0: Course of ASD weekly cough score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly cough score	Week 1	Tezepelumab	395	386 (97.7)	-0.19 (0.42)	-2.3	-0.40	-0.07	0.07	0.9	-0.24 [-0.38, -0.10]
		Placebo	391	382 (97.7)	-0.09 (0.41)	-1.9	-0.29	-0.05	0.08	1.5	
	Week 2	Tezepelumab	395	384 (97.2)	-0.32 (0.56)	-2.8	-0.64	-0.16	0.02	1.3	-0.30 [-0.45, -0.16]
		Placebo	391	379 (96.9)	-0.14 (0.62)	-3.0	-0.36	-0.07	0.10	2.4	
	Week 3	Tezepelumab	395	379 (95.9)	-0.37 (0.64)	-3.4	-0.75	-0.21	0.00	1.4	-0.19 [-0.33, -0.05]
		Placebo	391	371 (94.9)	-0.25 (0.66)	-3.1	-0.57	-0.14	0.07	2.8	
	Week 4	Tezepelumab	395	375 (94.9)	-0.41 (0.70)	-3.7	-0.79	-0.21	0.00	2.1	-0.17 [-0.32, -0.03]
		Placebo	391	370 (94.6)	-0.29 (0.65)	-2.9	-0.64	-0.17	0.07	1.4	
	Week 5	Tezepelumab	395	375 (94.9)	-0.48 (0.74)	-3.8	-0.96	-0.29	0.00	2.1	-0.18 [-0.33, -0.04]
		Placebo	391	360 (92.1)	-0.35 (0.64)	-2.9	-0.66	-0.29	0.00	1.7	
	Week 6	Tezepelumab	395	368 (93.2)	-0.51 (0.74)	-3.9	-1.00	-0.36	0.00	1.7	-0.23 [-0.37, -0.08]
		Placebo	391	365 (93.4)	-0.34 (0.72)	-3.1	-0.75	-0.21	0.04	1.8	
	Week 7	Tezepelumab	395	366 (92.7)	-0.53 (0.76)	-3.7	-1.00	-0.40	0.00	1.3	-0.18 [-0.32, -0.03]
		Placebo	391	365 (93.4)	-0.40 (0.71)	-3.2	-0.75	-0.25	0.00	1.5	
	Week 8	Tezepelumab	395	368 (93.2)	-0.55 (0.77)	-3.7	-1.00	-0.43	0.00	1.1	-0.23 [-0.37, -0.08]
		Placebo	391	356 (91.0)	-0.39 (0.70)	-3.1	-0.77	-0.24	0.00	1.7	
	Week 9	Tezepelumab	395	370 (93.7)	-0.59 (0.77)	-4.0	-1.00	-0.50	0.00	1.3	-0.22 [-0.37, -0.08]
		Placebo	391	357 (91.3)	-0.42 (0.70)	-3.1	-0.81	-0.29	0.00	2.0	
	Week 10	Tezepelumab	395	368 (93.2)	-0.57 (0.77)	-3.7	-1.00	-0.42	0.00	1.3	-0.21 [-0.36, -0.07]
		Placebo	391	353 (90.3)	-0.41 (0.72)	-3.1	-0.86	-0.33	0.00	1.6	
	Week 11	Tezepelumab	395	359 (90.9)	-0.56 (0.80)	-3.6	-1.00	-0.43	0.00	1.7	-0.19 [-0.34, -0.04]
		Placebo	391	351 (89.8)	-0.41 (0.71)	-3.1	-0.81	-0.29	0.00	1.7	
	Week 12	Tezepelumab	395	360 (91.1)	-0.55 (0.81)	-3.9	-1.00	-0.42	0.00	1.7	-0.14 [-0.29, 0.01]
		Placebo	391	347 (88.7)	-0.45 (0.72)	-3.1	-0.86	-0.36	0.00	2.1	
	Week 13	Tezepelumab	395	353 (89.4)	-0.56 (0.81)	-3.9	-1.08	-0.42	0.00	2.2	-0.11 [-0.26, 0.04]
		Placebo	391	345 (88.2)	-0.47 (0.73)	-3.1	-0.93	-0.36	0.00	2.0	
	Week 14	Tezepelumab	395	350 (88.6)	-0.63 (0.78)	-3.7	-1.07	-0.50	0.00	1.3	-0.19 [-0.34, -0.04]
		Placebo	391	343 (87.7)	-0.48 (0.72)	-3.1	-0.92	-0.36	0.00	1.1	
	Week 15	Tezepelumab	395	348 (88.1)	-0.59 (0.76)	-3.0	-1.08	-0.43	0.00	1.4	-0.16 [-0.31, -0.01]
		Placebo	391	335 (85.7)	-0.48 (0.71)	-3.1	-0.93	-0.42	0.00	1.5	
	Week 16	Tezepelumab	395	352 (89.1)	-0.63 (0.81)	-3.4	-1.08	-0.49	0.00	1.2	-0.21 [-0.36, -0.06]
		Placebo	391	333 (85.2)	-0.47 (0.73)	-3.1	-0.92	-0.36	0.00	1.4	
	Week 17	Tezepelumab	395	347 (87.8)	-0.66 (0.79)	-3.9	-1.10	-0.50	0.00	0.9	-0.24 [-0.39, -0.09]
		Placebo	391	327 (83.6)	-0.48 (0.71)	-3.1	-0.93	-0.37	0.00	1.7	
	Week 18	Tezepelumab	395	346 (87.6)	-0.63 (0.81)	-3.7	-1.14	-0.50	0.00	2.0	-0.20 [-0.35, -0.05]
		Placebo	391	322 (82.4)	-0.48 (0.75)	-3.1	-0.93	-0.42	0.00	2.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WHC\_ILMH0: Course of ASD weekly cough score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly cough score	Week 19	Tezepelumab	395	343 (86.8)	-0.65 (0.84)	-3.8	-1.14	-0.57	0.00	1.7	-0.23 [-0.38, -0.08]
		Placebo	391	332 (84.9)	-0.47 (0.79)	-3.1	-0.93	-0.36	0.00	2.1	
	Week 20	Tezepelumab	395	335 (84.8)	-0.65 (0.83)	-3.8	-1.14	-0.50	-0.04	1.7	-0.21 [-0.37, -0.06]
		Placebo	391	324 (82.9)	-0.48 (0.81)	-3.1	-0.93	-0.36	0.00	2.0	
	Week 21	Tezepelumab	395	334 (84.6)	-0.66 (0.82)	-3.9	-1.13	-0.60	-0.07	2.4	-0.21 [-0.36, -0.05]
		Placebo	391	319 (81.6)	-0.50 (0.77)	-3.1	-0.93	-0.36	0.00	1.8	
	Week 22	Tezepelumab	395	333 (84.3)	-0.63 (0.82)	-3.4	-1.12	-0.50	0.00	1.6	-0.19 [-0.34, -0.03]
		Placebo	391	312 (79.8)	-0.48 (0.75)	-3.1	-0.93	-0.36	0.00	1.2	
	Week 23	Tezepelumab	395	328 (83.0)	-0.64 (0.82)	-3.2	-1.14	-0.56	-0.07	1.4	-0.18 [-0.33, -0.02]
		Placebo	391	310 (79.3)	-0.50 (0.76)	-3.4	-0.92	-0.41	0.00	1.3	
	Week 24	Tezepelumab	395	337 (85.3)	-0.65 (0.83)	-3.9	-1.14	-0.57	-0.07	1.4	-0.19 [-0.35, -0.04]
		Placebo	391	310 (79.3)	-0.50 (0.76)	-3.1	-0.93	-0.43	0.00	1.7	
	Week 25	Tezepelumab	395	323 (81.8)	-0.65 (0.82)	-3.7	-1.14	-0.57	-0.07	1.5	-0.16 [-0.32, -0.01]
		Placebo	391	308 (78.8)	-0.52 (0.80)	-3.9	-0.93	-0.42	-0.03	1.6	
	Week 26	Tezepelumab	395	327 (82.8)	-0.63 (0.84)	-3.2	-1.21	-0.57	0.00	2.3	-0.16 [-0.32, -0.01]
		Placebo	391	303 (77.5)	-0.49 (0.79)	-3.1	-0.93	-0.42	0.00	1.9	
	Week 27	Tezepelumab	395	317 (80.3)	-0.66 (0.86)	-3.6	-1.17	-0.51	0.00	1.9	-0.23 [-0.39, -0.07]
		Placebo	391	313 (80.1)	-0.47 (0.80)	-3.1	-0.93	-0.42	0.00	2.0	
	Week 28	Tezepelumab	395	325 (82.3)	-0.67 (0.84)	-3.9	-1.14	-0.57	-0.07	1.4	-0.23 [-0.39, -0.08]
		Placebo	391	314 (80.3)	-0.48 (0.76)	-3.1	-0.93	-0.37	0.00	1.8	
	Week 29	Tezepelumab	395	317 (80.3)	-0.68 (0.85)	-3.8	-1.21	-0.64	-0.07	1.8	-0.23 [-0.39, -0.08]
		Placebo	391	312 (79.8)	-0.49 (0.79)	-3.1	-0.93	-0.36	0.00	1.4	
	Week 30	Tezepelumab	395	322 (81.5)	-0.65 (0.85)	-3.9	-1.14	-0.57	0.00	1.8	-0.19 [-0.35, -0.04]
		Placebo	391	303 (77.5)	-0.50 (0.75)	-3.1	-1.00	-0.39	0.00	1.4	
	Week 31	Tezepelumab	395	322 (81.5)	-0.68 (0.86)	-4.0	-1.20	-0.64	0.00	1.6	-0.21 [-0.36, -0.05]
		Placebo	391	308 (78.8)	-0.52 (0.75)	-3.1	-1.00	-0.42	0.00	2.2	
	Week 32	Tezepelumab	395	324 (82.0)	-0.63 (0.84)	-3.9	-1.13	-0.54	0.00	2.2	-0.14 [-0.30, 0.01]
		Placebo	391	308 (78.8)	-0.52 (0.81)	-3.5	-1.00	-0.42	0.00	2.4	
	Week 33	Tezepelumab	395	321 (81.3)	-0.65 (0.85)	-4.0	-1.14	-0.61	0.00	2.1	-0.19 [-0.35, -0.03]
		Placebo	391	304 (77.7)	-0.50 (0.82)	-3.7	-0.95	-0.36	0.00	2.5	
	Week 34	Tezepelumab	395	319 (80.8)	-0.67 (0.86)	-4.0	-1.14	-0.64	-0.07	2.0	-0.20 [-0.36, -0.04]
		Placebo	391	303 (77.5)	-0.51 (0.79)	-3.1	-1.00	-0.43	0.00	2.2	
	Week 35	Tezepelumab	395	320 (81.0)	-0.63 (0.86)	-3.9	-1.12	-0.55	0.00	2.1	-0.13 [-0.29, 0.03]
		Placebo	391	295 (75.4)	-0.52 (0.78)	-3.1	-1.00	-0.42	0.00	2.1	
	Week 36	Tezepelumab	395	317 (80.3)	-0.60 (0.89)	-3.8	-1.07	-0.57	0.00	2.1	-0.10 [-0.26, 0.06]
		Placebo	391	299 (76.5)	-0.51 (0.77)	-3.2	-1.00	-0.40	0.00	1.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WHC\_ILMH0: Course of ASD weekly cough score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly cough score	Week 37	Tezepelumab	395	320 (81.0)	-0.62 (0.88)	-4.0	-1.14	-0.54	0.00	2.1	-0.15 [-0.30, 0.01]
		Placebo	391	298 (76.2)	-0.50 (0.75)	-3.1	-1.00	-0.38	0.00	1.3	
	Week 38	Tezepelumab	395	317 (80.3)	-0.64 (0.87)	-4.0	-1.15	-0.57	-0.06	2.1	-0.12 [-0.28, 0.03]
		Placebo	391	299 (76.5)	-0.54 (0.70)	-3.1	-1.00	-0.50	-0.07	1.2	
	Week 39	Tezepelumab	395	325 (82.3)	-0.60 (0.89)	-3.9	-1.14	-0.50	0.00	2.0	-0.10 [-0.25, 0.06]
		Placebo	391	292 (74.7)	-0.52 (0.76)	-3.9	-1.00	-0.41	0.00	1.7	
	Week 40	Tezepelumab	395	321 (81.3)	-0.64 (0.87)	-3.9	-1.14	-0.57	-0.07	2.0	-0.18 [-0.34, -0.02]
		Placebo	391	297 (76.0)	-0.49 (0.76)	-3.7	-1.00	-0.39	0.00	1.9	
	Week 41	Tezepelumab	395	324 (82.0)	-0.68 (0.88)	-3.9	-1.21	-0.59	-0.07	2.1	-0.20 [-0.35, -0.04]
		Placebo	391	297 (76.0)	-0.52 (0.73)	-3.4	-1.00	-0.43	0.00	1.6	
	Week 42	Tezepelumab	395	316 (80.0)	-0.67 (0.86)	-3.6	-1.21	-0.57	-0.07	2.1	-0.25 [-0.41, -0.10]
		Placebo	391	298 (76.2)	-0.46 (0.78)	-3.8	-0.90	-0.36	0.00	1.3	
	Week 43	Tezepelumab	395	319 (80.8)	-0.68 (0.86)	-3.8	-1.21	-0.57	-0.07	2.1	-0.20 [-0.35, -0.04]
		Placebo	391	296 (75.7)	-0.52 (0.77)	-3.1	-1.00	-0.43	0.00	1.9	
	Week 44	Tezepelumab	395	316 (80.0)	-0.71 (0.84)	-3.9	-1.28	-0.64	-0.07	2.1	-0.25 [-0.41, -0.09]
		Placebo	391	294 (75.2)	-0.50 (0.78)	-3.4	-1.00	-0.37	0.00	2.0	
	Week 45	Tezepelumab	395	319 (80.8)	-0.70 (0.82)	-4.0	-1.20	-0.67	-0.07	2.0	-0.20 [-0.36, -0.04]
		Placebo	391	296 (75.7)	-0.54 (0.80)	-3.5	-1.00	-0.43	0.00	1.9	
	Week 46	Tezepelumab	395	314 (79.5)	-0.69 (0.85)	-4.0	-1.21	-0.64	-0.07	2.1	-0.20 [-0.36, -0.04]
		Placebo	391	287 (73.4)	-0.54 (0.77)	-3.1	-1.00	-0.43	0.00	1.8	
	Week 47	Tezepelumab	395	302 (76.5)	-0.69 (0.85)	-4.0	-1.21	-0.70	-0.07	2.0	-0.19 [-0.36, -0.03]
		Placebo	391	291 (74.4)	-0.54 (0.74)	-3.1	-1.00	-0.50	0.00	1.7	
	Week 48	Tezepelumab	395	323 (81.8)	-0.68 (0.86)	-4.0	-1.21	-0.64	0.00	2.0	-0.17 [-0.32, -0.01]
		Placebo	391	301 (77.0)	-0.54 (0.74)	-3.1	-1.00	-0.42	0.00	1.6	
	Week 49	Tezepelumab	395	315 (79.7)	-0.70 (0.85)	-3.9	-1.21	-0.64	-0.07	2.1	-0.19 [-0.35, -0.03]
		Placebo	391	290 (74.2)	-0.54 (0.75)	-3.1	-1.00	-0.42	0.00	1.3	
	Week 50	Tezepelumab	395	312 (79.0)	-0.71 (0.85)	-3.9	-1.21	-0.64	-0.07	2.1	-0.21 [-0.37, -0.04]
		Placebo	391	288 (73.7)	-0.54 (0.77)	-3.1	-1.00	-0.43	0.00	1.5	
	Week 51	Tezepelumab	395	307 (77.7)	-0.69 (0.87)	-4.0	-1.20	-0.64	-0.07	2.1	-0.16 [-0.33, -0.00]
		Placebo	391	282 (72.1)	-0.55 (0.80)	-3.7	-1.00	-0.44	0.00	1.6	
	Week 52	Tezepelumab	395	276 (69.9)	-0.68 (0.90)	-4.0	-1.21	-0.64	-0.01	2.1	-0.15 [-0.32, 0.02]
		Placebo	391	257 (65.7)	-0.55 (0.79)	-3.7	-1.00	-0.50	-0.07	1.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WHC\_ILMC0: Change from baseline in ASD weekly cough score - MMRM results  
 DITTTL

Change from baseline in ASD weekly cough score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 1	Tezepelumab	395	386 (97.7)	-0.18 (0.03)	(-0.25, -0.12)	-0.09 (0.05)	(-0.18, 0.01)	0.067	
	Placebo	391	382 (97.7)	-0.10 (0.03)	(-0.16, -0.03)				
Week 2	Tezepelumab	395	384 (97.2)	-0.31 (0.03)	(-0.38, -0.25)	-0.16 (0.05)	(-0.26, -0.07)	<0.001 *	
	Placebo	391	379 (96.9)	-0.15 (0.03)	(-0.21, -0.08)				
Week 3	Tezepelumab	395	379 (95.9)	-0.37 (0.03)	(-0.43, -0.30)	-0.12 (0.05)	(-0.22, -0.03)	0.009 *	
	Placebo	391	371 (94.9)	-0.24 (0.03)	(-0.31, -0.18)				
Week 4	Tezepelumab	395	375 (94.9)	-0.40 (0.03)	(-0.47, -0.34)	-0.11 (0.05)	(-0.20, -0.01)	0.024 *	
	Placebo	391	370 (94.6)	-0.30 (0.03)	(-0.36, -0.23)				
Week 5	Tezepelumab	395	375 (94.9)	-0.47 (0.03)	(-0.54, -0.40)	-0.12 (0.05)	(-0.21, -0.03)	0.012 *	
	Placebo	391	360 (92.1)	-0.35 (0.03)	(-0.42, -0.28)				
Week 6	Tezepelumab	395	368 (93.2)	-0.51 (0.03)	(-0.58, -0.44)	-0.16 (0.05)	(-0.26, -0.07)	<0.001 *	
	Placebo	391	365 (93.4)	-0.35 (0.03)	(-0.41, -0.28)				
Week 7	Tezepelumab	395	366 (92.7)	-0.52 (0.03)	(-0.59, -0.45)	-0.13 (0.05)	(-0.22, -0.03)	0.008 *	
	Placebo	391	365 (93.4)	-0.39 (0.03)	(-0.46, -0.33)				
Week 8	Tezepelumab	395	368 (93.2)	-0.55 (0.03)	(-0.61, -0.48)	-0.16 (0.05)	(-0.26, -0.07)	<0.001 *	
	Placebo	391	356 (91.0)	-0.38 (0.03)	(-0.45, -0.32)				
Week 9	Tezepelumab	395	370 (93.7)	-0.58 (0.03)	(-0.64, -0.51)	-0.17 (0.05)	(-0.26, -0.07)	<0.001 *	
	Placebo	391	357 (91.3)	-0.41 (0.03)	(-0.48, -0.34)				
Week 10	Tezepelumab	395	368 (93.2)	-0.58 (0.03)	(-0.64, -0.51)	-0.17 (0.05)	(-0.26, -0.08)	<0.001 *	
	Placebo	391	353 (90.3)	-0.40 (0.03)	(-0.47, -0.34)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table NT1WHC\_ILMC0: Change from baseline in ASD weekly cough score - MMRM results  
 DITTTL

Change from baseline in ASD weekly cough score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 11	Tezepelumab	395	359 (90.9)	-0.56 (0.03)	(-0.62, -0.49)	-0.15 (0.05)	(-0.25, -0.06)	0.002 *	
	Placebo	391	351 (89.8)	-0.41 (0.03)	(-0.47, -0.34)				
Week 12	Tezepelumab	395	360 (91.1)	-0.55 (0.03)	(-0.62, -0.49)	-0.12 (0.05)	(-0.21, -0.03)	0.012 *	
	Placebo	391	347 (88.7)	-0.43 (0.03)	(-0.50, -0.37)				
Week 13	Tezepelumab	395	353 (89.4)	-0.57 (0.03)	(-0.64, -0.51)	-0.12 (0.05)	(-0.22, -0.03)	0.010 *	
	Placebo	391	345 (88.2)	-0.45 (0.03)	(-0.52, -0.38)				
Week 14	Tezepelumab	395	350 (88.6)	-0.61 (0.03)	(-0.68, -0.54)	-0.15 (0.05)	(-0.24, -0.05)	0.002 *	
	Placebo	391	343 (87.7)	-0.46 (0.03)	(-0.53, -0.39)				
Week 15	Tezepelumab	395	348 (88.1)	-0.61 (0.03)	(-0.67, -0.54)	-0.13 (0.05)	(-0.23, -0.04)	0.006 *	
	Placebo	391	335 (85.7)	-0.47 (0.03)	(-0.54, -0.41)				
Week 16	Tezepelumab	395	352 (89.1)	-0.64 (0.03)	(-0.71, -0.57)	-0.19 (0.05)	(-0.28, -0.09)	<0.001 *	
	Placebo	391	333 (85.2)	-0.45 (0.03)	(-0.52, -0.38)				
Week 17	Tezepelumab	395	347 (87.8)	-0.65 (0.03)	(-0.72, -0.58)	-0.18 (0.05)	(-0.28, -0.09)	<0.001 *	
	Placebo	391	327 (83.6)	-0.47 (0.03)	(-0.54, -0.40)				
Week 18	Tezepelumab	395	346 (87.6)	-0.63 (0.03)	(-0.69, -0.56)	-0.17 (0.05)	(-0.26, -0.07)	<0.001 *	
	Placebo	391	322 (82.4)	-0.46 (0.03)	(-0.53, -0.39)				
Week 19	Tezepelumab	395	343 (86.8)	-0.65 (0.03)	(-0.71, -0.58)	-0.19 (0.05)	(-0.28, -0.09)	<0.001 *	
	Placebo	391	332 (84.9)	-0.46 (0.03)	(-0.53, -0.39)				
Week 20	Tezepelumab	395	335 (84.8)	-0.66 (0.03)	(-0.73, -0.59)	-0.20 (0.05)	(-0.29, -0.10)	<0.001 *	
	Placebo	391	324 (82.9)	-0.46 (0.03)	(-0.53, -0.40)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WHC\_ILMC0: Change from baseline in ASD weekly cough score - MMRM results  
 DITTTL

Change from baseline in ASD weekly cough score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 21	Tezepelumab	395	334 (84.6)	-0.66 (0.03)	(-0.73, -0.59)	-0.19 (0.05)	(-0.28, -0.09)	<0.001 *	
	Placebo	391	319 (81.6)	-0.47 (0.03)	(-0.54, -0.40)				
Week 22	Tezepelumab	395	333 (84.3)	-0.65 (0.03)	(-0.72, -0.58)	-0.18 (0.05)	(-0.27, -0.08)	<0.001 *	
	Placebo	391	312 (79.8)	-0.48 (0.04)	(-0.55, -0.41)				
Week 23	Tezepelumab	395	328 (83.0)	-0.66 (0.03)	(-0.73, -0.59)	-0.19 (0.05)	(-0.28, -0.09)	<0.001 *	
	Placebo	391	310 (79.3)	-0.47 (0.04)	(-0.54, -0.40)				
Week 24	Tezepelumab	395	337 (85.3)	-0.65 (0.03)	(-0.72, -0.58)	-0.18 (0.05)	(-0.28, -0.08)	<0.001 *	
	Placebo	391	310 (79.3)	-0.47 (0.04)	(-0.54, -0.40)				
Week 25	Tezepelumab	395	323 (81.8)	-0.65 (0.03)	(-0.72, -0.58)	-0.17 (0.05)	(-0.26, -0.07)	<0.001 *	
	Placebo	391	308 (78.8)	-0.48 (0.04)	(-0.55, -0.42)				
Week 26	Tezepelumab	395	327 (82.8)	-0.64 (0.03)	(-0.70, -0.57)	-0.17 (0.05)	(-0.27, -0.07)	<0.001 *	
	Placebo	391	303 (77.5)	-0.47 (0.04)	(-0.54, -0.40)				
Week 27	Tezepelumab	395	317 (80.3)	-0.66 (0.03)	(-0.73, -0.59)	-0.20 (0.05)	(-0.29, -0.10)	<0.001 *	
	Placebo	391	313 (80.1)	-0.47 (0.04)	(-0.54, -0.40)				
Week 28	Tezepelumab	395	325 (82.3)	-0.67 (0.03)	(-0.74, -0.60)	-0.19 (0.05)	(-0.29, -0.09)	<0.001 *	
	Placebo	391	314 (80.3)	-0.48 (0.04)	(-0.55, -0.41)				
Week 29	Tezepelumab	395	317 (80.3)	-0.67 (0.04)	(-0.74, -0.60)	-0.19 (0.05)	(-0.28, -0.09)	<0.001 *	
	Placebo	391	312 (79.8)	-0.48 (0.04)	(-0.55, -0.41)				
Week 30	Tezepelumab	395	322 (81.5)	-0.65 (0.04)	(-0.72, -0.58)	-0.16 (0.05)	(-0.26, -0.06)	0.002 *	
	Placebo	391	303 (77.5)	-0.49 (0.04)	(-0.56, -0.42)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WHC\_ILMC0: Change from baseline in ASD weekly cough score - MMRM results  
 DITTTL

Change from baseline in ASD weekly cough score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 31	Tezepelumab	395	322 (81.5)	-0.65 (0.04)	(-0.72, -0.58)	-0.14 (0.05)	(-0.23, -0.04)	0.007 *	
	Placebo	391	308 (78.8)	-0.51 (0.04)	(-0.59, -0.44)				
Week 32	Tezepelumab	395	324 (82.0)	-0.65 (0.04)	(-0.72, -0.58)	-0.14 (0.05)	(-0.24, -0.04)	0.004 *	
	Placebo	391	308 (78.8)	-0.50 (0.04)	(-0.57, -0.43)				
Week 33	Tezepelumab	395	321 (81.3)	-0.66 (0.04)	(-0.73, -0.59)	-0.15 (0.05)	(-0.25, -0.05)	0.003 *	
	Placebo	391	304 (77.7)	-0.51 (0.04)	(-0.58, -0.44)				
Week 34	Tezepelumab	395	319 (80.8)	-0.67 (0.04)	(-0.74, -0.60)	-0.16 (0.05)	(-0.26, -0.06)	0.001 *	
	Placebo	391	303 (77.5)	-0.50 (0.04)	(-0.57, -0.43)				
Week 35	Tezepelumab	395	320 (81.0)	-0.64 (0.04)	(-0.71, -0.57)	-0.13 (0.05)	(-0.23, -0.03)	0.010 *	
	Placebo	391	295 (75.4)	-0.51 (0.04)	(-0.58, -0.44)				
Week 36	Tezepelumab	395	317 (80.3)	-0.61 (0.04)	(-0.68, -0.54)	-0.11 (0.05)	(-0.21, -0.01)	0.028 *	
	Placebo	391	299 (76.5)	-0.50 (0.04)	(-0.57, -0.43)				
Week 37	Tezepelumab	395	320 (81.0)	-0.62 (0.04)	(-0.69, -0.55)	-0.12 (0.05)	(-0.22, -0.02)	0.016 *	
	Placebo	391	298 (76.2)	-0.50 (0.04)	(-0.57, -0.43)				
Week 38	Tezepelumab	395	317 (80.3)	-0.62 (0.04)	(-0.69, -0.56)	-0.10 (0.05)	(-0.20, -0.00)	0.042 *	
	Placebo	391	299 (76.5)	-0.52 (0.04)	(-0.59, -0.45)				
Week 39	Tezepelumab	395	325 (82.3)	-0.61 (0.04)	(-0.67, -0.54)	-0.08 (0.05)	(-0.17, 0.02)	0.138	
	Placebo	391	292 (74.7)	-0.53 (0.04)	(-0.60, -0.46)				
Week 40	Tezepelumab	395	321 (81.3)	-0.65 (0.04)	(-0.72, -0.58)	-0.15 (0.05)	(-0.24, -0.05)	0.004 *	
	Placebo	391	297 (76.0)	-0.50 (0.04)	(-0.57, -0.43)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WHC\_ILMC0: Change from baseline in ASD weekly cough score - MMRM results  
DITTTL

Change from baseline in ASD weekly cough score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 41	Tezepelumab	395	324 (82.0)	-0.67 (0.04)	(-0.74, -0.60)	-0.16 (0.05)	(-0.26, -0.06)	0.001 *	
	Placebo	391	297 (76.0)	-0.51 (0.04)	(-0.58, -0.44)				
Week 42	Tezepelumab	395	316 (80.0)	-0.67 (0.04)	(-0.74, -0.60)	-0.19 (0.05)	(-0.29, -0.09)	<0.001 *	
	Placebo	391	298 (76.2)	-0.47 (0.04)	(-0.55, -0.40)				
Week 43	Tezepelumab	395	319 (80.8)	-0.68 (0.04)	(-0.75, -0.61)	-0.16 (0.05)	(-0.26, -0.06)	0.002 *	
	Placebo	391	296 (75.7)	-0.52 (0.04)	(-0.59, -0.44)				
Week 44	Tezepelumab	395	316 (80.0)	-0.70 (0.04)	(-0.77, -0.63)	-0.19 (0.05)	(-0.29, -0.09)	<0.001 *	
	Placebo	391	294 (75.2)	-0.51 (0.04)	(-0.58, -0.44)				
Week 45	Tezepelumab	395	319 (80.8)	-0.70 (0.04)	(-0.77, -0.63)	-0.17 (0.05)	(-0.27, -0.07)	<0.001 *	
	Placebo	391	296 (75.7)	-0.52 (0.04)	(-0.59, -0.45)				
Week 46	Tezepelumab	395	314 (79.5)	-0.70 (0.04)	(-0.77, -0.63)	-0.15 (0.05)	(-0.25, -0.05)	0.003 *	
	Placebo	391	287 (73.4)	-0.55 (0.04)	(-0.62, -0.48)				
Week 47	Tezepelumab	395	302 (76.5)	-0.71 (0.04)	(-0.78, -0.64)	-0.17 (0.05)	(-0.27, -0.07)	0.001 *	
	Placebo	391	291 (74.4)	-0.54 (0.04)	(-0.61, -0.47)				
Week 48	Tezepelumab	395	323 (81.8)	-0.69 (0.04)	(-0.76, -0.62)	-0.16 (0.05)	(-0.26, -0.06)	0.002 *	
	Placebo	391	301 (77.0)	-0.53 (0.04)	(-0.60, -0.46)				
Week 49	Tezepelumab	395	315 (79.7)	-0.70 (0.04)	(-0.77, -0.63)	-0.17 (0.05)	(-0.27, -0.07)	0.001 *	
	Placebo	391	290 (74.2)	-0.54 (0.04)	(-0.61, -0.47)				
Week 50	Tezepelumab	395	312 (79.0)	-0.70 (0.04)	(-0.77, -0.63)	-0.16 (0.05)	(-0.26, -0.06)	0.002 *	
	Placebo	391	288 (73.7)	-0.55 (0.04)	(-0.62, -0.47)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WHC\_ILMC0: Change from baseline in ASD weekly cough score - MMRM results  
 DITTTL

Change from baseline in ASD weekly cough score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 51	Tezepelumab	395	307 (77.7)	-0.70 (0.04)	(-0.77, -0.63)	-0.15 (0.05)	(-0.25, -0.05)	0.004 *
	Placebo	391	282 (72.1)	-0.55 (0.04)	(-0.62, -0.47)			
Week 52	Tezepelumab	395	276 (69.9)	-0.69 (0.04)	(-0.76, -0.61)	-0.14 (0.05)	(-0.24, -0.04)	0.008 *
	Placebo	391	257 (65.7)	-0.54 (0.04)	(-0.62, -0.47)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WHC\_ILMH0: Course of ASD weekly cough score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly cough score	Baseline	Tezepelumab	73	73 (100.0)	1.25 (0.80)	0.0	0.79	1.21	2.00	3.1	
		Placebo	76	76 (100.0)	1.15 (0.81)	0.0	0.54	1.08	1.79	3.2	
	Week 1	Tezepelumab	73	71 (97.3)	1.15 (0.82)	0.0	0.42	1.07	1.93	3.1	
		Placebo	76	76 (100.0)	1.12 (0.75)	0.0	0.54	1.00	1.73	2.8	
	Week 2	Tezepelumab	73	73 (100.0)	1.07 (0.81)	0.0	0.36	1.00	1.80	3.2	
		Placebo	76	74 (97.4)	1.05 (0.70)	0.0	0.50	1.00	1.50	2.6	
	Week 3	Tezepelumab	73	73 (100.0)	1.03 (0.81)	0.0	0.17	1.00	1.75	2.9	
		Placebo	76	73 (96.1)	0.99 (0.73)	0.0	0.29	1.00	1.50	3.0	
	Week 4	Tezepelumab	73	71 (97.3)	0.97 (0.86)	0.0	0.00	1.00	1.90	3.1	
		Placebo	76	76 (100.0)	0.99 (0.76)	0.0	0.21	1.00	1.50	2.8	
	Week 5	Tezepelumab	73	71 (97.3)	0.92 (0.83)	0.0	0.07	1.00	1.79	3.0	
		Placebo	76	74 (97.4)	0.95 (0.75)	0.0	0.29	1.00	1.25	2.9	
	Week 6	Tezepelumab	73	69 (94.5)	0.91 (0.85)	0.0	0.00	0.86	1.71	3.1	
		Placebo	76	72 (94.7)	0.99 (0.77)	0.0	0.29	1.00	1.69	2.9	
	Week 7	Tezepelumab	73	69 (94.5)	0.90 (0.86)	0.0	0.07	0.88	1.58	3.0	
		Placebo	76	75 (98.7)	0.98 (0.74)	0.0	0.36	1.00	1.50	2.7	
	Week 8	Tezepelumab	73	68 (93.2)	0.96 (0.87)	0.0	0.07	1.00	1.70	3.3	
		Placebo	76	75 (98.7)	1.00 (0.76)	0.0	0.20	1.00	1.58	2.9	
	Week 9	Tezepelumab	73	69 (94.5)	0.94 (0.89)	0.0	0.00	1.00	1.93	3.1	
		Placebo	76	73 (96.1)	0.99 (0.81)	0.0	0.21	1.00	1.57	3.0	
	Week 10	Tezepelumab	73	70 (95.9)	1.05 (0.86)	0.0	0.13	1.00	1.86	3.1	
		Placebo	76	74 (97.4)	0.99 (0.71)	0.0	0.50	1.00	1.29	3.0	
	Week 11	Tezepelumab	73	70 (95.9)	1.03 (0.86)	0.0	0.08	1.00	1.90	3.3	
		Placebo	76	74 (97.4)	0.95 (0.72)	0.0	0.38	1.00	1.21	3.1	
	Week 12	Tezepelumab	73	70 (95.9)	0.97 (0.87)	0.0	0.08	1.00	1.70	3.4	
		Placebo	76	75 (98.7)	0.97 (0.71)	0.0	0.33	1.00	1.33	3.0	
	Week 13	Tezepelumab	73	68 (93.2)	0.99 (0.91)	0.0	0.04	0.96	1.96	3.6	
		Placebo	76	71 (93.4)	0.88 (0.71)	0.0	0.25	1.00	1.29	3.0	
	Week 14	Tezepelumab	73	69 (94.5)	1.02 (0.85)	0.0	0.25	1.00	1.86	3.3	
		Placebo	76	73 (96.1)	0.90 (0.75)	0.0	0.13	1.00	1.21	2.9	
	Week 15	Tezepelumab	73	69 (94.5)	1.03 (0.87)	0.0	0.14	1.00	2.00	3.4	
		Placebo	76	72 (94.7)	0.86 (0.71)	0.0	0.13	1.00	1.18	2.9	
	Week 16	Tezepelumab	73	69 (94.5)	1.05 (0.87)	0.0	0.21	1.00	1.93	3.6	
		Placebo	76	74 (97.4)	0.90 (0.71)	0.0	0.21	1.00	1.21	2.9	
Week 17	Tezepelumab	73	68 (93.2)	1.02 (0.86)	0.0	0.14	1.00	1.79	3.7		
	Placebo	76	74 (97.4)	0.91 (0.76)	0.0	0.13	1.00	1.21	2.9		

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WHC\_ILMH0: Course of ASD weekly cough score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly cough score	Week 18	Tezepelumab	73	68 (93.2)	0.97 (0.88)	0.0	0.09	1.00	1.85	3.4	
		Placebo	76	72 (94.7)	0.92 (0.76)	0.0	0.11	1.00	1.35	2.9	
	Week 19	Tezepelumab	73	67 (91.8)	0.92 (0.88)	0.0	0.07	1.00	1.67	3.4	
		Placebo	76	72 (94.7)	0.95 (0.76)	0.0	0.13	1.00	1.46	3.1	
	Week 20	Tezepelumab	73	70 (95.9)	0.98 (0.90)	0.0	0.00	1.00	1.93	3.3	
		Placebo	76	72 (94.7)	0.97 (0.77)	0.0	0.19	1.00	1.50	3.0	
	Week 21	Tezepelumab	73	67 (91.8)	1.01 (0.88)	0.0	0.07	1.00	1.86	3.4	
		Placebo	76	73 (96.1)	0.98 (0.81)	0.0	0.29	1.00	1.50	3.0	
	Week 22	Tezepelumab	73	69 (94.5)	0.98 (0.91)	0.0	0.00	1.00	1.92	3.3	
		Placebo	76	74 (97.4)	1.05 (0.88)	0.0	0.14	1.00	1.75	4.0	
	Week 23	Tezepelumab	73	69 (94.5)	0.98 (0.94)	0.0	0.00	0.92	2.00	3.4	
		Placebo	76	74 (97.4)	1.03 (0.87)	0.0	0.00	1.00	1.64	3.4	
	Week 24	Tezepelumab	73	69 (94.5)	0.99 (0.96)	0.0	0.00	1.00	2.00	3.4	
		Placebo	76	75 (98.7)	0.98 (0.81)	0.0	0.08	1.00	1.57	3.0	
	Week 25	Tezepelumab	73	68 (93.2)	0.95 (0.99)	0.0	0.00	0.89	2.00	3.7	
		Placebo	76	74 (97.4)	0.95 (0.77)	0.0	0.21	1.00	1.21	3.1	
	Week 26	Tezepelumab	73	67 (91.8)	0.94 (0.97)	0.0	0.00	0.86	1.93	3.6	
		Placebo	76	73 (96.1)	0.93 (0.82)	0.0	0.07	1.00	1.36	3.2	
	Week 27	Tezepelumab	73	68 (93.2)	1.00 (0.97)	0.0	0.00	1.00	2.00	3.3	
		Placebo	76	71 (93.4)	0.92 (0.82)	0.0	0.00	1.00	1.50	3.0	
	Week 28	Tezepelumab	73	67 (91.8)	1.01 (0.96)	0.0	0.00	1.00	1.93	3.4	
		Placebo	76	71 (93.4)	0.89 (0.84)	0.0	0.00	1.00	1.40	3.0	
	Week 29	Tezepelumab	73	64 (87.7)	0.89 (0.93)	0.0	0.00	0.71	1.57	3.4	
		Placebo	76	74 (97.4)	0.88 (0.83)	0.0	0.07	1.00	1.50	3.0	
	Week 30	Tezepelumab	73	66 (90.4)	0.91 (1.00)	0.0	0.00	0.68	2.00	3.7	
		Placebo	76	74 (97.4)	0.89 (0.80)	0.0	0.00	1.00	1.29	3.0	
	Week 31	Tezepelumab	73	66 (90.4)	0.87 (0.99)	0.0	0.00	0.64	1.36	3.9	
		Placebo	76	72 (94.7)	0.83 (0.80)	0.0	0.07	1.00	1.11	3.0	
	Week 32	Tezepelumab	73	64 (87.7)	0.97 (1.03)	0.0	0.00	0.82	1.82	3.9	
		Placebo	76	73 (96.1)	0.87 (0.74)	0.0	0.00	1.00	1.08	3.0	
	Week 33	Tezepelumab	73	67 (91.8)	0.92 (0.95)	0.0	0.00	0.93	1.64	3.8	
		Placebo	76	72 (94.7)	0.87 (0.72)	0.0	0.11	1.00	1.18	3.0	
	Week 34	Tezepelumab	73	67 (91.8)	0.85 (0.90)	0.0	0.00	0.71	1.42	3.5	
		Placebo	76	71 (93.4)	0.88 (0.77)	0.0	0.07	1.00	1.10	3.0	
	Week 35	Tezepelumab	73	65 (89.0)	0.83 (0.88)	0.0	0.00	0.64	1.14	3.1	
Placebo		76	74 (97.4)	0.85 (0.80)	0.0	0.08	1.00	1.07	3.0		

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WHC\_ILMH0: Course of ASD weekly cough score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly cough score	Week 36	Tezepelumab	73	69 (94.5)	0.94 (0.96)	0.0	0.00	0.86	1.90	3.4	
		Placebo	76	71 (93.4)	0.82 (0.79)	0.0	0.00	1.00	1.14	3.0	
	Week 37	Tezepelumab	73	66 (90.4)	0.94 (0.93)	0.0	0.00	0.89	1.92	3.4	
		Placebo	76	72 (94.7)	0.83 (0.77)	0.0	0.07	1.00	1.14	3.0	
	Week 38	Tezepelumab	73	64 (87.7)	0.87 (0.93)	0.0	0.00	0.64	1.68	3.3	
		Placebo	76	72 (94.7)	0.94 (0.82)	0.0	0.08	1.00	1.54	3.3	
	Week 39	Tezepelumab	73	64 (87.7)	0.88 (0.93)	0.0	0.00	0.79	1.68	3.5	
		Placebo	76	71 (93.4)	0.86 (0.83)	0.0	0.00	1.00	1.21	3.3	
	Week 40	Tezepelumab	73	64 (87.7)	0.92 (0.97)	0.0	0.00	0.82	1.88	3.6	
		Placebo	76	71 (93.4)	0.88 (0.81)	0.0	0.00	1.00	1.29	3.3	
	Week 41	Tezepelumab	73	63 (86.3)	0.85 (0.97)	0.0	0.00	0.50	1.50	3.5	
		Placebo	76	70 (92.1)	0.81 (0.72)	0.0	0.00	0.96	1.07	3.0	
	Week 42	Tezepelumab	73	63 (86.3)	0.85 (0.91)	0.0	0.00	0.79	1.43	3.6	
		Placebo	76	72 (94.7)	0.82 (0.71)	0.0	0.00	1.00	1.13	3.0	
	Week 43	Tezepelumab	73	63 (86.3)	0.83 (0.94)	0.0	0.00	0.71	1.25	3.9	
		Placebo	76	72 (94.7)	0.92 (0.80)	0.0	0.04	1.00	1.40	3.0	
	Week 44	Tezepelumab	73	63 (86.3)	0.85 (0.95)	0.0	0.00	0.71	1.07	3.7	
		Placebo	76	73 (96.1)	0.87 (0.75)	0.0	0.00	1.00	1.21	3.0	
	Week 45	Tezepelumab	73	62 (84.9)	0.82 (0.94)	0.0	0.00	0.41	1.29	3.3	
		Placebo	76	70 (92.1)	0.84 (0.74)	0.0	0.07	1.00	1.07	2.9	
	Week 46	Tezepelumab	73	62 (84.9)	0.84 (0.94)	0.0	0.00	0.46	1.79	3.3	
		Placebo	76	68 (89.5)	0.83 (0.76)	0.0	0.00	1.00	1.20	3.0	
	Week 47	Tezepelumab	73	62 (84.9)	0.81 (0.91)	0.0	0.00	0.43	1.57	3.4	
		Placebo	76	70 (92.1)	0.84 (0.76)	0.0	0.07	1.00	1.13	3.0	
	Week 48	Tezepelumab	73	57 (78.1)	0.94 (0.91)	0.0	0.00	1.00	1.50	3.2	
		Placebo	76	68 (89.5)	0.84 (0.80)	0.0	0.00	1.00	1.10	3.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table ST1WHC\_ILMH0: Course of ASD weekly cough score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly cough score	Week 1	Tezepelumab	73	71 (97.3)	-0.08 (0.43)	-1.8	-0.17	0.00	0.07	1.0	-0.10 [-0.42, 0.23]
		Placebo	76	76 (100.0)	-0.04 (0.39)	-1.0	-0.23	0.00	0.15	1.0	
	Week 2	Tezepelumab	73	73 (100.0)	-0.17 (0.44)	-2.0	-0.36	0.00	0.07	0.7	-0.21 [-0.53, 0.12]
		Placebo	76	74 (97.4)	-0.08 (0.49)	-1.6	-0.29	0.00	0.14	1.2	
	Week 3	Tezepelumab	73	73 (100.0)	-0.22 (0.55)	-2.0	-0.50	-0.07	0.04	1.3	-0.17 [-0.50, 0.15]
		Placebo	76	73 (96.1)	-0.13 (0.47)	-1.4	-0.43	-0.02	0.06	1.0	
	Week 4	Tezepelumab	73	71 (97.3)	-0.29 (0.57)	-2.0	-0.64	-0.07	0.00	1.1	-0.23 [-0.56, 0.09]
		Placebo	76	76 (100.0)	-0.16 (0.54)	-1.8	-0.49	0.00	0.07	1.1	
	Week 5	Tezepelumab	73	71 (97.3)	-0.33 (0.54)	-2.0	-0.79	-0.08	0.00	0.6	-0.23 [-0.56, 0.09]
		Placebo	76	74 (97.4)	-0.20 (0.60)	-2.5	-0.57	-0.08	0.01	1.7	
	Week 6	Tezepelumab	73	69 (94.5)	-0.33 (0.60)	-2.0	-0.76	-0.07	0.00	0.6	-0.29 [-0.62, 0.04]
		Placebo	76	72 (94.7)	-0.16 (0.61)	-2.4	-0.46	-0.01	0.14	1.2	
	Week 7	Tezepelumab	73	69 (94.5)	-0.33 (0.66)	-1.8	-0.79	-0.08	0.00	2.0	-0.25 [-0.58, 0.07]
		Placebo	76	75 (98.7)	-0.17 (0.64)	-2.3	-0.57	-0.06	0.10	1.6	
	Week 8	Tezepelumab	73	68 (93.2)	-0.31 (0.68)	-1.9	-0.71	-0.14	0.00	2.0	-0.25 [-0.58, 0.08]
		Placebo	76	75 (98.7)	-0.15 (0.57)	-1.9	-0.33	0.00	0.08	0.8	
	Week 9	Tezepelumab	73	69 (94.5)	-0.30 (0.67)	-1.9	-0.79	-0.07	0.00	1.2	-0.22 [-0.55, 0.11]
		Placebo	76	73 (96.1)	-0.16 (0.62)	-1.9	-0.46	0.00	0.14	1.2	
	Week 10	Tezepelumab	73	70 (95.9)	-0.18 (0.72)	-2.0	-0.64	-0.01	0.13	2.0	-0.06 [-0.39, 0.26]
		Placebo	76	74 (97.4)	-0.14 (0.67)	-1.9	-0.50	0.00	0.10	2.4	
	Week 11	Tezepelumab	73	70 (95.9)	-0.20 (0.69)	-2.0	-0.64	0.00	0.07	2.0	-0.03 [-0.36, 0.29]
		Placebo	76	74 (97.4)	-0.18 (0.72)	-2.0	-0.62	-0.07	0.10	2.9	
	Week 12	Tezepelumab	73	70 (95.9)	-0.30 (0.70)	-2.0	-0.79	-0.08	0.00	2.0	-0.17 [-0.49, 0.16]
		Placebo	76	75 (98.7)	-0.18 (0.68)	-1.9	-0.53	-0.08	0.14	2.1	
	Week 13	Tezepelumab	73	68 (93.2)	-0.26 (0.74)	-2.1	-0.75	0.00	0.07	2.0	-0.04 [-0.37, 0.30]
		Placebo	76	71 (93.4)	-0.24 (0.70)	-2.5	-0.75	-0.07	0.07	1.4	
	Week 14	Tezepelumab	73	69 (94.5)	-0.24 (0.71)	-1.9	-0.71	-0.06	0.00	1.9	-0.01 [-0.34, 0.32]
		Placebo	76	73 (96.1)	-0.23 (0.63)	-2.0	-0.71	-0.07	0.08	1.3	
	Week 15	Tezepelumab	73	69 (94.5)	-0.25 (0.74)	-1.9	-0.71	-0.14	0.00	2.0	0.06 [-0.27, 0.39]
		Placebo	76	72 (94.7)	-0.29 (0.64)	-2.6	-0.61	-0.14	0.07	1.0	
	Week 16	Tezepelumab	73	69 (94.5)	-0.23 (0.74)	-2.0	-0.64	-0.08	0.07	2.0	0.05 [-0.28, 0.38]
		Placebo	76	74 (97.4)	-0.27 (0.68)	-2.2	-0.71	-0.11	0.07	1.9	
	Week 17	Tezepelumab	73	68 (93.2)	-0.25 (0.69)	-2.0	-0.79	-0.11	0.00	1.7	0.01 [-0.32, 0.34]
		Placebo	76	74 (97.4)	-0.26 (0.71)	-2.2	-0.75	-0.08	0.07	1.6	
	Week 18	Tezepelumab	73	68 (93.2)	-0.28 (0.70)	-2.0	-0.86	-0.14	0.00	2.0	-0.05 [-0.38, 0.28]
		Placebo	76	72 (94.7)	-0.25 (0.70)	-2.1	-0.73	-0.08	0.19	1.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WHC\_ILMH0: Course of ASD weekly cough score  
 DITTTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly cough score	Week 19	Tezepelumab	73	67 (91.8)	-0.33 (0.75)	-2.0	-0.99	-0.20	0.00	2.1	-0.15 [-0.49, 0.18]
		Placebo	76	72 (94.7)	-0.22 (0.66)	-2.0	-0.65	-0.08	0.07	1.4	
	Week 20	Tezepelumab	73	70 (95.9)	-0.29 (0.77)	-2.0	-0.93	-0.13	0.00	2.0	-0.17 [-0.50, 0.16]
		Placebo	76	72 (94.7)	-0.16 (0.63)	-2.0	-0.56	-0.08	0.17	1.0	
	Week 21	Tezepelumab	73	67 (91.8)	-0.26 (0.71)	-2.0	-0.86	-0.13	0.07	1.9	-0.11 [-0.45, 0.22]
		Placebo	76	73 (96.1)	-0.18 (0.69)	-2.0	-0.54	-0.08	0.17	1.1	
	Week 22	Tezepelumab	73	69 (94.5)	-0.29 (0.69)	-2.0	-0.79	-0.11	0.00	1.3	-0.23 [-0.56, 0.10]
		Placebo	76	74 (97.4)	-0.12 (0.82)	-2.0	-0.58	-0.07	0.36	2.0	
	Week 23	Tezepelumab	73	69 (94.5)	-0.28 (0.74)	-2.2	-0.79	0.00	0.00	1.7	-0.21 [-0.54, 0.12]
		Placebo	76	74 (97.4)	-0.12 (0.79)	-2.0	-0.59	-0.02	0.36	1.8	
	Week 24	Tezepelumab	73	69 (94.5)	-0.28 (0.76)	-2.3	-0.81	0.00	0.00	1.6	-0.14 [-0.47, 0.19]
		Placebo	76	75 (98.7)	-0.17 (0.73)	-1.9	-0.70	-0.07	0.22	1.4	
	Week 25	Tezepelumab	73	68 (93.2)	-0.31 (0.80)	-2.3	-0.82	-0.04	0.00	1.7	-0.13 [-0.46, 0.20]
		Placebo	76	74 (97.4)	-0.20 (0.79)	-2.3	-0.69	-0.14	0.21	1.9	
	Week 26	Tezepelumab	73	67 (91.8)	-0.30 (0.77)	-2.4	-1.00	-0.07	0.01	1.9	-0.12 [-0.45, 0.21]
		Placebo	76	73 (96.1)	-0.20 (0.86)	-2.1	-0.75	-0.07	0.26	3.1	
	Week 27	Tezepelumab	73	68 (93.2)	-0.26 (0.77)	-2.4	-0.77	-0.07	0.00	2.0	-0.05 [-0.39, 0.28]
		Placebo	76	71 (93.4)	-0.22 (0.77)	-2.0	-0.71	-0.08	0.18	1.8	
	Week 28	Tezepelumab	73	67 (91.8)	-0.26 (0.78)	-2.4	-0.80	0.00	0.00	2.0	-0.04 [-0.38, 0.29]
		Placebo	76	71 (93.4)	-0.22 (0.75)	-2.0	-0.58	-0.08	0.07	1.9	
	Week 29	Tezepelumab	73	64 (87.7)	-0.36 (0.74)	-2.4	-0.90	-0.14	0.00	2.1	-0.15 [-0.49, 0.18]
		Placebo	76	74 (97.4)	-0.25 (0.78)	-2.0	-0.75	-0.14	0.08	1.9	
	Week 30	Tezepelumab	73	66 (90.4)	-0.35 (0.85)	-2.4	-0.93	-0.08	0.00	2.4	-0.15 [-0.48, 0.18]
		Placebo	76	74 (97.4)	-0.24 (0.70)	-2.0	-0.70	-0.11	0.07	1.0	
	Week 31	Tezepelumab	73	66 (90.4)	-0.37 (0.85)	-2.4	-1.00	-0.19	0.00	2.6	-0.09 [-0.42, 0.25]
		Placebo	76	72 (94.7)	-0.30 (0.72)	-2.0	-0.75	-0.04	0.07	1.5	
	Week 32	Tezepelumab	73	64 (87.7)	-0.33 (0.84)	-2.4	-0.89	-0.21	0.00	2.6	-0.08 [-0.42, 0.25]
		Placebo	76	73 (96.1)	-0.27 (0.74)	-2.0	-0.71	-0.08	0.00	1.9	
	Week 33	Tezepelumab	73	67 (91.8)	-0.33 (0.76)	-2.4	-0.86	-0.14	0.00	2.4	-0.08 [-0.41, 0.25]
		Placebo	76	72 (94.7)	-0.27 (0.76)	-2.1	-0.74	-0.08	0.09	1.3	
	Week 34	Tezepelumab	73	67 (91.8)	-0.39 (0.75)	-2.4	-0.93	-0.21	0.00	2.1	-0.17 [-0.51, 0.16]
		Placebo	76	71 (93.4)	-0.26 (0.73)	-2.1	-0.64	-0.08	0.07	1.4	
	Week 35	Tezepelumab	73	65 (89.0)	-0.40 (0.78)	-2.4	-1.00	-0.20	0.00	1.8	-0.17 [-0.50, 0.16]
		Placebo	76	74 (97.4)	-0.28 (0.74)	-2.1	-0.70	-0.08	0.00	1.4	
	Week 36	Tezepelumab	73	69 (94.5)	-0.32 (0.80)	-2.4	-0.86	-0.07	0.00	2.0	-0.00 [-0.33, 0.33]
		Placebo	76	71 (93.4)	-0.31 (0.78)	-2.1	-0.71	-0.14	0.00	1.4	

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WHC\_ILMH0: Course of ASD weekly cough score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly cough score	Week 37	Tezepelumab	73	66 (90.4)	-0.32 (0.79)	-2.4	-0.86	-0.12	0.00	1.6	-0.01 [-0.34, 0.33]
		Placebo	76	72 (94.7)	-0.32 (0.77)	-2.1	-0.79	-0.15	0.00	1.4	
	Week 38	Tezepelumab	73	64 (87.7)	-0.36 (0.76)	-2.4	-1.00	-0.14	0.00	2.0	-0.21 [-0.55, 0.13]
		Placebo	76	72 (94.7)	-0.19 (0.81)	-2.1	-0.58	-0.08	0.04	2.0	
	Week 39	Tezepelumab	73	64 (87.7)	-0.35 (0.78)	-2.4	-0.93	-0.14	0.00	2.1	-0.14 [-0.48, 0.20]
		Placebo	76	71 (93.4)	-0.24 (0.82)	-2.1	-0.75	-0.14	0.00	1.9	
	Week 40	Tezepelumab	73	64 (87.7)	-0.32 (0.80)	-2.2	-1.00	-0.08	0.00	2.2	-0.08 [-0.42, 0.26]
		Placebo	76	71 (93.4)	-0.25 (0.81)	-2.1	-0.79	-0.08	0.14	1.9	
	Week 41	Tezepelumab	73	63 (86.3)	-0.37 (0.82)	-2.3	-1.00	-0.14	0.00	2.1	-0.05 [-0.39, 0.29]
		Placebo	76	70 (92.1)	-0.33 (0.74)	-2.1	-0.75	-0.15	0.07	1.1	
	Week 42	Tezepelumab	73	63 (86.3)	-0.36 (0.80)	-2.1	-1.00	-0.08	0.00	1.7	-0.06 [-0.39, 0.28]
		Placebo	76	72 (94.7)	-0.32 (0.72)	-2.1	-0.71	-0.09	0.00	1.1	
	Week 43	Tezepelumab	73	63 (86.3)	-0.38 (0.82)	-2.2	-1.00	-0.14	0.00	1.9	-0.21 [-0.54, 0.13]
		Placebo	76	72 (94.7)	-0.21 (0.83)	-2.0	-0.71	-0.08	0.33	2.0	
	Week 44	Tezepelumab	73	63 (86.3)	-0.36 (0.81)	-2.2	-1.00	-0.14	0.00	2.2	-0.13 [-0.47, 0.20]
		Placebo	76	73 (96.1)	-0.26 (0.76)	-2.1	-0.71	-0.08	0.21	1.1	
	Week 45	Tezepelumab	73	62 (84.9)	-0.39 (0.81)	-2.3	-0.88	-0.18	0.00	2.1	-0.15 [-0.49, 0.20]
		Placebo	76	70 (92.1)	-0.28 (0.74)	-2.1	-0.64	-0.11	0.00	1.6	
	Week 46	Tezepelumab	73	62 (84.9)	-0.39 (0.81)	-2.3	-0.92	-0.18	0.00	2.1	-0.09 [-0.43, 0.26]
		Placebo	76	68 (89.5)	-0.32 (0.73)	-2.1	-0.65	-0.17	0.07	1.0	
	Week 47	Tezepelumab	73	62 (84.9)	-0.38 (0.85)	-2.3	-1.00	-0.14	0.02	2.1	-0.08 [-0.42, 0.26]
		Placebo	76	70 (92.1)	-0.32 (0.73)	-2.0	-0.71	-0.15	0.03	1.2	
	Week 48	Tezepelumab	73	57 (78.1)	-0.32 (0.84)	-2.4	-0.86	-0.14	0.00	2.1	-0.01 [-0.36, 0.35]
		Placebo	76	68 (89.5)	-0.31 (0.76)	-2.0	-0.75	-0.11	0.00	1.1	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WHC\_ILMC0: Change from baseline in ASD weekly cough score - MMRM results  
 DITTTL

Change from baseline in ASD weekly cough score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 1	Tezepelumab	73	71 (97.3)	-0.05 (0.08)	(-0.20, 0.10)	-0.00 (0.11)	(-0.21, 0.21)	0.966
	Placebo	76	76 (100.0)	-0.05 (0.07)	(-0.20, 0.10)			
Week 2	Tezepelumab	73	73 (100.0)	-0.15 (0.08)	(-0.30, -0.01)	-0.05 (0.11)	(-0.26, 0.16)	0.612
	Placebo	76	74 (97.4)	-0.10 (0.07)	(-0.25, 0.05)			
Week 3	Tezepelumab	73	73 (100.0)	-0.20 (0.08)	(-0.35, -0.05)	-0.03 (0.11)	(-0.24, 0.18)	0.761
	Placebo	76	73 (96.1)	-0.17 (0.07)	(-0.32, -0.02)			
Week 4	Tezepelumab	73	71 (97.3)	-0.28 (0.08)	(-0.43, -0.13)	-0.10 (0.11)	(-0.31, 0.11)	0.355
	Placebo	76	76 (100.0)	-0.18 (0.07)	(-0.32, -0.03)			
Week 5	Tezepelumab	73	71 (97.3)	-0.32 (0.08)	(-0.47, -0.17)	-0.10 (0.11)	(-0.31, 0.11)	0.357
	Placebo	76	74 (97.4)	-0.22 (0.07)	(-0.37, -0.08)			
Week 6	Tezepelumab	73	69 (94.5)	-0.32 (0.08)	(-0.47, -0.17)	-0.12 (0.11)	(-0.33, 0.09)	0.261
	Placebo	76	72 (94.7)	-0.20 (0.07)	(-0.35, -0.05)			
Week 7	Tezepelumab	73	69 (94.5)	-0.32 (0.08)	(-0.47, -0.17)	-0.13 (0.11)	(-0.34, 0.08)	0.211
	Placebo	76	75 (98.7)	-0.19 (0.07)	(-0.33, -0.04)			
Week 8	Tezepelumab	73	68 (93.2)	-0.29 (0.08)	(-0.44, -0.14)	-0.12 (0.11)	(-0.33, 0.09)	0.280
	Placebo	76	75 (98.7)	-0.17 (0.07)	(-0.32, -0.02)			
Week 9	Tezepelumab	73	69 (94.5)	-0.28 (0.08)	(-0.44, -0.13)	-0.12 (0.11)	(-0.33, 0.09)	0.279
	Placebo	76	73 (96.1)	-0.17 (0.08)	(-0.32, -0.02)			
Week 10	Tezepelumab	73	70 (95.9)	-0.17 (0.08)	(-0.32, -0.02)	-0.01 (0.11)	(-0.22, 0.20)	0.904
	Placebo	76	74 (97.4)	-0.15 (0.08)	(-0.30, -0.01)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WHC\_ILMC0: Change from baseline in ASD weekly cough score - MMRM results  
DITTTL

Change from baseline in ASD weekly cough score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 11	Tezepelumab	73	70 (95.9)	-0.19 (0.08)	(-0.34, -0.04)	0.00 (0.11)	(-0.21, 0.21)	0.980
	Placebo	76	74 (97.4)	-0.19 (0.08)	(-0.34, -0.04)			
Week 12	Tezepelumab	73	70 (95.9)	-0.28 (0.08)	(-0.43, -0.13)	-0.08 (0.11)	(-0.29, 0.13)	0.457
	Placebo	76	75 (98.7)	-0.20 (0.08)	(-0.35, -0.05)			
Week 13	Tezepelumab	73	68 (93.2)	-0.24 (0.08)	(-0.40, -0.09)	0.03 (0.11)	(-0.18, 0.24)	0.794
	Placebo	76	71 (93.4)	-0.27 (0.08)	(-0.42, -0.12)			
Week 14	Tezepelumab	73	69 (94.5)	-0.21 (0.08)	(-0.37, -0.06)	0.06 (0.11)	(-0.15, 0.27)	0.594
	Placebo	76	73 (96.1)	-0.27 (0.08)	(-0.42, -0.12)			
Week 15	Tezepelumab	73	69 (94.5)	-0.23 (0.08)	(-0.38, -0.08)	0.06 (0.11)	(-0.15, 0.28)	0.550
	Placebo	76	72 (94.7)	-0.29 (0.08)	(-0.44, -0.14)			
Week 16	Tezepelumab	73	69 (94.5)	-0.21 (0.08)	(-0.36, -0.06)	0.07 (0.11)	(-0.14, 0.28)	0.506
	Placebo	76	74 (97.4)	-0.28 (0.08)	(-0.43, -0.13)			
Week 17	Tezepelumab	73	68 (93.2)	-0.25 (0.08)	(-0.40, -0.09)	0.02 (0.11)	(-0.19, 0.24)	0.819
	Placebo	76	74 (97.4)	-0.27 (0.08)	(-0.42, -0.12)			
Week 18	Tezepelumab	73	68 (93.2)	-0.28 (0.08)	(-0.43, -0.12)	-0.02 (0.11)	(-0.23, 0.19)	0.857
	Placebo	76	72 (94.7)	-0.26 (0.08)	(-0.40, -0.11)			
Week 19	Tezepelumab	73	67 (91.8)	-0.31 (0.08)	(-0.46, -0.15)	-0.09 (0.11)	(-0.30, 0.13)	0.420
	Placebo	76	72 (94.7)	-0.22 (0.08)	(-0.37, -0.07)			
Week 20	Tezepelumab	73	70 (95.9)	-0.26 (0.08)	(-0.42, -0.11)	-0.08 (0.11)	(-0.29, 0.14)	0.479
	Placebo	76	72 (94.7)	-0.19 (0.08)	(-0.33, -0.04)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WHC\_ILMC0: Change from baseline in ASD weekly cough score - MMRM results  
 DITTTL

Change from baseline in ASD weekly cough score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 21	Tezepelumab	73	67 (91.8)	-0.25 (0.08)	(-0.40, -0.10)	-0.05 (0.11)	(-0.26, 0.16)	0.652
	Placebo	76	73 (96.1)	-0.20 (0.08)	(-0.35, -0.05)			
Week 22	Tezepelumab	73	69 (94.5)	-0.28 (0.08)	(-0.43, -0.13)	-0.15 (0.11)	(-0.36, 0.07)	0.176
	Placebo	76	74 (97.4)	-0.13 (0.08)	(-0.28, 0.02)			
Week 23	Tezepelumab	73	69 (94.5)	-0.27 (0.08)	(-0.42, -0.12)	-0.14 (0.11)	(-0.35, 0.07)	0.200
	Placebo	76	74 (97.4)	-0.13 (0.08)	(-0.28, 0.01)			
Week 24	Tezepelumab	73	69 (94.5)	-0.26 (0.08)	(-0.42, -0.11)	-0.08 (0.11)	(-0.29, 0.14)	0.481
	Placebo	76	75 (98.7)	-0.19 (0.08)	(-0.34, -0.04)			
Week 25	Tezepelumab	73	68 (93.2)	-0.28 (0.08)	(-0.43, -0.13)	-0.06 (0.11)	(-0.28, 0.15)	0.562
	Placebo	76	74 (97.4)	-0.22 (0.08)	(-0.36, -0.07)			
Week 26	Tezepelumab	73	67 (91.8)	-0.29 (0.08)	(-0.44, -0.14)	-0.07 (0.11)	(-0.29, 0.14)	0.492
	Placebo	76	73 (96.1)	-0.22 (0.08)	(-0.36, -0.07)			
Week 27	Tezepelumab	73	68 (93.2)	-0.26 (0.08)	(-0.42, -0.11)	-0.03 (0.11)	(-0.24, 0.19)	0.808
	Placebo	76	71 (93.4)	-0.24 (0.08)	(-0.39, -0.09)			
Week 28	Tezepelumab	73	67 (91.8)	-0.26 (0.08)	(-0.42, -0.11)	-0.03 (0.11)	(-0.25, 0.18)	0.760
	Placebo	76	71 (93.4)	-0.23 (0.08)	(-0.38, -0.08)			
Week 29	Tezepelumab	73	64 (87.7)	-0.33 (0.08)	(-0.48, -0.17)	-0.07 (0.11)	(-0.28, 0.15)	0.536
	Placebo	76	74 (97.4)	-0.26 (0.08)	(-0.41, -0.11)			
Week 30	Tezepelumab	73	66 (90.4)	-0.35 (0.08)	(-0.51, -0.20)	-0.10 (0.11)	(-0.32, 0.11)	0.337
	Placebo	76	74 (97.4)	-0.25 (0.08)	(-0.40, -0.10)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WHC\_ILMC0: Change from baseline in ASD weekly cough score - MMRM results  
 DITTTL

Change from baseline in ASD weekly cough score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 31	Tezepelumab	73	66 (90.4)	-0.36 (0.08)	(-0.51, -0.20)	-0.06 (0.11)	(-0.27, 0.16)	0.601
	Placebo	76	72 (94.7)	-0.30 (0.08)	(-0.45, -0.15)			
Week 32	Tezepelumab	73	64 (87.7)	-0.31 (0.08)	(-0.46, -0.15)	-0.04 (0.11)	(-0.25, 0.18)	0.729
	Placebo	76	73 (96.1)	-0.27 (0.08)	(-0.42, -0.12)			
Week 33	Tezepelumab	73	67 (91.8)	-0.30 (0.08)	(-0.45, -0.15)	-0.01 (0.11)	(-0.22, 0.20)	0.930
	Placebo	76	72 (94.7)	-0.29 (0.08)	(-0.44, -0.14)			
Week 34	Tezepelumab	73	67 (91.8)	-0.36 (0.08)	(-0.51, -0.20)	-0.09 (0.11)	(-0.30, 0.13)	0.419
	Placebo	76	71 (93.4)	-0.27 (0.08)	(-0.42, -0.12)			
Week 35	Tezepelumab	73	65 (89.0)	-0.37 (0.08)	(-0.52, -0.21)	-0.08 (0.11)	(-0.29, 0.14)	0.482
	Placebo	76	74 (97.4)	-0.29 (0.08)	(-0.44, -0.14)			
Week 36	Tezepelumab	73	69 (94.5)	-0.30 (0.08)	(-0.45, -0.15)	0.01 (0.11)	(-0.20, 0.23)	0.893
	Placebo	76	71 (93.4)	-0.32 (0.08)	(-0.46, -0.17)			
Week 37	Tezepelumab	73	66 (90.4)	-0.30 (0.08)	(-0.46, -0.15)	0.02 (0.11)	(-0.19, 0.24)	0.826
	Placebo	76	72 (94.7)	-0.33 (0.08)	(-0.48, -0.18)			
Week 38	Tezepelumab	73	64 (87.7)	-0.34 (0.08)	(-0.50, -0.19)	-0.15 (0.11)	(-0.36, 0.07)	0.178
	Placebo	76	72 (94.7)	-0.19 (0.08)	(-0.34, -0.04)			
Week 39	Tezepelumab	73	64 (87.7)	-0.32 (0.08)	(-0.48, -0.17)	-0.06 (0.11)	(-0.28, 0.15)	0.565
	Placebo	76	71 (93.4)	-0.26 (0.08)	(-0.41, -0.11)			
Week 40	Tezepelumab	73	64 (87.7)	-0.28 (0.08)	(-0.44, -0.13)	-0.01 (0.11)	(-0.22, 0.21)	0.958
	Placebo	76	71 (93.4)	-0.28 (0.08)	(-0.43, -0.13)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WHC\_ILMC0: Change from baseline in ASD weekly cough score - MMRM results  
 DITTTL

Change from baseline in ASD weekly cough score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 41	Tezepelumab	73	63 (86.3)	-0.33 (0.08)	(-0.48, -0.17)	0.01 (0.11)	(-0.21, 0.22)	0.953
	Placebo	76	70 (92.1)	-0.33 (0.08)	(-0.48, -0.18)			
Week 42	Tezepelumab	73	63 (86.3)	-0.32 (0.08)	(-0.47, -0.16)	0.02 (0.11)	(-0.20, 0.23)	0.882
	Placebo	76	72 (94.7)	-0.33 (0.08)	(-0.48, -0.18)			
Week 43	Tezepelumab	73	63 (86.3)	-0.34 (0.08)	(-0.50, -0.18)	-0.12 (0.11)	(-0.34, 0.09)	0.267
	Placebo	76	72 (94.7)	-0.22 (0.08)	(-0.36, -0.07)			
Week 44	Tezepelumab	73	63 (86.3)	-0.33 (0.08)	(-0.48, -0.17)	-0.05 (0.11)	(-0.27, 0.17)	0.657
	Placebo	76	73 (96.1)	-0.28 (0.08)	(-0.43, -0.13)			
Week 45	Tezepelumab	73	62 (84.9)	-0.35 (0.08)	(-0.51, -0.20)	-0.04 (0.11)	(-0.25, 0.18)	0.739
	Placebo	76	70 (92.1)	-0.32 (0.08)	(-0.47, -0.17)			
Week 46	Tezepelumab	73	62 (84.9)	-0.36 (0.08)	(-0.52, -0.20)	-0.06 (0.11)	(-0.28, 0.16)	0.572
	Placebo	76	68 (89.5)	-0.30 (0.08)	(-0.45, -0.15)			
Week 47	Tezepelumab	73	62 (84.9)	-0.34 (0.08)	(-0.50, -0.18)	-0.03 (0.11)	(-0.25, 0.19)	0.784
	Placebo	76	70 (92.1)	-0.31 (0.08)	(-0.46, -0.16)			
Week 48	Tezepelumab	73	57 (78.1)	-0.32 (0.08)	(-0.48, -0.15)	-0.02 (0.11)	(-0.24, 0.20)	0.840
	Placebo	76	68 (89.5)	-0.29 (0.08)	(-0.44, -0.14)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table NT1WEC\_ILMH0: Course of ASD weekly chest tightness score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly chest tightness score	Baseline	Tezepelumab	395	395 (100.0)	1.44 (0.85)	0.0	0.93	1.36	2.00	4.0	
		Placebo	391	391 (100.0)	1.38 (0.84)	0.0	0.79	1.29	2.00	3.8	
	Week 1	Tezepelumab	395	386 (97.7)	1.24 (0.79)	0.0	0.71	1.12	1.86	3.9	
		Placebo	391	382 (97.7)	1.29 (0.83)	0.0	0.79	1.18	1.93	3.9	
	Week 2	Tezepelumab	395	384 (97.2)	1.17 (0.79)	0.0	0.59	1.07	1.71	3.9	
		Placebo	391	379 (96.9)	1.23 (0.80)	0.0	0.71	1.14	1.90	3.5	
	Week 3	Tezepelumab	395	379 (95.9)	1.11 (0.79)	0.0	0.50	1.00	1.67	3.5	
		Placebo	391	371 (94.9)	1.13 (0.79)	0.0	0.50	1.07	1.71	3.8	
	Week 4	Tezepelumab	395	375 (94.9)	1.07 (0.81)	0.0	0.36	1.00	1.70	3.5	
		Placebo	391	370 (94.6)	1.11 (0.79)	0.0	0.36	1.07	1.75	3.6	
	Week 5	Tezepelumab	395	375 (94.9)	1.00 (0.80)	0.0	0.25	1.00	1.50	3.7	
		Placebo	391	360 (92.1)	1.04 (0.77)	0.0	0.36	1.00	1.60	3.4	
	Week 6	Tezepelumab	395	368 (93.2)	0.96 (0.81)	0.0	0.14	1.00	1.43	4.0	
		Placebo	391	365 (93.4)	1.05 (0.81)	0.0	0.36	1.00	1.57	3.9	
	Week 7	Tezepelumab	395	366 (92.7)	0.96 (0.82)	0.0	0.14	1.00	1.43	4.0	
		Placebo	391	365 (93.4)	1.03 (0.82)	0.0	0.25	1.00	1.57	3.9	
	Week 8	Tezepelumab	395	368 (93.2)	0.94 (0.79)	0.0	0.10	1.00	1.50	4.0	
		Placebo	391	356 (91.0)	0.99 (0.80)	0.0	0.18	1.00	1.57	3.8	
	Week 9	Tezepelumab	395	370 (93.7)	0.88 (0.78)	0.0	0.07	1.00	1.29	4.0	
		Placebo	391	357 (91.3)	0.96 (0.78)	0.0	0.21	1.00	1.43	4.0	
	Week 10	Tezepelumab	395	368 (93.2)	0.89 (0.80)	0.0	0.07	0.92	1.36	4.0	
		Placebo	391	353 (90.3)	0.95 (0.78)	0.0	0.13	1.00	1.50	3.6	
	Week 11	Tezepelumab	395	359 (90.9)	0.89 (0.82)	0.0	0.07	1.00	1.43	4.0	
		Placebo	391	351 (89.8)	0.95 (0.80)	0.0	0.08	1.00	1.43	3.3	
	Week 12	Tezepelumab	395	360 (91.1)	0.88 (0.82)	0.0	0.00	0.93	1.40	4.0	
		Placebo	391	347 (88.7)	0.93 (0.78)	0.0	0.08	1.00	1.36	3.7	
	Week 13	Tezepelumab	395	353 (89.4)	0.85 (0.81)	0.0	0.00	0.92	1.29	3.4	
		Placebo	391	345 (88.2)	0.92 (0.77)	0.0	0.13	1.00	1.29	3.3	
	Week 14	Tezepelumab	395	350 (88.6)	0.82 (0.78)	0.0	0.00	0.85	1.21	3.3	
		Placebo	391	343 (87.7)	0.91 (0.77)	0.0	0.10	1.00	1.29	3.5	
	Week 15	Tezepelumab	395	348 (88.1)	0.82 (0.79)	0.0	0.00	0.86	1.21	3.4	
		Placebo	391	335 (85.7)	0.93 (0.81)	0.0	0.07	1.00	1.43	4.0	
Week 16	Tezepelumab	395	352 (89.1)	0.80 (0.78)	0.0	0.00	0.79	1.20	3.5		
	Placebo	391	333 (85.2)	0.93 (0.80)	0.0	0.08	1.00	1.50	3.9		
Week 17	Tezepelumab	395	347 (87.8)	0.77 (0.78)	0.0	0.00	0.79	1.14	3.2		
	Placebo	391	327 (83.6)	0.89 (0.77)	0.0	0.08	1.00	1.42	3.6		

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WEC\_ILMH0: Course of ASD weekly chest tightness score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly chest tightness score	Week 18	Tezepelumab	395	346 (87.6)	0.80 (0.78)	0.0	0.00	0.86	1.17	3.1	
		Placebo	391	322 (82.4)	0.91 (0.81)	0.0	0.07	1.00	1.43	3.7	
	Week 19	Tezepelumab	395	343 (86.8)	0.78 (0.79)	0.0	0.00	0.86	1.10	4.0	
		Placebo	391	332 (84.9)	0.91 (0.83)	0.0	0.04	1.00	1.50	4.0	
	Week 20	Tezepelumab	395	335 (84.8)	0.81 (0.79)	0.0	0.00	0.83	1.25	3.1	
		Placebo	391	324 (82.9)	0.92 (0.83)	0.0	0.07	1.00	1.57	3.7	
	Week 21	Tezepelumab	395	334 (84.6)	0.79 (0.79)	0.0	0.00	0.82	1.21	3.1	
		Placebo	391	319 (81.6)	0.87 (0.84)	0.0	0.00	0.93	1.30	4.0	
	Week 22	Tezepelumab	395	333 (84.3)	0.82 (0.81)	0.0	0.00	0.92	1.21	3.4	
		Placebo	391	312 (79.8)	0.90 (0.83)	0.0	0.00	1.00	1.46	3.8	
	Week 23	Tezepelumab	395	328 (83.0)	0.81 (0.82)	0.0	0.00	0.79	1.25	3.5	
		Placebo	391	310 (79.3)	0.88 (0.83)	0.0	0.00	1.00	1.42	4.0	
	Week 24	Tezepelumab	395	337 (85.3)	0.78 (0.80)	0.0	0.00	0.71	1.14	3.1	
		Placebo	391	310 (79.3)	0.83 (0.81)	0.0	0.00	0.92	1.25	3.6	
	Week 25	Tezepelumab	395	323 (81.8)	0.79 (0.78)	0.0	0.00	0.83	1.21	3.0	
		Placebo	391	308 (78.8)	0.85 (0.81)	0.0	0.07	0.93	1.21	3.9	
	Week 26	Tezepelumab	395	327 (82.8)	0.78 (0.80)	0.0	0.00	0.71	1.17	3.3	
		Placebo	391	303 (77.5)	0.87 (0.82)	0.0	0.07	1.00	1.38	3.7	
	Week 27	Tezepelumab	395	317 (80.3)	0.78 (0.82)	0.0	0.00	0.75	1.17	3.6	
		Placebo	391	313 (80.1)	0.85 (0.81)	0.0	0.00	0.93	1.29	3.3	
	Week 28	Tezepelumab	395	325 (82.3)	0.75 (0.81)	0.0	0.00	0.57	1.14	3.6	
		Placebo	391	314 (80.3)	0.86 (0.81)	0.0	0.00	0.87	1.36	3.8	
	Week 29	Tezepelumab	395	317 (80.3)	0.74 (0.80)	0.0	0.00	0.58	1.13	3.4	
		Placebo	391	312 (79.8)	0.87 (0.84)	0.0	0.00	0.96	1.39	3.7	
	Week 30	Tezepelumab	395	322 (81.5)	0.75 (0.79)	0.0	0.00	0.54	1.14	3.9	
		Placebo	391	303 (77.5)	0.86 (0.82)	0.0	0.00	0.93	1.33	3.8	
	Week 31	Tezepelumab	395	322 (81.5)	0.74 (0.79)	0.0	0.00	0.59	1.07	4.0	
		Placebo	391	308 (78.8)	0.86 (0.78)	0.0	0.00	0.93	1.21	3.5	
	Week 32	Tezepelumab	395	324 (82.0)	0.74 (0.78)	0.0	0.00	0.58	1.14	3.8	
		Placebo	391	308 (78.8)	0.87 (0.78)	0.0	0.00	1.00	1.29	3.1	
	Week 33	Tezepelumab	395	321 (81.3)	0.74 (0.79)	0.0	0.00	0.57	1.10	3.3	
		Placebo	391	304 (77.7)	0.89 (0.80)	0.0	0.00	1.00	1.50	3.0	
	Week 34	Tezepelumab	395	319 (80.8)	0.73 (0.79)	0.0	0.00	0.43	1.14	3.3	
		Placebo	391	303 (77.5)	0.87 (0.81)	0.0	0.00	1.00	1.36	3.7	
	Week 35	Tezepelumab	395	320 (81.0)	0.74 (0.80)	0.0	0.00	0.50	1.09	3.5	
		Placebo	391	295 (75.4)	0.84 (0.79)	0.0	0.00	0.93	1.20	3.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WEC\_ILMH0: Course of ASD weekly chest tightness score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly chest tightness score	Week 36	Tezepelumab	395	317 (80.3)	0.75 (0.81)	0.0	0.00	0.50	1.14	3.4	
		Placebo	391	299 (76.5)	0.85 (0.78)	0.0	0.00	1.00	1.21	3.4	
	Week 37	Tezepelumab	395	320 (81.0)	0.73 (0.80)	0.0	0.00	0.50	1.08	3.3	
		Placebo	391	298 (76.2)	0.83 (0.77)	0.0	0.00	1.00	1.17	3.3	
	Week 38	Tezepelumab	395	317 (80.3)	0.77 (0.81)	0.0	0.00	0.75	1.21	3.4	
		Placebo	391	299 (76.5)	0.81 (0.77)	0.0	0.00	0.92	1.21	3.1	
	Week 39	Tezepelumab	395	325 (82.3)	0.76 (0.84)	0.0	0.00	0.50	1.20	3.9	
		Placebo	391	292 (74.7)	0.84 (0.80)	0.0	0.00	0.93	1.29	3.2	
	Week 40	Tezepelumab	395	321 (81.3)	0.76 (0.82)	0.0	0.00	0.58	1.20	3.7	
		Placebo	391	297 (76.0)	0.86 (0.81)	0.0	0.00	0.93	1.30	3.4	
	Week 41	Tezepelumab	395	324 (82.0)	0.73 (0.80)	0.0	0.00	0.50	1.13	3.5	
		Placebo	391	297 (76.0)	0.87 (0.79)	0.0	0.00	1.00	1.36	3.5	
	Week 42	Tezepelumab	395	316 (80.0)	0.73 (0.81)	0.0	0.00	0.43	1.09	3.9	
		Placebo	391	298 (76.2)	0.85 (0.83)	0.0	0.00	0.96	1.30	3.6	
	Week 43	Tezepelumab	395	319 (80.8)	0.74 (0.84)	0.0	0.00	0.42	1.14	3.6	
		Placebo	391	296 (75.7)	0.85 (0.81)	0.0	0.00	1.00	1.25	3.6	
	Week 44	Tezepelumab	395	316 (80.0)	0.74 (0.83)	0.0	0.00	0.50	1.08	3.7	
		Placebo	391	294 (75.2)	0.86 (0.82)	0.0	0.00	1.00	1.40	3.1	
	Week 45	Tezepelumab	395	319 (80.8)	0.74 (0.82)	0.0	0.00	0.43	1.14	3.9	
		Placebo	391	296 (75.7)	0.85 (0.82)	0.0	0.00	0.93	1.41	3.8	
	Week 46	Tezepelumab	395	314 (79.5)	0.76 (0.82)	0.0	0.00	0.64	1.21	3.8	
		Placebo	391	287 (73.4)	0.83 (0.80)	0.0	0.00	0.92	1.25	3.4	
	Week 47	Tezepelumab	395	302 (76.5)	0.75 (0.82)	0.0	0.00	0.50	1.14	3.1	
		Placebo	391	291 (74.4)	0.79 (0.78)	0.0	0.00	0.80	1.13	3.1	
	Week 48	Tezepelumab	395	323 (81.8)	0.75 (0.82)	0.0	0.00	0.50	1.14	3.8	
		Placebo	391	301 (77.0)	0.82 (0.79)	0.0	0.00	0.93	1.20	3.0	
	Week 49	Tezepelumab	395	315 (79.7)	0.74 (0.82)	0.0	0.00	0.43	1.07	3.2	
		Placebo	391	290 (74.2)	0.83 (0.78)	0.0	0.00	1.00	1.14	3.0	
	Week 50	Tezepelumab	395	312 (79.0)	0.76 (0.83)	0.0	0.00	0.57	1.15	3.0	
		Placebo	391	288 (73.7)	0.85 (0.79)	0.0	0.00	1.00	1.29	3.0	
	Week 51	Tezepelumab	395	307 (77.7)	0.78 (0.82)	0.0	0.00	0.71	1.25	3.0	
		Placebo	391	282 (72.1)	0.83 (0.79)	0.0	0.00	0.96	1.17	3.0	
	Week 52	Tezepelumab	395	276 (69.9)	0.79 (0.84)	0.0	0.00	0.71	1.15	3.1	
		Placebo	391	257 (65.7)	0.86 (0.82)	0.0	0.00	1.00	1.25	3.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WEC\_ILMH0: Course of ASD weekly chest tightness score  
 DITTTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly chest tightness score	Week 1	Tezepelumab	395	386 (97.7)	-0.18 (0.40)	-2.2	-0.36	-0.07	0.00	1.6	-0.23 [-0.38, -0.09]
		Placebo	391	382 (97.7)	-0.09 (0.37)	-1.9	-0.29	-0.07	0.07	1.2	
	Week 2	Tezepelumab	395	384 (97.2)	-0.26 (0.52)	-2.6	-0.57	-0.14	0.03	1.2	-0.21 [-0.35, -0.07]
		Placebo	391	379 (96.9)	-0.15 (0.52)	-3.1	-0.36	-0.08	0.08	1.6	
	Week 3	Tezepelumab	395	379 (95.9)	-0.32 (0.59)	-3.3	-0.64	-0.14	0.00	1.2	-0.13 [-0.28, 0.01]
		Placebo	391	371 (94.9)	-0.24 (0.57)	-2.6	-0.50	-0.13	0.00	1.6	
	Week 4	Tezepelumab	395	375 (94.9)	-0.36 (0.61)	-3.3	-0.66	-0.14	0.00	0.8	-0.15 [-0.30, -0.01]
		Placebo	391	370 (94.6)	-0.27 (0.59)	-2.7	-0.56	-0.14	0.00	1.9	
	Week 5	Tezepelumab	395	375 (94.9)	-0.42 (0.65)	-3.4	-0.86	-0.21	0.00	1.0	-0.14 [-0.28, 0.01]
		Placebo	391	360 (92.1)	-0.34 (0.63)	-2.9	-0.64	-0.21	0.00	2.1	
	Week 6	Tezepelumab	395	368 (93.2)	-0.46 (0.67)	-3.4	-0.87	-0.29	0.00	1.0	-0.17 [-0.32, -0.03]
		Placebo	391	365 (93.4)	-0.34 (0.68)	-3.1	-0.71	-0.21	0.00	2.0	
	Week 7	Tezepelumab	395	366 (92.7)	-0.47 (0.71)	-3.4	-0.86	-0.29	0.00	1.4	-0.17 [-0.31, -0.02]
		Placebo	391	365 (93.4)	-0.35 (0.67)	-3.1	-0.71	-0.23	0.00	2.0	
	Week 8	Tezepelumab	395	368 (93.2)	-0.49 (0.71)	-3.2	-0.92	-0.33	0.00	1.5	-0.16 [-0.30, -0.01]
		Placebo	391	356 (91.0)	-0.38 (0.68)	-3.1	-0.79	-0.29	0.00	2.0	
	Week 9	Tezepelumab	395	370 (93.7)	-0.54 (0.71)	-3.4	-1.00	-0.36	0.00	1.6	-0.17 [-0.32, -0.03]
		Placebo	391	357 (91.3)	-0.42 (0.68)	-3.1	-0.79	-0.30	0.00	2.0	
	Week 10	Tezepelumab	395	368 (93.2)	-0.53 (0.71)	-3.2	-1.00	-0.36	0.00	1.3	-0.13 [-0.28, 0.01]
		Placebo	391	353 (90.3)	-0.43 (0.70)	-3.1	-0.81	-0.31	0.00	2.0	
	Week 11	Tezepelumab	395	359 (90.9)	-0.54 (0.74)	-3.2	-1.00	-0.42	0.00	1.3	-0.14 [-0.28, 0.01]
		Placebo	391	351 (89.8)	-0.44 (0.73)	-3.1	-0.86	-0.36	0.00	2.0	
	Week 12	Tezepelumab	395	360 (91.1)	-0.53 (0.74)	-3.4	-1.00	-0.42	0.00	1.1	-0.12 [-0.27, 0.02]
		Placebo	391	347 (88.7)	-0.45 (0.69)	-3.1	-0.86	-0.36	0.00	2.0	
	Week 13	Tezepelumab	395	353 (89.4)	-0.55 (0.73)	-3.3	-1.00	-0.42	0.00	1.1	-0.11 [-0.26, 0.04]
		Placebo	391	345 (88.2)	-0.47 (0.71)	-3.1	-0.87	-0.42	0.00	2.0	
	Week 14	Tezepelumab	395	350 (88.6)	-0.61 (0.74)	-3.3	-1.00	-0.50	-0.07	1.0	-0.19 [-0.34, -0.04]
		Placebo	391	343 (87.7)	-0.47 (0.73)	-3.1	-0.88	-0.36	0.00	2.0	
	Week 15	Tezepelumab	395	348 (88.1)	-0.58 (0.72)	-3.1	-1.00	-0.43	0.00	1.1	-0.18 [-0.33, -0.03]
		Placebo	391	335 (85.7)	-0.45 (0.74)	-3.1	-0.86	-0.43	0.00	2.0	
	Week 16	Tezepelumab	395	352 (89.1)	-0.61 (0.75)	-3.3	-1.04	-0.49	0.00	1.1	-0.19 [-0.34, -0.04]
		Placebo	391	333 (85.2)	-0.47 (0.75)	-3.1	-0.93	-0.36	0.00	2.0	
	Week 17	Tezepelumab	395	347 (87.8)	-0.64 (0.75)	-3.5	-1.07	-0.50	-0.01	1.2	-0.19 [-0.34, -0.04]
		Placebo	391	327 (83.6)	-0.50 (0.72)	-3.1	-0.93	-0.43	0.00	2.0	
	Week 18	Tezepelumab	395	346 (87.6)	-0.61 (0.74)	-3.7	-1.00	-0.50	0.00	1.3	-0.19 [-0.34, -0.03]
		Placebo	391	322 (82.4)	-0.47 (0.75)	-3.1	-0.88	-0.33	0.00	2.0	

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WEC\_ILMH0: Course of ASD weekly chest tightness score  
 DITTTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly chest tightness score	Week 19	Tezepelumab	395	343 (86.8)	-0.62 (0.76)	-3.5	-1.00	-0.50	0.00	1.6	-0.18 [-0.34, -0.03]
		Placebo	391	332 (84.9)	-0.48 (0.76)	-3.1	-0.93	-0.36	0.00	2.0	
	Week 20	Tezepelumab	395	335 (84.8)	-0.60 (0.75)	-3.4	-1.00	-0.49	0.00	1.1	-0.16 [-0.32, -0.01]
		Placebo	391	324 (82.9)	-0.48 (0.78)	-3.1	-0.92	-0.36	0.00	2.0	
	Week 21	Tezepelumab	395	334 (84.6)	-0.60 (0.75)	-3.3	-1.00	-0.50	-0.01	1.9	-0.12 [-0.28, 0.03]
		Placebo	391	319 (81.6)	-0.51 (0.80)	-3.3	-0.93	-0.37	0.00	2.0	
	Week 22	Tezepelumab	395	333 (84.3)	-0.59 (0.77)	-3.7	-1.00	-0.43	0.00	1.4	-0.15 [-0.30, 0.01]
		Placebo	391	312 (79.8)	-0.47 (0.77)	-3.4	-0.92	-0.34	0.00	2.0	
	Week 23	Tezepelumab	395	328 (83.0)	-0.60 (0.75)	-3.3	-1.00	-0.50	0.00	1.3	-0.11 [-0.27, 0.04]
		Placebo	391	310 (79.3)	-0.51 (0.78)	-3.4	-0.95	-0.43	0.00	2.0	
	Week 24	Tezepelumab	395	337 (85.3)	-0.64 (0.76)	-3.8	-1.07	-0.57	-0.02	1.3	-0.14 [-0.30, 0.01]
		Placebo	391	310 (79.3)	-0.53 (0.78)	-3.4	-1.00	-0.45	0.00	2.0	
	Week 25	Tezepelumab	395	323 (81.8)	-0.63 (0.76)	-3.7	-1.10	-0.55	0.00	1.3	-0.13 [-0.29, 0.02]
		Placebo	391	308 (78.8)	-0.53 (0.81)	-3.4	-0.96	-0.50	0.00	2.0	
	Week 26	Tezepelumab	395	327 (82.8)	-0.63 (0.78)	-3.8	-1.07	-0.53	0.00	1.7	-0.15 [-0.30, 0.01]
		Placebo	391	303 (77.5)	-0.52 (0.79)	-3.4	-0.94	-0.42	0.00	2.0	
	Week 27	Tezepelumab	395	317 (80.3)	-0.64 (0.79)	-3.6	-1.07	-0.57	0.00	1.2	-0.16 [-0.32, -0.01]
		Placebo	391	313 (80.1)	-0.51 (0.80)	-3.1	-1.00	-0.42	0.00	2.6	
	Week 28	Tezepelumab	395	325 (82.3)	-0.66 (0.77)	-3.7	-1.07	-0.58	-0.07	1.1	-0.19 [-0.35, -0.04]
		Placebo	391	314 (80.3)	-0.51 (0.80)	-3.4	-0.93	-0.37	0.00	2.1	
	Week 29	Tezepelumab	395	317 (80.3)	-0.68 (0.77)	-3.8	-1.14	-0.58	-0.07	1.1	-0.22 [-0.37, -0.06]
		Placebo	391	312 (79.8)	-0.50 (0.82)	-3.3	-0.93	-0.36	0.00	2.0	
	Week 30	Tezepelumab	395	322 (81.5)	-0.66 (0.78)	-3.8	-1.11	-0.62	-0.07	1.1	-0.19 [-0.35, -0.03]
		Placebo	391	303 (77.5)	-0.51 (0.78)	-3.1	-1.00	-0.42	0.00	2.0	
	Week 31	Tezepelumab	395	322 (81.5)	-0.69 (0.80)	-3.8	-1.14	-0.58	-0.07	1.1	-0.22 [-0.38, -0.07]
		Placebo	391	308 (78.8)	-0.51 (0.76)	-3.4	-1.00	-0.45	0.00	2.0	
	Week 32	Tezepelumab	395	324 (82.0)	-0.67 (0.77)	-3.8	-1.08	-0.61	-0.07	1.2	-0.19 [-0.35, -0.04]
		Placebo	391	308 (78.8)	-0.51 (0.80)	-3.4	-0.93	-0.43	0.00	2.0	
	Week 33	Tezepelumab	395	321 (81.3)	-0.67 (0.79)	-3.8	-1.14	-0.64	-0.07	1.1	-0.20 [-0.36, -0.05]
		Placebo	391	304 (77.7)	-0.51 (0.80)	-3.3	-0.92	-0.43	0.00	1.9	
	Week 34	Tezepelumab	395	319 (80.8)	-0.69 (0.77)	-3.5	-1.10	-0.64	-0.07	1.1	-0.23 [-0.39, -0.07]
		Placebo	391	303 (77.5)	-0.51 (0.79)	-3.3	-0.92	-0.43	0.00	2.0	
	Week 35	Tezepelumab	395	320 (81.0)	-0.67 (0.79)	-3.8	-1.13	-0.62	-0.07	1.4	-0.20 [-0.36, -0.04]
		Placebo	391	295 (75.4)	-0.51 (0.79)	-3.4	-1.00	-0.42	0.00	2.0	
	Week 36	Tezepelumab	395	317 (80.3)	-0.67 (0.80)	-3.8	-1.07	-0.57	-0.07	1.2	-0.20 [-0.36, -0.04]
		Placebo	391	299 (76.5)	-0.51 (0.79)	-3.1	-0.93	-0.42	0.00	2.0	

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WEC\_ILMH0: Course of ASD weekly chest tightness score  
 DITTTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly chest tightness score	Week 37	Tezepelumab	395	320 (81.0)	-0.66 (0.79)	-3.6	-1.14	-0.61	-0.03	1.1	-0.19 [-0.35, -0.03]
		Placebo	391	298 (76.2)	-0.51 (0.77)	-3.3	-1.00	-0.42	0.00	2.0	
	Week 38	Tezepelumab	395	317 (80.3)	-0.66 (0.80)	-3.6	-1.14	-0.58	-0.07	1.1	-0.16 [-0.32, -0.01]
		Placebo	391	299 (76.5)	-0.53 (0.76)	-3.1	-1.00	-0.50	0.00	2.0	
	Week 39	Tezepelumab	395	325 (82.3)	-0.67 (0.82)	-3.8	-1.14	-0.58	-0.07	1.3	-0.21 [-0.37, -0.05]
		Placebo	391	292 (74.7)	-0.51 (0.79)	-3.1	-0.93	-0.42	0.00	1.9	
	Week 40	Tezepelumab	395	321 (81.3)	-0.67 (0.79)	-3.8	-1.14	-0.57	-0.07	1.3	-0.23 [-0.39, -0.08]
		Placebo	391	297 (76.0)	-0.49 (0.78)	-3.4	-0.93	-0.39	0.00	2.0	
	Week 41	Tezepelumab	395	324 (82.0)	-0.69 (0.79)	-3.8	-1.14	-0.58	-0.07	1.5	-0.19 [-0.35, -0.04]
		Placebo	391	297 (76.0)	-0.54 (0.78)	-3.3	-1.00	-0.43	0.00	2.2	
	Week 42	Tezepelumab	395	316 (80.0)	-0.69 (0.78)	-3.7	-1.14	-0.64	-0.07	1.1	-0.23 [-0.39, -0.07]
		Placebo	391	298 (76.2)	-0.51 (0.78)	-3.4	-0.93	-0.42	0.00	2.0	
	Week 43	Tezepelumab	395	319 (80.8)	-0.70 (0.81)	-3.8	-1.14	-0.60	-0.07	1.1	-0.22 [-0.37, -0.06]
		Placebo	391	296 (75.7)	-0.53 (0.77)	-3.3	-1.00	-0.38	0.00	2.0	
	Week 44	Tezepelumab	395	316 (80.0)	-0.69 (0.81)	-3.8	-1.14	-0.64	-0.07	1.1	-0.23 [-0.38, -0.07]
		Placebo	391	294 (75.2)	-0.51 (0.79)	-3.4	-0.93	-0.36	0.00	2.0	
	Week 45	Tezepelumab	395	319 (80.8)	-0.69 (0.80)	-3.8	-1.14	-0.64	-0.07	1.1	-0.19 [-0.35, -0.03]
		Placebo	391	296 (75.7)	-0.54 (0.81)	-3.4	-1.01	-0.46	0.00	2.0	
	Week 46	Tezepelumab	395	314 (79.5)	-0.69 (0.82)	-3.8	-1.14	-0.64	-0.07	1.3	-0.20 [-0.36, -0.04]
		Placebo	391	287 (73.4)	-0.53 (0.79)	-3.4	-0.95	-0.43	0.00	2.0	
	Week 47	Tezepelumab	395	302 (76.5)	-0.67 (0.80)	-3.7	-1.14	-0.64	-0.07	1.3	-0.14 [-0.30, 0.02]
		Placebo	391	291 (74.4)	-0.56 (0.76)	-3.4	-1.00	-0.43	-0.04	1.6	
	Week 48	Tezepelumab	395	323 (81.8)	-0.66 (0.82)	-3.8	-1.14	-0.57	0.00	1.6	-0.13 [-0.28, 0.03]
		Placebo	391	301 (77.0)	-0.56 (0.77)	-3.4	-1.00	-0.50	0.00	2.1	
	Week 49	Tezepelumab	395	315 (79.7)	-0.68 (0.80)	-3.7	-1.10	-0.61	-0.07	1.1	-0.16 [-0.32, 0.00]
		Placebo	391	290 (74.2)	-0.56 (0.76)	-3.4	-0.99	-0.50	0.00	1.6	
	Week 50	Tezepelumab	395	312 (79.0)	-0.66 (0.81)	-3.5	-1.11	-0.58	-0.07	1.3	-0.17 [-0.33, -0.01]
		Placebo	391	288 (73.7)	-0.53 (0.77)	-3.4	-1.00	-0.49	0.00	1.8	
	Week 51	Tezepelumab	395	307 (77.7)	-0.65 (0.84)	-3.8	-1.14	-0.57	0.00	1.7	-0.14 [-0.30, 0.03]
		Placebo	391	282 (72.1)	-0.54 (0.79)	-3.4	-1.00	-0.50	0.00	1.9	
	Week 52	Tezepelumab	395	276 (69.9)	-0.65 (0.86)	-3.8	-1.09	-0.60	-0.07	1.6	-0.12 [-0.29, 0.05]
		Placebo	391	257 (65.7)	-0.55 (0.82)	-3.4	-1.00	-0.48	0.00	1.7	

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WEC\_ILMC0: Change from baseline in ASD weekly chest tightness score - MMRM results  
 DITTTL

Change from baseline in ASD weekly chest tightness score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 1	Tezepelumab	395	386 (97.7)	-0.17 (0.03)	(-0.24, -0.11)	-0.07 (0.05)	(-0.16, 0.02)	0.117	
	Placebo	391	382 (97.7)	-0.10 (0.03)	(-0.16, -0.03)				
Week 2	Tezepelumab	395	384 (97.2)	-0.25 (0.03)	(-0.32, -0.19)	-0.10 (0.05)	(-0.19, -0.01)	0.038 *	
	Placebo	391	379 (96.9)	-0.16 (0.03)	(-0.22, -0.09)				
Week 3	Tezepelumab	395	379 (95.9)	-0.32 (0.03)	(-0.38, -0.25)	-0.08 (0.05)	(-0.17, 0.02)	0.108	
	Placebo	391	371 (94.9)	-0.24 (0.03)	(-0.31, -0.18)				
Week 4	Tezepelumab	395	375 (94.9)	-0.36 (0.03)	(-0.42, -0.29)	-0.08 (0.05)	(-0.17, 0.01)	0.081	
	Placebo	391	370 (94.6)	-0.28 (0.03)	(-0.34, -0.21)				
Week 5	Tezepelumab	395	375 (94.9)	-0.42 (0.03)	(-0.48, -0.35)	-0.07 (0.05)	(-0.16, 0.02)	0.134	
	Placebo	391	360 (92.1)	-0.35 (0.03)	(-0.41, -0.28)				
Week 6	Tezepelumab	395	368 (93.2)	-0.45 (0.03)	(-0.52, -0.39)	-0.10 (0.05)	(-0.19, -0.01)	0.028 *	
	Placebo	391	365 (93.4)	-0.35 (0.03)	(-0.41, -0.28)				
Week 7	Tezepelumab	395	366 (92.7)	-0.46 (0.03)	(-0.52, -0.39)	-0.10 (0.05)	(-0.19, -0.01)	0.035 *	
	Placebo	391	365 (93.4)	-0.36 (0.03)	(-0.43, -0.30)				
Week 8	Tezepelumab	395	368 (93.2)	-0.49 (0.03)	(-0.55, -0.42)	-0.11 (0.05)	(-0.20, -0.02)	0.020 *	
	Placebo	391	356 (91.0)	-0.38 (0.03)	(-0.44, -0.31)				
Week 9	Tezepelumab	395	370 (93.7)	-0.53 (0.03)	(-0.59, -0.46)	-0.11 (0.05)	(-0.20, -0.01)	0.023 *	
	Placebo	391	357 (91.3)	-0.42 (0.03)	(-0.49, -0.36)				
Week 10	Tezepelumab	395	368 (93.2)	-0.53 (0.03)	(-0.60, -0.47)	-0.11 (0.05)	(-0.20, -0.01)	0.023 *	
	Placebo	391	353 (90.3)	-0.43 (0.03)	(-0.49, -0.36)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WEC\_ILMC0: Change from baseline in ASD weekly chest tightness score - MMRM results  
DITTL

Change from baseline in ASD weekly chest tightness score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Time	Treatment	N	n (%)						
Week 11	Tezepelumab	395	359 (90.9)	-0.54 (0.03)	(-0.60, -0.47)	-0.10 (0.05)	(-0.20, -0.01)	0.028	*
	Placebo	391	351 (89.8)	-0.43 (0.03)	(-0.50, -0.37)				
Week 12	Tezepelumab	395	360 (91.1)	-0.53 (0.03)	(-0.59, -0.46)	-0.09 (0.05)	(-0.19, -0.00)	0.045	*
	Placebo	391	347 (88.7)	-0.43 (0.03)	(-0.50, -0.37)				
Week 13	Tezepelumab	395	353 (89.4)	-0.56 (0.03)	(-0.62, -0.49)	-0.11 (0.05)	(-0.20, -0.02)	0.017	*
	Placebo	391	345 (88.2)	-0.44 (0.03)	(-0.51, -0.38)				
Week 14	Tezepelumab	395	350 (88.6)	-0.58 (0.03)	(-0.65, -0.52)	-0.13 (0.05)	(-0.22, -0.03)	0.008	*
	Placebo	391	343 (87.7)	-0.46 (0.03)	(-0.52, -0.39)				
Week 15	Tezepelumab	395	348 (88.1)	-0.58 (0.03)	(-0.65, -0.52)	-0.13 (0.05)	(-0.22, -0.04)	0.005	*
	Placebo	391	335 (85.7)	-0.45 (0.03)	(-0.52, -0.39)				
Week 16	Tezepelumab	395	352 (89.1)	-0.61 (0.03)	(-0.68, -0.54)	-0.16 (0.05)	(-0.25, -0.07)	<0.001	*
	Placebo	391	333 (85.2)	-0.45 (0.03)	(-0.52, -0.38)				
Week 17	Tezepelumab	395	347 (87.8)	-0.62 (0.03)	(-0.68, -0.55)	-0.13 (0.05)	(-0.23, -0.04)	0.005	*
	Placebo	391	327 (83.6)	-0.48 (0.03)	(-0.55, -0.42)				
Week 18	Tezepelumab	395	346 (87.6)	-0.60 (0.03)	(-0.67, -0.54)	-0.13 (0.05)	(-0.22, -0.03)	0.008	*
	Placebo	391	322 (82.4)	-0.48 (0.03)	(-0.54, -0.41)				
Week 19	Tezepelumab	395	343 (86.8)	-0.62 (0.03)	(-0.68, -0.55)	-0.14 (0.05)	(-0.23, -0.04)	0.005	*
	Placebo	391	332 (84.9)	-0.48 (0.03)	(-0.55, -0.42)				
Week 20	Tezepelumab	395	335 (84.8)	-0.61 (0.03)	(-0.68, -0.55)	-0.14 (0.05)	(-0.23, -0.05)	0.003	*
	Placebo	391	324 (82.9)	-0.47 (0.03)	(-0.54, -0.41)				

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table NT1WEC\_ILMC0: Change from baseline in ASD weekly chest tightness score - MMRM results  
 DITTTL

Change from baseline in ASD weekly chest tightness score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 21	Tezepelumab	395	334 (84.6)	-0.61 (0.03)	(-0.68, -0.55)	-0.13 (0.05)	(-0.23, -0.04)	0.006 *	
	Placebo	391	319 (81.6)	-0.48 (0.03)	(-0.55, -0.42)				
Week 22	Tezepelumab	395	333 (84.3)	-0.61 (0.03)	(-0.67, -0.54)	-0.12 (0.05)	(-0.22, -0.03)	0.011 *	
	Placebo	391	312 (79.8)	-0.49 (0.03)	(-0.55, -0.42)				
Week 23	Tezepelumab	395	328 (83.0)	-0.62 (0.03)	(-0.68, -0.55)	-0.14 (0.05)	(-0.23, -0.04)	0.005 *	
	Placebo	391	310 (79.3)	-0.48 (0.03)	(-0.55, -0.41)				
Week 24	Tezepelumab	395	337 (85.3)	-0.63 (0.03)	(-0.70, -0.57)	-0.13 (0.05)	(-0.22, -0.03)	0.008 *	
	Placebo	391	310 (79.3)	-0.51 (0.03)	(-0.57, -0.44)				
Week 25	Tezepelumab	395	323 (81.8)	-0.63 (0.03)	(-0.70, -0.56)	-0.12 (0.05)	(-0.22, -0.03)	0.011 *	
	Placebo	391	308 (78.8)	-0.51 (0.03)	(-0.57, -0.44)				
Week 26	Tezepelumab	395	327 (82.8)	-0.64 (0.03)	(-0.71, -0.58)	-0.14 (0.05)	(-0.23, -0.04)	0.004 *	
	Placebo	391	303 (77.5)	-0.50 (0.03)	(-0.57, -0.44)				
Week 27	Tezepelumab	395	317 (80.3)	-0.63 (0.03)	(-0.70, -0.57)	-0.13 (0.05)	(-0.23, -0.03)	0.007 *	
	Placebo	391	313 (80.1)	-0.50 (0.03)	(-0.57, -0.44)				
Week 28	Tezepelumab	395	325 (82.3)	-0.65 (0.03)	(-0.72, -0.59)	-0.15 (0.05)	(-0.24, -0.05)	0.002 *	
	Placebo	391	314 (80.3)	-0.51 (0.03)	(-0.58, -0.44)				
Week 29	Tezepelumab	395	317 (80.3)	-0.66 (0.03)	(-0.73, -0.60)	-0.16 (0.05)	(-0.26, -0.07)	<0.001 *	
	Placebo	391	312 (79.8)	-0.50 (0.03)	(-0.57, -0.43)				
Week 30	Tezepelumab	395	322 (81.5)	-0.65 (0.03)	(-0.72, -0.59)	-0.15 (0.05)	(-0.25, -0.06)	0.002 *	
	Placebo	391	303 (77.5)	-0.50 (0.03)	(-0.57, -0.43)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WEC\_ILMC0: Change from baseline in ASD weekly chest tightness score - MMRM results  
DITTL

Change from baseline in ASD weekly chest tightness score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 31	Tezepelumab	395	322 (81.5)	-0.66 (0.03)	(-0.73, -0.59)	-0.14 (0.05)	(-0.24, -0.05)	0.004 *	
	Placebo	391	308 (78.8)	-0.52 (0.03)	(-0.59, -0.45)				
Week 32	Tezepelumab	395	324 (82.0)	-0.66 (0.03)	(-0.73, -0.60)	-0.16 (0.05)	(-0.26, -0.06)	0.001 *	
	Placebo	391	308 (78.8)	-0.50 (0.03)	(-0.57, -0.43)				
Week 33	Tezepelumab	395	321 (81.3)	-0.67 (0.03)	(-0.74, -0.61)	-0.17 (0.05)	(-0.27, -0.07)	<0.001 *	
	Placebo	391	304 (77.7)	-0.50 (0.03)	(-0.57, -0.43)				
Week 34	Tezepelumab	395	319 (80.8)	-0.69 (0.03)	(-0.76, -0.62)	-0.19 (0.05)	(-0.29, -0.10)	<0.001 *	
	Placebo	391	303 (77.5)	-0.50 (0.04)	(-0.57, -0.43)				
Week 35	Tezepelumab	395	320 (81.0)	-0.67 (0.03)	(-0.74, -0.61)	-0.17 (0.05)	(-0.26, -0.07)	<0.001 *	
	Placebo	391	295 (75.4)	-0.51 (0.04)	(-0.58, -0.44)				
Week 36	Tezepelumab	395	317 (80.3)	-0.67 (0.03)	(-0.73, -0.60)	-0.16 (0.05)	(-0.26, -0.06)	0.001 *	
	Placebo	391	299 (76.5)	-0.51 (0.04)	(-0.58, -0.44)				
Week 37	Tezepelumab	395	320 (81.0)	-0.66 (0.03)	(-0.73, -0.59)	-0.13 (0.05)	(-0.23, -0.03)	0.008 *	
	Placebo	391	298 (76.2)	-0.53 (0.04)	(-0.60, -0.46)				
Week 38	Tezepelumab	395	317 (80.3)	-0.65 (0.03)	(-0.72, -0.58)	-0.12 (0.05)	(-0.22, -0.03)	0.012 *	
	Placebo	391	299 (76.5)	-0.53 (0.04)	(-0.59, -0.46)				
Week 39	Tezepelumab	395	325 (82.3)	-0.65 (0.03)	(-0.72, -0.58)	-0.12 (0.05)	(-0.22, -0.03)	0.013 *	
	Placebo	391	292 (74.7)	-0.53 (0.04)	(-0.59, -0.46)				
Week 40	Tezepelumab	395	321 (81.3)	-0.67 (0.03)	(-0.73, -0.60)	-0.16 (0.05)	(-0.26, -0.06)	0.001 *	
	Placebo	391	297 (76.0)	-0.51 (0.04)	(-0.58, -0.44)				

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WEC\_ILMC0: Change from baseline in ASD weekly chest tightness score - MMRM results  
 DITTTL

Change from baseline in ASD weekly chest tightness score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 41	Tezepelumab	395	324 (82.0)	-0.68 (0.03)	(-0.75, -0.62)	-0.16 (0.05)	(-0.26, -0.06)	0.001 *	
	Placebo	391	297 (76.0)	-0.52 (0.04)	(-0.59, -0.45)				
Week 42	Tezepelumab	395	316 (80.0)	-0.68 (0.03)	(-0.75, -0.61)	-0.15 (0.05)	(-0.25, -0.05)	0.002 *	
	Placebo	391	298 (76.2)	-0.53 (0.04)	(-0.60, -0.46)				
Week 43	Tezepelumab	395	319 (80.8)	-0.68 (0.03)	(-0.74, -0.61)	-0.15 (0.05)	(-0.25, -0.06)	0.002 *	
	Placebo	391	296 (75.7)	-0.52 (0.04)	(-0.59, -0.45)				
Week 44	Tezepelumab	395	316 (80.0)	-0.68 (0.03)	(-0.74, -0.61)	-0.16 (0.05)	(-0.26, -0.06)	0.001 *	
	Placebo	391	294 (75.2)	-0.52 (0.04)	(-0.59, -0.45)				
Week 45	Tezepelumab	395	319 (80.8)	-0.69 (0.03)	(-0.75, -0.62)	-0.16 (0.05)	(-0.26, -0.06)	0.001 *	
	Placebo	391	296 (75.7)	-0.53 (0.04)	(-0.59, -0.46)				
Week 46	Tezepelumab	395	314 (79.5)	-0.69 (0.03)	(-0.75, -0.62)	-0.15 (0.05)	(-0.24, -0.05)	0.003 *	
	Placebo	391	287 (73.4)	-0.54 (0.04)	(-0.61, -0.47)				
Week 47	Tezepelumab	395	302 (76.5)	-0.68 (0.03)	(-0.75, -0.61)	-0.13 (0.05)	(-0.23, -0.03)	0.009 *	
	Placebo	391	291 (74.4)	-0.55 (0.04)	(-0.62, -0.48)				
Week 48	Tezepelumab	395	323 (81.8)	-0.66 (0.03)	(-0.73, -0.60)	-0.11 (0.05)	(-0.21, -0.02)	0.022 *	
	Placebo	391	301 (77.0)	-0.55 (0.04)	(-0.62, -0.48)				
Week 49	Tezepelumab	395	315 (79.7)	-0.68 (0.03)	(-0.75, -0.61)	-0.12 (0.05)	(-0.22, -0.03)	0.013 *	
	Placebo	391	290 (74.2)	-0.56 (0.04)	(-0.63, -0.49)				
Week 50	Tezepelumab	395	312 (79.0)	-0.67 (0.03)	(-0.74, -0.60)	-0.14 (0.05)	(-0.23, -0.04)	0.007 *	
	Placebo	391	288 (73.7)	-0.54 (0.04)	(-0.61, -0.47)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WEC\_ILMC0: Change from baseline in ASD weekly chest tightness score - MMRM results  
 DITTTL

Change from baseline in ASD weekly chest tightness score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 51	Tezepelumab	395	307 (77.7)	-0.65 (0.04)	(-0.72, -0.58)	-0.11 (0.05)	(-0.21, -0.01)	0.025 *	
	Placebo	391	282 (72.1)	-0.54 (0.04)	(-0.61, -0.47)				
Week 52	Tezepelumab	395	276 (69.9)	-0.66 (0.04)	(-0.73, -0.59)	-0.14 (0.05)	(-0.24, -0.04)	0.007 *	
	Placebo	391	257 (65.7)	-0.52 (0.04)	(-0.60, -0.45)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WEC\_ILMH0: Course of ASD weekly chest tightness score  
 DITTTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly chest tightness score	Baseline	Tezepelumab	73	73 (100.0)	1.33 (0.83)	0.0	0.93	1.29	2.00	3.1	
		Placebo	76	76 (100.0)	1.28 (0.92)	0.0	0.42	1.14	2.00	3.5	
	Week 1	Tezepelumab	73	71 (97.3)	1.17 (0.83)	0.0	0.57	1.00	2.00	3.0	
		Placebo	76	76 (100.0)	1.26 (0.84)	0.0	0.61	1.14	2.00	3.4	
	Week 2	Tezepelumab	73	73 (100.0)	1.08 (0.85)	0.0	0.21	1.00	1.71	3.2	
		Placebo	76	74 (97.4)	1.20 (0.84)	0.0	0.64	1.11	2.00	2.9	
	Week 3	Tezepelumab	73	73 (100.0)	1.02 (0.83)	0.0	0.14	1.00	1.71	3.0	
		Placebo	76	73 (96.1)	1.16 (0.82)	0.0	0.40	1.08	2.00	2.9	
	Week 4	Tezepelumab	73	71 (97.3)	0.99 (0.85)	0.0	0.07	1.00	1.71	3.1	
		Placebo	76	76 (100.0)	1.15 (0.81)	0.0	0.54	1.00	2.00	3.4	
	Week 5	Tezepelumab	73	71 (97.3)	0.98 (0.89)	0.0	0.00	1.00	1.79	3.0	
		Placebo	76	74 (97.4)	1.08 (0.81)	0.0	0.36	1.00	1.92	3.3	
	Week 6	Tezepelumab	73	69 (94.5)	0.99 (0.90)	0.0	0.07	1.00	1.92	3.1	
		Placebo	76	72 (94.7)	1.13 (0.83)	0.0	0.29	1.00	2.00	2.6	
	Week 7	Tezepelumab	73	69 (94.5)	0.96 (0.92)	0.0	0.07	0.88	1.93	3.4	
		Placebo	76	75 (98.7)	1.12 (0.82)	0.0	0.29	1.07	2.00	2.8	
	Week 8	Tezepelumab	73	68 (93.2)	0.99 (0.94)	0.0	0.00	1.00	1.96	3.3	
		Placebo	76	75 (98.7)	1.16 (0.84)	0.0	0.29	1.07	2.00	3.1	
	Week 9	Tezepelumab	73	69 (94.5)	0.98 (0.93)	0.0	0.00	1.00	2.00	3.1	
		Placebo	76	73 (96.1)	1.16 (0.86)	0.0	0.21	1.00	2.00	3.0	
	Week 10	Tezepelumab	73	70 (95.9)	0.95 (0.93)	0.0	0.00	1.00	2.00	3.3	
		Placebo	76	74 (97.4)	1.16 (0.82)	0.0	0.38	1.07	1.93	2.7	
	Week 11	Tezepelumab	73	70 (95.9)	0.96 (0.93)	0.0	0.07	1.00	1.90	3.5	
		Placebo	76	74 (97.4)	1.14 (0.85)	0.0	0.25	1.07	1.93	3.1	
	Week 12	Tezepelumab	73	70 (95.9)	0.97 (0.94)	0.0	0.07	1.00	1.86	3.6	
		Placebo	76	75 (98.7)	1.16 (0.82)	0.0	0.33	1.14	1.93	3.0	
	Week 13	Tezepelumab	73	68 (93.2)	0.97 (1.00)	0.0	0.00	0.93	2.00	3.6	
		Placebo	76	71 (93.4)	1.13 (0.83)	0.0	0.25	1.07	1.92	3.0	
	Week 14	Tezepelumab	73	69 (94.5)	0.96 (0.93)	0.0	0.00	0.93	2.00	3.3	
		Placebo	76	73 (96.1)	1.11 (0.77)	0.0	0.30	1.07	2.00	2.3	
	Week 15	Tezepelumab	73	69 (94.5)	0.98 (0.94)	0.0	0.00	1.00	2.00	3.2	
		Placebo	76	72 (94.7)	1.08 (0.77)	0.0	0.35	1.00	1.93	2.8	
Week 16	Tezepelumab	73	69 (94.5)	1.01 (0.99)	0.0	0.00	1.00	2.00	3.7		
	Placebo	76	74 (97.4)	1.07 (0.72)	0.0	0.36	1.00	1.71	2.4		
Week 17	Tezepelumab	73	68 (93.2)	0.99 (0.99)	0.0	0.00	1.00	1.89	3.6		
	Placebo	76	74 (97.4)	1.04 (0.74)	0.0	0.42	1.00	1.57	2.8		

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WEC\_ILMH0: Course of ASD weekly chest tightness score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly chest tightness score	Week 18	Tezepelumab	73	68 (93.2)	0.96 (1.00)	0.0	0.00	0.91	2.00	3.6	
		Placebo	76	72 (94.7)	1.04 (0.78)	0.0	0.10	1.00	1.65	2.8	
	Week 19	Tezepelumab	73	67 (91.8)	0.90 (0.93)	0.0	0.00	0.75	1.80	3.1	
		Placebo	76	72 (94.7)	1.05 (0.80)	0.0	0.15	1.00	1.89	3.2	
	Week 20	Tezepelumab	73	70 (95.9)	0.91 (0.95)	0.0	0.00	0.85	1.93	3.3	
		Placebo	76	72 (94.7)	1.08 (0.77)	0.0	0.40	1.00	1.91	2.8	
	Week 21	Tezepelumab	73	67 (91.8)	0.91 (0.91)	0.0	0.00	1.00	1.83	3.3	
		Placebo	76	73 (96.1)	1.08 (0.81)	0.0	0.36	1.00	1.92	3.4	
	Week 22	Tezepelumab	73	69 (94.5)	0.92 (0.89)	0.0	0.00	1.00	1.79	3.2	
		Placebo	76	74 (97.4)	1.15 (0.85)	0.0	0.50	1.07	1.93	4.0	
	Week 23	Tezepelumab	73	69 (94.5)	0.95 (0.95)	0.0	0.00	0.93	1.83	3.3	
		Placebo	76	74 (97.4)	1.14 (0.81)	0.0	0.30	1.00	2.00	3.6	
	Week 24	Tezepelumab	73	69 (94.5)	0.98 (0.93)	0.0	0.00	1.00	1.79	3.3	
		Placebo	76	75 (98.7)	1.12 (0.82)	0.0	0.30	1.07	1.93	3.3	
	Week 25	Tezepelumab	73	68 (93.2)	0.95 (0.97)	0.0	0.00	0.83	1.93	3.7	
		Placebo	76	74 (97.4)	1.10 (0.85)	0.0	0.29	1.00	1.93	3.9	
	Week 26	Tezepelumab	73	67 (91.8)	0.90 (0.95)	0.0	0.00	0.86	2.00	3.5	
		Placebo	76	73 (96.1)	1.12 (0.86)	0.0	0.20	1.00	1.86	4.0	
	Week 27	Tezepelumab	73	68 (93.2)	0.91 (0.94)	0.0	0.00	0.86	1.81	3.4	
		Placebo	76	71 (93.4)	1.09 (0.84)	0.0	0.20	1.00	1.92	3.9	
	Week 28	Tezepelumab	73	67 (91.8)	0.96 (0.93)	0.0	0.00	1.00	1.88	3.3	
		Placebo	76	71 (93.4)	1.12 (0.85)	0.0	0.14	1.00	1.67	3.9	
	Week 29	Tezepelumab	73	64 (87.7)	0.85 (0.92)	0.0	0.00	0.75	1.44	3.1	
		Placebo	76	74 (97.4)	1.17 (0.88)	0.0	0.21	1.12	2.00	3.6	
	Week 30	Tezepelumab	73	66 (90.4)	0.88 (0.94)	0.0	0.00	0.68	1.93	3.1	
		Placebo	76	74 (97.4)	1.11 (0.80)	0.0	0.17	1.09	1.88	2.7	
	Week 31	Tezepelumab	73	66 (90.4)	0.83 (0.94)	0.0	0.00	0.70	1.38	3.1	
		Placebo	76	72 (94.7)	1.12 (0.83)	0.0	0.14	1.04	1.93	3.1	
	Week 32	Tezepelumab	73	64 (87.7)	0.90 (0.96)	0.0	0.00	0.76	1.73	3.1	
		Placebo	76	73 (96.1)	1.07 (0.77)	0.0	0.36	1.00	1.92	2.2	
	Week 33	Tezepelumab	73	67 (91.8)	0.84 (0.91)	0.0	0.00	0.79	1.60	3.3	
		Placebo	76	72 (94.7)	1.04 (0.74)	0.0	0.24	1.00	1.61	2.3	
	Week 34	Tezepelumab	73	67 (91.8)	0.84 (0.92)	0.0	0.00	0.71	1.33	3.4	
		Placebo	76	71 (93.4)	1.04 (0.75)	0.0	0.25	1.00	1.79	2.6	
	Week 35	Tezepelumab	73	65 (89.0)	0.82 (0.90)	0.0	0.00	0.79	1.14	3.2	
		Placebo	76	74 (97.4)	1.04 (0.77)	0.0	0.21	1.00	1.64	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WEC\_ILMH0: Course of ASD weekly chest tightness score  
 DITTTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly chest tightness score	Week 36	Tezepelumab	73	69 (94.5)	0.89 (0.95)	0.0	0.00	0.83	1.64	3.1	
		Placebo	76	71 (93.4)	1.06 (0.77)	0.0	0.30	1.00	1.71	2.9	
	Week 37	Tezepelumab	73	66 (90.4)	0.88 (0.95)	0.0	0.00	0.75	1.70	3.4	
		Placebo	76	72 (94.7)	1.06 (0.76)	0.0	0.29	1.04	1.67	3.0	
	Week 38	Tezepelumab	73	64 (87.7)	0.83 (0.92)	0.0	0.00	0.57	1.29	3.3	
		Placebo	76	72 (94.7)	1.07 (0.77)	0.0	0.29	1.00	1.61	2.8	
	Week 39	Tezepelumab	73	64 (87.7)	0.83 (0.92)	0.0	0.00	0.75	1.54	3.3	
		Placebo	76	71 (93.4)	1.05 (0.80)	0.0	0.14	1.00	1.75	3.0	
	Week 40	Tezepelumab	73	64 (87.7)	0.84 (0.94)	0.0	0.00	0.50	1.66	3.5	
		Placebo	76	71 (93.4)	1.07 (0.82)	0.0	0.07	1.00	1.70	3.1	
	Week 41	Tezepelumab	73	63 (86.3)	0.83 (0.94)	0.0	0.00	0.50	1.57	3.5	
		Placebo	76	70 (92.1)	1.01 (0.79)	0.0	0.07	1.00	1.79	3.0	
	Week 42	Tezepelumab	73	63 (86.3)	0.83 (0.91)	0.0	0.00	0.86	1.43	3.6	
		Placebo	76	72 (94.7)	1.02 (0.76)	0.0	0.14	1.00	1.54	3.0	
	Week 43	Tezepelumab	73	63 (86.3)	0.87 (0.93)	0.0	0.00	0.92	1.43	3.8	
		Placebo	76	72 (94.7)	1.06 (0.81)	0.0	0.11	1.00	1.79	3.0	
	Week 44	Tezepelumab	73	63 (86.3)	0.83 (0.93)	0.0	0.00	0.57	1.50	3.7	
		Placebo	76	73 (96.1)	1.04 (0.77)	0.0	0.40	1.00	1.58	3.0	
	Week 45	Tezepelumab	73	62 (84.9)	0.83 (0.92)	0.0	0.00	0.61	1.50	3.3	
		Placebo	76	70 (92.1)	0.96 (0.77)	0.0	0.08	1.00	1.43	2.6	
	Week 46	Tezepelumab	73	62 (84.9)	0.84 (0.92)	0.0	0.00	0.64	1.83	3.3	
		Placebo	76	68 (89.5)	0.99 (0.80)	0.0	0.07	1.00	1.54	2.8	
	Week 47	Tezepelumab	73	62 (84.9)	0.83 (0.92)	0.0	0.00	0.71	1.64	3.4	
		Placebo	76	70 (92.1)	1.03 (0.74)	0.0	0.40	1.00	1.50	3.0	
	Week 48	Tezepelumab	73	57 (78.1)	0.94 (0.91)	0.0	0.00	0.93	1.83	3.2	
		Placebo	76	68 (89.5)	1.06 (0.81)	0.0	0.11	1.00	1.79	3.0	

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WEC\_ILMH0: Course of ASD weekly chest tightness score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly chest tightness score	Week 1	Tezepelumab	73	71 (97.3)	-0.14 (0.36)	-1.6	-0.29	0.00	0.00	0.8	-0.31 [-0.63, 0.02]
		Placebo	76	76 (100.0)	-0.03 (0.37)	-1.9	-0.14	0.00	0.14	0.8	
	Week 2	Tezepelumab	73	73 (100.0)	-0.25 (0.47)	-1.9	-0.43	-0.04	0.00	0.4	-0.45 [-0.78, -0.12]
		Placebo	76	74 (97.4)	-0.05 (0.40)	-1.8	-0.19	0.00	0.07	1.0	
	Week 3	Tezepelumab	73	73 (100.0)	-0.31 (0.56)	-2.0	-0.64	-0.07	0.00	1.0	-0.46 [-0.79, -0.13]
		Placebo	76	73 (96.1)	-0.09 (0.41)	-1.2	-0.29	0.00	0.06	1.1	
	Week 4	Tezepelumab	73	71 (97.3)	-0.34 (0.59)	-2.0	-0.79	-0.08	0.00	1.5	-0.38 [-0.71, -0.06]
		Placebo	76	76 (100.0)	-0.13 (0.51)	-2.8	-0.18	0.00	0.07	0.9	
	Week 5	Tezepelumab	73	71 (97.3)	-0.34 (0.59)	-2.0	-0.64	-0.07	0.00	1.1	-0.29 [-0.62, 0.04]
		Placebo	76	74 (97.4)	-0.17 (0.55)	-2.8	-0.35	-0.01	0.07	0.9	
	Week 6	Tezepelumab	73	69 (94.5)	-0.33 (0.65)	-2.0	-0.71	-0.07	0.00	1.1	-0.32 [-0.66, 0.01]
		Placebo	76	72 (94.7)	-0.13 (0.62)	-3.2	-0.35	0.00	0.07	1.1	
	Week 7	Tezepelumab	73	69 (94.5)	-0.35 (0.66)	-2.0	-0.64	-0.07	0.00	0.8	-0.29 [-0.62, 0.04]
		Placebo	76	75 (98.7)	-0.16 (0.66)	-2.9	-0.36	0.00	0.10	1.4	
	Week 8	Tezepelumab	73	68 (93.2)	-0.35 (0.69)	-2.0	-0.75	-0.07	0.00	1.0	-0.36 [-0.69, -0.03]
		Placebo	76	75 (98.7)	-0.12 (0.60)	-2.3	-0.36	0.00	0.14	1.1	
	Week 9	Tezepelumab	73	69 (94.5)	-0.32 (0.72)	-2.0	-0.79	0.00	0.00	1.2	-0.29 [-0.62, 0.04]
		Placebo	76	73 (96.1)	-0.12 (0.66)	-2.7	-0.26	0.00	0.14	1.4	
	Week 10	Tezepelumab	73	70 (95.9)	-0.35 (0.77)	-2.0	-0.86	-0.07	0.00	2.0	-0.33 [-0.66, -0.00]
		Placebo	76	74 (97.4)	-0.11 (0.66)	-2.3	-0.29	-0.07	0.10	2.4	
	Week 11	Tezepelumab	73	70 (95.9)	-0.33 (0.75)	-2.0	-0.79	-0.07	0.00	2.0	-0.26 [-0.59, 0.06]
		Placebo	76	74 (97.4)	-0.13 (0.75)	-2.6	-0.50	0.00	0.10	3.0	
	Week 12	Tezepelumab	73	70 (95.9)	-0.35 (0.79)	-2.0	-0.82	-0.07	0.00	2.1	-0.32 [-0.64, 0.01]
		Placebo	76	75 (98.7)	-0.12 (0.69)	-2.3	-0.43	0.00	0.19	2.2	
	Week 13	Tezepelumab	73	68 (93.2)	-0.34 (0.83)	-2.1	-0.96	-0.07	0.00	2.0	-0.25 [-0.59, 0.08]
		Placebo	76	71 (93.4)	-0.15 (0.70)	-2.7	-0.42	0.00	0.18	1.6	
	Week 14	Tezepelumab	73	69 (94.5)	-0.36 (0.77)	-2.0	-0.93	-0.07	0.00	2.0	-0.28 [-0.61, 0.05]
		Placebo	76	73 (96.1)	-0.16 (0.64)	-2.2	-0.43	0.00	0.08	1.9	
	Week 15	Tezepelumab	73	69 (94.5)	-0.35 (0.77)	-2.0	-1.00	-0.07	0.00	2.0	-0.19 [-0.52, 0.14]
		Placebo	76	72 (94.7)	-0.22 (0.67)	-2.8	-0.50	0.00	0.15	1.3	
	Week 16	Tezepelumab	73	69 (94.5)	-0.32 (0.80)	-2.0	-0.93	-0.07	0.00	1.8	-0.15 [-0.48, 0.18]
		Placebo	76	74 (97.4)	-0.21 (0.72)	-2.4	-0.57	0.00	0.14	1.6	
	Week 17	Tezepelumab	73	68 (93.2)	-0.34 (0.75)	-2.0	-0.89	-0.21	0.01	1.0	-0.15 [-0.48, 0.18]
		Placebo	76	74 (97.4)	-0.23 (0.72)	-2.9	-0.57	-0.04	0.07	1.2	
	Week 18	Tezepelumab	73	68 (93.2)	-0.35 (0.77)	-2.0	-0.93	-0.14	0.00	1.4	-0.15 [-0.49, 0.18]
		Placebo	76	72 (94.7)	-0.23 (0.73)	-2.5	-0.67	0.00	0.10	1.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table ST1WEC\_ILMH0: Course of ASD weekly chest tightness score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly chest tightness score	Week 19	Tezepelumab	73	67 (91.8)	-0.42 (0.77)	-2.0	-1.00	-0.20	0.00	1.8	-0.25 [-0.59, 0.08]
		Placebo	76	72 (94.7)	-0.24 (0.67)	-2.3	-0.57	-0.08	0.07	1.0	
	Week 20	Tezepelumab	73	70 (95.9)	-0.41 (0.77)	-2.0	-1.00	-0.18	0.00	1.5	-0.30 [-0.63, 0.03]
		Placebo	76	72 (94.7)	-0.19 (0.68)	-2.3	-0.46	-0.04	0.08	1.3	
	Week 21	Tezepelumab	73	67 (91.8)	-0.44 (0.78)	-2.0	-1.00	-0.29	0.00	1.6	-0.31 [-0.65, 0.02]
		Placebo	76	73 (96.1)	-0.21 (0.71)	-2.4	-0.50	-0.07	0.08	1.7	
	Week 22	Tezepelumab	73	69 (94.5)	-0.40 (0.73)	-2.0	-1.00	-0.17	0.01	0.9	-0.38 [-0.71, -0.05]
		Placebo	76	74 (97.4)	-0.12 (0.76)	-2.3	-0.50	0.00	0.20	1.6	
	Week 23	Tezepelumab	73	69 (94.5)	-0.38 (0.77)	-2.3	-0.93	-0.20	0.00	1.0	-0.31 [-0.64, 0.02]
		Placebo	76	74 (97.4)	-0.14 (0.75)	-2.5	-0.63	0.00	0.21	1.6	
	Week 24	Tezepelumab	73	69 (94.5)	-0.35 (0.80)	-2.3	-0.79	-0.14	0.00	1.7	-0.24 [-0.57, 0.08]
		Placebo	76	75 (98.7)	-0.16 (0.76)	-2.3	-0.50	0.00	0.15	1.9	
	Week 25	Tezepelumab	73	68 (93.2)	-0.37 (0.88)	-2.3	-0.96	-0.14	0.00	2.8	-0.21 [-0.55, 0.12]
		Placebo	76	74 (97.4)	-0.19 (0.78)	-3.2	-0.43	-0.07	0.06	1.9	
	Week 26	Tezepelumab	73	67 (91.8)	-0.43 (0.82)	-2.4	-0.93	-0.14	0.00	1.9	-0.32 [-0.66, 0.01]
		Placebo	76	73 (96.1)	-0.16 (0.84)	-2.7	-0.50	-0.08	0.07	3.1	
	Week 27	Tezepelumab	73	68 (93.2)	-0.40 (0.86)	-2.4	-0.89	-0.09	0.00	1.7	-0.30 [-0.64, 0.03]
		Placebo	76	71 (93.4)	-0.16 (0.74)	-2.3	-0.50	0.00	0.06	1.9	
	Week 28	Tezepelumab	73	67 (91.8)	-0.35 (0.85)	-2.4	-0.79	-0.07	0.00	1.6	-0.28 [-0.61, 0.06]
		Placebo	76	71 (93.4)	-0.13 (0.73)	-2.2	-0.42	0.00	0.14	1.7	
	Week 29	Tezepelumab	73	64 (87.7)	-0.45 (0.81)	-2.4	-0.89	-0.21	0.00	1.9	-0.46 [-0.80, -0.12]
		Placebo	76	74 (97.4)	-0.09 (0.74)	-2.3	-0.35	0.00	0.14	1.6	
	Week 30	Tezepelumab	73	66 (90.4)	-0.42 (0.88)	-2.4	-1.00	-0.11	0.00	1.9	-0.34 [-0.68, -0.01]
		Placebo	76	74 (97.4)	-0.15 (0.68)	-2.3	-0.42	-0.08	0.00	1.6	
	Week 31	Tezepelumab	73	66 (90.4)	-0.45 (0.88)	-2.4	-1.00	-0.19	0.00	1.7	-0.37 [-0.71, -0.03]
		Placebo	76	72 (94.7)	-0.16 (0.71)	-2.1	-0.46	-0.07	0.00	1.9	
	Week 32	Tezepelumab	73	64 (87.7)	-0.41 (0.87)	-2.4	-0.94	-0.17	0.00	1.8	-0.27 [-0.61, 0.06]
		Placebo	76	73 (96.1)	-0.20 (0.70)	-2.0	-0.50	-0.07	0.00	2.0	
	Week 33	Tezepelumab	73	67 (91.8)	-0.45 (0.81)	-2.4	-1.00	-0.21	0.00	2.0	-0.29 [-0.62, 0.05]
		Placebo	76	72 (94.7)	-0.24 (0.70)	-2.6	-0.64	-0.07	0.00	1.6	
	Week 34	Tezepelumab	73	67 (91.8)	-0.45 (0.84)	-2.4	-1.00	-0.21	0.00	2.1	-0.27 [-0.61, 0.06]
		Placebo	76	71 (93.4)	-0.25 (0.63)	-2.0	-0.57	-0.13	0.00	1.7	
	Week 35	Tezepelumab	73	65 (89.0)	-0.46 (0.86)	-2.4	-1.00	-0.17	0.00	1.9	-0.31 [-0.65, 0.02]
		Placebo	76	74 (97.4)	-0.23 (0.66)	-2.0	-0.55	-0.09	0.00	1.6	
	Week 36	Tezepelumab	73	69 (94.5)	-0.42 (0.86)	-2.4	-1.00	-0.08	0.00	1.8	-0.27 [-0.60, 0.06]
		Placebo	76	71 (93.4)	-0.21 (0.66)	-2.0	-0.76	-0.07	0.07	1.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WEC\_ILMH0: Course of ASD weekly chest tightness score  
 DITTTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly chest tightness score	Week 37	Tezepelumab	73	66 (90.4)	-0.43 (0.90)	-2.4	-1.00	-0.07	0.00	1.7	-0.28 [-0.62, 0.05]
		Placebo	76	72 (94.7)	-0.21 (0.64)	-2.2	-0.61	-0.04	0.08	1.4	
	Week 38	Tezepelumab	73	64 (87.7)	-0.45 (0.88)	-2.4	-0.96	-0.21	0.00	2.0	-0.33 [-0.67, 0.00]
		Placebo	76	72 (94.7)	-0.19 (0.65)	-2.4	-0.46	-0.04	0.08	1.3	
	Week 39	Tezepelumab	73	64 (87.7)	-0.46 (0.88)	-2.4	-1.00	-0.15	0.00	2.0	-0.36 [-0.70, -0.02]
		Placebo	76	71 (93.4)	-0.18 (0.62)	-2.0	-0.64	-0.07	0.08	1.0	
	Week 40	Tezepelumab	73	64 (87.7)	-0.44 (0.89)	-2.2	-1.00	-0.08	0.00	2.0	-0.31 [-0.65, 0.03]
		Placebo	76	71 (93.4)	-0.20 (0.67)	-2.0	-0.63	-0.07	0.08	1.2	
	Week 41	Tezepelumab	73	63 (86.3)	-0.47 (0.90)	-2.3	-1.00	-0.25	0.00	1.7	-0.32 [-0.66, 0.03]
		Placebo	76	70 (92.1)	-0.22 (0.66)	-2.5	-0.50	-0.08	0.08	1.0	
	Week 42	Tezepelumab	73	63 (86.3)	-0.46 (0.87)	-2.1	-0.93	-0.21	0.00	1.5	-0.28 [-0.62, 0.06]
		Placebo	76	72 (94.7)	-0.24 (0.64)	-2.3	-0.64	-0.12	0.08	1.3	
	Week 43	Tezepelumab	73	63 (86.3)	-0.42 (0.93)	-2.2	-0.93	-0.21	0.00	1.8	-0.27 [-0.61, 0.07]
		Placebo	76	72 (94.7)	-0.19 (0.70)	-2.3	-0.57	-0.10	0.04	1.8	
	Week 44	Tezepelumab	73	63 (86.3)	-0.46 (0.91)	-2.2	-1.00	-0.21	0.00	1.7	-0.30 [-0.64, 0.04]
		Placebo	76	73 (96.1)	-0.22 (0.66)	-2.4	-0.53	-0.07	0.00	1.0	
	Week 45	Tezepelumab	73	62 (84.9)	-0.46 (0.92)	-2.3	-1.00	-0.21	0.00	1.6	-0.20 [-0.54, 0.14]
		Placebo	76	70 (92.1)	-0.30 (0.70)	-3.1	-0.71	-0.15	0.00	1.1	
	Week 46	Tezepelumab	73	62 (84.9)	-0.45 (0.87)	-2.4	-1.00	-0.19	0.00	1.5	-0.21 [-0.55, 0.14]
		Placebo	76	68 (89.5)	-0.29 (0.64)	-2.4	-0.50	-0.14	0.00	1.1	
	Week 47	Tezepelumab	73	62 (84.9)	-0.45 (0.91)	-2.3	-1.00	-0.21	0.00	1.5	-0.21 [-0.55, 0.13]
		Placebo	76	70 (92.1)	-0.28 (0.64)	-2.4	-0.64	-0.08	0.07	1.1	
	Week 48	Tezepelumab	73	57 (78.1)	-0.37 (0.90)	-2.3	-0.88	-0.21	0.07	1.5	-0.17 [-0.52, 0.19]
		Placebo	76	68 (89.5)	-0.24 (0.65)	-2.1	-0.54	-0.07	0.07	1.4	

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WEC\_ILMC0: Change from baseline in ASD weekly chest tightness score - MMRM results  
 DITTTL

Change from baseline in ASD weekly chest tightness score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Time	Treatment	N	n (%)					
Week 1	Tezepelumab	73	71 (97.3)	-0.12 (0.08)	(-0.27, 0.03)	-0.09 (0.11)	(-0.30, 0.11)	0.381
	Placebo	76	76 (100.0)	-0.03 (0.07)	(-0.17, 0.12)			
Week 2	Tezepelumab	73	73 (100.0)	-0.23 (0.07)	(-0.38, -0.09)	-0.15 (0.11)	(-0.36, 0.05)	0.143
	Placebo	76	74 (97.4)	-0.08 (0.07)	(-0.22, 0.06)			
Week 3	Tezepelumab	73	73 (100.0)	-0.30 (0.07)	(-0.45, -0.15)	-0.18 (0.11)	(-0.39, 0.03)	0.086
	Placebo	76	73 (96.1)	-0.12 (0.07)	(-0.26, 0.03)			
Week 4	Tezepelumab	73	71 (97.3)	-0.31 (0.08)	(-0.46, -0.17)	-0.18 (0.11)	(-0.39, 0.02)	0.083
	Placebo	76	76 (100.0)	-0.13 (0.07)	(-0.28, 0.01)			
Week 5	Tezepelumab	73	71 (97.3)	-0.33 (0.08)	(-0.48, -0.18)	-0.14 (0.11)	(-0.35, 0.06)	0.178
	Placebo	76	74 (97.4)	-0.19 (0.07)	(-0.33, -0.04)			
Week 6	Tezepelumab	73	69 (94.5)	-0.32 (0.08)	(-0.46, -0.17)	-0.16 (0.11)	(-0.37, 0.05)	0.130
	Placebo	76	72 (94.7)	-0.16 (0.07)	(-0.30, -0.01)			
Week 7	Tezepelumab	73	69 (94.5)	-0.33 (0.08)	(-0.48, -0.18)	-0.16 (0.11)	(-0.37, 0.04)	0.118
	Placebo	76	75 (98.7)	-0.17 (0.07)	(-0.31, -0.02)			
Week 8	Tezepelumab	73	68 (93.2)	-0.33 (0.08)	(-0.47, -0.18)	-0.20 (0.11)	(-0.40, 0.01)	0.062
	Placebo	76	75 (98.7)	-0.13 (0.07)	(-0.27, 0.02)			
Week 9	Tezepelumab	73	69 (94.5)	-0.31 (0.08)	(-0.46, -0.17)	-0.19 (0.11)	(-0.40, 0.02)	0.074
	Placebo	76	73 (96.1)	-0.12 (0.07)	(-0.27, 0.02)			
Week 10	Tezepelumab	73	70 (95.9)	-0.33 (0.08)	(-0.48, -0.18)	-0.22 (0.11)	(-0.43, -0.01)	0.038 *
	Placebo	76	74 (97.4)	-0.11 (0.07)	(-0.25, 0.04)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WEC\_ILMC0: Change from baseline in ASD weekly chest tightness score - MMRM results  
 DITTTL

Change from baseline in ASD weekly chest tightness score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Time	Treatment	N	n (%)					
Week 11	Tezepelumab	73	70 (95.9)	-0.32 (0.08)	(-0.46, -0.17)	-0.18 (0.11)	(-0.39, 0.02)	0.083
	Placebo	76	74 (97.4)	-0.13 (0.07)	(-0.28, 0.01)			
Week 12	Tezepelumab	73	70 (95.9)	-0.33 (0.08)	(-0.48, -0.19)	-0.21 (0.11)	(-0.42, -0.00)	0.049 *
	Placebo	76	75 (98.7)	-0.13 (0.07)	(-0.27, 0.02)			
Week 13	Tezepelumab	73	68 (93.2)	-0.32 (0.08)	(-0.47, -0.17)	-0.15 (0.11)	(-0.35, 0.06)	0.166
	Placebo	76	71 (93.4)	-0.18 (0.07)	(-0.32, -0.03)			
Week 14	Tezepelumab	73	69 (94.5)	-0.33 (0.08)	(-0.48, -0.18)	-0.14 (0.11)	(-0.35, 0.07)	0.186
	Placebo	76	73 (96.1)	-0.19 (0.07)	(-0.34, -0.04)			
Week 15	Tezepelumab	73	69 (94.5)	-0.33 (0.08)	(-0.48, -0.18)	-0.12 (0.11)	(-0.33, 0.09)	0.251
	Placebo	76	72 (94.7)	-0.21 (0.07)	(-0.36, -0.06)			
Week 16	Tezepelumab	73	69 (94.5)	-0.30 (0.08)	(-0.45, -0.15)	-0.09 (0.11)	(-0.30, 0.12)	0.386
	Placebo	76	74 (97.4)	-0.21 (0.07)	(-0.36, -0.06)			
Week 17	Tezepelumab	73	68 (93.2)	-0.33 (0.08)	(-0.48, -0.18)	-0.10 (0.11)	(-0.31, 0.11)	0.355
	Placebo	76	74 (97.4)	-0.24 (0.07)	(-0.38, -0.09)			
Week 18	Tezepelumab	73	68 (93.2)	-0.34 (0.08)	(-0.49, -0.20)	-0.11 (0.11)	(-0.32, 0.10)	0.310
	Placebo	76	72 (94.7)	-0.24 (0.07)	(-0.38, -0.09)			
Week 19	Tezepelumab	73	67 (91.8)	-0.39 (0.08)	(-0.54, -0.24)	-0.17 (0.11)	(-0.38, 0.03)	0.102
	Placebo	76	72 (94.7)	-0.22 (0.07)	(-0.37, -0.08)			
Week 20	Tezepelumab	73	70 (95.9)	-0.40 (0.08)	(-0.55, -0.25)	-0.21 (0.11)	(-0.42, 0.00)	0.051
	Placebo	76	72 (94.7)	-0.19 (0.07)	(-0.34, -0.04)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WEC\_ILMC0: Change from baseline in ASD weekly chest tightness score - MMRM results  
 DITTTL

Change from baseline in ASD weekly chest tightness score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 21	Tezepelumab	73	67 (91.8)	-0.41 (0.08)	(-0.56, -0.26)	-0.20 (0.11)	(-0.40, 0.01)	0.067	
	Placebo	76	73 (96.1)	-0.21 (0.07)	(-0.36, -0.07)				
Week 22	Tezepelumab	73	69 (94.5)	-0.40 (0.08)	(-0.55, -0.25)	-0.28 (0.11)	(-0.48, -0.07)	0.010 *	
	Placebo	76	74 (97.4)	-0.12 (0.07)	(-0.27, 0.02)				
Week 23	Tezepelumab	73	69 (94.5)	-0.37 (0.08)	(-0.52, -0.22)	-0.22 (0.11)	(-0.43, -0.01)	0.037 *	
	Placebo	76	74 (97.4)	-0.15 (0.07)	(-0.29, -0.00)				
Week 24	Tezepelumab	73	69 (94.5)	-0.35 (0.08)	(-0.50, -0.20)	-0.18 (0.11)	(-0.39, 0.03)	0.092	
	Placebo	76	75 (98.7)	-0.17 (0.07)	(-0.31, -0.02)				
Week 25	Tezepelumab	73	68 (93.2)	-0.35 (0.08)	(-0.50, -0.20)	-0.14 (0.11)	(-0.35, 0.07)	0.182	
	Placebo	76	74 (97.4)	-0.21 (0.07)	(-0.35, -0.06)				
Week 26	Tezepelumab	73	67 (91.8)	-0.39 (0.08)	(-0.54, -0.24)	-0.24 (0.11)	(-0.44, -0.03)	0.027 *	
	Placebo	76	73 (96.1)	-0.16 (0.07)	(-0.30, -0.01)				
Week 27	Tezepelumab	73	68 (93.2)	-0.40 (0.08)	(-0.55, -0.25)	-0.23 (0.11)	(-0.44, -0.02)	0.032 *	
	Placebo	76	71 (93.4)	-0.17 (0.07)	(-0.32, -0.02)				
Week 28	Tezepelumab	73	67 (91.8)	-0.36 (0.08)	(-0.51, -0.21)	-0.22 (0.11)	(-0.43, -0.01)	0.036 *	
	Placebo	76	71 (93.4)	-0.14 (0.07)	(-0.28, 0.01)				
Week 29	Tezepelumab	73	64 (87.7)	-0.41 (0.08)	(-0.56, -0.26)	-0.32 (0.11)	(-0.53, -0.11)	0.003 *	
	Placebo	76	74 (97.4)	-0.10 (0.07)	(-0.24, 0.05)				
Week 30	Tezepelumab	73	66 (90.4)	-0.41 (0.08)	(-0.57, -0.26)	-0.26 (0.11)	(-0.47, -0.05)	0.015 *	
	Placebo	76	74 (97.4)	-0.15 (0.07)	(-0.30, -0.01)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WEC\_ILMC0: Change from baseline in ASD weekly chest tightness score - MMRM results  
 DITTTL

Change from baseline in ASD weekly chest tightness score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 31	Tezepelumab	73	66 (90.4)	-0.43 (0.08)	(-0.58, -0.28)	-0.29 (0.11)	(-0.50, -0.08)	0.008 *
	Placebo	76	72 (94.7)	-0.15 (0.07)	(-0.29, 0.00)			
Week 32	Tezepelumab	73	64 (87.7)	-0.41 (0.08)	(-0.56, -0.26)	-0.22 (0.11)	(-0.43, -0.01)	0.044 *
	Placebo	76	73 (96.1)	-0.19 (0.07)	(-0.34, -0.05)			
Week 33	Tezepelumab	73	67 (91.8)	-0.43 (0.08)	(-0.58, -0.28)	-0.19 (0.11)	(-0.40, 0.02)	0.082
	Placebo	76	72 (94.7)	-0.24 (0.07)	(-0.39, -0.10)			
Week 34	Tezepelumab	73	67 (91.8)	-0.42 (0.08)	(-0.57, -0.27)	-0.17 (0.11)	(-0.38, 0.04)	0.104
	Placebo	76	71 (93.4)	-0.25 (0.07)	(-0.39, -0.10)			
Week 35	Tezepelumab	73	65 (89.0)	-0.43 (0.08)	(-0.58, -0.28)	-0.20 (0.11)	(-0.41, 0.01)	0.066
	Placebo	76	74 (97.4)	-0.23 (0.07)	(-0.38, -0.08)			
Week 36	Tezepelumab	73	69 (94.5)	-0.41 (0.08)	(-0.56, -0.26)	-0.20 (0.11)	(-0.41, 0.01)	0.068
	Placebo	76	71 (93.4)	-0.21 (0.07)	(-0.36, -0.07)			
Week 37	Tezepelumab	73	66 (90.4)	-0.41 (0.08)	(-0.56, -0.26)	-0.20 (0.11)	(-0.41, 0.01)	0.060
	Placebo	76	72 (94.7)	-0.21 (0.07)	(-0.36, -0.06)			
Week 38	Tezepelumab	73	64 (87.7)	-0.43 (0.08)	(-0.59, -0.28)	-0.23 (0.11)	(-0.44, -0.02)	0.033 *
	Placebo	76	72 (94.7)	-0.20 (0.07)	(-0.35, -0.06)			
Week 39	Tezepelumab	73	64 (87.7)	-0.42 (0.08)	(-0.58, -0.27)	-0.20 (0.11)	(-0.41, 0.01)	0.060
	Placebo	76	71 (93.4)	-0.22 (0.07)	(-0.37, -0.08)			
Week 40	Tezepelumab	73	64 (87.7)	-0.41 (0.08)	(-0.56, -0.26)	-0.22 (0.11)	(-0.43, -0.01)	0.040 *
	Placebo	76	71 (93.4)	-0.19 (0.07)	(-0.34, -0.04)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WEC\_ILMC0: Change from baseline in ASD weekly chest tightness score - MMRM results  
 DITTTL

Change from baseline in ASD weekly chest tightness score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 41	Tezepelumab	73	63 (86.3)	-0.43 (0.08)	(-0.59, -0.28)	-0.20 (0.11)	(-0.41, 0.01)	0.066	
	Placebo	76	70 (92.1)	-0.23 (0.07)	(-0.38, -0.09)				
Week 42	Tezepelumab	73	63 (86.3)	-0.42 (0.08)	(-0.57, -0.27)	-0.18 (0.11)	(-0.39, 0.03)	0.093	
	Placebo	76	72 (94.7)	-0.24 (0.07)	(-0.38, -0.09)				
Week 43	Tezepelumab	73	63 (86.3)	-0.38 (0.08)	(-0.54, -0.23)	-0.18 (0.11)	(-0.39, 0.03)	0.100	
	Placebo	76	72 (94.7)	-0.20 (0.07)	(-0.35, -0.06)				
Week 44	Tezepelumab	73	63 (86.3)	-0.42 (0.08)	(-0.58, -0.27)	-0.20 (0.11)	(-0.41, 0.01)	0.066	
	Placebo	76	73 (96.1)	-0.22 (0.07)	(-0.37, -0.08)				
Week 45	Tezepelumab	73	62 (84.9)	-0.43 (0.08)	(-0.59, -0.28)	-0.13 (0.11)	(-0.35, 0.08)	0.221	
	Placebo	76	70 (92.1)	-0.30 (0.07)	(-0.45, -0.15)				
Week 46	Tezepelumab	73	62 (84.9)	-0.45 (0.08)	(-0.60, -0.29)	-0.19 (0.11)	(-0.41, 0.02)	0.077	
	Placebo	76	68 (89.5)	-0.25 (0.07)	(-0.40, -0.11)				
Week 47	Tezepelumab	73	62 (84.9)	-0.41 (0.08)	(-0.56, -0.25)	-0.15 (0.11)	(-0.36, 0.06)	0.170	
	Placebo	76	70 (92.1)	-0.26 (0.07)	(-0.40, -0.11)				
Week 48	Tezepelumab	73	57 (78.1)	-0.39 (0.08)	(-0.55, -0.24)	-0.17 (0.11)	(-0.39, 0.05)	0.124	
	Placebo	76	68 (89.5)	-0.23 (0.08)	(-0.37, -0.08)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WAC\_ILMH0: Course of ASD weekly waking score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly waking score	Baseline	Tezepelumab	395	395 (100.0)	0.92 (0.75)	0.0	0.29	1.00	1.14	4.0	
		Placebo	391	391 (100.0)	0.84 (0.69)	0.0	0.29	0.86	1.14	4.0	
	Week 1	Tezepelumab	395	391 (99.0)	0.69 (0.73)	0.0	0.00	0.57	1.00	4.0	
		Placebo	391	385 (98.5)	0.68 (0.65)	0.0	0.14	0.57	1.00	3.3	
	Week 2	Tezepelumab	395	387 (98.0)	0.65 (0.74)	0.0	0.00	0.50	1.00	4.0	
		Placebo	391	387 (99.0)	0.64 (0.67)	0.0	0.00	0.57	1.00	3.4	
	Week 3	Tezepelumab	395	387 (98.0)	0.59 (0.71)	0.0	0.00	0.40	1.00	4.0	
		Placebo	391	385 (98.5)	0.57 (0.64)	0.0	0.00	0.29	1.00	3.7	
	Week 4	Tezepelumab	395	387 (98.0)	0.56 (0.70)	0.0	0.00	0.33	1.00	4.0	
		Placebo	391	379 (96.9)	0.55 (0.62)	0.0	0.00	0.29	1.00	3.1	
	Week 5	Tezepelumab	395	382 (96.7)	0.51 (0.67)	0.0	0.00	0.18	1.00	4.0	
		Placebo	391	377 (96.4)	0.52 (0.62)	0.0	0.00	0.29	1.00	3.4	
	Week 6	Tezepelumab	395	386 (97.7)	0.50 (0.65)	0.0	0.00	0.18	1.00	3.4	
		Placebo	391	379 (96.9)	0.50 (0.60)	0.0	0.00	0.29	1.00	3.1	
	Week 7	Tezepelumab	395	378 (95.7)	0.49 (0.67)	0.0	0.00	0.14	1.00	3.9	
		Placebo	391	378 (96.7)	0.50 (0.61)	0.0	0.00	0.29	1.00	3.3	
	Week 8	Tezepelumab	395	378 (95.7)	0.46 (0.65)	0.0	0.00	0.14	1.00	3.8	
		Placebo	391	377 (96.4)	0.48 (0.60)	0.0	0.00	0.20	1.00	3.3	
	Week 9	Tezepelumab	395	385 (97.5)	0.43 (0.61)	0.0	0.00	0.14	0.86	3.6	
		Placebo	391	374 (95.7)	0.46 (0.60)	0.0	0.00	0.17	0.86	3.7	
	Week 10	Tezepelumab	395	379 (95.9)	0.43 (0.63)	0.0	0.00	0.14	0.83	3.9	
		Placebo	391	366 (93.6)	0.46 (0.59)	0.0	0.00	0.14	0.86	3.3	
	Week 11	Tezepelumab	395	376 (95.2)	0.44 (0.64)	0.0	0.00	0.14	0.86	3.4	
		Placebo	391	373 (95.4)	0.44 (0.60)	0.0	0.00	0.14	0.86	3.1	
	Week 12	Tezepelumab	395	373 (94.4)	0.45 (0.65)	0.0	0.00	0.14	1.00	4.0	
		Placebo	391	367 (93.9)	0.43 (0.59)	0.0	0.00	0.14	0.86	3.4	
	Week 13	Tezepelumab	395	375 (94.9)	0.41 (0.61)	0.0	0.00	0.00	0.86	3.4	
		Placebo	391	369 (94.4)	0.40 (0.59)	0.0	0.00	0.14	0.71	3.4	
	Week 14	Tezepelumab	395	370 (93.7)	0.40 (0.60)	0.0	0.00	0.00	0.86	3.3	
		Placebo	391	368 (94.1)	0.41 (0.57)	0.0	0.00	0.14	0.86	3.6	
	Week 15	Tezepelumab	395	367 (92.9)	0.40 (0.59)	0.0	0.00	0.00	0.86	3.9	
		Placebo	391	351 (89.8)	0.43 (0.61)	0.0	0.00	0.14	0.86	3.6	
	Week 16	Tezepelumab	395	370 (93.7)	0.39 (0.60)	0.0	0.00	0.00	0.80	4.0	
		Placebo	391	357 (91.3)	0.44 (0.62)	0.0	0.00	0.14	0.86	3.4	
Week 17	Tezepelumab	395	366 (92.7)	0.39 (0.62)	0.0	0.00	0.00	0.71	4.0		
	Placebo	391	352 (90.0)	0.41 (0.58)	0.0	0.00	0.00	0.83	3.3		

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table NT1WAC\_ILMH0: Course of ASD weekly waking score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly waking score	Week 18	Tezepelumab	395	362 (91.6)	0.40 (0.64)	0.0	0.00	0.00	0.80	4.0	
		Placebo	391	352 (90.0)	0.43 (0.63)	0.0	0.00	0.14	0.83	3.4	
	Week 19	Tezepelumab	395	366 (92.7)	0.39 (0.62)	0.0	0.00	0.00	0.71	4.0	
		Placebo	391	354 (90.5)	0.41 (0.60)	0.0	0.00	0.07	0.86	3.0	
	Week 20	Tezepelumab	395	358 (90.6)	0.36 (0.60)	0.0	0.00	0.00	0.67	4.0	
		Placebo	391	353 (90.3)	0.43 (0.61)	0.0	0.00	0.00	0.86	3.3	
	Week 21	Tezepelumab	395	360 (91.1)	0.38 (0.64)	0.0	0.00	0.00	0.71	4.0	
		Placebo	391	350 (89.5)	0.41 (0.62)	0.0	0.00	0.00	0.80	3.9	
	Week 22	Tezepelumab	395	360 (91.1)	0.39 (0.63)	0.0	0.00	0.00	0.69	4.0	
		Placebo	391	343 (87.7)	0.42 (0.60)	0.0	0.00	0.00	0.86	3.3	
	Week 23	Tezepelumab	395	355 (89.9)	0.38 (0.62)	0.0	0.00	0.00	0.83	4.0	
		Placebo	391	335 (85.7)	0.41 (0.61)	0.0	0.00	0.00	0.75	3.5	
	Week 24	Tezepelumab	395	354 (89.6)	0.38 (0.61)	0.0	0.00	0.00	0.71	4.0	
		Placebo	391	338 (86.4)	0.40 (0.63)	0.0	0.00	0.00	0.86	4.0	
	Week 25	Tezepelumab	395	358 (90.6)	0.37 (0.60)	0.0	0.00	0.00	0.71	4.0	
		Placebo	391	336 (85.9)	0.38 (0.57)	0.0	0.00	0.00	0.71	3.4	
	Week 26	Tezepelumab	395	352 (89.1)	0.40 (0.64)	0.0	0.00	0.00	0.80	4.0	
		Placebo	391	333 (85.2)	0.37 (0.56)	0.0	0.00	0.00	0.67	3.3	
	Week 27	Tezepelumab	395	358 (90.6)	0.38 (0.62)	0.0	0.00	0.00	0.80	4.0	
		Placebo	391	330 (84.4)	0.40 (0.61)	0.0	0.00	0.00	0.71	3.3	
	Week 28	Tezepelumab	395	356 (90.1)	0.37 (0.62)	0.0	0.00	0.00	0.82	4.0	
		Placebo	391	341 (87.2)	0.39 (0.58)	0.0	0.00	0.00	0.71	3.0	
	Week 29	Tezepelumab	395	352 (89.1)	0.37 (0.61)	0.0	0.00	0.00	0.71	4.0	
		Placebo	391	340 (87.0)	0.39 (0.59)	0.0	0.00	0.00	0.80	3.0	
	Week 30	Tezepelumab	395	352 (89.1)	0.39 (0.63)	0.0	0.00	0.00	0.76	4.0	
		Placebo	391	332 (84.9)	0.42 (0.63)	0.0	0.00	0.00	0.86	3.2	
	Week 31	Tezepelumab	395	354 (89.6)	0.38 (0.63)	0.0	0.00	0.00	0.75	4.0	
		Placebo	391	326 (83.4)	0.39 (0.58)	0.0	0.00	0.00	0.75	3.0	
	Week 32	Tezepelumab	395	356 (90.1)	0.39 (0.64)	0.0	0.00	0.00	0.78	4.0	
		Placebo	391	340 (87.0)	0.38 (0.59)	0.0	0.00	0.00	0.71	3.1	
	Week 33	Tezepelumab	395	352 (89.1)	0.36 (0.62)	0.0	0.00	0.00	0.59	4.0	
		Placebo	391	331 (84.7)	0.39 (0.60)	0.0	0.00	0.00	0.80	3.0	
	Week 34	Tezepelumab	395	354 (89.6)	0.38 (0.62)	0.0	0.00	0.00	0.71	4.0	
		Placebo	391	334 (85.4)	0.38 (0.60)	0.0	0.00	0.00	0.71	3.0	
	Week 35	Tezepelumab	395	349 (88.4)	0.39 (0.65)	0.0	0.00	0.00	0.83	4.0	
		Placebo	391	325 (83.1)	0.38 (0.61)	0.0	0.00	0.00	0.71	3.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WAC\_ILMH0: Course of ASD weekly waking score  
 DITTTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly waking score	Week 36	Tezepelumab	395	350 (88.6)	0.39 (0.64)	0.0	0.00	0.00	0.80	4.0	
		Placebo	391	329 (84.1)	0.38 (0.58)	0.0	0.00	0.00	0.71	3.1	
	Week 37	Tezepelumab	395	345 (87.3)	0.38 (0.63)	0.0	0.00	0.00	0.71	4.0	
		Placebo	391	331 (84.7)	0.37 (0.57)	0.0	0.00	0.00	0.71	3.0	
	Week 38	Tezepelumab	395	343 (86.8)	0.39 (0.64)	0.0	0.00	0.00	0.71	4.0	
		Placebo	391	329 (84.1)	0.39 (0.59)	0.0	0.00	0.00	0.80	3.1	
	Week 39	Tezepelumab	395	349 (88.4)	0.39 (0.66)	0.0	0.00	0.00	0.86	4.0	
		Placebo	391	331 (84.7)	0.38 (0.59)	0.0	0.00	0.00	0.71	3.1	
	Week 40	Tezepelumab	395	351 (88.9)	0.38 (0.64)	0.0	0.00	0.00	0.71	4.0	
		Placebo	391	329 (84.1)	0.41 (0.63)	0.0	0.00	0.00	0.86	3.5	
	Week 41	Tezepelumab	395	351 (88.9)	0.36 (0.64)	0.0	0.00	0.00	0.71	4.0	
		Placebo	391	328 (83.9)	0.38 (0.61)	0.0	0.00	0.00	0.75	4.0	
	Week 42	Tezepelumab	395	344 (87.1)	0.38 (0.66)	0.0	0.00	0.00	0.71	4.0	
		Placebo	391	328 (83.9)	0.42 (0.67)	0.0	0.00	0.00	0.86	4.0	
	Week 43	Tezepelumab	395	343 (86.8)	0.37 (0.64)	0.0	0.00	0.00	0.71	4.0	
		Placebo	391	325 (83.1)	0.39 (0.62)	0.0	0.00	0.00	0.71	4.0	
	Week 44	Tezepelumab	395	340 (86.1)	0.37 (0.64)	0.0	0.00	0.00	0.76	3.9	
		Placebo	391	323 (82.6)	0.39 (0.63)	0.0	0.00	0.00	0.71	4.0	
	Week 45	Tezepelumab	395	348 (88.1)	0.36 (0.63)	0.0	0.00	0.00	0.63	4.0	
		Placebo	391	327 (83.6)	0.37 (0.61)	0.0	0.00	0.00	0.80	4.0	
	Week 46	Tezepelumab	395	343 (86.8)	0.37 (0.64)	0.0	0.00	0.00	0.71	4.0	
		Placebo	391	320 (81.8)	0.36 (0.60)	0.0	0.00	0.00	0.62	4.0	
	Week 47	Tezepelumab	395	334 (84.6)	0.38 (0.65)	0.0	0.00	0.00	0.71	4.0	
		Placebo	391	319 (81.6)	0.36 (0.60)	0.0	0.00	0.00	0.60	4.0	
	Week 48	Tezepelumab	395	348 (88.1)	0.37 (0.64)	0.0	0.00	0.00	0.71	4.0	
		Placebo	391	323 (82.6)	0.37 (0.60)	0.0	0.00	0.00	0.75	3.3	
	Week 49	Tezepelumab	395	351 (88.9)	0.36 (0.62)	0.0	0.00	0.00	0.60	3.4	
		Placebo	391	320 (81.8)	0.36 (0.59)	0.0	0.00	0.00	0.67	3.1	
	Week 50	Tezepelumab	395	342 (86.6)	0.36 (0.62)	0.0	0.00	0.00	0.57	3.0	
		Placebo	391	314 (80.3)	0.37 (0.61)	0.0	0.00	0.00	0.71	3.0	
	Week 51	Tezepelumab	395	331 (83.8)	0.37 (0.64)	0.0	0.00	0.00	0.67	3.0	
		Placebo	391	314 (80.3)	0.38 (0.61)	0.0	0.00	0.00	0.71	3.0	
	Week 52	Tezepelumab	395	309 (78.2)	0.35 (0.61)	0.0	0.00	0.00	0.67	3.0	
		Placebo	391	286 (73.1)	0.36 (0.59)	0.0	0.00	0.00	0.67	3.1	

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WAC\_ILMH0: Course of ASD weekly waking score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly waking score	Week 1	Tezepelumab	395	391 (99.0)	-0.23 (0.40)	-2.6	-0.43	-0.14	0.00	1.0	-0.16 [-0.30, -0.02]
		Placebo	391	385 (98.5)	-0.16 (0.41)	-2.1	-0.36	-0.02	0.00	1.5	
	Week 2	Tezepelumab	395	387 (98.0)	-0.26 (0.48)	-2.6	-0.57	-0.14	0.00	2.9	-0.12 [-0.26, 0.02]
		Placebo	391	387 (99.0)	-0.21 (0.49)	-2.3	-0.43	-0.14	0.00	1.6	
	Week 3	Tezepelumab	395	387 (98.0)	-0.32 (0.51)	-2.6	-0.57	-0.14	0.00	1.6	-0.11 [-0.25, 0.04]
		Placebo	391	385 (98.5)	-0.27 (0.52)	-2.1	-0.57	-0.14	0.00	2.0	
	Week 4	Tezepelumab	395	387 (98.0)	-0.36 (0.52)	-2.9	-0.67	-0.25	0.00	1.3	-0.14 [-0.28, 0.00]
		Placebo	391	379 (96.9)	-0.29 (0.52)	-2.5	-0.57	-0.14	0.00	1.1	
	Week 5	Tezepelumab	395	382 (96.7)	-0.41 (0.53)	-2.9	-0.71	-0.29	0.00	1.0	-0.16 [-0.31, -0.02]
		Placebo	391	377 (96.4)	-0.33 (0.54)	-3.6	-0.57	-0.24	0.00	1.6	
	Week 6	Tezepelumab	395	386 (97.7)	-0.43 (0.54)	-2.6	-0.71	-0.29	0.00	1.1	-0.17 [-0.31, -0.03]
		Placebo	391	379 (96.9)	-0.33 (0.57)	-3.4	-0.67	-0.14	0.00	1.6	
	Week 7	Tezepelumab	395	378 (95.7)	-0.42 (0.56)	-3.0	-0.71	-0.29	0.00	1.5	-0.14 [-0.28, 0.00]
		Placebo	391	378 (96.7)	-0.34 (0.58)	-3.3	-0.67	-0.23	0.00	1.3	
	Week 8	Tezepelumab	395	378 (95.7)	-0.47 (0.56)	-3.0	-0.86	-0.29	0.00	1.1	-0.17 [-0.31, -0.03]
		Placebo	391	377 (96.4)	-0.37 (0.59)	-3.8	-0.67	-0.29	0.00	2.0	
	Week 9	Tezepelumab	395	385 (97.5)	-0.49 (0.56)	-2.8	-0.86	-0.43	0.00	0.9	-0.19 [-0.33, -0.04]
		Placebo	391	374 (95.7)	-0.38 (0.60)	-4.0	-0.71	-0.29	0.00	1.7	
	Week 10	Tezepelumab	395	379 (95.9)	-0.49 (0.57)	-3.2	-0.86	-0.43	0.00	1.0	-0.20 [-0.34, -0.05]
		Placebo	391	366 (93.6)	-0.38 (0.57)	-4.0	-0.71	-0.29	0.00	1.1	
	Week 11	Tezepelumab	395	376 (95.2)	-0.48 (0.59)	-3.0	-0.86	-0.32	0.00	1.0	-0.13 [-0.27, 0.02]
		Placebo	391	373 (95.4)	-0.40 (0.58)	-4.0	-0.71	-0.29	0.00	1.1	
	Week 12	Tezepelumab	395	373 (94.4)	-0.47 (0.59)	-3.0	-0.86	-0.37	0.00	1.3	-0.10 [-0.24, 0.05]
		Placebo	391	367 (93.9)	-0.41 (0.59)	-4.0	-0.71	-0.29	0.00	2.0	
	Week 13	Tezepelumab	395	375 (94.9)	-0.50 (0.59)	-3.0	-0.86	-0.43	0.00	1.0	-0.11 [-0.25, 0.04]
		Placebo	391	369 (94.4)	-0.44 (0.59)	-4.0	-0.71	-0.29	0.00	1.3	
	Week 14	Tezepelumab	395	370 (93.7)	-0.53 (0.60)	-3.0	-1.00	-0.43	0.00	1.1	-0.18 [-0.33, -0.04]
		Placebo	391	368 (94.1)	-0.42 (0.59)	-4.0	-0.71	-0.29	0.00	1.1	
	Week 15	Tezepelumab	395	367 (92.9)	-0.52 (0.61)	-3.0	-1.00	-0.43	0.00	1.1	-0.20 [-0.35, -0.06]
		Placebo	391	351 (89.8)	-0.40 (0.61)	-4.0	-0.71	-0.29	0.00	2.2	
	Week 16	Tezepelumab	395	370 (93.7)	-0.52 (0.62)	-3.0	-0.98	-0.43	0.00	1.4	-0.20 [-0.34, -0.05]
		Placebo	391	357 (91.3)	-0.40 (0.59)	-4.0	-0.71	-0.29	0.00	1.3	
	Week 17	Tezepelumab	395	366 (92.7)	-0.52 (0.61)	-3.0	-1.00	-0.43	0.00	1.5	-0.15 [-0.30, -0.00]
		Placebo	391	352 (90.0)	-0.43 (0.60)	-4.0	-0.82	-0.29	0.00	1.0	
	Week 18	Tezepelumab	395	362 (91.6)	-0.51 (0.61)	-3.1	-0.90	-0.43	0.00	1.1	-0.18 [-0.32, -0.03]
		Placebo	391	352 (90.0)	-0.41 (0.59)	-2.7	-0.71	-0.29	0.00	1.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WAC\_ILMH0: Course of ASD weekly waking score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly waking score	Week 19	Tezepelumab	395	366 (92.7)	-0.53 (0.59)	-3.0	-0.86	-0.44	0.00	1.6	-0.19 [-0.33, -0.04]
		Placebo	391	354 (90.5)	-0.42 (0.61)	-4.0	-0.83	-0.29	0.00	1.7	
	Week 20	Tezepelumab	395	358 (90.6)	-0.56 (0.59)	-3.0	-1.00	-0.57	-0.14	1.0	-0.27 [-0.42, -0.12]
		Placebo	391	353 (90.3)	-0.40 (0.58)	-2.7	-0.81	-0.29	0.00	1.1	
	Week 21	Tezepelumab	395	360 (91.1)	-0.52 (0.61)	-3.1	-0.86	-0.43	0.00	2.9	-0.17 [-0.32, -0.02]
		Placebo	391	350 (89.5)	-0.42 (0.61)	-4.0	-0.83	-0.29	0.00	1.8	
	Week 22	Tezepelumab	395	360 (91.1)	-0.52 (0.60)	-3.3	-0.86	-0.43	0.00	1.4	-0.19 [-0.34, -0.04]
		Placebo	391	343 (87.7)	-0.41 (0.58)	-2.7	-0.86	-0.29	0.00	1.3	
	Week 23	Tezepelumab	395	355 (89.9)	-0.54 (0.60)	-3.3	-1.00	-0.43	0.00	1.4	-0.20 [-0.35, -0.06]
		Placebo	391	335 (85.7)	-0.41 (0.58)	-2.7	-0.83	-0.29	0.00	1.0	
	Week 24	Tezepelumab	395	354 (89.6)	-0.53 (0.61)	-3.3	-1.00	-0.43	0.00	1.7	-0.20 [-0.35, -0.05]
		Placebo	391	338 (86.4)	-0.41 (0.61)	-2.9	-0.80	-0.29	0.00	1.7	
	Week 25	Tezepelumab	395	358 (90.6)	-0.54 (0.59)	-3.3	-1.00	-0.43	-0.06	1.0	-0.16 [-0.31, -0.01]
		Placebo	391	336 (85.9)	-0.44 (0.61)	-4.0	-0.83	-0.29	0.00	1.8	
	Week 26	Tezepelumab	395	352 (89.1)	-0.52 (0.61)	-3.3	-0.86	-0.43	-0.02	2.5	-0.13 [-0.28, 0.02]
		Placebo	391	333 (85.2)	-0.44 (0.61)	-2.7	-0.86	-0.29	0.00	1.3	
	Week 27	Tezepelumab	395	358 (90.6)	-0.53 (0.58)	-3.0	-1.00	-0.44	0.00	1.0	-0.21 [-0.36, -0.06]
		Placebo	391	330 (84.4)	-0.41 (0.60)	-2.7	-0.86	-0.29	0.00	1.6	
	Week 28	Tezepelumab	395	356 (90.1)	-0.53 (0.59)	-3.3	-1.00	-0.43	0.00	1.3	-0.16 [-0.31, -0.01]
		Placebo	391	341 (87.2)	-0.44 (0.64)	-4.0	-0.86	-0.33	0.00	1.8	
	Week 29	Tezepelumab	395	352 (89.1)	-0.54 (0.57)	-3.3	-1.00	-0.43	-0.14	1.3	-0.19 [-0.34, -0.04]
		Placebo	391	340 (87.0)	-0.43 (0.63)	-4.0	-0.83	-0.29	0.00	1.4	
	Week 30	Tezepelumab	395	352 (89.1)	-0.53 (0.57)	-3.3	-1.00	-0.43	0.00	1.0	-0.20 [-0.36, -0.05]
		Placebo	391	332 (84.9)	-0.40 (0.68)	-4.0	-0.82	-0.29	0.00	2.2	
	Week 31	Tezepelumab	395	354 (89.6)	-0.53 (0.59)	-3.3	-1.00	-0.43	-0.14	1.0	-0.20 [-0.35, -0.04]
		Placebo	391	326 (83.4)	-0.42 (0.61)	-2.7	-0.83	-0.29	0.00	1.6	
	Week 32	Tezepelumab	395	356 (90.1)	-0.52 (0.59)	-3.3	-1.00	-0.43	0.00	1.3	-0.11 [-0.26, 0.04]
		Placebo	391	340 (87.0)	-0.45 (0.65)	-4.0	-0.86	-0.35	0.00	2.0	
	Week 33	Tezepelumab	395	352 (89.1)	-0.55 (0.60)	-3.3	-1.00	-0.51	-0.06	1.1	-0.19 [-0.34, -0.04]
		Placebo	391	331 (84.7)	-0.43 (0.65)	-4.0	-0.86	-0.29	0.00	1.6	
	Week 34	Tezepelumab	395	354 (89.6)	-0.54 (0.60)	-3.0	-1.00	-0.43	0.00	1.3	-0.15 [-0.30, 0.00]
		Placebo	391	334 (85.4)	-0.45 (0.61)	-2.7	-0.86	-0.35	0.00	1.6	
	Week 35	Tezepelumab	395	349 (88.4)	-0.52 (0.64)	-3.3	-1.00	-0.43	0.00	1.8	-0.13 [-0.28, 0.02]
		Placebo	391	325 (83.1)	-0.44 (0.60)	-2.7	-0.86	-0.33	0.00	1.8	
	Week 36	Tezepelumab	395	350 (88.6)	-0.53 (0.62)	-3.3	-1.00	-0.43	0.00	2.1	-0.13 [-0.28, 0.02]
		Placebo	391	329 (84.1)	-0.44 (0.62)	-4.0	-0.86	-0.29	0.00	1.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WAC\_ILMH0: Course of ASD weekly waking score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly waking score	Week 37	Tezepelumab	395	345 (87.3)	-0.54 (0.62)	-3.0	-1.00	-0.50	0.00	1.8	-0.14 [-0.29, 0.01]
		Placebo	391	331 (84.7)	-0.45 (0.64)	-4.0	-0.86	-0.33	0.00	1.7	
	Week 38	Tezepelumab	395	343 (86.8)	-0.53 (0.63)	-3.1	-1.00	-0.57	0.00	2.0	-0.16 [-0.31, -0.01]
		Placebo	391	329 (84.1)	-0.43 (0.63)	-4.0	-0.86	-0.29	0.00	1.6	
	Week 39	Tezepelumab	395	349 (88.4)	-0.53 (0.61)	-3.3	-1.00	-0.43	0.00	2.0	-0.14 [-0.29, 0.01]
		Placebo	391	331 (84.7)	-0.44 (0.65)	-4.0	-0.86	-0.29	0.00	1.6	
	Week 40	Tezepelumab	395	351 (88.9)	-0.55 (0.62)	-3.3	-1.00	-0.50	0.00	1.3	-0.23 [-0.38, -0.08]
		Placebo	391	329 (84.1)	-0.41 (0.64)	-4.0	-0.86	-0.29	0.00	1.9	
	Week 41	Tezepelumab	395	351 (88.9)	-0.55 (0.62)	-3.3	-1.00	-0.50	0.00	1.1	-0.18 [-0.33, -0.03]
		Placebo	391	328 (83.9)	-0.44 (0.62)	-4.0	-0.86	-0.29	0.00	1.7	
	Week 42	Tezepelumab	395	344 (87.1)	-0.52 (0.59)	-3.0	-0.95	-0.50	-0.07	1.1	-0.18 [-0.33, -0.03]
		Placebo	391	328 (83.9)	-0.41 (0.67)	-4.0	-0.86	-0.29	0.00	2.0	
	Week 43	Tezepelumab	395	343 (86.8)	-0.55 (0.60)	-3.3	-1.00	-0.52	-0.06	1.9	-0.20 [-0.35, -0.04]
		Placebo	391	325 (83.1)	-0.43 (0.65)	-4.0	-0.86	-0.29	0.00	1.7	
	Week 44	Tezepelumab	395	340 (86.1)	-0.54 (0.60)	-3.3	-1.00	-0.57	0.00	1.3	-0.16 [-0.31, -0.01]
		Placebo	391	323 (82.6)	-0.44 (0.65)	-4.0	-0.86	-0.29	0.00	1.7	
	Week 45	Tezepelumab	395	348 (88.1)	-0.56 (0.60)	-3.3	-1.00	-0.51	-0.12	1.3	-0.17 [-0.32, -0.02]
		Placebo	391	327 (83.6)	-0.45 (0.64)	-4.0	-0.86	-0.33	0.00	1.7	
	Week 46	Tezepelumab	395	343 (86.8)	-0.55 (0.61)	-3.1	-1.00	-0.46	0.00	1.1	-0.14 [-0.29, 0.01]
		Placebo	391	320 (81.8)	-0.46 (0.65)	-4.0	-0.86	-0.29	0.00	1.7	
	Week 47	Tezepelumab	395	334 (84.6)	-0.55 (0.62)	-3.3	-1.00	-0.50	0.00	1.2	-0.16 [-0.31, -0.01]
		Placebo	391	319 (81.6)	-0.45 (0.63)	-4.0	-0.86	-0.29	0.00	1.7	
	Week 48	Tezepelumab	395	348 (88.1)	-0.55 (0.62)	-3.3	-1.00	-0.50	0.00	1.7	-0.15 [-0.30, 0.01]
		Placebo	391	323 (82.6)	-0.45 (0.63)	-4.0	-0.86	-0.29	0.00	1.6	
	Week 49	Tezepelumab	395	351 (88.9)	-0.56 (0.62)	-3.1	-1.00	-0.57	0.00	1.3	-0.15 [-0.30, 0.00]
		Placebo	391	320 (81.8)	-0.47 (0.62)	-4.0	-0.86	-0.43	0.00	1.6	
	Week 50	Tezepelumab	395	342 (86.6)	-0.55 (0.61)	-3.0	-1.00	-0.43	0.00	1.6	-0.16 [-0.31, -0.01]
		Placebo	391	314 (80.3)	-0.45 (0.67)	-4.0	-0.86	-0.42	0.00	2.0	
	Week 51	Tezepelumab	395	331 (83.8)	-0.55 (0.63)	-3.3	-1.00	-0.43	0.00	1.6	-0.15 [-0.31, 0.00]
		Placebo	391	314 (80.3)	-0.45 (0.67)	-4.0	-0.86	-0.29	0.00	2.0	
	Week 52	Tezepelumab	395	309 (78.2)	-0.55 (0.64)	-3.3	-1.00	-0.57	0.00	1.3	-0.14 [-0.30, 0.02]
		Placebo	391	286 (73.1)	-0.46 (0.66)	-4.0	-0.83	-0.33	0.00	1.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WAC\_ILMC0: Change from baseline in ASD weekly waking score - MMRM results  
 DITTTL

Change from baseline in ASD weekly waking score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 1	Tezepelumab	395	391 (99.0)	-0.20 (0.03)	(-0.25, -0.16)	-0.03 (0.04)	(-0.10, 0.04)	0.411	
	Placebo	391	385 (98.5)	-0.18 (0.03)	(-0.22, -0.13)				
Week 2	Tezepelumab	395	387 (98.0)	-0.24 (0.03)	(-0.29, -0.19)	-0.02 (0.04)	(-0.09, 0.05)	0.524	
	Placebo	391	387 (99.0)	-0.22 (0.03)	(-0.27, -0.17)				
Week 3	Tezepelumab	395	387 (98.0)	-0.31 (0.03)	(-0.36, -0.26)	-0.03 (0.04)	(-0.10, 0.04)	0.387	
	Placebo	391	385 (98.5)	-0.28 (0.03)	(-0.33, -0.23)				
Week 4	Tezepelumab	395	387 (98.0)	-0.34 (0.03)	(-0.39, -0.29)	-0.04 (0.04)	(-0.11, 0.03)	0.240	
	Placebo	391	379 (96.9)	-0.30 (0.03)	(-0.35, -0.25)				
Week 5	Tezepelumab	395	382 (96.7)	-0.40 (0.03)	(-0.44, -0.35)	-0.06 (0.04)	(-0.13, 0.01)	0.113	
	Placebo	391	377 (96.4)	-0.34 (0.03)	(-0.39, -0.29)				
Week 6	Tezepelumab	395	386 (97.7)	-0.40 (0.03)	(-0.45, -0.35)	-0.05 (0.04)	(-0.12, 0.02)	0.131	
	Placebo	391	379 (96.9)	-0.35 (0.03)	(-0.40, -0.30)				
Week 7	Tezepelumab	395	378 (95.7)	-0.41 (0.03)	(-0.46, -0.36)	-0.06 (0.04)	(-0.13, 0.01)	0.105	
	Placebo	391	378 (96.7)	-0.35 (0.03)	(-0.40, -0.30)				
Week 8	Tezepelumab	395	378 (95.7)	-0.45 (0.03)	(-0.50, -0.40)	-0.08 (0.04)	(-0.15, -0.01)	0.025 *	
	Placebo	391	377 (96.4)	-0.37 (0.03)	(-0.42, -0.32)				
Week 9	Tezepelumab	395	385 (97.5)	-0.48 (0.03)	(-0.52, -0.43)	-0.09 (0.04)	(-0.16, -0.02)	0.013 *	
	Placebo	391	374 (95.7)	-0.39 (0.03)	(-0.44, -0.34)				
Week 10	Tezepelumab	395	379 (95.9)	-0.47 (0.03)	(-0.52, -0.42)	-0.09 (0.04)	(-0.16, -0.02)	0.015 *	
	Placebo	391	366 (93.6)	-0.38 (0.03)	(-0.43, -0.33)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WAC\_ILMC0: Change from baseline in ASD weekly waking score - MMRM results  
DITTTL

Change from baseline in ASD weekly waking score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 11	Tezepelumab	395	376 (95.2)	-0.46 (0.03)	(-0.50, -0.41)	-0.05 (0.04)	(-0.12, 0.02)	0.178	
	Placebo	391	373 (95.4)	-0.41 (0.03)	(-0.46, -0.36)				
Week 12	Tezepelumab	395	373 (94.4)	-0.45 (0.03)	(-0.50, -0.40)	-0.04 (0.04)	(-0.11, 0.04)	0.325	
	Placebo	391	367 (93.9)	-0.42 (0.03)	(-0.47, -0.37)				
Week 13	Tezepelumab	395	375 (94.9)	-0.47 (0.03)	(-0.52, -0.42)	-0.04 (0.04)	(-0.11, 0.03)	0.267	
	Placebo	391	369 (94.4)	-0.43 (0.03)	(-0.48, -0.38)				
Week 14	Tezepelumab	395	370 (93.7)	-0.49 (0.03)	(-0.54, -0.44)	-0.07 (0.04)	(-0.14, -0.00)	0.047 *	
	Placebo	391	368 (94.1)	-0.42 (0.03)	(-0.47, -0.37)				
Week 15	Tezepelumab	395	367 (92.9)	-0.49 (0.03)	(-0.54, -0.44)	-0.09 (0.04)	(-0.16, -0.02)	0.016 *	
	Placebo	391	351 (89.8)	-0.41 (0.03)	(-0.46, -0.36)				
Week 16	Tezepelumab	395	370 (93.7)	-0.49 (0.03)	(-0.54, -0.44)	-0.09 (0.04)	(-0.17, -0.02)	0.010 *	
	Placebo	391	357 (91.3)	-0.40 (0.03)	(-0.45, -0.35)				
Week 17	Tezepelumab	395	366 (92.7)	-0.49 (0.03)	(-0.54, -0.44)	-0.07 (0.04)	(-0.14, 0.00)	0.063	
	Placebo	391	352 (90.0)	-0.43 (0.03)	(-0.48, -0.38)				
Week 18	Tezepelumab	395	362 (91.6)	-0.48 (0.03)	(-0.53, -0.43)	-0.06 (0.04)	(-0.14, 0.01)	0.078	
	Placebo	391	352 (90.0)	-0.42 (0.03)	(-0.47, -0.37)				
Week 19	Tezepelumab	395	366 (92.7)	-0.51 (0.03)	(-0.56, -0.46)	-0.08 (0.04)	(-0.15, -0.01)	0.030 *	
	Placebo	391	354 (90.5)	-0.43 (0.03)	(-0.48, -0.38)				
Week 20	Tezepelumab	395	358 (90.6)	-0.52 (0.03)	(-0.57, -0.47)	-0.11 (0.04)	(-0.18, -0.03)	0.004 *	
	Placebo	391	353 (90.3)	-0.42 (0.03)	(-0.47, -0.36)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WAC\_ILMC0: Change from baseline in ASD weekly waking score - MMRM results  
 DITTTL

Change from baseline in ASD weekly waking score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 21	Tezepelumab	395	360 (91.1)	-0.51 (0.03)	(-0.56, -0.45)	-0.07 (0.04)	(-0.14, 0.00)	0.068	
	Placebo	391	350 (89.5)	-0.44 (0.03)	(-0.49, -0.39)				
Week 22	Tezepelumab	395	360 (91.1)	-0.51 (0.03)	(-0.56, -0.45)	-0.07 (0.04)	(-0.14, 0.00)	0.062	
	Placebo	391	343 (87.7)	-0.44 (0.03)	(-0.49, -0.39)				
Week 23	Tezepelumab	395	355 (89.9)	-0.51 (0.03)	(-0.56, -0.46)	-0.09 (0.04)	(-0.16, -0.02)	0.018 *	
	Placebo	391	335 (85.7)	-0.42 (0.03)	(-0.48, -0.37)				
Week 24	Tezepelumab	395	354 (89.6)	-0.51 (0.03)	(-0.57, -0.46)	-0.09 (0.04)	(-0.16, -0.02)	0.015 *	
	Placebo	391	338 (86.4)	-0.43 (0.03)	(-0.48, -0.37)				
Week 25	Tezepelumab	395	358 (90.6)	-0.52 (0.03)	(-0.57, -0.47)	-0.07 (0.04)	(-0.15, -0.00)	0.043 *	
	Placebo	391	336 (85.9)	-0.44 (0.03)	(-0.50, -0.39)				
Week 26	Tezepelumab	395	352 (89.1)	-0.50 (0.03)	(-0.55, -0.45)	-0.06 (0.04)	(-0.14, 0.01)	0.089	
	Placebo	391	333 (85.2)	-0.44 (0.03)	(-0.49, -0.39)				
Week 27	Tezepelumab	395	358 (90.6)	-0.51 (0.03)	(-0.57, -0.46)	-0.09 (0.04)	(-0.16, -0.01)	0.020 *	
	Placebo	391	330 (84.4)	-0.43 (0.03)	(-0.48, -0.38)				
Week 28	Tezepelumab	395	356 (90.1)	-0.52 (0.03)	(-0.57, -0.47)	-0.08 (0.04)	(-0.16, -0.01)	0.024 *	
	Placebo	391	341 (87.2)	-0.44 (0.03)	(-0.49, -0.39)				
Week 29	Tezepelumab	395	352 (89.1)	-0.52 (0.03)	(-0.57, -0.47)	-0.09 (0.04)	(-0.16, -0.02)	0.018 *	
	Placebo	391	340 (87.0)	-0.43 (0.03)	(-0.48, -0.38)				
Week 30	Tezepelumab	395	352 (89.1)	-0.51 (0.03)	(-0.56, -0.46)	-0.09 (0.04)	(-0.17, -0.02)	0.011 *	
	Placebo	391	332 (84.9)	-0.42 (0.03)	(-0.47, -0.37)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table NT1WAC\_ILMC0: Change from baseline in ASD weekly waking score - MMRM results  
 DITTTL

Change from baseline in ASD weekly waking score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 31	Tezepelumab	395	354 (89.6)	-0.52 (0.03)	(-0.57, -0.47)	-0.08 (0.04)	(-0.15, -0.00)	0.043 *	
	Placebo	391	326 (83.4)	-0.44 (0.03)	(-0.49, -0.39)				
Week 32	Tezepelumab	395	356 (90.1)	-0.51 (0.03)	(-0.56, -0.46)	-0.05 (0.04)	(-0.12, 0.03)	0.199	
	Placebo	391	340 (87.0)	-0.46 (0.03)	(-0.51, -0.41)				
Week 33	Tezepelumab	395	352 (89.1)	-0.53 (0.03)	(-0.58, -0.48)	-0.09 (0.04)	(-0.16, -0.01)	0.020 *	
	Placebo	391	331 (84.7)	-0.44 (0.03)	(-0.50, -0.39)				
Week 34	Tezepelumab	395	354 (89.6)	-0.52 (0.03)	(-0.57, -0.47)	-0.06 (0.04)	(-0.13, 0.01)	0.099	
	Placebo	391	334 (85.4)	-0.46 (0.03)	(-0.51, -0.41)				
Week 35	Tezepelumab	395	349 (88.4)	-0.51 (0.03)	(-0.56, -0.46)	-0.05 (0.04)	(-0.12, 0.03)	0.219	
	Placebo	391	325 (83.1)	-0.46 (0.03)	(-0.52, -0.41)				
Week 36	Tezepelumab	395	350 (88.6)	-0.51 (0.03)	(-0.56, -0.46)	-0.06 (0.04)	(-0.13, 0.01)	0.105	
	Placebo	391	329 (84.1)	-0.45 (0.03)	(-0.51, -0.40)				
Week 37	Tezepelumab	395	345 (87.3)	-0.52 (0.03)	(-0.57, -0.47)	-0.06 (0.04)	(-0.13, 0.02)	0.123	
	Placebo	391	331 (84.7)	-0.46 (0.03)	(-0.52, -0.41)				
Week 38	Tezepelumab	395	343 (86.8)	-0.51 (0.03)	(-0.56, -0.46)	-0.07 (0.04)	(-0.14, 0.01)	0.074	
	Placebo	391	329 (84.1)	-0.44 (0.03)	(-0.50, -0.39)				
Week 39	Tezepelumab	395	349 (88.4)	-0.52 (0.03)	(-0.57, -0.46)	-0.05 (0.04)	(-0.13, 0.02)	0.156	
	Placebo	391	331 (84.7)	-0.46 (0.03)	(-0.51, -0.41)				
Week 40	Tezepelumab	395	351 (88.9)	-0.53 (0.03)	(-0.58, -0.48)	-0.10 (0.04)	(-0.17, -0.03)	0.008 *	
	Placebo	391	329 (84.1)	-0.43 (0.03)	(-0.48, -0.38)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WAC\_ILMC0: Change from baseline in ASD weekly waking score - MMRM results  
 DITTTL

Change from baseline in ASD weekly waking score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 41	Tezepelumab	395	351 (88.9)	-0.54 (0.03)	(-0.59, -0.49)	-0.08 (0.04)	(-0.15, -0.00)	0.038 *	
	Placebo	391	328 (83.9)	-0.46 (0.03)	(-0.51, -0.41)				
Week 42	Tezepelumab	395	344 (87.1)	-0.52 (0.03)	(-0.57, -0.47)	-0.08 (0.04)	(-0.16, -0.01)	0.027 *	
	Placebo	391	328 (83.9)	-0.43 (0.03)	(-0.49, -0.38)				
Week 43	Tezepelumab	395	343 (86.8)	-0.54 (0.03)	(-0.59, -0.49)	-0.08 (0.04)	(-0.15, -0.01)	0.034 *	
	Placebo	391	325 (83.1)	-0.46 (0.03)	(-0.51, -0.41)				
Week 44	Tezepelumab	395	340 (86.1)	-0.53 (0.03)	(-0.58, -0.48)	-0.08 (0.04)	(-0.15, -0.00)	0.043 *	
	Placebo	391	323 (82.6)	-0.45 (0.03)	(-0.51, -0.40)				
Week 45	Tezepelumab	395	348 (88.1)	-0.55 (0.03)	(-0.60, -0.49)	-0.08 (0.04)	(-0.15, -0.00)	0.038 *	
	Placebo	391	327 (83.6)	-0.47 (0.03)	(-0.52, -0.41)				
Week 46	Tezepelumab	395	343 (86.8)	-0.54 (0.03)	(-0.59, -0.49)	-0.07 (0.04)	(-0.14, 0.01)	0.075	
	Placebo	391	320 (81.8)	-0.47 (0.03)	(-0.52, -0.42)				
Week 47	Tezepelumab	395	334 (84.6)	-0.53 (0.03)	(-0.58, -0.48)	-0.07 (0.04)	(-0.14, 0.01)	0.083	
	Placebo	391	319 (81.6)	-0.47 (0.03)	(-0.52, -0.41)				
Week 48	Tezepelumab	395	348 (88.1)	-0.54 (0.03)	(-0.59, -0.48)	-0.06 (0.04)	(-0.14, 0.01)	0.101	
	Placebo	391	323 (82.6)	-0.47 (0.03)	(-0.53, -0.42)				
Week 49	Tezepelumab	395	351 (88.9)	-0.54 (0.03)	(-0.59, -0.49)	-0.07 (0.04)	(-0.14, 0.01)	0.084	
	Placebo	391	320 (81.8)	-0.48 (0.03)	(-0.53, -0.42)				
Week 50	Tezepelumab	395	342 (86.6)	-0.55 (0.03)	(-0.60, -0.50)	-0.08 (0.04)	(-0.15, -0.00)	0.045 *	
	Placebo	391	314 (80.3)	-0.47 (0.03)	(-0.52, -0.42)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WAC\_ILMC0: Change from baseline in ASD weekly waking score - MMRM results  
 DITTTL

Change from baseline in ASD weekly waking score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 51	Tezepelumab	395	331 (83.8)	-0.54 (0.03)	(-0.59, -0.49)	-0.08 (0.04)	(-0.15, -0.00)	0.046 *
	Placebo	391	314 (80.3)	-0.47 (0.03)	(-0.52, -0.41)			
Week 52	Tezepelumab	395	309 (78.2)	-0.54 (0.03)	(-0.60, -0.49)	-0.08 (0.04)	(-0.15, 0.00)	0.052
	Placebo	391	286 (73.1)	-0.47 (0.03)	(-0.52, -0.42)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WAC\_ILMH0: Course of ASD weekly waking score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly waking score	Baseline	Tezepelumab	73	73 (100.0)	0.68 (0.65)	0.0	0.00	0.71	1.00	3.0	
		Placebo	76	76 (100.0)	0.65 (0.79)	0.0	0.00	0.29	1.00	4.0	
	Week 1	Tezepelumab	73	73 (100.0)	0.55 (0.58)	0.0	0.00	0.29	1.00	2.0	
		Placebo	76	76 (100.0)	0.63 (0.70)	0.0	0.00	0.43	1.00	3.0	
	Week 2	Tezepelumab	73	73 (100.0)	0.51 (0.58)	0.0	0.00	0.29	1.00	2.0	
		Placebo	76	75 (98.7)	0.64 (0.77)	0.0	0.00	0.29	1.00	3.5	
	Week 3	Tezepelumab	73	73 (100.0)	0.52 (0.59)	0.0	0.00	0.29	1.00	2.0	
		Placebo	76	75 (98.7)	0.59 (0.67)	0.0	0.00	0.33	1.00	3.0	
	Week 4	Tezepelumab	73	71 (97.3)	0.47 (0.59)	0.0	0.00	0.00	1.00	2.0	
		Placebo	76	76 (100.0)	0.57 (0.67)	0.0	0.00	0.23	1.00	3.0	
	Week 5	Tezepelumab	73	72 (98.6)	0.46 (0.57)	0.0	0.00	0.14	1.00	2.0	
		Placebo	76	75 (98.7)	0.50 (0.68)	0.0	0.00	0.14	1.00	3.0	
	Week 6	Tezepelumab	73	71 (97.3)	0.48 (0.58)	0.0	0.00	0.17	1.00	2.1	
		Placebo	76	73 (96.1)	0.55 (0.69)	0.0	0.00	0.14	1.00	3.0	
	Week 7	Tezepelumab	73	70 (95.9)	0.52 (0.64)	0.0	0.00	0.21	1.00	2.3	
		Placebo	76	76 (100.0)	0.54 (0.70)	0.0	0.00	0.14	1.00	3.0	
	Week 8	Tezepelumab	73	71 (97.3)	0.51 (0.65)	0.0	0.00	0.14	1.00	2.9	
		Placebo	76	76 (100.0)	0.57 (0.70)	0.0	0.00	0.29	1.00	3.0	
	Week 9	Tezepelumab	73	71 (97.3)	0.49 (0.62)	0.0	0.00	0.00	1.00	2.1	
		Placebo	76	73 (96.1)	0.52 (0.70)	0.0	0.00	0.14	1.00	3.0	
	Week 10	Tezepelumab	73	70 (95.9)	0.52 (0.62)	0.0	0.00	0.29	1.00	2.2	
		Placebo	76	74 (97.4)	0.53 (0.73)	0.0	0.00	0.14	1.00	3.0	
	Week 11	Tezepelumab	73	72 (98.6)	0.50 (0.58)	0.0	0.00	0.15	1.00	2.0	
		Placebo	76	75 (98.7)	0.55 (0.74)	0.0	0.00	0.14	1.00	3.0	
	Week 12	Tezepelumab	73	70 (95.9)	0.48 (0.58)	0.0	0.00	0.14	1.00	2.0	
		Placebo	76	75 (98.7)	0.49 (0.66)	0.0	0.00	0.14	1.00	3.0	
	Week 13	Tezepelumab	73	69 (94.5)	0.46 (0.57)	0.0	0.00	0.14	1.00	2.0	
		Placebo	76	74 (97.4)	0.47 (0.72)	0.0	0.00	0.00	1.00	3.0	
	Week 14	Tezepelumab	73	70 (95.9)	0.50 (0.58)	0.0	0.00	0.23	1.00	2.0	
		Placebo	76	75 (98.7)	0.48 (0.70)	0.0	0.00	0.14	0.86	3.0	
	Week 15	Tezepelumab	73	70 (95.9)	0.51 (0.59)	0.0	0.00	0.24	1.00	2.3	
		Placebo	76	72 (94.7)	0.43 (0.68)	0.0	0.00	0.00	0.86	3.0	
	Week 16	Tezepelumab	73	70 (95.9)	0.49 (0.61)	0.0	0.00	0.14	1.00	2.3	
		Placebo	76	74 (97.4)	0.49 (0.72)	0.0	0.00	0.14	1.00	3.0	
Week 17	Tezepelumab	73	70 (95.9)	0.46 (0.54)	0.0	0.00	0.15	1.00	2.0		
	Placebo	76	74 (97.4)	0.47 (0.71)	0.0	0.00	0.00	1.00	3.0		

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WAC\_ILMH0: Course of ASD weekly waking score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly waking score	Week 18	Tezepelumab	73	69 (94.5)	0.48 (0.59)	0.0	0.00	0.14	1.00	2.3	
		Placebo	76	74 (97.4)	0.45 (0.72)	0.0	0.00	0.00	1.00	3.0	
	Week 19	Tezepelumab	73	70 (95.9)	0.47 (0.57)	0.0	0.00	0.14	1.00	2.0	
		Placebo	76	73 (96.1)	0.47 (0.69)	0.0	0.00	0.14	0.83	3.0	
	Week 20	Tezepelumab	73	70 (95.9)	0.46 (0.58)	0.0	0.00	0.14	1.00	2.0	
		Placebo	76	75 (98.7)	0.48 (0.71)	0.0	0.00	0.00	1.00	3.0	
	Week 21	Tezepelumab	73	69 (94.5)	0.49 (0.58)	0.0	0.00	0.14	1.00	2.4	
		Placebo	76	74 (97.4)	0.49 (0.71)	0.0	0.00	0.00	1.00	3.0	
	Week 22	Tezepelumab	73	70 (95.9)	0.49 (0.59)	0.0	0.00	0.20	1.00	2.3	
		Placebo	76	75 (98.7)	0.57 (0.79)	0.0	0.00	0.14	1.00	3.0	
	Week 23	Tezepelumab	73	70 (95.9)	0.46 (0.59)	0.0	0.00	0.14	1.00	2.3	
		Placebo	76	74 (97.4)	0.51 (0.73)	0.0	0.00	0.00	1.00	3.0	
	Week 24	Tezepelumab	73	70 (95.9)	0.47 (0.61)	0.0	0.00	0.07	1.00	2.1	
		Placebo	76	75 (98.7)	0.50 (0.69)	0.0	0.00	0.14	1.00	3.0	
	Week 25	Tezepelumab	73	68 (93.2)	0.47 (0.62)	0.0	0.00	0.00	1.00	2.1	
		Placebo	76	74 (97.4)	0.52 (0.69)	0.0	0.00	0.15	1.00	3.0	
	Week 26	Tezepelumab	73	69 (94.5)	0.48 (0.59)	0.0	0.00	0.14	1.00	2.0	
		Placebo	76	73 (96.1)	0.51 (0.74)	0.0	0.00	0.00	1.00	3.1	
	Week 27	Tezepelumab	73	69 (94.5)	0.46 (0.61)	0.0	0.00	0.00	1.00	2.6	
		Placebo	76	73 (96.1)	0.50 (0.70)	0.0	0.00	0.14	1.00	3.0	
	Week 28	Tezepelumab	73	67 (91.8)	0.44 (0.60)	0.0	0.00	0.00	1.00	2.4	
		Placebo	76	74 (97.4)	0.52 (0.73)	0.0	0.00	0.14	1.00	3.0	
	Week 29	Tezepelumab	73	66 (90.4)	0.42 (0.57)	0.0	0.00	0.00	1.00	2.0	
		Placebo	76	74 (97.4)	0.53 (0.75)	0.0	0.00	0.00	1.00	3.0	
	Week 30	Tezepelumab	73	68 (93.2)	0.43 (0.58)	0.0	0.00	0.00	1.00	2.3	
		Placebo	76	74 (97.4)	0.52 (0.76)	0.0	0.00	0.00	1.00	3.0	
	Week 31	Tezepelumab	73	67 (91.8)	0.46 (0.61)	0.0	0.00	0.00	1.00	2.1	
		Placebo	76	73 (96.1)	0.53 (0.76)	0.0	0.00	0.00	1.00	3.2	
	Week 32	Tezepelumab	73	67 (91.8)	0.45 (0.61)	0.0	0.00	0.00	1.00	2.1	
		Placebo	76	74 (97.4)	0.49 (0.70)	0.0	0.00	0.14	1.00	3.0	
	Week 33	Tezepelumab	73	68 (93.2)	0.41 (0.54)	0.0	0.00	0.00	1.00	2.0	
		Placebo	76	74 (97.4)	0.46 (0.69)	0.0	0.00	0.00	1.00	3.0	
	Week 34	Tezepelumab	73	68 (93.2)	0.40 (0.56)	0.0	0.00	0.00	0.93	2.3	
		Placebo	76	73 (96.1)	0.50 (0.74)	0.0	0.00	0.00	1.00	3.0	
	Week 35	Tezepelumab	73	66 (90.4)	0.42 (0.55)	0.0	0.00	0.00	1.00	2.1	
		Placebo	76	74 (97.4)	0.49 (0.74)	0.0	0.00	0.00	1.00	3.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WAC\_ILMH0: Course of ASD weekly waking score  
 DITTLL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly waking score	Week 36	Tezepelumab	73	69 (94.5)	0.45 (0.59)	0.0	0.00	0.00	1.00	2.4	
		Placebo	76	73 (96.1)	0.50 (0.74)	0.0	0.00	0.14	0.86	3.0	
	Week 37	Tezepelumab	73	68 (93.2)	0.43 (0.62)	0.0	0.00	0.00	1.00	2.8	
		Placebo	76	72 (94.7)	0.50 (0.76)	0.0	0.00	0.07	1.00	3.0	
	Week 38	Tezepelumab	73	67 (91.8)	0.42 (0.57)	0.0	0.00	0.00	1.00	2.2	
		Placebo	76	73 (96.1)	0.53 (0.77)	0.0	0.00	0.00	1.00	3.0	
	Week 39	Tezepelumab	73	66 (90.4)	0.41 (0.56)	0.0	0.00	0.00	1.00	2.4	
		Placebo	76	72 (94.7)	0.49 (0.75)	0.0	0.00	0.07	1.00	3.0	
	Week 40	Tezepelumab	73	66 (90.4)	0.41 (0.54)	0.0	0.00	0.07	1.00	2.3	
		Placebo	76	72 (94.7)	0.54 (0.81)	0.0	0.00	0.07	1.00	3.0	
	Week 41	Tezepelumab	73	64 (87.7)	0.40 (0.57)	0.0	0.00	0.00	1.00	2.3	
		Placebo	76	73 (96.1)	0.45 (0.71)	0.0	0.00	0.00	0.75	3.0	
	Week 42	Tezepelumab	73	65 (89.0)	0.40 (0.54)	0.0	0.00	0.00	1.00	2.3	
		Placebo	76	72 (94.7)	0.47 (0.69)	0.0	0.00	0.14	0.92	3.0	
	Week 43	Tezepelumab	73	64 (87.7)	0.40 (0.56)	0.0	0.00	0.00	0.93	2.3	
		Placebo	76	73 (96.1)	0.50 (0.73)	0.0	0.00	0.00	1.00	3.0	
	Week 44	Tezepelumab	73	65 (89.0)	0.40 (0.52)	0.0	0.00	0.00	1.00	2.0	
		Placebo	76	73 (96.1)	0.49 (0.74)	0.0	0.00	0.14	0.80	3.0	
	Week 45	Tezepelumab	73	64 (87.7)	0.38 (0.54)	0.0	0.00	0.00	1.00	2.4	
		Placebo	76	72 (94.7)	0.46 (0.70)	0.0	0.00	0.00	0.76	3.0	
	Week 46	Tezepelumab	73	65 (89.0)	0.40 (0.54)	0.0	0.00	0.00	1.00	2.1	
		Placebo	76	71 (93.4)	0.44 (0.70)	0.0	0.00	0.00	0.86	3.0	
	Week 47	Tezepelumab	73	65 (89.0)	0.41 (0.53)	0.0	0.00	0.00	1.00	2.0	
		Placebo	76	71 (93.4)	0.46 (0.68)	0.0	0.00	0.14	0.71	3.0	
	Week 48	Tezepelumab	73	58 (79.5)	0.39 (0.55)	0.0	0.00	0.00	1.00	2.1	
		Placebo	76	70 (92.1)	0.49 (0.72)	0.0	0.00	0.00	1.00	3.0	

Note: DITTLL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WAC\_ILMH0: Course of ASD weekly waking score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly waking score	Week 1	Tezepelumab	73	73 (100.0)	-0.12 (0.38)	-1.9	-0.20	0.00	0.00	0.7	-0.27 [-0.59, 0.05]
		Placebo	76	76 (100.0)	-0.01 (0.43)	-2.6	-0.14	0.00	0.21	0.7	
	Week 2	Tezepelumab	73	73 (100.0)	-0.17 (0.40)	-1.9	-0.29	0.00	0.00	0.8	-0.38 [-0.70, -0.05]
		Placebo	76	75 (98.7)	-0.01 (0.43)	-1.2	-0.14	0.00	0.14	1.6	
	Week 3	Tezepelumab	73	73 (100.0)	-0.15 (0.43)	-1.3	-0.29	0.00	0.00	1.2	-0.18 [-0.50, 0.14]
		Placebo	76	75 (98.7)	-0.07 (0.52)	-3.0	-0.14	0.00	0.00	1.2	
	Week 4	Tezepelumab	73	71 (97.3)	-0.21 (0.42)	-1.9	-0.29	0.00	0.00	1.1	-0.26 [-0.58, 0.06]
		Placebo	76	76 (100.0)	-0.08 (0.56)	-2.7	-0.14	0.00	0.10	1.0	
	Week 5	Tezepelumab	73	72 (98.6)	-0.21 (0.42)	-1.9	-0.29	0.00	0.00	0.5	-0.13 [-0.46, 0.19]
		Placebo	76	75 (98.7)	-0.14 (0.58)	-3.0	-0.29	0.00	0.00	1.3	
	Week 6	Tezepelumab	73	71 (97.3)	-0.18 (0.41)	-1.7	-0.29	0.00	0.00	0.7	-0.18 [-0.51, 0.14]
		Placebo	76	73 (96.1)	-0.09 (0.56)	-2.9	-0.14	0.00	0.00	1.2	
	Week 7	Tezepelumab	73	70 (95.9)	-0.15 (0.44)	-1.6	-0.29	0.00	0.00	1.1	-0.07 [-0.40, 0.25]
		Placebo	76	76 (100.0)	-0.11 (0.60)	-2.9	-0.29	0.00	0.00	1.3	
	Week 8	Tezepelumab	73	71 (97.3)	-0.16 (0.52)	-2.0	-0.29	0.00	0.00	1.9	-0.14 [-0.46, 0.19]
		Placebo	76	76 (100.0)	-0.08 (0.57)	-2.7	-0.14	0.00	0.00	1.3	
	Week 9	Tezepelumab	73	71 (97.3)	-0.18 (0.52)	-1.9	-0.43	0.00	0.00	1.1	-0.08 [-0.41, 0.25]
		Placebo	76	73 (96.1)	-0.14 (0.59)	-2.9	-0.29	0.00	0.00	0.9	
	Week 10	Tezepelumab	73	70 (95.9)	-0.15 (0.49)	-1.4	-0.43	0.00	0.00	1.0	-0.08 [-0.40, 0.25]
		Placebo	76	74 (97.4)	-0.11 (0.65)	-2.7	-0.29	0.00	0.00	2.0	
	Week 11	Tezepelumab	73	72 (98.6)	-0.17 (0.52)	-1.6	-0.53	0.00	0.00	1.1	-0.14 [-0.46, 0.18]
		Placebo	76	75 (98.7)	-0.09 (0.62)	-2.9	-0.29	0.00	0.14	1.9	
	Week 12	Tezepelumab	73	70 (95.9)	-0.20 (0.51)	-1.5	-0.57	0.00	0.00	1.3	-0.11 [-0.43, 0.22]
		Placebo	76	75 (98.7)	-0.15 (0.56)	-2.7	-0.29	0.00	0.00	1.1	
	Week 13	Tezepelumab	73	69 (94.5)	-0.21 (0.54)	-1.7	-0.57	0.00	0.00	1.3	-0.07 [-0.40, 0.26]
		Placebo	76	74 (97.4)	-0.17 (0.60)	-2.9	-0.29	0.00	0.00	1.3	
	Week 14	Tezepelumab	73	70 (95.9)	-0.19 (0.49)	-1.5	-0.43	0.00	0.00	1.0	-0.04 [-0.37, 0.28]
		Placebo	76	75 (98.7)	-0.16 (0.51)	-2.0	-0.33	0.00	0.00	1.0	
	Week 15	Tezepelumab	73	70 (95.9)	-0.17 (0.48)	-1.3	-0.43	0.00	0.00	1.0	0.07 [-0.26, 0.40]
		Placebo	76	72 (94.7)	-0.21 (0.54)	-2.6	-0.36	0.00	0.00	1.0	
	Week 16	Tezepelumab	73	70 (95.9)	-0.19 (0.52)	-1.3	-0.57	0.00	0.00	1.0	-0.08 [-0.41, 0.24]
		Placebo	76	74 (97.4)	-0.14 (0.60)	-2.6	-0.14	0.00	0.00	1.6	
	Week 17	Tezepelumab	73	70 (95.9)	-0.22 (0.53)	-2.0	-0.57	0.00	0.00	1.0	-0.11 [-0.44, 0.21]
		Placebo	76	74 (97.4)	-0.16 (0.60)	-2.7	-0.29	0.00	0.00	1.3	
	Week 18	Tezepelumab	73	69 (94.5)	-0.18 (0.50)	-1.3	-0.43	0.00	0.00	1.0	0.02 [-0.31, 0.35]
		Placebo	76	74 (97.4)	-0.19 (0.59)	-2.5	-0.43	0.00	0.00	1.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WAC\_ILMH0: Course of ASD weekly waking score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly waking score	Week 19	Tezepelumab	73	70 (95.9)	-0.21 (0.50)	-1.3	-0.57	0.00	0.00	1.1	-0.07 [-0.40, 0.26]
		Placebo	76	73 (96.1)	-0.17 (0.58)	-2.4	-0.43	0.00	0.00	1.3	
	Week 20	Tezepelumab	73	70 (95.9)	-0.22 (0.51)	-1.4	-0.57	0.00	0.00	1.2	-0.11 [-0.43, 0.22]
		Placebo	76	75 (98.7)	-0.16 (0.55)	-2.2	-0.43	0.00	0.00	1.0	
	Week 21	Tezepelumab	73	69 (94.5)	-0.20 (0.56)	-1.9	-0.43	0.00	0.00	1.2	-0.07 [-0.40, 0.26]
		Placebo	76	74 (97.4)	-0.16 (0.64)	-2.6	-0.43	0.00	0.00	1.4	
	Week 22	Tezepelumab	73	70 (95.9)	-0.19 (0.50)	-1.8	-0.33	0.00	0.00	1.0	-0.20 [-0.52, 0.13]
		Placebo	76	75 (98.7)	-0.07 (0.67)	-2.1	-0.17	0.00	0.00	2.4	
	Week 23	Tezepelumab	73	70 (95.9)	-0.22 (0.50)	-2.2	-0.43	0.00	0.00	1.0	-0.15 [-0.48, 0.17]
		Placebo	76	74 (97.4)	-0.14 (0.63)	-2.4	-0.29	0.00	0.00	2.0	
	Week 24	Tezepelumab	73	70 (95.9)	-0.21 (0.54)	-2.1	-0.57	0.00	0.00	1.0	-0.14 [-0.47, 0.18]
		Placebo	76	75 (98.7)	-0.14 (0.56)	-2.1	-0.29	0.00	0.00	1.4	
	Week 25	Tezepelumab	73	68 (93.2)	-0.20 (0.61)	-2.2	-0.50	0.00	0.00	2.1	-0.12 [-0.45, 0.21]
		Placebo	76	74 (97.4)	-0.13 (0.63)	-2.9	-0.29	0.00	0.00	1.4	
	Week 26	Tezepelumab	73	69 (94.5)	-0.21 (0.62)	-2.2	-0.57	0.00	0.00	1.6	-0.14 [-0.47, 0.19]
		Placebo	76	73 (96.1)	-0.12 (0.70)	-2.9	-0.29	0.00	0.00	3.1	
	Week 27	Tezepelumab	73	69 (94.5)	-0.20 (0.59)	-2.2	-0.43	0.00	0.00	1.0	-0.12 [-0.45, 0.21]
		Placebo	76	73 (96.1)	-0.13 (0.58)	-2.6	-0.36	0.00	0.00	1.7	
	Week 28	Tezepelumab	73	67 (91.8)	-0.21 (0.57)	-2.2	-0.57	0.00	0.00	1.2	-0.17 [-0.50, 0.16]
		Placebo	76	74 (97.4)	-0.11 (0.57)	-2.0	-0.29	0.00	0.00	2.0	
	Week 29	Tezepelumab	73	66 (90.4)	-0.22 (0.55)	-2.2	-0.57	0.00	0.00	1.2	-0.20 [-0.54, 0.13]
		Placebo	76	74 (97.4)	-0.10 (0.61)	-2.4	-0.29	0.00	0.00	2.1	
	Week 30	Tezepelumab	73	68 (93.2)	-0.22 (0.56)	-2.2	-0.59	0.00	0.00	1.0	-0.17 [-0.50, 0.16]
		Placebo	76	74 (97.4)	-0.12 (0.61)	-2.3	-0.29	0.00	0.00	2.4	
	Week 31	Tezepelumab	73	67 (91.8)	-0.20 (0.58)	-2.1	-0.57	0.00	0.00	1.1	-0.14 [-0.47, 0.20]
		Placebo	76	73 (96.1)	-0.11 (0.63)	-2.7	-0.17	0.00	0.00	1.9	
	Week 32	Tezepelumab	73	67 (91.8)	-0.22 (0.59)	-2.2	-0.71	0.00	0.00	1.2	-0.13 [-0.46, 0.20]
		Placebo	76	74 (97.4)	-0.15 (0.54)	-2.1	-0.29	0.00	0.00	1.1	
	Week 33	Tezepelumab	73	68 (93.2)	-0.25 (0.54)	-2.2	-0.50	0.00	0.00	1.0	-0.13 [-0.46, 0.20]
		Placebo	76	74 (97.4)	-0.17 (0.58)	-2.9	-0.29	0.00	0.00	1.3	
	Week 34	Tezepelumab	73	68 (93.2)	-0.25 (0.58)	-2.2	-0.63	0.00	0.00	1.0	-0.20 [-0.53, 0.13]
		Placebo	76	73 (96.1)	-0.14 (0.54)	-2.0	-0.29	0.00	0.00	1.9	
	Week 35	Tezepelumab	73	66 (90.4)	-0.24 (0.57)	-2.2	-0.43	0.00	0.00	1.0	-0.16 [-0.50, 0.17]
		Placebo	76	74 (97.4)	-0.15 (0.57)	-2.0	-0.29	0.00	0.00	2.0	
	Week 36	Tezepelumab	73	69 (94.5)	-0.21 (0.60)	-2.2	-0.57	0.00	0.00	1.2	-0.11 [-0.44, 0.22]
		Placebo	76	73 (96.1)	-0.14 (0.60)	-2.1	-0.29	0.00	0.00	2.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table ST1WAC\_ILMH0: Course of ASD weekly waking score  
 DITTTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly waking score	Week 37	Tezepelumab	73	68 (93.2)	-0.23 (0.61)	-2.2	-0.57	0.00	0.00	1.6	-0.13 [-0.46, 0.20]
		Placebo	76	72 (94.7)	-0.15 (0.65)	-2.5	-0.36	0.00	0.00	2.0	
	Week 38	Tezepelumab	73	67 (91.8)	-0.24 (0.58)	-2.2	-0.57	0.00	0.00	1.0	-0.21 [-0.54, 0.12]
		Placebo	76	73 (96.1)	-0.11 (0.66)	-3.0	-0.29	0.00	0.00	2.0	
	Week 39	Tezepelumab	73	66 (90.4)	-0.24 (0.59)	-2.2	-0.57	0.00	0.00	1.3	-0.24 [-0.57, 0.10]
		Placebo	76	72 (94.7)	-0.10 (0.56)	-2.0	-0.29	0.00	0.00	2.0	
	Week 40	Tezepelumab	73	66 (90.4)	-0.24 (0.57)	-2.1	-0.57	0.00	0.00	1.0	-0.22 [-0.56, 0.11]
		Placebo	76	72 (94.7)	-0.11 (0.60)	-2.0	-0.29	0.00	0.00	2.0	
	Week 41	Tezepelumab	73	64 (87.7)	-0.24 (0.59)	-2.1	-0.43	0.00	0.00	1.0	-0.09 [-0.43, 0.24]
		Placebo	76	73 (96.1)	-0.19 (0.62)	-2.7	-0.43	0.00	0.00	1.4	
	Week 42	Tezepelumab	73	65 (89.0)	-0.25 (0.56)	-2.0	-0.43	0.00	0.00	1.0	-0.14 [-0.47, 0.20]
		Placebo	76	72 (94.7)	-0.18 (0.58)	-2.6	-0.37	0.00	0.00	1.1	
	Week 43	Tezepelumab	73	64 (87.7)	-0.24 (0.63)	-2.2	-0.55	0.00	0.00	1.6	-0.16 [-0.50, 0.18]
		Placebo	76	73 (96.1)	-0.15 (0.59)	-2.3	-0.29	0.00	0.00	1.7	
	Week 44	Tezepelumab	73	65 (89.0)	-0.25 (0.55)	-1.9	-0.57	0.00	0.00	1.0	-0.17 [-0.50, 0.17]
		Placebo	76	73 (96.1)	-0.15 (0.62)	-2.3	-0.43	0.00	0.00	2.0	
	Week 45	Tezepelumab	73	64 (87.7)	-0.26 (0.61)	-2.1	-0.57	0.00	0.00	1.0	-0.11 [-0.44, 0.23]
		Placebo	76	72 (94.7)	-0.20 (0.64)	-3.0	-0.46	0.00	0.00	2.0	
	Week 46	Tezepelumab	73	65 (89.0)	-0.25 (0.59)	-2.2	-0.43	0.00	0.00	1.0	-0.06 [-0.40, 0.27]
		Placebo	76	71 (93.4)	-0.21 (0.64)	-2.4	-0.43	0.00	0.00	2.0	
	Week 47	Tezepelumab	73	65 (89.0)	-0.24 (0.58)	-2.0	-0.43	0.00	0.00	1.1	-0.08 [-0.42, 0.26]
		Placebo	76	71 (93.4)	-0.20 (0.61)	-2.3	-0.38	0.00	0.00	2.0	
	Week 48	Tezepelumab	73	58 (79.5)	-0.23 (0.60)	-2.0	-0.57	0.00	0.00	1.4	-0.09 [-0.44, 0.26]
		Placebo	76	70 (92.1)	-0.18 (0.59)	-2.1	-0.38	0.00	0.00	2.0	

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WAC\_ILMC0: Change from baseline in ASD weekly waking score - MMRM results  
 DITTTL

Change from baseline in ASD weekly waking score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 1	Tezepelumab	73	73 (100.0)	-0.11 (0.06)	(-0.22, -0.00)	-0.10 (0.08)	(-0.25, 0.06)	0.211
	Placebo	76	76 (100.0)	-0.01 (0.06)	(-0.12, 0.09)			
Week 2	Tezepelumab	73	73 (100.0)	-0.16 (0.06)	(-0.27, -0.05)	-0.15 (0.08)	(-0.30, 0.01)	0.064
	Placebo	76	75 (98.7)	-0.02 (0.06)	(-0.12, 0.09)			
Week 3	Tezepelumab	73	73 (100.0)	-0.15 (0.06)	(-0.26, -0.03)	-0.08 (0.08)	(-0.23, 0.08)	0.335
	Placebo	76	75 (98.7)	-0.07 (0.06)	(-0.18, 0.04)			
Week 4	Tezepelumab	73	71 (97.3)	-0.19 (0.06)	(-0.30, -0.08)	-0.11 (0.08)	(-0.26, 0.05)	0.183
	Placebo	76	76 (100.0)	-0.08 (0.06)	(-0.19, 0.02)			
Week 5	Tezepelumab	73	72 (98.6)	-0.20 (0.06)	(-0.31, -0.09)	-0.06 (0.08)	(-0.21, 0.10)	0.475
	Placebo	76	75 (98.7)	-0.14 (0.06)	(-0.25, -0.04)			
Week 6	Tezepelumab	73	71 (97.3)	-0.18 (0.06)	(-0.29, -0.07)	-0.08 (0.08)	(-0.24, 0.08)	0.314
	Placebo	76	73 (96.1)	-0.10 (0.06)	(-0.21, 0.00)			
Week 7	Tezepelumab	73	70 (95.9)	-0.14 (0.06)	(-0.26, -0.03)	-0.04 (0.08)	(-0.19, 0.12)	0.652
	Placebo	76	76 (100.0)	-0.11 (0.06)	(-0.22, -0.00)			
Week 8	Tezepelumab	73	71 (97.3)	-0.16 (0.06)	(-0.27, -0.05)	-0.07 (0.08)	(-0.23, 0.08)	0.352
	Placebo	76	76 (100.0)	-0.08 (0.06)	(-0.19, 0.02)			
Week 9	Tezepelumab	73	71 (97.3)	-0.17 (0.06)	(-0.28, -0.06)	-0.03 (0.08)	(-0.19, 0.13)	0.702
	Placebo	76	73 (96.1)	-0.14 (0.06)	(-0.25, -0.03)			
Week 10	Tezepelumab	73	70 (95.9)	-0.15 (0.06)	(-0.26, -0.03)	-0.04 (0.08)	(-0.19, 0.12)	0.652
	Placebo	76	74 (97.4)	-0.11 (0.06)	(-0.22, -0.00)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WAC\_ILMC0: Change from baseline in ASD weekly waking score - MMRM results  
 DITTTL

Change from baseline in ASD weekly waking score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 11	Tezepelumab	73	72 (98.6)	-0.16 (0.06)	(-0.27, -0.05)	-0.06 (0.08)	(-0.22, 0.09)	0.431
	Placebo	76	75 (98.7)	-0.10 (0.06)	(-0.21, 0.01)			
Week 12	Tezepelumab	73	70 (95.9)	-0.20 (0.06)	(-0.31, -0.09)	-0.05 (0.08)	(-0.20, 0.11)	0.569
	Placebo	76	75 (98.7)	-0.15 (0.06)	(-0.26, -0.05)			
Week 13	Tezepelumab	73	69 (94.5)	-0.21 (0.06)	(-0.32, -0.10)	-0.03 (0.08)	(-0.18, 0.13)	0.718
	Placebo	76	74 (97.4)	-0.18 (0.06)	(-0.29, -0.07)			
Week 14	Tezepelumab	73	70 (95.9)	-0.18 (0.06)	(-0.29, -0.07)	-0.01 (0.08)	(-0.17, 0.14)	0.888
	Placebo	76	75 (98.7)	-0.17 (0.06)	(-0.28, -0.06)			
Week 15	Tezepelumab	73	70 (95.9)	-0.16 (0.06)	(-0.27, -0.05)	0.04 (0.08)	(-0.12, 0.20)	0.621
	Placebo	76	72 (94.7)	-0.20 (0.06)	(-0.31, -0.09)			
Week 16	Tezepelumab	73	70 (95.9)	-0.18 (0.06)	(-0.29, -0.07)	-0.03 (0.08)	(-0.18, 0.13)	0.732
	Placebo	76	74 (97.4)	-0.15 (0.06)	(-0.26, -0.04)			
Week 17	Tezepelumab	73	70 (95.9)	-0.22 (0.06)	(-0.33, -0.11)	-0.05 (0.08)	(-0.21, 0.10)	0.504
	Placebo	76	74 (97.4)	-0.17 (0.06)	(-0.28, -0.06)			
Week 18	Tezepelumab	73	69 (94.5)	-0.19 (0.06)	(-0.30, -0.07)	0.01 (0.08)	(-0.15, 0.16)	0.932
	Placebo	76	74 (97.4)	-0.19 (0.06)	(-0.30, -0.08)			
Week 19	Tezepelumab	73	70 (95.9)	-0.20 (0.06)	(-0.31, -0.09)	-0.03 (0.08)	(-0.18, 0.13)	0.736
	Placebo	76	73 (96.1)	-0.17 (0.06)	(-0.28, -0.06)			
Week 20	Tezepelumab	73	70 (95.9)	-0.22 (0.06)	(-0.33, -0.10)	-0.04 (0.08)	(-0.20, 0.11)	0.579
	Placebo	76	75 (98.7)	-0.17 (0.06)	(-0.28, -0.06)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WAC\_ILMC0: Change from baseline in ASD weekly waking score - MMRM results  
 DITTTL

Change from baseline in ASD weekly waking score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 21	Tezepelumab	73	69 (94.5)	-0.19 (0.06)	(-0.31, -0.08)	-0.03 (0.08)	(-0.19, 0.13)	0.712
	Placebo	76	74 (97.4)	-0.16 (0.06)	(-0.27, -0.05)			
Week 22	Tezepelumab	73	70 (95.9)	-0.18 (0.06)	(-0.29, -0.07)	-0.10 (0.08)	(-0.26, 0.05)	0.193
	Placebo	76	75 (98.7)	-0.08 (0.06)	(-0.18, 0.03)			
Week 23	Tezepelumab	73	70 (95.9)	-0.22 (0.06)	(-0.33, -0.10)	-0.08 (0.08)	(-0.23, 0.08)	0.345
	Placebo	76	74 (97.4)	-0.14 (0.06)	(-0.25, -0.03)			
Week 24	Tezepelumab	73	70 (95.9)	-0.21 (0.06)	(-0.32, -0.09)	-0.06 (0.08)	(-0.22, 0.09)	0.422
	Placebo	76	75 (98.7)	-0.14 (0.06)	(-0.25, -0.03)			
Week 25	Tezepelumab	73	68 (93.2)	-0.19 (0.06)	(-0.30, -0.07)	-0.05 (0.08)	(-0.21, 0.10)	0.493
	Placebo	76	74 (97.4)	-0.13 (0.06)	(-0.24, -0.02)			
Week 26	Tezepelumab	73	69 (94.5)	-0.20 (0.06)	(-0.31, -0.09)	-0.09 (0.08)	(-0.25, 0.07)	0.265
	Placebo	76	73 (96.1)	-0.11 (0.06)	(-0.22, -0.00)			
Week 27	Tezepelumab	73	69 (94.5)	-0.19 (0.06)	(-0.30, -0.08)	-0.05 (0.08)	(-0.21, 0.11)	0.543
	Placebo	76	73 (96.1)	-0.14 (0.06)	(-0.25, -0.03)			
Week 28	Tezepelumab	73	67 (91.8)	-0.21 (0.06)	(-0.32, -0.09)	-0.10 (0.08)	(-0.26, 0.06)	0.225
	Placebo	76	74 (97.4)	-0.11 (0.06)	(-0.22, 0.00)			
Week 29	Tezepelumab	73	66 (90.4)	-0.21 (0.06)	(-0.33, -0.10)	-0.11 (0.08)	(-0.27, 0.05)	0.169
	Placebo	76	74 (97.4)	-0.10 (0.06)	(-0.21, 0.01)			
Week 30	Tezepelumab	73	68 (93.2)	-0.21 (0.06)	(-0.32, -0.10)	-0.09 (0.08)	(-0.25, 0.07)	0.265
	Placebo	76	74 (97.4)	-0.12 (0.06)	(-0.23, -0.01)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WAC\_ILMC0: Change from baseline in ASD weekly waking score - MMRM results  
 DITTTL

Change from baseline in ASD weekly waking score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Time	Treatment	N	n (%)						
Week 31	Tezepelumab	73	67 (91.8)	-0.18 (0.06)	(-0.30, -0.07)	-0.07 (0.08)	(-0.23, 0.08)	0.362	
	Placebo	76	73 (96.1)	-0.11 (0.06)	(-0.22, -0.00)				
Week 32	Tezepelumab	73	67 (91.8)	-0.20 (0.06)	(-0.32, -0.09)	-0.06 (0.08)	(-0.21, 0.10)	0.493	
	Placebo	76	74 (97.4)	-0.15 (0.06)	(-0.26, -0.04)				
Week 33	Tezepelumab	73	68 (93.2)	-0.23 (0.06)	(-0.35, -0.12)	-0.06 (0.08)	(-0.22, 0.10)	0.473	
	Placebo	76	74 (97.4)	-0.17 (0.06)	(-0.28, -0.07)				
Week 34	Tezepelumab	73	68 (93.2)	-0.23 (0.06)	(-0.35, -0.12)	-0.09 (0.08)	(-0.25, 0.07)	0.269	
	Placebo	76	73 (96.1)	-0.15 (0.06)	(-0.26, -0.04)				
Week 35	Tezepelumab	73	66 (90.4)	-0.22 (0.06)	(-0.33, -0.11)	-0.07 (0.08)	(-0.23, 0.09)	0.376	
	Placebo	76	74 (97.4)	-0.15 (0.06)	(-0.26, -0.04)				
Week 36	Tezepelumab	73	69 (94.5)	-0.21 (0.06)	(-0.32, -0.09)	-0.06 (0.08)	(-0.22, 0.10)	0.449	
	Placebo	76	73 (96.1)	-0.14 (0.06)	(-0.25, -0.03)				
Week 37	Tezepelumab	73	68 (93.2)	-0.22 (0.06)	(-0.33, -0.10)	-0.06 (0.08)	(-0.22, 0.09)	0.430	
	Placebo	76	72 (94.7)	-0.15 (0.06)	(-0.26, -0.04)				
Week 38	Tezepelumab	73	67 (91.8)	-0.24 (0.06)	(-0.35, -0.12)	-0.13 (0.08)	(-0.28, 0.03)	0.120	
	Placebo	76	73 (96.1)	-0.11 (0.06)	(-0.22, -0.00)				
Week 39	Tezepelumab	73	66 (90.4)	-0.22 (0.06)	(-0.34, -0.11)	-0.08 (0.08)	(-0.24, 0.07)	0.299	
	Placebo	76	72 (94.7)	-0.14 (0.06)	(-0.25, -0.03)				
Week 40	Tezepelumab	73	66 (90.4)	-0.23 (0.06)	(-0.34, -0.11)	-0.11 (0.08)	(-0.27, 0.05)	0.165	
	Placebo	76	72 (94.7)	-0.12 (0.06)	(-0.23, -0.01)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WAC\_ILMC0: Change from baseline in ASD weekly waking score - MMRM results  
 DITTTL

Change from baseline in ASD weekly waking score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 41	Tezepelumab	73	64 (87.7)	-0.23 (0.06)	(-0.35, -0.12)	-0.04 (0.08)	(-0.20, 0.12)	0.622
	Placebo	76	73 (96.1)	-0.19 (0.06)	(-0.30, -0.08)			
Week 42	Tezepelumab	73	65 (89.0)	-0.24 (0.06)	(-0.35, -0.12)	-0.06 (0.08)	(-0.22, 0.10)	0.461
	Placebo	76	72 (94.7)	-0.18 (0.06)	(-0.29, -0.07)			
Week 43	Tezepelumab	73	64 (87.7)	-0.23 (0.06)	(-0.35, -0.11)	-0.08 (0.08)	(-0.24, 0.08)	0.326
	Placebo	76	73 (96.1)	-0.15 (0.06)	(-0.26, -0.04)			
Week 44	Tezepelumab	73	65 (89.0)	-0.24 (0.06)	(-0.36, -0.13)	-0.09 (0.08)	(-0.25, 0.07)	0.288
	Placebo	76	73 (96.1)	-0.16 (0.06)	(-0.27, -0.05)			
Week 45	Tezepelumab	73	64 (87.7)	-0.26 (0.06)	(-0.37, -0.14)	-0.06 (0.08)	(-0.22, 0.10)	0.470
	Placebo	76	72 (94.7)	-0.20 (0.06)	(-0.31, -0.09)			
Week 46	Tezepelumab	73	65 (89.0)	-0.25 (0.06)	(-0.36, -0.13)	-0.05 (0.08)	(-0.21, 0.11)	0.534
	Placebo	76	71 (93.4)	-0.20 (0.06)	(-0.31, -0.09)			
Week 47	Tezepelumab	73	65 (89.0)	-0.23 (0.06)	(-0.35, -0.12)	-0.04 (0.08)	(-0.20, 0.12)	0.609
	Placebo	76	71 (93.4)	-0.19 (0.06)	(-0.30, -0.08)			
Week 48	Tezepelumab	73	58 (79.5)	-0.24 (0.06)	(-0.35, -0.12)	-0.07 (0.08)	(-0.23, 0.10)	0.420
	Placebo	76	70 (92.1)	-0.17 (0.06)	(-0.28, -0.06)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WLC\_ILMH0: Course of ASD weekly limiting activity score  
 DITTTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly limiting activity score	Baseline	Tezepelumab	395	395 (100.0)	1.62 (0.85)	0.0	1.00	1.50	2.14	4.0	
		Placebo	391	391 (100.0)	1.58 (0.84)	0.0	1.00	1.43	2.00	4.0	
	Week 1	Tezepelumab	395	388 (98.2)	1.39 (0.78)	0.0	1.00	1.24	2.00	3.9	
		Placebo	391	385 (98.5)	1.46 (0.83)	0.0	1.00	1.43	2.00	4.0	
	Week 2	Tezepelumab	395	387 (98.0)	1.25 (0.81)	0.0	0.86	1.00	1.86	3.4	
		Placebo	391	385 (98.5)	1.36 (0.81)	0.0	0.86	1.17	2.00	4.0	
	Week 3	Tezepelumab	395	385 (97.5)	1.20 (0.81)	0.0	0.71	1.00	1.71	3.3	
		Placebo	391	377 (96.4)	1.24 (0.81)	0.0	0.71	1.14	1.86	4.0	
	Week 4	Tezepelumab	395	382 (96.7)	1.16 (0.82)	0.0	0.57	1.00	1.71	3.6	
		Placebo	391	382 (97.7)	1.20 (0.79)	0.0	0.71	1.14	1.86	4.0	
	Week 5	Tezepelumab	395	385 (97.5)	1.12 (0.80)	0.0	0.57	1.00	1.57	3.7	
		Placebo	391	373 (95.4)	1.16 (0.78)	0.0	0.57	1.00	1.83	4.0	
	Week 6	Tezepelumab	395	378 (95.7)	1.09 (0.82)	0.0	0.50	1.00	1.71	4.0	
		Placebo	391	378 (96.7)	1.16 (0.82)	0.0	0.57	1.00	1.86	4.0	
	Week 7	Tezepelumab	395	381 (96.5)	1.08 (0.85)	0.0	0.29	1.00	1.71	4.0	
		Placebo	391	376 (96.2)	1.14 (0.82)	0.0	0.46	1.00	1.71	4.0	
	Week 8	Tezepelumab	395	380 (96.2)	1.05 (0.82)	0.0	0.31	1.00	1.71	4.0	
		Placebo	391	372 (95.1)	1.12 (0.83)	0.0	0.50	1.00	1.77	4.0	
	Week 9	Tezepelumab	395	381 (96.5)	1.00 (0.80)	0.0	0.29	1.00	1.50	4.0	
		Placebo	391	370 (94.6)	1.09 (0.80)	0.0	0.43	1.00	1.67	4.0	
	Week 10	Tezepelumab	395	385 (97.5)	0.98 (0.80)	0.0	0.14	1.00	1.43	4.0	
		Placebo	391	365 (93.4)	1.07 (0.80)	0.0	0.40	1.00	1.60	4.0	
	Week 11	Tezepelumab	395	375 (94.9)	0.98 (0.82)	0.0	0.14	1.00	1.43	4.0	
		Placebo	391	365 (93.4)	1.07 (0.82)	0.0	0.29	1.00	1.71	4.0	
	Week 12	Tezepelumab	395	377 (95.4)	1.00 (0.82)	0.0	0.20	1.00	1.40	4.0	
		Placebo	391	362 (92.6)	1.05 (0.84)	0.0	0.25	1.00	1.71	4.0	
	Week 13	Tezepelumab	395	369 (93.4)	0.98 (0.82)	0.0	0.17	1.00	1.43	3.9	
		Placebo	391	357 (91.3)	1.05 (0.83)	0.0	0.29	1.00	1.60	4.0	
	Week 14	Tezepelumab	395	366 (92.7)	0.95 (0.81)	0.0	0.14	1.00	1.40	4.0	
		Placebo	391	364 (93.1)	1.05 (0.82)	0.0	0.24	1.00	1.59	4.0	
	Week 15	Tezepelumab	395	370 (93.7)	0.94 (0.80)	0.0	0.00	1.00	1.43	3.9	
		Placebo	391	354 (90.5)	1.05 (0.86)	0.0	0.17	1.00	1.67	4.0	
	Week 16	Tezepelumab	395	365 (92.4)	0.93 (0.80)	0.0	0.14	1.00	1.29	4.0	
		Placebo	391	355 (90.8)	1.06 (0.87)	0.0	0.17	1.00	1.83	4.0	
Week 17	Tezepelumab	395	366 (92.7)	0.87 (0.80)	0.0	0.00	1.00	1.20	4.0		
	Placebo	391	351 (89.8)	1.01 (0.85)	0.0	0.14	1.00	1.67	4.0		

Note: DITTTL = Dossier Label Intent-to-Treat Set.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022

Table NT1WLC\_ILMH0: Course of ASD weekly limiting activity score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly limiting activity score	Week 18	Tezepelumab	395	365 (92.4)	0.90 (0.80)	0.0	0.00	1.00	1.25	4.0	
		Placebo	391	351 (89.8)	1.00 (0.85)	0.0	0.14	1.00	1.57	4.0	
	Week 19	Tezepelumab	395	356 (90.1)	0.90 (0.83)	0.0	0.00	1.00	1.29	4.0	
		Placebo	391	350 (89.5)	1.03 (0.86)	0.0	0.14	1.00	1.71	4.0	
	Week 20	Tezepelumab	395	354 (89.6)	0.90 (0.83)	0.0	0.00	1.00	1.17	4.0	
		Placebo	391	346 (88.5)	1.02 (0.86)	0.0	0.14	1.00	1.71	4.0	
	Week 21	Tezepelumab	395	357 (90.4)	0.88 (0.83)	0.0	0.00	1.00	1.25	4.0	
		Placebo	391	341 (87.2)	0.99 (0.88)	0.0	0.00	1.00	1.71	4.0	
	Week 22	Tezepelumab	395	353 (89.4)	0.91 (0.84)	0.0	0.00	1.00	1.29	4.0	
		Placebo	391	338 (86.4)	0.98 (0.86)	0.0	0.14	1.00	1.57	4.0	
	Week 23	Tezepelumab	395	356 (90.1)	0.89 (0.83)	0.0	0.00	1.00	1.31	4.0	
		Placebo	391	339 (86.7)	0.98 (0.86)	0.0	0.00	1.00	1.50	4.0	
	Week 24	Tezepelumab	395	356 (90.1)	0.91 (0.84)	0.0	0.00	1.00	1.29	4.0	
		Placebo	391	336 (85.9)	0.97 (0.87)	0.0	0.00	1.00	1.66	4.0	
	Week 25	Tezepelumab	395	351 (88.9)	0.90 (0.81)	0.0	0.00	1.00	1.33	4.0	
		Placebo	391	328 (83.9)	0.98 (0.87)	0.0	0.00	1.00	1.59	4.0	
	Week 26	Tezepelumab	395	348 (88.1)	0.90 (0.83)	0.0	0.00	1.00	1.27	4.0	
		Placebo	391	329 (84.1)	0.98 (0.89)	0.0	0.00	1.00	1.71	4.0	
	Week 27	Tezepelumab	395	347 (87.8)	0.88 (0.81)	0.0	0.00	1.00	1.17	4.0	
		Placebo	391	334 (85.4)	0.98 (0.91)	0.0	0.00	1.00	1.57	4.0	
	Week 28	Tezepelumab	395	349 (88.4)	0.87 (0.84)	0.0	0.00	1.00	1.17	4.0	
		Placebo	391	339 (86.7)	0.99 (0.89)	0.0	0.00	1.00	1.71	4.0	
	Week 29	Tezepelumab	395	348 (88.1)	0.85 (0.81)	0.0	0.00	1.00	1.14	4.0	
		Placebo	391	330 (84.4)	0.99 (0.89)	0.0	0.00	1.00	1.80	4.0	
	Week 30	Tezepelumab	395	344 (87.1)	0.89 (0.80)	0.0	0.00	1.00	1.27	4.0	
		Placebo	391	321 (82.1)	0.99 (0.88)	0.0	0.00	1.00	1.75	4.0	
	Week 31	Tezepelumab	395	354 (89.6)	0.88 (0.83)	0.0	0.00	1.00	1.29	4.0	
		Placebo	391	333 (85.2)	0.98 (0.85)	0.0	0.00	1.00	1.60	4.0	
	Week 32	Tezepelumab	395	345 (87.3)	0.89 (0.81)	0.0	0.00	1.00	1.29	3.9	
		Placebo	391	328 (83.9)	1.00 (0.87)	0.0	0.00	1.00	1.71	4.0	
	Week 33	Tezepelumab	395	342 (86.6)	0.86 (0.81)	0.0	0.00	1.00	1.20	4.0	
		Placebo	391	330 (84.4)	0.98 (0.87)	0.0	0.00	1.00	1.60	4.0	
	Week 34	Tezepelumab	395	347 (87.8)	0.84 (0.84)	0.0	0.00	1.00	1.17	4.0	
		Placebo	391	328 (83.9)	0.95 (0.87)	0.0	0.00	1.00	1.57	4.0	
	Week 35	Tezepelumab	395	342 (86.6)	0.86 (0.83)	0.0	0.00	1.00	1.20	4.0	
		Placebo	391	320 (81.8)	0.96 (0.85)	0.0	0.00	1.00	1.50	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table NT1WLC\_ILMH0: Course of ASD weekly limiting activity score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly limiting activity score	Week 36	Tezepelumab	395	345 (87.3)	0.87 (0.84)	0.0	0.00	1.00	1.20	4.0	
		Placebo	391	317 (81.1)	0.96 (0.83)	0.0	0.00	1.00	1.43	4.0	
	Week 37	Tezepelumab	395	338 (85.6)	0.87 (0.83)	0.0	0.00	1.00	1.14	4.0	
		Placebo	391	328 (83.9)	0.95 (0.84)	0.0	0.00	1.00	1.43	4.0	
	Week 38	Tezepelumab	395	343 (86.8)	0.86 (0.85)	0.0	0.00	1.00	1.20	4.0	
		Placebo	391	323 (82.6)	0.94 (0.85)	0.0	0.00	1.00	1.40	4.0	
	Week 39	Tezepelumab	395	345 (87.3)	0.88 (0.87)	0.0	0.00	1.00	1.20	4.0	
		Placebo	391	318 (81.3)	0.96 (0.85)	0.0	0.00	1.00	1.67	3.9	
	Week 40	Tezepelumab	395	344 (87.1)	0.86 (0.84)	0.0	0.00	1.00	1.17	3.9	
		Placebo	391	322 (82.4)	0.95 (0.86)	0.0	0.00	1.00	1.71	4.0	
	Week 41	Tezepelumab	395	342 (86.6)	0.84 (0.81)	0.0	0.00	1.00	1.14	3.0	
		Placebo	391	322 (82.4)	0.97 (0.87)	0.0	0.00	1.00	1.60	4.0	
	Week 42	Tezepelumab	395	340 (86.1)	0.84 (0.83)	0.0	0.00	1.00	1.20	3.0	
		Placebo	391	323 (82.6)	0.95 (0.88)	0.0	0.00	1.00	1.57	4.0	
	Week 43	Tezepelumab	395	342 (86.6)	0.85 (0.83)	0.0	0.00	1.00	1.14	3.8	
		Placebo	391	323 (82.6)	0.94 (0.87)	0.0	0.00	1.00	1.57	4.0	
	Week 44	Tezepelumab	395	339 (85.8)	0.85 (0.82)	0.0	0.00	1.00	1.14	3.8	
		Placebo	391	325 (83.1)	0.96 (0.86)	0.0	0.00	1.00	1.67	4.0	
	Week 45	Tezepelumab	395	341 (86.3)	0.84 (0.82)	0.0	0.00	1.00	1.14	3.3	
		Placebo	391	322 (82.4)	0.94 (0.86)	0.0	0.00	1.00	1.50	4.0	
	Week 46	Tezepelumab	395	339 (85.8)	0.84 (0.82)	0.0	0.00	1.00	1.29	3.4	
		Placebo	391	314 (80.3)	0.93 (0.85)	0.0	0.00	1.00	1.50	4.0	
	Week 47	Tezepelumab	395	337 (85.3)	0.85 (0.83)	0.0	0.00	1.00	1.14	3.0	
		Placebo	391	312 (79.8)	0.91 (0.82)	0.0	0.00	1.00	1.43	4.0	
	Week 48	Tezepelumab	395	339 (85.8)	0.85 (0.83)	0.0	0.00	1.00	1.29	4.0	
		Placebo	391	316 (80.8)	0.91 (0.82)	0.0	0.00	1.00	1.40	4.0	
	Week 49	Tezepelumab	395	336 (85.1)	0.85 (0.85)	0.0	0.00	1.00	1.15	3.4	
		Placebo	391	315 (80.6)	0.92 (0.82)	0.0	0.00	1.00	1.29	4.0	
	Week 50	Tezepelumab	395	336 (85.1)	0.84 (0.82)	0.0	0.00	1.00	1.18	3.0	
		Placebo	391	313 (80.1)	0.93 (0.84)	0.0	0.00	1.00	1.40	4.0	
	Week 51	Tezepelumab	395	330 (83.5)	0.84 (0.84)	0.0	0.00	1.00	1.25	3.0	
		Placebo	391	306 (78.3)	0.92 (0.85)	0.0	0.00	1.00	1.43	4.0	
	Week 52	Tezepelumab	395	303 (76.7)	0.87 (0.85)	0.0	0.00	1.00	1.17	3.2	
		Placebo	391	286 (73.1)	0.92 (0.87)	0.0	0.00	1.00	1.57	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WLC\_ILMH0: Course of ASD weekly limiting activity score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly limiting activity score	Week 1	Tezepelumab	395	388 (98.2)	-0.21 (0.46)	-1.8	-0.43	-0.14	0.00	1.1	-0.20 [-0.34, -0.06]
		Placebo	391	385 (98.5)	-0.12 (0.47)	-2.7	-0.31	0.00	0.14	1.4	
	Week 2	Tezepelumab	395	387 (98.0)	-0.36 (0.62)	-3.1	-0.71	-0.14	0.00	1.2	-0.24 [-0.38, -0.09]
		Placebo	391	385 (98.5)	-0.21 (0.64)	-3.0	-0.43	-0.09	0.10	1.6	
	Week 3	Tezepelumab	395	385 (97.5)	-0.41 (0.68)	-3.9	-0.71	-0.29	0.00	1.3	-0.11 [-0.25, 0.04]
		Placebo	391	377 (96.4)	-0.34 (0.67)	-3.0	-0.71	-0.21	0.00	1.7	
	Week 4	Tezepelumab	395	382 (96.7)	-0.44 (0.71)	-3.9	-0.86	-0.25	0.00	1.1	-0.09 [-0.23, 0.05]
		Placebo	391	382 (97.7)	-0.38 (0.72)	-3.1	-0.71	-0.29	0.00	2.3	
	Week 5	Tezepelumab	395	385 (97.5)	-0.49 (0.73)	-4.0	-0.86	-0.33	0.00	1.0	-0.10 [-0.24, 0.04]
		Placebo	391	373 (95.4)	-0.42 (0.72)	-3.9	-0.83	-0.29	0.00	2.0	
	Week 6	Tezepelumab	395	378 (95.7)	-0.52 (0.78)	-4.0	-1.00	-0.32	0.00	1.1	-0.13 [-0.28, 0.01]
		Placebo	391	378 (96.7)	-0.42 (0.77)	-3.5	-0.86	-0.29	0.00	2.0	
	Week 7	Tezepelumab	395	381 (96.5)	-0.54 (0.83)	-4.0	-1.00	-0.43	0.00	2.1	-0.11 [-0.25, 0.04]
		Placebo	391	376 (96.2)	-0.45 (0.81)	-3.8	-0.86	-0.29	0.00	1.9	
	Week 8	Tezepelumab	395	380 (96.2)	-0.56 (0.82)	-4.0	-1.00	-0.36	0.00	1.5	-0.13 [-0.27, 0.01]
		Placebo	391	372 (95.1)	-0.46 (0.79)	-4.0	-0.91	-0.29	0.00	1.9	
	Week 9	Tezepelumab	395	381 (96.5)	-0.60 (0.85)	-4.0	-1.00	-0.43	0.00	1.4	-0.13 [-0.27, 0.02]
		Placebo	391	370 (94.6)	-0.50 (0.78)	-4.0	-1.00	-0.40	0.00	1.9	
	Week 10	Tezepelumab	395	385 (97.5)	-0.62 (0.85)	-4.0	-1.02	-0.43	0.00	1.5	-0.16 [-0.30, -0.02]
		Placebo	391	365 (93.4)	-0.50 (0.78)	-4.0	-1.00	-0.33	0.00	1.9	
	Week 11	Tezepelumab	395	375 (94.9)	-0.61 (0.84)	-4.0	-1.00	-0.43	0.00	1.9	-0.14 [-0.28, 0.01]
		Placebo	391	365 (93.4)	-0.50 (0.80)	-4.0	-1.00	-0.38	0.00	1.9	
	Week 12	Tezepelumab	395	377 (95.4)	-0.60 (0.85)	-4.0	-1.00	-0.43	0.00	1.9	-0.09 [-0.24, 0.05]
		Placebo	391	362 (92.6)	-0.52 (0.82)	-4.0	-1.00	-0.43	0.00	2.3	
	Week 13	Tezepelumab	395	369 (93.4)	-0.62 (0.87)	-4.0	-1.06	-0.43	0.00	1.9	-0.09 [-0.23, 0.06]
		Placebo	391	357 (91.3)	-0.54 (0.83)	-4.0	-1.00	-0.43	0.00	2.4	
	Week 14	Tezepelumab	395	366 (92.7)	-0.66 (0.86)	-4.0	-1.14	-0.50	0.00	1.4	-0.17 [-0.32, -0.03]
		Placebo	391	364 (93.1)	-0.51 (0.82)	-4.0	-1.00	-0.43	0.00	2.3	
	Week 15	Tezepelumab	395	370 (93.7)	-0.66 (0.85)	-4.0	-1.14	-0.45	0.00	1.9	-0.16 [-0.31, -0.02]
		Placebo	391	354 (90.5)	-0.52 (0.84)	-4.0	-1.00	-0.43	0.00	2.3	
	Week 16	Tezepelumab	395	365 (92.4)	-0.68 (0.86)	-4.0	-1.14	-0.57	0.00	2.3	-0.18 [-0.33, -0.03]
		Placebo	391	355 (90.8)	-0.53 (0.85)	-4.0	-1.00	-0.43	0.00	2.2	
	Week 17	Tezepelumab	395	366 (92.7)	-0.73 (0.88)	-4.0	-1.25	-0.57	0.00	1.6	-0.19 [-0.33, -0.04]
		Placebo	391	351 (89.8)	-0.56 (0.83)	-4.0	-1.00	-0.43	0.00	2.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WLC\_ILMH0: Course of ASD weekly limiting activity score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly limiting activity score	Week 18	Tezepelumab	395	365 (92.4)	-0.70 (0.90)	-4.0	-1.14	-0.57	0.00	1.7	-0.15 [-0.29, 0.00]
		Placebo	391	351 (89.8)	-0.57 (0.86)	-4.0	-1.00	-0.50	0.00	2.0	
	Week 19	Tezepelumab	395	356 (90.1)	-0.70 (0.91)	-4.0	-1.14	-0.57	0.00	2.5	-0.17 [-0.32, -0.02]
		Placebo	391	350 (89.5)	-0.55 (0.87)	-4.0	-1.00	-0.43	0.00	2.0	
	Week 20	Tezepelumab	395	354 (89.6)	-0.70 (0.89)	-4.0	-1.14	-0.57	0.00	1.4	-0.16 [-0.31, -0.01]
		Placebo	391	346 (88.5)	-0.55 (0.89)	-4.0	-1.00	-0.43	0.00	2.0	
	Week 21	Tezepelumab	395	357 (90.4)	-0.72 (0.90)	-4.0	-1.17	-0.57	0.00	2.4	-0.14 [-0.29, 0.01]
		Placebo	391	341 (87.2)	-0.59 (0.88)	-4.0	-1.00	-0.50	0.00	2.0	
	Week 22	Tezepelumab	395	353 (89.4)	-0.67 (0.88)	-4.0	-1.14	-0.57	0.00	1.9	-0.10 [-0.25, 0.05]
		Placebo	391	338 (86.4)	-0.59 (0.87)	-4.0	-1.00	-0.46	0.00	2.0	
	Week 23	Tezepelumab	395	356 (90.1)	-0.69 (0.88)	-4.0	-1.14	-0.57	0.00	1.9	-0.11 [-0.26, 0.04]
		Placebo	391	339 (86.7)	-0.60 (0.89)	-4.0	-1.00	-0.50	0.00	2.0	
	Week 24	Tezepelumab	395	356 (90.1)	-0.68 (0.89)	-4.0	-1.14	-0.57	0.00	2.9	-0.09 [-0.24, 0.06]
		Placebo	391	336 (85.9)	-0.60 (0.89)	-4.0	-1.00	-0.50	0.00	2.0	
	Week 25	Tezepelumab	395	351 (88.9)	-0.69 (0.86)	-4.0	-1.14	-0.57	0.00	2.1	-0.13 [-0.28, 0.02]
		Placebo	391	328 (83.9)	-0.58 (0.90)	-4.0	-1.00	-0.56	0.00	2.6	
	Week 26	Tezepelumab	395	348 (88.1)	-0.69 (0.87)	-4.0	-1.14	-0.57	0.00	2.1	-0.11 [-0.26, 0.04]
		Placebo	391	329 (84.1)	-0.59 (0.93)	-4.0	-1.00	-0.43	0.00	2.0	
	Week 27	Tezepelumab	395	347 (87.8)	-0.71 (0.88)	-4.0	-1.14	-0.63	0.00	2.0	-0.15 [-0.30, -0.00]
		Placebo	391	334 (85.4)	-0.58 (0.92)	-4.0	-1.14	-0.43	0.00	2.0	
	Week 28	Tezepelumab	395	349 (88.4)	-0.72 (0.89)	-4.0	-1.26	-0.57	0.00	1.7	-0.17 [-0.32, -0.02]
		Placebo	391	339 (86.7)	-0.57 (0.88)	-4.0	-1.00	-0.43	0.00	2.0	
	Week 29	Tezepelumab	395	348 (88.1)	-0.74 (0.89)	-4.0	-1.15	-0.67	-0.13	1.6	-0.19 [-0.34, -0.04]
		Placebo	391	330 (84.4)	-0.57 (0.90)	-4.0	-1.00	-0.46	0.00	2.0	
	Week 30	Tezepelumab	395	344 (87.1)	-0.70 (0.85)	-4.0	-1.14	-0.57	0.00	2.4	-0.14 [-0.29, 0.01]
		Placebo	391	321 (82.1)	-0.57 (0.92)	-4.0	-1.00	-0.43	0.00	2.0	
	Week 31	Tezepelumab	395	354 (89.6)	-0.72 (0.90)	-4.0	-1.14	-0.66	0.00	2.7	-0.14 [-0.29, 0.01]
		Placebo	391	333 (85.2)	-0.59 (0.90)	-4.0	-1.00	-0.43	0.00	2.0	
	Week 32	Tezepelumab	395	345 (87.3)	-0.70 (0.86)	-4.0	-1.14	-0.57	0.00	2.9	-0.14 [-0.29, 0.01]
		Placebo	391	328 (83.9)	-0.58 (0.92)	-4.0	-1.00	-0.43	0.00	2.0	
	Week 33	Tezepelumab	395	342 (86.6)	-0.73 (0.90)	-4.0	-1.26	-0.71	0.00	2.9	-0.15 [-0.31, -0.00]
		Placebo	391	330 (84.4)	-0.59 (0.91)	-4.0	-1.00	-0.43	0.00	2.0	
	Week 34	Tezepelumab	395	347 (87.8)	-0.74 (0.89)	-4.0	-1.17	-0.67	0.00	2.7	-0.14 [-0.29, 0.01]
		Placebo	391	328 (83.9)	-0.61 (0.93)	-4.0	-1.10	-0.43	0.00	2.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WLC\_ILMH0: Course of ASD weekly limiting activity score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly limiting activity score	Week 35	Tezepelumab	395	342 (86.6)	-0.72 (0.88)	-4.0	-1.14	-0.67	0.00	1.9	-0.15 [-0.30, 0.00]
		Placebo	391	320 (81.8)	-0.58 (0.91)	-4.0	-1.06	-0.43	0.00	2.0	
	Week 36	Tezepelumab	395	345 (87.3)	-0.73 (0.90)	-4.0	-1.14	-0.60	0.00	1.9	-0.15 [-0.30, 0.00]
		Placebo	391	317 (81.1)	-0.60 (0.88)	-4.0	-1.07	-0.43	0.00	2.0	
	Week 37	Tezepelumab	395	338 (85.6)	-0.72 (0.89)	-4.0	-1.14	-0.69	0.00	1.7	-0.12 [-0.28, 0.03]
		Placebo	391	328 (83.9)	-0.61 (0.89)	-4.0	-1.00	-0.43	0.00	2.0	
	Week 38	Tezepelumab	395	343 (86.8)	-0.74 (0.91)	-4.0	-1.29	-0.64	0.00	1.9	-0.13 [-0.29, 0.02]
		Placebo	391	323 (82.6)	-0.62 (0.88)	-4.0	-1.14	-0.57	0.00	2.0	
	Week 39	Tezepelumab	395	345 (87.3)	-0.72 (0.92)	-4.0	-1.29	-0.57	0.00	2.1	-0.12 [-0.27, 0.03]
		Placebo	391	318 (81.3)	-0.61 (0.90)	-4.0	-1.07	-0.50	0.00	2.0	
	Week 40	Tezepelumab	395	344 (87.1)	-0.74 (0.90)	-4.0	-1.24	-0.66	0.00	1.9	-0.15 [-0.31, -0.00]
		Placebo	391	322 (82.4)	-0.60 (0.89)	-4.0	-1.10	-0.43	0.00	2.0	
	Week 41	Tezepelumab	395	342 (86.6)	-0.75 (0.89)	-4.0	-1.29	-0.62	-0.10	1.9	-0.17 [-0.32, -0.02]
		Placebo	391	322 (82.4)	-0.60 (0.89)	-4.0	-1.07	-0.43	0.00	2.1	
	Week 42	Tezepelumab	395	340 (86.1)	-0.76 (0.90)	-4.0	-1.29	-0.57	-0.12	1.9	-0.17 [-0.33, -0.02]
		Placebo	391	323 (82.6)	-0.60 (0.88)	-4.0	-1.14	-0.48	0.00	2.0	
	Week 43	Tezepelumab	395	342 (86.6)	-0.74 (0.90)	-4.0	-1.26	-0.58	-0.06	2.3	-0.12 [-0.27, 0.03]
		Placebo	391	323 (82.6)	-0.63 (0.92)	-4.0	-1.14	-0.54	0.00	2.0	
	Week 44	Tezepelumab	395	339 (85.8)	-0.75 (0.88)	-4.0	-1.29	-0.67	-0.14	1.9	-0.16 [-0.32, -0.01]
		Placebo	391	325 (83.1)	-0.60 (0.91)	-4.0	-1.12	-0.43	0.00	2.0	
	Week 45	Tezepelumab	395	341 (86.3)	-0.77 (0.87)	-4.0	-1.29	-0.71	-0.14	2.0	-0.14 [-0.30, 0.01]
		Placebo	391	322 (82.4)	-0.65 (0.91)	-4.0	-1.14	-0.57	0.00	2.0	
	Week 46	Tezepelumab	395	339 (85.8)	-0.77 (0.89)	-4.0	-1.29	-0.66	-0.14	1.9	-0.14 [-0.30, 0.01]
		Placebo	391	314 (80.3)	-0.64 (0.91)	-4.0	-1.14	-0.50	0.00	2.0	
	Week 47	Tezepelumab	395	337 (85.3)	-0.75 (0.89)	-4.0	-1.29	-0.57	-0.05	1.9	-0.10 [-0.26, 0.05]
		Placebo	391	312 (79.8)	-0.66 (0.88)	-4.0	-1.14	-0.48	0.00	2.0	
	Week 48	Tezepelumab	395	339 (85.8)	-0.75 (0.88)	-4.0	-1.29	-0.67	0.00	1.9	-0.09 [-0.24, 0.07]
		Placebo	391	316 (80.8)	-0.67 (0.87)	-4.0	-1.14	-0.57	0.00	2.0	
	Week 49	Tezepelumab	395	336 (85.1)	-0.75 (0.89)	-4.0	-1.29	-0.65	0.00	1.9	-0.13 [-0.28, 0.03]
		Placebo	391	315 (80.6)	-0.64 (0.88)	-4.0	-1.07	-0.50	0.00	2.0	
	Week 50	Tezepelumab	395	336 (85.1)	-0.77 (0.89)	-4.0	-1.29	-0.65	0.00	1.9	-0.13 [-0.28, 0.02]
		Placebo	391	313 (80.1)	-0.65 (0.90)	-4.0	-1.14	-0.50	0.00	2.0	
	Week 51	Tezepelumab	395	330 (83.5)	-0.74 (0.90)	-4.0	-1.19	-0.67	0.00	1.9	-0.11 [-0.27, 0.04]
		Placebo	391	306 (78.3)	-0.64 (0.89)	-4.0	-1.14	-0.57	0.00	2.2	
	Week 52	Tezepelumab	395	303 (76.7)	-0.75 (0.94)	-4.0	-1.29	-0.71	0.00	2.1	-0.13 [-0.29, 0.03]
		Placebo	391	286 (73.1)	-0.63 (0.86)	-4.0	-1.14	-0.55	0.00	1.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WLC\_ILMC0: Change from baseline in ASD weekly limiting activity score - MMRM results  
 DITTTL

Change from baseline in ASD weekly limiting activity score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 1	Tezepelumab	395	388 (98.2)	-0.20 (0.04)	(-0.27, -0.13)	-0.08 (0.05)	(-0.18, 0.02)	0.118	
	Placebo	391	385 (98.5)	-0.12 (0.04)	(-0.19, -0.05)				
Week 2	Tezepelumab	395	387 (98.0)	-0.35 (0.04)	(-0.43, -0.28)	-0.14 (0.05)	(-0.24, -0.04)	0.007 *	
	Placebo	391	385 (98.5)	-0.22 (0.04)	(-0.29, -0.14)				
Week 3	Tezepelumab	395	385 (97.5)	-0.41 (0.04)	(-0.48, -0.33)	-0.07 (0.05)	(-0.17, 0.03)	0.165	
	Placebo	391	377 (96.4)	-0.33 (0.04)	(-0.41, -0.26)				
Week 4	Tezepelumab	395	382 (96.7)	-0.44 (0.04)	(-0.51, -0.36)	-0.06 (0.05)	(-0.16, 0.04)	0.233	
	Placebo	391	382 (97.7)	-0.37 (0.04)	(-0.45, -0.30)				
Week 5	Tezepelumab	395	385 (97.5)	-0.48 (0.04)	(-0.55, -0.41)	-0.06 (0.05)	(-0.16, 0.05)	0.287	
	Placebo	391	373 (95.4)	-0.43 (0.04)	(-0.50, -0.35)				
Week 6	Tezepelumab	395	378 (95.7)	-0.51 (0.04)	(-0.58, -0.44)	-0.10 (0.05)	(-0.20, 0.00)	0.052	
	Placebo	391	378 (96.7)	-0.41 (0.04)	(-0.48, -0.34)				
Week 7	Tezepelumab	395	381 (96.5)	-0.52 (0.04)	(-0.59, -0.45)	-0.08 (0.05)	(-0.19, 0.02)	0.108	
	Placebo	391	376 (96.2)	-0.44 (0.04)	(-0.51, -0.37)				
Week 8	Tezepelumab	395	380 (96.2)	-0.55 (0.04)	(-0.62, -0.48)	-0.11 (0.05)	(-0.21, -0.01)	0.038 *	
	Placebo	391	372 (95.1)	-0.45 (0.04)	(-0.52, -0.37)				
Week 9	Tezepelumab	395	381 (96.5)	-0.61 (0.04)	(-0.68, -0.53)	-0.12 (0.05)	(-0.22, -0.02)	0.024 *	
	Placebo	391	370 (94.6)	-0.49 (0.04)	(-0.56, -0.42)				
Week 10	Tezepelumab	395	385 (97.5)	-0.61 (0.04)	(-0.69, -0.54)	-0.12 (0.05)	(-0.23, -0.02)	0.017 *	
	Placebo	391	365 (93.4)	-0.49 (0.04)	(-0.56, -0.42)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WLC\_ILMC0: Change from baseline in ASD weekly limiting activity score - MMRM results  
 DITTTL

Change from baseline in ASD weekly limiting activity score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 11	Tezepelumab	395	375 (94.9)	-0.62 (0.04)	(-0.69, -0.55)	-0.13 (0.05)	(-0.23, -0.02)	0.015 *	
	Placebo	391	365 (93.4)	-0.49 (0.04)	(-0.57, -0.42)				
Week 12	Tezepelumab	395	377 (95.4)	-0.59 (0.04)	(-0.66, -0.52)	-0.09 (0.05)	(-0.19, 0.01)	0.080	
	Placebo	391	362 (92.6)	-0.50 (0.04)	(-0.57, -0.43)				
Week 13	Tezepelumab	395	369 (93.4)	-0.62 (0.04)	(-0.69, -0.54)	-0.10 (0.05)	(-0.21, -0.00)	0.047 *	
	Placebo	391	357 (91.3)	-0.51 (0.04)	(-0.59, -0.44)				
Week 14	Tezepelumab	395	366 (92.7)	-0.65 (0.04)	(-0.72, -0.57)	-0.14 (0.05)	(-0.24, -0.04)	0.007 *	
	Placebo	391	364 (93.1)	-0.50 (0.04)	(-0.58, -0.43)				
Week 15	Tezepelumab	395	370 (93.7)	-0.66 (0.04)	(-0.73, -0.58)	-0.14 (0.05)	(-0.25, -0.04)	0.007 *	
	Placebo	391	354 (90.5)	-0.51 (0.04)	(-0.59, -0.44)				
Week 16	Tezepelumab	395	365 (92.4)	-0.68 (0.04)	(-0.76, -0.61)	-0.18 (0.05)	(-0.28, -0.08)	<0.001 *	
	Placebo	391	355 (90.8)	-0.50 (0.04)	(-0.58, -0.43)				
Week 17	Tezepelumab	395	366 (92.7)	-0.71 (0.04)	(-0.79, -0.64)	-0.17 (0.05)	(-0.27, -0.06)	0.002 *	
	Placebo	391	351 (89.8)	-0.55 (0.04)	(-0.62, -0.47)				
Week 18	Tezepelumab	395	365 (92.4)	-0.68 (0.04)	(-0.75, -0.61)	-0.13 (0.05)	(-0.23, -0.02)	0.015 *	
	Placebo	391	351 (89.8)	-0.55 (0.04)	(-0.63, -0.48)				
Week 19	Tezepelumab	395	356 (90.1)	-0.69 (0.04)	(-0.76, -0.61)	-0.15 (0.05)	(-0.25, -0.04)	0.006 *	
	Placebo	391	350 (89.5)	-0.54 (0.04)	(-0.61, -0.47)				
Week 20	Tezepelumab	395	354 (89.6)	-0.70 (0.04)	(-0.77, -0.62)	-0.15 (0.05)	(-0.25, -0.04)	0.006 *	
	Placebo	391	346 (88.5)	-0.55 (0.04)	(-0.62, -0.48)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WLC\_ILMC0: Change from baseline in ASD weekly limiting activity score - MMRM results  
 DITTTL

Change from baseline in ASD weekly limiting activity score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 21	Tezepelumab	395	357 (90.4)	-0.70 (0.04)	(-0.78, -0.63)	-0.14 (0.05)	(-0.24, -0.03)	0.011 *	
	Placebo	391	341 (87.2)	-0.57 (0.04)	(-0.64, -0.49)				
Week 22	Tezepelumab	395	353 (89.4)	-0.70 (0.04)	(-0.77, -0.62)	-0.12 (0.05)	(-0.22, -0.01)	0.029 *	
	Placebo	391	338 (86.4)	-0.58 (0.04)	(-0.65, -0.51)				
Week 23	Tezepelumab	395	356 (90.1)	-0.70 (0.04)	(-0.77, -0.63)	-0.13 (0.05)	(-0.23, -0.02)	0.016 *	
	Placebo	391	339 (86.7)	-0.57 (0.04)	(-0.64, -0.50)				
Week 24	Tezepelumab	395	356 (90.1)	-0.68 (0.04)	(-0.76, -0.61)	-0.12 (0.05)	(-0.22, -0.01)	0.030 *	
	Placebo	391	336 (85.9)	-0.57 (0.04)	(-0.64, -0.49)				
Week 25	Tezepelumab	395	351 (88.9)	-0.69 (0.04)	(-0.77, -0.62)	-0.11 (0.05)	(-0.22, -0.01)	0.039 *	
	Placebo	391	328 (83.9)	-0.58 (0.04)	(-0.66, -0.51)				
Week 26	Tezepelumab	395	348 (88.1)	-0.70 (0.04)	(-0.77, -0.62)	-0.12 (0.05)	(-0.23, -0.02)	0.024 *	
	Placebo	391	329 (84.1)	-0.57 (0.04)	(-0.65, -0.50)				
Week 27	Tezepelumab	395	347 (87.8)	-0.70 (0.04)	(-0.78, -0.63)	-0.14 (0.05)	(-0.24, -0.03)	0.011 *	
	Placebo	391	334 (85.4)	-0.57 (0.04)	(-0.64, -0.49)				
Week 28	Tezepelumab	395	349 (88.4)	-0.72 (0.04)	(-0.80, -0.65)	-0.14 (0.05)	(-0.25, -0.04)	0.008 *	
	Placebo	391	339 (86.7)	-0.58 (0.04)	(-0.66, -0.51)				
Week 29	Tezepelumab	395	348 (88.1)	-0.73 (0.04)	(-0.81, -0.66)	-0.15 (0.05)	(-0.25, -0.04)	0.006 *	
	Placebo	391	330 (84.4)	-0.58 (0.04)	(-0.66, -0.51)				
Week 30	Tezepelumab	395	344 (87.1)	-0.71 (0.04)	(-0.78, -0.63)	-0.13 (0.05)	(-0.24, -0.03)	0.014 *	
	Placebo	391	321 (82.1)	-0.57 (0.04)	(-0.65, -0.50)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WLC\_ILMC0: Change from baseline in ASD weekly limiting activity score - MMRM results  
 DITTTL

Change from baseline in ASD weekly limiting activity score				Repeated measures analysis																																																																																																																																							
				Change from Baseline		Treatment Difference																																																																																																																																					
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value																																																																																																																															
Week 31	Tezepelumab	395	354 (89.6)	-0.71 (0.04)	(-0.79, -0.64)	-0.12 (0.05)	(-0.22, -0.01)	0.028	*																																																																																																																																		
	Placebo	391	333 (85.2)	-0.60 (0.04)	(-0.67, -0.52)					Week 32	Tezepelumab	395	345 (87.3)	-0.71 (0.04)	(-0.78, -0.64)	-0.13 (0.05)	(-0.23, -0.02)	0.017	*	Placebo	391	328 (83.9)	-0.58 (0.04)	(-0.66, -0.51)	Week 33	Tezepelumab	395	342 (86.6)	-0.74 (0.04)	(-0.82, -0.67)	-0.15 (0.05)	(-0.25, -0.04)	0.006	*	Placebo	391	330 (84.4)	-0.59 (0.04)	(-0.67, -0.52)	Week 34	Tezepelumab	395	347 (87.8)	-0.75 (0.04)	(-0.82, -0.67)	-0.15 (0.05)	(-0.26, -0.05)	0.005	*	Placebo	391	328 (83.9)	-0.59 (0.04)	(-0.67, -0.52)	Week 35	Tezepelumab	395	342 (86.6)	-0.74 (0.04)	(-0.81, -0.66)	-0.14 (0.05)	(-0.25, -0.03)	0.010	*	Placebo	391	320 (81.8)	-0.60 (0.04)	(-0.67, -0.52)	Week 36	Tezepelumab	395	345 (87.3)	-0.73 (0.04)	(-0.80, -0.65)	-0.13 (0.05)	(-0.23, -0.02)	0.020	*	Placebo	391	317 (81.1)	-0.60 (0.04)	(-0.68, -0.52)	Week 37	Tezepelumab	395	338 (85.6)	-0.73 (0.04)	(-0.80, -0.65)	-0.12 (0.05)	(-0.23, -0.01)	0.028	*	Placebo	391	328 (83.9)	-0.61 (0.04)	(-0.68, -0.53)	Week 38	Tezepelumab	395	343 (86.8)	-0.73 (0.04)	(-0.80, -0.66)	-0.12 (0.05)	(-0.22, -0.01)	0.032	*	Placebo	391	323 (82.6)	-0.61 (0.04)	(-0.69, -0.54)	Week 39	Tezepelumab	395	345 (87.3)	-0.73 (0.04)	(-0.80, -0.65)	-0.10 (0.05)	(-0.21, 0.00)	0.061		Placebo	391	318 (81.3)	-0.62 (0.04)	(-0.70, -0.55)	Week 40	Tezepelumab	395	344 (87.1)	-0.74 (0.04)	(-0.81, -0.66)	-0.12 (0.05)	(-0.23, -0.01)	0.027	*
Week 32	Tezepelumab	395	345 (87.3)	-0.71 (0.04)	(-0.78, -0.64)	-0.13 (0.05)	(-0.23, -0.02)	0.017	*																																																																																																																																		
	Placebo	391	328 (83.9)	-0.58 (0.04)	(-0.66, -0.51)					Week 33	Tezepelumab	395	342 (86.6)	-0.74 (0.04)	(-0.82, -0.67)	-0.15 (0.05)	(-0.25, -0.04)	0.006	*	Placebo	391	330 (84.4)	-0.59 (0.04)	(-0.67, -0.52)	Week 34	Tezepelumab	395	347 (87.8)	-0.75 (0.04)	(-0.82, -0.67)	-0.15 (0.05)	(-0.26, -0.05)	0.005	*	Placebo	391	328 (83.9)	-0.59 (0.04)	(-0.67, -0.52)	Week 35	Tezepelumab	395	342 (86.6)	-0.74 (0.04)	(-0.81, -0.66)	-0.14 (0.05)	(-0.25, -0.03)	0.010	*	Placebo	391	320 (81.8)	-0.60 (0.04)	(-0.67, -0.52)	Week 36	Tezepelumab	395	345 (87.3)	-0.73 (0.04)	(-0.80, -0.65)	-0.13 (0.05)	(-0.23, -0.02)	0.020	*	Placebo	391	317 (81.1)	-0.60 (0.04)	(-0.68, -0.52)	Week 37	Tezepelumab	395	338 (85.6)	-0.73 (0.04)	(-0.80, -0.65)	-0.12 (0.05)	(-0.23, -0.01)	0.028	*	Placebo	391	328 (83.9)	-0.61 (0.04)	(-0.68, -0.53)	Week 38	Tezepelumab	395	343 (86.8)	-0.73 (0.04)	(-0.80, -0.66)	-0.12 (0.05)	(-0.22, -0.01)	0.032	*	Placebo	391	323 (82.6)	-0.61 (0.04)	(-0.69, -0.54)	Week 39	Tezepelumab	395	345 (87.3)	-0.73 (0.04)	(-0.80, -0.65)	-0.10 (0.05)	(-0.21, 0.00)	0.061		Placebo	391	318 (81.3)	-0.62 (0.04)	(-0.70, -0.55)	Week 40	Tezepelumab	395	344 (87.1)	-0.74 (0.04)	(-0.81, -0.66)	-0.12 (0.05)	(-0.23, -0.01)	0.027	*	Placebo	391	322 (82.4)	-0.62 (0.04)	(-0.69, -0.54)										
Week 33	Tezepelumab	395	342 (86.6)	-0.74 (0.04)	(-0.82, -0.67)	-0.15 (0.05)	(-0.25, -0.04)	0.006	*																																																																																																																																		
	Placebo	391	330 (84.4)	-0.59 (0.04)	(-0.67, -0.52)					Week 34	Tezepelumab	395	347 (87.8)	-0.75 (0.04)	(-0.82, -0.67)	-0.15 (0.05)	(-0.26, -0.05)	0.005	*	Placebo	391	328 (83.9)	-0.59 (0.04)	(-0.67, -0.52)	Week 35	Tezepelumab	395	342 (86.6)	-0.74 (0.04)	(-0.81, -0.66)	-0.14 (0.05)	(-0.25, -0.03)	0.010	*	Placebo	391	320 (81.8)	-0.60 (0.04)	(-0.67, -0.52)	Week 36	Tezepelumab	395	345 (87.3)	-0.73 (0.04)	(-0.80, -0.65)	-0.13 (0.05)	(-0.23, -0.02)	0.020	*	Placebo	391	317 (81.1)	-0.60 (0.04)	(-0.68, -0.52)	Week 37	Tezepelumab	395	338 (85.6)	-0.73 (0.04)	(-0.80, -0.65)	-0.12 (0.05)	(-0.23, -0.01)	0.028	*	Placebo	391	328 (83.9)	-0.61 (0.04)	(-0.68, -0.53)	Week 38	Tezepelumab	395	343 (86.8)	-0.73 (0.04)	(-0.80, -0.66)	-0.12 (0.05)	(-0.22, -0.01)	0.032	*	Placebo	391	323 (82.6)	-0.61 (0.04)	(-0.69, -0.54)	Week 39	Tezepelumab	395	345 (87.3)	-0.73 (0.04)	(-0.80, -0.65)	-0.10 (0.05)	(-0.21, 0.00)	0.061		Placebo	391	318 (81.3)	-0.62 (0.04)	(-0.70, -0.55)	Week 40	Tezepelumab	395	344 (87.1)	-0.74 (0.04)	(-0.81, -0.66)	-0.12 (0.05)	(-0.23, -0.01)	0.027	*	Placebo	391	322 (82.4)	-0.62 (0.04)	(-0.69, -0.54)																									
Week 34	Tezepelumab	395	347 (87.8)	-0.75 (0.04)	(-0.82, -0.67)	-0.15 (0.05)	(-0.26, -0.05)	0.005	*																																																																																																																																		
	Placebo	391	328 (83.9)	-0.59 (0.04)	(-0.67, -0.52)					Week 35	Tezepelumab	395	342 (86.6)	-0.74 (0.04)	(-0.81, -0.66)	-0.14 (0.05)	(-0.25, -0.03)	0.010	*	Placebo	391	320 (81.8)	-0.60 (0.04)	(-0.67, -0.52)	Week 36	Tezepelumab	395	345 (87.3)	-0.73 (0.04)	(-0.80, -0.65)	-0.13 (0.05)	(-0.23, -0.02)	0.020	*	Placebo	391	317 (81.1)	-0.60 (0.04)	(-0.68, -0.52)	Week 37	Tezepelumab	395	338 (85.6)	-0.73 (0.04)	(-0.80, -0.65)	-0.12 (0.05)	(-0.23, -0.01)	0.028	*	Placebo	391	328 (83.9)	-0.61 (0.04)	(-0.68, -0.53)	Week 38	Tezepelumab	395	343 (86.8)	-0.73 (0.04)	(-0.80, -0.66)	-0.12 (0.05)	(-0.22, -0.01)	0.032	*	Placebo	391	323 (82.6)	-0.61 (0.04)	(-0.69, -0.54)	Week 39	Tezepelumab	395	345 (87.3)	-0.73 (0.04)	(-0.80, -0.65)	-0.10 (0.05)	(-0.21, 0.00)	0.061		Placebo	391	318 (81.3)	-0.62 (0.04)	(-0.70, -0.55)	Week 40	Tezepelumab	395	344 (87.1)	-0.74 (0.04)	(-0.81, -0.66)	-0.12 (0.05)	(-0.23, -0.01)	0.027	*	Placebo	391	322 (82.4)	-0.62 (0.04)	(-0.69, -0.54)																																								
Week 35	Tezepelumab	395	342 (86.6)	-0.74 (0.04)	(-0.81, -0.66)	-0.14 (0.05)	(-0.25, -0.03)	0.010	*																																																																																																																																		
	Placebo	391	320 (81.8)	-0.60 (0.04)	(-0.67, -0.52)					Week 36	Tezepelumab	395	345 (87.3)	-0.73 (0.04)	(-0.80, -0.65)	-0.13 (0.05)	(-0.23, -0.02)	0.020	*	Placebo	391	317 (81.1)	-0.60 (0.04)	(-0.68, -0.52)	Week 37	Tezepelumab	395	338 (85.6)	-0.73 (0.04)	(-0.80, -0.65)	-0.12 (0.05)	(-0.23, -0.01)	0.028	*	Placebo	391	328 (83.9)	-0.61 (0.04)	(-0.68, -0.53)	Week 38	Tezepelumab	395	343 (86.8)	-0.73 (0.04)	(-0.80, -0.66)	-0.12 (0.05)	(-0.22, -0.01)	0.032	*	Placebo	391	323 (82.6)	-0.61 (0.04)	(-0.69, -0.54)	Week 39	Tezepelumab	395	345 (87.3)	-0.73 (0.04)	(-0.80, -0.65)	-0.10 (0.05)	(-0.21, 0.00)	0.061		Placebo	391	318 (81.3)	-0.62 (0.04)	(-0.70, -0.55)	Week 40	Tezepelumab	395	344 (87.1)	-0.74 (0.04)	(-0.81, -0.66)	-0.12 (0.05)	(-0.23, -0.01)	0.027	*	Placebo	391	322 (82.4)	-0.62 (0.04)	(-0.69, -0.54)																																																							
Week 36	Tezepelumab	395	345 (87.3)	-0.73 (0.04)	(-0.80, -0.65)	-0.13 (0.05)	(-0.23, -0.02)	0.020	*																																																																																																																																		
	Placebo	391	317 (81.1)	-0.60 (0.04)	(-0.68, -0.52)					Week 37	Tezepelumab	395	338 (85.6)	-0.73 (0.04)	(-0.80, -0.65)	-0.12 (0.05)	(-0.23, -0.01)	0.028	*	Placebo	391	328 (83.9)	-0.61 (0.04)	(-0.68, -0.53)	Week 38	Tezepelumab	395	343 (86.8)	-0.73 (0.04)	(-0.80, -0.66)	-0.12 (0.05)	(-0.22, -0.01)	0.032	*	Placebo	391	323 (82.6)	-0.61 (0.04)	(-0.69, -0.54)	Week 39	Tezepelumab	395	345 (87.3)	-0.73 (0.04)	(-0.80, -0.65)	-0.10 (0.05)	(-0.21, 0.00)	0.061		Placebo	391	318 (81.3)	-0.62 (0.04)	(-0.70, -0.55)	Week 40	Tezepelumab	395	344 (87.1)	-0.74 (0.04)	(-0.81, -0.66)	-0.12 (0.05)	(-0.23, -0.01)	0.027	*	Placebo	391	322 (82.4)	-0.62 (0.04)	(-0.69, -0.54)																																																																						
Week 37	Tezepelumab	395	338 (85.6)	-0.73 (0.04)	(-0.80, -0.65)	-0.12 (0.05)	(-0.23, -0.01)	0.028	*																																																																																																																																		
	Placebo	391	328 (83.9)	-0.61 (0.04)	(-0.68, -0.53)					Week 38	Tezepelumab	395	343 (86.8)	-0.73 (0.04)	(-0.80, -0.66)	-0.12 (0.05)	(-0.22, -0.01)	0.032	*	Placebo	391	323 (82.6)	-0.61 (0.04)	(-0.69, -0.54)	Week 39	Tezepelumab	395	345 (87.3)	-0.73 (0.04)	(-0.80, -0.65)	-0.10 (0.05)	(-0.21, 0.00)	0.061		Placebo	391	318 (81.3)	-0.62 (0.04)	(-0.70, -0.55)	Week 40	Tezepelumab	395	344 (87.1)	-0.74 (0.04)	(-0.81, -0.66)	-0.12 (0.05)	(-0.23, -0.01)	0.027	*	Placebo	391	322 (82.4)	-0.62 (0.04)	(-0.69, -0.54)																																																																																					
Week 38	Tezepelumab	395	343 (86.8)	-0.73 (0.04)	(-0.80, -0.66)	-0.12 (0.05)	(-0.22, -0.01)	0.032	*																																																																																																																																		
	Placebo	391	323 (82.6)	-0.61 (0.04)	(-0.69, -0.54)					Week 39	Tezepelumab	395	345 (87.3)	-0.73 (0.04)	(-0.80, -0.65)	-0.10 (0.05)	(-0.21, 0.00)	0.061		Placebo	391	318 (81.3)	-0.62 (0.04)	(-0.70, -0.55)	Week 40	Tezepelumab	395	344 (87.1)	-0.74 (0.04)	(-0.81, -0.66)	-0.12 (0.05)	(-0.23, -0.01)	0.027	*	Placebo	391	322 (82.4)	-0.62 (0.04)	(-0.69, -0.54)																																																																																																				
Week 39	Tezepelumab	395	345 (87.3)	-0.73 (0.04)	(-0.80, -0.65)	-0.10 (0.05)	(-0.21, 0.00)	0.061																																																																																																																																			
	Placebo	391	318 (81.3)	-0.62 (0.04)	(-0.70, -0.55)					Week 40	Tezepelumab	395	344 (87.1)	-0.74 (0.04)	(-0.81, -0.66)	-0.12 (0.05)	(-0.23, -0.01)	0.027	*	Placebo	391	322 (82.4)	-0.62 (0.04)	(-0.69, -0.54)																																																																																																																			
Week 40	Tezepelumab	395	344 (87.1)	-0.74 (0.04)	(-0.81, -0.66)	-0.12 (0.05)	(-0.23, -0.01)	0.027	*																																																																																																																																		
	Placebo	391	322 (82.4)	-0.62 (0.04)	(-0.69, -0.54)																																																																																																																																						

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table NT1WLC\_ILMC0: Change from baseline in ASD weekly limiting activity score - MMRM results  
 DITTTL

Change from baseline in ASD weekly limiting activity score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 41	Tezepelumab	395	342 (86.6)	-0.75 (0.04)	(-0.83, -0.68)	-0.14 (0.05)	(-0.25, -0.03)	0.010 *	
	Placebo	391	322 (82.4)	-0.61 (0.04)	(-0.69, -0.53)				
Week 42	Tezepelumab	395	340 (86.1)	-0.75 (0.04)	(-0.83, -0.68)	-0.14 (0.05)	(-0.25, -0.04)	0.009 *	
	Placebo	391	323 (82.6)	-0.61 (0.04)	(-0.69, -0.54)				
Week 43	Tezepelumab	395	342 (86.6)	-0.75 (0.04)	(-0.82, -0.67)	-0.12 (0.05)	(-0.23, -0.01)	0.027 *	
	Placebo	391	323 (82.6)	-0.63 (0.04)	(-0.70, -0.55)				
Week 44	Tezepelumab	395	339 (85.8)	-0.75 (0.04)	(-0.83, -0.68)	-0.14 (0.05)	(-0.25, -0.04)	0.009 *	
	Placebo	391	325 (83.1)	-0.61 (0.04)	(-0.69, -0.54)				
Week 45	Tezepelumab	395	341 (86.3)	-0.77 (0.04)	(-0.84, -0.69)	-0.14 (0.05)	(-0.25, -0.03)	0.009 *	
	Placebo	391	322 (82.4)	-0.63 (0.04)	(-0.70, -0.55)				
Week 46	Tezepelumab	395	339 (85.8)	-0.77 (0.04)	(-0.85, -0.70)	-0.14 (0.05)	(-0.25, -0.03)	0.010 *	
	Placebo	391	314 (80.3)	-0.63 (0.04)	(-0.71, -0.55)				
Week 47	Tezepelumab	395	337 (85.3)	-0.74 (0.04)	(-0.82, -0.67)	-0.10 (0.05)	(-0.21, 0.01)	0.072	
	Placebo	391	312 (79.8)	-0.64 (0.04)	(-0.72, -0.57)				
Week 48	Tezepelumab	395	339 (85.8)	-0.75 (0.04)	(-0.82, -0.67)	-0.09 (0.05)	(-0.20, 0.02)	0.092	
	Placebo	391	316 (80.8)	-0.65 (0.04)	(-0.73, -0.58)				
Week 49	Tezepelumab	395	336 (85.1)	-0.75 (0.04)	(-0.82, -0.67)	-0.11 (0.05)	(-0.22, -0.00)	0.045 *	
	Placebo	391	315 (80.6)	-0.64 (0.04)	(-0.72, -0.56)				
Week 50	Tezepelumab	395	336 (85.1)	-0.77 (0.04)	(-0.84, -0.69)	-0.13 (0.06)	(-0.24, -0.03)	0.015 *	
	Placebo	391	313 (80.1)	-0.63 (0.04)	(-0.71, -0.55)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WLC\_ILMC0: Change from baseline in ASD weekly limiting activity score - MMRM results  
 DITTTL

Change from baseline in ASD weekly limiting activity score				Repeated measures analysis						
				N		Change from Baseline		Treatment Difference		
						LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Time	Treatment		n (%)							
Week 51	Tezepelumab	395	330 (83.5)	-0.76 (0.04)	(-0.83, -0.68)	-0.12 (0.06)	(-0.23, -0.01)	0.027 *		
	Placebo	391	306 (78.3)	-0.64 (0.04)	(-0.71, -0.56)					
Week 52	Tezepelumab	395	303 (76.7)	-0.74 (0.04)	(-0.82, -0.67)	-0.11 (0.06)	(-0.22, 0.00)	0.054		
	Placebo	391	286 (73.1)	-0.64 (0.04)	(-0.71, -0.56)					

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WLC\_ILMH0: Course of ASD weekly limiting activity score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly limiting activity score	Baseline	Tezepelumab	73	73 (100.0)	1.49 (0.78)	0.0	1.00	1.57	2.00	3.0	
		Placebo	76	76 (100.0)	1.43 (0.87)	0.0	1.00	1.29	2.00	4.0	
	Week 1	Tezepelumab	73	72 (98.6)	1.34 (0.78)	0.0	1.00	1.14	2.00	3.2	
		Placebo	76	76 (100.0)	1.44 (0.81)	0.0	1.00	1.29	2.00	3.3	
	Week 2	Tezepelumab	73	73 (100.0)	1.23 (0.80)	0.0	0.86	1.00	2.00	3.2	
		Placebo	76	76 (100.0)	1.46 (0.84)	0.0	1.00	1.21	2.00	4.0	
	Week 3	Tezepelumab	73	73 (100.0)	1.23 (0.76)	0.0	0.86	1.00	2.00	3.0	
		Placebo	76	76 (100.0)	1.45 (0.83)	0.0	1.00	1.46	2.00	3.0	
	Week 4	Tezepelumab	73	72 (98.6)	1.18 (0.77)	0.0	0.71	1.00	1.85	3.0	
		Placebo	76	76 (100.0)	1.46 (0.81)	0.0	1.00	1.57	2.00	3.0	
	Week 5	Tezepelumab	73	72 (98.6)	1.15 (0.83)	0.0	0.29	1.00	2.00	3.0	
		Placebo	76	74 (97.4)	1.38 (0.81)	0.0	1.00	1.21	2.00	3.0	
	Week 6	Tezepelumab	73	70 (95.9)	1.21 (0.82)	0.0	0.71	1.00	2.00	3.0	
		Placebo	76	74 (97.4)	1.43 (0.85)	0.0	1.00	1.21	2.00	3.0	
	Week 7	Tezepelumab	73	71 (97.3)	1.21 (0.83)	0.0	0.57	1.00	2.00	3.0	
		Placebo	76	75 (98.7)	1.45 (0.83)	0.0	1.00	1.43	2.00	3.0	
	Week 8	Tezepelumab	73	71 (97.3)	1.21 (0.86)	0.0	0.57	1.00	2.00	3.0	
		Placebo	76	75 (98.7)	1.43 (0.85)	0.0	1.00	1.43	2.00	3.4	
	Week 9	Tezepelumab	73	72 (98.6)	1.20 (0.89)	0.0	0.23	1.00	2.00	3.3	
		Placebo	76	75 (98.7)	1.38 (0.87)	0.0	1.00	1.14	2.00	3.0	
	Week 10	Tezepelumab	73	71 (97.3)	1.24 (0.84)	0.0	0.80	1.00	2.00	3.0	
		Placebo	76	74 (97.4)	1.32 (0.86)	0.0	1.00	1.15	2.00	3.0	
	Week 11	Tezepelumab	73	70 (95.9)	1.15 (0.83)	0.0	0.43	1.00	2.00	3.2	
		Placebo	76	74 (97.4)	1.33 (0.83)	0.0	1.00	1.29	2.00	3.0	
	Week 12	Tezepelumab	73	70 (95.9)	1.15 (0.84)	0.0	0.43	1.00	2.00	3.2	
		Placebo	76	75 (98.7)	1.39 (0.82)	0.0	1.00	1.43	2.00	3.0	
	Week 13	Tezepelumab	73	68 (93.2)	1.17 (0.89)	0.0	0.38	1.00	2.00	3.4	
		Placebo	76	74 (97.4)	1.33 (0.88)	0.0	0.71	1.29	2.00	3.0	
	Week 14	Tezepelumab	73	70 (95.9)	1.18 (0.90)	0.0	0.43	1.00	2.00	3.3	
		Placebo	76	74 (97.4)	1.32 (0.90)	0.0	0.71	1.23	2.00	3.3	
	Week 15	Tezepelumab	73	69 (94.5)	1.21 (0.88)	0.0	0.71	1.00	2.00	3.0	
		Placebo	76	73 (96.1)	1.29 (0.89)	0.0	0.60	1.14	2.00	3.1	
Week 16	Tezepelumab	73	69 (94.5)	1.21 (0.85)	0.0	0.71	1.00	2.00	3.1		
	Placebo	76	74 (97.4)	1.24 (0.85)	0.0	0.71	1.14	2.00	3.1		
Week 17	Tezepelumab	73	70 (95.9)	1.18 (0.89)	0.0	0.43	1.00	2.00	3.2		
	Placebo	76	74 (97.4)	1.26 (0.82)	0.0	0.86	1.00	2.00	3.0		

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WLC\_ILMH0: Course of ASD weekly limiting activity score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly limiting activity score	Week 18	Tezepelumab	73	70 (95.9)	1.21 (0.87)	0.0	0.86	1.00	2.00	3.0	
		Placebo	76	73 (96.1)	1.27 (0.87)	0.0	0.86	1.00	2.00	3.0	
	Week 19	Tezepelumab	73	69 (94.5)	1.23 (0.89)	0.0	0.83	1.00	2.00	3.3	
		Placebo	76	74 (97.4)	1.25 (0.86)	0.0	0.67	1.00	2.00	3.3	
	Week 20	Tezepelumab	73	70 (95.9)	1.22 (0.92)	0.0	0.43	1.00	2.00	3.2	
		Placebo	76	74 (97.4)	1.27 (0.86)	0.0	0.86	1.14	2.00	3.0	
	Week 21	Tezepelumab	73	69 (94.5)	1.19 (0.89)	0.0	0.40	1.00	2.00	3.0	
		Placebo	76	73 (96.1)	1.27 (0.87)	0.0	0.86	1.14	2.00	3.1	
	Week 22	Tezepelumab	73	69 (94.5)	1.22 (0.88)	0.0	0.57	1.00	2.00	3.2	
		Placebo	76	75 (98.7)	1.34 (0.91)	0.0	1.00	1.14	2.00	4.0	
	Week 23	Tezepelumab	73	69 (94.5)	1.22 (0.92)	0.0	0.43	1.00	2.00	3.1	
		Placebo	76	74 (97.4)	1.32 (0.93)	0.0	0.67	1.00	2.00	3.9	
	Week 24	Tezepelumab	73	70 (95.9)	1.16 (0.89)	0.0	0.43	1.00	2.00	3.3	
		Placebo	76	75 (98.7)	1.32 (0.93)	0.0	0.83	1.14	2.00	3.7	
	Week 25	Tezepelumab	73	69 (94.5)	1.18 (0.92)	0.0	0.17	1.00	2.00	3.1	
		Placebo	76	74 (97.4)	1.31 (0.87)	0.0	0.86	1.07	2.00	3.0	
	Week 26	Tezepelumab	73	68 (93.2)	1.17 (0.94)	0.0	0.29	1.00	2.00	3.6	
		Placebo	76	73 (96.1)	1.31 (0.92)	0.0	0.67	1.14	2.00	3.1	
	Week 27	Tezepelumab	73	69 (94.5)	1.14 (0.92)	0.0	0.17	1.00	2.00	3.3	
		Placebo	76	73 (96.1)	1.29 (0.93)	0.0	0.80	1.00	2.00	3.3	
	Week 28	Tezepelumab	73	67 (91.8)	1.22 (0.92)	0.0	0.14	1.00	2.00	3.0	
		Placebo	76	74 (97.4)	1.30 (0.94)	0.0	0.57	1.00	2.00	3.8	
	Week 29	Tezepelumab	73	66 (90.4)	1.11 (0.90)	0.0	0.14	1.00	2.00	3.0	
		Placebo	76	74 (97.4)	1.30 (0.89)	0.0	0.86	1.15	2.00	3.3	
	Week 30	Tezepelumab	73	69 (94.5)	1.09 (0.90)	0.0	0.17	1.00	2.00	3.0	
		Placebo	76	74 (97.4)	1.33 (0.90)	0.0	1.00	1.23	2.00	3.0	
	Week 31	Tezepelumab	73	67 (91.8)	1.09 (0.91)	0.0	0.14	1.00	2.00	3.0	
		Placebo	76	73 (96.1)	1.31 (0.91)	0.0	1.00	1.14	2.00	3.0	
	Week 32	Tezepelumab	73	66 (90.4)	1.13 (0.94)	0.0	0.29	1.00	1.86	3.0	
		Placebo	76	73 (96.1)	1.27 (0.88)	0.0	1.00	1.00	2.00	3.1	
	Week 33	Tezepelumab	73	67 (91.8)	1.08 (0.87)	0.0	0.14	1.00	1.86	3.0	
		Placebo	76	74 (97.4)	1.24 (0.87)	0.0	1.00	1.07	2.00	3.0	
	Week 34	Tezepelumab	73	67 (91.8)	1.05 (0.88)	0.0	0.14	1.00	1.86	3.0	
		Placebo	76	72 (94.7)	1.23 (0.90)	0.0	0.62	1.00	2.00	3.1	
	Week 35	Tezepelumab	73	67 (91.8)	1.12 (0.90)	0.0	0.14	1.00	2.00	3.1	
		Placebo	76	74 (97.4)	1.25 (0.91)	0.0	0.86	1.00	2.00	3.1	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WLC\_ILMH0: Course of ASD weekly limiting activity score  
 DITTTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly limiting activity score	Week 36	Tezepelumab	73	69 (94.5)	1.11 (0.91)	0.0	0.14	1.00	2.00	3.1	
		Placebo	76	73 (96.1)	1.26 (0.86)	0.0	1.00	1.00	2.00	3.0	
	Week 37	Tezepelumab	73	68 (93.2)	1.05 (0.94)	0.0	0.07	1.00	2.00	3.3	
		Placebo	76	73 (96.1)	1.30 (0.86)	0.0	1.00	1.17	2.00	3.1	
	Week 38	Tezepelumab	73	67 (91.8)	1.06 (0.93)	0.0	0.14	1.00	2.00	3.5	
		Placebo	76	72 (94.7)	1.30 (0.86)	0.0	1.00	1.14	2.00	3.1	
	Week 39	Tezepelumab	73	65 (89.0)	1.07 (0.92)	0.0	0.14	1.00	1.86	3.0	
		Placebo	76	73 (96.1)	1.28 (0.90)	0.0	0.86	1.14	2.00	3.0	
	Week 40	Tezepelumab	73	65 (89.0)	1.05 (0.93)	0.0	0.14	1.00	2.00	3.0	
		Placebo	76	72 (94.7)	1.31 (0.90)	0.0	0.79	1.14	2.00	3.4	
	Week 41	Tezepelumab	73	63 (86.3)	1.00 (0.91)	0.0	0.00	1.00	1.67	3.3	
		Placebo	76	72 (94.7)	1.21 (0.84)	0.0	0.93	1.00	1.93	3.0	
	Week 42	Tezepelumab	73	64 (87.7)	1.04 (0.88)	0.0	0.00	1.00	1.71	3.0	
		Placebo	76	73 (96.1)	1.22 (0.82)	0.0	0.86	1.00	2.00	3.0	
	Week 43	Tezepelumab	73	64 (87.7)	1.06 (0.92)	0.0	0.14	1.00	1.79	3.3	
		Placebo	76	74 (97.4)	1.25 (0.87)	0.0	0.71	1.07	2.00	3.0	
	Week 44	Tezepelumab	73	63 (86.3)	0.99 (0.91)	0.0	0.00	1.00	1.43	3.0	
		Placebo	76	73 (96.1)	1.22 (0.84)	0.0	0.86	1.00	2.00	3.0	
	Week 45	Tezepelumab	73	63 (86.3)	1.01 (0.90)	0.0	0.00	1.00	1.33	3.0	
		Placebo	76	73 (96.1)	1.21 (0.85)	0.0	0.80	1.14	2.00	3.0	
	Week 46	Tezepelumab	73	64 (87.7)	1.04 (0.93)	0.0	0.00	1.00	1.93	3.0	
		Placebo	76	70 (92.1)	1.22 (0.85)	0.0	0.71	1.00	2.00	3.0	
	Week 47	Tezepelumab	73	63 (86.3)	1.04 (0.92)	0.0	0.00	1.00	1.83	3.0	
		Placebo	76	71 (93.4)	1.21 (0.83)	0.0	0.86	1.00	2.00	3.0	
	Week 48	Tezepelumab	73	58 (79.5)	1.14 (0.93)	0.0	0.00	1.00	2.00	3.0	
		Placebo	76	69 (90.8)	1.24 (0.84)	0.0	0.80	1.14	2.00	3.0	

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WLC\_ILMH0: Course of ASD weekly limiting activity score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly limiting activity score	Week 1	Tezepelumab	73	72 (98.6)	-0.15 (0.45)	-1.9	-0.35	0.00	0.00	1.0	-0.37 [-0.69, -0.04]
		Placebo	76	76 (100.0)	0.01 (0.38)	-1.6	-0.07	0.00	0.15	0.9	
	Week 2	Tezepelumab	73	73 (100.0)	-0.27 (0.50)	-1.9	-0.45	-0.14	0.00	0.9	-0.64 [-0.97, -0.31]
		Placebo	76	76 (100.0)	0.02 (0.40)	-1.2	-0.14	0.00	0.14	1.0	
	Week 3	Tezepelumab	73	73 (100.0)	-0.27 (0.54)	-1.9	-0.57	-0.14	0.00	1.0	-0.57 [-0.90, -0.24]
		Placebo	76	76 (100.0)	0.02 (0.45)	-1.6	-0.17	0.00	0.17	1.2	
	Week 4	Tezepelumab	73	72 (98.6)	-0.30 (0.57)	-1.7	-0.77	-0.14	0.00	0.9	-0.63 [-0.96, -0.30]
		Placebo	76	76 (100.0)	0.03 (0.45)	-1.3	-0.14	0.00	0.21	1.6	
	Week 5	Tezepelumab	73	72 (98.6)	-0.34 (0.62)	-2.3	-0.79	-0.07	0.00	1.0	-0.54 [-0.87, -0.21]
		Placebo	76	74 (97.4)	-0.04 (0.48)	-2.1	-0.29	0.00	0.14	1.0	
	Week 6	Tezepelumab	73	70 (95.9)	-0.29 (0.67)	-2.4	-0.71	-0.14	0.00	1.3	-0.45 [-0.78, -0.12]
		Placebo	76	74 (97.4)	-0.01 (0.59)	-2.4	-0.17	0.00	0.14	1.9	
	Week 7	Tezepelumab	73	71 (97.3)	-0.28 (0.71)	-2.4	-0.60	0.00	0.00	1.0	-0.47 [-0.80, -0.14]
		Placebo	76	75 (98.7)	0.02 (0.57)	-2.1	-0.29	0.00	0.29	1.3	
	Week 8	Tezepelumab	73	71 (97.3)	-0.28 (0.73)	-2.4	-0.57	0.00	0.00	1.4	-0.41 [-0.74, -0.09]
		Placebo	76	75 (98.7)	-0.01 (0.56)	-2.1	-0.29	0.00	0.17	1.7	
	Week 9	Tezepelumab	73	72 (98.6)	-0.28 (0.77)	-2.3	-0.79	0.00	0.00	1.1	-0.33 [-0.65, -0.00]
		Placebo	76	75 (98.7)	-0.06 (0.59)	-2.1	-0.29	0.00	0.14	1.4	
	Week 10	Tezepelumab	73	71 (97.3)	-0.24 (0.79)	-2.4	-0.71	0.00	0.10	2.0	-0.21 [-0.54, 0.12]
		Placebo	76	74 (97.4)	-0.09 (0.63)	-2.1	-0.29	0.00	0.14	1.9	
	Week 11	Tezepelumab	73	70 (95.9)	-0.33 (0.77)	-2.4	-0.71	-0.14	0.00	2.0	-0.36 [-0.68, -0.03]
		Placebo	76	74 (97.4)	-0.08 (0.62)	-2.1	-0.29	0.00	0.14	2.3	
	Week 12	Tezepelumab	73	70 (95.9)	-0.36 (0.78)	-2.4	-1.00	-0.14	0.00	2.0	-0.45 [-0.78, -0.12]
		Placebo	76	75 (98.7)	-0.05 (0.62)	-2.1	-0.29	0.00	0.17	2.1	
	Week 13	Tezepelumab	73	68 (93.2)	-0.33 (0.82)	-2.4	-1.00	-0.14	0.00	2.0	-0.30 [-0.63, 0.03]
		Placebo	76	74 (97.4)	-0.10 (0.72)	-2.1	-0.33	0.00	0.17	1.9	
	Week 14	Tezepelumab	73	70 (95.9)	-0.32 (0.82)	-2.4	-1.00	-0.14	0.00	2.0	-0.28 [-0.60, 0.05]
		Placebo	76	74 (97.4)	-0.12 (0.67)	-2.2	-0.43	0.00	0.14	1.9	
	Week 15	Tezepelumab	73	69 (94.5)	-0.30 (0.76)	-2.4	-0.86	-0.14	0.00	2.0	-0.21 [-0.54, 0.12]
		Placebo	76	73 (96.1)	-0.16 (0.64)	-2.3	-0.29	0.00	0.14	1.0	
	Week 16	Tezepelumab	73	69 (94.5)	-0.31 (0.74)	-2.4	-0.71	-0.14	0.00	1.7	-0.15 [-0.48, 0.18]
		Placebo	76	74 (97.4)	-0.20 (0.67)	-2.1	-0.50	0.00	0.14	1.2	
	Week 17	Tezepelumab	73	70 (95.9)	-0.33 (0.77)	-2.4	-0.86	-0.14	0.00	1.0	-0.20 [-0.52, 0.13]
		Placebo	76	74 (97.4)	-0.19 (0.67)	-2.1	-0.43	0.00	0.14	1.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WLC\_ILMH0: Course of ASD weekly limiting activity score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly limiting activity score	Week 18	Tezepelumab	73	70 (95.9)	-0.30 (0.77)	-2.3	-1.00	-0.14	0.00	1.3	-0.19 [-0.51, 0.14]
		Placebo	76	73 (96.1)	-0.17 (0.68)	-2.0	-0.43	0.00	0.14	1.6	
	Week 19	Tezepelumab	73	69 (94.5)	-0.29 (0.82)	-2.4	-1.00	-0.14	0.00	2.0	-0.13 [-0.46, 0.20]
		Placebo	76	74 (97.4)	-0.19 (0.67)	-2.1	-0.43	0.00	0.10	1.6	
	Week 20	Tezepelumab	73	70 (95.9)	-0.29 (0.81)	-2.0	-1.00	-0.07	0.00	2.0	-0.17 [-0.50, 0.16]
		Placebo	76	74 (97.4)	-0.17 (0.63)	-2.1	-0.43	0.00	0.05	1.2	
	Week 21	Tezepelumab	73	69 (94.5)	-0.33 (0.80)	-2.3	-0.86	-0.14	0.00	1.7	-0.21 [-0.54, 0.12]
		Placebo	76	73 (96.1)	-0.18 (0.66)	-2.0	-0.43	0.00	0.10	1.1	
	Week 22	Tezepelumab	73	69 (94.5)	-0.30 (0.71)	-2.0	-0.83	-0.14	0.00	1.1	-0.27 [-0.60, 0.06]
		Placebo	76	75 (98.7)	-0.10 (0.72)	-2.1	-0.43	0.00	0.17	2.3	
	Week 23	Tezepelumab	73	69 (94.5)	-0.29 (0.76)	-2.0	-0.83	-0.14	0.00	1.5	-0.23 [-0.56, 0.10]
		Placebo	76	74 (97.4)	-0.13 (0.66)	-2.1	-0.43	0.00	0.17	1.4	
	Week 24	Tezepelumab	73	70 (95.9)	-0.35 (0.77)	-2.4	-0.86	-0.15	0.00	1.3	-0.33 [-0.66, -0.00]
		Placebo	76	75 (98.7)	-0.12 (0.65)	-2.1	-0.43	0.00	0.17	1.2	
	Week 25	Tezepelumab	73	69 (94.5)	-0.32 (0.86)	-2.4	-0.86	-0.14	0.00	2.7	-0.25 [-0.58, 0.08]
		Placebo	76	74 (97.4)	-0.13 (0.67)	-2.2	-0.29	0.00	0.14	1.6	
	Week 26	Tezepelumab	73	68 (93.2)	-0.34 (0.85)	-2.1	-0.90	-0.29	0.00	1.9	-0.28 [-0.61, 0.06]
		Placebo	76	73 (96.1)	-0.12 (0.77)	-2.1	-0.29	0.00	0.17	3.0	
	Week 27	Tezepelumab	73	69 (94.5)	-0.34 (0.86)	-2.1	-1.00	-0.19	0.00	2.1	-0.29 [-0.62, 0.05]
		Placebo	76	73 (96.1)	-0.12 (0.71)	-2.1	-0.43	0.00	0.17	1.9	
	Week 28	Tezepelumab	73	67 (91.8)	-0.28 (0.85)	-2.1	-0.86	-0.02	0.00	1.9	-0.21 [-0.54, 0.12]
		Placebo	76	74 (97.4)	-0.12 (0.65)	-2.1	-0.43	0.00	0.17	1.3	
	Week 29	Tezepelumab	73	66 (90.4)	-0.39 (0.82)	-2.4	-1.00	-0.14	0.00	1.7	-0.36 [-0.70, -0.03]
		Placebo	76	74 (97.4)	-0.12 (0.69)	-2.1	-0.43	0.00	0.17	1.3	
	Week 30	Tezepelumab	73	69 (94.5)	-0.40 (0.83)	-2.4	-0.80	-0.29	0.00	1.9	-0.43 [-0.76, -0.10]
		Placebo	76	74 (97.4)	-0.09 (0.60)	-1.9	-0.29	0.00	0.14	1.0	
	Week 31	Tezepelumab	73	67 (91.8)	-0.39 (0.87)	-2.4	-1.00	-0.29	0.00	1.9	-0.35 [-0.69, -0.02]
		Placebo	76	73 (96.1)	-0.13 (0.62)	-1.6	-0.43	0.00	0.17	1.6	
	Week 32	Tezepelumab	73	66 (90.4)	-0.37 (0.87)	-2.4	-1.00	-0.01	0.00	1.9	-0.28 [-0.61, 0.06]
		Placebo	76	73 (96.1)	-0.16 (0.59)	-1.4	-0.43	0.00	0.14	1.1	
	Week 33	Tezepelumab	73	67 (91.8)	-0.41 (0.80)	-2.3	-1.00	-0.29	0.00	1.5	-0.30 [-0.64, 0.03]
		Placebo	76	74 (97.4)	-0.19 (0.63)	-2.1	-0.43	-0.13	0.00	1.4	
	Week 34	Tezepelumab	73	67 (91.8)	-0.43 (0.78)	-2.3	-1.00	-0.14	0.00	1.6	-0.33 [-0.66, 0.01]
		Placebo	76	72 (94.7)	-0.21 (0.56)	-2.1	-0.40	0.00	0.00	1.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WLC\_ILMH0: Course of ASD weekly limiting activity score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly limiting activity score	Week 35	Tezepelumab	73	67 (91.8)	-0.37 (0.84)	-2.3	-1.00	-0.14	0.00	1.9	-0.27 [-0.61, 0.06]
		Placebo	76	74 (97.4)	-0.18 (0.58)	-2.0	-0.43	-0.01	0.00	1.0	
	Week 36	Tezepelumab	73	69 (94.5)	-0.37 (0.83)	-2.4	-1.00	-0.14	0.00	1.3	-0.27 [-0.60, 0.06]
		Placebo	76	73 (96.1)	-0.17 (0.62)	-2.1	-0.43	0.00	0.14	1.3	
	Week 37	Tezepelumab	73	68 (93.2)	-0.42 (0.89)	-2.4	-1.00	-0.21	0.00	1.7	-0.39 [-0.73, -0.06]
		Placebo	76	73 (96.1)	-0.13 (0.58)	-1.9	-0.43	0.00	0.17	1.0	
	Week 38	Tezepelumab	73	67 (91.8)	-0.42 (0.87)	-2.3	-1.00	-0.19	0.00	2.2	-0.39 [-0.72, -0.05]
		Placebo	76	72 (94.7)	-0.13 (0.63)	-2.3	-0.39	0.00	0.17	1.1	
	Week 39	Tezepelumab	73	65 (89.0)	-0.43 (0.86)	-2.1	-1.00	-0.20	0.00	1.9	-0.40 [-0.74, -0.06]
		Placebo	76	73 (96.1)	-0.14 (0.58)	-1.9	-0.29	0.00	0.14	1.0	
	Week 40	Tezepelumab	73	65 (89.0)	-0.43 (0.85)	-2.0	-1.00	-0.20	0.00	1.7	-0.41 [-0.75, -0.08]
		Placebo	76	72 (94.7)	-0.13 (0.57)	-1.9	-0.39	0.00	0.14	1.1	
	Week 41	Tezepelumab	73	63 (86.3)	-0.47 (0.87)	-2.1	-1.00	-0.29	0.14	1.9	-0.33 [-0.67, 0.01]
		Placebo	76	72 (94.7)	-0.22 (0.62)	-2.0	-0.43	-0.14	0.00	1.4	
	Week 42	Tezepelumab	73	64 (87.7)	-0.43 (0.88)	-2.1	-1.00	-0.29	0.00	1.5	-0.30 [-0.64, 0.04]
		Placebo	76	73 (96.1)	-0.21 (0.58)	-1.6	-0.47	-0.14	0.00	1.2	
	Week 43	Tezepelumab	73	64 (87.7)	-0.41 (0.89)	-2.3	-1.00	-0.21	0.00	1.7	-0.30 [-0.64, 0.03]
		Placebo	76	74 (97.4)	-0.17 (0.64)	-1.9	-0.43	-0.01	0.14	1.3	
	Week 44	Tezepelumab	73	63 (86.3)	-0.46 (0.89)	-2.0	-1.00	-0.29	0.00	1.9	-0.33 [-0.67, 0.01]
		Placebo	76	73 (96.1)	-0.21 (0.63)	-1.9	-0.43	-0.14	0.00	1.4	
	Week 45	Tezepelumab	73	63 (86.3)	-0.45 (0.86)	-2.1	-1.00	-0.33	0.00	1.9	-0.32 [-0.65, 0.02]
		Placebo	76	73 (96.1)	-0.21 (0.63)	-2.2	-0.43	-0.14	0.00	1.0	
	Week 46	Tezepelumab	73	64 (87.7)	-0.42 (0.86)	-2.1	-1.00	-0.29	0.00	1.7	-0.28 [-0.62, 0.06]
		Placebo	76	70 (92.1)	-0.21 (0.64)	-2.1	-0.43	-0.14	0.00	1.2	
	Week 47	Tezepelumab	73	63 (86.3)	-0.41 (0.91)	-2.1	-1.00	-0.29	0.00	1.9	-0.26 [-0.60, 0.08]
		Placebo	76	71 (93.4)	-0.21 (0.58)	-1.7	-0.47	0.00	0.00	1.0	
	Week 48	Tezepelumab	73	58 (79.5)	-0.33 (0.89)	-2.1	-1.00	-0.17	0.14	1.9	-0.16 [-0.51, 0.19]
		Placebo	76	69 (90.8)	-0.21 (0.59)	-1.7	-0.54	0.00	0.14	1.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table ST1WLC\_ILMC0: Change from baseline in ASD weekly limiting activity score - MMRM results  
 DITTTL

Time	Treatment	N	n (%)	Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 1	Tezepelumab	73	72 (98.6)	-0.13 (0.08)	(-0.28, 0.01)	-0.13 (0.11)	(-0.34, 0.08)	0.213
	Placebo	76	76 (100.0)	-0.00 (0.07)	(-0.15, 0.14)			
Week 2	Tezepelumab	73	73 (100.0)	-0.26 (0.08)	(-0.41, -0.11)	-0.27 (0.11)	(-0.48, -0.06)	0.010 *
	Placebo	76	76 (100.0)	0.02 (0.07)	(-0.13, 0.16)			
Week 3	Tezepelumab	73	73 (100.0)	-0.26 (0.08)	(-0.41, -0.11)	-0.27 (0.11)	(-0.48, -0.06)	0.012 *
	Placebo	76	76 (100.0)	0.01 (0.07)	(-0.14, 0.16)			
Week 4	Tezepelumab	73	72 (98.6)	-0.29 (0.08)	(-0.44, -0.14)	-0.31 (0.11)	(-0.51, -0.10)	0.004 *
	Placebo	76	76 (100.0)	0.02 (0.07)	(-0.13, 0.16)			
Week 5	Tezepelumab	73	72 (98.6)	-0.33 (0.08)	(-0.48, -0.18)	-0.27 (0.11)	(-0.47, -0.06)	0.013 *
	Placebo	76	74 (97.4)	-0.06 (0.07)	(-0.21, 0.08)			
Week 6	Tezepelumab	73	70 (95.9)	-0.29 (0.08)	(-0.44, -0.14)	-0.26 (0.11)	(-0.46, -0.05)	0.017 *
	Placebo	76	74 (97.4)	-0.03 (0.07)	(-0.18, 0.12)			
Week 7	Tezepelumab	73	71 (97.3)	-0.28 (0.08)	(-0.43, -0.14)	-0.28 (0.11)	(-0.49, -0.08)	0.008 *
	Placebo	76	75 (98.7)	-0.00 (0.07)	(-0.15, 0.15)			
Week 8	Tezepelumab	73	71 (97.3)	-0.28 (0.08)	(-0.43, -0.13)	-0.25 (0.11)	(-0.46, -0.04)	0.017 *
	Placebo	76	75 (98.7)	-0.02 (0.07)	(-0.17, 0.12)			
Week 9	Tezepelumab	73	72 (98.6)	-0.28 (0.08)	(-0.42, -0.13)	-0.20 (0.11)	(-0.41, 0.01)	0.059
	Placebo	76	75 (98.7)	-0.07 (0.07)	(-0.22, 0.07)			
Week 10	Tezepelumab	73	71 (97.3)	-0.24 (0.08)	(-0.39, -0.09)	-0.13 (0.11)	(-0.34, 0.08)	0.214
	Placebo	76	74 (97.4)	-0.10 (0.07)	(-0.25, 0.04)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WLC\_ILMC0: Change from baseline in ASD weekly limiting activity score - MMRM results  
 DITTTL

Change from baseline in ASD weekly limiting activity score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Time	Treatment	N	n (%)						
Week 11	Tezepelumab	73	70 (95.9)	-0.32 (0.08)	(-0.47, -0.17)	-0.23 (0.11)	(-0.44, -0.02)	0.033	*
	Placebo	76	74 (97.4)	-0.10 (0.07)	(-0.24, 0.05)				
Week 12	Tezepelumab	73	70 (95.9)	-0.35 (0.08)	(-0.50, -0.20)	-0.29 (0.11)	(-0.50, -0.08)	0.007	*
	Placebo	76	75 (98.7)	-0.06 (0.07)	(-0.21, 0.09)				
Week 13	Tezepelumab	73	68 (93.2)	-0.32 (0.08)	(-0.47, -0.17)	-0.20 (0.11)	(-0.42, 0.01)	0.057	
	Placebo	76	74 (97.4)	-0.11 (0.07)	(-0.26, 0.03)				
Week 14	Tezepelumab	73	70 (95.9)	-0.31 (0.08)	(-0.46, -0.16)	-0.18 (0.11)	(-0.39, 0.03)	0.089	
	Placebo	76	74 (97.4)	-0.13 (0.07)	(-0.28, 0.02)				
Week 15	Tezepelumab	73	69 (94.5)	-0.29 (0.08)	(-0.44, -0.14)	-0.13 (0.11)	(-0.34, 0.08)	0.228	
	Placebo	76	73 (96.1)	-0.16 (0.07)	(-0.31, -0.02)				
Week 16	Tezepelumab	73	69 (94.5)	-0.30 (0.08)	(-0.45, -0.15)	-0.09 (0.11)	(-0.30, 0.12)	0.397	
	Placebo	76	74 (97.4)	-0.21 (0.07)	(-0.35, -0.06)				
Week 17	Tezepelumab	73	70 (95.9)	-0.31 (0.08)	(-0.47, -0.16)	-0.12 (0.11)	(-0.33, 0.09)	0.258	
	Placebo	76	74 (97.4)	-0.19 (0.07)	(-0.34, -0.05)				
Week 18	Tezepelumab	73	70 (95.9)	-0.29 (0.08)	(-0.44, -0.14)	-0.12 (0.11)	(-0.33, 0.09)	0.272	
	Placebo	76	73 (96.1)	-0.17 (0.07)	(-0.32, -0.02)				
Week 19	Tezepelumab	73	69 (94.5)	-0.29 (0.08)	(-0.44, -0.13)	-0.09 (0.11)	(-0.30, 0.12)	0.419	
	Placebo	76	74 (97.4)	-0.20 (0.07)	(-0.35, -0.05)				
Week 20	Tezepelumab	73	70 (95.9)	-0.28 (0.08)	(-0.43, -0.13)	-0.10 (0.11)	(-0.31, 0.11)	0.338	
	Placebo	76	74 (97.4)	-0.17 (0.07)	(-0.32, -0.03)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WLC\_ILMC0: Change from baseline in ASD weekly limiting activity score - MMRM results  
 DITTTL

Change from baseline in ASD weekly limiting activity score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 21	Tezepelumab	73	69 (94.5)	-0.31 (0.08)	(-0.46, -0.16)	-0.13 (0.11)	(-0.34, 0.08)	0.228
	Placebo	76	73 (96.1)	-0.18 (0.07)	(-0.33, -0.03)			
Week 22	Tezepelumab	73	69 (94.5)	-0.29 (0.08)	(-0.44, -0.14)	-0.18 (0.11)	(-0.39, 0.03)	0.091
	Placebo	76	75 (98.7)	-0.11 (0.07)	(-0.26, 0.04)			
Week 23	Tezepelumab	73	69 (94.5)	-0.29 (0.08)	(-0.44, -0.14)	-0.15 (0.11)	(-0.36, 0.06)	0.168
	Placebo	76	74 (97.4)	-0.14 (0.07)	(-0.29, 0.01)			
Week 24	Tezepelumab	73	70 (95.9)	-0.34 (0.08)	(-0.49, -0.19)	-0.21 (0.11)	(-0.42, -0.00)	0.048 *
	Placebo	76	75 (98.7)	-0.12 (0.07)	(-0.27, 0.02)			
Week 25	Tezepelumab	73	69 (94.5)	-0.30 (0.08)	(-0.46, -0.15)	-0.16 (0.11)	(-0.37, 0.06)	0.147
	Placebo	76	74 (97.4)	-0.15 (0.07)	(-0.29, -0.00)			
Week 26	Tezepelumab	73	68 (93.2)	-0.31 (0.08)	(-0.47, -0.16)	-0.19 (0.11)	(-0.40, 0.02)	0.080
	Placebo	76	73 (96.1)	-0.12 (0.07)	(-0.27, 0.02)			
Week 27	Tezepelumab	73	69 (94.5)	-0.32 (0.08)	(-0.47, -0.17)	-0.19 (0.11)	(-0.40, 0.02)	0.074
	Placebo	76	73 (96.1)	-0.13 (0.08)	(-0.28, 0.02)			
Week 28	Tezepelumab	73	67 (91.8)	-0.25 (0.08)	(-0.41, -0.10)	-0.13 (0.11)	(-0.35, 0.08)	0.214
	Placebo	76	74 (97.4)	-0.12 (0.08)	(-0.27, 0.03)			
Week 29	Tezepelumab	73	66 (90.4)	-0.34 (0.08)	(-0.49, -0.19)	-0.22 (0.11)	(-0.43, -0.01)	0.042 *
	Placebo	76	74 (97.4)	-0.12 (0.08)	(-0.27, 0.03)			
Week 30	Tezepelumab	73	69 (94.5)	-0.38 (0.08)	(-0.53, -0.23)	-0.29 (0.11)	(-0.50, -0.08)	0.008 *
	Placebo	76	74 (97.4)	-0.09 (0.08)	(-0.24, 0.05)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WLC\_ILMC0: Change from baseline in ASD weekly limiting activity score - MMRM results  
 DITTTL

Change from baseline in ASD weekly limiting activity score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 31	Tezepelumab	73	67 (91.8)	-0.37 (0.08)	(-0.52, -0.21)	-0.25 (0.11)	(-0.46, -0.04)	0.021 *	
	Placebo	76	73 (96.1)	-0.12 (0.08)	(-0.26, 0.03)				
Week 32	Tezepelumab	73	66 (90.4)	-0.36 (0.08)	(-0.51, -0.20)	-0.20 (0.11)	(-0.41, 0.01)	0.066	
	Placebo	76	73 (96.1)	-0.16 (0.08)	(-0.30, -0.01)				
Week 33	Tezepelumab	73	67 (91.8)	-0.38 (0.08)	(-0.53, -0.22)	-0.18 (0.11)	(-0.40, 0.03)	0.091	
	Placebo	76	74 (97.4)	-0.19 (0.08)	(-0.34, -0.05)				
Week 34	Tezepelumab	73	67 (91.8)	-0.40 (0.08)	(-0.55, -0.24)	-0.19 (0.11)	(-0.40, 0.02)	0.082	
	Placebo	76	72 (94.7)	-0.21 (0.08)	(-0.36, -0.06)				
Week 35	Tezepelumab	73	67 (91.8)	-0.35 (0.08)	(-0.51, -0.20)	-0.17 (0.11)	(-0.38, 0.04)	0.118	
	Placebo	76	74 (97.4)	-0.18 (0.08)	(-0.33, -0.04)				
Week 36	Tezepelumab	73	69 (94.5)	-0.36 (0.08)	(-0.51, -0.20)	-0.18 (0.11)	(-0.40, 0.03)	0.092	
	Placebo	76	73 (96.1)	-0.17 (0.08)	(-0.32, -0.03)				
Week 37	Tezepelumab	73	68 (93.2)	-0.40 (0.08)	(-0.55, -0.24)	-0.26 (0.11)	(-0.47, -0.05)	0.017 *	
	Placebo	76	73 (96.1)	-0.14 (0.08)	(-0.29, 0.01)				
Week 38	Tezepelumab	73	67 (91.8)	-0.40 (0.08)	(-0.55, -0.25)	-0.28 (0.11)	(-0.49, -0.06)	0.011 *	
	Placebo	76	72 (94.7)	-0.12 (0.08)	(-0.27, 0.02)				
Week 39	Tezepelumab	73	65 (89.0)	-0.40 (0.08)	(-0.55, -0.24)	-0.26 (0.11)	(-0.47, -0.05)	0.017 *	
	Placebo	76	73 (96.1)	-0.14 (0.08)	(-0.29, 0.01)				
Week 40	Tezepelumab	73	65 (89.0)	-0.39 (0.08)	(-0.54, -0.23)	-0.26 (0.11)	(-0.47, -0.05)	0.017 *	
	Placebo	76	72 (94.7)	-0.13 (0.08)	(-0.28, 0.02)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table ST1WLC\_ILMC0: Change from baseline in ASD weekly limiting activity score - MMRM results  
 DITTTL

Change from baseline in ASD weekly limiting activity score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 41	Tezepelumab	73	63 (86.3)	-0.43 (0.08)	(-0.58, -0.27)	-0.20 (0.11)	(-0.41, 0.02)	0.073
	Placebo	76	72 (94.7)	-0.23 (0.08)	(-0.38, -0.08)			
Week 42	Tezepelumab	73	64 (87.7)	-0.39 (0.08)	(-0.55, -0.23)	-0.18 (0.11)	(-0.39, 0.04)	0.107
	Placebo	76	73 (96.1)	-0.21 (0.08)	(-0.36, -0.06)			
Week 43	Tezepelumab	73	64 (87.7)	-0.37 (0.08)	(-0.53, -0.22)	-0.19 (0.11)	(-0.41, 0.03)	0.084
	Placebo	76	74 (97.4)	-0.18 (0.08)	(-0.33, -0.03)			
Week 44	Tezepelumab	73	63 (86.3)	-0.42 (0.08)	(-0.58, -0.26)	-0.21 (0.11)	(-0.43, 0.00)	0.055
	Placebo	76	73 (96.1)	-0.21 (0.08)	(-0.36, -0.06)			
Week 45	Tezepelumab	73	63 (86.3)	-0.41 (0.08)	(-0.57, -0.26)	-0.20 (0.11)	(-0.42, 0.01)	0.066
	Placebo	76	73 (96.1)	-0.21 (0.08)	(-0.36, -0.06)			
Week 46	Tezepelumab	73	64 (87.7)	-0.40 (0.08)	(-0.55, -0.24)	-0.20 (0.11)	(-0.42, 0.02)	0.072
	Placebo	76	70 (92.1)	-0.20 (0.08)	(-0.35, -0.05)			
Week 47	Tezepelumab	73	63 (86.3)	-0.38 (0.08)	(-0.54, -0.22)	-0.17 (0.11)	(-0.39, 0.04)	0.117
	Placebo	76	71 (93.4)	-0.21 (0.08)	(-0.36, -0.06)			
Week 48	Tezepelumab	73	58 (79.5)	-0.36 (0.08)	(-0.52, -0.20)	-0.17 (0.11)	(-0.39, 0.04)	0.118
	Placebo	76	69 (90.8)	-0.18 (0.08)	(-0.33, -0.03)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WTC\_KLMH0: Course of ASD weekly total score  
 DITTTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly total score	Baseline	Tezepelumab	15	15 (100.0)	1.22 (0.60)	0.1	0.87	1.15	1.68	2.4	
		Placebo	20	20 (100.0)	1.38 (0.83)	0.2	0.74	1.28	2.11	2.8	
	Week 1	Tezepelumab	15	14 (93.3)	0.98 (0.59)	0.1	0.50	0.93	1.39	2.2	
		Placebo	20	20 (100.0)	1.23 (0.97)	0.0	0.61	1.01	1.97	3.5	
	Week 2	Tezepelumab	15	14 (93.3)	0.96 (0.73)	0.0	0.33	0.86	1.21	2.5	
		Placebo	20	19 (95.0)	1.03 (0.92)	0.0	0.23	0.77	1.90	2.9	
	Week 3	Tezepelumab	15	14 (93.3)	0.90 (0.68)	0.0	0.46	0.85	1.28	2.2	
		Placebo	20	17 (85.0)	0.75 (0.85)	0.0	0.08	0.57	1.24	2.8	
	Week 4	Tezepelumab	15	12 (80.0)	0.83 (0.70)	0.0	0.16	0.87	1.30	2.1	
		Placebo	20	17 (85.0)	0.67 (0.69)	0.0	0.02	0.24	1.30	1.9	
	Week 5	Tezepelumab	15	12 (80.0)	0.84 (0.68)	0.0	0.18	0.82	1.30	2.1	
		Placebo	20	16 (80.0)	0.73 (0.57)	0.0	0.13	0.81	1.14	1.9	
	Week 6	Tezepelumab	15	11 (73.3)	0.77 (0.63)	0.0	0.06	0.90	1.19	1.9	
		Placebo	20	16 (80.0)	0.65 (0.63)	0.0	0.05	0.52	1.10	1.9	
	Week 7	Tezepelumab	15	12 (80.0)	0.78 (0.60)	0.0	0.26	0.82	1.20	1.9	
		Placebo	20	16 (80.0)	0.75 (0.68)	0.0	0.04	0.74	1.16	2.1	
	Week 8	Tezepelumab	15	13 (86.7)	0.85 (0.68)	0.0	0.09	0.75	1.25	2.2	
		Placebo	20	16 (80.0)	0.83 (0.68)	0.0	0.27	0.82	1.22	2.3	
	Week 9	Tezepelumab	15	10 (66.7)	0.76 (0.61)	0.0	0.12	0.79	1.15	1.9	
		Placebo	20	17 (85.0)	0.88 (0.74)	0.0	0.45	0.90	1.06	2.7	
	Week 10	Tezepelumab	15	10 (66.7)	0.65 (0.64)	0.0	0.08	0.43	1.27	1.5	
		Placebo	20	15 (75.0)	0.52 (0.49)	0.0	0.00	0.52	0.98	1.4	
	Week 11	Tezepelumab	15	12 (80.0)	0.74 (0.66)	0.0	0.03	1.00	1.27	1.6	
		Placebo	20	17 (85.0)	0.63 (0.70)	0.0	0.00	0.36	1.04	2.6	
	Week 12	Tezepelumab	15	12 (80.0)	0.73 (0.64)	0.0	0.04	0.87	1.29	1.5	
		Placebo	20	15 (75.0)	0.69 (0.67)	0.0	0.07	0.76	0.98	2.4	
	Week 13	Tezepelumab	15	9 (60.0)	0.58 (0.56)	0.0	0.00	0.73	1.11	1.3	
		Placebo	20	15 (75.0)	0.72 (0.80)	0.0	0.00	0.53	1.08	3.0	
	Week 14	Tezepelumab	15	8 (53.3)	0.66 (0.56)	0.0	0.05	0.77	1.16	1.3	
		Placebo	20	13 (65.0)	0.50 (0.48)	0.0	0.00	0.50	0.90	1.2	
	Week 15	Tezepelumab	15	10 (66.7)	0.57 (0.58)	0.0	0.00	0.47	1.06	1.5	
		Placebo	20	15 (75.0)	0.78 (0.74)	0.0	0.00	0.72	1.10	2.6	
	Week 16	Tezepelumab	15	10 (66.7)	0.59 (0.54)	0.0	0.03	0.64	1.01	1.4	
		Placebo	20	15 (75.0)	0.71 (0.67)	0.0	0.08	0.63	1.03	2.5	
Week 17	Tezepelumab	15	9 (60.0)	0.52 (0.54)	0.0	0.00	0.49	1.00	1.4		
	Placebo	20	13 (65.0)	0.63 (0.55)	0.0	0.02	0.50	1.09	1.6		

Note: DITTTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022

Table NT1WTC\_KLMH0: Course of ASD weekly total score  
 DITTTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly total score	Week 18	Tezepelumab	15	10 (66.7)	0.55 (0.48)	0.0	0.05	0.69	0.85	1.3	
		Placebo	20	13 (65.0)	0.79 (0.93)	0.0	0.10	0.58	1.13	3.4	
	Week 19	Tezepelumab	15	10 (66.7)	0.51 (0.46)	0.0	0.03	0.48	0.97	1.2	
		Placebo	20	15 (75.0)	0.78 (0.86)	0.0	0.03	0.45	1.06	3.1	
	Week 20	Tezepelumab	15	7 (46.7)	0.33 (0.40)	0.0	0.00	0.20	0.76	1.0	
		Placebo	20	15 (75.0)	0.69 (0.86)	0.0	0.00	0.43	0.92	3.3	
	Week 21	Tezepelumab	15	8 (53.3)	0.44 (0.50)	0.0	0.00	0.23	0.94	1.2	
		Placebo	20	14 (70.0)	0.62 (0.83)	0.0	0.00	0.36	0.90	3.1	
	Week 22	Tezepelumab	15	8 (53.3)	0.44 (0.52)	0.0	0.00	0.20	0.94	1.3	
		Placebo	20	13 (65.0)	0.80 (0.89)	0.0	0.22	0.50	1.01	3.1	
	Week 23	Tezepelumab	15	9 (60.0)	0.53 (0.61)	0.0	0.00	0.16	1.02	1.4	
		Placebo	20	14 (70.0)	0.81 (1.07)	0.0	0.01	0.49	0.98	3.8	
	Week 24	Tezepelumab	15	10 (66.7)	0.55 (0.54)	0.0	0.00	0.50	1.03	1.3	
		Placebo	20	13 (65.0)	0.67 (0.88)	0.0	0.03	0.51	0.73	3.3	
	Week 25	Tezepelumab	15	9 (60.0)	0.47 (0.51)	0.0	0.00	0.30	0.90	1.2	
		Placebo	20	12 (60.0)	0.57 (0.58)	0.0	0.13	0.46	0.72	2.0	
	Week 26	Tezepelumab	15	8 (53.3)	0.39 (0.46)	0.0	0.03	0.19	0.77	1.2	
		Placebo	20	14 (70.0)	0.49 (0.55)	0.0	0.00	0.35	0.78	1.9	
	Week 27	Tezepelumab	15	8 (53.3)	0.40 (0.47)	0.0	0.01	0.26	0.76	1.2	
		Placebo	20	13 (65.0)	0.63 (0.57)	0.0	0.21	0.53	0.90	2.0	
	Week 28	Tezepelumab	15	8 (53.3)	0.24 (0.38)	0.0	0.00	0.01	0.44	1.0	
		Placebo	20	14 (70.0)	0.76 (0.78)	0.0	0.05	0.62	1.10	2.8	
	Week 29	Tezepelumab	15	7 (46.7)	0.33 (0.37)	0.0	0.00	0.21	0.53	1.1	
		Placebo	20	13 (65.0)	0.78 (0.79)	0.0	0.44	0.50	0.90	2.7	
	Week 30	Tezepelumab	15	8 (53.3)	0.30 (0.43)	0.0	0.03	0.08	0.48	1.2	
		Placebo	20	8 (40.0)	0.57 (0.44)	0.0	0.21	0.60	0.84	1.3	
	Week 31	Tezepelumab	15	7 (46.7)	0.26 (0.41)	0.0	0.00	0.00	0.50	1.1	
		Placebo	20	12 (60.0)	0.42 (0.37)	0.0	0.10	0.40	0.64	1.2	
	Week 32	Tezepelumab	15	8 (53.3)	0.25 (0.38)	0.0	0.00	0.03	0.47	1.0	
		Placebo	20	11 (55.0)	0.60 (0.59)	0.0	0.14	0.46	0.90	1.9	
	Week 33	Tezepelumab	15	8 (53.3)	0.38 (0.50)	0.0	0.00	0.12	0.81	1.2	
		Placebo	20	13 (65.0)	0.44 (0.53)	0.0	0.00	0.33	0.66	1.9	
	Week 34	Tezepelumab	15	8 (53.3)	0.35 (0.50)	0.0	0.00	0.04	0.80	1.2	
		Placebo	20	10 (50.0)	0.66 (0.83)	0.0	0.05	0.36	0.90	2.4	
	Week 35	Tezepelumab	15	8 (53.3)	0.46 (0.53)	0.0	0.05	0.24	0.89	1.3	
		Placebo	20	10 (50.0)	0.36 (0.53)	0.0	0.00	0.13	0.54	1.6	

Note: DITTTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022

Table NT1WTC\_KLMH0: Course of ASD weekly total score  
 DITTTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly total score	Week 36	Tezepelumab	15	8 (53.3)	0.38 (0.50)	0.0	0.00	0.13	0.79	1.2	
		Placebo	20	11 (55.0)	0.41 (0.48)	0.0	0.00	0.23	0.88	1.4	
	Week 37	Tezepelumab	15	8 (53.3)	0.41 (0.53)	0.0	0.02	0.11	0.86	1.3	
		Placebo	20	11 (55.0)	0.45 (0.44)	0.0	0.00	0.37	0.90	1.4	
	Week 38	Tezepelumab	15	7 (46.7)	0.41 (0.53)	0.0	0.00	0.05	1.08	1.1	
		Placebo	20	12 (60.0)	0.56 (0.49)	0.0	0.16	0.44	0.93	1.4	
	Week 39	Tezepelumab	15	8 (53.3)	0.39 (0.50)	0.0	0.00	0.16	0.80	1.2	
		Placebo	20	11 (55.0)	0.50 (0.47)	0.0	0.00	0.35	0.92	1.4	
	Week 40	Tezepelumab	15	8 (53.3)	0.37 (0.49)	0.0	0.00	0.05	0.85	1.1	
		Placebo	20	10 (50.0)	0.55 (0.48)	0.0	0.04	0.51	0.90	1.4	
	Week 41	Tezepelumab	15	8 (53.3)	0.48 (0.56)	0.0	0.03	0.26	0.90	1.5	
		Placebo	20	9 (45.0)	0.57 (0.53)	0.0	0.08	0.50	0.90	1.6	
	Week 42	Tezepelumab	15	8 (53.3)	0.45 (0.65)	0.0	0.00	0.06	0.96	1.6	
		Placebo	20	10 (50.0)	0.71 (0.83)	0.0	0.00	0.50	0.90	2.7	
	Week 43	Tezepelumab	15	8 (53.3)	0.39 (0.57)	0.0	0.00	0.00	0.92	1.3	
		Placebo	20	11 (55.0)	0.60 (0.62)	0.0	0.00	0.47	1.22	1.6	
	Week 44	Tezepelumab	15	7 (46.7)	0.44 (0.59)	0.0	0.00	0.00	1.17	1.3	
		Placebo	20	11 (55.0)	0.67 (0.69)	0.0	0.00	0.70	0.92	2.2	
	Week 45	Tezepelumab	15	7 (46.7)	0.37 (0.49)	0.0	0.00	0.00	1.00	1.1	
		Placebo	20	11 (55.0)	0.75 (0.75)	0.0	0.04	0.62	1.38	2.1	
	Week 46	Tezepelumab	15	7 (46.7)	0.46 (0.49)	0.0	0.00	0.48	1.02	1.2	
		Placebo	20	9 (45.0)	0.78 (0.58)	0.0	0.47	0.90	1.00	1.8	
	Week 47	Tezepelumab	15	6 (40.0)	0.33 (0.44)	0.0	0.00	0.15	0.56	1.1	
		Placebo	20	10 (50.0)	0.54 (0.61)	0.0	0.00	0.39	0.90	1.7	
	Week 48	Tezepelumab	15	5 (33.3)	0.22 (0.30)	0.0	0.00	0.00	0.53	0.6	
		Placebo	20	10 (50.0)	0.49 (0.64)	0.0	0.00	0.26	0.80	1.9	
	Week 49	Tezepelumab	15	7 (46.7)	0.28 (0.41)	0.0	0.00	0.03	0.59	1.1	
		Placebo	20	10 (50.0)	0.53 (0.53)	0.0	0.00	0.44	0.90	1.3	
	Week 50	Tezepelumab	15	6 (40.0)	0.35 (0.48)	0.0	0.00	0.17	0.55	1.2	
		Placebo	20	10 (50.0)	0.57 (0.62)	0.0	0.02	0.45	0.90	1.8	
	Week 51	Tezepelumab	15	7 (46.7)	0.28 (0.42)	0.0	0.00	0.00	0.51	1.1	
		Placebo	20	12 (60.0)	0.71 (0.65)	0.0	0.00	0.75	1.16	1.8	
	Week 52	Tezepelumab	15	8 (53.3)	0.26 (0.42)	0.0	0.00	0.02	0.45	1.2	
		Placebo	20	11 (55.0)	0.42 (0.47)	0.0	0.00	0.40	0.80	1.4	

Note: DITTTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022



Table NT1WTC\_KLMH0: Course of ASD weekly total score  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly total score	Week 1	Tezepelumab	15	14 (93.3)	-0.24 (0.31)	-1.1	-0.24	-0.15	-0.04	0.1	-0.25 [-0.93, 0.44]
		Placebo	20	20 (100.0)	-0.16 (0.34)	-0.6	-0.41	-0.15	-0.05	0.7	
	Week 2	Tezepelumab	15	14 (93.3)	-0.25 (0.45)	-1.1	-0.56	-0.08	0.01	0.3	0.24 [-0.45, 0.94]
		Placebo	20	19 (95.0)	-0.38 (0.58)	-2.5	-0.55	-0.27	-0.07	0.1	
	Week 3	Tezepelumab	15	14 (93.3)	-0.32 (0.47)	-1.2	-0.63	-0.15	-0.04	0.3	0.42 [-0.30, 1.13]
		Placebo	20	17 (85.0)	-0.52 (0.49)	-2.0	-0.70	-0.42	-0.21	0.0	
	Week 4	Tezepelumab	15	12 (80.0)	-0.41 (0.48)	-1.4	-0.61	-0.19	-0.13	0.1	0.33 [-0.42, 1.07]
		Placebo	20	17 (85.0)	-0.58 (0.53)	-2.3	-0.70	-0.51	-0.33	0.0	
	Week 5	Tezepelumab	15	12 (80.0)	-0.40 (0.47)	-1.4	-0.75	-0.22	-0.05	0.0	0.34 [-0.41, 1.10]
		Placebo	20	16 (80.0)	-0.59 (0.59)	-1.8	-0.96	-0.42	-0.11	0.0	
	Week 6	Tezepelumab	15	11 (73.3)	-0.43 (0.40)	-1.4	-0.66	-0.42	-0.11	0.1	0.39 [-0.38, 1.17]
		Placebo	20	16 (80.0)	-0.65 (0.64)	-2.4	-0.74	-0.48	-0.24	0.0	
	Week 7	Tezepelumab	15	12 (80.0)	-0.45 (0.44)	-1.4	-0.61	-0.34	-0.16	0.1	0.16 [-0.59, 0.91]
		Placebo	20	16 (80.0)	-0.53 (0.47)	-1.7	-0.74	-0.38	-0.19	0.0	
	Week 8	Tezepelumab	15	13 (86.7)	-0.34 (0.40)	-1.3	-0.40	-0.30	-0.13	0.2	0.34 [-0.39, 1.08]
		Placebo	20	16 (80.0)	-0.49 (0.46)	-1.7	-0.67	-0.38	-0.21	0.1	
	Week 9	Tezepelumab	15	10 (66.7)	-0.37 (0.44)	-1.4	-0.53	-0.21	-0.11	0.2	0.29 [-0.49, 1.08]
		Placebo	20	17 (85.0)	-0.51 (0.48)	-1.8	-0.68	-0.43	-0.27	0.3	
	Week 10	Tezepelumab	15	10 (66.7)	-0.49 (0.48)	-1.3	-0.90	-0.43	-0.13	0.3	0.45 [-0.36, 1.26]
		Placebo	20	15 (75.0)	-0.71 (0.52)	-1.8	-0.89	-0.43	-0.36	-0.2	
	Week 11	Tezepelumab	15	12 (80.0)	-0.45 (0.55)	-1.4	-0.86	-0.37	-0.11	0.4	0.49 [-0.26, 1.25]
		Placebo	20	17 (85.0)	-0.75 (0.66)	-2.4	-0.90	-0.47	-0.33	-0.1	
	Week 12	Tezepelumab	15	12 (80.0)	-0.46 (0.58)	-1.4	-0.84	-0.43	-0.11	0.5	0.44 [-0.33, 1.20]
		Placebo	20	15 (75.0)	-0.69 (0.53)	-1.8	-1.01	-0.45	-0.36	-0.2	
	Week 13	Tezepelumab	15	9 (60.0)	-0.61 (0.59)	-1.4	-1.00	-0.51	-0.14	0.3	0.09 [-0.74, 0.92]
		Placebo	20	15 (75.0)	-0.66 (0.59)	-1.9	-0.89	-0.46	-0.33	0.2	
	Week 14	Tezepelumab	15	8 (53.3)	-0.54 (0.63)	-1.4	-1.17	-0.34	-0.09	0.3	0.56 [-0.34, 1.46]
		Placebo	20	13 (65.0)	-0.93 (0.74)	-2.5	-1.16	-0.80	-0.38	0.0	
	Week 15	Tezepelumab	15	10 (66.7)	-0.62 (0.62)	-1.4	-1.13	-0.62	-0.11	0.3	-0.01 [-0.81, 0.79]
		Placebo	20	15 (75.0)	-0.62 (0.63)	-1.9	-0.96	-0.38	-0.17	0.3	
	Week 16	Tezepelumab	15	10 (66.7)	-0.66 (0.64)	-1.4	-1.21	-0.75	-0.13	0.4	0.06 [-0.74, 0.86]
		Placebo	20	15 (75.0)	-0.70 (0.57)	-1.9	-1.00	-0.43	-0.33	-0.2	
	Week 17	Tezepelumab	15	9 (60.0)	-0.66 (0.65)	-1.4	-1.26	-0.66	-0.11	0.4	0.02 [-0.83, 0.87]
		Placebo	20	13 (65.0)	-0.68 (0.72)	-2.0	-0.95	-0.58	-0.31	0.3	
	Week 18	Tezepelumab	15	10 (66.7)	-0.58 (0.64)	-1.4	-1.14	-0.57	-0.09	0.3	-0.11 [-0.93, 0.72]
		Placebo	20	13 (65.0)	-0.51 (0.65)	-1.9	-0.90	-0.43	-0.14	0.6	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022

Table NT1WTC\_KLMH0: Course of ASD weekly total score  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly total score	Week 19	Tezepelumab	15	10 (66.7)	-0.62 (0.60)	-1.4	-1.16	-0.51	-0.11	0.2	-0.06 [-0.86, 0.74]
		Placebo	20	15 (75.0)	-0.58 (0.73)	-1.9	-1.13	-0.54	-0.21	0.8	
	Week 20	Tezepelumab	15	7 (46.7)	-0.70 (0.58)	-1.4	-1.40	-0.49	-0.11	-0.1	0.01 [-0.88, 0.91]
		Placebo	20	15 (75.0)	-0.71 (0.79)	-2.6	-1.16	-0.43	-0.29	0.5	
	Week 21	Tezepelumab	15	8 (53.3)	-0.76 (0.65)	-1.5	-1.41	-0.78	-0.13	0.0	0.13 [-0.74, 1.00]
		Placebo	20	14 (70.0)	-0.87 (0.91)	-2.7	-1.16	-0.77	-0.20	0.3	
	Week 22	Tezepelumab	15	8 (53.3)	-0.68 (0.70)	-1.4	-1.40	-0.68	-0.06	0.2	0.18 [-0.71, 1.06]
		Placebo	20	13 (65.0)	-0.84 (0.98)	-2.8	-1.17	-0.71	-0.38	0.6	
	Week 23	Tezepelumab	15	9 (60.0)	-0.65 (0.71)	-1.6	-1.38	-0.33	-0.11	0.3	0.02 [-0.82, 0.86]
		Placebo	20	14 (70.0)	-0.67 (1.03)	-2.8	-1.16	-0.56	-0.24	1.0	
	Week 24	Tezepelumab	15	10 (66.7)	-0.59 (0.71)	-1.6	-1.37	-0.45	0.00	0.3	0.30 [-0.53, 1.12]
		Placebo	20	13 (65.0)	-0.82 (0.87)	-2.8	-1.16	-0.64	-0.38	0.5	
	Week 25	Tezepelumab	15	9 (60.0)	-0.60 (0.69)	-1.4	-1.26	-0.33	-0.10	0.2	0.43 [-0.45, 1.30]
		Placebo	20	12 (60.0)	-0.97 (0.94)	-2.7	-1.77	-0.81	-0.42	0.7	
	Week 26	Tezepelumab	15	8 (53.3)	-0.73 (0.67)	-1.5	-1.40	-0.68	-0.16	0.1	0.12 [-0.75, 0.99]
		Placebo	20	14 (70.0)	-0.82 (0.83)	-2.8	-1.16	-0.72	-0.33	0.5	
	Week 27	Tezepelumab	15	8 (53.3)	-0.72 (0.62)	-1.4	-1.33	-0.70	-0.22	0.1	0.10 [-0.78, 0.99]
		Placebo	20	13 (65.0)	-0.80 (0.80)	-2.6	-1.16	-0.67	-0.38	0.7	
	Week 28	Tezepelumab	15	8 (53.3)	-0.84 (0.56)	-1.4	-1.40	-0.87	-0.31	-0.1	-0.15 [-1.02, 0.72]
		Placebo	20	14 (70.0)	-0.73 (0.81)	-2.8	-1.16	-0.69	-0.33	0.4	
	Week 29	Tezepelumab	15	7 (46.7)	-0.80 (0.54)	-1.4	-1.33	-0.90	-0.33	-0.1	-0.04 [-0.96, 0.88]
		Placebo	20	13 (65.0)	-0.77 (0.94)	-2.8	-0.96	-0.57	-0.33	0.8	
	Week 30	Tezepelumab	15	8 (53.3)	-0.78 (0.50)	-1.4	-1.24	-0.82	-0.31	-0.1	-0.26 [-1.24, 0.73]
		Placebo	20	8 (40.0)	-0.65 (0.52)	-1.6	-0.94	-0.54	-0.25	-0.1	
	Week 31	Tezepelumab	15	7 (46.7)	-0.88 (0.59)	-1.5	-1.41	-1.09	-0.33	-0.1	-0.07 [-1.00, 0.86]
		Placebo	20	12 (60.0)	-0.83 (0.76)	-2.8	-1.01	-0.71	-0.32	0.0	
	Week 32	Tezepelumab	15	8 (53.3)	-0.83 (0.55)	-1.4	-1.38	-0.87	-0.29	-0.1	0.01 [-0.90, 0.92]
		Placebo	20	11 (55.0)	-0.84 (0.79)	-2.8	-0.88	-0.55	-0.38	-0.1	
	Week 33	Tezepelumab	15	8 (53.3)	-0.89 (0.51)	-1.5	-1.39	-0.89	-0.40	-0.3	0.15 [-0.74, 1.03]
		Placebo	20	13 (65.0)	-1.00 (0.83)	-2.8	-1.83	-0.63	-0.38	-0.2	
	Week 34	Tezepelumab	15	8 (53.3)	-0.92 (0.53)	-1.7	-1.39	-0.89	-0.43	-0.3	-0.13 [-1.06, 0.80]
		Placebo	20	10 (50.0)	-0.83 (0.84)	-2.8	-0.85	-0.41	-0.33	-0.3	
	Week 35	Tezepelumab	15	8 (53.3)	-0.82 (0.49)	-1.4	-1.28	-0.83	-0.33	-0.2	0.06 [-0.87, 0.99]
		Placebo	20	10 (50.0)	-0.86 (0.86)	-2.8	-1.16	-0.43	-0.33	-0.2	
	Week 36	Tezepelumab	15	8 (53.3)	-0.89 (0.52)	-1.6	-1.39	-0.84	-0.40	-0.3	-0.47 [-1.40, 0.45]
		Placebo	20	11 (55.0)	-0.64 (0.55)	-2.0	-0.96	-0.43	-0.29	0.0	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022

Table NT1WTC\_KLMH0: Course of ASD weekly total score  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly total score	Week 37	Tezepelumab	15	8 (53.3)	-0.87 (0.56)	-1.7	-1.36	-0.77	-0.36	-0.3	-0.06 [-0.97, 0.85]
		Placebo	20	11 (55.0)	-0.82 (0.80)	-2.7	-1.16	-0.68	-0.20	0.0	
	Week 38	Tezepelumab	15	7 (46.7)	-0.95 (0.57)	-1.7	-1.41	-1.09	-0.33	-0.2	-0.46 [-1.40, 0.49]
		Placebo	20	12 (60.0)	-0.68 (0.59)	-1.8	-1.06	-0.62	-0.25	0.1	
	Week 39	Tezepelumab	15	8 (53.3)	-0.88 (0.59)	-1.7	-1.40	-0.77	-0.34	-0.3	-0.14 [-1.05, 0.77]
		Placebo	20	11 (55.0)	-0.78 (0.88)	-2.7	-1.16	-0.66	-0.20	0.5	
	Week 40	Tezepelumab	15	8 (53.3)	-0.84 (0.65)	-1.7	-1.41	-0.82	-0.20	-0.1	-0.01 [-0.94, 0.92]
		Placebo	20	10 (50.0)	-0.83 (0.93)	-2.8	-1.16	-0.68	-0.38	0.7	
	Week 41	Tezepelumab	15	8 (53.3)	-0.79 (0.59)	-1.7	-1.25	-0.76	-0.25	-0.1	0.05 [-0.91, 1.00]
		Placebo	20	9 (45.0)	-0.83 (0.96)	-2.7	-1.16	-0.46	-0.38	0.3	
	Week 42	Tezepelumab	15	8 (53.3)	-0.82 (0.55)	-1.7	-1.25	-0.69	-0.38	-0.2	0.01 [-0.92, 0.94]
		Placebo	20	10 (50.0)	-0.83 (0.91)	-2.8	-1.16	-0.63	-0.38	0.4	
	Week 43	Tezepelumab	15	8 (53.3)	-0.88 (0.57)	-1.7	-1.34	-0.89	-0.36	-0.2	0.11 [-0.80, 1.02]
		Placebo	20	11 (55.0)	-0.97 (0.92)	-2.7	-1.66	-0.83	-0.43	0.8	
	Week 44	Tezepelumab	15	7 (46.7)	-0.92 (0.57)	-1.7	-1.41	-1.08	-0.33	-0.3	-0.18 [-1.13, 0.77]
		Placebo	20	11 (55.0)	-0.78 (0.90)	-2.8	-1.16	-0.55	-0.16	0.5	
	Week 45	Tezepelumab	15	7 (46.7)	-0.99 (0.56)	-1.7	-1.41	-1.09	-0.33	-0.3	-0.06 [-1.00, 0.89]
		Placebo	20	11 (55.0)	-0.94 (0.92)	-2.8	-1.81	-0.68	-0.38	0.5	
	Week 46	Tezepelumab	15	7 (46.7)	-0.90 (0.50)	-1.4	-1.38	-1.09	-0.33	-0.3	-0.20 [-1.19, 0.79]
		Placebo	20	9 (45.0)	-0.74 (0.96)	-2.8	-0.83	-0.51	-0.38	0.5	
	Week 47	Tezepelumab	15	6 (40.0)	-0.98 (0.53)	-1.4	-1.41	-1.19	-0.33	-0.3	-0.06 [-1.08, 0.95]
		Placebo	20	10 (50.0)	-0.93 (0.82)	-2.8	-1.16	-0.64	-0.38	-0.2	
	Week 48	Tezepelumab	15	5 (33.3)	-0.87 (0.51)	-1.4	-1.21	-1.09	-0.33	-0.3	0.04 [-1.03, 1.12]
		Placebo	20	10 (50.0)	-0.90 (0.87)	-2.8	-1.14	-0.80	-0.41	0.3	
	Week 49	Tezepelumab	15	7 (46.7)	-0.94 (0.51)	-1.5	-1.41	-1.09	-0.33	-0.3	0.08 [-0.89, 1.04]
		Placebo	20	10 (50.0)	-0.99 (0.77)	-2.7	-1.53	-0.65	-0.43	-0.3	
	Week 50	Tezepelumab	15	6 (40.0)	-0.96 (0.50)	-1.4	-1.40	-1.13	-0.33	-0.3	-0.00 [-1.01, 1.01]
		Placebo	20	10 (50.0)	-0.95 (0.78)	-2.8	-1.16	-0.65	-0.42	-0.3	
	Week 51	Tezepelumab	15	7 (46.7)	-0.86 (0.57)	-1.4	-1.40	-1.09	-0.33	-0.1	-0.09 [-1.03, 0.84]
		Placebo	20	12 (60.0)	-0.79 (0.86)	-2.8	-1.18	-0.46	-0.36	0.5	
	Week 52	Tezepelumab	15	8 (53.3)	-0.82 (0.53)	-1.4	-1.32	-0.88	-0.31	-0.1	0.20 [-0.72, 1.11]
		Placebo	20	11 (55.0)	-0.95 (0.76)	-2.8	-1.31	-0.63	-0.43	-0.3	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022

Table NT1WTC\_KLMC0: Change from baseline in ASD weekly total score - MMRM results  
 DITTL - adolescents

Change from baseline in ASD weekly total score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 1	Tezepelumab	15	14 (93.3)	-0.29 (0.15)	(-0.59, 0.02)	-0.16 (0.20)	(-0.55, 0.24)	0.433
	Placebo	20	20 (100.0)	-0.13 (0.13)	(-0.38, 0.13)			
Week 2	Tezepelumab	15	14 (93.3)	-0.30 (0.15)	(-0.60, 0.00)	0.03 (0.20)	(-0.37, 0.42)	0.896
	Placebo	20	19 (95.0)	-0.33 (0.13)	(-0.58, -0.07)			
Week 3	Tezepelumab	15	14 (93.3)	-0.37 (0.15)	(-0.67, -0.06)	0.10 (0.20)	(-0.30, 0.50)	0.619
	Placebo	20	17 (85.0)	-0.47 (0.13)	(-0.73, -0.21)			
Week 4	Tezepelumab	15	12 (80.0)	-0.46 (0.15)	(-0.76, -0.15)	0.08 (0.20)	(-0.32, 0.48)	0.685
	Placebo	20	17 (85.0)	-0.54 (0.13)	(-0.80, -0.28)			
Week 5	Tezepelumab	15	12 (80.0)	-0.44 (0.15)	(-0.74, -0.13)	0.07 (0.20)	(-0.33, 0.48)	0.713
	Placebo	20	16 (80.0)	-0.51 (0.13)	(-0.77, -0.25)			
Week 6	Tezepelumab	15	11 (73.3)	-0.51 (0.15)	(-0.82, -0.20)	0.04 (0.20)	(-0.36, 0.44)	0.851
	Placebo	20	16 (80.0)	-0.55 (0.13)	(-0.81, -0.29)			
Week 7	Tezepelumab	15	12 (80.0)	-0.47 (0.15)	(-0.77, -0.17)	0.08 (0.20)	(-0.33, 0.48)	0.709
	Placebo	20	16 (80.0)	-0.55 (0.13)	(-0.81, -0.28)			
Week 8	Tezepelumab	15	13 (86.7)	-0.44 (0.15)	(-0.74, -0.14)	0.03 (0.20)	(-0.37, 0.42)	0.901
	Placebo	20	16 (80.0)	-0.47 (0.13)	(-0.73, -0.21)			
Week 9	Tezepelumab	15	10 (66.7)	-0.41 (0.16)	(-0.71, -0.10)	0.13 (0.20)	(-0.28, 0.53)	0.534
	Placebo	20	17 (85.0)	-0.53 (0.13)	(-0.80, -0.27)			
Week 10	Tezepelumab	15	10 (66.7)	-0.51 (0.16)	(-0.82, -0.20)	0.18 (0.20)	(-0.23, 0.58)	0.392
	Placebo	20	15 (75.0)	-0.68 (0.13)	(-0.95, -0.42)			

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WTC\_KLMC0: Change from baseline in ASD weekly total score - MMRM results  
 DITTL - adolescents

Change from baseline in ASD weekly total score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Time	Treatment	N	n (%)					
Week 11	Tezepelumab	15	12 (80.0)	-0.55 (0.16)	(-0.86, -0.25)	0.09 (0.20)	(-0.32, 0.49)	0.664
	Placebo	20	17 (85.0)	-0.64 (0.13)	(-0.91, -0.38)			
Week 12	Tezepelumab	15	12 (80.0)	-0.56 (0.16)	(-0.87, -0.25)	0.09 (0.21)	(-0.32, 0.50)	0.665
	Placebo	20	15 (75.0)	-0.65 (0.13)	(-0.91, -0.39)			
Week 13	Tezepelumab	15	9 (60.0)	-0.62 (0.16)	(-0.94, -0.31)	-0.01 (0.21)	(-0.42, 0.40)	0.960
	Placebo	20	15 (75.0)	-0.61 (0.13)	(-0.88, -0.35)			
Week 14	Tezepelumab	15	8 (53.3)	-0.62 (0.16)	(-0.93, -0.30)	0.00 (0.21)	(-0.42, 0.42)	0.997
	Placebo	20	13 (65.0)	-0.62 (0.14)	(-0.89, -0.35)			
Week 15	Tezepelumab	15	10 (66.7)	-0.62 (0.16)	(-0.94, -0.30)	-0.05 (0.21)	(-0.47, 0.36)	0.796
	Placebo	20	15 (75.0)	-0.57 (0.14)	(-0.83, -0.30)			
Week 16	Tezepelumab	15	10 (66.7)	-0.65 (0.16)	(-0.97, -0.33)	-0.02 (0.21)	(-0.44, 0.39)	0.912
	Placebo	20	15 (75.0)	-0.63 (0.14)	(-0.90, -0.36)			
Week 17	Tezepelumab	15	9 (60.0)	-0.68 (0.16)	(-1.01, -0.36)	-0.14 (0.21)	(-0.56, 0.28)	0.520
	Placebo	20	13 (65.0)	-0.54 (0.14)	(-0.82, -0.27)			
Week 18	Tezepelumab	15	10 (66.7)	-0.66 (0.17)	(-0.99, -0.33)	-0.21 (0.21)	(-0.64, 0.21)	0.328
	Placebo	20	13 (65.0)	-0.45 (0.14)	(-0.72, -0.18)			
Week 19	Tezepelumab	15	10 (66.7)	-0.70 (0.17)	(-1.03, -0.37)	-0.17 (0.22)	(-0.60, 0.26)	0.429
	Placebo	20	15 (75.0)	-0.53 (0.14)	(-0.80, -0.26)			
Week 20	Tezepelumab	15	7 (46.7)	-0.77 (0.17)	(-1.11, -0.43)	-0.15 (0.22)	(-0.58, 0.28)	0.498
	Placebo	20	15 (75.0)	-0.62 (0.14)	(-0.89, -0.36)			

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WTC\_KLMC0: Change from baseline in ASD weekly total score - MMRM results  
 DITTL - adolescents

Change from baseline in ASD weekly total score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Time	Treatment	N	n (%)					
Week 21	Tezepelumab	15	8 (53.3)	-0.69 (0.17)	(-1.03, -0.35)	-0.04 (0.22)	(-0.48, 0.40)	0.860
	Placebo	20	14 (70.0)	-0.65 (0.14)	(-0.92, -0.38)			
Week 22	Tezepelumab	15	8 (53.3)	-0.67 (0.17)	(-1.01, -0.32)	-0.05 (0.22)	(-0.49, 0.39)	0.834
	Placebo	20	13 (65.0)	-0.62 (0.14)	(-0.89, -0.35)			
Week 23	Tezepelumab	15	9 (60.0)	-0.65 (0.17)	(-1.00, -0.31)	-0.08 (0.22)	(-0.52, 0.37)	0.733
	Placebo	20	14 (70.0)	-0.58 (0.14)	(-0.85, -0.30)			
Week 24	Tezepelumab	15	10 (66.7)	-0.66 (0.17)	(-1.01, -0.32)	-0.05 (0.22)	(-0.50, 0.39)	0.811
	Placebo	20	13 (65.0)	-0.61 (0.14)	(-0.88, -0.33)			
Week 25	Tezepelumab	15	9 (60.0)	-0.68 (0.18)	(-1.03, -0.33)	0.02 (0.23)	(-0.42, 0.47)	0.921
	Placebo	20	12 (60.0)	-0.70 (0.14)	(-0.98, -0.42)			
Week 26	Tezepelumab	15	8 (53.3)	-0.72 (0.18)	(-1.08, -0.37)	-0.06 (0.23)	(-0.51, 0.39)	0.798
	Placebo	20	14 (70.0)	-0.67 (0.14)	(-0.94, -0.39)			
Week 27	Tezepelumab	15	8 (53.3)	-0.75 (0.18)	(-1.10, -0.39)	-0.11 (0.23)	(-0.56, 0.34)	0.634
	Placebo	20	13 (65.0)	-0.64 (0.14)	(-0.91, -0.36)			
Week 28	Tezepelumab	15	8 (53.3)	-0.80 (0.18)	(-1.16, -0.44)	-0.17 (0.23)	(-0.63, 0.28)	0.452
	Placebo	20	14 (70.0)	-0.63 (0.14)	(-0.91, -0.35)			
Week 29	Tezepelumab	15	7 (46.7)	-0.75 (0.18)	(-1.11, -0.38)	-0.05 (0.23)	(-0.51, 0.41)	0.840
	Placebo	20	13 (65.0)	-0.70 (0.14)	(-0.98, -0.42)			
Week 30	Tezepelumab	15	8 (53.3)	-0.75 (0.19)	(-1.11, -0.38)	-0.11 (0.24)	(-0.58, 0.36)	0.646
	Placebo	20	8 (40.0)	-0.64 (0.15)	(-0.93, -0.35)			

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WTC\_KLMC0: Change from baseline in ASD weekly total score - MMRM results  
DITTL - adolescents

Change from baseline in ASD weekly total score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 31	Tezepelumab	15	7 (46.7)	-0.83 (0.19)	(-1.19, -0.46)	-0.09 (0.24)	(-0.56, 0.37)	0.700
	Placebo	20	12 (60.0)	-0.73 (0.14)	(-1.02, -0.45)			
Week 32	Tezepelumab	15	8 (53.3)	-0.80 (0.19)	(-1.16, -0.43)	-0.01 (0.24)	(-0.48, 0.45)	0.957
	Placebo	20	11 (55.0)	-0.78 (0.14)	(-1.07, -0.50)			
Week 33	Tezepelumab	15	8 (53.3)	-0.82 (0.19)	(-1.19, -0.45)	-0.08 (0.24)	(-0.54, 0.39)	0.743
	Placebo	20	13 (65.0)	-0.74 (0.14)	(-1.02, -0.46)			
Week 34	Tezepelumab	15	8 (53.3)	-0.85 (0.19)	(-1.23, -0.48)	-0.12 (0.24)	(-0.59, 0.35)	0.625
	Placebo	20	10 (50.0)	-0.74 (0.14)	(-1.02, -0.45)			
Week 35	Tezepelumab	15	8 (53.3)	-0.75 (0.19)	(-1.12, -0.37)	-0.02 (0.24)	(-0.49, 0.46)	0.939
	Placebo	20	10 (50.0)	-0.73 (0.15)	(-1.02, -0.44)			
Week 36	Tezepelumab	15	8 (53.3)	-0.83 (0.19)	(-1.21, -0.45)	-0.06 (0.24)	(-0.54, 0.41)	0.792
	Placebo	20	11 (55.0)	-0.77 (0.15)	(-1.06, -0.48)			
Week 37	Tezepelumab	15	8 (53.3)	-0.81 (0.19)	(-1.18, -0.43)	-0.07 (0.24)	(-0.55, 0.41)	0.768
	Placebo	20	11 (55.0)	-0.74 (0.15)	(-1.03, -0.45)			
Week 38	Tezepelumab	15	7 (46.7)	-0.83 (0.19)	(-1.21, -0.45)	-0.23 (0.24)	(-0.71, 0.25)	0.351
	Placebo	20	12 (60.0)	-0.60 (0.15)	(-0.89, -0.31)			
Week 39	Tezepelumab	15	8 (53.3)	-0.83 (0.19)	(-1.20, -0.45)	-0.13 (0.24)	(-0.61, 0.35)	0.585
	Placebo	20	11 (55.0)	-0.69 (0.15)	(-0.99, -0.40)			
Week 40	Tezepelumab	15	8 (53.3)	-0.82 (0.19)	(-1.20, -0.44)	-0.13 (0.24)	(-0.61, 0.35)	0.591
	Placebo	20	10 (50.0)	-0.69 (0.15)	(-0.98, -0.40)			

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WTC\_KLMC0: Change from baseline in ASD weekly total score - MMRM results  
DITTL - adolescents

Change from baseline in ASD weekly total score				Repeated measures analysis																																																																																																																														
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference																																																																																																																												
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value																																																																																																																										
Week 41	Tezepelumab	15	8 (53.3)	-0.74 (0.19)	(-1.12, -0.36)	-0.07 (0.24)	(-0.55, 0.41)	0.774																																																																																																																										
	Placebo	20	9 (45.0)	-0.67 (0.15)	(-0.96, -0.37)				Week 42	Tezepelumab	15	8 (53.3)	-0.77 (0.19)	(-1.15, -0.39)	-0.10 (0.24)	(-0.58, 0.38)	0.675	Placebo	20	10 (50.0)	-0.67 (0.15)	(-0.96, -0.38)	Week 43	Tezepelumab	15	8 (53.3)	-0.84 (0.19)	(-1.22, -0.45)	-0.11 (0.24)	(-0.60, 0.37)	0.639	Placebo	20	11 (55.0)	-0.72 (0.15)	(-1.01, -0.43)	Week 44	Tezepelumab	15	7 (46.7)	-0.84 (0.20)	(-1.23, -0.46)	-0.07 (0.25)	(-0.56, 0.41)	0.771	Placebo	20	11 (55.0)	-0.77 (0.15)	(-1.06, -0.48)	Week 45	Tezepelumab	15	7 (46.7)	-0.91 (0.20)	(-1.30, -0.52)	-0.17 (0.25)	(-0.66, 0.31)	0.481	Placebo	20	11 (55.0)	-0.74 (0.15)	(-1.03, -0.45)	Week 46	Tezepelumab	15	7 (46.7)	-0.83 (0.20)	(-1.22, -0.43)	-0.06 (0.25)	(-0.55, 0.43)	0.808	Placebo	20	9 (45.0)	-0.77 (0.15)	(-1.06, -0.47)	Week 47	Tezepelumab	15	6 (40.0)	-0.85 (0.20)	(-1.24, -0.45)	0.01 (0.25)	(-0.49, 0.50)	0.979	Placebo	20	10 (50.0)	-0.85 (0.15)	(-1.15, -0.56)	Week 48	Tezepelumab	15	5 (33.3)	-0.81 (0.20)	(-1.21, -0.41)	0.11 (0.25)	(-0.39, 0.61)	0.666	Placebo	20	10 (50.0)	-0.92 (0.15)	(-1.22, -0.62)	Week 49	Tezepelumab	15	7 (46.7)	-0.86 (0.20)	(-1.26, -0.47)	-0.04 (0.25)	(-0.54, 0.45)	0.871	Placebo	20	10 (50.0)	-0.82 (0.15)	(-1.12, -0.52)	Week 50	Tezepelumab	15	6 (40.0)	-0.83 (0.20)	(-1.23, -0.44)	-0.05 (0.25)	(-0.54, 0.45)	0.852	Placebo
Week 42	Tezepelumab	15	8 (53.3)	-0.77 (0.19)	(-1.15, -0.39)	-0.10 (0.24)	(-0.58, 0.38)	0.675																																																																																																																										
	Placebo	20	10 (50.0)	-0.67 (0.15)	(-0.96, -0.38)				Week 43	Tezepelumab	15	8 (53.3)	-0.84 (0.19)	(-1.22, -0.45)	-0.11 (0.24)	(-0.60, 0.37)	0.639	Placebo	20	11 (55.0)	-0.72 (0.15)	(-1.01, -0.43)	Week 44	Tezepelumab	15	7 (46.7)	-0.84 (0.20)	(-1.23, -0.46)	-0.07 (0.25)	(-0.56, 0.41)	0.771	Placebo	20	11 (55.0)	-0.77 (0.15)	(-1.06, -0.48)	Week 45	Tezepelumab	15	7 (46.7)	-0.91 (0.20)	(-1.30, -0.52)	-0.17 (0.25)	(-0.66, 0.31)	0.481	Placebo	20	11 (55.0)	-0.74 (0.15)	(-1.03, -0.45)	Week 46	Tezepelumab	15	7 (46.7)	-0.83 (0.20)	(-1.22, -0.43)	-0.06 (0.25)	(-0.55, 0.43)	0.808	Placebo	20	9 (45.0)	-0.77 (0.15)	(-1.06, -0.47)	Week 47	Tezepelumab	15	6 (40.0)	-0.85 (0.20)	(-1.24, -0.45)	0.01 (0.25)	(-0.49, 0.50)	0.979	Placebo	20	10 (50.0)	-0.85 (0.15)	(-1.15, -0.56)	Week 48	Tezepelumab	15	5 (33.3)	-0.81 (0.20)	(-1.21, -0.41)	0.11 (0.25)	(-0.39, 0.61)	0.666	Placebo	20	10 (50.0)	-0.92 (0.15)	(-1.22, -0.62)	Week 49	Tezepelumab	15	7 (46.7)	-0.86 (0.20)	(-1.26, -0.47)	-0.04 (0.25)	(-0.54, 0.45)	0.871	Placebo	20	10 (50.0)	-0.82 (0.15)	(-1.12, -0.52)	Week 50	Tezepelumab	15	6 (40.0)	-0.83 (0.20)	(-1.23, -0.44)	-0.05 (0.25)	(-0.54, 0.45)	0.852	Placebo	20	10 (50.0)	-0.79 (0.15)	(-1.09, -0.49)										
Week 43	Tezepelumab	15	8 (53.3)	-0.84 (0.19)	(-1.22, -0.45)	-0.11 (0.24)	(-0.60, 0.37)	0.639																																																																																																																										
	Placebo	20	11 (55.0)	-0.72 (0.15)	(-1.01, -0.43)				Week 44	Tezepelumab	15	7 (46.7)	-0.84 (0.20)	(-1.23, -0.46)	-0.07 (0.25)	(-0.56, 0.41)	0.771	Placebo	20	11 (55.0)	-0.77 (0.15)	(-1.06, -0.48)	Week 45	Tezepelumab	15	7 (46.7)	-0.91 (0.20)	(-1.30, -0.52)	-0.17 (0.25)	(-0.66, 0.31)	0.481	Placebo	20	11 (55.0)	-0.74 (0.15)	(-1.03, -0.45)	Week 46	Tezepelumab	15	7 (46.7)	-0.83 (0.20)	(-1.22, -0.43)	-0.06 (0.25)	(-0.55, 0.43)	0.808	Placebo	20	9 (45.0)	-0.77 (0.15)	(-1.06, -0.47)	Week 47	Tezepelumab	15	6 (40.0)	-0.85 (0.20)	(-1.24, -0.45)	0.01 (0.25)	(-0.49, 0.50)	0.979	Placebo	20	10 (50.0)	-0.85 (0.15)	(-1.15, -0.56)	Week 48	Tezepelumab	15	5 (33.3)	-0.81 (0.20)	(-1.21, -0.41)	0.11 (0.25)	(-0.39, 0.61)	0.666	Placebo	20	10 (50.0)	-0.92 (0.15)	(-1.22, -0.62)	Week 49	Tezepelumab	15	7 (46.7)	-0.86 (0.20)	(-1.26, -0.47)	-0.04 (0.25)	(-0.54, 0.45)	0.871	Placebo	20	10 (50.0)	-0.82 (0.15)	(-1.12, -0.52)	Week 50	Tezepelumab	15	6 (40.0)	-0.83 (0.20)	(-1.23, -0.44)	-0.05 (0.25)	(-0.54, 0.45)	0.852	Placebo	20	10 (50.0)	-0.79 (0.15)	(-1.09, -0.49)																								
Week 44	Tezepelumab	15	7 (46.7)	-0.84 (0.20)	(-1.23, -0.46)	-0.07 (0.25)	(-0.56, 0.41)	0.771																																																																																																																										
	Placebo	20	11 (55.0)	-0.77 (0.15)	(-1.06, -0.48)				Week 45	Tezepelumab	15	7 (46.7)	-0.91 (0.20)	(-1.30, -0.52)	-0.17 (0.25)	(-0.66, 0.31)	0.481	Placebo	20	11 (55.0)	-0.74 (0.15)	(-1.03, -0.45)	Week 46	Tezepelumab	15	7 (46.7)	-0.83 (0.20)	(-1.22, -0.43)	-0.06 (0.25)	(-0.55, 0.43)	0.808	Placebo	20	9 (45.0)	-0.77 (0.15)	(-1.06, -0.47)	Week 47	Tezepelumab	15	6 (40.0)	-0.85 (0.20)	(-1.24, -0.45)	0.01 (0.25)	(-0.49, 0.50)	0.979	Placebo	20	10 (50.0)	-0.85 (0.15)	(-1.15, -0.56)	Week 48	Tezepelumab	15	5 (33.3)	-0.81 (0.20)	(-1.21, -0.41)	0.11 (0.25)	(-0.39, 0.61)	0.666	Placebo	20	10 (50.0)	-0.92 (0.15)	(-1.22, -0.62)	Week 49	Tezepelumab	15	7 (46.7)	-0.86 (0.20)	(-1.26, -0.47)	-0.04 (0.25)	(-0.54, 0.45)	0.871	Placebo	20	10 (50.0)	-0.82 (0.15)	(-1.12, -0.52)	Week 50	Tezepelumab	15	6 (40.0)	-0.83 (0.20)	(-1.23, -0.44)	-0.05 (0.25)	(-0.54, 0.45)	0.852	Placebo	20	10 (50.0)	-0.79 (0.15)	(-1.09, -0.49)																																						
Week 45	Tezepelumab	15	7 (46.7)	-0.91 (0.20)	(-1.30, -0.52)	-0.17 (0.25)	(-0.66, 0.31)	0.481																																																																																																																										
	Placebo	20	11 (55.0)	-0.74 (0.15)	(-1.03, -0.45)				Week 46	Tezepelumab	15	7 (46.7)	-0.83 (0.20)	(-1.22, -0.43)	-0.06 (0.25)	(-0.55, 0.43)	0.808	Placebo	20	9 (45.0)	-0.77 (0.15)	(-1.06, -0.47)	Week 47	Tezepelumab	15	6 (40.0)	-0.85 (0.20)	(-1.24, -0.45)	0.01 (0.25)	(-0.49, 0.50)	0.979	Placebo	20	10 (50.0)	-0.85 (0.15)	(-1.15, -0.56)	Week 48	Tezepelumab	15	5 (33.3)	-0.81 (0.20)	(-1.21, -0.41)	0.11 (0.25)	(-0.39, 0.61)	0.666	Placebo	20	10 (50.0)	-0.92 (0.15)	(-1.22, -0.62)	Week 49	Tezepelumab	15	7 (46.7)	-0.86 (0.20)	(-1.26, -0.47)	-0.04 (0.25)	(-0.54, 0.45)	0.871	Placebo	20	10 (50.0)	-0.82 (0.15)	(-1.12, -0.52)	Week 50	Tezepelumab	15	6 (40.0)	-0.83 (0.20)	(-1.23, -0.44)	-0.05 (0.25)	(-0.54, 0.45)	0.852	Placebo	20	10 (50.0)	-0.79 (0.15)	(-1.09, -0.49)																																																				
Week 46	Tezepelumab	15	7 (46.7)	-0.83 (0.20)	(-1.22, -0.43)	-0.06 (0.25)	(-0.55, 0.43)	0.808																																																																																																																										
	Placebo	20	9 (45.0)	-0.77 (0.15)	(-1.06, -0.47)				Week 47	Tezepelumab	15	6 (40.0)	-0.85 (0.20)	(-1.24, -0.45)	0.01 (0.25)	(-0.49, 0.50)	0.979	Placebo	20	10 (50.0)	-0.85 (0.15)	(-1.15, -0.56)	Week 48	Tezepelumab	15	5 (33.3)	-0.81 (0.20)	(-1.21, -0.41)	0.11 (0.25)	(-0.39, 0.61)	0.666	Placebo	20	10 (50.0)	-0.92 (0.15)	(-1.22, -0.62)	Week 49	Tezepelumab	15	7 (46.7)	-0.86 (0.20)	(-1.26, -0.47)	-0.04 (0.25)	(-0.54, 0.45)	0.871	Placebo	20	10 (50.0)	-0.82 (0.15)	(-1.12, -0.52)	Week 50	Tezepelumab	15	6 (40.0)	-0.83 (0.20)	(-1.23, -0.44)	-0.05 (0.25)	(-0.54, 0.45)	0.852	Placebo	20	10 (50.0)	-0.79 (0.15)	(-1.09, -0.49)																																																																		
Week 47	Tezepelumab	15	6 (40.0)	-0.85 (0.20)	(-1.24, -0.45)	0.01 (0.25)	(-0.49, 0.50)	0.979																																																																																																																										
	Placebo	20	10 (50.0)	-0.85 (0.15)	(-1.15, -0.56)				Week 48	Tezepelumab	15	5 (33.3)	-0.81 (0.20)	(-1.21, -0.41)	0.11 (0.25)	(-0.39, 0.61)	0.666	Placebo	20	10 (50.0)	-0.92 (0.15)	(-1.22, -0.62)	Week 49	Tezepelumab	15	7 (46.7)	-0.86 (0.20)	(-1.26, -0.47)	-0.04 (0.25)	(-0.54, 0.45)	0.871	Placebo	20	10 (50.0)	-0.82 (0.15)	(-1.12, -0.52)	Week 50	Tezepelumab	15	6 (40.0)	-0.83 (0.20)	(-1.23, -0.44)	-0.05 (0.25)	(-0.54, 0.45)	0.852	Placebo	20	10 (50.0)	-0.79 (0.15)	(-1.09, -0.49)																																																																																
Week 48	Tezepelumab	15	5 (33.3)	-0.81 (0.20)	(-1.21, -0.41)	0.11 (0.25)	(-0.39, 0.61)	0.666																																																																																																																										
	Placebo	20	10 (50.0)	-0.92 (0.15)	(-1.22, -0.62)				Week 49	Tezepelumab	15	7 (46.7)	-0.86 (0.20)	(-1.26, -0.47)	-0.04 (0.25)	(-0.54, 0.45)	0.871	Placebo	20	10 (50.0)	-0.82 (0.15)	(-1.12, -0.52)	Week 50	Tezepelumab	15	6 (40.0)	-0.83 (0.20)	(-1.23, -0.44)	-0.05 (0.25)	(-0.54, 0.45)	0.852	Placebo	20	10 (50.0)	-0.79 (0.15)	(-1.09, -0.49)																																																																																														
Week 49	Tezepelumab	15	7 (46.7)	-0.86 (0.20)	(-1.26, -0.47)	-0.04 (0.25)	(-0.54, 0.45)	0.871																																																																																																																										
	Placebo	20	10 (50.0)	-0.82 (0.15)	(-1.12, -0.52)				Week 50	Tezepelumab	15	6 (40.0)	-0.83 (0.20)	(-1.23, -0.44)	-0.05 (0.25)	(-0.54, 0.45)	0.852	Placebo	20	10 (50.0)	-0.79 (0.15)	(-1.09, -0.49)																																																																																																												
Week 50	Tezepelumab	15	6 (40.0)	-0.83 (0.20)	(-1.23, -0.44)	-0.05 (0.25)	(-0.54, 0.45)	0.852																																																																																																																										
	Placebo	20	10 (50.0)	-0.79 (0.15)	(-1.09, -0.49)																																																																																																																													

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table NT1WTC\_KLMC0: Change from baseline in ASD weekly total score - MMRM results  
 DITTTL - adolescents

Change from baseline in ASD weekly total score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 51	Tezepelumab	15	7 (46.7)	-0.86 (0.20)	(-1.26, -0.47)	-0.08 (0.25)	(-0.57, 0.41)	0.748
	Placebo	20	12 (60.0)	-0.78 (0.15)	(-1.08, -0.49)			
Week 52	Tezepelumab	15	8 (53.3)	-0.85 (0.20)	(-1.25, -0.46)	-0.01 (0.25)	(-0.51, 0.48)	0.964
	Placebo	20	11 (55.0)	-0.84 (0.15)	(-1.14, -0.54)			

Note: DITTTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WDC\_KLMH0: Course of ASD weekly daytime score  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly daytime score	Baseline	Tezepelumab	15	15 (100.0)	1.30 (0.63)	0.1	0.97	1.23	1.89	2.5	
		Placebo	20	20 (100.0)	1.49 (0.91)	0.2	0.76	1.34	2.30	3.2	
	Week 1	Tezepelumab	15	15 (100.0)	1.07 (0.63)	0.1	0.53	1.00	1.60	2.2	
		Placebo	20	20 (100.0)	1.33 (1.07)	0.0	0.71	1.06	2.09	3.7	
	Week 2	Tezepelumab	15	15 (100.0)	1.04 (0.76)	0.0	0.46	0.97	1.31	2.6	
		Placebo	20	20 (100.0)	1.18 (1.02)	0.0	0.27	0.97	2.02	3.3	
	Week 3	Tezepelumab	15	14 (93.3)	1.00 (0.72)	0.0	0.60	0.94	1.26	2.3	
		Placebo	20	18 (90.0)	0.81 (0.83)	0.0	0.03	0.66	1.60	2.3	
	Week 4	Tezepelumab	15	14 (93.3)	0.90 (0.68)	0.0	0.29	0.97	1.17	2.2	
		Placebo	20	19 (95.0)	0.80 (0.79)	0.0	0.00	0.91	1.51	2.0	
	Week 5	Tezepelumab	15	14 (93.3)	0.97 (0.68)	0.0	0.43	1.00	1.25	2.1	
		Placebo	20	19 (95.0)	0.93 (0.79)	0.0	0.07	0.97	1.49	2.7	
	Week 6	Tezepelumab	15	12 (80.0)	0.86 (0.65)	0.0	0.14	1.06	1.15	2.0	
		Placebo	20	18 (90.0)	0.77 (0.72)	0.0	0.09	0.72	1.31	2.2	
	Week 7	Tezepelumab	15	15 (100.0)	0.89 (0.66)	0.0	0.32	1.00	1.43	2.0	
		Placebo	20	18 (90.0)	0.87 (0.80)	0.0	0.03	0.87	1.29	2.4	
	Week 8	Tezepelumab	15	14 (93.3)	0.88 (0.72)	0.0	0.14	0.85	1.29	2.2	
		Placebo	20	19 (95.0)	0.91 (0.79)	0.0	0.03	0.83	1.43	2.5	
	Week 9	Tezepelumab	15	12 (80.0)	0.85 (0.63)	0.0	0.30	0.90	1.32	1.9	
		Placebo	20	19 (95.0)	0.92 (0.80)	0.0	0.07	0.86	1.56	2.9	
	Week 10	Tezepelumab	15	15 (100.0)	0.82 (0.71)	0.0	0.10	0.83	1.57	1.9	
		Placebo	20	18 (90.0)	0.78 (0.98)	0.0	0.00	0.54	1.07	4.0	
	Week 11	Tezepelumab	15	13 (86.7)	0.76 (0.71)	0.0	0.08	0.86	1.37	1.9	
		Placebo	20	18 (90.0)	0.64 (0.70)	0.0	0.00	0.39	1.09	2.4	
	Week 12	Tezepelumab	15	13 (86.7)	0.77 (0.70)	0.0	0.10	0.90	1.50	1.7	
		Placebo	20	18 (90.0)	0.69 (0.70)	0.0	0.00	0.73	1.10	2.3	
	Week 13	Tezepelumab	15	11 (73.3)	0.70 (0.62)	0.0	0.00	0.83	1.37	1.6	
		Placebo	20	16 (80.0)	0.88 (1.01)	0.0	0.04	0.68	1.29	3.5	
	Week 14	Tezepelumab	15	10 (66.7)	0.59 (0.60)	0.0	0.00	0.50	1.00	1.5	
		Placebo	20	17 (85.0)	0.67 (0.73)	0.0	0.00	0.34	1.04	2.6	
	Week 15	Tezepelumab	15	11 (73.3)	0.58 (0.59)	0.0	0.00	0.45	1.12	1.5	
		Placebo	20	16 (80.0)	0.81 (0.83)	0.0	0.00	0.84	1.17	3.0	
	Week 16	Tezepelumab	15	11 (73.3)	0.61 (0.54)	0.0	0.00	0.57	1.00	1.5	
		Placebo	20	17 (85.0)	0.93 (0.93)	0.0	0.16	0.77	1.23	3.5	
Week 17	Tezepelumab	15	12 (80.0)	0.51 (0.51)	0.0	0.01	0.41	0.93	1.5		
	Placebo	20	16 (80.0)	0.79 (0.79)	0.0	0.11	0.60	1.30	3.0		

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022

Table NT1WDC\_KLMH0: Course of ASD weekly daytime score  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly daytime score	Week 18	Tezepelumab	15	11 (73.3)	0.59 (0.52)	0.0	0.06	0.60	1.00	1.5	
		Placebo	20	16 (80.0)	0.87 (0.87)	0.0	0.11	0.79	1.29	3.3	
	Week 19	Tezepelumab	15	12 (80.0)	0.50 (0.50)	0.0	0.00	0.35	0.96	1.4	
		Placebo	20	17 (85.0)	0.83 (0.92)	0.0	0.04	0.50	1.00	3.1	
	Week 20	Tezepelumab	15	10 (66.7)	0.45 (0.47)	0.0	0.03	0.25	0.90	1.2	
		Placebo	20	16 (80.0)	0.73 (0.98)	0.0	0.05	0.41	1.00	3.8	
	Week 21	Tezepelumab	15	10 (66.7)	0.54 (0.59)	0.0	0.00	0.28	1.00	1.5	
		Placebo	20	16 (80.0)	0.79 (1.02)	0.0	0.00	0.55	1.07	3.1	
	Week 22	Tezepelumab	15	10 (66.7)	0.50 (0.57)	0.0	0.00	0.17	1.00	1.3	
		Placebo	20	17 (85.0)	0.87 (1.05)	0.0	0.00	0.51	1.14	3.2	
	Week 23	Tezepelumab	15	10 (66.7)	0.51 (0.60)	0.0	0.00	0.12	1.04	1.4	
		Placebo	20	15 (75.0)	0.81 (1.08)	0.0	0.00	0.54	1.03	3.9	
	Week 24	Tezepelumab	15	11 (73.3)	0.53 (0.57)	0.0	0.00	0.26	1.00	1.3	
		Placebo	20	15 (75.0)	0.87 (0.97)	0.0	0.00	0.74	1.33	3.7	
	Week 25	Tezepelumab	15	9 (60.0)	0.52 (0.60)	0.0	0.00	0.13	1.12	1.3	
		Placebo	20	16 (80.0)	0.61 (0.83)	0.0	0.02	0.21	0.82	2.7	
	Week 26	Tezepelumab	15	9 (60.0)	0.37 (0.46)	0.0	0.00	0.10	0.63	1.2	
		Placebo	20	15 (75.0)	0.57 (0.58)	0.0	0.00	0.50	0.97	2.0	
	Week 27	Tezepelumab	15	10 (66.7)	0.47 (0.53)	0.0	0.00	0.30	1.00	1.3	
		Placebo	20	15 (75.0)	0.82 (0.89)	0.0	0.14	0.57	1.40	3.1	
	Week 28	Tezepelumab	15	9 (60.0)	0.38 (0.50)	0.0	0.00	0.05	0.71	1.3	
		Placebo	20	17 (85.0)	0.90 (0.99)	0.0	0.03	0.66	1.26	3.2	
	Week 29	Tezepelumab	15	8 (53.3)	0.44 (0.43)	0.0	0.10	0.27	0.84	1.1	
		Placebo	20	15 (75.0)	0.74 (0.79)	0.0	0.20	0.43	1.00	2.7	
	Week 30	Tezepelumab	15	9 (60.0)	0.42 (0.52)	0.0	0.00	0.10	0.66	1.3	
		Placebo	20	14 (70.0)	0.87 (0.86)	0.0	0.29	0.73	1.00	2.8	
	Week 31	Tezepelumab	15	8 (53.3)	0.36 (0.48)	0.0	0.00	0.07	0.83	1.1	
		Placebo	20	15 (75.0)	0.60 (0.57)	0.0	0.14	0.48	1.00	1.8	
	Week 32	Tezepelumab	15	9 (60.0)	0.36 (0.50)	0.0	0.00	0.00	0.66	1.3	
		Placebo	20	14 (70.0)	0.69 (0.75)	0.0	0.00	0.48	1.00	2.2	
	Week 33	Tezepelumab	15	9 (60.0)	0.37 (0.54)	0.0	0.00	0.00	0.71	1.4	
		Placebo	20	16 (80.0)	0.59 (0.72)	0.0	0.04	0.44	0.78	2.5	
	Week 34	Tezepelumab	15	10 (66.7)	0.42 (0.56)	0.0	0.00	0.03	1.03	1.4	
		Placebo	20	16 (80.0)	0.58 (0.73)	0.0	0.00	0.30	1.01	2.3	
	Week 35	Tezepelumab	15	9 (60.0)	0.48 (0.56)	0.0	0.00	0.20	0.71	1.4	
		Placebo	20	15 (75.0)	0.66 (0.89)	0.0	0.00	0.12	1.00	2.6	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022

Table NT1WDC\_KLMH0: Course of ASD weekly daytime score  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly daytime score	Week 36	Tezepelumab	15	10 (66.7)	0.35 (0.51)	0.0	0.00	0.09	0.66	1.4	
		Placebo	20	14 (70.0)	0.57 (0.79)	0.0	0.00	0.30	0.97	2.7	
	Week 37	Tezepelumab	15	9 (60.0)	0.37 (0.53)	0.0	0.00	0.09	0.74	1.3	
		Placebo	20	15 (75.0)	0.53 (0.65)	0.0	0.00	0.29	1.00	2.1	
	Week 38	Tezepelumab	15	8 (53.3)	0.37 (0.53)	0.0	0.00	0.00	0.89	1.2	
		Placebo	20	14 (70.0)	0.55 (0.55)	0.0	0.17	0.33	1.00	1.6	
	Week 39	Tezepelumab	15	10 (66.7)	0.36 (0.53)	0.0	0.00	0.03	0.66	1.5	
		Placebo	20	14 (70.0)	0.69 (0.65)	0.0	0.20	0.47	1.00	1.8	
	Week 40	Tezepelumab	15	9 (60.0)	0.40 (0.47)	0.0	0.00	0.11	0.77	1.1	
		Placebo	20	12 (60.0)	0.55 (0.53)	0.0	0.01	0.55	0.97	1.7	
	Week 41	Tezepelumab	15	9 (60.0)	0.42 (0.60)	0.0	0.00	0.07	0.86	1.5	
		Placebo	20	12 (60.0)	0.87 (0.78)	0.0	0.29	0.61	1.38	2.5	
	Week 42	Tezepelumab	15	9 (60.0)	0.42 (0.65)	0.0	0.00	0.00	0.80	1.5	
		Placebo	20	14 (70.0)	0.64 (0.75)	0.0	0.00	0.57	0.96	2.6	
	Week 43	Tezepelumab	15	9 (60.0)	0.36 (0.55)	0.0	0.00	0.00	0.80	1.3	
		Placebo	20	15 (75.0)	0.86 (0.84)	0.0	0.03	0.66	1.63	2.5	
	Week 44	Tezepelumab	15	8 (53.3)	0.40 (0.55)	0.0	0.00	0.02	0.97	1.2	
		Placebo	20	16 (80.0)	0.85 (0.89)	0.0	0.03	0.67	1.33	2.9	
	Week 45	Tezepelumab	15	8 (53.3)	0.35 (0.49)	0.0	0.00	0.03	0.86	1.1	
		Placebo	20	14 (70.0)	0.78 (0.73)	0.0	0.14	0.58	1.15	2.1	
	Week 46	Tezepelumab	15	8 (53.3)	0.45 (0.52)	0.0	0.00	0.31	0.83	1.3	
		Placebo	20	12 (60.0)	0.80 (0.69)	0.0	0.10	0.81	1.26	1.9	
	Week 47	Tezepelumab	15	8 (53.3)	0.35 (0.48)	0.0	0.00	0.05	0.81	1.1	
		Placebo	20	14 (70.0)	0.64 (0.59)	0.0	0.00	0.56	1.00	1.7	
	Week 48	Tezepelumab	15	8 (53.3)	0.42 (0.50)	0.0	0.00	0.22	0.84	1.3	
		Placebo	20	12 (60.0)	0.69 (0.81)	0.0	0.01	0.41	1.11	2.3	
	Week 49	Tezepelumab	15	8 (53.3)	0.41 (0.53)	0.0	0.00	0.14	0.83	1.4	
		Placebo	20	14 (70.0)	0.53 (0.52)	0.0	0.00	0.47	0.97	1.6	
	Week 50	Tezepelumab	15	8 (53.3)	0.44 (0.58)	0.0	0.00	0.11	0.90	1.5	
		Placebo	20	13 (65.0)	0.57 (0.62)	0.0	0.03	0.43	0.80	1.9	
	Week 51	Tezepelumab	15	9 (60.0)	0.37 (0.53)	0.0	0.00	0.00	0.63	1.3	
		Placebo	20	14 (70.0)	0.73 (0.68)	0.0	0.00	0.66	1.11	2.1	
	Week 52	Tezepelumab	15	9 (60.0)	0.36 (0.49)	0.0	0.00	0.03	0.69	1.2	
		Placebo	20	13 (65.0)	0.51 (0.56)	0.0	0.00	0.33	0.94	1.6	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WDC\_KLMH0: Course of ASD weekly daytime score  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly daytime score	Week 1	Tezepelumab	15	15 (100.0)	-0.23 (0.31)	-1.0	-0.29	-0.17	0.00	0.2	-0.20 [-0.87, 0.48]
		Placebo	20	20 (100.0)	-0.16 (0.37)	-0.7	-0.38	-0.20	-0.05	0.9	
	Week 2	Tezepelumab	15	15 (100.0)	-0.26 (0.44)	-1.0	-0.63	-0.13	0.07	0.5	0.08 [-0.59, 0.75]
		Placebo	20	20 (100.0)	-0.31 (0.68)	-2.7	-0.49	-0.19	0.00	0.9	
	Week 3	Tezepelumab	15	14 (93.3)	-0.30 (0.46)	-1.1	-0.71	-0.16	0.03	0.4	0.66 [-0.05, 1.38]
		Placebo	20	18 (90.0)	-0.61 (0.48)	-2.1	-0.80	-0.59	-0.34	0.0	
	Week 4	Tezepelumab	15	14 (93.3)	-0.40 (0.45)	-1.3	-0.73	-0.24	-0.09	0.1	0.56 [-0.15, 1.26]
		Placebo	20	19 (95.0)	-0.71 (0.64)	-2.7	-0.90	-0.46	-0.37	0.0	
	Week 5	Tezepelumab	15	14 (93.3)	-0.33 (0.45)	-1.3	-0.66	-0.10	0.00	0.1	0.46 [-0.24, 1.16]
		Placebo	20	19 (95.0)	-0.59 (0.64)	-2.2	-0.89	-0.40	-0.18	0.1	
	Week 6	Tezepelumab	15	12 (80.0)	-0.42 (0.42)	-1.3	-0.78	-0.28	-0.10	0.1	0.41 [-0.33, 1.15]
		Placebo	20	18 (90.0)	-0.66 (0.67)	-2.4	-0.77	-0.47	-0.23	0.0	
	Week 7	Tezepelumab	15	15 (100.0)	-0.41 (0.51)	-1.3	-0.75	-0.31	-0.06	0.6	0.32 [-0.37, 1.01]
		Placebo	20	18 (90.0)	-0.57 (0.50)	-2.1	-0.61	-0.45	-0.26	0.0	
	Week 8	Tezepelumab	15	14 (93.3)	-0.40 (0.43)	-1.2	-0.73	-0.35	-0.06	0.2	0.35 [-0.35, 1.05]
		Placebo	20	19 (95.0)	-0.60 (0.65)	-2.2	-0.77	-0.40	-0.17	0.0	
	Week 9	Tezepelumab	15	12 (80.0)	-0.40 (0.50)	-1.3	-0.60	-0.26	-0.11	0.3	0.36 [-0.37, 1.09]
		Placebo	20	19 (95.0)	-0.59 (0.55)	-2.3	-0.77	-0.55	-0.22	0.4	
	Week 10	Tezepelumab	15	15 (100.0)	-0.48 (0.57)	-1.5	-0.93	-0.34	-0.06	0.4	0.28 [-0.40, 0.97]
		Placebo	20	18 (90.0)	-0.70 (0.89)	-2.7	-0.89	-0.53	-0.34	1.1	
	Week 11	Tezepelumab	15	13 (86.7)	-0.52 (0.59)	-1.3	-1.17	-0.43	-0.07	0.3	0.43 [-0.30, 1.15]
		Placebo	20	18 (90.0)	-0.81 (0.74)	-2.7	-1.01	-0.49	-0.34	-0.2	
	Week 12	Tezepelumab	15	13 (86.7)	-0.51 (0.61)	-1.3	-1.00	-0.37	-0.07	0.4	0.44 [-0.29, 1.16]
		Placebo	20	18 (90.0)	-0.77 (0.58)	-2.2	-1.09	-0.52	-0.37	-0.2	
	Week 13	Tezepelumab	15	11 (73.3)	-0.61 (0.72)	-1.6	-1.34	-0.56	-0.06	0.4	0.07 [-0.70, 0.84]
		Placebo	20	16 (80.0)	-0.66 (0.74)	-2.3	-0.99	-0.48	-0.35	1.0	
	Week 14	Tezepelumab	15	10 (66.7)	-0.74 (0.71)	-1.7	-1.26	-0.77	-0.09	0.4	0.14 [-0.64, 0.92]
		Placebo	20	17 (85.0)	-0.84 (0.76)	-2.7	-1.03	-0.49	-0.37	-0.0	
	Week 15	Tezepelumab	15	11 (73.3)	-0.73 (0.64)	-1.4	-1.31	-1.07	-0.06	0.4	-0.16 [-0.93, 0.61]
		Placebo	20	16 (80.0)	-0.62 (0.69)	-2.2	-0.91	-0.35	-0.21	0.2	
	Week 16	Tezepelumab	15	11 (73.3)	-0.72 (0.64)	-1.5	-1.32	-0.92	-0.11	0.4	-0.01 [-0.77, 0.75]
		Placebo	20	17 (85.0)	-0.72 (0.79)	-2.3	-0.97	-0.49	-0.33	0.9	
	Week 17	Tezepelumab	15	12 (80.0)	-0.78 (0.65)	-1.5	-1.32	-1.01	-0.23	0.4	0.03 [-0.72, 0.78]
		Placebo	20	16 (80.0)	-0.80 (0.80)	-2.3	-1.07	-0.73	-0.31	0.3	
Week 18	Tezepelumab	15	11 (73.3)	-0.64 (0.70)	-1.5	-1.29	-1.03	-0.06	0.5	0.10 [-0.67, 0.87]	
	Placebo	20	16 (80.0)	-0.72 (0.92)	-3.1	-1.01	-0.55	-0.24	0.4		

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022

Table NT1WDC\_KLMH0: Course of ASD weekly daytime score  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly daytime score	Week 19	Tezepelumab	15	12 (80.0)	-0.79 (0.72)	-2.0	-1.31	-0.96	-0.09	0.3	0.02 [-0.72, 0.76]
		Placebo	20	17 (85.0)	-0.82 (0.95)	-3.2	-1.07	-0.69	-0.29	0.5	
	Week 20	Tezepelumab	15	10 (66.7)	-0.76 (0.63)	-1.6	-1.31	-0.83	-0.14	0.1	0.11 [-0.68, 0.91]
		Placebo	20	16 (80.0)	-0.86 (1.00)	-3.0	-1.29	-0.60	-0.33	1.0	
	Week 21	Tezepelumab	15	10 (66.7)	-0.72 (0.74)	-1.7	-1.34	-0.82	-0.03	0.3	0.15 [-0.64, 0.94]
		Placebo	20	16 (80.0)	-0.86 (1.04)	-3.2	-1.17	-0.77	-0.13	0.6	
	Week 22	Tezepelumab	15	10 (66.7)	-0.72 (0.68)	-1.7	-1.34	-0.69	-0.06	0.3	0.06 [-0.73, 0.84]
		Placebo	20	17 (85.0)	-0.77 (1.02)	-3.2	-1.11	-0.66	-0.20	0.7	
	Week 23	Tezepelumab	15	10 (66.7)	-0.71 (0.70)	-1.8	-1.34	-0.66	-0.06	0.3	0.15 [-0.65, 0.95]
		Placebo	20	15 (75.0)	-0.86 (1.18)	-3.2	-1.83	-0.74	-0.31	1.0	
	Week 24	Tezepelumab	15	11 (73.3)	-0.70 (0.73)	-1.9	-1.34	-0.59	0.00	0.3	0.12 [-0.66, 0.90]
		Placebo	20	15 (75.0)	-0.80 (1.01)	-3.2	-1.41	-0.74	-0.17	0.8	
	Week 25	Tezepelumab	15	9 (60.0)	-0.62 (0.80)	-1.8	-1.34	-0.37	-0.06	0.4	0.38 [-0.45, 1.20]
		Placebo	20	16 (80.0)	-0.97 (0.98)	-3.1	-1.42	-0.78	-0.39	0.7	
	Week 26	Tezepelumab	15	9 (60.0)	-0.76 (0.69)	-1.8	-1.34	-0.43	-0.34	0.1	0.21 [-0.62, 1.04]
		Placebo	20	15 (75.0)	-0.94 (0.90)	-3.2	-1.57	-0.80	-0.34	0.5	
	Week 27	Tezepelumab	15	10 (66.7)	-0.74 (0.58)	-1.5	-1.31	-0.74	-0.37	0.2	0.00 [-0.80, 0.80]
		Placebo	20	15 (75.0)	-0.74 (0.89)	-3.0	-1.11	-0.50	-0.34	0.8	
	Week 28	Tezepelumab	15	9 (60.0)	-0.85 (0.56)	-1.6	-1.34	-0.78	-0.37	-0.1	-0.26 [-1.08, 0.55]
		Placebo	20	17 (85.0)	-0.64 (0.92)	-3.2	-0.94	-0.40	-0.06	0.6	
	Week 29	Tezepelumab	15	8 (53.3)	-0.84 (0.55)	-1.6	-1.29	-0.93	-0.34	-0.1	-0.03 [-0.89, 0.83]
		Placebo	20	15 (75.0)	-0.82 (1.01)	-3.2	-0.97	-0.54	-0.17	0.8	
	Week 30	Tezepelumab	15	9 (60.0)	-0.81 (0.48)	-1.4	-1.24	-0.83	-0.37	-0.1	-0.04 [-0.88, 0.80]
		Placebo	20	14 (70.0)	-0.78 (1.01)	-3.2	-1.11	-0.49	-0.31	1.1	
	Week 31	Tezepelumab	15	8 (53.3)	-0.93 (0.61)	-1.8	-1.39	-1.03	-0.37	-0.1	0.05 [-0.81, 0.91]
		Placebo	20	15 (75.0)	-0.97 (0.90)	-3.2	-1.46	-0.86	-0.40	0.4	
	Week 32	Tezepelumab	15	9 (60.0)	-0.87 (0.55)	-1.6	-1.34	-0.83	-0.37	-0.1	-0.10 [-0.94, 0.74]
		Placebo	20	14 (70.0)	-0.79 (0.91)	-3.2	-0.97	-0.67	-0.37	0.7	
	Week 33	Tezepelumab	15	9 (60.0)	-0.86 (0.59)	-1.7	-1.34	-0.83	-0.37	-0.1	0.17 [-0.64, 0.99]
		Placebo	20	16 (80.0)	-1.00 (0.84)	-3.1	-1.42	-0.61	-0.40	-0.2	
	Week 34	Tezepelumab	15	10 (66.7)	-0.79 (0.64)	-1.8	-1.34	-0.70	-0.31	0.0	0.12 [-0.67, 0.92]
		Placebo	20	16 (80.0)	-0.90 (0.94)	-3.2	-1.04	-0.49	-0.35	0.1	
	Week 35	Tezepelumab	15	9 (60.0)	-0.75 (0.51)	-1.3	-1.20	-0.77	-0.26	-0.1	0.06 [-0.77, 0.88]
		Placebo	20	15 (75.0)	-0.80 (1.06)	-3.2	-1.11	-0.40	-0.20	0.8	
	Week 36	Tezepelumab	15	10 (66.7)	-0.89 (0.56)	-1.7	-1.34	-0.96	-0.37	-0.1	-0.16 [-0.97, 0.65]
		Placebo	20	14 (70.0)	-0.78 (0.76)	-2.7	-0.97	-0.57	-0.34	0.1	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022

Table NT1WDC\_KLMH0: Course of ASD weekly daytime score  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly daytime score	Week 37	Tezepelumab	15	9 (60.0)	-0.86 (0.60)	-1.8	-1.34	-0.83	-0.37	-0.1	0.10 [-0.72, 0.93]
		Placebo	20	15 (75.0)	-0.95 (0.94)	-3.2	-1.11	-0.72	-0.34	0.1	
	Week 38	Tezepelumab	15	8 (53.3)	-0.91 (0.66)	-1.9	-1.40	-0.97	-0.30	-0.1	-0.11 [-0.98, 0.76]
		Placebo	20	14 (70.0)	-0.83 (0.73)	-2.3	-1.11	-0.59	-0.31	0.1	
	Week 39	Tezepelumab	15	10 (66.7)	-0.89 (0.62)	-1.9	-1.34	-0.83	-0.37	-0.1	-0.14 [-0.95, 0.67]
		Placebo	20	14 (70.0)	-0.78 (0.88)	-2.9	-1.11	-0.74	-0.20	0.4	
	Week 40	Tezepelumab	15	9 (60.0)	-0.84 (0.67)	-1.9	-1.34	-0.80	-0.26	-0.1	-0.04 [-0.90, 0.83]
		Placebo	20	12 (60.0)	-0.81 (0.93)	-3.2	-1.04	-0.64	-0.28	0.3	
	Week 41	Tezepelumab	15	9 (60.0)	-0.81 (0.59)	-1.8	-1.20	-0.77	-0.37	-0.1	-0.09 [-0.96, 0.77]
		Placebo	20	12 (60.0)	-0.73 (1.07)	-3.1	-1.19	-0.55	-0.20	1.1	
	Week 42	Tezepelumab	15	9 (60.0)	-0.82 (0.60)	-1.9	-1.20	-0.83	-0.37	-0.1	-0.09 [-0.93, 0.75]
		Placebo	20	14 (70.0)	-0.75 (0.87)	-3.2	-0.86	-0.50	-0.22	0.1	
	Week 43	Tezepelumab	15	9 (60.0)	-0.88 (0.62)	-1.9	-1.34	-0.83	-0.37	-0.1	-0.08 [-0.91, 0.74]
		Placebo	20	15 (75.0)	-0.80 (1.01)	-3.2	-1.11	-0.66	-0.37	1.1	
	Week 44	Tezepelumab	15	8 (53.3)	-0.98 (0.56)	-1.9	-1.34	-0.99	-0.55	-0.2	-0.28 [-1.13, 0.58]
		Placebo	20	16 (80.0)	-0.73 (1.05)	-3.2	-1.01	-0.52	-0.33	1.5	
	Week 45	Tezepelumab	15	8 (53.3)	-1.03 (0.55)	-1.9	-1.40	-1.04	-0.58	-0.3	-0.16 [-1.03, 0.71]
		Placebo	20	14 (70.0)	-0.90 (0.91)	-3.2	-1.11	-0.64	-0.40	0.4	
	Week 46	Tezepelumab	15	8 (53.3)	-0.93 (0.45)	-1.5	-1.31	-1.00	-0.51	-0.3	-0.07 [-0.97, 0.82]
		Placebo	20	12 (60.0)	-0.88 (0.93)	-3.2	-1.09	-0.70	-0.38	0.4	
	Week 47	Tezepelumab	15	8 (53.3)	-1.03 (0.51)	-1.8	-1.37	-1.08	-0.60	-0.3	-0.28 [-1.15, 0.59]
		Placebo	20	14 (70.0)	-0.82 (0.85)	-3.2	-0.97	-0.73	-0.34	0.1	
	Week 48	Tezepelumab	15	8 (53.3)	-0.96 (0.50)	-1.5	-1.42	-0.98	-0.52	-0.3	-0.21 [-1.10, 0.69]
		Placebo	20	12 (60.0)	-0.78 (1.02)	-3.2	-1.03	-0.67	-0.37	0.9	
	Week 49	Tezepelumab	15	8 (53.3)	-0.97 (0.53)	-1.7	-1.42	-0.99	-0.47	-0.3	0.04 [-0.83, 0.91]
		Placebo	20	14 (70.0)	-1.00 (0.89)	-3.2	-1.70	-0.77	-0.38	0.2	
	Week 50	Tezepelumab	15	8 (53.3)	-0.94 (0.52)	-1.7	-1.35	-1.01	-0.42	-0.3	0.04 [-0.84, 0.92]
		Placebo	20	13 (65.0)	-0.98 (0.90)	-3.2	-1.11	-0.63	-0.40	0.0	
	Week 51	Tezepelumab	15	9 (60.0)	-0.86 (0.55)	-1.6	-1.34	-0.83	-0.37	-0.1	-0.05 [-0.88, 0.79]
		Placebo	20	14 (70.0)	-0.82 (0.86)	-3.2	-1.11	-0.56	-0.34	0.2	
	Week 52	Tezepelumab	15	9 (60.0)	-0.88 (0.55)	-1.7	-1.31	-0.85	-0.37	-0.1	0.07 [-0.78, 0.92]
		Placebo	20	13 (65.0)	-0.93 (0.94)	-3.2	-1.43	-0.63	-0.40	0.5	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022

Table NT1WDC\_KLMC0: Change from baseline in ASD weekly daytime score - MMRM results  
 DITTL - adolescents

Change from baseline in ASD weekly daytime score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 1	Tezepelumab	15	15 (100.0)	-0.28 (0.17)	(-0.62, 0.05)	-0.15 (0.22)	(-0.59, 0.29)	0.499
	Placebo	20	20 (100.0)	-0.13 (0.15)	(-0.42, 0.16)			
Week 2	Tezepelumab	15	15 (100.0)	-0.32 (0.17)	(-0.65, 0.02)	-0.04 (0.22)	(-0.48, 0.41)	0.871
	Placebo	20	20 (100.0)	-0.28 (0.15)	(-0.57, 0.01)			
Week 3	Tezepelumab	15	14 (93.3)	-0.38 (0.17)	(-0.72, -0.04)	0.16 (0.22)	(-0.29, 0.60)	0.487
	Placebo	20	18 (90.0)	-0.54 (0.15)	(-0.83, -0.25)			
Week 4	Tezepelumab	15	14 (93.3)	-0.48 (0.17)	(-0.82, -0.14)	0.14 (0.23)	(-0.30, 0.59)	0.523
	Placebo	20	19 (95.0)	-0.62 (0.15)	(-0.91, -0.33)			
Week 5	Tezepelumab	15	14 (93.3)	-0.41 (0.17)	(-0.75, -0.07)	0.09 (0.23)	(-0.35, 0.54)	0.690
	Placebo	20	19 (95.0)	-0.50 (0.15)	(-0.79, -0.21)			
Week 6	Tezepelumab	15	12 (80.0)	-0.54 (0.17)	(-0.87, -0.20)	0.02 (0.23)	(-0.42, 0.47)	0.913
	Placebo	20	18 (90.0)	-0.56 (0.15)	(-0.85, -0.27)			
Week 7	Tezepelumab	15	15 (100.0)	-0.47 (0.17)	(-0.80, -0.13)	0.12 (0.22)	(-0.33, 0.56)	0.608
	Placebo	20	18 (90.0)	-0.58 (0.15)	(-0.87, -0.29)			
Week 8	Tezepelumab	15	14 (93.3)	-0.52 (0.17)	(-0.85, -0.18)	-0.00 (0.22)	(-0.45, 0.44)	0.990
	Placebo	20	19 (95.0)	-0.51 (0.15)	(-0.81, -0.22)			
Week 9	Tezepelumab	15	12 (80.0)	-0.45 (0.17)	(-0.79, -0.12)	0.05 (0.23)	(-0.39, 0.50)	0.814
	Placebo	20	19 (95.0)	-0.51 (0.15)	(-0.80, -0.22)			
Week 10	Tezepelumab	15	15 (100.0)	-0.54 (0.17)	(-0.87, -0.21)	0.07 (0.22)	(-0.37, 0.51)	0.752
	Placebo	20	18 (90.0)	-0.61 (0.15)	(-0.90, -0.32)			

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table NT1WDC\_KLMC0: Change from baseline in ASD weekly daytime score - MMRM results  
 DITTL - adolescents

Change from baseline in ASD weekly daytime score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 11	Tezepelumab	15	13 (86.7)	-0.62 (0.17)	(-0.96, -0.28)	0.04 (0.23)	(-0.40, 0.49)	0.845
	Placebo	20	18 (90.0)	-0.66 (0.15)	(-0.96, -0.37)			
Week 12	Tezepelumab	15	13 (86.7)	-0.60 (0.17)	(-0.94, -0.26)	0.01 (0.23)	(-0.44, 0.46)	0.963
	Placebo	20	18 (90.0)	-0.61 (0.15)	(-0.90, -0.32)			
Week 13	Tezepelumab	15	11 (73.3)	-0.75 (0.18)	(-1.09, -0.40)	-0.11 (0.23)	(-0.56, 0.35)	0.645
	Placebo	20	16 (80.0)	-0.64 (0.15)	(-0.93, -0.35)			
Week 14	Tezepelumab	15	10 (66.7)	-0.77 (0.18)	(-1.12, -0.41)	-0.10 (0.23)	(-0.56, 0.36)	0.659
	Placebo	20	17 (85.0)	-0.66 (0.15)	(-0.96, -0.37)			
Week 15	Tezepelumab	15	11 (73.3)	-0.73 (0.18)	(-1.08, -0.38)	-0.19 (0.23)	(-0.65, 0.27)	0.422
	Placebo	20	16 (80.0)	-0.54 (0.15)	(-0.84, -0.25)			
Week 16	Tezepelumab	15	11 (73.3)	-0.71 (0.18)	(-1.06, -0.35)	-0.09 (0.23)	(-0.56, 0.37)	0.689
	Placebo	20	17 (85.0)	-0.61 (0.15)	(-0.91, -0.31)			
Week 17	Tezepelumab	15	12 (80.0)	-0.79 (0.18)	(-1.14, -0.44)	-0.19 (0.24)	(-0.65, 0.28)	0.431
	Placebo	20	16 (80.0)	-0.60 (0.15)	(-0.91, -0.30)			
Week 18	Tezepelumab	15	11 (73.3)	-0.73 (0.18)	(-1.09, -0.37)	-0.20 (0.24)	(-0.67, 0.27)	0.405
	Placebo	20	16 (80.0)	-0.53 (0.15)	(-0.83, -0.23)			
Week 19	Tezepelumab	15	12 (80.0)	-0.81 (0.18)	(-1.17, -0.45)	-0.10 (0.24)	(-0.57, 0.37)	0.670
	Placebo	20	17 (85.0)	-0.71 (0.15)	(-1.02, -0.41)			
Week 20	Tezepelumab	15	10 (66.7)	-0.94 (0.19)	(-1.31, -0.57)	-0.26 (0.24)	(-0.74, 0.22)	0.282
	Placebo	20	16 (80.0)	-0.68 (0.15)	(-0.98, -0.37)			

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WDC\_KLMC0: Change from baseline in ASD weekly daytime score - MMRM results  
 DITTL - adolescents

Change from baseline in ASD weekly daytime score				Repeated measures analysis																																																																																																																														
				Change from Baseline		Treatment Difference																																																																																																																												
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value																																																																																																																						
Week 21	Tezepelumab	15	10 (66.7)	-0.83 (0.19)	(-1.20, -0.46)	-0.11 (0.24)	(-0.59, 0.37)	0.659																																																																																																																										
	Placebo	20	16 (80.0)	-0.72 (0.15)	(-1.03, -0.42)				Week 22	Tezepelumab	15	10 (66.7)	-0.89 (0.19)	(-1.26, -0.51)	-0.21 (0.25)	(-0.69, 0.27)	0.392	Placebo	20	17 (85.0)	-0.68 (0.15)	(-0.98, -0.38)	Week 23	Tezepelumab	15	10 (66.7)	-0.88 (0.19)	(-1.26, -0.50)	-0.23 (0.25)	(-0.72, 0.25)	0.345	Placebo	20	15 (75.0)	-0.64 (0.16)	(-0.95, -0.34)	Week 24	Tezepelumab	15	11 (73.3)	-0.81 (0.19)	(-1.19, -0.43)	-0.22 (0.25)	(-0.71, 0.26)	0.366	Placebo	20	15 (75.0)	-0.58 (0.16)	(-0.89, -0.28)	Week 25	Tezepelumab	15	9 (60.0)	-0.77 (0.20)	(-1.16, -0.39)	0.03 (0.25)	(-0.47, 0.52)	0.913	Placebo	20	16 (80.0)	-0.80 (0.15)	(-1.11, -0.50)	Week 26	Tezepelumab	15	9 (60.0)	-0.91 (0.20)	(-1.30, -0.52)	-0.21 (0.25)	(-0.70, 0.29)	0.409	Placebo	20	15 (75.0)	-0.70 (0.15)	(-1.01, -0.40)	Week 27	Tezepelumab	15	10 (66.7)	-0.89 (0.20)	(-1.28, -0.50)	-0.25 (0.25)	(-0.74, 0.25)	0.325	Placebo	20	15 (75.0)	-0.64 (0.15)	(-0.95, -0.34)	Week 28	Tezepelumab	15	9 (60.0)	-0.90 (0.20)	(-1.30, -0.51)	-0.25 (0.25)	(-0.75, 0.25)	0.326	Placebo	20	17 (85.0)	-0.65 (0.15)	(-0.95, -0.35)	Week 29	Tezepelumab	15	8 (53.3)	-0.89 (0.21)	(-1.29, -0.48)	-0.13 (0.26)	(-0.64, 0.38)	0.612	Placebo	20	15 (75.0)	-0.76 (0.15)	(-1.06, -0.45)	Week 30	Tezepelumab	15	9 (60.0)	-0.85 (0.20)	(-1.26, -0.45)	-0.23 (0.26)	(-0.73, 0.28)	0.382	Placebo
Week 22	Tezepelumab	15	10 (66.7)	-0.89 (0.19)	(-1.26, -0.51)	-0.21 (0.25)	(-0.69, 0.27)	0.392																																																																																																																										
	Placebo	20	17 (85.0)	-0.68 (0.15)	(-0.98, -0.38)				Week 23	Tezepelumab	15	10 (66.7)	-0.88 (0.19)	(-1.26, -0.50)	-0.23 (0.25)	(-0.72, 0.25)	0.345	Placebo	20	15 (75.0)	-0.64 (0.16)	(-0.95, -0.34)	Week 24	Tezepelumab	15	11 (73.3)	-0.81 (0.19)	(-1.19, -0.43)	-0.22 (0.25)	(-0.71, 0.26)	0.366	Placebo	20	15 (75.0)	-0.58 (0.16)	(-0.89, -0.28)	Week 25	Tezepelumab	15	9 (60.0)	-0.77 (0.20)	(-1.16, -0.39)	0.03 (0.25)	(-0.47, 0.52)	0.913	Placebo	20	16 (80.0)	-0.80 (0.15)	(-1.11, -0.50)	Week 26	Tezepelumab	15	9 (60.0)	-0.91 (0.20)	(-1.30, -0.52)	-0.21 (0.25)	(-0.70, 0.29)	0.409	Placebo	20	15 (75.0)	-0.70 (0.15)	(-1.01, -0.40)	Week 27	Tezepelumab	15	10 (66.7)	-0.89 (0.20)	(-1.28, -0.50)	-0.25 (0.25)	(-0.74, 0.25)	0.325	Placebo	20	15 (75.0)	-0.64 (0.15)	(-0.95, -0.34)	Week 28	Tezepelumab	15	9 (60.0)	-0.90 (0.20)	(-1.30, -0.51)	-0.25 (0.25)	(-0.75, 0.25)	0.326	Placebo	20	17 (85.0)	-0.65 (0.15)	(-0.95, -0.35)	Week 29	Tezepelumab	15	8 (53.3)	-0.89 (0.21)	(-1.29, -0.48)	-0.13 (0.26)	(-0.64, 0.38)	0.612	Placebo	20	15 (75.0)	-0.76 (0.15)	(-1.06, -0.45)	Week 30	Tezepelumab	15	9 (60.0)	-0.85 (0.20)	(-1.26, -0.45)	-0.23 (0.26)	(-0.73, 0.28)	0.382	Placebo	20	14 (70.0)	-0.63 (0.16)	(-0.93, -0.32)										
Week 23	Tezepelumab	15	10 (66.7)	-0.88 (0.19)	(-1.26, -0.50)	-0.23 (0.25)	(-0.72, 0.25)	0.345																																																																																																																										
	Placebo	20	15 (75.0)	-0.64 (0.16)	(-0.95, -0.34)				Week 24	Tezepelumab	15	11 (73.3)	-0.81 (0.19)	(-1.19, -0.43)	-0.22 (0.25)	(-0.71, 0.26)	0.366	Placebo	20	15 (75.0)	-0.58 (0.16)	(-0.89, -0.28)	Week 25	Tezepelumab	15	9 (60.0)	-0.77 (0.20)	(-1.16, -0.39)	0.03 (0.25)	(-0.47, 0.52)	0.913	Placebo	20	16 (80.0)	-0.80 (0.15)	(-1.11, -0.50)	Week 26	Tezepelumab	15	9 (60.0)	-0.91 (0.20)	(-1.30, -0.52)	-0.21 (0.25)	(-0.70, 0.29)	0.409	Placebo	20	15 (75.0)	-0.70 (0.15)	(-1.01, -0.40)	Week 27	Tezepelumab	15	10 (66.7)	-0.89 (0.20)	(-1.28, -0.50)	-0.25 (0.25)	(-0.74, 0.25)	0.325	Placebo	20	15 (75.0)	-0.64 (0.15)	(-0.95, -0.34)	Week 28	Tezepelumab	15	9 (60.0)	-0.90 (0.20)	(-1.30, -0.51)	-0.25 (0.25)	(-0.75, 0.25)	0.326	Placebo	20	17 (85.0)	-0.65 (0.15)	(-0.95, -0.35)	Week 29	Tezepelumab	15	8 (53.3)	-0.89 (0.21)	(-1.29, -0.48)	-0.13 (0.26)	(-0.64, 0.38)	0.612	Placebo	20	15 (75.0)	-0.76 (0.15)	(-1.06, -0.45)	Week 30	Tezepelumab	15	9 (60.0)	-0.85 (0.20)	(-1.26, -0.45)	-0.23 (0.26)	(-0.73, 0.28)	0.382	Placebo	20	14 (70.0)	-0.63 (0.16)	(-0.93, -0.32)																								
Week 24	Tezepelumab	15	11 (73.3)	-0.81 (0.19)	(-1.19, -0.43)	-0.22 (0.25)	(-0.71, 0.26)	0.366																																																																																																																										
	Placebo	20	15 (75.0)	-0.58 (0.16)	(-0.89, -0.28)				Week 25	Tezepelumab	15	9 (60.0)	-0.77 (0.20)	(-1.16, -0.39)	0.03 (0.25)	(-0.47, 0.52)	0.913	Placebo	20	16 (80.0)	-0.80 (0.15)	(-1.11, -0.50)	Week 26	Tezepelumab	15	9 (60.0)	-0.91 (0.20)	(-1.30, -0.52)	-0.21 (0.25)	(-0.70, 0.29)	0.409	Placebo	20	15 (75.0)	-0.70 (0.15)	(-1.01, -0.40)	Week 27	Tezepelumab	15	10 (66.7)	-0.89 (0.20)	(-1.28, -0.50)	-0.25 (0.25)	(-0.74, 0.25)	0.325	Placebo	20	15 (75.0)	-0.64 (0.15)	(-0.95, -0.34)	Week 28	Tezepelumab	15	9 (60.0)	-0.90 (0.20)	(-1.30, -0.51)	-0.25 (0.25)	(-0.75, 0.25)	0.326	Placebo	20	17 (85.0)	-0.65 (0.15)	(-0.95, -0.35)	Week 29	Tezepelumab	15	8 (53.3)	-0.89 (0.21)	(-1.29, -0.48)	-0.13 (0.26)	(-0.64, 0.38)	0.612	Placebo	20	15 (75.0)	-0.76 (0.15)	(-1.06, -0.45)	Week 30	Tezepelumab	15	9 (60.0)	-0.85 (0.20)	(-1.26, -0.45)	-0.23 (0.26)	(-0.73, 0.28)	0.382	Placebo	20	14 (70.0)	-0.63 (0.16)	(-0.93, -0.32)																																						
Week 25	Tezepelumab	15	9 (60.0)	-0.77 (0.20)	(-1.16, -0.39)	0.03 (0.25)	(-0.47, 0.52)	0.913																																																																																																																										
	Placebo	20	16 (80.0)	-0.80 (0.15)	(-1.11, -0.50)				Week 26	Tezepelumab	15	9 (60.0)	-0.91 (0.20)	(-1.30, -0.52)	-0.21 (0.25)	(-0.70, 0.29)	0.409	Placebo	20	15 (75.0)	-0.70 (0.15)	(-1.01, -0.40)	Week 27	Tezepelumab	15	10 (66.7)	-0.89 (0.20)	(-1.28, -0.50)	-0.25 (0.25)	(-0.74, 0.25)	0.325	Placebo	20	15 (75.0)	-0.64 (0.15)	(-0.95, -0.34)	Week 28	Tezepelumab	15	9 (60.0)	-0.90 (0.20)	(-1.30, -0.51)	-0.25 (0.25)	(-0.75, 0.25)	0.326	Placebo	20	17 (85.0)	-0.65 (0.15)	(-0.95, -0.35)	Week 29	Tezepelumab	15	8 (53.3)	-0.89 (0.21)	(-1.29, -0.48)	-0.13 (0.26)	(-0.64, 0.38)	0.612	Placebo	20	15 (75.0)	-0.76 (0.15)	(-1.06, -0.45)	Week 30	Tezepelumab	15	9 (60.0)	-0.85 (0.20)	(-1.26, -0.45)	-0.23 (0.26)	(-0.73, 0.28)	0.382	Placebo	20	14 (70.0)	-0.63 (0.16)	(-0.93, -0.32)																																																				
Week 26	Tezepelumab	15	9 (60.0)	-0.91 (0.20)	(-1.30, -0.52)	-0.21 (0.25)	(-0.70, 0.29)	0.409																																																																																																																										
	Placebo	20	15 (75.0)	-0.70 (0.15)	(-1.01, -0.40)				Week 27	Tezepelumab	15	10 (66.7)	-0.89 (0.20)	(-1.28, -0.50)	-0.25 (0.25)	(-0.74, 0.25)	0.325	Placebo	20	15 (75.0)	-0.64 (0.15)	(-0.95, -0.34)	Week 28	Tezepelumab	15	9 (60.0)	-0.90 (0.20)	(-1.30, -0.51)	-0.25 (0.25)	(-0.75, 0.25)	0.326	Placebo	20	17 (85.0)	-0.65 (0.15)	(-0.95, -0.35)	Week 29	Tezepelumab	15	8 (53.3)	-0.89 (0.21)	(-1.29, -0.48)	-0.13 (0.26)	(-0.64, 0.38)	0.612	Placebo	20	15 (75.0)	-0.76 (0.15)	(-1.06, -0.45)	Week 30	Tezepelumab	15	9 (60.0)	-0.85 (0.20)	(-1.26, -0.45)	-0.23 (0.26)	(-0.73, 0.28)	0.382	Placebo	20	14 (70.0)	-0.63 (0.16)	(-0.93, -0.32)																																																																		
Week 27	Tezepelumab	15	10 (66.7)	-0.89 (0.20)	(-1.28, -0.50)	-0.25 (0.25)	(-0.74, 0.25)	0.325																																																																																																																										
	Placebo	20	15 (75.0)	-0.64 (0.15)	(-0.95, -0.34)				Week 28	Tezepelumab	15	9 (60.0)	-0.90 (0.20)	(-1.30, -0.51)	-0.25 (0.25)	(-0.75, 0.25)	0.326	Placebo	20	17 (85.0)	-0.65 (0.15)	(-0.95, -0.35)	Week 29	Tezepelumab	15	8 (53.3)	-0.89 (0.21)	(-1.29, -0.48)	-0.13 (0.26)	(-0.64, 0.38)	0.612	Placebo	20	15 (75.0)	-0.76 (0.15)	(-1.06, -0.45)	Week 30	Tezepelumab	15	9 (60.0)	-0.85 (0.20)	(-1.26, -0.45)	-0.23 (0.26)	(-0.73, 0.28)	0.382	Placebo	20	14 (70.0)	-0.63 (0.16)	(-0.93, -0.32)																																																																																
Week 28	Tezepelumab	15	9 (60.0)	-0.90 (0.20)	(-1.30, -0.51)	-0.25 (0.25)	(-0.75, 0.25)	0.326																																																																																																																										
	Placebo	20	17 (85.0)	-0.65 (0.15)	(-0.95, -0.35)				Week 29	Tezepelumab	15	8 (53.3)	-0.89 (0.21)	(-1.29, -0.48)	-0.13 (0.26)	(-0.64, 0.38)	0.612	Placebo	20	15 (75.0)	-0.76 (0.15)	(-1.06, -0.45)	Week 30	Tezepelumab	15	9 (60.0)	-0.85 (0.20)	(-1.26, -0.45)	-0.23 (0.26)	(-0.73, 0.28)	0.382	Placebo	20	14 (70.0)	-0.63 (0.16)	(-0.93, -0.32)																																																																																														
Week 29	Tezepelumab	15	8 (53.3)	-0.89 (0.21)	(-1.29, -0.48)	-0.13 (0.26)	(-0.64, 0.38)	0.612																																																																																																																										
	Placebo	20	15 (75.0)	-0.76 (0.15)	(-1.06, -0.45)				Week 30	Tezepelumab	15	9 (60.0)	-0.85 (0.20)	(-1.26, -0.45)	-0.23 (0.26)	(-0.73, 0.28)	0.382	Placebo	20	14 (70.0)	-0.63 (0.16)	(-0.93, -0.32)																																																																																																												
Week 30	Tezepelumab	15	9 (60.0)	-0.85 (0.20)	(-1.26, -0.45)	-0.23 (0.26)	(-0.73, 0.28)	0.382																																																																																																																										
	Placebo	20	14 (70.0)	-0.63 (0.16)	(-0.93, -0.32)																																																																																																																													

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WDC\_KLMC0: Change from baseline in ASD weekly daytime score - MMRM results  
 DITTL - adolescents

Change from baseline in ASD weekly daytime score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Time	Treatment	N	n (%)					
Week 31	Tezepelumab	15	8 (53.3)	-0.97 (0.21)	(-1.37, -0.56)	-0.09 (0.26)	(-0.60, 0.42)	0.725
	Placebo	20	15 (75.0)	-0.88 (0.16)	(-1.18, -0.57)			
Week 32	Tezepelumab	15	9 (60.0)	-0.91 (0.20)	(-1.31, -0.51)	-0.12 (0.26)	(-0.62, 0.39)	0.656
	Placebo	20	14 (70.0)	-0.79 (0.16)	(-1.10, -0.49)			
Week 33	Tezepelumab	15	9 (60.0)	-0.90 (0.20)	(-1.30, -0.50)	-0.06 (0.26)	(-0.56, 0.44)	0.817
	Placebo	20	16 (80.0)	-0.84 (0.15)	(-1.15, -0.54)			
Week 34	Tezepelumab	15	10 (66.7)	-0.92 (0.20)	(-1.31, -0.53)	-0.07 (0.25)	(-0.57, 0.43)	0.793
	Placebo	20	16 (80.0)	-0.85 (0.15)	(-1.16, -0.55)			
Week 35	Tezepelumab	15	9 (60.0)	-0.79 (0.20)	(-1.19, -0.40)	-0.01 (0.25)	(-0.52, 0.49)	0.953
	Placebo	20	15 (75.0)	-0.78 (0.16)	(-1.08, -0.47)			
Week 36	Tezepelumab	15	10 (66.7)	-0.91 (0.20)	(-1.31, -0.52)	-0.11 (0.26)	(-0.62, 0.39)	0.659
	Placebo	20	14 (70.0)	-0.80 (0.16)	(-1.11, -0.49)			
Week 37	Tezepelumab	15	9 (60.0)	-0.92 (0.20)	(-1.32, -0.52)	-0.10 (0.26)	(-0.61, 0.41)	0.692
	Placebo	20	15 (75.0)	-0.82 (0.16)	(-1.13, -0.51)			
Week 38	Tezepelumab	15	8 (53.3)	-0.96 (0.21)	(-1.36, -0.55)	-0.25 (0.26)	(-0.76, 0.27)	0.345
	Placebo	20	14 (70.0)	-0.71 (0.16)	(-1.02, -0.40)			
Week 39	Tezepelumab	15	10 (66.7)	-0.92 (0.20)	(-1.32, -0.52)	-0.10 (0.26)	(-0.61, 0.41)	0.700
	Placebo	20	14 (70.0)	-0.82 (0.16)	(-1.14, -0.51)			
Week 40	Tezepelumab	15	9 (60.0)	-0.92 (0.21)	(-1.33, -0.51)	-0.15 (0.26)	(-0.67, 0.37)	0.563
	Placebo	20	12 (60.0)	-0.77 (0.16)	(-1.09, -0.45)			

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WDC\_KLMC0: Change from baseline in ASD weekly daytime score - MMRM results  
 DITTL - adolescents

Change from baseline in ASD weekly daytime score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Time	Treatment	N	n (%)					
Week 41	Tezepelumab	15	9 (60.0)	-0.90 (0.21)	(-1.31, -0.49)	-0.14 (0.26)	(-0.66, 0.38)	0.587
	Placebo	20	12 (60.0)	-0.75 (0.16)	(-1.07, -0.43)			
Week 42	Tezepelumab	15	9 (60.0)	-0.90 (0.21)	(-1.31, -0.49)	-0.21 (0.26)	(-0.73, 0.31)	0.422
	Placebo	20	14 (70.0)	-0.69 (0.16)	(-1.00, -0.37)			
Week 43	Tezepelumab	15	9 (60.0)	-0.96 (0.21)	(-1.38, -0.54)	-0.21 (0.26)	(-0.73, 0.32)	0.438
	Placebo	20	15 (75.0)	-0.75 (0.16)	(-1.07, -0.44)			
Week 44	Tezepelumab	15	8 (53.3)	-0.96 (0.22)	(-1.39, -0.54)	-0.26 (0.27)	(-0.79, 0.26)	0.325
	Placebo	20	16 (80.0)	-0.70 (0.16)	(-1.01, -0.39)			
Week 45	Tezepelumab	15	8 (53.3)	-1.01 (0.22)	(-1.44, -0.58)	-0.30 (0.27)	(-0.84, 0.23)	0.267
	Placebo	20	14 (70.0)	-0.71 (0.16)	(-1.03, -0.39)			
Week 46	Tezepelumab	15	8 (53.3)	-0.92 (0.22)	(-1.35, -0.48)	-0.16 (0.27)	(-0.70, 0.38)	0.550
	Placebo	20	12 (60.0)	-0.75 (0.16)	(-1.08, -0.43)			
Week 47	Tezepelumab	15	8 (53.3)	-1.01 (0.22)	(-1.44, -0.58)	-0.12 (0.27)	(-0.66, 0.42)	0.657
	Placebo	20	14 (70.0)	-0.89 (0.16)	(-1.21, -0.57)			
Week 48	Tezepelumab	15	8 (53.3)	-0.94 (0.22)	(-1.38, -0.51)	-0.13 (0.28)	(-0.67, 0.42)	0.641
	Placebo	20	12 (60.0)	-0.81 (0.16)	(-1.14, -0.49)			
Week 49	Tezepelumab	15	8 (53.3)	-0.95 (0.22)	(-1.38, -0.52)	-0.04 (0.27)	(-0.59, 0.50)	0.872
	Placebo	20	14 (70.0)	-0.91 (0.16)	(-1.23, -0.58)			
Week 50	Tezepelumab	15	8 (53.3)	-0.93 (0.22)	(-1.36, -0.50)	-0.01 (0.27)	(-0.55, 0.53)	0.964
	Placebo	20	13 (65.0)	-0.92 (0.16)	(-1.24, -0.59)			

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WDC\_KLMC0: Change from baseline in ASD weekly daytime score - MMRM results  
 DITTL - adolescents

Change from baseline in ASD weekly daytime score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 51	Tezepelumab	15	9 (60.0)	-0.94 (0.22)	(-1.37, -0.52)	-0.06 (0.27)	(-0.60, 0.47)	0.812
	Placebo	20	14 (70.0)	-0.88 (0.16)	(-1.20, -0.56)			
Week 52	Tezepelumab	15	9 (60.0)	-0.96 (0.22)	(-1.39, -0.53)	-0.09 (0.27)	(-0.63, 0.45)	0.751
	Placebo	20	13 (65.0)	-0.87 (0.17)	(-1.20, -0.55)			

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WNC\_KLMH0: Course of ASD weekly night-time score  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly night-time score	Baseline	Tezepelumab	15	15 (100.0)	1.13 (0.56)	0.2	0.77	1.06	1.60	2.2	
		Placebo	20	20 (100.0)	1.27 (0.78)	0.2	0.61	1.20	1.89	2.8	
	Week 1	Tezepelumab	15	15 (100.0)	0.84 (0.57)	0.1	0.31	0.86	1.17	2.1	
		Placebo	20	20 (100.0)	1.13 (0.87)	0.0	0.51	0.98	1.73	3.3	
	Week 2	Tezepelumab	15	14 (93.3)	0.86 (0.68)	0.0	0.29	0.71	1.23	2.4	
		Placebo	20	20 (100.0)	0.88 (0.81)	0.0	0.20	0.59	1.61	2.5	
	Week 3	Tezepelumab	15	14 (93.3)	0.83 (0.65)	0.0	0.20	0.76	1.30	2.1	
		Placebo	20	20 (100.0)	0.80 (0.83)	0.0	0.17	0.50	1.31	3.2	
	Week 4	Tezepelumab	15	14 (93.3)	0.80 (0.63)	0.0	0.20	0.91	1.20	2.0	
		Placebo	20	18 (90.0)	0.68 (0.64)	0.0	0.03	0.53	1.26	1.8	
	Week 5	Tezepelumab	15	12 (80.0)	0.72 (0.64)	0.0	0.15	0.73	1.11	2.1	
		Placebo	20	19 (95.0)	0.77 (0.66)	0.0	0.09	0.80	1.09	2.1	
	Week 6	Tezepelumab	15	13 (86.7)	0.67 (0.58)	0.0	0.09	0.66	1.09	1.9	
		Placebo	20	18 (90.0)	0.65 (0.64)	0.0	0.03	0.49	1.06	2.0	
	Week 7	Tezepelumab	15	13 (86.7)	0.79 (0.58)	0.0	0.40	0.80	1.17	1.9	
		Placebo	20	17 (85.0)	0.72 (0.62)	0.0	0.06	0.66	1.09	2.1	
	Week 8	Tezepelumab	15	14 (93.3)	0.72 (0.62)	0.0	0.07	0.69	1.17	2.1	
		Placebo	20	18 (90.0)	0.91 (0.68)	0.0	0.43	0.89	1.40	2.1	
	Week 9	Tezepelumab	15	12 (80.0)	0.75 (0.56)	0.0	0.32	0.79	1.04	1.9	
		Placebo	20	19 (95.0)	0.78 (0.67)	0.0	0.03	0.71	1.15	2.4	
	Week 10	Tezepelumab	15	12 (80.0)	0.69 (0.56)	0.0	0.12	0.87	1.12	1.5	
		Placebo	20	16 (80.0)	0.60 (0.66)	0.0	0.00	0.61	0.90	2.5	
	Week 11	Tezepelumab	15	13 (86.7)	0.72 (0.61)	0.0	0.00	0.97	1.25	1.4	
		Placebo	20	18 (90.0)	0.73 (0.89)	0.0	0.00	0.53	0.97	3.0	
	Week 12	Tezepelumab	15	13 (86.7)	0.71 (0.59)	0.0	0.03	0.77	1.20	1.6	
		Placebo	20	17 (85.0)	0.76 (0.85)	0.0	0.11	0.63	1.03	3.0	
	Week 13	Tezepelumab	15	12 (80.0)	0.53 (0.55)	0.0	0.00	0.40	1.04	1.5	
		Placebo	20	17 (85.0)	0.67 (0.87)	0.0	0.04	0.51	0.88	3.6	
	Week 14	Tezepelumab	15	12 (80.0)	0.49 (0.48)	0.0	0.06	0.35	0.86	1.3	
		Placebo	20	17 (85.0)	0.47 (0.45)	0.0	0.00	0.34	0.80	1.1	
	Week 15	Tezepelumab	15	12 (80.0)	0.50 (0.52)	0.0	0.01	0.38	0.93	1.4	
		Placebo	20	16 (80.0)	0.63 (0.64)	0.0	0.00	0.51	0.94	2.2	
	Week 16	Tezepelumab	15	11 (73.3)	0.50 (0.50)	0.0	0.03	0.49	1.03	1.4	
		Placebo	20	17 (85.0)	0.56 (0.60)	0.0	0.00	0.49	0.83	2.1	
Week 17	Tezepelumab	15	12 (80.0)	0.48 (0.44)	0.0	0.00	0.55	0.79	1.2		
	Placebo	20	15 (75.0)	0.55 (0.46)	0.0	0.00	0.50	0.83	1.5		

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022

Table NT1WNC\_KLMH0: Course of ASD weekly night-time score  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly night-time score	Week 18	Tezepelumab	15	10 (66.7)	0.49 (0.43)	0.0	0.03	0.61	0.73	1.1	
		Placebo	20	15 (75.0)	0.67 (0.89)	0.0	0.00	0.43	0.97	3.5	
	Week 19	Tezepelumab	15	12 (80.0)	0.42 (0.41)	0.0	0.03	0.36	0.76	1.1	
		Placebo	20	17 (85.0)	0.66 (0.83)	0.0	0.00	0.31	0.96	2.9	
	Week 20	Tezepelumab	15	9 (60.0)	0.32 (0.38)	0.0	0.00	0.13	0.65	1.0	
		Placebo	20	17 (85.0)	0.80 (0.91)	0.0	0.16	0.55	0.97	3.0	
	Week 21	Tezepelumab	15	10 (66.7)	0.44 (0.48)	0.0	0.00	0.27	0.94	1.2	
		Placebo	20	16 (80.0)	0.55 (0.78)	0.0	0.00	0.34	0.76	3.1	
	Week 22	Tezepelumab	15	10 (66.7)	0.50 (0.46)	0.0	0.00	0.56	0.90	1.2	
		Placebo	20	16 (80.0)	0.82 (0.96)	0.0	0.17	0.52	0.94	3.1	
	Week 23	Tezepelumab	15	10 (66.7)	0.48 (0.51)	0.0	0.00	0.34	1.00	1.2	
		Placebo	20	16 (80.0)	0.87 (1.08)	0.0	0.09	0.56	0.99	3.8	
	Week 24	Tezepelumab	15	10 (66.7)	0.51 (0.50)	0.0	0.00	0.50	0.96	1.2	
		Placebo	20	15 (75.0)	0.81 (0.89)	0.0	0.20	0.49	1.00	3.0	
	Week 25	Tezepelumab	15	11 (73.3)	0.49 (0.49)	0.0	0.00	0.49	1.00	1.3	
		Placebo	20	15 (75.0)	0.47 (0.55)	0.0	0.00	0.40	0.80	1.9	
	Week 26	Tezepelumab	15	11 (73.3)	0.41 (0.45)	0.0	0.05	0.23	1.03	1.1	
		Placebo	20	15 (75.0)	0.45 (0.46)	0.0	0.00	0.37	0.80	1.5	
	Week 27	Tezepelumab	15	10 (66.7)	0.40 (0.46)	0.0	0.00	0.21	1.00	1.0	
		Placebo	20	16 (80.0)	0.42 (0.48)	0.0	0.00	0.32	0.63	1.8	
	Week 28	Tezepelumab	15	9 (60.0)	0.31 (0.43)	0.0	0.00	0.03	0.46	1.0	
		Placebo	20	15 (75.0)	0.65 (0.71)	0.0	0.00	0.53	0.91	2.4	
	Week 29	Tezepelumab	15	10 (66.7)	0.44 (0.45)	0.0	0.13	0.27	1.00	1.1	
		Placebo	20	15 (75.0)	0.64 (0.77)	0.0	0.00	0.49	0.80	2.7	
	Week 30	Tezepelumab	15	9 (60.0)	0.35 (0.45)	0.0	0.03	0.10	0.49	1.2	
		Placebo	20	14 (70.0)	0.53 (0.63)	0.0	0.04	0.49	0.80	2.3	
	Week 31	Tezepelumab	15	8 (53.3)	0.22 (0.39)	0.0	0.00	0.00	0.33	1.1	
		Placebo	20	14 (70.0)	0.46 (0.48)	0.0	0.00	0.34	0.80	1.7	
	Week 32	Tezepelumab	15	9 (60.0)	0.33 (0.42)	0.0	0.00	0.09	0.49	1.0	
		Placebo	20	16 (80.0)	0.63 (0.68)	0.0	0.11	0.42	1.03	2.3	
	Week 33	Tezepelumab	15	8 (53.3)	0.38 (0.47)	0.0	0.00	0.20	0.75	1.1	
		Placebo	20	14 (70.0)	0.39 (0.49)	0.0	0.00	0.24	0.70	1.7	
	Week 34	Tezepelumab	15	8 (53.3)	0.32 (0.46)	0.0	0.00	0.03	0.73	1.0	
		Placebo	20	12 (60.0)	0.53 (0.80)	0.0	0.00	0.21	0.64	2.6	
	Week 35	Tezepelumab	15	9 (60.0)	0.45 (0.51)	0.0	0.07	0.15	0.88	1.2	
		Placebo	20	15 (75.0)	0.42 (0.53)	0.0	0.00	0.15	0.72	1.6	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022

Table NT1WNC\_KLMH0: Course of ASD weekly night-time score  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly night-time score	Week 36	Tezepelumab	15	8 (53.3)	0.36 (0.45)	0.0	0.00	0.17	0.73	1.1	
		Placebo	20	14 (70.0)	0.39 (0.49)	0.0	0.00	0.17	0.80	1.4	
	Week 37	Tezepelumab	15	9 (60.0)	0.35 (0.50)	0.0	0.00	0.10	0.49	1.2	
		Placebo	20	14 (70.0)	0.33 (0.36)	0.0	0.00	0.24	0.49	1.1	
	Week 38	Tezepelumab	15	8 (53.3)	0.38 (0.54)	0.0	0.00	0.05	0.82	1.3	
		Placebo	20	15 (75.0)	0.55 (0.56)	0.0	0.00	0.43	0.90	1.8	
	Week 39	Tezepelumab	15	10 (66.7)	0.27 (0.40)	0.0	0.00	0.03	0.49	1.0	
		Placebo	20	13 (65.0)	0.57 (0.63)	0.0	0.12	0.43	0.83	2.2	
	Week 40	Tezepelumab	15	10 (66.7)	0.33 (0.45)	0.0	0.00	0.04	0.63	1.1	
		Placebo	20	13 (65.0)	0.56 (0.72)	0.0	0.06	0.30	0.80	2.5	
	Week 41	Tezepelumab	15	9 (60.0)	0.43 (0.52)	0.0	0.00	0.37	0.66	1.5	
		Placebo	20	13 (65.0)	0.56 (0.61)	0.0	0.09	0.46	0.75	2.1	
	Week 42	Tezepelumab	15	9 (60.0)	0.37 (0.59)	0.0	0.00	0.00	0.54	1.6	
		Placebo	20	13 (65.0)	0.56 (0.75)	0.0	0.00	0.20	0.80	2.6	
	Week 43	Tezepelumab	15	8 (53.3)	0.38 (0.57)	0.0	0.00	0.00	0.87	1.3	
		Placebo	20	14 (70.0)	0.78 (0.80)	0.0	0.13	0.45	1.34	2.3	
	Week 44	Tezepelumab	15	8 (53.3)	0.38 (0.59)	0.0	0.00	0.00	0.80	1.4	
		Placebo	20	14 (70.0)	0.77 (0.75)	0.0	0.03	0.56	1.31	2.3	
	Week 45	Tezepelumab	15	8 (53.3)	0.31 (0.46)	0.0	0.00	0.01	0.69	1.1	
		Placebo	20	12 (60.0)	0.69 (0.70)	0.0	0.03	0.57	1.09	2.1	
	Week 46	Tezepelumab	15	7 (46.7)	0.43 (0.47)	0.0	0.00	0.43	1.00	1.1	
		Placebo	20	11 (55.0)	0.75 (0.62)	0.0	0.07	0.80	1.17	1.8	
	Week 47	Tezepelumab	15	6 (40.0)	0.36 (0.46)	0.0	0.00	0.23	0.57	1.1	
		Placebo	20	13 (65.0)	0.55 (0.62)	0.0	0.00	0.36	0.80	1.7	
	Week 48	Tezepelumab	15	6 (40.0)	0.36 (0.44)	0.0	0.00	0.21	0.74	1.0	
		Placebo	20	14 (70.0)	0.59 (0.69)	0.0	0.00	0.31	0.85	2.1	
	Week 49	Tezepelumab	15	7 (46.7)	0.29 (0.42)	0.0	0.00	0.10	0.51	1.1	
		Placebo	20	12 (60.0)	0.54 (0.49)	0.0	0.08	0.52	0.93	1.3	
	Week 50	Tezepelumab	15	7 (46.7)	0.42 (0.49)	0.0	0.00	0.43	0.75	1.3	
		Placebo	20	12 (60.0)	0.62 (0.77)	0.0	0.00	0.45	1.00	2.5	
	Week 51	Tezepelumab	15	8 (53.3)	0.25 (0.43)	0.0	0.00	0.00	0.40	1.2	
		Placebo	20	14 (70.0)	0.60 (0.59)	0.0	0.00	0.59	1.00	1.8	
	Week 52	Tezepelumab	15	8 (53.3)	0.25 (0.40)	0.0	0.00	0.02	0.43	1.1	
		Placebo	20	12 (60.0)	0.32 (0.40)	0.0	0.02	0.14	0.58	1.2	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022



Table NT1WNC\_KLMH0: Course of ASD weekly night-time score  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly night-time score	Week 1	Tezepelumab	15	15 (100.0)	-0.29 (0.39)	-1.2	-0.43	-0.11	-0.06	0.0	-0.41 [-1.08, 0.27]
		Placebo	20	20 (100.0)	-0.14 (0.34)	-0.7	-0.41	-0.09	0.00	0.5	
	Week 2	Tezepelumab	15	14 (93.3)	-0.28 (0.48)	-1.3	-0.53	-0.16	0.10	0.3	0.23 [-0.45, 0.92]
		Placebo	20	20 (100.0)	-0.39 (0.54)	-2.3	-0.61	-0.31	-0.06	0.1	
	Week 3	Tezepelumab	15	14 (93.3)	-0.31 (0.49)	-1.3	-0.48	-0.15	-0.06	0.3	0.32 [-0.36, 1.01]
		Placebo	20	20 (100.0)	-0.48 (0.52)	-1.9	-0.74	-0.39	-0.11	0.4	
	Week 4	Tezepelumab	15	14 (93.3)	-0.34 (0.50)	-1.4	-0.34	-0.16	-0.09	0.1	0.42 [-0.29, 1.12]
		Placebo	20	18 (90.0)	-0.54 (0.49)	-2.0	-0.63	-0.46	-0.31	0.1	
	Week 5	Tezepelumab	15	12 (80.0)	-0.43 (0.49)	-1.5	-0.59	-0.23	-0.12	0.0	0.20 [-0.52, 0.93]
		Placebo	20	19 (95.0)	-0.53 (0.48)	-1.5	-0.81	-0.40	-0.14	0.1	
	Week 6	Tezepelumab	15	13 (86.7)	-0.47 (0.43)	-1.4	-0.51	-0.40	-0.17	0.1	0.17 [-0.55, 0.88]
		Placebo	20	18 (90.0)	-0.56 (0.59)	-2.4	-0.63	-0.43	-0.20	0.0	
	Week 7	Tezepelumab	15	13 (86.7)	-0.36 (0.48)	-1.5	-0.51	-0.23	-0.14	0.3	0.15 [-0.57, 0.87]
		Placebo	20	17 (85.0)	-0.43 (0.43)	-1.3	-0.66	-0.31	-0.08	0.2	
	Week 8	Tezepelumab	15	14 (93.3)	-0.42 (0.51)	-1.5	-0.51	-0.31	-0.11	0.2	0.02 [-0.68, 0.72]
		Placebo	20	18 (90.0)	-0.43 (0.45)	-1.2	-0.80	-0.36	-0.17	0.3	
	Week 9	Tezepelumab	15	12 (80.0)	-0.36 (0.44)	-1.5	-0.49	-0.30	-0.17	0.2	0.35 [-0.38, 1.07]
		Placebo	20	19 (95.0)	-0.51 (0.45)	-1.3	-0.73	-0.40	-0.29	0.3	
	Week 10	Tezepelumab	15	12 (80.0)	-0.41 (0.44)	-1.4	-0.69	-0.29	-0.13	0.2	0.33 [-0.42, 1.09]
		Placebo	20	16 (80.0)	-0.58 (0.54)	-1.8	-0.84	-0.40	-0.26	0.4	
	Week 11	Tezepelumab	15	13 (86.7)	-0.38 (0.52)	-1.5	-0.54	-0.29	-0.11	0.4	0.37 [-0.35, 1.09]
		Placebo	20	18 (90.0)	-0.61 (0.68)	-2.0	-0.83	-0.57	-0.27	0.8	
	Week 12	Tezepelumab	15	13 (86.7)	-0.39 (0.56)	-1.5	-0.69	-0.51	-0.11	0.6	0.25 [-0.47, 0.98]
		Placebo	20	17 (85.0)	-0.54 (0.57)	-1.7	-0.63	-0.51	-0.31	0.9	
	Week 13	Tezepelumab	15	12 (80.0)	-0.56 (0.62)	-1.5	-1.05	-0.43	-0.17	0.5	-0.06 [-0.80, 0.68]
		Placebo	20	17 (85.0)	-0.52 (0.60)	-1.8	-0.66	-0.40	-0.31	0.8	
	Week 14	Tezepelumab	15	12 (80.0)	-0.61 (0.57)	-1.5	-1.10	-0.45	-0.15	0.2	0.13 [-0.61, 0.87]
		Placebo	20	17 (85.0)	-0.69 (0.69)	-2.4	-0.91	-0.47	-0.28	0.5	
	Week 15	Tezepelumab	15	12 (80.0)	-0.59 (0.56)	-1.5	-1.05	-0.56	-0.10	0.3	-0.00 [-0.75, 0.75]
		Placebo	20	16 (80.0)	-0.59 (0.55)	-1.8	-0.94	-0.45	-0.24	0.3	
	Week 16	Tezepelumab	15	11 (73.3)	-0.60 (0.60)	-1.5	-1.20	-0.30	-0.17	0.4	0.04 [-0.72, 0.80]
		Placebo	20	17 (85.0)	-0.63 (0.53)	-1.8	-0.94	-0.53	-0.31	0.2	
	Week 17	Tezepelumab	15	12 (80.0)	-0.62 (0.59)	-1.5	-1.11	-0.73	-0.12	0.3	-0.03 [-0.79, 0.73]
		Placebo	20	15 (75.0)	-0.60 (0.65)	-1.8	-0.89	-0.45	-0.31	0.4	
Week 18	Tezepelumab	15	10 (66.7)	-0.56 (0.58)	-1.5	-1.00	-0.46	-0.06	0.1	-0.00 [-0.80, 0.80]	
	Placebo	20	15 (75.0)	-0.56 (0.74)	-2.1	-0.91	-0.40	0.00	0.7		

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022

Table NT1WNC\_KLMH0: Course of ASD weekly night-time score  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly night-time score	Week 19	Tezepelumab	15	12 (80.0)	-0.63 (0.50)	-1.5	-0.99	-0.61	-0.23	0.1	-0.24 [-0.98, 0.50]
		Placebo	20	17 (85.0)	-0.48 (0.68)	-1.8	-0.83	-0.40	-0.20	0.9	
	Week 20	Tezepelumab	15	9 (60.0)	-0.74 (0.52)	-1.5	-1.23	-0.75	-0.29	-0.1	-0.19 [-1.00, 0.62]
		Placebo	20	17 (85.0)	-0.60 (0.77)	-2.2	-1.20	-0.43	-0.20	0.9	
	Week 21	Tezepelumab	15	10 (66.7)	-0.60 (0.59)	-1.5	-1.23	-0.40	-0.17	0.2	0.21 [-0.58, 1.00]
		Placebo	20	16 (80.0)	-0.75 (0.77)	-2.3	-1.09	-0.55	-0.26	0.4	
	Week 22	Tezepelumab	15	10 (66.7)	-0.54 (0.62)	-1.5	-1.17	-0.39	-0.03	0.2	0.05 [-0.74, 0.84]
		Placebo	20	16 (80.0)	-0.58 (0.90)	-2.3	-0.94	-0.44	0.05	0.8	
	Week 23	Tezepelumab	15	10 (66.7)	-0.56 (0.64)	-1.5	-1.23	-0.24	-0.06	0.2	0.04 [-0.75, 0.83]
		Placebo	20	16 (80.0)	-0.60 (0.94)	-2.4	-1.29	-0.40	-0.23	1.1	
	Week 24	Tezepelumab	15	10 (66.7)	-0.53 (0.68)	-1.5	-1.18	-0.40	0.00	0.4	0.09 [-0.71, 0.89]
		Placebo	20	15 (75.0)	-0.60 (0.77)	-2.0	-1.20	-0.40	0.14	0.5	
	Week 25	Tezepelumab	15	11 (73.3)	-0.56 (0.55)	-1.5	-1.11	-0.29	-0.07	0.1	0.33 [-0.45, 1.12]
		Placebo	20	15 (75.0)	-0.78 (0.77)	-2.4	-1.27	-0.73	-0.24	0.7	
	Week 26	Tezepelumab	15	11 (73.3)	-0.63 (0.55)	-1.5	-1.17	-0.42	-0.29	0.2	0.27 [-0.51, 1.05]
		Placebo	20	15 (75.0)	-0.81 (0.73)	-2.4	-1.24	-0.83	-0.31	0.3	
	Week 27	Tezepelumab	15	10 (66.7)	-0.65 (0.52)	-1.5	-1.11	-0.47	-0.29	0.1	0.19 [-0.60, 0.98]
		Placebo	20	16 (80.0)	-0.78 (0.75)	-2.2	-1.39	-0.52	-0.36	0.6	
	Week 28	Tezepelumab	15	9 (60.0)	-0.69 (0.56)	-1.5	-1.20	-0.51	-0.29	0.0	0.06 [-0.76, 0.89]
		Placebo	20	15 (75.0)	-0.74 (0.75)	-2.4	-1.20	-0.70	-0.33	0.6	
	Week 29	Tezepelumab	15	10 (66.7)	-0.60 (0.49)	-1.3	-1.12	-0.40	-0.29	0.1	0.25 [-0.55, 1.06]
		Placebo	20	15 (75.0)	-0.79 (0.85)	-2.4	-1.49	-0.57	-0.40	0.8	
	Week 30	Tezepelumab	15	9 (60.0)	-0.66 (0.52)	-1.4	-1.00	-0.44	-0.29	-0.0	0.19 [-0.65, 1.02]
		Placebo	20	14 (70.0)	-0.81 (0.97)	-2.4	-1.49	-0.64	-0.40	1.1	
	Week 31	Tezepelumab	15	8 (53.3)	-0.79 (0.51)	-1.5	-1.23	-0.76	-0.33	-0.2	-0.08 [-0.95, 0.79]
		Placebo	20	14 (70.0)	-0.73 (0.79)	-2.4	-1.20	-0.54	-0.09	0.5	
	Week 32	Tezepelumab	15	9 (60.0)	-0.67 (0.55)	-1.5	-1.20	-0.51	-0.20	-0.0	0.12 [-0.69, 0.94]
		Placebo	20	16 (80.0)	-0.76 (0.75)	-2.4	-1.13	-0.58	-0.26	0.3	
	Week 33	Tezepelumab	15	8 (53.3)	-0.78 (0.49)	-1.5	-1.19	-0.76	-0.34	-0.2	0.14 [-0.73, 1.01]
		Placebo	20	14 (70.0)	-0.88 (0.79)	-2.4	-1.67	-0.60	-0.31	-0.0	
	Week 34	Tezepelumab	15	8 (53.3)	-0.84 (0.52)	-1.5	-1.34	-0.76	-0.35	-0.3	-0.09 [-0.98, 0.81]
		Placebo	20	12 (60.0)	-0.78 (0.78)	-2.4	-1.31	-0.40	-0.21	-0.1	
	Week 35	Tezepelumab	15	9 (60.0)	-0.69 (0.54)	-1.5	-1.00	-0.48	-0.29	-0.1	0.31 [-0.52, 1.15]
		Placebo	20	15 (75.0)	-0.91 (0.75)	-2.4	-1.65	-0.66	-0.40	0.2	
	Week 36	Tezepelumab	15	8 (53.3)	-0.80 (0.51)	-1.5	-1.29	-0.69	-0.35	-0.3	0.12 [-0.75, 0.99]
		Placebo	20	14 (70.0)	-0.88 (0.76)	-2.4	-1.37	-0.67	-0.31	0.0	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022

Table NT1WNC\_KLMH0: Course of ASD weekly night-time score  
 DITTTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly night-time score	Week 37	Tezepelumab	15	9 (60.0)	-0.80 (0.55)	-1.6	-1.09	-0.96	-0.29	-0.2	-0.02 [-0.86, 0.82]
		Placebo	20	14 (70.0)	-0.79 (0.70)	-2.1	-1.20	-0.53	-0.31	0.1	
	Week 38	Tezepelumab	15	8 (53.3)	-0.78 (0.52)	-1.5	-1.23	-0.75	-0.28	-0.3	-0.19 [-1.05, 0.67]
		Placebo	20	15 (75.0)	-0.68 (0.60)	-1.8	-1.15	-0.54	-0.31	0.4	
	Week 39	Tezepelumab	15	10 (66.7)	-0.78 (0.54)	-1.6	-1.23	-0.73	-0.29	-0.2	-0.02 [-0.84, 0.81]
		Placebo	20	13 (65.0)	-0.77 (0.78)	-2.2	-1.20	-0.63	-0.40	0.7	
	Week 40	Tezepelumab	15	10 (66.7)	-0.72 (0.61)	-1.6	-1.23	-0.61	-0.17	-0.1	0.13 [-0.69, 0.96]
		Placebo	20	13 (65.0)	-0.82 (0.82)	-2.4	-1.20	-0.69	-0.40	0.8	
	Week 41	Tezepelumab	15	9 (60.0)	-0.62 (0.61)	-1.6	-0.97	-0.53	-0.14	0.1	0.27 [-0.59, 1.12]
		Placebo	20	13 (65.0)	-0.82 (0.77)	-2.3	-1.20	-0.58	-0.40	0.4	
	Week 42	Tezepelumab	15	9 (60.0)	-0.68 (0.54)	-1.6	-0.97	-0.40	-0.29	-0.2	0.07 [-0.78, 0.92]
		Placebo	20	13 (65.0)	-0.73 (0.85)	-2.4	-1.20	-0.40	-0.20	0.7	
	Week 43	Tezepelumab	15	8 (53.3)	-0.78 (0.60)	-1.6	-1.29	-0.76	-0.23	-0.1	-0.16 [-1.03, 0.71]
		Placebo	20	14 (70.0)	-0.64 (0.95)	-2.3	-1.30	-0.47	-0.40	1.0	
	Week 44	Tezepelumab	15	8 (53.3)	-0.78 (0.53)	-1.6	-1.23	-0.67	-0.30	-0.3	-0.11 [-0.98, 0.76]
		Placebo	20	14 (70.0)	-0.70 (0.87)	-2.4	-1.20	-0.58	-0.32	0.8	
	Week 45	Tezepelumab	15	8 (53.3)	-0.85 (0.52)	-1.6	-1.33	-0.76	-0.39	-0.3	-0.04 [-0.94, 0.85]
		Placebo	20	12 (60.0)	-0.82 (0.85)	-2.4	-1.44	-0.70	-0.32	0.7	
	Week 46	Tezepelumab	15	7 (46.7)	-0.82 (0.49)	-1.5	-1.17	-0.97	-0.29	-0.3	-0.04 [-0.99, 0.90]
		Placebo	20	11 (55.0)	-0.79 (0.84)	-2.4	-1.29	-0.63	-0.33	0.7	
	Week 47	Tezepelumab	15	6 (40.0)	-0.86 (0.47)	-1.5	-1.09	-1.00	-0.31	-0.3	0.00 [-0.97, 0.97]
		Placebo	20	13 (65.0)	-0.86 (0.77)	-2.4	-1.20	-0.63	-0.40	0.4	
	Week 48	Tezepelumab	15	6 (40.0)	-0.86 (0.48)	-1.5	-1.23	-0.91	-0.34	-0.3	-0.32 [-1.29, 0.64]
		Placebo	20	14 (70.0)	-0.62 (0.83)	-2.4	-0.89	-0.40	-0.31	0.9	
	Week 49	Tezepelumab	15	7 (46.7)	-0.84 (0.51)	-1.5	-1.31	-0.97	-0.29	-0.3	-0.09 [-1.02, 0.84]
		Placebo	20	12 (60.0)	-0.77 (0.78)	-2.3	-1.31	-0.71	-0.40	0.9	
	Week 50	Tezepelumab	15	7 (46.7)	-0.77 (0.49)	-1.5	-1.14	-0.93	-0.29	-0.2	0.10 [-0.83, 1.04]
		Placebo	20	12 (60.0)	-0.84 (0.73)	-2.4	-1.30	-0.63	-0.40	0.4	
	Week 51	Tezepelumab	15	8 (53.3)	-0.75 (0.48)	-1.5	-1.10	-0.76	-0.33	-0.2	0.01 [-0.86, 0.87]
		Placebo	20	14 (70.0)	-0.76 (0.75)	-2.4	-1.20	-0.50	-0.40	0.7	
	Week 52	Tezepelumab	15	8 (53.3)	-0.75 (0.50)	-1.5	-1.15	-0.74	-0.30	-0.2	0.22 [-0.68, 1.12]
		Placebo	20	12 (60.0)	-0.89 (0.66)	-2.4	-1.18	-0.58	-0.40	-0.3	

Note: DITTTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022

Table NT1WNC\_KLMC0: Change from baseline in ASD weekly night-time score - MMRM results  
 DITTTL - adolescents

Change from baseline in ASD weekly night-time score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 1	Tezepelumab	15	15 (100.0)	-0.32 (0.15)	(-0.61, -0.04)	-0.21 (0.19)	(-0.59, 0.17)	0.282
	Placebo	20	20 (100.0)	-0.12 (0.13)	(-0.37, 0.13)			
Week 2	Tezepelumab	15	14 (93.3)	-0.33 (0.15)	(-0.62, -0.04)	0.04 (0.19)	(-0.34, 0.42)	0.833
	Placebo	20	20 (100.0)	-0.37 (0.13)	(-0.62, -0.12)			
Week 3	Tezepelumab	15	14 (93.3)	-0.37 (0.15)	(-0.66, -0.08)	0.08 (0.19)	(-0.30, 0.47)	0.663
	Placebo	20	20 (100.0)	-0.45 (0.13)	(-0.70, -0.20)			
Week 4	Tezepelumab	15	14 (93.3)	-0.40 (0.15)	(-0.68, -0.11)	0.08 (0.19)	(-0.30, 0.46)	0.685
	Placebo	20	18 (90.0)	-0.47 (0.13)	(-0.72, -0.22)			
Week 5	Tezepelumab	15	12 (80.0)	-0.42 (0.15)	(-0.71, -0.13)	0.06 (0.19)	(-0.32, 0.44)	0.756
	Placebo	20	19 (95.0)	-0.48 (0.13)	(-0.73, -0.23)			
Week 6	Tezepelumab	15	13 (86.7)	-0.43 (0.15)	(-0.72, -0.14)	0.11 (0.19)	(-0.28, 0.49)	0.585
	Placebo	20	18 (90.0)	-0.54 (0.13)	(-0.79, -0.28)			
Week 7	Tezepelumab	15	13 (86.7)	-0.38 (0.15)	(-0.67, -0.09)	0.09 (0.19)	(-0.30, 0.47)	0.658
	Placebo	20	17 (85.0)	-0.47 (0.13)	(-0.72, -0.21)			
Week 8	Tezepelumab	15	14 (93.3)	-0.47 (0.15)	(-0.76, -0.19)	-0.09 (0.19)	(-0.47, 0.30)	0.655
	Placebo	20	18 (90.0)	-0.39 (0.13)	(-0.64, -0.13)			
Week 9	Tezepelumab	15	12 (80.0)	-0.44 (0.15)	(-0.73, -0.15)	0.03 (0.20)	(-0.36, 0.42)	0.879
	Placebo	20	19 (95.0)	-0.47 (0.13)	(-0.72, -0.22)			
Week 10	Tezepelumab	15	12 (80.0)	-0.48 (0.15)	(-0.77, -0.19)	0.11 (0.20)	(-0.28, 0.50)	0.592
	Placebo	20	16 (80.0)	-0.59 (0.13)	(-0.84, -0.33)			

Note: DITTTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WNC\_KLMC0: Change from baseline in ASD weekly night-time score - MMRM results  
 DITTTL - adolescents

Change from baseline in ASD weekly night-time score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 11	Tezepelumab	15	13 (86.7)	-0.50 (0.15)	(-0.79, -0.21)	0.06 (0.20)	(-0.33, 0.44)	0.774
	Placebo	20	18 (90.0)	-0.56 (0.13)	(-0.81, -0.31)			
Week 12	Tezepelumab	15	13 (86.7)	-0.51 (0.15)	(-0.80, -0.22)	0.05 (0.20)	(-0.33, 0.44)	0.789
	Placebo	20	17 (85.0)	-0.56 (0.13)	(-0.82, -0.31)			
Week 13	Tezepelumab	15	12 (80.0)	-0.57 (0.15)	(-0.86, -0.28)	-0.08 (0.20)	(-0.47, 0.31)	0.688
	Placebo	20	17 (85.0)	-0.49 (0.13)	(-0.75, -0.24)			
Week 14	Tezepelumab	15	12 (80.0)	-0.56 (0.15)	(-0.85, -0.26)	-0.02 (0.20)	(-0.41, 0.37)	0.911
	Placebo	20	17 (85.0)	-0.53 (0.13)	(-0.79, -0.28)			
Week 15	Tezepelumab	15	12 (80.0)	-0.56 (0.15)	(-0.86, -0.27)	-0.00 (0.20)	(-0.40, 0.39)	0.982
	Placebo	20	16 (80.0)	-0.56 (0.13)	(-0.82, -0.30)			
Week 16	Tezepelumab	15	11 (73.3)	-0.62 (0.15)	(-0.92, -0.33)	-0.03 (0.20)	(-0.42, 0.36)	0.882
	Placebo	20	17 (85.0)	-0.59 (0.13)	(-0.85, -0.34)			
Week 17	Tezepelumab	15	12 (80.0)	-0.63 (0.15)	(-0.93, -0.33)	-0.13 (0.20)	(-0.53, 0.26)	0.508
	Placebo	20	15 (75.0)	-0.50 (0.13)	(-0.76, -0.24)			
Week 18	Tezepelumab	15	10 (66.7)	-0.65 (0.15)	(-0.96, -0.35)	-0.23 (0.20)	(-0.63, 0.17)	0.253
	Placebo	20	15 (75.0)	-0.42 (0.13)	(-0.68, -0.16)			
Week 19	Tezepelumab	15	12 (80.0)	-0.71 (0.15)	(-1.01, -0.40)	-0.22 (0.20)	(-0.61, 0.18)	0.283
	Placebo	20	17 (85.0)	-0.49 (0.13)	(-0.75, -0.24)			
Week 20	Tezepelumab	15	9 (60.0)	-0.75 (0.16)	(-1.07, -0.44)	-0.21 (0.21)	(-0.62, 0.19)	0.304
	Placebo	20	17 (85.0)	-0.54 (0.13)	(-0.80, -0.29)			

Note: DITTTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WNC\_KLMC0: Change from baseline in ASD weekly night-time score - MMRM results  
 DITTTL - adolescents

Change from baseline in ASD weekly night-time score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 21	Tezepelumab	15	10 (66.7)	-0.70 (0.16)	(-1.01, -0.38)	-0.12 (0.21)	(-0.53, 0.29)	0.553
	Placebo	20	16 (80.0)	-0.57 (0.13)	(-0.83, -0.32)			
Week 22	Tezepelumab	15	10 (66.7)	-0.64 (0.16)	(-0.96, -0.32)	-0.08 (0.21)	(-0.49, 0.34)	0.717
	Placebo	20	16 (80.0)	-0.56 (0.13)	(-0.82, -0.30)			
Week 23	Tezepelumab	15	10 (66.7)	-0.66 (0.16)	(-0.98, -0.33)	-0.15 (0.21)	(-0.56, 0.27)	0.488
	Placebo	20	16 (80.0)	-0.51 (0.13)	(-0.77, -0.25)			
Week 24	Tezepelumab	15	10 (66.7)	-0.63 (0.16)	(-0.95, -0.30)	-0.07 (0.21)	(-0.49, 0.35)	0.738
	Placebo	20	15 (75.0)	-0.56 (0.13)	(-0.82, -0.29)			
Week 25	Tezepelumab	15	11 (73.3)	-0.63 (0.16)	(-0.95, -0.30)	-0.01 (0.21)	(-0.43, 0.41)	0.962
	Placebo	20	15 (75.0)	-0.62 (0.13)	(-0.88, -0.35)			
Week 26	Tezepelumab	15	11 (73.3)	-0.70 (0.17)	(-1.03, -0.38)	-0.06 (0.21)	(-0.48, 0.36)	0.788
	Placebo	20	15 (75.0)	-0.65 (0.13)	(-0.91, -0.38)			
Week 27	Tezepelumab	15	10 (66.7)	-0.75 (0.17)	(-1.08, -0.42)	-0.09 (0.21)	(-0.52, 0.33)	0.659
	Placebo	20	16 (80.0)	-0.66 (0.13)	(-0.92, -0.40)			
Week 28	Tezepelumab	15	9 (60.0)	-0.77 (0.17)	(-1.11, -0.44)	-0.18 (0.22)	(-0.61, 0.25)	0.406
	Placebo	20	15 (75.0)	-0.59 (0.13)	(-0.85, -0.33)			
Week 29	Tezepelumab	15	10 (66.7)	-0.70 (0.17)	(-1.04, -0.37)	-0.08 (0.22)	(-0.51, 0.34)	0.695
	Placebo	20	15 (75.0)	-0.62 (0.13)	(-0.88, -0.36)			
Week 30	Tezepelumab	15	9 (60.0)	-0.73 (0.17)	(-1.07, -0.39)	-0.15 (0.22)	(-0.58, 0.28)	0.483
	Placebo	20	14 (70.0)	-0.58 (0.13)	(-0.84, -0.32)			

Note: DITTTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WNC\_KLMC0: Change from baseline in ASD weekly night-time score - MMRM results  
 DITTTL - adolescents

Change from baseline in ASD weekly night-time score				Repeated measures analysis																																																																																																																														
				Change from Baseline		Treatment Difference																																																																																																																												
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value																																																																																																																						
Week 31	Tezepelumab	15	8 (53.3)	-0.78 (0.17)	(-1.13, -0.44)	-0.13 (0.22)	(-0.57, 0.30)	0.543																																																																																																																										
	Placebo	20	14 (70.0)	-0.65 (0.13)	(-0.91, -0.39)				Week 32	Tezepelumab	15	9 (60.0)	-0.74 (0.17)	(-1.08, -0.40)	-0.12 (0.22)	(-0.55, 0.31)	0.595	Placebo	20	16 (80.0)	-0.63 (0.13)	(-0.88, -0.37)	Week 33	Tezepelumab	15	8 (53.3)	-0.75 (0.18)	(-1.09, -0.40)	-0.11 (0.22)	(-0.54, 0.33)	0.625	Placebo	20	14 (70.0)	-0.64 (0.13)	(-0.90, -0.38)	Week 34	Tezepelumab	15	8 (53.3)	-0.81 (0.18)	(-1.16, -0.46)	-0.19 (0.22)	(-0.63, 0.24)	0.381	Placebo	20	12 (60.0)	-0.61 (0.13)	(-0.88, -0.35)	Week 35	Tezepelumab	15	9 (60.0)	-0.74 (0.17)	(-1.08, -0.39)	-0.06 (0.22)	(-0.49, 0.38)	0.799	Placebo	20	15 (75.0)	-0.68 (0.13)	(-0.94, -0.42)	Week 36	Tezepelumab	15	8 (53.3)	-0.78 (0.17)	(-1.12, -0.43)	-0.04 (0.22)	(-0.47, 0.40)	0.862	Placebo	20	14 (70.0)	-0.74 (0.13)	(-1.00, -0.47)	Week 37	Tezepelumab	15	9 (60.0)	-0.75 (0.17)	(-1.10, -0.41)	-0.06 (0.22)	(-0.50, 0.37)	0.780	Placebo	20	14 (70.0)	-0.69 (0.14)	(-0.96, -0.42)	Week 38	Tezepelumab	15	8 (53.3)	-0.76 (0.18)	(-1.11, -0.41)	-0.21 (0.22)	(-0.65, 0.23)	0.345	Placebo	20	15 (75.0)	-0.55 (0.14)	(-0.82, -0.28)	Week 39	Tezepelumab	15	10 (66.7)	-0.81 (0.17)	(-1.15, -0.47)	-0.22 (0.22)	(-0.66, 0.22)	0.319	Placebo	20	13 (65.0)	-0.59 (0.14)	(-0.86, -0.31)	Week 40	Tezepelumab	15	10 (66.7)	-0.75 (0.17)	(-1.09, -0.40)	-0.14 (0.22)	(-0.58, 0.30)	0.527	Placebo
Week 32	Tezepelumab	15	9 (60.0)	-0.74 (0.17)	(-1.08, -0.40)	-0.12 (0.22)	(-0.55, 0.31)	0.595																																																																																																																										
	Placebo	20	16 (80.0)	-0.63 (0.13)	(-0.88, -0.37)				Week 33	Tezepelumab	15	8 (53.3)	-0.75 (0.18)	(-1.09, -0.40)	-0.11 (0.22)	(-0.54, 0.33)	0.625	Placebo	20	14 (70.0)	-0.64 (0.13)	(-0.90, -0.38)	Week 34	Tezepelumab	15	8 (53.3)	-0.81 (0.18)	(-1.16, -0.46)	-0.19 (0.22)	(-0.63, 0.24)	0.381	Placebo	20	12 (60.0)	-0.61 (0.13)	(-0.88, -0.35)	Week 35	Tezepelumab	15	9 (60.0)	-0.74 (0.17)	(-1.08, -0.39)	-0.06 (0.22)	(-0.49, 0.38)	0.799	Placebo	20	15 (75.0)	-0.68 (0.13)	(-0.94, -0.42)	Week 36	Tezepelumab	15	8 (53.3)	-0.78 (0.17)	(-1.12, -0.43)	-0.04 (0.22)	(-0.47, 0.40)	0.862	Placebo	20	14 (70.0)	-0.74 (0.13)	(-1.00, -0.47)	Week 37	Tezepelumab	15	9 (60.0)	-0.75 (0.17)	(-1.10, -0.41)	-0.06 (0.22)	(-0.50, 0.37)	0.780	Placebo	20	14 (70.0)	-0.69 (0.14)	(-0.96, -0.42)	Week 38	Tezepelumab	15	8 (53.3)	-0.76 (0.18)	(-1.11, -0.41)	-0.21 (0.22)	(-0.65, 0.23)	0.345	Placebo	20	15 (75.0)	-0.55 (0.14)	(-0.82, -0.28)	Week 39	Tezepelumab	15	10 (66.7)	-0.81 (0.17)	(-1.15, -0.47)	-0.22 (0.22)	(-0.66, 0.22)	0.319	Placebo	20	13 (65.0)	-0.59 (0.14)	(-0.86, -0.31)	Week 40	Tezepelumab	15	10 (66.7)	-0.75 (0.17)	(-1.09, -0.40)	-0.14 (0.22)	(-0.58, 0.30)	0.527	Placebo	20	13 (65.0)	-0.61 (0.14)	(-0.88, -0.33)										
Week 33	Tezepelumab	15	8 (53.3)	-0.75 (0.18)	(-1.09, -0.40)	-0.11 (0.22)	(-0.54, 0.33)	0.625																																																																																																																										
	Placebo	20	14 (70.0)	-0.64 (0.13)	(-0.90, -0.38)				Week 34	Tezepelumab	15	8 (53.3)	-0.81 (0.18)	(-1.16, -0.46)	-0.19 (0.22)	(-0.63, 0.24)	0.381	Placebo	20	12 (60.0)	-0.61 (0.13)	(-0.88, -0.35)	Week 35	Tezepelumab	15	9 (60.0)	-0.74 (0.17)	(-1.08, -0.39)	-0.06 (0.22)	(-0.49, 0.38)	0.799	Placebo	20	15 (75.0)	-0.68 (0.13)	(-0.94, -0.42)	Week 36	Tezepelumab	15	8 (53.3)	-0.78 (0.17)	(-1.12, -0.43)	-0.04 (0.22)	(-0.47, 0.40)	0.862	Placebo	20	14 (70.0)	-0.74 (0.13)	(-1.00, -0.47)	Week 37	Tezepelumab	15	9 (60.0)	-0.75 (0.17)	(-1.10, -0.41)	-0.06 (0.22)	(-0.50, 0.37)	0.780	Placebo	20	14 (70.0)	-0.69 (0.14)	(-0.96, -0.42)	Week 38	Tezepelumab	15	8 (53.3)	-0.76 (0.18)	(-1.11, -0.41)	-0.21 (0.22)	(-0.65, 0.23)	0.345	Placebo	20	15 (75.0)	-0.55 (0.14)	(-0.82, -0.28)	Week 39	Tezepelumab	15	10 (66.7)	-0.81 (0.17)	(-1.15, -0.47)	-0.22 (0.22)	(-0.66, 0.22)	0.319	Placebo	20	13 (65.0)	-0.59 (0.14)	(-0.86, -0.31)	Week 40	Tezepelumab	15	10 (66.7)	-0.75 (0.17)	(-1.09, -0.40)	-0.14 (0.22)	(-0.58, 0.30)	0.527	Placebo	20	13 (65.0)	-0.61 (0.14)	(-0.88, -0.33)																								
Week 34	Tezepelumab	15	8 (53.3)	-0.81 (0.18)	(-1.16, -0.46)	-0.19 (0.22)	(-0.63, 0.24)	0.381																																																																																																																										
	Placebo	20	12 (60.0)	-0.61 (0.13)	(-0.88, -0.35)				Week 35	Tezepelumab	15	9 (60.0)	-0.74 (0.17)	(-1.08, -0.39)	-0.06 (0.22)	(-0.49, 0.38)	0.799	Placebo	20	15 (75.0)	-0.68 (0.13)	(-0.94, -0.42)	Week 36	Tezepelumab	15	8 (53.3)	-0.78 (0.17)	(-1.12, -0.43)	-0.04 (0.22)	(-0.47, 0.40)	0.862	Placebo	20	14 (70.0)	-0.74 (0.13)	(-1.00, -0.47)	Week 37	Tezepelumab	15	9 (60.0)	-0.75 (0.17)	(-1.10, -0.41)	-0.06 (0.22)	(-0.50, 0.37)	0.780	Placebo	20	14 (70.0)	-0.69 (0.14)	(-0.96, -0.42)	Week 38	Tezepelumab	15	8 (53.3)	-0.76 (0.18)	(-1.11, -0.41)	-0.21 (0.22)	(-0.65, 0.23)	0.345	Placebo	20	15 (75.0)	-0.55 (0.14)	(-0.82, -0.28)	Week 39	Tezepelumab	15	10 (66.7)	-0.81 (0.17)	(-1.15, -0.47)	-0.22 (0.22)	(-0.66, 0.22)	0.319	Placebo	20	13 (65.0)	-0.59 (0.14)	(-0.86, -0.31)	Week 40	Tezepelumab	15	10 (66.7)	-0.75 (0.17)	(-1.09, -0.40)	-0.14 (0.22)	(-0.58, 0.30)	0.527	Placebo	20	13 (65.0)	-0.61 (0.14)	(-0.88, -0.33)																																						
Week 35	Tezepelumab	15	9 (60.0)	-0.74 (0.17)	(-1.08, -0.39)	-0.06 (0.22)	(-0.49, 0.38)	0.799																																																																																																																										
	Placebo	20	15 (75.0)	-0.68 (0.13)	(-0.94, -0.42)				Week 36	Tezepelumab	15	8 (53.3)	-0.78 (0.17)	(-1.12, -0.43)	-0.04 (0.22)	(-0.47, 0.40)	0.862	Placebo	20	14 (70.0)	-0.74 (0.13)	(-1.00, -0.47)	Week 37	Tezepelumab	15	9 (60.0)	-0.75 (0.17)	(-1.10, -0.41)	-0.06 (0.22)	(-0.50, 0.37)	0.780	Placebo	20	14 (70.0)	-0.69 (0.14)	(-0.96, -0.42)	Week 38	Tezepelumab	15	8 (53.3)	-0.76 (0.18)	(-1.11, -0.41)	-0.21 (0.22)	(-0.65, 0.23)	0.345	Placebo	20	15 (75.0)	-0.55 (0.14)	(-0.82, -0.28)	Week 39	Tezepelumab	15	10 (66.7)	-0.81 (0.17)	(-1.15, -0.47)	-0.22 (0.22)	(-0.66, 0.22)	0.319	Placebo	20	13 (65.0)	-0.59 (0.14)	(-0.86, -0.31)	Week 40	Tezepelumab	15	10 (66.7)	-0.75 (0.17)	(-1.09, -0.40)	-0.14 (0.22)	(-0.58, 0.30)	0.527	Placebo	20	13 (65.0)	-0.61 (0.14)	(-0.88, -0.33)																																																				
Week 36	Tezepelumab	15	8 (53.3)	-0.78 (0.17)	(-1.12, -0.43)	-0.04 (0.22)	(-0.47, 0.40)	0.862																																																																																																																										
	Placebo	20	14 (70.0)	-0.74 (0.13)	(-1.00, -0.47)				Week 37	Tezepelumab	15	9 (60.0)	-0.75 (0.17)	(-1.10, -0.41)	-0.06 (0.22)	(-0.50, 0.37)	0.780	Placebo	20	14 (70.0)	-0.69 (0.14)	(-0.96, -0.42)	Week 38	Tezepelumab	15	8 (53.3)	-0.76 (0.18)	(-1.11, -0.41)	-0.21 (0.22)	(-0.65, 0.23)	0.345	Placebo	20	15 (75.0)	-0.55 (0.14)	(-0.82, -0.28)	Week 39	Tezepelumab	15	10 (66.7)	-0.81 (0.17)	(-1.15, -0.47)	-0.22 (0.22)	(-0.66, 0.22)	0.319	Placebo	20	13 (65.0)	-0.59 (0.14)	(-0.86, -0.31)	Week 40	Tezepelumab	15	10 (66.7)	-0.75 (0.17)	(-1.09, -0.40)	-0.14 (0.22)	(-0.58, 0.30)	0.527	Placebo	20	13 (65.0)	-0.61 (0.14)	(-0.88, -0.33)																																																																		
Week 37	Tezepelumab	15	9 (60.0)	-0.75 (0.17)	(-1.10, -0.41)	-0.06 (0.22)	(-0.50, 0.37)	0.780																																																																																																																										
	Placebo	20	14 (70.0)	-0.69 (0.14)	(-0.96, -0.42)				Week 38	Tezepelumab	15	8 (53.3)	-0.76 (0.18)	(-1.11, -0.41)	-0.21 (0.22)	(-0.65, 0.23)	0.345	Placebo	20	15 (75.0)	-0.55 (0.14)	(-0.82, -0.28)	Week 39	Tezepelumab	15	10 (66.7)	-0.81 (0.17)	(-1.15, -0.47)	-0.22 (0.22)	(-0.66, 0.22)	0.319	Placebo	20	13 (65.0)	-0.59 (0.14)	(-0.86, -0.31)	Week 40	Tezepelumab	15	10 (66.7)	-0.75 (0.17)	(-1.09, -0.40)	-0.14 (0.22)	(-0.58, 0.30)	0.527	Placebo	20	13 (65.0)	-0.61 (0.14)	(-0.88, -0.33)																																																																																
Week 38	Tezepelumab	15	8 (53.3)	-0.76 (0.18)	(-1.11, -0.41)	-0.21 (0.22)	(-0.65, 0.23)	0.345																																																																																																																										
	Placebo	20	15 (75.0)	-0.55 (0.14)	(-0.82, -0.28)				Week 39	Tezepelumab	15	10 (66.7)	-0.81 (0.17)	(-1.15, -0.47)	-0.22 (0.22)	(-0.66, 0.22)	0.319	Placebo	20	13 (65.0)	-0.59 (0.14)	(-0.86, -0.31)	Week 40	Tezepelumab	15	10 (66.7)	-0.75 (0.17)	(-1.09, -0.40)	-0.14 (0.22)	(-0.58, 0.30)	0.527	Placebo	20	13 (65.0)	-0.61 (0.14)	(-0.88, -0.33)																																																																																														
Week 39	Tezepelumab	15	10 (66.7)	-0.81 (0.17)	(-1.15, -0.47)	-0.22 (0.22)	(-0.66, 0.22)	0.319																																																																																																																										
	Placebo	20	13 (65.0)	-0.59 (0.14)	(-0.86, -0.31)				Week 40	Tezepelumab	15	10 (66.7)	-0.75 (0.17)	(-1.09, -0.40)	-0.14 (0.22)	(-0.58, 0.30)	0.527	Placebo	20	13 (65.0)	-0.61 (0.14)	(-0.88, -0.33)																																																																																																												
Week 40	Tezepelumab	15	10 (66.7)	-0.75 (0.17)	(-1.09, -0.40)	-0.14 (0.22)	(-0.58, 0.30)	0.527																																																																																																																										
	Placebo	20	13 (65.0)	-0.61 (0.14)	(-0.88, -0.33)																																																																																																																													

Note: DITTTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WNC\_KLMC0: Change from baseline in ASD weekly night-time score - MMRM results  
 DITTLL - adolescents

Change from baseline in ASD weekly night-time score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 41	Tezepelumab	15	9 (60.0)	-0.69 (0.18)	(-1.04, -0.34)	-0.09 (0.22)	(-0.54, 0.35)	0.681
	Placebo	20	13 (65.0)	-0.60 (0.14)	(-0.87, -0.32)			
Week 42	Tezepelumab	15	9 (60.0)	-0.74 (0.18)	(-1.09, -0.39)	-0.22 (0.23)	(-0.66, 0.23)	0.338
	Placebo	20	13 (65.0)	-0.53 (0.14)	(-0.80, -0.25)			
Week 43	Tezepelumab	15	8 (53.3)	-0.77 (0.18)	(-1.13, -0.42)	-0.18 (0.23)	(-0.63, 0.26)	0.419
	Placebo	20	14 (70.0)	-0.59 (0.14)	(-0.86, -0.32)			
Week 44	Tezepelumab	15	8 (53.3)	-0.78 (0.18)	(-1.14, -0.42)	-0.15 (0.23)	(-0.61, 0.30)	0.506
	Placebo	20	14 (70.0)	-0.62 (0.14)	(-0.90, -0.35)			
Week 45	Tezepelumab	15	8 (53.3)	-0.84 (0.18)	(-1.20, -0.48)	-0.24 (0.23)	(-0.69, 0.22)	0.311
	Placebo	20	12 (60.0)	-0.61 (0.14)	(-0.88, -0.33)			
Week 46	Tezepelumab	15	7 (46.7)	-0.76 (0.19)	(-1.13, -0.39)	-0.17 (0.24)	(-0.64, 0.29)	0.463
	Placebo	20	11 (55.0)	-0.59 (0.14)	(-0.87, -0.31)			
Week 47	Tezepelumab	15	6 (40.0)	-0.73 (0.19)	(-1.11, -0.36)	-0.07 (0.24)	(-0.54, 0.39)	0.760
	Placebo	20	13 (65.0)	-0.66 (0.14)	(-0.94, -0.39)			
Week 48	Tezepelumab	15	6 (40.0)	-0.73 (0.19)	(-1.11, -0.36)	-0.04 (0.24)	(-0.50, 0.43)	0.875
	Placebo	20	14 (70.0)	-0.70 (0.14)	(-0.97, -0.42)			
Week 49	Tezepelumab	15	7 (46.7)	-0.77 (0.19)	(-1.14, -0.41)	-0.10 (0.23)	(-0.57, 0.36)	0.657
	Placebo	20	12 (60.0)	-0.67 (0.14)	(-0.95, -0.39)			
Week 50	Tezepelumab	15	7 (46.7)	-0.74 (0.19)	(-1.10, -0.37)	-0.05 (0.23)	(-0.51, 0.41)	0.834
	Placebo	20	12 (60.0)	-0.69 (0.14)	(-0.97, -0.41)			

Note: DITTLL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table NT1WNC\_KLMC0: Change from baseline in ASD weekly night-time score - MMRM results  
 DITTTL - adolescents

Change from baseline in ASD weekly night-time score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 51	Tezepelumab	15	8 (53.3)	-0.78 (0.18)	(-1.14, -0.41)	-0.03 (0.23)	(-0.49, 0.43)	0.890
	Placebo	20	14 (70.0)	-0.74 (0.14)	(-1.03, -0.46)			
Week 52	Tezepelumab	15	8 (53.3)	-0.78 (0.19)	(-1.15, -0.41)	0.02 (0.24)	(-0.45, 0.49)	0.930
	Placebo	20	12 (60.0)	-0.80 (0.15)	(-1.09, -0.52)			

Note: DITTTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WWC\_KLMH0: Course of ASD weekly wheezing score  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly wheezing score	Baseline	Tezepelumab	15	15 (100.0)	1.29 (0.64)	0.0	0.93	1.17	1.92	2.0	
		Placebo	20	20 (100.0)	1.39 (0.97)	0.0	0.54	1.43	2.00	3.1	
	Week 1	Tezepelumab	15	14 (93.3)	1.06 (0.68)	0.0	0.50	1.04	1.57	2.0	
		Placebo	20	20 (100.0)	1.23 (1.02)	0.0	0.25	1.12	2.00	3.6	
	Week 2	Tezepelumab	15	14 (93.3)	1.00 (0.90)	0.0	0.25	0.82	2.00	2.7	
		Placebo	20	19 (95.0)	0.99 (0.95)	0.0	0.00	0.86	2.00	2.9	
	Week 3	Tezepelumab	15	14 (93.3)	0.92 (0.82)	0.0	0.08	0.96	1.67	2.3	
		Placebo	20	17 (85.0)	0.77 (0.88)	0.0	0.00	0.64	1.20	2.9	
	Week 4	Tezepelumab	15	12 (80.0)	0.92 (0.83)	0.0	0.04	0.83	1.84	2.0	
		Placebo	20	17 (85.0)	0.68 (0.71)	0.0	0.00	0.36	1.00	2.0	
	Week 5	Tezepelumab	15	12 (80.0)	0.83 (0.81)	0.0	0.04	0.73	1.50	2.1	
		Placebo	20	16 (80.0)	0.69 (0.64)	0.0	0.04	0.75	1.07	2.0	
	Week 6	Tezepelumab	15	11 (73.3)	0.83 (0.82)	0.0	0.00	0.50	1.71	2.0	
		Placebo	20	16 (80.0)	0.59 (0.65)	0.0	0.04	0.18	1.11	2.0	
	Week 7	Tezepelumab	15	12 (80.0)	0.83 (0.73)	0.0	0.14	0.92	1.25	2.0	
		Placebo	20	16 (80.0)	0.71 (0.70)	0.0	0.00	0.53	1.14	2.0	
	Week 8	Tezepelumab	15	13 (86.7)	0.86 (0.83)	0.0	0.00	0.90	1.25	2.2	
		Placebo	20	16 (80.0)	0.80 (0.74)	0.0	0.00	0.82	1.29	2.3	
	Week 9	Tezepelumab	15	10 (66.7)	0.74 (0.75)	0.0	0.00	0.63	1.00	2.0	
		Placebo	20	17 (85.0)	0.82 (0.70)	0.0	0.08	0.90	1.10	2.3	
	Week 10	Tezepelumab	15	10 (66.7)	0.58 (0.73)	0.0	0.00	0.15	1.14	2.0	
		Placebo	20	15 (75.0)	0.52 (0.50)	0.0	0.00	0.64	1.00	1.3	
	Week 11	Tezepelumab	15	12 (80.0)	0.73 (0.84)	0.0	0.00	0.42	1.54	2.0	
		Placebo	20	17 (85.0)	0.59 (0.67)	0.0	0.00	0.36	1.00	2.6	
	Week 12	Tezepelumab	15	12 (80.0)	0.73 (0.80)	0.0	0.00	0.54	1.41	2.1	
		Placebo	20	15 (75.0)	0.68 (0.68)	0.0	0.00	0.64	1.00	2.5	
	Week 13	Tezepelumab	15	9 (60.0)	0.57 (0.74)	0.0	0.00	0.08	1.00	2.1	
		Placebo	20	15 (75.0)	0.69 (0.79)	0.0	0.00	0.67	1.00	3.0	
	Week 14	Tezepelumab	15	8 (53.3)	0.68 (0.76)	0.0	0.00	0.54	1.17	2.0	
		Placebo	20	13 (65.0)	0.45 (0.46)	0.0	0.00	0.50	1.00	1.1	
	Week 15	Tezepelumab	15	10 (66.7)	0.52 (0.71)	0.0	0.00	0.04	1.00	2.0	
		Placebo	20	15 (75.0)	0.67 (0.85)	0.0	0.00	0.29	1.00	2.8	
	Week 16	Tezepelumab	15	10 (66.7)	0.60 (0.68)	0.0	0.00	0.47	1.00	2.0	
		Placebo	20	15 (75.0)	0.64 (0.79)	0.0	0.00	0.29	1.00	2.8	
Week 17	Tezepelumab	15	9 (60.0)	0.58 (0.74)	0.0	0.00	0.00	1.07	2.0		
	Placebo	20	13 (65.0)	0.46 (0.55)	0.0	0.00	0.29	0.90	1.8		

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022

Table NT1WWC\_KLMH0: Course of ASD weekly wheezing score  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly wheezing score	Week 18	Tezepelumab	15	10 (66.7)	0.62 (0.69)	0.0	0.00	0.48	1.00	2.0	
		Placebo	20	13 (65.0)	0.70 (0.93)	0.0	0.00	0.36	1.10	3.3	
	Week 19	Tezepelumab	15	10 (66.7)	0.56 (0.67)	0.0	0.00	0.31	1.00	2.0	
		Placebo	20	15 (75.0)	0.79 (0.98)	0.0	0.00	0.64	1.13	3.3	
	Week 20	Tezepelumab	15	7 (46.7)	0.30 (0.45)	0.0	0.00	0.00	0.92	1.0	
		Placebo	20	15 (75.0)	0.72 (0.92)	0.0	0.00	0.43	1.00	3.4	
	Week 21	Tezepelumab	15	8 (53.3)	0.38 (0.51)	0.0	0.00	0.04	0.92	1.1	
		Placebo	20	14 (70.0)	0.56 (0.85)	0.0	0.00	0.23	0.93	3.1	
	Week 22	Tezepelumab	15	8 (53.3)	0.50 (0.76)	0.0	0.00	0.00	1.00	2.0	
		Placebo	20	13 (65.0)	0.79 (1.13)	0.0	0.00	0.43	1.00	3.4	
	Week 23	Tezepelumab	15	9 (60.0)	0.57 (0.79)	0.0	0.00	0.00	1.00	2.0	
		Placebo	20	14 (70.0)	0.72 (1.16)	0.0	0.00	0.21	0.88	3.6	
	Week 24	Tezepelumab	15	10 (66.7)	0.53 (0.69)	0.0	0.00	0.15	1.00	2.0	
		Placebo	20	13 (65.0)	0.56 (0.91)	0.0	0.00	0.21	0.83	3.3	
	Week 25	Tezepelumab	15	9 (60.0)	0.49 (0.68)	0.0	0.00	0.00	0.90	1.9	
		Placebo	20	12 (60.0)	0.56 (0.81)	0.0	0.04	0.27	0.81	2.9	
	Week 26	Tezepelumab	15	8 (53.3)	0.48 (0.71)	0.0	0.00	0.11	0.79	2.0	
		Placebo	20	14 (70.0)	0.45 (0.76)	0.0	0.00	0.04	0.88	2.8	
	Week 27	Tezepelumab	15	8 (53.3)	0.49 (0.75)	0.0	0.00	0.00	0.96	2.0	
		Placebo	20	13 (65.0)	0.61 (0.84)	0.0	0.00	0.25	1.00	3.0	
	Week 28	Tezepelumab	15	8 (53.3)	0.24 (0.44)	0.0	0.00	0.00	0.45	1.0	
		Placebo	20	14 (70.0)	0.73 (0.97)	0.0	0.00	0.32	1.00	3.0	
	Week 29	Tezepelumab	15	7 (46.7)	0.31 (0.43)	0.0	0.00	0.14	0.86	1.0	
		Placebo	20	13 (65.0)	0.74 (1.01)	0.0	0.00	0.43	1.00	3.0	
	Week 30	Tezepelumab	15	8 (53.3)	0.24 (0.41)	0.0	0.00	0.00	0.41	1.1	
		Placebo	20	8 (40.0)	0.43 (0.36)	0.0	0.14	0.38	0.69	1.0	
	Week 31	Tezepelumab	15	7 (46.7)	0.21 (0.39)	0.0	0.00	0.00	0.50	1.0	
		Placebo	20	12 (60.0)	0.29 (0.37)	0.0	0.00	0.14	0.58	1.0	
	Week 32	Tezepelumab	15	8 (53.3)	0.21 (0.38)	0.0	0.00	0.00	0.33	1.0	
		Placebo	20	11 (55.0)	0.59 (0.68)	0.0	0.00	0.36	1.00	2.1	
	Week 33	Tezepelumab	15	8 (53.3)	0.33 (0.48)	0.0	0.00	0.00	0.75	1.1	
		Placebo	20	13 (65.0)	0.38 (0.45)	0.0	0.00	0.13	0.75	1.1	
	Week 34	Tezepelumab	15	8 (53.3)	0.29 (0.52)	0.0	0.00	0.00	0.55	1.3	
		Placebo	20	10 (50.0)	0.68 (0.88)	0.0	0.00	0.25	1.00	2.7	
	Week 35	Tezepelumab	15	8 (53.3)	0.36 (0.49)	0.0	0.00	0.10	0.75	1.2	
		Placebo	20	10 (50.0)	0.31 (0.47)	0.0	0.00	0.08	0.36	1.3	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022

Table NT1WWC\_KLMH0: Course of ASD weekly wheezing score  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly wheezing score	Week 36	Tezepelumab	15	8 (53.3)	0.38 (0.57)	0.0	0.00	0.08	0.68	1.5	
		Placebo	20	11 (55.0)	0.38 (0.46)	0.0	0.00	0.10	1.00	1.0	
	Week 37	Tezepelumab	15	8 (53.3)	0.29 (0.51)	0.0	0.00	0.00	0.57	1.1	
		Placebo	20	11 (55.0)	0.43 (0.45)	0.0	0.00	0.25	1.00	1.0	
	Week 38	Tezepelumab	15	7 (46.7)	0.31 (0.51)	0.0	0.00	0.00	1.00	1.1	
		Placebo	20	12 (60.0)	0.55 (0.56)	0.0	0.00	0.36	1.00	1.6	
	Week 39	Tezepelumab	15	8 (53.3)	0.29 (0.47)	0.0	0.00	0.00	0.63	1.1	
		Placebo	20	11 (55.0)	0.48 (0.51)	0.0	0.00	0.13	1.00	1.1	
	Week 40	Tezepelumab	15	8 (53.3)	0.31 (0.54)	0.0	0.00	0.00	0.57	1.3	
		Placebo	20	10 (50.0)	0.51 (0.49)	0.0	0.00	0.52	1.00	1.1	
	Week 41	Tezepelumab	15	8 (53.3)	0.38 (0.52)	0.0	0.00	0.17	0.67	1.4	
		Placebo	20	9 (45.0)	0.48 (0.47)	0.0	0.08	0.29	1.00	1.1	
	Week 42	Tezepelumab	15	8 (53.3)	0.35 (0.62)	0.0	0.00	0.00	0.65	1.5	
		Placebo	20	10 (50.0)	0.59 (0.92)	0.0	0.00	0.13	1.00	2.9	
	Week 43	Tezepelumab	15	8 (53.3)	0.30 (0.56)	0.0	0.00	0.00	0.58	1.3	
		Placebo	20	11 (55.0)	0.50 (0.63)	0.0	0.00	0.08	1.07	1.8	
	Week 44	Tezepelumab	15	7 (46.7)	0.36 (0.61)	0.0	0.00	0.00	1.17	1.3	
		Placebo	20	11 (55.0)	0.67 (0.77)	0.0	0.00	0.80	1.00	2.5	
	Week 45	Tezepelumab	15	7 (46.7)	0.31 (0.53)	0.0	0.00	0.00	1.08	1.1	
		Placebo	20	11 (55.0)	0.72 (0.89)	0.0	0.00	0.30	1.00	2.6	
	Week 46	Tezepelumab	15	7 (46.7)	0.40 (0.53)	0.0	0.00	0.00	1.00	1.2	
		Placebo	20	9 (45.0)	0.71 (0.66)	0.0	0.00	0.93	1.00	2.0	
	Week 47	Tezepelumab	15	6 (40.0)	0.23 (0.45)	0.0	0.00	0.00	0.25	1.1	
		Placebo	20	10 (50.0)	0.49 (0.67)	0.0	0.00	0.13	0.86	2.0	
	Week 48	Tezepelumab	15	5 (33.3)	0.12 (0.26)	0.0	0.00	0.00	0.00	0.6	
		Placebo	20	10 (50.0)	0.39 (0.64)	0.0	0.00	0.08	0.64	2.0	
	Week 49	Tezepelumab	15	7 (46.7)	0.16 (0.37)	0.0	0.00	0.00	0.14	1.0	
		Placebo	20	10 (50.0)	0.40 (0.47)	0.0	0.00	0.21	0.92	1.3	
	Week 50	Tezepelumab	15	6 (40.0)	0.23 (0.47)	0.0	0.00	0.00	0.21	1.2	
		Placebo	20	10 (50.0)	0.48 (0.63)	0.0	0.00	0.15	1.00	1.9	
	Week 51	Tezepelumab	15	7 (46.7)	0.17 (0.37)	0.0	0.00	0.00	0.21	1.0	
		Placebo	20	12 (60.0)	0.68 (0.70)	0.0	0.00	0.49	1.00	2.0	
	Week 52	Tezepelumab	15	8 (53.3)	0.15 (0.41)	0.0	0.00	0.00	0.00	1.2	
		Placebo	20	11 (55.0)	0.35 (0.46)	0.0	0.00	0.00	1.00	1.1	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022

Table NT1WWC\_KLMH0: Course of ASD weekly wheezing score  
 DITTTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly wheezing score	Week 1	Tezepelumab	15	14 (93.3)	-0.24 (0.39)	-1.2	-0.43	-0.16	0.00	0.3	-0.20 [-0.89, 0.48]
		Placebo	20	20 (100.0)	-0.15 (0.42)	-1.0	-0.43	-0.07	0.05	0.7	
	Week 2	Tezepelumab	15	14 (93.3)	-0.30 (0.59)	-1.6	-0.67	-0.19	0.00	0.7	0.18 [-0.51, 0.87]
		Placebo	20	19 (95.0)	-0.43 (0.77)	-3.1	-0.57	-0.14	0.00	0.3	
	Week 3	Tezepelumab	15	14 (93.3)	-0.38 (0.56)	-1.6	-0.86	-0.15	0.00	0.3	0.25 [-0.46, 0.96]
		Placebo	20	17 (85.0)	-0.54 (0.66)	-2.4	-0.79	-0.50	0.00	0.1	
	Week 4	Tezepelumab	15	12 (80.0)	-0.43 (0.55)	-1.6	-0.85	-0.15	0.00	0.2	0.22 [-0.52, 0.97]
		Placebo	20	17 (85.0)	-0.58 (0.72)	-2.7	-1.00	-0.50	0.00	0.2	
	Week 5	Tezepelumab	15	12 (80.0)	-0.52 (0.62)	-1.6	-1.00	-0.34	0.00	0.3	0.21 [-0.54, 0.96]
		Placebo	20	16 (80.0)	-0.65 (0.70)	-2.1	-1.02	-0.61	0.00	0.3	
	Week 6	Tezepelumab	15	11 (73.3)	-0.47 (0.60)	-1.6	-0.92	-0.29	0.00	0.3	0.43 [-0.35, 1.20]
		Placebo	20	16 (80.0)	-0.79 (0.81)	-2.9	-1.15	-0.62	-0.11	0.2	
	Week 7	Tezepelumab	15	12 (80.0)	-0.51 (0.54)	-1.6	-0.86	-0.55	-0.07	0.3	0.14 [-0.61, 0.89]
		Placebo	20	16 (80.0)	-0.60 (0.67)	-1.7	-1.11	-0.43	0.00	0.3	
	Week 8	Tezepelumab	15	13 (86.7)	-0.41 (0.56)	-1.6	-0.76	-0.24	0.00	0.3	0.24 [-0.49, 0.98]
		Placebo	20	16 (80.0)	-0.55 (0.65)	-1.7	-1.00	-0.46	0.00	0.4	
	Week 9	Tezepelumab	15	10 (66.7)	-0.49 (0.59)	-1.6	-0.93	-0.32	-0.07	0.3	0.10 [-0.69, 0.88]
		Placebo	20	17 (85.0)	-0.55 (0.56)	-1.7	-0.92	-0.71	0.00	0.3	
	Week 10	Tezepelumab	15	10 (66.7)	-0.66 (0.55)	-1.6	-1.00	-0.80	-0.14	0.3	0.08 [-0.72, 0.88]
		Placebo	20	15 (75.0)	-0.71 (0.63)	-1.9	-1.21	-0.75	-0.07	0.0	
	Week 11	Tezepelumab	15	12 (80.0)	-0.56 (0.69)	-1.6	-1.04	-0.82	-0.06	0.7	0.42 [-0.33, 1.17]
		Placebo	20	17 (85.0)	-0.87 (0.77)	-2.8	-1.13	-0.79	-0.32	0.1	
	Week 12	Tezepelumab	15	12 (80.0)	-0.56 (0.67)	-1.6	-1.00	-0.88	-0.07	0.6	0.35 [-0.41, 1.12]
		Placebo	20	15 (75.0)	-0.78 (0.57)	-1.9	-1.21	-0.83	-0.29	-0.1	
	Week 13	Tezepelumab	15	9 (60.0)	-0.69 (0.62)	-1.6	-1.00	-0.93	-0.14	0.4	0.12 [-0.71, 0.95]
		Placebo	20	15 (75.0)	-0.77 (0.66)	-2.0	-1.21	-0.86	-0.07	0.1	
	Week 14	Tezepelumab	15	8 (53.3)	-0.60 (0.61)	-1.6	-0.93	-0.76	-0.07	0.3	0.66 [-0.25, 1.56]
		Placebo	20	13 (65.0)	-1.12 (0.88)	-3.1	-1.57	-1.00	-0.50	0.2	
	Week 15	Tezepelumab	15	10 (66.7)	-0.72 (0.58)	-1.6	-1.08	-0.89	-0.14	0.3	0.03 [-0.77, 0.83]
		Placebo	20	15 (75.0)	-0.75 (0.86)	-2.0	-1.64	-0.93	-0.07	1.0	
	Week 16	Tezepelumab	15	10 (66.7)	-0.73 (0.59)	-1.6	-1.14	-0.87	-0.14	0.3	0.07 [-0.73, 0.87]
		Placebo	20	15 (75.0)	-0.78 (0.78)	-1.9	-1.57	-0.75	-0.07	0.5	
	Week 17	Tezepelumab	15	9 (60.0)	-0.68 (0.60)	-1.6	-1.00	-0.86	-0.14	0.3	0.16 [-0.70, 1.01]
		Placebo	20	13 (65.0)	-0.80 (0.85)	-2.0	-1.56	-1.00	-0.07	0.7	
Week 18	Tezepelumab	15	10 (66.7)	-0.62 (0.60)	-1.6	-1.00	-0.86	-0.13	0.3	0.04 [-0.78, 0.87]	
	Placebo	20	13 (65.0)	-0.65 (0.80)	-2.0	-1.21	-0.64	0.07	0.4		

Note: DITTTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022

Table NT1WWC\_KLMH0: Course of ASD weekly wheezing score  
DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly wheezing score	Week 19	Tezepelumab	15	10 (66.7)	-0.68 (0.57)	-1.6	-1.00	-0.80	-0.14	0.3	-0.09 [-0.89, 0.71]
		Placebo	20	15 (75.0)	-0.60 (1.05)	-2.0	-1.36	-0.86	0.00	1.4	
	Week 20	Tezepelumab	15	7 (46.7)	-0.72 (0.46)	-1.1	-1.01	-0.93	-0.14	0.0	-0.03 [-0.92, 0.87]
		Placebo	20	15 (75.0)	-0.70 (0.85)	-2.3	-1.21	-0.50	0.00	0.5	
	Week 21	Tezepelumab	15	8 (53.3)	-0.82 (0.52)	-1.6	-1.12	-0.92	-0.46	0.0	0.15 [-0.72, 1.02]
		Placebo	20	14 (70.0)	-0.95 (1.01)	-2.7	-1.64	-0.96	0.00	0.3	
	Week 22	Tezepelumab	15	8 (53.3)	-0.68 (0.65)	-1.6	-1.07	-0.93	-0.07	0.3	0.21 [-0.67, 1.10]
		Placebo	20	13 (65.0)	-0.92 (1.32)	-2.6	-1.79	-1.00	0.00	1.9	
	Week 23	Tezepelumab	15	9 (60.0)	-0.69 (0.67)	-1.6	-1.14	-0.93	-0.14	0.3	0.10 [-0.74, 0.94]
		Placebo	20	14 (70.0)	-0.80 (1.22)	-2.6	-1.57	-1.11	-0.05	1.9	
	Week 24	Tezepelumab	15	10 (66.7)	-0.70 (0.70)	-1.7	-1.06	-0.92	0.00	0.3	0.34 [-0.49, 1.17]
		Placebo	20	13 (65.0)	-0.99 (0.94)	-2.6	-1.67	-1.00	-0.10	0.4	
	Week 25	Tezepelumab	15	9 (60.0)	-0.67 (0.66)	-1.6	-1.14	-0.90	-0.10	0.2	0.44 [-0.43, 1.32]
		Placebo	20	12 (60.0)	-1.12 (1.19)	-2.4	-2.00	-1.35	-0.46	1.8	
	Week 26	Tezepelumab	15	8 (53.3)	-0.70 (0.70)	-1.6	-1.20	-0.96	0.00	0.3	0.16 [-0.71, 1.03]
		Placebo	20	14 (70.0)	-0.86 (1.11)	-2.6	-1.64	-1.06	-0.07	1.7	
	Week 27	Tezepelumab	15	8 (53.3)	-0.69 (0.65)	-1.6	-1.07	-0.96	-0.07	0.3	0.20 [-0.69, 1.08]
		Placebo	20	13 (65.0)	-0.88 (1.14)	-2.6	-1.75	-1.00	-0.33	1.9	
	Week 28	Tezepelumab	15	8 (53.3)	-0.85 (0.52)	-1.6	-1.09	-1.00	-0.54	0.0	-0.06 [-0.93, 0.81]
		Placebo	20	14 (70.0)	-0.80 (1.08)	-2.6	-1.58	-1.06	0.00	1.4	
	Week 29	Tezepelumab	15	7 (46.7)	-0.79 (0.52)	-1.4	-1.07	-0.98	-0.14	0.0	0.08 [-0.84, 1.00]
		Placebo	20	13 (65.0)	-0.88 (1.24)	-2.6	-2.00	-1.00	0.00	1.7	
	Week 30	Tezepelumab	15	8 (53.3)	-0.85 (0.53)	-1.6	-1.19	-0.93	-0.51	0.0	0.07 [-0.91, 1.05]
		Placebo	20	8 (40.0)	-0.89 (0.68)	-1.7	-1.40	-1.11	-0.28	0.1	
	Week 31	Tezepelumab	15	7 (46.7)	-0.89 (0.60)	-1.6	-1.43	-1.00	-0.14	0.0	0.13 [-0.81, 1.06]
		Placebo	20	12 (60.0)	-0.98 (0.83)	-2.6	-1.51	-1.08	-0.16	0.0	
	Week 32	Tezepelumab	15	8 (53.3)	-0.88 (0.55)	-1.6	-1.24	-1.00	-0.50	0.0	0.10 [-0.81, 1.02]
		Placebo	20	11 (55.0)	-0.95 (0.76)	-2.6	-1.29	-0.79	-0.43	-0.1	
	Week 33	Tezepelumab	15	8 (53.3)	-0.99 (0.47)	-1.6	-1.29	-1.00	-0.87	0.0	0.28 [-0.61, 1.16]
		Placebo	20	13 (65.0)	-1.19 (0.84)	-2.6	-1.88	-1.00	-0.50	-0.1	
	Week 34	Tezepelumab	15	8 (53.3)	-1.02 (0.55)	-1.8	-1.36	-1.00	-0.80	0.0	-0.13 [-1.06, 0.80]
		Placebo	20	10 (50.0)	-0.92 (0.83)	-2.5	-1.36	-0.75	-0.22	-0.1	
	Week 35	Tezepelumab	15	8 (53.3)	-0.95 (0.49)	-1.6	-1.29	-1.00	-0.72	0.0	-0.03 [-0.96, 0.90]
		Placebo	20	10 (50.0)	-0.93 (0.85)	-2.6	-1.29	-0.83	-0.07	0.0	
	Week 36	Tezepelumab	15	8 (53.3)	-0.93 (0.54)	-1.6	-1.36	-0.96	-0.63	0.0	-0.26 [-1.17, 0.66]
		Placebo	20	11 (55.0)	-0.77 (0.68)	-1.9	-1.21	-1.00	-0.07	0.1	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
Source Data: aasd, created on: 20FEB2022

Table NT1WWC\_KLMH0: Course of ASD weekly wheezing score  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly wheezing score	Week 37	Tezepelumab	15	8 (53.3)	-1.03 (0.55)	-1.9	-1.36	-0.96	-0.85	0.0	-0.10 [-1.01, 0.81]
		Placebo	20	11 (55.0)	-0.95 (0.81)	-2.4	-1.57	-1.00	0.00	0.1	
	Week 38	Tezepelumab	15	7 (46.7)	-1.04 (0.59)	-1.8	-1.57	-1.00	-0.82	0.0	-0.52 [-1.46, 0.43]
		Placebo	20	12 (60.0)	-0.72 (0.66)	-1.8	-1.12	-0.96	0.00	0.2	
	Week 39	Tezepelumab	15	8 (53.3)	-1.02 (0.57)	-1.9	-1.36	-0.96	-0.79	0.0	-0.14 [-1.06, 0.77]
		Placebo	20	11 (55.0)	-0.90 (0.93)	-2.5	-1.64	-1.00	0.00	0.6	
	Week 40	Tezepelumab	15	8 (53.3)	-0.89 (0.66)	-1.9	-1.36	-0.89	-0.36	0.0	0.15 [-0.79, 1.08]
		Placebo	20	10 (50.0)	-1.01 (0.93)	-2.6	-1.64	-1.06	-0.50	0.8	
	Week 41	Tezepelumab	15	8 (53.3)	-0.93 (0.61)	-1.9	-1.36	-0.79	-0.62	0.0	0.07 [-0.89, 1.02]
		Placebo	20	9 (45.0)	-0.99 (0.93)	-2.6	-1.36	-1.00	-0.50	0.5	
	Week 42	Tezepelumab	15	8 (53.3)	-0.96 (0.60)	-1.9	-1.36	-0.90	-0.63	0.0	-0.04 [-0.97, 0.89]
		Placebo	20	10 (50.0)	-0.93 (0.94)	-2.6	-1.64	-1.00	-0.02	0.5	
	Week 43	Tezepelumab	15	8 (53.3)	-1.01 (0.58)	-1.9	-1.36	-0.96	-0.75	0.0	0.07 [-0.84, 0.98]
		Placebo	20	11 (55.0)	-1.07 (0.95)	-2.6	-1.64	-1.17	-0.50	0.9	
	Week 44	Tezepelumab	15	7 (46.7)	-1.00 (0.63)	-1.9	-1.57	-0.93	-0.67	0.0	-0.11 [-1.06, 0.84]
		Placebo	20	11 (55.0)	-0.90 (0.99)	-2.6	-1.54	-1.00	-0.13	0.6	
	Week 45	Tezepelumab	15	7 (46.7)	-1.04 (0.61)	-1.9	-1.57	-0.93	-0.82	0.0	-0.02 [-0.97, 0.93]
		Placebo	20	11 (55.0)	-1.02 (1.01)	-2.6	-1.70	-1.00	-0.50	0.7	
	Week 46	Tezepelumab	15	7 (46.7)	-0.96 (0.50)	-1.6	-1.33	-1.00	-0.72	0.0	-0.14 [-1.12, 0.85]
		Placebo	20	9 (45.0)	-0.84 (1.03)	-2.6	-1.50	-1.00	0.00	0.7	
	Week 47	Tezepelumab	15	6 (40.0)	-1.03 (0.60)	-1.7	-1.57	-1.04	-0.88	0.0	-0.02 [-1.04, 0.99]
		Placebo	20	10 (50.0)	-1.01 (0.85)	-2.6	-1.64	-1.07	-0.18	0.0	
	Week 48	Tezepelumab	15	5 (33.3)	-1.00 (0.61)	-1.6	-1.35	-1.14	-0.93	0.0	-0.07 [-1.14, 1.01]
		Placebo	20	10 (50.0)	-0.94 (0.97)	-2.6	-1.64	-0.92	-0.07	0.5	
	Week 49	Tezepelumab	15	7 (46.7)	-1.06 (0.57)	-1.8	-1.57	-1.00	-0.93	0.0	0.19 [-0.78, 1.16]
		Placebo	20	10 (50.0)	-1.19 (0.71)	-2.6	-1.63	-1.15	-0.63	-0.1	
	Week 50	Tezepelumab	15	6 (40.0)	-1.03 (0.61)	-1.7	-1.57	-1.04	-0.83	0.0	0.12 [-0.90, 1.13]
		Placebo	20	10 (50.0)	-1.11 (0.72)	-2.5	-1.54	-1.01	-0.50	-0.1	
	Week 51	Tezepelumab	15	7 (46.7)	-0.93 (0.65)	-1.7	-1.57	-1.00	-0.14	0.0	-0.11 [-1.04, 0.82]
		Placebo	20	12 (60.0)	-0.84 (0.88)	-2.6	-1.24	-1.00	-0.20	0.7	
	Week 52	Tezepelumab	15	8 (53.3)	-0.94 (0.65)	-1.9	-1.36	-0.96	-0.49	0.0	0.25 [-0.66, 1.17]
		Placebo	20	11 (55.0)	-1.11 (0.69)	-2.6	-1.63	-1.00	-0.55	-0.1	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022

Table NT1WWC\_KLMC0: Change from baseline in ASD weekly wheezing score - MMRM results  
 DITTL - adolescents

Change from baseline in ASD weekly wheezing score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 1	Tezepelumab	15	14 (93.3)	-0.28 (0.18)	(-0.63, 0.07)	-0.14 (0.23)	(-0.59, 0.32)	0.558
	Placebo	20	20 (100.0)	-0.14 (0.15)	(-0.44, 0.15)			
Week 2	Tezepelumab	15	14 (93.3)	-0.34 (0.18)	(-0.69, 0.01)	0.05 (0.23)	(-0.41, 0.51)	0.837
	Placebo	20	19 (95.0)	-0.39 (0.15)	(-0.69, -0.09)			
Week 3	Tezepelumab	15	14 (93.3)	-0.43 (0.18)	(-0.78, -0.08)	0.04 (0.23)	(-0.42, 0.51)	0.848
	Placebo	20	17 (85.0)	-0.47 (0.15)	(-0.77, -0.17)			
Week 4	Tezepelumab	15	12 (80.0)	-0.48 (0.18)	(-0.83, -0.12)	0.06 (0.23)	(-0.40, 0.53)	0.783
	Placebo	20	17 (85.0)	-0.54 (0.15)	(-0.84, -0.24)			
Week 5	Tezepelumab	15	12 (80.0)	-0.55 (0.18)	(-0.91, -0.20)	0.02 (0.24)	(-0.45, 0.48)	0.933
	Placebo	20	16 (80.0)	-0.57 (0.15)	(-0.88, -0.27)			
Week 6	Tezepelumab	15	11 (73.3)	-0.53 (0.18)	(-0.89, -0.18)	0.14 (0.24)	(-0.33, 0.61)	0.557
	Placebo	20	16 (80.0)	-0.67 (0.15)	(-0.97, -0.37)			
Week 7	Tezepelumab	15	12 (80.0)	-0.53 (0.18)	(-0.88, -0.17)	0.10 (0.23)	(-0.36, 0.57)	0.658
	Placebo	20	16 (80.0)	-0.63 (0.15)	(-0.93, -0.33)			
Week 8	Tezepelumab	15	13 (86.7)	-0.48 (0.18)	(-0.83, -0.13)	0.05 (0.23)	(-0.41, 0.52)	0.821
	Placebo	20	16 (80.0)	-0.53 (0.15)	(-0.83, -0.23)			
Week 9	Tezepelumab	15	10 (66.7)	-0.45 (0.18)	(-0.81, -0.09)	0.14 (0.24)	(-0.33, 0.60)	0.562
	Placebo	20	17 (85.0)	-0.59 (0.15)	(-0.89, -0.29)			
Week 10	Tezepelumab	15	10 (66.7)	-0.59 (0.18)	(-0.95, -0.23)	0.11 (0.24)	(-0.36, 0.58)	0.639
	Placebo	20	15 (75.0)	-0.70 (0.15)	(-1.01, -0.40)			

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table NT1WWC\_KLMC0: Change from baseline in ASD weekly wheezing score - MMRM results  
 DITTL - adolescents

Change from baseline in ASD weekly wheezing score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 11	Tezepelumab	15	12 (80.0)	-0.64 (0.18)	(-0.99, -0.28)	0.10 (0.24)	(-0.37, 0.57)	0.671
	Placebo	20	17 (85.0)	-0.74 (0.15)	(-1.04, -0.43)			
Week 12	Tezepelumab	15	12 (80.0)	-0.64 (0.18)	(-1.00, -0.28)	0.08 (0.24)	(-0.39, 0.55)	0.747
	Placebo	20	15 (75.0)	-0.72 (0.16)	(-1.02, -0.41)			
Week 13	Tezepelumab	15	9 (60.0)	-0.67 (0.18)	(-1.03, -0.30)	0.04 (0.24)	(-0.44, 0.52)	0.870
	Placebo	20	15 (75.0)	-0.71 (0.16)	(-1.01, -0.40)			
Week 14	Tezepelumab	15	8 (53.3)	-0.65 (0.19)	(-1.02, -0.28)	0.06 (0.24)	(-0.42, 0.54)	0.810
	Placebo	20	13 (65.0)	-0.71 (0.16)	(-1.02, -0.40)			
Week 15	Tezepelumab	15	10 (66.7)	-0.70 (0.19)	(-1.06, -0.33)	0.01 (0.24)	(-0.47, 0.49)	0.960
	Placebo	20	15 (75.0)	-0.71 (0.16)	(-1.02, -0.40)			
Week 16	Tezepelumab	15	10 (66.7)	-0.70 (0.19)	(-1.07, -0.33)	0.02 (0.25)	(-0.46, 0.50)	0.933
	Placebo	20	15 (75.0)	-0.72 (0.16)	(-1.04, -0.41)			
Week 17	Tezepelumab	15	9 (60.0)	-0.69 (0.19)	(-1.07, -0.32)	-0.01 (0.25)	(-0.50, 0.48)	0.977
	Placebo	20	13 (65.0)	-0.68 (0.16)	(-1.00, -0.37)			
Week 18	Tezepelumab	15	10 (66.7)	-0.67 (0.19)	(-1.05, -0.29)	-0.16 (0.25)	(-0.65, 0.33)	0.521
	Placebo	20	13 (65.0)	-0.51 (0.16)	(-0.82, -0.19)			
Week 19	Tezepelumab	15	10 (66.7)	-0.73 (0.19)	(-1.11, -0.34)	-0.19 (0.25)	(-0.68, 0.31)	0.456
	Placebo	20	15 (75.0)	-0.54 (0.16)	(-0.85, -0.23)			
Week 20	Tezepelumab	15	7 (46.7)	-0.79 (0.20)	(-1.18, -0.39)	-0.18 (0.25)	(-0.69, 0.32)	0.476
	Placebo	20	15 (75.0)	-0.60 (0.16)	(-0.92, -0.29)			

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WWC\_KLMC0: Change from baseline in ASD weekly wheezing score - MMRM results  
 DITTL - adolescents

Change from baseline in ASD weekly wheezing score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Time	Treatment	N	n (%)					
Week 21	Tezepelumab	15	8 (53.3)	-0.74 (0.20)	(-1.14, -0.34)	-0.08 (0.26)	(-0.58, 0.43)	0.762
	Placebo	20	14 (70.0)	-0.66 (0.16)	(-0.97, -0.35)			
Week 22	Tezepelumab	15	8 (53.3)	-0.67 (0.20)	(-1.07, -0.27)	-0.03 (0.26)	(-0.54, 0.48)	0.898
	Placebo	20	13 (65.0)	-0.64 (0.16)	(-0.96, -0.32)			
Week 23	Tezepelumab	15	9 (60.0)	-0.68 (0.20)	(-1.09, -0.28)	-0.00 (0.26)	(-0.51, 0.51)	0.998
	Placebo	20	14 (70.0)	-0.68 (0.16)	(-1.00, -0.37)			
Week 24	Tezepelumab	15	10 (66.7)	-0.76 (0.20)	(-1.16, -0.35)	-0.09 (0.26)	(-0.60, 0.42)	0.728
	Placebo	20	13 (65.0)	-0.66 (0.16)	(-0.99, -0.34)			
Week 25	Tezepelumab	15	9 (60.0)	-0.74 (0.21)	(-1.15, -0.34)	0.00 (0.26)	(-0.52, 0.52)	0.993
	Placebo	20	12 (60.0)	-0.74 (0.16)	(-1.07, -0.42)			
Week 26	Tezepelumab	15	8 (53.3)	-0.74 (0.21)	(-1.15, -0.32)	-0.04 (0.26)	(-0.56, 0.49)	0.892
	Placebo	20	14 (70.0)	-0.70 (0.16)	(-1.02, -0.38)			
Week 27	Tezepelumab	15	8 (53.3)	-0.75 (0.21)	(-1.17, -0.34)	-0.09 (0.27)	(-0.61, 0.44)	0.748
	Placebo	20	13 (65.0)	-0.67 (0.16)	(-0.99, -0.34)			
Week 28	Tezepelumab	15	8 (53.3)	-0.80 (0.21)	(-1.22, -0.39)	-0.13 (0.27)	(-0.66, 0.40)	0.631
	Placebo	20	14 (70.0)	-0.68 (0.16)	(-1.00, -0.35)			
Week 29	Tezepelumab	15	7 (46.7)	-0.76 (0.22)	(-1.19, -0.34)	0.00 (0.27)	(-0.53, 0.54)	0.993
	Placebo	20	13 (65.0)	-0.77 (0.16)	(-1.09, -0.44)			
Week 30	Tezepelumab	15	8 (53.3)	-0.82 (0.22)	(-1.24, -0.39)	-0.14 (0.27)	(-0.68, 0.40)	0.605
	Placebo	20	8 (40.0)	-0.67 (0.17)	(-1.01, -0.34)			

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WWC\_KLMC0: Change from baseline in ASD weekly wheezing score - MMRM results  
 DITTL - adolescents

Change from baseline in ASD weekly wheezing score				Repeated measures analysis																																																																																																																														
				Change from Baseline		Treatment Difference																																																																																																																												
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value																																																																																																																										
Time	Treatment	N	n (%)																																																																																																																															
Week 31	Tezepelumab	15	7 (46.7)	-0.87 (0.22)	(-1.30, -0.44)	-0.05 (0.27)	(-0.59, 0.49)	0.852																																																																																																																										
	Placebo	20	12 (60.0)	-0.82 (0.17)	(-1.14, -0.49)				Week 32	Tezepelumab	15	8 (53.3)	-0.86 (0.22)	(-1.28, -0.43)	-0.09 (0.27)	(-0.63, 0.45)	0.755	Placebo	20	11 (55.0)	-0.77 (0.17)	(-1.10, -0.44)	Week 33	Tezepelumab	15	8 (53.3)	-0.88 (0.22)	(-1.31, -0.45)	-0.10 (0.27)	(-0.64, 0.44)	0.717	Placebo	20	13 (65.0)	-0.78 (0.17)	(-1.11, -0.46)	Week 34	Tezepelumab	15	8 (53.3)	-0.92 (0.22)	(-1.35, -0.49)	-0.23 (0.28)	(-0.77, 0.32)	0.414	Placebo	20	10 (50.0)	-0.69 (0.17)	(-1.03, -0.36)	Week 35	Tezepelumab	15	8 (53.3)	-0.86 (0.22)	(-1.29, -0.42)	-0.15 (0.28)	(-0.70, 0.40)	0.594	Placebo	20	10 (50.0)	-0.71 (0.17)	(-1.04, -0.37)	Week 36	Tezepelumab	15	8 (53.3)	-0.85 (0.22)	(-1.29, -0.41)	-0.08 (0.28)	(-0.63, 0.48)	0.784	Placebo	20	11 (55.0)	-0.77 (0.17)	(-1.11, -0.43)	Week 37	Tezepelumab	15	8 (53.3)	-0.94 (0.22)	(-1.38, -0.51)	-0.21 (0.28)	(-0.76, 0.34)	0.455	Placebo	20	11 (55.0)	-0.73 (0.17)	(-1.07, -0.40)	Week 38	Tezepelumab	15	7 (46.7)	-0.95 (0.22)	(-1.39, -0.50)	-0.38 (0.28)	(-0.93, 0.18)	0.182	Placebo	20	12 (60.0)	-0.57 (0.17)	(-0.91, -0.23)	Week 39	Tezepelumab	15	8 (53.3)	-0.95 (0.22)	(-1.38, -0.51)	-0.26 (0.28)	(-0.81, 0.30)	0.362	Placebo	20	11 (55.0)	-0.69 (0.17)	(-1.03, -0.35)	Week 40	Tezepelumab	15	8 (53.3)	-0.89 (0.22)	(-1.33, -0.46)	-0.19 (0.28)	(-0.74, 0.37)	0.507	Placebo
Week 32	Tezepelumab	15	8 (53.3)	-0.86 (0.22)	(-1.28, -0.43)	-0.09 (0.27)	(-0.63, 0.45)	0.755																																																																																																																										
	Placebo	20	11 (55.0)	-0.77 (0.17)	(-1.10, -0.44)				Week 33	Tezepelumab	15	8 (53.3)	-0.88 (0.22)	(-1.31, -0.45)	-0.10 (0.27)	(-0.64, 0.44)	0.717	Placebo	20	13 (65.0)	-0.78 (0.17)	(-1.11, -0.46)	Week 34	Tezepelumab	15	8 (53.3)	-0.92 (0.22)	(-1.35, -0.49)	-0.23 (0.28)	(-0.77, 0.32)	0.414	Placebo	20	10 (50.0)	-0.69 (0.17)	(-1.03, -0.36)	Week 35	Tezepelumab	15	8 (53.3)	-0.86 (0.22)	(-1.29, -0.42)	-0.15 (0.28)	(-0.70, 0.40)	0.594	Placebo	20	10 (50.0)	-0.71 (0.17)	(-1.04, -0.37)	Week 36	Tezepelumab	15	8 (53.3)	-0.85 (0.22)	(-1.29, -0.41)	-0.08 (0.28)	(-0.63, 0.48)	0.784	Placebo	20	11 (55.0)	-0.77 (0.17)	(-1.11, -0.43)	Week 37	Tezepelumab	15	8 (53.3)	-0.94 (0.22)	(-1.38, -0.51)	-0.21 (0.28)	(-0.76, 0.34)	0.455	Placebo	20	11 (55.0)	-0.73 (0.17)	(-1.07, -0.40)	Week 38	Tezepelumab	15	7 (46.7)	-0.95 (0.22)	(-1.39, -0.50)	-0.38 (0.28)	(-0.93, 0.18)	0.182	Placebo	20	12 (60.0)	-0.57 (0.17)	(-0.91, -0.23)	Week 39	Tezepelumab	15	8 (53.3)	-0.95 (0.22)	(-1.38, -0.51)	-0.26 (0.28)	(-0.81, 0.30)	0.362	Placebo	20	11 (55.0)	-0.69 (0.17)	(-1.03, -0.35)	Week 40	Tezepelumab	15	8 (53.3)	-0.89 (0.22)	(-1.33, -0.46)	-0.19 (0.28)	(-0.74, 0.37)	0.507	Placebo	20	10 (50.0)	-0.71 (0.17)	(-1.05, -0.36)										
Week 33	Tezepelumab	15	8 (53.3)	-0.88 (0.22)	(-1.31, -0.45)	-0.10 (0.27)	(-0.64, 0.44)	0.717																																																																																																																										
	Placebo	20	13 (65.0)	-0.78 (0.17)	(-1.11, -0.46)				Week 34	Tezepelumab	15	8 (53.3)	-0.92 (0.22)	(-1.35, -0.49)	-0.23 (0.28)	(-0.77, 0.32)	0.414	Placebo	20	10 (50.0)	-0.69 (0.17)	(-1.03, -0.36)	Week 35	Tezepelumab	15	8 (53.3)	-0.86 (0.22)	(-1.29, -0.42)	-0.15 (0.28)	(-0.70, 0.40)	0.594	Placebo	20	10 (50.0)	-0.71 (0.17)	(-1.04, -0.37)	Week 36	Tezepelumab	15	8 (53.3)	-0.85 (0.22)	(-1.29, -0.41)	-0.08 (0.28)	(-0.63, 0.48)	0.784	Placebo	20	11 (55.0)	-0.77 (0.17)	(-1.11, -0.43)	Week 37	Tezepelumab	15	8 (53.3)	-0.94 (0.22)	(-1.38, -0.51)	-0.21 (0.28)	(-0.76, 0.34)	0.455	Placebo	20	11 (55.0)	-0.73 (0.17)	(-1.07, -0.40)	Week 38	Tezepelumab	15	7 (46.7)	-0.95 (0.22)	(-1.39, -0.50)	-0.38 (0.28)	(-0.93, 0.18)	0.182	Placebo	20	12 (60.0)	-0.57 (0.17)	(-0.91, -0.23)	Week 39	Tezepelumab	15	8 (53.3)	-0.95 (0.22)	(-1.38, -0.51)	-0.26 (0.28)	(-0.81, 0.30)	0.362	Placebo	20	11 (55.0)	-0.69 (0.17)	(-1.03, -0.35)	Week 40	Tezepelumab	15	8 (53.3)	-0.89 (0.22)	(-1.33, -0.46)	-0.19 (0.28)	(-0.74, 0.37)	0.507	Placebo	20	10 (50.0)	-0.71 (0.17)	(-1.05, -0.36)																								
Week 34	Tezepelumab	15	8 (53.3)	-0.92 (0.22)	(-1.35, -0.49)	-0.23 (0.28)	(-0.77, 0.32)	0.414																																																																																																																										
	Placebo	20	10 (50.0)	-0.69 (0.17)	(-1.03, -0.36)				Week 35	Tezepelumab	15	8 (53.3)	-0.86 (0.22)	(-1.29, -0.42)	-0.15 (0.28)	(-0.70, 0.40)	0.594	Placebo	20	10 (50.0)	-0.71 (0.17)	(-1.04, -0.37)	Week 36	Tezepelumab	15	8 (53.3)	-0.85 (0.22)	(-1.29, -0.41)	-0.08 (0.28)	(-0.63, 0.48)	0.784	Placebo	20	11 (55.0)	-0.77 (0.17)	(-1.11, -0.43)	Week 37	Tezepelumab	15	8 (53.3)	-0.94 (0.22)	(-1.38, -0.51)	-0.21 (0.28)	(-0.76, 0.34)	0.455	Placebo	20	11 (55.0)	-0.73 (0.17)	(-1.07, -0.40)	Week 38	Tezepelumab	15	7 (46.7)	-0.95 (0.22)	(-1.39, -0.50)	-0.38 (0.28)	(-0.93, 0.18)	0.182	Placebo	20	12 (60.0)	-0.57 (0.17)	(-0.91, -0.23)	Week 39	Tezepelumab	15	8 (53.3)	-0.95 (0.22)	(-1.38, -0.51)	-0.26 (0.28)	(-0.81, 0.30)	0.362	Placebo	20	11 (55.0)	-0.69 (0.17)	(-1.03, -0.35)	Week 40	Tezepelumab	15	8 (53.3)	-0.89 (0.22)	(-1.33, -0.46)	-0.19 (0.28)	(-0.74, 0.37)	0.507	Placebo	20	10 (50.0)	-0.71 (0.17)	(-1.05, -0.36)																																						
Week 35	Tezepelumab	15	8 (53.3)	-0.86 (0.22)	(-1.29, -0.42)	-0.15 (0.28)	(-0.70, 0.40)	0.594																																																																																																																										
	Placebo	20	10 (50.0)	-0.71 (0.17)	(-1.04, -0.37)				Week 36	Tezepelumab	15	8 (53.3)	-0.85 (0.22)	(-1.29, -0.41)	-0.08 (0.28)	(-0.63, 0.48)	0.784	Placebo	20	11 (55.0)	-0.77 (0.17)	(-1.11, -0.43)	Week 37	Tezepelumab	15	8 (53.3)	-0.94 (0.22)	(-1.38, -0.51)	-0.21 (0.28)	(-0.76, 0.34)	0.455	Placebo	20	11 (55.0)	-0.73 (0.17)	(-1.07, -0.40)	Week 38	Tezepelumab	15	7 (46.7)	-0.95 (0.22)	(-1.39, -0.50)	-0.38 (0.28)	(-0.93, 0.18)	0.182	Placebo	20	12 (60.0)	-0.57 (0.17)	(-0.91, -0.23)	Week 39	Tezepelumab	15	8 (53.3)	-0.95 (0.22)	(-1.38, -0.51)	-0.26 (0.28)	(-0.81, 0.30)	0.362	Placebo	20	11 (55.0)	-0.69 (0.17)	(-1.03, -0.35)	Week 40	Tezepelumab	15	8 (53.3)	-0.89 (0.22)	(-1.33, -0.46)	-0.19 (0.28)	(-0.74, 0.37)	0.507	Placebo	20	10 (50.0)	-0.71 (0.17)	(-1.05, -0.36)																																																				
Week 36	Tezepelumab	15	8 (53.3)	-0.85 (0.22)	(-1.29, -0.41)	-0.08 (0.28)	(-0.63, 0.48)	0.784																																																																																																																										
	Placebo	20	11 (55.0)	-0.77 (0.17)	(-1.11, -0.43)				Week 37	Tezepelumab	15	8 (53.3)	-0.94 (0.22)	(-1.38, -0.51)	-0.21 (0.28)	(-0.76, 0.34)	0.455	Placebo	20	11 (55.0)	-0.73 (0.17)	(-1.07, -0.40)	Week 38	Tezepelumab	15	7 (46.7)	-0.95 (0.22)	(-1.39, -0.50)	-0.38 (0.28)	(-0.93, 0.18)	0.182	Placebo	20	12 (60.0)	-0.57 (0.17)	(-0.91, -0.23)	Week 39	Tezepelumab	15	8 (53.3)	-0.95 (0.22)	(-1.38, -0.51)	-0.26 (0.28)	(-0.81, 0.30)	0.362	Placebo	20	11 (55.0)	-0.69 (0.17)	(-1.03, -0.35)	Week 40	Tezepelumab	15	8 (53.3)	-0.89 (0.22)	(-1.33, -0.46)	-0.19 (0.28)	(-0.74, 0.37)	0.507	Placebo	20	10 (50.0)	-0.71 (0.17)	(-1.05, -0.36)																																																																		
Week 37	Tezepelumab	15	8 (53.3)	-0.94 (0.22)	(-1.38, -0.51)	-0.21 (0.28)	(-0.76, 0.34)	0.455																																																																																																																										
	Placebo	20	11 (55.0)	-0.73 (0.17)	(-1.07, -0.40)				Week 38	Tezepelumab	15	7 (46.7)	-0.95 (0.22)	(-1.39, -0.50)	-0.38 (0.28)	(-0.93, 0.18)	0.182	Placebo	20	12 (60.0)	-0.57 (0.17)	(-0.91, -0.23)	Week 39	Tezepelumab	15	8 (53.3)	-0.95 (0.22)	(-1.38, -0.51)	-0.26 (0.28)	(-0.81, 0.30)	0.362	Placebo	20	11 (55.0)	-0.69 (0.17)	(-1.03, -0.35)	Week 40	Tezepelumab	15	8 (53.3)	-0.89 (0.22)	(-1.33, -0.46)	-0.19 (0.28)	(-0.74, 0.37)	0.507	Placebo	20	10 (50.0)	-0.71 (0.17)	(-1.05, -0.36)																																																																																
Week 38	Tezepelumab	15	7 (46.7)	-0.95 (0.22)	(-1.39, -0.50)	-0.38 (0.28)	(-0.93, 0.18)	0.182																																																																																																																										
	Placebo	20	12 (60.0)	-0.57 (0.17)	(-0.91, -0.23)				Week 39	Tezepelumab	15	8 (53.3)	-0.95 (0.22)	(-1.38, -0.51)	-0.26 (0.28)	(-0.81, 0.30)	0.362	Placebo	20	11 (55.0)	-0.69 (0.17)	(-1.03, -0.35)	Week 40	Tezepelumab	15	8 (53.3)	-0.89 (0.22)	(-1.33, -0.46)	-0.19 (0.28)	(-0.74, 0.37)	0.507	Placebo	20	10 (50.0)	-0.71 (0.17)	(-1.05, -0.36)																																																																																														
Week 39	Tezepelumab	15	8 (53.3)	-0.95 (0.22)	(-1.38, -0.51)	-0.26 (0.28)	(-0.81, 0.30)	0.362																																																																																																																										
	Placebo	20	11 (55.0)	-0.69 (0.17)	(-1.03, -0.35)				Week 40	Tezepelumab	15	8 (53.3)	-0.89 (0.22)	(-1.33, -0.46)	-0.19 (0.28)	(-0.74, 0.37)	0.507	Placebo	20	10 (50.0)	-0.71 (0.17)	(-1.05, -0.36)																																																																																																												
Week 40	Tezepelumab	15	8 (53.3)	-0.89 (0.22)	(-1.33, -0.46)	-0.19 (0.28)	(-0.74, 0.37)	0.507																																																																																																																										
	Placebo	20	10 (50.0)	-0.71 (0.17)	(-1.05, -0.36)																																																																																																																													

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WWC\_KLMC0: Change from baseline in ASD weekly wheezing score - MMRM results  
 DITTL - adolescents

Change from baseline in ASD weekly wheezing score				Repeated measures analysis																																																																																																																														
				Change from Baseline		Treatment Difference																																																																																																																												
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value																																																																																																																						
Week 41	Tezepelumab	15	8 (53.3)	-0.87 (0.22)	(-1.31, -0.43)	-0.19 (0.28)	(-0.74, 0.37)	0.511																																																																																																																										
	Placebo	20	9 (45.0)	-0.68 (0.17)	(-1.02, -0.34)				Week 42	Tezepelumab	15	8 (53.3)	-0.90 (0.22)	(-1.34, -0.46)	-0.19 (0.28)	(-0.74, 0.37)	0.514	Placebo	20	10 (50.0)	-0.71 (0.17)	(-1.06, -0.37)	Week 43	Tezepelumab	15	8 (53.3)	-0.95 (0.22)	(-1.39, -0.51)	-0.19 (0.28)	(-0.75, 0.37)	0.506	Placebo	20	11 (55.0)	-0.76 (0.17)	(-1.10, -0.42)	Week 44	Tezepelumab	15	7 (46.7)	-0.94 (0.23)	(-1.39, -0.49)	-0.15 (0.28)	(-0.71, 0.41)	0.595	Placebo	20	11 (55.0)	-0.79 (0.17)	(-1.13, -0.45)	Week 45	Tezepelumab	15	7 (46.7)	-0.99 (0.23)	(-1.44, -0.53)	-0.23 (0.29)	(-0.79, 0.34)	0.428	Placebo	20	11 (55.0)	-0.76 (0.17)	(-1.10, -0.42)	Week 46	Tezepelumab	15	7 (46.7)	-0.90 (0.23)	(-1.35, -0.44)	-0.09 (0.29)	(-0.66, 0.48)	0.755	Placebo	20	9 (45.0)	-0.81 (0.17)	(-1.15, -0.46)	Week 47	Tezepelumab	15	6 (40.0)	-0.94 (0.23)	(-1.40, -0.48)	-0.05 (0.29)	(-0.63, 0.52)	0.861	Placebo	20	10 (50.0)	-0.89 (0.18)	(-1.24, -0.54)	Week 48	Tezepelumab	15	5 (33.3)	-0.89 (0.23)	(-1.35, -0.43)	0.10 (0.29)	(-0.48, 0.68)	0.731	Placebo	20	10 (50.0)	-0.99 (0.18)	(-1.34, -0.64)	Week 49	Tezepelumab	15	7 (46.7)	-0.99 (0.23)	(-1.45, -0.54)	-0.06 (0.29)	(-0.64, 0.51)	0.833	Placebo	20	10 (50.0)	-0.93 (0.18)	(-1.28, -0.58)	Week 50	Tezepelumab	15	6 (40.0)	-0.96 (0.23)	(-1.41, -0.50)	-0.10 (0.29)	(-0.67, 0.48)	0.743	Placebo
Week 42	Tezepelumab	15	8 (53.3)	-0.90 (0.22)	(-1.34, -0.46)	-0.19 (0.28)	(-0.74, 0.37)	0.514																																																																																																																										
	Placebo	20	10 (50.0)	-0.71 (0.17)	(-1.06, -0.37)				Week 43	Tezepelumab	15	8 (53.3)	-0.95 (0.22)	(-1.39, -0.51)	-0.19 (0.28)	(-0.75, 0.37)	0.506	Placebo	20	11 (55.0)	-0.76 (0.17)	(-1.10, -0.42)	Week 44	Tezepelumab	15	7 (46.7)	-0.94 (0.23)	(-1.39, -0.49)	-0.15 (0.28)	(-0.71, 0.41)	0.595	Placebo	20	11 (55.0)	-0.79 (0.17)	(-1.13, -0.45)	Week 45	Tezepelumab	15	7 (46.7)	-0.99 (0.23)	(-1.44, -0.53)	-0.23 (0.29)	(-0.79, 0.34)	0.428	Placebo	20	11 (55.0)	-0.76 (0.17)	(-1.10, -0.42)	Week 46	Tezepelumab	15	7 (46.7)	-0.90 (0.23)	(-1.35, -0.44)	-0.09 (0.29)	(-0.66, 0.48)	0.755	Placebo	20	9 (45.0)	-0.81 (0.17)	(-1.15, -0.46)	Week 47	Tezepelumab	15	6 (40.0)	-0.94 (0.23)	(-1.40, -0.48)	-0.05 (0.29)	(-0.63, 0.52)	0.861	Placebo	20	10 (50.0)	-0.89 (0.18)	(-1.24, -0.54)	Week 48	Tezepelumab	15	5 (33.3)	-0.89 (0.23)	(-1.35, -0.43)	0.10 (0.29)	(-0.48, 0.68)	0.731	Placebo	20	10 (50.0)	-0.99 (0.18)	(-1.34, -0.64)	Week 49	Tezepelumab	15	7 (46.7)	-0.99 (0.23)	(-1.45, -0.54)	-0.06 (0.29)	(-0.64, 0.51)	0.833	Placebo	20	10 (50.0)	-0.93 (0.18)	(-1.28, -0.58)	Week 50	Tezepelumab	15	6 (40.0)	-0.96 (0.23)	(-1.41, -0.50)	-0.10 (0.29)	(-0.67, 0.48)	0.743	Placebo	20	10 (50.0)	-0.86 (0.18)	(-1.21, -0.51)										
Week 43	Tezepelumab	15	8 (53.3)	-0.95 (0.22)	(-1.39, -0.51)	-0.19 (0.28)	(-0.75, 0.37)	0.506																																																																																																																										
	Placebo	20	11 (55.0)	-0.76 (0.17)	(-1.10, -0.42)				Week 44	Tezepelumab	15	7 (46.7)	-0.94 (0.23)	(-1.39, -0.49)	-0.15 (0.28)	(-0.71, 0.41)	0.595	Placebo	20	11 (55.0)	-0.79 (0.17)	(-1.13, -0.45)	Week 45	Tezepelumab	15	7 (46.7)	-0.99 (0.23)	(-1.44, -0.53)	-0.23 (0.29)	(-0.79, 0.34)	0.428	Placebo	20	11 (55.0)	-0.76 (0.17)	(-1.10, -0.42)	Week 46	Tezepelumab	15	7 (46.7)	-0.90 (0.23)	(-1.35, -0.44)	-0.09 (0.29)	(-0.66, 0.48)	0.755	Placebo	20	9 (45.0)	-0.81 (0.17)	(-1.15, -0.46)	Week 47	Tezepelumab	15	6 (40.0)	-0.94 (0.23)	(-1.40, -0.48)	-0.05 (0.29)	(-0.63, 0.52)	0.861	Placebo	20	10 (50.0)	-0.89 (0.18)	(-1.24, -0.54)	Week 48	Tezepelumab	15	5 (33.3)	-0.89 (0.23)	(-1.35, -0.43)	0.10 (0.29)	(-0.48, 0.68)	0.731	Placebo	20	10 (50.0)	-0.99 (0.18)	(-1.34, -0.64)	Week 49	Tezepelumab	15	7 (46.7)	-0.99 (0.23)	(-1.45, -0.54)	-0.06 (0.29)	(-0.64, 0.51)	0.833	Placebo	20	10 (50.0)	-0.93 (0.18)	(-1.28, -0.58)	Week 50	Tezepelumab	15	6 (40.0)	-0.96 (0.23)	(-1.41, -0.50)	-0.10 (0.29)	(-0.67, 0.48)	0.743	Placebo	20	10 (50.0)	-0.86 (0.18)	(-1.21, -0.51)																								
Week 44	Tezepelumab	15	7 (46.7)	-0.94 (0.23)	(-1.39, -0.49)	-0.15 (0.28)	(-0.71, 0.41)	0.595																																																																																																																										
	Placebo	20	11 (55.0)	-0.79 (0.17)	(-1.13, -0.45)				Week 45	Tezepelumab	15	7 (46.7)	-0.99 (0.23)	(-1.44, -0.53)	-0.23 (0.29)	(-0.79, 0.34)	0.428	Placebo	20	11 (55.0)	-0.76 (0.17)	(-1.10, -0.42)	Week 46	Tezepelumab	15	7 (46.7)	-0.90 (0.23)	(-1.35, -0.44)	-0.09 (0.29)	(-0.66, 0.48)	0.755	Placebo	20	9 (45.0)	-0.81 (0.17)	(-1.15, -0.46)	Week 47	Tezepelumab	15	6 (40.0)	-0.94 (0.23)	(-1.40, -0.48)	-0.05 (0.29)	(-0.63, 0.52)	0.861	Placebo	20	10 (50.0)	-0.89 (0.18)	(-1.24, -0.54)	Week 48	Tezepelumab	15	5 (33.3)	-0.89 (0.23)	(-1.35, -0.43)	0.10 (0.29)	(-0.48, 0.68)	0.731	Placebo	20	10 (50.0)	-0.99 (0.18)	(-1.34, -0.64)	Week 49	Tezepelumab	15	7 (46.7)	-0.99 (0.23)	(-1.45, -0.54)	-0.06 (0.29)	(-0.64, 0.51)	0.833	Placebo	20	10 (50.0)	-0.93 (0.18)	(-1.28, -0.58)	Week 50	Tezepelumab	15	6 (40.0)	-0.96 (0.23)	(-1.41, -0.50)	-0.10 (0.29)	(-0.67, 0.48)	0.743	Placebo	20	10 (50.0)	-0.86 (0.18)	(-1.21, -0.51)																																						
Week 45	Tezepelumab	15	7 (46.7)	-0.99 (0.23)	(-1.44, -0.53)	-0.23 (0.29)	(-0.79, 0.34)	0.428																																																																																																																										
	Placebo	20	11 (55.0)	-0.76 (0.17)	(-1.10, -0.42)				Week 46	Tezepelumab	15	7 (46.7)	-0.90 (0.23)	(-1.35, -0.44)	-0.09 (0.29)	(-0.66, 0.48)	0.755	Placebo	20	9 (45.0)	-0.81 (0.17)	(-1.15, -0.46)	Week 47	Tezepelumab	15	6 (40.0)	-0.94 (0.23)	(-1.40, -0.48)	-0.05 (0.29)	(-0.63, 0.52)	0.861	Placebo	20	10 (50.0)	-0.89 (0.18)	(-1.24, -0.54)	Week 48	Tezepelumab	15	5 (33.3)	-0.89 (0.23)	(-1.35, -0.43)	0.10 (0.29)	(-0.48, 0.68)	0.731	Placebo	20	10 (50.0)	-0.99 (0.18)	(-1.34, -0.64)	Week 49	Tezepelumab	15	7 (46.7)	-0.99 (0.23)	(-1.45, -0.54)	-0.06 (0.29)	(-0.64, 0.51)	0.833	Placebo	20	10 (50.0)	-0.93 (0.18)	(-1.28, -0.58)	Week 50	Tezepelumab	15	6 (40.0)	-0.96 (0.23)	(-1.41, -0.50)	-0.10 (0.29)	(-0.67, 0.48)	0.743	Placebo	20	10 (50.0)	-0.86 (0.18)	(-1.21, -0.51)																																																				
Week 46	Tezepelumab	15	7 (46.7)	-0.90 (0.23)	(-1.35, -0.44)	-0.09 (0.29)	(-0.66, 0.48)	0.755																																																																																																																										
	Placebo	20	9 (45.0)	-0.81 (0.17)	(-1.15, -0.46)				Week 47	Tezepelumab	15	6 (40.0)	-0.94 (0.23)	(-1.40, -0.48)	-0.05 (0.29)	(-0.63, 0.52)	0.861	Placebo	20	10 (50.0)	-0.89 (0.18)	(-1.24, -0.54)	Week 48	Tezepelumab	15	5 (33.3)	-0.89 (0.23)	(-1.35, -0.43)	0.10 (0.29)	(-0.48, 0.68)	0.731	Placebo	20	10 (50.0)	-0.99 (0.18)	(-1.34, -0.64)	Week 49	Tezepelumab	15	7 (46.7)	-0.99 (0.23)	(-1.45, -0.54)	-0.06 (0.29)	(-0.64, 0.51)	0.833	Placebo	20	10 (50.0)	-0.93 (0.18)	(-1.28, -0.58)	Week 50	Tezepelumab	15	6 (40.0)	-0.96 (0.23)	(-1.41, -0.50)	-0.10 (0.29)	(-0.67, 0.48)	0.743	Placebo	20	10 (50.0)	-0.86 (0.18)	(-1.21, -0.51)																																																																		
Week 47	Tezepelumab	15	6 (40.0)	-0.94 (0.23)	(-1.40, -0.48)	-0.05 (0.29)	(-0.63, 0.52)	0.861																																																																																																																										
	Placebo	20	10 (50.0)	-0.89 (0.18)	(-1.24, -0.54)				Week 48	Tezepelumab	15	5 (33.3)	-0.89 (0.23)	(-1.35, -0.43)	0.10 (0.29)	(-0.48, 0.68)	0.731	Placebo	20	10 (50.0)	-0.99 (0.18)	(-1.34, -0.64)	Week 49	Tezepelumab	15	7 (46.7)	-0.99 (0.23)	(-1.45, -0.54)	-0.06 (0.29)	(-0.64, 0.51)	0.833	Placebo	20	10 (50.0)	-0.93 (0.18)	(-1.28, -0.58)	Week 50	Tezepelumab	15	6 (40.0)	-0.96 (0.23)	(-1.41, -0.50)	-0.10 (0.29)	(-0.67, 0.48)	0.743	Placebo	20	10 (50.0)	-0.86 (0.18)	(-1.21, -0.51)																																																																																
Week 48	Tezepelumab	15	5 (33.3)	-0.89 (0.23)	(-1.35, -0.43)	0.10 (0.29)	(-0.48, 0.68)	0.731																																																																																																																										
	Placebo	20	10 (50.0)	-0.99 (0.18)	(-1.34, -0.64)				Week 49	Tezepelumab	15	7 (46.7)	-0.99 (0.23)	(-1.45, -0.54)	-0.06 (0.29)	(-0.64, 0.51)	0.833	Placebo	20	10 (50.0)	-0.93 (0.18)	(-1.28, -0.58)	Week 50	Tezepelumab	15	6 (40.0)	-0.96 (0.23)	(-1.41, -0.50)	-0.10 (0.29)	(-0.67, 0.48)	0.743	Placebo	20	10 (50.0)	-0.86 (0.18)	(-1.21, -0.51)																																																																																														
Week 49	Tezepelumab	15	7 (46.7)	-0.99 (0.23)	(-1.45, -0.54)	-0.06 (0.29)	(-0.64, 0.51)	0.833																																																																																																																										
	Placebo	20	10 (50.0)	-0.93 (0.18)	(-1.28, -0.58)				Week 50	Tezepelumab	15	6 (40.0)	-0.96 (0.23)	(-1.41, -0.50)	-0.10 (0.29)	(-0.67, 0.48)	0.743	Placebo	20	10 (50.0)	-0.86 (0.18)	(-1.21, -0.51)																																																																																																												
Week 50	Tezepelumab	15	6 (40.0)	-0.96 (0.23)	(-1.41, -0.50)	-0.10 (0.29)	(-0.67, 0.48)	0.743																																																																																																																										
	Placebo	20	10 (50.0)	-0.86 (0.18)	(-1.21, -0.51)																																																																																																																													

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WWC\_KLMC0: Change from baseline in ASD weekly wheezing score - MMRM results  
 DITTL - adolescents

Change from baseline in ASD weekly wheezing score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 51	Tezepelumab	15	7 (46.7)	-0.99 (0.23)	(-1.44, -0.53)	-0.15 (0.29)	(-0.73, 0.42)	0.599
	Placebo	20	12 (60.0)	-0.83 (0.17)	(-1.18, -0.49)			
Week 52	Tezepelumab	15	8 (53.3)	-1.00 (0.23)	(-1.45, -0.54)	-0.09 (0.29)	(-0.67, 0.49)	0.757
	Placebo	20	11 (55.0)	-0.91 (0.18)	(-1.26, -0.56)			

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC\_KLMH0: Course of ASD weekly shortness of breath score  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly shortness of breath score	Baseline	Tezepelumab	15	15 (100.0)	1.34 (0.64)	0.1	1.00	1.43	1.79	2.5	
		Placebo	20	20 (100.0)	1.58 (1.02)	0.0	0.61	1.57	2.61	3.1	
	Week 1	Tezepelumab	15	14 (93.3)	1.11 (0.61)	0.1	0.71	1.14	1.33	2.1	
		Placebo	20	20 (100.0)	1.40 (1.04)	0.0	0.50	1.32	2.11	3.6	
	Week 2	Tezepelumab	15	14 (93.3)	1.07 (0.71)	0.0	0.36	1.08	1.79	2.1	
		Placebo	20	19 (95.0)	1.18 (1.02)	0.0	0.21	1.13	2.00	3.1	
	Week 3	Tezepelumab	15	14 (93.3)	1.00 (0.77)	0.0	0.21	1.00	2.00	2.1	
		Placebo	20	17 (85.0)	0.84 (0.94)	0.0	0.07	0.43	1.50	2.9	
	Week 4	Tezepelumab	15	12 (80.0)	0.91 (0.78)	0.0	0.15	1.00	1.70	2.0	
		Placebo	20	17 (85.0)	0.77 (0.79)	0.0	0.00	0.43	1.64	2.0	
	Week 5	Tezepelumab	15	12 (80.0)	0.96 (0.78)	0.0	0.33	0.96	1.50	2.2	
		Placebo	20	16 (80.0)	0.87 (0.74)	0.0	0.18	0.80	1.46	2.1	
	Week 6	Tezepelumab	15	11 (73.3)	0.94 (0.80)	0.0	0.00	1.00	1.50	2.2	
		Placebo	20	16 (80.0)	0.67 (0.75)	0.0	0.05	0.23	1.25	2.0	
	Week 7	Tezepelumab	15	12 (80.0)	0.89 (0.73)	0.0	0.15	0.96	1.53	2.0	
		Placebo	20	16 (80.0)	0.85 (0.87)	0.0	0.04	0.71	1.37	2.8	
	Week 8	Tezepelumab	15	13 (86.7)	1.00 (0.80)	0.0	0.14	1.00	1.71	2.2	
		Placebo	20	16 (80.0)	0.99 (0.84)	0.0	0.04	0.94	1.75	2.4	
	Week 9	Tezepelumab	15	10 (66.7)	0.93 (0.77)	0.0	0.08	0.95	1.83	2.0	
		Placebo	20	17 (85.0)	1.03 (0.94)	0.0	0.20	1.00	1.64	3.3	
	Week 10	Tezepelumab	15	10 (66.7)	0.75 (0.83)	0.0	0.13	0.42	1.14	2.1	
		Placebo	20	15 (75.0)	0.58 (0.61)	0.0	0.00	0.50	1.00	1.9	
	Week 11	Tezepelumab	15	12 (80.0)	0.90 (0.79)	0.0	0.06	1.00	1.63	1.9	
		Placebo	20	17 (85.0)	0.66 (0.77)	0.0	0.00	0.36	1.00	2.6	
	Week 12	Tezepelumab	15	12 (80.0)	0.83 (0.73)	0.0	0.13	0.86	1.50	2.0	
		Placebo	20	15 (75.0)	0.72 (0.75)	0.0	0.00	0.64	1.14	2.4	
	Week 13	Tezepelumab	15	9 (60.0)	0.66 (0.76)	0.0	0.00	0.25	1.00	2.0	
		Placebo	20	15 (75.0)	0.78 (0.87)	0.0	0.00	0.50	1.30	3.0	
	Week 14	Tezepelumab	15	8 (53.3)	0.75 (0.81)	0.0	0.04	0.57	1.38	2.0	
		Placebo	20	13 (65.0)	0.53 (0.62)	0.0	0.00	0.50	1.00	1.9	
	Week 15	Tezepelumab	15	10 (66.7)	0.61 (0.74)	0.0	0.00	0.31	1.00	2.0	
		Placebo	20	15 (75.0)	0.95 (0.91)	0.0	0.00	0.75	1.90	2.7	
	Week 16	Tezepelumab	15	10 (66.7)	0.64 (0.70)	0.0	0.00	0.42	1.00	1.9	
		Placebo	20	15 (75.0)	0.87 (0.88)	0.0	0.08	0.50	1.58	2.8	
Week 17	Tezepelumab	15	9 (60.0)	0.58 (0.73)	0.0	0.00	0.07	1.00	2.0		
	Placebo	20	13 (65.0)	0.84 (0.84)	0.0	0.00	0.67	1.42	2.5		

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022

Table NT1WBC\_KLMH0: Course of ASD weekly shortness of breath score  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly shortness of breath score	Week 18	Tezepelumab	15	10 (66.7)	0.63 (0.66)	0.0	0.07	0.46	1.00	2.0	
		Placebo	20	13 (65.0)	0.96 (1.09)	0.0	0.00	0.93	1.57	3.6	
	Week 19	Tezepelumab	15	10 (66.7)	0.57 (0.61)	0.0	0.00	0.44	1.00	1.8	
		Placebo	20	15 (75.0)	0.97 (1.08)	0.0	0.00	1.00	1.14	3.8	
	Week 20	Tezepelumab	15	7 (46.7)	0.32 (0.47)	0.0	0.00	0.07	1.00	1.0	
		Placebo	20	15 (75.0)	0.81 (0.93)	0.0	0.00	0.90	1.08	3.4	
	Week 21	Tezepelumab	15	8 (53.3)	0.46 (0.59)	0.0	0.00	0.13	1.00	1.4	
		Placebo	20	14 (70.0)	0.75 (0.90)	0.0	0.00	0.62	1.00	3.1	
	Week 22	Tezepelumab	15	8 (53.3)	0.53 (0.74)	0.0	0.00	0.11	1.00	2.0	
		Placebo	20	13 (65.0)	1.06 (1.13)	0.0	0.00	1.00	1.29	3.4	
	Week 23	Tezepelumab	15	9 (60.0)	0.62 (0.78)	0.0	0.00	0.07	1.00	2.0	
		Placebo	20	14 (70.0)	1.03 (1.18)	0.0	0.00	0.84	1.00	3.9	
	Week 24	Tezepelumab	15	10 (66.7)	0.68 (0.70)	0.0	0.00	0.67	1.00	1.9	
		Placebo	20	13 (65.0)	0.80 (0.95)	0.0	0.00	0.71	1.00	3.3	
	Week 25	Tezepelumab	15	9 (60.0)	0.57 (0.68)	0.0	0.00	0.17	1.00	1.8	
		Placebo	20	12 (60.0)	0.72 (0.90)	0.0	0.04	0.50	0.96	2.9	
	Week 26	Tezepelumab	15	8 (53.3)	0.50 (0.65)	0.0	0.00	0.15	1.00	1.7	
		Placebo	20	14 (70.0)	0.67 (0.84)	0.0	0.00	0.48	1.00	2.8	
	Week 27	Tezepelumab	15	8 (53.3)	0.45 (0.61)	0.0	0.00	0.05	1.00	1.5	
		Placebo	20	13 (65.0)	0.81 (0.87)	0.0	0.20	0.60	1.00	3.0	
	Week 28	Tezepelumab	15	8 (53.3)	0.27 (0.46)	0.0	0.00	0.00	0.56	1.0	
		Placebo	20	14 (70.0)	0.95 (0.97)	0.0	0.00	0.88	1.25	3.0	
	Week 29	Tezepelumab	15	7 (46.7)	0.35 (0.45)	0.0	0.00	0.21	1.00	1.0	
		Placebo	20	13 (65.0)	0.98 (0.99)	0.0	0.43	0.63	1.00	3.0	
	Week 30	Tezepelumab	15	8 (53.3)	0.34 (0.48)	0.0	0.04	0.10	0.60	1.2	
		Placebo	20	8 (40.0)	0.73 (0.65)	0.0	0.21	0.69	1.00	2.0	
	Week 31	Tezepelumab	15	7 (46.7)	0.30 (0.51)	0.0	0.00	0.00	1.00	1.1	
		Placebo	20	12 (60.0)	0.55 (0.63)	0.0	0.00	0.46	0.96	2.0	
	Week 32	Tezepelumab	15	8 (53.3)	0.25 (0.46)	0.0	0.00	0.00	0.50	1.0	
		Placebo	20	11 (55.0)	0.67 (0.80)	0.0	0.08	0.38	1.00	2.3	
	Week 33	Tezepelumab	15	8 (53.3)	0.44 (0.61)	0.0	0.00	0.00	1.04	1.4	
		Placebo	20	13 (65.0)	0.45 (0.60)	0.0	0.00	0.21	0.75	2.1	
	Week 34	Tezepelumab	15	8 (53.3)	0.41 (0.57)	0.0	0.00	0.00	1.00	1.3	
		Placebo	20	10 (50.0)	0.66 (0.92)	0.0	0.00	0.21	1.00	2.5	
	Week 35	Tezepelumab	15	8 (53.3)	0.57 (0.62)	0.0	0.10	0.24	1.13	1.6	
		Placebo	20	10 (50.0)	0.41 (0.65)	0.0	0.00	0.13	0.57	2.0	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022

Table NT1WBC\_KLMH0: Course of ASD weekly shortness of breath score  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly shortness of breath score	Week 36	Tezepelumab	15	8 (53.3)	0.39 (0.54)	0.0	0.00	0.00	1.00	1.1	
		Placebo	20	11 (55.0)	0.44 (0.65)	0.0	0.00	0.08	1.00	2.0	
	Week 37	Tezepelumab	15	8 (53.3)	0.51 (0.62)	0.0	0.00	0.21	1.00	1.6	
		Placebo	20	11 (55.0)	0.52 (0.63)	0.0	0.00	0.25	1.00	2.0	
	Week 38	Tezepelumab	15	7 (46.7)	0.56 (0.74)	0.0	0.00	0.00	1.13	1.8	
		Placebo	20	12 (60.0)	0.65 (0.62)	0.0	0.18	0.46	1.00	2.1	
	Week 39	Tezepelumab	15	8 (53.3)	0.46 (0.56)	0.0	0.00	0.19	1.00	1.3	
		Placebo	20	11 (55.0)	0.57 (0.68)	0.0	0.00	0.13	1.00	2.0	
	Week 40	Tezepelumab	15	8 (53.3)	0.44 (0.60)	0.0	0.00	0.04	1.00	1.4	
		Placebo	20	10 (50.0)	0.57 (0.64)	0.0	0.00	0.48	1.00	1.9	
	Week 41	Tezepelumab	15	8 (53.3)	0.51 (0.59)	0.0	0.00	0.25	1.11	1.4	
		Placebo	20	9 (45.0)	0.65 (0.70)	0.0	0.07	0.71	1.00	2.1	
	Week 42	Tezepelumab	15	8 (53.3)	0.45 (0.60)	0.0	0.00	0.06	1.13	1.3	
		Placebo	20	10 (50.0)	0.95 (1.02)	0.0	0.00	0.92	1.10	3.2	
	Week 43	Tezepelumab	15	8 (53.3)	0.44 (0.62)	0.0	0.00	0.00	1.00	1.5	
		Placebo	20	11 (55.0)	0.75 (0.73)	0.0	0.00	0.75	1.17	2.0	
	Week 44	Tezepelumab	15	7 (46.7)	0.52 (0.66)	0.0	0.00	0.00	1.25	1.4	
		Placebo	20	11 (55.0)	0.72 (0.85)	0.0	0.00	0.80	1.00	2.3	
	Week 45	Tezepelumab	15	7 (46.7)	0.50 (0.63)	0.0	0.00	0.00	1.08	1.4	
		Placebo	20	11 (55.0)	0.92 (0.94)	0.0	0.00	1.00	2.00	2.5	
	Week 46	Tezepelumab	15	7 (46.7)	0.57 (0.64)	0.0	0.00	0.40	1.00	1.6	
		Placebo	20	9 (45.0)	0.97 (0.78)	0.0	0.60	1.00	1.00	2.3	
	Week 47	Tezepelumab	15	6 (40.0)	0.35 (0.55)	0.0	0.00	0.00	1.00	1.1	
		Placebo	20	10 (50.0)	0.67 (0.81)	0.0	0.00	0.43	1.00	2.1	
	Week 48	Tezepelumab	15	5 (33.3)	0.20 (0.45)	0.0	0.00	0.00	0.00	1.0	
		Placebo	20	10 (50.0)	0.63 (0.86)	0.0	0.00	0.22	0.80	2.4	
	Week 49	Tezepelumab	15	7 (46.7)	0.32 (0.50)	0.0	0.00	0.00	1.00	1.1	
		Placebo	20	10 (50.0)	0.65 (0.72)	0.0	0.00	0.45	1.00	2.0	
	Week 50	Tezepelumab	15	6 (40.0)	0.39 (0.61)	0.0	0.00	0.00	1.00	1.3	
		Placebo	20	10 (50.0)	0.65 (0.77)	0.0	0.00	0.35	1.00	2.0	
	Week 51	Tezepelumab	15	7 (46.7)	0.31 (0.54)	0.0	0.00	0.00	1.00	1.2	
		Placebo	20	12 (60.0)	0.82 (0.82)	0.0	0.00	0.73	1.35	2.3	
	Week 52	Tezepelumab	15	8 (53.3)	0.28 (0.50)	0.0	0.00	0.00	0.54	1.2	
		Placebo	20	11 (55.0)	0.41 (0.62)	0.0	0.00	0.14	0.60	2.0	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022



Table NT1WBC\_KLMH0: Course of ASD weekly shortness of breath score  
 DITTTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly shortness of breath score	Week 1	Tezepelumab	15	14 (93.3)	-0.20 (0.24)	-0.6	-0.33	-0.21	-0.08	0.3	-0.05 [-0.73, 0.63]
		Placebo	20	20 (100.0)	-0.18 (0.42)	-0.8	-0.43	-0.26	-0.05	0.8	
	Week 2	Tezepelumab	15	14 (93.3)	-0.24 (0.44)	-1.1	-0.50	-0.18	0.04	0.6	0.31 [-0.39, 1.00]
		Placebo	20	19 (95.0)	-0.44 (0.75)	-3.1	-0.50	-0.26	0.00	0.4	
	Week 3	Tezepelumab	15	14 (93.3)	-0.30 (0.51)	-1.2	-0.79	-0.18	-0.08	0.5	0.56 [-0.16, 1.29]
		Placebo	20	17 (85.0)	-0.64 (0.65)	-2.4	-0.85	-0.50	-0.21	0.1	
	Week 4	Tezepelumab	15	12 (80.0)	-0.39 (0.46)	-1.3	-0.79	-0.18	-0.07	0.2	0.51 [-0.24, 1.26]
		Placebo	20	17 (85.0)	-0.71 (0.73)	-2.9	-0.92	-0.50	-0.21	0.0	
	Week 5	Tezepelumab	15	12 (80.0)	-0.35 (0.52)	-1.2	-0.72	-0.31	-0.10	0.5	0.48 [-0.28, 1.24]
		Placebo	20	16 (80.0)	-0.65 (0.71)	-2.4	-0.96	-0.52	-0.04	0.1	
	Week 6	Tezepelumab	15	11 (73.3)	-0.35 (0.47)	-1.0	-0.71	-0.14	-0.07	0.6	0.58 [-0.20, 1.36]
		Placebo	20	16 (80.0)	-0.73 (0.76)	-3.0	-0.84	-0.58	-0.21	0.0	
	Week 7	Tezepelumab	15	12 (80.0)	-0.41 (0.42)	-1.1	-0.73	-0.31	-0.14	0.3	0.27 [-0.48, 1.03]
		Placebo	20	16 (80.0)	-0.54 (0.51)	-1.7	-0.79	-0.39	-0.20	0.0	
	Week 8	Tezepelumab	15	13 (86.7)	-0.30 (0.45)	-1.1	-0.58	-0.29	-0.14	0.4	0.48 [-0.27, 1.22]
		Placebo	20	16 (80.0)	-0.55 (0.58)	-2.2	-0.80	-0.41	-0.13	0.0	
	Week 9	Tezepelumab	15	10 (66.7)	-0.27 (0.43)	-1.0	-0.50	-0.17	-0.14	0.4	0.65 [-0.15, 1.45]
		Placebo	20	17 (85.0)	-0.56 (0.46)	-1.6	-0.77	-0.53	-0.23	0.3	
	Week 10	Tezepelumab	15	10 (66.7)	-0.46 (0.70)	-1.4	-1.00	-0.47	-0.12	0.6	0.61 [-0.21, 1.43]
		Placebo	20	15 (75.0)	-0.84 (0.58)	-1.9	-1.29	-0.65	-0.43	0.0	
	Week 11	Tezepelumab	15	12 (80.0)	-0.38 (0.62)	-1.5	-0.90	-0.25	0.09	0.4	0.63 [-0.13, 1.39]
		Placebo	20	17 (85.0)	-0.82 (0.76)	-2.9	-1.00	-0.57	-0.23	0.0	
	Week 12	Tezepelumab	15	12 (80.0)	-0.45 (0.64)	-1.5	-0.95	-0.48	-0.11	0.6	0.51 [-0.27, 1.28]
		Placebo	20	15 (75.0)	-0.75 (0.56)	-1.9	-1.21	-0.50	-0.36	-0.2	
	Week 13	Tezepelumab	15	9 (60.0)	-0.58 (0.72)	-1.5	-1.06	-0.29	-0.14	0.5	0.18 [-0.65, 1.00]
		Placebo	20	15 (75.0)	-0.69 (0.62)	-2.0	-1.00	-0.50	-0.26	0.2	
	Week 14	Tezepelumab	15	8 (53.3)	-0.50 (0.79)	-1.7	-1.18	-0.21	0.01	0.5	0.63 [-0.27, 1.53]
		Placebo	20	13 (65.0)	-1.01 (0.84)	-3.1	-1.29	-0.92	-0.43	-0.1	
	Week 15	Tezepelumab	15	10 (66.7)	-0.68 (0.74)	-1.8	-1.21	-0.64	-0.14	0.5	-0.03 [-0.83, 0.77]
		Placebo	20	15 (75.0)	-0.66 (0.63)	-2.0	-0.93	-0.50	-0.18	0.3	
	Week 16	Tezepelumab	15	10 (66.7)	-0.69 (0.77)	-1.8	-1.50	-0.57	-0.14	0.4	0.08 [-0.72, 0.88]
		Placebo	20	15 (75.0)	-0.75 (0.60)	-2.1	-0.93	-0.58	-0.29	-0.1	
	Week 17	Tezepelumab	15	9 (60.0)	-0.65 (0.75)	-1.8	-1.14	-0.46	-0.14	0.5	0.17 [-0.68, 1.02]
		Placebo	20	13 (65.0)	-0.77 (0.65)	-2.0	-0.94	-0.63	-0.21	0.0	

Note: DITTTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC\_KLMH0: Course of ASD weekly shortness of breath score  
 DITTTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly shortness of breath score	Week 18	Tezepelumab	15	10 (66.7)	-0.57 (0.70)	-1.8	-0.98	-0.34	-0.14	0.5	-0.02 [-0.85, 0.80]
		Placebo	20	13 (65.0)	-0.56 (0.69)	-2.0	-0.89	-0.50	-0.29	0.8	
	Week 19	Tezepelumab	15	10 (66.7)	-0.63 (0.68)	-1.8	-1.06	-0.48	-0.14	0.3	0.06 [-0.74, 0.86]
		Placebo	20	15 (75.0)	-0.68 (0.87)	-2.1	-1.29	-0.58	-0.21	0.8	
	Week 20	Tezepelumab	15	7 (46.7)	-0.81 (0.67)	-1.8	-1.50	-0.73	-0.14	-0.1	-0.01 [-0.90, 0.89]
		Placebo	20	15 (75.0)	-0.80 (0.86)	-2.6	-1.36	-0.58	-0.21	0.5	
	Week 21	Tezepelumab	15	8 (53.3)	-0.74 (0.70)	-1.8	-1.32	-0.58	-0.14	-0.0	0.32 [-0.56, 1.19]
		Placebo	20	14 (70.0)	-1.03 (1.01)	-2.8	-2.00	-0.82	0.00	0.3	
	Week 22	Tezepelumab	15	8 (53.3)	-0.66 (0.77)	-1.8	-1.25	-0.61	-0.14	0.5	0.18 [-0.70, 1.07]
		Placebo	20	13 (65.0)	-0.85 (1.16)	-2.7	-1.54	-0.58	-0.36	1.3	
	Week 23	Tezepelumab	15	9 (60.0)	-0.61 (0.76)	-1.8	-1.07	-0.29	-0.14	0.5	0.07 [-0.77, 0.91]
		Placebo	20	14 (70.0)	-0.68 (1.13)	-2.7	-1.64	-0.54	-0.05	1.3	
	Week 24	Tezepelumab	15	10 (66.7)	-0.53 (0.71)	-1.8	-1.00	-0.21	-0.01	0.4	0.48 [-0.36, 1.32]
		Placebo	20	13 (65.0)	-0.91 (0.87)	-2.7	-1.52	-0.71	-0.26	0.5	
	Week 25	Tezepelumab	15	9 (60.0)	-0.58 (0.69)	-1.6	-1.14	-0.29	-0.14	0.3	0.40 [-0.47, 1.28]
		Placebo	20	12 (60.0)	-0.97 (1.10)	-2.6	-1.93	-0.50	-0.43	1.2	
	Week 26	Tezepelumab	15	8 (53.3)	-0.69 (0.73)	-1.8	-1.25	-0.63	-0.07	0.2	0.20 [-0.67, 1.07]
		Placebo	20	14 (70.0)	-0.86 (0.94)	-2.7	-1.61	-0.63	-0.43	1.0	
	Week 27	Tezepelumab	15	8 (53.3)	-0.74 (0.69)	-1.8	-1.27	-0.64	-0.14	0.0	0.18 [-0.71, 1.06]
		Placebo	20	13 (65.0)	-0.89 (0.99)	-2.5	-1.64	-0.58	-0.43	1.3	
	Week 28	Tezepelumab	15	8 (53.3)	-0.85 (0.62)	-1.8	-1.32	-0.90	-0.21	-0.1	-0.08 [-0.95, 0.79]
		Placebo	20	14 (70.0)	-0.79 (0.94)	-2.7	-1.61	-0.54	-0.21	0.8	
	Week 29	Tezepelumab	15	7 (46.7)	-0.79 (0.66)	-1.8	-1.50	-0.79	-0.14	-0.1	0.06 [-0.86, 0.98]
		Placebo	20	13 (65.0)	-0.85 (1.08)	-2.7	-1.64	-0.58	-0.26	1.0	
	Week 30	Tezepelumab	15	8 (53.3)	-0.78 (0.54)	-1.6	-1.18	-0.86	-0.21	-0.1	-0.09 [-1.07, 0.89]
		Placebo	20	8 (40.0)	-0.73 (0.60)	-1.9	-1.10	-0.54	-0.32	-0.1	
	Week 31	Tezepelumab	15	7 (46.7)	-0.85 (0.66)	-1.8	-1.43	-1.00	-0.14	-0.1	0.10 [-0.83, 1.03]
		Placebo	20	12 (60.0)	-0.92 (0.76)	-2.7	-1.46	-0.54	-0.43	-0.2	
	Week 32	Tezepelumab	15	8 (53.3)	-0.87 (0.62)	-1.8	-1.32	-0.96	-0.21	-0.1	-0.05 [-0.96, 0.86]
		Placebo	20	11 (55.0)	-0.83 (0.76)	-2.6	-0.92	-0.51	-0.43	-0.1	
	Week 33	Tezepelumab	15	8 (53.3)	-0.86 (0.61)	-1.8	-1.28	-0.96	-0.23	-0.1	0.29 [-0.59, 1.18]
		Placebo	20	13 (65.0)	-1.09 (0.87)	-2.7	-1.98	-0.64	-0.43	-0.2	
	Week 34	Tezepelumab	15	8 (53.3)	-0.89 (0.60)	-1.8	-1.32	-0.96	-0.31	-0.1	0.02 [-0.91, 0.95]
		Placebo	20	10 (50.0)	-0.90 (0.84)	-2.7	-0.92	-0.51	-0.43	-0.2	

Note: DITTTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC\_KLMH0: Course of ASD weekly shortness of breath score  
 DITTTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly shortness of breath score	Week 35	Tezepelumab	15	8 (53.3)	-0.73 (0.58)	-1.5	-1.13	-0.92	-0.11	0.0	0.30 [-0.64, 1.24]
		Placebo	20	10 (50.0)	-0.95 (0.86)	-2.7	-1.29	-0.72	-0.36	0.0	
	Week 36	Tezepelumab	15	8 (53.3)	-0.91 (0.58)	-1.8	-1.32	-0.96	-0.38	-0.1	-0.37 [-1.29, 0.55]
		Placebo	20	11 (55.0)	-0.68 (0.66)	-2.3	-0.92	-0.50	-0.21	0.1	
	Week 37	Tezepelumab	15	8 (53.3)	-0.79 (0.65)	-1.8	-1.25	-0.83	-0.21	0.1	0.05 [-0.86, 0.96]
		Placebo	20	11 (55.0)	-0.83 (0.87)	-2.6	-1.29	-0.58	-0.23	0.1	
	Week 38	Tezepelumab	15	7 (46.7)	-0.79 (0.73)	-1.8	-1.38	-1.00	-0.14	0.2	0.01 [-0.92, 0.95]
		Placebo	20	12 (60.0)	-0.80 (0.72)	-2.1	-1.38	-0.71	-0.16	0.1	
	Week 39	Tezepelumab	15	8 (53.3)	-0.83 (0.62)	-1.8	-1.32	-0.78	-0.27	-0.1	-0.07 [-0.98, 0.85]
		Placebo	20	11 (55.0)	-0.78 (0.95)	-2.6	-1.29	-0.58	0.00	0.5	
	Week 40	Tezepelumab	15	8 (53.3)	-0.76 (0.68)	-1.8	-1.32	-0.61	-0.15	-0.1	0.18 [-0.75, 1.11]
		Placebo	20	10 (50.0)	-0.91 (0.91)	-2.7	-1.29	-0.74	-0.43	0.4	
	Week 41	Tezepelumab	15	8 (53.3)	-0.78 (0.62)	-1.8	-1.21	-0.80	-0.16	-0.1	0.20 [-0.75, 1.16]
		Placebo	20	9 (45.0)	-0.95 (0.97)	-2.7	-1.29	-0.71	-0.43	0.1	
	Week 42	Tezepelumab	15	8 (53.3)	-0.84 (0.56)	-1.8	-1.20	-0.90	-0.31	-0.1	0.12 [-0.81, 1.05]
		Placebo	20	10 (50.0)	-0.94 (0.98)	-2.7	-1.56	-0.75	-0.33	0.4	
	Week 43	Tezepelumab	15	8 (53.3)	-0.86 (0.63)	-1.8	-1.32	-0.96	-0.21	-0.1	0.37 [-0.55, 1.29]
		Placebo	20	11 (55.0)	-1.15 (0.88)	-2.6	-1.98	-0.96	-0.58	0.5	
	Week 44	Tezepelumab	15	7 (46.7)	-0.82 (0.64)	-1.8	-1.25	-1.00	-0.17	-0.1	0.05 [-0.90, 1.00]
		Placebo	20	11 (55.0)	-0.86 (0.86)	-2.7	-1.29	-0.63	-0.30	0.3	
	Week 45	Tezepelumab	15	7 (46.7)	-0.85 (0.65)	-1.8	-1.42	-1.00	-0.18	-0.1	0.20 [-0.75, 1.15]
		Placebo	20	11 (55.0)	-1.02 (0.90)	-2.7	-1.93	-0.71	-0.50	0.4	
	Week 46	Tezepelumab	15	7 (46.7)	-0.78 (0.63)	-1.5	-1.39	-1.00	-0.14	0.0	0.05 [-0.94, 1.03]
		Placebo	20	9 (45.0)	-0.82 (0.93)	-2.7	-0.92	-0.60	-0.50	0.4	
	Week 47	Tezepelumab	15	6 (40.0)	-0.96 (0.63)	-1.8	-1.38	-1.07	-0.29	-0.1	0.09 [-0.92, 1.10]
		Placebo	20	10 (50.0)	-1.02 (0.82)	-2.7	-1.29	-0.86	-0.50	-0.2	
	Week 48	Tezepelumab	15	5 (33.3)	-0.87 (0.67)	-1.8	-1.14	-1.00	-0.29	-0.1	0.08 [-0.99, 1.15]
		Placebo	20	10 (50.0)	-0.94 (0.85)	-2.7	-1.21	-0.71	-0.50	0.2	
	Week 49	Tezepelumab	15	7 (46.7)	-0.94 (0.59)	-1.8	-1.40	-1.00	-0.29	-0.1	0.13 [-0.83, 1.10]
		Placebo	20	10 (50.0)	-1.03 (0.75)	-2.6	-1.29	-0.75	-0.53	-0.2	
	Week 50	Tezepelumab	15	6 (40.0)	-0.92 (0.61)	-1.8	-1.17	-1.07	-0.29	-0.1	0.15 [-0.87, 1.16]
		Placebo	20	10 (50.0)	-1.03 (0.78)	-2.6	-1.29	-0.77	-0.50	-0.2	
	Week 51	Tezepelumab	15	7 (46.7)	-0.83 (0.65)	-1.8	-1.30	-1.00	-0.14	-0.1	0.07 [-0.86, 1.01]
		Placebo	20	12 (60.0)	-0.89 (0.83)	-2.7	-1.21	-0.69	-0.36	0.4	
	Week 52	Tezepelumab	15	8 (53.3)	-0.84 (0.60)	-1.8	-1.24	-0.93	-0.21	-0.1	0.30 [-0.62, 1.22]
		Placebo	20	11 (55.0)	-1.05 (0.79)	-2.7	-1.71	-0.83	-0.50	-0.2	

Note: DITTTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC\_KLMC0: Change from baseline in ASD weekly shortness of breath score - MMRM results  
 DITTL - adolescents

Change from baseline in ASD weekly shortness of breath score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 1	Tezepelumab	15	14 (93.3)	-0.26 (0.17)	(-0.61, 0.08)	-0.13 (0.23)	(-0.58, 0.32)	0.567
	Placebo	20	20 (100.0)	-0.13 (0.15)	(-0.42, 0.16)			
Week 2	Tezepelumab	15	14 (93.3)	-0.30 (0.17)	(-0.65, 0.04)	0.06 (0.23)	(-0.39, 0.51)	0.801
	Placebo	20	19 (95.0)	-0.36 (0.15)	(-0.65, -0.07)			
Week 3	Tezepelumab	15	14 (93.3)	-0.37 (0.17)	(-0.71, -0.02)	0.20 (0.23)	(-0.26, 0.65)	0.391
	Placebo	20	17 (85.0)	-0.56 (0.15)	(-0.86, -0.27)			
Week 4	Tezepelumab	15	12 (80.0)	-0.45 (0.17)	(-0.80, -0.10)	0.18 (0.23)	(-0.28, 0.63)	0.439
	Placebo	20	17 (85.0)	-0.63 (0.15)	(-0.92, -0.33)			
Week 5	Tezepelumab	15	12 (80.0)	-0.40 (0.18)	(-0.75, -0.05)	0.15 (0.23)	(-0.30, 0.61)	0.508
	Placebo	20	16 (80.0)	-0.55 (0.15)	(-0.85, -0.26)			
Week 6	Tezepelumab	15	11 (73.3)	-0.43 (0.18)	(-0.78, -0.09)	0.19 (0.23)	(-0.26, 0.65)	0.405
	Placebo	20	16 (80.0)	-0.63 (0.15)	(-0.92, -0.33)			
Week 7	Tezepelumab	15	12 (80.0)	-0.45 (0.17)	(-0.80, -0.11)	0.13 (0.23)	(-0.33, 0.59)	0.575
	Placebo	20	16 (80.0)	-0.58 (0.15)	(-0.88, -0.29)			
Week 8	Tezepelumab	15	13 (86.7)	-0.42 (0.17)	(-0.76, -0.07)	0.07 (0.23)	(-0.39, 0.52)	0.777
	Placebo	20	16 (80.0)	-0.48 (0.15)	(-0.78, -0.18)			
Week 9	Tezepelumab	15	10 (66.7)	-0.35 (0.18)	(-0.70, 0.00)	0.24 (0.23)	(-0.22, 0.69)	0.313
	Placebo	20	17 (85.0)	-0.58 (0.15)	(-0.88, -0.29)			
Week 10	Tezepelumab	15	10 (66.7)	-0.53 (0.18)	(-0.88, -0.18)	0.27 (0.23)	(-0.19, 0.73)	0.252
	Placebo	20	15 (75.0)	-0.79 (0.15)	(-1.09, -0.50)			

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC\_KLMC0: Change from baseline in ASD weekly shortness of breath score - MMRM results  
 DITTL - adolescents

Change from baseline in ASD weekly shortness of breath score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 11	Tezepelumab	15	12 (80.0)	-0.51 (0.18)	(-0.86, -0.17)	0.22 (0.23)	(-0.24, 0.68)	0.353
	Placebo	20	17 (85.0)	-0.73 (0.15)	(-1.03, -0.43)			
Week 12	Tezepelumab	15	12 (80.0)	-0.58 (0.18)	(-0.93, -0.23)	0.15 (0.23)	(-0.31, 0.62)	0.514
	Placebo	20	15 (75.0)	-0.74 (0.15)	(-1.04, -0.44)			
Week 13	Tezepelumab	15	9 (60.0)	-0.66 (0.18)	(-1.02, -0.30)	0.01 (0.24)	(-0.46, 0.48)	0.955
	Placebo	20	15 (75.0)	-0.67 (0.15)	(-0.97, -0.37)			
Week 14	Tezepelumab	15	8 (53.3)	-0.65 (0.18)	(-1.02, -0.29)	0.02 (0.24)	(-0.45, 0.50)	0.922
	Placebo	20	13 (65.0)	-0.68 (0.15)	(-0.98, -0.37)			
Week 15	Tezepelumab	15	10 (66.7)	-0.73 (0.18)	(-1.09, -0.37)	-0.15 (0.24)	(-0.63, 0.32)	0.520
	Placebo	20	15 (75.0)	-0.57 (0.15)	(-0.88, -0.27)			
Week 16	Tezepelumab	15	10 (66.7)	-0.72 (0.18)	(-1.08, -0.36)	-0.07 (0.24)	(-0.55, 0.40)	0.760
	Placebo	20	15 (75.0)	-0.65 (0.16)	(-0.95, -0.34)			
Week 17	Tezepelumab	15	9 (60.0)	-0.76 (0.19)	(-1.12, -0.39)	-0.20 (0.24)	(-0.68, 0.28)	0.409
	Placebo	20	13 (65.0)	-0.55 (0.16)	(-0.86, -0.25)			
Week 18	Tezepelumab	15	10 (66.7)	-0.70 (0.19)	(-1.08, -0.33)	-0.25 (0.24)	(-0.74, 0.23)	0.304
	Placebo	20	13 (65.0)	-0.45 (0.16)	(-0.76, -0.14)			
Week 19	Tezepelumab	15	10 (66.7)	-0.76 (0.19)	(-1.14, -0.38)	-0.21 (0.25)	(-0.70, 0.28)	0.395
	Placebo	20	15 (75.0)	-0.55 (0.15)	(-0.86, -0.25)			
Week 20	Tezepelumab	15	7 (46.7)	-0.82 (0.20)	(-1.21, -0.43)	-0.14 (0.25)	(-0.63, 0.36)	0.591
	Placebo	20	15 (75.0)	-0.68 (0.15)	(-0.99, -0.38)			

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC\_KLMC0: Change from baseline in ASD weekly shortness of breath score - MMRM results  
 DITTL - adolescents

Change from baseline in ASD weekly shortness of breath score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 21	Tezepelumab	15	8 (53.3)	-0.72 (0.20)	(-1.11, -0.33)	-0.00 (0.25)	(-0.50, 0.49)	0.987
	Placebo	20	14 (70.0)	-0.71 (0.16)	(-1.02, -0.41)			
Week 22	Tezepelumab	15	8 (53.3)	-0.69 (0.20)	(-1.08, -0.30)	-0.13 (0.25)	(-0.63, 0.37)	0.608
	Placebo	20	13 (65.0)	-0.56 (0.16)	(-0.87, -0.25)			
Week 23	Tezepelumab	15	9 (60.0)	-0.68 (0.20)	(-1.08, -0.29)	-0.13 (0.26)	(-0.63, 0.38)	0.622
	Placebo	20	14 (70.0)	-0.56 (0.16)	(-0.87, -0.24)			
Week 24	Tezepelumab	15	10 (66.7)	-0.64 (0.20)	(-1.04, -0.25)	-0.01 (0.26)	(-0.51, 0.50)	0.984
	Placebo	20	13 (65.0)	-0.64 (0.16)	(-0.95, -0.32)			
Week 25	Tezepelumab	15	9 (60.0)	-0.64 (0.20)	(-1.04, -0.25)	0.07 (0.26)	(-0.44, 0.58)	0.791
	Placebo	20	12 (60.0)	-0.71 (0.16)	(-1.03, -0.40)			
Week 26	Tezepelumab	15	8 (53.3)	-0.69 (0.20)	(-1.10, -0.29)	-0.01 (0.26)	(-0.52, 0.51)	0.984
	Placebo	20	14 (70.0)	-0.69 (0.16)	(-1.00, -0.37)			
Week 27	Tezepelumab	15	8 (53.3)	-0.77 (0.21)	(-1.18, -0.36)	-0.11 (0.26)	(-0.63, 0.41)	0.685
	Placebo	20	13 (65.0)	-0.66 (0.16)	(-0.98, -0.35)			
Week 28	Tezepelumab	15	8 (53.3)	-0.82 (0.21)	(-1.23, -0.41)	-0.18 (0.26)	(-0.70, 0.34)	0.488
	Placebo	20	14 (70.0)	-0.64 (0.16)	(-0.96, -0.32)			
Week 29	Tezepelumab	15	7 (46.7)	-0.77 (0.21)	(-1.18, -0.35)	-0.03 (0.27)	(-0.56, 0.49)	0.901
	Placebo	20	13 (65.0)	-0.73 (0.16)	(-1.05, -0.41)			
Week 30	Tezepelumab	15	8 (53.3)	-0.76 (0.21)	(-1.18, -0.34)	-0.06 (0.27)	(-0.59, 0.48)	0.838
	Placebo	20	8 (40.0)	-0.70 (0.17)	(-1.03, -0.37)			

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC\_KLMC0: Change from baseline in ASD weekly shortness of breath score - MMRM results  
 DITTL - adolescents

Change from baseline in ASD weekly shortness of breath score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 31	Tezepelumab	15	7 (46.7)	-0.84 (0.21)	(-1.26, -0.42)	-0.07 (0.27)	(-0.60, 0.46)	0.799
	Placebo	20	12 (60.0)	-0.77 (0.16)	(-1.09, -0.44)			
Week 32	Tezepelumab	15	8 (53.3)	-0.85 (0.21)	(-1.27, -0.43)	-0.01 (0.27)	(-0.54, 0.52)	0.960
	Placebo	20	11 (55.0)	-0.84 (0.16)	(-1.16, -0.51)			
Week 33	Tezepelumab	15	8 (53.3)	-0.84 (0.21)	(-1.26, -0.42)	-0.01 (0.27)	(-0.54, 0.52)	0.966
	Placebo	20	13 (65.0)	-0.83 (0.16)	(-1.15, -0.51)			
Week 34	Tezepelumab	15	8 (53.3)	-0.87 (0.22)	(-1.30, -0.45)	-0.01 (0.27)	(-0.55, 0.52)	0.958
	Placebo	20	10 (50.0)	-0.86 (0.17)	(-1.19, -0.53)			
Week 35	Tezepelumab	15	8 (53.3)	-0.72 (0.22)	(-1.14, -0.29)	0.13 (0.27)	(-0.42, 0.67)	0.649
	Placebo	20	10 (50.0)	-0.84 (0.17)	(-1.17, -0.51)			
Week 36	Tezepelumab	15	8 (53.3)	-0.90 (0.22)	(-1.33, -0.47)	-0.04 (0.28)	(-0.59, 0.50)	0.877
	Placebo	20	11 (55.0)	-0.86 (0.17)	(-1.19, -0.53)			
Week 37	Tezepelumab	15	8 (53.3)	-0.78 (0.22)	(-1.21, -0.35)	0.00 (0.28)	(-0.55, 0.55)	0.999
	Placebo	20	11 (55.0)	-0.78 (0.17)	(-1.12, -0.45)			
Week 38	Tezepelumab	15	7 (46.7)	-0.76 (0.22)	(-1.19, -0.33)	-0.08 (0.28)	(-0.62, 0.47)	0.785
	Placebo	20	12 (60.0)	-0.68 (0.17)	(-1.01, -0.35)			
Week 39	Tezepelumab	15	8 (53.3)	-0.83 (0.22)	(-1.26, -0.40)	-0.10 (0.28)	(-0.64, 0.45)	0.731
	Placebo	20	11 (55.0)	-0.74 (0.17)	(-1.07, -0.40)			
Week 40	Tezepelumab	15	8 (53.3)	-0.82 (0.22)	(-1.25, -0.39)	-0.03 (0.28)	(-0.58, 0.51)	0.906
	Placebo	20	10 (50.0)	-0.79 (0.17)	(-1.12, -0.45)			

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC\_KLMC0: Change from baseline in ASD weekly shortness of breath score - MMRM results  
 DITTL - adolescents

Change from baseline in ASD weekly shortness of breath score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 41	Tezepelumab	15	8 (53.3)	-0.79 (0.22)	(-1.22, -0.36)	-0.02 (0.28)	(-0.57, 0.53)	0.956
	Placebo	20	9 (45.0)	-0.77 (0.17)	(-1.11, -0.43)			
Week 42	Tezepelumab	15	8 (53.3)	-0.85 (0.22)	(-1.28, -0.42)	-0.12 (0.28)	(-0.67, 0.43)	0.656
	Placebo	20	10 (50.0)	-0.72 (0.17)	(-1.06, -0.39)			
Week 43	Tezepelumab	15	8 (53.3)	-0.87 (0.22)	(-1.30, -0.43)	-0.01 (0.28)	(-0.56, 0.54)	0.976
	Placebo	20	11 (55.0)	-0.86 (0.17)	(-1.19, -0.53)			
Week 44	Tezepelumab	15	7 (46.7)	-0.84 (0.22)	(-1.28, -0.40)	0.02 (0.28)	(-0.53, 0.58)	0.937
	Placebo	20	11 (55.0)	-0.86 (0.17)	(-1.19, -0.53)			
Week 45	Tezepelumab	15	7 (46.7)	-0.87 (0.23)	(-1.31, -0.42)	-0.07 (0.28)	(-0.63, 0.49)	0.802
	Placebo	20	11 (55.0)	-0.79 (0.17)	(-1.13, -0.46)			
Week 46	Tezepelumab	15	7 (46.7)	-0.79 (0.23)	(-1.24, -0.34)	0.02 (0.28)	(-0.55, 0.58)	0.957
	Placebo	20	9 (45.0)	-0.80 (0.17)	(-1.14, -0.47)			
Week 47	Tezepelumab	15	6 (40.0)	-0.84 (0.23)	(-1.29, -0.39)	0.09 (0.29)	(-0.47, 0.66)	0.745
	Placebo	20	10 (50.0)	-0.94 (0.17)	(-1.28, -0.60)			
Week 48	Tezepelumab	15	5 (33.3)	-0.85 (0.23)	(-1.30, -0.40)	0.12 (0.29)	(-0.45, 0.69)	0.678
	Placebo	20	10 (50.0)	-0.97 (0.17)	(-1.31, -0.63)			
Week 49	Tezepelumab	15	7 (46.7)	-0.86 (0.23)	(-1.30, -0.41)	0.04 (0.29)	(-0.53, 0.60)	0.901
	Placebo	20	10 (50.0)	-0.89 (0.17)	(-1.24, -0.55)			
Week 50	Tezepelumab	15	6 (40.0)	-0.83 (0.23)	(-1.28, -0.38)	0.06 (0.29)	(-0.51, 0.63)	0.837
	Placebo	20	10 (50.0)	-0.89 (0.17)	(-1.24, -0.55)			

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table NT1WBC\_KLMC0: Change from baseline in ASD weekly shortness of breath score - MMRM results  
 DITTL - adolescents

Change from baseline in ASD weekly shortness of breath score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 51	Tezepelumab	15	7 (46.7)	-0.87 (0.23)	(-1.32, -0.42)	0.03 (0.29)	(-0.54, 0.59)	0.925
	Placebo	20	12 (60.0)	-0.90 (0.17)	(-1.23, -0.56)			
Week 52	Tezepelumab	15	8 (53.3)	-0.88 (0.23)	(-1.32, -0.43)	0.08 (0.29)	(-0.48, 0.65)	0.771
	Placebo	20	11 (55.0)	-0.96 (0.17)	(-1.30, -0.62)			

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WHC\_KLMH0: Course of ASD weekly cough score  
 DITTTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly cough score	Baseline	Tezepelumab	15	15 (100.0)	1.18 (0.93)	0.1	0.33	1.00	2.07	3.0	
		Placebo	20	20 (100.0)	1.44 (0.81)	0.2	0.86	1.18	2.00	3.1	
	Week 1	Tezepelumab	15	14 (93.3)	1.00 (0.91)	0.0	0.17	0.90	1.70	2.9	
		Placebo	20	20 (100.0)	1.24 (1.00)	0.0	0.45	1.04	1.96	3.3	
	Week 2	Tezepelumab	15	14 (93.3)	1.00 (1.04)	0.0	0.17	0.83	1.57	3.8	
		Placebo	20	19 (95.0)	1.09 (0.98)	0.0	0.08	1.00	1.93	3.1	
	Week 3	Tezepelumab	15	14 (93.3)	0.90 (0.89)	0.0	0.17	0.75	1.57	3.0	
		Placebo	20	17 (85.0)	0.77 (0.88)	0.0	0.10	0.50	1.40	2.8	
	Week 4	Tezepelumab	15	12 (80.0)	0.88 (0.92)	0.0	0.13	0.70	1.36	3.0	
		Placebo	20	17 (85.0)	0.66 (0.78)	0.0	0.00	0.29	1.21	2.1	
	Week 5	Tezepelumab	15	12 (80.0)	0.87 (0.87)	0.0	0.08	0.75	1.49	2.6	
		Placebo	20	16 (80.0)	0.74 (0.72)	0.0	0.07	0.65	1.32	2.0	
	Week 6	Tezepelumab	15	11 (73.3)	0.72 (0.69)	0.0	0.00	0.83	1.33	2.0	
		Placebo	20	16 (80.0)	0.83 (0.81)	0.0	0.04	0.64	1.50	2.4	
	Week 7	Tezepelumab	15	12 (80.0)	0.76 (0.68)	0.0	0.11	0.70	1.28	2.0	
		Placebo	20	16 (80.0)	0.84 (0.70)	0.0	0.11	0.88	1.27	2.1	
	Week 8	Tezepelumab	15	13 (86.7)	0.92 (0.78)	0.0	0.14	1.00	1.36	2.3	
		Placebo	20	16 (80.0)	0.82 (0.71)	0.0	0.20	0.86	1.11	2.3	
	Week 9	Tezepelumab	15	10 (66.7)	0.77 (0.78)	0.0	0.00	0.77	1.00	2.1	
		Placebo	20	17 (85.0)	0.96 (0.86)	0.0	0.08	0.83	1.50	2.8	
	Week 10	Tezepelumab	15	10 (66.7)	0.71 (0.89)	0.0	0.07	0.17	1.29	2.5	
		Placebo	20	15 (75.0)	0.61 (0.65)	0.0	0.00	0.50	1.20	1.9	
	Week 11	Tezepelumab	15	12 (80.0)	0.76 (0.79)	0.0	0.00	0.65	1.40	2.1	
		Placebo	20	17 (85.0)	0.72 (0.80)	0.0	0.00	0.43	1.07	2.6	
	Week 12	Tezepelumab	15	12 (80.0)	0.82 (0.81)	0.0	0.00	0.67	1.68	1.9	
		Placebo	20	15 (75.0)	0.76 (0.75)	0.0	0.08	0.71	1.00	2.4	
	Week 13	Tezepelumab	15	9 (60.0)	0.62 (0.69)	0.0	0.00	0.14	1.29	1.6	
		Placebo	20	15 (75.0)	0.80 (0.91)	0.0	0.00	0.67	1.40	3.0	
	Week 14	Tezepelumab	15	8 (53.3)	0.68 (0.65)	0.0	0.00	0.75	1.15	1.7	
		Placebo	20	13 (65.0)	0.62 (0.68)	0.0	0.00	0.43	1.00	2.0	
	Week 15	Tezepelumab	15	10 (66.7)	0.61 (0.72)	0.0	0.00	0.36	1.10	2.0	
		Placebo	20	15 (75.0)	0.85 (0.78)	0.0	0.00	1.00	1.50	2.2	
	Week 16	Tezepelumab	15	10 (66.7)	0.58 (0.64)	0.0	0.00	0.40	1.07	1.7	
		Placebo	20	15 (75.0)	0.71 (0.69)	0.0	0.00	0.83	1.00	2.3	
Week 17	Tezepelumab	15	9 (60.0)	0.50 (0.58)	0.0	0.00	0.42	1.00	1.5		
	Placebo	20	13 (65.0)	0.71 (0.69)	0.0	0.08	0.57	1.21	1.8		

Note: DITTTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022

Table NT1WHC\_KLMH0: Course of ASD weekly cough score  
 DITTTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly cough score	Week 18	Tezepelumab	15	10 (66.7)	0.51 (0.50)	0.0	0.00	0.43	0.93	1.4	
		Placebo	20	13 (65.0)	0.85 (0.95)	0.0	0.00	0.50	1.25	3.1	
	Week 19	Tezepelumab	15	10 (66.7)	0.52 (0.54)	0.0	0.00	0.38	1.00	1.2	
		Placebo	20	15 (75.0)	0.88 (0.97)	0.0	0.00	0.88	1.36	3.0	
	Week 20	Tezepelumab	15	7 (46.7)	0.21 (0.36)	0.0	0.00	0.08	0.29	1.0	
		Placebo	20	15 (75.0)	0.67 (0.86)	0.0	0.00	0.30	1.08	2.9	
	Week 21	Tezepelumab	15	8 (53.3)	0.42 (0.56)	0.0	0.00	0.08	0.93	1.4	
		Placebo	20	14 (70.0)	0.59 (0.83)	0.0	0.00	0.17	1.00	2.9	
	Week 22	Tezepelumab	15	8 (53.3)	0.43 (0.52)	0.0	0.00	0.16	0.93	1.3	
		Placebo	20	13 (65.0)	0.71 (0.84)	0.0	0.00	0.29	1.33	2.8	
	Week 23	Tezepelumab	15	9 (60.0)	0.54 (0.65)	0.0	0.00	0.07	1.10	1.6	
		Placebo	20	14 (70.0)	0.73 (1.04)	0.0	0.00	0.54	1.00	3.9	
	Week 24	Tezepelumab	15	10 (66.7)	0.58 (0.59)	0.0	0.00	0.51	1.17	1.3	
		Placebo	20	13 (65.0)	0.70 (0.89)	0.0	0.00	0.50	1.17	3.1	
	Week 25	Tezepelumab	15	9 (60.0)	0.43 (0.52)	0.0	0.00	0.08	1.00	1.2	
		Placebo	20	12 (60.0)	0.58 (0.57)	0.0	0.11	0.50	1.00	1.8	
	Week 26	Tezepelumab	15	8 (53.3)	0.31 (0.49)	0.0	0.00	0.07	0.63	1.1	
		Placebo	20	14 (70.0)	0.44 (0.48)	0.0	0.00	0.23	1.00	1.1	
	Week 27	Tezepelumab	15	8 (53.3)	0.33 (0.44)	0.0	0.00	0.09	0.71	1.0	
		Placebo	20	13 (65.0)	0.57 (0.51)	0.0	0.07	0.60	1.00	1.3	
	Week 28	Tezepelumab	15	8 (53.3)	0.19 (0.39)	0.0	0.00	0.00	0.21	1.1	
		Placebo	20	14 (70.0)	0.67 (0.67)	0.0	0.00	0.85	1.00	2.0	
	Week 29	Tezepelumab	15	7 (46.7)	0.29 (0.43)	0.0	0.00	0.14	0.36	1.2	
		Placebo	20	13 (65.0)	0.74 (0.73)	0.0	0.07	0.63	1.00	2.7	
	Week 30	Tezepelumab	15	8 (53.3)	0.27 (0.48)	0.0	0.00	0.10	0.26	1.4	
		Placebo	20	8 (40.0)	0.56 (0.53)	0.0	0.00	0.62	1.04	1.2	
	Week 31	Tezepelumab	15	7 (46.7)	0.18 (0.49)	0.0	0.00	0.00	0.00	1.3	
		Placebo	20	12 (60.0)	0.49 (0.49)	0.0	0.00	0.40	0.91	1.4	
	Week 32	Tezepelumab	15	8 (53.3)	0.23 (0.36)	0.0	0.00	0.13	0.26	1.1	
		Placebo	20	11 (55.0)	0.67 (0.53)	0.0	0.14	0.88	1.14	1.4	
	Week 33	Tezepelumab	15	8 (53.3)	0.36 (0.53)	0.0	0.00	0.05	0.76	1.3	
		Placebo	20	13 (65.0)	0.54 (0.74)	0.0	0.00	0.29	0.75	2.7	
	Week 34	Tezepelumab	15	8 (53.3)	0.35 (0.56)	0.0	0.00	0.00	0.71	1.4	
		Placebo	20	10 (50.0)	0.71 (0.84)	0.0	0.00	0.43	1.00	2.2	
	Week 35	Tezepelumab	15	8 (53.3)	0.51 (0.68)	0.0	0.00	0.27	0.88	1.8	
		Placebo	20	10 (50.0)	0.40 (0.65)	0.0	0.00	0.11	0.58	2.0	

Note: DITTTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022

Table NT1WHC\_KLMH0: Course of ASD weekly cough score  
 DITTTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly cough score	Week 36	Tezepelumab	15	8 (53.3)	0.40 (0.65)	0.0	0.00	0.08	0.68	1.7	
		Placebo	20	11 (55.0)	0.47 (0.58)	0.0	0.00	0.17	1.00	1.7	
	Week 37	Tezepelumab	15	8 (53.3)	0.44 (0.58)	0.0	0.00	0.17	0.86	1.5	
		Placebo	20	11 (55.0)	0.51 (0.55)	0.0	0.00	0.33	1.00	1.6	
	Week 38	Tezepelumab	15	7 (46.7)	0.42 (0.56)	0.0	0.00	0.00	1.13	1.2	
		Placebo	20	12 (60.0)	0.64 (0.60)	0.0	0.04	0.57	1.00	1.8	
	Week 39	Tezepelumab	15	8 (53.3)	0.44 (0.62)	0.0	0.00	0.18	0.74	1.7	
		Placebo	20	11 (55.0)	0.56 (0.50)	0.0	0.00	0.75	1.00	1.3	
	Week 40	Tezepelumab	15	8 (53.3)	0.43 (0.54)	0.0	0.00	0.14	0.96	1.3	
		Placebo	20	10 (50.0)	0.60 (0.54)	0.0	0.00	0.73	1.00	1.4	
	Week 41	Tezepelumab	15	8 (53.3)	0.65 (0.73)	0.0	0.00	0.38	1.34	1.8	
		Placebo	20	9 (45.0)	0.57 (0.57)	0.0	0.00	0.71	1.00	1.6	
	Week 42	Tezepelumab	15	8 (53.3)	0.56 (0.79)	0.0	0.00	0.06	1.30	1.8	
		Placebo	20	10 (50.0)	0.57 (0.59)	0.0	0.00	0.49	1.00	1.5	
	Week 43	Tezepelumab	15	8 (53.3)	0.49 (0.70)	0.0	0.00	0.00	1.13	1.7	
		Placebo	20	11 (55.0)	0.55 (0.60)	0.0	0.00	0.25	1.13	1.5	
	Week 44	Tezepelumab	15	7 (46.7)	0.46 (0.63)	0.0	0.00	0.00	1.33	1.3	
		Placebo	20	11 (55.0)	0.66 (0.73)	0.0	0.00	0.80	1.00	2.1	
	Week 45	Tezepelumab	15	7 (46.7)	0.35 (0.52)	0.0	0.00	0.00	1.08	1.1	
		Placebo	20	11 (55.0)	0.63 (0.61)	0.0	0.00	0.70	1.17	1.5	
	Week 46	Tezepelumab	15	7 (46.7)	0.41 (0.56)	0.0	0.00	0.20	1.00	1.4	
		Placebo	20	9 (45.0)	0.70 (0.52)	0.0	0.08	1.00	1.00	1.4	
	Week 47	Tezepelumab	15	6 (40.0)	0.24 (0.39)	0.0	0.00	0.08	0.29	1.0	
		Placebo	20	10 (50.0)	0.46 (0.47)	0.0	0.00	0.41	1.00	1.1	
	Week 48	Tezepelumab	15	5 (33.3)	0.16 (0.23)	0.0	0.00	0.00	0.29	0.5	
		Placebo	20	10 (50.0)	0.45 (0.56)	0.0	0.00	0.09	1.00	1.3	
	Week 49	Tezepelumab	15	7 (46.7)	0.21 (0.38)	0.0	0.00	0.00	0.43	1.0	
		Placebo	20	10 (50.0)	0.55 (0.58)	0.0	0.00	0.34	1.00	1.6	
	Week 50	Tezepelumab	15	6 (40.0)	0.25 (0.50)	0.0	0.00	0.00	0.25	1.3	
		Placebo	20	10 (50.0)	0.48 (0.44)	0.0	0.00	0.45	1.00	1.1	
	Week 51	Tezepelumab	15	7 (46.7)	0.18 (0.41)	0.0	0.00	0.00	0.07	1.1	
		Placebo	20	12 (60.0)	0.66 (0.52)	0.0	0.00	0.92	1.04	1.3	
	Week 52	Tezepelumab	15	8 (53.3)	0.21 (0.38)	0.0	0.00	0.00	0.32	1.1	
		Placebo	20	11 (55.0)	0.44 (0.46)	0.0	0.00	0.38	1.00	1.1	

Note: DITTTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022

Table NT1WHC\_KLMH0: Course of ASD weekly cough score  
 DITTTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly cough score	Week 1	Tezepelumab	15	14 (93.3)	-0.24 (0.46)	-1.4	-0.43	-0.07	0.00	0.3	-0.08 [-0.76, 0.61]
		Placebo	20	20 (100.0)	-0.20 (0.45)	-1.2	-0.46	-0.18	0.01	0.6	
	Week 2	Tezepelumab	15	14 (93.3)	-0.24 (0.57)	-1.3	-0.60	-0.11	0.13	0.8	0.20 [-0.49, 0.90]
		Placebo	20	19 (95.0)	-0.37 (0.67)	-1.9	-0.64	-0.29	0.00	1.0	
	Week 3	Tezepelumab	15	14 (93.3)	-0.34 (0.47)	-1.3	-0.58	-0.14	0.00	0.2	0.43 [-0.28, 1.15]
		Placebo	20	17 (85.0)	-0.55 (0.49)	-1.6	-0.79	-0.43	-0.17	0.1	
	Week 4	Tezepelumab	15	12 (80.0)	-0.42 (0.57)	-1.3	-1.00	-0.16	-0.04	0.2	0.38 [-0.37, 1.12]
		Placebo	20	17 (85.0)	-0.63 (0.55)	-1.9	-1.00	-0.50	-0.21	0.1	
	Week 5	Tezepelumab	15	12 (80.0)	-0.43 (0.52)	-1.4	-0.77	-0.21	-0.07	0.1	0.43 [-0.33, 1.19]
		Placebo	20	16 (80.0)	-0.66 (0.57)	-2.0	-1.04	-0.54	-0.14	0.0	
	Week 6	Tezepelumab	15	11 (73.3)	-0.56 (0.53)	-1.3	-1.00	-0.36	-0.07	0.1	-0.00 [-0.77, 0.77]
		Placebo	20	16 (80.0)	-0.56 (0.70)	-2.1	-0.89	-0.43	-0.08	0.6	
	Week 7	Tezepelumab	15	12 (80.0)	-0.54 (0.56)	-1.2	-1.08	-0.54	-0.07	0.3	-0.00 [-0.75, 0.75]
		Placebo	20	16 (80.0)	-0.54 (0.58)	-1.9	-1.04	-0.36	-0.11	0.1	
	Week 8	Tezepelumab	15	13 (86.7)	-0.30 (0.49)	-1.1	-0.70	-0.07	0.07	0.3	0.52 [-0.22, 1.27]
		Placebo	20	16 (80.0)	-0.55 (0.46)	-1.6	-0.96	-0.46	-0.15	0.1	
	Week 9	Tezepelumab	15	10 (66.7)	-0.43 (0.65)	-1.5	-0.86	-0.46	0.01	0.7	0.13 [-0.65, 0.91]
		Placebo	20	17 (85.0)	-0.51 (0.62)	-2.1	-0.79	-0.43	-0.21	0.8	
	Week 10	Tezepelumab	15	10 (66.7)	-0.49 (0.48)	-1.1	-0.89	-0.50	-0.02	0.1	0.47 [-0.35, 1.28]
		Placebo	20	15 (75.0)	-0.74 (0.59)	-2.1	-1.00	-0.54	-0.37	-0.1	
	Week 11	Tezepelumab	15	12 (80.0)	-0.49 (0.52)	-1.2	-0.96	-0.47	-0.04	0.2	0.40 [-0.34, 1.15]
		Placebo	20	17 (85.0)	-0.75 (0.70)	-2.1	-1.00	-0.64	-0.21	0.1	
	Week 12	Tezepelumab	15	12 (80.0)	-0.43 (0.59)	-1.2	-1.02	-0.35	-0.07	0.6	0.41 [-0.36, 1.18]
		Placebo	20	15 (75.0)	-0.69 (0.67)	-2.1	-1.10	-0.54	-0.27	0.3	
	Week 13	Tezepelumab	15	9 (60.0)	-0.69 (0.66)	-1.5	-1.13	-0.88	-0.07	0.4	-0.05 [-0.87, 0.78]
		Placebo	20	15 (75.0)	-0.66 (0.74)	-2.1	-1.07	-0.50	-0.17	0.3	
	Week 14	Tezepelumab	15	8 (53.3)	-0.64 (0.80)	-2.0	-1.28	-0.36	-0.07	0.3	0.26 [-0.63, 1.14]
		Placebo	20	13 (65.0)	-0.85 (0.79)	-2.1	-1.07	-0.86	-0.21	0.4	
	Week 15	Tezepelumab	15	10 (66.7)	-0.60 (0.78)	-1.9	-1.21	-0.25	-0.07	0.4	0.02 [-0.78, 0.82]
		Placebo	20	15 (75.0)	-0.62 (0.71)	-2.1	-0.93	-0.47	-0.08	0.3	
	Week 16	Tezepelumab	15	10 (66.7)	-0.81 (0.88)	-2.1	-1.27	-0.88	-0.07	0.8	-0.08 [-0.88, 0.72]
		Placebo	20	15 (75.0)	-0.75 (0.67)	-2.3	-1.07	-0.57	-0.21	0.2	
	Week 17	Tezepelumab	15	9 (60.0)	-0.81 (0.92)	-2.1	-1.21	-1.00	-0.07	0.6	-0.21 [-1.06, 0.65]
		Placebo	20	13 (65.0)	-0.63 (0.85)	-2.3	-0.89	-0.50	-0.08	0.7	
	Week 18	Tezepelumab	15	10 (66.7)	-0.69 (0.86)	-2.0	-1.29	-0.68	-0.07	0.4	-0.27 [-1.09, 0.56]
		Placebo	20	13 (65.0)	-0.48 (0.73)	-2.0	-0.93	-0.42	0.04	0.5	

Note: DITTTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022

Table NT1WHC\_KLMH0: Course of ASD weekly cough score  
 DITTTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly cough score	Week 19	Tezepelumab	15	10 (66.7)	-0.68 (0.79)	-2.0	-1.21	-0.51	-0.07	0.3	-0.26 [-1.06, 0.55]
		Placebo	20	15 (75.0)	-0.47 (0.81)	-2.0	-0.95	-0.41	-0.21	1.2	
	Week 20	Tezepelumab	15	7 (46.7)	-0.91 (1.03)	-2.6	-2.00	-0.43	-0.07	-0.0	-0.12 [-1.02, 0.78]
		Placebo	20	15 (75.0)	-0.80 (0.89)	-2.8	-1.55	-0.57	-0.20	0.4	
	Week 21	Tezepelumab	15	8 (53.3)	-0.94 (0.98)	-2.6	-1.61	-0.90	-0.03	0.1	-0.01 [-0.88, 0.86]
		Placebo	20	14 (70.0)	-0.93 (0.91)	-3.1	-1.46	-0.86	-0.23	0.2	
	Week 22	Tezepelumab	15	8 (53.3)	-0.78 (1.02)	-2.4	-1.57	-0.54	0.04	0.3	0.17 [-0.71, 1.05]
		Placebo	20	13 (65.0)	-0.94 (0.94)	-3.1	-1.36	-0.79	-0.21	0.1	
	Week 23	Tezepelumab	15	9 (60.0)	-0.77 (0.98)	-2.6	-1.14	-0.54	-0.07	0.3	0.06 [-0.78, 0.89]
		Placebo	20	14 (70.0)	-0.82 (1.01)	-3.1	-1.07	-0.68	-0.30	1.2	
	Week 24	Tezepelumab	15	10 (66.7)	-0.62 (1.12)	-2.6	-1.17	-0.54	0.21	1.1	0.24 [-0.59, 1.06]
		Placebo	20	13 (65.0)	-0.86 (0.94)	-3.1	-1.07	-0.76	-0.30	0.4	
	Week 25	Tezepelumab	15	9 (60.0)	-0.66 (1.08)	-2.6	-1.21	-0.29	0.00	0.9	0.37 [-0.50, 1.25]
		Placebo	20	12 (60.0)	-1.03 (0.95)	-3.1	-1.64	-0.79	-0.30	0.2	
	Week 26	Tezepelumab	15	8 (53.3)	-0.89 (0.96)	-2.5	-1.56	-0.86	0.00	0.2	0.06 [-0.81, 0.93]
		Placebo	20	14 (70.0)	-0.94 (0.85)	-3.1	-1.43	-0.60	-0.41	-0.1	
	Week 27	Tezepelumab	15	8 (53.3)	-0.88 (0.88)	-2.2	-1.56	-0.82	-0.07	0.1	0.03 [-0.85, 0.91]
		Placebo	20	13 (65.0)	-0.91 (0.77)	-3.0	-1.07	-0.79	-0.44	-0.1	
	Week 28	Tezepelumab	15	8 (53.3)	-0.92 (0.96)	-2.6	-1.57	-0.64	-0.11	-0.1	-0.12 [-0.99, 0.75]
		Placebo	20	14 (70.0)	-0.81 (0.83)	-3.1	-0.93	-0.62	-0.44	0.3	
	Week 29	Tezepelumab	15	7 (46.7)	-0.95 (0.94)	-2.6	-1.79	-0.64	-0.07	-0.1	-0.11 [-1.03, 0.81]
		Placebo	20	13 (65.0)	-0.85 (0.86)	-3.1	-0.86	-0.66	-0.32	0.0	
	Week 30	Tezepelumab	15	8 (53.3)	-0.84 (0.92)	-2.6	-1.36	-0.60	-0.07	-0.0	-0.26 [-1.24, 0.73]
		Placebo	20	8 (40.0)	-0.64 (0.53)	-1.6	-1.00	-0.46	-0.26	-0.1	
	Week 31	Tezepelumab	15	7 (46.7)	-1.06 (0.92)	-2.6	-1.71	-1.00	-0.07	-0.1	-0.24 [-1.18, 0.69]
		Placebo	20	12 (60.0)	-0.82 (1.03)	-3.1	-1.21	-0.68	-0.43	1.2	
	Week 32	Tezepelumab	15	8 (53.3)	-0.87 (0.95)	-2.5	-1.57	-0.68	-0.04	0.1	-0.04 [-0.95, 0.87]
		Placebo	20	11 (55.0)	-0.83 (1.02)	-3.1	-1.29	-0.76	-0.36	0.9	
	Week 33	Tezepelumab	15	8 (53.3)	-1.01 (0.88)	-2.5	-1.57	-0.93	-0.21	-0.1	-0.09 [-0.97, 0.80]
		Placebo	20	13 (65.0)	-0.92 (1.05)	-3.0	-1.32	-0.69	-0.36	1.1	
	Week 34	Tezepelumab	15	8 (53.3)	-1.02 (0.89)	-2.6	-1.57	-0.90	-0.26	-0.1	-0.21 [-1.14, 0.72]
		Placebo	20	10 (50.0)	-0.81 (1.08)	-3.1	-1.35	-0.48	-0.21	0.6	
	Week 35	Tezepelumab	15	8 (53.3)	-0.86 (0.81)	-2.4	-1.33	-0.67	-0.21	-0.1	0.02 [-0.91, 0.95]
		Placebo	20	10 (50.0)	-0.87 (1.06)	-3.1	-1.07	-0.61	-0.21	0.4	
	Week 36	Tezepelumab	15	8 (53.3)	-0.97 (0.92)	-2.6	-1.54	-0.75	-0.27	0.0	-0.35 [-1.27, 0.57]
		Placebo	20	11 (55.0)	-0.69 (0.66)	-2.2	-1.07	-0.50	-0.21	0.1	

Note: DITTTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022

Table NT1WHC\_KLMH0: Course of ASD weekly cough score  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly cough score	Week 37	Tezepelumab	15	8 (53.3)	-0.93 (0.95)	-2.6	-1.49	-0.83	-0.11	0.1	-0.01 [-0.92, 0.90]
		Placebo	20	11 (55.0)	-0.92 (0.91)	-3.0	-1.07	-0.93	-0.17	-0.0	
	Week 38	Tezepelumab	15	7 (46.7)	-1.12 (0.93)	-2.6	-1.88	-1.00	-0.07	-0.1	-0.51 [-1.45, 0.44]
		Placebo	20	12 (60.0)	-0.74 (0.63)	-2.1	-1.06	-0.82	-0.15	0.0	
	Week 39	Tezepelumab	15	8 (53.3)	-0.93 (0.97)	-2.6	-1.56	-0.75	-0.21	0.2	-0.06 [-0.97, 0.85]
		Placebo	20	11 (55.0)	-0.87 (0.91)	-2.8	-1.07	-0.93	-0.29	0.4	
	Week 40	Tezepelumab	15	8 (53.3)	-0.93 (1.04)	-2.6	-1.61	-0.96	0.07	0.2	-0.05 [-0.98, 0.88]
		Placebo	20	10 (50.0)	-0.87 (1.05)	-3.1	-1.07	-0.73	-0.15	0.7	
	Week 41	Tezepelumab	15	8 (53.3)	-0.72 (1.06)	-2.6	-1.21	-0.88	0.27	0.6	0.13 [-0.82, 1.08]
		Placebo	20	9 (45.0)	-0.85 (1.07)	-3.1	-1.07	-0.50	-0.08	0.3	
	Week 42	Tezepelumab	15	8 (53.3)	-0.81 (0.92)	-2.6	-1.23	-0.71	-0.04	0.1	0.12 [-0.81, 1.05]
		Placebo	20	10 (50.0)	-0.92 (1.04)	-3.1	-1.17	-0.66	-0.17	0.3	
	Week 43	Tezepelumab	15	8 (53.3)	-0.88 (0.98)	-2.6	-1.48	-0.75	-0.11	0.3	0.11 [-0.80, 1.03]
		Placebo	20	11 (55.0)	-1.00 (1.08)	-3.1	-1.84	-0.79	-0.08	0.8	
	Week 44	Tezepelumab	15	7 (46.7)	-1.08 (0.89)	-2.6	-1.67	-1.00	-0.14	-0.1	-0.29 [-1.24, 0.67]
		Placebo	20	11 (55.0)	-0.80 (1.03)	-3.1	-1.07	-0.50	-0.08	0.4	
	Week 45	Tezepelumab	15	7 (46.7)	-1.19 (0.87)	-2.6	-1.92	-1.07	-0.43	-0.1	-0.17 [-1.12, 0.78]
		Placebo	20	11 (55.0)	-1.03 (1.03)	-3.1	-1.93	-0.83	-0.42	0.5	
	Week 46	Tezepelumab	15	7 (46.7)	-1.13 (0.84)	-2.4	-2.00	-1.00	-0.43	-0.1	-0.31 [-1.31, 0.68]
		Placebo	20	9 (45.0)	-0.82 (1.09)	-3.1	-1.00	-0.50	-0.23	0.5	
	Week 47	Tezepelumab	15	6 (40.0)	-1.20 (0.91)	-2.5	-2.00	-1.11	-0.43	-0.1	-0.23 [-1.24, 0.79]
		Placebo	20	10 (50.0)	-0.99 (0.94)	-3.1	-1.07	-0.63	-0.50	-0.1	
	Week 48	Tezepelumab	15	5 (33.3)	-0.97 (0.80)	-2.1	-1.21	-1.00	-0.43	-0.1	-0.03 [-1.10, 1.04]
		Placebo	20	10 (50.0)	-0.94 (0.95)	-3.1	-1.19	-0.77	-0.37	0.3	
	Week 49	Tezepelumab	15	7 (46.7)	-1.04 (0.97)	-2.6	-2.00	-1.00	-0.14	-0.1	-0.06 [-1.03, 0.90]
		Placebo	20	10 (50.0)	-0.97 (1.12)	-3.1	-1.71	-0.74	-0.21	0.7	
	Week 50	Tezepelumab	15	6 (40.0)	-1.19 (0.92)	-2.6	-1.75	-1.11	-0.46	-0.1	-0.15 [-1.16, 0.86]
		Placebo	20	10 (50.0)	-1.04 (1.02)	-3.1	-1.71	-0.65	-0.23	-0.1	
	Week 51	Tezepelumab	15	7 (46.7)	-1.07 (0.93)	-2.6	-1.90	-1.00	-0.07	-0.1	-0.26 [-1.20, 0.68]
		Placebo	20	12 (60.0)	-0.81 (1.02)	-3.1	-1.37	-0.60	-0.15	0.5	
	Week 52	Tezepelumab	15	8 (53.3)	-0.89 (0.91)	-2.4	-1.57	-0.65	-0.11	-0.1	0.13 [-0.78, 1.04]
		Placebo	20	11 (55.0)	-1.01 (0.94)	-3.1	-1.57	-0.86	-0.21	-0.1	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022

Table NT1WHC\_KLMC0: Change from baseline in ASD weekly cough score - MMRM results  
 DITTL - adolescents

Change from baseline in ASD weekly cough score				Repeated measures analysis																																																																																																																														
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference																																																																																																																												
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value																																																																																																																										
Week 1	Tezepelumab	15	14 (93.3)	-0.31 (0.17)	(-0.64, 0.02)	-0.14 (0.22)	(-0.57, 0.29)	0.517																																																																																																																										
	Placebo	20	20 (100.0)	-0.17 (0.14)	(-0.45, 0.11)				Week 2	Tezepelumab	15	14 (93.3)	-0.32 (0.17)	(-0.65, 0.02)	-0.00 (0.22)	(-0.43, 0.43)	0.994	Placebo	20	19 (95.0)	-0.31 (0.14)	(-0.59, -0.04)	Week 3	Tezepelumab	15	14 (93.3)	-0.42 (0.17)	(-0.75, -0.09)	0.07 (0.22)	(-0.36, 0.51)	0.739	Placebo	20	17 (85.0)	-0.49 (0.14)	(-0.77, -0.21)	Week 4	Tezepelumab	15	12 (80.0)	-0.46 (0.17)	(-0.80, -0.13)	0.13 (0.22)	(-0.31, 0.56)	0.572	Placebo	20	17 (85.0)	-0.59 (0.14)	(-0.87, -0.31)	Week 5	Tezepelumab	15	12 (80.0)	-0.46 (0.17)	(-0.79, -0.12)	0.11 (0.22)	(-0.34, 0.55)	0.636	Placebo	20	16 (80.0)	-0.56 (0.14)	(-0.85, -0.28)	Week 6	Tezepelumab	15	11 (73.3)	-0.65 (0.17)	(-0.98, -0.31)	-0.20 (0.23)	(-0.64, 0.25)	0.381	Placebo	20	16 (80.0)	-0.45 (0.15)	(-0.73, -0.16)	Week 7	Tezepelumab	15	12 (80.0)	-0.54 (0.17)	(-0.88, -0.21)	0.00 (0.22)	(-0.44, 0.44)	0.991	Placebo	20	16 (80.0)	-0.54 (0.14)	(-0.83, -0.26)	Week 8	Tezepelumab	15	13 (86.7)	-0.43 (0.17)	(-0.76, -0.10)	0.10 (0.22)	(-0.34, 0.54)	0.657	Placebo	20	16 (80.0)	-0.53 (0.14)	(-0.81, -0.24)	Week 9	Tezepelumab	15	10 (66.7)	-0.43 (0.17)	(-0.78, -0.09)	0.09 (0.23)	(-0.35, 0.54)	0.683	Placebo	20	17 (85.0)	-0.53 (0.14)	(-0.81, -0.24)	Week 10	Tezepelumab	15	10 (66.7)	-0.50 (0.17)	(-0.84, -0.15)	0.17 (0.23)	(-0.28, 0.62)	0.457	Placebo
Week 2	Tezepelumab	15	14 (93.3)	-0.32 (0.17)	(-0.65, 0.02)	-0.00 (0.22)	(-0.43, 0.43)	0.994																																																																																																																										
	Placebo	20	19 (95.0)	-0.31 (0.14)	(-0.59, -0.04)				Week 3	Tezepelumab	15	14 (93.3)	-0.42 (0.17)	(-0.75, -0.09)	0.07 (0.22)	(-0.36, 0.51)	0.739	Placebo	20	17 (85.0)	-0.49 (0.14)	(-0.77, -0.21)	Week 4	Tezepelumab	15	12 (80.0)	-0.46 (0.17)	(-0.80, -0.13)	0.13 (0.22)	(-0.31, 0.56)	0.572	Placebo	20	17 (85.0)	-0.59 (0.14)	(-0.87, -0.31)	Week 5	Tezepelumab	15	12 (80.0)	-0.46 (0.17)	(-0.79, -0.12)	0.11 (0.22)	(-0.34, 0.55)	0.636	Placebo	20	16 (80.0)	-0.56 (0.14)	(-0.85, -0.28)	Week 6	Tezepelumab	15	11 (73.3)	-0.65 (0.17)	(-0.98, -0.31)	-0.20 (0.23)	(-0.64, 0.25)	0.381	Placebo	20	16 (80.0)	-0.45 (0.15)	(-0.73, -0.16)	Week 7	Tezepelumab	15	12 (80.0)	-0.54 (0.17)	(-0.88, -0.21)	0.00 (0.22)	(-0.44, 0.44)	0.991	Placebo	20	16 (80.0)	-0.54 (0.14)	(-0.83, -0.26)	Week 8	Tezepelumab	15	13 (86.7)	-0.43 (0.17)	(-0.76, -0.10)	0.10 (0.22)	(-0.34, 0.54)	0.657	Placebo	20	16 (80.0)	-0.53 (0.14)	(-0.81, -0.24)	Week 9	Tezepelumab	15	10 (66.7)	-0.43 (0.17)	(-0.78, -0.09)	0.09 (0.23)	(-0.35, 0.54)	0.683	Placebo	20	17 (85.0)	-0.53 (0.14)	(-0.81, -0.24)	Week 10	Tezepelumab	15	10 (66.7)	-0.50 (0.17)	(-0.84, -0.15)	0.17 (0.23)	(-0.28, 0.62)	0.457	Placebo	20	15 (75.0)	-0.67 (0.15)	(-0.96, -0.38)										
Week 3	Tezepelumab	15	14 (93.3)	-0.42 (0.17)	(-0.75, -0.09)	0.07 (0.22)	(-0.36, 0.51)	0.739																																																																																																																										
	Placebo	20	17 (85.0)	-0.49 (0.14)	(-0.77, -0.21)				Week 4	Tezepelumab	15	12 (80.0)	-0.46 (0.17)	(-0.80, -0.13)	0.13 (0.22)	(-0.31, 0.56)	0.572	Placebo	20	17 (85.0)	-0.59 (0.14)	(-0.87, -0.31)	Week 5	Tezepelumab	15	12 (80.0)	-0.46 (0.17)	(-0.79, -0.12)	0.11 (0.22)	(-0.34, 0.55)	0.636	Placebo	20	16 (80.0)	-0.56 (0.14)	(-0.85, -0.28)	Week 6	Tezepelumab	15	11 (73.3)	-0.65 (0.17)	(-0.98, -0.31)	-0.20 (0.23)	(-0.64, 0.25)	0.381	Placebo	20	16 (80.0)	-0.45 (0.15)	(-0.73, -0.16)	Week 7	Tezepelumab	15	12 (80.0)	-0.54 (0.17)	(-0.88, -0.21)	0.00 (0.22)	(-0.44, 0.44)	0.991	Placebo	20	16 (80.0)	-0.54 (0.14)	(-0.83, -0.26)	Week 8	Tezepelumab	15	13 (86.7)	-0.43 (0.17)	(-0.76, -0.10)	0.10 (0.22)	(-0.34, 0.54)	0.657	Placebo	20	16 (80.0)	-0.53 (0.14)	(-0.81, -0.24)	Week 9	Tezepelumab	15	10 (66.7)	-0.43 (0.17)	(-0.78, -0.09)	0.09 (0.23)	(-0.35, 0.54)	0.683	Placebo	20	17 (85.0)	-0.53 (0.14)	(-0.81, -0.24)	Week 10	Tezepelumab	15	10 (66.7)	-0.50 (0.17)	(-0.84, -0.15)	0.17 (0.23)	(-0.28, 0.62)	0.457	Placebo	20	15 (75.0)	-0.67 (0.15)	(-0.96, -0.38)																								
Week 4	Tezepelumab	15	12 (80.0)	-0.46 (0.17)	(-0.80, -0.13)	0.13 (0.22)	(-0.31, 0.56)	0.572																																																																																																																										
	Placebo	20	17 (85.0)	-0.59 (0.14)	(-0.87, -0.31)				Week 5	Tezepelumab	15	12 (80.0)	-0.46 (0.17)	(-0.79, -0.12)	0.11 (0.22)	(-0.34, 0.55)	0.636	Placebo	20	16 (80.0)	-0.56 (0.14)	(-0.85, -0.28)	Week 6	Tezepelumab	15	11 (73.3)	-0.65 (0.17)	(-0.98, -0.31)	-0.20 (0.23)	(-0.64, 0.25)	0.381	Placebo	20	16 (80.0)	-0.45 (0.15)	(-0.73, -0.16)	Week 7	Tezepelumab	15	12 (80.0)	-0.54 (0.17)	(-0.88, -0.21)	0.00 (0.22)	(-0.44, 0.44)	0.991	Placebo	20	16 (80.0)	-0.54 (0.14)	(-0.83, -0.26)	Week 8	Tezepelumab	15	13 (86.7)	-0.43 (0.17)	(-0.76, -0.10)	0.10 (0.22)	(-0.34, 0.54)	0.657	Placebo	20	16 (80.0)	-0.53 (0.14)	(-0.81, -0.24)	Week 9	Tezepelumab	15	10 (66.7)	-0.43 (0.17)	(-0.78, -0.09)	0.09 (0.23)	(-0.35, 0.54)	0.683	Placebo	20	17 (85.0)	-0.53 (0.14)	(-0.81, -0.24)	Week 10	Tezepelumab	15	10 (66.7)	-0.50 (0.17)	(-0.84, -0.15)	0.17 (0.23)	(-0.28, 0.62)	0.457	Placebo	20	15 (75.0)	-0.67 (0.15)	(-0.96, -0.38)																																						
Week 5	Tezepelumab	15	12 (80.0)	-0.46 (0.17)	(-0.79, -0.12)	0.11 (0.22)	(-0.34, 0.55)	0.636																																																																																																																										
	Placebo	20	16 (80.0)	-0.56 (0.14)	(-0.85, -0.28)				Week 6	Tezepelumab	15	11 (73.3)	-0.65 (0.17)	(-0.98, -0.31)	-0.20 (0.23)	(-0.64, 0.25)	0.381	Placebo	20	16 (80.0)	-0.45 (0.15)	(-0.73, -0.16)	Week 7	Tezepelumab	15	12 (80.0)	-0.54 (0.17)	(-0.88, -0.21)	0.00 (0.22)	(-0.44, 0.44)	0.991	Placebo	20	16 (80.0)	-0.54 (0.14)	(-0.83, -0.26)	Week 8	Tezepelumab	15	13 (86.7)	-0.43 (0.17)	(-0.76, -0.10)	0.10 (0.22)	(-0.34, 0.54)	0.657	Placebo	20	16 (80.0)	-0.53 (0.14)	(-0.81, -0.24)	Week 9	Tezepelumab	15	10 (66.7)	-0.43 (0.17)	(-0.78, -0.09)	0.09 (0.23)	(-0.35, 0.54)	0.683	Placebo	20	17 (85.0)	-0.53 (0.14)	(-0.81, -0.24)	Week 10	Tezepelumab	15	10 (66.7)	-0.50 (0.17)	(-0.84, -0.15)	0.17 (0.23)	(-0.28, 0.62)	0.457	Placebo	20	15 (75.0)	-0.67 (0.15)	(-0.96, -0.38)																																																				
Week 6	Tezepelumab	15	11 (73.3)	-0.65 (0.17)	(-0.98, -0.31)	-0.20 (0.23)	(-0.64, 0.25)	0.381																																																																																																																										
	Placebo	20	16 (80.0)	-0.45 (0.15)	(-0.73, -0.16)				Week 7	Tezepelumab	15	12 (80.0)	-0.54 (0.17)	(-0.88, -0.21)	0.00 (0.22)	(-0.44, 0.44)	0.991	Placebo	20	16 (80.0)	-0.54 (0.14)	(-0.83, -0.26)	Week 8	Tezepelumab	15	13 (86.7)	-0.43 (0.17)	(-0.76, -0.10)	0.10 (0.22)	(-0.34, 0.54)	0.657	Placebo	20	16 (80.0)	-0.53 (0.14)	(-0.81, -0.24)	Week 9	Tezepelumab	15	10 (66.7)	-0.43 (0.17)	(-0.78, -0.09)	0.09 (0.23)	(-0.35, 0.54)	0.683	Placebo	20	17 (85.0)	-0.53 (0.14)	(-0.81, -0.24)	Week 10	Tezepelumab	15	10 (66.7)	-0.50 (0.17)	(-0.84, -0.15)	0.17 (0.23)	(-0.28, 0.62)	0.457	Placebo	20	15 (75.0)	-0.67 (0.15)	(-0.96, -0.38)																																																																		
Week 7	Tezepelumab	15	12 (80.0)	-0.54 (0.17)	(-0.88, -0.21)	0.00 (0.22)	(-0.44, 0.44)	0.991																																																																																																																										
	Placebo	20	16 (80.0)	-0.54 (0.14)	(-0.83, -0.26)				Week 8	Tezepelumab	15	13 (86.7)	-0.43 (0.17)	(-0.76, -0.10)	0.10 (0.22)	(-0.34, 0.54)	0.657	Placebo	20	16 (80.0)	-0.53 (0.14)	(-0.81, -0.24)	Week 9	Tezepelumab	15	10 (66.7)	-0.43 (0.17)	(-0.78, -0.09)	0.09 (0.23)	(-0.35, 0.54)	0.683	Placebo	20	17 (85.0)	-0.53 (0.14)	(-0.81, -0.24)	Week 10	Tezepelumab	15	10 (66.7)	-0.50 (0.17)	(-0.84, -0.15)	0.17 (0.23)	(-0.28, 0.62)	0.457	Placebo	20	15 (75.0)	-0.67 (0.15)	(-0.96, -0.38)																																																																																
Week 8	Tezepelumab	15	13 (86.7)	-0.43 (0.17)	(-0.76, -0.10)	0.10 (0.22)	(-0.34, 0.54)	0.657																																																																																																																										
	Placebo	20	16 (80.0)	-0.53 (0.14)	(-0.81, -0.24)				Week 9	Tezepelumab	15	10 (66.7)	-0.43 (0.17)	(-0.78, -0.09)	0.09 (0.23)	(-0.35, 0.54)	0.683	Placebo	20	17 (85.0)	-0.53 (0.14)	(-0.81, -0.24)	Week 10	Tezepelumab	15	10 (66.7)	-0.50 (0.17)	(-0.84, -0.15)	0.17 (0.23)	(-0.28, 0.62)	0.457	Placebo	20	15 (75.0)	-0.67 (0.15)	(-0.96, -0.38)																																																																																														
Week 9	Tezepelumab	15	10 (66.7)	-0.43 (0.17)	(-0.78, -0.09)	0.09 (0.23)	(-0.35, 0.54)	0.683																																																																																																																										
	Placebo	20	17 (85.0)	-0.53 (0.14)	(-0.81, -0.24)				Week 10	Tezepelumab	15	10 (66.7)	-0.50 (0.17)	(-0.84, -0.15)	0.17 (0.23)	(-0.28, 0.62)	0.457	Placebo	20	15 (75.0)	-0.67 (0.15)	(-0.96, -0.38)																																																																																																												
Week 10	Tezepelumab	15	10 (66.7)	-0.50 (0.17)	(-0.84, -0.15)	0.17 (0.23)	(-0.28, 0.62)	0.457																																																																																																																										
	Placebo	20	15 (75.0)	-0.67 (0.15)	(-0.96, -0.38)																																																																																																																													

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table NT1WHC\_KLMC0: Change from baseline in ASD weekly cough score - MMRM results  
 DITTL - adolescents

Change from baseline in ASD weekly cough score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 11	Tezepelumab	15	12 (80.0)	-0.58 (0.17)	(-0.92, -0.24)	0.05 (0.23)	(-0.40, 0.49)	0.834
	Placebo	20	17 (85.0)	-0.62 (0.15)	(-0.91, -0.34)			
Week 12	Tezepelumab	15	12 (80.0)	-0.52 (0.17)	(-0.86, -0.18)	0.13 (0.23)	(-0.32, 0.58)	0.573
	Placebo	20	15 (75.0)	-0.65 (0.15)	(-0.94, -0.36)			
Week 13	Tezepelumab	15	9 (60.0)	-0.64 (0.18)	(-0.99, -0.28)	-0.04 (0.23)	(-0.50, 0.42)	0.871
	Placebo	20	15 (75.0)	-0.60 (0.15)	(-0.89, -0.30)			
Week 14	Tezepelumab	15	8 (53.3)	-0.67 (0.18)	(-1.03, -0.31)	-0.10 (0.24)	(-0.57, 0.37)	0.671
	Placebo	20	13 (65.0)	-0.57 (0.15)	(-0.87, -0.27)			
Week 15	Tezepelumab	15	10 (66.7)	-0.62 (0.18)	(-0.97, -0.26)	-0.06 (0.24)	(-0.52, 0.40)	0.802
	Placebo	20	15 (75.0)	-0.56 (0.15)	(-0.85, -0.26)			
Week 16	Tezepelumab	15	10 (66.7)	-0.75 (0.18)	(-1.11, -0.39)	-0.08 (0.24)	(-0.54, 0.39)	0.751
	Placebo	20	15 (75.0)	-0.68 (0.15)	(-0.97, -0.38)			
Week 17	Tezepelumab	15	9 (60.0)	-0.79 (0.18)	(-1.15, -0.42)	-0.24 (0.24)	(-0.71, 0.24)	0.328
	Placebo	20	13 (65.0)	-0.55 (0.15)	(-0.85, -0.25)			
Week 18	Tezepelumab	15	10 (66.7)	-0.77 (0.19)	(-1.14, -0.40)	-0.36 (0.24)	(-0.84, 0.11)	0.132
	Placebo	20	13 (65.0)	-0.40 (0.15)	(-0.70, -0.10)			
Week 19	Tezepelumab	15	10 (66.7)	-0.76 (0.19)	(-1.13, -0.39)	-0.27 (0.24)	(-0.75, 0.20)	0.258
	Placebo	20	15 (75.0)	-0.49 (0.15)	(-0.78, -0.19)			
Week 20	Tezepelumab	15	7 (46.7)	-0.94 (0.20)	(-1.32, -0.55)	-0.23 (0.25)	(-0.72, 0.25)	0.345
	Placebo	20	15 (75.0)	-0.70 (0.15)	(-1.00, -0.41)			

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WHC\_KLMC0: Change from baseline in ASD weekly cough score - MMRM results  
 DITTL - adolescents

Change from baseline in ASD weekly cough score				Repeated measures analysis																																																																																																																														
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference																																																																																																																												
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value																																																																																																																										
Week 21	Tezepelumab	15	8 (53.3)	-0.78 (0.20)	(-1.17, -0.39)	-0.03 (0.25)	(-0.52, 0.46)	0.915																																																																																																																										
	Placebo	20	14 (70.0)	-0.75 (0.15)	(-1.05, -0.45)				Week 22	Tezepelumab	15	8 (53.3)	-0.71 (0.20)	(-1.10, -0.32)	0.04 (0.25)	(-0.46, 0.53)	0.877	Placebo	20	13 (65.0)	-0.75 (0.15)	(-1.05, -0.45)	Week 23	Tezepelumab	15	9 (60.0)	-0.69 (0.20)	(-1.08, -0.30)	0.03 (0.25)	(-0.47, 0.52)	0.912	Placebo	20	14 (70.0)	-0.72 (0.15)	(-1.02, -0.41)	Week 24	Tezepelumab	15	10 (66.7)	-0.71 (0.20)	(-1.09, -0.32)	-0.00 (0.25)	(-0.50, 0.49)	0.987	Placebo	20	13 (65.0)	-0.70 (0.16)	(-1.01, -0.39)	Week 25	Tezepelumab	15	9 (60.0)	-0.80 (0.20)	(-1.19, -0.41)	-0.00 (0.25)	(-0.50, 0.50)	0.991	Placebo	20	12 (60.0)	-0.80 (0.16)	(-1.11, -0.49)	Week 26	Tezepelumab	15	8 (53.3)	-0.88 (0.20)	(-1.28, -0.48)	-0.06 (0.26)	(-0.57, 0.44)	0.809	Placebo	20	14 (70.0)	-0.82 (0.16)	(-1.12, -0.51)	Week 27	Tezepelumab	15	8 (53.3)	-0.90 (0.20)	(-1.30, -0.49)	-0.09 (0.26)	(-0.60, 0.42)	0.721	Placebo	20	13 (65.0)	-0.80 (0.16)	(-1.11, -0.49)	Week 28	Tezepelumab	15	8 (53.3)	-0.95 (0.21)	(-1.36, -0.55)	-0.18 (0.26)	(-0.69, 0.33)	0.488	Placebo	20	14 (70.0)	-0.77 (0.16)	(-1.08, -0.46)	Week 29	Tezepelumab	15	7 (46.7)	-0.87 (0.21)	(-1.29, -0.46)	-0.10 (0.26)	(-0.62, 0.41)	0.693	Placebo	20	13 (65.0)	-0.77 (0.16)	(-1.08, -0.46)	Week 30	Tezepelumab	15	8 (53.3)	-0.88 (0.21)	(-1.29, -0.46)	-0.15 (0.27)	(-0.67, 0.38)	0.588	Placebo
Week 22	Tezepelumab	15	8 (53.3)	-0.71 (0.20)	(-1.10, -0.32)	0.04 (0.25)	(-0.46, 0.53)	0.877																																																																																																																										
	Placebo	20	13 (65.0)	-0.75 (0.15)	(-1.05, -0.45)				Week 23	Tezepelumab	15	9 (60.0)	-0.69 (0.20)	(-1.08, -0.30)	0.03 (0.25)	(-0.47, 0.52)	0.912	Placebo	20	14 (70.0)	-0.72 (0.15)	(-1.02, -0.41)	Week 24	Tezepelumab	15	10 (66.7)	-0.71 (0.20)	(-1.09, -0.32)	-0.00 (0.25)	(-0.50, 0.49)	0.987	Placebo	20	13 (65.0)	-0.70 (0.16)	(-1.01, -0.39)	Week 25	Tezepelumab	15	9 (60.0)	-0.80 (0.20)	(-1.19, -0.41)	-0.00 (0.25)	(-0.50, 0.50)	0.991	Placebo	20	12 (60.0)	-0.80 (0.16)	(-1.11, -0.49)	Week 26	Tezepelumab	15	8 (53.3)	-0.88 (0.20)	(-1.28, -0.48)	-0.06 (0.26)	(-0.57, 0.44)	0.809	Placebo	20	14 (70.0)	-0.82 (0.16)	(-1.12, -0.51)	Week 27	Tezepelumab	15	8 (53.3)	-0.90 (0.20)	(-1.30, -0.49)	-0.09 (0.26)	(-0.60, 0.42)	0.721	Placebo	20	13 (65.0)	-0.80 (0.16)	(-1.11, -0.49)	Week 28	Tezepelumab	15	8 (53.3)	-0.95 (0.21)	(-1.36, -0.55)	-0.18 (0.26)	(-0.69, 0.33)	0.488	Placebo	20	14 (70.0)	-0.77 (0.16)	(-1.08, -0.46)	Week 29	Tezepelumab	15	7 (46.7)	-0.87 (0.21)	(-1.29, -0.46)	-0.10 (0.26)	(-0.62, 0.41)	0.693	Placebo	20	13 (65.0)	-0.77 (0.16)	(-1.08, -0.46)	Week 30	Tezepelumab	15	8 (53.3)	-0.88 (0.21)	(-1.29, -0.46)	-0.15 (0.27)	(-0.67, 0.38)	0.588	Placebo	20	8 (40.0)	-0.73 (0.17)	(-1.06, -0.40)										
Week 23	Tezepelumab	15	9 (60.0)	-0.69 (0.20)	(-1.08, -0.30)	0.03 (0.25)	(-0.47, 0.52)	0.912																																																																																																																										
	Placebo	20	14 (70.0)	-0.72 (0.15)	(-1.02, -0.41)				Week 24	Tezepelumab	15	10 (66.7)	-0.71 (0.20)	(-1.09, -0.32)	-0.00 (0.25)	(-0.50, 0.49)	0.987	Placebo	20	13 (65.0)	-0.70 (0.16)	(-1.01, -0.39)	Week 25	Tezepelumab	15	9 (60.0)	-0.80 (0.20)	(-1.19, -0.41)	-0.00 (0.25)	(-0.50, 0.50)	0.991	Placebo	20	12 (60.0)	-0.80 (0.16)	(-1.11, -0.49)	Week 26	Tezepelumab	15	8 (53.3)	-0.88 (0.20)	(-1.28, -0.48)	-0.06 (0.26)	(-0.57, 0.44)	0.809	Placebo	20	14 (70.0)	-0.82 (0.16)	(-1.12, -0.51)	Week 27	Tezepelumab	15	8 (53.3)	-0.90 (0.20)	(-1.30, -0.49)	-0.09 (0.26)	(-0.60, 0.42)	0.721	Placebo	20	13 (65.0)	-0.80 (0.16)	(-1.11, -0.49)	Week 28	Tezepelumab	15	8 (53.3)	-0.95 (0.21)	(-1.36, -0.55)	-0.18 (0.26)	(-0.69, 0.33)	0.488	Placebo	20	14 (70.0)	-0.77 (0.16)	(-1.08, -0.46)	Week 29	Tezepelumab	15	7 (46.7)	-0.87 (0.21)	(-1.29, -0.46)	-0.10 (0.26)	(-0.62, 0.41)	0.693	Placebo	20	13 (65.0)	-0.77 (0.16)	(-1.08, -0.46)	Week 30	Tezepelumab	15	8 (53.3)	-0.88 (0.21)	(-1.29, -0.46)	-0.15 (0.27)	(-0.67, 0.38)	0.588	Placebo	20	8 (40.0)	-0.73 (0.17)	(-1.06, -0.40)																								
Week 24	Tezepelumab	15	10 (66.7)	-0.71 (0.20)	(-1.09, -0.32)	-0.00 (0.25)	(-0.50, 0.49)	0.987																																																																																																																										
	Placebo	20	13 (65.0)	-0.70 (0.16)	(-1.01, -0.39)				Week 25	Tezepelumab	15	9 (60.0)	-0.80 (0.20)	(-1.19, -0.41)	-0.00 (0.25)	(-0.50, 0.50)	0.991	Placebo	20	12 (60.0)	-0.80 (0.16)	(-1.11, -0.49)	Week 26	Tezepelumab	15	8 (53.3)	-0.88 (0.20)	(-1.28, -0.48)	-0.06 (0.26)	(-0.57, 0.44)	0.809	Placebo	20	14 (70.0)	-0.82 (0.16)	(-1.12, -0.51)	Week 27	Tezepelumab	15	8 (53.3)	-0.90 (0.20)	(-1.30, -0.49)	-0.09 (0.26)	(-0.60, 0.42)	0.721	Placebo	20	13 (65.0)	-0.80 (0.16)	(-1.11, -0.49)	Week 28	Tezepelumab	15	8 (53.3)	-0.95 (0.21)	(-1.36, -0.55)	-0.18 (0.26)	(-0.69, 0.33)	0.488	Placebo	20	14 (70.0)	-0.77 (0.16)	(-1.08, -0.46)	Week 29	Tezepelumab	15	7 (46.7)	-0.87 (0.21)	(-1.29, -0.46)	-0.10 (0.26)	(-0.62, 0.41)	0.693	Placebo	20	13 (65.0)	-0.77 (0.16)	(-1.08, -0.46)	Week 30	Tezepelumab	15	8 (53.3)	-0.88 (0.21)	(-1.29, -0.46)	-0.15 (0.27)	(-0.67, 0.38)	0.588	Placebo	20	8 (40.0)	-0.73 (0.17)	(-1.06, -0.40)																																						
Week 25	Tezepelumab	15	9 (60.0)	-0.80 (0.20)	(-1.19, -0.41)	-0.00 (0.25)	(-0.50, 0.50)	0.991																																																																																																																										
	Placebo	20	12 (60.0)	-0.80 (0.16)	(-1.11, -0.49)				Week 26	Tezepelumab	15	8 (53.3)	-0.88 (0.20)	(-1.28, -0.48)	-0.06 (0.26)	(-0.57, 0.44)	0.809	Placebo	20	14 (70.0)	-0.82 (0.16)	(-1.12, -0.51)	Week 27	Tezepelumab	15	8 (53.3)	-0.90 (0.20)	(-1.30, -0.49)	-0.09 (0.26)	(-0.60, 0.42)	0.721	Placebo	20	13 (65.0)	-0.80 (0.16)	(-1.11, -0.49)	Week 28	Tezepelumab	15	8 (53.3)	-0.95 (0.21)	(-1.36, -0.55)	-0.18 (0.26)	(-0.69, 0.33)	0.488	Placebo	20	14 (70.0)	-0.77 (0.16)	(-1.08, -0.46)	Week 29	Tezepelumab	15	7 (46.7)	-0.87 (0.21)	(-1.29, -0.46)	-0.10 (0.26)	(-0.62, 0.41)	0.693	Placebo	20	13 (65.0)	-0.77 (0.16)	(-1.08, -0.46)	Week 30	Tezepelumab	15	8 (53.3)	-0.88 (0.21)	(-1.29, -0.46)	-0.15 (0.27)	(-0.67, 0.38)	0.588	Placebo	20	8 (40.0)	-0.73 (0.17)	(-1.06, -0.40)																																																				
Week 26	Tezepelumab	15	8 (53.3)	-0.88 (0.20)	(-1.28, -0.48)	-0.06 (0.26)	(-0.57, 0.44)	0.809																																																																																																																										
	Placebo	20	14 (70.0)	-0.82 (0.16)	(-1.12, -0.51)				Week 27	Tezepelumab	15	8 (53.3)	-0.90 (0.20)	(-1.30, -0.49)	-0.09 (0.26)	(-0.60, 0.42)	0.721	Placebo	20	13 (65.0)	-0.80 (0.16)	(-1.11, -0.49)	Week 28	Tezepelumab	15	8 (53.3)	-0.95 (0.21)	(-1.36, -0.55)	-0.18 (0.26)	(-0.69, 0.33)	0.488	Placebo	20	14 (70.0)	-0.77 (0.16)	(-1.08, -0.46)	Week 29	Tezepelumab	15	7 (46.7)	-0.87 (0.21)	(-1.29, -0.46)	-0.10 (0.26)	(-0.62, 0.41)	0.693	Placebo	20	13 (65.0)	-0.77 (0.16)	(-1.08, -0.46)	Week 30	Tezepelumab	15	8 (53.3)	-0.88 (0.21)	(-1.29, -0.46)	-0.15 (0.27)	(-0.67, 0.38)	0.588	Placebo	20	8 (40.0)	-0.73 (0.17)	(-1.06, -0.40)																																																																		
Week 27	Tezepelumab	15	8 (53.3)	-0.90 (0.20)	(-1.30, -0.49)	-0.09 (0.26)	(-0.60, 0.42)	0.721																																																																																																																										
	Placebo	20	13 (65.0)	-0.80 (0.16)	(-1.11, -0.49)				Week 28	Tezepelumab	15	8 (53.3)	-0.95 (0.21)	(-1.36, -0.55)	-0.18 (0.26)	(-0.69, 0.33)	0.488	Placebo	20	14 (70.0)	-0.77 (0.16)	(-1.08, -0.46)	Week 29	Tezepelumab	15	7 (46.7)	-0.87 (0.21)	(-1.29, -0.46)	-0.10 (0.26)	(-0.62, 0.41)	0.693	Placebo	20	13 (65.0)	-0.77 (0.16)	(-1.08, -0.46)	Week 30	Tezepelumab	15	8 (53.3)	-0.88 (0.21)	(-1.29, -0.46)	-0.15 (0.27)	(-0.67, 0.38)	0.588	Placebo	20	8 (40.0)	-0.73 (0.17)	(-1.06, -0.40)																																																																																
Week 28	Tezepelumab	15	8 (53.3)	-0.95 (0.21)	(-1.36, -0.55)	-0.18 (0.26)	(-0.69, 0.33)	0.488																																																																																																																										
	Placebo	20	14 (70.0)	-0.77 (0.16)	(-1.08, -0.46)				Week 29	Tezepelumab	15	7 (46.7)	-0.87 (0.21)	(-1.29, -0.46)	-0.10 (0.26)	(-0.62, 0.41)	0.693	Placebo	20	13 (65.0)	-0.77 (0.16)	(-1.08, -0.46)	Week 30	Tezepelumab	15	8 (53.3)	-0.88 (0.21)	(-1.29, -0.46)	-0.15 (0.27)	(-0.67, 0.38)	0.588	Placebo	20	8 (40.0)	-0.73 (0.17)	(-1.06, -0.40)																																																																																														
Week 29	Tezepelumab	15	7 (46.7)	-0.87 (0.21)	(-1.29, -0.46)	-0.10 (0.26)	(-0.62, 0.41)	0.693																																																																																																																										
	Placebo	20	13 (65.0)	-0.77 (0.16)	(-1.08, -0.46)				Week 30	Tezepelumab	15	8 (53.3)	-0.88 (0.21)	(-1.29, -0.46)	-0.15 (0.27)	(-0.67, 0.38)	0.588	Placebo	20	8 (40.0)	-0.73 (0.17)	(-1.06, -0.40)																																																																																																												
Week 30	Tezepelumab	15	8 (53.3)	-0.88 (0.21)	(-1.29, -0.46)	-0.15 (0.27)	(-0.67, 0.38)	0.588																																																																																																																										
	Placebo	20	8 (40.0)	-0.73 (0.17)	(-1.06, -0.40)																																																																																																																													

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WHC\_KLMC0: Change from baseline in ASD weekly cough score - MMRM results  
 DITTL - adolescents

Change from baseline in ASD weekly cough score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 31	Tezepelumab	15	7 (46.7)	-0.98 (0.21)	(-1.39, -0.56)	-0.16 (0.27)	(-0.68, 0.37)	0.558
	Placebo	20	12 (60.0)	-0.82 (0.16)	(-1.14, -0.51)			
Week 32	Tezepelumab	15	8 (53.3)	-0.91 (0.21)	(-1.32, -0.50)	-0.05 (0.26)	(-0.57, 0.47)	0.843
	Placebo	20	11 (55.0)	-0.85 (0.16)	(-1.17, -0.54)			
Week 33	Tezepelumab	15	8 (53.3)	-0.94 (0.21)	(-1.35, -0.53)	-0.14 (0.26)	(-0.66, 0.37)	0.583
	Placebo	20	13 (65.0)	-0.80 (0.16)	(-1.11, -0.48)			
Week 34	Tezepelumab	15	8 (53.3)	-0.96 (0.21)	(-1.38, -0.55)	-0.14 (0.27)	(-0.67, 0.38)	0.592
	Placebo	20	10 (50.0)	-0.82 (0.16)	(-1.14, -0.50)			
Week 35	Tezepelumab	15	8 (53.3)	-0.81 (0.21)	(-1.23, -0.39)	0.04 (0.27)	(-0.50, 0.57)	0.895
	Placebo	20	10 (50.0)	-0.84 (0.17)	(-1.17, -0.52)			
Week 36	Tezepelumab	15	8 (53.3)	-0.92 (0.21)	(-1.34, -0.50)	-0.04 (0.27)	(-0.57, 0.49)	0.882
	Placebo	20	11 (55.0)	-0.88 (0.17)	(-1.21, -0.55)			
Week 37	Tezepelumab	15	8 (53.3)	-0.88 (0.21)	(-1.30, -0.46)	-0.03 (0.27)	(-0.57, 0.50)	0.906
	Placebo	20	11 (55.0)	-0.85 (0.17)	(-1.18, -0.52)			
Week 38	Tezepelumab	15	7 (46.7)	-0.93 (0.21)	(-1.35, -0.50)	-0.24 (0.27)	(-0.78, 0.29)	0.371
	Placebo	20	12 (60.0)	-0.68 (0.17)	(-1.01, -0.35)			
Week 39	Tezepelumab	15	8 (53.3)	-0.90 (0.21)	(-1.31, -0.48)	-0.08 (0.27)	(-0.61, 0.46)	0.776
	Placebo	20	11 (55.0)	-0.82 (0.17)	(-1.15, -0.49)			
Week 40	Tezepelumab	15	8 (53.3)	-0.87 (0.21)	(-1.29, -0.46)	-0.05 (0.27)	(-0.58, 0.49)	0.864
	Placebo	20	10 (50.0)	-0.83 (0.17)	(-1.16, -0.49)			

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WHC\_KLMC0: Change from baseline in ASD weekly cough score - MMRM results  
 DITTL - adolescents

Change from baseline in ASD weekly cough score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 41	Tezepelumab	15	8 (53.3)	-0.68 (0.21)	(-1.10, -0.27)	0.14 (0.27)	(-0.40, 0.68)	0.605
	Placebo	20	9 (45.0)	-0.83 (0.17)	(-1.16, -0.49)			
Week 42	Tezepelumab	15	8 (53.3)	-0.78 (0.21)	(-1.20, -0.36)	0.04 (0.27)	(-0.50, 0.57)	0.889
	Placebo	20	10 (50.0)	-0.82 (0.17)	(-1.15, -0.48)			
Week 43	Tezepelumab	15	8 (53.3)	-0.85 (0.21)	(-1.27, -0.43)	-0.06 (0.27)	(-0.60, 0.48)	0.825
	Placebo	20	11 (55.0)	-0.79 (0.17)	(-1.12, -0.46)			
Week 44	Tezepelumab	15	7 (46.7)	-0.94 (0.22)	(-1.38, -0.51)	-0.11 (0.27)	(-0.65, 0.43)	0.688
	Placebo	20	11 (55.0)	-0.83 (0.17)	(-1.16, -0.51)			
Week 45	Tezepelumab	15	7 (46.7)	-1.05 (0.22)	(-1.49, -0.62)	-0.17 (0.28)	(-0.72, 0.37)	0.533
	Placebo	20	11 (55.0)	-0.88 (0.17)	(-1.21, -0.55)			
Week 46	Tezepelumab	15	7 (46.7)	-0.99 (0.22)	(-1.42, -0.55)	-0.10 (0.28)	(-0.65, 0.45)	0.716
	Placebo	20	9 (45.0)	-0.89 (0.17)	(-1.22, -0.55)			
Week 47	Tezepelumab	15	6 (40.0)	-1.00 (0.22)	(-1.44, -0.56)	-0.01 (0.28)	(-0.57, 0.55)	0.967
	Placebo	20	10 (50.0)	-0.99 (0.17)	(-1.33, -0.65)			
Week 48	Tezepelumab	15	5 (33.3)	-0.94 (0.23)	(-1.39, -0.49)	0.07 (0.29)	(-0.49, 0.64)	0.793
	Placebo	20	10 (50.0)	-1.01 (0.17)	(-1.35, -0.67)			
Week 49	Tezepelumab	15	7 (46.7)	-1.00 (0.22)	(-1.43, -0.56)	-0.15 (0.28)	(-0.70, 0.40)	0.595
	Placebo	20	10 (50.0)	-0.85 (0.17)	(-1.19, -0.51)			
Week 50	Tezepelumab	15	6 (40.0)	-1.00 (0.22)	(-1.44, -0.56)	-0.08 (0.28)	(-0.64, 0.47)	0.765
	Placebo	20	10 (50.0)	-0.92 (0.17)	(-1.26, -0.58)			

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WHC\_KLMC0: Change from baseline in ASD weekly cough score - MMRM results  
 DITTL - adolescents

Change from baseline in ASD weekly cough score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 51	Tezepelumab	15	7 (46.7)	-1.05 (0.22)	(-1.48, -0.61)	-0.23 (0.28)	(-0.78, 0.32)	0.414
	Placebo	20	12 (60.0)	-0.82 (0.17)	(-1.15, -0.49)			
Week 52	Tezepelumab	15	8 (53.3)	-0.99 (0.22)	(-1.42, -0.56)	-0.05 (0.28)	(-0.60, 0.50)	0.850
	Placebo	20	11 (55.0)	-0.94 (0.17)	(-1.27, -0.60)			

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WEC\_KLMH0: Course of ASD weekly chest tightness score  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly chest tightness score	Baseline	Tezepelumab	15	15 (100.0)	1.37 (0.84)	0.0	0.86	1.67	1.93	2.9	
		Placebo	20	20 (100.0)	1.39 (1.01)	0.0	0.71	1.14	2.00	3.4	
	Week 1	Tezepelumab	15	14 (93.3)	1.10 (0.72)	0.0	0.50	1.04	1.60	2.1	
		Placebo	20	20 (100.0)	1.28 (1.06)	0.0	0.52	1.07	2.00	3.6	
	Week 2	Tezepelumab	15	14 (93.3)	1.08 (0.79)	0.0	0.25	1.04	2.00	2.4	
		Placebo	20	19 (95.0)	1.09 (1.01)	0.0	0.07	1.00	2.00	3.2	
	Week 3	Tezepelumab	15	14 (93.3)	1.05 (0.79)	0.0	0.36	1.00	2.00	2.3	
		Placebo	20	17 (85.0)	0.77 (0.90)	0.0	0.00	0.43	1.50	2.8	
	Week 4	Tezepelumab	15	12 (80.0)	0.89 (0.86)	0.0	0.11	0.67	1.80	2.1	
		Placebo	20	17 (85.0)	0.70 (0.76)	0.0	0.00	0.33	1.50	2.0	
	Week 5	Tezepelumab	15	12 (80.0)	0.92 (0.90)	0.0	0.07	0.92	1.67	2.4	
		Placebo	20	16 (80.0)	0.74 (0.65)	0.0	0.00	0.88	1.11	2.0	
	Week 6	Tezepelumab	15	11 (73.3)	0.81 (0.83)	0.0	0.00	0.64	1.83	2.0	
		Placebo	20	16 (80.0)	0.66 (0.64)	0.0	0.00	0.57	1.14	2.0	
	Week 7	Tezepelumab	15	12 (80.0)	0.90 (0.77)	0.0	0.11	0.85	1.60	2.0	
		Placebo	20	16 (80.0)	0.82 (0.74)	0.0	0.00	1.00	1.25	2.3	
	Week 8	Tezepelumab	15	13 (86.7)	0.85 (0.78)	0.0	0.10	1.00	1.13	2.2	
		Placebo	20	16 (80.0)	0.88 (0.78)	0.0	0.00	0.96	1.36	2.5	
	Week 9	Tezepelumab	15	10 (66.7)	0.84 (0.83)	0.0	0.00	0.81	1.75	2.0	
		Placebo	20	17 (85.0)	0.90 (0.79)	0.0	0.00	1.00	1.29	2.6	
	Week 10	Tezepelumab	15	10 (66.7)	0.75 (0.82)	0.0	0.00	0.40	1.36	2.0	
		Placebo	20	15 (75.0)	0.53 (0.54)	0.0	0.00	0.50	1.00	1.3	
	Week 11	Tezepelumab	15	12 (80.0)	0.74 (0.80)	0.0	0.00	0.54	1.40	2.1	
		Placebo	20	17 (85.0)	0.64 (0.71)	0.0	0.00	0.36	1.00	2.5	
	Week 12	Tezepelumab	15	12 (80.0)	0.75 (0.74)	0.0	0.00	0.63	1.46	2.0	
		Placebo	20	15 (75.0)	0.74 (0.71)	0.0	0.00	1.00	1.00	2.4	
	Week 13	Tezepelumab	15	9 (60.0)	0.62 (0.76)	0.0	0.00	0.08	1.14	2.0	
		Placebo	20	15 (75.0)	0.77 (0.83)	0.0	0.00	1.00	1.14	3.0	
	Week 14	Tezepelumab	15	8 (53.3)	0.72 (0.77)	0.0	0.00	0.61	1.29	2.0	
		Placebo	20	13 (65.0)	0.55 (0.50)	0.0	0.00	0.57	1.00	1.3	
	Week 15	Tezepelumab	15	10 (66.7)	0.67 (0.75)	0.0	0.00	0.50	1.10	2.0	
		Placebo	20	15 (75.0)	0.75 (0.79)	0.0	0.00	0.86	1.00	2.9	
Week 16	Tezepelumab	15	10 (66.7)	0.65 (0.71)	0.0	0.07	0.39	1.00	2.0		
	Placebo	20	15 (75.0)	0.71 (0.75)	0.0	0.00	0.83	1.00	2.8		
Week 17	Tezepelumab	15	9 (60.0)	0.57 (0.74)	0.0	0.00	0.00	1.00	2.0		
	Placebo	20	13 (65.0)	0.63 (0.56)	0.0	0.00	0.50	1.00	1.8		

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022

Table NT1WEC\_KLMH0: Course of ASD weekly chest tightness score  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly chest tightness score	Week 18	Tezepelumab	15	10 (66.7)	0.63 (0.68)	0.0	0.08	0.45	1.00	2.0	
		Placebo	20	13 (65.0)	0.77 (0.99)	0.0	0.00	0.79	1.00	3.6	
	Week 19	Tezepelumab	15	10 (66.7)	0.57 (0.67)	0.0	0.00	0.33	1.00	2.0	
		Placebo	20	15 (75.0)	0.74 (0.89)	0.0	0.00	0.75	1.00	3.4	
	Week 20	Tezepelumab	15	7 (46.7)	0.59 (0.73)	0.0	0.00	0.40	1.00	2.0	
		Placebo	20	15 (75.0)	0.74 (0.91)	0.0	0.00	0.50	1.00	3.4	
	Week 21	Tezepelumab	15	8 (53.3)	0.61 (0.73)	0.0	0.00	0.33	1.11	2.0	
		Placebo	20	14 (70.0)	0.69 (0.89)	0.0	0.00	0.48	1.00	3.3	
	Week 22	Tezepelumab	15	8 (53.3)	0.43 (0.73)	0.0	0.00	0.00	0.71	2.0	
		Placebo	20	13 (65.0)	0.81 (0.91)	0.0	0.00	0.70	1.07	3.3	
	Week 23	Tezepelumab	15	9 (60.0)	0.51 (0.76)	0.0	0.00	0.00	1.00	2.0	
		Placebo	20	14 (70.0)	0.89 (1.17)	0.0	0.00	0.54	1.36	4.0	
	Week 24	Tezepelumab	15	10 (66.7)	0.53 (0.68)	0.0	0.00	0.15	1.00	1.9	
		Placebo	20	13 (65.0)	0.75 (0.95)	0.0	0.00	0.50	1.00	3.4	
	Week 25	Tezepelumab	15	9 (60.0)	0.48 (0.61)	0.0	0.00	0.00	0.90	1.6	
		Placebo	20	12 (60.0)	0.62 (0.57)	0.0	0.11	0.56	0.96	1.8	
	Week 26	Tezepelumab	15	8 (53.3)	0.36 (0.48)	0.0	0.00	0.08	0.79	1.1	
		Placebo	20	14 (70.0)	0.50 (0.53)	0.0	0.00	0.31	0.92	1.6	
	Week 27	Tezepelumab	15	8 (53.3)	0.38 (0.52)	0.0	0.00	0.00	1.00	1.0	
		Placebo	20	13 (65.0)	0.67 (0.55)	0.0	0.21	0.60	1.00	1.6	
	Week 28	Tezepelumab	15	8 (53.3)	0.33 (0.47)	0.0	0.00	0.00	0.80	1.0	
		Placebo	20	14 (70.0)	0.77 (0.83)	0.0	0.00	0.77	1.07	3.0	
	Week 29	Tezepelumab	15	7 (46.7)	0.42 (0.47)	0.0	0.00	0.14	1.00	1.0	
		Placebo	20	13 (65.0)	0.86 (0.88)	0.0	0.13	0.63	1.00	2.8	
	Week 30	Tezepelumab	15	8 (53.3)	0.45 (0.59)	0.0	0.00	0.08	1.00	1.4	
		Placebo	20	8 (40.0)	0.68 (0.61)	0.0	0.14	0.62	1.13	1.6	
	Week 31	Tezepelumab	15	7 (46.7)	0.37 (0.49)	0.0	0.00	0.00	1.00	1.1	
		Placebo	20	12 (60.0)	0.50 (0.56)	0.0	0.06	0.31	0.83	1.9	
	Week 32	Tezepelumab	15	8 (53.3)	0.39 (0.53)	0.0	0.00	0.00	1.00	1.1	
		Placebo	20	11 (55.0)	0.63 (0.70)	0.0	0.00	0.50	1.00	2.1	
	Week 33	Tezepelumab	15	8 (53.3)	0.51 (0.60)	0.0	0.00	0.30	1.00	1.5	
		Placebo	20	13 (65.0)	0.47 (0.55)	0.0	0.00	0.14	0.79	1.8	
	Week 34	Tezepelumab	15	8 (53.3)	0.44 (0.54)	0.0	0.00	0.15	1.00	1.3	
		Placebo	20	10 (50.0)	0.71 (0.88)	0.0	0.00	0.27	1.00	2.4	
	Week 35	Tezepelumab	15	8 (53.3)	0.50 (0.55)	0.0	0.00	0.33	1.05	1.3	
		Placebo	20	10 (50.0)	0.40 (0.59)	0.0	0.00	0.08	0.93	1.7	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022

Table NT1WEC\_KLMH0: Course of ASD weekly chest tightness score  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly chest tightness score	Week 36	Tezepelumab	15	8 (53.3)	0.45 (0.51)	0.0	0.00	0.25	1.00	1.1	
		Placebo	20	11 (55.0)	0.48 (0.54)	0.0	0.00	0.17	1.00	1.5	
	Week 37	Tezepelumab	15	8 (53.3)	0.46 (0.54)	0.0	0.00	0.20	1.04	1.2	
		Placebo	20	11 (55.0)	0.48 (0.47)	0.0	0.00	0.42	1.00	1.3	
	Week 38	Tezepelumab	15	7 (46.7)	0.48 (0.56)	0.0	0.00	0.17	1.00	1.2	
		Placebo	20	12 (60.0)	0.58 (0.52)	0.0	0.07	0.56	1.00	1.5	
	Week 39	Tezepelumab	15	8 (53.3)	0.45 (0.54)	0.0	0.00	0.19	1.00	1.3	
		Placebo	20	11 (55.0)	0.55 (0.52)	0.0	0.00	0.50	1.00	1.6	
	Week 40	Tezepelumab	15	8 (53.3)	0.40 (0.56)	0.0	0.00	0.00	1.04	1.2	
		Placebo	20	10 (50.0)	0.64 (0.54)	0.0	0.00	0.75	1.00	1.5	
	Week 41	Tezepelumab	15	8 (53.3)	0.52 (0.59)	0.0	0.00	0.38	0.90	1.6	
		Placebo	20	9 (45.0)	0.67 (0.65)	0.0	0.14	0.75	1.00	1.9	
	Week 42	Tezepelumab	15	8 (53.3)	0.49 (0.66)	0.0	0.00	0.10	1.04	1.7	
		Placebo	20	10 (50.0)	0.78 (0.97)	0.0	0.00	0.54	1.10	3.0	
	Week 43	Tezepelumab	15	8 (53.3)	0.43 (0.60)	0.0	0.00	0.00	1.00	1.4	
		Placebo	20	11 (55.0)	0.67 (0.74)	0.0	0.00	0.38	1.33	1.9	
	Week 44	Tezepelumab	15	7 (46.7)	0.48 (0.60)	0.0	0.00	0.00	1.08	1.3	
		Placebo	20	11 (55.0)	0.77 (0.76)	0.0	0.00	0.80	1.13	2.4	
	Week 45	Tezepelumab	15	7 (46.7)	0.40 (0.50)	0.0	0.00	0.00	1.00	1.0	
		Placebo	20	11 (55.0)	0.83 (0.79)	0.0	0.00	1.00	1.75	2.0	
	Week 46	Tezepelumab	15	7 (46.7)	0.60 (0.56)	0.0	0.00	1.00	1.10	1.1	
		Placebo	20	9 (45.0)	0.89 (0.66)	0.0	0.50	1.00	1.00	2.0	
	Week 47	Tezepelumab	15	6 (40.0)	0.51 (0.56)	0.0	0.00	0.50	1.00	1.1	
		Placebo	20	10 (50.0)	0.68 (0.81)	0.0	0.00	0.48	1.00	2.2	
	Week 48	Tezepelumab	15	5 (33.3)	0.52 (0.74)	0.0	0.00	0.00	1.00	1.6	
		Placebo	20	10 (50.0)	0.52 (0.74)	0.0	0.00	0.13	0.80	2.2	
	Week 49	Tezepelumab	15	7 (46.7)	0.44 (0.55)	0.0	0.00	0.00	1.00	1.1	
		Placebo	20	10 (50.0)	0.60 (0.66)	0.0	0.00	0.34	1.00	1.8	
	Week 50	Tezepelumab	15	6 (40.0)	0.61 (0.69)	0.0	0.00	0.50	1.17	1.5	
		Placebo	20	10 (50.0)	0.69 (0.83)	0.0	0.00	0.35	1.10	2.2	
	Week 51	Tezepelumab	15	7 (46.7)	0.50 (0.64)	0.0	0.00	0.00	1.10	1.4	
		Placebo	20	12 (60.0)	0.80 (0.75)	0.0	0.00	0.80	1.47	2.1	
	Week 52	Tezepelumab	15	8 (53.3)	0.43 (0.60)	0.0	0.00	0.00	1.04	1.4	
		Placebo	20	11 (55.0)	0.56 (0.68)	0.0	0.00	0.38	1.10	2.0	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022



Table NT1WEC\_KLMH0: Course of ASD weekly chest tightness score  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly chest tightness score	Week 1	Tezepelumab	15	14 (93.3)	-0.25 (0.37)	-1.0	-0.36	-0.11	0.00	0.2	-0.40 [-1.09, 0.29]
		Placebo	20	20 (100.0)	-0.10 (0.35)	-0.7	-0.32	-0.09	0.11	0.8	
	Week 2	Tezepelumab	15	14 (93.3)	-0.27 (0.47)	-1.0	-0.61	-0.15	0.07	0.5	0.06 [-0.63, 0.75]
		Placebo	20	19 (95.0)	-0.31 (0.73)	-3.1	-0.21	-0.14	0.07	0.3	
	Week 3	Tezepelumab	15	14 (93.3)	-0.30 (0.51)	-1.1	-0.77	-0.07	0.07	0.5	0.27 [-0.44, 0.98]
		Placebo	20	17 (85.0)	-0.46 (0.65)	-2.4	-0.76	-0.17	0.00	0.1	
	Week 4	Tezepelumab	15	12 (80.0)	-0.46 (0.65)	-1.9	-0.71	-0.24	0.00	0.3	0.05 [-0.69, 0.78]
		Placebo	20	17 (85.0)	-0.49 (0.75)	-2.7	-0.71	-0.43	-0.07	0.9	
	Week 5	Tezepelumab	15	12 (80.0)	-0.42 (0.66)	-2.0	-0.70	-0.32	0.00	0.5	0.16 [-0.59, 0.91]
		Placebo	20	16 (80.0)	-0.55 (0.88)	-2.4	-1.00	-0.39	0.00	1.0	
	Week 6	Tezepelumab	15	11 (73.3)	-0.48 (0.61)	-1.7	-0.90	-0.14	0.00	0.0	0.25 [-0.52, 1.02]
		Placebo	20	16 (80.0)	-0.67 (0.86)	-2.9	-0.79	-0.57	-0.08	0.4	
	Week 7	Tezepelumab	15	12 (80.0)	-0.45 (0.62)	-1.9	-0.73	-0.20	-0.04	0.1	0.03 [-0.72, 0.78]
		Placebo	20	16 (80.0)	-0.47 (0.69)	-2.4	-0.80	-0.30	0.00	0.5	
	Week 8	Tezepelumab	15	13 (86.7)	-0.45 (0.55)	-1.9	-0.70	-0.43	-0.05	0.1	-0.12 [-0.86, 0.61]
		Placebo	20	16 (80.0)	-0.38 (0.63)	-2.1	-0.64	-0.25	0.00	0.5	
	Week 9	Tezepelumab	15	10 (66.7)	-0.39 (0.64)	-2.0	-0.23	-0.13	-0.07	0.0	0.07 [-0.71, 0.85]
		Placebo	20	17 (85.0)	-0.43 (0.70)	-2.2	-0.86	-0.43	0.00	0.8	
	Week 10	Tezepelumab	15	10 (66.7)	-0.48 (0.66)	-1.5	-1.00	-0.12	0.00	0.2	0.22 [-0.58, 1.02]
		Placebo	20	15 (75.0)	-0.64 (0.79)	-2.4	-1.14	-0.43	-0.07	0.6	
	Week 11	Tezepelumab	15	12 (80.0)	-0.53 (0.80)	-2.0	-0.96	-0.29	0.00	0.6	0.28 [-0.46, 1.03]
		Placebo	20	17 (85.0)	-0.78 (0.95)	-2.9	-1.14	-0.57	-0.07	0.7	
	Week 12	Tezepelumab	15	12 (80.0)	-0.51 (0.78)	-2.0	-0.84	-0.36	-0.04	0.5	0.20 [-0.56, 0.96]
		Placebo	20	15 (75.0)	-0.67 (0.76)	-2.4	-1.00	-0.50	-0.17	0.6	
	Week 13	Tezepelumab	15	9 (60.0)	-0.65 (0.81)	-2.0	-0.99	-0.14	-0.07	0.0	-0.02 [-0.85, 0.80]
		Placebo	20	15 (75.0)	-0.64 (0.82)	-2.4	-1.00	-0.71	-0.17	0.8	
	Week 14	Tezepelumab	15	8 (53.3)	-0.57 (0.80)	-1.9	-1.14	-0.16	-0.04	0.0	0.35 [-0.53, 1.24]
		Placebo	20	13 (65.0)	-0.91 (1.04)	-3.1	-1.14	-0.86	-0.17	0.5	
	Week 15	Tezepelumab	15	10 (66.7)	-0.65 (0.76)	-2.0	-1.07	-0.39	-0.07	0.1	-0.04 [-0.84, 0.76]
		Placebo	20	15 (75.0)	-0.61 (0.85)	-2.4	-1.00	-0.57	-0.07	0.9	
	Week 16	Tezepelumab	15	10 (66.7)	-0.69 (0.77)	-1.9	-1.23	-0.38	-0.07	0.1	-0.03 [-0.83, 0.77]
		Placebo	20	15 (75.0)	-0.66 (0.73)	-2.4	-0.93	-0.43	-0.08	0.1	
	Week 17	Tezepelumab	15	9 (60.0)	-0.70 (0.79)	-2.0	-1.07	-0.57	-0.07	0.0	-0.03 [-0.88, 0.82]
		Placebo	20	13 (65.0)	-0.68 (0.90)	-2.6	-1.07	-0.53	0.04	0.4	
	Week 18	Tezepelumab	15	10 (66.7)	-0.60 (0.83)	-1.9	-1.08	-0.29	0.00	0.4	-0.25 [-1.07, 0.58]
		Placebo	20	13 (65.0)	-0.41 (0.75)	-2.0	-0.86	-0.17	0.08	0.8	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022

Table NT1WEC\_KLMH0: Course of ASD weekly chest tightness score  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly chest tightness score	Week 19	Tezepelumab	15	10 (66.7)	-0.66 (0.76)	-2.0	-0.99	-0.43	0.00	0.0	-0.11 [-0.91, 0.69]
		Placebo	20	15 (75.0)	-0.56 (0.85)	-2.3	-1.07	-0.36	0.05	1.1	
	Week 20	Tezepelumab	15	7 (46.7)	-0.62 (0.68)	-1.9	-1.00	-0.46	-0.07	0.0	0.01 [-0.89, 0.90]
		Placebo	20	15 (75.0)	-0.63 (0.98)	-3.1	-1.14	-0.29	0.00	0.5	
	Week 21	Tezepelumab	15	8 (53.3)	-0.82 (0.83)	-2.0	-1.49	-0.82	-0.04	0.1	-0.06 [-0.93, 0.81]
		Placebo	20	14 (70.0)	-0.76 (1.20)	-3.3	-1.14	-0.15	0.00	0.4	
	Week 22	Tezepelumab	15	8 (53.3)	-0.77 (0.85)	-2.0	-1.49	-0.58	-0.04	0.0	0.00 [-0.88, 0.89]
		Placebo	20	13 (65.0)	-0.78 (1.19)	-3.4	-1.07	-0.36	-0.01	0.4	
	Week 23	Tezepelumab	15	9 (60.0)	-0.76 (0.81)	-2.0	-1.21	-0.46	-0.07	0.0	-0.22 [-1.06, 0.62]
		Placebo	20	14 (70.0)	-0.51 (1.25)	-3.4	-1.14	-0.12	0.08	1.2	
	Week 24	Tezepelumab	15	10 (66.7)	-0.70 (0.80)	-2.0	-1.21	-0.45	-0.07	0.1	-0.07 [-0.90, 0.75]
		Placebo	20	13 (65.0)	-0.63 (1.12)	-3.4	-1.14	-0.18	0.08	0.6	
	Week 25	Tezepelumab	15	9 (60.0)	-0.68 (0.78)	-2.0	-1.07	-0.43	-0.07	0.0	0.25 [-0.62, 1.12]
		Placebo	20	12 (60.0)	-0.93 (1.13)	-3.4	-1.83	-0.38	-0.13	0.1	
	Week 26	Tezepelumab	15	8 (53.3)	-0.84 (0.79)	-2.0	-1.44	-0.85	-0.07	0.0	-0.09 [-0.96, 0.78]
		Placebo	20	14 (70.0)	-0.76 (0.98)	-3.4	-1.14	-0.43	-0.07	0.2	
	Week 27	Tezepelumab	15	8 (53.3)	-0.83 (0.80)	-2.0	-1.49	-0.71	-0.11	0.0	-0.14 [-1.02, 0.74]
		Placebo	20	13 (65.0)	-0.70 (0.97)	-2.9	-1.14	-0.36	-0.07	0.6	
	Week 28	Tezepelumab	15	8 (53.3)	-0.98 (0.70)	-2.0	-1.49	-0.93	-0.49	-0.1	-0.31 [-1.18, 0.57]
		Placebo	20	14 (70.0)	-0.70 (1.02)	-3.4	-1.14	-0.50	0.04	0.5	
	Week 29	Tezepelumab	15	7 (46.7)	-0.95 (0.73)	-1.9	-1.86	-0.99	-0.14	-0.1	-0.29 [-1.21, 0.64]
		Placebo	20	13 (65.0)	-0.65 (1.20)	-3.3	-0.64	-0.17	0.08	0.5	
	Week 30	Tezepelumab	15	8 (53.3)	-0.86 (0.64)	-1.9	-1.24	-0.93	-0.29	-0.1	-0.68 [-1.69, 0.33]
		Placebo	20	8 (40.0)	-0.43 (0.62)	-1.6	-0.75	-0.17	-0.03	0.1	
	Week 31	Tezepelumab	15	7 (46.7)	-1.01 (0.74)	-2.0	-1.83	-1.00	-0.14	-0.1	-0.37 [-1.31, 0.57]
		Placebo	20	12 (60.0)	-0.66 (1.03)	-3.4	-0.96	-0.17	-0.01	0.2	
	Week 32	Tezepelumab	15	8 (53.3)	-0.92 (0.74)	-2.0	-1.49	-0.93	-0.24	-0.1	-0.15 [-1.06, 0.76]
		Placebo	20	11 (55.0)	-0.79 (1.03)	-3.4	-0.86	-0.50	-0.14	0.1	
	Week 33	Tezepelumab	15	8 (53.3)	-1.02 (0.66)	-2.0	-1.49	-0.93	-0.58	-0.1	-0.03 [-0.91, 0.85]
		Placebo	20	13 (65.0)	-0.99 (1.08)	-3.3	-1.88	-0.64	-0.17	0.2	
	Week 34	Tezepelumab	15	8 (53.3)	-1.09 (0.62)	-2.0	-1.51	-1.04	-0.72	-0.1	-0.36 [-1.30, 0.58]
		Placebo	20	10 (50.0)	-0.76 (1.08)	-3.3	-0.86	-0.40	-0.07	0.1	
	Week 35	Tezepelumab	15	8 (53.3)	-1.03 (0.57)	-2.0	-1.36	-0.93	-0.75	-0.1	-0.23 [-1.16, 0.71]
		Placebo	20	10 (50.0)	-0.83 (1.09)	-3.4	-1.14	-0.42	-0.07	0.1	
	Week 36	Tezepelumab	15	8 (53.3)	-1.08 (0.61)	-2.0	-1.49	-0.96	-0.80	-0.1	-0.97 [-1.93, -0.00]
		Placebo	20	11 (55.0)	-0.47 (0.64)	-1.9	-0.86	-0.17	0.07	0.1	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022

Table NT1WEC\_KLMH0: Course of ASD weekly chest tightness score  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly chest tightness score	Week 37	Tezepelumab	15	8 (53.3)	-1.07 (0.63)	-2.0	-1.56	-1.04	-0.61	-0.1	-0.41 [-1.33, 0.51]
		Placebo	20	11 (55.0)	-0.70 (1.04)	-3.3	-1.14	-0.30	0.07	0.1	
	Week 38	Tezepelumab	15	7 (46.7)	-1.14 (0.66)	-2.0	-1.90	-1.07	-0.63	-0.1	-0.84 [-1.82, 0.13]
		Placebo	20	12 (60.0)	-0.51 (0.79)	-2.2	-0.93	-0.08	0.04	0.2	
	Week 39	Tezepelumab	15	8 (53.3)	-1.08 (0.67)	-2.0	-1.66	-1.04	-0.53	-0.1	-0.48 [-1.41, 0.44]
		Placebo	20	11 (55.0)	-0.63 (1.07)	-3.1	-1.14	-0.21	0.07	0.6	
	Week 40	Tezepelumab	15	8 (53.3)	-1.03 (0.73)	-2.0	-1.66	-1.00	-0.40	-0.1	-0.35 [-1.29, 0.58]
		Placebo	20	10 (50.0)	-0.67 (1.20)	-3.4	-1.14	-0.34	0.04	0.9	
	Week 41	Tezepelumab	15	8 (53.3)	-1.01 (0.57)	-2.0	-1.22	-1.05	-0.68	-0.1	-0.33 [-1.29, 0.63]
		Placebo	20	9 (45.0)	-0.69 (1.20)	-3.3	-1.14	-0.17	0.07	0.5	
	Week 42	Tezepelumab	15	8 (53.3)	-1.04 (0.54)	-2.0	-1.30	-1.04	-0.74	-0.1	-0.40 [-1.34, 0.54]
		Placebo	20	10 (50.0)	-0.65 (1.18)	-3.4	-1.14	-0.25	0.08	0.5	
	Week 43	Tezepelumab	15	8 (53.3)	-1.10 (0.66)	-2.0	-1.66	-1.04	-0.64	-0.1	-0.29 [-1.21, 0.63]
		Placebo	20	11 (55.0)	-0.81 (1.20)	-3.3	-1.63	-0.51	-0.07	1.0	
	Week 44	Tezepelumab	15	7 (46.7)	-1.15 (0.61)	-2.0	-1.65	-1.07	-0.75	-0.1	-0.52 [-1.49, 0.44]
		Placebo	20	11 (55.0)	-0.62 (1.19)	-3.4	-1.14	-0.17	0.09	0.6	
	Week 45	Tezepelumab	15	7 (46.7)	-1.23 (0.63)	-2.0	-1.90	-1.07	-1.00	-0.1	-0.38 [-1.33, 0.58]
		Placebo	20	11 (55.0)	-0.85 (1.17)	-3.4	-1.70	-0.29	-0.13	0.7	
	Week 46	Tezepelumab	15	7 (46.7)	-1.03 (0.71)	-2.0	-1.90	-1.00	-0.33	-0.1	-0.41 [-1.41, 0.59]
		Placebo	20	9 (45.0)	-0.61 (1.21)	-3.4	-0.51	-0.29	0.07	0.7	
	Week 47	Tezepelumab	15	6 (40.0)	-1.08 (0.77)	-2.0	-1.90	-1.04	-0.35	-0.1	-0.24 [-1.26, 0.77]
		Placebo	20	10 (50.0)	-0.84 (1.08)	-3.4	-1.14	-0.45	-0.14	0.1	
	Week 48	Tezepelumab	15	5 (33.3)	-0.81 (0.85)	-2.0	-1.07	-1.00	-0.14	0.2	0.12 [-0.96, 1.19]
		Placebo	20	10 (50.0)	-0.93 (1.08)	-3.4	-1.14	-0.80	-0.17	0.5	
	Week 49	Tezepelumab	15	7 (46.7)	-1.05 (0.70)	-2.0	-1.90	-1.00	-0.36	-0.1	-0.09 [-1.05, 0.88]
		Placebo	20	10 (50.0)	-0.97 (1.00)	-3.4	-1.33	-0.74	-0.25	0.1	
	Week 50	Tezepelumab	15	6 (40.0)	-0.98 (0.83)	-2.0	-1.73	-1.04	-0.14	0.1	-0.10 [-1.12, 0.91]
		Placebo	20	10 (50.0)	-0.88 (1.06)	-3.4	-1.14	-0.53	-0.17	0.1	
	Week 51	Tezepelumab	15	7 (46.7)	-0.87 (0.83)	-2.0	-1.80	-1.00	-0.07	0.0	-0.15 [-1.08, 0.79]
		Placebo	20	12 (60.0)	-0.72 (1.07)	-3.4	-1.19	-0.38	-0.11	0.7	
	Week 52	Tezepelumab	15	8 (53.3)	-0.88 (0.76)	-2.0	-1.44	-0.93	-0.11	-0.1	-0.05 [-0.96, 0.86]
		Placebo	20	11 (55.0)	-0.83 (1.11)	-3.4	-1.63	-0.43	0.00	0.5	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022

Table NT1WEC\_KLMC0: Change from baseline in ASD weekly chest tightness score - MMRM results  
 DITTL - adolescents

Change from baseline in ASD weekly chest tightness score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 1	Tezepelumab	15	14 (93.3)	-0.25 (0.18)	(-0.61, 0.10)	-0.16 (0.23)	(-0.63, 0.30)	0.489
	Placebo	20	20 (100.0)	-0.09 (0.15)	(-0.39, 0.21)			
Week 2	Tezepelumab	15	14 (93.3)	-0.27 (0.18)	(-0.63, 0.08)	0.00 (0.24)	(-0.46, 0.47)	0.994
	Placebo	20	19 (95.0)	-0.28 (0.15)	(-0.58, 0.02)			
Week 3	Tezepelumab	15	14 (93.3)	-0.30 (0.18)	(-0.66, 0.05)	0.16 (0.24)	(-0.31, 0.63)	0.502
	Placebo	20	17 (85.0)	-0.46 (0.15)	(-0.77, -0.16)			
Week 4	Tezepelumab	15	12 (80.0)	-0.46 (0.18)	(-0.82, -0.10)	0.05 (0.24)	(-0.42, 0.52)	0.843
	Placebo	20	17 (85.0)	-0.51 (0.15)	(-0.81, -0.21)			
Week 5	Tezepelumab	15	12 (80.0)	-0.42 (0.18)	(-0.78, -0.06)	0.10 (0.24)	(-0.38, 0.57)	0.691
	Placebo	20	16 (80.0)	-0.51 (0.15)	(-0.82, -0.21)			
Week 6	Tezepelumab	15	11 (73.3)	-0.53 (0.18)	(-0.89, -0.17)	0.04 (0.24)	(-0.44, 0.51)	0.877
	Placebo	20	16 (80.0)	-0.57 (0.15)	(-0.87, -0.26)			
Week 7	Tezepelumab	15	12 (80.0)	-0.42 (0.18)	(-0.78, -0.06)	0.09 (0.24)	(-0.38, 0.56)	0.696
	Placebo	20	16 (80.0)	-0.51 (0.15)	(-0.82, -0.21)			
Week 8	Tezepelumab	15	13 (86.7)	-0.52 (0.18)	(-0.87, -0.16)	-0.09 (0.24)	(-0.56, 0.38)	0.700
	Placebo	20	16 (80.0)	-0.43 (0.15)	(-0.73, -0.12)			
Week 9	Tezepelumab	15	10 (66.7)	-0.43 (0.18)	(-0.79, -0.06)	0.09 (0.24)	(-0.38, 0.57)	0.693
	Placebo	20	17 (85.0)	-0.52 (0.15)	(-0.83, -0.21)			
Week 10	Tezepelumab	15	10 (66.7)	-0.48 (0.18)	(-0.85, -0.12)	0.20 (0.24)	(-0.27, 0.68)	0.401
	Placebo	20	15 (75.0)	-0.68 (0.16)	(-0.99, -0.38)			

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WEC\_KLMC0: Change from baseline in ASD weekly chest tightness score - MMRM results  
 DITTL - adolescents

Change from baseline in ASD weekly chest tightness score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 11	Tezepelumab	15	12 (80.0)	-0.60 (0.18)	(-0.96, -0.24)	0.06 (0.24)	(-0.41, 0.54)	0.801
	Placebo	20	17 (85.0)	-0.66 (0.16)	(-0.97, -0.35)			
Week 12	Tezepelumab	15	12 (80.0)	-0.59 (0.18)	(-0.95, -0.22)	0.05 (0.24)	(-0.43, 0.53)	0.828
	Placebo	20	15 (75.0)	-0.64 (0.16)	(-0.95, -0.33)			
Week 13	Tezepelumab	15	9 (60.0)	-0.63 (0.19)	(-1.00, -0.26)	-0.02 (0.25)	(-0.51, 0.46)	0.927
	Placebo	20	15 (75.0)	-0.61 (0.16)	(-0.92, -0.30)			
Week 14	Tezepelumab	15	8 (53.3)	-0.60 (0.19)	(-0.98, -0.22)	0.05 (0.25)	(-0.44, 0.55)	0.833
	Placebo	20	13 (65.0)	-0.65 (0.16)	(-0.97, -0.34)			
Week 15	Tezepelumab	15	10 (66.7)	-0.62 (0.19)	(-1.00, -0.25)	-0.01 (0.25)	(-0.50, 0.48)	0.968
	Placebo	20	15 (75.0)	-0.61 (0.16)	(-0.93, -0.30)			
Week 16	Tezepelumab	15	10 (66.7)	-0.62 (0.19)	(-0.99, -0.24)	0.03 (0.25)	(-0.46, 0.52)	0.910
	Placebo	20	15 (75.0)	-0.64 (0.16)	(-0.96, -0.33)			
Week 17	Tezepelumab	15	9 (60.0)	-0.67 (0.19)	(-1.05, -0.29)	-0.15 (0.25)	(-0.65, 0.34)	0.543
	Placebo	20	13 (65.0)	-0.52 (0.16)	(-0.84, -0.20)			
Week 18	Tezepelumab	15	10 (66.7)	-0.65 (0.20)	(-1.04, -0.27)	-0.15 (0.25)	(-0.65, 0.35)	0.565
	Placebo	20	13 (65.0)	-0.51 (0.16)	(-0.83, -0.19)			
Week 19	Tezepelumab	15	10 (66.7)	-0.71 (0.20)	(-1.10, -0.32)	-0.14 (0.25)	(-0.64, 0.36)	0.584
	Placebo	20	15 (75.0)	-0.57 (0.16)	(-0.89, -0.26)			
Week 20	Tezepelumab	15	7 (46.7)	-0.77 (0.20)	(-1.18, -0.37)	-0.19 (0.26)	(-0.70, 0.33)	0.472
	Placebo	20	15 (75.0)	-0.58 (0.16)	(-0.90, -0.27)			

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WEC\_KLMC0: Change from baseline in ASD weekly chest tightness score - MMRM results  
 DITTLL - adolescents

Change from baseline in ASD weekly chest tightness score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 21	Tezepelumab	15	8 (53.3)	-0.74 (0.21)	(-1.15, -0.34)	-0.16 (0.26)	(-0.67, 0.36)	0.549
	Placebo	20	14 (70.0)	-0.58 (0.16)	(-0.90, -0.27)			
Week 22	Tezepelumab	15	8 (53.3)	-0.74 (0.21)	(-1.15, -0.34)	-0.13 (0.26)	(-0.65, 0.40)	0.634
	Placebo	20	13 (65.0)	-0.62 (0.16)	(-0.94, -0.30)			
Week 23	Tezepelumab	15	9 (60.0)	-0.74 (0.21)	(-1.15, -0.33)	-0.24 (0.26)	(-0.76, 0.28)	0.366
	Placebo	20	14 (70.0)	-0.50 (0.16)	(-0.83, -0.18)			
Week 24	Tezepelumab	15	10 (66.7)	-0.76 (0.21)	(-1.17, -0.35)	-0.21 (0.26)	(-0.73, 0.32)	0.439
	Placebo	20	13 (65.0)	-0.55 (0.17)	(-0.88, -0.23)			
Week 25	Tezepelumab	15	9 (60.0)	-0.74 (0.21)	(-1.16, -0.33)	-0.08 (0.27)	(-0.60, 0.45)	0.777
	Placebo	20	12 (60.0)	-0.67 (0.17)	(-0.99, -0.34)			
Week 26	Tezepelumab	15	8 (53.3)	-0.83 (0.21)	(-1.25, -0.41)	-0.19 (0.27)	(-0.72, 0.34)	0.478
	Placebo	20	14 (70.0)	-0.64 (0.17)	(-0.97, -0.32)			
Week 27	Tezepelumab	15	8 (53.3)	-0.84 (0.21)	(-1.27, -0.42)	-0.25 (0.27)	(-0.79, 0.29)	0.359
	Placebo	20	13 (65.0)	-0.59 (0.17)	(-0.92, -0.26)			
Week 28	Tezepelumab	15	8 (53.3)	-0.93 (0.22)	(-1.35, -0.50)	-0.30 (0.27)	(-0.84, 0.24)	0.273
	Placebo	20	14 (70.0)	-0.63 (0.17)	(-0.96, -0.30)			
Week 29	Tezepelumab	15	7 (46.7)	-0.88 (0.22)	(-1.31, -0.45)	-0.23 (0.28)	(-0.78, 0.31)	0.402
	Placebo	20	13 (65.0)	-0.65 (0.17)	(-0.98, -0.32)			
Week 30	Tezepelumab	15	8 (53.3)	-0.79 (0.22)	(-1.23, -0.36)	-0.24 (0.28)	(-0.80, 0.31)	0.384
	Placebo	20	8 (40.0)	-0.55 (0.17)	(-0.89, -0.21)			

Note: DITTLL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WEC\_KLMC0: Change from baseline in ASD weekly chest tightness score - MMRM results  
 DITTL - adolescents

Change from baseline in ASD weekly chest tightness score				Repeated measures analysis																																																																																																																														
				Change from Baseline		Treatment Difference																																																																																																																												
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value																																																																																																																						
Week 31	Tezepelumab	15	7 (46.7)	-0.93 (0.22)	(-1.36, -0.49)	-0.28 (0.28)	(-0.83, 0.27)	0.320																																																																																																																										
	Placebo	20	12 (60.0)	-0.65 (0.17)	(-0.98, -0.31)				Week 32	Tezepelumab	15	8 (53.3)	-0.84 (0.22)	(-1.27, -0.41)	-0.06 (0.28)	(-0.61, 0.49)	0.833	Placebo	20	11 (55.0)	-0.78 (0.17)	(-1.12, -0.45)	Week 33	Tezepelumab	15	8 (53.3)	-0.90 (0.22)	(-1.34, -0.46)	-0.18 (0.28)	(-0.73, 0.37)	0.524	Placebo	20	13 (65.0)	-0.72 (0.17)	(-1.05, -0.39)	Week 34	Tezepelumab	15	8 (53.3)	-0.97 (0.22)	(-1.41, -0.53)	-0.26 (0.28)	(-0.81, 0.30)	0.362	Placebo	20	10 (50.0)	-0.71 (0.17)	(-1.05, -0.37)	Week 35	Tezepelumab	15	8 (53.3)	-0.91 (0.22)	(-1.35, -0.47)	-0.20 (0.28)	(-0.76, 0.36)	0.489	Placebo	20	10 (50.0)	-0.71 (0.17)	(-1.05, -0.37)	Week 36	Tezepelumab	15	8 (53.3)	-0.96 (0.23)	(-1.41, -0.51)	-0.24 (0.28)	(-0.80, 0.33)	0.406	Placebo	20	11 (55.0)	-0.72 (0.17)	(-1.07, -0.38)	Week 37	Tezepelumab	15	8 (53.3)	-0.95 (0.23)	(-1.40, -0.50)	-0.22 (0.29)	(-0.79, 0.34)	0.436	Placebo	20	11 (55.0)	-0.73 (0.17)	(-1.07, -0.38)	Week 38	Tezepelumab	15	7 (46.7)	-0.95 (0.23)	(-1.40, -0.50)	-0.37 (0.29)	(-0.93, 0.20)	0.200	Placebo	20	12 (60.0)	-0.58 (0.17)	(-0.92, -0.23)	Week 39	Tezepelumab	15	8 (53.3)	-0.95 (0.22)	(-1.40, -0.51)	-0.30 (0.29)	(-0.86, 0.27)	0.298	Placebo	20	11 (55.0)	-0.66 (0.18)	(-1.00, -0.31)	Week 40	Tezepelumab	15	8 (53.3)	-0.95 (0.22)	(-1.39, -0.51)	-0.32 (0.29)	(-0.89, 0.24)	0.258	Placebo
Week 32	Tezepelumab	15	8 (53.3)	-0.84 (0.22)	(-1.27, -0.41)	-0.06 (0.28)	(-0.61, 0.49)	0.833																																																																																																																										
	Placebo	20	11 (55.0)	-0.78 (0.17)	(-1.12, -0.45)				Week 33	Tezepelumab	15	8 (53.3)	-0.90 (0.22)	(-1.34, -0.46)	-0.18 (0.28)	(-0.73, 0.37)	0.524	Placebo	20	13 (65.0)	-0.72 (0.17)	(-1.05, -0.39)	Week 34	Tezepelumab	15	8 (53.3)	-0.97 (0.22)	(-1.41, -0.53)	-0.26 (0.28)	(-0.81, 0.30)	0.362	Placebo	20	10 (50.0)	-0.71 (0.17)	(-1.05, -0.37)	Week 35	Tezepelumab	15	8 (53.3)	-0.91 (0.22)	(-1.35, -0.47)	-0.20 (0.28)	(-0.76, 0.36)	0.489	Placebo	20	10 (50.0)	-0.71 (0.17)	(-1.05, -0.37)	Week 36	Tezepelumab	15	8 (53.3)	-0.96 (0.23)	(-1.41, -0.51)	-0.24 (0.28)	(-0.80, 0.33)	0.406	Placebo	20	11 (55.0)	-0.72 (0.17)	(-1.07, -0.38)	Week 37	Tezepelumab	15	8 (53.3)	-0.95 (0.23)	(-1.40, -0.50)	-0.22 (0.29)	(-0.79, 0.34)	0.436	Placebo	20	11 (55.0)	-0.73 (0.17)	(-1.07, -0.38)	Week 38	Tezepelumab	15	7 (46.7)	-0.95 (0.23)	(-1.40, -0.50)	-0.37 (0.29)	(-0.93, 0.20)	0.200	Placebo	20	12 (60.0)	-0.58 (0.17)	(-0.92, -0.23)	Week 39	Tezepelumab	15	8 (53.3)	-0.95 (0.22)	(-1.40, -0.51)	-0.30 (0.29)	(-0.86, 0.27)	0.298	Placebo	20	11 (55.0)	-0.66 (0.18)	(-1.00, -0.31)	Week 40	Tezepelumab	15	8 (53.3)	-0.95 (0.22)	(-1.39, -0.51)	-0.32 (0.29)	(-0.89, 0.24)	0.258	Placebo	20	10 (50.0)	-0.63 (0.18)	(-0.98, -0.28)										
Week 33	Tezepelumab	15	8 (53.3)	-0.90 (0.22)	(-1.34, -0.46)	-0.18 (0.28)	(-0.73, 0.37)	0.524																																																																																																																										
	Placebo	20	13 (65.0)	-0.72 (0.17)	(-1.05, -0.39)				Week 34	Tezepelumab	15	8 (53.3)	-0.97 (0.22)	(-1.41, -0.53)	-0.26 (0.28)	(-0.81, 0.30)	0.362	Placebo	20	10 (50.0)	-0.71 (0.17)	(-1.05, -0.37)	Week 35	Tezepelumab	15	8 (53.3)	-0.91 (0.22)	(-1.35, -0.47)	-0.20 (0.28)	(-0.76, 0.36)	0.489	Placebo	20	10 (50.0)	-0.71 (0.17)	(-1.05, -0.37)	Week 36	Tezepelumab	15	8 (53.3)	-0.96 (0.23)	(-1.41, -0.51)	-0.24 (0.28)	(-0.80, 0.33)	0.406	Placebo	20	11 (55.0)	-0.72 (0.17)	(-1.07, -0.38)	Week 37	Tezepelumab	15	8 (53.3)	-0.95 (0.23)	(-1.40, -0.50)	-0.22 (0.29)	(-0.79, 0.34)	0.436	Placebo	20	11 (55.0)	-0.73 (0.17)	(-1.07, -0.38)	Week 38	Tezepelumab	15	7 (46.7)	-0.95 (0.23)	(-1.40, -0.50)	-0.37 (0.29)	(-0.93, 0.20)	0.200	Placebo	20	12 (60.0)	-0.58 (0.17)	(-0.92, -0.23)	Week 39	Tezepelumab	15	8 (53.3)	-0.95 (0.22)	(-1.40, -0.51)	-0.30 (0.29)	(-0.86, 0.27)	0.298	Placebo	20	11 (55.0)	-0.66 (0.18)	(-1.00, -0.31)	Week 40	Tezepelumab	15	8 (53.3)	-0.95 (0.22)	(-1.39, -0.51)	-0.32 (0.29)	(-0.89, 0.24)	0.258	Placebo	20	10 (50.0)	-0.63 (0.18)	(-0.98, -0.28)																								
Week 34	Tezepelumab	15	8 (53.3)	-0.97 (0.22)	(-1.41, -0.53)	-0.26 (0.28)	(-0.81, 0.30)	0.362																																																																																																																										
	Placebo	20	10 (50.0)	-0.71 (0.17)	(-1.05, -0.37)				Week 35	Tezepelumab	15	8 (53.3)	-0.91 (0.22)	(-1.35, -0.47)	-0.20 (0.28)	(-0.76, 0.36)	0.489	Placebo	20	10 (50.0)	-0.71 (0.17)	(-1.05, -0.37)	Week 36	Tezepelumab	15	8 (53.3)	-0.96 (0.23)	(-1.41, -0.51)	-0.24 (0.28)	(-0.80, 0.33)	0.406	Placebo	20	11 (55.0)	-0.72 (0.17)	(-1.07, -0.38)	Week 37	Tezepelumab	15	8 (53.3)	-0.95 (0.23)	(-1.40, -0.50)	-0.22 (0.29)	(-0.79, 0.34)	0.436	Placebo	20	11 (55.0)	-0.73 (0.17)	(-1.07, -0.38)	Week 38	Tezepelumab	15	7 (46.7)	-0.95 (0.23)	(-1.40, -0.50)	-0.37 (0.29)	(-0.93, 0.20)	0.200	Placebo	20	12 (60.0)	-0.58 (0.17)	(-0.92, -0.23)	Week 39	Tezepelumab	15	8 (53.3)	-0.95 (0.22)	(-1.40, -0.51)	-0.30 (0.29)	(-0.86, 0.27)	0.298	Placebo	20	11 (55.0)	-0.66 (0.18)	(-1.00, -0.31)	Week 40	Tezepelumab	15	8 (53.3)	-0.95 (0.22)	(-1.39, -0.51)	-0.32 (0.29)	(-0.89, 0.24)	0.258	Placebo	20	10 (50.0)	-0.63 (0.18)	(-0.98, -0.28)																																						
Week 35	Tezepelumab	15	8 (53.3)	-0.91 (0.22)	(-1.35, -0.47)	-0.20 (0.28)	(-0.76, 0.36)	0.489																																																																																																																										
	Placebo	20	10 (50.0)	-0.71 (0.17)	(-1.05, -0.37)				Week 36	Tezepelumab	15	8 (53.3)	-0.96 (0.23)	(-1.41, -0.51)	-0.24 (0.28)	(-0.80, 0.33)	0.406	Placebo	20	11 (55.0)	-0.72 (0.17)	(-1.07, -0.38)	Week 37	Tezepelumab	15	8 (53.3)	-0.95 (0.23)	(-1.40, -0.50)	-0.22 (0.29)	(-0.79, 0.34)	0.436	Placebo	20	11 (55.0)	-0.73 (0.17)	(-1.07, -0.38)	Week 38	Tezepelumab	15	7 (46.7)	-0.95 (0.23)	(-1.40, -0.50)	-0.37 (0.29)	(-0.93, 0.20)	0.200	Placebo	20	12 (60.0)	-0.58 (0.17)	(-0.92, -0.23)	Week 39	Tezepelumab	15	8 (53.3)	-0.95 (0.22)	(-1.40, -0.51)	-0.30 (0.29)	(-0.86, 0.27)	0.298	Placebo	20	11 (55.0)	-0.66 (0.18)	(-1.00, -0.31)	Week 40	Tezepelumab	15	8 (53.3)	-0.95 (0.22)	(-1.39, -0.51)	-0.32 (0.29)	(-0.89, 0.24)	0.258	Placebo	20	10 (50.0)	-0.63 (0.18)	(-0.98, -0.28)																																																				
Week 36	Tezepelumab	15	8 (53.3)	-0.96 (0.23)	(-1.41, -0.51)	-0.24 (0.28)	(-0.80, 0.33)	0.406																																																																																																																										
	Placebo	20	11 (55.0)	-0.72 (0.17)	(-1.07, -0.38)				Week 37	Tezepelumab	15	8 (53.3)	-0.95 (0.23)	(-1.40, -0.50)	-0.22 (0.29)	(-0.79, 0.34)	0.436	Placebo	20	11 (55.0)	-0.73 (0.17)	(-1.07, -0.38)	Week 38	Tezepelumab	15	7 (46.7)	-0.95 (0.23)	(-1.40, -0.50)	-0.37 (0.29)	(-0.93, 0.20)	0.200	Placebo	20	12 (60.0)	-0.58 (0.17)	(-0.92, -0.23)	Week 39	Tezepelumab	15	8 (53.3)	-0.95 (0.22)	(-1.40, -0.51)	-0.30 (0.29)	(-0.86, 0.27)	0.298	Placebo	20	11 (55.0)	-0.66 (0.18)	(-1.00, -0.31)	Week 40	Tezepelumab	15	8 (53.3)	-0.95 (0.22)	(-1.39, -0.51)	-0.32 (0.29)	(-0.89, 0.24)	0.258	Placebo	20	10 (50.0)	-0.63 (0.18)	(-0.98, -0.28)																																																																		
Week 37	Tezepelumab	15	8 (53.3)	-0.95 (0.23)	(-1.40, -0.50)	-0.22 (0.29)	(-0.79, 0.34)	0.436																																																																																																																										
	Placebo	20	11 (55.0)	-0.73 (0.17)	(-1.07, -0.38)				Week 38	Tezepelumab	15	7 (46.7)	-0.95 (0.23)	(-1.40, -0.50)	-0.37 (0.29)	(-0.93, 0.20)	0.200	Placebo	20	12 (60.0)	-0.58 (0.17)	(-0.92, -0.23)	Week 39	Tezepelumab	15	8 (53.3)	-0.95 (0.22)	(-1.40, -0.51)	-0.30 (0.29)	(-0.86, 0.27)	0.298	Placebo	20	11 (55.0)	-0.66 (0.18)	(-1.00, -0.31)	Week 40	Tezepelumab	15	8 (53.3)	-0.95 (0.22)	(-1.39, -0.51)	-0.32 (0.29)	(-0.89, 0.24)	0.258	Placebo	20	10 (50.0)	-0.63 (0.18)	(-0.98, -0.28)																																																																																
Week 38	Tezepelumab	15	7 (46.7)	-0.95 (0.23)	(-1.40, -0.50)	-0.37 (0.29)	(-0.93, 0.20)	0.200																																																																																																																										
	Placebo	20	12 (60.0)	-0.58 (0.17)	(-0.92, -0.23)				Week 39	Tezepelumab	15	8 (53.3)	-0.95 (0.22)	(-1.40, -0.51)	-0.30 (0.29)	(-0.86, 0.27)	0.298	Placebo	20	11 (55.0)	-0.66 (0.18)	(-1.00, -0.31)	Week 40	Tezepelumab	15	8 (53.3)	-0.95 (0.22)	(-1.39, -0.51)	-0.32 (0.29)	(-0.89, 0.24)	0.258	Placebo	20	10 (50.0)	-0.63 (0.18)	(-0.98, -0.28)																																																																																														
Week 39	Tezepelumab	15	8 (53.3)	-0.95 (0.22)	(-1.40, -0.51)	-0.30 (0.29)	(-0.86, 0.27)	0.298																																																																																																																										
	Placebo	20	11 (55.0)	-0.66 (0.18)	(-1.00, -0.31)				Week 40	Tezepelumab	15	8 (53.3)	-0.95 (0.22)	(-1.39, -0.51)	-0.32 (0.29)	(-0.89, 0.24)	0.258	Placebo	20	10 (50.0)	-0.63 (0.18)	(-0.98, -0.28)																																																																																																												
Week 40	Tezepelumab	15	8 (53.3)	-0.95 (0.22)	(-1.39, -0.51)	-0.32 (0.29)	(-0.89, 0.24)	0.258																																																																																																																										
	Placebo	20	10 (50.0)	-0.63 (0.18)	(-0.98, -0.28)																																																																																																																													

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WEC\_KLMC0: Change from baseline in ASD weekly chest tightness score - MMRM results  
 DITTL - adolescents

Change from baseline in ASD weekly chest tightness score				Repeated measures analysis																																																																																																																														
				Change from Baseline		Treatment Difference																																																																																																																												
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value																																																																																																																						
Week 41	Tezepelumab	15	8 (53.3)	-0.88 (0.23)	(-1.33, -0.44)	-0.33 (0.29)	(-0.89, 0.24)	0.259																																																																																																																										
	Placebo	20	9 (45.0)	-0.56 (0.18)	(-0.91, -0.21)				Week 42	Tezepelumab	15	8 (53.3)	-0.92 (0.23)	(-1.37, -0.47)	-0.34 (0.29)	(-0.91, 0.23)	0.240	Placebo	20	10 (50.0)	-0.58 (0.18)	(-0.93, -0.23)	Week 43	Tezepelumab	15	8 (53.3)	-0.99 (0.23)	(-1.44, -0.53)	-0.37 (0.29)	(-0.94, 0.19)	0.195	Placebo	20	11 (55.0)	-0.61 (0.17)	(-0.96, -0.27)	Week 44	Tezepelumab	15	7 (46.7)	-1.00 (0.23)	(-1.46, -0.54)	-0.28 (0.29)	(-0.85, 0.29)	0.334	Placebo	20	11 (55.0)	-0.72 (0.17)	(-1.06, -0.38)	Week 45	Tezepelumab	15	7 (46.7)	-1.08 (0.23)	(-1.54, -0.62)	-0.42 (0.29)	(-1.00, 0.16)	0.152	Placebo	20	11 (55.0)	-0.66 (0.17)	(-1.01, -0.32)	Week 46	Tezepelumab	15	7 (46.7)	-0.88 (0.23)	(-1.35, -0.42)	-0.19 (0.29)	(-0.77, 0.39)	0.523	Placebo	20	9 (45.0)	-0.70 (0.18)	(-1.05, -0.34)	Week 47	Tezepelumab	15	6 (40.0)	-0.90 (0.24)	(-1.36, -0.43)	-0.17 (0.30)	(-0.75, 0.42)	0.572	Placebo	20	10 (50.0)	-0.73 (0.18)	(-1.08, -0.37)	Week 48	Tezepelumab	15	5 (33.3)	-0.80 (0.24)	(-1.27, -0.33)	0.08 (0.30)	(-0.51, 0.67)	0.797	Placebo	20	10 (50.0)	-0.88 (0.18)	(-1.24, -0.53)	Week 49	Tezepelumab	15	7 (46.7)	-0.91 (0.23)	(-1.38, -0.45)	-0.18 (0.30)	(-0.76, 0.41)	0.550	Placebo	20	10 (50.0)	-0.74 (0.18)	(-1.09, -0.38)	Week 50	Tezepelumab	15	6 (40.0)	-0.82 (0.24)	(-1.29, -0.36)	-0.17 (0.30)	(-0.76, 0.42)	0.569	Placebo
Week 42	Tezepelumab	15	8 (53.3)	-0.92 (0.23)	(-1.37, -0.47)	-0.34 (0.29)	(-0.91, 0.23)	0.240																																																																																																																										
	Placebo	20	10 (50.0)	-0.58 (0.18)	(-0.93, -0.23)				Week 43	Tezepelumab	15	8 (53.3)	-0.99 (0.23)	(-1.44, -0.53)	-0.37 (0.29)	(-0.94, 0.19)	0.195	Placebo	20	11 (55.0)	-0.61 (0.17)	(-0.96, -0.27)	Week 44	Tezepelumab	15	7 (46.7)	-1.00 (0.23)	(-1.46, -0.54)	-0.28 (0.29)	(-0.85, 0.29)	0.334	Placebo	20	11 (55.0)	-0.72 (0.17)	(-1.06, -0.38)	Week 45	Tezepelumab	15	7 (46.7)	-1.08 (0.23)	(-1.54, -0.62)	-0.42 (0.29)	(-1.00, 0.16)	0.152	Placebo	20	11 (55.0)	-0.66 (0.17)	(-1.01, -0.32)	Week 46	Tezepelumab	15	7 (46.7)	-0.88 (0.23)	(-1.35, -0.42)	-0.19 (0.29)	(-0.77, 0.39)	0.523	Placebo	20	9 (45.0)	-0.70 (0.18)	(-1.05, -0.34)	Week 47	Tezepelumab	15	6 (40.0)	-0.90 (0.24)	(-1.36, -0.43)	-0.17 (0.30)	(-0.75, 0.42)	0.572	Placebo	20	10 (50.0)	-0.73 (0.18)	(-1.08, -0.37)	Week 48	Tezepelumab	15	5 (33.3)	-0.80 (0.24)	(-1.27, -0.33)	0.08 (0.30)	(-0.51, 0.67)	0.797	Placebo	20	10 (50.0)	-0.88 (0.18)	(-1.24, -0.53)	Week 49	Tezepelumab	15	7 (46.7)	-0.91 (0.23)	(-1.38, -0.45)	-0.18 (0.30)	(-0.76, 0.41)	0.550	Placebo	20	10 (50.0)	-0.74 (0.18)	(-1.09, -0.38)	Week 50	Tezepelumab	15	6 (40.0)	-0.82 (0.24)	(-1.29, -0.36)	-0.17 (0.30)	(-0.76, 0.42)	0.569	Placebo	20	10 (50.0)	-0.65 (0.18)	(-1.01, -0.30)										
Week 43	Tezepelumab	15	8 (53.3)	-0.99 (0.23)	(-1.44, -0.53)	-0.37 (0.29)	(-0.94, 0.19)	0.195																																																																																																																										
	Placebo	20	11 (55.0)	-0.61 (0.17)	(-0.96, -0.27)				Week 44	Tezepelumab	15	7 (46.7)	-1.00 (0.23)	(-1.46, -0.54)	-0.28 (0.29)	(-0.85, 0.29)	0.334	Placebo	20	11 (55.0)	-0.72 (0.17)	(-1.06, -0.38)	Week 45	Tezepelumab	15	7 (46.7)	-1.08 (0.23)	(-1.54, -0.62)	-0.42 (0.29)	(-1.00, 0.16)	0.152	Placebo	20	11 (55.0)	-0.66 (0.17)	(-1.01, -0.32)	Week 46	Tezepelumab	15	7 (46.7)	-0.88 (0.23)	(-1.35, -0.42)	-0.19 (0.29)	(-0.77, 0.39)	0.523	Placebo	20	9 (45.0)	-0.70 (0.18)	(-1.05, -0.34)	Week 47	Tezepelumab	15	6 (40.0)	-0.90 (0.24)	(-1.36, -0.43)	-0.17 (0.30)	(-0.75, 0.42)	0.572	Placebo	20	10 (50.0)	-0.73 (0.18)	(-1.08, -0.37)	Week 48	Tezepelumab	15	5 (33.3)	-0.80 (0.24)	(-1.27, -0.33)	0.08 (0.30)	(-0.51, 0.67)	0.797	Placebo	20	10 (50.0)	-0.88 (0.18)	(-1.24, -0.53)	Week 49	Tezepelumab	15	7 (46.7)	-0.91 (0.23)	(-1.38, -0.45)	-0.18 (0.30)	(-0.76, 0.41)	0.550	Placebo	20	10 (50.0)	-0.74 (0.18)	(-1.09, -0.38)	Week 50	Tezepelumab	15	6 (40.0)	-0.82 (0.24)	(-1.29, -0.36)	-0.17 (0.30)	(-0.76, 0.42)	0.569	Placebo	20	10 (50.0)	-0.65 (0.18)	(-1.01, -0.30)																								
Week 44	Tezepelumab	15	7 (46.7)	-1.00 (0.23)	(-1.46, -0.54)	-0.28 (0.29)	(-0.85, 0.29)	0.334																																																																																																																										
	Placebo	20	11 (55.0)	-0.72 (0.17)	(-1.06, -0.38)				Week 45	Tezepelumab	15	7 (46.7)	-1.08 (0.23)	(-1.54, -0.62)	-0.42 (0.29)	(-1.00, 0.16)	0.152	Placebo	20	11 (55.0)	-0.66 (0.17)	(-1.01, -0.32)	Week 46	Tezepelumab	15	7 (46.7)	-0.88 (0.23)	(-1.35, -0.42)	-0.19 (0.29)	(-0.77, 0.39)	0.523	Placebo	20	9 (45.0)	-0.70 (0.18)	(-1.05, -0.34)	Week 47	Tezepelumab	15	6 (40.0)	-0.90 (0.24)	(-1.36, -0.43)	-0.17 (0.30)	(-0.75, 0.42)	0.572	Placebo	20	10 (50.0)	-0.73 (0.18)	(-1.08, -0.37)	Week 48	Tezepelumab	15	5 (33.3)	-0.80 (0.24)	(-1.27, -0.33)	0.08 (0.30)	(-0.51, 0.67)	0.797	Placebo	20	10 (50.0)	-0.88 (0.18)	(-1.24, -0.53)	Week 49	Tezepelumab	15	7 (46.7)	-0.91 (0.23)	(-1.38, -0.45)	-0.18 (0.30)	(-0.76, 0.41)	0.550	Placebo	20	10 (50.0)	-0.74 (0.18)	(-1.09, -0.38)	Week 50	Tezepelumab	15	6 (40.0)	-0.82 (0.24)	(-1.29, -0.36)	-0.17 (0.30)	(-0.76, 0.42)	0.569	Placebo	20	10 (50.0)	-0.65 (0.18)	(-1.01, -0.30)																																						
Week 45	Tezepelumab	15	7 (46.7)	-1.08 (0.23)	(-1.54, -0.62)	-0.42 (0.29)	(-1.00, 0.16)	0.152																																																																																																																										
	Placebo	20	11 (55.0)	-0.66 (0.17)	(-1.01, -0.32)				Week 46	Tezepelumab	15	7 (46.7)	-0.88 (0.23)	(-1.35, -0.42)	-0.19 (0.29)	(-0.77, 0.39)	0.523	Placebo	20	9 (45.0)	-0.70 (0.18)	(-1.05, -0.34)	Week 47	Tezepelumab	15	6 (40.0)	-0.90 (0.24)	(-1.36, -0.43)	-0.17 (0.30)	(-0.75, 0.42)	0.572	Placebo	20	10 (50.0)	-0.73 (0.18)	(-1.08, -0.37)	Week 48	Tezepelumab	15	5 (33.3)	-0.80 (0.24)	(-1.27, -0.33)	0.08 (0.30)	(-0.51, 0.67)	0.797	Placebo	20	10 (50.0)	-0.88 (0.18)	(-1.24, -0.53)	Week 49	Tezepelumab	15	7 (46.7)	-0.91 (0.23)	(-1.38, -0.45)	-0.18 (0.30)	(-0.76, 0.41)	0.550	Placebo	20	10 (50.0)	-0.74 (0.18)	(-1.09, -0.38)	Week 50	Tezepelumab	15	6 (40.0)	-0.82 (0.24)	(-1.29, -0.36)	-0.17 (0.30)	(-0.76, 0.42)	0.569	Placebo	20	10 (50.0)	-0.65 (0.18)	(-1.01, -0.30)																																																				
Week 46	Tezepelumab	15	7 (46.7)	-0.88 (0.23)	(-1.35, -0.42)	-0.19 (0.29)	(-0.77, 0.39)	0.523																																																																																																																										
	Placebo	20	9 (45.0)	-0.70 (0.18)	(-1.05, -0.34)				Week 47	Tezepelumab	15	6 (40.0)	-0.90 (0.24)	(-1.36, -0.43)	-0.17 (0.30)	(-0.75, 0.42)	0.572	Placebo	20	10 (50.0)	-0.73 (0.18)	(-1.08, -0.37)	Week 48	Tezepelumab	15	5 (33.3)	-0.80 (0.24)	(-1.27, -0.33)	0.08 (0.30)	(-0.51, 0.67)	0.797	Placebo	20	10 (50.0)	-0.88 (0.18)	(-1.24, -0.53)	Week 49	Tezepelumab	15	7 (46.7)	-0.91 (0.23)	(-1.38, -0.45)	-0.18 (0.30)	(-0.76, 0.41)	0.550	Placebo	20	10 (50.0)	-0.74 (0.18)	(-1.09, -0.38)	Week 50	Tezepelumab	15	6 (40.0)	-0.82 (0.24)	(-1.29, -0.36)	-0.17 (0.30)	(-0.76, 0.42)	0.569	Placebo	20	10 (50.0)	-0.65 (0.18)	(-1.01, -0.30)																																																																		
Week 47	Tezepelumab	15	6 (40.0)	-0.90 (0.24)	(-1.36, -0.43)	-0.17 (0.30)	(-0.75, 0.42)	0.572																																																																																																																										
	Placebo	20	10 (50.0)	-0.73 (0.18)	(-1.08, -0.37)				Week 48	Tezepelumab	15	5 (33.3)	-0.80 (0.24)	(-1.27, -0.33)	0.08 (0.30)	(-0.51, 0.67)	0.797	Placebo	20	10 (50.0)	-0.88 (0.18)	(-1.24, -0.53)	Week 49	Tezepelumab	15	7 (46.7)	-0.91 (0.23)	(-1.38, -0.45)	-0.18 (0.30)	(-0.76, 0.41)	0.550	Placebo	20	10 (50.0)	-0.74 (0.18)	(-1.09, -0.38)	Week 50	Tezepelumab	15	6 (40.0)	-0.82 (0.24)	(-1.29, -0.36)	-0.17 (0.30)	(-0.76, 0.42)	0.569	Placebo	20	10 (50.0)	-0.65 (0.18)	(-1.01, -0.30)																																																																																
Week 48	Tezepelumab	15	5 (33.3)	-0.80 (0.24)	(-1.27, -0.33)	0.08 (0.30)	(-0.51, 0.67)	0.797																																																																																																																										
	Placebo	20	10 (50.0)	-0.88 (0.18)	(-1.24, -0.53)				Week 49	Tezepelumab	15	7 (46.7)	-0.91 (0.23)	(-1.38, -0.45)	-0.18 (0.30)	(-0.76, 0.41)	0.550	Placebo	20	10 (50.0)	-0.74 (0.18)	(-1.09, -0.38)	Week 50	Tezepelumab	15	6 (40.0)	-0.82 (0.24)	(-1.29, -0.36)	-0.17 (0.30)	(-0.76, 0.42)	0.569	Placebo	20	10 (50.0)	-0.65 (0.18)	(-1.01, -0.30)																																																																																														
Week 49	Tezepelumab	15	7 (46.7)	-0.91 (0.23)	(-1.38, -0.45)	-0.18 (0.30)	(-0.76, 0.41)	0.550																																																																																																																										
	Placebo	20	10 (50.0)	-0.74 (0.18)	(-1.09, -0.38)				Week 50	Tezepelumab	15	6 (40.0)	-0.82 (0.24)	(-1.29, -0.36)	-0.17 (0.30)	(-0.76, 0.42)	0.569	Placebo	20	10 (50.0)	-0.65 (0.18)	(-1.01, -0.30)																																																																																																												
Week 50	Tezepelumab	15	6 (40.0)	-0.82 (0.24)	(-1.29, -0.36)	-0.17 (0.30)	(-0.76, 0.42)	0.569																																																																																																																										
	Placebo	20	10 (50.0)	-0.65 (0.18)	(-1.01, -0.30)																																																																																																																													

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table NT1WEC\_KLMC0: Change from baseline in ASD weekly chest tightness score - MMRM results  
 DITTLL - adolescents

Change from baseline in ASD weekly chest tightness score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 51	Tezepelumab	15	7 (46.7)	-0.85 (0.23)	(-1.31, -0.39)	-0.15 (0.29)	(-0.73, 0.43)	0.618
	Placebo	20	12 (60.0)	-0.71 (0.18)	(-1.06, -0.35)			
Week 52	Tezepelumab	15	8 (53.3)	-0.87 (0.23)	(-1.33, -0.41)	-0.16 (0.29)	(-0.74, 0.43)	0.594
	Placebo	20	11 (55.0)	-0.71 (0.18)	(-1.07, -0.36)			

Note: DITTLL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WAC\_KLMH0: Course of ASD weekly waking score  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly waking score	Baseline	Tezepelumab	15	15 (100.0)	0.63 (0.59)	0.0	0.14	0.57	1.00	2.0	
		Placebo	20	20 (100.0)	0.69 (0.60)	0.0	0.21	0.71	1.00	2.5	
	Week 1	Tezepelumab	15	15 (100.0)	0.22 (0.40)	0.0	0.00	0.00	0.20	1.3	
		Placebo	20	20 (100.0)	0.56 (0.72)	0.0	0.00	0.36	1.00	2.9	
	Week 2	Tezepelumab	15	14 (93.3)	0.35 (0.50)	0.0	0.00	0.14	0.57	1.6	
		Placebo	20	20 (100.0)	0.40 (0.53)	0.0	0.00	0.20	0.69	1.8	
	Week 3	Tezepelumab	15	14 (93.3)	0.30 (0.46)	0.0	0.00	0.07	0.43	1.3	
		Placebo	20	20 (100.0)	0.43 (0.67)	0.0	0.00	0.23	0.66	2.8	
	Week 4	Tezepelumab	15	14 (93.3)	0.31 (0.44)	0.0	0.00	0.00	0.83	1.0	
		Placebo	20	18 (90.0)	0.30 (0.39)	0.0	0.00	0.14	0.57	1.0	
	Week 5	Tezepelumab	15	12 (80.0)	0.23 (0.39)	0.0	0.00	0.00	0.28	1.1	
		Placebo	20	19 (95.0)	0.36 (0.48)	0.0	0.00	0.00	0.57	1.6	
	Week 6	Tezepelumab	15	13 (86.7)	0.23 (0.47)	0.0	0.00	0.00	0.14	1.5	
		Placebo	20	18 (90.0)	0.27 (0.40)	0.0	0.00	0.07	0.29	1.1	
	Week 7	Tezepelumab	15	13 (86.7)	0.24 (0.40)	0.0	0.00	0.00	0.29	1.3	
		Placebo	20	17 (85.0)	0.31 (0.45)	0.0	0.00	0.00	0.43	1.4	
	Week 8	Tezepelumab	15	14 (93.3)	0.24 (0.52)	0.0	0.00	0.00	0.00	1.7	
		Placebo	20	18 (90.0)	0.44 (0.56)	0.0	0.00	0.00	1.00	1.8	
	Week 9	Tezepelumab	15	12 (80.0)	0.22 (0.43)	0.0	0.00	0.00	0.33	1.3	
		Placebo	20	19 (95.0)	0.34 (0.47)	0.0	0.00	0.14	0.57	1.4	
	Week 10	Tezepelumab	15	12 (80.0)	0.17 (0.30)	0.0	0.00	0.00	0.23	1.0	
		Placebo	20	16 (80.0)	0.17 (0.37)	0.0	0.00	0.00	0.07	1.1	
	Week 11	Tezepelumab	15	13 (86.7)	0.36 (0.45)	0.0	0.00	0.14	0.75	1.1	
		Placebo	20	18 (90.0)	0.37 (0.76)	0.0	0.00	0.00	0.43	3.0	
	Week 12	Tezepelumab	15	13 (86.7)	0.32 (0.49)	0.0	0.00	0.00	0.75	1.3	
		Placebo	20	17 (85.0)	0.35 (0.62)	0.0	0.00	0.00	0.43	2.2	
	Week 13	Tezepelumab	15	12 (80.0)	0.22 (0.43)	0.0	0.00	0.00	0.21	1.2	
		Placebo	20	17 (85.0)	0.37 (0.85)	0.0	0.00	0.00	0.40	3.4	
	Week 14	Tezepelumab	15	12 (80.0)	0.22 (0.37)	0.0	0.00	0.00	0.38	1.0	
		Placebo	20	17 (85.0)	0.19 (0.34)	0.0	0.00	0.00	0.14	1.0	
	Week 15	Tezepelumab	15	12 (80.0)	0.22 (0.39)	0.0	0.00	0.00	0.29	1.1	
		Placebo	20	16 (80.0)	0.33 (0.54)	0.0	0.00	0.00	0.55	1.8	
	Week 16	Tezepelumab	15	11 (73.3)	0.23 (0.42)	0.0	0.00	0.00	0.57	1.0	
		Placebo	20	17 (85.0)	0.31 (0.52)	0.0	0.00	0.00	0.50	1.8	
Week 17	Tezepelumab	15	12 (80.0)	0.22 (0.36)	0.0	0.00	0.00	0.38	1.0		
	Placebo	20	15 (75.0)	0.18 (0.27)	0.0	0.00	0.00	0.43	0.7		

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022

Table NT1WAC\_KLMH0: Course of ASD weekly waking score  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly waking score	Week 18	Tezepelumab	15	10 (66.7)	0.14 (0.33)	0.0	0.00	0.00	0.00	1.0	
		Placebo	20	15 (75.0)	0.36 (0.88)	0.0	0.00	0.00	0.43	3.4	
	Week 19	Tezepelumab	15	12 (80.0)	0.13 (0.31)	0.0	0.00	0.00	0.00	1.0	
		Placebo	20	17 (85.0)	0.20 (0.31)	0.0	0.00	0.00	0.29	1.0	
	Week 20	Tezepelumab	15	9 (60.0)	0.11 (0.33)	0.0	0.00	0.00	0.00	1.0	
		Placebo	20	17 (85.0)	0.42 (0.75)	0.0	0.00	0.00	0.50	2.8	
	Week 21	Tezepelumab	15	10 (66.7)	0.17 (0.35)	0.0	0.00	0.00	0.14	1.0	
		Placebo	20	16 (80.0)	0.28 (0.70)	0.0	0.00	0.00	0.15	2.8	
	Week 22	Tezepelumab	15	10 (66.7)	0.18 (0.37)	0.0	0.00	0.00	0.00	1.0	
		Placebo	20	16 (80.0)	0.41 (0.69)	0.0	0.00	0.00	0.61	2.5	
	Week 23	Tezepelumab	15	10 (66.7)	0.20 (0.37)	0.0	0.00	0.00	0.20	1.0	
		Placebo	20	16 (80.0)	0.46 (0.92)	0.0	0.00	0.07	0.45	3.5	
	Week 24	Tezepelumab	15	10 (66.7)	0.27 (0.41)	0.0	0.00	0.07	0.40	1.0	
		Placebo	20	15 (75.0)	0.40 (0.81)	0.0	0.00	0.00	0.57	3.0	
	Week 25	Tezepelumab	15	11 (73.3)	0.16 (0.31)	0.0	0.00	0.00	0.17	1.0	
		Placebo	20	15 (75.0)	0.12 (0.19)	0.0	0.00	0.00	0.17	0.6	
	Week 26	Tezepelumab	15	11 (73.3)	0.22 (0.36)	0.0	0.00	0.00	0.25	1.0	
		Placebo	20	15 (75.0)	0.12 (0.21)	0.0	0.00	0.00	0.14	0.7	
	Week 27	Tezepelumab	15	10 (66.7)	0.23 (0.42)	0.0	0.00	0.00	0.25	1.0	
		Placebo	20	16 (80.0)	0.14 (0.25)	0.0	0.00	0.00	0.23	1.0	
	Week 28	Tezepelumab	15	9 (60.0)	0.18 (0.37)	0.0	0.00	0.00	0.00	1.0	
		Placebo	20	15 (75.0)	0.35 (0.59)	0.0	0.00	0.00	0.43	2.0	
	Week 29	Tezepelumab	15	10 (66.7)	0.25 (0.43)	0.0	0.00	0.07	0.20	1.3	
		Placebo	20	15 (75.0)	0.29 (0.50)	0.0	0.00	0.00	0.43	1.7	
	Week 30	Tezepelumab	15	9 (60.0)	0.14 (0.33)	0.0	0.00	0.00	0.00	1.0	
		Placebo	20	14 (70.0)	0.19 (0.28)	0.0	0.00	0.14	0.20	1.0	
	Week 31	Tezepelumab	15	8 (53.3)	0.13 (0.35)	0.0	0.00	0.00	0.00	1.0	
		Placebo	20	14 (70.0)	0.11 (0.22)	0.0	0.00	0.00	0.14	0.8	
	Week 32	Tezepelumab	15	9 (60.0)	0.16 (0.34)	0.0	0.00	0.00	0.00	1.0	
		Placebo	20	16 (80.0)	0.26 (0.45)	0.0	0.00	0.00	0.21	1.3	
	Week 33	Tezepelumab	15	8 (53.3)	0.17 (0.40)	0.0	0.00	0.00	0.10	1.1	
		Placebo	20	14 (70.0)	0.12 (0.23)	0.0	0.00	0.00	0.20	0.7	
	Week 34	Tezepelumab	15	8 (53.3)	0.15 (0.41)	0.0	0.00	0.00	0.00	1.2	
		Placebo	20	12 (60.0)	0.25 (0.74)	0.0	0.00	0.00	0.14	2.6	
Week 35	Tezepelumab	15	9 (60.0)	0.20 (0.42)	0.0	0.00	0.00	0.20	1.3		
	Placebo	20	15 (75.0)	0.22 (0.41)	0.0	0.00	0.00	0.40	1.5		

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022

Table NT1WAC\_KLMH0: Course of ASD weekly waking score  
 DITTLL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly waking score	Week 36	Tezepelumab	15	8 (53.3)	0.16 (0.40)	0.0	0.00	0.00	0.08	1.1	
		Placebo	20	14 (70.0)	0.12 (0.34)	0.0	0.00	0.00	0.00	1.3	
	Week 37	Tezepelumab	15	9 (60.0)	0.21 (0.43)	0.0	0.00	0.00	0.14	1.3	
		Placebo	20	14 (70.0)	0.06 (0.13)	0.0	0.00	0.00	0.00	0.3	
	Week 38	Tezepelumab	15	8 (53.3)	0.20 (0.49)	0.0	0.00	0.00	0.08	1.4	
		Placebo	20	15 (75.0)	0.23 (0.45)	0.0	0.00	0.00	0.50	1.6	
	Week 39	Tezepelumab	15	10 (66.7)	0.13 (0.32)	0.0	0.00	0.00	0.00	1.0	
		Placebo	20	13 (65.0)	0.27 (0.71)	0.0	0.00	0.00	0.00	2.5	
	Week 40	Tezepelumab	15	10 (66.7)	0.15 (0.32)	0.0	0.00	0.00	0.14	1.0	
		Placebo	20	13 (65.0)	0.30 (0.72)	0.0	0.00	0.00	0.14	2.5	
	Week 41	Tezepelumab	15	9 (60.0)	0.24 (0.61)	0.0	0.00	0.00	0.14	1.9	
		Placebo	20	13 (65.0)	0.26 (0.57)	0.0	0.00	0.00	0.14	2.0	
	Week 42	Tezepelumab	15	9 (60.0)	0.24 (0.66)	0.0	0.00	0.00	0.00	2.0	
		Placebo	20	13 (65.0)	0.31 (0.80)	0.0	0.00	0.00	0.00	2.8	
	Week 43	Tezepelumab	15	8 (53.3)	0.19 (0.47)	0.0	0.00	0.00	0.08	1.3	
		Placebo	20	14 (70.0)	0.38 (0.52)	0.0	0.00	0.07	0.80	1.3	
	Week 44	Tezepelumab	15	8 (53.3)	0.23 (0.58)	0.0	0.00	0.00	0.08	1.7	
		Placebo	20	14 (70.0)	0.40 (0.69)	0.0	0.00	0.07	0.50	2.3	
	Week 45	Tezepelumab	15	8 (53.3)	0.13 (0.35)	0.0	0.00	0.00	0.00	1.0	
		Placebo	20	12 (60.0)	0.44 (0.68)	0.0	0.00	0.10	0.64	1.8	
	Week 46	Tezepelumab	15	7 (46.7)	0.17 (0.44)	0.0	0.00	0.00	0.00	1.2	
		Placebo	20	11 (55.0)	0.44 (0.70)	0.0	0.00	0.00	1.00	2.0	
	Week 47	Tezepelumab	15	6 (40.0)	0.24 (0.58)	0.0	0.00	0.00	0.00	1.4	
		Placebo	20	13 (65.0)	0.29 (0.57)	0.0	0.00	0.00	0.14	1.7	
	Week 48	Tezepelumab	15	6 (40.0)	0.17 (0.41)	0.0	0.00	0.00	0.00	1.0	
		Placebo	20	14 (70.0)	0.20 (0.36)	0.0	0.00	0.00	0.17	1.0	
	Week 49	Tezepelumab	15	7 (46.7)	0.21 (0.50)	0.0	0.00	0.00	0.17	1.3	
		Placebo	20	12 (60.0)	0.28 (0.54)	0.0	0.00	0.00	0.34	1.7	
	Week 50	Tezepelumab	15	7 (46.7)	0.17 (0.44)	0.0	0.00	0.00	0.00	1.2	
		Placebo	20	12 (60.0)	0.27 (0.54)	0.0	0.00	0.00	0.25	1.6	
	Week 51	Tezepelumab	15	8 (53.3)	0.17 (0.47)	0.0	0.00	0.00	0.00	1.3	
		Placebo	20	14 (70.0)	0.28 (0.55)	0.0	0.00	0.00	0.17	1.7	
	Week 52	Tezepelumab	15	8 (53.3)	0.21 (0.53)	0.0	0.00	0.00	0.08	1.5	
		Placebo	20	12 (60.0)	0.03 (0.08)	0.0	0.00	0.00	0.00	0.3	

Note: DITTLL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022

Table NT1WAC\_KLMH0: Course of ASD weekly waking score  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly waking score	Week 1	Tezepelumab	15	15 (100.0)	-0.41 (0.59)	-2.0	-0.57	-0.14	0.00	0.1	-0.61 [-1.30, 0.07]
		Placebo	20	20 (100.0)	-0.13 (0.32)	-1.0	-0.29	0.00	0.00	0.4	
	Week 2	Tezepelumab	15	14 (93.3)	-0.26 (0.67)	-2.0	-0.43	-0.07	0.02	0.6	0.05 [-0.63, 0.74]
		Placebo	20	20 (100.0)	-0.29 (0.36)	-1.0	-0.48	-0.29	0.00	0.3	
	Week 3	Tezepelumab	15	14 (93.3)	-0.31 (0.66)	-2.0	-0.43	-0.14	0.00	0.4	-0.10 [-0.78, 0.58]
		Placebo	20	20 (100.0)	-0.26 (0.36)	-1.0	-0.46	-0.14	0.00	0.3	
	Week 4	Tezepelumab	15	14 (93.3)	-0.30 (0.65)	-2.0	-0.29	-0.07	0.00	0.3	-0.03 [-0.72, 0.67]
		Placebo	20	18 (90.0)	-0.29 (0.36)	-1.0	-0.50	-0.21	0.00	0.1	
	Week 5	Tezepelumab	15	12 (80.0)	-0.35 (0.68)	-2.0	-0.36	-0.13	0.00	0.4	-0.03 [-0.75, 0.69]
		Placebo	20	19 (95.0)	-0.33 (0.36)	-1.0	-0.57	-0.29	0.00	0.1	
	Week 6	Tezepelumab	15	13 (86.7)	-0.37 (0.68)	-2.0	-0.43	-0.14	0.00	0.3	-0.09 [-0.81, 0.62]
		Placebo	20	18 (90.0)	-0.32 (0.37)	-1.0	-0.50	-0.27	0.00	0.2	
	Week 7	Tezepelumab	15	13 (86.7)	-0.34 (0.59)	-2.0	-0.29	-0.14	0.00	0.1	-0.16 [-0.88, 0.56]
		Placebo	20	17 (85.0)	-0.26 (0.42)	-1.0	-0.57	-0.14	0.00	0.4	
	Week 8	Tezepelumab	15	14 (93.3)	-0.37 (0.64)	-2.0	-0.57	-0.14	0.00	0.5	-0.19 [-0.89, 0.51]
		Placebo	20	18 (90.0)	-0.27 (0.45)	-1.0	-0.71	-0.14	0.00	0.5	
	Week 9	Tezepelumab	15	12 (80.0)	-0.29 (0.57)	-2.0	-0.29	-0.14	0.00	0.1	0.14 [-0.58, 0.86]
		Placebo	20	19 (95.0)	-0.36 (0.43)	-1.1	-0.71	-0.29	0.00	0.3	
	Week 10	Tezepelumab	15	12 (80.0)	-0.34 (0.57)	-2.0	-0.43	-0.22	0.00	0.1	0.13 [-0.62, 0.88]
		Placebo	20	16 (80.0)	-0.41 (0.41)	-1.0	-0.79	-0.29	0.00	0.0	
	Week 11	Tezepelumab	15	13 (86.7)	-0.19 (0.59)	-2.0	-0.29	-0.02	0.08	0.5	0.31 [-0.40, 1.03]
		Placebo	20	18 (90.0)	-0.35 (0.46)	-1.0	-0.80	-0.29	0.00	0.5	
	Week 12	Tezepelumab	15	13 (86.7)	-0.22 (0.58)	-2.0	-0.29	0.00	0.00	0.4	0.27 [-0.45, 1.00]
		Placebo	20	17 (85.0)	-0.36 (0.42)	-1.0	-0.71	-0.29	0.00	0.2	
	Week 13	Tezepelumab	15	12 (80.0)	-0.44 (0.64)	-2.0	-0.50	-0.23	-0.07	0.2	-0.28 [-1.02, 0.47]
		Placebo	20	17 (85.0)	-0.28 (0.51)	-1.0	-0.71	-0.14	0.00	0.9	
	Week 14	Tezepelumab	15	12 (80.0)	-0.43 (0.66)	-2.0	-0.71	-0.23	-0.07	0.5	-0.10 [-0.84, 0.64]
		Placebo	20	17 (85.0)	-0.37 (0.47)	-1.0	-0.86	-0.29	0.00	0.4	
	Week 15	Tezepelumab	15	12 (80.0)	-0.43 (0.64)	-2.0	-0.71	-0.21	-0.01	0.3	-0.16 [-0.91, 0.59]
		Placebo	20	16 (80.0)	-0.34 (0.48)	-1.0	-0.76	-0.21	0.00	0.7	
	Week 16	Tezepelumab	15	11 (73.3)	-0.26 (0.64)	-2.0	-0.29	-0.14	0.00	0.6	0.16 [-0.60, 0.92]
		Placebo	20	17 (85.0)	-0.35 (0.46)	-1.0	-0.75	-0.14	0.00	0.3	
	Week 17	Tezepelumab	15	12 (80.0)	-0.31 (0.64)	-2.0	-0.43	-0.15	-0.01	0.5	0.16 [-0.60, 0.92]
		Placebo	20	15 (75.0)	-0.40 (0.48)	-1.0	-0.86	-0.50	0.00	0.4	
Week 18	Tezepelumab	15	10 (66.7)	-0.40 (0.59)	-2.0	-0.43	-0.23	-0.14	0.0	-0.08 [-0.88, 0.72]	
	Placebo	20	15 (75.0)	-0.36 (0.53)	-1.0	-0.86	-0.43	0.00	0.9		

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022

Table NT1WAC\_KLMH0: Course of ASD weekly waking score  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly waking score	Week 19	Tezepelumab	15	12 (80.0)	-0.46 (0.55)	-2.0	-0.62	-0.29	-0.14	0.0	-0.20 [-0.94, 0.54]
		Placebo	20	17 (85.0)	-0.36 (0.46)	-1.0	-0.71	-0.29	0.00	0.8	
	Week 20	Tezepelumab	15	9 (60.0)	-0.40 (0.62)	-2.0	-0.29	-0.17	-0.14	0.0	-0.13 [-0.94, 0.68]
		Placebo	20	17 (85.0)	-0.33 (0.54)	-1.0	-0.81	-0.43	0.00	0.8	
	Week 21	Tezepelumab	15	10 (66.7)	-0.37 (0.60)	-2.0	-0.29	-0.21	-0.14	0.1	0.16 [-0.63, 0.95]
		Placebo	20	16 (80.0)	-0.45 (0.47)	-1.0	-0.86	-0.57	0.00	0.3	
	Week 22	Tezepelumab	15	10 (66.7)	-0.37 (0.60)	-2.0	-0.29	-0.15	-0.11	0.0	-0.11 [-0.90, 0.68]
		Placebo	20	16 (80.0)	-0.31 (0.57)	-1.0	-0.79	-0.32	0.00	1.0	
	Week 23	Tezepelumab	15	10 (66.7)	-0.35 (0.61)	-2.0	-0.29	-0.15	-0.11	0.2	-0.05 [-0.84, 0.74]
		Placebo	20	16 (80.0)	-0.32 (0.69)	-1.0	-1.00	-0.41	0.00	1.0	
	Week 24	Tezepelumab	15	10 (66.7)	-0.28 (0.64)	-2.0	-0.29	-0.15	0.14	0.3	0.13 [-0.67, 0.93]
		Placebo	20	15 (75.0)	-0.36 (0.63)	-1.1	-1.00	-0.50	0.00	1.0	
	Week 25	Tezepelumab	15	11 (73.3)	-0.42 (0.60)	-2.0	-0.57	-0.29	0.00	0.2	0.11 [-0.67, 0.88]
		Placebo	20	15 (75.0)	-0.48 (0.53)	-1.1	-1.00	-0.50	0.00	0.6	
	Week 26	Tezepelumab	15	11 (73.3)	-0.35 (0.63)	-2.0	-0.57	-0.14	0.00	0.3	0.26 [-0.52, 1.04]
		Placebo	20	15 (75.0)	-0.50 (0.49)	-1.0	-1.00	-0.50	-0.14	0.7	
	Week 27	Tezepelumab	15	10 (66.7)	-0.32 (0.63)	-2.0	-0.29	-0.15	0.00	0.3	0.19 [-0.60, 0.98]
		Placebo	20	16 (80.0)	-0.43 (0.57)	-1.0	-1.00	-0.46	-0.07	1.0	
	Week 28	Tezepelumab	15	9 (60.0)	-0.43 (0.61)	-2.0	-0.29	-0.26	-0.14	0.0	0.00 [-0.82, 0.83]
		Placebo	20	15 (75.0)	-0.43 (0.53)	-1.0	-0.86	-0.50	0.00	0.6	
	Week 29	Tezepelumab	15	10 (66.7)	-0.29 (0.59)	-1.9	-0.29	-0.13	0.00	0.2	0.31 [-0.49, 1.12]
		Placebo	20	15 (75.0)	-0.47 (0.57)	-1.1	-1.00	-0.57	0.00	1.0	
	Week 30	Tezepelumab	15	9 (60.0)	-0.47 (0.61)	-2.0	-0.57	-0.29	-0.14	0.0	0.01 [-0.83, 0.84]
		Placebo	20	14 (70.0)	-0.47 (0.59)	-1.0	-0.94	-0.70	0.00	1.0	
	Week 31	Tezepelumab	15	8 (53.3)	-0.45 (0.65)	-2.0	-0.43	-0.23	-0.14	0.0	0.04 [-0.83, 0.91]
		Placebo	20	14 (70.0)	-0.47 (0.57)	-1.1	-1.00	-0.61	0.00	0.8	
	Week 32	Tezepelumab	15	9 (60.0)	-0.45 (0.61)	-2.0	-0.46	-0.29	-0.14	0.0	0.14 [-0.68, 0.96]
		Placebo	20	16 (80.0)	-0.53 (0.49)	-1.3	-1.00	-0.54	0.00	0.2	
	Week 33	Tezepelumab	15	8 (53.3)	-0.37 (0.70)	-2.0	-0.43	-0.14	-0.01	0.2	0.30 [-0.57, 1.18]
		Placebo	20	14 (70.0)	-0.54 (0.44)	-1.1	-1.00	-0.50	-0.14	0.2	
	Week 34	Tezepelumab	15	8 (53.3)	-0.39 (0.68)	-2.0	-0.43	-0.14	0.00	0.0	0.28 [-0.62, 1.18]
		Placebo	20	12 (60.0)	-0.55 (0.44)	-1.1	-0.93	-0.61	-0.14	0.1	
	Week 35	Tezepelumab	15	9 (60.0)	-0.38 (0.68)	-2.0	-0.57	-0.14	0.00	0.3	0.37 [-0.46, 1.20]
		Placebo	20	15 (75.0)	-0.58 (0.47)	-1.1	-1.00	-0.60	0.00	0.1	
	Week 36	Tezepelumab	15	8 (53.3)	-0.38 (0.69)	-2.0	-0.43	-0.08	0.00	0.0	0.45 [-0.43, 1.33]
		Placebo	20	14 (70.0)	-0.63 (0.50)	-1.3	-1.00	-0.79	-0.10	0.1	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022

Table NT1WAC\_KLMH0: Course of ASD weekly waking score  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly waking score	Week 37	Tezepelumab	15	9 (60.0)	-0.37 (0.72)	-2.0	-0.57	-0.14	0.00	0.4	0.28 [-0.56, 1.12]
		Placebo	20	14 (70.0)	-0.52 (0.42)	-1.0	-0.86	-0.61	-0.10	0.0	
	Week 38	Tezepelumab	15	8 (53.3)	-0.34 (0.72)	-2.0	-0.43	-0.14	0.08	0.2	0.25 [-0.62, 1.11]
		Placebo	20	15 (75.0)	-0.49 (0.52)	-1.1	-1.00	-0.57	0.00	0.5	
	Week 39	Tezepelumab	15	10 (66.7)	-0.42 (0.63)	-2.0	-0.57	-0.23	0.00	0.1	0.17 [-0.65, 1.00]
		Placebo	20	13 (65.0)	-0.52 (0.56)	-1.1	-1.00	-0.71	0.00	0.4	
	Week 40	Tezepelumab	15	10 (66.7)	-0.40 (0.65)	-2.0	-0.57	-0.23	0.00	0.2	0.18 [-0.65, 1.00]
		Placebo	20	13 (65.0)	-0.50 (0.53)	-1.0	-1.00	-0.71	0.00	0.6	
	Week 41	Tezepelumab	15	9 (60.0)	-0.27 (0.74)	-2.0	-0.29	-0.14	0.00	0.7	0.45 [-0.41, 1.31]
		Placebo	20	13 (65.0)	-0.55 (0.51)	-1.1	-1.00	-0.71	-0.14	0.3	
	Week 42	Tezepelumab	15	9 (60.0)	-0.27 (0.76)	-2.0	-0.29	-0.14	0.00	0.8	0.26 [-0.59, 1.11]
		Placebo	20	13 (65.0)	-0.44 (0.59)	-1.1	-1.00	-0.50	0.00	0.6	
	Week 43	Tezepelumab	15	8 (53.3)	-0.35 (0.71)	-2.0	-0.43	-0.14	0.08	0.2	0.05 [-0.81, 0.92]
		Placebo	20	14 (70.0)	-0.39 (0.66)	-1.2	-0.89	-0.65	0.00	0.8	
	Week 44	Tezepelumab	15	8 (53.3)	-0.31 (0.75)	-2.0	-0.43	-0.14	0.08	0.5	0.15 [-0.72, 1.02]
		Placebo	20	14 (70.0)	-0.41 (0.62)	-1.1	-1.00	-0.61	0.17	0.5	
	Week 45	Tezepelumab	15	8 (53.3)	-0.41 (0.67)	-2.0	-0.43	-0.15	-0.07	0.0	0.04 [-0.85, 0.94]
		Placebo	20	12 (60.0)	-0.44 (0.66)	-1.1	-1.00	-0.66	0.13	0.7	
	Week 46	Tezepelumab	15	7 (46.7)	-0.43 (0.72)	-2.0	-0.57	-0.14	0.00	0.0	-0.00 [-0.95, 0.94]
		Placebo	20	11 (55.0)	-0.43 (0.58)	-1.0	-1.00	-0.50	0.00	0.6	
	Week 47	Tezepelumab	15	6 (40.0)	-0.46 (0.81)	-2.0	-0.57	-0.21	0.00	0.3	0.14 [-0.83, 1.11]
		Placebo	20	13 (65.0)	-0.54 (0.53)	-1.1	-1.00	-0.71	0.00	0.3	
	Week 48	Tezepelumab	15	6 (40.0)	-0.53 (0.75)	-2.0	-0.57	-0.23	-0.14	0.0	-0.23 [-1.19, 0.73]
		Placebo	20	14 (70.0)	-0.38 (0.57)	-1.1	-1.00	-0.39	0.00	0.8	
	Week 49	Tezepelumab	15	7 (46.7)	-0.40 (0.74)	-2.0	-0.57	-0.14	0.02	0.2	0.19 [-0.74, 1.13]
		Placebo	20	12 (60.0)	-0.51 (0.49)	-1.0	-0.86	-0.73	-0.14	0.6	
	Week 50	Tezepelumab	15	7 (46.7)	-0.55 (0.71)	-2.0	-0.86	-0.29	0.00	0.0	-0.06 [-1.00, 0.87]
		Placebo	20	12 (60.0)	-0.51 (0.54)	-1.1	-0.99	-0.68	0.00	0.3	
	Week 51	Tezepelumab	15	8 (53.3)	-0.41 (0.68)	-2.0	-0.43	-0.21	-0.07	0.2	0.12 [-0.75, 0.99]
		Placebo	20	14 (70.0)	-0.48 (0.55)	-1.1	-1.00	-0.61	0.00	0.6	
	Week 52	Tezepelumab	15	8 (53.3)	-0.37 (0.71)	-2.0	-0.43	-0.21	0.01	0.3	0.28 [-0.62, 1.18]
		Placebo	20	12 (60.0)	-0.53 (0.48)	-1.1	-0.99	-0.61	-0.07	0.3	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022

Table NT1WAC\_KLMC0: Change from baseline in ASD weekly waking score - MMRM results  
 DITTL - adolescents

Change from baseline in ASD weekly waking score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 1	Tezepelumab	15	15 (100.0)	-0.42 (0.12)	(-0.65, -0.19)	-0.31 (0.15)	(-0.62, -0.01)	0.045 *	
	Placebo	20	20 (100.0)	-0.11 (0.10)	(-0.31, 0.09)				
Week 2	Tezepelumab	15	14 (93.3)	-0.31 (0.12)	(-0.54, -0.07)	-0.04 (0.16)	(-0.35, 0.27)	0.798	
	Placebo	20	20 (100.0)	-0.27 (0.10)	(-0.46, -0.07)				
Week 3	Tezepelumab	15	14 (93.3)	-0.36 (0.12)	(-0.59, -0.12)	-0.12 (0.16)	(-0.42, 0.19)	0.451	
	Placebo	20	20 (100.0)	-0.24 (0.10)	(-0.44, -0.04)				
Week 4	Tezepelumab	15	14 (93.3)	-0.35 (0.12)	(-0.58, -0.12)	-0.09 (0.16)	(-0.40, 0.22)	0.570	
	Placebo	20	18 (90.0)	-0.26 (0.10)	(-0.46, -0.06)				
Week 5	Tezepelumab	15	12 (80.0)	-0.35 (0.12)	(-0.58, -0.11)	-0.04 (0.16)	(-0.35, 0.27)	0.789	
	Placebo	20	19 (95.0)	-0.30 (0.10)	(-0.51, -0.10)				
Week 6	Tezepelumab	15	13 (86.7)	-0.34 (0.12)	(-0.58, -0.11)	-0.02 (0.16)	(-0.33, 0.29)	0.892	
	Placebo	20	18 (90.0)	-0.32 (0.10)	(-0.53, -0.12)				
Week 7	Tezepelumab	15	13 (86.7)	-0.36 (0.12)	(-0.59, -0.13)	-0.09 (0.16)	(-0.40, 0.22)	0.580	
	Placebo	20	17 (85.0)	-0.27 (0.10)	(-0.48, -0.07)				
Week 8	Tezepelumab	15	14 (93.3)	-0.42 (0.12)	(-0.65, -0.18)	-0.17 (0.16)	(-0.48, 0.14)	0.272	
	Placebo	20	18 (90.0)	-0.24 (0.10)	(-0.45, -0.04)				
Week 9	Tezepelumab	15	12 (80.0)	-0.39 (0.12)	(-0.63, -0.16)	-0.06 (0.16)	(-0.38, 0.25)	0.690	
	Placebo	20	19 (95.0)	-0.33 (0.10)	(-0.53, -0.13)				
Week 10	Tezepelumab	15	12 (80.0)	-0.45 (0.12)	(-0.69, -0.21)	-0.06 (0.16)	(-0.37, 0.26)	0.713	
	Placebo	20	16 (80.0)	-0.39 (0.10)	(-0.60, -0.19)				

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table NT1WAC\_KLMC0: Change from baseline in ASD weekly waking score - MMRM results  
 DITTTL - adolescents

Change from baseline in ASD weekly waking score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 11	Tezepelumab	15	13 (86.7)	-0.31 (0.12)	(-0.55, -0.08)	-0.00 (0.16)	(-0.31, 0.31)	0.990
	Placebo	20	18 (90.0)	-0.31 (0.10)	(-0.52, -0.11)			
Week 12	Tezepelumab	15	13 (86.7)	-0.35 (0.12)	(-0.59, -0.12)	-0.00 (0.16)	(-0.32, 0.31)	0.981
	Placebo	20	17 (85.0)	-0.35 (0.10)	(-0.55, -0.14)			
Week 13	Tezepelumab	15	12 (80.0)	-0.43 (0.12)	(-0.66, -0.19)	-0.16 (0.16)	(-0.48, 0.15)	0.302
	Placebo	20	17 (85.0)	-0.26 (0.10)	(-0.47, -0.05)			
Week 14	Tezepelumab	15	12 (80.0)	-0.32 (0.12)	(-0.56, -0.09)	-0.03 (0.16)	(-0.34, 0.29)	0.858
	Placebo	20	17 (85.0)	-0.30 (0.10)	(-0.50, -0.09)			
Week 15	Tezepelumab	15	12 (80.0)	-0.33 (0.12)	(-0.57, -0.09)	-0.03 (0.16)	(-0.35, 0.29)	0.847
	Placebo	20	16 (80.0)	-0.30 (0.11)	(-0.51, -0.09)			
Week 16	Tezepelumab	15	11 (73.3)	-0.36 (0.12)	(-0.60, -0.11)	-0.03 (0.16)	(-0.35, 0.29)	0.865
	Placebo	20	17 (85.0)	-0.33 (0.11)	(-0.54, -0.12)			
Week 17	Tezepelumab	15	12 (80.0)	-0.36 (0.12)	(-0.61, -0.12)	-0.03 (0.16)	(-0.35, 0.29)	0.845
	Placebo	20	15 (75.0)	-0.33 (0.11)	(-0.54, -0.12)			
Week 18	Tezepelumab	15	10 (66.7)	-0.44 (0.13)	(-0.69, -0.19)	-0.19 (0.16)	(-0.51, 0.14)	0.253
	Placebo	20	15 (75.0)	-0.25 (0.11)	(-0.46, -0.04)			
Week 19	Tezepelumab	15	12 (80.0)	-0.45 (0.13)	(-0.69, -0.20)	-0.14 (0.16)	(-0.46, 0.18)	0.401
	Placebo	20	17 (85.0)	-0.31 (0.10)	(-0.52, -0.10)			
Week 20	Tezepelumab	15	9 (60.0)	-0.45 (0.13)	(-0.70, -0.19)	-0.17 (0.17)	(-0.50, 0.16)	0.318
	Placebo	20	17 (85.0)	-0.28 (0.10)	(-0.48, -0.07)			

Note: DITTTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WAC\_KLMC0: Change from baseline in ASD weekly waking score - MMRM results  
 DITTL - adolescents

Change from baseline in ASD weekly waking score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Time	Treatment	N	n (%)						
Week 21	Tezepelumab	15	10 (66.7)	-0.43 (0.13)	(-0.69, -0.17)	-0.11 (0.17)	(-0.44, 0.23)	0.523	
	Placebo	20	16 (80.0)	-0.32 (0.11)	(-0.53, -0.11)				
Week 22	Tezepelumab	15	10 (66.7)	-0.43 (0.13)	(-0.69, -0.17)	-0.12 (0.17)	(-0.45, 0.22)	0.496	
	Placebo	20	16 (80.0)	-0.31 (0.11)	(-0.52, -0.10)				
Week 23	Tezepelumab	15	10 (66.7)	-0.41 (0.13)	(-0.68, -0.15)	-0.15 (0.17)	(-0.49, 0.19)	0.374	
	Placebo	20	16 (80.0)	-0.26 (0.11)	(-0.47, -0.05)				
Week 24	Tezepelumab	15	10 (66.7)	-0.34 (0.13)	(-0.61, -0.08)	-0.03 (0.17)	(-0.37, 0.31)	0.843	
	Placebo	20	15 (75.0)	-0.31 (0.11)	(-0.52, -0.10)				
Week 25	Tezepelumab	15	11 (73.3)	-0.44 (0.13)	(-0.70, -0.18)	-0.06 (0.17)	(-0.40, 0.27)	0.709	
	Placebo	20	15 (75.0)	-0.38 (0.11)	(-0.59, -0.16)				
Week 26	Tezepelumab	15	11 (73.3)	-0.38 (0.13)	(-0.64, -0.11)	0.02 (0.17)	(-0.32, 0.36)	0.927	
	Placebo	20	15 (75.0)	-0.40 (0.11)	(-0.61, -0.18)				
Week 27	Tezepelumab	15	10 (66.7)	-0.40 (0.14)	(-0.66, -0.13)	-0.02 (0.17)	(-0.36, 0.32)	0.908	
	Placebo	20	16 (80.0)	-0.38 (0.11)	(-0.59, -0.16)				
Week 28	Tezepelumab	15	9 (60.0)	-0.44 (0.14)	(-0.72, -0.17)	-0.13 (0.18)	(-0.48, 0.22)	0.463	
	Placebo	20	15 (75.0)	-0.32 (0.11)	(-0.53, -0.10)				
Week 29	Tezepelumab	15	10 (66.7)	-0.37 (0.14)	(-0.64, -0.09)	0.01 (0.18)	(-0.34, 0.36)	0.954	
	Placebo	20	15 (75.0)	-0.38 (0.11)	(-0.59, -0.17)				
Week 30	Tezepelumab	15	9 (60.0)	-0.48 (0.14)	(-0.76, -0.21)	-0.09 (0.18)	(-0.44, 0.26)	0.597	
	Placebo	20	14 (70.0)	-0.39 (0.11)	(-0.60, -0.18)				

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WAC\_KLMC0: Change from baseline in ASD weekly waking score - MMRM results  
 DITTL - adolescents

Change from baseline in ASD weekly waking score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Time	Treatment	N	n (%)					
Week 31	Tezepelumab	15	8 (53.3)	-0.47 (0.14)	(-0.76, -0.19)	-0.05 (0.18)	(-0.40, 0.30)	0.783
	Placebo	20	14 (70.0)	-0.43 (0.11)	(-0.64, -0.21)			
Week 32	Tezepelumab	15	9 (60.0)	-0.46 (0.14)	(-0.74, -0.19)	-0.07 (0.18)	(-0.42, 0.28)	0.695
	Placebo	20	16 (80.0)	-0.40 (0.11)	(-0.60, -0.19)			
Week 33	Tezepelumab	15	8 (53.3)	-0.45 (0.14)	(-0.73, -0.17)	-0.09 (0.18)	(-0.44, 0.27)	0.634
	Placebo	20	14 (70.0)	-0.37 (0.11)	(-0.58, -0.15)			
Week 34	Tezepelumab	15	8 (53.3)	-0.48 (0.14)	(-0.77, -0.20)	-0.13 (0.18)	(-0.48, 0.23)	0.479
	Placebo	20	12 (60.0)	-0.36 (0.11)	(-0.57, -0.14)			
Week 35	Tezepelumab	15	9 (60.0)	-0.44 (0.14)	(-0.72, -0.16)	-0.04 (0.18)	(-0.39, 0.32)	0.836
	Placebo	20	15 (75.0)	-0.41 (0.11)	(-0.62, -0.19)			
Week 36	Tezepelumab	15	8 (53.3)	-0.48 (0.14)	(-0.76, -0.20)	-0.01 (0.18)	(-0.36, 0.34)	0.954
	Placebo	20	14 (70.0)	-0.47 (0.11)	(-0.68, -0.25)			
Week 37	Tezepelumab	15	9 (60.0)	-0.41 (0.14)	(-0.69, -0.13)	0.01 (0.18)	(-0.34, 0.37)	0.934
	Placebo	20	14 (70.0)	-0.43 (0.11)	(-0.65, -0.21)			
Week 38	Tezepelumab	15	8 (53.3)	-0.45 (0.14)	(-0.73, -0.16)	-0.09 (0.18)	(-0.44, 0.27)	0.628
	Placebo	20	15 (75.0)	-0.36 (0.11)	(-0.58, -0.14)			
Week 39	Tezepelumab	15	10 (66.7)	-0.48 (0.14)	(-0.76, -0.20)	-0.13 (0.18)	(-0.49, 0.22)	0.463
	Placebo	20	13 (65.0)	-0.35 (0.11)	(-0.57, -0.13)			
Week 40	Tezepelumab	15	10 (66.7)	-0.46 (0.14)	(-0.74, -0.18)	-0.15 (0.18)	(-0.50, 0.21)	0.420
	Placebo	20	13 (65.0)	-0.31 (0.11)	(-0.54, -0.09)			

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WAC\_KLMC0: Change from baseline in ASD weekly waking score - MMRM results  
 DITTLL - adolescents

Change from baseline in ASD weekly waking score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Time	Treatment	N	n (%)					
Week 41	Tezepelumab	15	9 (60.0)	-0.38 (0.14)	(-0.66, -0.10)	-0.02 (0.18)	(-0.38, 0.34)	0.897
	Placebo	20	13 (65.0)	-0.36 (0.11)	(-0.58, -0.13)			
Week 42	Tezepelumab	15	9 (60.0)	-0.38 (0.14)	(-0.66, -0.09)	-0.08 (0.18)	(-0.44, 0.28)	0.661
	Placebo	20	13 (65.0)	-0.30 (0.11)	(-0.52, -0.07)			
Week 43	Tezepelumab	15	8 (53.3)	-0.46 (0.15)	(-0.75, -0.17)	-0.11 (0.19)	(-0.47, 0.26)	0.564
	Placebo	20	14 (70.0)	-0.35 (0.11)	(-0.57, -0.13)			
Week 44	Tezepelumab	15	8 (53.3)	-0.41 (0.15)	(-0.71, -0.12)	-0.08 (0.19)	(-0.45, 0.29)	0.663
	Placebo	20	14 (70.0)	-0.33 (0.11)	(-0.55, -0.11)			
Week 45	Tezepelumab	15	8 (53.3)	-0.51 (0.15)	(-0.81, -0.22)	-0.21 (0.19)	(-0.59, 0.16)	0.266
	Placebo	20	12 (60.0)	-0.30 (0.12)	(-0.53, -0.07)			
Week 46	Tezepelumab	15	7 (46.7)	-0.49 (0.15)	(-0.79, -0.18)	-0.16 (0.19)	(-0.54, 0.22)	0.408
	Placebo	20	11 (55.0)	-0.33 (0.12)	(-0.56, -0.10)			
Week 47	Tezepelumab	15	6 (40.0)	-0.44 (0.16)	(-0.75, -0.13)	-0.03 (0.19)	(-0.41, 0.35)	0.876
	Placebo	20	13 (65.0)	-0.41 (0.11)	(-0.63, -0.18)			
Week 48	Tezepelumab	15	6 (40.0)	-0.51 (0.16)	(-0.82, -0.20)	-0.11 (0.19)	(-0.49, 0.27)	0.561
	Placebo	20	14 (70.0)	-0.40 (0.11)	(-0.62, -0.17)			
Week 49	Tezepelumab	15	7 (46.7)	-0.45 (0.15)	(-0.75, -0.15)	-0.09 (0.19)	(-0.46, 0.29)	0.656
	Placebo	20	12 (60.0)	-0.37 (0.12)	(-0.59, -0.14)			
Week 50	Tezepelumab	15	7 (46.7)	-0.49 (0.15)	(-0.79, -0.20)	-0.08 (0.19)	(-0.46, 0.30)	0.670
	Placebo	20	12 (60.0)	-0.41 (0.12)	(-0.64, -0.18)			

Note: DITTLL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WAC\_KLMC0: Change from baseline in ASD weekly waking score - MMRM results  
 DITTTL - adolescents

Change from baseline in ASD weekly waking score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 51	Tezepelumab	15	8 (53.3)	-0.47 (0.15)	(-0.77, -0.18)	-0.04 (0.19)	(-0.41, 0.34)	0.848
	Placebo	20	14 (70.0)	-0.44 (0.12)	(-0.66, -0.21)			
Week 52	Tezepelumab	15	8 (53.3)	-0.43 (0.15)	(-0.73, -0.13)	0.00 (0.19)	(-0.38, 0.39)	0.980
	Placebo	20	12 (60.0)	-0.43 (0.12)	(-0.67, -0.20)			

Note: DITTTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WLC\_KLMH0: Course of ASD weekly limiting activity score  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly limiting activity score	Baseline	Tezepelumab	15	15 (100.0)	1.20 (0.57)	0.0	1.00	1.17	1.57	2.0	
		Placebo	20	20 (100.0)	1.56 (1.04)	0.0	0.79	1.21	2.29	3.6	
	Week 1	Tezepelumab	15	15 (100.0)	0.99 (0.64)	0.0	0.57	1.00	1.29	2.0	
		Placebo	20	20 (100.0)	1.41 (1.17)	0.0	0.64	1.00	2.36	4.0	
	Week 2	Tezepelumab	15	15 (100.0)	1.00 (0.88)	0.0	0.17	1.00	1.29	3.0	
		Placebo	20	20 (100.0)	1.21 (1.12)	0.0	0.14	0.93	2.21	3.1	
	Week 3	Tezepelumab	15	14 (93.3)	0.98 (0.75)	0.0	0.60	1.00	1.29	2.5	
		Placebo	20	18 (90.0)	0.85 (0.85)	0.0	0.00	0.79	1.75	2.3	
	Week 4	Tezepelumab	15	14 (93.3)	0.85 (0.70)	0.0	0.17	1.00	1.14	2.0	
		Placebo	20	19 (95.0)	0.83 (0.80)	0.0	0.00	1.00	1.71	2.0	
	Week 5	Tezepelumab	15	14 (93.3)	0.97 (0.71)	0.0	0.50	1.00	1.17	2.5	
		Placebo	20	19 (95.0)	1.03 (0.82)	0.0	0.17	1.00	1.86	2.6	
	Week 6	Tezepelumab	15	12 (80.0)	0.85 (0.70)	0.0	0.14	0.92	1.14	2.0	
		Placebo	20	18 (90.0)	0.82 (0.74)	0.0	0.14	0.92	1.43	2.0	
	Week 7	Tezepelumab	15	15 (100.0)	0.87 (0.71)	0.0	0.00	1.00	1.67	2.0	
		Placebo	20	18 (90.0)	0.88 (0.82)	0.0	0.00	1.00	1.29	2.4	
	Week 8	Tezepelumab	15	14 (93.3)	0.88 (0.80)	0.0	0.00	0.75	1.71	2.2	
		Placebo	20	19 (95.0)	1.00 (0.88)	0.0	0.00	1.00	1.67	2.8	
	Week 9	Tezepelumab	15	12 (80.0)	0.82 (0.66)	0.0	0.17	1.00	1.23	2.0	
		Placebo	20	19 (95.0)	0.98 (0.91)	0.0	0.00	1.00	1.60	3.4	
	Week 10	Tezepelumab	15	15 (100.0)	0.79 (0.77)	0.0	0.00	1.00	1.60	2.0	
		Placebo	20	18 (90.0)	0.84 (1.03)	0.0	0.00	0.49	1.20	4.0	
	Week 11	Tezepelumab	15	13 (86.7)	0.76 (0.78)	0.0	0.00	1.00	1.40	2.0	
		Placebo	20	18 (90.0)	0.72 (0.82)	0.0	0.00	0.36	1.29	2.4	
	Week 12	Tezepelumab	15	13 (86.7)	0.73 (0.77)	0.0	0.00	0.71	1.33	2.2	
		Placebo	20	18 (90.0)	0.76 (0.76)	0.0	0.00	0.79	1.17	2.3	
	Week 13	Tezepelumab	15	11 (73.3)	0.71 (0.73)	0.0	0.00	0.40	1.50	1.9	
		Placebo	20	16 (80.0)	0.89 (1.02)	0.0	0.00	0.63	1.30	3.4	
	Week 14	Tezepelumab	15	10 (66.7)	0.57 (0.64)	0.0	0.00	0.28	1.00	1.9	
		Placebo	20	17 (85.0)	0.75 (0.79)	0.0	0.00	0.43	1.40	2.6	
	Week 15	Tezepelumab	15	11 (73.3)	0.59 (0.74)	0.0	0.00	0.14	1.20	1.9	
		Placebo	20	16 (80.0)	0.94 (0.91)	0.0	0.00	0.77	1.63	3.0	
	Week 16	Tezepelumab	15	11 (73.3)	0.59 (0.70)	0.0	0.00	0.17	1.00	2.0	
		Placebo	20	17 (85.0)	1.02 (0.90)	0.0	0.20	1.00	1.29	3.0	
Week 17	Tezepelumab	15	12 (80.0)	0.50 (0.60)	0.0	0.00	0.30	0.93	1.8		
	Placebo	20	16 (80.0)	0.91 (0.94)	0.0	0.10	0.61	1.53	3.0		

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022

Table NT1WLC\_KLMH0: Course of ASD weekly limiting activity score  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly limiting activity score	Week 18	Tezepelumab	15	11 (73.3)	0.56 (0.65)	0.0	0.00	0.14	1.00	1.9	
		Placebo	20	16 (80.0)	0.94 (0.96)	0.0	0.00	0.92	1.46	3.5	
	Week 19	Tezepelumab	15	12 (80.0)	0.47 (0.63)	0.0	0.00	0.07	1.00	1.7	
		Placebo	20	17 (85.0)	0.88 (0.96)	0.0	0.00	0.60	1.00	3.0	
	Week 20	Tezepelumab	15	10 (66.7)	0.42 (0.51)	0.0	0.00	0.08	1.00	1.2	
		Placebo	20	16 (80.0)	0.70 (1.02)	0.0	0.00	0.43	1.00	3.8	
	Week 21	Tezepelumab	15	10 (66.7)	0.60 (0.72)	0.0	0.00	0.25	1.00	1.8	
		Placebo	20	16 (80.0)	0.83 (1.04)	0.0	0.00	0.64	1.07	3.2	
	Week 22	Tezepelumab	15	10 (66.7)	0.46 (0.61)	0.0	0.00	0.00	1.00	1.3	
		Placebo	20	17 (85.0)	0.87 (1.07)	0.0	0.00	0.57	1.00	3.3	
	Week 23	Tezepelumab	15	10 (66.7)	0.53 (0.67)	0.0	0.00	0.08	1.00	1.6	
		Placebo	20	15 (75.0)	0.92 (1.14)	0.0	0.00	0.86	1.17	4.0	
	Week 24	Tezepelumab	15	11 (73.3)	0.53 (0.65)	0.0	0.00	0.14	1.00	1.7	
		Placebo	20	15 (75.0)	0.94 (1.06)	0.0	0.00	0.71	1.50	3.8	
	Week 25	Tezepelumab	15	9 (60.0)	0.56 (0.68)	0.0	0.00	0.00	1.20	1.6	
		Placebo	20	16 (80.0)	0.61 (0.85)	0.0	0.00	0.21	0.92	2.7	
	Week 26	Tezepelumab	15	9 (60.0)	0.40 (0.51)	0.0	0.00	0.00	1.00	1.2	
		Placebo	20	15 (75.0)	0.68 (0.73)	0.0	0.00	0.50	1.00	2.4	
	Week 27	Tezepelumab	15	10 (66.7)	0.49 (0.61)	0.0	0.00	0.08	1.00	1.5	
		Placebo	20	15 (75.0)	0.89 (0.95)	0.0	0.00	0.71	1.60	3.0	
	Week 28	Tezepelumab	15	9 (60.0)	0.39 (0.60)	0.0	0.00	0.00	1.00	1.5	
		Placebo	20	17 (85.0)	1.00 (1.10)	0.0	0.00	0.86	1.00	3.4	
	Week 29	Tezepelumab	15	8 (53.3)	0.40 (0.42)	0.0	0.07	0.21	0.80	1.0	
		Placebo	20	15 (75.0)	0.82 (0.83)	0.0	0.25	0.50	1.00	2.5	
	Week 30	Tezepelumab	15	9 (60.0)	0.41 (0.54)	0.0	0.00	0.14	1.00	1.2	
		Placebo	20	14 (70.0)	0.97 (0.92)	0.0	0.25	0.88	1.14	2.8	
	Week 31	Tezepelumab	15	8 (53.3)	0.38 (0.52)	0.0	0.00	0.00	1.00	1.0	
		Placebo	20	15 (75.0)	0.66 (0.69)	0.0	0.00	0.50	1.20	2.0	
	Week 32	Tezepelumab	15	9 (60.0)	0.38 (0.58)	0.0	0.00	0.00	1.00	1.4	
		Placebo	20	14 (70.0)	0.72 (0.84)	0.0	0.00	0.57	1.00	2.2	
	Week 33	Tezepelumab	15	9 (60.0)	0.38 (0.58)	0.0	0.00	0.00	1.00	1.4	
		Placebo	20	16 (80.0)	0.66 (0.81)	0.0	0.00	0.46	1.00	2.5	
	Week 34	Tezepelumab	15	10 (66.7)	0.49 (0.65)	0.0	0.00	0.00	1.00	1.5	
		Placebo	20	16 (80.0)	0.59 (0.75)	0.0	0.00	0.32	0.93	2.3	
	Week 35	Tezepelumab	15	9 (60.0)	0.46 (0.53)	0.0	0.00	0.20	1.00	1.2	
		Placebo	20	15 (75.0)	0.75 (0.99)	0.0	0.00	0.00	1.00	3.0	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022

Table NT1WLC\_KLMH0: Course of ASD weekly limiting activity score  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly limiting activity score	Week 36	Tezepelumab	15	10 (66.7)	0.36 (0.60)	0.0	0.00	0.00	1.00	1.6	
		Placebo	20	14 (70.0)	0.58 (0.72)	0.0	0.00	0.33	0.86	2.0	
	Week 37	Tezepelumab	15	9 (60.0)	0.40 (0.62)	0.0	0.00	0.00	1.00	1.6	
		Placebo	20	15 (75.0)	0.55 (0.71)	0.0	0.00	0.17	1.00	2.0	
	Week 38	Tezepelumab	15	8 (53.3)	0.33 (0.47)	0.0	0.00	0.00	0.83	1.0	
		Placebo	20	14 (70.0)	0.59 (0.61)	0.0	0.00	0.46	1.00	2.0	
	Week 39	Tezepelumab	15	10 (66.7)	0.40 (0.61)	0.0	0.00	0.00	1.00	1.7	
		Placebo	20	14 (70.0)	0.71 (0.73)	0.0	0.00	0.67	1.00	2.0	
	Week 40	Tezepelumab	15	9 (60.0)	0.37 (0.46)	0.0	0.00	0.00	0.83	1.0	
		Placebo	20	12 (60.0)	0.64 (0.64)	0.0	0.00	0.82	1.00	2.0	
	Week 41	Tezepelumab	15	9 (60.0)	0.40 (0.57)	0.0	0.00	0.00	1.00	1.3	
		Placebo	20	12 (60.0)	0.94 (0.82)	0.0	0.20	0.93	1.38	2.5	
	Week 42	Tezepelumab	15	9 (60.0)	0.48 (0.74)	0.0	0.00	0.00	1.00	1.7	
		Placebo	20	14 (70.0)	0.73 (0.81)	0.0	0.00	0.71	1.00	2.7	
	Week 43	Tezepelumab	15	9 (60.0)	0.37 (0.55)	0.0	0.00	0.00	1.00	1.1	
		Placebo	20	15 (75.0)	0.88 (0.78)	0.0	0.00	0.86	1.25	2.5	
	Week 44	Tezepelumab	15	8 (53.3)	0.46 (0.66)	0.0	0.00	0.00	1.07	1.6	
		Placebo	20	16 (80.0)	0.88 (0.84)	0.0	0.00	0.92	1.42	2.5	
	Week 45	Tezepelumab	15	8 (53.3)	0.38 (0.52)	0.0	0.00	0.00	1.00	1.0	
		Placebo	20	14 (70.0)	0.85 (0.74)	0.0	0.14	0.76	1.25	2.0	
	Week 46	Tezepelumab	15	8 (53.3)	0.42 (0.53)	0.0	0.00	0.10	1.00	1.2	
		Placebo	20	12 (60.0)	0.92 (0.84)	0.0	0.00	1.00	1.36	2.5	
	Week 47	Tezepelumab	15	8 (53.3)	0.36 (0.49)	0.0	0.00	0.00	0.93	1.0	
		Placebo	20	14 (70.0)	0.70 (0.63)	0.0	0.00	0.80	1.00	1.9	
	Week 48	Tezepelumab	15	8 (53.3)	0.35 (0.49)	0.0	0.00	0.00	0.92	1.0	
		Placebo	20	12 (60.0)	0.79 (0.90)	0.0	0.00	0.60	1.43	2.4	
	Week 49	Tezepelumab	15	8 (53.3)	0.39 (0.54)	0.0	0.00	0.00	1.00	1.1	
		Placebo	20	14 (70.0)	0.55 (0.60)	0.0	0.00	0.41	1.00	1.9	
	Week 50	Tezepelumab	15	8 (53.3)	0.50 (0.74)	0.0	0.00	0.00	1.08	1.9	
		Placebo	20	13 (65.0)	0.73 (0.84)	0.0	0.00	0.60	1.00	2.8	
	Week 51	Tezepelumab	15	9 (60.0)	0.37 (0.55)	0.0	0.00	0.00	1.00	1.3	
		Placebo	20	14 (70.0)	0.81 (0.76)	0.0	0.00	0.79	1.57	2.0	
	Week 52	Tezepelumab	15	9 (60.0)	0.35 (0.53)	0.0	0.00	0.00	1.00	1.1	
		Placebo	20	13 (65.0)	0.57 (0.63)	0.0	0.00	0.33	1.00	1.8	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022



Table NT1WLC\_KLMH0: Course of ASD weekly limiting activity score  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly limiting activity score	Week 1	Tezepelumab	15	15 (100.0)	-0.21 (0.35)	-1.0	-0.29	-0.17	0.00	0.3	-0.14 [-0.81, 0.53]
		Placebo	20	20 (100.0)	-0.15 (0.53)	-1.3	-0.50	-0.21	0.00	1.0	
	Week 2	Tezepelumab	15	15 (100.0)	-0.20 (0.58)	-1.0	-0.71	-0.17	0.14	1.2	0.23 [-0.44, 0.90]
		Placebo	20	20 (100.0)	-0.35 (0.70)	-2.0	-0.57	-0.29	0.00	1.3	
	Week 3	Tezepelumab	15	14 (93.3)	-0.20 (0.52)	-1.0	-0.54	-0.15	0.00	0.7	0.85 [0.12, 1.58]
		Placebo	20	18 (90.0)	-0.65 (0.53)	-1.8	-1.00	-0.62	-0.29	0.0	
	Week 4	Tezepelumab	15	14 (93.3)	-0.33 (0.45)	-1.4	-0.39	-0.21	0.00	0.0	0.72 [0.00, 1.43]
		Placebo	20	19 (95.0)	-0.76 (0.68)	-2.1	-1.14	-0.57	-0.29	0.0	
	Week 5	Tezepelumab	15	14 (93.3)	-0.22 (0.45)	-1.0	-0.57	-0.14	0.00	0.7	0.61 [-0.10, 1.32]
		Placebo	20	19 (95.0)	-0.55 (0.62)	-2.1	-0.98	-0.40	-0.14	0.3	
	Week 6	Tezepelumab	15	12 (80.0)	-0.30 (0.42)	-1.0	-0.65	-0.17	0.00	0.2	0.68 [-0.07, 1.43]
		Placebo	20	18 (90.0)	-0.69 (0.65)	-2.1	-1.07	-0.57	-0.14	0.1	
	Week 7	Tezepelumab	15	15 (100.0)	-0.34 (0.55)	-1.6	-0.43	-0.29	0.00	0.6	0.58 [-0.12, 1.28]
		Placebo	20	18 (90.0)	-0.69 (0.64)	-2.1	-1.14	-0.59	-0.29	0.3	
	Week 8	Tezepelumab	15	14 (93.3)	-0.30 (0.57)	-1.5	-0.71	-0.20	0.00	0.7	0.48 [-0.22, 1.18]
		Placebo	20	19 (95.0)	-0.58 (0.60)	-2.1	-1.00	-0.43	-0.14	0.3	
	Week 9	Tezepelumab	15	12 (80.0)	-0.30 (0.52)	-1.6	-0.39	-0.13	0.00	0.3	0.55 [-0.19, 1.28]
		Placebo	20	19 (95.0)	-0.60 (0.58)	-2.4	-0.86	-0.52	-0.17	0.1	
	Week 10	Tezepelumab	15	15 (100.0)	-0.42 (0.65)	-1.6	-1.00	-0.29	0.00	0.7	0.31 [-0.38, 1.00]
		Placebo	20	18 (90.0)	-0.66 (0.87)	-2.1	-1.14	-0.64	0.00	1.0	
	Week 11	Tezepelumab	15	13 (86.7)	-0.42 (0.64)	-1.5	-0.86	-0.29	0.00	0.5	0.48 [-0.24, 1.21]
		Placebo	20	18 (90.0)	-0.75 (0.72)	-2.0	-1.14	-0.59	-0.29	0.3	
	Week 12	Tezepelumab	15	13 (86.7)	-0.45 (0.64)	-1.4	-1.00	-0.33	0.00	0.5	0.43 [-0.30, 1.15]
		Placebo	20	18 (90.0)	-0.71 (0.61)	-2.0	-1.00	-0.57	-0.29	0.0	
	Week 13	Tezepelumab	15	11 (73.3)	-0.47 (0.77)	-1.6	-1.12	-0.29	0.00	0.9	0.42 [-0.36, 1.19]
		Placebo	20	16 (80.0)	-0.76 (0.65)	-2.3	-1.00	-0.57	-0.36	0.0	
	Week 14	Tezepelumab	15	10 (66.7)	-0.61 (0.76)	-1.6	-1.12	-0.77	0.00	0.9	0.23 [-0.56, 1.01]
		Placebo	20	17 (85.0)	-0.78 (0.75)	-2.1	-1.14	-0.57	-0.31	0.5	
	Week 15	Tezepelumab	15	11 (73.3)	-0.59 (0.74)	-1.5	-1.14	-0.80	0.00	0.9	-0.03 [-0.80, 0.74]
		Placebo	20	16 (80.0)	-0.56 (0.77)	-2.3	-0.85	-0.43	-0.07	0.9	
	Week 16	Tezepelumab	15	11 (73.3)	-0.62 (0.75)	-1.5	-1.12	-1.00	0.00	1.0	0.14 [-0.62, 0.90]
		Placebo	20	17 (85.0)	-0.72 (0.62)	-2.1	-1.00	-0.57	-0.43	0.3	
	Week 17	Tezepelumab	15	12 (80.0)	-0.69 (0.73)	-1.5	-1.31	-0.99	-0.13	0.8	0.04 [-0.71, 0.79]
		Placebo	20	16 (80.0)	-0.72 (0.83)	-2.3	-1.32	-0.61	-0.14	0.7	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022

Table NT1WLC\_KLMH0: Course of ASD weekly limiting activity score  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly limiting activity score	Week 18	Tezepelumab	15	11 (73.3)	-0.55 (0.77)	-1.5	-1.14	-1.00	0.00	0.9	0.15 [-0.62, 0.92]
		Placebo	20	16 (80.0)	-0.68 (0.95)	-3.1	-1.14	-0.57	-0.11	0.5	
	Week 19	Tezepelumab	15	12 (80.0)	-0.71 (0.78)	-2.0	-1.36	-0.73	-0.07	0.7	0.18 [-0.56, 0.92]
		Placebo	20	17 (85.0)	-0.86 (0.88)	-3.1	-1.50	-0.57	-0.29	0.1	
	Week 20	Tezepelumab	15	10 (66.7)	-0.65 (0.58)	-1.4	-1.00	-0.85	0.00	0.2	0.31 [-0.49, 1.10]
		Placebo	20	16 (80.0)	-0.92 (1.02)	-3.1	-1.64	-0.86	-0.14	0.8	
	Week 21	Tezepelumab	15	10 (66.7)	-0.54 (0.79)	-1.5	-1.29	-0.56	0.00	0.8	0.45 [-0.35, 1.26]
		Placebo	20	16 (80.0)	-0.94 (0.95)	-3.1	-1.57	-0.79	-0.07	0.2	
	Week 22	Tezepelumab	15	10 (66.7)	-0.61 (0.59)	-1.4	-1.00	-0.68	0.00	0.3	0.30 [-0.48, 1.09]
		Placebo	20	17 (85.0)	-0.85 (0.91)	-3.1	-1.29	-0.71	-0.02	0.2	
	Week 23	Tezepelumab	15	10 (66.7)	-0.54 (0.66)	-1.4	-1.00	-0.60	0.00	0.6	0.25 [-0.55, 1.05]
		Placebo	20	15 (75.0)	-0.80 (1.19)	-3.1	-1.71	-0.83	0.00	1.3	
	Week 24	Tezepelumab	15	11 (73.3)	-0.58 (0.65)	-1.5	-1.29	-0.36	0.00	0.4	0.21 [-0.57, 0.99]
		Placebo	20	15 (75.0)	-0.78 (1.07)	-3.1	-1.57	-0.86	-0.14	1.0	
	Week 25	Tezepelumab	15	9 (60.0)	-0.43 (0.73)	-1.4	-1.00	-0.29	0.00	0.6	0.64 [-0.20, 1.47]
		Placebo	20	16 (80.0)	-0.99 (0.96)	-3.1	-1.64	-0.79	-0.38	0.8	
	Week 26	Tezepelumab	15	9 (60.0)	-0.59 (0.60)	-1.4	-1.00	-0.46	0.00	0.2	0.30 [-0.53, 1.13]
		Placebo	20	15 (75.0)	-0.86 (1.02)	-3.1	-1.25	-0.86	-0.29	1.4	
	Week 27	Tezepelumab	15	10 (66.7)	-0.58 (0.62)	-1.4	-1.00	-0.73	0.00	0.5	0.15 [-0.65, 0.95]
		Placebo	20	15 (75.0)	-0.71 (0.97)	-3.0	-1.20	-0.57	-0.14	1.3	
	Week 28	Tezepelumab	15	9 (60.0)	-0.69 (0.54)	-1.4	-1.00	-0.86	-0.29	0.0	-0.07 [-0.88, 0.74]
		Placebo	20	17 (85.0)	-0.62 (1.04)	-3.1	-1.14	-0.43	0.00	1.5	
	Week 29	Tezepelumab	15	8 (53.3)	-0.71 (0.54)	-1.3	-1.19	-0.86	-0.14	0.0	0.08 [-0.78, 0.93]
		Placebo	20	15 (75.0)	-0.78 (1.03)	-3.1	-1.57	-0.50	-0.19	1.3	
	Week 30	Tezepelumab	15	9 (60.0)	-0.67 (0.49)	-1.3	-0.86	-0.83	-0.29	0.0	0.06 [-0.78, 0.90]
		Placebo	20	14 (70.0)	-0.73 (1.07)	-3.1	-1.25	-0.64	-0.14	1.7	
	Week 31	Tezepelumab	15	8 (53.3)	-0.73 (0.56)	-1.4	-1.14	-0.92	-0.14	0.0	0.25 [-0.61, 1.12]
		Placebo	20	15 (75.0)	-0.94 (0.96)	-3.1	-1.50	-1.00	-0.36	1.0	
	Week 32	Tezepelumab	15	9 (60.0)	-0.70 (0.54)	-1.4	-1.00	-0.86	-0.29	0.0	0.18 [-0.66, 1.02]
		Placebo	20	14 (70.0)	-0.85 (1.00)	-3.1	-1.17	-0.86	-0.29	1.2	
	Week 33	Tezepelumab	15	9 (60.0)	-0.70 (0.54)	-1.4	-1.00	-0.86	-0.29	0.0	0.36 [-0.46, 1.18]
		Placebo	20	16 (80.0)	-0.97 (0.85)	-3.1	-1.54	-0.57	-0.43	0.0	
	Week 34	Tezepelumab	15	10 (66.7)	-0.58 (0.63)	-1.4	-1.00	-0.65	0.00	0.5	0.42 [-0.38, 1.21]
		Placebo	20	16 (80.0)	-0.91 (0.89)	-3.1	-1.61	-0.64	-0.34	0.1	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WLC\_KLMH0: Course of ASD weekly limiting activity score  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly limiting activity score	Week 35	Tezepelumab	15	9 (60.0)	-0.62 (0.50)	-1.4	-0.86	-0.71	-0.09	0.0	0.14 [-0.69, 0.97]
		Placebo	20	15 (75.0)	-0.75 (1.18)	-3.1	-1.57	-0.71	0.00	2.0	
	Week 36	Tezepelumab	15	10 (66.7)	-0.76 (0.58)	-1.5	-1.29	-0.93	-0.26	0.0	0.12 [-0.70, 0.93]
		Placebo	20	14 (70.0)	-0.84 (0.67)	-2.0	-1.20	-0.79	-0.29	0.1	
	Week 37	Tezepelumab	15	9 (60.0)	-0.68 (0.55)	-1.4	-1.00	-0.86	-0.26	0.0	0.36 [-0.47, 1.20]
		Placebo	20	15 (75.0)	-0.98 (0.95)	-3.1	-1.74	-1.00	-0.14	0.1	
	Week 38	Tezepelumab	15	8 (53.3)	-0.77 (0.58)	-1.4	-1.23	-1.00	-0.14	0.0	0.10 [-0.77, 0.97]
		Placebo	20	14 (70.0)	-0.84 (0.72)	-2.0	-1.50	-0.86	-0.29	0.1	
	Week 39	Tezepelumab	15	10 (66.7)	-0.72 (0.59)	-1.5	-1.29	-0.79	-0.17	0.0	0.13 [-0.68, 0.95]
		Placebo	20	14 (70.0)	-0.84 (1.05)	-3.1	-1.71	-0.82	0.00	0.8	
	Week 40	Tezepelumab	15	9 (60.0)	-0.71 (0.55)	-1.4	-1.00	-1.00	-0.29	0.0	0.16 [-0.71, 1.03]
		Placebo	20	12 (60.0)	-0.84 (0.99)	-3.1	-1.39	-0.65	0.00	0.3	
	Week 41	Tezepelumab	15	9 (60.0)	-0.68 (0.51)	-1.4	-1.00	-0.71	-0.29	0.0	0.06 [-0.81, 0.92]
		Placebo	20	12 (60.0)	-0.73 (1.17)	-3.1	-1.49	-0.57	-0.07	1.5	
	Week 42	Tezepelumab	15	9 (60.0)	-0.60 (0.55)	-1.4	-1.00	-0.43	-0.12	0.0	0.21 [-0.62, 1.05]
		Placebo	20	14 (70.0)	-0.77 (0.89)	-3.1	-1.29	-0.43	0.00	0.1	
	Week 43	Tezepelumab	15	9 (60.0)	-0.71 (0.52)	-1.4	-1.00	-0.86	-0.29	0.0	0.24 [-0.59, 1.07]
		Placebo	20	15 (75.0)	-0.94 (1.13)	-3.1	-1.57	-1.14	-0.43	1.5	
	Week 44	Tezepelumab	15	8 (53.3)	-0.75 (0.51)	-1.4	-1.14	-0.86	-0.27	0.0	0.10 [-0.75, 0.95]
		Placebo	20	16 (80.0)	-0.84 (1.09)	-3.1	-1.64	-0.93	-0.15	1.5	
	Week 45	Tezepelumab	15	8 (53.3)	-0.84 (0.48)	-1.4	-1.14	-0.93	-0.56	0.0	0.25 [-0.62, 1.12]
		Placebo	20	14 (70.0)	-1.03 (0.89)	-3.1	-1.57	-0.93	-0.43	0.3	
	Week 46	Tezepelumab	15	8 (53.3)	-0.79 (0.45)	-1.4	-1.04	-0.85	-0.56	0.0	0.18 [-0.72, 1.08]
		Placebo	20	12 (60.0)	-0.94 (1.00)	-3.1	-1.64	-0.82	-0.14	0.3	
	Week 47	Tezepelumab	15	8 (53.3)	-0.85 (0.48)	-1.4	-1.14	-0.99	-0.57	0.0	0.06 [-0.81, 0.93]
		Placebo	20	14 (70.0)	-0.91 (1.02)	-3.1	-1.71	-0.71	-0.05	0.5	
	Week 48	Tezepelumab	15	8 (53.3)	-0.86 (0.48)	-1.4	-1.14	-1.00	-0.57	0.0	-0.02 [-0.91, 0.88]
		Placebo	20	12 (60.0)	-0.84 (1.12)	-3.1	-1.49	-0.76	-0.36	1.4	
	Week 49	Tezepelumab	15	8 (53.3)	-0.82 (0.48)	-1.4	-1.14	-0.93	-0.49	0.0	0.25 [-0.62, 1.12]
		Placebo	20	14 (70.0)	-1.02 (0.92)	-3.1	-1.71	-0.80	-0.29	0.1	
	Week 50	Tezepelumab	15	8 (53.3)	-0.71 (0.56)	-1.4	-1.14	-0.85	-0.14	0.0	0.25 [-0.64, 1.13]
		Placebo	20	13 (65.0)	-0.91 (0.91)	-3.1	-1.20	-0.43	-0.29	0.0	
	Week 51	Tezepelumab	15	9 (60.0)	-0.71 (0.53)	-1.4	-1.00	-0.86	-0.29	0.0	0.29 [-0.55, 1.13]
		Placebo	20	14 (70.0)	-0.95 (0.94)	-3.1	-1.57	-1.07	-0.19	0.3	
	Week 52	Tezepelumab	15	9 (60.0)	-0.73 (0.52)	-1.4	-1.00	-0.86	-0.29	0.0	0.23 [-0.62, 1.08]
		Placebo	20	13 (65.0)	-0.91 (0.93)	-3.1	-1.14	-0.86	-0.29	0.4	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.  
 Source Data: aasd, created on: 20FEB2022

Table NT1WLC\_KLMC0: Change from baseline in ASD weekly limiting activity score - MMRM results  
 DITTL - adolescents

Change from baseline in ASD weekly limiting activity score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 1	Tezepelumab	15	15 (100.0)	-0.31 (0.18)	(-0.65, 0.04)	-0.22 (0.23)	(-0.68, 0.24)	0.350
	Placebo	20	20 (100.0)	-0.09 (0.15)	(-0.39, 0.21)			
Week 2	Tezepelumab	15	15 (100.0)	-0.29 (0.18)	(-0.64, 0.05)	-0.00 (0.23)	(-0.46, 0.45)	0.988
	Placebo	20	20 (100.0)	-0.29 (0.15)	(-0.59, 0.01)			
Week 3	Tezepelumab	15	14 (93.3)	-0.31 (0.18)	(-0.66, 0.04)	0.22 (0.23)	(-0.24, 0.68)	0.355
	Placebo	20	18 (90.0)	-0.53 (0.15)	(-0.83, -0.23)			
Week 4	Tezepelumab	15	14 (93.3)	-0.45 (0.18)	(-0.80, -0.11)	0.16 (0.23)	(-0.30, 0.63)	0.485
	Placebo	20	19 (95.0)	-0.62 (0.15)	(-0.92, -0.32)			
Week 5	Tezepelumab	15	14 (93.3)	-0.35 (0.18)	(-0.70, -0.00)	0.07 (0.23)	(-0.40, 0.53)	0.777
	Placebo	20	19 (95.0)	-0.42 (0.15)	(-0.72, -0.11)			
Week 6	Tezepelumab	15	12 (80.0)	-0.50 (0.18)	(-0.85, -0.14)	0.05 (0.24)	(-0.41, 0.52)	0.827
	Placebo	20	18 (90.0)	-0.55 (0.15)	(-0.85, -0.24)			
Week 7	Tezepelumab	15	15 (100.0)	-0.43 (0.18)	(-0.77, -0.08)	0.18 (0.23)	(-0.28, 0.64)	0.453
	Placebo	20	18 (90.0)	-0.60 (0.15)	(-0.91, -0.30)			
Week 8	Tezepelumab	15	14 (93.3)	-0.48 (0.18)	(-0.83, -0.13)	-0.03 (0.23)	(-0.49, 0.43)	0.896
	Placebo	20	19 (95.0)	-0.45 (0.15)	(-0.75, -0.15)			
Week 9	Tezepelumab	15	12 (80.0)	-0.45 (0.18)	(-0.81, -0.10)	0.01 (0.23)	(-0.45, 0.48)	0.958
	Placebo	20	19 (95.0)	-0.47 (0.15)	(-0.77, -0.17)			
Week 10	Tezepelumab	15	15 (100.0)	-0.51 (0.18)	(-0.86, -0.16)	0.07 (0.23)	(-0.39, 0.52)	0.780
	Placebo	20	18 (90.0)	-0.58 (0.15)	(-0.88, -0.27)			

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WLC\_KLMC0: Change from baseline in ASD weekly limiting activity score - MMRM results  
 DITTL - adolescents

Change from baseline in ASD weekly limiting activity score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 11	Tezepelumab	15	13 (86.7)	-0.57 (0.18)	(-0.92, -0.22)	0.03 (0.24)	(-0.44, 0.49)	0.909
	Placebo	20	18 (90.0)	-0.60 (0.15)	(-0.90, -0.30)			
Week 12	Tezepelumab	15	13 (86.7)	-0.59 (0.18)	(-0.94, -0.23)	-0.03 (0.24)	(-0.50, 0.44)	0.907
	Placebo	20	18 (90.0)	-0.56 (0.15)	(-0.86, -0.26)			
Week 13	Tezepelumab	15	11 (73.3)	-0.71 (0.18)	(-1.07, -0.35)	-0.07 (0.24)	(-0.54, 0.41)	0.780
	Placebo	20	16 (80.0)	-0.64 (0.16)	(-0.95, -0.34)			
Week 14	Tezepelumab	15	10 (66.7)	-0.76 (0.19)	(-1.13, -0.39)	-0.13 (0.24)	(-0.61, 0.35)	0.608
	Placebo	20	17 (85.0)	-0.63 (0.16)	(-0.94, -0.33)			
Week 15	Tezepelumab	15	11 (73.3)	-0.65 (0.19)	(-1.02, -0.28)	-0.16 (0.24)	(-0.65, 0.32)	0.501
	Placebo	20	16 (80.0)	-0.48 (0.16)	(-0.80, -0.17)			
Week 16	Tezepelumab	15	11 (73.3)	-0.66 (0.19)	(-1.03, -0.29)	-0.10 (0.25)	(-0.58, 0.39)	0.688
	Placebo	20	17 (85.0)	-0.56 (0.16)	(-0.87, -0.25)			
Week 17	Tezepelumab	15	12 (80.0)	-0.76 (0.19)	(-1.13, -0.38)	-0.20 (0.25)	(-0.69, 0.28)	0.413
	Placebo	20	16 (80.0)	-0.55 (0.16)	(-0.87, -0.24)			
Week 18	Tezepelumab	15	11 (73.3)	-0.71 (0.19)	(-1.08, -0.33)	-0.19 (0.25)	(-0.69, 0.30)	0.438
	Placebo	20	16 (80.0)	-0.51 (0.16)	(-0.83, -0.19)			
Week 19	Tezepelumab	15	12 (80.0)	-0.79 (0.19)	(-1.17, -0.41)	-0.08 (0.25)	(-0.57, 0.41)	0.745
	Placebo	20	17 (85.0)	-0.71 (0.16)	(-1.02, -0.39)			
Week 20	Tezepelumab	15	10 (66.7)	-0.93 (0.20)	(-1.32, -0.55)	-0.19 (0.25)	(-0.69, 0.31)	0.465
	Placebo	20	16 (80.0)	-0.75 (0.16)	(-1.06, -0.43)			

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WLC\_KLMC0: Change from baseline in ASD weekly limiting activity score - MMRM results  
 DITTL - adolescents

Time	Treatment	N	n (%)	Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 21	Tezepelumab	15	10 (66.7)	-0.72 (0.20)	(-1.11, -0.33)	0.03 (0.26)	(-0.48, 0.53)	0.916
	Placebo	20	16 (80.0)	-0.75 (0.16)	(-1.06, -0.43)			
Week 22	Tezepelumab	15	10 (66.7)	-0.87 (0.20)	(-1.27, -0.48)	-0.16 (0.26)	(-0.67, 0.35)	0.536
	Placebo	20	17 (85.0)	-0.72 (0.16)	(-1.03, -0.40)			
Week 23	Tezepelumab	15	10 (66.7)	-0.80 (0.20)	(-1.20, -0.41)	-0.24 (0.26)	(-0.75, 0.28)	0.367
	Placebo	20	15 (75.0)	-0.57 (0.16)	(-0.89, -0.25)			
Week 24	Tezepelumab	15	11 (73.3)	-0.75 (0.20)	(-1.14, -0.35)	-0.19 (0.26)	(-0.70, 0.32)	0.466
	Placebo	20	15 (75.0)	-0.56 (0.16)	(-0.88, -0.24)			
Week 25	Tezepelumab	15	9 (60.0)	-0.65 (0.21)	(-1.06, -0.24)	0.20 (0.26)	(-0.32, 0.71)	0.459
	Placebo	20	16 (80.0)	-0.85 (0.16)	(-1.16, -0.53)			
Week 26	Tezepelumab	15	9 (60.0)	-0.82 (0.21)	(-1.23, -0.41)	-0.18 (0.26)	(-0.70, 0.34)	0.501
	Placebo	20	15 (75.0)	-0.64 (0.16)	(-0.96, -0.32)			
Week 27	Tezepelumab	15	10 (66.7)	-0.81 (0.21)	(-1.22, -0.40)	-0.19 (0.26)	(-0.71, 0.33)	0.482
	Placebo	20	15 (75.0)	-0.63 (0.16)	(-0.94, -0.31)			
Week 28	Tezepelumab	15	9 (60.0)	-0.80 (0.21)	(-1.22, -0.38)	-0.21 (0.27)	(-0.73, 0.32)	0.434
	Placebo	20	17 (85.0)	-0.59 (0.16)	(-0.90, -0.28)			
Week 29	Tezepelumab	15	8 (53.3)	-0.84 (0.22)	(-1.27, -0.41)	-0.09 (0.27)	(-0.62, 0.45)	0.747
	Placebo	20	15 (75.0)	-0.75 (0.16)	(-1.07, -0.44)			
Week 30	Tezepelumab	15	9 (60.0)	-0.78 (0.22)	(-1.20, -0.35)	-0.19 (0.27)	(-0.72, 0.35)	0.494
	Placebo	20	14 (70.0)	-0.59 (0.16)	(-0.91, -0.27)			

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WLC\_KLMC0: Change from baseline in ASD weekly limiting activity score - MMRM results  
 DITTL - adolescents

Change from baseline in ASD weekly limiting activity score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 31	Tezepelumab	15	8 (53.3)	-0.86 (0.22)	(-1.29, -0.43)	0.02 (0.27)	(-0.52, 0.55)	0.955
	Placebo	20	15 (75.0)	-0.87 (0.16)	(-1.19, -0.55)			
Week 32	Tezepelumab	15	9 (60.0)	-0.80 (0.21)	(-1.23, -0.38)	0.02 (0.27)	(-0.51, 0.56)	0.928
	Placebo	20	14 (70.0)	-0.83 (0.16)	(-1.15, -0.51)			
Week 33	Tezepelumab	15	9 (60.0)	-0.80 (0.21)	(-1.22, -0.38)	0.04 (0.27)	(-0.49, 0.56)	0.893
	Placebo	20	16 (80.0)	-0.83 (0.16)	(-1.15, -0.52)			
Week 34	Tezepelumab	15	10 (66.7)	-0.80 (0.21)	(-1.21, -0.38)	0.11 (0.26)	(-0.41, 0.63)	0.681
	Placebo	20	16 (80.0)	-0.90 (0.16)	(-1.22, -0.59)			
Week 35	Tezepelumab	15	9 (60.0)	-0.73 (0.21)	(-1.14, -0.32)	0.01 (0.27)	(-0.52, 0.53)	0.974
	Placebo	20	15 (75.0)	-0.74 (0.16)	(-1.06, -0.42)			
Week 36	Tezepelumab	15	10 (66.7)	-0.81 (0.21)	(-1.22, -0.40)	0.02 (0.27)	(-0.51, 0.54)	0.952
	Placebo	20	14 (70.0)	-0.83 (0.16)	(-1.15, -0.50)			
Week 37	Tezepelumab	15	9 (60.0)	-0.82 (0.21)	(-1.24, -0.40)	0.02 (0.27)	(-0.51, 0.55)	0.937
	Placebo	20	15 (75.0)	-0.84 (0.17)	(-1.17, -0.52)			
Week 38	Tezepelumab	15	8 (53.3)	-0.93 (0.22)	(-1.35, -0.51)	-0.19 (0.27)	(-0.73, 0.34)	0.478
	Placebo	20	14 (70.0)	-0.74 (0.17)	(-1.06, -0.41)			
Week 39	Tezepelumab	15	10 (66.7)	-0.80 (0.21)	(-1.22, -0.38)	0.09 (0.27)	(-0.45, 0.62)	0.753
	Placebo	20	14 (70.0)	-0.88 (0.17)	(-1.21, -0.56)			
Week 40	Tezepelumab	15	9 (60.0)	-0.87 (0.22)	(-1.29, -0.44)	-0.09 (0.28)	(-0.64, 0.45)	0.731
	Placebo	20	12 (60.0)	-0.77 (0.17)	(-1.11, -0.44)			

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WLC\_KLMC0: Change from baseline in ASD weekly limiting activity score - MMRM results  
 DITTL - adolescents

Change from baseline in ASD weekly limiting activity score				Repeated measures analysis																																																																																																																														
				Change from Baseline		Treatment Difference																																																																																																																												
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value																																																																																																																						
Week 41	Tezepelumab	15	9 (60.0)	-0.84 (0.22)	(-1.27, -0.41)	-0.03 (0.28)	(-0.58, 0.51)	0.909																																																																																																																										
	Placebo	20	12 (60.0)	-0.80 (0.17)	(-1.14, -0.47)				Week 42	Tezepelumab	15	9 (60.0)	-0.76 (0.22)	(-1.19, -0.32)	-0.05 (0.28)	(-0.60, 0.49)	0.844	Placebo	20	14 (70.0)	-0.70 (0.17)	(-1.03, -0.38)	Week 43	Tezepelumab	15	9 (60.0)	-0.87 (0.22)	(-1.30, -0.43)	-0.08 (0.28)	(-0.63, 0.46)	0.767	Placebo	20	15 (75.0)	-0.78 (0.17)	(-1.11, -0.46)	Week 44	Tezepelumab	15	8 (53.3)	-0.81 (0.23)	(-1.26, -0.37)	-0.09 (0.28)	(-0.65, 0.46)	0.741	Placebo	20	16 (80.0)	-0.72 (0.17)	(-1.05, -0.39)	Week 45	Tezepelumab	15	8 (53.3)	-0.90 (0.23)	(-1.35, -0.45)	-0.18 (0.29)	(-0.75, 0.38)	0.522	Placebo	20	14 (70.0)	-0.72 (0.17)	(-1.05, -0.39)	Week 46	Tezepelumab	15	8 (53.3)	-0.86 (0.23)	(-1.31, -0.40)	-0.16 (0.29)	(-0.72, 0.41)	0.592	Placebo	20	12 (60.0)	-0.70 (0.17)	(-1.04, -0.36)	Week 47	Tezepelumab	15	8 (53.3)	-0.92 (0.23)	(-1.38, -0.47)	-0.07 (0.29)	(-0.64, 0.50)	0.810	Placebo	20	14 (70.0)	-0.85 (0.17)	(-1.19, -0.52)	Week 48	Tezepelumab	15	8 (53.3)	-0.92 (0.23)	(-1.38, -0.47)	-0.17 (0.29)	(-0.74, 0.40)	0.564	Placebo	20	12 (60.0)	-0.76 (0.17)	(-1.10, -0.41)	Week 49	Tezepelumab	15	8 (53.3)	-0.88 (0.23)	(-1.34, -0.43)	0.06 (0.29)	(-0.50, 0.63)	0.826	Placebo	20	14 (70.0)	-0.95 (0.17)	(-1.28, -0.61)	Week 50	Tezepelumab	15	8 (53.3)	-0.77 (0.23)	(-1.22, -0.32)	0.08 (0.29)	(-0.49, 0.65)	0.786	Placebo
Week 42	Tezepelumab	15	9 (60.0)	-0.76 (0.22)	(-1.19, -0.32)	-0.05 (0.28)	(-0.60, 0.49)	0.844																																																																																																																										
	Placebo	20	14 (70.0)	-0.70 (0.17)	(-1.03, -0.38)				Week 43	Tezepelumab	15	9 (60.0)	-0.87 (0.22)	(-1.30, -0.43)	-0.08 (0.28)	(-0.63, 0.46)	0.767	Placebo	20	15 (75.0)	-0.78 (0.17)	(-1.11, -0.46)	Week 44	Tezepelumab	15	8 (53.3)	-0.81 (0.23)	(-1.26, -0.37)	-0.09 (0.28)	(-0.65, 0.46)	0.741	Placebo	20	16 (80.0)	-0.72 (0.17)	(-1.05, -0.39)	Week 45	Tezepelumab	15	8 (53.3)	-0.90 (0.23)	(-1.35, -0.45)	-0.18 (0.29)	(-0.75, 0.38)	0.522	Placebo	20	14 (70.0)	-0.72 (0.17)	(-1.05, -0.39)	Week 46	Tezepelumab	15	8 (53.3)	-0.86 (0.23)	(-1.31, -0.40)	-0.16 (0.29)	(-0.72, 0.41)	0.592	Placebo	20	12 (60.0)	-0.70 (0.17)	(-1.04, -0.36)	Week 47	Tezepelumab	15	8 (53.3)	-0.92 (0.23)	(-1.38, -0.47)	-0.07 (0.29)	(-0.64, 0.50)	0.810	Placebo	20	14 (70.0)	-0.85 (0.17)	(-1.19, -0.52)	Week 48	Tezepelumab	15	8 (53.3)	-0.92 (0.23)	(-1.38, -0.47)	-0.17 (0.29)	(-0.74, 0.40)	0.564	Placebo	20	12 (60.0)	-0.76 (0.17)	(-1.10, -0.41)	Week 49	Tezepelumab	15	8 (53.3)	-0.88 (0.23)	(-1.34, -0.43)	0.06 (0.29)	(-0.50, 0.63)	0.826	Placebo	20	14 (70.0)	-0.95 (0.17)	(-1.28, -0.61)	Week 50	Tezepelumab	15	8 (53.3)	-0.77 (0.23)	(-1.22, -0.32)	0.08 (0.29)	(-0.49, 0.65)	0.786	Placebo	20	13 (65.0)	-0.85 (0.17)	(-1.19, -0.51)										
Week 43	Tezepelumab	15	9 (60.0)	-0.87 (0.22)	(-1.30, -0.43)	-0.08 (0.28)	(-0.63, 0.46)	0.767																																																																																																																										
	Placebo	20	15 (75.0)	-0.78 (0.17)	(-1.11, -0.46)				Week 44	Tezepelumab	15	8 (53.3)	-0.81 (0.23)	(-1.26, -0.37)	-0.09 (0.28)	(-0.65, 0.46)	0.741	Placebo	20	16 (80.0)	-0.72 (0.17)	(-1.05, -0.39)	Week 45	Tezepelumab	15	8 (53.3)	-0.90 (0.23)	(-1.35, -0.45)	-0.18 (0.29)	(-0.75, 0.38)	0.522	Placebo	20	14 (70.0)	-0.72 (0.17)	(-1.05, -0.39)	Week 46	Tezepelumab	15	8 (53.3)	-0.86 (0.23)	(-1.31, -0.40)	-0.16 (0.29)	(-0.72, 0.41)	0.592	Placebo	20	12 (60.0)	-0.70 (0.17)	(-1.04, -0.36)	Week 47	Tezepelumab	15	8 (53.3)	-0.92 (0.23)	(-1.38, -0.47)	-0.07 (0.29)	(-0.64, 0.50)	0.810	Placebo	20	14 (70.0)	-0.85 (0.17)	(-1.19, -0.52)	Week 48	Tezepelumab	15	8 (53.3)	-0.92 (0.23)	(-1.38, -0.47)	-0.17 (0.29)	(-0.74, 0.40)	0.564	Placebo	20	12 (60.0)	-0.76 (0.17)	(-1.10, -0.41)	Week 49	Tezepelumab	15	8 (53.3)	-0.88 (0.23)	(-1.34, -0.43)	0.06 (0.29)	(-0.50, 0.63)	0.826	Placebo	20	14 (70.0)	-0.95 (0.17)	(-1.28, -0.61)	Week 50	Tezepelumab	15	8 (53.3)	-0.77 (0.23)	(-1.22, -0.32)	0.08 (0.29)	(-0.49, 0.65)	0.786	Placebo	20	13 (65.0)	-0.85 (0.17)	(-1.19, -0.51)																								
Week 44	Tezepelumab	15	8 (53.3)	-0.81 (0.23)	(-1.26, -0.37)	-0.09 (0.28)	(-0.65, 0.46)	0.741																																																																																																																										
	Placebo	20	16 (80.0)	-0.72 (0.17)	(-1.05, -0.39)				Week 45	Tezepelumab	15	8 (53.3)	-0.90 (0.23)	(-1.35, -0.45)	-0.18 (0.29)	(-0.75, 0.38)	0.522	Placebo	20	14 (70.0)	-0.72 (0.17)	(-1.05, -0.39)	Week 46	Tezepelumab	15	8 (53.3)	-0.86 (0.23)	(-1.31, -0.40)	-0.16 (0.29)	(-0.72, 0.41)	0.592	Placebo	20	12 (60.0)	-0.70 (0.17)	(-1.04, -0.36)	Week 47	Tezepelumab	15	8 (53.3)	-0.92 (0.23)	(-1.38, -0.47)	-0.07 (0.29)	(-0.64, 0.50)	0.810	Placebo	20	14 (70.0)	-0.85 (0.17)	(-1.19, -0.52)	Week 48	Tezepelumab	15	8 (53.3)	-0.92 (0.23)	(-1.38, -0.47)	-0.17 (0.29)	(-0.74, 0.40)	0.564	Placebo	20	12 (60.0)	-0.76 (0.17)	(-1.10, -0.41)	Week 49	Tezepelumab	15	8 (53.3)	-0.88 (0.23)	(-1.34, -0.43)	0.06 (0.29)	(-0.50, 0.63)	0.826	Placebo	20	14 (70.0)	-0.95 (0.17)	(-1.28, -0.61)	Week 50	Tezepelumab	15	8 (53.3)	-0.77 (0.23)	(-1.22, -0.32)	0.08 (0.29)	(-0.49, 0.65)	0.786	Placebo	20	13 (65.0)	-0.85 (0.17)	(-1.19, -0.51)																																						
Week 45	Tezepelumab	15	8 (53.3)	-0.90 (0.23)	(-1.35, -0.45)	-0.18 (0.29)	(-0.75, 0.38)	0.522																																																																																																																										
	Placebo	20	14 (70.0)	-0.72 (0.17)	(-1.05, -0.39)				Week 46	Tezepelumab	15	8 (53.3)	-0.86 (0.23)	(-1.31, -0.40)	-0.16 (0.29)	(-0.72, 0.41)	0.592	Placebo	20	12 (60.0)	-0.70 (0.17)	(-1.04, -0.36)	Week 47	Tezepelumab	15	8 (53.3)	-0.92 (0.23)	(-1.38, -0.47)	-0.07 (0.29)	(-0.64, 0.50)	0.810	Placebo	20	14 (70.0)	-0.85 (0.17)	(-1.19, -0.52)	Week 48	Tezepelumab	15	8 (53.3)	-0.92 (0.23)	(-1.38, -0.47)	-0.17 (0.29)	(-0.74, 0.40)	0.564	Placebo	20	12 (60.0)	-0.76 (0.17)	(-1.10, -0.41)	Week 49	Tezepelumab	15	8 (53.3)	-0.88 (0.23)	(-1.34, -0.43)	0.06 (0.29)	(-0.50, 0.63)	0.826	Placebo	20	14 (70.0)	-0.95 (0.17)	(-1.28, -0.61)	Week 50	Tezepelumab	15	8 (53.3)	-0.77 (0.23)	(-1.22, -0.32)	0.08 (0.29)	(-0.49, 0.65)	0.786	Placebo	20	13 (65.0)	-0.85 (0.17)	(-1.19, -0.51)																																																				
Week 46	Tezepelumab	15	8 (53.3)	-0.86 (0.23)	(-1.31, -0.40)	-0.16 (0.29)	(-0.72, 0.41)	0.592																																																																																																																										
	Placebo	20	12 (60.0)	-0.70 (0.17)	(-1.04, -0.36)				Week 47	Tezepelumab	15	8 (53.3)	-0.92 (0.23)	(-1.38, -0.47)	-0.07 (0.29)	(-0.64, 0.50)	0.810	Placebo	20	14 (70.0)	-0.85 (0.17)	(-1.19, -0.52)	Week 48	Tezepelumab	15	8 (53.3)	-0.92 (0.23)	(-1.38, -0.47)	-0.17 (0.29)	(-0.74, 0.40)	0.564	Placebo	20	12 (60.0)	-0.76 (0.17)	(-1.10, -0.41)	Week 49	Tezepelumab	15	8 (53.3)	-0.88 (0.23)	(-1.34, -0.43)	0.06 (0.29)	(-0.50, 0.63)	0.826	Placebo	20	14 (70.0)	-0.95 (0.17)	(-1.28, -0.61)	Week 50	Tezepelumab	15	8 (53.3)	-0.77 (0.23)	(-1.22, -0.32)	0.08 (0.29)	(-0.49, 0.65)	0.786	Placebo	20	13 (65.0)	-0.85 (0.17)	(-1.19, -0.51)																																																																		
Week 47	Tezepelumab	15	8 (53.3)	-0.92 (0.23)	(-1.38, -0.47)	-0.07 (0.29)	(-0.64, 0.50)	0.810																																																																																																																										
	Placebo	20	14 (70.0)	-0.85 (0.17)	(-1.19, -0.52)				Week 48	Tezepelumab	15	8 (53.3)	-0.92 (0.23)	(-1.38, -0.47)	-0.17 (0.29)	(-0.74, 0.40)	0.564	Placebo	20	12 (60.0)	-0.76 (0.17)	(-1.10, -0.41)	Week 49	Tezepelumab	15	8 (53.3)	-0.88 (0.23)	(-1.34, -0.43)	0.06 (0.29)	(-0.50, 0.63)	0.826	Placebo	20	14 (70.0)	-0.95 (0.17)	(-1.28, -0.61)	Week 50	Tezepelumab	15	8 (53.3)	-0.77 (0.23)	(-1.22, -0.32)	0.08 (0.29)	(-0.49, 0.65)	0.786	Placebo	20	13 (65.0)	-0.85 (0.17)	(-1.19, -0.51)																																																																																
Week 48	Tezepelumab	15	8 (53.3)	-0.92 (0.23)	(-1.38, -0.47)	-0.17 (0.29)	(-0.74, 0.40)	0.564																																																																																																																										
	Placebo	20	12 (60.0)	-0.76 (0.17)	(-1.10, -0.41)				Week 49	Tezepelumab	15	8 (53.3)	-0.88 (0.23)	(-1.34, -0.43)	0.06 (0.29)	(-0.50, 0.63)	0.826	Placebo	20	14 (70.0)	-0.95 (0.17)	(-1.28, -0.61)	Week 50	Tezepelumab	15	8 (53.3)	-0.77 (0.23)	(-1.22, -0.32)	0.08 (0.29)	(-0.49, 0.65)	0.786	Placebo	20	13 (65.0)	-0.85 (0.17)	(-1.19, -0.51)																																																																																														
Week 49	Tezepelumab	15	8 (53.3)	-0.88 (0.23)	(-1.34, -0.43)	0.06 (0.29)	(-0.50, 0.63)	0.826																																																																																																																										
	Placebo	20	14 (70.0)	-0.95 (0.17)	(-1.28, -0.61)				Week 50	Tezepelumab	15	8 (53.3)	-0.77 (0.23)	(-1.22, -0.32)	0.08 (0.29)	(-0.49, 0.65)	0.786	Placebo	20	13 (65.0)	-0.85 (0.17)	(-1.19, -0.51)																																																																																																												
Week 50	Tezepelumab	15	8 (53.3)	-0.77 (0.23)	(-1.22, -0.32)	0.08 (0.29)	(-0.49, 0.65)	0.786																																																																																																																										
	Placebo	20	13 (65.0)	-0.85 (0.17)	(-1.19, -0.51)																																																																																																																													

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table NT1WLC\_KLMC0: Change from baseline in ASD weekly limiting activity score - MMRM results  
 DITTL - adolescents

Change from baseline in ASD weekly limiting activity score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 51	Tezepelumab	15	9 (60.0)	-0.86 (0.23)	(-1.31, -0.42)	0.02 (0.29)	(-0.55, 0.58)	0.955
	Placebo	20	14 (70.0)	-0.88 (0.17)	(-1.22, -0.54)			
Week 52	Tezepelumab	15	9 (60.0)	-0.88 (0.23)	(-1.32, -0.43)	0.02 (0.29)	(-0.55, 0.58)	0.954
	Placebo	20	13 (65.0)	-0.89 (0.17)	(-1.24, -0.55)			

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WTC\_ALMH0: Course of ASD weekly total score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly total score	Baseline	Tezepelumab	380	380 (100.0)	1.45 (0.72)	0.0	0.96	1.39	1.90	4.0	
		Placebo	371	371 (100.0)	1.40 (0.70)	0.1	0.89	1.31	1.87	3.9	
	Week 1	Tezepelumab	380	372 (97.9)	1.23 (0.67)	0.0	0.80	1.13	1.64	3.8	
		Placebo	371	362 (97.6)	1.28 (0.68)	0.0	0.80	1.22	1.69	3.7	
	Week 2	Tezepelumab	380	370 (97.4)	1.12 (0.68)	0.0	0.69	1.00	1.50	3.4	
		Placebo	371	360 (97.0)	1.23 (0.69)	0.0	0.71	1.16	1.74	3.7	
	Week 3	Tezepelumab	380	365 (96.1)	1.06 (0.67)	0.0	0.60	1.00	1.42	3.2	
		Placebo	371	354 (95.4)	1.13 (0.68)	0.0	0.63	1.05	1.60	3.9	
	Week 4	Tezepelumab	380	363 (95.5)	1.02 (0.69)	0.0	0.51	0.95	1.45	3.4	
		Placebo	371	353 (95.1)	1.11 (0.67)	0.0	0.58	1.03	1.53	3.7	
	Week 5	Tezepelumab	380	363 (95.5)	0.96 (0.69)	0.0	0.47	0.89	1.37	3.5	
		Placebo	371	344 (92.7)	1.04 (0.67)	0.0	0.50	0.97	1.49	3.8	
	Week 6	Tezepelumab	380	357 (93.9)	0.92 (0.69)	0.0	0.39	0.85	1.36	3.7	
		Placebo	371	349 (94.1)	1.04 (0.69)	0.0	0.51	0.94	1.51	3.9	
	Week 7	Tezepelumab	380	354 (93.2)	0.91 (0.70)	0.0	0.31	0.86	1.31	3.8	
		Placebo	371	349 (94.1)	1.01 (0.70)	0.0	0.44	0.91	1.50	3.9	
	Week 8	Tezepelumab	380	355 (93.4)	0.88 (0.68)	0.0	0.31	0.80	1.33	3.8	
		Placebo	371	340 (91.6)	0.98 (0.68)	0.0	0.45	0.91	1.41	3.9	
	Week 9	Tezepelumab	380	360 (94.7)	0.84 (0.67)	0.0	0.31	0.77	1.24	3.7	
		Placebo	371	340 (91.6)	0.95 (0.67)	0.0	0.40	0.92	1.34	4.0	
	Week 10	Tezepelumab	380	358 (94.2)	0.85 (0.68)	0.0	0.28	0.81	1.21	3.7	
		Placebo	371	338 (91.1)	0.97 (0.68)	0.0	0.40	0.94	1.45	3.8	
	Week 11	Tezepelumab	380	347 (91.3)	0.86 (0.69)	0.0	0.25	0.84	1.27	3.6	
		Placebo	371	334 (90.0)	0.95 (0.69)	0.0	0.38	0.90	1.38	3.7	
	Week 12	Tezepelumab	380	348 (91.6)	0.86 (0.69)	0.0	0.28	0.81	1.20	3.6	
		Placebo	371	332 (89.5)	0.92 (0.68)	0.0	0.33	0.88	1.33	3.8	
	Week 13	Tezepelumab	380	344 (90.5)	0.83 (0.68)	0.0	0.27	0.74	1.18	3.2	
		Placebo	371	330 (88.9)	0.90 (0.66)	0.0	0.33	0.90	1.27	3.7	
	Week 14	Tezepelumab	380	342 (90.0)	0.79 (0.66)	0.0	0.20	0.70	1.13	3.1	
		Placebo	371	330 (88.9)	0.91 (0.67)	0.0	0.37	0.88	1.31	3.8	
	Week 15	Tezepelumab	380	338 (88.9)	0.79 (0.67)	0.0	0.22	0.72	1.12	3.2	
		Placebo	371	320 (86.3)	0.90 (0.70)	0.0	0.31	0.87	1.32	4.0	
	Week 16	Tezepelumab	380	342 (90.0)	0.78 (0.68)	0.0	0.20	0.68	1.12	3.2	
		Placebo	371	318 (85.7)	0.93 (0.71)	0.0	0.31	0.89	1.44	3.9	
Week 17	Tezepelumab	380	338 (88.9)	0.75 (0.67)	0.0	0.18	0.66	1.11	3.2		
	Placebo	371	314 (84.6)	0.89 (0.68)	0.0	0.33	0.87	1.33	3.9		

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WTC\_ALMH0: Course of ASD weekly total score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly total score	Week 18	Tezepelumab	380	336 (88.4)	0.78 (0.68)	0.0	0.20	0.70	1.13	3.4	
		Placebo	371	309 (83.3)	0.89 (0.70)	0.0	0.26	0.82	1.34	3.9	
	Week 19	Tezepelumab	380	333 (87.6)	0.76 (0.68)	0.0	0.14	0.64	1.12	3.3	
		Placebo	371	317 (85.4)	0.90 (0.72)	0.0	0.27	0.88	1.40	3.7	
	Week 20	Tezepelumab	380	328 (86.3)	0.77 (0.68)	0.0	0.16	0.68	1.11	3.2	
		Placebo	371	309 (83.3)	0.91 (0.72)	0.0	0.30	0.84	1.46	3.9	
	Week 21	Tezepelumab	380	326 (85.8)	0.75 (0.68)	0.0	0.12	0.65	1.08	3.3	
		Placebo	371	305 (82.2)	0.86 (0.72)	0.0	0.20	0.82	1.30	4.0	
	Week 22	Tezepelumab	380	325 (85.5)	0.79 (0.69)	0.0	0.16	0.72	1.17	3.3	
		Placebo	371	299 (80.6)	0.88 (0.71)	0.0	0.22	0.88	1.37	3.9	
	Week 23	Tezepelumab	380	319 (83.9)	0.78 (0.70)	0.0	0.13	0.69	1.20	3.3	
		Placebo	371	296 (79.8)	0.87 (0.70)	0.0	0.21	0.87	1.36	3.8	
	Week 24	Tezepelumab	380	327 (86.1)	0.76 (0.69)	0.0	0.13	0.67	1.14	3.2	
		Placebo	371	297 (80.1)	0.85 (0.71)	0.0	0.21	0.81	1.30	3.8	
	Week 25	Tezepelumab	380	314 (82.6)	0.78 (0.68)	0.0	0.16	0.70	1.13	3.2	
		Placebo	371	296 (79.8)	0.86 (0.72)	0.0	0.20	0.82	1.31	3.9	
	Week 26	Tezepelumab	380	319 (83.9)	0.78 (0.68)	0.0	0.17	0.70	1.15	3.2	
		Placebo	371	289 (77.9)	0.88 (0.72)	0.0	0.20	0.84	1.36	3.9	
	Week 27	Tezepelumab	380	309 (81.3)	0.76 (0.70)	0.0	0.14	0.66	1.10	3.3	
		Placebo	371	300 (80.9)	0.86 (0.74)	0.0	0.19	0.78	1.34	3.8	
	Week 28	Tezepelumab	380	317 (83.4)	0.74 (0.70)	0.0	0.07	0.66	1.15	3.4	
		Placebo	371	300 (80.9)	0.86 (0.72)	0.0	0.20	0.75	1.36	3.7	
	Week 29	Tezepelumab	380	310 (81.6)	0.74 (0.70)	0.0	0.10	0.61	1.12	3.4	
		Placebo	371	299 (80.6)	0.86 (0.73)	0.0	0.20	0.74	1.36	3.7	
	Week 30	Tezepelumab	380	314 (82.6)	0.75 (0.67)	0.0	0.17	0.64	1.11	3.9	
		Placebo	371	295 (79.5)	0.86 (0.72)	0.0	0.20	0.77	1.39	3.7	
	Week 31	Tezepelumab	380	315 (82.9)	0.74 (0.69)	0.0	0.11	0.64	1.10	4.0	
		Placebo	371	296 (79.8)	0.86 (0.70)	0.0	0.26	0.77	1.33	3.7	
	Week 32	Tezepelumab	380	316 (83.2)	0.76 (0.69)	0.0	0.15	0.68	1.10	3.8	
		Placebo	371	297 (80.1)	0.86 (0.69)	0.0	0.27	0.78	1.36	3.7	
	Week 33	Tezepelumab	380	313 (82.4)	0.73 (0.68)	0.0	0.10	0.60	1.09	3.5	
		Placebo	371	291 (78.4)	0.89 (0.71)	0.0	0.22	0.82	1.42	3.7	
	Week 34	Tezepelumab	380	311 (81.8)	0.73 (0.69)	0.0	0.07	0.63	1.12	3.5	
		Placebo	371	293 (79.0)	0.86 (0.72)	0.0	0.20	0.80	1.37	3.7	
	Week 35	Tezepelumab	380	312 (82.1)	0.74 (0.70)	0.0	0.09	0.60	1.09	3.6	
		Placebo	371	285 (76.8)	0.84 (0.71)	0.0	0.21	0.77	1.37	3.7	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WTC\_ALMH0: Course of ASD weekly total score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly total score	Week 36	Tezepelumab	380	309 (81.3)	0.76 (0.70)	0.0	0.10	0.69	1.12	3.5	
		Placebo	371	288 (77.6)	0.85 (0.69)	0.0	0.23	0.80	1.32	3.7	
	Week 37	Tezepelumab	380	312 (82.1)	0.74 (0.70)	0.0	0.10	0.59	1.11	3.4	
		Placebo	371	287 (77.4)	0.83 (0.68)	0.0	0.20	0.78	1.22	3.7	
	Week 38	Tezepelumab	380	310 (81.6)	0.76 (0.72)	0.0	0.11	0.60	1.20	3.4	
		Placebo	371	287 (77.4)	0.81 (0.68)	0.0	0.20	0.73	1.20	3.7	
	Week 39	Tezepelumab	380	317 (83.4)	0.77 (0.74)	0.0	0.10	0.61	1.20	3.9	
		Placebo	371	281 (75.7)	0.83 (0.71)	0.0	0.20	0.73	1.29	3.7	
	Week 40	Tezepelumab	380	313 (82.4)	0.76 (0.72)	0.0	0.10	0.61	1.20	3.4	
		Placebo	371	287 (77.4)	0.85 (0.72)	0.0	0.20	0.78	1.33	3.7	
	Week 41	Tezepelumab	380	316 (83.2)	0.72 (0.70)	0.0	0.10	0.58	1.12	3.1	
		Placebo	371	288 (77.6)	0.86 (0.69)	0.0	0.22	0.82	1.39	3.7	
	Week 42	Tezepelumab	380	308 (81.1)	0.73 (0.70)	0.0	0.10	0.55	1.11	3.1	
		Placebo	371	288 (77.6)	0.86 (0.73)	0.0	0.20	0.79	1.32	3.8	
	Week 43	Tezepelumab	380	311 (81.8)	0.73 (0.71)	0.0	0.08	0.53	1.14	3.1	
		Placebo	371	285 (76.8)	0.84 (0.71)	0.0	0.20	0.77	1.31	3.7	
	Week 44	Tezepelumab	380	309 (81.3)	0.72 (0.71)	0.0	0.09	0.54	1.08	3.1	
		Placebo	371	283 (76.3)	0.85 (0.71)	0.0	0.20	0.76	1.34	3.7	
	Week 45	Tezepelumab	380	312 (82.1)	0.72 (0.70)	0.0	0.10	0.52	1.11	3.2	
		Placebo	371	285 (76.8)	0.83 (0.71)	0.0	0.20	0.75	1.32	3.7	
	Week 46	Tezepelumab	380	307 (80.8)	0.73 (0.71)	0.0	0.10	0.50	1.16	3.2	
		Placebo	371	278 (74.9)	0.81 (0.69)	0.0	0.21	0.71	1.20	3.7	
	Week 47	Tezepelumab	380	296 (77.9)	0.73 (0.71)	0.0	0.10	0.49	1.13	3.0	
		Placebo	371	281 (75.7)	0.79 (0.67)	0.0	0.20	0.71	1.19	3.7	
	Week 48	Tezepelumab	380	318 (83.7)	0.72 (0.70)	0.0	0.10	0.52	1.10	3.0	
		Placebo	371	291 (78.4)	0.82 (0.69)	0.0	0.22	0.74	1.20	3.7	
	Week 49	Tezepelumab	380	308 (81.1)	0.72 (0.71)	0.0	0.08	0.56	1.11	3.0	
		Placebo	371	280 (75.5)	0.83 (0.68)	0.0	0.22	0.76	1.23	3.7	
	Week 50	Tezepelumab	380	306 (80.5)	0.72 (0.70)	0.0	0.05	0.53	1.13	3.0	
		Placebo	371	278 (74.9)	0.84 (0.69)	0.0	0.20	0.78	1.30	3.7	
	Week 51	Tezepelumab	380	300 (78.9)	0.74 (0.70)	0.0	0.08	0.57	1.10	3.0	
		Placebo	371	270 (72.8)	0.82 (0.70)	0.0	0.22	0.74	1.17	3.7	
	Week 52	Tezepelumab	380	268 (70.5)	0.76 (0.72)	0.0	0.08	0.62	1.16	3.0	
		Placebo	371	246 (66.3)	0.84 (0.73)	0.0	0.20	0.76	1.28	3.7	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WTC\_ALMH0: Course of ASD weekly total score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly total score	Week 1	Tezepelumab	380	372 (97.9)	-0.21 (0.36)	-2.2	-0.36	-0.13	0.00	1.0	-0.26 [-0.40, -0.11]
		Placebo	371	362 (97.6)	-0.12 (0.35)	-2.0	-0.27	-0.08	0.06	1.2	
	Week 2	Tezepelumab	380	370 (97.4)	-0.32 (0.49)	-2.7	-0.56	-0.19	0.00	0.8	-0.32 [-0.47, -0.18]
		Placebo	371	360 (97.0)	-0.17 (0.49)	-2.4	-0.34	-0.10	0.05	1.4	
	Week 3	Tezepelumab	380	365 (96.1)	-0.39 (0.54)	-3.4	-0.64	-0.27	-0.02	0.7	-0.22 [-0.36, -0.07]
		Placebo	371	354 (95.4)	-0.27 (0.54)	-2.4	-0.51	-0.17	0.01	1.8	
	Week 4	Tezepelumab	380	363 (95.5)	-0.42 (0.57)	-3.4	-0.69	-0.27	-0.01	0.7	-0.21 [-0.36, -0.07]
		Placebo	371	353 (95.1)	-0.30 (0.56)	-2.5	-0.60	-0.18	0.03	1.6	
	Week 5	Tezepelumab	380	363 (95.5)	-0.48 (0.60)	-3.5	-0.79	-0.35	-0.06	0.8	-0.20 [-0.35, -0.05]
		Placebo	371	344 (92.7)	-0.37 (0.56)	-2.7	-0.67	-0.26	-0.01	1.4	
	Week 6	Tezepelumab	380	357 (93.9)	-0.51 (0.63)	-3.5	-0.80	-0.39	-0.08	0.8	-0.24 [-0.39, -0.09]
		Placebo	371	349 (94.1)	-0.37 (0.61)	-3.0	-0.67	-0.27	0.01	1.5	
	Week 7	Tezepelumab	380	354 (93.2)	-0.53 (0.66)	-3.5	-0.83	-0.42	-0.06	1.2	-0.21 [-0.36, -0.07]
		Placebo	371	349 (94.1)	-0.39 (0.63)	-3.1	-0.71	-0.27	0.00	1.5	
	Week 8	Tezepelumab	380	355 (93.4)	-0.56 (0.65)	-3.4	-0.90	-0.41	-0.07	1.2	-0.24 [-0.38, -0.09]
		Placebo	371	340 (91.6)	-0.41 (0.62)	-3.0	-0.78	-0.31	0.00	1.5	
	Week 9	Tezepelumab	380	360 (94.7)	-0.60 (0.66)	-3.5	-1.00	-0.49	-0.09	1.3	-0.23 [-0.38, -0.08]
		Placebo	371	340 (91.6)	-0.45 (0.62)	-3.1	-0.82	-0.38	-0.03	1.6	
	Week 10	Tezepelumab	380	358 (94.2)	-0.58 (0.64)	-3.4	-0.97	-0.44	-0.09	0.8	-0.21 [-0.36, -0.06]
		Placebo	371	338 (91.1)	-0.44 (0.63)	-3.2	-0.81	-0.31	-0.05	1.5	
	Week 11	Tezepelumab	380	347 (91.3)	-0.58 (0.67)	-3.4	-0.98	-0.47	-0.09	0.9	-0.20 [-0.35, -0.05]
		Placebo	371	334 (90.0)	-0.45 (0.64)	-3.1	-0.80	-0.37	-0.05	1.5	
	Week 12	Tezepelumab	380	348 (91.6)	-0.57 (0.68)	-3.5	-0.94	-0.45	-0.07	1.0	-0.16 [-0.31, -0.01]
		Placebo	371	332 (89.5)	-0.47 (0.62)	-3.1	-0.83	-0.37	-0.09	1.5	
	Week 13	Tezepelumab	380	344 (90.5)	-0.59 (0.67)	-3.4	-1.01	-0.49	-0.09	1.1	-0.14 [-0.29, 0.01]
		Placebo	371	330 (88.9)	-0.50 (0.63)	-3.1	-0.90	-0.42	-0.08	1.4	
	Week 14	Tezepelumab	380	342 (90.0)	-0.65 (0.67)	-3.4	-1.04	-0.51	-0.11	0.8	-0.25 [-0.40, -0.10]
		Placebo	371	330 (88.9)	-0.49 (0.63)	-3.1	-0.86	-0.40	-0.07	1.4	
	Week 15	Tezepelumab	380	338 (88.9)	-0.62 (0.66)	-3.0	-1.05	-0.50	-0.10	0.8	-0.20 [-0.35, -0.05]
		Placebo	371	320 (86.3)	-0.49 (0.64)	-3.1	-0.86	-0.47	-0.06	1.4	
	Week 16	Tezepelumab	380	342 (90.0)	-0.64 (0.69)	-3.4	-1.05	-0.49	-0.10	1.4	-0.24 [-0.39, -0.08]
		Placebo	371	318 (85.7)	-0.48 (0.65)	-3.0	-0.90	-0.39	-0.04	1.5	
	Week 17	Tezepelumab	380	338 (88.9)	-0.68 (0.69)	-3.5	-1.07	-0.57	-0.14	0.8	-0.26 [-0.41, -0.11]
		Placebo	371	314 (84.6)	-0.51 (0.63)	-3.1	-0.90	-0.44	-0.06	1.4	
	Week 18	Tezepelumab	380	336 (88.4)	-0.65 (0.69)	-3.4	-1.04	-0.53	-0.13	0.8	-0.21 [-0.36, -0.06]
		Placebo	371	309 (83.3)	-0.51 (0.66)	-3.1	-0.89	-0.42	-0.07	1.5	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WTC\_ALMH0: Course of ASD weekly total score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly total score	Week 19	Tezepelumab	380	333 (87.6)	-0.66 (0.71)	-3.5	-1.01	-0.57	-0.13	1.2	-0.23 [-0.39, -0.08]
		Placebo	371	317 (85.4)	-0.50 (0.68)	-3.1	-0.87	-0.40	-0.07	2.0	
	Week 20	Tezepelumab	380	328 (86.3)	-0.65 (0.70)	-3.5	-1.07	-0.54	-0.12	0.8	-0.22 [-0.38, -0.07]
		Placebo	371	309 (83.3)	-0.50 (0.69)	-3.1	-0.89	-0.44	-0.07	1.5	
	Week 21	Tezepelumab	380	326 (85.8)	-0.66 (0.68)	-3.4	-1.01	-0.61	-0.13	1.8	-0.20 [-0.36, -0.05]
		Placebo	371	305 (82.2)	-0.52 (0.68)	-3.2	-0.88	-0.44	-0.06	1.4	
	Week 22	Tezepelumab	380	325 (85.5)	-0.63 (0.70)	-3.2	-1.02	-0.53	-0.12	1.0	-0.19 [-0.35, -0.03]
		Placebo	371	299 (80.6)	-0.50 (0.64)	-2.9	-0.80	-0.46	-0.07	1.4	
	Week 23	Tezepelumab	380	319 (83.9)	-0.64 (0.69)	-3.2	-1.02	-0.54	-0.16	1.0	-0.17 [-0.33, -0.01]
		Placebo	371	296 (79.8)	-0.53 (0.66)	-3.1	-0.91	-0.45	-0.12	1.5	
	Week 24	Tezepelumab	380	327 (86.1)	-0.66 (0.70)	-3.4	-1.11	-0.60	-0.17	1.2	-0.20 [-0.36, -0.04]
		Placebo	371	297 (80.1)	-0.53 (0.67)	-3.1	-0.89	-0.50	-0.08	1.5	
	Week 25	Tezepelumab	380	314 (82.6)	-0.66 (0.68)	-3.4	-1.06	-0.61	-0.17	1.2	-0.19 [-0.35, -0.03]
		Placebo	371	296 (79.8)	-0.53 (0.69)	-3.4	-0.97	-0.47	-0.13	1.7	
	Week 26	Tezepelumab	380	319 (83.9)	-0.64 (0.70)	-3.3	-1.04	-0.59	-0.10	1.6	-0.18 [-0.34, -0.02]
		Placebo	371	289 (77.9)	-0.52 (0.68)	-3.1	-0.93	-0.43	-0.08	1.4	
	Week 27	Tezepelumab	380	309 (81.3)	-0.67 (0.71)	-3.5	-1.06	-0.61	-0.13	1.0	-0.23 [-0.39, -0.07]
		Placebo	371	300 (80.9)	-0.51 (0.71)	-3.1	-0.93	-0.46	-0.08	2.0	
	Week 28	Tezepelumab	380	317 (83.4)	-0.68 (0.70)	-3.5	-1.09	-0.60	-0.15	0.9	-0.23 [-0.39, -0.07]
		Placebo	371	300 (80.9)	-0.52 (0.69)	-3.1	-0.96	-0.44	-0.08	1.7	
	Week 29	Tezepelumab	380	310 (81.6)	-0.69 (0.71)	-3.5	-1.11	-0.64	-0.15	0.9	-0.25 [-0.41, -0.09]
		Placebo	371	299 (80.6)	-0.52 (0.70)	-3.1	-0.95	-0.44	-0.07	1.4	
	Week 30	Tezepelumab	380	314 (82.6)	-0.67 (0.70)	-3.5	-1.09	-0.64	-0.13	0.9	-0.21 [-0.36, -0.05]
		Placebo	371	295 (79.5)	-0.53 (0.70)	-3.1	-0.96	-0.47	-0.08	1.4	
	Week 31	Tezepelumab	380	315 (82.9)	-0.69 (0.72)	-3.5	-1.11	-0.61	-0.13	1.4	-0.25 [-0.41, -0.09]
		Placebo	371	296 (79.8)	-0.52 (0.65)	-2.7	-0.99	-0.46	-0.08	1.4	
	Week 32	Tezepelumab	380	316 (83.2)	-0.66 (0.70)	-3.5	-1.06	-0.60	-0.13	1.8	-0.19 [-0.35, -0.03]
		Placebo	371	297 (80.1)	-0.53 (0.71)	-3.3	-1.00	-0.46	-0.04	1.4	
	Week 33	Tezepelumab	380	313 (82.4)	-0.69 (0.72)	-3.5	-1.10	-0.64	-0.13	1.7	-0.25 [-0.41, -0.09]
		Placebo	371	291 (78.4)	-0.51 (0.70)	-3.3	-0.95	-0.41	-0.08	1.5	
	Week 34	Tezepelumab	380	311 (81.8)	-0.70 (0.70)	-3.5	-1.09	-0.64	-0.15	1.7	-0.24 [-0.40, -0.08]
		Placebo	371	293 (79.0)	-0.53 (0.69)	-3.1	-0.93	-0.46	-0.11	1.4	
	Week 35	Tezepelumab	380	312 (82.1)	-0.68 (0.72)	-3.5	-1.09	-0.60	-0.14	1.6	-0.20 [-0.37, -0.04]
		Placebo	371	285 (76.8)	-0.53 (0.68)	-3.1	-0.96	-0.46	-0.12	1.4	
	Week 36	Tezepelumab	380	309 (81.3)	-0.66 (0.72)	-3.5	-1.09	-0.56	-0.13	1.6	-0.18 [-0.34, -0.02]
		Placebo	371	288 (77.6)	-0.53 (0.69)	-3.4	-0.96	-0.43	-0.09	1.4	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WTC\_ALMH0: Course of ASD weekly total score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly total score	Week 37	Tezepelumab	380	312 (82.1)	-0.67 (0.73)	-3.5	-1.11	-0.62	-0.12	1.6	-0.20 [-0.37, -0.04]
		Placebo	371	287 (77.4)	-0.53 (0.66)	-3.1	-0.96	-0.46	-0.10	1.4	
	Week 38	Tezepelumab	380	310 (81.6)	-0.67 (0.73)	-3.5	-1.08	-0.58	-0.14	1.6	-0.17 [-0.33, -0.01]
		Placebo	371	287 (77.4)	-0.56 (0.65)	-3.1	-1.01	-0.50	-0.10	1.4	
	Week 39	Tezepelumab	380	317 (83.4)	-0.67 (0.74)	-3.5	-1.11	-0.61	-0.14	1.6	-0.19 [-0.35, -0.03]
		Placebo	371	281 (75.7)	-0.54 (0.68)	-3.4	-1.01	-0.47	-0.08	1.6	
	Week 40	Tezepelumab	380	313 (82.4)	-0.67 (0.73)	-3.5	-1.11	-0.62	-0.13	1.6	-0.23 [-0.39, -0.07]
		Placebo	371	287 (77.4)	-0.51 (0.67)	-3.5	-0.96	-0.43	-0.06	1.5	
	Week 41	Tezepelumab	380	316 (83.2)	-0.71 (0.72)	-3.5	-1.14	-0.63	-0.17	1.6	-0.23 [-0.39, -0.07]
		Placebo	371	288 (77.6)	-0.55 (0.66)	-3.3	-0.96	-0.47	-0.11	1.5	
	Week 42	Tezepelumab	380	308 (81.1)	-0.71 (0.71)	-3.4	-1.10	-0.64	-0.17	1.6	-0.28 [-0.44, -0.12]
		Placebo	371	288 (77.6)	-0.51 (0.67)	-3.4	-0.89	-0.43	-0.09	1.4	
	Week 43	Tezepelumab	380	311 (81.8)	-0.71 (0.72)	-3.5	-1.11	-0.62	-0.17	1.5	-0.25 [-0.41, -0.09]
		Placebo	371	285 (76.8)	-0.54 (0.66)	-3.1	-0.96	-0.46	-0.10	1.4	
	Week 44	Tezepelumab	380	309 (81.3)	-0.72 (0.72)	-3.5	-1.11	-0.64	-0.17	1.6	-0.26 [-0.42, -0.10]
		Placebo	371	283 (76.3)	-0.54 (0.69)	-3.3	-0.93	-0.46	-0.09	1.4	
	Week 45	Tezepelumab	380	312 (82.1)	-0.72 (0.71)	-3.5	-1.10	-0.65	-0.20	1.6	-0.23 [-0.39, -0.07]
		Placebo	371	285 (76.8)	-0.56 (0.70)	-3.4	-1.03	-0.47	-0.08	1.4	
	Week 46	Tezepelumab	380	307 (80.8)	-0.71 (0.73)	-3.5	-1.11	-0.64	-0.19	1.6	-0.22 [-0.38, -0.06]
		Placebo	371	278 (74.9)	-0.56 (0.69)	-3.3	-1.01	-0.47	-0.07	1.4	
	Week 47	Tezepelumab	380	296 (77.9)	-0.70 (0.71)	-3.5	-1.12	-0.64	-0.16	1.5	-0.20 [-0.36, -0.03]
		Placebo	371	281 (75.7)	-0.57 (0.66)	-3.1	-0.96	-0.47	-0.14	1.2	
	Week 48	Tezepelumab	380	318 (83.7)	-0.70 (0.73)	-3.5	-1.11	-0.64	-0.17	1.6	-0.18 [-0.34, -0.02]
		Placebo	371	291 (78.4)	-0.57 (0.65)	-3.1	-0.99	-0.48	-0.13	1.3	
	Week 49	Tezepelumab	380	308 (81.1)	-0.70 (0.72)	-3.5	-1.11	-0.62	-0.17	1.6	-0.21 [-0.37, -0.04]
		Placebo	371	280 (75.5)	-0.56 (0.65)	-3.1	-0.94	-0.50	-0.09	1.2	
	Week 50	Tezepelumab	380	306 (80.5)	-0.70 (0.72)	-3.5	-1.11	-0.63	-0.17	1.5	-0.22 [-0.39, -0.06]
		Placebo	371	278 (74.9)	-0.55 (0.67)	-3.1	-0.98	-0.47	-0.10	1.5	
	Week 51	Tezepelumab	380	300 (78.9)	-0.69 (0.74)	-3.5	-1.11	-0.64	-0.14	1.6	-0.19 [-0.35, -0.02]
		Placebo	371	270 (72.8)	-0.56 (0.70)	-3.5	-1.01	-0.48	-0.10	1.5	
	Week 52	Tezepelumab	380	268 (70.5)	-0.69 (0.77)	-3.5	-1.13	-0.64	-0.11	1.6	-0.17 [-0.34, 0.00]
		Placebo	371	246 (66.3)	-0.56 (0.70)	-3.6	-0.97	-0.48	-0.10	1.4	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WTC\_ALMC0: Change from baseline in ASD weekly total score - MMRM results  
DITTL - adult

Change from baseline in ASD weekly total score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 1	Tezepelumab	380	372 (97.9)	-0.20 (0.03)	(-0.26, -0.14)	-0.07 (0.04)	(-0.16, 0.01)	0.087	
	Placebo	371	362 (97.6)	-0.12 (0.03)	(-0.18, -0.06)				
Week 2	Tezepelumab	380	370 (97.4)	-0.32 (0.03)	(-0.37, -0.26)	-0.14 (0.04)	(-0.22, -0.06)	0.001 *	
	Placebo	371	360 (97.0)	-0.18 (0.03)	(-0.24, -0.12)				
Week 3	Tezepelumab	380	365 (96.1)	-0.38 (0.03)	(-0.44, -0.32)	-0.12 (0.04)	(-0.20, -0.03)	0.007 *	
	Placebo	371	354 (95.4)	-0.27 (0.03)	(-0.32, -0.21)				
Week 4	Tezepelumab	380	363 (95.5)	-0.42 (0.03)	(-0.47, -0.36)	-0.11 (0.04)	(-0.20, -0.03)	0.009 *	
	Placebo	371	353 (95.1)	-0.30 (0.03)	(-0.36, -0.24)				
Week 5	Tezepelumab	380	363 (95.5)	-0.47 (0.03)	(-0.53, -0.42)	-0.10 (0.04)	(-0.19, -0.02)	0.015 *	
	Placebo	371	344 (92.7)	-0.37 (0.03)	(-0.43, -0.31)				
Week 6	Tezepelumab	380	357 (93.9)	-0.51 (0.03)	(-0.57, -0.45)	-0.13 (0.04)	(-0.22, -0.05)	0.002 *	
	Placebo	371	349 (94.1)	-0.37 (0.03)	(-0.43, -0.31)				
Week 7	Tezepelumab	380	354 (93.2)	-0.52 (0.03)	(-0.58, -0.46)	-0.13 (0.04)	(-0.21, -0.05)	0.002 *	
	Placebo	371	349 (94.1)	-0.39 (0.03)	(-0.45, -0.33)				
Week 8	Tezepelumab	380	355 (93.4)	-0.55 (0.03)	(-0.61, -0.49)	-0.15 (0.04)	(-0.23, -0.06)	<0.001 *	
	Placebo	371	340 (91.6)	-0.40 (0.03)	(-0.46, -0.34)				
Week 9	Tezepelumab	380	360 (94.7)	-0.59 (0.03)	(-0.65, -0.53)	-0.15 (0.04)	(-0.23, -0.06)	<0.001 *	
	Placebo	371	340 (91.6)	-0.44 (0.03)	(-0.50, -0.38)				
Week 10	Tezepelumab	380	358 (94.2)	-0.58 (0.03)	(-0.64, -0.52)	-0.15 (0.04)	(-0.23, -0.07)	<0.001 *	
	Placebo	371	338 (91.1)	-0.43 (0.03)	(-0.49, -0.37)				

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table NT1WTC\_ALMC0: Change from baseline in ASD weekly total score - MMRM results  
 DITTL - adult

Change from baseline in ASD weekly total score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 11	Tezepelumab	380	347 (91.3)	-0.58 (0.03)	(-0.64, -0.52)	-0.14 (0.04)	(-0.22, -0.05)	0.002 *	
	Placebo	371	334 (90.0)	-0.45 (0.03)	(-0.51, -0.39)				
Week 12	Tezepelumab	380	348 (91.6)	-0.57 (0.03)	(-0.63, -0.51)	-0.12 (0.04)	(-0.20, -0.03)	0.007 *	
	Placebo	371	332 (89.5)	-0.45 (0.03)	(-0.51, -0.39)				
Week 13	Tezepelumab	380	344 (90.5)	-0.60 (0.03)	(-0.66, -0.54)	-0.13 (0.04)	(-0.21, -0.04)	0.003 *	
	Placebo	371	330 (88.9)	-0.47 (0.03)	(-0.53, -0.41)				
Week 14	Tezepelumab	380	342 (90.0)	-0.63 (0.03)	(-0.69, -0.57)	-0.15 (0.04)	(-0.23, -0.07)	<0.001 *	
	Placebo	371	330 (88.9)	-0.48 (0.03)	(-0.54, -0.42)				
Week 15	Tezepelumab	380	338 (88.9)	-0.62 (0.03)	(-0.68, -0.57)	-0.14 (0.04)	(-0.23, -0.06)	0.001 *	
	Placebo	371	320 (86.3)	-0.48 (0.03)	(-0.54, -0.42)				
Week 16	Tezepelumab	380	342 (90.0)	-0.65 (0.03)	(-0.71, -0.59)	-0.19 (0.04)	(-0.27, -0.10)	<0.001 *	
	Placebo	371	318 (85.7)	-0.46 (0.03)	(-0.52, -0.40)				
Week 17	Tezepelumab	380	338 (88.9)	-0.66 (0.03)	(-0.72, -0.60)	-0.16 (0.04)	(-0.25, -0.08)	<0.001 *	
	Placebo	371	314 (84.6)	-0.50 (0.03)	(-0.56, -0.43)				
Week 18	Tezepelumab	380	336 (88.4)	-0.64 (0.03)	(-0.70, -0.58)	-0.14 (0.04)	(-0.23, -0.06)	<0.001 *	
	Placebo	371	309 (83.3)	-0.49 (0.03)	(-0.56, -0.43)				
Week 19	Tezepelumab	380	333 (87.6)	-0.65 (0.03)	(-0.71, -0.59)	-0.16 (0.04)	(-0.25, -0.07)	<0.001 *	
	Placebo	371	317 (85.4)	-0.49 (0.03)	(-0.55, -0.43)				
Week 20	Tezepelumab	380	328 (86.3)	-0.65 (0.03)	(-0.71, -0.59)	-0.17 (0.04)	(-0.25, -0.08)	<0.001 *	
	Placebo	371	309 (83.3)	-0.49 (0.03)	(-0.55, -0.43)				

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WTC\_ALMC0: Change from baseline in ASD weekly total score - MMRM results  
 DITTL - adult

Change from baseline in ASD weekly total score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 21	Tezepelumab	380	326 (85.8)	-0.66 (0.03)	(-0.72, -0.60)	-0.16 (0.04)	(-0.24, -0.07)	<0.001 *	
	Placebo	371	305 (82.2)	-0.50 (0.03)	(-0.57, -0.44)				
Week 22	Tezepelumab	380	325 (85.5)	-0.65 (0.03)	(-0.71, -0.59)	-0.14 (0.04)	(-0.23, -0.06)	0.001 *	
	Placebo	371	299 (80.6)	-0.51 (0.03)	(-0.57, -0.45)				
Week 23	Tezepelumab	380	319 (83.9)	-0.66 (0.03)	(-0.72, -0.60)	-0.16 (0.04)	(-0.25, -0.07)	<0.001 *	
	Placebo	371	296 (79.8)	-0.50 (0.03)	(-0.56, -0.44)				
Week 24	Tezepelumab	380	327 (86.1)	-0.66 (0.03)	(-0.72, -0.60)	-0.15 (0.04)	(-0.24, -0.06)	<0.001 *	
	Placebo	371	297 (80.1)	-0.51 (0.03)	(-0.57, -0.45)				
Week 25	Tezepelumab	380	314 (82.6)	-0.66 (0.03)	(-0.72, -0.60)	-0.14 (0.04)	(-0.23, -0.06)	0.001 *	
	Placebo	371	296 (79.8)	-0.51 (0.03)	(-0.58, -0.45)				
Week 26	Tezepelumab	380	319 (83.9)	-0.65 (0.03)	(-0.71, -0.59)	-0.15 (0.04)	(-0.23, -0.06)	<0.001 *	
	Placebo	371	289 (77.9)	-0.51 (0.03)	(-0.57, -0.44)				
Week 27	Tezepelumab	380	309 (81.3)	-0.66 (0.03)	(-0.72, -0.60)	-0.16 (0.04)	(-0.24, -0.07)	<0.001 *	
	Placebo	371	300 (80.9)	-0.51 (0.03)	(-0.57, -0.44)				
Week 28	Tezepelumab	380	317 (83.4)	-0.68 (0.03)	(-0.74, -0.62)	-0.16 (0.04)	(-0.24, -0.07)	<0.001 *	
	Placebo	371	300 (80.9)	-0.52 (0.03)	(-0.58, -0.46)				
Week 29	Tezepelumab	380	310 (81.6)	-0.68 (0.03)	(-0.74, -0.62)	-0.16 (0.04)	(-0.25, -0.08)	<0.001 *	
	Placebo	371	299 (80.6)	-0.51 (0.03)	(-0.58, -0.45)				
Week 30	Tezepelumab	380	314 (82.6)	-0.67 (0.03)	(-0.73, -0.61)	-0.16 (0.04)	(-0.24, -0.07)	<0.001 *	
	Placebo	371	295 (79.5)	-0.51 (0.03)	(-0.57, -0.45)				

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WTC\_ALMC0: Change from baseline in ASD weekly total score - MMRM results  
 DITTL - adult

Change from baseline in ASD weekly total score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 31	Tezepelumab	380	315 (82.9)	-0.67 (0.03)	(-0.73, -0.61)	-0.15 (0.04)	(-0.24, -0.06)	<0.001 *	
	Placebo	371	296 (79.8)	-0.52 (0.03)	(-0.58, -0.46)				
Week 32	Tezepelumab	380	316 (83.2)	-0.67 (0.03)	(-0.73, -0.61)	-0.15 (0.04)	(-0.24, -0.07)	<0.001 *	
	Placebo	371	297 (80.1)	-0.51 (0.03)	(-0.58, -0.45)				
Week 33	Tezepelumab	380	313 (82.4)	-0.69 (0.03)	(-0.75, -0.63)	-0.17 (0.04)	(-0.26, -0.08)	<0.001 *	
	Placebo	371	291 (78.4)	-0.52 (0.03)	(-0.58, -0.45)				
Week 34	Tezepelumab	380	311 (81.8)	-0.70 (0.03)	(-0.76, -0.64)	-0.18 (0.04)	(-0.27, -0.09)	<0.001 *	
	Placebo	371	293 (79.0)	-0.52 (0.03)	(-0.58, -0.45)				
Week 35	Tezepelumab	380	312 (82.1)	-0.68 (0.03)	(-0.74, -0.62)	-0.16 (0.04)	(-0.25, -0.07)	<0.001 *	
	Placebo	371	285 (76.8)	-0.52 (0.03)	(-0.58, -0.46)				
Week 36	Tezepelumab	380	309 (81.3)	-0.67 (0.03)	(-0.73, -0.61)	-0.15 (0.04)	(-0.24, -0.06)	<0.001 *	
	Placebo	371	288 (77.6)	-0.52 (0.03)	(-0.58, -0.45)				
Week 37	Tezepelumab	380	312 (82.1)	-0.67 (0.03)	(-0.74, -0.61)	-0.14 (0.04)	(-0.23, -0.05)	0.002 *	
	Placebo	371	287 (77.4)	-0.53 (0.03)	(-0.60, -0.47)				
Week 38	Tezepelumab	380	310 (81.6)	-0.66 (0.03)	(-0.73, -0.60)	-0.12 (0.04)	(-0.21, -0.04)	0.006 *	
	Placebo	371	287 (77.4)	-0.54 (0.03)	(-0.60, -0.48)				
Week 39	Tezepelumab	380	317 (83.4)	-0.66 (0.03)	(-0.72, -0.60)	-0.11 (0.04)	(-0.20, -0.03)	0.011 *	
	Placebo	371	281 (75.7)	-0.55 (0.03)	(-0.61, -0.48)				
Week 40	Tezepelumab	380	313 (82.4)	-0.68 (0.03)	(-0.74, -0.62)	-0.15 (0.04)	(-0.24, -0.06)	<0.001 *	
	Placebo	371	287 (77.4)	-0.52 (0.03)	(-0.59, -0.46)				

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WTC\_ALMC0: Change from baseline in ASD weekly total score - MMRM results  
 DITTL - adult

Change from baseline in ASD weekly total score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 41	Tezepelumab	380	316 (83.2)	-0.70 (0.03)	(-0.76, -0.64)	-0.17 (0.04)	(-0.25, -0.08)	<0.001 *	
	Placebo	371	288 (77.6)	-0.54 (0.03)	(-0.60, -0.47)				
Week 42	Tezepelumab	380	308 (81.1)	-0.70 (0.03)	(-0.76, -0.64)	-0.17 (0.05)	(-0.26, -0.08)	<0.001 *	
	Placebo	371	288 (77.6)	-0.53 (0.03)	(-0.59, -0.46)				
Week 43	Tezepelumab	380	311 (81.8)	-0.70 (0.03)	(-0.76, -0.64)	-0.16 (0.05)	(-0.25, -0.07)	<0.001 *	
	Placebo	371	285 (76.8)	-0.55 (0.03)	(-0.61, -0.48)				
Week 44	Tezepelumab	380	309 (81.3)	-0.71 (0.03)	(-0.77, -0.65)	-0.17 (0.05)	(-0.26, -0.08)	<0.001 *	
	Placebo	371	283 (76.3)	-0.53 (0.03)	(-0.60, -0.47)				
Week 45	Tezepelumab	380	312 (82.1)	-0.72 (0.03)	(-0.78, -0.65)	-0.17 (0.05)	(-0.26, -0.08)	<0.001 *	
	Placebo	371	285 (76.8)	-0.55 (0.03)	(-0.61, -0.48)				
Week 46	Tezepelumab	380	307 (80.8)	-0.72 (0.03)	(-0.78, -0.66)	-0.16 (0.05)	(-0.25, -0.07)	<0.001 *	
	Placebo	371	278 (74.9)	-0.56 (0.03)	(-0.62, -0.49)				
Week 47	Tezepelumab	380	296 (77.9)	-0.71 (0.03)	(-0.77, -0.65)	-0.15 (0.05)	(-0.24, -0.06)	<0.001 *	
	Placebo	371	281 (75.7)	-0.56 (0.03)	(-0.62, -0.50)				
Week 48	Tezepelumab	380	318 (83.7)	-0.70 (0.03)	(-0.76, -0.64)	-0.14 (0.05)	(-0.23, -0.05)	0.002 *	
	Placebo	371	291 (78.4)	-0.56 (0.03)	(-0.62, -0.50)				
Week 49	Tezepelumab	380	308 (81.1)	-0.71 (0.03)	(-0.77, -0.64)	-0.14 (0.05)	(-0.23, -0.05)	0.002 *	
	Placebo	371	280 (75.5)	-0.56 (0.03)	(-0.63, -0.50)				
Week 50	Tezepelumab	380	306 (80.5)	-0.71 (0.03)	(-0.77, -0.65)	-0.15 (0.05)	(-0.24, -0.06)	<0.001 *	
	Placebo	371	278 (74.9)	-0.56 (0.03)	(-0.62, -0.49)				

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WTC\_ALMC0: Change from baseline in ASD weekly total score - MMRM results  
 DITTL - adult

Change from baseline in ASD weekly total score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 51	Tezepelumab	380	300 (78.9)	-0.70 (0.03)	(-0.76, -0.64)	-0.14 (0.05)	(-0.23, -0.05)	0.002 *
	Placebo	371	270 (72.8)	-0.56 (0.03)	(-0.62, -0.49)			
Week 52	Tezepelumab	380	268 (70.5)	-0.69 (0.03)	(-0.75, -0.63)	-0.14 (0.05)	(-0.23, -0.05)	0.002 *
	Placebo	371	246 (66.3)	-0.55 (0.03)	(-0.61, -0.48)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WDC\_ALMH0: Course of ASD weekly daytime score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly daytime score	Baseline	Tezepelumab	380	380 (100.0)	1.54 (0.76)	0.0	1.00	1.49	2.00	4.0	
		Placebo	371	371 (100.0)	1.49 (0.74)	0.0	1.00	1.43	2.03	4.0	
	Week 1	Tezepelumab	380	373 (98.2)	1.33 (0.69)	0.0	0.89	1.23	1.77	3.8	
		Placebo	371	365 (98.4)	1.40 (0.72)	0.0	0.91	1.31	1.86	3.9	
	Week 2	Tezepelumab	380	372 (97.9)	1.19 (0.71)	0.0	0.74	1.07	1.61	3.4	
		Placebo	371	365 (98.4)	1.32 (0.72)	0.0	0.83	1.23	1.89	3.9	
	Week 3	Tezepelumab	380	371 (97.6)	1.13 (0.70)	0.0	0.66	1.03	1.54	3.2	
		Placebo	371	359 (96.8)	1.22 (0.73)	0.0	0.71	1.14	1.73	4.0	
	Week 4	Tezepelumab	380	368 (96.8)	1.09 (0.72)	0.0	0.59	1.00	1.53	3.4	
		Placebo	371	363 (97.8)	1.18 (0.72)	0.0	0.60	1.09	1.71	3.9	
	Week 5	Tezepelumab	380	371 (97.6)	1.04 (0.71)	0.0	0.54	1.00	1.51	3.6	
		Placebo	371	354 (95.4)	1.12 (0.71)	0.0	0.57	1.05	1.63	3.9	
	Week 6	Tezepelumab	380	366 (96.3)	1.01 (0.72)	0.0	0.43	0.94	1.47	3.8	
		Placebo	371	360 (97.0)	1.12 (0.74)	0.0	0.57	1.03	1.68	4.0	
	Week 7	Tezepelumab	380	366 (96.3)	0.99 (0.74)	0.0	0.40	0.94	1.44	3.8	
		Placebo	371	358 (96.5)	1.10 (0.75)	0.0	0.53	1.00	1.57	4.0	
	Week 8	Tezepelumab	380	366 (96.3)	0.96 (0.72)	0.0	0.40	0.90	1.43	3.7	
		Placebo	371	353 (95.1)	1.07 (0.73)	0.0	0.53	1.00	1.60	3.9	
	Week 9	Tezepelumab	380	369 (97.1)	0.92 (0.71)	0.0	0.34	0.88	1.37	3.8	
		Placebo	371	351 (94.6)	1.04 (0.72)	0.0	0.49	1.00	1.49	4.0	
	Week 10	Tezepelumab	380	370 (97.4)	0.90 (0.71)	0.0	0.29	0.87	1.33	3.7	
		Placebo	371	347 (93.5)	1.04 (0.72)	0.0	0.46	1.00	1.54	3.9	
	Week 11	Tezepelumab	380	362 (95.3)	0.91 (0.73)	0.0	0.27	0.91	1.37	3.6	
		Placebo	371	347 (93.5)	1.03 (0.74)	0.0	0.43	1.00	1.54	3.8	
	Week 12	Tezepelumab	380	364 (95.8)	0.91 (0.72)	0.0	0.31	0.90	1.30	3.6	
		Placebo	371	344 (92.7)	1.01 (0.74)	0.0	0.43	0.97	1.45	3.8	
	Week 13	Tezepelumab	380	358 (94.2)	0.89 (0.71)	0.0	0.30	0.83	1.31	3.3	
		Placebo	371	341 (91.9)	0.99 (0.72)	0.0	0.43	1.00	1.43	3.8	
	Week 14	Tezepelumab	380	356 (93.7)	0.86 (0.70)	0.0	0.23	0.80	1.29	3.3	
		Placebo	371	347 (93.5)	0.99 (0.71)	0.0	0.40	1.00	1.50	3.8	
	Week 15	Tezepelumab	380	359 (94.5)	0.86 (0.71)	0.0	0.26	0.83	1.23	3.3	
		Placebo	371	338 (91.1)	0.99 (0.75)	0.0	0.34	1.00	1.43	4.0	
	Week 16	Tezepelumab	380	354 (93.2)	0.85 (0.71)	0.0	0.20	0.80	1.20	3.2	
		Placebo	371	338 (91.1)	1.00 (0.76)	0.0	0.30	0.96	1.57	4.0	
Week 17	Tezepelumab	380	354 (93.2)	0.80 (0.71)	0.0	0.17	0.73	1.20	3.1		
	Placebo	371	335 (90.3)	0.97 (0.75)	0.0	0.31	0.94	1.43	3.9		

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WDC\_ALMH0: Course of ASD weekly daytime score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly daytime score	Week 18	Tezepelumab	380	354 (93.2)	0.83 (0.72)	0.0	0.17	0.77	1.20	3.4	
		Placebo	371	335 (90.3)	0.97 (0.75)	0.0	0.29	0.91	1.43	4.0	
	Week 19	Tezepelumab	380	344 (90.5)	0.82 (0.72)	0.0	0.17	0.76	1.20	3.4	
		Placebo	371	333 (89.8)	0.98 (0.77)	0.0	0.26	0.96	1.54	3.8	
	Week 20	Tezepelumab	380	344 (90.5)	0.82 (0.72)	0.0	0.14	0.79	1.20	3.2	
		Placebo	371	330 (88.9)	0.97 (0.76)	0.0	0.29	0.90	1.60	3.9	
	Week 21	Tezepelumab	380	347 (91.3)	0.81 (0.72)	0.0	0.12	0.73	1.17	3.3	
		Placebo	371	325 (87.6)	0.95 (0.78)	0.0	0.20	0.91	1.49	4.0	
	Week 22	Tezepelumab	380	343 (90.3)	0.84 (0.73)	0.0	0.14	0.80	1.23	3.4	
		Placebo	371	321 (86.5)	0.94 (0.76)	0.0	0.20	0.97	1.50	4.0	
	Week 23	Tezepelumab	380	346 (91.1)	0.82 (0.73)	0.0	0.14	0.75	1.26	3.3	
		Placebo	371	324 (87.3)	0.95 (0.76)	0.0	0.23	0.97	1.47	3.9	
	Week 24	Tezepelumab	380	345 (90.8)	0.83 (0.74)	0.0	0.15	0.77	1.25	3.2	
		Placebo	371	321 (86.5)	0.92 (0.76)	0.0	0.26	0.84	1.43	3.9	
	Week 25	Tezepelumab	380	342 (90.0)	0.82 (0.71)	0.0	0.16	0.77	1.20	3.3	
		Placebo	371	312 (84.1)	0.94 (0.77)	0.0	0.23	0.89	1.43	4.0	
	Week 26	Tezepelumab	380	339 (89.2)	0.82 (0.73)	0.0	0.14	0.74	1.23	3.2	
		Placebo	371	314 (84.6)	0.94 (0.77)	0.0	0.20	0.88	1.49	4.0	
	Week 27	Tezepelumab	380	337 (88.7)	0.80 (0.73)	0.0	0.13	0.74	1.20	3.5	
		Placebo	371	319 (86.0)	0.94 (0.80)	0.0	0.20	0.83	1.40	3.9	
	Week 28	Tezepelumab	380	340 (89.5)	0.79 (0.74)	0.0	0.06	0.71	1.19	3.5	
		Placebo	371	322 (86.8)	0.94 (0.79)	0.0	0.20	0.86	1.49	3.8	
	Week 29	Tezepelumab	380	340 (89.5)	0.78 (0.72)	0.0	0.09	0.66	1.19	3.5	
		Placebo	371	315 (84.9)	0.94 (0.79)	0.0	0.20	0.80	1.48	3.8	
	Week 30	Tezepelumab	380	335 (88.2)	0.81 (0.71)	0.0	0.16	0.71	1.20	3.9	
		Placebo	371	307 (82.7)	0.94 (0.78)	0.0	0.20	0.89	1.51	3.8	
	Week 31	Tezepelumab	380	346 (91.1)	0.80 (0.73)	0.0	0.10	0.74	1.23	4.0	
		Placebo	371	318 (85.7)	0.94 (0.76)	0.0	0.23	0.89	1.40	3.8	
	Week 32	Tezepelumab	380	336 (88.4)	0.81 (0.71)	0.0	0.15	0.77	1.23	3.9	
		Placebo	371	314 (84.6)	0.96 (0.76)	0.0	0.29	0.85	1.46	3.8	
	Week 33	Tezepelumab	380	333 (87.6)	0.79 (0.71)	0.0	0.10	0.69	1.17	3.5	
		Placebo	371	314 (84.6)	0.94 (0.77)	0.0	0.23	0.89	1.57	3.8	
	Week 34	Tezepelumab	380	337 (88.7)	0.77 (0.74)	0.0	0.06	0.69	1.17	3.5	
		Placebo	371	312 (84.1)	0.92 (0.77)	0.0	0.23	0.85	1.45	3.8	
	Week 35	Tezepelumab	380	333 (87.6)	0.79 (0.74)	0.0	0.11	0.70	1.20	3.6	
		Placebo	371	305 (82.2)	0.93 (0.76)	0.0	0.26	0.88	1.45	3.8	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WDC\_ALMH0: Course of ASD weekly daytime score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly daytime score	Week 36	Tezepelumab	380	335 (88.2)	0.81 (0.74)	0.0	0.08	0.72	1.20	3.5	
		Placebo	371	303 (81.7)	0.94 (0.75)	0.0	0.26	0.91	1.46	3.8	
	Week 37	Tezepelumab	380	329 (86.6)	0.80 (0.73)	0.0	0.14	0.73	1.20	3.4	
		Placebo	371	313 (84.4)	0.93 (0.75)	0.0	0.20	0.94	1.40	3.8	
	Week 38	Tezepelumab	380	335 (88.2)	0.80 (0.75)	0.0	0.10	0.69	1.29	3.4	
		Placebo	371	309 (83.3)	0.92 (0.75)	0.0	0.23	0.86	1.40	3.8	
	Week 39	Tezepelumab	380	335 (88.2)	0.82 (0.78)	0.0	0.11	0.70	1.23	3.9	
		Placebo	371	304 (81.9)	0.93 (0.76)	0.0	0.23	0.88	1.46	3.8	
	Week 40	Tezepelumab	380	335 (88.2)	0.80 (0.75)	0.0	0.06	0.67	1.26	3.4	
		Placebo	371	310 (83.6)	0.93 (0.77)	0.0	0.20	0.88	1.57	3.8	
	Week 41	Tezepelumab	380	333 (87.6)	0.78 (0.72)	0.0	0.06	0.67	1.17	3.0	
		Placebo	371	310 (83.6)	0.93 (0.76)	0.0	0.23	0.90	1.47	3.8	
	Week 42	Tezepelumab	380	331 (87.1)	0.78 (0.74)	0.0	0.06	0.63	1.20	3.2	
		Placebo	371	309 (83.3)	0.92 (0.79)	0.0	0.20	0.83	1.40	3.8	
	Week 43	Tezepelumab	380	333 (87.6)	0.79 (0.75)	0.0	0.11	0.63	1.20	3.1	
		Placebo	371	308 (83.0)	0.91 (0.78)	0.0	0.19	0.83	1.42	3.8	
	Week 44	Tezepelumab	380	331 (87.1)	0.78 (0.74)	0.0	0.06	0.63	1.20	3.1	
		Placebo	371	309 (83.3)	0.93 (0.76)	0.0	0.20	0.85	1.43	3.8	
	Week 45	Tezepelumab	380	333 (87.6)	0.76 (0.73)	0.0	0.07	0.60	1.20	3.1	
		Placebo	371	308 (83.0)	0.92 (0.77)	0.0	0.20	0.81	1.40	3.8	
	Week 46	Tezepelumab	380	331 (87.1)	0.77 (0.73)	0.0	0.07	0.60	1.20	3.3	
		Placebo	371	302 (81.4)	0.90 (0.75)	0.0	0.20	0.83	1.46	3.8	
	Week 47	Tezepelumab	380	329 (86.6)	0.77 (0.73)	0.0	0.09	0.60	1.20	3.0	
		Placebo	371	298 (80.3)	0.88 (0.73)	0.0	0.20	0.80	1.43	3.8	
	Week 48	Tezepelumab	380	331 (87.1)	0.78 (0.74)	0.0	0.05	0.60	1.20	3.0	
		Placebo	371	304 (81.9)	0.89 (0.73)	0.0	0.20	0.86	1.39	3.8	
	Week 49	Tezepelumab	380	328 (86.3)	0.76 (0.74)	0.0	0.03	0.60	1.20	3.0	
		Placebo	371	301 (81.1)	0.90 (0.73)	0.0	0.20	0.86	1.37	3.8	
	Week 50	Tezepelumab	380	328 (86.3)	0.77 (0.72)	0.0	0.04	0.60	1.20	3.0	
		Placebo	371	300 (80.9)	0.90 (0.74)	0.0	0.20	0.86	1.35	3.8	
	Week 51	Tezepelumab	380	321 (84.5)	0.78 (0.73)	0.0	0.03	0.63	1.20	3.0	
		Placebo	371	292 (78.7)	0.89 (0.75)	0.0	0.20	0.84	1.37	3.8	
	Week 52	Tezepelumab	380	294 (77.4)	0.80 (0.75)	0.0	0.07	0.63	1.23	3.0	
		Placebo	371	273 (73.6)	0.90 (0.79)	0.0	0.20	0.80	1.43	3.8	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table NT1WDC\_ALMH0: Course of ASD weekly daytime score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly daytime score	Week 1	Tezepelumab	380	373 (98.2)	-0.19 (0.39)	-1.7	-0.37	-0.11	0.03	0.8	-0.24 [-0.39, -0.10]
		Placebo	371	365 (98.4)	-0.10 (0.37)	-1.8	-0.26	-0.06	0.09	1.5	
	Week 2	Tezepelumab	380	372 (97.9)	-0.34 (0.53)	-2.9	-0.61	-0.20	0.00	0.7	-0.34 [-0.49, -0.20]
		Placebo	371	365 (98.4)	-0.16 (0.52)	-2.2	-0.34	-0.11	0.09	1.5	
	Week 3	Tezepelumab	380	371 (97.6)	-0.41 (0.59)	-3.6	-0.71	-0.26	0.00	0.7	-0.23 [-0.38, -0.08]
		Placebo	371	359 (96.8)	-0.28 (0.58)	-2.6	-0.51	-0.19	0.03	1.6	
	Week 4	Tezepelumab	380	368 (96.8)	-0.44 (0.62)	-3.6	-0.74	-0.26	0.00	0.8	-0.21 [-0.36, -0.07]
		Placebo	371	363 (97.8)	-0.31 (0.60)	-2.6	-0.62	-0.20	0.03	2.1	
	Week 5	Tezepelumab	380	371 (97.6)	-0.50 (0.64)	-3.7	-0.89	-0.34	-0.02	0.8	-0.21 [-0.35, -0.06]
		Placebo	371	354 (95.4)	-0.37 (0.60)	-2.8	-0.69	-0.26	-0.01	1.6	
	Week 6	Tezepelumab	380	366 (96.3)	-0.53 (0.69)	-3.7	-0.91	-0.38	-0.03	0.9	-0.23 [-0.38, -0.09]
		Placebo	371	360 (97.0)	-0.37 (0.67)	-3.1	-0.74	-0.29	0.01	1.9	
	Week 7	Tezepelumab	380	366 (96.3)	-0.55 (0.72)	-3.7	-0.96	-0.43	-0.03	1.2	-0.21 [-0.36, -0.07]
		Placebo	371	358 (96.5)	-0.40 (0.68)	-3.1	-0.77	-0.29	0.00	1.7	
	Week 8	Tezepelumab	380	366 (96.3)	-0.57 (0.71)	-3.7	-0.97	-0.41	-0.03	1.3	-0.21 [-0.36, -0.07]
		Placebo	371	353 (95.1)	-0.42 (0.66)	-3.0	-0.83	-0.30	0.00	1.7	
	Week 9	Tezepelumab	380	369 (97.1)	-0.61 (0.72)	-3.7	-1.03	-0.51	-0.06	1.5	-0.22 [-0.37, -0.07]
		Placebo	371	351 (94.6)	-0.46 (0.66)	-3.1	-0.89	-0.37	0.00	1.7	
	Week 10	Tezepelumab	380	370 (97.4)	-0.62 (0.73)	-3.6	-1.07	-0.46	-0.06	1.1	-0.25 [-0.40, -0.10]
		Placebo	371	347 (93.5)	-0.45 (0.67)	-3.1	-0.87	-0.31	-0.02	1.8	
	Week 11	Tezepelumab	380	362 (95.3)	-0.61 (0.72)	-3.6	-1.03	-0.47	-0.08	1.0	-0.21 [-0.36, -0.06]
		Placebo	371	347 (93.5)	-0.46 (0.67)	-3.1	-0.86	-0.37	-0.03	1.7	
	Week 12	Tezepelumab	380	364 (95.8)	-0.60 (0.74)	-3.7	-1.06	-0.47	-0.06	1.2	-0.17 [-0.31, -0.02]
		Placebo	371	344 (92.7)	-0.48 (0.68)	-3.1	-0.86	-0.37	-0.04	1.7	
	Week 13	Tezepelumab	380	358 (94.2)	-0.63 (0.75)	-3.7	-1.09	-0.51	-0.07	1.3	-0.18 [-0.33, -0.03]
		Placebo	371	341 (91.9)	-0.50 (0.68)	-3.1	-0.91	-0.40	-0.03	1.7	
	Week 14	Tezepelumab	380	356 (93.7)	-0.66 (0.74)	-3.7	-1.14	-0.54	-0.09	1.0	-0.23 [-0.38, -0.08]
		Placebo	371	347 (93.5)	-0.50 (0.68)	-3.1	-0.86	-0.40	-0.06	1.7	
	Week 15	Tezepelumab	380	359 (94.5)	-0.66 (0.74)	-3.0	-1.17	-0.52	-0.06	1.1	-0.21 [-0.36, -0.06]
		Placebo	371	338 (91.1)	-0.51 (0.70)	-3.1	-0.89	-0.43	-0.05	1.7	
	Week 16	Tezepelumab	380	354 (93.2)	-0.67 (0.74)	-3.7	-1.17	-0.52	-0.11	1.5	-0.25 [-0.40, -0.10]
		Placebo	371	338 (91.1)	-0.50 (0.70)	-2.9	-0.89	-0.42	-0.04	1.7	
	Week 17	Tezepelumab	380	354 (93.2)	-0.71 (0.76)	-3.7	-1.20	-0.61	-0.11	1.4	-0.26 [-0.41, -0.11]
		Placebo	371	335 (90.3)	-0.52 (0.69)	-3.1	-0.94	-0.43	-0.06	1.7	
	Week 18	Tezepelumab	380	354 (93.2)	-0.69 (0.78)	-3.7	-1.17	-0.59	-0.11	1.2	-0.23 [-0.38, -0.08]
		Placebo	371	335 (90.3)	-0.52 (0.71)	-3.3	-0.95	-0.43	-0.05	1.7	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WDC\_ALMH0: Course of ASD weekly daytime score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly daytime score	Week 19	Tezepelumab	380	344 (90.5)	-0.69 (0.78)	-3.7	-1.15	-0.60	-0.09	1.6	-0.24 [-0.39, -0.09]
		Placebo	371	333 (89.8)	-0.51 (0.73)	-3.2	-0.94	-0.40	-0.04	2.0	
	Week 20	Tezepelumab	380	344 (90.5)	-0.69 (0.76)	-3.7	-1.20	-0.61	-0.11	1.1	-0.23 [-0.38, -0.08]
		Placebo	371	330 (88.9)	-0.51 (0.74)	-3.3	-0.92	-0.45	-0.06	1.7	
	Week 21	Tezepelumab	380	347 (91.3)	-0.71 (0.75)	-3.7	-1.17	-0.63	-0.11	1.7	-0.24 [-0.39, -0.08]
		Placebo	371	325 (87.6)	-0.53 (0.72)	-3.0	-0.92	-0.47	-0.03	1.7	
	Week 22	Tezepelumab	380	343 (90.3)	-0.67 (0.76)	-3.4	-1.17	-0.60	-0.10	1.1	-0.18 [-0.33, -0.03]
		Placebo	371	321 (86.5)	-0.54 (0.71)	-3.5	-0.91	-0.46	-0.06	1.7	
	Week 23	Tezepelumab	380	346 (91.1)	-0.69 (0.78)	-3.5	-1.17	-0.62	-0.11	1.3	-0.20 [-0.35, -0.05]
		Placebo	371	324 (87.3)	-0.54 (0.74)	-3.4	-0.97	-0.45	-0.06	1.7	
	Week 24	Tezepelumab	380	345 (90.8)	-0.68 (0.76)	-3.7	-1.17	-0.60	-0.13	1.4	-0.17 [-0.32, -0.02]
		Placebo	371	321 (86.5)	-0.56 (0.74)	-3.4	-1.00	-0.50	-0.08	1.7	
	Week 25	Tezepelumab	380	342 (90.0)	-0.69 (0.75)	-3.7	-1.14	-0.60	-0.14	1.3	-0.21 [-0.36, -0.05]
		Placebo	371	312 (84.1)	-0.54 (0.74)	-3.3	-0.97	-0.46	-0.11	1.7	
	Week 26	Tezepelumab	380	339 (89.2)	-0.68 (0.76)	-3.6	-1.17	-0.63	-0.14	1.4	-0.19 [-0.34, -0.04]
		Placebo	371	314 (84.6)	-0.54 (0.77)	-3.2	-0.97	-0.43	-0.03	1.7	
	Week 27	Tezepelumab	380	337 (88.7)	-0.71 (0.77)	-3.7	-1.17	-0.63	-0.11	1.2	-0.22 [-0.38, -0.07]
		Placebo	371	319 (86.0)	-0.53 (0.79)	-3.2	-1.01	-0.43	-0.03	2.2	
	Week 28	Tezepelumab	380	340 (89.5)	-0.71 (0.78)	-3.7	-1.20	-0.61	-0.11	1.3	-0.23 [-0.39, -0.08]
		Placebo	371	322 (86.8)	-0.53 (0.74)	-3.1	-1.03	-0.43	-0.03	1.7	
	Week 29	Tezepelumab	380	340 (89.5)	-0.73 (0.78)	-3.7	-1.20	-0.63	-0.14	1.1	-0.26 [-0.41, -0.10]
		Placebo	371	315 (84.9)	-0.53 (0.75)	-3.1	-0.97	-0.45	-0.03	1.7	
	Week 30	Tezepelumab	380	335 (88.2)	-0.71 (0.76)	-3.7	-1.20	-0.67	-0.11	1.3	-0.23 [-0.38, -0.07]
		Placebo	371	307 (82.7)	-0.53 (0.75)	-3.1	-1.00	-0.47	-0.03	1.7	
	Week 31	Tezepelumab	380	346 (91.1)	-0.71 (0.79)	-3.7	-1.20	-0.65	-0.11	1.6	-0.22 [-0.38, -0.07]
		Placebo	371	318 (85.7)	-0.54 (0.74)	-3.2	-1.00	-0.45	-0.03	1.7	
	Week 32	Tezepelumab	380	336 (88.4)	-0.70 (0.76)	-3.7	-1.17	-0.61	-0.14	2.0	-0.22 [-0.37, -0.06]
		Placebo	371	314 (84.6)	-0.54 (0.76)	-3.3	-1.02	-0.46	-0.03	1.7	
	Week 33	Tezepelumab	380	333 (87.6)	-0.72 (0.79)	-3.7	-1.19	-0.63	-0.14	2.1	-0.23 [-0.38, -0.07]
		Placebo	371	314 (84.6)	-0.54 (0.77)	-3.3	-1.00	-0.40	-0.06	1.7	
	Week 34	Tezepelumab	380	337 (88.7)	-0.73 (0.78)	-3.7	-1.20	-0.69	-0.15	2.0	-0.22 [-0.37, -0.06]
		Placebo	371	312 (84.1)	-0.56 (0.78)	-3.4	-0.98	-0.46	-0.09	1.7	
	Week 35	Tezepelumab	380	333 (87.6)	-0.71 (0.79)	-3.7	-1.20	-0.66	-0.14	1.8	-0.23 [-0.38, -0.07]
		Placebo	371	305 (82.2)	-0.53 (0.74)	-3.1	-1.01	-0.43	-0.05	1.7	
	Week 36	Tezepelumab	380	335 (88.2)	-0.71 (0.79)	-3.7	-1.17	-0.63	-0.14	1.8	-0.23 [-0.38, -0.07]
		Placebo	371	303 (81.7)	-0.54 (0.75)	-3.3	-1.04	-0.43	-0.06	1.7	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WDC\_ALMH0: Course of ASD weekly daytime score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly daytime score	Week 37	Tezepelumab	380	329 (86.6)	-0.70 (0.78)	-3.7	-1.23	-0.63	-0.11	1.8	-0.19 [-0.35, -0.04]
		Placebo	371	313 (84.4)	-0.55 (0.75)	-3.4	-1.03	-0.43	-0.06	1.7	
	Week 38	Tezepelumab	380	335 (88.2)	-0.71 (0.79)	-3.7	-1.20	-0.60	-0.14	1.8	-0.19 [-0.34, -0.03]
		Placebo	371	309 (83.3)	-0.56 (0.73)	-3.5	-1.06	-0.43	-0.06	1.7	
	Week 39	Tezepelumab	380	335 (88.2)	-0.70 (0.81)	-3.7	-1.20	-0.63	-0.09	1.8	-0.18 [-0.34, -0.03]
		Placebo	371	304 (81.9)	-0.55 (0.73)	-3.3	-1.06	-0.44	-0.03	1.7	
	Week 40	Tezepelumab	380	335 (88.2)	-0.72 (0.79)	-3.7	-1.20	-0.69	-0.11	1.8	-0.23 [-0.39, -0.08]
		Placebo	371	310 (83.6)	-0.54 (0.74)	-3.5	-1.00	-0.40	-0.06	1.7	
	Week 41	Tezepelumab	380	333 (87.6)	-0.74 (0.79)	-3.7	-1.26	-0.67	-0.14	1.8	-0.25 [-0.41, -0.10]
		Placebo	371	310 (83.6)	-0.55 (0.72)	-3.1	-1.03	-0.46	-0.06	1.7	
	Week 42	Tezepelumab	380	331 (87.1)	-0.74 (0.80)	-3.7	-1.22	-0.67	-0.14	1.8	-0.26 [-0.41, -0.10]
		Placebo	371	309 (83.3)	-0.55 (0.74)	-3.2	-0.99	-0.43	-0.06	1.7	
	Week 43	Tezepelumab	380	333 (87.6)	-0.72 (0.80)	-3.7	-1.23	-0.68	-0.17	1.8	-0.19 [-0.35, -0.04]
		Placebo	371	308 (83.0)	-0.57 (0.75)	-3.1	-1.05	-0.47	-0.06	1.7	
	Week 44	Tezepelumab	380	331 (87.1)	-0.73 (0.79)	-3.7	-1.20	-0.66	-0.17	1.8	-0.25 [-0.40, -0.09]
		Placebo	371	309 (83.3)	-0.55 (0.74)	-3.2	-1.01	-0.40	-0.05	1.7	
	Week 45	Tezepelumab	380	333 (87.6)	-0.75 (0.76)	-3.7	-1.20	-0.70	-0.17	1.8	-0.24 [-0.40, -0.09]
		Placebo	371	308 (83.0)	-0.57 (0.74)	-3.3	-1.10	-0.43	-0.04	1.7	
	Week 46	Tezepelumab	380	331 (87.1)	-0.75 (0.80)	-3.7	-1.23	-0.69	-0.17	1.8	-0.22 [-0.38, -0.07]
		Placebo	371	302 (81.4)	-0.58 (0.75)	-3.2	-1.09	-0.47	-0.06	1.7	
	Week 47	Tezepelumab	380	329 (86.6)	-0.75 (0.79)	-3.7	-1.23	-0.67	-0.14	1.8	-0.20 [-0.36, -0.04]
		Placebo	371	298 (80.3)	-0.60 (0.72)	-3.1	-1.03	-0.49	-0.11	1.3	
	Week 48	Tezepelumab	380	331 (87.1)	-0.73 (0.78)	-3.7	-1.20	-0.71	-0.15	1.8	-0.17 [-0.32, -0.01]
		Placebo	371	304 (81.9)	-0.60 (0.71)	-3.2	-1.08	-0.50	-0.11	1.3	
	Week 49	Tezepelumab	380	328 (86.3)	-0.75 (0.78)	-3.7	-1.22	-0.69	-0.18	1.8	-0.22 [-0.38, -0.07]
		Placebo	371	301 (81.1)	-0.58 (0.73)	-3.4	-1.00	-0.50	-0.06	1.3	
	Week 50	Tezepelumab	380	328 (86.3)	-0.75 (0.78)	-3.7	-1.20	-0.71	-0.20	1.8	-0.21 [-0.36, -0.05]
		Placebo	371	300 (80.9)	-0.60 (0.75)	-3.7	-1.07	-0.49	-0.03	1.3	
	Week 51	Tezepelumab	380	321 (84.5)	-0.72 (0.80)	-3.7	-1.20	-0.66	-0.17	1.8	-0.17 [-0.33, -0.01]
		Placebo	371	292 (78.7)	-0.59 (0.75)	-3.3	-1.07	-0.51	-0.09	1.3	
	Week 52	Tezepelumab	380	294 (77.4)	-0.73 (0.83)	-3.7	-1.23	-0.68	-0.14	1.8	-0.19 [-0.35, -0.02]
		Placebo	371	273 (73.6)	-0.58 (0.75)	-3.5	-1.00	-0.50	-0.06	1.3	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WDC\_ALMC0: Change from baseline in ASD weekly daytime score - MMRM results  
 DITTTL - adult

Change from baseline in ASD weekly daytime score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Time	Treatment	N	n (%)						
Week 1	Tezepelumab	380	373 (98.2)	-0.18 (0.03)	(-0.25, -0.12)	-0.08 (0.05)	(-0.17, 0.01)	0.091	
	Placebo	371	365 (98.4)	-0.11 (0.03)	(-0.17, -0.04)				
Week 2	Tezepelumab	380	372 (97.9)	-0.33 (0.03)	(-0.40, -0.27)	-0.17 (0.05)	(-0.26, -0.08)	<0.001 *	
	Placebo	371	365 (98.4)	-0.17 (0.03)	(-0.23, -0.10)				
Week 3	Tezepelumab	380	371 (97.6)	-0.40 (0.03)	(-0.46, -0.34)	-0.13 (0.05)	(-0.22, -0.04)	0.006 *	
	Placebo	371	359 (96.8)	-0.27 (0.03)	(-0.34, -0.21)				
Week 4	Tezepelumab	380	368 (96.8)	-0.43 (0.03)	(-0.49, -0.36)	-0.12 (0.05)	(-0.21, -0.03)	0.008 *	
	Placebo	371	363 (97.8)	-0.31 (0.03)	(-0.37, -0.24)				
Week 5	Tezepelumab	380	371 (97.6)	-0.48 (0.03)	(-0.55, -0.42)	-0.10 (0.05)	(-0.19, -0.01)	0.024 *	
	Placebo	371	354 (95.4)	-0.38 (0.03)	(-0.44, -0.32)				
Week 6	Tezepelumab	380	366 (96.3)	-0.52 (0.03)	(-0.58, -0.45)	-0.14 (0.05)	(-0.23, -0.05)	0.002 *	
	Placebo	371	360 (97.0)	-0.37 (0.03)	(-0.44, -0.31)				
Week 7	Tezepelumab	380	366 (96.3)	-0.53 (0.03)	(-0.60, -0.47)	-0.14 (0.05)	(-0.23, -0.05)	0.002 *	
	Placebo	371	358 (96.5)	-0.39 (0.03)	(-0.46, -0.33)				
Week 8	Tezepelumab	380	366 (96.3)	-0.56 (0.03)	(-0.62, -0.50)	-0.14 (0.05)	(-0.23, -0.05)	0.002 *	
	Placebo	371	353 (95.1)	-0.42 (0.03)	(-0.48, -0.35)				
Week 9	Tezepelumab	380	369 (97.1)	-0.61 (0.03)	(-0.67, -0.55)	-0.16 (0.05)	(-0.25, -0.07)	<0.001 *	
	Placebo	371	351 (94.6)	-0.45 (0.03)	(-0.51, -0.39)				
Week 10	Tezepelumab	380	370 (97.4)	-0.61 (0.03)	(-0.68, -0.55)	-0.17 (0.05)	(-0.26, -0.08)	<0.001 *	
	Placebo	371	347 (93.5)	-0.45 (0.03)	(-0.51, -0.38)				

Note: DITTTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WDC\_ALMC0: Change from baseline in ASD weekly daytime score - MMRM results  
 DITTTL - adult

Change from baseline in ASD weekly daytime score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Time	Treatment	N	n (%)						
Week 11	Tezepelumab	380	362 (95.3)	-0.61 (0.03)	(-0.67, -0.55)	-0.15 (0.05)	(-0.24, -0.06)	<0.001	*
	Placebo	371	347 (93.5)	-0.46 (0.03)	(-0.52, -0.39)				
Week 12	Tezepelumab	380	364 (95.8)	-0.59 (0.03)	(-0.66, -0.53)	-0.13 (0.05)	(-0.22, -0.04)	0.007	*
	Placebo	371	344 (92.7)	-0.47 (0.03)	(-0.53, -0.40)				
Week 13	Tezepelumab	380	358 (94.2)	-0.62 (0.03)	(-0.68, -0.56)	-0.14 (0.05)	(-0.24, -0.05)	0.002	*
	Placebo	371	341 (91.9)	-0.48 (0.03)	(-0.54, -0.41)				
Week 14	Tezepelumab	380	356 (93.7)	-0.65 (0.03)	(-0.71, -0.58)	-0.16 (0.05)	(-0.25, -0.07)	<0.001	*
	Placebo	371	347 (93.5)	-0.49 (0.03)	(-0.55, -0.42)				
Week 15	Tezepelumab	380	359 (94.5)	-0.65 (0.03)	(-0.71, -0.59)	-0.15 (0.05)	(-0.24, -0.06)	0.001	*
	Placebo	371	338 (91.1)	-0.50 (0.03)	(-0.56, -0.43)				
Week 16	Tezepelumab	380	354 (93.2)	-0.68 (0.03)	(-0.74, -0.62)	-0.20 (0.05)	(-0.30, -0.11)	<0.001	*
	Placebo	371	338 (91.1)	-0.48 (0.03)	(-0.54, -0.41)				
Week 17	Tezepelumab	380	354 (93.2)	-0.70 (0.03)	(-0.76, -0.64)	-0.19 (0.05)	(-0.28, -0.10)	<0.001	*
	Placebo	371	335 (90.3)	-0.51 (0.03)	(-0.57, -0.44)				
Week 18	Tezepelumab	380	354 (93.2)	-0.67 (0.03)	(-0.74, -0.61)	-0.17 (0.05)	(-0.26, -0.08)	<0.001	*
	Placebo	371	335 (90.3)	-0.51 (0.03)	(-0.57, -0.44)				
Week 19	Tezepelumab	380	344 (90.5)	-0.68 (0.03)	(-0.75, -0.62)	-0.18 (0.05)	(-0.27, -0.09)	<0.001	*
	Placebo	371	333 (89.8)	-0.50 (0.03)	(-0.57, -0.44)				
Week 20	Tezepelumab	380	344 (90.5)	-0.69 (0.03)	(-0.75, -0.62)	-0.17 (0.05)	(-0.27, -0.08)	<0.001	*
	Placebo	371	330 (88.9)	-0.51 (0.03)	(-0.58, -0.45)				

Note: DITTTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WDC\_ALMC0: Change from baseline in ASD weekly daytime score - MMRM results  
 DITTTL - adult

Change from baseline in ASD weekly daytime score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 21	Tezepelumab	380	347 (91.3)	-0.70 (0.03)	(-0.76, -0.63)	-0.18 (0.05)	(-0.27, -0.08)	<0.001 *	
	Placebo	371	325 (87.6)	-0.52 (0.03)	(-0.59, -0.45)				
Week 22	Tezepelumab	380	343 (90.3)	-0.69 (0.03)	(-0.75, -0.62)	-0.16 (0.05)	(-0.25, -0.07)	<0.001 *	
	Placebo	371	321 (86.5)	-0.53 (0.03)	(-0.60, -0.47)				
Week 23	Tezepelumab	380	346 (91.1)	-0.69 (0.03)	(-0.75, -0.62)	-0.17 (0.05)	(-0.26, -0.08)	<0.001 *	
	Placebo	371	324 (87.3)	-0.52 (0.03)	(-0.59, -0.45)				
Week 24	Tezepelumab	380	345 (90.8)	-0.68 (0.03)	(-0.74, -0.62)	-0.15 (0.05)	(-0.24, -0.06)	0.001 *	
	Placebo	371	321 (86.5)	-0.53 (0.03)	(-0.59, -0.46)				
Week 25	Tezepelumab	380	342 (90.0)	-0.69 (0.03)	(-0.75, -0.63)	-0.15 (0.05)	(-0.25, -0.06)	0.001 *	
	Placebo	371	312 (84.1)	-0.54 (0.03)	(-0.60, -0.47)				
Week 26	Tezepelumab	380	339 (89.2)	-0.69 (0.03)	(-0.75, -0.62)	-0.16 (0.05)	(-0.25, -0.06)	<0.001 *	
	Placebo	371	314 (84.6)	-0.53 (0.03)	(-0.60, -0.46)				
Week 27	Tezepelumab	380	337 (88.7)	-0.70 (0.03)	(-0.76, -0.63)	-0.17 (0.05)	(-0.27, -0.08)	<0.001 *	
	Placebo	371	319 (86.0)	-0.52 (0.03)	(-0.59, -0.46)				
Week 28	Tezepelumab	380	340 (89.5)	-0.72 (0.03)	(-0.78, -0.65)	-0.18 (0.05)	(-0.27, -0.08)	<0.001 *	
	Placebo	371	322 (86.8)	-0.54 (0.03)	(-0.61, -0.47)				
Week 29	Tezepelumab	380	340 (89.5)	-0.72 (0.03)	(-0.78, -0.66)	-0.18 (0.05)	(-0.27, -0.09)	<0.001 *	
	Placebo	371	315 (84.9)	-0.54 (0.03)	(-0.61, -0.47)				
Week 30	Tezepelumab	380	335 (88.2)	-0.71 (0.03)	(-0.77, -0.64)	-0.17 (0.05)	(-0.26, -0.08)	<0.001 *	
	Placebo	371	307 (82.7)	-0.54 (0.03)	(-0.61, -0.47)				

Note: DITTTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WDC\_ALMC0: Change from baseline in ASD weekly daytime score - MMRM results  
DITTL - adult

Change from baseline in ASD weekly daytime score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Time	Treatment	N	n (%)						
Week 31	Tezepelumab	380	346 (91.1)	-0.71 (0.03)	(-0.77, -0.64)	-0.16 (0.05)	(-0.25, -0.06)	<0.001	*
	Placebo	371	318 (85.7)	-0.55 (0.03)	(-0.61, -0.48)				
Week 32	Tezepelumab	380	336 (88.4)	-0.71 (0.03)	(-0.77, -0.64)	-0.17 (0.05)	(-0.26, -0.08)	<0.001	*
	Placebo	371	314 (84.6)	-0.54 (0.03)	(-0.60, -0.47)				
Week 33	Tezepelumab	380	333 (87.6)	-0.73 (0.03)	(-0.79, -0.66)	-0.18 (0.05)	(-0.28, -0.09)	<0.001	*
	Placebo	371	314 (84.6)	-0.54 (0.03)	(-0.61, -0.48)				
Week 34	Tezepelumab	380	337 (88.7)	-0.74 (0.03)	(-0.80, -0.67)	-0.20 (0.05)	(-0.29, -0.10)	<0.001	*
	Placebo	371	312 (84.1)	-0.54 (0.03)	(-0.61, -0.47)				
Week 35	Tezepelumab	380	333 (87.6)	-0.72 (0.03)	(-0.79, -0.66)	-0.18 (0.05)	(-0.27, -0.09)	<0.001	*
	Placebo	371	305 (82.2)	-0.54 (0.03)	(-0.61, -0.47)				
Week 36	Tezepelumab	380	335 (88.2)	-0.71 (0.03)	(-0.77, -0.64)	-0.17 (0.05)	(-0.26, -0.08)	<0.001	*
	Placebo	371	303 (81.7)	-0.54 (0.03)	(-0.60, -0.47)				
Week 37	Tezepelumab	380	329 (86.6)	-0.71 (0.03)	(-0.77, -0.64)	-0.16 (0.05)	(-0.25, -0.06)	<0.001	*
	Placebo	371	313 (84.4)	-0.55 (0.03)	(-0.62, -0.49)				
Week 38	Tezepelumab	380	335 (88.2)	-0.70 (0.03)	(-0.77, -0.64)	-0.14 (0.05)	(-0.24, -0.05)	0.002	*
	Placebo	371	309 (83.3)	-0.56 (0.03)	(-0.63, -0.49)				
Week 39	Tezepelumab	380	335 (88.2)	-0.70 (0.03)	(-0.76, -0.63)	-0.14 (0.05)	(-0.23, -0.04)	0.004	*
	Placebo	371	304 (81.9)	-0.56 (0.03)	(-0.63, -0.49)				
Week 40	Tezepelumab	380	335 (88.2)	-0.72 (0.03)	(-0.78, -0.65)	-0.17 (0.05)	(-0.26, -0.08)	<0.001	*
	Placebo	371	310 (83.6)	-0.55 (0.03)	(-0.61, -0.48)				

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WDC\_ALMC0: Change from baseline in ASD weekly daytime score - MMRM results  
 DITTTL - adult

Change from baseline in ASD weekly daytime score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Time	Treatment	N	n (%)						
Week 41	Tezepelumab	380	333 (87.6)	-0.74 (0.03)	(-0.80, -0.67)	-0.18 (0.05)	(-0.28, -0.09)	<0.001	*
	Placebo	371	310 (83.6)	-0.55 (0.03)	(-0.62, -0.48)				
Week 42	Tezepelumab	380	331 (87.1)	-0.74 (0.03)	(-0.80, -0.67)	-0.18 (0.05)	(-0.28, -0.09)	<0.001	*
	Placebo	371	309 (83.3)	-0.55 (0.03)	(-0.62, -0.49)				
Week 43	Tezepelumab	380	333 (87.6)	-0.73 (0.03)	(-0.79, -0.66)	-0.16 (0.05)	(-0.25, -0.07)	<0.001	*
	Placebo	371	308 (83.0)	-0.57 (0.03)	(-0.64, -0.50)				
Week 44	Tezepelumab	380	331 (87.1)	-0.74 (0.03)	(-0.81, -0.68)	-0.18 (0.05)	(-0.28, -0.09)	<0.001	*
	Placebo	371	309 (83.3)	-0.56 (0.03)	(-0.63, -0.49)				
Week 45	Tezepelumab	380	333 (87.6)	-0.75 (0.03)	(-0.82, -0.69)	-0.19 (0.05)	(-0.28, -0.09)	<0.001	*
	Placebo	371	308 (83.0)	-0.57 (0.03)	(-0.63, -0.50)				
Week 46	Tezepelumab	380	331 (87.1)	-0.75 (0.03)	(-0.82, -0.69)	-0.17 (0.05)	(-0.27, -0.08)	<0.001	*
	Placebo	371	302 (81.4)	-0.58 (0.03)	(-0.65, -0.51)				
Week 47	Tezepelumab	380	329 (86.6)	-0.74 (0.03)	(-0.80, -0.67)	-0.15 (0.05)	(-0.25, -0.06)	0.001	*
	Placebo	371	298 (80.3)	-0.58 (0.03)	(-0.65, -0.52)				
Week 48	Tezepelumab	380	331 (87.1)	-0.73 (0.03)	(-0.80, -0.67)	-0.14 (0.05)	(-0.24, -0.05)	0.003	*
	Placebo	371	304 (81.9)	-0.59 (0.03)	(-0.66, -0.52)				
Week 49	Tezepelumab	380	328 (86.3)	-0.74 (0.03)	(-0.81, -0.68)	-0.16 (0.05)	(-0.26, -0.07)	<0.001	*
	Placebo	371	301 (81.1)	-0.58 (0.03)	(-0.65, -0.51)				
Week 50	Tezepelumab	380	328 (86.3)	-0.75 (0.03)	(-0.82, -0.69)	-0.17 (0.05)	(-0.27, -0.08)	<0.001	*
	Placebo	371	300 (80.9)	-0.58 (0.03)	(-0.65, -0.51)				

Note: DITTTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table NT1WDC\_ALMC0: Change from baseline in ASD weekly daytime score - MMRM results  
 DITTL - adult

Change from baseline in ASD weekly daytime score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 51	Tezepelumab	380	321 (84.5)	-0.73 (0.03)	(-0.80, -0.67)	-0.16 (0.05)	(-0.25, -0.06)	0.001 *	
	Placebo	371	292 (78.7)	-0.58 (0.03)	(-0.65, -0.51)				
Week 52	Tezepelumab	380	294 (77.4)	-0.73 (0.03)	(-0.79, -0.66)	-0.15 (0.05)	(-0.25, -0.06)	0.002 *	
	Placebo	371	273 (73.6)	-0.57 (0.04)	(-0.64, -0.50)				

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WNC\_ALMH0: Course of ASD weekly night-time score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly night-time score	Baseline	Tezepelumab	380	380 (100.0)	1.36 (0.72)	0.0	0.86	1.31	1.77	4.0	
		Placebo	371	371 (100.0)	1.31 (0.69)	0.1	0.80	1.20	1.74	3.8	
	Week 1	Tezepelumab	380	376 (98.9)	1.14 (0.69)	0.0	0.69	1.00	1.54	3.7	
		Placebo	371	365 (98.4)	1.17 (0.67)	0.0	0.66	1.09	1.60	3.5	
	Week 2	Tezepelumab	380	373 (98.2)	1.04 (0.68)	0.0	0.54	0.97	1.40	3.5	
		Placebo	371	367 (98.9)	1.13 (0.68)	0.0	0.60	1.06	1.60	3.6	
	Week 3	Tezepelumab	380	373 (98.2)	0.99 (0.67)	0.0	0.51	0.91	1.31	3.3	
		Placebo	371	365 (98.4)	1.03 (0.67)	0.0	0.54	0.97	1.46	3.9	
	Week 4	Tezepelumab	380	373 (98.2)	0.94 (0.67)	0.0	0.43	0.86	1.29	3.5	
		Placebo	371	361 (97.3)	1.01 (0.65)	0.0	0.49	0.90	1.43	3.6	
	Week 5	Tezepelumab	380	370 (97.4)	0.88 (0.67)	0.0	0.37	0.80	1.26	3.6	
		Placebo	371	358 (96.5)	0.95 (0.65)	0.0	0.40	0.89	1.34	3.7	
	Week 6	Tezepelumab	380	373 (98.2)	0.84 (0.67)	0.0	0.29	0.77	1.29	3.7	
		Placebo	371	361 (97.3)	0.94 (0.67)	0.0	0.43	0.87	1.34	3.8	
	Week 7	Tezepelumab	380	365 (96.1)	0.83 (0.69)	0.0	0.26	0.74	1.20	3.8	
		Placebo	371	361 (97.3)	0.92 (0.68)	0.0	0.40	0.83	1.40	3.8	
	Week 8	Tezepelumab	380	364 (95.8)	0.81 (0.66)	0.0	0.27	0.71	1.20	3.8	
		Placebo	371	359 (96.8)	0.91 (0.66)	0.0	0.40	0.83	1.23	3.8	
	Week 9	Tezepelumab	380	373 (98.2)	0.78 (0.65)	0.0	0.23	0.69	1.11	3.7	
		Placebo	371	355 (95.7)	0.87 (0.66)	0.0	0.31	0.80	1.23	3.9	
	Week 10	Tezepelumab	380	367 (96.6)	0.78 (0.66)	0.0	0.23	0.69	1.14	3.7	
		Placebo	371	350 (94.3)	0.88 (0.65)	0.0	0.34	0.86	1.26	3.8	
	Week 11	Tezepelumab	380	363 (95.5)	0.79 (0.68)	0.0	0.20	0.74	1.14	3.5	
		Placebo	371	355 (95.7)	0.86 (0.66)	0.0	0.27	0.80	1.26	3.6	
	Week 12	Tezepelumab	380	360 (94.7)	0.79 (0.67)	0.0	0.20	0.77	1.12	3.6	
		Placebo	371	350 (94.3)	0.85 (0.66)	0.0	0.28	0.80	1.23	3.7	
	Week 13	Tezepelumab	380	363 (95.5)	0.75 (0.65)	0.0	0.20	0.66	1.11	3.1	
		Placebo	371	352 (94.9)	0.83 (0.63)	0.0	0.31	0.80	1.20	3.7	
	Week 14	Tezepelumab	380	358 (94.2)	0.72 (0.64)	0.0	0.17	0.61	1.09	3.0	
		Placebo	371	351 (94.6)	0.82 (0.64)	0.0	0.29	0.77	1.16	3.7	
	Week 15	Tezepelumab	380	355 (93.4)	0.73 (0.64)	0.0	0.17	0.65	1.11	3.2	
		Placebo	371	335 (90.3)	0.82 (0.67)	0.0	0.20	0.77	1.20	3.9	
	Week 16	Tezepelumab	380	359 (94.5)	0.71 (0.65)	0.0	0.14	0.60	1.03	3.3	
		Placebo	371	340 (91.6)	0.83 (0.67)	0.0	0.23	0.80	1.20	3.9	
	Week 17	Tezepelumab	380	354 (93.2)	0.71 (0.65)	0.0	0.17	0.59	1.06	3.2	
		Placebo	371	337 (90.8)	0.81 (0.65)	0.0	0.26	0.74	1.17	3.8	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WNC\_ALMH0: Course of ASD weekly night-time score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly night-time score	Week 18	Tezepelumab	380	352 (92.6)	0.71 (0.65)	0.0	0.20	0.60	1.05	3.4	
		Placebo	371	337 (90.8)	0.82 (0.68)	0.0	0.20	0.74	1.25	3.7	
	Week 19	Tezepelumab	380	354 (93.2)	0.71 (0.65)	0.0	0.14	0.60	1.03	3.3	
		Placebo	371	337 (90.8)	0.82 (0.69)	0.0	0.20	0.77	1.23	3.6	
	Week 20	Tezepelumab	380	349 (91.8)	0.70 (0.66)	0.0	0.13	0.60	1.00	3.2	
		Placebo	371	336 (90.6)	0.84 (0.68)	0.0	0.23	0.80	1.29	3.8	
	Week 21	Tezepelumab	380	350 (92.1)	0.71 (0.67)	0.0	0.10	0.60	1.06	3.3	
		Placebo	371	334 (90.0)	0.81 (0.69)	0.0	0.20	0.77	1.26	4.0	
	Week 22	Tezepelumab	380	350 (92.1)	0.71 (0.67)	0.0	0.11	0.60	1.10	3.3	
		Placebo	371	327 (88.1)	0.81 (0.67)	0.0	0.20	0.80	1.23	3.8	
	Week 23	Tezepelumab	380	345 (90.8)	0.70 (0.66)	0.0	0.09	0.60	1.09	3.4	
		Placebo	371	319 (86.0)	0.80 (0.66)	0.0	0.20	0.80	1.20	3.7	
	Week 24	Tezepelumab	380	344 (90.5)	0.70 (0.66)	0.0	0.11	0.60	1.06	3.2	
		Placebo	371	323 (87.1)	0.78 (0.68)	0.0	0.20	0.73	1.20	3.8	
	Week 25	Tezepelumab	380	347 (91.3)	0.70 (0.66)	0.0	0.11	0.60	1.03	3.1	
		Placebo	371	321 (86.5)	0.77 (0.67)	0.0	0.20	0.73	1.17	3.9	
	Week 26	Tezepelumab	380	341 (89.7)	0.71 (0.66)	0.0	0.15	0.60	1.09	3.3	
		Placebo	371	318 (85.7)	0.77 (0.67)	0.0	0.17	0.71	1.17	3.8	
	Week 27	Tezepelumab	380	348 (91.6)	0.69 (0.67)	0.0	0.12	0.57	1.06	3.3	
		Placebo	371	314 (84.6)	0.80 (0.70)	0.0	0.20	0.69	1.26	3.7	
	Week 28	Tezepelumab	380	347 (91.3)	0.69 (0.67)	0.0	0.05	0.57	1.10	3.4	
		Placebo	371	326 (87.9)	0.79 (0.69)	0.0	0.20	0.68	1.20	3.6	
	Week 29	Tezepelumab	380	342 (90.0)	0.67 (0.66)	0.0	0.10	0.53	1.00	3.4	
		Placebo	371	325 (87.6)	0.78 (0.68)	0.0	0.20	0.69	1.20	3.6	
	Week 30	Tezepelumab	380	343 (90.3)	0.69 (0.65)	0.0	0.14	0.56	1.06	3.8	
		Placebo	371	318 (85.7)	0.80 (0.69)	0.0	0.17	0.72	1.29	3.6	
	Week 31	Tezepelumab	380	346 (91.1)	0.70 (0.67)	0.0	0.14	0.57	1.09	4.0	
		Placebo	371	312 (84.1)	0.79 (0.66)	0.0	0.21	0.71	1.25	3.6	
	Week 32	Tezepelumab	380	347 (91.3)	0.69 (0.66)	0.0	0.14	0.57	1.00	3.8	
		Placebo	371	324 (87.3)	0.78 (0.66)	0.0	0.23	0.66	1.17	3.7	
	Week 33	Tezepelumab	380	344 (90.5)	0.67 (0.66)	0.0	0.09	0.51	1.00	3.4	
		Placebo	371	317 (85.4)	0.79 (0.67)	0.0	0.20	0.72	1.31	3.6	
	Week 34	Tezepelumab	380	346 (91.1)	0.67 (0.66)	0.0	0.06	0.54	1.04	3.4	
		Placebo	371	322 (86.8)	0.77 (0.66)	0.0	0.20	0.71	1.20	3.6	
	Week 35	Tezepelumab	380	340 (89.5)	0.68 (0.67)	0.0	0.06	0.56	1.03	3.5	
		Placebo	371	310 (83.6)	0.78 (0.68)	0.0	0.20	0.69	1.20	3.7	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WNC\_ALMH0: Course of ASD weekly night-time score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly night-time score	Week 36	Tezepelumab	380	342 (90.0)	0.69 (0.68)	0.0	0.07	0.60	1.09	3.4	
		Placebo	371	315 (84.9)	0.79 (0.65)	0.0	0.20	0.74	1.14	3.6	
	Week 37	Tezepelumab	380	336 (88.4)	0.67 (0.68)	0.0	0.06	0.54	1.03	3.5	
		Placebo	371	317 (85.4)	0.77 (0.65)	0.0	0.20	0.71	1.17	3.6	
	Week 38	Tezepelumab	380	335 (88.2)	0.69 (0.70)	0.0	0.07	0.49	1.13	3.4	
		Placebo	371	314 (84.6)	0.76 (0.65)	0.0	0.20	0.71	1.12	3.7	
	Week 39	Tezepelumab	380	339 (89.2)	0.70 (0.72)	0.0	0.07	0.50	1.11	4.0	
		Placebo	371	318 (85.7)	0.76 (0.66)	0.0	0.17	0.69	1.17	3.6	
	Week 40	Tezepelumab	380	341 (89.7)	0.68 (0.68)	0.0	0.06	0.49	1.03	3.4	
		Placebo	371	316 (85.2)	0.79 (0.68)	0.0	0.20	0.70	1.20	3.6	
	Week 41	Tezepelumab	380	342 (90.0)	0.66 (0.67)	0.0	0.05	0.45	1.00	3.2	
		Placebo	371	315 (84.9)	0.78 (0.67)	0.0	0.17	0.70	1.26	3.7	
	Week 42	Tezepelumab	380	335 (88.2)	0.66 (0.68)	0.0	0.06	0.43	1.03	3.2	
		Placebo	371	315 (84.9)	0.79 (0.70)	0.0	0.17	0.72	1.20	3.7	
	Week 43	Tezepelumab	380	335 (88.2)	0.66 (0.69)	0.0	0.05	0.46	1.03	3.2	
		Placebo	371	311 (83.8)	0.77 (0.68)	0.0	0.16	0.69	1.20	3.7	
	Week 44	Tezepelumab	380	332 (87.4)	0.65 (0.68)	0.0	0.04	0.43	1.04	3.2	
		Placebo	371	309 (83.3)	0.77 (0.67)	0.0	0.20	0.70	1.20	3.7	
	Week 45	Tezepelumab	380	340 (89.5)	0.66 (0.68)	0.0	0.06	0.43	1.03	3.3	
		Placebo	371	315 (84.9)	0.75 (0.67)	0.0	0.20	0.66	1.20	3.6	
	Week 46	Tezepelumab	380	336 (88.4)	0.66 (0.69)	0.0	0.03	0.41	1.09	3.2	
		Placebo	371	309 (83.3)	0.74 (0.65)	0.0	0.20	0.64	1.11	3.7	
	Week 47	Tezepelumab	380	328 (86.3)	0.65 (0.69)	0.0	0.03	0.40	1.04	3.2	
		Placebo	371	306 (82.5)	0.74 (0.64)	0.0	0.20	0.63	1.07	3.6	
	Week 48	Tezepelumab	380	342 (90.0)	0.66 (0.68)	0.0	0.06	0.43	1.03	3.2	
		Placebo	371	309 (83.3)	0.75 (0.66)	0.0	0.17	0.69	1.16	3.7	
	Week 49	Tezepelumab	380	344 (90.5)	0.64 (0.67)	0.0	0.03	0.43	1.00	3.1	
		Placebo	371	308 (83.0)	0.75 (0.65)	0.0	0.18	0.68	1.11	3.6	
	Week 50	Tezepelumab	380	335 (88.2)	0.66 (0.67)	0.0	0.03	0.44	1.05	3.0	
		Placebo	371	302 (81.4)	0.74 (0.66)	0.0	0.16	0.66	1.11	3.6	
	Week 51	Tezepelumab	380	323 (85.0)	0.67 (0.69)	0.0	0.00	0.44	1.00	3.0	
		Placebo	371	300 (80.9)	0.76 (0.67)	0.0	0.17	0.69	1.09	3.6	
	Week 52	Tezepelumab	380	301 (79.2)	0.65 (0.68)	0.0	0.00	0.45	1.00	3.0	
		Placebo	371	274 (73.9)	0.75 (0.68)	0.0	0.17	0.64	1.17	3.6	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WNC\_ALMH0: Course of ASD weekly night-time score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly night-time score	Week 1	Tezepelumab	380	376 (98.9)	-0.22 (0.37)	-2.5	-0.40	-0.14	0.00	1.1	-0.22 [-0.37, -0.08]
		Placebo	371	365 (98.4)	-0.13 (0.37)	-2.1	-0.29	-0.09	0.06	1.1	
	Week 2	Tezepelumab	380	373 (98.2)	-0.32 (0.48)	-2.8	-0.54	-0.20	0.00	0.9	-0.29 [-0.43, -0.14]
		Placebo	371	367 (98.9)	-0.18 (0.48)	-2.3	-0.37	-0.10	0.06	1.3	
	Week 3	Tezepelumab	380	373 (98.2)	-0.37 (0.53)	-3.1	-0.60	-0.26	-0.03	0.9	-0.19 [-0.33, -0.04]
		Placebo	371	365 (98.4)	-0.27 (0.55)	-2.4	-0.51	-0.17	0.00	2.0	
	Week 4	Tezepelumab	380	373 (98.2)	-0.41 (0.56)	-3.2	-0.66	-0.29	0.00	0.7	-0.20 [-0.35, -0.06]
		Placebo	371	361 (97.3)	-0.30 (0.54)	-2.5	-0.58	-0.18	0.03	1.4	
	Week 5	Tezepelumab	380	370 (97.4)	-0.48 (0.58)	-3.2	-0.79	-0.37	-0.04	0.8	-0.22 [-0.37, -0.08]
		Placebo	371	358 (96.5)	-0.35 (0.55)	-2.7	-0.66	-0.28	0.00	1.4	
	Week 6	Tezepelumab	380	373 (98.2)	-0.51 (0.60)	-3.3	-0.83	-0.40	-0.09	0.8	-0.26 [-0.41, -0.12]
		Placebo	371	361 (97.3)	-0.36 (0.59)	-3.0	-0.66	-0.26	0.00	1.5	
	Week 7	Tezepelumab	380	365 (96.1)	-0.52 (0.64)	-3.2	-0.83	-0.40	-0.09	1.1	-0.22 [-0.36, -0.07]
		Placebo	371	361 (97.3)	-0.38 (0.60)	-3.1	-0.69	-0.28	0.00	1.3	
	Week 8	Tezepelumab	380	364 (95.8)	-0.55 (0.63)	-3.1	-0.89	-0.40	-0.09	1.2	-0.24 [-0.39, -0.10]
		Placebo	371	359 (96.8)	-0.40 (0.60)	-3.1	-0.73	-0.30	-0.03	1.9	
	Week 9	Tezepelumab	380	373 (98.2)	-0.57 (0.64)	-3.3	-0.91	-0.46	-0.09	0.9	-0.22 [-0.37, -0.08]
		Placebo	371	355 (95.7)	-0.43 (0.60)	-3.1	-0.80	-0.37	-0.06	1.8	
	Week 10	Tezepelumab	380	367 (96.6)	-0.57 (0.64)	-3.2	-0.94	-0.46	-0.10	0.8	-0.24 [-0.38, -0.09]
		Placebo	371	350 (94.3)	-0.42 (0.61)	-3.2	-0.74	-0.31	-0.04	1.3	
	Week 11	Tezepelumab	380	363 (95.5)	-0.57 (0.65)	-3.1	-0.94	-0.43	-0.11	1.0	-0.21 [-0.36, -0.06]
		Placebo	371	355 (95.7)	-0.44 (0.61)	-3.1	-0.77	-0.38	-0.09	1.4	
	Week 12	Tezepelumab	380	360 (94.7)	-0.57 (0.67)	-3.3	-0.94	-0.46	-0.09	0.9	-0.18 [-0.33, -0.04]
		Placebo	371	350 (94.3)	-0.45 (0.61)	-3.3	-0.80	-0.37	-0.06	1.7	
	Week 13	Tezepelumab	380	363 (95.5)	-0.59 (0.65)	-3.1	-0.97	-0.51	-0.11	0.7	-0.20 [-0.34, -0.05]
		Placebo	371	352 (94.9)	-0.47 (0.60)	-3.1	-0.80	-0.34	-0.06	1.3	
	Week 14	Tezepelumab	380	358 (94.2)	-0.62 (0.64)	-3.0	-1.00	-0.49	-0.14	0.8	-0.24 [-0.39, -0.09]
		Placebo	371	351 (94.6)	-0.47 (0.62)	-3.2	-0.80	-0.40	-0.06	1.2	
	Week 15	Tezepelumab	380	355 (93.4)	-0.61 (0.65)	-3.0	-1.00	-0.51	-0.12	0.7	-0.23 [-0.38, -0.08]
		Placebo	371	335 (90.3)	-0.47 (0.63)	-3.2	-0.80	-0.43	-0.04	1.5	
	Week 16	Tezepelumab	380	359 (94.5)	-0.63 (0.67)	-3.0	-1.00	-0.51	-0.14	1.5	-0.26 [-0.41, -0.11]
		Placebo	371	340 (91.6)	-0.47 (0.62)	-3.1	-0.81	-0.39	-0.06	1.2	
	Week 17	Tezepelumab	380	354 (93.2)	-0.62 (0.66)	-3.3	-1.00	-0.55	-0.17	1.0	-0.21 [-0.36, -0.06]
		Placebo	371	337 (90.8)	-0.49 (0.62)	-3.1	-0.85	-0.40	-0.06	1.1	
Week 18	Tezepelumab	380	352 (92.6)	-0.62 (0.66)	-3.2	-1.00	-0.54	-0.14	0.9	-0.24 [-0.39, -0.09]	
	Placebo	371	337 (90.8)	-0.47 (0.64)	-3.0	-0.80	-0.34	-0.07	1.6		

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WNC\_ALMH0: Course of ASD weekly night-time score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly night-time score	Week 19	Tezepelumab	380	354 (93.2)	-0.64 (0.67)	-3.2	-1.01	-0.57	-0.14	0.9	-0.24 [-0.39, -0.09]
		Placebo	371	337 (90.8)	-0.48 (0.66)	-3.3	-0.82	-0.37	-0.09	1.9	
	Week 20	Tezepelumab	380	349 (91.8)	-0.65 (0.67)	-3.2	-1.03	-0.57	-0.14	0.9	-0.28 [-0.43, -0.13]
		Placebo	371	336 (90.6)	-0.46 (0.65)	-3.1	-0.80	-0.40	-0.07	1.3	
	Week 21	Tezepelumab	380	350 (92.1)	-0.63 (0.67)	-3.2	-1.00	-0.57	-0.14	1.9	-0.24 [-0.39, -0.09]
		Placebo	371	334 (90.0)	-0.48 (0.64)	-3.3	-0.80	-0.39	-0.09	1.5	
	Week 22	Tezepelumab	380	350 (92.1)	-0.63 (0.67)	-3.3	-1.00	-0.53	-0.14	1.1	-0.22 [-0.38, -0.07]
		Placebo	371	327 (88.1)	-0.48 (0.61)	-2.9	-0.77	-0.43	-0.09	1.3	
	Week 23	Tezepelumab	380	345 (90.8)	-0.64 (0.68)	-3.3	-1.00	-0.57	-0.16	1.0	-0.23 [-0.38, -0.08]
		Placebo	371	319 (86.0)	-0.49 (0.63)	-3.1	-0.86	-0.40	-0.10	1.3	
	Week 24	Tezepelumab	380	344 (90.5)	-0.63 (0.68)	-3.3	-1.00	-0.60	-0.17	1.3	-0.22 [-0.37, -0.07]
		Placebo	371	323 (87.1)	-0.49 (0.64)	-3.1	-0.86	-0.43	-0.13	1.6	
	Week 25	Tezepelumab	380	347 (91.3)	-0.63 (0.66)	-3.3	-1.00	-0.60	-0.15	1.2	-0.20 [-0.35, -0.05]
		Placebo	371	321 (86.5)	-0.50 (0.66)	-3.5	-0.85	-0.43	-0.11	1.6	
	Week 26	Tezepelumab	380	341 (89.7)	-0.63 (0.69)	-3.3	-1.00	-0.57	-0.11	1.6	-0.18 [-0.33, -0.03]
		Placebo	371	318 (85.7)	-0.51 (0.64)	-3.1	-0.90	-0.43	-0.09	1.3	
	Week 27	Tezepelumab	380	348 (91.6)	-0.64 (0.68)	-3.2	-1.03	-0.58	-0.12	0.8	-0.24 [-0.39, -0.08]
		Placebo	371	314 (84.6)	-0.48 (0.67)	-3.1	-0.89	-0.43	-0.09	1.8	
	Week 28	Tezepelumab	380	347 (91.3)	-0.64 (0.68)	-3.3	-1.03	-0.57	-0.14	1.0	-0.21 [-0.37, -0.06]
		Placebo	371	326 (87.9)	-0.50 (0.68)	-3.3	-0.89	-0.43	-0.11	2.1	
	Week 29	Tezepelumab	380	342 (90.0)	-0.67 (0.67)	-3.3	-1.09	-0.57	-0.17	0.8	-0.24 [-0.40, -0.09]
		Placebo	371	325 (87.6)	-0.50 (0.67)	-3.1	-0.89	-0.40	-0.10	1.3	
	Week 30	Tezepelumab	380	343 (90.3)	-0.65 (0.67)	-3.3	-1.00	-0.57	-0.17	0.8	-0.24 [-0.39, -0.08]
		Placebo	371	318 (85.7)	-0.49 (0.69)	-3.1	-0.89	-0.43	-0.07	2.0	
	Week 31	Tezepelumab	380	346 (91.1)	-0.65 (0.69)	-3.3	-1.00	-0.57	-0.17	1.1	-0.23 [-0.39, -0.08]
		Placebo	371	312 (84.1)	-0.49 (0.63)	-2.7	-0.89	-0.44	-0.09	1.2	
	Week 32	Tezepelumab	380	347 (91.3)	-0.64 (0.68)	-3.3	-1.03	-0.57	-0.17	1.5	-0.20 [-0.35, -0.05]
		Placebo	371	324 (87.3)	-0.51 (0.67)	-3.4	-0.89	-0.45	-0.09	1.8	
	Week 33	Tezepelumab	380	344 (90.5)	-0.67 (0.70)	-3.3	-1.06	-0.60	-0.20	1.3	-0.24 [-0.40, -0.09]
		Placebo	371	317 (85.4)	-0.50 (0.68)	-3.4	-0.89	-0.43	-0.11	1.2	
	Week 34	Tezepelumab	380	346 (91.1)	-0.67 (0.69)	-3.3	-1.04	-0.59	-0.17	1.4	-0.24 [-0.39, -0.09]
		Placebo	371	322 (86.8)	-0.51 (0.67)	-3.1	-0.91	-0.44	-0.11	1.1	
	Week 35	Tezepelumab	380	340 (89.5)	-0.66 (0.69)	-3.3	-1.03	-0.57	-0.18	1.4	-0.23 [-0.39, -0.08]
		Placebo	371	310 (83.6)	-0.50 (0.66)	-3.1	-0.91	-0.45	-0.13	1.7	
	Week 36	Tezepelumab	380	342 (90.0)	-0.65 (0.70)	-3.3	-1.03	-0.57	-0.17	1.5	-0.22 [-0.37, -0.06]
		Placebo	371	315 (84.9)	-0.50 (0.66)	-3.4	-0.89	-0.40	-0.11	1.1	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WNC\_ALMH0: Course of ASD weekly night-time score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly night-time score	Week 37	Tezepelumab	380	336 (88.4)	-0.66 (0.70)	-3.3	-1.05	-0.60	-0.15	1.6	-0.21 [-0.36, -0.05]
		Placebo	371	317 (85.4)	-0.52 (0.67)	-3.5	-0.89	-0.43	-0.11	1.1	
	Week 38	Tezepelumab	380	335 (88.2)	-0.66 (0.71)	-3.3	-1.00	-0.60	-0.18	1.7	-0.18 [-0.33, -0.02]
		Placebo	371	314 (84.6)	-0.53 (0.65)	-3.6	-0.93	-0.43	-0.11	1.2	
	Week 39	Tezepelumab	380	339 (89.2)	-0.64 (0.71)	-3.3	-1.03	-0.54	-0.17	1.8	-0.16 [-0.31, -0.01]
		Placebo	371	318 (85.7)	-0.53 (0.68)	-3.5	-0.94	-0.45	-0.10	1.4	
	Week 40	Tezepelumab	380	341 (89.7)	-0.67 (0.70)	-3.3	-1.09	-0.60	-0.14	1.4	-0.26 [-0.42, -0.11]
		Placebo	371	316 (85.2)	-0.50 (0.66)	-3.5	-0.91	-0.40	-0.06	1.7	
	Week 41	Tezepelumab	380	342 (90.0)	-0.69 (0.70)	-3.3	-1.06	-0.60	-0.15	1.4	-0.26 [-0.41, -0.10]
		Placebo	371	315 (84.9)	-0.52 (0.63)	-3.5	-0.91	-0.43	-0.11	1.4	
	Week 42	Tezepelumab	380	335 (88.2)	-0.66 (0.67)	-3.1	-1.06	-0.57	-0.20	1.4	-0.26 [-0.41, -0.10]
		Placebo	371	315 (84.9)	-0.49 (0.66)	-3.5	-0.89	-0.43	-0.11	1.8	
	Week 43	Tezepelumab	380	335 (88.2)	-0.68 (0.70)	-3.3	-1.06	-0.60	-0.17	1.3	-0.25 [-0.40, -0.09]
		Placebo	371	311 (83.8)	-0.51 (0.65)	-3.3	-0.90	-0.43	-0.11	1.3	
	Week 44	Tezepelumab	380	332 (87.4)	-0.69 (0.68)	-3.3	-1.09	-0.63	-0.18	1.4	-0.26 [-0.42, -0.11]
		Placebo	371	309 (83.3)	-0.51 (0.66)	-3.5	-0.89	-0.43	-0.11	1.1	
	Week 45	Tezepelumab	380	340 (89.5)	-0.69 (0.69)	-3.3	-1.07	-0.62	-0.20	1.4	-0.23 [-0.39, -0.08]
		Placebo	371	315 (84.9)	-0.53 (0.67)	-3.5	-0.91	-0.46	-0.07	1.1	
	Week 46	Tezepelumab	380	336 (88.4)	-0.69 (0.70)	-3.3	-1.07	-0.60	-0.20	1.4	-0.21 [-0.36, -0.05]
		Placebo	371	309 (83.3)	-0.54 (0.68)	-3.5	-0.94	-0.46	-0.11	1.1	
	Week 47	Tezepelumab	380	328 (86.3)	-0.69 (0.71)	-3.3	-1.09	-0.60	-0.17	1.3	-0.23 [-0.39, -0.08]
		Placebo	371	306 (82.5)	-0.53 (0.65)	-3.2	-0.89	-0.46	-0.14	1.1	
	Week 48	Tezepelumab	380	342 (90.0)	-0.67 (0.69)	-3.3	-1.09	-0.60	-0.20	1.4	-0.19 [-0.34, -0.03]
		Placebo	371	309 (83.3)	-0.54 (0.66)	-3.4	-0.89	-0.46	-0.15	1.5	
	Week 49	Tezepelumab	380	344 (90.5)	-0.69 (0.70)	-3.3	-1.09	-0.60	-0.20	1.4	-0.22 [-0.37, -0.06]
		Placebo	371	308 (83.0)	-0.55 (0.66)	-3.5	-0.88	-0.46	-0.14	1.1	
	Week 50	Tezepelumab	380	335 (88.2)	-0.67 (0.68)	-3.3	-1.09	-0.60	-0.17	1.3	-0.17 [-0.33, -0.01]
		Placebo	371	302 (81.4)	-0.55 (0.70)	-3.7	-0.93	-0.46	-0.13	1.8	
	Week 51	Tezepelumab	380	323 (85.0)	-0.67 (0.72)	-3.3	-1.06	-0.60	-0.17	1.4	-0.19 [-0.34, -0.03]
		Placebo	371	300 (80.9)	-0.54 (0.70)	-3.7	-0.94	-0.46	-0.11	1.8	
	Week 52	Tezepelumab	380	301 (79.2)	-0.68 (0.74)	-3.3	-1.11	-0.60	-0.17	1.3	-0.18 [-0.34, -0.02]
		Placebo	371	274 (73.9)	-0.55 (0.70)	-3.7	-0.90	-0.46	-0.14	1.5	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WNC\_ALMC0: Change from baseline in ASD weekly night-time score - MMRM results  
 DITTL - adult

Change from baseline in ASD weekly night-time score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 1	Tezepelumab	380	376 (98.9)	-0.20 (0.03)	(-0.26, -0.14)	-0.06 (0.04)	(-0.14, 0.02)	0.148	
	Placebo	371	365 (98.4)	-0.14 (0.03)	(-0.20, -0.08)				
Week 2	Tezepelumab	380	373 (98.2)	-0.30 (0.03)	(-0.35, -0.24)	-0.11 (0.04)	(-0.19, -0.03)	0.006 *	
	Placebo	371	367 (98.9)	-0.18 (0.03)	(-0.24, -0.13)				
Week 3	Tezepelumab	380	373 (98.2)	-0.36 (0.03)	(-0.41, -0.30)	-0.09 (0.04)	(-0.17, -0.01)	0.031 *	
	Placebo	371	365 (98.4)	-0.27 (0.03)	(-0.32, -0.21)				
Week 4	Tezepelumab	380	373 (98.2)	-0.39 (0.03)	(-0.45, -0.34)	-0.09 (0.04)	(-0.17, -0.01)	0.030 *	
	Placebo	371	361 (97.3)	-0.30 (0.03)	(-0.36, -0.25)				
Week 5	Tezepelumab	380	370 (97.4)	-0.46 (0.03)	(-0.52, -0.41)	-0.11 (0.04)	(-0.19, -0.03)	0.007 *	
	Placebo	371	358 (96.5)	-0.35 (0.03)	(-0.41, -0.30)				
Week 6	Tezepelumab	380	373 (98.2)	-0.49 (0.03)	(-0.55, -0.44)	-0.13 (0.04)	(-0.21, -0.05)	0.002 *	
	Placebo	371	361 (97.3)	-0.36 (0.03)	(-0.42, -0.31)				
Week 7	Tezepelumab	380	365 (96.1)	-0.50 (0.03)	(-0.56, -0.45)	-0.12 (0.04)	(-0.20, -0.04)	0.003 *	
	Placebo	371	361 (97.3)	-0.38 (0.03)	(-0.44, -0.32)				
Week 8	Tezepelumab	380	364 (95.8)	-0.53 (0.03)	(-0.59, -0.47)	-0.15 (0.04)	(-0.23, -0.07)	<0.001 *	
	Placebo	371	359 (96.8)	-0.39 (0.03)	(-0.44, -0.33)				
Week 9	Tezepelumab	380	373 (98.2)	-0.56 (0.03)	(-0.62, -0.50)	-0.13 (0.04)	(-0.21, -0.05)	0.001 *	
	Placebo	371	355 (95.7)	-0.43 (0.03)	(-0.49, -0.37)				
Week 10	Tezepelumab	380	367 (96.6)	-0.56 (0.03)	(-0.61, -0.50)	-0.14 (0.04)	(-0.22, -0.06)	<0.001 *	
	Placebo	371	350 (94.3)	-0.42 (0.03)	(-0.48, -0.36)				

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table NT1WNC\_ALMC0: Change from baseline in ASD weekly night-time score - MMRM results  
 DITTTL - adult

Change from baseline in ASD weekly night-time score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 11	Tezepelumab	380	363 (95.5)	-0.55 (0.03)	(-0.60, -0.49)	-0.11 (0.04)	(-0.19, -0.03)	0.006 *	
	Placebo	371	355 (95.7)	-0.44 (0.03)	(-0.49, -0.38)				
Week 12	Tezepelumab	380	360 (94.7)	-0.55 (0.03)	(-0.60, -0.49)	-0.10 (0.04)	(-0.18, -0.02)	0.011 *	
	Placebo	371	350 (94.3)	-0.44 (0.03)	(-0.50, -0.39)				
Week 13	Tezepelumab	380	363 (95.5)	-0.57 (0.03)	(-0.63, -0.52)	-0.11 (0.04)	(-0.19, -0.03)	0.007 *	
	Placebo	371	352 (94.9)	-0.46 (0.03)	(-0.52, -0.40)				
Week 14	Tezepelumab	380	358 (94.2)	-0.60 (0.03)	(-0.66, -0.54)	-0.13 (0.04)	(-0.21, -0.05)	0.002 *	
	Placebo	371	351 (94.6)	-0.47 (0.03)	(-0.53, -0.41)				
Week 15	Tezepelumab	380	355 (93.4)	-0.60 (0.03)	(-0.65, -0.54)	-0.13 (0.04)	(-0.21, -0.05)	0.002 *	
	Placebo	371	335 (90.3)	-0.47 (0.03)	(-0.52, -0.41)				
Week 16	Tezepelumab	380	359 (94.5)	-0.62 (0.03)	(-0.67, -0.56)	-0.16 (0.04)	(-0.24, -0.08)	<0.001 *	
	Placebo	371	340 (91.6)	-0.46 (0.03)	(-0.52, -0.40)				
Week 17	Tezepelumab	380	354 (93.2)	-0.62 (0.03)	(-0.68, -0.56)	-0.14 (0.04)	(-0.22, -0.06)	<0.001 *	
	Placebo	371	337 (90.8)	-0.48 (0.03)	(-0.54, -0.42)				
Week 18	Tezepelumab	380	352 (92.6)	-0.61 (0.03)	(-0.66, -0.55)	-0.13 (0.04)	(-0.21, -0.05)	0.001 *	
	Placebo	371	337 (90.8)	-0.47 (0.03)	(-0.53, -0.42)				
Week 19	Tezepelumab	380	354 (93.2)	-0.62 (0.03)	(-0.68, -0.57)	-0.14 (0.04)	(-0.22, -0.06)	<0.001 *	
	Placebo	371	337 (90.8)	-0.48 (0.03)	(-0.54, -0.43)				
Week 20	Tezepelumab	380	349 (91.8)	-0.63 (0.03)	(-0.68, -0.57)	-0.16 (0.04)	(-0.24, -0.07)	<0.001 *	
	Placebo	371	336 (90.6)	-0.47 (0.03)	(-0.53, -0.41)				

Note: DITTTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WNC\_ALMC0: Change from baseline in ASD weekly night-time score - MMRM results  
 DITTL - adult

Change from baseline in ASD weekly night-time score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 21	Tezepelumab	380	350 (92.1)	-0.63 (0.03)	(-0.68, -0.57)	-0.14 (0.04)	(-0.22, -0.06)	<0.001 *	
	Placebo	371	334 (90.0)	-0.49 (0.03)	(-0.55, -0.43)				
Week 22	Tezepelumab	380	350 (92.1)	-0.62 (0.03)	(-0.68, -0.57)	-0.13 (0.04)	(-0.21, -0.05)	0.002 *	
	Placebo	371	327 (88.1)	-0.49 (0.03)	(-0.55, -0.43)				
Week 23	Tezepelumab	380	345 (90.8)	-0.63 (0.03)	(-0.69, -0.58)	-0.16 (0.04)	(-0.24, -0.07)	<0.001 *	
	Placebo	371	319 (86.0)	-0.48 (0.03)	(-0.53, -0.42)				
Week 24	Tezepelumab	380	344 (90.5)	-0.63 (0.03)	(-0.69, -0.58)	-0.14 (0.04)	(-0.22, -0.06)	<0.001 *	
	Placebo	371	323 (87.1)	-0.49 (0.03)	(-0.55, -0.43)				
Week 25	Tezepelumab	380	347 (91.3)	-0.63 (0.03)	(-0.69, -0.57)	-0.13 (0.04)	(-0.21, -0.04)	0.002 *	
	Placebo	371	321 (86.5)	-0.50 (0.03)	(-0.56, -0.44)				
Week 26	Tezepelumab	380	341 (89.7)	-0.62 (0.03)	(-0.68, -0.57)	-0.13 (0.04)	(-0.21, -0.05)	0.002 *	
	Placebo	371	318 (85.7)	-0.50 (0.03)	(-0.55, -0.44)				
Week 27	Tezepelumab	380	348 (91.6)	-0.64 (0.03)	(-0.69, -0.58)	-0.15 (0.04)	(-0.23, -0.07)	<0.001 *	
	Placebo	371	314 (84.6)	-0.49 (0.03)	(-0.55, -0.43)				
Week 28	Tezepelumab	380	347 (91.3)	-0.64 (0.03)	(-0.70, -0.59)	-0.15 (0.04)	(-0.24, -0.07)	<0.001 *	
	Placebo	371	326 (87.9)	-0.49 (0.03)	(-0.55, -0.43)				
Week 29	Tezepelumab	380	342 (90.0)	-0.65 (0.03)	(-0.71, -0.59)	-0.15 (0.04)	(-0.23, -0.07)	<0.001 *	
	Placebo	371	325 (87.6)	-0.50 (0.03)	(-0.56, -0.44)				
Week 30	Tezepelumab	380	343 (90.3)	-0.64 (0.03)	(-0.70, -0.58)	-0.14 (0.04)	(-0.22, -0.06)	<0.001 *	
	Placebo	371	318 (85.7)	-0.50 (0.03)	(-0.56, -0.44)				

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WNC\_ALMC0: Change from baseline in ASD weekly night-time score - MMRM results  
 DITTL - adult

Change from baseline in ASD weekly night-time score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 31	Tezepelumab	380	346 (91.1)	-0.64 (0.03)	(-0.70, -0.58)	-0.13 (0.04)	(-0.21, -0.05)	0.002 *	
	Placebo	371	312 (84.1)	-0.51 (0.03)	(-0.57, -0.45)				
Week 32	Tezepelumab	380	347 (91.3)	-0.64 (0.03)	(-0.70, -0.58)	-0.13 (0.04)	(-0.21, -0.05)	0.002 *	
	Placebo	371	324 (87.3)	-0.51 (0.03)	(-0.57, -0.45)				
Week 33	Tezepelumab	380	344 (90.5)	-0.66 (0.03)	(-0.72, -0.60)	-0.15 (0.04)	(-0.23, -0.07)	<0.001 *	
	Placebo	371	317 (85.4)	-0.51 (0.03)	(-0.57, -0.45)				
Week 34	Tezepelumab	380	346 (91.1)	-0.66 (0.03)	(-0.72, -0.61)	-0.15 (0.04)	(-0.23, -0.07)	<0.001 *	
	Placebo	371	322 (86.8)	-0.51 (0.03)	(-0.57, -0.45)				
Week 35	Tezepelumab	380	340 (89.5)	-0.65 (0.03)	(-0.71, -0.59)	-0.14 (0.04)	(-0.22, -0.05)	0.001 *	
	Placebo	371	310 (83.6)	-0.51 (0.03)	(-0.57, -0.45)				
Week 36	Tezepelumab	380	342 (90.0)	-0.64 (0.03)	(-0.70, -0.58)	-0.14 (0.04)	(-0.22, -0.06)	<0.001 *	
	Placebo	371	315 (84.9)	-0.50 (0.03)	(-0.56, -0.44)				
Week 37	Tezepelumab	380	336 (88.4)	-0.65 (0.03)	(-0.71, -0.59)	-0.13 (0.04)	(-0.21, -0.05)	0.002 *	
	Placebo	371	317 (85.4)	-0.52 (0.03)	(-0.58, -0.46)				
Week 38	Tezepelumab	380	335 (88.2)	-0.64 (0.03)	(-0.70, -0.58)	-0.11 (0.04)	(-0.20, -0.03)	0.007 *	
	Placebo	371	314 (84.6)	-0.53 (0.03)	(-0.59, -0.47)				
Week 39	Tezepelumab	380	339 (89.2)	-0.64 (0.03)	(-0.70, -0.58)	-0.10 (0.04)	(-0.18, -0.02)	0.017 *	
	Placebo	371	318 (85.7)	-0.54 (0.03)	(-0.60, -0.48)				
Week 40	Tezepelumab	380	341 (89.7)	-0.65 (0.03)	(-0.71, -0.59)	-0.15 (0.04)	(-0.23, -0.06)	<0.001 *	
	Placebo	371	316 (85.2)	-0.51 (0.03)	(-0.57, -0.45)				

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WNC\_ALMC0: Change from baseline in ASD weekly night-time score - MMRM results  
 DITTl - adult

Change from baseline in ASD weekly night-time score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 41	Tezepelumab	380	342 (90.0)	-0.68 (0.03)	(-0.73, -0.62)	-0.15 (0.04)	(-0.23, -0.06)	<0.001 *	
	Placebo	371	315 (84.9)	-0.53 (0.03)	(-0.59, -0.47)				
Week 42	Tezepelumab	380	335 (88.2)	-0.66 (0.03)	(-0.72, -0.61)	-0.15 (0.04)	(-0.23, -0.07)	<0.001 *	
	Placebo	371	315 (84.9)	-0.51 (0.03)	(-0.57, -0.45)				
Week 43	Tezepelumab	380	335 (88.2)	-0.67 (0.03)	(-0.73, -0.61)	-0.14 (0.04)	(-0.22, -0.06)	0.001 *	
	Placebo	371	311 (83.8)	-0.53 (0.03)	(-0.59, -0.47)				
Week 44	Tezepelumab	380	332 (87.4)	-0.68 (0.03)	(-0.74, -0.62)	-0.16 (0.04)	(-0.24, -0.07)	<0.001 *	
	Placebo	371	309 (83.3)	-0.52 (0.03)	(-0.58, -0.46)				
Week 45	Tezepelumab	380	340 (89.5)	-0.68 (0.03)	(-0.74, -0.62)	-0.14 (0.04)	(-0.23, -0.06)	<0.001 *	
	Placebo	371	315 (84.9)	-0.54 (0.03)	(-0.60, -0.48)				
Week 46	Tezepelumab	380	336 (88.4)	-0.68 (0.03)	(-0.74, -0.62)	-0.14 (0.04)	(-0.22, -0.05)	0.001 *	
	Placebo	371	309 (83.3)	-0.54 (0.03)	(-0.60, -0.48)				
Week 47	Tezepelumab	380	328 (86.3)	-0.67 (0.03)	(-0.73, -0.61)	-0.13 (0.04)	(-0.21, -0.05)	0.002 *	
	Placebo	371	306 (82.5)	-0.54 (0.03)	(-0.60, -0.48)				
Week 48	Tezepelumab	380	342 (90.0)	-0.67 (0.03)	(-0.73, -0.61)	-0.13 (0.04)	(-0.21, -0.04)	0.003 *	
	Placebo	371	309 (83.3)	-0.54 (0.03)	(-0.60, -0.48)				
Week 49	Tezepelumab	380	344 (90.5)	-0.68 (0.03)	(-0.74, -0.62)	-0.13 (0.04)	(-0.22, -0.05)	0.002 *	
	Placebo	371	308 (83.0)	-0.55 (0.03)	(-0.61, -0.49)				
Week 50	Tezepelumab	380	335 (88.2)	-0.68 (0.03)	(-0.74, -0.62)	-0.12 (0.04)	(-0.21, -0.04)	0.004 *	
	Placebo	371	302 (81.4)	-0.55 (0.03)	(-0.62, -0.49)				

Note: DITTl - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WNC\_ALMC0: Change from baseline in ASD weekly night-time score - MMRM results  
 DITTL - adult

Change from baseline in ASD weekly night-time score				Repeated measures analysis						
				N		Change from Baseline		Treatment Difference		
						LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Time	Treatment		(%)							
Week 51	Tezepelumab	380	323 (85.0)	-0.67 (0.03)	(-0.73, -0.61)	-0.13 (0.04)	(-0.22, -0.05)	0.002	*	
	Placebo	371	300 (80.9)	-0.54 (0.03)	(-0.60, -0.48)					
Week 52	Tezepelumab	380	301 (79.2)	-0.67 (0.03)	(-0.73, -0.61)	-0.13 (0.04)	(-0.22, -0.05)	0.003	*	
	Placebo	371	274 (73.9)	-0.54 (0.03)	(-0.60, -0.48)					

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WWC\_ALMH0: Course of ASD weekly wheezing score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly wheezing score	Baseline	Tezepelumab	380	380 (100.0)	1.50 (0.81)	0.0	1.00	1.43	2.00	4.0	
		Placebo	371	371 (100.0)	1.47 (0.79)	0.0	1.00	1.43	2.00	4.0	
Week 1		Tezepelumab	380	372 (97.9)	1.26 (0.76)	0.0	0.79	1.14	1.79	3.8	
		Placebo	371	362 (97.6)	1.32 (0.80)	0.0	0.79	1.23	1.93	3.6	
Week 2		Tezepelumab	380	370 (97.4)	1.11 (0.76)	0.0	0.57	1.00	1.50	3.4	
		Placebo	371	360 (97.0)	1.28 (0.80)	0.0	0.79	1.14	1.93	3.7	
Week 3		Tezepelumab	380	365 (96.1)	1.04 (0.75)	0.0	0.50	1.00	1.50	3.1	
		Placebo	371	354 (95.4)	1.18 (0.79)	0.0	0.63	1.04	1.79	4.0	
Week 4		Tezepelumab	380	363 (95.5)	1.01 (0.76)	0.0	0.36	1.00	1.43	3.4	
		Placebo	371	353 (95.1)	1.15 (0.78)	0.0	0.58	1.00	1.67	4.0	
Week 5		Tezepelumab	380	363 (95.5)	0.95 (0.78)	0.0	0.21	1.00	1.36	3.8	
		Placebo	371	344 (92.7)	1.06 (0.79)	0.0	0.38	1.00	1.64	3.6	
Week 6		Tezepelumab	380	357 (93.9)	0.90 (0.77)	0.0	0.14	0.93	1.29	4.0	
		Placebo	371	349 (94.1)	1.07 (0.81)	0.0	0.36	1.00	1.71	4.0	
Week 7		Tezepelumab	380	354 (93.2)	0.89 (0.78)	0.0	0.10	0.93	1.33	4.0	
		Placebo	371	349 (94.1)	1.06 (0.82)	0.0	0.33	1.00	1.58	4.0	
Week 8		Tezepelumab	380	355 (93.4)	0.86 (0.76)	0.0	0.08	0.93	1.33	4.0	
		Placebo	371	340 (91.6)	1.03 (0.79)	0.0	0.29	1.00	1.46	3.9	
Week 9		Tezepelumab	380	360 (94.7)	0.82 (0.75)	0.0	0.07	0.86	1.14	4.0	
		Placebo	371	340 (91.6)	0.99 (0.78)	0.0	0.25	1.00	1.42	4.0	
Week 10		Tezepelumab	380	358 (94.2)	0.84 (0.78)	0.0	0.07	0.92	1.21	4.0	
		Placebo	371	338 (91.1)	1.01 (0.79)	0.0	0.21	1.00	1.50	4.0	
Week 11		Tezepelumab	380	347 (91.3)	0.84 (0.79)	0.0	0.00	0.93	1.21	4.0	
		Placebo	371	334 (90.0)	0.98 (0.82)	0.0	0.17	1.00	1.42	4.0	
Week 12		Tezepelumab	380	348 (91.6)	0.84 (0.78)	0.0	0.07	0.85	1.14	4.0	
		Placebo	371	332 (89.5)	0.96 (0.82)	0.0	0.14	1.00	1.41	4.0	
Week 13		Tezepelumab	380	344 (90.5)	0.81 (0.76)	0.0	0.00	0.86	1.13	3.5	
		Placebo	371	330 (88.9)	0.93 (0.80)	0.0	0.14	1.00	1.29	4.0	
Week 14		Tezepelumab	380	342 (90.0)	0.77 (0.75)	0.0	0.00	0.79	1.13	3.3	
		Placebo	371	330 (88.9)	0.94 (0.80)	0.0	0.13	1.00	1.36	4.0	
Week 15		Tezepelumab	380	338 (88.9)	0.78 (0.77)	0.0	0.00	0.79	1.10	3.6	
		Placebo	371	320 (86.3)	0.92 (0.82)	0.0	0.08	1.00	1.29	4.0	
Week 16		Tezepelumab	380	342 (90.0)	0.76 (0.77)	0.0	0.00	0.71	1.07	3.8	
		Placebo	371	318 (85.7)	0.95 (0.83)	0.0	0.13	1.00	1.50	4.0	
Week 17		Tezepelumab	380	338 (88.9)	0.72 (0.76)	0.0	0.00	0.60	1.07	3.1	
		Placebo	371	314 (84.6)	0.92 (0.82)	0.0	0.08	1.00	1.43	4.0	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WWC\_ALMH0: Course of ASD weekly wheezing score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly wheezing score	Week 18	Tezepelumab	380	336 (88.4)	0.77 (0.78)	0.0	0.00	0.70	1.07	3.1	
		Placebo	371	309 (83.3)	0.92 (0.85)	0.0	0.07	1.00	1.50	4.0	
	Week 19	Tezepelumab	380	333 (87.6)	0.75 (0.78)	0.0	0.00	0.79	1.07	3.9	
		Placebo	371	317 (85.4)	0.94 (0.86)	0.0	0.07	1.00	1.57	4.0	
	Week 20	Tezepelumab	380	328 (86.3)	0.76 (0.78)	0.0	0.00	0.75	1.07	3.0	
		Placebo	371	309 (83.3)	0.93 (0.85)	0.0	0.07	1.00	1.60	4.0	
	Week 21	Tezepelumab	380	326 (85.8)	0.72 (0.76)	0.0	0.00	0.58	1.00	3.1	
		Placebo	371	305 (82.2)	0.89 (0.84)	0.0	0.07	1.00	1.36	4.0	
	Week 22	Tezepelumab	380	325 (85.5)	0.79 (0.80)	0.0	0.00	0.80	1.07	3.8	
		Placebo	371	299 (80.6)	0.91 (0.84)	0.0	0.07	1.00	1.43	4.0	
	Week 23	Tezepelumab	380	319 (83.9)	0.78 (0.81)	0.0	0.00	0.90	1.10	3.9	
		Placebo	371	296 (79.8)	0.92 (0.83)	0.0	0.07	1.00	1.54	4.0	
	Week 24	Tezepelumab	380	327 (86.1)	0.76 (0.81)	0.0	0.00	0.70	1.00	3.2	
		Placebo	371	297 (80.1)	0.89 (0.84)	0.0	0.00	1.00	1.42	4.0	
	Week 25	Tezepelumab	380	314 (82.6)	0.77 (0.78)	0.0	0.00	0.79	1.07	3.3	
		Placebo	371	296 (79.8)	0.88 (0.84)	0.0	0.07	0.93	1.35	4.0	
	Week 26	Tezepelumab	380	319 (83.9)	0.77 (0.77)	0.0	0.00	0.83	1.08	3.1	
		Placebo	371	289 (77.9)	0.90 (0.85)	0.0	0.00	0.93	1.50	4.0	
	Week 27	Tezepelumab	380	309 (81.3)	0.75 (0.80)	0.0	0.00	0.64	1.07	4.0	
		Placebo	371	300 (80.9)	0.90 (0.86)	0.0	0.07	0.92	1.57	4.0	
	Week 28	Tezepelumab	380	317 (83.4)	0.75 (0.80)	0.0	0.00	0.70	1.07	3.9	
		Placebo	371	300 (80.9)	0.88 (0.85)	0.0	0.00	0.96	1.46	4.0	
	Week 29	Tezepelumab	380	310 (81.6)	0.74 (0.80)	0.0	0.00	0.71	1.00	3.9	
		Placebo	371	299 (80.6)	0.89 (0.86)	0.0	0.00	0.93	1.50	4.0	
	Week 30	Tezepelumab	380	314 (82.6)	0.74 (0.76)	0.0	0.00	0.75	1.00	3.7	
		Placebo	371	295 (79.5)	0.90 (0.85)	0.0	0.00	1.00	1.50	4.0	
	Week 31	Tezepelumab	380	315 (82.9)	0.74 (0.79)	0.0	0.00	0.75	1.00	4.0	
		Placebo	371	296 (79.8)	0.91 (0.83)	0.0	0.00	1.00	1.36	4.0	
	Week 32	Tezepelumab	380	316 (83.2)	0.77 (0.79)	0.0	0.00	0.77	1.08	3.8	
		Placebo	371	297 (80.1)	0.90 (0.82)	0.0	0.00	0.92	1.38	4.0	
	Week 33	Tezepelumab	380	313 (82.4)	0.73 (0.78)	0.0	0.00	0.64	1.07	3.1	
		Placebo	371	291 (78.4)	0.93 (0.83)	0.0	0.00	1.00	1.64	4.0	
	Week 34	Tezepelumab	380	311 (81.8)	0.73 (0.79)	0.0	0.00	0.63	1.07	3.4	
		Placebo	371	293 (79.0)	0.90 (0.84)	0.0	0.00	1.00	1.50	4.0	
	Week 35	Tezepelumab	380	312 (82.1)	0.74 (0.80)	0.0	0.00	0.57	1.07	4.0	
		Placebo	371	285 (76.8)	0.88 (0.84)	0.0	0.00	0.93	1.36	4.0	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WWC\_ALMH0: Course of ASD weekly wheezing score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly wheezing score	Week 36	Tezepelumab	380	309 (81.3)	0.76 (0.80)	0.0	0.00	0.79	1.07	3.9	
		Placebo	371	288 (77.6)	0.90 (0.83)	0.0	0.07	1.00	1.39	4.0	
	Week 37	Tezepelumab	380	312 (82.1)	0.73 (0.80)	0.0	0.00	0.68	1.00	4.0	
		Placebo	371	287 (77.4)	0.87 (0.81)	0.0	0.00	1.00	1.36	4.0	
	Week 38	Tezepelumab	380	310 (81.6)	0.76 (0.82)	0.0	0.00	0.63	1.00	4.0	
		Placebo	371	287 (77.4)	0.84 (0.82)	0.0	0.00	0.93	1.29	4.0	
	Week 39	Tezepelumab	380	317 (83.4)	0.76 (0.85)	0.0	0.00	0.50	1.07	3.9	
		Placebo	371	281 (75.7)	0.86 (0.84)	0.0	0.00	0.90	1.40	4.0	
	Week 40	Tezepelumab	380	313 (82.4)	0.77 (0.83)	0.0	0.00	0.75	1.07	3.9	
		Placebo	371	287 (77.4)	0.90 (0.85)	0.0	0.00	1.00	1.50	4.0	
	Week 41	Tezepelumab	380	316 (83.2)	0.72 (0.81)	0.0	0.00	0.39	1.00	4.0	
		Placebo	371	288 (77.6)	0.90 (0.83)	0.0	0.00	1.00	1.50	4.0	
	Week 42	Tezepelumab	380	308 (81.1)	0.72 (0.81)	0.0	0.00	0.46	1.00	4.0	
		Placebo	371	288 (77.6)	0.89 (0.86)	0.0	0.00	1.00	1.50	4.0	
	Week 43	Tezepelumab	380	311 (81.8)	0.71 (0.81)	0.0	0.00	0.42	1.00	4.0	
		Placebo	371	285 (76.8)	0.88 (0.85)	0.0	0.00	1.00	1.50	4.0	
	Week 44	Tezepelumab	380	309 (81.3)	0.70 (0.81)	0.0	0.00	0.33	1.00	4.0	
		Placebo	371	283 (76.3)	0.88 (0.84)	0.0	0.00	0.93	1.50	4.0	
	Week 45	Tezepelumab	380	312 (82.1)	0.71 (0.79)	0.0	0.00	0.41	1.00	3.9	
		Placebo	371	285 (76.8)	0.86 (0.84)	0.0	0.00	1.00	1.30	4.0	
	Week 46	Tezepelumab	380	307 (80.8)	0.73 (0.82)	0.0	0.00	0.58	1.00	4.0	
		Placebo	371	278 (74.9)	0.85 (0.83)	0.0	0.00	0.83	1.36	4.0	
	Week 47	Tezepelumab	380	296 (77.9)	0.71 (0.81)	0.0	0.00	0.43	1.00	3.8	
		Placebo	371	281 (75.7)	0.84 (0.81)	0.0	0.00	0.92	1.25	4.0	
	Week 48	Tezepelumab	380	318 (83.7)	0.71 (0.81)	0.0	0.00	0.41	1.00	3.6	
		Placebo	371	291 (78.4)	0.87 (0.82)	0.0	0.00	0.93	1.29	4.0	
	Week 49	Tezepelumab	380	308 (81.1)	0.71 (0.81)	0.0	0.00	0.41	1.00	4.0	
		Placebo	371	280 (75.5)	0.87 (0.83)	0.0	0.00	1.00	1.39	4.0	
	Week 50	Tezepelumab	380	306 (80.5)	0.71 (0.81)	0.0	0.00	0.43	1.00	4.0	
		Placebo	371	278 (74.9)	0.88 (0.83)	0.0	0.00	0.93	1.43	4.0	
	Week 51	Tezepelumab	380	300 (78.9)	0.73 (0.81)	0.0	0.00	0.43	1.00	3.9	
		Placebo	371	270 (72.8)	0.87 (0.84)	0.0	0.00	1.00	1.21	4.0	
	Week 52	Tezepelumab	380	268 (70.5)	0.75 (0.84)	0.0	0.00	0.60	1.00	4.0	
		Placebo	371	246 (66.3)	0.86 (0.86)	0.0	0.00	1.00	1.29	4.0	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table NT1WWC\_ALMH0: Course of ASD weekly wheezing score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly wheezing score	Week 1	Tezepelumab	380	372 (97.9)	-0.22 (0.41)	-2.1	-0.41	-0.14	0.00	1.3	-0.20 [-0.34, -0.05]
		Placebo	371	362 (97.6)	-0.14 (0.40)	-2.1	-0.36	-0.08	0.07	1.1	
	Week 2	Tezepelumab	380	370 (97.4)	-0.38 (0.57)	-2.7	-0.71	-0.21	0.00	1.1	-0.35 [-0.50, -0.21]
		Placebo	371	360 (97.0)	-0.18 (0.52)	-2.4	-0.40	-0.08	0.03	1.4	
	Week 3	Tezepelumab	380	365 (96.1)	-0.44 (0.63)	-3.6	-0.85	-0.29	0.00	0.9	-0.26 [-0.41, -0.11]
		Placebo	371	354 (95.4)	-0.28 (0.59)	-2.4	-0.58	-0.17	0.00	1.4	
	Week 4	Tezepelumab	380	363 (95.5)	-0.48 (0.66)	-3.6	-0.86	-0.29	0.00	0.9	-0.23 [-0.38, -0.08]
		Placebo	371	353 (95.1)	-0.33 (0.64)	-2.6	-0.60	-0.21	0.00	2.2	
	Week 5	Tezepelumab	380	363 (95.5)	-0.54 (0.69)	-3.6	-1.00	-0.43	0.00	1.1	-0.20 [-0.35, -0.05]
		Placebo	371	344 (92.7)	-0.41 (0.64)	-2.7	-0.72	-0.29	0.00	1.9	
	Week 6	Tezepelumab	380	357 (93.9)	-0.58 (0.72)	-3.6	-0.98	-0.48	-0.06	1.1	-0.26 [-0.41, -0.11]
		Placebo	371	349 (94.1)	-0.40 (0.68)	-3.1	-0.75	-0.29	0.00	2.0	
	Week 7	Tezepelumab	380	354 (93.2)	-0.59 (0.77)	-3.5	-1.00	-0.43	0.00	1.2	-0.25 [-0.40, -0.10]
		Placebo	371	349 (94.1)	-0.41 (0.69)	-3.2	-0.80	-0.29	0.00	1.9	
	Week 8	Tezepelumab	380	355 (93.4)	-0.62 (0.76)	-3.5	-1.06	-0.50	-0.01	1.4	-0.26 [-0.41, -0.11]
		Placebo	371	340 (91.6)	-0.43 (0.69)	-3.1	-0.86	-0.36	0.00	1.9	
	Week 9	Tezepelumab	380	360 (94.7)	-0.66 (0.76)	-3.6	-1.07	-0.59	-0.07	1.4	-0.25 [-0.40, -0.11]
		Placebo	371	340 (91.6)	-0.47 (0.69)	-3.2	-0.92	-0.37	0.00	1.9	
	Week 10	Tezepelumab	380	358 (94.2)	-0.63 (0.75)	-3.6	-1.07	-0.50	-0.07	1.0	-0.24 [-0.39, -0.09]
		Placebo	371	338 (91.1)	-0.46 (0.70)	-3.2	-0.86	-0.36	0.00	1.8	
	Week 11	Tezepelumab	380	347 (91.3)	-0.64 (0.77)	-3.3	-1.07	-0.57	0.00	1.3	-0.21 [-0.36, -0.06]
		Placebo	371	334 (90.0)	-0.48 (0.71)	-3.2	-0.92	-0.43	0.00	1.9	
	Week 12	Tezepelumab	380	348 (91.6)	-0.62 (0.79)	-3.6	-1.02	-0.50	0.00	1.6	-0.17 [-0.32, -0.02]
		Placebo	371	332 (89.5)	-0.50 (0.70)	-3.2	-0.92	-0.40	0.00	1.9	
	Week 13	Tezepelumab	380	344 (90.5)	-0.65 (0.78)	-3.4	-1.07	-0.51	-0.07	1.9	-0.15 [-0.30, 0.00]
		Placebo	371	330 (88.9)	-0.54 (0.71)	-3.2	-1.00	-0.43	-0.04	1.9	
	Week 14	Tezepelumab	380	342 (90.0)	-0.71 (0.77)	-3.3	-1.14	-0.64	-0.08	1.0	-0.24 [-0.40, -0.09]
		Placebo	371	330 (88.9)	-0.53 (0.72)	-3.2	-0.93	-0.45	0.00	1.9	
	Week 15	Tezepelumab	380	338 (88.9)	-0.67 (0.78)	-3.1	-1.10	-0.57	-0.04	1.9	-0.19 [-0.34, -0.03]
		Placebo	371	320 (86.3)	-0.53 (0.73)	-3.2	-1.00	-0.50	0.00	1.9	
	Week 16	Tezepelumab	380	342 (90.0)	-0.70 (0.80)	-3.5	-1.14	-0.57	-0.07	2.1	-0.24 [-0.39, -0.08]
		Placebo	371	318 (85.7)	-0.52 (0.74)	-3.0	-1.00	-0.42	0.00	1.9	
	Week 17	Tezepelumab	380	338 (88.9)	-0.74 (0.80)	-3.6	-1.14	-0.65	-0.07	1.0	-0.27 [-0.42, -0.11]
		Placebo	371	314 (84.6)	-0.54 (0.73)	-3.2	-1.00	-0.50	0.00	1.9	
Week 18	Tezepelumab	380	336 (88.4)	-0.70 (0.82)	-3.4	-1.14	-0.58	-0.07	1.0	-0.21 [-0.36, -0.05]	
	Placebo	371	309 (83.3)	-0.53 (0.77)	-3.1	-1.00	-0.42	0.00	1.9		

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WWC\_ALMH0: Course of ASD weekly wheezing score  
 DITTl - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly wheezing score	Week 19	Tezepelumab	380	333 (87.6)	-0.71 (0.84)	-3.6	-1.14	-0.64	-0.04	2.3	-0.23 [-0.38, -0.08]
		Placebo	371	317 (85.4)	-0.52 (0.77)	-3.2	-1.00	-0.40	0.00	2.0	
	Week 20	Tezepelumab	380	328 (86.3)	-0.71 (0.82)	-3.6	-1.14	-0.64	-0.07	1.5	-0.21 [-0.37, -0.06]
		Placebo	371	309 (83.3)	-0.54 (0.78)	-3.2	-1.00	-0.47	0.00	1.9	
	Week 21	Tezepelumab	380	326 (85.8)	-0.72 (0.78)	-3.4	-1.14	-0.64	-0.08	1.0	-0.21 [-0.37, -0.06]
		Placebo	371	305 (82.2)	-0.56 (0.76)	-3.2	-1.00	-0.49	0.00	1.9	
	Week 22	Tezepelumab	380	325 (85.5)	-0.67 (0.83)	-3.2	-1.10	-0.61	-0.07	2.2	-0.18 [-0.34, -0.03]
		Placebo	371	299 (80.6)	-0.53 (0.73)	-3.2	-1.00	-0.43	0.00	1.9	
	Week 23	Tezepelumab	380	319 (83.9)	-0.68 (0.82)	-3.3	-1.14	-0.64	-0.05	2.3	-0.17 [-0.33, -0.01]
		Placebo	371	296 (79.8)	-0.54 (0.75)	-3.2	-0.96	-0.43	0.00	1.9	
	Week 24	Tezepelumab	380	327 (86.1)	-0.71 (0.83)	-3.4	-1.17	-0.64	-0.07	1.8	-0.19 [-0.35, -0.04]
		Placebo	371	297 (80.1)	-0.55 (0.76)	-3.2	-1.00	-0.50	-0.02	1.9	
	Week 25	Tezepelumab	380	314 (82.6)	-0.71 (0.79)	-3.5	-1.14	-0.66	-0.07	1.4	-0.19 [-0.35, -0.03]
		Placebo	371	296 (79.8)	-0.56 (0.76)	-3.2	-1.00	-0.50	-0.07	1.9	
	Week 26	Tezepelumab	380	319 (83.9)	-0.69 (0.81)	-3.5	-1.13	-0.64	-0.04	1.4	-0.16 [-0.32, -0.00]
		Placebo	371	289 (77.9)	-0.56 (0.76)	-3.1	-1.00	-0.43	0.00	1.9	
	Week 27	Tezepelumab	380	309 (81.3)	-0.73 (0.83)	-3.6	-1.21	-0.64	-0.08	2.3	-0.23 [-0.39, -0.07]
		Placebo	371	300 (80.9)	-0.54 (0.79)	-3.1	-1.00	-0.50	0.00	1.9	
	Week 28	Tezepelumab	380	317 (83.4)	-0.71 (0.82)	-3.6	-1.14	-0.64	-0.07	1.0	-0.19 [-0.35, -0.03]
		Placebo	371	300 (80.9)	-0.56 (0.77)	-3.2	-1.00	-0.50	0.00	1.9	
	Week 29	Tezepelumab	380	310 (81.6)	-0.73 (0.82)	-3.4	-1.26	-0.64	-0.07	1.0	-0.22 [-0.38, -0.06]
		Placebo	371	299 (80.6)	-0.55 (0.79)	-3.2	-1.00	-0.50	0.00	1.9	
	Week 30	Tezepelumab	380	314 (82.6)	-0.72 (0.83)	-3.6	-1.21	-0.64	-0.07	1.0	-0.21 [-0.37, -0.05]
		Placebo	371	295 (79.5)	-0.55 (0.80)	-3.2	-1.02	-0.50	0.00	1.9	
	Week 31	Tezepelumab	380	315 (82.9)	-0.72 (0.83)	-3.6	-1.21	-0.64	-0.07	1.2	-0.23 [-0.39, -0.07]
		Placebo	371	296 (79.8)	-0.54 (0.75)	-3.0	-1.01	-0.50	0.00	2.0	
	Week 32	Tezepelumab	380	316 (83.2)	-0.69 (0.83)	-3.6	-1.14	-0.58	-0.04	1.9	-0.17 [-0.33, -0.01]
		Placebo	371	297 (80.1)	-0.55 (0.80)	-3.0	-1.01	-0.50	0.00	1.9	
	Week 33	Tezepelumab	380	313 (82.4)	-0.73 (0.84)	-3.6	-1.21	-0.71	-0.07	1.8	-0.24 [-0.40, -0.08]
		Placebo	371	291 (78.4)	-0.54 (0.78)	-3.2	-1.00	-0.49	0.00	1.9	
	Week 34	Tezepelumab	380	311 (81.8)	-0.74 (0.83)	-3.6	-1.21	-0.67	-0.07	1.7	-0.22 [-0.38, -0.06]
		Placebo	371	293 (79.0)	-0.55 (0.78)	-3.2	-1.00	-0.50	0.00	1.9	
	Week 35	Tezepelumab	380	312 (82.1)	-0.71 (0.84)	-3.6	-1.18	-0.64	-0.07	1.9	-0.19 [-0.35, -0.03]
		Placebo	371	285 (76.8)	-0.56 (0.79)	-3.2	-1.00	-0.50	0.00	1.9	
	Week 36	Tezepelumab	380	309 (81.3)	-0.70 (0.83)	-3.6	-1.14	-0.64	-0.07	1.8	-0.19 [-0.35, -0.03]
		Placebo	371	288 (77.6)	-0.54 (0.79)	-3.2	-1.00	-0.50	0.00	1.9	

Note: DITTl - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WWC\_ALMH0: Course of ASD weekly wheezing score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly wheezing score	Week 37	Tezepelumab	380	312 (82.1)	-0.72 (0.86)	-3.6	-1.21	-0.67	-0.07	1.9	-0.21 [-0.37, -0.05]
		Placebo	371	287 (77.4)	-0.55 (0.77)	-3.2	-1.00	-0.50	0.00	1.9	
	Week 38	Tezepelumab	380	310 (81.6)	-0.72 (0.85)	-3.6	-1.14	-0.64	-0.07	1.9	-0.17 [-0.33, -0.01]
		Placebo	371	287 (77.4)	-0.58 (0.76)	-3.2	-1.07	-0.52	0.00	1.9	
	Week 39	Tezepelumab	380	317 (83.4)	-0.72 (0.86)	-3.6	-1.21	-0.71	-0.07	1.9	-0.19 [-0.35, -0.03]
		Placebo	371	281 (75.7)	-0.57 (0.77)	-3.2	-1.07	-0.49	-0.03	1.9	
	Week 40	Tezepelumab	380	313 (82.4)	-0.70 (0.85)	-3.6	-1.14	-0.64	-0.07	1.9	-0.21 [-0.37, -0.05]
		Placebo	371	287 (77.4)	-0.53 (0.76)	-3.0	-1.00	-0.44	0.00	1.9	
	Week 41	Tezepelumab	380	316 (83.2)	-0.75 (0.85)	-3.5	-1.29	-0.71	-0.08	1.9	-0.24 [-0.40, -0.08]
		Placebo	371	288 (77.6)	-0.56 (0.74)	-3.0	-1.00	-0.50	-0.07	1.9	
	Week 42	Tezepelumab	380	308 (81.1)	-0.75 (0.83)	-3.5	-1.21	-0.71	-0.08	1.9	-0.26 [-0.43, -0.10]
		Placebo	371	288 (77.6)	-0.54 (0.75)	-3.0	-1.00	-0.46	-0.02	1.9	
	Week 43	Tezepelumab	380	311 (81.8)	-0.76 (0.84)	-3.6	-1.21	-0.71	-0.08	1.9	-0.25 [-0.41, -0.09]
		Placebo	371	285 (76.8)	-0.56 (0.76)	-3.2	-1.00	-0.50	0.00	1.9	
	Week 44	Tezepelumab	380	309 (81.3)	-0.78 (0.84)	-3.4	-1.21	-0.71	-0.14	1.9	-0.27 [-0.43, -0.11]
		Placebo	371	283 (76.3)	-0.56 (0.77)	-3.2	-1.00	-0.47	0.00	1.9	
	Week 45	Tezepelumab	380	312 (82.1)	-0.77 (0.84)	-3.6	-1.21	-0.71	-0.14	1.8	-0.23 [-0.39, -0.07]
		Placebo	371	285 (76.8)	-0.59 (0.78)	-3.2	-1.04	-0.50	0.00	1.9	
	Week 46	Tezepelumab	380	307 (80.8)	-0.77 (0.87)	-3.6	-1.29	-0.79	-0.08	2.4	-0.23 [-0.39, -0.07]
		Placebo	371	278 (74.9)	-0.57 (0.79)	-3.2	-1.07	-0.50	-0.07	1.9	
	Week 47	Tezepelumab	380	296 (77.9)	-0.76 (0.84)	-3.6	-1.22	-0.73	-0.08	1.7	-0.23 [-0.39, -0.06]
		Placebo	371	281 (75.7)	-0.58 (0.74)	-3.2	-1.00	-0.57	0.00	1.6	
	Week 48	Tezepelumab	380	318 (83.7)	-0.76 (0.84)	-3.6	-1.25	-0.71	-0.08	1.7	-0.22 [-0.38, -0.06]
		Placebo	371	291 (78.4)	-0.58 (0.74)	-3.2	-1.00	-0.54	-0.07	1.6	
	Week 49	Tezepelumab	380	308 (81.1)	-0.76 (0.85)	-3.6	-1.29	-0.68	-0.08	1.9	-0.23 [-0.39, -0.07]
		Placebo	371	280 (75.5)	-0.57 (0.76)	-3.2	-1.00	-0.50	0.00	1.6	
	Week 50	Tezepelumab	380	306 (80.5)	-0.75 (0.85)	-3.6	-1.29	-0.65	-0.14	1.9	-0.23 [-0.40, -0.07]
		Placebo	371	278 (74.9)	-0.57 (0.75)	-3.2	-1.00	-0.50	0.00	1.6	
	Week 51	Tezepelumab	380	300 (78.9)	-0.74 (0.86)	-3.6	-1.21	-0.64	-0.07	1.9	-0.20 [-0.37, -0.04]
		Placebo	371	270 (72.8)	-0.57 (0.77)	-3.2	-1.00	-0.50	-0.03	1.6	
	Week 52	Tezepelumab	380	268 (70.5)	-0.73 (0.89)	-3.6	-1.29	-0.64	-0.07	1.9	-0.17 [-0.34, 0.01]
		Placebo	371	246 (66.3)	-0.59 (0.77)	-3.5	-1.00	-0.52	-0.07	1.6	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WWC\_ALMC0: Change from baseline in ASD weekly wheezing score - MMRM results  
 DITTTL - adult

Change from baseline in ASD weekly wheezing score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 1	Tezepelumab	380	372 (97.9)	-0.22 (0.03)	(-0.28, -0.15)	-0.07 (0.05)	(-0.17, 0.02)	0.142	
	Placebo	371	362 (97.6)	-0.14 (0.04)	(-0.21, -0.07)				
Week 2	Tezepelumab	380	370 (97.4)	-0.37 (0.03)	(-0.44, -0.30)	-0.18 (0.05)	(-0.28, -0.09)	<0.001 *	
	Placebo	371	360 (97.0)	-0.19 (0.04)	(-0.26, -0.12)				
Week 3	Tezepelumab	380	365 (96.1)	-0.44 (0.03)	(-0.51, -0.37)	-0.17 (0.05)	(-0.26, -0.07)	<0.001 *	
	Placebo	371	354 (95.4)	-0.27 (0.04)	(-0.34, -0.20)				
Week 4	Tezepelumab	380	363 (95.5)	-0.48 (0.03)	(-0.54, -0.41)	-0.16 (0.05)	(-0.25, -0.06)	0.001 *	
	Placebo	371	353 (95.1)	-0.32 (0.04)	(-0.39, -0.25)				
Week 5	Tezepelumab	380	363 (95.5)	-0.53 (0.03)	(-0.60, -0.46)	-0.13 (0.05)	(-0.23, -0.04)	0.007 *	
	Placebo	371	344 (92.7)	-0.40 (0.04)	(-0.47, -0.33)				
Week 6	Tezepelumab	380	357 (93.9)	-0.58 (0.03)	(-0.64, -0.51)	-0.18 (0.05)	(-0.28, -0.08)	<0.001 *	
	Placebo	371	349 (94.1)	-0.39 (0.04)	(-0.46, -0.33)				
Week 7	Tezepelumab	380	354 (93.2)	-0.59 (0.03)	(-0.65, -0.52)	-0.19 (0.05)	(-0.29, -0.09)	<0.001 *	
	Placebo	371	349 (94.1)	-0.40 (0.04)	(-0.47, -0.33)				
Week 8	Tezepelumab	380	355 (93.4)	-0.61 (0.03)	(-0.68, -0.54)	-0.19 (0.05)	(-0.29, -0.10)	<0.001 *	
	Placebo	371	340 (91.6)	-0.42 (0.04)	(-0.49, -0.35)				
Week 9	Tezepelumab	380	360 (94.7)	-0.65 (0.03)	(-0.72, -0.58)	-0.19 (0.05)	(-0.29, -0.10)	<0.001 *	
	Placebo	371	340 (91.6)	-0.46 (0.04)	(-0.53, -0.39)				
Week 10	Tezepelumab	380	358 (94.2)	-0.64 (0.03)	(-0.71, -0.57)	-0.20 (0.05)	(-0.29, -0.10)	<0.001 *	
	Placebo	371	338 (91.1)	-0.44 (0.04)	(-0.51, -0.37)				

Note: DITTTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WWC\_ALMC0: Change from baseline in ASD weekly wheezing score - MMRM results  
 DITTTL - adult

Change from baseline in ASD weekly wheezing score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 11	Tezepelumab	380	347 (91.3)	-0.64 (0.03)	(-0.71, -0.57)	-0.17 (0.05)	(-0.27, -0.07)	<0.001 *	
	Placebo	371	334 (90.0)	-0.47 (0.04)	(-0.54, -0.40)				
Week 12	Tezepelumab	380	348 (91.6)	-0.63 (0.03)	(-0.70, -0.56)	-0.15 (0.05)	(-0.25, -0.06)	0.002 *	
	Placebo	371	332 (89.5)	-0.47 (0.04)	(-0.54, -0.41)				
Week 13	Tezepelumab	380	344 (90.5)	-0.66 (0.03)	(-0.73, -0.59)	-0.16 (0.05)	(-0.26, -0.06)	0.001 *	
	Placebo	371	330 (88.9)	-0.50 (0.04)	(-0.57, -0.43)				
Week 14	Tezepelumab	380	342 (90.0)	-0.69 (0.03)	(-0.76, -0.62)	-0.18 (0.05)	(-0.28, -0.09)	<0.001 *	
	Placebo	371	330 (88.9)	-0.51 (0.04)	(-0.58, -0.44)				
Week 15	Tezepelumab	380	338 (88.9)	-0.68 (0.04)	(-0.75, -0.61)	-0.16 (0.05)	(-0.26, -0.07)	0.001 *	
	Placebo	371	320 (86.3)	-0.52 (0.04)	(-0.59, -0.45)				
Week 16	Tezepelumab	380	342 (90.0)	-0.72 (0.04)	(-0.78, -0.65)	-0.23 (0.05)	(-0.32, -0.13)	<0.001 *	
	Placebo	371	318 (85.7)	-0.49 (0.04)	(-0.56, -0.42)				
Week 17	Tezepelumab	380	338 (88.9)	-0.73 (0.04)	(-0.80, -0.66)	-0.21 (0.05)	(-0.31, -0.11)	<0.001 *	
	Placebo	371	314 (84.6)	-0.52 (0.04)	(-0.59, -0.45)				
Week 18	Tezepelumab	380	336 (88.4)	-0.70 (0.04)	(-0.76, -0.63)	-0.18 (0.05)	(-0.28, -0.08)	<0.001 *	
	Placebo	371	309 (83.3)	-0.51 (0.04)	(-0.58, -0.44)				
Week 19	Tezepelumab	380	333 (87.6)	-0.71 (0.04)	(-0.78, -0.64)	-0.20 (0.05)	(-0.30, -0.10)	<0.001 *	
	Placebo	371	317 (85.4)	-0.51 (0.04)	(-0.58, -0.44)				
Week 20	Tezepelumab	380	328 (86.3)	-0.71 (0.04)	(-0.78, -0.64)	-0.20 (0.05)	(-0.30, -0.10)	<0.001 *	
	Placebo	371	309 (83.3)	-0.52 (0.04)	(-0.59, -0.45)				

Note: DITTTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WWC\_ALMC0: Change from baseline in ASD weekly wheezing score - MMRM results  
 DITTTL - adult

Change from baseline in ASD weekly wheezing score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Time	Treatment	N	n (%)						
Week 21	Tezepelumab	380	326 (85.8)	-0.72 (0.04)	(-0.79, -0.65)	-0.19 (0.05)	(-0.29, -0.09)	<0.001	*
	Placebo	371	305 (82.2)	-0.53 (0.04)	(-0.60, -0.46)				
Week 22	Tezepelumab	380	325 (85.5)	-0.71 (0.04)	(-0.77, -0.64)	-0.18 (0.05)	(-0.28, -0.08)	<0.001	*
	Placebo	371	299 (80.6)	-0.53 (0.04)	(-0.60, -0.46)				
Week 23	Tezepelumab	380	319 (83.9)	-0.70 (0.04)	(-0.77, -0.63)	-0.20 (0.05)	(-0.30, -0.10)	<0.001	*
	Placebo	371	296 (79.8)	-0.51 (0.04)	(-0.58, -0.43)				
Week 24	Tezepelumab	380	327 (86.1)	-0.70 (0.04)	(-0.77, -0.63)	-0.17 (0.05)	(-0.27, -0.07)	<0.001	*
	Placebo	371	297 (80.1)	-0.53 (0.04)	(-0.60, -0.46)				
Week 25	Tezepelumab	380	314 (82.6)	-0.71 (0.04)	(-0.78, -0.64)	-0.17 (0.05)	(-0.27, -0.07)	<0.001	*
	Placebo	371	296 (79.8)	-0.54 (0.04)	(-0.61, -0.47)				
Week 26	Tezepelumab	380	319 (83.9)	-0.69 (0.04)	(-0.76, -0.62)	-0.16 (0.05)	(-0.26, -0.06)	0.002	*
	Placebo	371	289 (77.9)	-0.54 (0.04)	(-0.61, -0.47)				
Week 27	Tezepelumab	380	309 (81.3)	-0.71 (0.04)	(-0.78, -0.64)	-0.18 (0.05)	(-0.28, -0.08)	<0.001	*
	Placebo	371	300 (80.9)	-0.53 (0.04)	(-0.60, -0.46)				
Week 28	Tezepelumab	380	317 (83.4)	-0.70 (0.04)	(-0.77, -0.63)	-0.15 (0.05)	(-0.25, -0.05)	0.003	*
	Placebo	371	300 (80.9)	-0.55 (0.04)	(-0.62, -0.48)				
Week 29	Tezepelumab	380	310 (81.6)	-0.71 (0.04)	(-0.78, -0.64)	-0.17 (0.05)	(-0.27, -0.07)	0.001	*
	Placebo	371	299 (80.6)	-0.54 (0.04)	(-0.61, -0.47)				
Week 30	Tezepelumab	380	314 (82.6)	-0.71 (0.04)	(-0.78, -0.64)	-0.18 (0.05)	(-0.28, -0.08)	<0.001	*
	Placebo	371	295 (79.5)	-0.53 (0.04)	(-0.60, -0.46)				

Note: DITTTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WWC\_ALMC0: Change from baseline in ASD weekly wheezing score - MMRM results  
 DITTL - adult

Change from baseline in ASD weekly wheezing score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 31	Tezepelumab	380	315 (82.9)	-0.71 (0.04)	(-0.78, -0.64)	-0.18 (0.05)	(-0.28, -0.08)	<0.001 *	
	Placebo	371	296 (79.8)	-0.53 (0.04)	(-0.60, -0.46)				
Week 32	Tezepelumab	380	316 (83.2)	-0.70 (0.04)	(-0.77, -0.63)	-0.16 (0.05)	(-0.26, -0.06)	0.002 *	
	Placebo	371	297 (80.1)	-0.54 (0.04)	(-0.61, -0.46)				
Week 33	Tezepelumab	380	313 (82.4)	-0.73 (0.04)	(-0.80, -0.66)	-0.20 (0.05)	(-0.30, -0.09)	<0.001 *	
	Placebo	371	291 (78.4)	-0.54 (0.04)	(-0.61, -0.47)				
Week 34	Tezepelumab	380	311 (81.8)	-0.74 (0.04)	(-0.81, -0.67)	-0.21 (0.05)	(-0.32, -0.11)	<0.001 *	
	Placebo	371	293 (79.0)	-0.53 (0.04)	(-0.60, -0.46)				
Week 35	Tezepelumab	380	312 (82.1)	-0.72 (0.04)	(-0.79, -0.65)	-0.19 (0.05)	(-0.29, -0.08)	<0.001 *	
	Placebo	371	285 (76.8)	-0.54 (0.04)	(-0.61, -0.46)				
Week 36	Tezepelumab	380	309 (81.3)	-0.71 (0.04)	(-0.78, -0.64)	-0.19 (0.05)	(-0.29, -0.09)	<0.001 *	
	Placebo	371	288 (77.6)	-0.52 (0.04)	(-0.59, -0.45)				
Week 37	Tezepelumab	380	312 (82.1)	-0.72 (0.04)	(-0.79, -0.65)	-0.17 (0.05)	(-0.27, -0.07)	<0.001 *	
	Placebo	371	287 (77.4)	-0.54 (0.04)	(-0.62, -0.47)				
Week 38	Tezepelumab	380	310 (81.6)	-0.71 (0.04)	(-0.78, -0.64)	-0.16 (0.05)	(-0.26, -0.05)	0.003 *	
	Placebo	371	287 (77.4)	-0.56 (0.04)	(-0.63, -0.48)				
Week 39	Tezepelumab	380	317 (83.4)	-0.71 (0.04)	(-0.78, -0.64)	-0.15 (0.05)	(-0.25, -0.05)	0.004 *	
	Placebo	371	281 (75.7)	-0.56 (0.04)	(-0.64, -0.49)				
Week 40	Tezepelumab	380	313 (82.4)	-0.72 (0.04)	(-0.79, -0.65)	-0.19 (0.05)	(-0.29, -0.08)	<0.001 *	
	Placebo	371	287 (77.4)	-0.53 (0.04)	(-0.61, -0.46)				

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WWC\_ALMC0: Change from baseline in ASD weekly wheezing score - MMRM results  
 DITTL - adult

Change from baseline in ASD weekly wheezing score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 41	Tezepelumab	380	316 (83.2)	-0.75 (0.04)	(-0.82, -0.68)	-0.20 (0.05)	(-0.30, -0.10)	<0.001 *	
	Placebo	371	288 (77.6)	-0.55 (0.04)	(-0.62, -0.47)				
Week 42	Tezepelumab	380	308 (81.1)	-0.75 (0.04)	(-0.82, -0.68)	-0.20 (0.05)	(-0.31, -0.10)	<0.001 *	
	Placebo	371	288 (77.6)	-0.55 (0.04)	(-0.62, -0.47)				
Week 43	Tezepelumab	380	311 (81.8)	-0.75 (0.04)	(-0.83, -0.68)	-0.20 (0.05)	(-0.30, -0.09)	<0.001 *	
	Placebo	371	285 (76.8)	-0.56 (0.04)	(-0.63, -0.48)				
Week 44	Tezepelumab	380	309 (81.3)	-0.76 (0.04)	(-0.83, -0.69)	-0.22 (0.05)	(-0.32, -0.11)	<0.001 *	
	Placebo	371	283 (76.3)	-0.55 (0.04)	(-0.62, -0.48)				
Week 45	Tezepelumab	380	312 (82.1)	-0.77 (0.04)	(-0.84, -0.70)	-0.20 (0.05)	(-0.31, -0.10)	<0.001 *	
	Placebo	371	285 (76.8)	-0.57 (0.04)	(-0.64, -0.50)				
Week 46	Tezepelumab	380	307 (80.8)	-0.77 (0.04)	(-0.84, -0.70)	-0.21 (0.05)	(-0.31, -0.11)	<0.001 *	
	Placebo	371	278 (74.9)	-0.56 (0.04)	(-0.64, -0.49)				
Week 47	Tezepelumab	380	296 (77.9)	-0.77 (0.04)	(-0.84, -0.70)	-0.20 (0.05)	(-0.30, -0.09)	<0.001 *	
	Placebo	371	281 (75.7)	-0.57 (0.04)	(-0.65, -0.50)				
Week 48	Tezepelumab	380	318 (83.7)	-0.76 (0.04)	(-0.83, -0.69)	-0.19 (0.05)	(-0.29, -0.08)	<0.001 *	
	Placebo	371	291 (78.4)	-0.57 (0.04)	(-0.64, -0.50)				
Week 49	Tezepelumab	380	308 (81.1)	-0.75 (0.04)	(-0.83, -0.68)	-0.19 (0.05)	(-0.29, -0.08)	<0.001 *	
	Placebo	371	280 (75.5)	-0.57 (0.04)	(-0.64, -0.50)				
Week 50	Tezepelumab	380	306 (80.5)	-0.76 (0.04)	(-0.83, -0.69)	-0.19 (0.05)	(-0.29, -0.08)	<0.001 *	
	Placebo	371	278 (74.9)	-0.57 (0.04)	(-0.64, -0.50)				

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table NT1WWC\_ALMC0: Change from baseline in ASD weekly wheezing score - MMRM results  
 DITTTL - adult

Change from baseline in ASD weekly wheezing score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 51	Tezepelumab	380	300 (78.9)	-0.75 (0.04)	(-0.82, -0.68)	-0.18 (0.05)	(-0.28, -0.08)	<0.001 *	
	Placebo	371	270 (72.8)	-0.57 (0.04)	(-0.64, -0.49)				
Week 52	Tezepelumab	380	268 (70.5)	-0.73 (0.04)	(-0.80, -0.66)	-0.16 (0.05)	(-0.26, -0.05)	0.003 *	
	Placebo	371	246 (66.3)	-0.57 (0.04)	(-0.65, -0.50)				

Note: DITTTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC\_ALMH0: Course of ASD weekly shortness of breath score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly shortness of breath score	Baseline	Tezepelumab	380	380 (100.0)	1.63 (0.78)	0.0	1.00	1.58	2.07	4.0	
		Placebo	371	371 (100.0)	1.58 (0.77)	0.0	1.00	1.50	2.07	3.9	
	Week 1	Tezepelumab	380	372 (97.9)	1.39 (0.75)	0.0	1.00	1.23	1.93	4.0	
		Placebo	371	362 (97.6)	1.45 (0.76)	0.0	0.93	1.36	2.00	3.8	
	Week 2	Tezepelumab	380	370 (97.4)	1.27 (0.76)	0.0	0.90	1.14	1.86	3.9	
		Placebo	371	360 (97.0)	1.39 (0.77)	0.0	0.92	1.29	2.00	3.9	
	Week 3	Tezepelumab	380	365 (96.1)	1.20 (0.76)	0.0	0.75	1.08	1.79	3.9	
		Placebo	371	354 (95.4)	1.28 (0.77)	0.0	0.75	1.14	1.93	4.0	
	Week 4	Tezepelumab	380	363 (95.5)	1.17 (0.78)	0.0	0.57	1.00	1.79	3.9	
		Placebo	371	353 (95.1)	1.27 (0.77)	0.0	0.75	1.14	1.92	3.9	
	Week 5	Tezepelumab	380	363 (95.5)	1.10 (0.79)	0.0	0.50	1.00	1.70	4.0	
		Placebo	371	344 (92.7)	1.20 (0.78)	0.0	0.58	1.10	1.83	4.0	
	Week 6	Tezepelumab	380	357 (93.9)	1.07 (0.81)	0.0	0.36	1.00	1.71	4.0	
		Placebo	371	349 (94.1)	1.18 (0.79)	0.0	0.67	1.00	1.83	4.0	
	Week 7	Tezepelumab	380	354 (93.2)	1.04 (0.83)	0.0	0.21	1.00	1.64	4.0	
		Placebo	371	349 (94.1)	1.15 (0.81)	0.0	0.50	1.00	1.75	4.0	
	Week 8	Tezepelumab	380	355 (93.4)	1.02 (0.81)	0.0	0.25	1.00	1.64	4.0	
		Placebo	371	340 (91.6)	1.12 (0.79)	0.0	0.54	1.00	1.71	4.0	
	Week 9	Tezepelumab	380	360 (94.7)	0.97 (0.79)	0.0	0.18	1.00	1.50	4.0	
		Placebo	371	340 (91.6)	1.08 (0.79)	0.0	0.40	1.00	1.57	4.0	
	Week 10	Tezepelumab	380	358 (94.2)	1.00 (0.80)	0.0	0.25	1.00	1.50	4.0	
		Placebo	371	338 (91.1)	1.09 (0.79)	0.0	0.40	1.00	1.63	4.0	
	Week 11	Tezepelumab	380	347 (91.3)	0.98 (0.82)	0.0	0.14	1.00	1.50	4.0	
		Placebo	371	334 (90.0)	1.07 (0.80)	0.0	0.40	1.00	1.64	4.0	
	Week 12	Tezepelumab	380	348 (91.6)	0.99 (0.82)	0.0	0.21	1.00	1.54	4.0	
		Placebo	371	332 (89.5)	1.06 (0.81)	0.0	0.29	1.00	1.58	4.0	
	Week 13	Tezepelumab	380	344 (90.5)	0.95 (0.80)	0.0	0.14	1.00	1.50	4.0	
		Placebo	371	330 (88.9)	1.05 (0.79)	0.0	0.30	1.00	1.57	4.0	
	Week 14	Tezepelumab	380	342 (90.0)	0.91 (0.80)	0.0	0.08	1.00	1.38	4.0	
		Placebo	371	330 (88.9)	1.05 (0.78)	0.0	0.30	1.00	1.57	4.0	
	Week 15	Tezepelumab	380	338 (88.9)	0.92 (0.80)	0.0	0.08	1.00	1.43	4.0	
		Placebo	371	320 (86.3)	1.03 (0.81)	0.0	0.25	1.00	1.58	4.0	
	Week 16	Tezepelumab	380	342 (90.0)	0.91 (0.80)	0.0	0.08	1.00	1.40	4.0	
		Placebo	371	318 (85.7)	1.07 (0.82)	0.0	0.25	1.00	1.79	4.0	
	Week 17	Tezepelumab	380	338 (88.9)	0.88 (0.80)	0.0	0.07	1.00	1.25	4.0	
		Placebo	371	314 (84.6)	1.03 (0.80)	0.0	0.21	1.00	1.64	4.0	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC\_ALMH0: Course of ASD weekly shortness of breath score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly shortness of breath score	Week 18	Tezepelumab	380	336 (88.4)	0.91 (0.80)	0.0	0.07	1.00	1.42	4.0	
		Placebo	371	309 (83.3)	1.03 (0.83)	0.0	0.14	1.00	1.63	4.0	
	Week 19	Tezepelumab	380	333 (87.6)	0.89 (0.81)	0.0	0.00	1.00	1.29	4.0	
		Placebo	371	317 (85.4)	1.04 (0.84)	0.0	0.17	1.00	1.71	4.0	
	Week 20	Tezepelumab	380	328 (86.3)	0.91 (0.82)	0.0	0.07	1.00	1.50	4.0	
		Placebo	371	309 (83.3)	1.04 (0.84)	0.0	0.21	1.00	1.86	4.0	
	Week 21	Tezepelumab	380	326 (85.8)	0.87 (0.81)	0.0	0.00	1.00	1.29	4.0	
		Placebo	371	305 (82.2)	0.99 (0.82)	0.0	0.14	1.00	1.71	4.0	
	Week 22	Tezepelumab	380	325 (85.5)	0.92 (0.84)	0.0	0.00	1.00	1.50	4.0	
		Placebo	371	299 (80.6)	0.99 (0.81)	0.0	0.14	1.00	1.63	4.0	
	Week 23	Tezepelumab	380	319 (83.9)	0.90 (0.84)	0.0	0.00	1.00	1.38	4.0	
		Placebo	371	296 (79.8)	0.99 (0.82)	0.0	0.11	1.00	1.69	4.0	
	Week 24	Tezepelumab	380	327 (86.1)	0.89 (0.84)	0.0	0.00	1.00	1.43	4.0	
		Placebo	371	297 (80.1)	0.96 (0.81)	0.0	0.10	1.00	1.57	4.0	
	Week 25	Tezepelumab	380	314 (82.6)	0.91 (0.82)	0.0	0.00	1.00	1.42	4.0	
		Placebo	371	296 (79.8)	0.98 (0.84)	0.0	0.13	1.00	1.58	4.0	
	Week 26	Tezepelumab	380	319 (83.9)	0.90 (0.83)	0.0	0.00	1.00	1.36	4.0	
		Placebo	371	289 (77.9)	1.02 (0.84)	0.0	0.14	1.00	1.75	4.0	
	Week 27	Tezepelumab	380	309 (81.3)	0.88 (0.85)	0.0	0.00	1.00	1.30	4.0	
		Placebo	371	300 (80.9)	0.99 (0.85)	0.0	0.10	1.00	1.75	4.0	
	Week 28	Tezepelumab	380	317 (83.4)	0.85 (0.83)	0.0	0.00	1.00	1.25	4.0	
		Placebo	371	300 (80.9)	0.99 (0.85)	0.0	0.13	1.00	1.71	4.0	
	Week 29	Tezepelumab	380	310 (81.6)	0.86 (0.84)	0.0	0.00	1.00	1.29	4.0	
		Placebo	371	299 (80.6)	0.98 (0.86)	0.0	0.07	1.00	1.80	4.0	
	Week 30	Tezepelumab	380	314 (82.6)	0.87 (0.80)	0.0	0.00	1.00	1.29	3.9	
		Placebo	371	295 (79.5)	0.99 (0.85)	0.0	0.08	1.00	1.83	4.0	
	Week 31	Tezepelumab	380	315 (82.9)	0.86 (0.81)	0.0	0.00	1.00	1.33	4.0	
		Placebo	371	296 (79.8)	1.00 (0.83)	0.0	0.17	1.00	1.71	4.0	
	Week 32	Tezepelumab	380	316 (83.2)	0.86 (0.80)	0.0	0.00	1.00	1.25	3.9	
		Placebo	371	297 (80.1)	0.99 (0.82)	0.0	0.14	1.00	1.70	4.0	
	Week 33	Tezepelumab	380	313 (82.4)	0.84 (0.81)	0.0	0.00	0.93	1.21	3.9	
		Placebo	371	291 (78.4)	1.02 (0.84)	0.0	0.17	1.00	1.80	4.0	
	Week 34	Tezepelumab	380	311 (81.8)	0.83 (0.82)	0.0	0.00	1.00	1.25	4.0	
		Placebo	371	293 (79.0)	0.99 (0.84)	0.0	0.14	1.00	1.71	4.0	
	Week 35	Tezepelumab	380	312 (82.1)	0.83 (0.82)	0.0	0.00	0.95	1.17	4.0	
		Placebo	371	285 (76.8)	0.97 (0.83)	0.0	0.13	1.00	1.64	4.0	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC\_ALMH0: Course of ASD weekly shortness of breath score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly shortness of breath score	Week 36	Tezepelumab	380	309 (81.3)	0.84 (0.83)	0.0	0.00	1.00	1.21	3.9	
		Placebo	371	288 (77.6)	0.97 (0.83)	0.0	0.13	1.00	1.58	4.0	
	Week 37	Tezepelumab	380	312 (82.1)	0.82 (0.82)	0.0	0.00	1.00	1.14	3.9	
		Placebo	371	287 (77.4)	0.95 (0.81)	0.0	0.08	1.00	1.50	4.0	
	Week 38	Tezepelumab	380	310 (81.6)	0.86 (0.85)	0.0	0.00	1.00	1.29	3.9	
		Placebo	371	287 (77.4)	0.93 (0.82)	0.0	0.00	1.00	1.50	4.0	
	Week 39	Tezepelumab	380	317 (83.4)	0.86 (0.86)	0.0	0.00	1.00	1.29	4.0	
		Placebo	371	281 (75.7)	0.94 (0.84)	0.0	0.00	1.00	1.57	4.0	
	Week 40	Tezepelumab	380	313 (82.4)	0.87 (0.84)	0.0	0.00	1.00	1.36	4.0	
		Placebo	371	287 (77.4)	0.96 (0.84)	0.0	0.07	1.00	1.71	4.0	
	Week 41	Tezepelumab	380	316 (83.2)	0.82 (0.82)	0.0	0.00	0.92	1.23	3.5	
		Placebo	371	288 (77.6)	0.97 (0.81)	0.0	0.10	1.00	1.63	4.0	
	Week 42	Tezepelumab	380	308 (81.1)	0.84 (0.83)	0.0	0.00	1.00	1.21	4.0	
		Placebo	371	288 (77.6)	0.97 (0.84)	0.0	0.13	1.00	1.68	4.0	
	Week 43	Tezepelumab	380	311 (81.8)	0.84 (0.83)	0.0	0.00	1.00	1.17	3.6	
		Placebo	371	285 (76.8)	0.95 (0.85)	0.0	0.07	1.00	1.57	4.0	
	Week 44	Tezepelumab	380	309 (81.3)	0.83 (0.83)	0.0	0.00	0.93	1.17	3.6	
		Placebo	371	283 (76.3)	0.95 (0.84)	0.0	0.13	1.00	1.58	4.0	
	Week 45	Tezepelumab	380	312 (82.1)	0.82 (0.84)	0.0	0.00	0.91	1.21	3.7	
		Placebo	371	285 (76.8)	0.96 (0.84)	0.0	0.13	1.00	1.57	4.0	
	Week 46	Tezepelumab	380	307 (80.8)	0.84 (0.86)	0.0	0.00	0.93	1.29	3.9	
		Placebo	371	278 (74.9)	0.93 (0.83)	0.0	0.08	1.00	1.50	4.0	
	Week 47	Tezepelumab	380	296 (77.9)	0.85 (0.85)	0.0	0.00	0.96	1.32	3.2	
		Placebo	371	281 (75.7)	0.91 (0.80)	0.0	0.10	1.00	1.43	4.0	
	Week 48	Tezepelumab	380	318 (83.7)	0.84 (0.85)	0.0	0.00	1.00	1.29	3.4	
		Placebo	371	291 (78.4)	0.92 (0.81)	0.0	0.08	1.00	1.50	4.0	
	Week 49	Tezepelumab	380	308 (81.1)	0.85 (0.85)	0.0	0.00	1.00	1.25	3.2	
		Placebo	371	280 (75.5)	0.95 (0.81)	0.0	0.08	1.00	1.40	4.0	
	Week 50	Tezepelumab	380	306 (80.5)	0.84 (0.85)	0.0	0.00	0.93	1.14	3.2	
		Placebo	371	278 (74.9)	0.94 (0.81)	0.0	0.10	1.00	1.50	4.0	
	Week 51	Tezepelumab	380	300 (78.9)	0.86 (0.85)	0.0	0.00	1.00	1.29	3.1	
		Placebo	371	270 (72.8)	0.95 (0.83)	0.0	0.08	1.00	1.40	4.0	
	Week 52	Tezepelumab	380	268 (70.5)	0.89 (0.86)	0.0	0.00	1.00	1.25	3.2	
		Placebo	371	246 (66.3)	0.96 (0.86)	0.0	0.07	1.00	1.60	4.0	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC\_ALMH0: Course of ASD weekly shortness of breath score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly shortness of breath score	Week 1	Tezepelumab	380	372 (97.9)	-0.23 (0.41)	-2.1	-0.43	-0.14	0.00	0.9	-0.25 [-0.39, -0.10]
		Placebo	371	362 (97.6)	-0.13 (0.42)	-2.0	-0.35	-0.08	0.07	1.4	
	Week 2	Tezepelumab	380	370 (97.4)	-0.35 (0.55)	-3.2	-0.64	-0.21	0.00	0.9	-0.31 [-0.46, -0.16]
		Placebo	371	360 (97.0)	-0.18 (0.54)	-2.4	-0.42	-0.07	0.07	1.5	
	Week 3	Tezepelumab	380	365 (96.1)	-0.43 (0.60)	-3.8	-0.73	-0.29	0.00	0.9	-0.21 [-0.35, -0.06]
		Placebo	371	354 (95.4)	-0.30 (0.62)	-2.7	-0.57	-0.19	0.00	1.6	
	Week 4	Tezepelumab	380	363 (95.5)	-0.46 (0.64)	-3.8	-0.79	-0.29	0.00	0.9	-0.22 [-0.36, -0.07]
		Placebo	371	353 (95.1)	-0.32 (0.65)	-2.7	-0.64	-0.18	0.01	1.8	
	Week 5	Tezepelumab	380	363 (95.5)	-0.52 (0.66)	-3.8	-0.93	-0.36	-0.05	0.9	-0.20 [-0.35, -0.05]
		Placebo	371	344 (92.7)	-0.39 (0.65)	-2.7	-0.71	-0.29	0.00	1.8	
	Week 6	Tezepelumab	380	357 (93.9)	-0.55 (0.70)	-3.8	-0.93	-0.44	-0.04	1.1	-0.21 [-0.36, -0.06]
		Placebo	371	349 (94.1)	-0.41 (0.69)	-3.0	-0.79	-0.29	0.00	1.8	
	Week 7	Tezepelumab	380	354 (93.2)	-0.58 (0.74)	-3.8	-1.00	-0.43	-0.07	1.6	-0.21 [-0.35, -0.06]
		Placebo	371	349 (94.1)	-0.43 (0.73)	-3.2	-0.86	-0.29	0.00	1.9	
	Week 8	Tezepelumab	380	355 (93.4)	-0.60 (0.72)	-3.8	-1.00	-0.49	-0.07	1.6	-0.21 [-0.36, -0.06]
		Placebo	371	340 (91.6)	-0.45 (0.71)	-3.1	-0.93	-0.33	0.00	1.9	
	Week 9	Tezepelumab	380	360 (94.7)	-0.64 (0.73)	-3.8	-1.00	-0.57	-0.07	1.7	-0.19 [-0.34, -0.04]
		Placebo	371	340 (91.6)	-0.50 (0.73)	-3.2	-1.00	-0.43	0.00	1.9	
	Week 10	Tezepelumab	380	358 (94.2)	-0.61 (0.72)	-3.8	-1.00	-0.50	-0.06	1.0	-0.16 [-0.31, -0.01]
		Placebo	371	338 (91.1)	-0.50 (0.74)	-3.1	-0.93	-0.36	0.00	1.7	
	Week 11	Tezepelumab	380	347 (91.3)	-0.63 (0.73)	-3.8	-1.00	-0.50	-0.07	1.1	-0.17 [-0.32, -0.02]
		Placebo	371	334 (90.0)	-0.51 (0.74)	-3.2	-0.93	-0.43	0.00	1.9	
	Week 12	Tezepelumab	380	348 (91.6)	-0.62 (0.75)	-3.8	-1.00	-0.50	-0.07	1.3	-0.14 [-0.29, 0.01]
		Placebo	371	332 (89.5)	-0.51 (0.73)	-3.1	-0.93	-0.43	-0.04	1.9	
	Week 13	Tezepelumab	380	344 (90.5)	-0.65 (0.74)	-3.8	-1.00	-0.50	-0.07	1.0	-0.15 [-0.30, 0.00]
		Placebo	371	330 (88.9)	-0.53 (0.75)	-3.2	-1.00	-0.43	-0.02	1.9	
	Week 14	Tezepelumab	380	342 (90.0)	-0.70 (0.75)	-3.8	-1.07	-0.58	-0.12	0.9	-0.22 [-0.37, -0.07]
		Placebo	371	330 (88.9)	-0.53 (0.74)	-3.1	-1.00	-0.43	0.00	1.9	
	Week 15	Tezepelumab	380	338 (88.9)	-0.67 (0.75)	-3.3	-1.07	-0.54	-0.07	1.1	-0.17 [-0.33, -0.02]
		Placebo	371	320 (86.3)	-0.54 (0.75)	-3.2	-1.00	-0.50	0.00	1.9	
	Week 16	Tezepelumab	380	342 (90.0)	-0.69 (0.77)	-3.8	-1.13	-0.50	-0.07	1.4	-0.22 [-0.37, -0.06]
		Placebo	371	318 (85.7)	-0.52 (0.76)	-3.1	-1.00	-0.42	0.00	1.9	
	Week 17	Tezepelumab	380	338 (88.9)	-0.72 (0.77)	-3.8	-1.13	-0.58	-0.10	0.9	-0.23 [-0.39, -0.08]
		Placebo	371	314 (84.6)	-0.55 (0.73)	-3.2	-1.00	-0.45	0.00	1.9	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC\_ALMH0: Course of ASD weekly shortness of breath score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly shortness of breath score	Week 18	Tezepelumab	380	336 (88.4)	-0.69 (0.77)	-3.8	-1.14	-0.57	-0.07	1.0	-0.19 [-0.35, -0.04]
		Placebo	371	309 (83.3)	-0.55 (0.77)	-3.1	-1.00	-0.43	0.00	1.9	
	Week 19	Tezepelumab	380	333 (87.6)	-0.70 (0.78)	-3.8	-1.07	-0.63	-0.07	1.4	-0.20 [-0.36, -0.05]
		Placebo	371	317 (85.4)	-0.54 (0.78)	-3.2	-1.00	-0.43	0.00	2.0	
	Week 20	Tezepelumab	380	328 (86.3)	-0.68 (0.78)	-3.8	-1.08	-0.57	-0.07	1.2	-0.17 [-0.33, -0.02]
		Placebo	371	309 (83.3)	-0.55 (0.79)	-3.2	-1.00	-0.45	0.00	1.9	
	Week 21	Tezepelumab	380	326 (85.8)	-0.70 (0.77)	-3.8	-1.14	-0.64	-0.12	2.2	-0.17 [-0.33, -0.02]
		Placebo	371	305 (82.2)	-0.57 (0.77)	-3.2	-1.00	-0.43	-0.07	1.9	
	Week 22	Tezepelumab	380	325 (85.5)	-0.68 (0.78)	-3.4	-1.07	-0.57	-0.10	1.3	-0.14 [-0.30, 0.01]
		Placebo	371	299 (80.6)	-0.57 (0.74)	-3.2	-1.00	-0.50	-0.07	1.9	
	Week 23	Tezepelumab	380	319 (83.9)	-0.70 (0.78)	-3.6	-1.14	-0.64	-0.07	1.2	-0.14 [-0.30, 0.02]
		Placebo	371	296 (79.8)	-0.59 (0.77)	-3.3	-1.03	-0.50	-0.07	1.9	
	Week 24	Tezepelumab	380	327 (86.1)	-0.72 (0.78)	-3.7	-1.17	-0.64	-0.13	1.3	-0.16 [-0.32, -0.00]
		Placebo	371	297 (80.1)	-0.59 (0.77)	-3.2	-1.07	-0.57	-0.07	1.9	
	Week 25	Tezepelumab	380	314 (82.6)	-0.70 (0.77)	-3.8	-1.14	-0.64	-0.07	1.0	-0.16 [-0.31, 0.00]
		Placebo	371	296 (79.8)	-0.58 (0.80)	-3.2	-1.07	-0.57	-0.08	2.0	
	Week 26	Tezepelumab	380	319 (83.9)	-0.70 (0.79)	-3.8	-1.12	-0.63	-0.07	1.8	-0.17 [-0.33, -0.01]
		Placebo	371	289 (77.9)	-0.56 (0.81)	-3.1	-1.07	-0.44	-0.05	1.9	
	Week 27	Tezepelumab	380	309 (81.3)	-0.73 (0.81)	-3.8	-1.17	-0.64	-0.14	1.2	-0.20 [-0.36, -0.04]
		Placebo	371	300 (80.9)	-0.56 (0.83)	-3.1	-1.07	-0.50	0.00	2.4	
	Week 28	Tezepelumab	380	317 (83.4)	-0.75 (0.79)	-3.8	-1.24	-0.64	-0.14	0.9	-0.23 [-0.38, -0.07]
		Placebo	371	300 (80.9)	-0.56 (0.82)	-3.2	-1.04	-0.43	-0.01	1.9	
	Week 29	Tezepelumab	380	310 (81.6)	-0.76 (0.80)	-3.8	-1.29	-0.71	-0.07	1.0	-0.23 [-0.38, -0.07]
		Placebo	371	299 (80.6)	-0.58 (0.81)	-3.2	-1.08	-0.43	0.00	1.9	
	Week 30	Tezepelumab	380	314 (82.6)	-0.73 (0.80)	-3.8	-1.21	-0.64	-0.07	1.0	-0.19 [-0.34, -0.03]
		Placebo	371	295 (79.5)	-0.58 (0.83)	-3.2	-1.14	-0.50	0.00	1.9	
	Week 31	Tezepelumab	380	315 (82.9)	-0.75 (0.80)	-3.8	-1.21	-0.64	-0.14	1.1	-0.23 [-0.39, -0.07]
		Placebo	371	296 (79.8)	-0.57 (0.76)	-3.0	-1.08	-0.43	0.00	1.9	
	Week 32	Tezepelumab	380	316 (83.2)	-0.74 (0.77)	-3.8	-1.17	-0.64	-0.12	1.7	-0.20 [-0.36, -0.04]
		Placebo	371	297 (80.1)	-0.58 (0.81)	-3.4	-1.07	-0.43	0.00	1.9	
	Week 33	Tezepelumab	380	313 (82.4)	-0.75 (0.81)	-3.8	-1.21	-0.71	-0.14	1.6	-0.24 [-0.41, -0.08]
		Placebo	371	291 (78.4)	-0.56 (0.80)	-3.5	-1.05	-0.50	0.00	1.9	
	Week 34	Tezepelumab	380	311 (81.8)	-0.76 (0.79)	-3.8	-1.21	-0.71	-0.14	1.6	-0.23 [-0.39, -0.07]
		Placebo	371	293 (79.0)	-0.58 (0.81)	-3.2	-1.07	-0.57	0.00	1.9	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC\_ALMH0: Course of ASD weekly shortness of breath score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly shortness of breath score	Week 35	Tezepelumab	380	312 (82.1)	-0.76 (0.80)	-3.8	-1.21	-0.71	-0.14	1.6	-0.23 [-0.40, -0.07]
		Placebo	371	285 (76.8)	-0.58 (0.80)	-3.2	-1.07	-0.50	0.00	1.9	
	Week 36	Tezepelumab	380	309 (81.3)	-0.75 (0.81)	-3.8	-1.14	-0.71	-0.14	1.8	-0.20 [-0.36, -0.04]
		Placebo	371	288 (77.6)	-0.59 (0.81)	-3.9	-1.07	-0.49	0.00	1.9	
	Week 37	Tezepelumab	380	312 (82.1)	-0.76 (0.82)	-3.8	-1.29	-0.71	-0.14	1.6	-0.21 [-0.37, -0.05]
		Placebo	371	287 (77.4)	-0.59 (0.78)	-3.2	-1.03	-0.50	0.00	1.9	
	Week 38	Tezepelumab	380	310 (81.6)	-0.75 (0.82)	-3.8	-1.21	-0.71	-0.08	1.6	-0.16 [-0.32, 0.00]
		Placebo	371	287 (77.4)	-0.62 (0.77)	-3.2	-1.14	-0.57	-0.07	1.9	
	Week 39	Tezepelumab	380	317 (83.4)	-0.75 (0.83)	-3.8	-1.14	-0.67	-0.14	1.7	-0.18 [-0.34, -0.02]
		Placebo	371	281 (75.7)	-0.61 (0.80)	-3.3	-1.10	-0.55	-0.07	1.9	
	Week 40	Tezepelumab	380	313 (82.4)	-0.74 (0.81)	-3.8	-1.21	-0.71	-0.14	1.6	-0.21 [-0.37, -0.05]
		Placebo	371	287 (77.4)	-0.58 (0.80)	-3.9	-1.08	-0.50	0.00	1.9	
	Week 41	Tezepelumab	380	316 (83.2)	-0.78 (0.81)	-3.8	-1.31	-0.73	-0.14	1.6	-0.22 [-0.38, -0.05]
		Placebo	371	288 (77.6)	-0.61 (0.78)	-3.5	-1.07	-0.56	-0.05	1.9	
	Week 42	Tezepelumab	380	308 (81.1)	-0.78 (0.81)	-3.8	-1.29	-0.71	-0.14	1.6	-0.24 [-0.41, -0.08]
		Placebo	371	288 (77.6)	-0.59 (0.79)	-3.4	-1.07	-0.47	-0.07	1.9	
	Week 43	Tezepelumab	380	311 (81.8)	-0.79 (0.81)	-3.8	-1.25	-0.75	-0.14	1.6	-0.22 [-0.38, -0.06]
		Placebo	371	285 (76.8)	-0.61 (0.79)	-3.2	-1.07	-0.57	-0.07	1.9	
	Week 44	Tezepelumab	380	309 (81.3)	-0.78 (0.81)	-3.8	-1.21	-0.73	-0.16	1.6	-0.21 [-0.37, -0.05]
		Placebo	371	283 (76.3)	-0.61 (0.82)	-3.6	-1.07	-0.50	0.00	1.9	
	Week 45	Tezepelumab	380	312 (82.1)	-0.80 (0.81)	-3.8	-1.25	-0.79	-0.14	1.6	-0.22 [-0.38, -0.06]
		Placebo	371	285 (76.8)	-0.62 (0.83)	-3.6	-1.14	-0.57	0.00	1.9	
	Week 46	Tezepelumab	380	307 (80.8)	-0.79 (0.84)	-3.8	-1.29	-0.71	-0.17	1.7	-0.21 [-0.37, -0.05]
		Placebo	371	278 (74.9)	-0.62 (0.81)	-3.8	-1.07	-0.57	-0.07	1.9	
	Week 47	Tezepelumab	380	296 (77.9)	-0.77 (0.80)	-3.8	-1.29	-0.75	-0.14	1.6	-0.16 [-0.32, 0.00]
		Placebo	371	281 (75.7)	-0.64 (0.78)	-3.4	-1.08	-0.57	-0.08	1.4	
	Week 48	Tezepelumab	380	318 (83.7)	-0.76 (0.83)	-3.8	-1.29	-0.71	-0.14	2.0	-0.15 [-0.31, 0.01]
		Placebo	371	291 (78.4)	-0.64 (0.76)	-3.2	-1.07	-0.61	-0.07	1.4	
	Week 49	Tezepelumab	380	308 (81.1)	-0.75 (0.82)	-3.8	-1.29	-0.64	-0.14	1.6	-0.16 [-0.33, -0.00]
		Placebo	371	280 (75.5)	-0.62 (0.78)	-3.2	-1.07	-0.58	-0.03	1.4	
	Week 50	Tezepelumab	380	306 (80.5)	-0.76 (0.82)	-3.8	-1.26	-0.65	-0.14	1.6	-0.17 [-0.33, -0.01]
		Placebo	371	278 (74.9)	-0.63 (0.78)	-3.2	-1.08	-0.58	-0.07	1.6	
	Week 51	Tezepelumab	380	300 (78.9)	-0.75 (0.83)	-3.8	-1.25	-0.64	-0.14	1.6	-0.17 [-0.33, -0.00]
		Placebo	371	270 (72.8)	-0.61 (0.82)	-3.5	-1.07	-0.57	-0.01	1.6	
	Week 52	Tezepelumab	380	268 (70.5)	-0.75 (0.87)	-3.8	-1.29	-0.64	-0.13	1.7	-0.15 [-0.33, 0.02]
		Placebo	371	246 (66.3)	-0.62 (0.82)	-3.7	-1.07	-0.58	-0.07	1.5	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC\_ALMC0: Change from baseline in ASD weekly shortness of breath score - MMRM results  
 DITTl - adult

Change from baseline in ASD weekly shortness of breath score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 1	Tezepelumab	380	372 (97.9)	-0.22 (0.04)	(-0.29, -0.15)	-0.09 (0.05)	(-0.19, 0.01)	0.081	
	Placebo	371	362 (97.6)	-0.13 (0.04)	(-0.20, -0.06)				
Week 2	Tezepelumab	380	370 (97.4)	-0.35 (0.04)	(-0.42, -0.28)	-0.15 (0.05)	(-0.25, -0.06)	0.002 *	
	Placebo	371	360 (97.0)	-0.19 (0.04)	(-0.26, -0.12)				
Week 3	Tezepelumab	380	365 (96.1)	-0.42 (0.04)	(-0.49, -0.35)	-0.13 (0.05)	(-0.22, -0.03)	0.012 *	
	Placebo	371	354 (95.4)	-0.30 (0.04)	(-0.36, -0.23)				
Week 4	Tezepelumab	380	363 (95.5)	-0.45 (0.04)	(-0.52, -0.38)	-0.13 (0.05)	(-0.23, -0.03)	0.010 *	
	Placebo	371	353 (95.1)	-0.32 (0.04)	(-0.39, -0.25)				
Week 5	Tezepelumab	380	363 (95.5)	-0.51 (0.04)	(-0.58, -0.44)	-0.12 (0.05)	(-0.22, -0.03)	0.013 *	
	Placebo	371	344 (92.7)	-0.39 (0.04)	(-0.46, -0.32)				
Week 6	Tezepelumab	380	357 (93.9)	-0.54 (0.04)	(-0.61, -0.47)	-0.13 (0.05)	(-0.23, -0.03)	0.010 *	
	Placebo	371	349 (94.1)	-0.41 (0.04)	(-0.48, -0.34)				
Week 7	Tezepelumab	380	354 (93.2)	-0.57 (0.04)	(-0.64, -0.50)	-0.14 (0.05)	(-0.24, -0.05)	0.004 *	
	Placebo	371	349 (94.1)	-0.43 (0.04)	(-0.50, -0.36)				
Week 8	Tezepelumab	380	355 (93.4)	-0.59 (0.04)	(-0.66, -0.52)	-0.15 (0.05)	(-0.25, -0.05)	0.003 *	
	Placebo	371	340 (91.6)	-0.44 (0.04)	(-0.51, -0.37)				
Week 9	Tezepelumab	380	360 (94.7)	-0.63 (0.04)	(-0.70, -0.56)	-0.14 (0.05)	(-0.24, -0.04)	0.007 *	
	Placebo	371	340 (91.6)	-0.49 (0.04)	(-0.56, -0.42)				
Week 10	Tezepelumab	380	358 (94.2)	-0.62 (0.04)	(-0.69, -0.55)	-0.13 (0.05)	(-0.23, -0.03)	0.010 *	
	Placebo	371	338 (91.1)	-0.49 (0.04)	(-0.56, -0.42)				

Note: DITTl - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table NT1WBC\_ALMC0: Change from baseline in ASD weekly shortness of breath score - MMRM results  
 DITTl - adult

Change from baseline in ASD weekly shortness of breath score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 11	Tezepelumab	380	347 (91.3)	-0.63 (0.04)	(-0.70, -0.56)	-0.13 (0.05)	(-0.23, -0.03)	0.012 *	
	Placebo	371	334 (90.0)	-0.51 (0.04)	(-0.58, -0.43)				
Week 12	Tezepelumab	380	348 (91.6)	-0.61 (0.04)	(-0.68, -0.54)	-0.12 (0.05)	(-0.22, -0.02)	0.020 *	
	Placebo	371	332 (89.5)	-0.50 (0.04)	(-0.57, -0.43)				
Week 13	Tezepelumab	380	344 (90.5)	-0.65 (0.04)	(-0.72, -0.58)	-0.15 (0.05)	(-0.25, -0.05)	0.003 *	
	Placebo	371	330 (88.9)	-0.50 (0.04)	(-0.57, -0.43)				
Week 14	Tezepelumab	380	342 (90.0)	-0.68 (0.04)	(-0.75, -0.61)	-0.15 (0.05)	(-0.25, -0.06)	0.002 *	
	Placebo	371	330 (88.9)	-0.52 (0.04)	(-0.59, -0.45)				
Week 15	Tezepelumab	380	338 (88.9)	-0.68 (0.04)	(-0.75, -0.61)	-0.14 (0.05)	(-0.24, -0.04)	0.005 *	
	Placebo	371	320 (86.3)	-0.53 (0.04)	(-0.60, -0.46)				
Week 16	Tezepelumab	380	342 (90.0)	-0.70 (0.04)	(-0.77, -0.63)	-0.20 (0.05)	(-0.30, -0.10)	<0.001 *	
	Placebo	371	318 (85.7)	-0.50 (0.04)	(-0.57, -0.43)				
Week 17	Tezepelumab	380	338 (88.9)	-0.70 (0.04)	(-0.77, -0.63)	-0.17 (0.05)	(-0.27, -0.07)	0.001 *	
	Placebo	371	314 (84.6)	-0.54 (0.04)	(-0.61, -0.47)				
Week 18	Tezepelumab	380	336 (88.4)	-0.69 (0.04)	(-0.76, -0.62)	-0.15 (0.05)	(-0.25, -0.05)	0.003 *	
	Placebo	371	309 (83.3)	-0.54 (0.04)	(-0.61, -0.47)				
Week 19	Tezepelumab	380	333 (87.6)	-0.70 (0.04)	(-0.77, -0.63)	-0.16 (0.05)	(-0.26, -0.06)	0.002 *	
	Placebo	371	317 (85.4)	-0.54 (0.04)	(-0.62, -0.47)				
Week 20	Tezepelumab	380	328 (86.3)	-0.69 (0.04)	(-0.76, -0.62)	-0.16 (0.05)	(-0.26, -0.05)	0.002 *	
	Placebo	371	309 (83.3)	-0.54 (0.04)	(-0.61, -0.47)				

Note: DITTl - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC\_ALMC0: Change from baseline in ASD weekly shortness of breath score - MMRM results  
 DITTl - adult

Change from baseline in ASD weekly shortness of breath score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Time	Treatment	N	n (%)						
Week 21	Tezepelumab	380	326 (85.8)	-0.71 (0.04)	(-0.78, -0.64)	-0.14 (0.05)	(-0.25, -0.04)	0.005	*
	Placebo	371	305 (82.2)	-0.56 (0.04)	(-0.64, -0.49)				
Week 22	Tezepelumab	380	325 (85.5)	-0.71 (0.04)	(-0.78, -0.64)	-0.12 (0.05)	(-0.22, -0.02)	0.018	*
	Placebo	371	299 (80.6)	-0.58 (0.04)	(-0.66, -0.51)				
Week 23	Tezepelumab	380	319 (83.9)	-0.72 (0.04)	(-0.79, -0.65)	-0.16 (0.05)	(-0.26, -0.06)	0.002	*
	Placebo	371	296 (79.8)	-0.55 (0.04)	(-0.63, -0.48)				
Week 24	Tezepelumab	380	327 (86.1)	-0.72 (0.04)	(-0.79, -0.64)	-0.14 (0.05)	(-0.24, -0.04)	0.006	*
	Placebo	371	297 (80.1)	-0.57 (0.04)	(-0.65, -0.50)				
Week 25	Tezepelumab	380	314 (82.6)	-0.70 (0.04)	(-0.78, -0.63)	-0.13 (0.05)	(-0.24, -0.03)	0.009	*
	Placebo	371	296 (79.8)	-0.57 (0.04)	(-0.64, -0.50)				
Week 26	Tezepelumab	380	319 (83.9)	-0.71 (0.04)	(-0.78, -0.64)	-0.16 (0.05)	(-0.26, -0.06)	0.002	*
	Placebo	371	289 (77.9)	-0.55 (0.04)	(-0.62, -0.48)				
Week 27	Tezepelumab	380	309 (81.3)	-0.72 (0.04)	(-0.79, -0.65)	-0.16 (0.05)	(-0.26, -0.05)	0.003	*
	Placebo	371	300 (80.9)	-0.56 (0.04)	(-0.63, -0.49)				
Week 28	Tezepelumab	380	317 (83.4)	-0.74 (0.04)	(-0.81, -0.67)	-0.17 (0.05)	(-0.27, -0.07)	0.001	*
	Placebo	371	300 (80.9)	-0.57 (0.04)	(-0.65, -0.50)				
Week 29	Tezepelumab	380	310 (81.6)	-0.74 (0.04)	(-0.81, -0.67)	-0.16 (0.05)	(-0.27, -0.06)	0.002	*
	Placebo	371	299 (80.6)	-0.57 (0.04)	(-0.65, -0.50)				
Week 30	Tezepelumab	380	314 (82.6)	-0.73 (0.04)	(-0.80, -0.66)	-0.17 (0.05)	(-0.27, -0.07)	0.001	*
	Placebo	371	295 (79.5)	-0.56 (0.04)	(-0.64, -0.49)				

Note: DITTl - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC\_ALMC0: Change from baseline in ASD weekly shortness of breath score - MMRM results  
 DITTl - adult

Change from baseline in ASD weekly shortness of breath score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 31	Tezepelumab	380	315 (82.9)	-0.74 (0.04)	(-0.81, -0.67)	-0.17 (0.05)	(-0.27, -0.07)	<0.001 *	
	Placebo	371	296 (79.8)	-0.57 (0.04)	(-0.64, -0.50)				
Week 32	Tezepelumab	380	316 (83.2)	-0.74 (0.04)	(-0.82, -0.67)	-0.18 (0.05)	(-0.28, -0.08)	<0.001 *	
	Placebo	371	297 (80.1)	-0.56 (0.04)	(-0.64, -0.49)				
Week 33	Tezepelumab	380	313 (82.4)	-0.76 (0.04)	(-0.83, -0.69)	-0.20 (0.05)	(-0.30, -0.09)	<0.001 *	
	Placebo	371	291 (78.4)	-0.56 (0.04)	(-0.64, -0.49)				
Week 34	Tezepelumab	380	311 (81.8)	-0.77 (0.04)	(-0.84, -0.70)	-0.20 (0.05)	(-0.31, -0.10)	<0.001 *	
	Placebo	371	293 (79.0)	-0.57 (0.04)	(-0.64, -0.49)				
Week 35	Tezepelumab	380	312 (82.1)	-0.77 (0.04)	(-0.84, -0.70)	-0.20 (0.05)	(-0.31, -0.10)	<0.001 *	
	Placebo	371	285 (76.8)	-0.57 (0.04)	(-0.64, -0.49)				
Week 36	Tezepelumab	380	309 (81.3)	-0.76 (0.04)	(-0.83, -0.69)	-0.19 (0.05)	(-0.29, -0.09)	<0.001 *	
	Placebo	371	288 (77.6)	-0.57 (0.04)	(-0.65, -0.50)				
Week 37	Tezepelumab	380	312 (82.1)	-0.76 (0.04)	(-0.84, -0.69)	-0.17 (0.05)	(-0.27, -0.06)	0.002 *	
	Placebo	371	287 (77.4)	-0.60 (0.04)	(-0.67, -0.53)				
Week 38	Tezepelumab	380	310 (81.6)	-0.74 (0.04)	(-0.81, -0.67)	-0.14 (0.05)	(-0.24, -0.04)	0.007 *	
	Placebo	371	287 (77.4)	-0.60 (0.04)	(-0.67, -0.53)				
Week 39	Tezepelumab	380	317 (83.4)	-0.74 (0.04)	(-0.81, -0.67)	-0.13 (0.05)	(-0.24, -0.03)	0.012 *	
	Placebo	371	281 (75.7)	-0.61 (0.04)	(-0.68, -0.53)				
Week 40	Tezepelumab	380	313 (82.4)	-0.75 (0.04)	(-0.82, -0.67)	-0.16 (0.05)	(-0.26, -0.05)	0.003 *	
	Placebo	371	287 (77.4)	-0.59 (0.04)	(-0.67, -0.52)				

Note: DITTl - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC\_ALMC0: Change from baseline in ASD weekly shortness of breath score - MMRM results  
DITTL - adult

Change from baseline in ASD weekly shortness of breath score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 41	Tezepelumab	380	316 (83.2)	-0.78 (0.04)	(-0.85, -0.71)	-0.18 (0.05)	(-0.28, -0.08)	<0.001 *	
	Placebo	371	288 (77.6)	-0.60 (0.04)	(-0.67, -0.52)				
Week 42	Tezepelumab	380	308 (81.1)	-0.77 (0.04)	(-0.85, -0.70)	-0.17 (0.05)	(-0.27, -0.07)	0.001 *	
	Placebo	371	288 (77.6)	-0.60 (0.04)	(-0.68, -0.53)				
Week 43	Tezepelumab	380	311 (81.8)	-0.77 (0.04)	(-0.85, -0.70)	-0.16 (0.05)	(-0.26, -0.05)	0.003 *	
	Placebo	371	285 (76.8)	-0.62 (0.04)	(-0.69, -0.54)				
Week 44	Tezepelumab	380	309 (81.3)	-0.78 (0.04)	(-0.85, -0.71)	-0.18 (0.05)	(-0.28, -0.07)	<0.001 *	
	Placebo	371	283 (76.3)	-0.60 (0.04)	(-0.68, -0.53)				
Week 45	Tezepelumab	380	312 (82.1)	-0.79 (0.04)	(-0.86, -0.72)	-0.19 (0.05)	(-0.29, -0.09)	<0.001 *	
	Placebo	371	285 (76.8)	-0.60 (0.04)	(-0.68, -0.53)				
Week 46	Tezepelumab	380	307 (80.8)	-0.80 (0.04)	(-0.87, -0.73)	-0.18 (0.05)	(-0.29, -0.08)	<0.001 *	
	Placebo	371	278 (74.9)	-0.62 (0.04)	(-0.69, -0.54)				
Week 47	Tezepelumab	380	296 (77.9)	-0.78 (0.04)	(-0.85, -0.70)	-0.15 (0.05)	(-0.25, -0.04)	0.005 *	
	Placebo	371	281 (75.7)	-0.63 (0.04)	(-0.70, -0.55)				
Week 48	Tezepelumab	380	318 (83.7)	-0.76 (0.04)	(-0.83, -0.69)	-0.13 (0.05)	(-0.23, -0.03)	0.014 *	
	Placebo	371	291 (78.4)	-0.63 (0.04)	(-0.70, -0.55)				
Week 49	Tezepelumab	380	308 (81.1)	-0.76 (0.04)	(-0.83, -0.69)	-0.13 (0.05)	(-0.24, -0.03)	0.013 *	
	Placebo	371	280 (75.5)	-0.63 (0.04)	(-0.70, -0.55)				
Week 50	Tezepelumab	380	306 (80.5)	-0.77 (0.04)	(-0.85, -0.70)	-0.14 (0.05)	(-0.25, -0.04)	0.008 *	
	Placebo	371	278 (74.9)	-0.63 (0.04)	(-0.71, -0.56)				

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WBC\_ALMC0: Change from baseline in ASD weekly shortness of breath score - MMRM results  
 DITTl - adult

Change from baseline in ASD weekly shortness of breath score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 51	Tezepelumab	380	300 (78.9)	-0.76 (0.04)	(-0.83, -0.69)	-0.15 (0.05)	(-0.26, -0.05)	0.004 *	
	Placebo	371	270 (72.8)	-0.61 (0.04)	(-0.68, -0.53)				
Week 52	Tezepelumab	380	268 (70.5)	-0.75 (0.04)	(-0.83, -0.68)	-0.15 (0.05)	(-0.26, -0.04)	0.006 *	
	Placebo	371	246 (66.3)	-0.61 (0.04)	(-0.68, -0.53)				

Note: DITTl - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WHC\_ALMH0: Course of ASD weekly cough score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly cough score	Baseline	Tezepelumab	380	380 (100.0)	1.41 (0.81)	0.0	1.00	1.36	2.00	4.0	
		Placebo	371	371 (100.0)	1.35 (0.83)	0.0	0.79	1.29	2.00	3.9	
	Week 1	Tezepelumab	380	372 (97.9)	1.20 (0.78)	0.0	0.64	1.14	1.73	3.8	
		Placebo	371	362 (97.6)	1.27 (0.81)	0.0	0.75	1.17	1.92	4.0	
	Week 2	Tezepelumab	380	370 (97.4)	1.08 (0.79)	0.0	0.43	1.00	1.64	3.9	
		Placebo	371	360 (97.0)	1.23 (0.81)	0.0	0.64	1.08	1.92	4.0	
	Week 3	Tezepelumab	380	365 (96.1)	1.02 (0.78)	0.0	0.29	1.00	1.50	3.9	
		Placebo	371	354 (95.4)	1.13 (0.79)	0.0	0.50	1.07	1.71	4.0	
	Week 4	Tezepelumab	380	363 (95.5)	0.99 (0.80)	0.0	0.21	1.00	1.43	4.0	
		Placebo	371	353 (95.1)	1.09 (0.77)	0.0	0.43	1.00	1.70	4.0	
	Week 5	Tezepelumab	380	363 (95.5)	0.91 (0.80)	0.0	0.14	0.92	1.36	4.0	
		Placebo	371	344 (92.7)	1.02 (0.79)	0.0	0.29	1.00	1.50	4.0	
	Week 6	Tezepelumab	380	357 (93.9)	0.88 (0.78)	0.0	0.14	0.88	1.36	3.9	
		Placebo	371	349 (94.1)	1.03 (0.82)	0.0	0.25	1.00	1.64	4.0	
	Week 7	Tezepelumab	380	354 (93.2)	0.87 (0.79)	0.0	0.08	0.92	1.33	4.0	
		Placebo	371	349 (94.1)	0.97 (0.81)	0.0	0.17	1.00	1.50	4.0	
	Week 8	Tezepelumab	380	355 (93.4)	0.83 (0.78)	0.0	0.00	0.79	1.30	3.9	
		Placebo	371	340 (91.6)	0.97 (0.81)	0.0	0.17	1.00	1.43	4.0	
	Week 9	Tezepelumab	380	360 (94.7)	0.81 (0.76)	0.0	0.00	0.77	1.17	3.1	
		Placebo	371	340 (91.6)	0.94 (0.81)	0.0	0.14	1.00	1.43	4.0	
	Week 10	Tezepelumab	380	358 (94.2)	0.81 (0.76)	0.0	0.00	0.92	1.17	3.0	
		Placebo	371	338 (91.1)	0.97 (0.80)	0.0	0.21	1.00	1.50	4.0	
	Week 11	Tezepelumab	380	347 (91.3)	0.83 (0.78)	0.0	0.00	0.86	1.33	3.0	
		Placebo	371	334 (90.0)	0.95 (0.79)	0.0	0.17	1.00	1.43	4.0	
	Week 12	Tezepelumab	380	348 (91.6)	0.83 (0.77)	0.0	0.00	0.96	1.21	3.1	
		Placebo	371	332 (89.5)	0.91 (0.79)	0.0	0.14	1.00	1.32	4.0	
	Week 13	Tezepelumab	380	344 (90.5)	0.80 (0.78)	0.0	0.00	0.79	1.21	3.5	
		Placebo	371	330 (88.9)	0.88 (0.78)	0.0	0.10	0.93	1.33	4.0	
	Week 14	Tezepelumab	380	342 (90.0)	0.76 (0.75)	0.0	0.00	0.75	1.08	3.1	
		Placebo	371	330 (88.9)	0.89 (0.80)	0.0	0.08	1.00	1.36	4.0	
	Week 15	Tezepelumab	380	338 (88.9)	0.77 (0.73)	0.0	0.00	0.79	1.14	3.0	
		Placebo	371	320 (86.3)	0.87 (0.80)	0.0	0.07	0.92	1.29	4.0	
	Week 16	Tezepelumab	380	342 (90.0)	0.75 (0.77)	0.0	0.00	0.68	1.07	3.1	
		Placebo	371	318 (85.7)	0.91 (0.82)	0.0	0.08	1.00	1.33	4.0	
Week 17	Tezepelumab	380	338 (88.9)	0.72 (0.75)	0.0	0.00	0.58	1.07	3.1		
	Placebo	371	314 (84.6)	0.88 (0.76)	0.0	0.10	1.00	1.29	4.0		

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WHC\_ALMH0: Course of ASD weekly cough score  
DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly cough score	Week 18	Tezepelumab	380	336 (88.4)	0.75 (0.76)	0.0	0.00	0.61	1.14	3.4	
		Placebo	371	309 (83.3)	0.88 (0.78)	0.0	0.10	0.92	1.29	4.0	
	Week 19	Tezepelumab	380	333 (87.6)	0.73 (0.75)	0.0	0.00	0.64	1.08	3.1	
		Placebo	371	317 (85.4)	0.89 (0.81)	0.0	0.07	1.00	1.33	4.0	
	Week 20	Tezepelumab	380	328 (86.3)	0.73 (0.77)	0.0	0.00	0.61	1.00	3.1	
		Placebo	371	309 (83.3)	0.90 (0.80)	0.0	0.10	1.00	1.43	4.0	
	Week 21	Tezepelumab	380	326 (85.8)	0.70 (0.75)	0.0	0.00	0.50	1.00	3.4	
		Placebo	371	305 (82.2)	0.86 (0.79)	0.0	0.07	0.93	1.20	4.0	
	Week 22	Tezepelumab	380	325 (85.5)	0.73 (0.75)	0.0	0.00	0.67	1.07	3.1	
		Placebo	371	299 (80.6)	0.88 (0.79)	0.0	0.07	1.00	1.29	4.0	
	Week 23	Tezepelumab	380	319 (83.9)	0.73 (0.75)	0.0	0.00	0.71	1.00	3.1	
		Placebo	371	296 (79.8)	0.87 (0.77)	0.0	0.10	1.00	1.27	4.0	
	Week 24	Tezepelumab	380	327 (86.1)	0.72 (0.75)	0.0	0.00	0.67	1.00	3.3	
		Placebo	371	297 (80.1)	0.86 (0.79)	0.0	0.07	1.00	1.21	4.0	
	Week 25	Tezepelumab	380	314 (82.6)	0.74 (0.73)	0.0	0.00	0.70	1.07	3.6	
		Placebo	371	296 (79.8)	0.86 (0.81)	0.0	0.07	0.93	1.23	4.0	
	Week 26	Tezepelumab	380	319 (83.9)	0.76 (0.75)	0.0	0.00	0.75	1.07	3.0	
		Placebo	371	289 (77.9)	0.88 (0.80)	0.0	0.08	1.00	1.29	4.0	
	Week 27	Tezepelumab	380	309 (81.3)	0.72 (0.75)	0.0	0.00	0.57	1.00	3.1	
		Placebo	371	300 (80.9)	0.88 (0.84)	0.0	0.00	1.00	1.30	4.0	
	Week 28	Tezepelumab	380	317 (83.4)	0.70 (0.76)	0.0	0.00	0.57	1.00	3.1	
		Placebo	371	300 (80.9)	0.87 (0.80)	0.0	0.04	1.00	1.29	4.0	
	Week 29	Tezepelumab	380	310 (81.6)	0.71 (0.77)	0.0	0.00	0.46	1.00	3.4	
		Placebo	371	299 (80.6)	0.87 (0.81)	0.0	0.07	0.90	1.30	4.0	
	Week 30	Tezepelumab	380	314 (82.6)	0.72 (0.75)	0.0	0.00	0.68	1.00	3.8	
		Placebo	371	295 (79.5)	0.86 (0.79)	0.0	0.07	1.00	1.25	4.0	
	Week 31	Tezepelumab	380	315 (82.9)	0.72 (0.76)	0.0	0.00	0.57	1.07	4.0	
		Placebo	371	296 (79.8)	0.84 (0.76)	0.0	0.07	0.89	1.14	4.0	
	Week 32	Tezepelumab	380	316 (83.2)	0.74 (0.76)	0.0	0.00	0.64	1.07	3.8	
		Placebo	371	297 (80.1)	0.85 (0.77)	0.0	0.07	0.93	1.14	4.0	
	Week 33	Tezepelumab	380	313 (82.4)	0.72 (0.76)	0.0	0.00	0.60	1.07	3.2	
		Placebo	371	291 (78.4)	0.87 (0.80)	0.0	0.07	0.93	1.29	4.0	
	Week 34	Tezepelumab	380	311 (81.8)	0.71 (0.77)	0.0	0.00	0.43	1.08	3.5	
		Placebo	371	293 (79.0)	0.85 (0.79)	0.0	0.07	0.92	1.21	4.0	
	Week 35	Tezepelumab	380	312 (82.1)	0.75 (0.80)	0.0	0.00	0.57	1.11	4.0	
		Placebo	371	285 (76.8)	0.84 (0.78)	0.0	0.07	1.00	1.14	4.0	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WHC\_ALMH0: Course of ASD weekly cough score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly cough score	Week 36	Tezepelumab	380	309 (81.3)	0.79 (0.82)	0.0	0.00	0.70	1.07	4.0	
		Placebo	371	288 (77.6)	0.85 (0.76)	0.0	0.08	1.00	1.21	4.0	
	Week 37	Tezepelumab	380	312 (82.1)	0.75 (0.81)	0.0	0.00	0.64	1.07	4.0	
		Placebo	371	287 (77.4)	0.84 (0.77)	0.0	0.07	0.93	1.14	4.0	
	Week 38	Tezepelumab	380	310 (81.6)	0.76 (0.80)	0.0	0.00	0.58	1.00	4.0	
		Placebo	371	287 (77.4)	0.79 (0.73)	0.0	0.07	0.90	1.10	4.0	
	Week 39	Tezepelumab	380	317 (83.4)	0.79 (0.83)	0.0	0.00	0.63	1.14	3.9	
		Placebo	371	281 (75.7)	0.82 (0.78)	0.0	0.07	0.88	1.14	4.0	
	Week 40	Tezepelumab	380	313 (82.4)	0.75 (0.80)	0.0	0.00	0.50	1.08	3.7	
		Placebo	371	287 (77.4)	0.85 (0.78)	0.0	0.08	0.88	1.14	4.0	
	Week 41	Tezepelumab	380	316 (83.2)	0.70 (0.79)	0.0	0.00	0.50	1.00	4.0	
		Placebo	371	288 (77.6)	0.85 (0.75)	0.0	0.07	1.00	1.23	4.0	
	Week 42	Tezepelumab	380	308 (81.1)	0.72 (0.80)	0.0	0.00	0.50	1.07	4.0	
		Placebo	371	288 (77.6)	0.89 (0.80)	0.0	0.08	1.00	1.21	4.0	
	Week 43	Tezepelumab	380	311 (81.8)	0.71 (0.80)	0.0	0.00	0.43	1.00	4.0	
		Placebo	371	285 (76.8)	0.84 (0.77)	0.0	0.07	1.00	1.20	4.0	
	Week 44	Tezepelumab	380	309 (81.3)	0.69 (0.79)	0.0	0.00	0.36	1.00	4.0	
		Placebo	371	283 (76.3)	0.85 (0.77)	0.0	0.08	1.00	1.21	4.0	
	Week 45	Tezepelumab	380	312 (82.1)	0.70 (0.78)	0.0	0.00	0.42	1.00	3.9	
		Placebo	371	285 (76.8)	0.84 (0.79)	0.0	0.08	0.88	1.14	4.0	
	Week 46	Tezepelumab	380	307 (80.8)	0.71 (0.79)	0.0	0.00	0.42	1.07	3.9	
		Placebo	371	278 (74.9)	0.79 (0.75)	0.0	0.00	0.92	1.07	4.0	
	Week 47	Tezepelumab	380	296 (77.9)	0.70 (0.79)	0.0	0.00	0.50	1.00	3.8	
		Placebo	371	281 (75.7)	0.79 (0.71)	0.0	0.10	1.00	1.00	4.0	
	Week 48	Tezepelumab	380	318 (83.7)	0.69 (0.78)	0.0	0.00	0.41	1.00	3.6	
		Placebo	371	291 (78.4)	0.83 (0.73)	0.0	0.07	1.00	1.10	4.0	
	Week 49	Tezepelumab	380	308 (81.1)	0.68 (0.78)	0.0	0.00	0.42	1.00	4.0	
		Placebo	371	280 (75.5)	0.83 (0.73)	0.0	0.07	1.00	1.07	4.0	
	Week 50	Tezepelumab	380	306 (80.5)	0.68 (0.77)	0.0	0.00	0.43	1.00	4.0	
		Placebo	371	278 (74.9)	0.83 (0.76)	0.0	0.00	1.00	1.14	4.0	
	Week 51	Tezepelumab	380	300 (78.9)	0.69 (0.77)	0.0	0.00	0.46	1.00	3.9	
		Placebo	371	270 (72.8)	0.81 (0.78)	0.0	0.00	1.00	1.08	4.0	
	Week 52	Tezepelumab	380	268 (70.5)	0.71 (0.80)	0.0	0.00	0.50	1.00	4.0	
		Placebo	371	246 (66.3)	0.82 (0.80)	0.0	0.00	0.92	1.08	4.0	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table NT1WHC\_ALMH0: Course of ASD weekly cough score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly cough score	Week 1	Tezepelumab	380	372 (97.9)	-0.19 (0.42)	-2.3	-0.40	-0.07	0.07	0.9	-0.25 [-0.40, -0.11]
		Placebo	371	362 (97.6)	-0.09 (0.41)	-1.9	-0.29	-0.03	0.08	1.5	
	Week 2	Tezepelumab	380	370 (97.4)	-0.32 (0.56)	-2.8	-0.64	-0.17	0.01	1.3	-0.33 [-0.48, -0.18]
		Placebo	371	360 (97.0)	-0.13 (0.61)	-3.0	-0.36	-0.07	0.11	2.4	
	Week 3	Tezepelumab	380	365 (96.1)	-0.37 (0.65)	-3.4	-0.75	-0.21	0.00	1.4	-0.21 [-0.36, -0.06]
		Placebo	371	354 (95.4)	-0.23 (0.67)	-3.1	-0.57	-0.14	0.07	2.8	
	Week 4	Tezepelumab	380	363 (95.5)	-0.40 (0.71)	-3.7	-0.79	-0.21	0.00	2.1	-0.19 [-0.34, -0.05]
		Placebo	371	353 (95.1)	-0.27 (0.65)	-2.9	-0.61	-0.14	0.07	1.4	
	Week 5	Tezepelumab	380	363 (95.5)	-0.48 (0.75)	-3.8	-0.96	-0.29	0.00	2.1	-0.20 [-0.35, -0.05]
		Placebo	371	344 (92.7)	-0.34 (0.64)	-2.9	-0.64	-0.25	0.00	1.7	
	Week 6	Tezepelumab	380	357 (93.9)	-0.51 (0.75)	-3.9	-1.00	-0.36	0.00	1.7	-0.24 [-0.38, -0.09]
		Placebo	371	349 (94.1)	-0.33 (0.72)	-3.1	-0.75	-0.21	0.07	1.8	
	Week 7	Tezepelumab	380	354 (93.2)	-0.53 (0.77)	-3.7	-1.00	-0.37	0.00	1.3	-0.19 [-0.33, -0.04]
		Placebo	371	349 (94.1)	-0.39 (0.72)	-3.2	-0.75	-0.21	0.00	1.5	
	Week 8	Tezepelumab	380	355 (93.4)	-0.56 (0.78)	-3.7	-1.00	-0.43	0.00	1.1	-0.25 [-0.40, -0.10]
		Placebo	371	340 (91.6)	-0.38 (0.71)	-3.1	-0.75	-0.21	0.00	1.7	
	Week 9	Tezepelumab	380	360 (94.7)	-0.59 (0.78)	-4.0	-1.00	-0.50	0.00	1.3	-0.24 [-0.38, -0.09]
		Placebo	371	340 (91.6)	-0.42 (0.70)	-3.1	-0.82	-0.29	0.00	2.0	
	Week 10	Tezepelumab	380	358 (94.2)	-0.57 (0.78)	-3.7	-1.00	-0.42	0.00	1.3	-0.23 [-0.38, -0.08]
		Placebo	371	338 (91.1)	-0.40 (0.73)	-3.1	-0.86	-0.30	0.00	1.6	
	Week 11	Tezepelumab	380	347 (91.3)	-0.56 (0.80)	-3.6	-1.00	-0.43	0.00	1.7	-0.21 [-0.36, -0.06]
		Placebo	371	334 (90.0)	-0.40 (0.71)	-3.1	-0.79	-0.29	0.00	1.7	
	Week 12	Tezepelumab	380	348 (91.6)	-0.56 (0.82)	-3.9	-1.00	-0.43	0.00	1.7	-0.16 [-0.31, -0.01]
		Placebo	371	332 (89.5)	-0.43 (0.72)	-3.1	-0.86	-0.36	0.00	2.1	
	Week 13	Tezepelumab	380	344 (90.5)	-0.56 (0.81)	-3.9	-1.08	-0.42	0.00	2.2	-0.12 [-0.27, 0.04]
		Placebo	371	330 (88.9)	-0.47 (0.73)	-3.1	-0.92	-0.35	0.00	2.0	
	Week 14	Tezepelumab	380	342 (90.0)	-0.63 (0.79)	-3.7	-1.07	-0.50	0.00	1.3	-0.21 [-0.36, -0.06]
		Placebo	371	330 (88.9)	-0.47 (0.72)	-3.1	-0.92	-0.34	0.00	1.1	
	Week 15	Tezepelumab	380	338 (88.9)	-0.59 (0.76)	-3.0	-1.07	-0.43	0.00	1.4	-0.17 [-0.32, -0.01]
		Placebo	371	320 (86.3)	-0.47 (0.71)	-3.1	-0.92	-0.41	0.00	1.5	
	Week 16	Tezepelumab	380	342 (90.0)	-0.63 (0.80)	-3.4	-1.07	-0.46	0.00	1.2	-0.22 [-0.37, -0.07]
		Placebo	371	318 (85.7)	-0.46 (0.73)	-3.1	-0.92	-0.33	0.00	1.4	
	Week 17	Tezepelumab	380	338 (88.9)	-0.65 (0.79)	-3.9	-1.08	-0.50	0.00	0.9	-0.24 [-0.40, -0.09]
		Placebo	371	314 (84.6)	-0.47 (0.71)	-3.1	-0.93	-0.36	0.00	1.7	
	Week 18	Tezepelumab	380	336 (88.4)	-0.63 (0.81)	-3.7	-1.11	-0.50	0.00	2.0	-0.20 [-0.35, -0.04]
		Placebo	371	309 (83.3)	-0.48 (0.75)	-3.1	-0.93	-0.42	0.00	2.0	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WHC\_ALMH0: Course of ASD weekly cough score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly cough score	Week 19	Tezepelumab	380	333 (87.6)	-0.65 (0.84)	-3.8	-1.14	-0.57	0.00	1.7	-0.23 [-0.39, -0.08]
		Placebo	371	317 (85.4)	-0.46 (0.79)	-3.1	-0.93	-0.36	0.00	2.1	
	Week 20	Tezepelumab	380	328 (86.3)	-0.65 (0.83)	-3.8	-1.14	-0.50	-0.01	1.7	-0.23 [-0.38, -0.07]
		Placebo	371	309 (83.3)	-0.46 (0.80)	-3.1	-0.93	-0.36	0.00	2.0	
	Week 21	Tezepelumab	380	326 (85.8)	-0.66 (0.81)	-3.9	-1.08	-0.59	-0.07	2.4	-0.23 [-0.38, -0.07]
		Placebo	371	305 (82.2)	-0.48 (0.76)	-3.0	-0.92	-0.36	0.00	1.8	
	Week 22	Tezepelumab	380	325 (85.5)	-0.63 (0.82)	-3.4	-1.09	-0.50	0.00	1.6	-0.21 [-0.37, -0.05]
		Placebo	371	299 (80.6)	-0.46 (0.74)	-3.1	-0.92	-0.36	0.00	1.2	
	Week 23	Tezepelumab	380	319 (83.9)	-0.64 (0.81)	-3.2	-1.14	-0.57	-0.07	1.4	-0.19 [-0.35, -0.03]
		Placebo	371	296 (79.8)	-0.49 (0.74)	-3.4	-0.91	-0.36	0.00	1.3	
	Week 24	Tezepelumab	380	327 (86.1)	-0.65 (0.82)	-3.9	-1.14	-0.57	-0.07	1.4	-0.21 [-0.37, -0.06]
		Placebo	371	297 (80.1)	-0.48 (0.75)	-3.1	-0.92	-0.43	0.00	1.7	
	Week 25	Tezepelumab	380	314 (82.6)	-0.65 (0.81)	-3.7	-1.14	-0.57	-0.07	1.5	-0.19 [-0.35, -0.03]
		Placebo	371	296 (79.8)	-0.50 (0.78)	-3.9	-0.92	-0.40	0.00	1.6	
	Week 26	Tezepelumab	380	319 (83.9)	-0.62 (0.84)	-3.2	-1.20	-0.54	0.00	2.3	-0.18 [-0.34, -0.02]
		Placebo	371	289 (77.9)	-0.47 (0.78)	-3.1	-0.93	-0.36	0.00	1.9	
	Week 27	Tezepelumab	380	309 (81.3)	-0.65 (0.86)	-3.6	-1.17	-0.50	0.00	1.9	-0.24 [-0.40, -0.09]
		Placebo	371	300 (80.9)	-0.45 (0.80)	-3.1	-0.93	-0.36	0.00	2.0	
	Week 28	Tezepelumab	380	317 (83.4)	-0.66 (0.84)	-3.9	-1.14	-0.57	0.00	1.4	-0.25 [-0.40, -0.09]
		Placebo	371	300 (80.9)	-0.47 (0.75)	-3.1	-0.92	-0.36	0.00	1.8	
	Week 29	Tezepelumab	380	310 (81.6)	-0.68 (0.85)	-3.8	-1.21	-0.64	0.00	1.8	-0.25 [-0.41, -0.09]
		Placebo	371	299 (80.6)	-0.47 (0.78)	-3.1	-0.93	-0.36	0.00	1.4	
	Week 30	Tezepelumab	380	314 (82.6)	-0.65 (0.85)	-3.9	-1.14	-0.57	0.00	1.8	-0.19 [-0.35, -0.03]
		Placebo	371	295 (79.5)	-0.50 (0.76)	-3.1	-1.00	-0.38	0.00	1.4	
	Week 31	Tezepelumab	380	315 (82.9)	-0.67 (0.85)	-4.0	-1.18	-0.64	0.00	1.6	-0.21 [-0.37, -0.06]
		Placebo	371	296 (79.8)	-0.50 (0.73)	-3.0	-0.96	-0.42	0.00	2.2	
	Week 32	Tezepelumab	380	316 (83.2)	-0.63 (0.84)	-3.9	-1.12	-0.54	0.00	2.2	-0.15 [-0.31, 0.01]
		Placebo	371	297 (80.1)	-0.50 (0.81)	-3.5	-1.00	-0.37	0.00	2.4	
	Week 33	Tezepelumab	380	313 (82.4)	-0.65 (0.85)	-4.0	-1.14	-0.60	0.00	2.1	-0.20 [-0.36, -0.04]
		Placebo	371	291 (78.4)	-0.48 (0.80)	-3.7	-0.93	-0.36	0.00	2.5	
	Week 34	Tezepelumab	380	311 (81.8)	-0.66 (0.85)	-4.0	-1.14	-0.63	-0.01	2.0	-0.21 [-0.37, -0.05]
		Placebo	371	293 (79.0)	-0.50 (0.78)	-3.1	-1.00	-0.43	0.00	2.2	
	Week 35	Tezepelumab	380	312 (82.1)	-0.62 (0.86)	-3.9	-1.12	-0.55	0.00	2.1	-0.14 [-0.30, 0.02]
		Placebo	371	285 (76.8)	-0.51 (0.77)	-3.1	-1.00	-0.42	0.00	2.1	
	Week 36	Tezepelumab	380	309 (81.3)	-0.59 (0.89)	-3.8	-1.04	-0.57	0.00	2.1	-0.10 [-0.26, 0.06]
		Placebo	371	288 (77.6)	-0.51 (0.77)	-3.2	-0.99	-0.40	0.00	1.6	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WHC\_ALMH0: Course of ASD weekly cough score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly cough score	Week 37	Tezepelumab	380	312 (82.1)	-0.61 (0.88)	-4.0	-1.14	-0.51	0.00	2.1	-0.16 [-0.32, 0.00]
		Placebo	371	287 (77.4)	-0.48 (0.74)	-3.1	-0.93	-0.36	0.00	1.3	
	Week 38	Tezepelumab	380	310 (81.6)	-0.63 (0.87)	-4.0	-1.14	-0.57	0.00	2.1	-0.12 [-0.28, 0.04]
		Placebo	371	287 (77.4)	-0.54 (0.71)	-3.1	-0.98	-0.43	0.00	1.2	
	Week 39	Tezepelumab	380	317 (83.4)	-0.60 (0.89)	-3.9	-1.08	-0.50	0.00	2.0	-0.10 [-0.26, 0.06]
		Placebo	371	281 (75.7)	-0.51 (0.76)	-3.9	-1.00	-0.40	0.00	1.7	
	Week 40	Tezepelumab	380	313 (82.4)	-0.64 (0.87)	-3.9	-1.14	-0.54	-0.07	2.0	-0.19 [-0.35, -0.03]
		Placebo	371	287 (77.4)	-0.48 (0.75)	-3.7	-1.00	-0.36	0.00	1.9	
	Week 41	Tezepelumab	380	316 (83.2)	-0.68 (0.88)	-3.9	-1.25	-0.58	-0.07	2.1	-0.21 [-0.37, -0.05]
		Placebo	371	288 (77.6)	-0.51 (0.72)	-3.4	-1.00	-0.43	0.00	1.6	
	Week 42	Tezepelumab	380	308 (81.1)	-0.67 (0.86)	-3.6	-1.21	-0.57	-0.07	2.1	-0.27 [-0.43, -0.11]
		Placebo	371	288 (77.6)	-0.45 (0.77)	-3.8	-0.86	-0.36	0.00	1.3	
	Week 43	Tezepelumab	380	311 (81.8)	-0.68 (0.86)	-3.8	-1.21	-0.57	-0.04	2.1	-0.21 [-0.38, -0.05]
		Placebo	371	285 (76.8)	-0.50 (0.75)	-3.1	-1.00	-0.42	0.00	1.9	
	Week 44	Tezepelumab	380	309 (81.3)	-0.70 (0.84)	-3.9	-1.28	-0.64	-0.07	2.1	-0.26 [-0.42, -0.10]
		Placebo	371	283 (76.3)	-0.49 (0.76)	-3.4	-1.00	-0.36	0.00	2.0	
	Week 45	Tezepelumab	380	312 (82.1)	-0.69 (0.82)	-4.0	-1.14	-0.64	-0.07	2.0	-0.21 [-0.37, -0.05]
		Placebo	371	285 (76.8)	-0.52 (0.78)	-3.5	-1.00	-0.42	0.00	1.9	
	Week 46	Tezepelumab	380	307 (80.8)	-0.68 (0.85)	-4.0	-1.20	-0.61	-0.07	2.1	-0.20 [-0.36, -0.03]
		Placebo	371	278 (74.9)	-0.53 (0.76)	-3.1	-1.00	-0.43	0.00	1.8	
	Week 47	Tezepelumab	380	296 (77.9)	-0.68 (0.84)	-4.0	-1.21	-0.67	-0.07	2.0	-0.20 [-0.37, -0.04]
		Placebo	371	281 (75.7)	-0.52 (0.73)	-3.1	-1.00	-0.43	0.00	1.7	
	Week 48	Tezepelumab	380	318 (83.7)	-0.67 (0.86)	-4.0	-1.21	-0.64	0.00	2.0	-0.18 [-0.34, -0.02]
		Placebo	371	291 (78.4)	-0.53 (0.73)	-3.1	-1.00	-0.42	0.00	1.6	
	Week 49	Tezepelumab	380	308 (81.1)	-0.69 (0.85)	-3.9	-1.21	-0.64	-0.07	2.1	-0.21 [-0.37, -0.04]
		Placebo	371	280 (75.5)	-0.53 (0.73)	-3.1	-1.00	-0.41	0.00	1.3	
	Week 50	Tezepelumab	380	306 (80.5)	-0.70 (0.85)	-3.9	-1.21	-0.64	-0.07	2.1	-0.22 [-0.38, -0.05]
		Placebo	371	278 (74.9)	-0.53 (0.76)	-3.1	-1.00	-0.39	0.00	1.5	
	Week 51	Tezepelumab	380	300 (78.9)	-0.68 (0.87)	-4.0	-1.18	-0.64	-0.07	2.1	-0.17 [-0.33, -0.00]
		Placebo	371	270 (72.8)	-0.54 (0.79)	-3.7	-1.00	-0.43	0.00	1.6	
	Week 52	Tezepelumab	380	268 (70.5)	-0.67 (0.90)	-4.0	-1.18	-0.64	0.00	2.1	-0.17 [-0.34, 0.01]
		Placebo	371	246 (66.3)	-0.53 (0.78)	-3.7	-1.00	-0.46	0.00	1.6	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WHC\_ALMC0: Change from baseline in ASD weekly cough score - MMRM results  
 DITTL - adult

Change from baseline in ASD weekly cough score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 1	Tezepelumab	380	372 (97.9)	-0.18 (0.03)	(-0.25, -0.11)	-0.09 (0.05)	(-0.18, 0.01)	0.075	
	Placebo	371	362 (97.6)	-0.09 (0.03)	(-0.16, -0.03)				
Week 2	Tezepelumab	380	370 (97.4)	-0.31 (0.03)	(-0.38, -0.24)	-0.17 (0.05)	(-0.27, -0.08)	<0.001 *	
	Placebo	371	360 (97.0)	-0.14 (0.03)	(-0.21, -0.07)				
Week 3	Tezepelumab	380	365 (96.1)	-0.37 (0.03)	(-0.43, -0.30)	-0.14 (0.05)	(-0.23, -0.04)	0.005 *	
	Placebo	371	354 (95.4)	-0.23 (0.03)	(-0.30, -0.16)				
Week 4	Tezepelumab	380	363 (95.5)	-0.40 (0.03)	(-0.47, -0.33)	-0.12 (0.05)	(-0.22, -0.03)	0.013 *	
	Placebo	371	353 (95.1)	-0.28 (0.03)	(-0.35, -0.21)				
Week 5	Tezepelumab	380	363 (95.5)	-0.47 (0.03)	(-0.54, -0.40)	-0.13 (0.05)	(-0.23, -0.04)	0.007 *	
	Placebo	371	344 (92.7)	-0.34 (0.03)	(-0.41, -0.27)				
Week 6	Tezepelumab	380	357 (93.9)	-0.51 (0.03)	(-0.57, -0.44)	-0.17 (0.05)	(-0.26, -0.07)	<0.001 *	
	Placebo	371	349 (94.1)	-0.34 (0.03)	(-0.41, -0.27)				
Week 7	Tezepelumab	380	354 (93.2)	-0.52 (0.03)	(-0.59, -0.45)	-0.13 (0.05)	(-0.23, -0.04)	0.006 *	
	Placebo	371	349 (94.1)	-0.39 (0.03)	(-0.45, -0.32)				
Week 8	Tezepelumab	380	355 (93.4)	-0.55 (0.03)	(-0.62, -0.48)	-0.17 (0.05)	(-0.27, -0.08)	<0.001 *	
	Placebo	371	340 (91.6)	-0.38 (0.03)	(-0.44, -0.31)				
Week 9	Tezepelumab	380	360 (94.7)	-0.58 (0.03)	(-0.65, -0.51)	-0.18 (0.05)	(-0.27, -0.08)	<0.001 *	
	Placebo	371	340 (91.6)	-0.40 (0.03)	(-0.47, -0.34)				
Week 10	Tezepelumab	380	358 (94.2)	-0.58 (0.03)	(-0.65, -0.51)	-0.19 (0.05)	(-0.28, -0.09)	<0.001 *	
	Placebo	371	338 (91.1)	-0.39 (0.03)	(-0.46, -0.32)				

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WHC\_ALMC0: Change from baseline in ASD weekly cough score - MMRM results  
 DITTL - adult

Change from baseline in ASD weekly cough score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 11	Tezepelumab	380	347 (91.3)	-0.56 (0.03)	(-0.63, -0.49)	-0.16 (0.05)	(-0.26, -0.07)	<0.001 *	
	Placebo	371	334 (90.0)	-0.39 (0.04)	(-0.46, -0.33)				
Week 12	Tezepelumab	380	348 (91.6)	-0.55 (0.03)	(-0.62, -0.49)	-0.13 (0.05)	(-0.23, -0.04)	0.007 *	
	Placebo	371	332 (89.5)	-0.42 (0.04)	(-0.49, -0.35)				
Week 13	Tezepelumab	380	344 (90.5)	-0.57 (0.03)	(-0.64, -0.50)	-0.13 (0.05)	(-0.23, -0.03)	0.008 *	
	Placebo	371	330 (88.9)	-0.44 (0.04)	(-0.51, -0.37)				
Week 14	Tezepelumab	380	342 (90.0)	-0.61 (0.03)	(-0.68, -0.54)	-0.15 (0.05)	(-0.25, -0.06)	0.002 *	
	Placebo	371	330 (88.9)	-0.46 (0.04)	(-0.53, -0.39)				
Week 15	Tezepelumab	380	338 (88.9)	-0.61 (0.03)	(-0.68, -0.54)	-0.14 (0.05)	(-0.24, -0.04)	0.005 *	
	Placebo	371	320 (86.3)	-0.47 (0.04)	(-0.54, -0.40)				
Week 16	Tezepelumab	380	342 (90.0)	-0.64 (0.03)	(-0.70, -0.57)	-0.20 (0.05)	(-0.30, -0.10)	<0.001 *	
	Placebo	371	318 (85.7)	-0.44 (0.04)	(-0.51, -0.37)				
Week 17	Tezepelumab	380	338 (88.9)	-0.65 (0.03)	(-0.71, -0.58)	-0.18 (0.05)	(-0.28, -0.08)	<0.001 *	
	Placebo	371	314 (84.6)	-0.46 (0.04)	(-0.53, -0.39)				
Week 18	Tezepelumab	380	336 (88.4)	-0.62 (0.03)	(-0.69, -0.55)	-0.16 (0.05)	(-0.26, -0.06)	0.001 *	
	Placebo	371	309 (83.3)	-0.46 (0.04)	(-0.53, -0.39)				
Week 19	Tezepelumab	380	333 (87.6)	-0.64 (0.03)	(-0.71, -0.58)	-0.19 (0.05)	(-0.29, -0.09)	<0.001 *	
	Placebo	371	317 (85.4)	-0.46 (0.04)	(-0.53, -0.39)				
Week 20	Tezepelumab	380	328 (86.3)	-0.65 (0.04)	(-0.72, -0.58)	-0.20 (0.05)	(-0.30, -0.10)	<0.001 *	
	Placebo	371	309 (83.3)	-0.45 (0.04)	(-0.52, -0.38)				

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WHC\_ALMC0: Change from baseline in ASD weekly cough score - MMRM results  
 DITTL - adult

Change from baseline in ASD weekly cough score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Time	Treatment	N	n (%)						
Week 21	Tezepelumab	380	326 (85.8)	-0.66 (0.04)	(-0.72, -0.59)	-0.20 (0.05)	(-0.29, -0.10)	<0.001	*
	Placebo	371	305 (82.2)	-0.46 (0.04)	(-0.53, -0.39)				
Week 22	Tezepelumab	380	325 (85.5)	-0.65 (0.04)	(-0.72, -0.58)	-0.19 (0.05)	(-0.29, -0.09)	<0.001	*
	Placebo	371	299 (80.6)	-0.46 (0.04)	(-0.53, -0.39)				
Week 23	Tezepelumab	380	319 (83.9)	-0.66 (0.04)	(-0.73, -0.59)	-0.20 (0.05)	(-0.30, -0.10)	<0.001	*
	Placebo	371	296 (79.8)	-0.46 (0.04)	(-0.53, -0.39)				
Week 24	Tezepelumab	380	327 (86.1)	-0.65 (0.04)	(-0.72, -0.58)	-0.19 (0.05)	(-0.29, -0.09)	<0.001	*
	Placebo	371	297 (80.1)	-0.46 (0.04)	(-0.53, -0.39)				
Week 25	Tezepelumab	380	314 (82.6)	-0.65 (0.04)	(-0.72, -0.58)	-0.18 (0.05)	(-0.28, -0.08)	<0.001	*
	Placebo	371	296 (79.8)	-0.47 (0.04)	(-0.54, -0.40)				
Week 26	Tezepelumab	380	319 (83.9)	-0.63 (0.04)	(-0.70, -0.56)	-0.18 (0.05)	(-0.28, -0.08)	<0.001	*
	Placebo	371	289 (77.9)	-0.45 (0.04)	(-0.52, -0.38)				
Week 27	Tezepelumab	380	309 (81.3)	-0.66 (0.04)	(-0.73, -0.59)	-0.21 (0.05)	(-0.31, -0.11)	<0.001	*
	Placebo	371	300 (80.9)	-0.45 (0.04)	(-0.52, -0.38)				
Week 28	Tezepelumab	380	317 (83.4)	-0.67 (0.04)	(-0.74, -0.60)	-0.20 (0.05)	(-0.30, -0.10)	<0.001	*
	Placebo	371	300 (80.9)	-0.47 (0.04)	(-0.54, -0.40)				
Week 29	Tezepelumab	380	310 (81.6)	-0.66 (0.04)	(-0.73, -0.59)	-0.20 (0.05)	(-0.30, -0.10)	<0.001	*
	Placebo	371	299 (80.6)	-0.47 (0.04)	(-0.54, -0.40)				
Week 30	Tezepelumab	380	314 (82.6)	-0.65 (0.04)	(-0.71, -0.58)	-0.17 (0.05)	(-0.27, -0.07)	0.001	*
	Placebo	371	295 (79.5)	-0.48 (0.04)	(-0.55, -0.41)				

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WHC\_ALMC0: Change from baseline in ASD weekly cough score - MMRM results  
 DITTL - adult

Change from baseline in ASD weekly cough score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 31	Tezepelumab	380	315 (82.9)	-0.64 (0.04)	(-0.71, -0.57)	-0.14 (0.05)	(-0.24, -0.04)	0.005 *	
	Placebo	371	296 (79.8)	-0.50 (0.04)	(-0.57, -0.43)				
Week 32	Tezepelumab	380	316 (83.2)	-0.64 (0.04)	(-0.71, -0.57)	-0.15 (0.05)	(-0.25, -0.05)	0.003 *	
	Placebo	371	297 (80.1)	-0.49 (0.04)	(-0.56, -0.41)				
Week 33	Tezepelumab	380	313 (82.4)	-0.65 (0.04)	(-0.72, -0.58)	-0.16 (0.05)	(-0.26, -0.06)	0.002 *	
	Placebo	371	291 (78.4)	-0.49 (0.04)	(-0.57, -0.42)				
Week 34	Tezepelumab	380	311 (81.8)	-0.66 (0.04)	(-0.73, -0.59)	-0.17 (0.05)	(-0.27, -0.07)	<0.001 *	
	Placebo	371	293 (79.0)	-0.49 (0.04)	(-0.56, -0.42)				
Week 35	Tezepelumab	380	312 (82.1)	-0.63 (0.04)	(-0.70, -0.56)	-0.14 (0.05)	(-0.24, -0.04)	0.006 *	
	Placebo	371	285 (76.8)	-0.49 (0.04)	(-0.56, -0.42)				
Week 36	Tezepelumab	380	309 (81.3)	-0.60 (0.04)	(-0.67, -0.53)	-0.12 (0.05)	(-0.22, -0.02)	0.018 *	
	Placebo	371	288 (77.6)	-0.48 (0.04)	(-0.55, -0.41)				
Week 37	Tezepelumab	380	312 (82.1)	-0.62 (0.04)	(-0.69, -0.55)	-0.13 (0.05)	(-0.23, -0.03)	0.010 *	
	Placebo	371	287 (77.4)	-0.49 (0.04)	(-0.56, -0.41)				
Week 38	Tezepelumab	380	310 (81.6)	-0.62 (0.04)	(-0.69, -0.55)	-0.10 (0.05)	(-0.21, -0.00)	0.042 *	
	Placebo	371	287 (77.4)	-0.51 (0.04)	(-0.59, -0.44)				
Week 39	Tezepelumab	380	317 (83.4)	-0.60 (0.04)	(-0.67, -0.53)	-0.08 (0.05)	(-0.18, 0.02)	0.109	
	Placebo	371	281 (75.7)	-0.52 (0.04)	(-0.59, -0.44)				
Week 40	Tezepelumab	380	313 (82.4)	-0.64 (0.04)	(-0.71, -0.57)	-0.16 (0.05)	(-0.26, -0.05)	0.003 *	
	Placebo	371	287 (77.4)	-0.49 (0.04)	(-0.56, -0.41)				

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WHC\_ALMC0: Change from baseline in ASD weekly cough score - MMRM results  
 DITTL - adult

Change from baseline in ASD weekly cough score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 41	Tezepelumab	380	316 (83.2)	-0.67 (0.04)	(-0.74, -0.60)	-0.18 (0.05)	(-0.28, -0.08)	<0.001 *	
	Placebo	371	288 (77.6)	-0.50 (0.04)	(-0.57, -0.42)				
Week 42	Tezepelumab	380	308 (81.1)	-0.67 (0.04)	(-0.74, -0.60)	-0.21 (0.05)	(-0.31, -0.11)	<0.001 *	
	Placebo	371	288 (77.6)	-0.46 (0.04)	(-0.53, -0.38)				
Week 43	Tezepelumab	380	311 (81.8)	-0.67 (0.04)	(-0.74, -0.60)	-0.17 (0.05)	(-0.27, -0.07)	<0.001 *	
	Placebo	371	285 (76.8)	-0.50 (0.04)	(-0.57, -0.43)				
Week 44	Tezepelumab	380	309 (81.3)	-0.69 (0.04)	(-0.76, -0.62)	-0.20 (0.05)	(-0.30, -0.10)	<0.001 *	
	Placebo	371	283 (76.3)	-0.49 (0.04)	(-0.57, -0.42)				
Week 45	Tezepelumab	380	312 (82.1)	-0.69 (0.04)	(-0.76, -0.62)	-0.18 (0.05)	(-0.28, -0.08)	<0.001 *	
	Placebo	371	285 (76.8)	-0.50 (0.04)	(-0.58, -0.43)				
Week 46	Tezepelumab	380	307 (80.8)	-0.69 (0.04)	(-0.76, -0.62)	-0.16 (0.05)	(-0.26, -0.06)	0.002 *	
	Placebo	371	278 (74.9)	-0.53 (0.04)	(-0.60, -0.46)				
Week 47	Tezepelumab	380	296 (77.9)	-0.70 (0.04)	(-0.77, -0.63)	-0.18 (0.05)	(-0.28, -0.08)	<0.001 *	
	Placebo	371	281 (75.7)	-0.52 (0.04)	(-0.59, -0.45)				
Week 48	Tezepelumab	380	318 (83.7)	-0.68 (0.04)	(-0.75, -0.61)	-0.17 (0.05)	(-0.27, -0.07)	<0.001 *	
	Placebo	371	291 (78.4)	-0.51 (0.04)	(-0.58, -0.44)				
Week 49	Tezepelumab	380	308 (81.1)	-0.70 (0.04)	(-0.77, -0.63)	-0.17 (0.05)	(-0.28, -0.07)	<0.001 *	
	Placebo	371	280 (75.5)	-0.52 (0.04)	(-0.60, -0.45)				
Week 50	Tezepelumab	380	306 (80.5)	-0.69 (0.04)	(-0.77, -0.62)	-0.17 (0.05)	(-0.27, -0.06)	0.001 *	
	Placebo	371	278 (74.9)	-0.53 (0.04)	(-0.60, -0.45)				

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table NT1WHC\_ALMC0: Change from baseline in ASD weekly cough score - MMRM results  
 DITTl - adult

Change from baseline in ASD weekly cough score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 51	Tezepelumab	380	300 (78.9)	-0.69 (0.04)	(-0.76, -0.62)	-0.16 (0.05)	(-0.26, -0.05)	0.003 *
	Placebo	371	270 (72.8)	-0.53 (0.04)	(-0.61, -0.46)			
Week 52	Tezepelumab	380	268 (70.5)	-0.68 (0.04)	(-0.75, -0.60)	-0.15 (0.05)	(-0.26, -0.05)	0.005 *
	Placebo	371	246 (66.3)	-0.53 (0.04)	(-0.60, -0.45)			

Note: DITTl - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WEC\_ALMH0: Course of ASD weekly chest tightness score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly chest tightness score	Baseline	Tezepelumab	380	380 (100.0)	1.44 (0.85)	0.0	0.93	1.36	2.00	4.0	
		Placebo	371	371 (100.0)	1.38 (0.83)	0.0	0.79	1.33	2.00	3.8	
	Week 1	Tezepelumab	380	372 (97.9)	1.25 (0.79)	0.0	0.71	1.14	1.86	3.9	
		Placebo	371	362 (97.6)	1.29 (0.82)	0.0	0.79	1.21	1.93	3.9	
	Week 2	Tezepelumab	380	370 (97.4)	1.17 (0.79)	0.0	0.60	1.07	1.71	3.9	
		Placebo	371	360 (97.0)	1.24 (0.79)	0.0	0.75	1.14	1.88	3.5	
	Week 3	Tezepelumab	380	365 (96.1)	1.11 (0.79)	0.0	0.50	1.00	1.64	3.5	
		Placebo	371	354 (95.4)	1.15 (0.79)	0.0	0.57	1.07	1.71	3.8	
	Week 4	Tezepelumab	380	363 (95.5)	1.08 (0.81)	0.0	0.36	1.00	1.70	3.5	
		Placebo	371	353 (95.1)	1.13 (0.78)	0.0	0.50	1.07	1.79	3.6	
	Week 5	Tezepelumab	380	363 (95.5)	1.00 (0.79)	0.0	0.29	1.00	1.50	3.7	
		Placebo	371	344 (92.7)	1.06 (0.77)	0.0	0.39	1.00	1.63	3.4	
	Week 6	Tezepelumab	380	357 (93.9)	0.97 (0.81)	0.0	0.14	1.00	1.43	4.0	
		Placebo	371	349 (94.1)	1.06 (0.81)	0.0	0.40	1.00	1.64	3.9	
	Week 7	Tezepelumab	380	354 (93.2)	0.96 (0.82)	0.0	0.14	1.00	1.43	4.0	
		Placebo	371	349 (94.1)	1.04 (0.82)	0.0	0.29	1.00	1.63	3.9	
	Week 8	Tezepelumab	380	355 (93.4)	0.94 (0.79)	0.0	0.10	1.00	1.50	4.0	
		Placebo	371	340 (91.6)	0.99 (0.80)	0.0	0.20	1.00	1.57	3.8	
	Week 9	Tezepelumab	380	360 (94.7)	0.88 (0.78)	0.0	0.07	1.00	1.29	4.0	
		Placebo	371	340 (91.6)	0.96 (0.78)	0.0	0.21	1.00	1.43	4.0	
	Week 10	Tezepelumab	380	358 (94.2)	0.89 (0.80)	0.0	0.08	0.93	1.36	4.0	
		Placebo	371	338 (91.1)	0.97 (0.79)	0.0	0.14	1.00	1.50	3.6	
	Week 11	Tezepelumab	380	347 (91.3)	0.89 (0.82)	0.0	0.07	1.00	1.43	4.0	
		Placebo	371	334 (90.0)	0.96 (0.80)	0.0	0.10	1.00	1.50	3.3	
	Week 12	Tezepelumab	380	348 (91.6)	0.89 (0.82)	0.0	0.00	0.93	1.38	4.0	
		Placebo	371	332 (89.5)	0.94 (0.78)	0.0	0.10	1.00	1.37	3.7	
	Week 13	Tezepelumab	380	344 (90.5)	0.86 (0.81)	0.0	0.00	0.92	1.29	3.4	
		Placebo	371	330 (88.9)	0.93 (0.76)	0.0	0.14	1.00	1.29	3.3	
	Week 14	Tezepelumab	380	342 (90.0)	0.82 (0.78)	0.0	0.00	0.85	1.21	3.3	
		Placebo	371	330 (88.9)	0.93 (0.77)	0.0	0.13	1.00	1.36	3.5	
	Week 15	Tezepelumab	380	338 (88.9)	0.82 (0.79)	0.0	0.00	0.86	1.21	3.4	
		Placebo	371	320 (86.3)	0.94 (0.81)	0.0	0.08	1.00	1.50	4.0	
Week 16	Tezepelumab	380	342 (90.0)	0.81 (0.79)	0.0	0.00	0.79	1.20	3.5		
	Placebo	371	318 (85.7)	0.94 (0.81)	0.0	0.10	1.00	1.50	3.9		
Week 17	Tezepelumab	380	338 (88.9)	0.78 (0.79)	0.0	0.00	0.81	1.14	3.2		
	Placebo	371	314 (84.6)	0.91 (0.78)	0.0	0.10	1.00	1.50	3.6		

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WEC\_ALMH0: Course of ASD weekly chest tightness score  
 DITTl - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly chest tightness score	Week 18	Tezepelumab	380	336 (88.4)	0.81 (0.78)	0.0	0.00	0.86	1.18	3.1	
		Placebo	371	309 (83.3)	0.91 (0.80)	0.0	0.07	1.00	1.50	3.7	
	Week 19	Tezepelumab	380	333 (87.6)	0.79 (0.79)	0.0	0.00	0.86	1.13	4.0	
		Placebo	371	317 (85.4)	0.92 (0.82)	0.0	0.07	1.00	1.50	4.0	
	Week 20	Tezepelumab	380	328 (86.3)	0.81 (0.79)	0.0	0.00	0.85	1.25	3.1	
		Placebo	371	309 (83.3)	0.93 (0.82)	0.0	0.07	1.00	1.57	3.7	
	Week 21	Tezepelumab	380	326 (85.8)	0.80 (0.80)	0.0	0.00	0.86	1.21	3.1	
		Placebo	371	305 (82.2)	0.88 (0.84)	0.0	0.00	0.93	1.33	4.0	
	Week 22	Tezepelumab	380	325 (85.5)	0.83 (0.81)	0.0	0.00	0.93	1.21	3.4	
		Placebo	371	299 (80.6)	0.91 (0.83)	0.0	0.00	1.00	1.50	3.8	
	Week 23	Tezepelumab	380	319 (83.9)	0.82 (0.82)	0.0	0.00	0.83	1.25	3.5	
		Placebo	371	296 (79.8)	0.88 (0.81)	0.0	0.00	1.00	1.42	3.5	
	Week 24	Tezepelumab	380	327 (86.1)	0.78 (0.80)	0.0	0.00	0.75	1.14	3.1	
		Placebo	371	297 (80.1)	0.84 (0.81)	0.0	0.00	1.00	1.29	3.6	
	Week 25	Tezepelumab	380	314 (82.6)	0.80 (0.79)	0.0	0.00	0.88	1.25	3.0	
		Placebo	371	296 (79.8)	0.86 (0.82)	0.0	0.07	0.93	1.23	3.9	
	Week 26	Tezepelumab	380	319 (83.9)	0.79 (0.80)	0.0	0.00	0.75	1.21	3.3	
		Placebo	371	289 (77.9)	0.88 (0.82)	0.0	0.07	1.00	1.43	3.7	
	Week 27	Tezepelumab	380	309 (81.3)	0.79 (0.82)	0.0	0.00	0.79	1.20	3.6	
		Placebo	371	300 (80.9)	0.86 (0.82)	0.0	0.00	0.93	1.29	3.3	
	Week 28	Tezepelumab	380	317 (83.4)	0.76 (0.81)	0.0	0.00	0.58	1.17	3.6	
		Placebo	371	300 (80.9)	0.86 (0.81)	0.0	0.00	0.89	1.37	3.8	
	Week 29	Tezepelumab	380	310 (81.6)	0.75 (0.80)	0.0	0.00	0.58	1.14	3.4	
		Placebo	371	299 (80.6)	0.88 (0.84)	0.0	0.00	1.00	1.40	3.7	
	Week 30	Tezepelumab	380	314 (82.6)	0.76 (0.79)	0.0	0.00	0.58	1.14	3.9	
		Placebo	371	295 (79.5)	0.86 (0.82)	0.0	0.00	0.93	1.36	3.8	
	Week 31	Tezepelumab	380	315 (82.9)	0.75 (0.79)	0.0	0.00	0.63	1.14	4.0	
		Placebo	371	296 (79.8)	0.87 (0.78)	0.0	0.00	1.00	1.21	3.5	
	Week 32	Tezepelumab	380	316 (83.2)	0.75 (0.78)	0.0	0.00	0.58	1.17	3.8	
		Placebo	371	297 (80.1)	0.88 (0.79)	0.0	0.00	1.00	1.29	3.1	
	Week 33	Tezepelumab	380	313 (82.4)	0.75 (0.79)	0.0	0.00	0.57	1.10	3.3	
		Placebo	371	291 (78.4)	0.90 (0.80)	0.0	0.00	1.00	1.50	3.0	
	Week 34	Tezepelumab	380	311 (81.8)	0.73 (0.79)	0.0	0.00	0.50	1.17	3.3	
		Placebo	371	293 (79.0)	0.87 (0.81)	0.0	0.00	1.00	1.36	3.7	
	Week 35	Tezepelumab	380	312 (82.1)	0.75 (0.81)	0.0	0.00	0.50	1.09	3.5	
		Placebo	371	285 (76.8)	0.86 (0.79)	0.0	0.00	0.93	1.21	3.2	

Note: DITTl - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WEC\_ALMH0: Course of ASD weekly chest tightness score  
 DITTl - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly chest tightness score	Week 36	Tezepelumab	380	309 (81.3)	0.76 (0.81)	0.0	0.00	0.57	1.14	3.4	
		Placebo	371	288 (77.6)	0.86 (0.78)	0.0	0.00	1.00	1.21	3.4	
	Week 37	Tezepelumab	380	312 (82.1)	0.74 (0.81)	0.0	0.00	0.50	1.08	3.3	
		Placebo	371	287 (77.4)	0.84 (0.78)	0.0	0.00	1.00	1.21	3.3	
	Week 38	Tezepelumab	380	310 (81.6)	0.78 (0.82)	0.0	0.00	0.75	1.21	3.4	
		Placebo	371	287 (77.4)	0.82 (0.78)	0.0	0.00	0.92	1.21	3.1	
	Week 39	Tezepelumab	380	317 (83.4)	0.77 (0.84)	0.0	0.00	0.63	1.21	3.9	
		Placebo	371	281 (75.7)	0.85 (0.80)	0.0	0.00	0.93	1.29	3.2	
	Week 40	Tezepelumab	380	313 (82.4)	0.77 (0.83)	0.0	0.00	0.64	1.21	3.7	
		Placebo	371	287 (77.4)	0.87 (0.81)	0.0	0.00	1.00	1.30	3.4	
	Week 41	Tezepelumab	380	316 (83.2)	0.73 (0.81)	0.0	0.00	0.50	1.14	3.5	
		Placebo	371	288 (77.6)	0.87 (0.79)	0.0	0.00	1.00	1.38	3.5	
	Week 42	Tezepelumab	380	308 (81.1)	0.74 (0.82)	0.0	0.00	0.46	1.11	3.9	
		Placebo	371	288 (77.6)	0.86 (0.83)	0.0	0.00	1.00	1.32	3.6	
	Week 43	Tezepelumab	380	311 (81.8)	0.75 (0.84)	0.0	0.00	0.42	1.14	3.6	
		Placebo	371	285 (76.8)	0.85 (0.81)	0.0	0.00	1.00	1.25	3.6	
	Week 44	Tezepelumab	380	309 (81.3)	0.75 (0.84)	0.0	0.00	0.50	1.08	3.7	
		Placebo	371	283 (76.3)	0.86 (0.82)	0.0	0.00	1.00	1.42	3.1	
	Week 45	Tezepelumab	380	312 (82.1)	0.75 (0.83)	0.0	0.00	0.46	1.14	3.9	
		Placebo	371	285 (76.8)	0.85 (0.82)	0.0	0.00	0.93	1.40	3.8	
	Week 46	Tezepelumab	380	307 (80.8)	0.76 (0.83)	0.0	0.00	0.64	1.25	3.8	
		Placebo	371	278 (74.9)	0.83 (0.81)	0.0	0.00	0.88	1.25	3.4	
	Week 47	Tezepelumab	380	296 (77.9)	0.75 (0.83)	0.0	0.00	0.50	1.14	3.1	
		Placebo	371	281 (75.7)	0.80 (0.78)	0.0	0.00	0.86	1.13	3.1	
	Week 48	Tezepelumab	380	318 (83.7)	0.76 (0.82)	0.0	0.00	0.54	1.14	3.8	
		Placebo	371	291 (78.4)	0.83 (0.79)	0.0	0.00	1.00	1.20	3.0	
	Week 49	Tezepelumab	380	308 (81.1)	0.74 (0.82)	0.0	0.00	0.43	1.08	3.2	
		Placebo	371	280 (75.5)	0.84 (0.79)	0.0	0.00	1.00	1.15	3.0	
	Week 50	Tezepelumab	380	306 (80.5)	0.76 (0.83)	0.0	0.00	0.57	1.14	3.0	
		Placebo	371	278 (74.9)	0.86 (0.79)	0.0	0.00	1.00	1.29	3.0	
	Week 51	Tezepelumab	380	300 (78.9)	0.79 (0.83)	0.0	0.00	0.73	1.27	3.0	
		Placebo	371	270 (72.8)	0.83 (0.79)	0.0	0.00	0.96	1.14	3.0	
	Week 52	Tezepelumab	380	268 (70.5)	0.80 (0.84)	0.0	0.00	0.73	1.19	3.1	
		Placebo	371	246 (66.3)	0.87 (0.82)	0.0	0.00	1.00	1.25	3.0	

Note: DITTl - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WEC\_ALMH0: Course of ASD weekly chest tightness score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly chest tightness score	Week 1	Tezepelumab	380	372 (97.9)	-0.18 (0.41)	-2.2	-0.36	-0.07	0.00	1.6	-0.23 [-0.37, -0.08]
		Placebo	371	362 (97.6)	-0.09 (0.37)	-1.9	-0.29	-0.07	0.07	1.2	
	Week 2	Tezepelumab	380	370 (97.4)	-0.26 (0.52)	-2.6	-0.57	-0.14	0.02	1.2	-0.23 [-0.37, -0.08]
		Placebo	371	360 (97.0)	-0.14 (0.51)	-2.2	-0.36	-0.08	0.08	1.6	
	Week 3	Tezepelumab	380	365 (96.1)	-0.32 (0.59)	-3.3	-0.64	-0.14	0.00	1.2	-0.15 [-0.30, -0.01]
		Placebo	371	354 (95.4)	-0.23 (0.57)	-2.6	-0.50	-0.13	0.00	1.6	
	Week 4	Tezepelumab	380	363 (95.5)	-0.36 (0.61)	-3.3	-0.66	-0.14	0.00	0.8	-0.17 [-0.31, -0.02]
		Placebo	371	353 (95.1)	-0.26 (0.58)	-2.6	-0.55	-0.14	0.01	1.9	
	Week 5	Tezepelumab	380	363 (95.5)	-0.43 (0.65)	-3.4	-0.86	-0.21	0.00	1.0	-0.15 [-0.30, -0.00]
		Placebo	371	344 (92.7)	-0.33 (0.62)	-2.9	-0.64	-0.21	0.00	2.1	
	Week 6	Tezepelumab	380	357 (93.9)	-0.46 (0.68)	-3.4	-0.86	-0.29	0.00	1.0	-0.19 [-0.34, -0.05]
		Placebo	371	349 (94.1)	-0.33 (0.67)	-3.1	-0.67	-0.21	0.00	2.0	
	Week 7	Tezepelumab	380	354 (93.2)	-0.47 (0.71)	-3.4	-0.86	-0.29	0.00	1.4	-0.18 [-0.32, -0.03]
		Placebo	371	349 (94.1)	-0.35 (0.67)	-3.1	-0.70	-0.23	0.00	2.0	
	Week 8	Tezepelumab	380	355 (93.4)	-0.49 (0.72)	-3.2	-0.93	-0.32	0.00	1.5	-0.16 [-0.30, -0.01]
		Placebo	371	340 (91.6)	-0.38 (0.68)	-3.1	-0.79	-0.29	0.00	2.0	
	Week 9	Tezepelumab	380	360 (94.7)	-0.54 (0.71)	-3.4	-1.00	-0.36	0.00	1.6	-0.18 [-0.33, -0.03]
		Placebo	371	340 (91.6)	-0.41 (0.68)	-3.1	-0.79	-0.29	0.00	2.0	
	Week 10	Tezepelumab	380	358 (94.2)	-0.53 (0.71)	-3.2	-1.00	-0.37	0.00	1.3	-0.15 [-0.30, 0.00]
		Placebo	371	338 (91.1)	-0.42 (0.70)	-3.1	-0.81	-0.30	0.00	2.0	
	Week 11	Tezepelumab	380	347 (91.3)	-0.54 (0.74)	-3.2	-1.00	-0.42	0.00	1.3	-0.16 [-0.31, -0.01]
		Placebo	371	334 (90.0)	-0.42 (0.71)	-3.1	-0.79	-0.36	0.00	2.0	
	Week 12	Tezepelumab	380	348 (91.6)	-0.54 (0.74)	-3.4	-1.00	-0.42	0.00	1.1	-0.14 [-0.29, 0.01]
		Placebo	371	332 (89.5)	-0.44 (0.68)	-3.1	-0.85	-0.36	0.00	2.0	
	Week 13	Tezepelumab	380	344 (90.5)	-0.55 (0.73)	-3.3	-1.00	-0.42	0.00	1.1	-0.12 [-0.27, 0.03]
		Placebo	371	330 (88.9)	-0.46 (0.71)	-3.1	-0.87	-0.41	0.00	2.0	
	Week 14	Tezepelumab	380	342 (90.0)	-0.61 (0.74)	-3.3	-1.00	-0.50	-0.07	1.0	-0.22 [-0.37, -0.06]
		Placebo	371	330 (88.9)	-0.45 (0.71)	-3.1	-0.86	-0.34	0.00	2.0	
	Week 15	Tezepelumab	380	338 (88.9)	-0.57 (0.72)	-3.1	-1.00	-0.43	0.00	1.1	-0.18 [-0.34, -0.03]
		Placebo	371	320 (86.3)	-0.44 (0.73)	-3.1	-0.86	-0.43	0.00	2.0	
	Week 16	Tezepelumab	380	342 (90.0)	-0.61 (0.75)	-3.3	-1.00	-0.50	0.00	1.1	-0.19 [-0.35, -0.04]
		Placebo	371	318 (85.7)	-0.46 (0.75)	-3.1	-0.93	-0.36	0.00	2.0	
	Week 17	Tezepelumab	380	338 (88.9)	-0.63 (0.75)	-3.5	-1.03	-0.50	-0.01	1.2	-0.20 [-0.35, -0.04]
		Placebo	371	314 (84.6)	-0.49 (0.71)	-3.1	-0.93	-0.43	0.00	2.0	
Week 18	Tezepelumab	380	336 (88.4)	-0.61 (0.74)	-3.7	-1.00	-0.50	0.00	1.3	-0.18 [-0.34, -0.03]	
	Placebo	371	309 (83.3)	-0.48 (0.75)	-3.1	-0.88	-0.33	0.00	2.0		

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WEC\_ALMH0: Course of ASD weekly chest tightness score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly chest tightness score	Week 19	Tezepelumab	380	333 (87.6)	-0.62 (0.76)	-3.5	-1.00	-0.50	0.00	1.6	-0.19 [-0.34, -0.03]
		Placebo	371	317 (85.4)	-0.47 (0.76)	-3.1	-0.93	-0.36	0.00	2.0	
	Week 20	Tezepelumab	380	328 (86.3)	-0.60 (0.75)	-3.4	-1.00	-0.49	0.00	1.1	-0.17 [-0.33, -0.02]
		Placebo	371	309 (83.3)	-0.47 (0.77)	-3.1	-0.92	-0.36	0.00	2.0	
	Week 21	Tezepelumab	380	326 (85.8)	-0.60 (0.75)	-3.3	-1.00	-0.50	-0.01	1.9	-0.13 [-0.29, 0.02]
		Placebo	371	305 (82.2)	-0.50 (0.77)	-3.1	-0.93	-0.42	0.00	2.0	
	Week 22	Tezepelumab	380	325 (85.5)	-0.58 (0.77)	-3.7	-1.00	-0.43	0.00	1.4	-0.16 [-0.32, -0.00]
		Placebo	371	299 (80.6)	-0.46 (0.74)	-3.1	-0.92	-0.33	0.00	2.0	
	Week 23	Tezepelumab	380	319 (83.9)	-0.60 (0.75)	-3.3	-1.00	-0.50	0.00	1.3	-0.11 [-0.27, 0.05]
		Placebo	371	296 (79.8)	-0.51 (0.76)	-3.4	-0.94	-0.43	0.00	2.0	
	Week 24	Tezepelumab	380	327 (86.1)	-0.63 (0.76)	-3.8	-1.07	-0.57	0.00	1.3	-0.15 [-0.31, 0.01]
		Placebo	371	297 (80.1)	-0.52 (0.76)	-3.1	-1.00	-0.49	0.00	2.0	
	Week 25	Tezepelumab	380	314 (82.6)	-0.63 (0.76)	-3.7	-1.10	-0.56	0.00	1.3	-0.15 [-0.31, 0.01]
		Placebo	371	296 (79.8)	-0.51 (0.79)	-3.1	-0.95	-0.50	0.00	2.0	
	Week 26	Tezepelumab	380	319 (83.9)	-0.63 (0.78)	-3.8	-1.07	-0.50	0.00	1.7	-0.15 [-0.31, 0.01]
		Placebo	371	289 (77.9)	-0.51 (0.78)	-3.1	-0.93	-0.42	0.00	2.0	
	Week 27	Tezepelumab	380	309 (81.3)	-0.64 (0.79)	-3.6	-1.07	-0.57	0.00	1.2	-0.17 [-0.33, -0.01]
		Placebo	371	300 (80.9)	-0.50 (0.79)	-3.1	-1.00	-0.42	0.00	2.6	
	Week 28	Tezepelumab	380	317 (83.4)	-0.65 (0.77)	-3.7	-1.07	-0.57	-0.07	1.1	-0.19 [-0.35, -0.04]
		Placebo	371	300 (80.9)	-0.50 (0.79)	-3.1	-0.93	-0.37	0.00	2.1	
	Week 29	Tezepelumab	380	310 (81.6)	-0.67 (0.77)	-3.8	-1.14	-0.57	-0.07	1.1	-0.22 [-0.38, -0.06]
		Placebo	371	299 (80.6)	-0.50 (0.80)	-3.1	-0.93	-0.36	0.00	2.0	
	Week 30	Tezepelumab	380	314 (82.6)	-0.65 (0.79)	-3.8	-1.11	-0.60	-0.06	1.1	-0.18 [-0.34, -0.02]
		Placebo	371	295 (79.5)	-0.51 (0.79)	-3.1	-1.00	-0.43	0.00	2.0	
	Week 31	Tezepelumab	380	315 (82.9)	-0.68 (0.80)	-3.8	-1.14	-0.57	-0.06	1.1	-0.22 [-0.38, -0.06]
		Placebo	371	296 (79.8)	-0.51 (0.75)	-2.9	-1.00	-0.48	0.00	2.0	
	Week 32	Tezepelumab	380	316 (83.2)	-0.66 (0.77)	-3.8	-1.08	-0.58	-0.07	1.2	-0.20 [-0.36, -0.04]
		Placebo	371	297 (80.1)	-0.50 (0.80)	-3.1	-0.93	-0.43	0.00	2.0	
	Week 33	Tezepelumab	380	313 (82.4)	-0.66 (0.80)	-3.8	-1.14	-0.64	-0.07	1.1	-0.22 [-0.38, -0.06]
		Placebo	371	291 (78.4)	-0.49 (0.78)	-3.1	-0.92	-0.43	0.00	1.9	
	Week 34	Tezepelumab	380	311 (81.8)	-0.68 (0.77)	-3.5	-1.08	-0.64	-0.07	1.1	-0.23 [-0.39, -0.07]
		Placebo	371	293 (79.0)	-0.50 (0.78)	-3.1	-0.92	-0.43	0.00	2.0	
	Week 35	Tezepelumab	380	312 (82.1)	-0.66 (0.80)	-3.8	-1.13	-0.58	-0.07	1.4	-0.21 [-0.37, -0.04]
		Placebo	371	285 (76.8)	-0.50 (0.78)	-3.1	-0.99	-0.42	0.00	2.0	
	Week 36	Tezepelumab	380	309 (81.3)	-0.66 (0.80)	-3.8	-1.07	-0.57	-0.07	1.2	-0.19 [-0.35, -0.02]
		Placebo	371	288 (77.6)	-0.51 (0.80)	-3.1	-0.96	-0.42	0.00	2.0	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WEC\_ALMH0: Course of ASD weekly chest tightness score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly chest tightness score	Week 37	Tezepelumab	380	312 (82.1)	-0.65 (0.80)	-3.6	-1.14	-0.58	0.00	1.1	-0.19 [-0.35, -0.03]
		Placebo	371	287 (77.4)	-0.50 (0.76)	-3.1	-1.00	-0.43	0.00	2.0	
	Week 38	Tezepelumab	380	310 (81.6)	-0.65 (0.80)	-3.6	-1.14	-0.58	-0.07	1.1	-0.15 [-0.31, 0.01]
		Placebo	371	287 (77.4)	-0.53 (0.75)	-3.1	-1.00	-0.50	0.00	2.0	
	Week 39	Tezepelumab	380	317 (83.4)	-0.66 (0.82)	-3.8	-1.13	-0.57	0.00	1.3	-0.20 [-0.36, -0.04]
		Placebo	371	281 (75.7)	-0.50 (0.78)	-3.1	-0.93	-0.42	0.00	1.9	
	Week 40	Tezepelumab	380	313 (82.4)	-0.66 (0.79)	-3.8	-1.14	-0.57	-0.07	1.3	-0.23 [-0.39, -0.07]
		Placebo	371	287 (77.4)	-0.48 (0.77)	-3.1	-0.93	-0.39	0.00	2.0	
	Week 41	Tezepelumab	380	316 (83.2)	-0.68 (0.79)	-3.8	-1.14	-0.58	-0.07	1.5	-0.19 [-0.35, -0.03]
		Placebo	371	288 (77.6)	-0.53 (0.76)	-3.1	-0.99	-0.43	0.00	2.2	
	Week 42	Tezepelumab	380	308 (81.1)	-0.68 (0.79)	-3.7	-1.14	-0.59	-0.07	1.1	-0.23 [-0.39, -0.07]
		Placebo	371	288 (77.6)	-0.50 (0.77)	-3.1	-0.92	-0.43	0.00	2.0	
	Week 43	Tezepelumab	380	311 (81.8)	-0.69 (0.81)	-3.8	-1.14	-0.57	-0.07	1.1	-0.22 [-0.38, -0.06]
		Placebo	371	285 (76.8)	-0.51 (0.75)	-3.1	-0.96	-0.36	0.00	2.0	
	Week 44	Tezepelumab	380	309 (81.3)	-0.68 (0.81)	-3.8	-1.14	-0.60	-0.07	1.1	-0.22 [-0.38, -0.06]
		Placebo	371	283 (76.3)	-0.50 (0.78)	-3.1	-0.93	-0.36	0.00	2.0	
	Week 45	Tezepelumab	380	312 (82.1)	-0.68 (0.80)	-3.8	-1.14	-0.61	-0.07	1.1	-0.19 [-0.36, -0.03]
		Placebo	371	285 (76.8)	-0.53 (0.80)	-3.1	-1.00	-0.49	0.00	2.0	
	Week 46	Tezepelumab	380	307 (80.8)	-0.68 (0.82)	-3.8	-1.14	-0.64	-0.07	1.3	-0.20 [-0.36, -0.03]
		Placebo	371	278 (74.9)	-0.52 (0.78)	-3.1	-0.95	-0.43	0.00	2.0	
	Week 47	Tezepelumab	380	296 (77.9)	-0.66 (0.80)	-3.7	-1.14	-0.61	-0.07	1.3	-0.14 [-0.31, 0.02]
		Placebo	371	281 (75.7)	-0.55 (0.75)	-3.1	-1.00	-0.43	0.00	1.6	
	Week 48	Tezepelumab	380	318 (83.7)	-0.65 (0.82)	-3.8	-1.14	-0.55	0.00	1.6	-0.14 [-0.30, 0.02]
		Placebo	371	291 (78.4)	-0.55 (0.76)	-3.1	-1.00	-0.50	0.00	2.1	
	Week 49	Tezepelumab	380	308 (81.1)	-0.67 (0.80)	-3.7	-1.09	-0.59	-0.07	1.1	-0.17 [-0.33, -0.01]
		Placebo	371	280 (75.5)	-0.54 (0.75)	-3.1	-0.97	-0.50	0.00	1.6	
	Week 50	Tezepelumab	380	306 (80.5)	-0.65 (0.81)	-3.5	-1.09	-0.57	-0.07	1.3	-0.17 [-0.34, -0.01]
		Placebo	371	278 (74.9)	-0.52 (0.76)	-3.1	-1.00	-0.49	0.00	1.8	
	Week 51	Tezepelumab	380	300 (78.9)	-0.64 (0.84)	-3.8	-1.14	-0.57	0.00	1.7	-0.14 [-0.31, 0.02]
		Placebo	371	270 (72.8)	-0.53 (0.78)	-3.1	-1.00	-0.50	0.00	1.9	
	Week 52	Tezepelumab	380	268 (70.5)	-0.64 (0.86)	-3.8	-1.09	-0.58	-0.04	1.6	-0.13 [-0.30, 0.04]
		Placebo	371	246 (66.3)	-0.53 (0.80)	-3.1	-1.00	-0.49	0.00	1.7	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WEC\_ALMC0: Change from baseline in ASD weekly chest tightness score - MMRM results  
 DITTL - adult

Change from baseline in ASD weekly chest tightness score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 1	Tezepelumab	380	372 (97.9)	-0.17 (0.03)	(-0.23, -0.10)	-0.07 (0.05)	(-0.16, 0.02)	0.141	
	Placebo	371	362 (97.6)	-0.10 (0.03)	(-0.17, -0.03)				
Week 2	Tezepelumab	380	370 (97.4)	-0.25 (0.03)	(-0.32, -0.19)	-0.10 (0.05)	(-0.20, -0.01)	0.031 *	
	Placebo	371	360 (97.0)	-0.15 (0.03)	(-0.22, -0.08)				
Week 3	Tezepelumab	380	365 (96.1)	-0.32 (0.03)	(-0.38, -0.25)	-0.09 (0.05)	(-0.18, 0.01)	0.067	
	Placebo	371	354 (95.4)	-0.23 (0.03)	(-0.30, -0.17)				
Week 4	Tezepelumab	380	363 (95.5)	-0.36 (0.03)	(-0.42, -0.29)	-0.09 (0.05)	(-0.18, 0.00)	0.058	
	Placebo	371	353 (95.1)	-0.27 (0.03)	(-0.33, -0.20)				
Week 5	Tezepelumab	380	363 (95.5)	-0.42 (0.03)	(-0.48, -0.35)	-0.08 (0.05)	(-0.17, 0.01)	0.096	
	Placebo	371	344 (92.7)	-0.34 (0.03)	(-0.40, -0.27)				
Week 6	Tezepelumab	380	357 (93.9)	-0.45 (0.03)	(-0.52, -0.38)	-0.11 (0.05)	(-0.20, -0.02)	0.019 *	
	Placebo	371	349 (94.1)	-0.34 (0.03)	(-0.40, -0.27)				
Week 7	Tezepelumab	380	354 (93.2)	-0.46 (0.03)	(-0.53, -0.39)	-0.11 (0.05)	(-0.20, -0.01)	0.024 *	
	Placebo	371	349 (94.1)	-0.35 (0.03)	(-0.42, -0.29)				
Week 8	Tezepelumab	380	355 (93.4)	-0.49 (0.03)	(-0.55, -0.42)	-0.11 (0.05)	(-0.20, -0.02)	0.020 *	
	Placebo	371	340 (91.6)	-0.38 (0.03)	(-0.44, -0.31)				
Week 9	Tezepelumab	380	360 (94.7)	-0.53 (0.03)	(-0.60, -0.46)	-0.12 (0.05)	(-0.21, -0.02)	0.016 *	
	Placebo	371	340 (91.6)	-0.41 (0.03)	(-0.48, -0.35)				
Week 10	Tezepelumab	380	358 (94.2)	-0.54 (0.03)	(-0.60, -0.47)	-0.12 (0.05)	(-0.21, -0.03)	0.012 *	
	Placebo	371	338 (91.1)	-0.41 (0.03)	(-0.48, -0.35)				

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table NT1WEC\_ALMC0: Change from baseline in ASD weekly chest tightness score - MMRM results  
 DITTTL - adult

Change from baseline in ASD weekly chest tightness score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 11	Tezepelumab	380	347 (91.3)	-0.53 (0.03)	(-0.60, -0.47)	-0.11 (0.05)	(-0.21, -0.02)	0.018 *	
	Placebo	371	334 (90.0)	-0.42 (0.03)	(-0.49, -0.35)				
Week 12	Tezepelumab	380	348 (91.6)	-0.53 (0.03)	(-0.59, -0.46)	-0.10 (0.05)	(-0.20, -0.01)	0.031 *	
	Placebo	371	332 (89.5)	-0.42 (0.03)	(-0.49, -0.35)				
Week 13	Tezepelumab	380	344 (90.5)	-0.55 (0.03)	(-0.62, -0.49)	-0.12 (0.05)	(-0.21, -0.03)	0.013 *	
	Placebo	371	330 (88.9)	-0.43 (0.03)	(-0.50, -0.37)				
Week 14	Tezepelumab	380	342 (90.0)	-0.58 (0.03)	(-0.65, -0.51)	-0.14 (0.05)	(-0.23, -0.04)	0.005 *	
	Placebo	371	330 (88.9)	-0.45 (0.03)	(-0.51, -0.38)				
Week 15	Tezepelumab	380	338 (88.9)	-0.58 (0.03)	(-0.65, -0.52)	-0.14 (0.05)	(-0.23, -0.04)	0.004 *	
	Placebo	371	320 (86.3)	-0.44 (0.03)	(-0.51, -0.38)				
Week 16	Tezepelumab	380	342 (90.0)	-0.61 (0.03)	(-0.68, -0.54)	-0.17 (0.05)	(-0.27, -0.08)	<0.001 *	
	Placebo	371	318 (85.7)	-0.44 (0.03)	(-0.51, -0.37)				
Week 17	Tezepelumab	380	338 (88.9)	-0.61 (0.03)	(-0.68, -0.55)	-0.13 (0.05)	(-0.23, -0.04)	0.006 *	
	Placebo	371	314 (84.6)	-0.48 (0.03)	(-0.55, -0.41)				
Week 18	Tezepelumab	380	336 (88.4)	-0.60 (0.03)	(-0.67, -0.54)	-0.13 (0.05)	(-0.22, -0.03)	0.008 *	
	Placebo	371	309 (83.3)	-0.47 (0.03)	(-0.54, -0.41)				
Week 19	Tezepelumab	380	333 (87.6)	-0.61 (0.03)	(-0.68, -0.55)	-0.14 (0.05)	(-0.23, -0.04)	0.005 *	
	Placebo	371	317 (85.4)	-0.48 (0.03)	(-0.54, -0.41)				
Week 20	Tezepelumab	380	328 (86.3)	-0.61 (0.03)	(-0.68, -0.54)	-0.14 (0.05)	(-0.24, -0.05)	0.003 *	
	Placebo	371	309 (83.3)	-0.47 (0.03)	(-0.53, -0.40)				

Note: DITTTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WEC\_ALMC0: Change from baseline in ASD weekly chest tightness score - MMRM results  
 DITTTL - adult

Change from baseline in ASD weekly chest tightness score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 21	Tezepelumab	380	326 (85.8)	-0.61 (0.03)	(-0.68, -0.54)	-0.13 (0.05)	(-0.23, -0.04)	0.006 *	
	Placebo	371	305 (82.2)	-0.48 (0.03)	(-0.54, -0.41)				
Week 22	Tezepelumab	380	325 (85.5)	-0.60 (0.03)	(-0.67, -0.54)	-0.13 (0.05)	(-0.22, -0.03)	0.010 *	
	Placebo	371	299 (80.6)	-0.48 (0.03)	(-0.55, -0.41)				
Week 23	Tezepelumab	380	319 (83.9)	-0.61 (0.03)	(-0.68, -0.55)	-0.13 (0.05)	(-0.23, -0.04)	0.006 *	
	Placebo	371	296 (79.8)	-0.48 (0.04)	(-0.55, -0.41)				
Week 24	Tezepelumab	380	327 (86.1)	-0.63 (0.03)	(-0.70, -0.56)	-0.13 (0.05)	(-0.22, -0.03)	0.009 *	
	Placebo	371	297 (80.1)	-0.50 (0.04)	(-0.57, -0.43)				
Week 25	Tezepelumab	380	314 (82.6)	-0.63 (0.03)	(-0.70, -0.56)	-0.13 (0.05)	(-0.23, -0.03)	0.009 *	
	Placebo	371	296 (79.8)	-0.50 (0.04)	(-0.57, -0.43)				
Week 26	Tezepelumab	380	319 (83.9)	-0.64 (0.03)	(-0.70, -0.57)	-0.14 (0.05)	(-0.24, -0.04)	0.004 *	
	Placebo	371	289 (77.9)	-0.50 (0.04)	(-0.57, -0.43)				
Week 27	Tezepelumab	380	309 (81.3)	-0.63 (0.03)	(-0.70, -0.56)	-0.13 (0.05)	(-0.23, -0.03)	0.008 *	
	Placebo	371	300 (80.9)	-0.50 (0.04)	(-0.57, -0.43)				
Week 28	Tezepelumab	380	317 (83.4)	-0.65 (0.03)	(-0.72, -0.58)	-0.15 (0.05)	(-0.24, -0.05)	0.003 *	
	Placebo	371	300 (80.9)	-0.50 (0.04)	(-0.57, -0.43)				
Week 29	Tezepelumab	380	310 (81.6)	-0.66 (0.03)	(-0.73, -0.59)	-0.17 (0.05)	(-0.26, -0.07)	<0.001 *	
	Placebo	371	299 (80.6)	-0.49 (0.04)	(-0.56, -0.42)				
Week 30	Tezepelumab	380	314 (82.6)	-0.65 (0.03)	(-0.72, -0.58)	-0.16 (0.05)	(-0.25, -0.06)	0.002 *	
	Placebo	371	295 (79.5)	-0.49 (0.04)	(-0.56, -0.42)				

Note: DITTTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WEC\_ALMC0: Change from baseline in ASD weekly chest tightness score - MMRM results  
 DITTTL - adult

Time	Treatment	N	n (%)	Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 31	Tezepelumab	380	315 (82.9)	-0.65 (0.03)	(-0.72, -0.58)	-0.14 (0.05)	(-0.24, -0.05)	0.004	*
	Placebo	371	296 (79.8)	-0.51 (0.04)	(-0.58, -0.44)				
Week 32	Tezepelumab	380	316 (83.2)	-0.66 (0.03)	(-0.73, -0.59)	-0.17 (0.05)	(-0.27, -0.07)	<0.001	*
	Placebo	371	297 (80.1)	-0.49 (0.04)	(-0.56, -0.42)				
Week 33	Tezepelumab	380	313 (82.4)	-0.67 (0.03)	(-0.73, -0.60)	-0.18 (0.05)	(-0.27, -0.08)	<0.001	*
	Placebo	371	291 (78.4)	-0.49 (0.04)	(-0.56, -0.42)				
Week 34	Tezepelumab	380	311 (81.8)	-0.68 (0.03)	(-0.75, -0.62)	-0.20 (0.05)	(-0.29, -0.10)	<0.001	*
	Placebo	371	293 (79.0)	-0.49 (0.04)	(-0.56, -0.42)				
Week 35	Tezepelumab	380	312 (82.1)	-0.67 (0.03)	(-0.74, -0.60)	-0.17 (0.05)	(-0.27, -0.07)	<0.001	*
	Placebo	371	285 (76.8)	-0.50 (0.04)	(-0.57, -0.43)				
Week 36	Tezepelumab	380	309 (81.3)	-0.66 (0.03)	(-0.73, -0.59)	-0.16 (0.05)	(-0.26, -0.07)	0.001	*
	Placebo	371	288 (77.6)	-0.50 (0.04)	(-0.57, -0.43)				
Week 37	Tezepelumab	380	312 (82.1)	-0.65 (0.03)	(-0.72, -0.58)	-0.13 (0.05)	(-0.23, -0.04)	0.007	*
	Placebo	371	287 (77.4)	-0.52 (0.04)	(-0.59, -0.45)				
Week 38	Tezepelumab	380	310 (81.6)	-0.64 (0.03)	(-0.71, -0.57)	-0.12 (0.05)	(-0.22, -0.02)	0.016	*
	Placebo	371	287 (77.4)	-0.52 (0.04)	(-0.59, -0.45)				
Week 39	Tezepelumab	380	317 (83.4)	-0.64 (0.03)	(-0.71, -0.57)	-0.12 (0.05)	(-0.22, -0.02)	0.015	*
	Placebo	371	281 (75.7)	-0.52 (0.04)	(-0.59, -0.45)				
Week 40	Tezepelumab	380	313 (82.4)	-0.66 (0.03)	(-0.73, -0.59)	-0.16 (0.05)	(-0.26, -0.06)	0.002	*
	Placebo	371	287 (77.4)	-0.50 (0.04)	(-0.57, -0.43)				

Note: DITTTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WEC\_ALMC0: Change from baseline in ASD weekly chest tightness score - MMRM results  
 DITTL - adult

Change from baseline in ASD weekly chest tightness score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Time	Treatment	N	n (%)						
Week 41	Tezepelumab	380	316 (83.2)	-0.68 (0.03)	(-0.75, -0.61)	-0.16 (0.05)	(-0.26, -0.06)	0.001	*
	Placebo	371	288 (77.6)	-0.52 (0.04)	(-0.59, -0.45)				
Week 42	Tezepelumab	380	308 (81.1)	-0.67 (0.03)	(-0.74, -0.60)	-0.15 (0.05)	(-0.25, -0.05)	0.003	*
	Placebo	371	288 (77.6)	-0.52 (0.04)	(-0.59, -0.45)				
Week 43	Tezepelumab	380	311 (81.8)	-0.67 (0.03)	(-0.74, -0.60)	-0.15 (0.05)	(-0.25, -0.05)	0.003	*
	Placebo	371	285 (76.8)	-0.52 (0.04)	(-0.59, -0.45)				
Week 44	Tezepelumab	380	309 (81.3)	-0.67 (0.03)	(-0.74, -0.60)	-0.16 (0.05)	(-0.26, -0.06)	0.001	*
	Placebo	371	283 (76.3)	-0.51 (0.04)	(-0.58, -0.44)				
Week 45	Tezepelumab	380	312 (82.1)	-0.68 (0.03)	(-0.74, -0.61)	-0.16 (0.05)	(-0.26, -0.06)	0.002	*
	Placebo	371	285 (76.8)	-0.52 (0.04)	(-0.59, -0.45)				
Week 46	Tezepelumab	380	307 (80.8)	-0.68 (0.04)	(-0.75, -0.61)	-0.15 (0.05)	(-0.25, -0.05)	0.003	*
	Placebo	371	278 (74.9)	-0.53 (0.04)	(-0.60, -0.46)				
Week 47	Tezepelumab	380	296 (77.9)	-0.67 (0.04)	(-0.74, -0.61)	-0.13 (0.05)	(-0.23, -0.03)	0.008	*
	Placebo	371	281 (75.7)	-0.54 (0.04)	(-0.61, -0.47)				
Week 48	Tezepelumab	380	318 (83.7)	-0.66 (0.03)	(-0.73, -0.59)	-0.12 (0.05)	(-0.22, -0.03)	0.014	*
	Placebo	371	291 (78.4)	-0.53 (0.04)	(-0.61, -0.46)				
Week 49	Tezepelumab	380	308 (81.1)	-0.68 (0.04)	(-0.74, -0.61)	-0.13 (0.05)	(-0.23, -0.03)	0.012	*
	Placebo	371	280 (75.5)	-0.55 (0.04)	(-0.62, -0.48)				
Week 50	Tezepelumab	380	306 (80.5)	-0.67 (0.04)	(-0.74, -0.60)	-0.14 (0.05)	(-0.24, -0.04)	0.006	*
	Placebo	371	278 (74.9)	-0.53 (0.04)	(-0.60, -0.46)				

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WEC\_ALMC0: Change from baseline in ASD weekly chest tightness score - MMRM results  
 DITTL - adult

Change from baseline in ASD weekly chest tightness score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 51	Tezepelumab	380	300 (78.9)	-0.65 (0.04)	(-0.72, -0.58)	-0.12 (0.05)	(-0.22, -0.02)	0.022 *	
	Placebo	371	270 (72.8)	-0.53 (0.04)	(-0.60, -0.46)				
Week 52	Tezepelumab	380	268 (70.5)	-0.66 (0.04)	(-0.73, -0.59)	-0.14 (0.05)	(-0.24, -0.04)	0.006 *	
	Placebo	371	246 (66.3)	-0.51 (0.04)	(-0.59, -0.44)				

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WAC\_ALMH0: Course of ASD weekly waking score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly waking score	Baseline	Tezepelumab	380	380 (100.0)	0.93 (0.75)	0.0	0.43	1.00	1.14	4.0	
		Placebo	371	371 (100.0)	0.85 (0.69)	0.0	0.29	0.86	1.14	4.0	
	Week 1	Tezepelumab	380	376 (98.9)	0.71 (0.74)	0.0	0.14	0.57	1.00	4.0	
		Placebo	371	365 (98.4)	0.68 (0.65)	0.0	0.14	0.57	1.00	3.3	
	Week 2	Tezepelumab	380	373 (98.2)	0.67 (0.74)	0.0	0.00	0.50	1.00	4.0	
		Placebo	371	367 (98.9)	0.65 (0.67)	0.0	0.00	0.57	1.00	3.4	
	Week 3	Tezepelumab	380	373 (98.2)	0.60 (0.71)	0.0	0.00	0.43	1.00	4.0	
		Placebo	371	365 (98.4)	0.57 (0.64)	0.0	0.00	0.29	1.00	3.7	
	Week 4	Tezepelumab	380	373 (98.2)	0.57 (0.70)	0.0	0.00	0.33	1.00	4.0	
		Placebo	371	361 (97.3)	0.57 (0.63)	0.0	0.00	0.33	1.00	3.1	
	Week 5	Tezepelumab	380	370 (97.4)	0.52 (0.68)	0.0	0.00	0.29	1.00	4.0	
		Placebo	371	358 (96.5)	0.52 (0.62)	0.0	0.00	0.29	1.00	3.4	
	Week 6	Tezepelumab	380	373 (98.2)	0.51 (0.66)	0.0	0.00	0.20	1.00	3.4	
		Placebo	371	361 (97.3)	0.51 (0.61)	0.0	0.00	0.29	1.00	3.1	
	Week 7	Tezepelumab	380	365 (96.1)	0.49 (0.68)	0.0	0.00	0.17	1.00	3.9	
		Placebo	371	361 (97.3)	0.51 (0.62)	0.0	0.00	0.29	1.00	3.3	
	Week 8	Tezepelumab	380	364 (95.8)	0.47 (0.65)	0.0	0.00	0.14	1.00	3.8	
		Placebo	371	359 (96.8)	0.48 (0.60)	0.0	0.00	0.20	1.00	3.3	
	Week 9	Tezepelumab	380	373 (98.2)	0.43 (0.62)	0.0	0.00	0.14	0.86	3.6	
		Placebo	371	355 (95.7)	0.47 (0.60)	0.0	0.00	0.17	1.00	3.7	
	Week 10	Tezepelumab	380	367 (96.6)	0.44 (0.64)	0.0	0.00	0.14	0.86	3.9	
		Placebo	371	350 (94.3)	0.48 (0.60)	0.0	0.00	0.17	1.00	3.3	
	Week 11	Tezepelumab	380	363 (95.5)	0.45 (0.65)	0.0	0.00	0.14	0.86	3.4	
		Placebo	371	355 (95.7)	0.44 (0.59)	0.0	0.00	0.14	0.86	3.1	
	Week 12	Tezepelumab	380	360 (94.7)	0.46 (0.66)	0.0	0.00	0.14	1.00	4.0	
		Placebo	371	350 (94.3)	0.44 (0.59)	0.0	0.00	0.14	1.00	3.4	
	Week 13	Tezepelumab	380	363 (95.5)	0.42 (0.61)	0.0	0.00	0.00	0.86	3.4	
		Placebo	371	352 (94.9)	0.40 (0.57)	0.0	0.00	0.14	0.71	3.3	
	Week 14	Tezepelumab	380	358 (94.2)	0.40 (0.60)	0.0	0.00	0.00	0.86	3.3	
		Placebo	371	351 (94.6)	0.42 (0.58)	0.0	0.00	0.14	0.86	3.6	
	Week 15	Tezepelumab	380	355 (93.4)	0.40 (0.60)	0.0	0.00	0.00	0.86	3.9	
		Placebo	371	335 (90.3)	0.43 (0.61)	0.0	0.00	0.14	0.86	3.6	
	Week 16	Tezepelumab	380	359 (94.5)	0.40 (0.60)	0.0	0.00	0.00	0.80	4.0	
		Placebo	371	340 (91.6)	0.44 (0.63)	0.0	0.00	0.14	0.86	3.4	
Week 17	Tezepelumab	380	354 (93.2)	0.40 (0.63)	0.0	0.00	0.00	0.71	4.0		
	Placebo	371	337 (90.8)	0.42 (0.59)	0.0	0.00	0.00	0.86	3.3		

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WAC\_ALMH0: Course of ASD weekly waking score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly waking score	Week 18	Tezepelumab	380	352 (92.6)	0.41 (0.64)	0.0	0.00	0.00	0.82	4.0	
		Placebo	371	337 (90.8)	0.43 (0.62)	0.0	0.00	0.14	0.86	3.1	
	Week 19	Tezepelumab	380	354 (93.2)	0.40 (0.63)	0.0	0.00	0.00	0.83	4.0	
		Placebo	371	337 (90.8)	0.42 (0.61)	0.0	0.00	0.14	0.86	3.0	
	Week 20	Tezepelumab	380	349 (91.8)	0.37 (0.60)	0.0	0.00	0.00	0.67	4.0	
		Placebo	371	336 (90.6)	0.44 (0.61)	0.0	0.00	0.07	0.86	3.3	
	Week 21	Tezepelumab	380	350 (92.1)	0.39 (0.64)	0.0	0.00	0.00	0.71	4.0	
		Placebo	371	334 (90.0)	0.41 (0.62)	0.0	0.00	0.00	0.83	3.9	
	Week 22	Tezepelumab	380	350 (92.1)	0.39 (0.63)	0.0	0.00	0.00	0.71	4.0	
		Placebo	371	327 (88.1)	0.42 (0.60)	0.0	0.00	0.00	0.86	3.3	
	Week 23	Tezepelumab	380	345 (90.8)	0.38 (0.62)	0.0	0.00	0.00	0.83	4.0	
		Placebo	371	319 (86.0)	0.41 (0.59)	0.0	0.00	0.00	0.80	3.3	
	Week 24	Tezepelumab	380	344 (90.5)	0.38 (0.62)	0.0	0.00	0.00	0.71	4.0	
		Placebo	371	323 (87.1)	0.40 (0.62)	0.0	0.00	0.00	0.86	4.0	
	Week 25	Tezepelumab	380	347 (91.3)	0.38 (0.60)	0.0	0.00	0.00	0.71	4.0	
		Placebo	371	321 (86.5)	0.39 (0.58)	0.0	0.00	0.00	0.71	3.4	
	Week 26	Tezepelumab	380	341 (89.7)	0.40 (0.64)	0.0	0.00	0.00	0.80	4.0	
		Placebo	371	318 (85.7)	0.38 (0.57)	0.0	0.00	0.00	0.71	3.3	
	Week 27	Tezepelumab	380	348 (91.6)	0.38 (0.62)	0.0	0.00	0.00	0.80	4.0	
		Placebo	371	314 (84.6)	0.41 (0.62)	0.0	0.00	0.00	0.83	3.3	
	Week 28	Tezepelumab	380	347 (91.3)	0.38 (0.62)	0.0	0.00	0.00	0.83	4.0	
		Placebo	371	326 (87.9)	0.40 (0.58)	0.0	0.00	0.00	0.71	3.0	
	Week 29	Tezepelumab	380	342 (90.0)	0.38 (0.62)	0.0	0.00	0.00	0.71	4.0	
		Placebo	371	325 (87.6)	0.40 (0.60)	0.0	0.00	0.00	0.83	3.0	
	Week 30	Tezepelumab	380	343 (90.3)	0.39 (0.63)	0.0	0.00	0.00	0.80	4.0	
		Placebo	371	318 (85.7)	0.43 (0.64)	0.0	0.00	0.00	0.86	3.2	
	Week 31	Tezepelumab	380	346 (91.1)	0.39 (0.64)	0.0	0.00	0.00	0.80	4.0	
		Placebo	371	312 (84.1)	0.41 (0.59)	0.0	0.00	0.00	0.85	3.0	
	Week 32	Tezepelumab	380	347 (91.3)	0.40 (0.64)	0.0	0.00	0.00	0.83	4.0	
		Placebo	371	324 (87.3)	0.39 (0.60)	0.0	0.00	0.00	0.71	3.1	
	Week 33	Tezepelumab	380	344 (90.5)	0.37 (0.62)	0.0	0.00	0.00	0.66	4.0	
		Placebo	371	317 (85.4)	0.40 (0.61)	0.0	0.00	0.00	0.83	3.0	
	Week 34	Tezepelumab	380	346 (91.1)	0.39 (0.63)	0.0	0.00	0.00	0.80	4.0	
		Placebo	371	322 (86.8)	0.38 (0.59)	0.0	0.00	0.00	0.83	3.0	
	Week 35	Tezepelumab	380	340 (89.5)	0.40 (0.66)	0.0	0.00	0.00	0.83	4.0	
		Placebo	371	310 (83.6)	0.38 (0.61)	0.0	0.00	0.00	0.86	3.4	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WAC\_ALMH0: Course of ASD weekly waking score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly waking score	Week 36	Tezepelumab	380	342 (90.0)	0.39 (0.65)	0.0	0.00	0.00	0.83	4.0	
		Placebo	371	315 (84.9)	0.39 (0.59)	0.0	0.00	0.00	0.83	3.1	
	Week 37	Tezepelumab	380	336 (88.4)	0.39 (0.64)	0.0	0.00	0.00	0.78	4.0	
		Placebo	371	317 (85.4)	0.38 (0.58)	0.0	0.00	0.00	0.83	3.0	
	Week 38	Tezepelumab	380	335 (88.2)	0.39 (0.65)	0.0	0.00	0.00	0.71	4.0	
		Placebo	371	314 (84.6)	0.40 (0.59)	0.0	0.00	0.00	0.86	3.1	
	Week 39	Tezepelumab	380	339 (89.2)	0.40 (0.66)	0.0	0.00	0.00	0.86	4.0	
		Placebo	371	318 (85.7)	0.39 (0.59)	0.0	0.00	0.00	0.71	3.1	
	Week 40	Tezepelumab	380	341 (89.7)	0.38 (0.65)	0.0	0.00	0.00	0.71	4.0	
		Placebo	371	316 (85.2)	0.42 (0.63)	0.0	0.00	0.00	1.00	3.5	
	Week 41	Tezepelumab	380	342 (90.0)	0.37 (0.64)	0.0	0.00	0.00	0.71	4.0	
		Placebo	371	315 (84.9)	0.39 (0.61)	0.0	0.00	0.00	0.80	4.0	
	Week 42	Tezepelumab	380	335 (88.2)	0.38 (0.66)	0.0	0.00	0.00	0.71	4.0	
		Placebo	371	315 (84.9)	0.42 (0.66)	0.0	0.00	0.00	0.86	4.0	
	Week 43	Tezepelumab	380	335 (88.2)	0.37 (0.65)	0.0	0.00	0.00	0.71	4.0	
		Placebo	371	311 (83.8)	0.39 (0.63)	0.0	0.00	0.00	0.71	4.0	
	Week 44	Tezepelumab	380	332 (87.4)	0.38 (0.65)	0.0	0.00	0.00	0.82	3.9	
		Placebo	371	309 (83.3)	0.39 (0.62)	0.0	0.00	0.00	0.71	4.0	
	Week 45	Tezepelumab	380	340 (89.5)	0.36 (0.64)	0.0	0.00	0.00	0.67	4.0	
		Placebo	371	315 (84.9)	0.37 (0.61)	0.0	0.00	0.00	0.80	4.0	
	Week 46	Tezepelumab	380	336 (88.4)	0.37 (0.64)	0.0	0.00	0.00	0.71	4.0	
		Placebo	371	309 (83.3)	0.36 (0.60)	0.0	0.00	0.00	0.57	4.0	
	Week 47	Tezepelumab	380	328 (86.3)	0.38 (0.65)	0.0	0.00	0.00	0.71	4.0	
		Placebo	371	306 (82.5)	0.36 (0.61)	0.0	0.00	0.00	0.60	4.0	
	Week 48	Tezepelumab	380	342 (90.0)	0.37 (0.64)	0.0	0.00	0.00	0.71	4.0	
		Placebo	371	309 (83.3)	0.37 (0.61)	0.0	0.00	0.00	0.80	3.3	
	Week 49	Tezepelumab	380	344 (90.5)	0.36 (0.63)	0.0	0.00	0.00	0.63	3.4	
		Placebo	371	308 (83.0)	0.37 (0.59)	0.0	0.00	0.00	0.67	3.1	
	Week 50	Tezepelumab	380	335 (88.2)	0.37 (0.62)	0.0	0.00	0.00	0.57	3.0	
		Placebo	371	302 (81.4)	0.38 (0.62)	0.0	0.00	0.00	0.71	3.0	
	Week 51	Tezepelumab	380	323 (85.0)	0.37 (0.65)	0.0	0.00	0.00	0.71	3.0	
		Placebo	371	300 (80.9)	0.38 (0.62)	0.0	0.00	0.00	0.71	3.0	
	Week 52	Tezepelumab	380	301 (79.2)	0.35 (0.62)	0.0	0.00	0.00	0.71	3.0	
		Placebo	371	274 (73.9)	0.38 (0.60)	0.0	0.00	0.00	0.71	3.1	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table NT1WAC\_ALMH0: Course of ASD weekly waking score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly waking score	Week 1	Tezepelumab	380	376 (98.9)	-0.22 (0.39)	-2.6	-0.43	-0.14	0.00	1.0	-0.14 [-0.28, 0.01]
		Placebo	371	365 (98.4)	-0.16 (0.41)	-2.1	-0.36	-0.02	0.00	1.5	
	Week 2	Tezepelumab	380	373 (98.2)	-0.26 (0.47)	-2.6	-0.57	-0.14	0.00	2.9	-0.13 [-0.27, 0.02]
		Placebo	371	367 (98.9)	-0.20 (0.50)	-2.3	-0.43	-0.14	0.00	1.6	
	Week 3	Tezepelumab	380	373 (98.2)	-0.32 (0.51)	-2.6	-0.57	-0.14	0.00	1.6	-0.11 [-0.25, 0.04]
		Placebo	371	365 (98.4)	-0.27 (0.53)	-2.1	-0.57	-0.14	0.00	2.0	
	Week 4	Tezepelumab	380	373 (98.2)	-0.36 (0.51)	-2.9	-0.67	-0.29	0.00	1.3	-0.14 [-0.29, 0.00]
		Placebo	371	361 (97.3)	-0.29 (0.53)	-2.5	-0.57	-0.14	0.00	1.1	
	Week 5	Tezepelumab	380	370 (97.4)	-0.42 (0.53)	-2.9	-0.71	-0.29	0.00	1.0	-0.17 [-0.31, -0.02]
		Placebo	371	358 (96.5)	-0.33 (0.55)	-3.6	-0.57	-0.23	0.00	1.6	
	Week 6	Tezepelumab	380	373 (98.2)	-0.43 (0.53)	-2.6	-0.71	-0.29	0.00	1.1	-0.17 [-0.32, -0.03]
		Placebo	371	361 (97.3)	-0.33 (0.58)	-3.4	-0.67	-0.14	0.00	1.6	
	Week 7	Tezepelumab	380	365 (96.1)	-0.43 (0.56)	-3.0	-0.71	-0.29	0.00	1.5	-0.14 [-0.28, 0.01]
		Placebo	371	361 (97.3)	-0.35 (0.59)	-3.3	-0.67	-0.24	0.00	1.3	
	Week 8	Tezepelumab	380	364 (95.8)	-0.47 (0.56)	-3.0	-0.86	-0.39	0.00	1.1	-0.17 [-0.31, -0.02]
		Placebo	371	359 (96.8)	-0.38 (0.60)	-3.8	-0.67	-0.29	0.00	2.0	
	Week 9	Tezepelumab	380	373 (98.2)	-0.50 (0.56)	-2.8	-0.86	-0.43	0.00	0.9	-0.20 [-0.34, -0.05]
		Placebo	371	355 (95.7)	-0.39 (0.61)	-4.0	-0.71	-0.29	0.00	1.7	
	Week 10	Tezepelumab	380	367 (96.6)	-0.49 (0.57)	-3.2	-0.86	-0.43	0.00	1.0	-0.21 [-0.35, -0.06]
		Placebo	371	350 (94.3)	-0.38 (0.58)	-4.0	-0.71	-0.29	0.00	1.1	
	Week 11	Tezepelumab	380	363 (95.5)	-0.49 (0.58)	-3.0	-0.86	-0.43	0.00	1.0	-0.14 [-0.29, 0.01]
		Placebo	371	355 (95.7)	-0.40 (0.59)	-4.0	-0.71	-0.29	0.00	1.1	
	Week 12	Tezepelumab	380	360 (94.7)	-0.48 (0.59)	-3.0	-0.86	-0.43	0.00	1.3	-0.11 [-0.25, 0.04]
		Placebo	371	350 (94.3)	-0.42 (0.60)	-4.0	-0.71	-0.29	0.00	2.0	
	Week 13	Tezepelumab	380	363 (95.5)	-0.50 (0.59)	-3.0	-0.86	-0.43	0.00	1.0	-0.10 [-0.25, 0.05]
		Placebo	371	352 (94.9)	-0.45 (0.59)	-4.0	-0.71	-0.29	0.00	1.3	
	Week 14	Tezepelumab	380	358 (94.2)	-0.53 (0.60)	-3.0	-1.00	-0.43	0.00	1.1	-0.18 [-0.33, -0.04]
		Placebo	371	351 (94.6)	-0.42 (0.59)	-4.0	-0.71	-0.29	0.00	1.1	
	Week 15	Tezepelumab	380	355 (93.4)	-0.53 (0.61)	-3.0	-1.00	-0.43	0.00	1.1	-0.20 [-0.35, -0.05]
		Placebo	371	335 (90.3)	-0.40 (0.61)	-4.0	-0.71	-0.29	0.00	2.2	
	Week 16	Tezepelumab	380	359 (94.5)	-0.53 (0.62)	-3.0	-1.00	-0.43	0.00	1.4	-0.20 [-0.35, -0.05]
		Placebo	371	340 (91.6)	-0.41 (0.60)	-4.0	-0.71	-0.29	0.00	1.3	
	Week 17	Tezepelumab	380	354 (93.2)	-0.52 (0.61)	-3.0	-1.00	-0.43	0.00	1.5	-0.16 [-0.31, -0.01]
		Placebo	371	337 (90.8)	-0.43 (0.61)	-4.0	-0.80	-0.29	0.00	1.0	
	Week 18	Tezepelumab	380	352 (92.6)	-0.52 (0.61)	-3.1	-0.97	-0.43	0.00	1.1	-0.18 [-0.33, -0.03]
		Placebo	371	337 (90.8)	-0.41 (0.59)	-2.7	-0.71	-0.29	0.00	1.4	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WAC\_ALMH0: Course of ASD weekly waking score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly waking score	Week 19	Tezepelumab	380	354 (93.2)	-0.54 (0.59)	-3.0	-0.89	-0.50	0.00	1.6	-0.18 [-0.33, -0.03]
		Placebo	371	337 (90.8)	-0.43 (0.62)	-4.0	-0.83	-0.29	0.00	1.7	
	Week 20	Tezepelumab	380	349 (91.8)	-0.56 (0.59)	-3.0	-1.00	-0.57	-0.14	1.0	-0.27 [-0.42, -0.12]
		Placebo	371	336 (90.6)	-0.40 (0.59)	-2.7	-0.82	-0.29	0.00	1.1	
	Week 21	Tezepelumab	380	350 (92.1)	-0.53 (0.61)	-3.1	-0.86	-0.43	0.00	2.9	-0.18 [-0.33, -0.03]
		Placebo	371	334 (90.0)	-0.42 (0.61)	-4.0	-0.83	-0.29	0.00	1.8	
	Week 22	Tezepelumab	380	350 (92.1)	-0.53 (0.60)	-3.3	-0.86	-0.43	0.00	1.4	-0.19 [-0.34, -0.03]
		Placebo	371	327 (88.1)	-0.42 (0.58)	-2.7	-0.71	-0.29	0.00	1.3	
	Week 23	Tezepelumab	380	345 (90.8)	-0.54 (0.60)	-3.3	-1.00	-0.43	0.00	1.4	-0.21 [-0.36, -0.05]
		Placebo	371	319 (86.0)	-0.42 (0.58)	-2.7	-0.81	-0.29	0.00	1.0	
	Week 24	Tezepelumab	380	344 (90.5)	-0.54 (0.61)	-3.3	-1.00	-0.43	0.00	1.7	-0.21 [-0.36, -0.05]
		Placebo	371	323 (87.1)	-0.41 (0.61)	-2.9	-0.80	-0.29	0.00	1.7	
	Week 25	Tezepelumab	380	347 (91.3)	-0.54 (0.59)	-3.3	-1.00	-0.46	-0.06	1.0	-0.17 [-0.32, -0.02]
		Placebo	371	321 (86.5)	-0.44 (0.62)	-4.0	-0.80	-0.29	0.00	1.8	
	Week 26	Tezepelumab	380	341 (89.7)	-0.52 (0.61)	-3.3	-0.86	-0.43	-0.14	2.5	-0.14 [-0.30, 0.01]
		Placebo	371	318 (85.7)	-0.43 (0.62)	-2.7	-0.86	-0.29	0.00	1.3	
	Week 27	Tezepelumab	380	348 (91.6)	-0.54 (0.58)	-3.0	-1.00	-0.50	0.00	1.0	-0.22 [-0.37, -0.06]
		Placebo	371	314 (84.6)	-0.41 (0.61)	-2.7	-0.83	-0.29	0.00	1.6	
	Week 28	Tezepelumab	380	347 (91.3)	-0.53 (0.59)	-3.3	-1.00	-0.49	0.00	1.3	-0.16 [-0.31, -0.01]
		Placebo	371	326 (87.9)	-0.44 (0.65)	-4.0	-0.86	-0.29	0.00	1.8	
	Week 29	Tezepelumab	380	342 (90.0)	-0.55 (0.57)	-3.3	-1.00	-0.43	-0.14	1.3	-0.21 [-0.36, -0.05]
		Placebo	371	325 (87.6)	-0.42 (0.63)	-4.0	-0.79	-0.29	0.00	1.4	
	Week 30	Tezepelumab	380	343 (90.3)	-0.53 (0.57)	-3.3	-1.00	-0.43	0.00	1.0	-0.21 [-0.36, -0.06]
		Placebo	371	318 (85.7)	-0.40 (0.68)	-4.0	-0.71	-0.29	0.00	2.2	
	Week 31	Tezepelumab	380	346 (91.1)	-0.54 (0.59)	-3.3	-1.00	-0.43	-0.12	1.0	-0.20 [-0.36, -0.05]
		Placebo	371	312 (84.1)	-0.41 (0.61)	-2.7	-0.80	-0.29	0.00	1.6	
	Week 32	Tezepelumab	380	347 (91.3)	-0.52 (0.59)	-3.3	-1.00	-0.43	0.00	1.3	-0.12 [-0.27, 0.03]
		Placebo	371	324 (87.3)	-0.45 (0.65)	-4.0	-0.85	-0.33	0.00	2.0	
	Week 33	Tezepelumab	380	344 (90.5)	-0.56 (0.60)	-3.3	-1.00	-0.54	-0.12	1.1	-0.20 [-0.36, -0.05]
		Placebo	371	317 (85.4)	-0.43 (0.66)	-4.0	-0.83	-0.29	0.00	1.6	
	Week 34	Tezepelumab	380	346 (91.1)	-0.54 (0.60)	-3.0	-1.00	-0.46	0.00	1.3	-0.16 [-0.31, -0.01]
		Placebo	371	322 (86.8)	-0.45 (0.61)	-2.7	-0.86	-0.33	0.00	1.6	
	Week 35	Tezepelumab	380	340 (89.5)	-0.52 (0.64)	-3.3	-1.00	-0.43	0.00	1.8	-0.14 [-0.30, 0.01]
		Placebo	371	310 (83.6)	-0.43 (0.61)	-2.7	-0.86	-0.31	0.00	1.8	
	Week 36	Tezepelumab	380	342 (90.0)	-0.53 (0.62)	-3.3	-1.00	-0.43	0.00	2.1	-0.15 [-0.31, 0.00]
		Placebo	371	315 (84.9)	-0.43 (0.63)	-4.0	-0.83	-0.29	0.00	1.4	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WAC\_ALMH0: Course of ASD weekly waking score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly waking score	Week 37	Tezepelumab	380	336 (88.4)	-0.54 (0.62)	-3.0	-1.00	-0.54	0.00	1.8	-0.15 [-0.31, -0.00]
		Placebo	371	317 (85.4)	-0.44 (0.65)	-4.0	-0.86	-0.30	0.00	1.7	
	Week 38	Tezepelumab	380	335 (88.2)	-0.54 (0.63)	-3.1	-1.00	-0.57	0.00	2.0	-0.17 [-0.33, -0.02]
		Placebo	371	314 (84.6)	-0.43 (0.63)	-4.0	-0.80	-0.29	0.00	1.6	
	Week 39	Tezepelumab	380	339 (89.2)	-0.53 (0.61)	-3.3	-1.00	-0.43	0.00	2.0	-0.15 [-0.30, 0.01]
		Placebo	371	318 (85.7)	-0.44 (0.65)	-4.0	-0.86	-0.29	0.00	1.6	
	Week 40	Tezepelumab	380	341 (89.7)	-0.56 (0.62)	-3.3	-1.00	-0.50	0.00	1.3	-0.24 [-0.40, -0.09]
		Placebo	371	316 (85.2)	-0.40 (0.64)	-4.0	-0.85	-0.29	0.00	1.9	
	Week 41	Tezepelumab	380	342 (90.0)	-0.56 (0.62)	-3.3	-1.00	-0.54	-0.14	1.1	-0.20 [-0.35, -0.04]
		Placebo	371	315 (84.9)	-0.44 (0.63)	-4.0	-0.86	-0.29	0.00	1.7	
	Week 42	Tezepelumab	380	335 (88.2)	-0.53 (0.59)	-3.0	-1.00	-0.50	-0.14	1.1	-0.19 [-0.35, -0.04]
		Placebo	371	315 (84.9)	-0.41 (0.67)	-4.0	-0.86	-0.29	0.00	2.0	
	Week 43	Tezepelumab	380	335 (88.2)	-0.56 (0.60)	-3.3	-1.00	-0.57	-0.06	1.9	-0.20 [-0.36, -0.05]
		Placebo	371	311 (83.8)	-0.43 (0.65)	-4.0	-0.86	-0.29	0.00	1.7	
	Week 44	Tezepelumab	380	332 (87.4)	-0.54 (0.60)	-3.3	-1.00	-0.57	0.00	1.3	-0.17 [-0.32, -0.01]
		Placebo	371	309 (83.3)	-0.44 (0.65)	-4.0	-0.86	-0.29	0.00	1.7	
	Week 45	Tezepelumab	380	340 (89.5)	-0.56 (0.60)	-3.3	-1.00	-0.55	-0.12	1.3	-0.18 [-0.33, -0.02]
		Placebo	371	315 (84.9)	-0.45 (0.64)	-4.0	-0.86	-0.33	0.00	1.7	
	Week 46	Tezepelumab	380	336 (88.4)	-0.55 (0.61)	-3.1	-1.00	-0.50	-0.07	1.1	-0.14 [-0.30, 0.01]
		Placebo	371	309 (83.3)	-0.46 (0.65)	-4.0	-0.86	-0.29	0.00	1.7	
	Week 47	Tezepelumab	380	328 (86.3)	-0.55 (0.62)	-3.3	-1.00	-0.50	0.00	1.2	-0.17 [-0.33, -0.01]
		Placebo	371	306 (82.5)	-0.44 (0.64)	-4.0	-0.83	-0.29	0.00	1.7	
	Week 48	Tezepelumab	380	342 (90.0)	-0.55 (0.62)	-3.3	-1.00	-0.50	0.00	1.7	-0.14 [-0.29, 0.01]
		Placebo	371	309 (83.3)	-0.46 (0.63)	-4.0	-0.86	-0.29	0.00	1.6	
	Week 49	Tezepelumab	380	344 (90.5)	-0.56 (0.61)	-3.1	-1.00	-0.57	0.00	1.3	-0.16 [-0.31, -0.00]
		Placebo	371	308 (83.0)	-0.46 (0.62)	-4.0	-0.86	-0.40	0.00	1.6	
	Week 50	Tezepelumab	380	335 (88.2)	-0.55 (0.61)	-3.0	-1.00	-0.43	0.00	1.6	-0.16 [-0.32, -0.01]
		Placebo	371	302 (81.4)	-0.45 (0.67)	-4.0	-0.86	-0.40	0.00	2.0	
	Week 51	Tezepelumab	380	323 (85.0)	-0.55 (0.63)	-3.3	-1.00	-0.43	0.00	1.6	-0.16 [-0.31, 0.00]
		Placebo	371	300 (80.9)	-0.45 (0.68)	-4.0	-0.86	-0.29	0.00	2.0	
	Week 52	Tezepelumab	380	301 (79.2)	-0.56 (0.64)	-3.3	-1.00	-0.57	0.00	1.3	-0.15 [-0.32, 0.01]
		Placebo	371	274 (73.9)	-0.46 (0.67)	-4.0	-0.83	-0.33	0.00	1.7	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WAC\_ALMC0: Change from baseline in ASD weekly waking score - MMRM results  
 DITTL - adult

Change from baseline in ASD weekly waking score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 1	Tezepelumab	380	376 (98.9)	-0.20 (0.03)	(-0.25, -0.15)	-0.02 (0.04)	(-0.09, 0.05)	0.608	
	Placebo	371	365 (98.4)	-0.18 (0.03)	(-0.23, -0.13)				
Week 2	Tezepelumab	380	373 (98.2)	-0.24 (0.03)	(-0.29, -0.19)	-0.02 (0.04)	(-0.10, 0.05)	0.507	
	Placebo	371	367 (98.9)	-0.21 (0.03)	(-0.27, -0.16)				
Week 3	Tezepelumab	380	373 (98.2)	-0.30 (0.03)	(-0.36, -0.25)	-0.03 (0.04)	(-0.10, 0.04)	0.436	
	Placebo	371	365 (98.4)	-0.28 (0.03)	(-0.33, -0.23)				
Week 4	Tezepelumab	380	373 (98.2)	-0.34 (0.03)	(-0.39, -0.29)	-0.04 (0.04)	(-0.11, 0.03)	0.261	
	Placebo	371	361 (97.3)	-0.30 (0.03)	(-0.35, -0.25)				
Week 5	Tezepelumab	380	370 (97.4)	-0.40 (0.03)	(-0.45, -0.35)	-0.06 (0.04)	(-0.13, 0.01)	0.113	
	Placebo	371	358 (96.5)	-0.34 (0.03)	(-0.39, -0.29)				
Week 6	Tezepelumab	380	373 (98.2)	-0.41 (0.03)	(-0.46, -0.35)	-0.06 (0.04)	(-0.13, 0.02)	0.124	
	Placebo	371	361 (97.3)	-0.35 (0.03)	(-0.40, -0.30)				
Week 7	Tezepelumab	380	365 (96.1)	-0.41 (0.03)	(-0.46, -0.36)	-0.06 (0.04)	(-0.13, 0.01)	0.118	
	Placebo	371	361 (97.3)	-0.35 (0.03)	(-0.40, -0.30)				
Week 8	Tezepelumab	380	364 (95.8)	-0.45 (0.03)	(-0.50, -0.40)	-0.08 (0.04)	(-0.15, -0.00)	0.036 *	
	Placebo	371	359 (96.8)	-0.37 (0.03)	(-0.42, -0.32)				
Week 9	Tezepelumab	380	373 (98.2)	-0.48 (0.03)	(-0.53, -0.43)	-0.09 (0.04)	(-0.16, -0.02)	0.013 *	
	Placebo	371	355 (95.7)	-0.39 (0.03)	(-0.44, -0.34)				
Week 10	Tezepelumab	380	367 (96.6)	-0.47 (0.03)	(-0.52, -0.42)	-0.09 (0.04)	(-0.16, -0.02)	0.014 *	
	Placebo	371	350 (94.3)	-0.38 (0.03)	(-0.43, -0.33)				

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WAC\_ALMC0: Change from baseline in ASD weekly waking score - MMRM results  
 DITTL - adult

Change from baseline in ASD weekly waking score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 11	Tezepelumab	380	363 (95.5)	-0.46 (0.03)	(-0.51, -0.41)	-0.05 (0.04)	(-0.12, 0.02)	0.169	
	Placebo	371	355 (95.7)	-0.41 (0.03)	(-0.46, -0.36)				
Week 12	Tezepelumab	380	360 (94.7)	-0.46 (0.03)	(-0.51, -0.40)	-0.04 (0.04)	(-0.11, 0.04)	0.313	
	Placebo	371	350 (94.3)	-0.42 (0.03)	(-0.47, -0.37)				
Week 13	Tezepelumab	380	363 (95.5)	-0.48 (0.03)	(-0.53, -0.43)	-0.04 (0.04)	(-0.11, 0.04)	0.339	
	Placebo	371	352 (94.9)	-0.44 (0.03)	(-0.49, -0.39)				
Week 14	Tezepelumab	380	358 (94.2)	-0.50 (0.03)	(-0.55, -0.45)	-0.07 (0.04)	(-0.15, -0.00)	0.049 *	
	Placebo	371	351 (94.6)	-0.43 (0.03)	(-0.48, -0.37)				
Week 15	Tezepelumab	380	355 (93.4)	-0.50 (0.03)	(-0.55, -0.45)	-0.09 (0.04)	(-0.16, -0.02)	0.016 *	
	Placebo	371	335 (90.3)	-0.41 (0.03)	(-0.46, -0.36)				
Week 16	Tezepelumab	380	359 (94.5)	-0.50 (0.03)	(-0.55, -0.45)	-0.10 (0.04)	(-0.17, -0.02)	0.009 *	
	Placebo	371	340 (91.6)	-0.40 (0.03)	(-0.45, -0.35)				
Week 17	Tezepelumab	380	354 (93.2)	-0.50 (0.03)	(-0.55, -0.45)	-0.07 (0.04)	(-0.14, 0.00)	0.064	
	Placebo	371	337 (90.8)	-0.43 (0.03)	(-0.48, -0.38)				
Week 18	Tezepelumab	380	352 (92.6)	-0.49 (0.03)	(-0.54, -0.43)	-0.06 (0.04)	(-0.13, 0.01)	0.109	
	Placebo	371	337 (90.8)	-0.43 (0.03)	(-0.48, -0.37)				
Week 19	Tezepelumab	380	354 (93.2)	-0.51 (0.03)	(-0.56, -0.46)	-0.08 (0.04)	(-0.15, -0.00)	0.039 *	
	Placebo	371	337 (90.8)	-0.43 (0.03)	(-0.48, -0.38)				
Week 20	Tezepelumab	380	349 (91.8)	-0.52 (0.03)	(-0.58, -0.47)	-0.10 (0.04)	(-0.18, -0.03)	0.006 *	
	Placebo	371	336 (90.6)	-0.42 (0.03)	(-0.47, -0.37)				

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WAC\_ALMC0: Change from baseline in ASD weekly waking score - MMRM results  
 DITTTL - adult

Change from baseline in ASD weekly waking score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Time	Treatment	N	n (%)						
Week 21	Tezepelumab	380	350 (92.1)	-0.51 (0.03)	(-0.56, -0.46)	-0.07 (0.04)	(-0.14, 0.01)	0.081	
	Placebo	371	334 (90.0)	-0.44 (0.03)	(-0.50, -0.39)				
Week 22	Tezepelumab	380	350 (92.1)	-0.51 (0.03)	(-0.56, -0.46)	-0.07 (0.04)	(-0.14, 0.01)	0.075	
	Placebo	371	327 (88.1)	-0.44 (0.03)	(-0.49, -0.39)				
Week 23	Tezepelumab	380	345 (90.8)	-0.51 (0.03)	(-0.57, -0.46)	-0.08 (0.04)	(-0.16, -0.01)	0.025 *	
	Placebo	371	319 (86.0)	-0.43 (0.03)	(-0.48, -0.38)				
Week 24	Tezepelumab	380	344 (90.5)	-0.52 (0.03)	(-0.57, -0.47)	-0.09 (0.04)	(-0.17, -0.02)	0.015 *	
	Placebo	371	323 (87.1)	-0.43 (0.03)	(-0.48, -0.38)				
Week 25	Tezepelumab	380	347 (91.3)	-0.52 (0.03)	(-0.57, -0.47)	-0.08 (0.04)	(-0.15, -0.00)	0.044 *	
	Placebo	371	321 (86.5)	-0.45 (0.03)	(-0.50, -0.39)				
Week 26	Tezepelumab	380	341 (89.7)	-0.51 (0.03)	(-0.56, -0.45)	-0.07 (0.04)	(-0.14, 0.01)	0.078	
	Placebo	371	318 (85.7)	-0.44 (0.03)	(-0.49, -0.39)				
Week 27	Tezepelumab	380	348 (91.6)	-0.52 (0.03)	(-0.57, -0.47)	-0.09 (0.04)	(-0.16, -0.02)	0.018 *	
	Placebo	371	314 (84.6)	-0.43 (0.03)	(-0.48, -0.38)				
Week 28	Tezepelumab	380	347 (91.3)	-0.52 (0.03)	(-0.58, -0.47)	-0.08 (0.04)	(-0.16, -0.01)	0.029 *	
	Placebo	371	326 (87.9)	-0.44 (0.03)	(-0.49, -0.39)				
Week 29	Tezepelumab	380	342 (90.0)	-0.53 (0.03)	(-0.58, -0.47)	-0.09 (0.04)	(-0.17, -0.02)	0.015 *	
	Placebo	371	325 (87.6)	-0.43 (0.03)	(-0.49, -0.38)				
Week 30	Tezepelumab	380	343 (90.3)	-0.51 (0.03)	(-0.57, -0.46)	-0.10 (0.04)	(-0.17, -0.02)	0.011 *	
	Placebo	371	318 (85.7)	-0.42 (0.03)	(-0.47, -0.37)				

Note: DITTTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WAC\_ALMC0: Change from baseline in ASD weekly waking score - MMRM results  
 DITTTL - adult

Change from baseline in ASD weekly waking score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Time	Treatment	N	n (%)						
Week 31	Tezepelumab	380	346 (91.1)	-0.52 (0.03)	(-0.57, -0.47)	-0.08 (0.04)	(-0.15, -0.00)	0.039	*
	Placebo	371	312 (84.1)	-0.44 (0.03)	(-0.50, -0.39)				
Week 32	Tezepelumab	380	347 (91.3)	-0.51 (0.03)	(-0.56, -0.46)	-0.05 (0.04)	(-0.12, 0.03)	0.199	
	Placebo	371	324 (87.3)	-0.46 (0.03)	(-0.51, -0.41)				
Week 33	Tezepelumab	380	344 (90.5)	-0.53 (0.03)	(-0.59, -0.48)	-0.09 (0.04)	(-0.16, -0.01)	0.021	*
	Placebo	371	317 (85.4)	-0.45 (0.03)	(-0.50, -0.39)				
Week 34	Tezepelumab	380	346 (91.1)	-0.53 (0.03)	(-0.58, -0.47)	-0.06 (0.04)	(-0.14, 0.01)	0.111	
	Placebo	371	322 (86.8)	-0.46 (0.03)	(-0.52, -0.41)				
Week 35	Tezepelumab	380	340 (89.5)	-0.51 (0.03)	(-0.56, -0.46)	-0.05 (0.04)	(-0.12, 0.03)	0.210	
	Placebo	371	310 (83.6)	-0.46 (0.03)	(-0.52, -0.41)				
Week 36	Tezepelumab	380	342 (90.0)	-0.52 (0.03)	(-0.57, -0.46)	-0.06 (0.04)	(-0.14, 0.01)	0.089	
	Placebo	371	315 (84.9)	-0.45 (0.03)	(-0.50, -0.40)				
Week 37	Tezepelumab	380	336 (88.4)	-0.53 (0.03)	(-0.58, -0.47)	-0.06 (0.04)	(-0.14, 0.01)	0.108	
	Placebo	371	317 (85.4)	-0.46 (0.03)	(-0.52, -0.41)				
Week 38	Tezepelumab	380	335 (88.2)	-0.51 (0.03)	(-0.57, -0.46)	-0.07 (0.04)	(-0.14, 0.01)	0.080	
	Placebo	371	314 (84.6)	-0.45 (0.03)	(-0.50, -0.39)				
Week 39	Tezepelumab	380	339 (89.2)	-0.52 (0.03)	(-0.57, -0.47)	-0.05 (0.04)	(-0.13, 0.02)	0.181	
	Placebo	371	318 (85.7)	-0.47 (0.03)	(-0.52, -0.41)				
Week 40	Tezepelumab	380	341 (89.7)	-0.53 (0.03)	(-0.58, -0.48)	-0.10 (0.04)	(-0.17, -0.02)	0.011	*
	Placebo	371	316 (85.2)	-0.43 (0.03)	(-0.49, -0.38)				

Note: DITTTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WAC\_ALMC0: Change from baseline in ASD weekly waking score - MMRM results  
 DITTl - adult

Change from baseline in ASD weekly waking score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 41	Tezepelumab	380	342 (90.0)	-0.54 (0.03)	(-0.60, -0.49)	-0.08 (0.04)	(-0.15, -0.00)	0.038 *	
	Placebo	371	315 (84.9)	-0.46 (0.03)	(-0.52, -0.41)				
Week 42	Tezepelumab	380	335 (88.2)	-0.52 (0.03)	(-0.58, -0.47)	-0.08 (0.04)	(-0.16, -0.01)	0.030 *	
	Placebo	371	315 (84.9)	-0.44 (0.03)	(-0.49, -0.39)				
Week 43	Tezepelumab	380	335 (88.2)	-0.54 (0.03)	(-0.60, -0.49)	-0.08 (0.04)	(-0.15, -0.00)	0.039 *	
	Placebo	371	311 (83.8)	-0.46 (0.03)	(-0.52, -0.41)				
Week 44	Tezepelumab	380	332 (87.4)	-0.53 (0.03)	(-0.59, -0.48)	-0.08 (0.04)	(-0.15, -0.00)	0.048 *	
	Placebo	371	309 (83.3)	-0.46 (0.03)	(-0.51, -0.40)				
Week 45	Tezepelumab	380	340 (89.5)	-0.55 (0.03)	(-0.60, -0.50)	-0.07 (0.04)	(-0.15, 0.00)	0.053	
	Placebo	371	315 (84.9)	-0.47 (0.03)	(-0.53, -0.42)				
Week 46	Tezepelumab	380	336 (88.4)	-0.54 (0.03)	(-0.59, -0.49)	-0.06 (0.04)	(-0.14, 0.01)	0.092	
	Placebo	371	309 (83.3)	-0.48 (0.03)	(-0.53, -0.42)				
Week 47	Tezepelumab	380	328 (86.3)	-0.54 (0.03)	(-0.59, -0.48)	-0.07 (0.04)	(-0.14, 0.01)	0.081	
	Placebo	371	306 (82.5)	-0.47 (0.03)	(-0.52, -0.41)				
Week 48	Tezepelumab	380	342 (90.0)	-0.54 (0.03)	(-0.59, -0.49)	-0.06 (0.04)	(-0.14, 0.01)	0.109	
	Placebo	371	309 (83.3)	-0.48 (0.03)	(-0.53, -0.42)				
Week 49	Tezepelumab	380	344 (90.5)	-0.55 (0.03)	(-0.60, -0.49)	-0.07 (0.04)	(-0.14, 0.01)	0.091	
	Placebo	371	308 (83.0)	-0.48 (0.03)	(-0.54, -0.43)				
Week 50	Tezepelumab	380	335 (88.2)	-0.55 (0.03)	(-0.60, -0.50)	-0.08 (0.04)	(-0.15, -0.00)	0.046 *	
	Placebo	371	302 (81.4)	-0.47 (0.03)	(-0.53, -0.42)				

Note: DITTl - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table NT1WAC\_ALMC0: Change from baseline in ASD weekly waking score - MMRM results  
 DITTL - adult

Change from baseline in ASD weekly waking score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 51	Tezepelumab	380	323 (85.0)	-0.55 (0.03)	(-0.60, -0.49)	-0.08 (0.04)	(-0.16, -0.00)	0.043 *
	Placebo	371	300 (80.9)	-0.47 (0.03)	(-0.52, -0.41)			
Week 52	Tezepelumab	380	301 (79.2)	-0.55 (0.03)	(-0.60, -0.50)	-0.08 (0.04)	(-0.16, -0.00)	0.045 *
	Placebo	371	274 (73.9)	-0.47 (0.03)	(-0.53, -0.41)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WLC\_ALMH0: Course of ASD weekly limiting activity score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly limiting activity score	Baseline	Tezepelumab	380	380 (100.0)	1.64 (0.86)	0.0	1.00	1.57	2.14	4.0	
		Placebo	371	371 (100.0)	1.58 (0.83)	0.0	1.00	1.43	2.00	4.0	
	Week 1	Tezepelumab	380	373 (98.2)	1.41 (0.78)	0.0	1.00	1.29	2.00	3.9	
		Placebo	371	365 (98.4)	1.47 (0.81)	0.0	1.00	1.43	2.00	3.9	
	Week 2	Tezepelumab	380	372 (97.9)	1.26 (0.80)	0.0	0.86	1.00	1.86	3.4	
		Placebo	371	365 (98.4)	1.37 (0.79)	0.0	0.86	1.17	2.00	4.0	
	Week 3	Tezepelumab	380	371 (97.6)	1.21 (0.81)	0.0	0.75	1.00	1.71	3.3	
		Placebo	371	359 (96.8)	1.26 (0.80)	0.0	0.83	1.14	1.86	4.0	
	Week 4	Tezepelumab	380	368 (96.8)	1.17 (0.82)	0.0	0.67	1.00	1.76	3.6	
		Placebo	371	363 (97.8)	1.22 (0.79)	0.0	0.71	1.14	1.86	4.0	
	Week 5	Tezepelumab	380	371 (97.6)	1.13 (0.81)	0.0	0.57	1.00	1.60	3.7	
		Placebo	371	354 (95.4)	1.17 (0.78)	0.0	0.57	1.00	1.83	4.0	
	Week 6	Tezepelumab	380	366 (96.3)	1.10 (0.82)	0.0	0.50	1.00	1.71	4.0	
		Placebo	371	360 (97.0)	1.18 (0.82)	0.0	0.57	1.00	1.86	4.0	
	Week 7	Tezepelumab	380	366 (96.3)	1.09 (0.86)	0.0	0.33	1.00	1.71	4.0	
		Placebo	371	358 (96.5)	1.15 (0.82)	0.0	0.57	1.00	1.71	4.0	
	Week 8	Tezepelumab	380	366 (96.3)	1.06 (0.82)	0.0	0.33	1.00	1.71	4.0	
		Placebo	371	353 (95.1)	1.13 (0.83)	0.0	0.50	1.00	1.83	4.0	
	Week 9	Tezepelumab	380	369 (97.1)	1.01 (0.80)	0.0	0.29	1.00	1.57	4.0	
		Placebo	371	351 (94.6)	1.09 (0.80)	0.0	0.43	1.00	1.67	4.0	
	Week 10	Tezepelumab	380	370 (97.4)	0.99 (0.80)	0.0	0.17	1.00	1.43	4.0	
		Placebo	371	347 (93.5)	1.09 (0.78)	0.0	0.43	1.00	1.60	4.0	
	Week 11	Tezepelumab	380	362 (95.3)	0.99 (0.82)	0.0	0.14	1.00	1.43	4.0	
		Placebo	371	347 (93.5)	1.09 (0.82)	0.0	0.29	1.00	1.71	4.0	
	Week 12	Tezepelumab	380	364 (95.8)	1.01 (0.82)	0.0	0.24	1.00	1.41	4.0	
		Placebo	371	344 (92.7)	1.07 (0.84)	0.0	0.29	1.00	1.77	4.0	
	Week 13	Tezepelumab	380	358 (94.2)	0.99 (0.82)	0.0	0.17	1.00	1.43	3.9	
		Placebo	371	341 (91.9)	1.05 (0.82)	0.0	0.29	1.00	1.67	4.0	
	Week 14	Tezepelumab	380	356 (93.7)	0.96 (0.81)	0.0	0.14	1.00	1.43	4.0	
		Placebo	371	347 (93.5)	1.07 (0.82)	0.0	0.29	1.00	1.71	4.0	
	Week 15	Tezepelumab	380	359 (94.5)	0.95 (0.80)	0.0	0.14	1.00	1.43	3.9	
		Placebo	371	338 (91.1)	1.06 (0.86)	0.0	0.17	1.00	1.67	4.0	
Week 16	Tezepelumab	380	354 (93.2)	0.94 (0.80)	0.0	0.14	1.00	1.29	4.0		
	Placebo	371	338 (91.1)	1.07 (0.87)	0.0	0.17	1.00	1.83	4.0		
Week 17	Tezepelumab	380	354 (93.2)	0.88 (0.80)	0.0	0.00	1.00	1.29	4.0		
	Placebo	371	335 (90.3)	1.02 (0.85)	0.0	0.14	1.00	1.67	4.0		

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WLC\_ALMH0: Course of ASD weekly limiting activity score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly limiting activity score	Week 18	Tezepelumab	380	354 (93.2)	0.92 (0.81)	0.0	0.14	1.00	1.29	4.0	
		Placebo	371	335 (90.3)	1.00 (0.84)	0.0	0.14	1.00	1.57	4.0	
	Week 19	Tezepelumab	380	344 (90.5)	0.92 (0.83)	0.0	0.00	1.00	1.29	4.0	
		Placebo	371	333 (89.8)	1.04 (0.86)	0.0	0.14	1.00	1.71	4.0	
	Week 20	Tezepelumab	380	344 (90.5)	0.91 (0.84)	0.0	0.00	1.00	1.24	4.0	
		Placebo	371	330 (88.9)	1.03 (0.85)	0.0	0.17	1.00	1.75	4.0	
	Week 21	Tezepelumab	380	347 (91.3)	0.89 (0.83)	0.0	0.00	1.00	1.25	4.0	
		Placebo	371	325 (87.6)	1.00 (0.87)	0.0	0.00	1.00	1.71	4.0	
	Week 22	Tezepelumab	380	343 (90.3)	0.93 (0.85)	0.0	0.00	1.00	1.29	4.0	
		Placebo	371	321 (86.5)	0.99 (0.85)	0.0	0.14	1.00	1.57	4.0	
	Week 23	Tezepelumab	380	346 (91.1)	0.90 (0.84)	0.0	0.00	1.00	1.33	4.0	
		Placebo	371	324 (87.3)	0.98 (0.85)	0.0	0.14	1.00	1.54	4.0	
	Week 24	Tezepelumab	380	345 (90.8)	0.92 (0.84)	0.0	0.00	1.00	1.29	4.0	
		Placebo	371	321 (86.5)	0.97 (0.86)	0.0	0.00	1.00	1.71	4.0	
	Week 25	Tezepelumab	380	342 (90.0)	0.91 (0.81)	0.0	0.00	1.00	1.40	4.0	
		Placebo	371	312 (84.1)	0.99 (0.87)	0.0	0.00	1.00	1.60	4.0	
	Week 26	Tezepelumab	380	339 (89.2)	0.91 (0.83)	0.0	0.00	1.00	1.33	4.0	
		Placebo	371	314 (84.6)	0.99 (0.89)	0.0	0.00	1.00	1.71	4.0	
	Week 27	Tezepelumab	380	337 (88.7)	0.89 (0.82)	0.0	0.00	1.00	1.17	4.0	
		Placebo	371	319 (86.0)	0.98 (0.91)	0.0	0.00	1.00	1.57	4.0	
	Week 28	Tezepelumab	380	340 (89.5)	0.88 (0.84)	0.0	0.00	1.00	1.20	4.0	
		Placebo	371	322 (86.8)	0.99 (0.88)	0.0	0.00	1.00	1.71	4.0	
	Week 29	Tezepelumab	380	340 (89.5)	0.86 (0.81)	0.0	0.00	1.00	1.17	4.0	
		Placebo	371	315 (84.9)	1.00 (0.90)	0.0	0.00	1.00	1.80	4.0	
	Week 30	Tezepelumab	380	335 (88.2)	0.90 (0.81)	0.0	0.00	1.00	1.29	4.0	
		Placebo	371	307 (82.7)	0.99 (0.88)	0.0	0.00	1.00	1.75	4.0	
	Week 31	Tezepelumab	380	346 (91.1)	0.89 (0.84)	0.0	0.00	1.00	1.29	4.0	
		Placebo	371	318 (85.7)	0.99 (0.85)	0.0	0.00	1.00	1.67	4.0	
	Week 32	Tezepelumab	380	336 (88.4)	0.90 (0.81)	0.0	0.00	1.00	1.29	3.9	
		Placebo	371	314 (84.6)	1.02 (0.87)	0.0	0.14	1.00	1.71	4.0	
	Week 33	Tezepelumab	380	333 (87.6)	0.87 (0.81)	0.0	0.00	1.00	1.20	4.0	
		Placebo	371	314 (84.6)	1.00 (0.87)	0.0	0.00	1.00	1.71	4.0	
	Week 34	Tezepelumab	380	337 (88.7)	0.86 (0.84)	0.0	0.00	1.00	1.17	4.0	
		Placebo	371	312 (84.1)	0.97 (0.87)	0.0	0.00	1.00	1.57	4.0	
	Week 35	Tezepelumab	380	333 (87.6)	0.87 (0.83)	0.0	0.00	1.00	1.29	4.0	
		Placebo	371	305 (82.2)	0.97 (0.84)	0.0	0.00	1.00	1.50	4.0	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WLC\_ALMH0: Course of ASD weekly limiting activity score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ASD weekly limiting activity score	Week 36	Tezepelumab	380	335 (88.2)	0.88 (0.84)	0.0	0.00	1.00	1.25	4.0	
		Placebo	371	303 (81.7)	0.98 (0.83)	0.0	0.00	1.00	1.43	4.0	
	Week 37	Tezepelumab	380	329 (86.6)	0.88 (0.83)	0.0	0.00	1.00	1.17	4.0	
		Placebo	371	313 (84.4)	0.97 (0.85)	0.0	0.00	1.00	1.43	4.0	
	Week 38	Tezepelumab	380	335 (88.2)	0.87 (0.85)	0.0	0.00	1.00	1.20	4.0	
		Placebo	371	309 (83.3)	0.96 (0.85)	0.0	0.00	1.00	1.50	4.0	
	Week 39	Tezepelumab	380	335 (88.2)	0.89 (0.87)	0.0	0.00	1.00	1.29	4.0	
		Placebo	371	304 (81.9)	0.97 (0.86)	0.0	0.00	1.00	1.67	3.9	
	Week 40	Tezepelumab	380	335 (88.2)	0.88 (0.84)	0.0	0.00	1.00	1.20	3.9	
		Placebo	371	310 (83.6)	0.96 (0.87)	0.0	0.00	1.00	1.71	4.0	
	Week 41	Tezepelumab	380	333 (87.6)	0.86 (0.81)	0.0	0.00	1.00	1.14	3.0	
		Placebo	371	310 (83.6)	0.97 (0.87)	0.0	0.00	1.00	1.60	4.0	
	Week 42	Tezepelumab	380	331 (87.1)	0.85 (0.83)	0.0	0.00	1.00	1.20	3.0	
		Placebo	371	309 (83.3)	0.96 (0.88)	0.0	0.00	1.00	1.60	4.0	
	Week 43	Tezepelumab	380	333 (87.6)	0.87 (0.84)	0.0	0.00	1.00	1.17	3.8	
		Placebo	371	308 (83.0)	0.95 (0.87)	0.0	0.00	1.00	1.57	4.0	
	Week 44	Tezepelumab	380	331 (87.1)	0.86 (0.83)	0.0	0.00	1.00	1.17	3.8	
		Placebo	371	309 (83.3)	0.97 (0.86)	0.0	0.00	1.00	1.67	4.0	
	Week 45	Tezepelumab	380	333 (87.6)	0.85 (0.82)	0.0	0.00	1.00	1.14	3.3	
		Placebo	371	308 (83.0)	0.94 (0.86)	0.0	0.00	1.00	1.54	4.0	
	Week 46	Tezepelumab	380	331 (87.1)	0.85 (0.82)	0.0	0.00	1.00	1.29	3.4	
		Placebo	371	302 (81.4)	0.93 (0.85)	0.0	0.00	1.00	1.50	4.0	
	Week 47	Tezepelumab	380	329 (86.6)	0.86 (0.83)	0.0	0.00	1.00	1.14	3.0	
		Placebo	371	298 (80.3)	0.92 (0.83)	0.0	0.00	1.00	1.43	4.0	
	Week 48	Tezepelumab	380	331 (87.1)	0.86 (0.84)	0.0	0.00	1.00	1.29	4.0	
		Placebo	371	304 (81.9)	0.91 (0.82)	0.0	0.00	1.00	1.40	4.0	
	Week 49	Tezepelumab	380	328 (86.3)	0.86 (0.86)	0.0	0.00	1.00	1.18	3.4	
		Placebo	371	301 (81.1)	0.94 (0.82)	0.0	0.00	1.00	1.33	4.0	
	Week 50	Tezepelumab	380	328 (86.3)	0.85 (0.82)	0.0	0.00	1.00	1.20	3.0	
		Placebo	371	300 (80.9)	0.94 (0.84)	0.0	0.00	1.00	1.41	4.0	
	Week 51	Tezepelumab	380	321 (84.5)	0.85 (0.84)	0.0	0.00	1.00	1.29	3.0	
		Placebo	371	292 (78.7)	0.93 (0.85)	0.0	0.00	1.00	1.43	4.0	
	Week 52	Tezepelumab	380	294 (77.4)	0.88 (0.86)	0.0	0.00	1.00	1.20	3.2	
		Placebo	371	273 (73.6)	0.94 (0.88)	0.0	0.00	1.00	1.57	4.0	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WLC\_ALMH0: Course of ASD weekly limiting activity score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly limiting activity score	Week 1	Tezepelumab	380	373 (98.2)	-0.21 (0.46)	-1.8	-0.43	-0.14	0.00	1.1	-0.20 [-0.35, -0.06]
		Placebo	371	365 (98.4)	-0.12 (0.47)	-2.7	-0.29	0.00	0.14	1.4	
	Week 2	Tezepelumab	380	372 (97.9)	-0.37 (0.63)	-3.1	-0.69	-0.14	0.00	1.0	-0.26 [-0.40, -0.11]
		Placebo	371	365 (98.4)	-0.20 (0.63)	-3.0	-0.43	-0.09	0.14	1.6	
	Week 3	Tezepelumab	380	371 (97.6)	-0.42 (0.68)	-3.9	-0.71	-0.29	0.00	1.3	-0.14 [-0.29, 0.00]
		Placebo	371	359 (96.8)	-0.32 (0.67)	-3.0	-0.67	-0.17	0.00	1.7	
	Week 4	Tezepelumab	380	368 (96.8)	-0.45 (0.71)	-3.9	-0.86	-0.25	0.00	1.1	-0.12 [-0.27, 0.02]
		Placebo	371	363 (97.8)	-0.36 (0.72)	-3.1	-0.71	-0.23	0.00	2.3	
	Week 5	Tezepelumab	380	371 (97.6)	-0.50 (0.73)	-4.0	-0.86	-0.33	0.00	1.0	-0.13 [-0.27, 0.02]
		Placebo	371	354 (95.4)	-0.41 (0.73)	-3.9	-0.83	-0.29	0.00	2.0	
	Week 6	Tezepelumab	380	366 (96.3)	-0.53 (0.79)	-4.0	-1.00	-0.32	0.00	1.1	-0.16 [-0.31, -0.01]
		Placebo	371	360 (97.0)	-0.40 (0.77)	-3.5	-0.83	-0.29	0.00	2.0	
	Week 7	Tezepelumab	380	366 (96.3)	-0.55 (0.84)	-4.0	-1.00	-0.43	0.00	2.1	-0.13 [-0.28, 0.02]
		Placebo	371	358 (96.5)	-0.44 (0.82)	-3.8	-0.86	-0.29	0.00	1.9	
	Week 8	Tezepelumab	380	366 (96.3)	-0.57 (0.83)	-4.0	-1.00	-0.38	0.00	1.5	-0.15 [-0.30, -0.00]
		Placebo	371	353 (95.1)	-0.45 (0.80)	-4.0	-0.86	-0.29	0.00	1.9	
	Week 9	Tezepelumab	380	369 (97.1)	-0.61 (0.85)	-4.0	-1.00	-0.43	0.00	1.4	-0.14 [-0.29, 0.00]
		Placebo	371	351 (94.6)	-0.49 (0.79)	-4.0	-1.00	-0.33	0.00	1.9	
	Week 10	Tezepelumab	380	370 (97.4)	-0.63 (0.85)	-4.0	-1.07	-0.43	0.00	1.5	-0.18 [-0.33, -0.03]
		Placebo	371	347 (93.5)	-0.49 (0.77)	-4.0	-1.00	-0.31	0.00	1.9	
	Week 11	Tezepelumab	380	362 (95.3)	-0.62 (0.85)	-4.0	-1.00	-0.43	0.00	1.9	-0.16 [-0.31, -0.01]
		Placebo	371	347 (93.5)	-0.49 (0.80)	-4.0	-1.00	-0.36	0.00	1.9	
	Week 12	Tezepelumab	380	364 (95.8)	-0.61 (0.86)	-4.0	-1.00	-0.43	0.00	1.9	-0.11 [-0.26, 0.04]
		Placebo	371	344 (92.7)	-0.51 (0.82)	-4.0	-1.00	-0.43	0.00	2.3	
	Week 13	Tezepelumab	380	358 (94.2)	-0.62 (0.87)	-4.0	-1.06	-0.43	0.00	1.9	-0.10 [-0.25, 0.04]
		Placebo	371	341 (91.9)	-0.53 (0.84)	-4.0	-1.00	-0.43	0.00	2.4	
	Week 14	Tezepelumab	380	356 (93.7)	-0.66 (0.87)	-4.0	-1.14	-0.48	0.00	1.4	-0.19 [-0.34, -0.04]
		Placebo	371	347 (93.5)	-0.50 (0.83)	-4.0	-1.00	-0.43	0.00	2.3	
	Week 15	Tezepelumab	380	359 (94.5)	-0.66 (0.86)	-4.0	-1.14	-0.43	0.00	1.9	-0.17 [-0.32, -0.02]
		Placebo	371	338 (91.1)	-0.52 (0.85)	-4.0	-1.00	-0.43	0.00	2.3	
	Week 16	Tezepelumab	380	354 (93.2)	-0.68 (0.86)	-4.0	-1.14	-0.57	0.00	2.3	-0.19 [-0.34, -0.04]
		Placebo	371	338 (91.1)	-0.52 (0.86)	-4.0	-1.00	-0.43	0.00	2.2	
	Week 17	Tezepelumab	380	354 (93.2)	-0.73 (0.89)	-4.0	-1.25	-0.57	0.00	1.6	-0.20 [-0.35, -0.05]
		Placebo	371	335 (90.3)	-0.56 (0.83)	-4.0	-1.00	-0.43	0.00	2.0	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WLC\_ALMH0: Course of ASD weekly limiting activity score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly limiting activity score	Week 18	Tezepelumab	380	354 (93.2)	-0.71 (0.91)	-4.0	-1.14	-0.57	0.00	1.7	-0.16 [-0.31, -0.01]
		Placebo	371	335 (90.3)	-0.57 (0.86)	-4.0	-1.00	-0.50	0.00	2.0	
	Week 19	Tezepelumab	380	344 (90.5)	-0.70 (0.91)	-4.0	-1.14	-0.57	0.00	2.5	-0.19 [-0.34, -0.04]
		Placebo	371	333 (89.8)	-0.53 (0.87)	-4.0	-1.00	-0.43	0.00	2.0	
	Week 20	Tezepelumab	380	344 (90.5)	-0.70 (0.89)	-4.0	-1.14	-0.57	0.00	1.4	-0.19 [-0.34, -0.03]
		Placebo	371	330 (88.9)	-0.53 (0.88)	-4.0	-1.00	-0.43	0.00	2.0	
	Week 21	Tezepelumab	380	347 (91.3)	-0.72 (0.90)	-4.0	-1.17	-0.57	0.00	2.4	-0.17 [-0.32, -0.02]
		Placebo	371	325 (87.6)	-0.57 (0.87)	-4.0	-1.00	-0.50	0.00	2.0	
	Week 22	Tezepelumab	380	343 (90.3)	-0.67 (0.88)	-4.0	-1.14	-0.57	0.00	1.9	-0.12 [-0.27, 0.04]
		Placebo	371	321 (86.5)	-0.57 (0.86)	-4.0	-1.00	-0.43	0.00	2.0	
	Week 23	Tezepelumab	380	346 (91.1)	-0.70 (0.89)	-4.0	-1.14	-0.57	0.00	1.9	-0.13 [-0.28, 0.03]
		Placebo	371	324 (87.3)	-0.59 (0.88)	-4.0	-1.00	-0.48	0.00	2.0	
	Week 24	Tezepelumab	380	345 (90.8)	-0.68 (0.90)	-4.0	-1.14	-0.57	0.00	2.9	-0.10 [-0.26, 0.05]
		Placebo	371	321 (86.5)	-0.59 (0.89)	-4.0	-1.00	-0.50	0.00	2.0	
	Week 25	Tezepelumab	380	342 (90.0)	-0.70 (0.87)	-4.0	-1.14	-0.57	0.00	2.1	-0.16 [-0.31, -0.01]
		Placebo	371	312 (84.1)	-0.56 (0.89)	-4.0	-1.00	-0.50	0.00	2.6	
	Week 26	Tezepelumab	380	339 (89.2)	-0.69 (0.87)	-4.0	-1.14	-0.57	0.00	2.1	-0.13 [-0.28, 0.03]
		Placebo	371	314 (84.6)	-0.58 (0.92)	-4.0	-1.00	-0.43	0.00	2.0	
	Week 27	Tezepelumab	380	337 (88.7)	-0.72 (0.89)	-4.0	-1.14	-0.57	0.00	2.0	-0.16 [-0.32, -0.01]
		Placebo	371	319 (86.0)	-0.57 (0.92)	-4.0	-1.14	-0.43	0.00	2.0	
	Week 28	Tezepelumab	380	340 (89.5)	-0.72 (0.90)	-4.0	-1.26	-0.57	0.00	1.7	-0.17 [-0.32, -0.02]
		Placebo	371	322 (86.8)	-0.57 (0.87)	-4.0	-1.00	-0.45	0.00	2.0	
	Week 29	Tezepelumab	380	340 (89.5)	-0.74 (0.89)	-4.0	-1.15	-0.67	-0.13	1.6	-0.20 [-0.36, -0.05]
		Placebo	371	315 (84.9)	-0.56 (0.90)	-4.0	-1.00	-0.43	0.00	2.0	
	Week 30	Tezepelumab	380	335 (88.2)	-0.70 (0.86)	-4.0	-1.14	-0.57	0.00	2.4	-0.15 [-0.30, 0.01]
		Placebo	371	307 (82.7)	-0.57 (0.91)	-4.0	-1.00	-0.43	0.00	2.0	
	Week 31	Tezepelumab	380	346 (91.1)	-0.72 (0.91)	-4.0	-1.14	-0.64	0.00	2.7	-0.16 [-0.31, -0.01]
		Placebo	371	318 (85.7)	-0.57 (0.90)	-4.0	-1.00	-0.43	0.00	2.0	
	Week 32	Tezepelumab	380	336 (88.4)	-0.70 (0.87)	-4.0	-1.14	-0.57	0.00	2.9	-0.16 [-0.31, -0.00]
		Placebo	371	314 (84.6)	-0.56 (0.92)	-4.0	-1.00	-0.43	0.00	2.0	
	Week 33	Tezepelumab	380	333 (87.6)	-0.73 (0.91)	-4.0	-1.26	-0.71	0.00	2.9	-0.18 [-0.33, -0.02]
		Placebo	371	314 (84.6)	-0.57 (0.92)	-4.0	-1.00	-0.43	0.00	2.0	
	Week 34	Tezepelumab	380	337 (88.7)	-0.74 (0.89)	-4.0	-1.17	-0.67	0.00	2.7	-0.16 [-0.31, -0.00]
		Placebo	371	312 (84.1)	-0.60 (0.93)	-4.0	-1.00	-0.43	0.00	2.0	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WLC\_ALMH0: Course of ASD weekly limiting activity score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ASD weekly limiting activity score	Week 35	Tezepelumab	380	333 (87.6)	-0.72 (0.89)	-4.0	-1.14	-0.67	0.00	1.9	-0.16 [-0.32, -0.01]
		Placebo	371	305 (82.2)	-0.58 (0.89)	-4.0	-1.00	-0.43	0.00	2.0	
	Week 36	Tezepelumab	380	335 (88.2)	-0.73 (0.91)	-4.0	-1.14	-0.57	0.00	1.9	-0.16 [-0.32, -0.00]
		Placebo	371	303 (81.7)	-0.59 (0.89)	-4.0	-1.00	-0.43	0.00	2.0	
	Week 37	Tezepelumab	380	329 (86.6)	-0.72 (0.90)	-4.0	-1.14	-0.67	0.00	1.7	-0.14 [-0.30, 0.01]
		Placebo	371	313 (84.4)	-0.59 (0.89)	-4.0	-1.00	-0.43	0.00	2.0	
	Week 38	Tezepelumab	380	335 (88.2)	-0.74 (0.92)	-4.0	-1.29	-0.64	0.00	1.9	-0.14 [-0.30, 0.01]
		Placebo	371	309 (83.3)	-0.61 (0.88)	-4.0	-1.14	-0.57	0.00	2.0	
	Week 39	Tezepelumab	380	335 (88.2)	-0.72 (0.93)	-4.0	-1.29	-0.57	0.00	2.1	-0.13 [-0.29, 0.02]
		Placebo	371	304 (81.9)	-0.60 (0.89)	-4.0	-1.04	-0.50	0.00	2.0	
	Week 40	Tezepelumab	380	335 (88.2)	-0.74 (0.90)	-4.0	-1.29	-0.66	0.00	1.9	-0.16 [-0.32, -0.01]
		Placebo	371	310 (83.6)	-0.59 (0.88)	-4.0	-1.05	-0.43	0.00	2.0	
	Week 41	Tezepelumab	380	333 (87.6)	-0.75 (0.90)	-4.0	-1.29	-0.60	-0.10	1.9	-0.18 [-0.33, -0.02]
		Placebo	371	310 (83.6)	-0.59 (0.88)	-4.0	-1.00	-0.43	0.00	2.1	
	Week 42	Tezepelumab	380	331 (87.1)	-0.76 (0.91)	-4.0	-1.29	-0.57	-0.12	1.9	-0.19 [-0.34, -0.03]
		Placebo	371	309 (83.3)	-0.59 (0.88)	-4.0	-1.11	-0.49	0.00	2.0	
	Week 43	Tezepelumab	380	333 (87.6)	-0.74 (0.90)	-4.0	-1.26	-0.57	-0.06	2.3	-0.14 [-0.29, 0.02]
		Placebo	371	308 (83.0)	-0.61 (0.91)	-4.0	-1.10	-0.50	0.00	2.0	
	Week 44	Tezepelumab	380	331 (87.1)	-0.75 (0.88)	-4.0	-1.29	-0.67	-0.14	1.9	-0.18 [-0.33, -0.02]
		Placebo	371	309 (83.3)	-0.59 (0.90)	-4.0	-1.00	-0.43	0.00	2.0	
	Week 45	Tezepelumab	380	333 (87.6)	-0.77 (0.88)	-4.0	-1.29	-0.71	-0.14	2.0	-0.16 [-0.32, -0.00]
		Placebo	371	308 (83.0)	-0.63 (0.90)	-4.0	-1.14	-0.57	0.00	2.0	
	Week 46	Tezepelumab	380	331 (87.1)	-0.77 (0.90)	-4.0	-1.29	-0.64	-0.14	1.9	-0.16 [-0.31, 0.00]
		Placebo	371	302 (81.4)	-0.63 (0.90)	-4.0	-1.14	-0.50	0.00	2.0	
	Week 47	Tezepelumab	380	329 (86.6)	-0.75 (0.90)	-4.0	-1.29	-0.57	-0.05	1.9	-0.11 [-0.27, 0.04]
		Placebo	371	298 (80.3)	-0.65 (0.88)	-4.0	-1.14	-0.48	0.00	2.0	
	Week 48	Tezepelumab	380	331 (87.1)	-0.74 (0.88)	-4.0	-1.29	-0.60	0.00	1.9	-0.09 [-0.25, 0.06]
		Placebo	371	304 (81.9)	-0.66 (0.86)	-4.0	-1.13	-0.57	0.00	2.0	
	Week 49	Tezepelumab	380	328 (86.3)	-0.75 (0.90)	-4.0	-1.29	-0.58	0.00	1.9	-0.15 [-0.30, 0.01]
		Placebo	371	301 (81.1)	-0.62 (0.88)	-4.0	-1.00	-0.45	0.00	2.0	
	Week 50	Tezepelumab	380	328 (86.3)	-0.77 (0.89)	-4.0	-1.29	-0.63	0.00	1.9	-0.14 [-0.30, 0.01]
		Placebo	371	300 (80.9)	-0.64 (0.90)	-4.0	-1.14	-0.52	0.00	2.0	
	Week 51	Tezepelumab	380	321 (84.5)	-0.75 (0.91)	-4.0	-1.19	-0.67	0.00	1.9	-0.13 [-0.29, 0.03]
		Placebo	371	292 (78.7)	-0.63 (0.89)	-4.0	-1.11	-0.54	0.00	2.2	
	Week 52	Tezepelumab	380	294 (77.4)	-0.75 (0.95)	-4.0	-1.29	-0.71	0.00	2.1	-0.14 [-0.31, 0.02]
		Placebo	371	273 (73.6)	-0.61 (0.86)	-4.0	-1.14	-0.50	0.00	1.6	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WLC\_ALMC0: Change from baseline in ASD weekly limiting activity score - MMRM results  
 DITTL - adult

Change from baseline in ASD weekly limiting activity score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 1	Tezepelumab	380	373 (98.2)	-0.20 (0.04)	(-0.27, -0.12)	-0.08 (0.05)	(-0.18, 0.03)	0.157	
	Placebo	371	365 (98.4)	-0.12 (0.04)	(-0.19, -0.05)				
Week 2	Tezepelumab	380	372 (97.9)	-0.36 (0.04)	(-0.43, -0.28)	-0.15 (0.05)	(-0.25, -0.04)	0.006 *	
	Placebo	371	365 (98.4)	-0.21 (0.04)	(-0.28, -0.14)				
Week 3	Tezepelumab	380	371 (97.6)	-0.41 (0.04)	(-0.48, -0.33)	-0.09 (0.05)	(-0.19, 0.02)	0.106	
	Placebo	371	359 (96.8)	-0.32 (0.04)	(-0.40, -0.25)				
Week 4	Tezepelumab	380	368 (96.8)	-0.44 (0.04)	(-0.51, -0.36)	-0.07 (0.05)	(-0.18, 0.03)	0.164	
	Placebo	371	363 (97.8)	-0.36 (0.04)	(-0.44, -0.29)				
Week 5	Tezepelumab	380	371 (97.6)	-0.48 (0.04)	(-0.56, -0.41)	-0.06 (0.05)	(-0.16, 0.04)	0.264	
	Placebo	371	354 (95.4)	-0.43 (0.04)	(-0.50, -0.35)				
Week 6	Tezepelumab	380	366 (96.3)	-0.51 (0.04)	(-0.58, -0.44)	-0.11 (0.05)	(-0.21, -0.00)	0.040 *	
	Placebo	371	360 (97.0)	-0.40 (0.04)	(-0.47, -0.33)				
Week 7	Tezepelumab	380	366 (96.3)	-0.52 (0.04)	(-0.60, -0.45)	-0.10 (0.05)	(-0.20, 0.01)	0.073	
	Placebo	371	358 (96.5)	-0.43 (0.04)	(-0.50, -0.35)				
Week 8	Tezepelumab	380	366 (96.3)	-0.56 (0.04)	(-0.63, -0.48)	-0.11 (0.05)	(-0.22, -0.01)	0.038 *	
	Placebo	371	353 (95.1)	-0.44 (0.04)	(-0.52, -0.37)				
Week 9	Tezepelumab	380	369 (97.1)	-0.61 (0.04)	(-0.68, -0.54)	-0.12 (0.05)	(-0.23, -0.02)	0.022 *	
	Placebo	371	351 (94.6)	-0.49 (0.04)	(-0.56, -0.41)				
Week 10	Tezepelumab	380	370 (97.4)	-0.62 (0.04)	(-0.69, -0.54)	-0.13 (0.05)	(-0.24, -0.03)	0.013 *	
	Placebo	371	347 (93.5)	-0.49 (0.04)	(-0.56, -0.41)				

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022



Table NT1WLC\_ALMC0: Change from baseline in ASD weekly limiting activity score - MMRM results  
 DITTL - adult

Time	Treatment	N	n (%)	Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 11	Tezepelumab	380	362 (95.3)	-0.62 (0.04)	(-0.70, -0.55)	-0.13 (0.05)	(-0.24, -0.03)	0.012 *	
	Placebo	371	347 (93.5)	-0.49 (0.04)	(-0.56, -0.41)				
Week 12	Tezepelumab	380	364 (95.8)	-0.59 (0.04)	(-0.67, -0.52)	-0.10 (0.05)	(-0.20, 0.01)	0.075	
	Placebo	371	344 (92.7)	-0.50 (0.04)	(-0.57, -0.42)				
Week 13	Tezepelumab	380	358 (94.2)	-0.61 (0.04)	(-0.69, -0.54)	-0.11 (0.05)	(-0.21, -0.00)	0.044 *	
	Placebo	371	341 (91.9)	-0.51 (0.04)	(-0.58, -0.43)				
Week 14	Tezepelumab	380	356 (93.7)	-0.64 (0.04)	(-0.72, -0.57)	-0.15 (0.05)	(-0.25, -0.04)	0.007 *	
	Placebo	371	347 (93.5)	-0.50 (0.04)	(-0.57, -0.42)				
Week 15	Tezepelumab	380	359 (94.5)	-0.66 (0.04)	(-0.73, -0.58)	-0.14 (0.05)	(-0.25, -0.04)	0.008 *	
	Placebo	371	338 (91.1)	-0.51 (0.04)	(-0.59, -0.44)				
Week 16	Tezepelumab	380	354 (93.2)	-0.68 (0.04)	(-0.76, -0.61)	-0.18 (0.05)	(-0.29, -0.08)	<0.001 *	
	Placebo	371	338 (91.1)	-0.50 (0.04)	(-0.58, -0.42)				
Week 17	Tezepelumab	380	354 (93.2)	-0.71 (0.04)	(-0.79, -0.64)	-0.17 (0.05)	(-0.27, -0.06)	0.002 *	
	Placebo	371	335 (90.3)	-0.54 (0.04)	(-0.62, -0.47)				
Week 18	Tezepelumab	380	354 (93.2)	-0.68 (0.04)	(-0.75, -0.61)	-0.13 (0.05)	(-0.23, -0.02)	0.020 *	
	Placebo	371	335 (90.3)	-0.55 (0.04)	(-0.63, -0.48)				
Week 19	Tezepelumab	380	344 (90.5)	-0.68 (0.04)	(-0.76, -0.61)	-0.15 (0.05)	(-0.26, -0.04)	0.005 *	
	Placebo	371	333 (89.8)	-0.53 (0.04)	(-0.61, -0.46)				
Week 20	Tezepelumab	380	344 (90.5)	-0.69 (0.04)	(-0.76, -0.61)	-0.15 (0.05)	(-0.26, -0.04)	0.006 *	
	Placebo	371	330 (88.9)	-0.54 (0.04)	(-0.61, -0.46)				

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WLC\_ALMC0: Change from baseline in ASD weekly limiting activity score - MMRM results  
 DITTL - adult

Change from baseline in ASD weekly limiting activity score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 21	Tezepelumab	380	347 (91.3)	-0.70 (0.04)	(-0.78, -0.63)	-0.14 (0.05)	(-0.25, -0.04)	0.008 *	
	Placebo	371	325 (87.6)	-0.56 (0.04)	(-0.63, -0.48)				
Week 22	Tezepelumab	380	343 (90.3)	-0.69 (0.04)	(-0.77, -0.62)	-0.12 (0.05)	(-0.23, -0.01)	0.029 *	
	Placebo	371	321 (86.5)	-0.57 (0.04)	(-0.65, -0.50)				
Week 23	Tezepelumab	380	346 (91.1)	-0.70 (0.04)	(-0.77, -0.62)	-0.13 (0.05)	(-0.23, -0.02)	0.020 *	
	Placebo	371	324 (87.3)	-0.57 (0.04)	(-0.65, -0.49)				
Week 24	Tezepelumab	380	345 (90.8)	-0.68 (0.04)	(-0.76, -0.61)	-0.11 (0.05)	(-0.22, -0.01)	0.036 *	
	Placebo	371	321 (86.5)	-0.57 (0.04)	(-0.64, -0.49)				
Week 25	Tezepelumab	380	342 (90.0)	-0.69 (0.04)	(-0.77, -0.62)	-0.13 (0.05)	(-0.23, -0.02)	0.022 *	
	Placebo	371	312 (84.1)	-0.57 (0.04)	(-0.64, -0.49)				
Week 26	Tezepelumab	380	339 (89.2)	-0.69 (0.04)	(-0.77, -0.62)	-0.12 (0.05)	(-0.23, -0.01)	0.026 *	
	Placebo	371	314 (84.6)	-0.57 (0.04)	(-0.65, -0.49)				
Week 27	Tezepelumab	380	337 (88.7)	-0.70 (0.04)	(-0.78, -0.63)	-0.14 (0.05)	(-0.25, -0.03)	0.012 *	
	Placebo	371	319 (86.0)	-0.56 (0.04)	(-0.64, -0.49)				
Week 28	Tezepelumab	380	340 (89.5)	-0.72 (0.04)	(-0.80, -0.65)	-0.14 (0.05)	(-0.25, -0.03)	0.009 *	
	Placebo	371	322 (86.8)	-0.58 (0.04)	(-0.66, -0.50)				
Week 29	Tezepelumab	380	340 (89.5)	-0.73 (0.04)	(-0.80, -0.65)	-0.15 (0.06)	(-0.26, -0.05)	0.005 *	
	Placebo	371	315 (84.9)	-0.57 (0.04)	(-0.65, -0.50)				
Week 30	Tezepelumab	380	335 (88.2)	-0.70 (0.04)	(-0.78, -0.63)	-0.13 (0.06)	(-0.24, -0.02)	0.016 *	
	Placebo	371	307 (82.7)	-0.57 (0.04)	(-0.65, -0.49)				

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WLC\_ALMC0: Change from baseline in ASD weekly limiting activity score - MMRM results  
 DITTL - adult

Time	Treatment	N	n (%)	Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 31	Tezepelumab	380	346 (91.1)	-0.71 (0.04)	(-0.79, -0.64)	-0.13 (0.06)	(-0.24, -0.02)	0.019	*
	Placebo	371	318 (85.7)	-0.58 (0.04)	(-0.66, -0.50)				
Week 32	Tezepelumab	380	336 (88.4)	-0.71 (0.04)	(-0.78, -0.63)	-0.14 (0.06)	(-0.25, -0.03)	0.012	*
	Placebo	371	314 (84.6)	-0.57 (0.04)	(-0.65, -0.49)				
Week 33	Tezepelumab	380	333 (87.6)	-0.74 (0.04)	(-0.82, -0.66)	-0.16 (0.06)	(-0.27, -0.05)	0.004	*
	Placebo	371	314 (84.6)	-0.58 (0.04)	(-0.66, -0.50)				
Week 34	Tezepelumab	380	337 (88.7)	-0.74 (0.04)	(-0.82, -0.67)	-0.17 (0.06)	(-0.28, -0.06)	0.002	*
	Placebo	371	312 (84.1)	-0.58 (0.04)	(-0.65, -0.50)				
Week 35	Tezepelumab	380	333 (87.6)	-0.74 (0.04)	(-0.81, -0.66)	-0.15 (0.06)	(-0.26, -0.04)	0.008	*
	Placebo	371	305 (82.2)	-0.59 (0.04)	(-0.67, -0.51)				
Week 36	Tezepelumab	380	335 (88.2)	-0.72 (0.04)	(-0.80, -0.65)	-0.14 (0.06)	(-0.24, -0.03)	0.014	*
	Placebo	371	303 (81.7)	-0.59 (0.04)	(-0.66, -0.51)				
Week 37	Tezepelumab	380	329 (86.6)	-0.73 (0.04)	(-0.80, -0.65)	-0.13 (0.06)	(-0.24, -0.02)	0.019	*
	Placebo	371	313 (84.4)	-0.60 (0.04)	(-0.67, -0.52)				
Week 38	Tezepelumab	380	335 (88.2)	-0.72 (0.04)	(-0.80, -0.65)	-0.12 (0.06)	(-0.23, -0.01)	0.031	*
	Placebo	371	309 (83.3)	-0.61 (0.04)	(-0.68, -0.53)				
Week 39	Tezepelumab	380	335 (88.2)	-0.72 (0.04)	(-0.80, -0.65)	-0.11 (0.06)	(-0.22, -0.01)	0.040	*
	Placebo	371	304 (81.9)	-0.61 (0.04)	(-0.69, -0.53)				
Week 40	Tezepelumab	380	335 (88.2)	-0.73 (0.04)	(-0.81, -0.66)	-0.13 (0.06)	(-0.23, -0.02)	0.023	*
	Placebo	371	310 (83.6)	-0.61 (0.04)	(-0.69, -0.53)				

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WLC\_ALMC0: Change from baseline in ASD weekly limiting activity score - MMRM results  
 DITTL - adult

Change from baseline in ASD weekly limiting activity score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 41	Tezepelumab	380	333 (87.6)	-0.75 (0.04)	(-0.82, -0.67)	-0.15 (0.06)	(-0.26, -0.04)	0.008 *	
	Placebo	371	310 (83.6)	-0.60 (0.04)	(-0.68, -0.52)				
Week 42	Tezepelumab	380	331 (87.1)	-0.75 (0.04)	(-0.83, -0.68)	-0.15 (0.06)	(-0.26, -0.04)	0.008 *	
	Placebo	371	309 (83.3)	-0.61 (0.04)	(-0.68, -0.53)				
Week 43	Tezepelumab	380	333 (87.6)	-0.74 (0.04)	(-0.82, -0.67)	-0.13 (0.06)	(-0.23, -0.02)	0.024 *	
	Placebo	371	308 (83.0)	-0.62 (0.04)	(-0.70, -0.54)				
Week 44	Tezepelumab	380	331 (87.1)	-0.75 (0.04)	(-0.83, -0.68)	-0.15 (0.06)	(-0.26, -0.04)	0.008 *	
	Placebo	371	309 (83.3)	-0.61 (0.04)	(-0.68, -0.53)				
Week 45	Tezepelumab	380	333 (87.6)	-0.77 (0.04)	(-0.84, -0.69)	-0.14 (0.06)	(-0.25, -0.04)	0.010 *	
	Placebo	371	308 (83.0)	-0.62 (0.04)	(-0.70, -0.54)				
Week 46	Tezepelumab	380	331 (87.1)	-0.77 (0.04)	(-0.84, -0.69)	-0.14 (0.06)	(-0.25, -0.03)	0.010 *	
	Placebo	371	302 (81.4)	-0.62 (0.04)	(-0.70, -0.55)				
Week 47	Tezepelumab	380	329 (86.6)	-0.74 (0.04)	(-0.81, -0.66)	-0.11 (0.06)	(-0.22, 0.00)	0.059	
	Placebo	371	298 (80.3)	-0.63 (0.04)	(-0.71, -0.55)				
Week 48	Tezepelumab	380	331 (87.1)	-0.74 (0.04)	(-0.82, -0.67)	-0.10 (0.06)	(-0.21, 0.01)	0.088	
	Placebo	371	304 (81.9)	-0.65 (0.04)	(-0.73, -0.57)				
Week 49	Tezepelumab	380	328 (86.3)	-0.75 (0.04)	(-0.82, -0.67)	-0.12 (0.06)	(-0.23, -0.01)	0.029 *	
	Placebo	371	301 (81.1)	-0.62 (0.04)	(-0.70, -0.55)				
Week 50	Tezepelumab	380	328 (86.3)	-0.77 (0.04)	(-0.84, -0.69)	-0.15 (0.06)	(-0.26, -0.04)	0.009 *	
	Placebo	371	300 (80.9)	-0.62 (0.04)	(-0.70, -0.54)				

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table NT1WLC\_ALMC0: Change from baseline in ASD weekly limiting activity score - MMRM results  
 DITTL - adult

Change from baseline in ASD weekly limiting activity score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 51	Tezepelumab	380	321 (84.5)	-0.76 (0.04)	(-0.83, -0.68)	-0.13 (0.06)	(-0.24, -0.02)	0.019 *	
	Placebo	371	292 (78.7)	-0.62 (0.04)	(-0.70, -0.54)				
Week 52	Tezepelumab	380	294 (77.4)	-0.74 (0.04)	(-0.82, -0.66)	-0.12 (0.06)	(-0.23, -0.01)	0.039 *	
	Placebo	371	273 (73.6)	-0.62 (0.04)	(-0.70, -0.54)				

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.

ASD = asthma symptom diary.

Source Data: aasd, created on: 20FEB2022

Table MT1VSC\_ILMH0: Course of EQ-5D-VAS  
 DITTTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
EQ-5D-VAS	Baseline	Tezepelumab	446	437 (98.0)	60.8 (18.3)	2	50.0	62.0	73.0	100	
		Placebo	436	424 (97.2)	61.1 (16.8)	8	50.0	61.0	73.0	100	
	Week 2	Tezepelumab	446	429 (96.2)	66.5 (17.8)	7	53.0	68.0	80.0	100	
		Placebo	436	416 (95.4)	65.7 (17.4)	5	51.0	68.5	80.0	100	
	Week 4	Tezepelumab	446	437 (98.0)	69.4 (16.8)	14	59.0	71.0	82.0	100	
		Placebo	436	423 (97.0)	67.7 (17.3)	0	55.0	70.0	80.0	100	
	Week 6	Tezepelumab	446	412 (92.4)	71.7 (16.3)	17	60.0	73.0	85.0	100	
		Placebo	436	390 (89.4)	69.0 (18.0)	17	57.0	71.0	82.0	100	
	Week 8	Tezepelumab	446	436 (97.8)	71.1 (17.3)	0	60.0	74.0	84.0	100	
		Placebo	436	422 (96.8)	69.2 (18.3)	10	57.0	72.0	82.0	100	
	Week 10	Tezepelumab	446	412 (92.4)	73.0 (16.5)	19	62.0	77.0	85.0	100	
		Placebo	436	390 (89.4)	69.7 (17.7)	17	57.0	72.0	84.0	100	
	Week 12	Tezepelumab	446	435 (97.5)	72.6 (16.8)	20	60.0	76.0	85.0	100	
		Placebo	436	418 (95.9)	69.8 (18.2)	10	60.0	72.0	84.0	100	
	Week 14	Tezepelumab	446	407 (91.3)	73.0 (17.2)	17	60.0	75.0	87.0	100	
		Placebo	436	388 (89.0)	70.8 (17.3)	9	60.0	73.0	83.0	100	
	Week 16	Tezepelumab	446	428 (96.0)	73.4 (16.6)	27	62.0	76.0	87.0	100	
		Placebo	436	414 (95.0)	70.7 (17.7)	13	59.0	73.0	84.0	100	
	Week 18	Tezepelumab	446	412 (92.4)	73.1 (17.2)	0	61.0	75.0	87.0	100	
		Placebo	436	381 (87.4)	70.9 (17.3)	19	60.0	73.0	84.0	100	
	Week 20	Tezepelumab	446	426 (95.5)	73.4 (17.8)	18	61.0	77.0	88.0	100	
		Placebo	436	411 (94.3)	70.9 (18.1)	18	60.0	74.0	85.0	100	
	Week 22	Tezepelumab	446	411 (92.2)	73.1 (18.1)	0	60.0	77.0	87.0	100	
		Placebo	436	375 (86.0)	71.3 (17.7)	20	60.0	74.0	85.0	100	
	Week 24	Tezepelumab	446	424 (95.1)	73.9 (17.8)	9	64.5	77.0	89.0	100	
		Placebo	436	404 (92.7)	71.2 (18.0)	12	60.0	74.0	85.0	100	
	Week 26	Tezepelumab	446	406 (91.0)	73.9 (17.4)	19	63.0	77.0	88.0	100	
		Placebo	436	374 (85.8)	71.2 (17.7)	15	60.0	73.5	85.0	100	
	Week 28	Tezepelumab	446	424 (95.1)	74.6 (17.2)	8	65.0	78.0	88.0	100	
		Placebo	436	400 (91.7)	71.1 (17.5)	15	60.0	74.0	85.0	100	
	Week 30	Tezepelumab	446	403 (90.4)	74.5 (17.0)	9	64.0	78.0	89.0	100	
		Placebo	436	374 (85.8)	71.6 (17.8)	12	60.0	74.5	85.0	100	
	Week 32	Tezepelumab	446	426 (95.5)	74.3 (17.4)	9	64.0	78.0	89.0	100	
		Placebo	436	401 (92.0)	71.9 (17.8)	9	61.0	74.0	85.0	100	
	Week 34	Tezepelumab	446	405 (90.8)	75.4 (16.7)	10	67.0	78.0	89.0	100	
		Placebo	436	374 (85.8)	71.8 (18.2)	15	60.0	75.0	85.0	100	

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.

Last observation carried forward is applied in case of missing values.

Source Data: avas, created on: 21FEB2022

Table MT1VSC\_ILMH0: Course of EQ-5D-VAS  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
EQ-5D-VAS	Week 36	Tezepelumab	446	421 (94.4)	73.9 (17.7)	17	62.0	77.0	89.0	100	
		Placebo	436	398 (91.3)	71.1 (18.5)	12	60.0	74.0	85.0	100	
	Week 38	Tezepelumab	446	402 (90.1)	74.5 (17.5)	13	63.0	78.0	88.0	100	
		Placebo	436	372 (85.3)	72.7 (17.3)	15	60.5	76.0	86.0	100	
	Week 40	Tezepelumab	446	423 (94.8)	74.6 (17.6)	9	65.0	79.0	89.0	100	
		Placebo	436	399 (91.5)	71.5 (17.9)	10	60.0	75.0	85.0	100	
	Week 42	Tezepelumab	446	405 (90.8)	74.5 (17.8)	9	63.0	79.0	90.0	100	
		Placebo	436	372 (85.3)	71.9 (17.7)	13	61.0	75.0	85.0	100	
	Week 44	Tezepelumab	446	419 (93.9)	74.6 (18.0)	0	64.0	79.0	89.0	100	
		Placebo	436	395 (90.6)	71.6 (17.3)	15	60.0	75.0	85.0	100	
	Week 46	Tezepelumab	446	407 (91.3)	74.6 (17.7)	4	66.0	79.0	89.0	100	
		Placebo	436	368 (84.4)	72.7 (17.3)	10	62.0	76.0	85.0	100	
	Week 48	Tezepelumab	446	421 (94.4)	74.8 (17.7)	9	65.0	78.0	90.0	100	
		Placebo	436	398 (91.3)	71.8 (17.6)	15	61.0	75.0	84.0	100	
	Week 50	Tezepelumab	446	406 (91.0)	75.1 (17.9)	10	65.0	80.0	90.0	100	
		Placebo	436	364 (83.5)	72.6 (17.5)	10	61.0	75.0	86.0	100	
	Week 52	Tezepelumab	446	384 (86.1)	76.0 (17.3)	16	68.0	80.0	90.0	100	
		Placebo	436	359 (82.3)	73.2 (17.7)	9	61.0	76.0	86.0	100	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.

Last observation carried forward is applied in case of missing values.

Source Data: avas, created on: 21FEB2022

Table MT1VSC\_ILMH0: Course of EQ-5D-VAS  
DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in EQ-5D-VAS	Week 2	Tezepelumab	446	423 (94.8)	5.9 (17.8)	-53	-3.0	4.0	15.0	76	0.09 [-0.05, 0.22]
		Placebo	436	413 (94.7)	4.4 (16.1)	-48	-4.0	2.0	12.0	60	
	Week 4	Tezepelumab	446	432 (96.9)	8.8 (18.4)	-48	-2.0	6.0	18.5	76	0.13 [-0.01, 0.26]
		Placebo	436	420 (96.3)	6.5 (16.6)	-50	-4.0	4.5	17.0	61	
	Week 6	Tezepelumab	446	406 (91.0)	11.1 (18.3)	-45	0.0	8.0	21.0	77	0.19 [0.05, 0.33]
		Placebo	436	386 (88.5)	7.7 (17.5)	-46	-3.0	5.5	17.0	69	
	Week 8	Tezepelumab	446	431 (96.6)	10.3 (19.7)	-70	-1.0	9.0	20.0	73	0.11 [-0.02, 0.25]
		Placebo	436	417 (95.6)	8.1 (18.4)	-51	-3.0	6.0	20.0	64	
	Week 10	Tezepelumab	446	406 (91.0)	12.2 (19.5)	-59	0.0	10.0	24.0	77	0.21 [0.07, 0.35]
		Placebo	436	385 (88.3)	8.3 (18.5)	-34	-3.0	6.0	20.0	67	
	Week 12	Tezepelumab	446	430 (96.4)	11.6 (19.7)	-58	0.0	10.0	23.0	81	0.16 [0.02, 0.29]
		Placebo	436	413 (94.7)	8.6 (18.4)	-40	-2.0	7.0	19.0	72	
	Week 14	Tezepelumab	446	402 (90.1)	12.0 (19.4)	-40	1.0	10.0	24.0	79	0.16 [0.01, 0.30]
		Placebo	436	383 (87.8)	9.1 (17.8)	-35	-2.0	8.0	20.0	68	
	Week 16	Tezepelumab	446	423 (94.8)	12.2 (19.4)	-46	0.0	10.0	22.0	85	0.13 [-0.00, 0.27]
		Placebo	436	409 (93.8)	9.6 (18.8)	-46	-1.0	8.0	20.0	91	
	Week 18	Tezepelumab	446	405 (90.8)	12.0 (19.5)	-40	0.0	10.0	24.0	80	0.15 [0.01, 0.29]
		Placebo	436	376 (86.2)	9.2 (17.9)	-35	-2.0	8.0	20.0	70	
	Week 20	Tezepelumab	446	420 (94.2)	12.3 (20.0)	-45	0.0	10.0	24.5	85	0.14 [-0.00, 0.27]
		Placebo	436	406 (93.1)	9.7 (18.1)	-35	-2.0	8.0	21.0	91	
	Week 22	Tezepelumab	446	404 (90.6)	12.2 (20.4)	-41	0.0	10.0	25.0	68	0.12 [-0.02, 0.26]
		Placebo	436	370 (84.9)	9.9 (17.8)	-50	-1.0	9.0	21.0	68	
	Week 24	Tezepelumab	446	418 (93.7)	12.9 (20.2)	-53	0.0	11.0	25.0	79	0.15 [0.01, 0.29]
		Placebo	436	399 (91.5)	10.0 (18.6)	-65	-2.0	9.0	22.0	84	
	Week 26	Tezepelumab	446	399 (89.5)	12.6 (20.7)	-46	0.0	10.0	26.0	71	0.17 [0.02, 0.31]
		Placebo	436	369 (84.6)	9.4 (17.6)	-53	-2.0	8.0	21.0	66	
	Week 28	Tezepelumab	446	417 (93.5)	13.1 (19.9)	-43	0.0	10.0	26.0	69	0.18 [0.04, 0.32]
		Placebo	436	394 (90.4)	9.7 (17.6)	-55	-2.0	7.0	20.0	67	
	Week 30	Tezepelumab	446	396 (88.8)	13.3 (20.1)	-43	0.0	11.0	25.0	80	0.18 [0.04, 0.32]
		Placebo	436	368 (84.4)	9.9 (17.9)	-54	-1.5	9.0	21.0	68	
	Week 32	Tezepelumab	446	418 (93.7)	13.2 (20.1)	-43	0.0	11.0	26.0	79	0.12 [-0.01, 0.26]
		Placebo	436	395 (90.6)	10.8 (18.2)	-56	-2.0	9.0	23.0	82	
	Week 34	Tezepelumab	446	398 (89.2)	14.2 (20.4)	-43	2.0	12.0	29.0	76	0.21 [0.07, 0.35]
		Placebo	436	368 (84.4)	10.2 (18.7)	-56	-2.0	8.0	23.0	67	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.

Last observation carried forward is applied in case of missing values.

Source Data: avas, created on: 21FEB2022



Table MT1VSC\_ILMH0: Course of EQ-5D-VAS  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in EQ-5D-VAS	Week 36	Tezepelumab	446	413 (92.6)	12.8 (20.9)	-46	0.0	11.0	25.0	88	0.16 [0.02, 0.30]
		Placebo	436	392 (89.9)	9.6 (18.4)	-55	-2.0	9.0	21.0	68	
	Week 38	Tezepelumab	446	395 (88.6)	13.5 (20.8)	-43	0.0	12.0	26.0	80	0.12 [-0.02, 0.26]
		Placebo	436	366 (83.9)	11.2 (18.5)	-57	-1.0	9.0	23.0	82	
	Week 40	Tezepelumab	446	415 (93.0)	13.3 (21.3)	-43	0.0	11.0	26.0	77	0.15 [0.01, 0.29]
		Placebo	436	393 (90.1)	10.3 (18.5)	-55	-2.0	10.0	22.0	82	
	Week 42	Tezepelumab	446	398 (89.2)	13.5 (21.4)	-43	0.0	11.0	27.0	81	0.16 [0.02, 0.30]
		Placebo	436	366 (83.9)	10.3 (18.1)	-60	-1.0	9.0	22.0	67	
	Week 44	Tezepelumab	446	411 (92.2)	13.6 (21.1)	-50	0.0	12.0	27.0	81	0.16 [0.02, 0.30]
		Placebo	436	389 (89.2)	10.4 (18.4)	-56	-1.0	8.0	23.0	83	
	Week 46	Tezepelumab	446	399 (89.5)	13.5 (21.2)	-46	0.0	12.0	28.0	79	0.13 [-0.01, 0.27]
		Placebo	436	362 (83.0)	10.9 (18.4)	-56	-2.0	10.0	23.0	68	
	Week 48	Tezepelumab	446	412 (92.4)	13.7 (21.2)	-50	0.0	11.0	27.0	89	0.16 [0.02, 0.30]
		Placebo	436	392 (89.9)	10.5 (19.1)	-65	-2.0	10.0	22.0	83	
	Week 50	Tezepelumab	446	398 (89.2)	13.8 (21.3)	-45	0.0	12.0	26.0	90	0.14 [-0.01, 0.28]
		Placebo	436	358 (82.1)	11.1 (18.9)	-65	-2.0	10.0	24.0	68	
	Week 52	Tezepelumab	446	376 (84.3)	14.8 (20.9)	-56	1.5	13.0	28.0	89	0.15 [0.01, 0.30]
		Placebo	436	353 (81.0)	11.8 (18.5)	-60	-1.0	10.0	24.0	72	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.

Last observation carried forward is applied in case of missing values.

Source Data: avas, created on: 21FEB2022

Table MT1VSC\_ILMC0: Change from baseline in EQ-5D-VAS - MMRM results  
DITTL

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 2	Tezepelumab	446	423 (94.8)	5.5 (0.7)	(4.0, 6.9)	1.1 (1.0)	(-0.9, 3.1)	0.285
	Placebo	436	413 (94.7)	4.4 (0.7)	(2.9, 5.8)			
Week 4	Tezepelumab	446	428 (96.0)	8.5 (0.7)	(7.1, 9.9)	2.1 (1.0)	(0.1, 4.1)	0.041 *
	Placebo	436	415 (95.2)	6.4 (0.7)	(5.0, 7.8)			
Week 6	Tezepelumab	446	402 (90.1)	10.7 (0.7)	(9.2, 12.1)	3.2 (1.1)	(1.1, 5.3)	0.002 *
	Placebo	436	379 (86.9)	7.5 (0.8)	(6.0, 9.0)			
Week 8	Tezepelumab	446	426 (95.5)	10.0 (0.8)	(8.5, 11.5)	1.9 (1.1)	(-0.3, 4.1)	0.083
	Placebo	436	411 (94.3)	8.1 (0.8)	(6.5, 9.6)			
Week 10	Tezepelumab	446	399 (89.5)	11.9 (0.8)	(10.4, 13.4)	3.9 (1.1)	(1.8, 6.1)	<0.001 *
	Placebo	436	378 (86.7)	8.0 (0.8)	(6.4, 9.5)			
Week 12	Tezepelumab	446	422 (94.6)	11.6 (0.8)	(10.0, 13.1)	3.0 (1.1)	(0.8, 5.2)	0.007 *
	Placebo	436	404 (92.7)	8.6 (0.8)	(7.0, 10.1)			
Week 14	Tezepelumab	446	395 (88.6)	11.8 (0.8)	(10.3, 13.3)	2.7 (1.1)	(0.6, 4.9)	0.013 *
	Placebo	436	374 (85.8)	9.1 (0.8)	(7.6, 10.7)			
Week 16	Tezepelumab	446	415 (93.0)	12.2 (0.8)	(10.7, 13.8)	2.7 (1.1)	(0.6, 4.9)	0.014 *
	Placebo	436	400 (91.7)	9.5 (0.8)	(8.0, 11.1)			
Week 18	Tezepelumab	446	398 (89.2)	12.1 (0.8)	(10.6, 13.6)	3.0 (1.1)	(0.8, 5.1)	0.007 *
	Placebo	436	366 (83.9)	9.1 (0.8)	(7.5, 10.6)			
Week 20	Tezepelumab	446	412 (92.4)	12.2 (0.8)	(10.7, 13.8)	2.5 (1.1)	(0.3, 4.7)	0.025 *
	Placebo	436	396 (90.8)	9.7 (0.8)	(8.1, 11.3)			

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

VAS = visual analogue scale.

Source Data: avas, created on: 21FEB2022

Table MT1VSC\_ILMC0: Change from baseline in EQ-5D-VAS - MMRM results  
DITTL

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 22	Tezepelumab	446	396 (88.8)	12.2 (0.8)	(10.7, 13.8)	2.4 (1.1)	(0.2, 4.7)	0.033 *
	Placebo	436	360 (82.6)	9.8 (0.8)	(8.2, 11.4)			
Week 24	Tezepelumab	446	410 (91.9)	13.0 (0.8)	(11.5, 14.6)	3.1 (1.1)	(0.9, 5.4)	0.006 *
	Placebo	436	389 (89.2)	9.9 (0.8)	(8.3, 11.5)			
Week 26	Tezepelumab	446	391 (87.7)	12.7 (0.8)	(11.1, 14.3)	3.2 (1.1)	(0.9, 5.4)	0.006 *
	Placebo	436	358 (82.1)	9.5 (0.8)	(7.9, 11.2)			
Week 28	Tezepelumab	446	406 (91.0)	13.6 (0.8)	(12.1, 15.1)	4.0 (1.1)	(1.9, 6.2)	<0.001 *
	Placebo	436	383 (87.8)	9.6 (0.8)	(8.0, 11.1)			
Week 30	Tezepelumab	446	386 (86.5)	13.4 (0.8)	(11.8, 14.9)	3.3 (1.1)	(1.1, 5.5)	0.003 *
	Placebo	436	355 (81.4)	10.0 (0.8)	(8.5, 11.6)			
Week 32	Tezepelumab	446	409 (91.7)	13.3 (0.8)	(11.8, 14.8)	2.4 (1.1)	(0.2, 4.6)	0.030 *
	Placebo	436	383 (87.8)	10.9 (0.8)	(9.3, 12.4)			
Week 34	Tezepelumab	446	389 (87.2)	14.3 (0.8)	(12.8, 15.9)	4.2 (1.1)	(1.9, 6.4)	<0.001 *
	Placebo	436	355 (81.4)	10.2 (0.8)	(8.6, 11.8)			
Week 36	Tezepelumab	446	404 (90.6)	12.8 (0.8)	(11.2, 14.4)	3.0 (1.2)	(0.7, 5.3)	0.010 *
	Placebo	436	381 (87.4)	9.7 (0.8)	(8.1, 11.4)			
Week 38	Tezepelumab	446	385 (86.3)	13.4 (0.8)	(11.8, 15.0)	2.4 (1.1)	(0.2, 4.7)	0.034 *
	Placebo	436	355 (81.4)	11.0 (0.8)	(9.4, 12.6)			
Week 40	Tezepelumab	446	405 (90.8)	13.5 (0.8)	(11.9, 15.0)	3.2 (1.2)	(0.9, 5.5)	0.006 *
	Placebo	436	383 (87.8)	10.3 (0.8)	(8.6, 11.9)			

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

VAS = visual analogue scale.

Source Data: avas, created on: 21FEB2022

Table MT1VSC\_ILMC0: Change from baseline in EQ-5D-VAS - MMRM results  
 DITTTL

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 42	Tezepelumab	446	388 (87.0)	13.5 (0.8)	(11.9, 15.1)	3.3 (1.2)	(1.0, 5.6)	0.004 *
	Placebo	436	354 (81.2)	10.1 (0.8)	(8.5, 11.8)			
Week 44	Tezepelumab	446	400 (89.7)	13.8 (0.8)	(12.3, 15.4)	3.7 (1.2)	(1.5, 6.0)	0.001 *
	Placebo	436	378 (86.7)	10.1 (0.8)	(8.5, 11.7)			
Week 46	Tezepelumab	446	389 (87.2)	13.6 (0.8)	(12.0, 15.2)	2.7 (1.2)	(0.4, 5.0)	0.019 *
	Placebo	436	352 (80.7)	10.9 (0.8)	(9.3, 12.5)			
Week 48	Tezepelumab	446	400 (89.7)	13.8 (0.8)	(12.2, 15.4)	3.5 (1.2)	(1.2, 5.8)	0.003 *
	Placebo	436	381 (87.4)	10.3 (0.8)	(8.7, 12.0)			
Week 50	Tezepelumab	446	386 (86.5)	13.7 (0.8)	(12.1, 15.3)	2.7 (1.2)	(0.3, 5.0)	0.024 *
	Placebo	436	348 (79.8)	11.0 (0.9)	(9.3, 12.7)			
Week 52	Tezepelumab	446	332 (74.4)	14.9 (0.8)	(13.3, 16.5)	3.3 (1.2)	(1.0, 5.6)	0.005 *
	Placebo	436	313 (71.8)	11.6 (0.8)	(9.9, 13.2)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

VAS = visual analogue scale.

Source Data: avas, created on: 21FEB2022

Table NT1VSC\_ILMH0: Course of EQ-5D-VAS  
DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
EQ-5D-VAS	Baseline	Tezepelumab	395	394 (99.7)	61.2 (18.4)	2	50.0	65.0	73.0	98	
		Placebo	391	389 (99.5)	61.7 (17.3)	8	50.0	62.0	75.0	100	
	Week 2	Tezepelumab	395	380 (96.2)	67.0 (17.8)	7	54.0	69.0	80.0	100	
		Placebo	391	378 (96.7)	66.8 (17.2)	5	53.0	70.0	80.0	100	
	Week 4	Tezepelumab	395	389 (98.5)	69.9 (16.3)	17	60.0	72.0	81.0	100	
		Placebo	391	383 (98.0)	68.5 (17.3)	0	55.0	70.0	81.0	100	
	Week 6	Tezepelumab	395	361 (91.4)	72.2 (16.1)	17	61.0	74.0	85.0	100	
		Placebo	391	348 (89.0)	69.5 (17.9)	19	57.0	72.0	82.5	100	
	Week 8	Tezepelumab	395	388 (98.2)	71.7 (17.0)	0	61.0	75.0	84.0	100	
		Placebo	391	381 (97.4)	70.1 (18.0)	10	60.0	73.0	83.0	100	
	Week 10	Tezepelumab	395	362 (91.6)	73.9 (15.9)	19	65.0	78.0	85.0	100	
		Placebo	391	350 (89.5)	70.0 (17.8)	17	58.0	72.0	85.0	100	
	Week 12	Tezepelumab	395	387 (98.0)	73.2 (16.4)	20	62.0	77.0	86.0	100	
		Placebo	391	379 (96.9)	70.4 (18.2)	10	60.0	74.0	85.0	100	
	Week 14	Tezepelumab	395	357 (90.4)	73.6 (16.9)	17	62.0	76.0	87.0	100	
		Placebo	391	346 (88.5)	71.4 (17.3)	9	60.0	74.5	84.0	100	
	Week 16	Tezepelumab	395	379 (95.9)	74.4 (15.9)	27	65.0	78.0	87.0	100	
		Placebo	391	374 (95.7)	71.7 (17.5)	13	60.0	75.0	85.0	100	
	Week 18	Tezepelumab	395	360 (91.1)	74.1 (17.0)	0	63.0	78.0	88.0	100	
		Placebo	391	339 (86.7)	71.9 (16.9)	19	61.0	74.0	85.0	100	
	Week 20	Tezepelumab	395	376 (95.2)	74.2 (17.6)	20	63.5	79.0	89.0	100	
		Placebo	391	371 (94.9)	71.9 (18.0)	18	60.0	76.0	86.0	100	
	Week 22	Tezepelumab	395	357 (90.4)	74.2 (17.8)	0	64.0	79.0	88.0	100	
		Placebo	391	334 (85.4)	72.4 (17.6)	20	62.0	75.0	86.0	100	
	Week 24	Tezepelumab	395	373 (94.4)	74.9 (17.2)	9	65.0	78.0	90.0	100	
		Placebo	391	363 (92.8)	72.0 (17.9)	12	60.0	75.0	85.0	100	
	Week 26	Tezepelumab	395	353 (89.4)	75.1 (16.9)	20	65.0	79.0	90.0	100	
		Placebo	391	333 (85.2)	72.2 (17.4)	15	61.0	75.0	86.0	100	
	Week 28	Tezepelumab	395	373 (94.4)	75.7 (16.6)	26	66.0	80.0	89.0	100	
		Placebo	391	360 (92.1)	71.8 (17.4)	15	61.0	75.0	85.0	100	
	Week 30	Tezepelumab	395	348 (88.1)	76.0 (16.2)	22	66.0	80.0	89.0	100	
		Placebo	391	332 (84.9)	72.7 (17.7)	12	63.0	75.0	87.0	100	
	Week 32	Tezepelumab	395	375 (94.9)	75.3 (16.9)	25	65.0	79.0	89.0	100	
		Placebo	391	360 (92.1)	72.9 (17.4)	9	62.0	75.0	86.0	100	
Week 34	Tezepelumab	395	350 (88.6)	76.6 (15.9)	24	69.0	79.0	90.0	100		
	Placebo	391	330 (84.4)	72.3 (18.0)	15	60.0	76.0	86.0	100		

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.

Source Data: avas, created on: 20FEB2022

Table NT1VSC\_ILMH0: Course of EQ-5D-VAS  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
EQ-5D-VAS	Week 36	Tezepelumab	395	369 (93.4)	74.7 (17.3)	22	64.0	78.0	90.0	100	
		Placebo	391	358 (91.6)	71.9 (18.7)	12	60.0	75.0	86.0	100	
	Week 38	Tezepelumab	395	347 (87.8)	75.9 (16.5)	22	67.0	79.0	89.0	100	
		Placebo	391	329 (84.1)	73.6 (17.1)	15	63.0	77.0	88.0	100	
	Week 40	Tezepelumab	395	372 (94.2)	75.5 (17.3)	9	66.0	80.0	89.0	100	
		Placebo	391	359 (91.8)	72.7 (17.7)	10	61.0	75.0	85.0	100	
	Week 42	Tezepelumab	395	350 (88.6)	75.7 (17.2)	15	65.0	80.0	90.0	100	
		Placebo	391	329 (84.1)	73.0 (17.8)	13	64.0	75.0	86.0	100	
	Week 44	Tezepelumab	395	367 (92.9)	75.7 (17.5)	0	66.0	80.0	90.0	100	
		Placebo	391	354 (90.5)	72.9 (17.0)	15	62.0	75.0	85.0	100	
	Week 46	Tezepelumab	395	351 (88.9)	76.0 (17.2)	4	69.0	80.0	90.0	100	
		Placebo	391	323 (82.6)	73.9 (17.1)	10	65.0	78.0	87.0	100	
	Week 48	Tezepelumab	395	368 (93.2)	75.8 (17.2)	22	66.5	79.5	90.0	100	
		Placebo	391	357 (91.3)	73.0 (17.3)	15	63.0	76.0	86.0	100	
	Week 50	Tezepelumab	395	349 (88.4)	76.1 (17.3)	10	68.0	80.0	90.0	100	
		Placebo	391	321 (82.1)	73.7 (17.2)	10	63.0	76.0	86.0	100	
	Week 52	Tezepelumab	395	330 (83.5)	77.4 (16.6)	16	70.0	81.0	90.0	100	
		Placebo	391	318 (81.3)	74.3 (17.4)	9	64.0	77.5	89.0	100	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.

Source Data: avas, created on: 20FEB2022

Table NT1VSC\_ILMH0: Course of EQ-5D-VAS  
 DITTLL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in EQ-5D-VAS	Week 2	Tezepelumab	395	379 (95.9)	6.0 (18.0)	-44	-3.0	3.0	14.0	76	0.06 [-0.08, 0.21]
		Placebo	391	378 (96.7)	4.9 (16.5)	-48	-3.0	2.0	13.0	60	
	Week 4	Tezepelumab	395	389 (98.5)	8.8 (18.3)	-48	-2.0	6.0	18.0	76	0.11 [-0.03, 0.26]
		Placebo	391	383 (98.0)	6.7 (17.0)	-50	-3.0	4.0	17.0	61	
	Week 6	Tezepelumab	395	360 (91.1)	11.3 (18.2)	-45	0.0	8.0	21.0	77	0.21 [0.06, 0.36]
		Placebo	391	347 (88.7)	7.5 (17.6)	-46	-3.0	5.0	17.0	69	
	Week 8	Tezepelumab	395	388 (98.2)	10.4 (19.6)	-70	0.0	9.0	20.0	73	0.11 [-0.03, 0.25]
		Placebo	391	380 (97.2)	8.4 (18.4)	-51	-2.0	7.0	20.0	64	
	Week 10	Tezepelumab	395	361 (91.4)	12.7 (19.4)	-59	1.0	10.0	23.0	77	0.26 [0.11, 0.41]
		Placebo	391	349 (89.3)	7.8 (18.7)	-44	-3.0	5.0	19.0	67	
	Week 12	Tezepelumab	395	387 (98.0)	11.7 (19.7)	-58	0.0	10.0	23.0	81	0.17 [0.03, 0.31]
		Placebo	391	378 (96.7)	8.5 (18.5)	-56	-2.0	6.0	19.0	72	
	Week 14	Tezepelumab	395	357 (90.4)	12.2 (19.7)	-49	1.0	10.0	24.0	79	0.17 [0.03, 0.32]
		Placebo	391	345 (88.2)	8.9 (17.8)	-35	-2.0	8.0	20.0	68	
	Week 16	Tezepelumab	395	379 (95.9)	12.7 (19.4)	-46	0.0	10.0	22.0	85	0.14 [-0.00, 0.28]
		Placebo	391	373 (95.4)	10.0 (19.2)	-46	-1.0	8.0	20.0	91	
	Week 18	Tezepelumab	395	359 (90.9)	12.6 (19.4)	-35	1.0	10.0	24.0	80	0.17 [0.02, 0.32]
		Placebo	391	338 (86.4)	9.4 (17.9)	-49	-1.0	8.0	20.0	70	
	Week 20	Tezepelumab	395	376 (95.2)	12.5 (20.1)	-45	0.0	10.0	24.0	85	0.14 [-0.01, 0.28]
		Placebo	391	370 (94.6)	9.9 (18.4)	-47	-2.0	7.5	22.0	91	
	Week 22	Tezepelumab	395	356 (90.1)	12.7 (20.6)	-41	0.0	10.0	26.0	68	0.13 [-0.02, 0.28]
		Placebo	391	333 (85.2)	10.2 (18.2)	-50	0.0	10.0	21.0	68	
	Week 24	Tezepelumab	395	373 (94.4)	13.3 (20.2)	-53	0.0	11.0	25.0	79	0.17 [0.03, 0.32]
		Placebo	391	362 (92.6)	10.0 (18.6)	-50	-2.0	10.0	21.0	84	
	Week 26	Tezepelumab	395	353 (89.4)	13.1 (20.6)	-46	1.0	10.0	25.0	71	0.19 [0.04, 0.34]
		Placebo	391	332 (84.9)	9.5 (17.8)	-45	-2.0	8.0	21.0	66	
	Week 28	Tezepelumab	395	373 (94.4)	13.6 (19.6)	-40	1.0	11.0	26.0	69	0.20 [0.06, 0.35]
		Placebo	391	359 (91.8)	9.8 (18.0)	-55	-2.0	7.0	20.0	67	
	Week 30	Tezepelumab	395	348 (88.1)	14.1 (20.1)	-38	1.0	11.0	27.0	80	0.20 [0.05, 0.35]
		Placebo	391	331 (84.7)	10.3 (18.4)	-54	0.0	9.0	21.0	68	
	Week 32	Tezepelumab	395	374 (94.7)	13.5 (19.8)	-38	1.0	10.0	26.0	79	0.14 [-0.01, 0.28]
		Placebo	391	359 (91.8)	10.9 (18.6)	-56	-1.0	10.0	23.0	82	
	Week 34	Tezepelumab	395	350 (88.6)	14.9 (20.1)	-38	2.0	12.0	28.0	76	0.25 [0.10, 0.40]
		Placebo	391	329 (84.1)	9.9 (19.0)	-56	-1.0	8.0	23.0	67	
	Week 36	Tezepelumab	395	368 (93.2)	13.2 (20.9)	-46	1.0	11.0	25.0	88	0.17 [0.03, 0.32]
		Placebo	391	357 (91.3)	9.7 (19.5)	-59	-2.0	10.0	21.0	68	

Note: DITTLL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.

Source Data: avas, created on: 20FEB2022

Table NT1VSC\_ILMH0: Course of EQ-5D-VAS  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in EQ-5D-VAS	Week 38	Tezepelumab	395	347 (87.8)	14.2 (20.6)	-38	1.0	12.0	26.0	80	0.15 [-0.00, 0.30]
		Placebo	391	328 (83.9)	11.3 (19.0)	-57	0.0	9.5	22.5	82	
	Week 40	Tezepelumab	395	371 (93.9)	13.8 (21.4)	-41	0.0	11.0	26.0	77	0.15 [0.01, 0.30]
		Placebo	391	358 (91.6)	10.7 (19.0)	-55	-1.0	10.5	22.0	82	
	Week 42	Tezepelumab	395	350 (88.6)	14.0 (21.4)	-42	1.0	11.0	28.0	81	0.17 [0.02, 0.32]
		Placebo	391	328 (83.9)	10.6 (18.6)	-60	0.0	10.0	22.0	67	
	Week 44	Tezepelumab	395	366 (92.7)	14.2 (21.1)	-50	1.0	11.0	26.0	81	0.16 [0.02, 0.31]
		Placebo	391	353 (90.3)	10.9 (18.7)	-56	0.0	9.0	24.0	83	
	Week 46	Tezepelumab	395	351 (88.9)	14.2 (21.1)	-46	0.0	12.0	28.0	79	0.14 [-0.01, 0.30]
		Placebo	391	322 (82.4)	11.3 (18.7)	-56	-1.0	11.0	23.0	68	
	Week 48	Tezepelumab	395	367 (92.9)	14.2 (20.9)	-50	1.0	10.0	27.0	89	0.16 [0.01, 0.30]
		Placebo	391	356 (91.0)	11.0 (19.6)	-65	-1.0	10.0	22.0	83	
	Week 50	Tezepelumab	395	349 (88.4)	14.3 (21.2)	-45	1.0	12.0	26.0	90	0.15 [-0.00, 0.30]
		Placebo	391	320 (81.8)	11.3 (18.9)	-65	0.0	10.0	23.5	68	
	Week 52	Tezepelumab	395	330 (83.5)	15.6 (20.8)	-56	2.0	13.0	28.0	89	0.18 [0.03, 0.34]
		Placebo	391	317 (81.1)	12.0 (18.8)	-60	0.0	10.0	24.0	72	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.

Source Data: avas, created on: 20FEB2022



Table NT1VSC\_ILMC0: Change from baseline in EQ-5D-VAS - MMRM results  
DITTTL

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 2	Tezepelumab	395	379 (95.9)	5.5 (0.8)	(4.0, 7.0)	0.6 (1.1)	(-1.5, 2.8)	0.559
	Placebo	391	378 (96.7)	4.9 (0.8)	(3.3, 6.4)			
Week 4	Tezepelumab	395	389 (98.5)	8.4 (0.7)	(6.9, 9.8)	1.7 (1.1)	(-0.3, 3.8)	0.099
	Placebo	391	383 (98.0)	6.6 (0.7)	(5.2, 8.1)			
Week 6	Tezepelumab	395	360 (91.1)	10.7 (0.8)	(9.2, 12.2)	3.3 (1.1)	(1.2, 5.5)	0.002 *
	Placebo	391	347 (88.7)	7.4 (0.8)	(5.9, 8.9)			
Week 8	Tezepelumab	395	388 (98.2)	10.1 (0.8)	(8.5, 11.7)	1.8 (1.1)	(-0.5, 4.0)	0.120
	Placebo	391	380 (97.2)	8.3 (0.8)	(6.7, 9.9)			
Week 10	Tezepelumab	395	361 (91.4)	12.2 (0.8)	(10.6, 13.7)	4.6 (1.1)	(2.3, 6.8)	<0.001 *
	Placebo	391	349 (89.3)	7.6 (0.8)	(6.0, 9.2)			
Week 12	Tezepelumab	395	387 (98.0)	11.6 (0.8)	(10.0, 13.2)	3.1 (1.1)	(0.9, 5.4)	0.007 *
	Placebo	391	378 (96.7)	8.5 (0.8)	(6.9, 10.1)			
Week 14	Tezepelumab	395	357 (90.4)	11.8 (0.8)	(10.2, 13.4)	2.7 (1.1)	(0.5, 5.0)	0.016 *
	Placebo	391	345 (88.2)	9.1 (0.8)	(7.5, 10.7)			
Week 16	Tezepelumab	395	379 (95.9)	12.6 (0.8)	(11.0, 14.1)	2.7 (1.1)	(0.5, 4.9)	0.016 *
	Placebo	391	373 (95.4)	9.8 (0.8)	(8.3, 11.4)			
Week 18	Tezepelumab	395	359 (90.9)	12.3 (0.8)	(10.8, 13.9)	3.0 (1.1)	(0.8, 5.3)	0.008 *
	Placebo	391	338 (86.4)	9.3 (0.8)	(7.7, 10.9)			
Week 20	Tezepelumab	395	376 (95.2)	12.3 (0.8)	(10.6, 13.9)	2.3 (1.2)	(0.0, 4.6)	0.048 *
	Placebo	391	370 (94.6)	9.9 (0.8)	(8.3, 11.6)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

VAS = visual analogue scale.

Source Data: avas, created on: 20FEB2022

Table NT1VSC\_ILMC0: Change from baseline in EQ-5D-VAS - MMRM results  
 DITTTL

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 22	Tezepelumab	395	356 (90.1)	12.5 (0.8)	(10.8, 14.1)	2.4 (1.2)	(0.1, 4.8)	0.045 *
	Placebo	391	333 (85.2)	10.0 (0.9)	(8.4, 11.7)			
Week 24	Tezepelumab	395	373 (94.4)	13.1 (0.8)	(11.5, 14.7)	3.2 (1.2)	(0.9, 5.5)	0.007 *
	Placebo	391	362 (92.6)	9.9 (0.8)	(8.3, 11.6)			
Week 26	Tezepelumab	395	353 (89.4)	12.9 (0.8)	(11.3, 14.5)	3.3 (1.2)	(0.9, 5.6)	0.006 *
	Placebo	391	332 (84.9)	9.6 (0.8)	(8.0, 11.3)			
Week 28	Tezepelumab	395	373 (94.4)	13.8 (0.8)	(12.3, 15.4)	4.3 (1.1)	(2.1, 6.6)	<0.001 *
	Placebo	391	359 (91.8)	9.5 (0.8)	(7.9, 11.1)			
Week 30	Tezepelumab	395	348 (88.1)	13.8 (0.8)	(12.2, 15.4)	3.6 (1.2)	(1.3, 5.9)	0.002 *
	Placebo	391	331 (84.7)	10.2 (0.8)	(8.6, 11.9)			
Week 32	Tezepelumab	395	374 (94.7)	13.4 (0.8)	(11.8, 15.0)	2.4 (1.2)	(0.1, 4.7)	0.038 *
	Placebo	391	359 (91.8)	11.0 (0.8)	(9.3, 12.6)			
Week 34	Tezepelumab	395	350 (88.6)	14.7 (0.8)	(13.0, 16.3)	4.8 (1.2)	(2.5, 7.2)	<0.001 *
	Placebo	391	329 (84.1)	9.8 (0.8)	(8.2, 11.5)			
Week 36	Tezepelumab	395	368 (93.2)	12.8 (0.9)	(11.1, 14.6)	3.1 (1.2)	(0.6, 5.5)	0.013 *
	Placebo	391	357 (91.3)	9.8 (0.9)	(8.1, 11.5)			
Week 38	Tezepelumab	395	347 (87.8)	13.7 (0.8)	(12.1, 15.4)	2.9 (1.2)	(0.5, 5.2)	0.016 *
	Placebo	391	328 (83.9)	10.9 (0.8)	(9.2, 12.5)			
Week 40	Tezepelumab	395	371 (93.9)	13.6 (0.9)	(11.9, 15.2)	3.1 (1.2)	(0.7, 5.4)	0.012 *
	Placebo	391	358 (91.6)	10.5 (0.9)	(8.8, 12.2)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

VAS = visual analogue scale.

Source Data: avas, created on: 20FEB2022

Table NT1VSC\_ILMC0: Change from baseline in EQ-5D-VAS - MMRM results  
 DITTTL

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 42	Tezepelumab	395	350 (88.6)	13.6 (0.9)	(12.0, 15.3)	3.1 (1.2)	(0.7, 5.5)	0.012 *
	Placebo	391	328 (83.9)	10.5 (0.9)	(8.8, 12.3)			
Week 44	Tezepelumab	395	366 (92.7)	14.1 (0.8)	(12.4, 15.7)	3.4 (1.2)	(1.1, 5.8)	0.004 *
	Placebo	391	353 (90.3)	10.6 (0.8)	(9.0, 12.3)			
Week 46	Tezepelumab	395	351 (88.9)	13.9 (0.8)	(12.3, 15.6)	2.6 (1.2)	(0.2, 4.9)	0.032 *
	Placebo	391	322 (82.4)	11.3 (0.9)	(9.7, 13.0)			
Week 48	Tezepelumab	395	367 (92.9)	13.9 (0.9)	(12.2, 15.6)	3.1 (1.2)	(0.7, 5.5)	0.010 *
	Placebo	391	356 (91.0)	10.8 (0.9)	(9.1, 12.5)			
Week 50	Tezepelumab	395	349 (88.4)	13.8 (0.9)	(12.1, 15.5)	2.5 (1.2)	(0.1, 5.0)	0.039 *
	Placebo	391	320 (81.8)	11.3 (0.9)	(9.5, 13.0)			
Week 52	Tezepelumab	395	330 (83.5)	14.9 (0.8)	(13.3, 16.6)	3.1 (1.2)	(0.7, 5.4)	0.011 *
	Placebo	391	317 (81.1)	11.9 (0.9)	(10.2, 13.6)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

VAS = visual analogue scale.

Source Data: avas, created on: 20FEB2022

Table PT3VSC\_ILMH0: Course of EQ-5D-VAS  
 DITTTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
EQ-5D-VAS	Baseline	Tezepelumab	66	58 (87.9)	57.9 (17.3)	20	49.0	52.5	71.0	100	
		Placebo	65	55 (84.6)	58.9 (14.3)	29	50.0	55.0	69.0	96	
	Week 1	Tezepelumab	66	61 (92.4)	62.3 (17.7)	13	51.0	61.0	76.0	99	
		Placebo	65	56 (86.2)	63.1 (17.6)	18	50.0	63.5	75.5	98	
	Week 2	Tezepelumab	66	63 (95.5)	62.9 (17.9)	20	50.0	62.0	79.0	100	
		Placebo	65	58 (89.2)	61.9 (18.3)	19	48.0	59.0	75.0	96	
	Week 3	Tezepelumab	66	63 (95.5)	65.7 (17.1)	28	53.0	66.0	82.0	97	
		Placebo	65	58 (89.2)	67.7 (15.6)	30	56.0	67.0	81.0	94	
	Week 4	Tezepelumab	66	63 (95.5)	66.3 (19.4)	14	50.0	66.0	84.0	100	
		Placebo	65	58 (89.2)	65.5 (17.5)	17	54.0	65.0	77.0	99	
	Week 5	Tezepelumab	66	63 (95.5)	68.0 (17.3)	29	53.0	68.0	81.0	100	
		Placebo	65	58 (89.2)	67.4 (16.8)	21	57.0	69.0	80.0	100	
	Week 6	Tezepelumab	66	63 (95.5)	68.3 (17.4)	24	53.0	70.0	84.0	100	
		Placebo	65	58 (89.2)	68.0 (18.8)	17	55.0	69.0	84.0	100	
	Week 7	Tezepelumab	66	63 (95.5)	66.1 (18.3)	30	50.0	69.0	81.0	100	
		Placebo	65	58 (89.2)	69.4 (17.6)	17	61.0	70.0	85.0	100	
	Week 8	Tezepelumab	66	63 (95.5)	68.2 (19.5)	20	55.0	70.0	87.0	100	
		Placebo	65	59 (90.8)	66.0 (19.9)	14	51.0	62.0	85.0	100	
	Week 9	Tezepelumab	66	63 (95.5)	67.9 (19.1)	34	50.0	69.0	85.0	100	
		Placebo	65	59 (90.8)	67.1 (17.9)	26	54.0	69.0	83.0	100	
	Week 10	Tezepelumab	66	63 (95.5)	67.2 (19.1)	28	51.0	65.0	83.0	100	
		Placebo	65	59 (90.8)	69.3 (18.1)	28	55.0	72.0	85.0	100	
	Week 11	Tezepelumab	66	63 (95.5)	68.6 (19.4)	18	53.0	69.0	85.0	100	
		Placebo	65	59 (90.8)	69.1 (17.6)	20	56.0	69.0	84.0	100	
	Week 12	Tezepelumab	66	63 (95.5)	69.1 (19.2)	26	56.0	70.0	85.0	100	
		Placebo	65	59 (90.8)	68.3 (18.7)	20	57.0	69.0	87.0	100	
	Week 13	Tezepelumab	66	63 (95.5)	69.1 (18.9)	31	55.0	71.0	85.0	100	
		Placebo	65	59 (90.8)	70.1 (16.5)	28	57.0	71.0	84.0	100	
	Week 14	Tezepelumab	66	63 (95.5)	69.6 (19.9)	20	53.0	73.0	87.0	100	
		Placebo	65	59 (90.8)	69.5 (17.3)	19	58.0	70.0	83.0	100	
	Week 15	Tezepelumab	66	63 (95.5)	68.7 (20.7)	12	52.0	71.0	87.0	100	
		Placebo	65	59 (90.8)	69.6 (17.8)	12	60.0	71.0	83.0	100	
	Week 16	Tezepelumab	66	63 (95.5)	68.4 (19.5)	28	53.0	70.0	85.0	100	
		Placebo	65	59 (90.8)	67.1 (18.5)	27	54.0	65.0	83.0	100	
Week 17	Tezepelumab	66	63 (95.5)	69.3 (18.6)	9	54.0	73.0	83.0	100		
	Placebo	65	59 (90.8)	68.3 (19.4)	7	59.0	69.0	83.0	100		

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.

Last observation carried forward is applied in case of missing values.

Source Data: avas, created on: 21FEB2022

Table PT3VSC\_ILMH0: Course of EQ-5D-VAS  
 DITTTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
EQ-5D-VAS	Week 18	Tezepelumab	66	64 (97.0)	68.2 (19.0)	14	54.0	72.0	81.5	100	
		Placebo	65	59 (90.8)	66.9 (19.3)	23	54.0	66.0	83.0	100	
	Week 19	Tezepelumab	66	64 (97.0)	67.7 (18.9)	20	51.5	70.5	84.5	100	
		Placebo	65	59 (90.8)	67.3 (18.9)	22	54.0	69.0	83.0	100	
	Week 20	Tezepelumab	66	64 (97.0)	69.1 (19.5)	18	54.5	71.0	82.5	100	
		Placebo	65	59 (90.8)	67.2 (19.8)	20	54.0	68.0	85.0	100	
	Week 21	Tezepelumab	66	64 (97.0)	68.0 (20.2)	11	50.0	68.5	85.0	100	
		Placebo	65	59 (90.8)	67.3 (18.7)	16	54.0	69.0	84.0	100	
	Week 22	Tezepelumab	66	64 (97.0)	68.0 (18.5)	19	54.0	69.0	84.0	100	
		Placebo	65	59 (90.8)	67.7 (18.6)	26	53.0	69.0	83.0	100	
	Week 23	Tezepelumab	66	64 (97.0)	68.0 (18.0)	15	53.0	70.5	82.5	100	
		Placebo	65	59 (90.8)	68.8 (17.9)	24	54.0	70.0	84.0	100	
	Week 24	Tezepelumab	66	64 (97.0)	68.5 (20.1)	13	51.5	71.0	84.0	100	
		Placebo	65	59 (90.8)	68.9 (18.6)	26	55.0	70.0	83.0	100	
	Week 25	Tezepelumab	66	64 (97.0)	67.6 (19.7)	19	53.0	70.5	82.5	100	
		Placebo	65	59 (90.8)	68.6 (18.3)	22	54.0	71.0	83.0	100	
	Week 26	Tezepelumab	66	65 (98.5)	68.2 (19.0)	19	52.0	73.0	82.0	100	
		Placebo	65	59 (90.8)	68.1 (19.1)	20	51.0	69.0	82.0	100	
	Week 27	Tezepelumab	66	65 (98.5)	66.8 (19.6)	13	50.0	68.0	83.0	100	
		Placebo	65	59 (90.8)	68.2 (17.7)	22	54.0	70.0	81.0	100	
	Week 28	Tezepelumab	66	65 (98.5)	69.0 (19.5)	8	53.0	71.0	83.0	100	
		Placebo	65	60 (92.3)	69.3 (18.9)	27	53.5	69.5	85.5	100	
	Week 29	Tezepelumab	66	65 (98.5)	68.8 (19.6)	7	53.0	72.0	86.0	100	
		Placebo	65	60 (92.3)	68.4 (18.6)	19	54.5	70.0	82.0	100	
	Week 30	Tezepelumab	66	65 (98.5)	67.9 (18.7)	9	56.0	70.0	82.0	100	
		Placebo	65	60 (92.3)	68.1 (18.2)	25	57.5	69.0	82.0	100	
	Week 31	Tezepelumab	66	65 (98.5)	68.2 (18.7)	18	53.0	68.0	85.0	100	
		Placebo	65	60 (92.3)	70.4 (17.1)	27	59.5	71.5	84.0	100	
	Week 32	Tezepelumab	66	65 (98.5)	69.2 (20.0)	9	57.0	73.0	86.0	100	
		Placebo	65	60 (92.3)	68.2 (19.3)	20	54.0	71.0	82.5	100	
	Week 33	Tezepelumab	66	65 (98.5)	69.3 (19.4)	11	53.0	70.0	85.0	100	
		Placebo	65	60 (92.3)	69.7 (18.9)	20	55.0	72.0	82.5	100	
	Week 34	Tezepelumab	66	65 (98.5)	69.4 (18.9)	10	54.0	72.0	84.0	100	
		Placebo	65	60 (92.3)	70.5 (19.3)	23	55.0	72.0	89.5	100	
	Week 35	Tezepelumab	66	65 (98.5)	69.4 (19.3)	7	54.0	72.0	84.0	100	
		Placebo	65	60 (92.3)	68.5 (17.8)	27	55.5	69.5	81.0	100	

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.

Last observation carried forward is applied in case of missing values.

Source Data: avas, created on: 21FEB2022

Table PT3VSC\_ILMH0: Course of EQ-5D-VAS  
 DITTTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
EQ-5D-VAS	Week 36	Tezepelumab	66	65 (98.5)	69.5 (19.3)	17	52.0	71.0	85.0	100	
		Placebo	65	60 (92.3)	68.2 (17.9)	27	55.0	69.0	81.0	100	
	Week 37	Tezepelumab	66	65 (98.5)	69.2 (19.2)	17	54.0	70.0	85.0	100	
		Placebo	65	60 (92.3)	68.3 (18.8)	10	55.0	69.0	82.5	100	
	Week 38	Tezepelumab	66	65 (98.5)	68.2 (20.5)	13	51.0	72.0	85.0	100	
		Placebo	65	60 (92.3)	70.0 (17.7)	27	57.5	72.5	81.0	100	
	Week 39	Tezepelumab	66	65 (98.5)	68.4 (20.4)	11	52.0	70.0	86.0	100	
		Placebo	65	60 (92.3)	70.0 (18.9)	20	58.5	74.0	84.5	100	
	Week 40	Tezepelumab	66	65 (98.5)	70.2 (19.2)	18	53.0	75.0	84.0	100	
		Placebo	65	60 (92.3)	67.7 (19.2)	20	53.5	68.5	85.5	100	
	Week 41	Tezepelumab	66	65 (98.5)	69.4 (19.9)	11	53.0	72.0	87.0	100	
		Placebo	65	60 (92.3)	69.0 (19.1)	27	54.5	72.0	84.5	100	
	Week 42	Tezepelumab	66	65 (98.5)	69.2 (19.5)	9	52.0	72.0	85.0	100	
		Placebo	65	60 (92.3)	68.8 (18.4)	27	54.5	71.5	83.5	100	
	Week 43	Tezepelumab	66	65 (98.5)	69.0 (19.7)	13	53.0	72.0	84.0	100	
		Placebo	65	60 (92.3)	68.5 (18.6)	18	55.0	70.5	82.0	100	
	Week 44	Tezepelumab	66	65 (98.5)	68.6 (19.3)	21	50.0	71.0	83.0	100	
		Placebo	65	60 (92.3)	67.2 (18.8)	23	54.5	68.0	85.0	100	
	Week 45	Tezepelumab	66	66 (100.0)	68.9 (19.1)	22	52.0	72.0	85.0	100	
		Placebo	65	60 (92.3)	69.8 (17.7)	25	56.5	71.0	84.5	100	
	Week 46	Tezepelumab	66	66 (100.0)	68.8 (19.0)	14	53.0	72.0	84.0	100	
		Placebo	65	60 (92.3)	68.8 (17.9)	27	55.5	69.5	82.5	100	
	Week 47	Tezepelumab	66	66 (100.0)	69.3 (18.7)	19	52.0	73.0	83.0	100	
		Placebo	65	60 (92.3)	69.3 (17.4)	27	58.5	71.5	83.5	100	
	Week 48	Tezepelumab	66	66 (100.0)	70.0 (20.1)	9	53.0	74.0	85.0	100	
		Placebo	65	60 (92.3)	68.1 (18.8)	27	53.5	70.0	82.0	100	
	Week 49	Tezepelumab	66	66 (100.0)	69.5 (19.3)	19	53.0	73.0	86.0	100	
		Placebo	65	60 (92.3)	70.7 (18.1)	27	54.0	74.0	84.0	100	
	Week 50	Tezepelumab	66	66 (100.0)	70.6 (19.2)	19	56.0	73.5	87.0	100	
		Placebo	65	60 (92.3)	69.1 (18.7)	27	54.0	70.0	85.0	100	
	Week 51	Tezepelumab	66	66 (100.0)	69.5 (20.0)	19	53.0	73.0	86.0	100	
		Placebo	65	60 (92.3)	71.1 (18.3)	21	59.5	74.0	85.5	100	
	Week 52	Tezepelumab	66	66 (100.0)	69.6 (20.0)	19	53.0	73.0	85.0	100	
		Placebo	65	60 (92.3)	70.1 (19.4)	21	56.5	74.0	85.0	100	

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.

Last observation carried forward is applied in case of missing values.

Source Data: avas, created on: 21FEB2022

Table PT3VSC\_ILMH0: Course of EQ-5D-VAS  
 DITTTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in EQ-5D-VAS	Week 1	Tezepelumab	66	58 (87.9)	4.2 (13.6)	-24	-6.0	2.5	14.0	43	0.01 [-0.36, 0.38]
		Placebo	65	55 (84.6)	4.1 (14.0)	-36	-2.0	3.0	10.0	38	
	Week 2	Tezepelumab	66	58 (87.9)	4.1 (15.8)	-53	-6.0	5.0	17.0	33	0.08 [-0.29, 0.45]
		Placebo	65	55 (84.6)	2.9 (15.8)	-26	-7.0	3.0	10.0	51	
	Week 3	Tezepelumab	66	58 (87.9)	7.0 (15.1)	-29	-2.0	8.0	17.0	37	-0.13 [-0.50, 0.24]
		Placebo	65	55 (84.6)	9.0 (15.4)	-16	-2.0	6.0	18.0	51	
	Week 4	Tezepelumab	66	58 (87.9)	8.2 (19.1)	-40	-5.0	11.0	20.0	47	0.07 [-0.30, 0.44]
		Placebo	65	55 (84.6)	7.0 (14.8)	-26	-4.0	7.0	17.0	51	
	Week 5	Tezepelumab	66	58 (87.9)	9.8 (18.7)	-37	-1.0	10.0	20.0	58	0.08 [-0.29, 0.45]
		Placebo	65	55 (84.6)	8.5 (15.7)	-28	-2.0	6.0	15.0	51	
	Week 6	Tezepelumab	66	58 (87.9)	10.0 (18.9)	-30	-3.0	10.0	23.0	51	0.04 [-0.33, 0.41]
		Placebo	65	55 (84.6)	9.3 (17.4)	-29	-2.0	6.0	22.0	52	
	Week 7	Tezepelumab	66	58 (87.9)	7.5 (18.6)	-39	-3.0	10.0	20.0	61	-0.17 [-0.54, 0.20]
		Placebo	65	55 (84.6)	10.6 (17.2)	-33	-1.0	8.0	23.0	60	
	Week 8	Tezepelumab	66	58 (87.9)	9.5 (20.0)	-59	-1.0	12.0	20.0	69	0.11 [-0.26, 0.48]
		Placebo	65	55 (84.6)	7.3 (19.2)	-36	-5.0	4.0	19.0	62	
	Week 9	Tezepelumab	66	58 (87.9)	9.6 (17.5)	-36	-2.0	10.5	21.0	63	0.07 [-0.29, 0.44]
		Placebo	65	55 (84.6)	8.3 (17.7)	-27	-4.0	5.0	19.0	52	
	Week 10	Tezepelumab	66	58 (87.9)	8.5 (19.9)	-45	-4.0	9.0	24.0	65	-0.11 [-0.48, 0.26]
		Placebo	65	55 (84.6)	10.6 (18.0)	-26	-1.0	8.0	21.0	59	
	Week 11	Tezepelumab	66	58 (87.9)	10.3 (20.7)	-41	-2.0	11.5	24.0	64	-0.00 [-0.37, 0.36]
		Placebo	65	55 (84.6)	10.4 (17.9)	-27	-2.0	8.0	22.0	62	
	Week 12	Tezepelumab	66	58 (87.9)	10.4 (19.4)	-34	-1.0	8.0	23.0	65	0.04 [-0.33, 0.41]
		Placebo	65	55 (84.6)	9.6 (19.0)	-34	-2.0	8.0	21.0	68	
	Week 13	Tezepelumab	66	58 (87.9)	10.6 (20.3)	-44	-3.0	10.0	23.0	63	-0.05 [-0.42, 0.32]
		Placebo	65	55 (84.6)	11.6 (17.1)	-26	-1.0	7.0	24.0	62	
	Week 14	Tezepelumab	66	58 (87.9)	11.1 (19.6)	-38	-1.0	12.0	25.0	56	0.02 [-0.35, 0.39]
		Placebo	65	55 (84.6)	10.8 (17.5)	-25	-2.0	8.0	24.0	67	
	Week 15	Tezepelumab	66	58 (87.9)	11.1 (20.5)	-51	-2.0	14.0	25.0	56	0.00 [-0.37, 0.37]
		Placebo	65	55 (84.6)	11.1 (16.3)	-35	-1.0	10.0	22.0	68	
	Week 16	Tezepelumab	66	58 (87.9)	10.0 (20.0)	-37	-2.0	6.5	25.0	65	0.09 [-0.28, 0.46]
		Placebo	65	55 (84.6)	8.4 (16.9)	-28	-2.0	6.0	16.0	58	
	Week 17	Tezepelumab	66	58 (87.9)	10.9 (20.6)	-41	-1.0	12.5	30.0	59	0.06 [-0.31, 0.43]
		Placebo	65	55 (84.6)	9.7 (18.2)	-40	-2.0	7.0	21.0	58	

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.

Last observation carried forward is applied in case of missing values.

Source Data: avas, created on: 21FEB2022

Table PT3VSC\_ILMH0: Course of EQ-5D-VAS  
 DITTTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in EQ-5D-VAS	Week 18	Tezepelumab	66	58 (87.9)	10.1 (20.3)	-40	-2.0	8.5	25.0	58	0.09 [-0.28, 0.46]
		Placebo	65	55 (84.6)	8.4 (18.5)	-32	-3.0	8.0	22.0	60	
	Week 19	Tezepelumab	66	58 (87.9)	9.7 (19.3)	-38	-3.0	9.0	22.0	62	0.05 [-0.31, 0.42]
		Placebo	65	55 (84.6)	8.7 (17.3)	-32	-2.0	8.0	20.0	52	
	Week 20	Tezepelumab	66	58 (87.9)	10.9 (20.4)	-44	-4.0	12.0	25.0	51	0.11 [-0.26, 0.48]
		Placebo	65	55 (84.6)	8.9 (17.2)	-32	-4.0	8.0	21.0	51	
	Week 21	Tezepelumab	66	58 (87.9)	9.5 (19.4)	-38	-1.0	10.0	23.0	49	0.03 [-0.34, 0.39]
		Placebo	65	55 (84.6)	9.1 (17.1)	-31	-2.0	6.0	20.0	54	
	Week 22	Tezepelumab	66	58 (87.9)	9.9 (19.8)	-34	-5.0	10.0	25.0	48	0.04 [-0.32, 0.41]
		Placebo	65	55 (84.6)	9.1 (17.2)	-25	-2.0	7.0	22.0	58	
	Week 23	Tezepelumab	66	58 (87.9)	10.0 (20.1)	-34	-2.0	10.5	26.0	56	-0.01 [-0.38, 0.36]
		Placebo	65	55 (84.6)	10.2 (17.2)	-23	-2.0	8.0	23.0	62	
	Week 24	Tezepelumab	66	58 (87.9)	11.2 (20.0)	-38	-3.0	12.0	25.0	51	0.04 [-0.33, 0.41]
		Placebo	65	55 (84.6)	10.4 (18.9)	-65	-1.0	8.0	23.0	66	
	Week 25	Tezepelumab	66	58 (87.9)	9.9 (21.0)	-37	-3.0	7.0	25.0	57	0.00 [-0.36, 0.37]
		Placebo	65	55 (84.6)	9.8 (15.7)	-25	-1.0	8.0	20.0	62	
	Week 26	Tezepelumab	66	58 (87.9)	9.9 (21.0)	-43	-3.0	10.5	27.0	56	0.03 [-0.34, 0.40]
		Placebo	65	55 (84.6)	9.4 (17.5)	-53	-1.0	8.0	18.0	65	
	Week 27	Tezepelumab	66	58 (87.9)	8.9 (20.3)	-43	-7.0	6.0	23.0	56	-0.03 [-0.40, 0.34]
		Placebo	65	55 (84.6)	9.5 (15.3)	-25	-2.0	6.0	20.0	60	
	Week 28	Tezepelumab	66	58 (87.9)	10.7 (21.7)	-43	-3.0	10.0	28.0	60	0.03 [-0.33, 0.40]
		Placebo	65	55 (84.6)	10.1 (16.1)	-20	-2.0	8.0	20.0	65	
	Week 29	Tezepelumab	66	58 (87.9)	10.1 (20.3)	-43	-2.0	11.5	25.0	45	0.05 [-0.32, 0.42]
		Placebo	65	55 (84.6)	9.2 (16.1)	-28	-3.0	8.0	19.0	61	
	Week 30	Tezepelumab	66	58 (87.9)	9.6 (19.7)	-43	-3.0	10.5	23.0	44	0.04 [-0.33, 0.40]
		Placebo	65	55 (84.6)	9.0 (16.3)	-22	-3.0	8.0	23.0	47	
	Week 31	Tezepelumab	66	58 (87.9)	9.8 (19.2)	-43	-4.0	11.5	25.0	44	-0.06 [-0.43, 0.31]
		Placebo	65	55 (84.6)	10.9 (15.9)	-20	-2.0	11.0	23.0	57	
	Week 32	Tezepelumab	66	58 (87.9)	11.3 (21.9)	-43	-3.0	12.0	29.0	68	0.09 [-0.28, 0.46]
		Placebo	65	55 (84.6)	9.6 (16.6)	-30	-2.0	8.0	21.0	53	
	Week 33	Tezepelumab	66	58 (87.9)	11.2 (21.0)	-43	-4.0	12.0	27.0	60	0.04 [-0.33, 0.41]
		Placebo	65	55 (84.6)	10.4 (16.9)	-25	-2.0	8.0	23.0	64	
	Week 34	Tezepelumab	66	58 (87.9)	11.3 (21.8)	-43	-1.0	12.5	30.0	58	-0.01 [-0.38, 0.36]
		Placebo	65	55 (84.6)	11.5 (16.9)	-24	-1.0	8.0	23.0	61	

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.

Last observation carried forward is applied in case of missing values.

Source Data: avas, created on: 21FEB2022



Table PT3VSC\_ILMH0: Course of EQ-5D-VAS  
 DITTTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in EQ-5D-VAS	Week 35	Tezepelumab	66	58 (87.9)	11.2 (21.5)	-43	-3.0	12.0	27.0	55	0.11 [-0.25, 0.48]
		Placebo	65	55 (84.6)	9.1 (14.9)	-21	-2.0	8.0	20.0	44	
	Week 36	Tezepelumab	66	58 (87.9)	11.3 (21.6)	-43	-4.0	16.0	26.0	67	0.13 [-0.24, 0.50]
		Placebo	65	55 (84.6)	8.9 (14.8)	-21	-3.0	7.0	18.0	42	
	Week 37	Tezepelumab	66	58 (87.9)	11.2 (22.4)	-43	-7.0	13.5	26.0	68	0.12 [-0.25, 0.49]
		Placebo	65	55 (84.6)	8.9 (16.8)	-35	-2.0	6.0	23.0	43	
	Week 38	Tezepelumab	66	58 (87.9)	10.3 (21.8)	-43	-5.0	10.5	25.0	61	-0.02 [-0.39, 0.35]
		Placebo	65	55 (84.6)	10.7 (16.3)	-26	-2.0	7.0	21.0	57	
	Week 39	Tezepelumab	66	58 (87.9)	10.1 (21.1)	-43	-2.0	7.5	25.0	57	-0.04 [-0.41, 0.33]
		Placebo	65	55 (84.6)	10.9 (17.2)	-25	-2.0	7.0	24.0	65	
	Week 40	Tezepelumab	66	58 (87.9)	11.7 (20.8)	-43	-3.0	14.0	26.0	58	0.14 [-0.23, 0.51]
		Placebo	65	55 (84.6)	9.1 (17.3)	-25	-3.0	5.0	21.0	55	
	Week 41	Tezepelumab	66	58 (87.9)	10.9 (22.3)	-43	-6.0	14.5	26.0	58	0.03 [-0.34, 0.40]
		Placebo	65	55 (84.6)	10.3 (16.8)	-20	-2.0	6.0	22.0	56	
	Week 42	Tezepelumab	66	58 (87.9)	11.0 (21.5)	-43	-5.0	14.0	26.0	53	0.05 [-0.32, 0.42]
		Placebo	65	55 (84.6)	10.1 (16.8)	-30	-2.0	7.0	22.0	54	
	Week 43	Tezepelumab	66	58 (87.9)	11.2 (21.1)	-43	-3.0	15.5	28.0	55	0.09 [-0.28, 0.46]
		Placebo	65	55 (84.6)	9.5 (16.1)	-29	-2.0	6.0	20.0	57	
	Week 44	Tezepelumab	66	58 (87.9)	10.7 (20.8)	-43	-7.0	13.5	29.0	51	0.12 [-0.25, 0.49]
		Placebo	65	55 (84.6)	8.4 (17.4)	-24	-4.0	6.0	20.0	58	
	Week 45	Tezepelumab	66	58 (87.9)	10.7 (20.8)	-43	-4.0	15.0	26.0	60	-0.02 [-0.39, 0.35]
		Placebo	65	55 (84.6)	11.1 (16.8)	-22	-3.0	8.0	20.0	58	
	Week 46	Tezepelumab	66	58 (87.9)	11.0 (21.5)	-43	-6.0	15.5	26.0	66	0.05 [-0.32, 0.42]
		Placebo	65	55 (84.6)	10.0 (17.1)	-18	-3.0	7.0	19.0	58	
	Week 47	Tezepelumab	66	58 (87.9)	10.8 (21.4)	-43	-9.0	16.5	25.0	59	0.02 [-0.35, 0.39]
		Placebo	65	55 (84.6)	10.4 (17.2)	-18	-2.0	6.0	23.0	58	
	Week 48	Tezepelumab	66	58 (87.9)	11.9 (22.7)	-43	-7.0	18.0	29.0	65	0.12 [-0.25, 0.49]
		Placebo	65	55 (84.6)	9.5 (16.2)	-19	-2.0	8.0	16.0	58	
	Week 49	Tezepelumab	66	58 (87.9)	11.1 (21.8)	-43	-6.0	17.5	25.0	65	-0.04 [-0.41, 0.33]
		Placebo	65	55 (84.6)	11.9 (17.0)	-16	-2.0	9.0	23.0	58	
	Week 50	Tezepelumab	66	58 (87.9)	11.6 (21.1)	-43	-2.0	14.0	27.0	58	0.06 [-0.31, 0.43]
		Placebo	65	55 (84.6)	10.4 (19.3)	-23	-4.0	8.0	23.0	60	
	Week 51	Tezepelumab	66	58 (87.9)	10.9 (21.6)	-43	-5.0	16.0	25.0	58	-0.08 [-0.45, 0.29]
		Placebo	65	55 (84.6)	12.5 (18.0)	-26	-2.0	10.0	27.0	58	
	Week 52	Tezepelumab	66	58 (87.9)	11.1 (21.4)	-43	-5.0	17.0	25.0	58	-0.02 [-0.38, 0.35]
		Placebo	65	55 (84.6)	11.5 (18.4)	-26	-3.0	10.0	23.0	65	

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.

Last observation carried forward is applied in case of missing values.

Source Data: avas, created on: 21FEB2022

Table PT3VSC\_ILMC0: Change from baseline in EQ-5D-VAS - MMRM results  
DITTTL

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 1	Tezepelumab	66	58 (87.9)	NE		NE		
	Placebo	65	55 (84.6)					
Week 2	Tezepelumab	66	58 (87.9)	NE		NE		
	Placebo	65	55 (84.6)					
Week 3	Tezepelumab	66	56 (84.8)	NE		NE		
	Placebo	65	49 (75.4)					
Week 4	Tezepelumab	66	54 (81.8)	NE		NE		
	Placebo	65	50 (76.9)					
Week 5	Tezepelumab	66	54 (81.8)	NE		NE		
	Placebo	65	49 (75.4)					
Week 6	Tezepelumab	66	54 (81.8)	NE		NE		
	Placebo	65	48 (73.8)					
Week 7	Tezepelumab	66	54 (81.8)	NE		NE		
	Placebo	65	49 (75.4)					
Week 8	Tezepelumab	66	53 (80.3)	NE		NE		
	Placebo	65	49 (75.4)					
Week 9	Tezepelumab	66	52 (78.8)	NE		NE		
	Placebo	65	48 (73.8)					
Week 10	Tezepelumab	66	51 (77.3)	NE		NE		
	Placebo	65	48 (73.8)					

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

VAS = visual analogue scale.

Source Data: avas, created on: 21FEB2022

Table PT3VSC\_ILMC0: Change from baseline in EQ-5D-VAS - MMRM results  
 DITTTL

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 11	Tezepelumab	66	50 (75.8)	NE		NE		
	Placebo	65	46 (70.8)					
Week 12	Tezepelumab	66	50 (75.8)	NE		NE		
	Placebo	65	46 (70.8)					
Week 13	Tezepelumab	66	51 (77.3)	NE		NE		
	Placebo	65	46 (70.8)					
Week 14	Tezepelumab	66	51 (77.3)	NE		NE		
	Placebo	65	46 (70.8)					
Week 15	Tezepelumab	66	50 (75.8)	NE		NE		
	Placebo	65	46 (70.8)					
Week 16	Tezepelumab	66	50 (75.8)	NE		NE		
	Placebo	65	46 (70.8)					
Week 17	Tezepelumab	66	51 (77.3)	NE		NE		
	Placebo	65	43 (66.2)					
Week 18	Tezepelumab	66	51 (77.3)	NE		NE		
	Placebo	65	45 (69.2)					
Week 19	Tezepelumab	66	50 (75.8)	NE		NE		
	Placebo	65	45 (69.2)					
Week 20	Tezepelumab	66	50 (75.8)	NE		NE		
	Placebo	65	45 (69.2)					

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

VAS = visual analogue scale.

Source Data: avas, created on: 21FEB2022

Table PT3VSC\_ILMC0: Change from baseline in EQ-5D-VAS - MMRM results  
 DITTTL

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 21	Tezepelumab	66	51 (77.3)	NE		NE		
	Placebo	65	46 (70.8)					
Week 22	Tezepelumab	66	50 (75.8)	NE		NE		
	Placebo	65	45 (69.2)					
Week 23	Tezepelumab	66	49 (74.2)	NE		NE		
	Placebo	65	43 (66.2)					
Week 24	Tezepelumab	66	50 (75.8)	NE		NE		
	Placebo	65	45 (69.2)					
Week 25	Tezepelumab	66	50 (75.8)	NE		NE		
	Placebo	65	44 (67.7)					
Week 26	Tezepelumab	66	50 (75.8)	NE		NE		
	Placebo	65	44 (67.7)					
Week 27	Tezepelumab	66	49 (74.2)	NE		NE		
	Placebo	65	44 (67.7)					
Week 28	Tezepelumab	66	47 (71.2)	NE		NE		
	Placebo	65	44 (67.7)					
Week 29	Tezepelumab	66	48 (72.7)	NE		NE		
	Placebo	65	42 (64.6)					
Week 30	Tezepelumab	66	48 (72.7)	NE		NE		
	Placebo	65	42 (64.6)					

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

VAS = visual analogue scale.

Source Data: avas, created on: 21FEB2022

Table PT3VSC\_ILMC0: Change from baseline in EQ-5D-VAS - MMRM results  
 DITTTL

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 31	Tezepelumab	66	48 (72.7)	NE		NE		
	Placebo	65	42 (64.6)					
Week 32	Tezepelumab	66	49 (74.2)	NE		NE		
	Placebo	65	43 (66.2)					
Week 33	Tezepelumab	66	49 (74.2)	NE		NE		
	Placebo	65	40 (61.5)					
Week 34	Tezepelumab	66	49 (74.2)	NE		NE		
	Placebo	65	42 (64.6)					
Week 35	Tezepelumab	66	49 (74.2)	NE		NE		
	Placebo	65	44 (67.7)					
Week 36	Tezepelumab	66	49 (74.2)	NE		NE		
	Placebo	65	44 (67.7)					
Week 37	Tezepelumab	66	49 (74.2)	NE		NE		
	Placebo	65	43 (66.2)					
Week 38	Tezepelumab	66	48 (72.7)	NE		NE		
	Placebo	65	44 (67.7)					
Week 39	Tezepelumab	66	49 (74.2)	NE		NE		
	Placebo	65	42 (64.6)					
Week 40	Tezepelumab	66	48 (72.7)	NE		NE		
	Placebo	65	45 (69.2)					

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

VAS = visual analogue scale.

Source Data: avas, created on: 21FEB2022

Table PT3VSC\_ILMC0: Change from baseline in EQ-5D-VAS - MMRM results  
DITTTL

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 41	Tezepelumab	66	47 (71.2)	NE		NE		
	Placebo	65	44 (67.7)					
Week 42	Tezepelumab	66	48 (72.7)	NE		NE		
	Placebo	65	43 (66.2)					
Week 43	Tezepelumab	66	47 (71.2)	NE		NE		
	Placebo	65	43 (66.2)					
Week 44	Tezepelumab	66	47 (71.2)	NE		NE		
	Placebo	65	44 (67.7)					
Week 45	Tezepelumab	66	48 (72.7)	NE		NE		
	Placebo	65	45 (69.2)					
Week 46	Tezepelumab	66	48 (72.7)	NE		NE		
	Placebo	65	45 (69.2)					
Week 47	Tezepelumab	66	48 (72.7)	NE		NE		
	Placebo	65	43 (66.2)					
Week 48	Tezepelumab	66	46 (69.7)	NE		NE		
	Placebo	65	44 (67.7)					
Week 49	Tezepelumab	66	48 (72.7)	NE		NE		
	Placebo	65	44 (67.7)					
Week 50	Tezepelumab	66	46 (69.7)	NE		NE		
	Placebo	65	45 (69.2)					

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

VAS = visual analogue scale.

Source Data: avas, created on: 21FEB2022

Table PT3VSC\_ILMC0: Change from baseline in EQ-5D-VAS - MMRM results  
 DITTTL

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 51	Tezepelumab	66	43 (65.2)	NE		NE		
	Placebo	65	44 (67.7)					
Week 52	Tezepelumab	66	14 (21.2)	NE		NE		
	Placebo	65	15 (23.1)					

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

VAS = visual analogue scale.

Source Data: avas, created on: 21FEB2022

Table ST1VSC\_ILMH0: Course of EQ-5D-VAS  
 DITTLL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
EQ-5D-VAS	Baseline	Tezepelumab	73	73 (100.0)	62.4 (18.5)	17	50.0	61.0	80.0	100	
		Placebo	76	73 (96.1)	61.5 (17.4)	20	51.0	65.0	71.0	91	
	Week 2	Tezepelumab	73	69 (94.5)	64.9 (17.3)	19	51.0	66.0	77.0	100	
		Placebo	76	72 (94.7)	59.9 (20.1)	4	48.0	59.0	76.0	98	
	Week 4	Tezepelumab	73	72 (98.6)	67.9 (19.1)	13	56.0	70.0	81.0	100	
		Placebo	76	75 (98.7)	61.2 (17.2)	8	50.0	60.0	72.0	98	
	Week 6	Tezepelumab	73	69 (94.5)	68.9 (18.8)	13	59.0	70.0	83.0	100	
		Placebo	76	74 (97.4)	61.1 (17.6)	18	50.0	60.0	75.0	95	
	Week 8	Tezepelumab	73	72 (98.6)	70.0 (17.8)	12	59.0	70.0	85.0	100	
		Placebo	76	75 (98.7)	60.4 (17.9)	10	48.0	61.0	75.0	98	
	Week 10	Tezepelumab	73	70 (95.9)	68.4 (18.7)	14	58.0	70.0	80.0	100	
		Placebo	76	72 (94.7)	60.7 (18.6)	14	46.5	60.0	77.5	97	
	Week 12	Tezepelumab	73	70 (95.9)	68.1 (17.6)	12	58.0	68.5	80.0	100	
		Placebo	76	73 (96.1)	61.6 (17.5)	15	48.0	60.0	75.0	97	
	Week 14	Tezepelumab	73	69 (94.5)	66.6 (19.4)	11	51.0	70.0	80.0	100	
		Placebo	76	72 (94.7)	61.8 (17.4)	16	49.0	60.0	74.5	100	
	Week 16	Tezepelumab	73	71 (97.3)	67.2 (19.1)	10	54.0	69.0	80.0	100	
		Placebo	76	72 (94.7)	62.6 (18.5)	12	50.0	61.0	77.0	98	
	Week 18	Tezepelumab	73	68 (93.2)	67.2 (19.2)	14	56.0	70.0	80.5	100	
		Placebo	76	71 (93.4)	62.1 (19.1)	11	50.0	60.0	79.0	99	
	Week 20	Tezepelumab	73	69 (94.5)	68.0 (19.2)	10	56.0	69.0	80.0	99	
		Placebo	76	73 (96.1)	63.6 (19.1)	10	50.0	61.0	80.0	98	
	Week 22	Tezepelumab	73	69 (94.5)	67.3 (20.6)	9	57.0	70.0	81.0	100	
		Placebo	76	72 (94.7)	62.0 (19.0)	16	49.5	60.5	75.0	96	
	Week 24	Tezepelumab	73	70 (95.9)	67.5 (19.4)	9	51.0	70.0	80.0	100	
		Placebo	76	74 (97.4)	62.2 (19.9)	13	45.0	63.0	79.0	98	
	Week 26	Tezepelumab	73	69 (94.5)	67.6 (20.9)	9	56.0	73.0	80.0	100	
		Placebo	76	72 (94.7)	61.2 (19.2)	10	49.5	59.5	75.5	96	
	Week 28	Tezepelumab	73	68 (93.2)	67.8 (20.9)	13	53.0	70.5	83.0	100	
		Placebo	76	74 (97.4)	62.5 (18.8)	10	48.0	61.0	77.0	96	
	Week 30	Tezepelumab	73	67 (91.8)	68.9 (20.5)	9	55.0	72.0	84.0	100	
		Placebo	76	73 (96.1)	62.0 (18.9)	10	47.0	60.0	77.0	98	
	Week 32	Tezepelumab	73	69 (94.5)	68.3 (19.9)	8	52.0	71.0	82.0	100	
		Placebo	76	74 (97.4)	63.8 (18.5)	11	50.0	61.0	79.0	99	
Week 34	Tezepelumab	73	67 (91.8)	69.3 (19.4)	11	56.0	72.0	84.0	100		
	Placebo	76	73 (96.1)	64.9 (18.3)	10	51.0	65.0	79.0	100		

Note: DITTLL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.

Source Data: avas, created on: 23FEB2022



Table ST1VSC\_ILMH0: Course of EQ-5D-VAS  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
EQ-5D-VAS	Week 36	Tezepelumab	73	68 (93.2)	69.6 (19.8)	11	52.5	75.0	85.5	100	
		Placebo	76	74 (97.4)	65.1 (18.5)	10	51.0	69.0	77.0	100	
	Week 38	Tezepelumab	73	64 (87.7)	70.3 (18.8)	12	58.5	74.0	85.0	100	
		Placebo	76	73 (96.1)	63.5 (18.4)	10	50.0	61.0	76.0	100	
	Week 40	Tezepelumab	73	67 (91.8)	72.0 (19.3)	13	60.0	77.0	87.0	100	
		Placebo	76	73 (96.1)	63.4 (18.9)	10	50.0	65.0	80.0	95	
	Week 42	Tezepelumab	73	62 (84.9)	70.7 (20.2)	10	58.0	75.0	87.0	100	
		Placebo	76	74 (97.4)	64.6 (18.8)	10	50.0	61.0	80.0	98	
	Week 44	Tezepelumab	73	64 (87.7)	72.8 (19.2)	11	60.0	78.5	86.0	100	
		Placebo	76	74 (97.4)	62.8 (20.1)	10	50.0	60.5	77.0	98	
	Week 46	Tezepelumab	73	64 (87.7)	71.0 (19.3)	12	58.0	75.0	84.5	100	
		Placebo	76	72 (94.7)	64.1 (20.0)	10	50.0	64.0	80.0	100	
	Week 48	Tezepelumab	73	61 (83.6)	73.4 (20.3)	11	60.0	80.0	87.0	100	
		Placebo	76	60 (78.9)	64.4 (20.5)	10	50.0	64.0	80.0	97	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.

Source Data: avas, created on: 23FEB2022

Table ST1VSC\_ILMH0: Course of EQ-5D-VAS  
 DITTLL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in EQ-5D-VAS	Week 2	Tezepelumab	73	69 (94.5)	3.7 (14.2)	-35	-4.0	2.0	11.0	43	0.33 [-0.01, 0.67]
		Placebo	76	69 (90.8)	-1.6 (17.6)	-51	-10.0	0.0	8.0	61	
	Week 4	Tezepelumab	73	72 (98.6)	5.3 (16.3)	-40	-2.5	5.0	12.5	49	0.34 [0.01, 0.67]
		Placebo	76	72 (94.7)	-0.4 (17.4)	-38	-9.0	0.0	10.0	73	
	Week 6	Tezepelumab	73	69 (94.5)	6.5 (16.3)	-40	-1.0	4.0	12.0	48	0.41 [0.07, 0.74]
		Placebo	76	71 (93.4)	-0.0 (15.8)	-34	-9.0	1.0	10.0	42	
	Week 8	Tezepelumab	73	72 (98.6)	7.4 (17.0)	-31	-5.0	6.5	15.5	48	0.51 [0.18, 0.84]
		Placebo	76	72 (94.7)	-1.5 (17.8)	-36	-10.0	0.0	7.0	53	
	Week 10	Tezepelumab	73	70 (95.9)	6.2 (16.6)	-40	-2.0	4.0	15.0	58	0.41 [0.07, 0.74]
		Placebo	76	70 (92.1)	-1.0 (18.7)	-57	-11.0	0.0	8.0	72	
	Week 12	Tezepelumab	73	70 (95.9)	5.9 (18.5)	-45	-4.0	4.5	15.0	54	0.32 [-0.01, 0.66]
		Placebo	76	71 (93.4)	-0.1 (18.5)	-50	-10.0	0.0	9.0	72	
	Week 14	Tezepelumab	73	69 (94.5)	4.7 (19.1)	-40	-7.0	2.0	16.0	61	0.24 [-0.09, 0.57]
		Placebo	76	70 (92.1)	0.1 (18.8)	-42	-11.0	1.0	10.0	51	
	Week 16	Tezepelumab	73	71 (97.3)	4.8 (18.3)	-34	-10.0	3.0	13.0	51	0.20 [-0.13, 0.53]
		Placebo	76	70 (92.1)	1.1 (18.6)	-46	-5.0	3.0	9.0	61	
	Week 18	Tezepelumab	73	68 (93.2)	5.4 (17.4)	-43	-5.0	1.5	16.5	51	0.25 [-0.09, 0.58]
		Placebo	76	69 (90.8)	0.7 (20.2)	-53	-7.0	0.0	10.0	58	
	Week 20	Tezepelumab	73	69 (94.5)	5.4 (17.8)	-42	-5.0	4.0	16.0	45	0.20 [-0.13, 0.53]
		Placebo	76	71 (93.4)	1.7 (18.7)	-39	-8.0	3.0	10.0	71	
	Week 22	Tezepelumab	73	69 (94.5)	5.4 (18.5)	-40	-5.0	5.0	18.0	60	0.26 [-0.07, 0.59]
		Placebo	76	70 (92.1)	0.4 (19.3)	-50	-10.0	0.5	10.0	68	
	Week 24	Tezepelumab	73	70 (95.9)	5.3 (18.4)	-40	-5.0	2.5	18.0	59	0.24 [-0.09, 0.57]
		Placebo	76	72 (94.7)	0.5 (21.0)	-57	-10.0	1.0	12.5	60	
	Week 26	Tezepelumab	73	69 (94.5)	5.0 (19.1)	-60	-5.0	4.0	14.0	54	0.26 [-0.08, 0.59]
		Placebo	76	69 (90.8)	-0.1 (20.7)	-51	-10.0	1.0	10.0	65	
	Week 28	Tezepelumab	73	68 (93.2)	5.1 (20.0)	-39	-5.0	2.5	16.5	50	0.22 [-0.12, 0.55]
		Placebo	76	71 (93.4)	0.8 (19.5)	-40	-10.0	3.0	11.0	71	
	Week 30	Tezepelumab	73	67 (91.8)	6.0 (19.4)	-31	-8.0	3.0	19.0	51	0.27 [-0.07, 0.61]
		Placebo	76	70 (92.1)	0.5 (21.0)	-51	-10.0	1.0	13.0	68	
	Week 32	Tezepelumab	73	69 (94.5)	5.4 (18.8)	-30	-6.0	2.0	12.0	57	0.17 [-0.17, 0.50]
		Placebo	76	71 (93.4)	2.2 (20.0)	-48	-8.0	0.0	15.0	68	
	Week 34	Tezepelumab	73	67 (91.8)	6.4 (18.1)	-29	-5.0	3.0	12.0	50	0.14 [-0.19, 0.48]
		Placebo	76	70 (92.1)	3.7 (19.3)	-40	-10.0	2.5	13.0	67	
	Week 36	Tezepelumab	73	68 (93.2)	6.4 (20.1)	-50	-5.0	3.0	17.0	50	0.14 [-0.20, 0.47]
		Placebo	76	71 (93.4)	3.6 (20.8)	-41	-9.0	4.0	14.0	62	

Note: DITTLL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.

Source Data: avas, created on: 23FEB2022

Table ST1VSC\_ILMH0: Course of EQ-5D-VAS  
 DITTLL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in EQ-5D-VAS	Week 38	Tezepelumab	73	64 (87.7)	7.0 (18.1)	-39	-3.0	3.5	17.5	49	0.26 [-0.08, 0.60]
		Placebo	76	70 (92.1)	1.8 (21.7)	-56	-9.0	0.5	13.0	69	
	Week 40	Tezepelumab	73	67 (91.8)	8.8 (18.6)	-28	-3.0	6.0	22.0	54	0.36 [0.02, 0.70]
		Placebo	76	70 (92.1)	1.8 (20.4)	-42	-6.0	2.0	13.0	63	
	Week 42	Tezepelumab	73	62 (84.9)	7.2 (18.3)	-39	-3.0	6.5	17.0	50	0.21 [-0.14, 0.55]
		Placebo	76	71 (93.4)	3.2 (20.5)	-41	-8.0	3.0	15.0	69	
	Week 44	Tezepelumab	73	64 (87.7)	9.1 (18.0)	-29	-2.0	6.0	19.0	50	0.39 [0.05, 0.73]
		Placebo	76	71 (93.4)	1.4 (21.0)	-44	-10.0	0.0	13.0	62	
	Week 46	Tezepelumab	73	64 (87.7)	7.3 (17.8)	-34	-4.0	5.0	13.5	48	0.25 [-0.09, 0.59]
		Placebo	76	70 (92.1)	2.4 (21.8)	-47	-10.0	2.0	10.0	67	
	Week 48	Tezepelumab	73	61 (83.6)	9.2 (18.9)	-33	0.0	7.0	20.0	51	0.34 [-0.03, 0.70]
		Placebo	76	58 (76.3)	2.4 (22.0)	-58	-7.0	2.5	11.0	61	

Note: DITTLL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.

Source Data: avas, created on: 23FEB2022

Table ST1VSC\_ILMC0: Change from baseline in EQ-5D-VAS - MMRM results  
 DITTTL

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 2	Tezepelumab	73	69 (94.5)	3.2 (1.8)	(-0.3, 6.7)	4.6 (2.5)	(-0.4, 9.6)	0.069
	Placebo	76	69 (90.8)	-1.4 (1.8)	(-5.0, 2.1)			
Week 4	Tezepelumab	73	72 (98.6)	5.4 (1.8)	(1.9, 8.9)	5.6 (2.5)	(0.6, 10.6)	0.028 *
	Placebo	76	72 (94.7)	-0.2 (1.8)	(-3.8, 3.3)			
Week 6	Tezepelumab	73	69 (94.5)	6.5 (1.7)	(3.2, 9.9)	6.9 (2.4)	(2.1, 11.6)	0.005 *
	Placebo	76	71 (93.4)	-0.3 (1.7)	(-3.7, 3.0)			
Week 8	Tezepelumab	73	72 (98.6)	7.5 (1.8)	(3.9, 11.1)	9.0 (2.6)	(3.9, 14.0)	<0.001 *
	Placebo	76	72 (94.7)	-1.5 (1.8)	(-5.1, 2.1)			
Week 10	Tezepelumab	73	70 (95.9)	6.1 (1.9)	(2.3, 9.8)	7.2 (2.6)	(2.0, 12.4)	0.007 *
	Placebo	76	70 (92.1)	-1.1 (1.9)	(-4.8, 2.6)			
Week 12	Tezepelumab	73	70 (95.9)	5.3 (1.9)	(1.6, 9.1)	5.2 (2.7)	(-0.1, 10.5)	0.054
	Placebo	76	71 (93.4)	0.1 (1.9)	(-3.6, 3.9)			
Week 14	Tezepelumab	73	69 (94.5)	4.7 (2.0)	(0.8, 8.6)	4.2 (2.8)	(-1.3, 9.7)	0.136
	Placebo	76	70 (92.1)	0.5 (2.0)	(-3.4, 4.4)			
Week 16	Tezepelumab	73	71 (97.3)	4.6 (1.9)	(0.8, 8.5)	3.5 (2.7)	(-1.9, 8.9)	0.203
	Placebo	76	70 (92.1)	1.1 (1.9)	(-2.7, 4.9)			
Week 18	Tezepelumab	73	68 (93.2)	4.7 (2.0)	(0.7, 8.6)	4.4 (2.8)	(-1.1, 10.0)	0.117
	Placebo	76	69 (90.8)	0.2 (2.0)	(-3.7, 4.2)			
Week 20	Tezepelumab	73	69 (94.5)	4.9 (2.0)	(1.0, 8.8)	3.1 (2.8)	(-2.3, 8.6)	0.258
	Placebo	76	71 (93.4)	1.8 (1.9)	(-2.1, 5.6)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

VAS = visual analogue scale.

Source Data: avas, created on: 23FEB2022

Table ST1VSC\_ILMC0: Change from baseline in EQ-5D-VAS - MMRM results  
 DITTTL

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 22	Tezepelumab	73	69 (94.5)	5.0 (2.0)	(0.9, 9.0)	4.6 (2.9)	(-1.1, 10.3)	0.113
	Placebo	76	70 (92.1)	0.4 (2.0)	(-3.6, 4.4)			
Week 24	Tezepelumab	73	70 (95.9)	4.8 (2.1)	(0.7, 9.0)	4.3 (3.0)	(-1.5, 10.2)	0.145
	Placebo	76	72 (94.7)	0.5 (2.1)	(-3.7, 4.6)			
Week 26	Tezepelumab	73	69 (94.5)	4.6 (2.1)	(0.4, 8.8)	4.9 (3.0)	(-1.1, 10.8)	0.107
	Placebo	76	69 (90.8)	-0.3 (2.1)	(-4.5, 3.9)			
Week 28	Tezepelumab	73	68 (93.2)	4.4 (2.1)	(0.2, 8.6)	3.6 (3.0)	(-2.3, 9.5)	0.229
	Placebo	76	71 (93.4)	0.8 (2.1)	(-3.4, 5.0)			
Week 30	Tezepelumab	73	67 (91.8)	5.9 (2.1)	(1.7, 10.1)	5.5 (3.0)	(-0.5, 11.4)	0.070
	Placebo	76	70 (92.1)	0.4 (2.1)	(-3.8, 4.6)			
Week 32	Tezepelumab	73	69 (94.5)	5.2 (2.0)	(1.1, 9.2)	3.0 (2.9)	(-2.7, 8.7)	0.300
	Placebo	76	71 (93.4)	2.2 (2.0)	(-1.8, 6.2)			
Week 34	Tezepelumab	73	67 (91.8)	6.3 (2.0)	(2.4, 10.1)	2.7 (2.8)	(-2.8, 8.2)	0.337
	Placebo	76	70 (92.1)	3.6 (2.0)	(-0.3, 7.4)			
Week 36	Tezepelumab	73	68 (93.2)	6.1 (2.1)	(1.8, 10.3)	2.4 (3.0)	(-3.6, 8.4)	0.430
	Placebo	76	71 (93.4)	3.7 (2.1)	(-0.5, 7.9)			
Week 38	Tezepelumab	73	64 (87.7)	6.6 (2.1)	(2.5, 10.7)	5.0 (2.9)	(-0.7, 10.8)	0.088
	Placebo	76	70 (92.1)	1.6 (2.0)	(-2.5, 5.6)			
Week 40	Tezepelumab	73	67 (91.8)	8.1 (2.1)	(4.0, 12.2)	6.5 (2.9)	(0.7, 12.2)	0.028 *
	Placebo	76	70 (92.1)	1.6 (2.1)	(-2.4, 5.7)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

VAS = visual analogue scale.

Source Data: avas, created on: 23FEB2022

Table ST1VSC\_ILMC0: Change from baseline in EQ-5D-VAS - MMRM results  
 DITTTL

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 42	Tezepelumab	73	62 (84.9)	6.0 (2.1)	(1.8, 10.2)	2.8 (3.0)	(-3.1, 8.7)	0.346
	Placebo	76	71 (93.4)	3.2 (2.1)	(-1.0, 7.3)			
Week 44	Tezepelumab	73	64 (87.7)	7.8 (2.1)	(3.6, 12.0)	6.3 (3.0)	(0.4, 12.2)	0.036 *
	Placebo	76	71 (93.4)	1.4 (2.1)	(-2.7, 5.6)			
Week 46	Tezepelumab	73	64 (87.7)	6.7 (2.2)	(2.5, 11.0)	4.6 (3.0)	(-1.3, 10.6)	0.127
	Placebo	76	70 (92.1)	2.1 (2.1)	(-2.1, 6.3)			
Week 48	Tezepelumab	73	61 (83.6)	9.0 (2.2)	(4.6, 13.4)	7.0 (3.1)	(0.8, 13.3)	0.027 *
	Placebo	76	58 (76.3)	1.9 (2.2)	(-2.5, 6.3)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

VAS = visual analogue scale.

Source Data: avas, created on: 23FEB2022

Table NT1VSC\_KLMH0: Course of EQ-5D-VAS  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
EQ-5D-VAS	Baseline	Tezepelumab	15	15 (100.0)	62.6 (18.1)	30	45.0	70.0	80.0	90	
		Placebo	20	20 (100.0)	66.3 (18.9)	30	50.0	75.0	80.0	90	
	Week 2	Tezepelumab	15	14 (93.3)	63.0 (19.6)	20	50.0	67.0	78.0	91	
		Placebo	20	20 (100.0)	74.9 (15.7)	47	67.0	76.5	86.5	100	
	Week 4	Tezepelumab	15	15 (100.0)	68.1 (19.4)	25	53.0	75.0	81.0	92	
		Placebo	20	18 (90.0)	77.3 (15.6)	50	63.0	81.5	90.0	95	
	Week 6	Tezepelumab	15	12 (80.0)	70.7 (17.8)	35	56.0	76.0	83.5	94	
		Placebo	20	16 (80.0)	76.5 (17.6)	47	61.0	82.0	90.0	100	
	Week 8	Tezepelumab	15	15 (100.0)	74.0 (20.4)	21	60.0	75.0	89.0	100	
		Placebo	20	18 (90.0)	77.1 (16.7)	50	60.0	82.5	90.0	100	
	Week 10	Tezepelumab	15	13 (86.7)	69.2 (19.6)	30	60.0	76.0	85.0	96	
		Placebo	20	19 (95.0)	73.9 (21.1)	27	52.0	80.0	90.0	100	
	Week 12	Tezepelumab	15	15 (100.0)	73.7 (18.0)	30	60.0	76.0	90.0	95	
		Placebo	20	20 (100.0)	76.0 (20.1)	29	59.0	84.0	90.0	100	
	Week 14	Tezepelumab	15	13 (86.7)	73.0 (22.7)	31	60.0	81.0	91.0	100	
		Placebo	20	17 (85.0)	78.5 (17.1)	40	69.0	86.0	90.0	98	
	Week 16	Tezepelumab	15	14 (93.3)	78.4 (15.8)	45	70.0	83.5	90.0	100	
		Placebo	20	19 (95.0)	79.2 (16.1)	50	65.0	85.0	91.0	100	
	Week 18	Tezepelumab	15	12 (80.0)	77.3 (23.3)	30	74.0	84.5	92.0	100	
		Placebo	20	17 (85.0)	77.8 (18.2)	36	70.0	85.0	90.0	100	
	Week 20	Tezepelumab	15	14 (93.3)	74.6 (23.1)	20	70.0	80.5	90.0	100	
		Placebo	20	19 (95.0)	79.1 (19.9)	38	60.0	88.0	94.0	100	
	Week 22	Tezepelumab	15	10 (66.7)	79.9 (16.2)	49	70.0	85.0	95.0	97	
		Placebo	20	18 (90.0)	80.0 (17.3)	36	75.0	89.5	90.0	100	
	Week 24	Tezepelumab	15	13 (86.7)	75.7 (17.5)	49	60.0	80.0	89.0	98	
		Placebo	20	18 (90.0)	78.3 (16.2)	50	70.0	83.5	90.0	100	
	Week 26	Tezepelumab	15	12 (80.0)	78.4 (16.1)	41	67.5	80.5	91.0	97	
		Placebo	20	18 (90.0)	80.1 (14.7)	50	70.0	83.5	91.0	100	
	Week 28	Tezepelumab	15	14 (93.3)	79.5 (18.8)	31	70.0	83.0	95.0	100	
		Placebo	20	20 (100.0)	78.9 (17.9)	38	72.5	82.5	91.0	100	
	Week 30	Tezepelumab	15	10 (66.7)	82.8 (10.2)	60	80.0	80.5	92.0	96	
		Placebo	20	18 (90.0)	81.0 (15.3)	50	70.0	87.5	92.0	100	
	Week 32	Tezepelumab	15	14 (93.3)	76.9 (20.2)	34	66.0	82.5	91.0	100	
		Placebo	20	19 (95.0)	77.6 (15.7)	40	72.0	81.0	87.0	100	
	Week 34	Tezepelumab	15	10 (66.7)	82.2 (9.2)	70	75.0	82.0	90.0	96	
		Placebo	20	16 (80.0)	77.3 (15.4)	49	67.5	80.0	90.0	100	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.  
 Source Data: avas, created on: 20FEB2022

Table NT1VSC\_KLMH0: Course of EQ-5D-VAS  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
EQ-5D-VAS	Week 36	Tezepelumab	15	13 (86.7)	77.7 (17.5)	35	73.0	80.0	87.0	100	
		Placebo	20	20 (100.0)	76.4 (21.5)	16	72.0	82.0	92.0	100	
	Week 38	Tezepelumab	15	10 (66.7)	82.2 (12.0)	64	74.0	82.5	91.0	99	
		Placebo	20	17 (85.0)	80.1 (14.8)	50	68.0	89.0	90.0	100	
	Week 40	Tezepelumab	15	14 (93.3)	79.9 (19.5)	26	76.0	84.0	92.0	100	
		Placebo	20	20 (100.0)	80.6 (18.2)	42	69.0	89.0	95.0	100	
	Week 42	Tezepelumab	15	10 (66.7)	81.2 (14.2)	54	80.0	83.0	90.0	97	
		Placebo	20	17 (85.0)	81.8 (20.4)	40	72.0	90.0	95.0	100	
	Week 44	Tezepelumab	15	13 (86.7)	75.6 (17.6)	40	60.0	80.0	90.0	98	
		Placebo	20	19 (95.0)	80.7 (15.3)	50	70.0	88.0	92.0	100	
	Week 46	Tezepelumab	15	10 (66.7)	84.5 (10.6)	70	75.0	85.5	95.0	98	
		Placebo	20	15 (75.0)	81.7 (14.5)	50	71.0	88.0	92.0	100	
	Week 48	Tezepelumab	15	13 (86.7)	78.2 (19.4)	36	68.0	85.0	90.0	100	
		Placebo	20	19 (95.0)	82.7 (14.3)	50	70.0	90.0	92.0	100	
	Week 50	Tezepelumab	15	9 (60.0)	79.0 (8.0)	67	75.0	80.0	82.0	90	
		Placebo	20	17 (85.0)	79.7 (17.4)	45	72.0	88.0	90.0	100	
	Week 52	Tezepelumab	15	12 (80.0)	80.3 (19.6)	30	75.5	85.0	94.5	100	
		Placebo	20	19 (95.0)	81.9 (16.8)	44	80.0	89.0	92.0	100	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.  
 Source Data: avas, created on: 20FEB2022



Table NT1VSC\_KLMH0: Course of EQ-5D-VAS  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in EQ-5D-VAS	Week 2	Tezepelumab	15	14 (93.3)	1.6 (12.5)	-14	-10.0	0.0	10.0	32	-0.38 [-1.07, 0.31]
		Placebo	20	20 (100.0)	8.6 (21.3)	-36	0.0	2.5	17.0	53	
	Week 4	Tezepelumab	15	15 (100.0)	5.5 (17.7)	-27	-5.0	2.0	11.0	35	-0.36 [-1.05, 0.33]
		Placebo	20	18 (90.0)	12.3 (19.7)	-32	0.0	9.0	20.0	50	
	Week 6	Tezepelumab	15	12 (80.0)	11.6 (17.1)	-27	2.5	12.0	23.0	37	0.14 [-0.61, 0.89]
		Placebo	20	16 (80.0)	8.9 (20.0)	-35	-0.5	6.5	18.5	51	
	Week 8	Tezepelumab	15	15 (100.0)	11.4 (18.7)	-27	0.0	10.0	20.0	49	0.05 [-0.63, 0.74]
		Placebo	20	18 (90.0)	10.4 (19.6)	-34	0.0	10.0	20.0	51	
	Week 10	Tezepelumab	15	13 (86.7)	9.3 (19.5)	-34	2.0	10.0	16.0	46	0.15 [-0.56, 0.86]
		Placebo	20	19 (95.0)	6.2 (21.5)	-44	-3.0	5.0	15.0	46	
	Week 12	Tezepelumab	15	15 (100.0)	11.1 (19.0)	-25	0.0	6.0	20.0	50	0.07 [-0.60, 0.74]
		Placebo	20	20 (100.0)	9.7 (22.3)	-56	0.0	5.0	17.0	50	
	Week 14	Tezepelumab	15	13 (86.7)	13.1 (27.1)	-49	5.0	13.0	26.0	54	0.13 [-0.59, 0.85]
		Placebo	20	17 (85.0)	10.2 (17.5)	-30	4.0	9.0	13.0	50	
	Week 16	Tezepelumab	15	14 (93.3)	16.6 (20.1)	-24	9.0	12.5	28.0	50	0.16 [-0.53, 0.85]
		Placebo	20	19 (95.0)	13.4 (20.1)	-35	5.0	10.0	20.0	58	
	Week 18	Tezepelumab	15	12 (80.0)	18.5 (21.4)	-19	0.5	15.0	35.5	53	0.43 [-0.31, 1.18]
		Placebo	20	17 (85.0)	9.5 (20.3)	-49	2.0	10.0	19.0	49	
	Week 20	Tezepelumab	15	14 (93.3)	12.8 (24.3)	-31	-5.0	12.0	33.0	53	0.06 [-0.63, 0.75]
		Placebo	20	19 (95.0)	11.4 (22.6)	-47	0.0	13.0	20.0	54	
	Week 22	Tezepelumab	15	10 (66.7)	17.4 (26.0)	-31	1.0	17.0	41.0	55	0.17 [-0.60, 0.95]
		Placebo	20	18 (90.0)	13.3 (22.1)	-32	2.0	9.0	22.0	60	
	Week 24	Tezepelumab	15	13 (86.7)	16.1 (19.4)	-25	10.0	17.0	25.0	56	0.26 [-0.45, 0.98]
		Placebo	20	18 (90.0)	11.0 (19.3)	-25	0.0	9.0	20.0	55	
	Week 26	Tezepelumab	15	12 (80.0)	14.7 (20.7)	-15	0.0	14.5	27.0	55	0.16 [-0.57, 0.89]
		Placebo	20	18 (90.0)	11.4 (21.0)	-35	0.0	7.5	16.0	55	
	Week 28	Tezepelumab	15	14 (93.3)	17.7 (18.8)	-13	8.0	17.5	27.0	55	0.25 [-0.44, 0.94]
		Placebo	20	20 (100.0)	12.6 (21.4)	-47	2.5	10.0	20.0	57	
	Week 30	Tezepelumab	15	10 (66.7)	20.3 (17.3)	0	10.0	14.5	35.0	56	0.30 [-0.48, 1.08]
		Placebo	20	18 (90.0)	14.3 (21.4)	-16	0.0	8.5	20.0	60	
	Week 32	Tezepelumab	15	14 (93.3)	15.1 (20.2)	-14	4.0	10.0	17.0	51	0.24 [-0.45, 0.94]
		Placebo	20	19 (95.0)	9.9 (21.9)	-45	0.0	5.0	17.0	54	
	Week 34	Tezepelumab	15	10 (66.7)	19.7 (19.5)	-9	10.0	18.5	32.0	56	0.52 [-0.29, 1.32]
		Placebo	20	16 (80.0)	9.4 (20.0)	-36	0.0	7.0	17.0	51	
	Week 36	Tezepelumab	15	13 (86.7)	18.1 (21.7)	-17	5.0	11.0	35.0	56	0.31 [-0.39, 1.01]
		Placebo	20	20 (100.0)	10.1 (28.0)	-59	-3.0	10.0	20.0	54	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.

Source Data: avas, created on: 20FEB2022

Table NT1VSC\_KLMH0: Course of EQ-5D-VAS  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in EQ-5D-VAS	Week 38	Tezepelumab	15	10 (66.7)	19.7 (20.8)	-16	8.0	16.5	29.0	55	0.37 [-0.42, 1.16]
		Placebo	20	17 (85.0)	11.8 (21.6)	-29	0.0	10.0	20.0	56	
	Week 40	Tezepelumab	15	14 (93.3)	18.1 (21.5)	-22	10.0	15.0	33.0	56	0.17 [-0.51, 0.85]
		Placebo	20	20 (100.0)	14.3 (23.7)	-43	3.0	10.5	20.0	60	
	Week 42	Tezepelumab	15	10 (66.7)	18.7 (22.9)	-26	10.0	17.5	35.0	55	0.16 [-0.62, 0.94]
		Placebo	20	17 (85.0)	15.0 (23.0)	-45	9.0	12.0	20.0	56	
	Week 44	Tezepelumab	15	13 (86.7)	16.0 (19.6)	-20	7.0	10.0	25.0	51	0.05 [-0.65, 0.76]
		Placebo	20	19 (95.0)	14.9 (22.2)	-34	3.0	10.0	20.0	60	
	Week 46	Tezepelumab	15	10 (66.7)	22.0 (18.6)	-10	9.0	20.5	32.0	55	0.36 [-0.44, 1.17]
		Placebo	20	15 (75.0)	14.8 (20.7)	-25	1.0	15.0	20.0	54	
	Week 48	Tezepelumab	15	13 (86.7)	18.6 (19.1)	-12	6.0	12.0	32.0	54	0.09 [-0.62, 0.80]
		Placebo	20	19 (95.0)	16.8 (20.1)	-25	7.0	12.0	20.0	53	
	Week 50	Tezepelumab	15	9 (60.0)	18.6 (16.8)	-5	10.0	20.0	25.0	50	0.29 [-0.53, 1.10]
		Placebo	20	17 (85.0)	12.9 (21.2)	-40	2.0	10.0	18.0	56	
	Week 52	Tezepelumab	15	12 (80.0)	18.5 (22.0)	-20	5.5	14.5	34.5	55	0.16 [-0.57, 0.88]
		Placebo	20	19 (95.0)	15.0 (22.6)	-41	5.0	12.0	20.0	60	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.  
 Source Data: avas, created on: 20FEB2022

Table NT1VSC\_KLMC0: Change from baseline in EQ-5D-VAS - MMRM results  
DITTLL - adolescents

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 2	Tezepelumab	15	14 (93.3)	NE		NE		
	Placebo	20	20 (100.0)					
Week 4	Tezepelumab	15	15 (100.0)	NE		NE		
	Placebo	20	18 (90.0)					
Week 6	Tezepelumab	15	12 (80.0)	NE		NE		
	Placebo	20	16 (80.0)					
Week 8	Tezepelumab	15	15 (100.0)	NE		NE		
	Placebo	20	18 (90.0)					
Week 10	Tezepelumab	15	13 (86.7)	NE		NE		
	Placebo	20	19 (95.0)					
Week 12	Tezepelumab	15	15 (100.0)	NE		NE		
	Placebo	20	20 (100.0)					
Week 14	Tezepelumab	15	13 (86.7)	NE		NE		
	Placebo	20	17 (85.0)					
Week 16	Tezepelumab	15	14 (93.3)	NE		NE		
	Placebo	20	19 (95.0)					
Week 18	Tezepelumab	15	12 (80.0)	NE		NE		
	Placebo	20	17 (85.0)					
Week 20	Tezepelumab	15	14 (93.3)	NE		NE		
	Placebo	20	19 (95.0)					

Note: DITTLL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

VAS = visual analogue scale.

Source Data: avas, created on: 20FEB2022

Table NT1VSC\_KLMC0: Change from baseline in EQ-5D-VAS - MMRM results  
 DITTLL - adolescents

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 22	Tezepelumab	15	10 (66.7)	NE		NE		
	Placebo	20	18 (90.0)					
Week 24	Tezepelumab	15	13 (86.7)	NE		NE		
	Placebo	20	18 (90.0)					
Week 26	Tezepelumab	15	12 (80.0)	NE		NE		
	Placebo	20	18 (90.0)					
Week 28	Tezepelumab	15	14 (93.3)	NE		NE		
	Placebo	20	20 (100.0)					
Week 30	Tezepelumab	15	10 (66.7)	NE		NE		
	Placebo	20	18 (90.0)					
Week 32	Tezepelumab	15	14 (93.3)	NE		NE		
	Placebo	20	19 (95.0)					
Week 34	Tezepelumab	15	10 (66.7)	NE		NE		
	Placebo	20	16 (80.0)					
Week 36	Tezepelumab	15	13 (86.7)	NE		NE		
	Placebo	20	20 (100.0)					
Week 38	Tezepelumab	15	10 (66.7)	NE		NE		
	Placebo	20	17 (85.0)					
Week 40	Tezepelumab	15	14 (93.3)	NE		NE		
	Placebo	20	20 (100.0)					

Note: DITTLL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

VAS = visual analogue scale.

Source Data: avas, created on: 20FEB2022

Table NT1VSC\_KLMC0: Change from baseline in EQ-5D-VAS - MMRM results  
 DITTLL - adolescents

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 42	Tezepelumab	15	10 (66.7)	NE		NE		
	Placebo	20	17 (85.0)					
Week 44	Tezepelumab	15	13 (86.7)	NE		NE		
	Placebo	20	19 (95.0)					
Week 46	Tezepelumab	15	10 (66.7)	NE		NE		
	Placebo	20	15 (75.0)					
Week 48	Tezepelumab	15	13 (86.7)	NE		NE		
	Placebo	20	19 (95.0)					
Week 50	Tezepelumab	15	9 (60.0)	NE		NE		
	Placebo	20	17 (85.0)					
Week 52	Tezepelumab	15	12 (80.0)	NE		NE		
	Placebo	20	19 (95.0)					

Note: DITTLL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

VAS = visual analogue scale.

Source Data: avas, created on: 20FEB2022

Table NT1VSC\_ALMH0: Course of EQ-5D-VAS  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
EQ-5D-VAS	Baseline	Tezepelumab	380	379 (99.7)	61.2 (18.4)	2	50.0	65.0	73.0	98	
		Placebo	371	369 (99.5)	61.5 (17.1)	8	50.0	62.0	75.0	100	
	Week 2	Tezepelumab	380	366 (96.3)	67.1 (17.8)	7	55.0	69.0	80.0	100	
		Placebo	371	358 (96.5)	66.3 (17.2)	5	53.0	70.0	80.0	100	
	Week 4	Tezepelumab	380	374 (98.4)	70.0 (16.2)	17	60.0	71.5	82.0	100	
		Placebo	371	365 (98.4)	68.1 (17.3)	0	55.0	70.0	80.0	100	
	Week 6	Tezepelumab	380	349 (91.8)	72.3 (16.0)	17	61.0	74.0	85.0	100	
		Placebo	371	332 (89.5)	69.2 (17.8)	19	57.0	71.0	82.0	100	
	Week 8	Tezepelumab	380	373 (98.2)	71.6 (16.9)	0	61.0	75.0	83.0	100	
		Placebo	371	363 (97.8)	69.7 (18.0)	10	60.0	73.0	82.0	100	
	Week 10	Tezepelumab	380	349 (91.8)	74.0 (15.8)	19	65.0	78.0	85.0	100	
		Placebo	371	331 (89.2)	69.7 (17.6)	17	58.0	72.0	83.0	100	
	Week 12	Tezepelumab	380	372 (97.9)	73.2 (16.4)	20	62.0	77.0	85.5	100	
		Placebo	371	359 (96.8)	70.1 (18.1)	10	60.0	73.0	84.0	100	
	Week 14	Tezepelumab	380	344 (90.5)	73.6 (16.7)	17	62.5	76.0	87.0	100	
		Placebo	371	329 (88.7)	71.0 (17.3)	9	60.0	74.0	83.0	100	
	Week 16	Tezepelumab	380	365 (96.1)	74.3 (15.9)	27	65.0	77.0	87.0	100	
		Placebo	371	355 (95.7)	71.3 (17.5)	13	60.0	75.0	85.0	100	
	Week 18	Tezepelumab	380	348 (91.6)	74.0 (16.7)	0	63.0	76.5	87.0	100	
		Placebo	371	322 (86.8)	71.6 (16.8)	19	60.0	74.0	85.0	100	
	Week 20	Tezepelumab	380	362 (95.3)	74.2 (17.4)	22	63.0	79.0	89.0	100	
		Placebo	371	352 (94.9)	71.5 (17.8)	18	60.0	75.0	85.0	100	
	Week 22	Tezepelumab	380	347 (91.3)	74.1 (17.8)	0	63.0	79.0	88.0	100	
		Placebo	371	316 (85.2)	72.0 (17.5)	20	62.0	75.0	85.0	100	
	Week 24	Tezepelumab	380	360 (94.7)	74.9 (17.2)	9	65.0	78.0	90.0	100	
		Placebo	371	345 (93.0)	71.6 (17.9)	12	60.0	75.0	85.0	100	
	Week 26	Tezepelumab	380	341 (89.7)	75.0 (16.9)	20	65.0	79.0	90.0	100	
		Placebo	371	315 (84.9)	71.8 (17.4)	15	61.0	75.0	86.0	100	
	Week 28	Tezepelumab	380	359 (94.5)	75.6 (16.6)	26	66.0	80.0	89.0	100	
		Placebo	371	340 (91.6)	71.4 (17.3)	15	61.0	74.0	84.5	100	
	Week 30	Tezepelumab	380	338 (88.9)	75.8 (16.3)	22	66.0	80.0	89.0	100	
		Placebo	371	314 (84.6)	72.2 (17.7)	12	62.0	75.0	85.0	100	
	Week 32	Tezepelumab	380	361 (95.0)	75.3 (16.7)	25	65.0	79.0	89.0	100	
		Placebo	371	341 (91.9)	72.6 (17.4)	9	62.0	75.0	86.0	100	
Week 34	Tezepelumab	380	340 (89.5)	76.5 (16.1)	24	68.5	79.0	90.0	100		
	Placebo	371	314 (84.6)	72.1 (18.1)	15	60.0	76.0	85.0	100		

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.

Source Data: avas, created on: 20FEB2022

Table NT1VSC\_ALMH0: Course of EQ-5D-VAS  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
EQ-5D-VAS	Week 36	Tezepelumab	380	356 (93.7)	74.6 (17.3)	22	64.0	78.0	90.0	100	
		Placebo	371	338 (91.1)	71.6 (18.6)	12	60.0	75.0	85.0	100	
	Week 38	Tezepelumab	380	337 (88.7)	75.7 (16.6)	22	67.0	79.0	89.0	100	
		Placebo	371	312 (84.1)	73.3 (17.2)	15	62.0	77.0	87.0	100	
	Week 40	Tezepelumab	380	358 (94.2)	75.4 (17.2)	9	66.0	80.0	89.0	100	
		Placebo	371	339 (91.4)	72.2 (17.6)	10	60.0	75.0	85.0	100	
	Week 42	Tezepelumab	380	340 (89.5)	75.5 (17.3)	15	65.0	80.0	90.0	100	
		Placebo	371	312 (84.1)	72.5 (17.6)	13	63.5	75.0	85.0	100	
	Week 44	Tezepelumab	380	354 (93.2)	75.7 (17.6)	0	66.0	80.0	90.0	100	
		Placebo	371	335 (90.3)	72.4 (17.0)	15	61.0	75.0	85.0	100	
	Week 46	Tezepelumab	380	341 (89.7)	75.8 (17.3)	4	69.0	79.0	90.0	100	
		Placebo	371	308 (83.0)	73.5 (17.1)	10	65.0	77.0	86.0	100	
	Week 48	Tezepelumab	380	355 (93.4)	75.7 (17.1)	22	66.0	79.0	90.0	100	
		Placebo	371	338 (91.1)	72.5 (17.3)	15	63.0	75.5	84.0	100	
	Week 50	Tezepelumab	380	340 (89.5)	76.0 (17.5)	10	67.0	80.0	90.0	100	
		Placebo	371	304 (81.9)	73.3 (17.2)	10	62.0	76.0	86.0	100	
	Week 52	Tezepelumab	380	318 (83.7)	77.3 (16.5)	16	70.0	80.5	90.0	100	
		Placebo	371	299 (80.6)	73.8 (17.4)	9	63.0	76.0	87.0	100	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.

Source Data: avas, created on: 20FEB2022

Table NT1VSC\_ALMH0: Course of EQ-5D-VAS  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in EQ-5D-VAS	Week 2	Tezepelumab	380	365 (96.1)	6.1 (18.1)	-44	-3.0	4.0	15.0	76	0.09 [-0.06, 0.23]
		Placebo	371	358 (96.5)	4.7 (16.2)	-48	-3.0	2.0	13.0	60	
	Week 4	Tezepelumab	380	374 (98.4)	8.9 (18.3)	-48	-2.0	6.0	18.0	76	0.14 [-0.01, 0.28]
		Placebo	371	365 (98.4)	6.5 (16.8)	-50	-4.0	4.0	17.0	61	
	Week 6	Tezepelumab	380	348 (91.6)	11.3 (18.2)	-45	0.0	8.0	21.0	77	0.21 [0.06, 0.37]
		Placebo	371	331 (89.2)	7.4 (17.5)	-46	-3.0	5.0	17.0	69	
	Week 8	Tezepelumab	380	373 (98.2)	10.4 (19.7)	-70	0.0	8.0	20.0	73	0.11 [-0.03, 0.26]
		Placebo	371	362 (97.6)	8.3 (18.3)	-51	-2.0	6.5	20.0	64	
	Week 10	Tezepelumab	380	348 (91.6)	12.9 (19.4)	-59	1.0	10.0	23.5	77	0.26 [0.11, 0.41]
		Placebo	371	330 (88.9)	7.9 (18.5)	-34	-4.0	5.0	19.0	67	
	Week 12	Tezepelumab	380	372 (97.9)	11.8 (19.8)	-58	0.0	10.0	23.0	81	0.18 [0.03, 0.32]
		Placebo	371	358 (96.5)	8.4 (18.3)	-40	-3.0	6.5	19.0	72	
	Week 14	Tezepelumab	380	344 (90.5)	12.2 (19.4)	-40	1.0	10.0	24.0	79	0.18 [0.03, 0.33]
		Placebo	371	328 (88.4)	8.8 (17.8)	-35	-2.5	8.0	20.0	68	
	Week 16	Tezepelumab	380	365 (96.1)	12.5 (19.3)	-46	0.0	10.0	22.0	85	0.14 [-0.01, 0.29]
		Placebo	371	354 (95.4)	9.8 (19.1)	-46	-1.0	8.0	20.0	91	
	Week 18	Tezepelumab	380	347 (91.3)	12.4 (19.4)	-35	1.0	10.0	23.0	80	0.16 [0.01, 0.31]
		Placebo	371	321 (86.5)	9.4 (17.8)	-35	-2.0	8.0	20.0	70	
	Week 20	Tezepelumab	380	362 (95.3)	12.5 (20.0)	-45	1.0	9.5	24.0	85	0.14 [-0.01, 0.29]
		Placebo	371	351 (94.6)	9.8 (18.2)	-35	-2.0	7.0	22.0	91	
	Week 22	Tezepelumab	380	346 (91.1)	12.6 (20.5)	-41	0.0	10.0	25.0	68	0.13 [-0.02, 0.28]
		Placebo	371	315 (84.9)	10.0 (17.9)	-50	-1.0	10.0	21.0	68	
	Week 24	Tezepelumab	380	360 (94.7)	13.2 (20.2)	-53	0.0	11.0	25.0	79	0.17 [0.02, 0.32]
		Placebo	371	344 (92.7)	9.9 (18.5)	-50	-2.5	10.0	21.0	84	
	Week 26	Tezepelumab	380	341 (89.7)	13.0 (20.7)	-46	1.0	10.0	25.0	71	0.19 [0.04, 0.34]
		Placebo	371	314 (84.6)	9.4 (17.7)	-45	-2.0	8.0	21.0	66	
	Week 28	Tezepelumab	380	359 (94.5)	13.5 (19.6)	-40	1.0	10.0	26.0	69	0.21 [0.06, 0.35]
		Placebo	371	339 (91.4)	9.6 (17.8)	-55	-2.0	7.0	20.0	67	
	Week 30	Tezepelumab	380	338 (88.9)	14.0 (20.2)	-38	1.0	11.0	27.0	80	0.20 [0.05, 0.36]
		Placebo	371	313 (84.4)	10.1 (18.2)	-54	-1.0	9.0	21.0	68	
	Week 32	Tezepelumab	380	360 (94.7)	13.5 (19.9)	-38	0.5	10.0	26.0	79	0.13 [-0.02, 0.28]
		Placebo	371	340 (91.6)	11.0 (18.5)	-56	-1.5	10.0	23.0	82	
	Week 34	Tezepelumab	380	340 (89.5)	14.7 (20.1)	-38	2.0	11.5	27.5	76	0.25 [0.09, 0.40]
		Placebo	371	313 (84.4)	9.9 (19.0)	-56	-2.0	8.0	23.0	67	
	Week 36	Tezepelumab	380	355 (93.4)	13.0 (20.9)	-46	1.0	11.0	25.0	88	0.17 [0.02, 0.32]
		Placebo	371	337 (90.8)	9.7 (18.9)	-55	-2.0	10.0	21.0	68	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.

Source Data: avas, created on: 20FEB2022



Table NT1VSC\_ALMH0: Course of EQ-5D-VAS  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in EQ-5D-VAS	Week 38	Tezepelumab	380	337 (88.7)	14.1 (20.6)	-38	1.0	12.0	26.0	80	0.14 [-0.01, 0.30]
		Placebo	371	311 (83.8)	11.2 (18.9)	-57	-1.0	9.0	23.0	82	
	Week 40	Tezepelumab	380	357 (93.9)	13.6 (21.4)	-41	0.0	11.0	26.0	77	0.15 [0.00, 0.30]
		Placebo	371	338 (91.1)	10.5 (18.7)	-55	-2.0	10.5	22.0	82	
	Week 42	Tezepelumab	380	340 (89.5)	13.9 (21.4)	-42	0.5	11.0	27.5	81	0.18 [0.02, 0.33]
		Placebo	371	311 (83.8)	10.4 (18.3)	-60	0.0	9.0	22.0	67	
	Week 44	Tezepelumab	380	353 (92.9)	14.1 (21.2)	-50	0.0	11.0	26.0	81	0.17 [0.02, 0.32]
		Placebo	371	334 (90.0)	10.7 (18.5)	-56	-1.0	9.0	24.0	83	
	Week 46	Tezepelumab	380	341 (89.7)	13.9 (21.2)	-46	0.0	12.0	28.0	79	0.14 [-0.01, 0.30]
		Placebo	371	307 (82.7)	11.1 (18.6)	-56	-2.0	11.0	23.0	68	
	Week 48	Tezepelumab	380	354 (93.2)	14.0 (21.0)	-50	1.0	10.0	27.0	89	0.16 [0.01, 0.31]
		Placebo	371	337 (90.8)	10.7 (19.6)	-65	-2.0	10.0	22.0	83	
	Week 50	Tezepelumab	380	340 (89.5)	14.2 (21.3)	-45	1.0	11.0	26.0	90	0.15 [-0.01, 0.30]
		Placebo	371	303 (81.7)	11.2 (18.8)	-65	-1.0	10.0	24.0	68	
	Week 52	Tezepelumab	380	318 (83.7)	15.5 (20.8)	-56	2.0	12.0	28.0	89	0.19 [0.03, 0.34]
		Placebo	371	298 (80.3)	11.8 (18.6)	-60	0.0	10.0	24.0	72	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.

Source Data: avas, created on: 20FEB2022

Table NT1VSC\_ALMC0: Change from baseline in EQ-5D-VAS - MMRM results  
 DITTL - adult

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 2	Tezepelumab	380	365 (96.1)	5.7 (0.8)	(4.2, 7.2)	1.1 (1.1)	(-1.0, 3.3)	0.307
	Placebo	371	358 (96.5)	4.6 (0.8)	(3.0, 6.1)			
Week 4	Tezepelumab	380	374 (98.4)	8.5 (0.8)	(7.1, 10.0)	2.3 (1.1)	(0.2, 4.4)	0.035 *
	Placebo	371	365 (98.4)	6.3 (0.8)	(4.8, 7.8)			
Week 6	Tezepelumab	380	348 (91.6)	10.8 (0.8)	(9.2, 12.3)	3.6 (1.1)	(1.5, 5.8)	0.001 *
	Placebo	371	331 (89.2)	7.1 (0.8)	(5.6, 8.7)			
Week 8	Tezepelumab	380	373 (98.2)	10.1 (0.8)	(8.5, 11.7)	1.9 (1.2)	(-0.4, 4.2)	0.098
	Placebo	371	362 (97.6)	8.1 (0.8)	(6.5, 9.8)			
Week 10	Tezepelumab	380	348 (91.6)	12.3 (0.8)	(10.7, 13.9)	4.8 (1.1)	(2.6, 7.1)	<0.001 *
	Placebo	371	330 (88.9)	7.5 (0.8)	(5.9, 9.1)			
Week 12	Tezepelumab	380	372 (97.9)	11.6 (0.8)	(10.0, 13.2)	3.3 (1.2)	(1.0, 5.6)	0.005 *
	Placebo	371	358 (96.5)	8.3 (0.8)	(6.7, 10.0)			
Week 14	Tezepelumab	380	344 (90.5)	11.9 (0.8)	(10.3, 13.4)	3.0 (1.2)	(0.7, 5.3)	0.010 *
	Placebo	371	328 (88.4)	8.9 (0.8)	(7.2, 10.5)			
Week 16	Tezepelumab	380	365 (96.1)	12.5 (0.8)	(10.9, 14.1)	2.9 (1.2)	(0.6, 5.2)	0.013 *
	Placebo	371	354 (95.4)	9.6 (0.8)	(8.0, 11.2)			
Week 18	Tezepelumab	380	347 (91.3)	12.2 (0.8)	(10.6, 13.8)	3.1 (1.2)	(0.8, 5.4)	0.008 *
	Placebo	371	321 (86.5)	9.1 (0.8)	(7.5, 10.8)			
Week 20	Tezepelumab	380	362 (95.3)	12.3 (0.8)	(10.7, 14.0)	2.7 (1.2)	(0.3, 5.0)	0.026 *
	Placebo	371	351 (94.6)	9.7 (0.8)	(8.0, 11.3)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

VAS = visual analogue scale.

Source Data: avas, created on: 20FEB2022

Table NT1VSC\_ALMC0: Change from baseline in EQ-5D-VAS - MMRM results  
DITTL - adult

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 22	Tezepelumab	380	346 (91.1)	12.4 (0.9)	(10.7, 14.1)	2.6 (1.2)	(0.2, 5.0)	0.033 *
	Placebo	371	315 (84.9)	9.8 (0.9)	(8.1, 11.5)			
Week 24	Tezepelumab	380	360 (94.7)	13.1 (0.8)	(11.4, 14.8)	3.4 (1.2)	(1.1, 5.8)	0.004 *
	Placebo	371	344 (92.7)	9.7 (0.9)	(8.0, 11.3)			
Week 26	Tezepelumab	380	341 (89.7)	12.9 (0.8)	(11.3, 14.6)	3.6 (1.2)	(1.2, 6.0)	0.003 *
	Placebo	371	314 (84.6)	9.4 (0.9)	(7.7, 11.1)			
Week 28	Tezepelumab	380	359 (94.5)	13.8 (0.8)	(12.2, 15.4)	4.5 (1.2)	(2.2, 6.8)	<0.001 *
	Placebo	371	339 (91.4)	9.3 (0.8)	(7.7, 10.9)			
Week 30	Tezepelumab	380	338 (88.9)	13.7 (0.8)	(12.0, 15.3)	3.7 (1.2)	(1.3, 6.0)	0.002 *
	Placebo	371	313 (84.4)	10.0 (0.9)	(8.3, 11.7)			
Week 32	Tezepelumab	380	360 (94.7)	13.4 (0.8)	(11.8, 15.0)	2.6 (1.2)	(0.2, 4.9)	0.030 *
	Placebo	371	340 (91.6)	10.8 (0.8)	(9.2, 12.5)			
Week 34	Tezepelumab	380	340 (89.5)	14.6 (0.8)	(12.9, 16.2)	4.8 (1.2)	(2.5, 7.2)	<0.001 *
	Placebo	371	313 (84.4)	9.7 (0.9)	(8.0, 11.4)			
Week 36	Tezepelumab	380	355 (93.4)	12.8 (0.9)	(11.0, 14.5)	3.1 (1.3)	(0.6, 5.5)	0.015 *
	Placebo	371	337 (90.8)	9.7 (0.9)	(7.9, 11.5)			
Week 38	Tezepelumab	380	337 (88.7)	13.6 (0.8)	(12.0, 15.3)	3.0 (1.2)	(0.6, 5.3)	0.015 *
	Placebo	371	311 (83.8)	10.7 (0.9)	(9.0, 12.4)			
Week 40	Tezepelumab	380	357 (93.9)	13.5 (0.9)	(11.8, 15.2)	3.2 (1.2)	(0.8, 5.7)	0.009 *
	Placebo	371	338 (91.1)	10.2 (0.9)	(8.5, 12.0)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

VAS = visual analogue scale.

Source Data: avas, created on: 20FEB2022

Table NT1VSC\_ALMC0: Change from baseline in EQ-5D-VAS - MMRM results  
DITTL - adult

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 42	Tezepelumab	380	340 (89.5)	13.6 (0.9)	(11.9, 15.3)	3.5 (1.2)	(1.1, 6.0)	0.005 *
	Placebo	371	311 (83.8)	10.1 (0.9)	(8.3, 11.8)			
Week 44	Tezepelumab	380	353 (92.9)	14.1 (0.9)	(12.4, 15.8)	3.8 (1.2)	(1.4, 6.2)	0.002 *
	Placebo	371	334 (90.0)	10.3 (0.9)	(8.6, 12.0)			
Week 46	Tezepelumab	380	341 (89.7)	13.8 (0.9)	(12.1, 15.5)	2.8 (1.2)	(0.4, 5.2)	0.023 *
	Placebo	371	307 (82.7)	11.0 (0.9)	(9.2, 12.7)			
Week 48	Tezepelumab	380	354 (93.2)	13.8 (0.9)	(12.1, 15.6)	3.4 (1.2)	(1.0, 5.9)	0.006 *
	Placebo	371	337 (90.8)	10.4 (0.9)	(8.7, 12.2)			
Week 50	Tezepelumab	380	340 (89.5)	13.7 (0.9)	(12.0, 15.5)	2.8 (1.3)	(0.3, 5.2)	0.028 *
	Placebo	371	303 (81.7)	11.0 (0.9)	(9.2, 12.7)			
Week 52	Tezepelumab	380	318 (83.7)	14.9 (0.9)	(13.2, 16.6)	3.2 (1.2)	(0.8, 5.6)	0.009 *
	Placebo	371	298 (80.3)	11.7 (0.9)	(9.9, 13.4)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

VAS = visual analogue scale.

Source Data: avas, created on: 20FEB2022

Table NT1SNC\_RLMH0: Course of in SNOT-22 total score  
 DITTTLR

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
SNOT-22 total score	Baseline	Tezepelumab	30	30 (100.0)	50.3 (22.8)	7	33.0	48.5	70.0	90	
		Placebo	30	30 (100.0)	48.8 (19.7)	11	35.0	57.0	62.0	80	
	Week 28	Tezepelumab	30	29 (96.7)	31.6 (17.9)	2	16.0	30.0	45.0	63	
		Placebo	30	29 (96.7)	43.4 (24.2)	2	23.0	51.0	63.0	88	
	Week 52	Tezepelumab	30	28 (93.3)	27.9 (19.9)	0	10.5	22.5	43.5	71	
		Placebo	30	27 (90.0)	37.7 (21.4)	1	19.0	38.0	53.0	78	

Note: DITTTLR = Dossier Label Nasal Polyps Intent-to-Treat Set.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SNOT-22 = Sinal-nasal outcome test.  
 Source Data: asnot, created on: 22FEB2022

Table NT1SNC\_RLMH0: Course of in SNOT-22 total score  
 DITTLR

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in in SNOT-22 total score	Week 28	Tezepelumab	30	29 (96.7)	-17.5 (21.0)	-58	-37.0	-17.0	0.0	22	-0.51 [-1.03, 0.02]
		Placebo	30	29 (96.7)	-6.4 (23.0)	-58	-18.0	-2.0	8.0	42	
	Week 52	Tezepelumab	30	28 (93.3)	-21.3 (22.6)	-66	-37.0	-18.5	-0.5	7	-0.45 [-0.99, 0.08]
		Placebo	30	27 (90.0)	-11.5 (20.1)	-59	-27.0	-8.0	5.0	20	

Note: DITTLR = Dossier Label Nasal Polyps Intent-to-Treat Set.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SNOT-22 = Sinal-nasal outcome test.  
 Source Data: asnot, created on: 22FEB2022

Table NT1SNC\_NLMH0: Course of in SNOT-22 total score  
 DITTTLR-adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
SNOT-22 total score	Baseline	Tezepelumab	29	29 (100.0)	51.2 (22.6)	7	33.0	49.0	70.0	90	
		Placebo	28	28 (100.0)	48.4 (19.2)	11	35.5	57.0	62.0	80	
	Week 28	Tezepelumab	29	28 (96.6)	31.1 (18.0)	2	16.0	29.0	45.5	63	
		Placebo	28	27 (96.4)	42.3 (24.2)	2	21.0	51.0	63.0	88	
	Week 52	Tezepelumab	29	27 (93.1)	28.0 (20.3)	0	10.0	22.0	44.0	71	
		Placebo	28	25 (89.3)	37.1 (22.1)	1	19.0	36.0	53.0	78	

Note: DITTTLR-adult = Dossier Label Nasal Polyps Intent-to-Treat Set - adult.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SNOT-22 = Sinal-nasal outcome test.  
 Source Data: asnot, created on: 22FEB2022

Table NT1SNC\_NLMH0: Course of in SNOT-22 total score  
 DITTTLR-adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in in SNOT-22 total score	Week 28	Tezepelumab	29	28 (96.6)	-18.9 (19.9)	-58	-37.5	-17.0	-1.5	14	-0.54 [-1.08, 0.00]
		Placebo	28	27 (96.4)	-7.2 (23.5)	-58	-19.0	-3.0	8.0	42	
	Week 52	Tezepelumab	29	27 (93.1)	-22.0 (22.6)	-66	-41.0	-19.0	-1.0	7	-0.48 [-1.03, 0.07]
		Placebo	28	25 (89.3)	-11.8 (19.9)	-59	-24.0	-8.0	5.0	20	

Note: DITTTLR-adult = Dossier Label Nasal Polyps Intent-to-Treat Set - adult.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SNOT-22 = Sinal-nasal outcome test.  
 Source Data: asnot, created on: 22FEB2022



Table NT1SNC\_RLMC0: Change from baseline in in SNOT-22 total score - MMRM results  
 DITTTLR

Change from baseline in in SNOT-22 total score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 28	Tezepelumab	30	29 (96.7)	-17.6 (3.6)	(-24.7, -10.5)	-11.5 (5.0)	(-21.6, -1.4)	0.026 *
	Placebo	30	29 (96.7)	-6.1 (3.6)	(-13.2, 1.0)			
Week 52	Tezepelumab	30	28 (93.3)	-21.9 (3.5)	(-28.9, -15.0)	-10.7 (4.9)	(-20.6, -0.8)	0.034 *
	Placebo	30	27 (90.0)	-11.2 (3.5)	(-18.3, -4.2)			

Note: DITTTLR = Dossier Label Nasal Polyps Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

SNOT-22 = Sinal-nasal outcome test.

Source Data: asnot, created on: 22FEB2022

Table NT1SNC\_NLMC0: Change from baseline in in SNOT-22 total score - MMRM results  
 DITTTLR-adult

Change from baseline in in SNOT-22 total score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 28	Tezepelumab	29	28 (96.6)	-18.7 (3.6)	(-26.0, -11.5)	-11.5 (5.2)	(-21.8, -1.1)	0.031 *
	Placebo	28	27 (96.4)	-7.3 (3.7)	(-14.7, 0.1)			
Week 52	Tezepelumab	29	27 (93.1)	-22.4 (3.6)	(-29.7, -15.2)	-10.7 (5.2)	(-21.1, -0.3)	0.044 *
	Placebo	28	25 (89.3)	-11.8 (3.7)	(-19.2, -4.3)			

Note: DITTTLR-adult = Dossier Label Nasal Polyps Intent-to-Treat Set - adult.  
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.  
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.  
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.  
 SNOT-22 = Sinal-nasal outcome test.  
 Source Data: asnot, created on: 22FEB2022

Table MT1QTC\_ILMH0: Course of AQLQ+12 total score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 total score	Baseline	Tezepelumab	446	437 (98.0)	3.79 (1.04)	1.2	3.09	3.81	4.47	6.5	
		Placebo	436	424 (97.2)	3.89 (1.01)	1.2	3.27	3.97	4.56	6.6	
	Week 4	Tezepelumab	446	428 (96.0)	4.76 (1.15)	1.3	3.97	4.83	5.66	7.0	
		Placebo	436	415 (95.2)	4.58 (1.14)	1.0	3.81	4.69	5.34	7.0	
	Week 12	Tezepelumab	446	426 (95.5)	5.07 (1.20)	1.6	4.22	5.19	6.03	7.0	
		Placebo	436	414 (95.0)	4.86 (1.16)	1.0	4.09	4.91	5.75	7.0	
	Week 24	Tezepelumab	446	415 (93.0)	5.21 (1.22)	1.0	4.28	5.38	6.13	7.0	
		Placebo	436	396 (90.8)	4.89 (1.23)	1.0	4.09	4.98	5.84	7.0	
	Week 36	Tezepelumab	446	415 (93.0)	5.24 (1.23)	1.9	4.31	5.47	6.25	7.0	
		Placebo	436	394 (90.4)	4.94 (1.22)	1.2	4.06	4.94	5.91	7.0	
	Week 52	Tezepelumab	446	407 (91.3)	5.31 (1.21)	1.5	4.38	5.50	6.34	7.0	
		Placebo	436	381 (87.4)	5.00 (1.21)	1.3	4.16	5.03	5.97	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Last observation carried forward is applied in case of missing values.

Source Data: aqlq, created on: 22FEB2022

Table MT1QTC\_ILMH0: Course of AQLQ+12 total score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 total score	Week 4	Tezepelumab	446	422 (94.6)	0.96 (1.09)	-3.7	0.19	0.81	1.56	4.6	0.26 [0.13, 0.40]
		Placebo	436	412 (94.5)	0.70 (0.91)	-2.8	0.14	0.63	1.22	4.8	
	Week 12	Tezepelumab	446	421 (94.4)	1.27 (1.19)	-2.1	0.44	1.16	2.06	4.6	0.27 [0.13, 0.41]
		Placebo	436	409 (93.8)	0.96 (1.08)	-2.0	0.28	0.81	1.59	5.4	
	Week 24	Tezepelumab	446	409 (91.7)	1.40 (1.29)	-4.7	0.50	1.31	2.28	4.8	0.33 [0.19, 0.47]
		Placebo	436	391 (89.7)	1.00 (1.13)	-3.2	0.28	0.91	1.69	5.5	
	Week 36	Tezepelumab	446	407 (91.3)	1.43 (1.26)	-2.2	0.56	1.31	2.34	4.8	0.33 [0.19, 0.47]
		Placebo	436	388 (89.0)	1.03 (1.14)	-2.2	0.28	0.88	1.66	5.5	
	Week 52	Tezepelumab	446	399 (89.5)	1.49 (1.25)	-2.7	0.56	1.44	2.34	5.0	0.34 [0.19, 0.48]
		Placebo	436	375 (86.0)	1.09 (1.17)	-2.0	0.25	0.97	1.91	5.1	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Last observation carried forward is applied in case of missing values.

Source Data: aqlq, created on: 22FEB2022

Table MT1QTC\_ILMC0: Change from baseline in AQLQ+12 total score - MMRM results  
 DITTTL

Change from baseline in AQLQ+12 total score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	446	422 (94.6)	0.94 (0.05)	(0.85, 1.03)	0.23 (0.06)	(0.10, 0.35)	<0.001 *
	Placebo	436	412 (94.5)	0.72 (0.05)	(0.63, 0.81)			
Week 12	Tezepelumab	446	418 (93.7)	1.26 (0.05)	(1.16, 1.35)	0.28 (0.07)	(0.14, 0.42)	<0.001 *
	Placebo	436	406 (93.1)	0.97 (0.05)	(0.87, 1.07)			
Week 24	Tezepelumab	446	402 (90.1)	1.37 (0.05)	(1.27, 1.48)	0.36 (0.08)	(0.21, 0.51)	<0.001 *
	Placebo	436	381 (87.4)	1.01 (0.06)	(0.90, 1.12)			
Week 36	Tezepelumab	446	399 (89.5)	1.41 (0.05)	(1.30, 1.52)	0.38 (0.08)	(0.22, 0.53)	<0.001 *
	Placebo	436	377 (86.5)	1.03 (0.06)	(0.92, 1.14)			
Week 52	Tezepelumab	446	360 (80.7)	1.49 (0.06)	(1.38, 1.60)	0.38 (0.08)	(0.22, 0.54)	<0.001 *
	Placebo	436	336 (77.1)	1.11 (0.06)	(1.00, 1.22)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 22FEB2022

Table NT1QTC\_ILMH0: Course of AQLQ+12 total score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 total score	Baseline	Tezepelumab	395	394 (99.7)	3.75 (1.05)	1.2	3.03	3.77	4.47	6.5	
		Placebo	391	389 (99.5)	3.85 (1.03)	1.2	3.19	3.91	4.53	6.6	
	Week 4	Tezepelumab	395	382 (96.7)	4.76 (1.16)	1.3	3.97	4.83	5.72	7.0	
		Placebo	391	376 (96.2)	4.59 (1.18)	1.0	3.78	4.69	5.41	7.0	
	Week 12	Tezepelumab	395	377 (95.4)	5.04 (1.22)	1.6	4.19	5.19	6.00	7.0	
		Placebo	391	375 (95.9)	4.88 (1.20)	1.0	4.09	4.94	5.78	7.0	
	Week 24	Tezepelumab	395	365 (92.4)	5.22 (1.24)	1.0	4.28	5.44	6.16	7.0	
		Placebo	391	354 (90.5)	4.91 (1.23)	1.0	4.13	5.05	5.88	7.0	
	Week 36	Tezepelumab	395	363 (91.9)	5.24 (1.26)	1.9	4.28	5.50	6.25	7.0	
		Placebo	391	352 (90.0)	4.97 (1.25)	1.2	4.09	4.97	5.94	7.0	
	Week 52	Tezepelumab	395	354 (89.6)	5.32 (1.23)	1.5	4.47	5.56	6.38	7.0	
		Placebo	391	341 (87.2)	5.03 (1.22)	1.3	4.19	5.09	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QTC\_ILMH0: Course of AQLQ+12 total score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 total score	Week 4	Tezepelumab	395	381 (96.5)	1.00 (1.09)	-1.7	0.22	0.81	1.59	4.6	0.24 [0.10, 0.39]
		Placebo	391	376 (96.2)	0.75 (0.93)	-2.8	0.19	0.72	1.27	4.8	
	Week 12	Tezepelumab	395	377 (95.4)	1.28 (1.21)	-1.7	0.41	1.16	2.13	4.6	0.23 [0.09, 0.38]
		Placebo	391	374 (95.7)	1.01 (1.09)	-2.0	0.28	0.91	1.66	5.4	
	Week 24	Tezepelumab	395	365 (92.4)	1.45 (1.32)	-4.7	0.56	1.28	2.38	4.8	0.32 [0.18, 0.47]
		Placebo	391	353 (90.3)	1.05 (1.12)	-1.8	0.28	0.97	1.75	5.5	
	Week 36	Tezepelumab	395	363 (91.9)	1.47 (1.29)	-2.2	0.56	1.34	2.38	4.8	0.30 [0.16, 0.45]
		Placebo	391	351 (89.8)	1.09 (1.19)	-3.5	0.31	0.94	1.75	5.5	
	Week 52	Tezepelumab	395	354 (89.6)	1.54 (1.27)	-2.7	0.59	1.52	2.38	5.0	0.31 [0.16, 0.46]
		Placebo	391	340 (87.0)	1.16 (1.19)	-2.0	0.34	1.03	1.91	5.1	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QTC\_ILMC0: Change from baseline in AQLQ+12 total score - MMRM results  
 DITTTL

Change from baseline in AQLQ+12 total score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 4	Tezepelumab	395	381 (96.5)	0.98 (0.05)	(0.88, 1.07)	0.21 (0.07)	(0.07, 0.34)	0.002	*
	Placebo	391	376 (96.2)	0.77 (0.05)	(0.67, 0.86)				
Week 12	Tezepelumab	395	377 (95.4)	1.27 (0.05)	(1.16, 1.37)	0.25 (0.08)	(0.10, 0.40)	0.001	*
	Placebo	391	374 (95.7)	1.02 (0.05)	(0.91, 1.12)				
Week 24	Tezepelumab	395	365 (92.4)	1.41 (0.06)	(1.30, 1.52)	0.36 (0.08)	(0.20, 0.52)	<0.001	*
	Placebo	391	353 (90.3)	1.05 (0.06)	(0.94, 1.17)				
Week 36	Tezepelumab	395	363 (91.9)	1.44 (0.06)	(1.32, 1.55)	0.35 (0.08)	(0.19, 0.52)	<0.001	*
	Placebo	391	351 (89.8)	1.09 (0.06)	(0.97, 1.20)				
Week 52	Tezepelumab	395	354 (89.6)	1.52 (0.06)	(1.40, 1.63)	0.36 (0.08)	(0.19, 0.52)	<0.001	*
	Placebo	391	340 (87.0)	1.16 (0.06)	(1.04, 1.28)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022



Table PT3QTC\_ILMH0: Course of AQLQ+12 total score  
 DITTLL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 total score	Baseline	Tezepelumab	66	58 (87.9)	4.08 (0.90)	2.0	3.63	4.06	4.59	6.3	
		Placebo	65	55 (84.6)	4.26 (0.81)	1.8	3.75	4.28	4.72	6.3	
	Week 4	Tezepelumab	66	60 (90.9)	4.82 (1.05)	1.4	4.03	4.97	5.66	6.8	
		Placebo	65	57 (87.7)	4.77 (0.93)	2.4	4.06	4.81	5.28	6.8	
	Week 8	Tezepelumab	66	62 (93.9)	5.10 (1.05)	3.0	4.16	5.14	5.97	6.8	
		Placebo	65	59 (90.8)	4.84 (1.00)	2.4	4.22	4.75	5.53	7.0	
	Week 12	Tezepelumab	66	62 (93.9)	5.30 (1.00)	3.0	4.50	5.16	6.22	7.0	
		Placebo	65	59 (90.8)	4.96 (1.01)	2.8	4.22	4.94	5.56	7.0	
	Week 16	Tezepelumab	66	62 (93.9)	5.26 (1.03)	2.7	4.44	5.23	6.09	7.0	
		Placebo	65	59 (90.8)	4.95 (1.19)	1.2	4.13	4.94	5.72	7.0	
	Week 20	Tezepelumab	66	63 (95.5)	5.22 (1.03)	3.2	4.31	5.22	6.13	7.0	
		Placebo	65	59 (90.8)	4.87 (1.18)	1.2	4.03	4.88	5.88	7.0	
	Week 24	Tezepelumab	66	63 (95.5)	5.25 (1.04)	3.3	4.34	5.16	6.06	7.0	
		Placebo	65	59 (90.8)	4.85 (1.21)	1.2	4.00	4.81	5.75	7.0	
	Week 28	Tezepelumab	66	65 (98.5)	5.23 (1.04)	3.3	4.47	5.19	6.03	7.0	
		Placebo	65	60 (92.3)	4.95 (1.28)	1.2	3.98	4.97	5.94	7.0	
	Week 32	Tezepelumab	66	65 (98.5)	5.29 (1.06)	2.9	4.34	5.28	6.09	7.0	
		Placebo	65	60 (92.3)	5.00 (1.19)	1.2	4.13	5.11	5.91	7.0	
	Week 36	Tezepelumab	66	65 (98.5)	5.34 (1.05)	3.3	4.59	5.38	6.22	7.0	
		Placebo	65	60 (92.3)	4.92 (1.15)	2.2	4.00	4.84	5.83	7.0	
	Week 40	Tezepelumab	66	65 (98.5)	5.28 (1.06)	3.2	4.47	5.25	6.06	7.0	
		Placebo	65	60 (92.3)	5.00 (1.19)	2.3	4.02	5.06	6.00	7.0	
	Week 44	Tezepelumab	66	65 (98.5)	5.30 (1.03)	3.5	4.34	5.19	6.16	7.0	
		Placebo	65	60 (92.3)	5.00 (1.13)	2.8	4.02	5.00	5.89	7.0	
	Week 48	Tezepelumab	66	65 (98.5)	5.34 (1.06)	2.9	4.50	5.34	6.16	7.0	
		Placebo	65	60 (92.3)	4.99 (1.13)	2.1	4.16	4.80	5.98	7.0	
	Week 52	Tezepelumab	66	65 (98.5)	5.34 (1.06)	2.9	4.56	5.28	6.22	7.0	
		Placebo	65	60 (92.3)	5.04 (1.11)	2.9	4.11	4.80	6.00	7.0	

Note: DITTLL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Last observation carried forward is applied in case of missing values.

Source Data: aqlq, created on: 22FEB2022

Table PT3QTC\_ILMH0: Course of AQLQ+12 total score  
 DITTLL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 total score	Week 4	Tezepelumab	66	55 (83.3)	0.75 (1.03)	-3.7	0.22	0.75	1.44	3.3	0.25 [-0.12, 0.63]
		Placebo	65	54 (83.1)	0.52 (0.80)	-1.2	0.13	0.44	0.94	2.6	
	Week 8	Tezepelumab	66	57 (86.4)	0.96 (1.00)	-1.0	0.31	0.81	1.75	3.8	0.36 [-0.01, 0.73]
		Placebo	65	55 (84.6)	0.62 (0.90)	-1.4	0.09	0.50	1.00	3.1	
	Week 12	Tezepelumab	66	57 (86.4)	1.17 (1.00)	-2.1	0.59	1.22	1.91	4.0	0.45 [0.08, 0.83]
		Placebo	65	55 (84.6)	0.71 (1.02)	-1.7	0.22	0.72	1.22	3.5	
	Week 16	Tezepelumab	66	57 (86.4)	1.14 (1.00)	-2.4	0.53	1.25	1.78	3.4	0.39 [0.02, 0.77]
		Placebo	65	55 (84.6)	0.73 (1.11)	-3.2	0.31	0.72	1.16	3.8	
	Week 20	Tezepelumab	66	57 (86.4)	1.14 (0.99)	-1.2	0.47	1.09	1.78	3.4	0.47 [0.10, 0.85]
		Placebo	65	55 (84.6)	0.65 (1.06)	-3.2	0.19	0.72	1.09	3.2	
	Week 24	Tezepelumab	66	57 (86.4)	1.20 (1.01)	-1.2	0.38	1.34	1.78	3.4	0.51 [0.14, 0.89]
		Placebo	65	55 (84.6)	0.64 (1.15)	-3.2	0.09	0.72	1.22	3.2	
	Week 28	Tezepelumab	66	57 (86.4)	1.15 (1.03)	-1.3	0.34	1.00	1.97	3.4	0.40 [0.02, 0.77]
		Placebo	65	55 (84.6)	0.71 (1.21)	-3.2	0.09	0.84	1.25	4.0	
	Week 32	Tezepelumab	66	57 (86.4)	1.20 (1.05)	-1.2	0.41	1.06	2.19	3.4	0.41 [0.03, 0.78]
		Placebo	65	55 (84.6)	0.77 (1.07)	-3.2	0.25	0.72	1.38	3.2	
	Week 36	Tezepelumab	66	57 (86.4)	1.26 (1.09)	-1.3	0.66	1.03	2.25	3.4	0.56 [0.18, 0.93]
		Placebo	65	55 (84.6)	0.68 (1.00)	-2.0	0.19	0.66	1.19	2.9	
	Week 40	Tezepelumab	66	57 (86.4)	1.21 (1.05)	-1.3	0.63	1.06	2.06	3.4	0.41 [0.04, 0.78]
		Placebo	65	55 (84.6)	0.77 (1.10)	-2.0	0.06	0.78	1.50	3.8	
	Week 44	Tezepelumab	66	57 (86.4)	1.23 (1.06)	-1.1	0.59	0.97	2.06	3.4	0.44 [0.07, 0.82]
		Placebo	65	55 (84.6)	0.75 (1.09)	-2.0	-0.03	0.75	1.31	3.4	
	Week 48	Tezepelumab	66	57 (86.4)	1.27 (1.06)	-1.1	0.50	1.19	2.13	3.4	0.50 [0.13, 0.88]
		Placebo	65	55 (84.6)	0.75 (1.04)	-2.0	0.09	0.72	1.38	3.3	
	Week 52	Tezepelumab	66	57 (86.4)	1.27 (1.06)	-1.2	0.50	1.19	2.13	3.4	0.44 [0.07, 0.82]
		Placebo	65	55 (84.6)	0.80 (1.04)	-2.0	0.19	0.72	1.41	3.8	

Note: DITTLL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.  
 Last observation carried forward is applied in case of missing values.

Source Data: aqlq, created on: 22FEB2022

Table PT3QTC\_ILMC0: Change from baseline in AQLQ+12 total score - MMRM results  
 DITTTL

Change from baseline in AQLQ+12 total score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 4	Tezepelumab	66	55 (83.3)	NE		NE			
	Placebo	65	54 (83.1)						
Week 8	Tezepelumab	66	55 (83.3)	NE		NE			
	Placebo	65	55 (84.6)						
Week 12	Tezepelumab	66	54 (81.8)	NE		NE			
	Placebo	65	52 (80.0)						
Week 16	Tezepelumab	66	53 (80.3)	NE		NE			
	Placebo	65	50 (76.9)						
Week 20	Tezepelumab	66	51 (77.3)	NE		NE			
	Placebo	65	47 (72.3)						
Week 24	Tezepelumab	66	50 (75.8)	NE		NE			
	Placebo	65	45 (69.2)						
Week 28	Tezepelumab	66	47 (71.2)	NE		NE			
	Placebo	65	44 (67.7)						
Week 32	Tezepelumab	66	48 (72.7)	NE		NE			
	Placebo	65	43 (66.2)						
Week 36	Tezepelumab	66	49 (74.2)	NE		NE			
	Placebo	65	44 (67.7)						
Week 40	Tezepelumab	66	48 (72.7)	NE		NE			
	Placebo	65	45 (69.2)						

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 22FEB2022

Table PT3QTC\_ILMC0: Change from baseline in AQLQ+12 total score - MMRM results  
 DITTTL

Change from baseline in AQLQ+12 total score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 44	Tezepelumab	66	47 (71.2)	NE		NE		
	Placebo	65	44 (67.7)					
Week 48	Tezepelumab	66	46 (69.7)	NE		NE		
	Placebo	65	44 (67.7)					
Week 52	Tezepelumab	66	18 (27.3)	NE		NE		
	Placebo	65	16 (24.6)					

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 22FEB2022

Table ST1QTC\_ILMH0: Course of AQLQ+12 total score  
 DITTLL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 total score	Baseline	Tezepelumab	73	73 (100.0)	4.15 (1.18)	1.7	3.28	4.28	4.88	6.9	
		Placebo	76	74 (97.4)	4.11 (1.02)	1.8	3.31	4.19	4.84	6.0	
	Week 4	Tezepelumab	73	71 (97.3)	4.75 (1.29)	1.7	3.72	4.63	5.88	7.0	
		Placebo	76	76 (100.0)	4.54 (0.99)	2.7	3.88	4.41	5.25	7.0	
	Week 40	Tezepelumab	73	61 (83.6)	5.23 (1.35)	1.3	4.41	5.34	6.38	7.0	
		Placebo	76	68 (89.5)	4.72 (1.15)	2.3	3.84	4.66	5.53	7.0	
	Week 44	Tezepelumab	73	64 (87.7)	5.15 (1.28)	1.5	4.53	5.16	6.17	7.0	
		Placebo	76	72 (94.7)	4.75 (1.21)	1.9	3.91	4.75	5.67	7.0	
	Week 48	Tezepelumab	73	65 (89.0)	5.11 (1.41)	1.4	4.09	5.47	6.06	7.0	
		Placebo	76	68 (89.5)	4.72 (1.16)	1.7	4.03	4.81	5.42	7.0	

Note: DITTLL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 23FEB2022

Table ST1QTC\_ILMH0: Course of AQLQ+12 total score  
 DITTLL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 total score	Week 4	Tezepelumab	73	71 (97.3)	0.60 (1.09)	-3.2	-0.09	0.44	1.13	3.4	0.17 [-0.15, 0.50]
		Placebo	76	74 (97.4)	0.43 (0.93)	-2.0	-0.06	0.36	0.81	3.0	
	Week 40	Tezepelumab	73	61 (83.6)	1.02 (1.23)	-1.5	0.03	1.00	1.97	3.8	0.34 [-0.01, 0.69]
		Placebo	76	66 (86.8)	0.61 (1.19)	-1.8	-0.16	0.55	1.47	4.1	
	Week 44	Tezepelumab	73	64 (87.7)	0.96 (1.21)	-2.3	0.22	0.84	1.91	3.4	0.32 [-0.02, 0.66]
		Placebo	76	70 (92.1)	0.57 (1.24)	-2.3	-0.03	0.50	1.28	4.6	
	Week 48	Tezepelumab	73	65 (89.0)	0.95 (1.18)	-1.8	0.16	0.91	1.84	3.3	0.33 [-0.02, 0.67]
		Placebo	76	67 (88.2)	0.59 (1.01)	-1.8	-0.06	0.50	1.09	3.4	

Note: DITTLL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 23FEB2022

Table ST1QTC\_ILMC0: Change from baseline in AQLQ+12 total score - MMRM results  
 DITTTL

Change from baseline in AQLQ+12 total score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	73	71 (97.3)	0.60 (0.11)	(0.38, 0.82)	0.19 (0.15)	(-0.12, 0.49)	0.225
	Placebo	76	74 (97.4)	0.41 (0.11)	(0.20, 0.62)			
Week 40	Tezepelumab	73	61 (83.6)	0.98 (0.13)	(0.72, 1.25)	0.36 (0.19)	(-0.01, 0.73)	0.060
	Placebo	76	66 (86.8)	0.63 (0.13)	(0.37, 0.88)			
Week 44	Tezepelumab	73	64 (87.7)	0.91 (0.14)	(0.64, 1.18)	0.32 (0.19)	(-0.06, 0.70)	0.094
	Placebo	76	70 (92.1)	0.59 (0.13)	(0.33, 0.85)			
Week 48	Tezepelumab	73	65 (89.0)	0.93 (0.13)	(0.68, 1.18)	0.36 (0.18)	(0.01, 0.71)	0.044 *
	Placebo	76	67 (88.2)	0.57 (0.12)	(0.33, 0.82)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 23FEB2022

Table MT1QAC\_ILMH0: Course of AQLQ+12 activity limitations score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 activity limitations score	Baseline	Tezepelumab	446	437 (98.0)	3.92 (1.05)	1.1	3.27	3.91	4.55	6.9	
		Placebo	436	424 (97.2)	4.00 (1.02)	1.2	3.27	4.00	4.64	6.7	
	Week 4	Tezepelumab	446	428 (96.0)	4.79 (1.21)	1.6	3.91	4.82	5.82	7.0	
		Placebo	436	415 (95.2)	4.64 (1.20)	1.0	3.82	4.64	5.55	7.0	
	Week 12	Tezepelumab	446	426 (95.5)	5.09 (1.24)	1.5	4.18	5.14	6.09	7.0	
		Placebo	436	414 (95.0)	4.89 (1.23)	1.1	4.00	4.91	5.91	7.0	
	Week 24	Tezepelumab	446	415 (93.0)	5.23 (1.25)	1.0	4.27	5.45	6.18	7.0	
		Placebo	436	396 (90.8)	4.92 (1.28)	1.0	4.00	5.00	5.91	7.0	
	Week 36	Tezepelumab	446	415 (93.0)	5.24 (1.26)	1.4	4.27	5.45	6.27	7.0	
		Placebo	436	394 (90.4)	4.95 (1.25)	1.3	4.00	5.00	6.00	7.0	
	Week 52	Tezepelumab	446	407 (91.3)	5.28 (1.24)	1.7	4.27	5.45	6.36	7.0	
		Placebo	436	381 (87.4)	5.01 (1.25)	1.5	4.00	5.09	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Last observation carried forward is applied in case of missing values.

Source Data: aqlq, created on: 22FEB2022



Table MT1QAC\_ILMH0: Course of AQLQ+12 activity limitations score  
 DITTTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 activity limitations score	Week 4	Tezepelumab	446	422 (94.6)	0.87 (1.07)	-2.8	0.09	0.73	1.55	4.3	0.21 [0.08, 0.35]
		Placebo	436	412 (94.5)	0.65 (0.94)	-2.8	0.09	0.55	1.18	5.4	
	Week 12	Tezepelumab	446	421 (94.4)	1.15 (1.18)	-1.9	0.36	1.09	1.91	4.3	0.24 [0.10, 0.37]
		Placebo	436	409 (93.8)	0.89 (1.09)	-2.2	0.18	0.82	1.55	5.3	
	Week 24	Tezepelumab	446	409 (91.7)	1.29 (1.25)	-5.1	0.45	1.18	2.18	4.4	0.30 [0.16, 0.44]
		Placebo	436	391 (89.7)	0.92 (1.15)	-3.2	0.18	0.82	1.64	5.2	
	Week 36	Tezepelumab	446	407 (91.3)	1.29 (1.22)	-2.3	0.45	1.18	2.18	4.9	0.30 [0.16, 0.44]
		Placebo	436	388 (89.0)	0.94 (1.12)	-2.1	0.18	0.91	1.59	5.3	
	Week 52	Tezepelumab	446	399 (89.5)	1.33 (1.21)	-2.9	0.45	1.27	2.09	4.6	0.27 [0.13, 0.42]
		Placebo	436	375 (86.0)	1.00 (1.18)	-2.5	0.18	0.91	1.73	4.9	

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Last observation carried forward is applied in case of missing values.

Source Data: aqlq, created on: 22FEB2022

Table MT1QAC\_ILMC0: Change from baseline in AQLQ+12 activity limitations score - MMRM results  
 DITTL

Change from baseline in AQLQ+12 activity limitations score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	446	422 (94.6)	0.85 (0.05)	(0.76, 0.94)	0.19 (0.07)	(0.06, 0.32)	0.004 *
	Placebo	436	412 (94.5)	0.66 (0.05)	(0.57, 0.75)			
Week 12	Tezepelumab	446	418 (93.7)	1.15 (0.05)	(1.05, 1.25)	0.26 (0.07)	(0.12, 0.41)	<0.001 *
	Placebo	436	406 (93.1)	0.89 (0.05)	(0.78, 0.99)			
Week 24	Tezepelumab	446	402 (90.1)	1.27 (0.05)	(1.16, 1.38)	0.34 (0.08)	(0.19, 0.49)	<0.001 *
	Placebo	436	381 (87.4)	0.93 (0.06)	(0.82, 1.04)			
Week 36	Tezepelumab	446	399 (89.5)	1.29 (0.05)	(1.18, 1.39)	0.35 (0.08)	(0.20, 0.50)	<0.001 *
	Placebo	436	377 (86.5)	0.94 (0.06)	(0.83, 1.05)			
Week 52	Tezepelumab	446	360 (80.7)	1.33 (0.06)	(1.22, 1.44)	0.32 (0.08)	(0.16, 0.48)	<0.001 *
	Placebo	436	336 (77.1)	1.01 (0.06)	(0.90, 1.13)			

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 22FEB2022

Table NT1QAC\_ILMH0: Course of AQLQ+12 activity limitations score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 activity limitations score	Baseline	Tezepelumab	395	394 (99.7)	3.89 (1.06)	1.1	3.27	3.91	4.64	6.9	
		Placebo	391	389 (99.5)	3.97 (1.05)	1.2	3.18	4.00	4.73	6.7	
	Week 4	Tezepelumab	395	382 (96.7)	4.79 (1.23)	1.6	3.91	4.82	5.82	7.0	
		Placebo	391	376 (96.2)	4.65 (1.22)	1.0	3.82	4.64	5.55	7.0	
	Week 12	Tezepelumab	395	377 (95.4)	5.06 (1.25)	1.5	4.09	5.09	6.09	7.0	
		Placebo	391	375 (95.9)	4.91 (1.26)	1.1	4.00	5.00	6.00	7.0	
	Week 24	Tezepelumab	395	365 (92.4)	5.23 (1.27)	1.0	4.27	5.45	6.18	7.0	
		Placebo	391	354 (90.5)	4.94 (1.28)	1.0	4.00	5.00	6.00	7.0	
	Week 36	Tezepelumab	395	363 (91.9)	5.24 (1.28)	1.4	4.18	5.45	6.27	7.0	
		Placebo	391	352 (90.0)	4.97 (1.27)	1.3	4.09	5.00	6.00	7.0	
	Week 52	Tezepelumab	395	354 (89.6)	5.28 (1.27)	1.7	4.27	5.55	6.36	7.0	
		Placebo	391	341 (87.2)	5.04 (1.27)	1.5	4.09	5.09	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QAC\_ILMH0: Course of AQLQ+12 activity limitations score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 activity limitations score	Week 4	Tezepelumab	395	381 (96.5)	0.89 (1.08)	-2.3	0.18	0.73	1.55	4.3	0.18 [0.04, 0.33]
		Placebo	391	376 (96.2)	0.70 (0.95)	-2.8	0.18	0.64	1.27	5.4	
	Week 12	Tezepelumab	395	377 (95.4)	1.16 (1.20)	-1.9	0.27	1.09	2.00	4.3	0.19 [0.05, 0.34]
		Placebo	391	374 (95.7)	0.93 (1.11)	-2.2	0.18	0.82	1.55	5.3	
	Week 24	Tezepelumab	395	365 (92.4)	1.32 (1.27)	-5.1	0.55	1.27	2.27	4.4	0.29 [0.14, 0.44]
		Placebo	391	353 (90.3)	0.97 (1.14)	-2.5	0.27	0.91	1.64	5.2	
	Week 36	Tezepelumab	395	363 (91.9)	1.32 (1.25)	-2.3	0.45	1.27	2.18	4.9	0.27 [0.12, 0.42]
		Placebo	391	351 (89.8)	1.00 (1.16)	-2.9	0.18	0.91	1.73	5.3	
	Week 52	Tezepelumab	395	354 (89.6)	1.36 (1.24)	-2.9	0.55	1.36	2.09	4.6	0.24 [0.09, 0.39]
		Placebo	391	340 (87.0)	1.06 (1.21)	-2.5	0.27	1.00	1.91	4.9	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QAC\_ILMC0: Change from baseline in AQLQ+12 activity limitations score - MMRM results  
 DITTL

Change from baseline in AQLQ+12 activity limitations score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	395	381 (96.5)	0.87 (0.05)	(0.78, 0.97)	0.16 (0.07)	(0.02, 0.30)	0.022 *
	Placebo	391	376 (96.2)	0.71 (0.05)	(0.61, 0.81)			
Week 12	Tezepelumab	395	377 (95.4)	1.15 (0.06)	(1.04, 1.26)	0.22 (0.08)	(0.07, 0.38)	0.005 *
	Placebo	391	374 (95.7)	0.93 (0.06)	(0.82, 1.04)			
Week 24	Tezepelumab	395	365 (92.4)	1.30 (0.06)	(1.18, 1.41)	0.34 (0.08)	(0.17, 0.50)	<0.001 *
	Placebo	391	353 (90.3)	0.96 (0.06)	(0.85, 1.08)			
Week 36	Tezepelumab	395	363 (91.9)	1.31 (0.06)	(1.19, 1.42)	0.32 (0.08)	(0.16, 0.49)	<0.001 *
	Placebo	391	351 (89.8)	0.98 (0.06)	(0.87, 1.10)			
Week 52	Tezepelumab	395	354 (89.6)	1.35 (0.06)	(1.24, 1.47)	0.30 (0.08)	(0.14, 0.47)	<0.001 *
	Placebo	391	340 (87.0)	1.05 (0.06)	(0.93, 1.17)			

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table PT3QAC\_ILMH0: Course of AQLQ+12 activity limitations score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 activity limitations score	Baseline	Tezepelumab	66	58 (87.9)	4.13 (0.89)	2.1	3.64	4.09	4.55	6.3	
		Placebo	65	55 (84.6)	4.31 (0.78)	2.3	3.82	4.27	4.64	6.2	
	Week 4	Tezepelumab	66	60 (90.9)	4.87 (1.06)	1.6	4.14	4.95	5.73	6.9	
		Placebo	65	57 (87.7)	4.75 (1.03)	2.5	4.00	4.55	5.45	7.0	
	Week 8	Tezepelumab	66	62 (93.9)	5.15 (1.08)	2.9	4.18	5.27	6.09	6.9	
		Placebo	65	59 (90.8)	4.85 (1.07)	2.3	4.09	4.73	5.64	7.0	
	Week 12	Tezepelumab	66	62 (93.9)	5.37 (1.04)	3.0	4.64	5.18	6.36	7.0	
		Placebo	65	59 (90.8)	4.98 (1.11)	2.8	4.09	4.91	6.00	7.0	
	Week 16	Tezepelumab	66	62 (93.9)	5.31 (1.06)	2.8	4.36	5.27	6.18	7.0	
		Placebo	65	59 (90.8)	5.03 (1.25)	1.1	4.09	4.91	6.00	7.0	
	Week 20	Tezepelumab	66	63 (95.5)	5.25 (1.11)	2.8	4.27	5.18	6.27	7.0	
		Placebo	65	59 (90.8)	4.92 (1.25)	1.1	4.09	4.82	5.91	7.0	
	Week 24	Tezepelumab	66	63 (95.5)	5.31 (1.09)	2.9	4.27	5.18	6.27	7.0	
		Placebo	65	59 (90.8)	4.94 (1.27)	1.1	4.09	5.00	5.82	7.0	
	Week 28	Tezepelumab	66	65 (98.5)	5.28 (1.08)	2.9	4.45	5.27	6.27	7.0	
		Placebo	65	60 (92.3)	4.99 (1.36)	1.1	3.91	5.09	6.00	7.0	
	Week 32	Tezepelumab	66	65 (98.5)	5.34 (1.09)	2.9	4.36	5.27	6.18	7.0	
		Placebo	65	60 (92.3)	5.05 (1.26)	1.1	4.09	5.09	6.00	7.0	
	Week 36	Tezepelumab	66	65 (98.5)	5.37 (1.07)	3.0	4.45	5.45	6.18	7.0	
		Placebo	65	60 (92.3)	4.98 (1.22)	2.4	4.05	4.95	6.00	7.0	
	Week 40	Tezepelumab	66	65 (98.5)	5.34 (1.06)	3.3	4.36	5.18	6.18	7.0	
		Placebo	65	60 (92.3)	5.05 (1.28)	2.0	4.09	5.09	6.14	7.0	
	Week 44	Tezepelumab	66	65 (98.5)	5.34 (1.07)	3.0	4.45	5.36	6.27	7.0	
		Placebo	65	60 (92.3)	5.07 (1.20)	2.5	4.05	5.14	5.95	7.0	
	Week 48	Tezepelumab	66	65 (98.5)	5.39 (1.09)	2.6	4.36	5.45	6.36	7.0	
		Placebo	65	60 (92.3)	5.02 (1.21)	2.3	4.05	4.95	6.05	7.0	
	Week 52	Tezepelumab	66	65 (98.5)	5.39 (1.09)	2.6	4.45	5.36	6.36	7.0	
		Placebo	65	60 (92.3)	5.08 (1.17)	2.9	4.05	5.00	6.05	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Last observation carried forward is applied in case of missing values.

Source Data: aqlq, created on: 22FEB2022

Table PT3QAC\_ILMH0: Course of AQLQ+12 activity limitations score  
 DITTTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 activity limitations score	Week 4	Tezepelumab	66	55 (83.3)	0.76 (0.99)	-2.8	0.00	0.82	1.45	3.1	0.34 [-0.04, 0.72]
		Placebo	65	54 (83.1)	0.44 (0.86)	-1.5	0.00	0.36	0.82	2.5	
	Week 8	Tezepelumab	66	57 (86.4)	0.97 (0.98)	-1.3	0.27	0.91	1.55	3.7	0.42 [0.04, 0.79]
		Placebo	65	55 (84.6)	0.58 (0.89)	-1.3	-0.09	0.55	1.00	2.6	
	Week 12	Tezepelumab	66	57 (86.4)	1.20 (1.01)	-1.5	0.64	1.09	1.73	4.2	0.53 [0.15, 0.90]
		Placebo	65	55 (84.6)	0.68 (0.97)	-1.3	0.09	0.73	1.18	3.3	
	Week 16	Tezepelumab	66	57 (86.4)	1.15 (1.00)	-1.6	0.36	1.09	1.82	3.5	0.37 [-0.00, 0.75]
		Placebo	65	55 (84.6)	0.76 (1.08)	-3.2	0.27	0.82	1.55	3.5	
	Week 20	Tezepelumab	66	57 (86.4)	1.11 (1.07)	-0.9	0.36	1.00	1.91	3.5	0.42 [0.04, 0.79]
		Placebo	65	55 (84.6)	0.67 (1.04)	-3.2	0.18	0.64	1.27	2.5	
	Week 24	Tezepelumab	66	57 (86.4)	1.22 (1.03)	-0.7	0.45	1.09	1.91	3.5	0.50 [0.12, 0.88]
		Placebo	65	55 (84.6)	0.68 (1.13)	-3.2	0.09	0.64	1.45	2.9	
	Week 28	Tezepelumab	66	57 (86.4)	1.18 (1.04)	-0.8	0.45	1.09	2.00	3.5	0.43 [0.05, 0.80]
		Placebo	65	55 (84.6)	0.70 (1.20)	-3.2	0.09	0.82	1.36	3.7	
	Week 32	Tezepelumab	66	57 (86.4)	1.19 (1.05)	-0.7	0.45	1.00	1.91	3.5	0.41 [0.03, 0.78]
		Placebo	65	55 (84.6)	0.76 (1.11)	-3.2	0.27	0.82	1.55	3.3	
	Week 36	Tezepelumab	66	57 (86.4)	1.25 (1.06)	-0.7	0.64	1.09	1.91	3.5	0.53 [0.15, 0.91]
		Placebo	65	55 (84.6)	0.69 (1.02)	-1.8	0.09	0.73	1.27	2.7	
	Week 40	Tezepelumab	66	57 (86.4)	1.22 (1.02)	-0.9	0.45	1.09	1.91	3.5	0.42 [0.05, 0.80]
		Placebo	65	55 (84.6)	0.77 (1.10)	-1.6	0.18	0.73	1.64	3.5	
	Week 44	Tezepelumab	66	57 (86.4)	1.23 (1.05)	-0.7	0.45	1.09	1.91	3.5	0.43 [0.06, 0.80]
		Placebo	65	55 (84.6)	0.77 (1.11)	-1.6	0.09	0.73	1.55	3.4	
	Week 48	Tezepelumab	66	57 (86.4)	1.30 (1.03)	-0.7	0.45	1.18	2.00	3.5	0.56 [0.18, 0.93]
		Placebo	65	55 (84.6)	0.71 (1.06)	-1.6	0.09	0.82	1.27	3.2	
	Week 52	Tezepelumab	66	57 (86.4)	1.28 (1.03)	-0.7	0.55	1.18	1.91	3.5	0.46 [0.09, 0.84]
		Placebo	65	55 (84.6)	0.80 (1.04)	-1.6	0.09	0.82	1.55	3.5	

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older. Last observation carried forward is applied in case of missing values.

Source Data: aqlq, created on: 22FEB2022

Table PT3QAC\_ILMC0: Change from baseline in AQLQ+12 activity limitations score - MMRM results  
 DITTTL

Change from baseline in AQLQ+12 activity limitations score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	66	55 (83.3)	0.73 (0.12)	(0.49, 0.97)	0.29 (0.17)	(-0.05, 0.63)	0.097
	Placebo	65	54 (83.1)	0.45 (0.12)	(0.20, 0.69)			
Week 8	Tezepelumab	66	55 (83.3)	0.95 (0.12)	(0.71, 1.19)	0.35 (0.17)	(0.00, 0.69)	0.049 *
	Placebo	65	55 (84.6)	0.60 (0.12)	(0.36, 0.85)			
Week 12	Tezepelumab	66	54 (81.8)	1.20 (0.13)	(0.95, 1.45)	0.47 (0.18)	(0.10, 0.83)	0.012 *
	Placebo	65	52 (80.0)	0.73 (0.13)	(0.48, 0.99)			
Week 16	Tezepelumab	66	53 (80.3)	1.14 (0.14)	(0.86, 1.41)	0.36 (0.20)	(-0.03, 0.75)	0.068
	Placebo	65	50 (76.9)	0.77 (0.14)	(0.50, 1.05)			
Week 20	Tezepelumab	66	51 (77.3)	1.09 (0.13)	(0.82, 1.36)	0.37 (0.19)	(-0.01, 0.75)	0.056
	Placebo	65	47 (72.3)	0.72 (0.14)	(0.45, 0.99)			
Week 24	Tezepelumab	66	50 (75.8)	1.21 (0.14)	(0.94, 1.49)	0.49 (0.20)	(0.10, 0.89)	0.014 *
	Placebo	65	45 (69.2)	0.72 (0.14)	(0.44, 1.00)			
Week 28	Tezepelumab	66	47 (71.2)	1.15 (0.15)	(0.86, 1.45)	0.40 (0.21)	(-0.02, 0.82)	0.061
	Placebo	65	44 (67.7)	0.75 (0.15)	(0.45, 1.05)			
Week 32	Tezepelumab	66	48 (72.7)	1.20 (0.14)	(0.92, 1.47)	0.37 (0.20)	(-0.03, 0.76)	0.068
	Placebo	65	43 (66.2)	0.83 (0.14)	(0.55, 1.11)			
Week 36	Tezepelumab	66	49 (74.2)	1.26 (0.14)	(0.98, 1.53)	0.50 (0.20)	(0.11, 0.90)	0.014 *
	Placebo	65	44 (67.7)	0.75 (0.14)	(0.47, 1.04)			
Week 40	Tezepelumab	66	48 (72.7)	1.22 (0.14)	(0.93, 1.50)	0.38 (0.21)	(-0.02, 0.79)	0.065
	Placebo	65	45 (69.2)	0.83 (0.15)	(0.54, 1.12)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 22FEB2022



Table PT3QAC\_ILMC0: Change from baseline in AQLQ+12 activity limitations score - MMRM results  
 DITTTL

Change from baseline in AQLQ+12 activity limitations score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 44	Tezepelumab	66	47 (71.2)	1.25 (0.14)	(0.97, 1.53)	0.45 (0.20)	(0.05, 0.86)	0.029 *
	Placebo	65	44 (67.7)	0.80 (0.15)	(0.51, 1.09)			
Week 48	Tezepelumab	66	46 (69.7)	1.31 (0.14)	(1.04, 1.59)	0.58 (0.20)	(0.19, 0.97)	0.004 *
	Placebo	65	44 (67.7)	0.73 (0.14)	(0.45, 1.01)			
Week 52	Tezepelumab	66	18 (27.3)	1.09 (0.23)	(0.63, 1.55)	0.24 (0.33)	(-0.44, 0.91)	0.482
	Placebo	65	16 (24.6)	0.85 (0.24)	(0.36, 1.34)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 22FEB2022

Table ST1QAC\_ILMH0: Course of AQLQ+12 activity limitations score  
 DITTTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 activity limitations score	Baseline	Tezepelumab	73	73 (100.0)	4.18 (1.25)	1.6	3.27	4.27	5.00	7.0	
		Placebo	76	74 (97.4)	4.10 (1.01)	1.9	3.45	4.09	4.82	6.1	
	Week 4	Tezepelumab	73	71 (97.3)	4.73 (1.30)	1.8	3.73	4.55	5.82	7.0	
		Placebo	76	76 (100.0)	4.49 (1.01)	2.6	3.73	4.41	5.09	7.0	
	Week 40	Tezepelumab	73	61 (83.6)	5.22 (1.36)	1.6	4.36	5.36	6.45	7.0	
		Placebo	76	68 (89.5)	4.56 (1.20)	1.7	3.68	4.45	5.55	7.0	
	Week 44	Tezepelumab	73	64 (87.7)	5.05 (1.34)	1.7	4.14	5.18	6.23	7.0	
		Placebo	76	72 (94.7)	4.66 (1.29)	1.4	3.68	4.77	5.55	7.0	
	Week 48	Tezepelumab	73	65 (89.0)	5.06 (1.43)	1.5	4.00	5.27	6.18	7.0	
		Placebo	76	68 (89.5)	4.67 (1.17)	1.6	4.09	4.68	5.32	7.0	

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 23FEB2022

Table ST1QAC\_ILMH0: Course of AQLQ+12 activity limitations score  
 DITTTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 activity limitations score	Week 4	Tezepelumab	73	71 (97.3)	0.56 (1.05)	-3.0	-0.09	0.45	1.18	3.5	0.16 [-0.17, 0.49]
		Placebo	76	74 (97.4)	0.40 (0.95)	-2.5	0.00	0.36	0.82	3.1	
	Week 40	Tezepelumab	73	61 (83.6)	0.99 (1.23)	-1.2	0.00	0.82	2.00	3.7	0.42 [0.07, 0.77]
		Placebo	76	66 (86.8)	0.48 (1.23)	-2.1	-0.36	0.50	1.45	3.5	
	Week 44	Tezepelumab	73	64 (87.7)	0.84 (1.19)	-1.9	-0.09	0.73	1.82	3.5	0.26 [-0.08, 0.60]
		Placebo	76	70 (92.1)	0.51 (1.31)	-2.8	-0.18	0.50	1.36	4.4	
	Week 48	Tezepelumab	73	65 (89.0)	0.87 (1.14)	-1.5	0.00	0.64	1.82	3.5	0.28 [-0.06, 0.63]
		Placebo	76	67 (88.2)	0.56 (1.04)	-2.4	-0.18	0.55	1.18	2.8	

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 23FEB2022

Table ST1QAC\_ILMC0: Change from baseline in AQLQ+12 activity limitations score - MMRM results  
 DITTL

Change from baseline in AQLQ+12 activity limitations score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	73	71 (97.3)	0.56 (0.11)	(0.35, 0.78)	0.19 (0.15)	(-0.11, 0.49)	0.221
	Placebo	76	74 (97.4)	0.37 (0.11)	(0.16, 0.58)			
Week 40	Tezepelumab	73	61 (83.6)	0.95 (0.14)	(0.68, 1.22)	0.47 (0.19)	(0.09, 0.85)	0.015 *
	Placebo	76	66 (86.8)	0.48 (0.13)	(0.21, 0.74)			
Week 44	Tezepelumab	73	64 (87.7)	0.79 (0.14)	(0.51, 1.07)	0.29 (0.20)	(-0.11, 0.68)	0.150
	Placebo	76	70 (92.1)	0.50 (0.14)	(0.23, 0.78)			
Week 48	Tezepelumab	73	65 (89.0)	0.86 (0.13)	(0.61, 1.11)	0.32 (0.18)	(-0.03, 0.67)	0.073
	Placebo	76	67 (88.2)	0.54 (0.12)	(0.30, 0.79)			

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 23FEB2022

Table MT1QEC\_ILMH0: Course of AQLQ+12 environmental stimuli score  
 DITTL

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 environmental stimuli score	Tezepelumab	446	437 (98.0)	3.87 (1.39)	1.0	2.75	4.00	5.00	7.0	
	Placebo	436	424 (97.2)	3.97 (1.41)	1.0	3.00	4.00	4.75	7.0	
Week 4	Tezepelumab	446	428 (96.0)	4.75 (1.47)	1.0	3.75	5.00	6.00	7.0	
	Placebo	436	415 (95.2)	4.58 (1.49)	1.0	3.75	4.75	5.75	7.0	
Week 12	Tezepelumab	446	426 (95.5)	5.01 (1.46)	1.0	4.00	5.25	6.25	7.0	
	Placebo	436	414 (95.0)	4.82 (1.41)	1.0	4.00	5.00	6.00	7.0	
Week 24	Tezepelumab	446	415 (93.0)	5.14 (1.48)	1.0	4.25	5.50	6.25	7.0	
	Placebo	436	396 (90.8)	4.85 (1.50)	1.0	4.00	5.00	6.00	7.0	
Week 36	Tezepelumab	446	415 (93.0)	5.19 (1.42)	1.0	4.25	5.50	6.25	7.0	
	Placebo	436	394 (90.4)	4.89 (1.57)	1.0	4.00	5.25	6.25	7.0	
Week 52	Tezepelumab	446	407 (91.3)	5.26 (1.41)	1.0	4.50	5.50	6.25	7.0	
	Placebo	436	381 (87.4)	4.94 (1.51)	1.0	4.00	5.25	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Last observation carried forward is applied in case of missing values.

Source Data: aqlq, created on: 22FEB2022

Table MT1QEC\_ILMH0: Course of AQLQ+12 environmental stimuli score  
 DITTTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 environmental stimuli score	Week 4	Tezepelumab	446	422 (94.6)	0.86 (1.26)	-4.3	0.00	0.75	1.50	5.3	0.21 [0.07, 0.34]
		Placebo	436	412 (94.5)	0.62 (1.11)	-3.0	0.00	0.50	1.25	4.5	
	Week 12	Tezepelumab	446	421 (94.4)	1.12 (1.33)	-2.5	0.25	1.00	2.00	5.5	0.22 [0.08, 0.36]
		Placebo	436	409 (93.8)	0.84 (1.21)	-3.8	0.00	0.75	1.50	4.5	
	Week 24	Tezepelumab	446	409 (91.7)	1.26 (1.46)	-4.3	0.25	1.25	2.25	5.5	0.25 [0.11, 0.39]
		Placebo	436	391 (89.7)	0.91 (1.35)	-2.8	0.00	0.75	1.75	4.8	
	Week 36	Tezepelumab	446	407 (91.3)	1.30 (1.43)	-3.3	0.25	1.25	2.25	5.8	0.25 [0.11, 0.39]
		Placebo	436	388 (89.0)	0.94 (1.34)	-2.8	0.00	0.75	1.75	5.3	
	Week 52	Tezepelumab	446	399 (89.5)	1.37 (1.46)	-2.8	0.25	1.25	2.25	6.0	0.27 [0.13, 0.41]
		Placebo	436	375 (86.0)	0.99 (1.33)	-2.8	0.00	0.75	1.75	5.5	

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Last observation carried forward is applied in case of missing values.

Source Data: aqlq, created on: 22FEB2022

Table MT1QEC\_ILMC0: Change from baseline in AQLQ+12 environmental stimuli score - MMRM results  
 DITTTL

Change from baseline in AQLQ+12 environmental stimuli score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 4	Tezepelumab	446	422 (94.6)	0.85 (0.05)	(0.75, 0.96)	0.21 (0.08)	(0.06, 0.36)	0.007	*
	Placebo	436	412 (94.5)	0.64 (0.05)	(0.54, 0.75)				
Week 12	Tezepelumab	446	418 (93.7)	1.12 (0.06)	(1.01, 1.23)	0.25 (0.08)	(0.09, 0.41)	0.002	*
	Placebo	436	406 (93.1)	0.87 (0.06)	(0.76, 0.98)				
Week 24	Tezepelumab	446	402 (90.1)	1.24 (0.06)	(1.12, 1.37)	0.31 (0.09)	(0.13, 0.49)	<0.001	*
	Placebo	436	381 (87.4)	0.93 (0.06)	(0.81, 1.06)				
Week 36	Tezepelumab	446	399 (89.5)	1.28 (0.06)	(1.16, 1.41)	0.32 (0.09)	(0.15, 0.50)	<0.001	*
	Placebo	436	377 (86.5)	0.96 (0.06)	(0.83, 1.09)				
Week 52	Tezepelumab	446	360 (80.7)	1.36 (0.06)	(1.24, 1.49)	0.34 (0.09)	(0.16, 0.52)	<0.001	*
	Placebo	436	336 (77.1)	1.02 (0.07)	(0.89, 1.15)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 22FEB2022

Table NT1QEC\_ILMH0: Course of AQLQ+12 environmental stimuli score  
 DITTL

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 environmental stimuli Baseline score	Tezepelumab	395	394 (99.7)	3.85 (1.43)	1.0	2.75	4.00	5.00	7.0	
	Placebo	391	389 (99.5)	3.92 (1.43)	1.0	3.00	4.00	4.75	7.0	
Week 4	Tezepelumab	395	382 (96.7)	4.74 (1.51)	1.0	3.75	5.00	6.00	7.0	
	Placebo	391	376 (96.2)	4.56 (1.54)	1.0	3.50	4.75	5.75	7.0	
Week 12	Tezepelumab	395	377 (95.4)	4.96 (1.50)	1.0	4.00	5.25	6.25	7.0	
	Placebo	391	375 (95.9)	4.82 (1.47)	1.0	4.00	5.00	6.00	7.0	
Week 24	Tezepelumab	395	365 (92.4)	5.13 (1.50)	1.0	4.25	5.50	6.25	7.0	
	Placebo	391	354 (90.5)	4.87 (1.50)	1.0	4.00	5.00	6.00	7.0	
Week 36	Tezepelumab	395	363 (91.9)	5.17 (1.46)	1.0	4.25	5.50	6.25	7.0	
	Placebo	391	352 (90.0)	4.92 (1.60)	1.0	4.00	5.25	6.25	7.0	
Week 52	Tezepelumab	395	354 (89.6)	5.24 (1.45)	1.0	4.25	5.50	6.25	7.0	
	Placebo	391	341 (87.2)	4.95 (1.55)	1.0	4.00	5.25	6.25	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022



Table NT1QEC\_ILMH0: Course of AQLQ+12 environmental stimuli score  
 DITTTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 environmental stimuli score	Week 4	Tezepelumab	395	381 (96.5)	0.87 (1.25)	-4.3	0.00	0.75	1.50	5.3	0.17 [0.02, 0.31]
		Placebo	391	376 (96.2)	0.67 (1.14)	-3.0	0.00	0.50	1.25	4.5	
	Week 12	Tezepelumab	395	377 (95.4)	1.10 (1.38)	-2.5	0.00	1.00	2.00	5.5	0.16 [0.02, 0.31]
		Placebo	391	374 (95.7)	0.89 (1.24)	-3.8	0.00	0.75	1.50	4.5	
	Week 24	Tezepelumab	395	365 (92.4)	1.27 (1.51)	-4.3	0.25	1.00	2.25	5.5	0.20 [0.06, 0.35]
		Placebo	391	353 (90.3)	0.98 (1.36)	-2.3	0.00	0.75	1.75	4.8	
	Week 36	Tezepelumab	395	363 (91.9)	1.30 (1.52)	-4.8	0.25	1.25	2.25	5.8	0.20 [0.05, 0.35]
		Placebo	391	351 (89.8)	1.01 (1.39)	-5.0	0.25	1.00	2.00	5.3	
	Week 52	Tezepelumab	395	354 (89.6)	1.37 (1.53)	-2.8	0.25	1.25	2.25	6.0	0.21 [0.06, 0.36]
		Placebo	391	340 (87.0)	1.06 (1.35)	-2.8	0.25	1.00	2.00	5.5	

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QEC\_ILMC0: Change from baseline in AQLQ+12 environmental stimuli score - MMRM results  
 DITTL

Change from baseline in AQLQ+12 environmental stimuli score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 4	Tezepelumab	395	381 (96.5)	0.86 (0.06)	(0.75, 0.97)	0.18 (0.08)	(0.02, 0.34)	0.028	*
	Placebo	391	376 (96.2)	0.68 (0.06)	(0.56, 0.79)				
Week 12	Tezepelumab	395	377 (95.4)	1.09 (0.06)	(0.97, 1.21)	0.19 (0.09)	(0.02, 0.36)	0.026	*
	Placebo	391	374 (95.7)	0.90 (0.06)	(0.78, 1.02)				
Week 24	Tezepelumab	395	365 (92.4)	1.25 (0.07)	(1.12, 1.38)	0.27 (0.10)	(0.09, 0.46)	0.004	*
	Placebo	391	353 (90.3)	0.98 (0.07)	(0.85, 1.11)				
Week 36	Tezepelumab	395	363 (91.9)	1.29 (0.07)	(1.15, 1.42)	0.27 (0.10)	(0.08, 0.46)	0.006	*
	Placebo	391	351 (89.8)	1.01 (0.07)	(0.88, 1.15)				
Week 52	Tezepelumab	395	354 (89.6)	1.36 (0.07)	(1.22, 1.49)	0.29 (0.10)	(0.10, 0.48)	0.003	*
	Placebo	391	340 (87.0)	1.07 (0.07)	(0.93, 1.20)				

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table PT3QEC\_ILMH0: Course of AQLQ+12 environmental stimuli score  
 DITTL

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 environmental stimuli Baseline score	Tezepelumab	66	58 (87.9)	3.99 (1.06)	1.8	3.25	4.00	4.75	6.8	
	Placebo	65	55 (84.6)	4.38 (1.22)	1.5	3.50	4.25	5.50	7.0	
Week 4	Tezepelumab	66	60 (90.9)	4.80 (1.12)	1.3	4.00	5.00	5.75	7.0	
	Placebo	65	57 (87.7)	4.84 (1.21)	2.0	4.25	5.00	5.50	7.0	
Week 8	Tezepelumab	66	62 (93.9)	5.15 (1.15)	1.0	4.25	5.38	6.00	7.0	
	Placebo	65	59 (90.8)	4.91 (1.29)	1.5	4.00	5.00	5.75	7.0	
Week 12	Tezepelumab	66	62 (93.9)	5.27 (1.14)	1.0	4.50	5.50	6.25	7.0	
	Placebo	65	59 (90.8)	4.92 (1.16)	2.0	4.00	5.00	5.75	7.0	
Week 16	Tezepelumab	66	62 (93.9)	5.16 (1.19)	1.0	4.50	5.25	6.00	7.0	
	Placebo	65	59 (90.8)	4.88 (1.38)	1.3	4.00	5.00	5.75	7.0	
Week 20	Tezepelumab	66	63 (95.5)	5.13 (1.24)	1.0	4.50	5.00	6.00	7.0	
	Placebo	65	59 (90.8)	4.84 (1.41)	1.3	4.00	5.00	5.75	7.0	
Week 24	Tezepelumab	66	63 (95.5)	5.23 (1.26)	1.0	4.50	5.00	6.25	7.0	
	Placebo	65	59 (90.8)	4.80 (1.50)	1.0	4.25	5.00	5.75	7.0	
Week 28	Tezepelumab	66	65 (98.5)	5.20 (1.25)	1.0	4.50	5.00	6.25	7.0	
	Placebo	65	60 (92.3)	5.00 (1.49)	1.3	4.13	5.25	6.00	7.0	
Week 32	Tezepelumab	66	65 (98.5)	5.28 (1.27)	1.0	4.50	5.25	6.00	7.0	
	Placebo	65	60 (92.3)	5.04 (1.47)	1.3	4.00	5.25	6.00	7.0	
Week 36	Tezepelumab	66	65 (98.5)	5.30 (1.23)	1.0	4.50	5.25	6.25	7.0	
	Placebo	65	60 (92.3)	4.87 (1.49)	1.0	4.00	5.00	6.00	7.0	
Week 40	Tezepelumab	66	65 (98.5)	5.32 (1.14)	2.0	4.50	5.25	6.00	7.0	
	Placebo	65	60 (92.3)	5.04 (1.48)	1.0	4.00	5.25	6.13	7.0	
Week 44	Tezepelumab	66	65 (98.5)	5.32 (1.19)	1.3	4.50	5.25	6.25	7.0	
	Placebo	65	60 (92.3)	5.03 (1.41)	1.3	4.00	5.13	6.13	7.0	
Week 48	Tezepelumab	66	65 (98.5)	5.35 (1.21)	1.0	4.50	5.25	6.25	7.0	
	Placebo	65	60 (92.3)	5.00 (1.37)	1.0	4.00	5.00	6.00	7.0	
Week 52	Tezepelumab	66	65 (98.5)	5.35 (1.20)	1.0	4.50	5.50	6.25	7.0	
	Placebo	65	60 (92.3)	5.07 (1.32)	1.8	4.25	5.00	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Last observation carried forward is applied in case of missing values.

Source Data: aqlq, created on: 22FEB2022

Table PT3QEC\_ILMH0: Course of AQLQ+12 environmental stimuli score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 environmental stimuli score	Week 4	Tezepelumab	66	55 (83.3)	0.83 (1.24)	-4.0	0.00	0.75	1.75	4.0	0.33 [-0.05, 0.71]
		Placebo	65	54 (83.1)	0.45 (1.04)	-2.0	-0.25	0.38	1.00	3.0	
	Week 8	Tezepelumab	66	57 (86.4)	1.14 (1.21)	-1.3	0.25	1.25	2.00	4.3	0.45 [0.08, 0.83]
		Placebo	65	55 (84.6)	0.60 (1.17)	-1.8	-0.25	0.50	1.25	3.3	
	Week 12	Tezepelumab	66	57 (86.4)	1.26 (1.17)	-2.3	0.50	1.25	2.25	4.8	0.62 [0.24, 1.00]
		Placebo	65	55 (84.6)	0.57 (1.05)	-1.8	-0.25	0.75	1.25	3.0	
	Week 16	Tezepelumab	66	57 (86.4)	1.17 (1.24)	-2.8	0.25	1.25	2.25	3.3	0.56 [0.18, 0.94]
		Placebo	65	55 (84.6)	0.53 (1.04)	-1.8	0.00	0.50	1.00	3.0	
	Week 20	Tezepelumab	66	57 (86.4)	1.15 (1.22)	-1.8	0.25	1.25	2.25	3.5	0.55 [0.18, 0.93]
		Placebo	65	55 (84.6)	0.51 (1.07)	-2.3	0.00	0.50	1.25	3.0	
	Week 24	Tezepelumab	66	57 (86.4)	1.26 (1.22)	-1.5	0.25	1.50	2.25	3.5	0.64 [0.26, 1.02]
		Placebo	65	55 (84.6)	0.48 (1.21)	-2.8	-0.25	0.50	1.25	3.8	
	Week 28	Tezepelumab	66	57 (86.4)	1.24 (1.24)	-1.5	0.25	1.50	2.25	3.3	0.46 [0.09, 0.84]
		Placebo	65	55 (84.6)	0.66 (1.27)	-2.8	0.00	0.75	1.25	3.8	
	Week 32	Tezepelumab	66	57 (86.4)	1.31 (1.27)	-1.3	0.25	1.50	2.25	3.5	0.51 [0.13, 0.88]
		Placebo	65	55 (84.6)	0.72 (1.07)	-1.8	0.00	0.75	1.25	3.8	
	Week 36	Tezepelumab	66	57 (86.4)	1.33 (1.25)	-1.3	0.25	1.50	2.25	3.5	0.65 [0.27, 1.03]
		Placebo	65	55 (84.6)	0.54 (1.20)	-2.8	0.00	0.25	1.25	3.8	
	Week 40	Tezepelumab	66	57 (86.4)	1.36 (1.16)	-1.3	0.25	1.50	2.25	3.3	0.56 [0.18, 0.94]
		Placebo	65	55 (84.6)	0.70 (1.22)	-2.5	0.00	0.75	1.25	3.8	
	Week 44	Tezepelumab	66	57 (86.4)	1.39 (1.24)	-1.5	0.50	1.50	2.25	3.8	0.56 [0.19, 0.94]
		Placebo	65	55 (84.6)	0.69 (1.22)	-1.5	0.00	0.50	1.25	3.8	
	Week 48	Tezepelumab	66	57 (86.4)	1.40 (1.25)	-1.3	0.50	1.50	2.25	3.8	0.58 [0.21, 0.96]
		Placebo	65	55 (84.6)	0.66 (1.30)	-2.8	0.00	0.50	1.25	3.8	
	Week 52	Tezepelumab	66	57 (86.4)	1.41 (1.22)	-1.3	0.50	1.50	2.25	3.8	0.56 [0.18, 0.94]
		Placebo	65	55 (84.6)	0.72 (1.23)	-1.3	0.00	0.50	1.25	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Last observation carried forward is applied in case of missing values.

Source Data: aqlq, created on: 22FEB2022

Table PT3QEC\_ILMC0: Change from baseline in AQLQ+12 environmental stimuli score - MMRM results  
 DITTTL

Change from baseline in AQLQ+12 environmental stimuli score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 4	Tezepelumab	66	55 (83.3)	NE		NE			
	Placebo	65	54 (83.1)						
Week 8	Tezepelumab	66	55 (83.3)	NE		NE			
	Placebo	65	55 (84.6)						
Week 12	Tezepelumab	66	54 (81.8)	NE		NE			
	Placebo	65	52 (80.0)						
Week 16	Tezepelumab	66	53 (80.3)	NE		NE			
	Placebo	65	50 (76.9)						
Week 20	Tezepelumab	66	51 (77.3)	NE		NE			
	Placebo	65	47 (72.3)						
Week 24	Tezepelumab	66	50 (75.8)	NE		NE			
	Placebo	65	45 (69.2)						
Week 28	Tezepelumab	66	47 (71.2)	NE		NE			
	Placebo	65	44 (67.7)						
Week 32	Tezepelumab	66	48 (72.7)	NE		NE			
	Placebo	65	43 (66.2)						
Week 36	Tezepelumab	66	49 (74.2)	NE		NE			
	Placebo	65	44 (67.7)						
Week 40	Tezepelumab	66	48 (72.7)	NE		NE			
	Placebo	65	45 (69.2)						

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 22FEB2022

Table PT3QEC\_ILMC0: Change from baseline in AQLQ+12 environmental stimuli score - MMRM results  
 DITTTL

Change from baseline in AQLQ+12 environmental stimuli score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 44	Tezepelumab	66	47 (71.2)	NE		NE		
	Placebo	65	44 (67.7)					
Week 48	Tezepelumab	66	46 (69.7)	NE		NE		
	Placebo	65	44 (67.7)					
Week 52	Tezepelumab	66	18 (27.3)	NE		NE		
	Placebo	65	16 (24.6)					

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 22FEB2022

Table ST1QEC\_ILMH0: Course of AQLQ+12 environmental stimuli score  
 DITTLL

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 environmental stimuli Baseline score	Tezepelumab	73	73 (100.0)	4.23 (1.37)	1.0	3.50	4.25	5.25	6.8	
	Placebo	76	74 (97.4)	4.34 (1.22)	1.3	3.75	4.50	5.25	7.0	
Week 4	Tezepelumab	73	71 (97.3)	4.69 (1.61)	1.0	3.50	4.75	6.00	7.0	
	Placebo	76	76 (100.0)	4.70 (1.31)	1.8	3.75	4.75	5.88	7.0	
Week 40	Tezepelumab	73	61 (83.6)	5.03 (1.66)	1.3	3.75	5.50	6.50	7.0	
	Placebo	76	68 (89.5)	4.81 (1.41)	1.0	4.00	5.00	5.75	7.0	
Week 44	Tezepelumab	73	64 (87.7)	5.05 (1.57)	1.0	4.00	5.13	6.50	7.0	
	Placebo	76	72 (94.7)	4.89 (1.44)	1.5	4.00	5.00	6.00	7.0	
Week 48	Tezepelumab	73	65 (89.0)	5.12 (1.65)	1.0	4.00	5.50	6.50	7.0	
	Placebo	76	68 (89.5)	4.75 (1.40)	1.5	3.88	4.75	6.00	7.0	

Note: DITTLL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 23FEB2022

Table ST1QEC\_ILMH0: Course of AQLQ+12 environmental stimuli score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 environmental stimuli score	Week 4	Tezepelumab	73	71 (97.3)	0.48 (1.11)	-3.3	-0.25	0.25	1.00	3.3	0.11 [-0.21, 0.44]
		Placebo	76	74 (97.4)	0.35 (1.18)	-2.8	-0.25	0.25	1.00	3.3	
	Week 40	Tezepelumab	73	61 (83.6)	0.86 (1.19)	-1.3	-0.25	0.75	1.50	3.3	0.31 [-0.04, 0.66]
		Placebo	76	66 (86.8)	0.45 (1.45)	-3.3	-0.50	0.38	1.25	5.5	
	Week 44	Tezepelumab	73	64 (87.7)	0.86 (1.25)	-2.3	0.00	0.75	1.75	4.0	0.27 [-0.07, 0.61]
		Placebo	76	70 (92.1)	0.48 (1.47)	-2.8	-0.50	0.50	1.25	5.5	
	Week 48	Tezepelumab	73	65 (89.0)	0.97 (1.16)	-1.5	0.00	0.75	1.75	3.5	0.45 [0.10, 0.79]
		Placebo	76	67 (88.2)	0.40 (1.38)	-2.8	-0.50	0.50	1.25	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 23FEB2022



Table ST1QEC\_ILMC0: Change from baseline in AQLQ+12 environmental stimuli score - MMRM results  
 DITTL

Change from baseline in AQLQ+12 environmental stimuli score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 4	Tezepelumab	73	71 (97.3)	0.46 (0.13)	(0.20, 0.72)	0.09 (0.18)	(-0.27, 0.46)	0.607
	Placebo	76	74 (97.4)	0.37 (0.13)	(0.11, 0.62)			
Week 40	Tezepelumab	73	61 (83.6)	0.79 (0.15)	(0.49, 1.10)	0.28 (0.21)	(-0.14, 0.71)	0.192
	Placebo	76	66 (86.8)	0.51 (0.15)	(0.21, 0.80)			
Week 44	Tezepelumab	73	64 (87.7)	0.78 (0.16)	(0.47, 1.09)	0.24 (0.22)	(-0.19, 0.67)	0.272
	Placebo	76	70 (92.1)	0.54 (0.15)	(0.24, 0.84)			
Week 48	Tezepelumab	73	65 (89.0)	0.93 (0.15)	(0.64, 1.22)	0.50 (0.21)	(0.09, 0.90)	0.017 *
	Placebo	76	67 (88.2)	0.43 (0.14)	(0.15, 0.71)			

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 23FEB2022

Table MT1QGC\_ILMH0: Course of AQLQ+12 emotional function score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 emotional function score	Baseline	Tezepelumab	446	437 (98.0)	3.70 (1.43)	1.0	2.60	3.80	4.60	7.0	
		Placebo	436	424 (97.2)	3.81 (1.40)	1.0	2.80	3.80	4.80	7.0	
	Week 4	Tezepelumab	446	428 (96.0)	4.72 (1.44)	1.0	3.80	4.80	5.80	7.0	
		Placebo	436	415 (95.2)	4.57 (1.51)	1.0	3.60	4.60	5.80	7.0	
	Week 12	Tezepelumab	446	426 (95.5)	5.05 (1.51)	1.0	4.20	5.40	6.20	7.0	
		Placebo	436	414 (95.0)	4.89 (1.52)	1.0	4.00	5.20	6.20	7.0	
	Week 24	Tezepelumab	446	415 (93.0)	5.21 (1.51)	1.0	4.20	5.60	6.40	7.0	
		Placebo	436	396 (90.8)	4.90 (1.54)	1.0	4.00	5.20	6.00	7.0	
	Week 36	Tezepelumab	446	415 (93.0)	5.28 (1.53)	1.0	4.20	5.80	6.60	7.0	
		Placebo	436	394 (90.4)	4.98 (1.49)	1.0	4.00	5.20	6.00	7.0	
	Week 52	Tezepelumab	446	407 (91.3)	5.31 (1.47)	1.0	4.40	5.60	6.60	7.0	
		Placebo	436	381 (87.4)	5.02 (1.45)	1.0	4.20	5.20	6.20	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Last observation carried forward is applied in case of missing values.

Source Data: aqlq, created on: 22FEB2022

Table MT1QGC\_ILMH0: Course of AQLQ+12 emotional function score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 emotional function score	Week 4	Tezepelumab	446	422 (94.6)	1.01 (1.38)	-4.2	0.00	0.80	1.80	5.2	0.19 [0.06, 0.33]
		Placebo	436	412 (94.5)	0.76 (1.21)	-3.0	0.00	0.60	1.40	4.8	
	Week 12	Tezepelumab	446	421 (94.4)	1.33 (1.48)	-3.4	0.20	1.20	2.40	5.2	0.18 [0.05, 0.32]
		Placebo	436	409 (93.8)	1.06 (1.43)	-2.6	0.00	1.00	1.80	6.0	
	Week 24	Tezepelumab	446	409 (91.7)	1.48 (1.62)	-5.2	0.40	1.40	2.60	5.6	0.26 [0.13, 0.40]
		Placebo	436	391 (89.7)	1.07 (1.44)	-3.4	0.00	1.00	2.00	6.0	
	Week 36	Tezepelumab	446	407 (91.3)	1.54 (1.62)	-3.4	0.40	1.40	2.80	5.4	0.27 [0.13, 0.41]
		Placebo	436	388 (89.0)	1.12 (1.43)	-5.0	0.20	1.00	2.00	6.0	
	Week 52	Tezepelumab	446	399 (89.5)	1.58 (1.57)	-3.0	0.40	1.40	2.60	5.6	0.27 [0.13, 0.41]
		Placebo	436	375 (86.0)	1.17 (1.50)	-2.8	0.00	1.00	2.00	6.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Last observation carried forward is applied in case of missing values.

Source Data: aqlq, created on: 22FEB2022

Table MT1QGC\_ILMC0: Change from baseline in AQLQ+12 emotional function score - MMRM results  
 DITTTL

Change from baseline in AQLQ+12 emotional function score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	446	422 (94.6)	0.98 (0.06)	(0.86, 1.09)	0.19 (0.08)	(0.03, 0.35)	0.023 *
	Placebo	436	412 (94.5)	0.79 (0.06)	(0.68, 0.91)			
Week 12	Tezepelumab	446	418 (93.7)	1.32 (0.06)	(1.19, 1.44)	0.23 (0.09)	(0.06, 0.41)	0.010 *
	Placebo	436	406 (93.1)	1.08 (0.06)	(0.96, 1.21)			
Week 24	Tezepelumab	446	402 (90.1)	1.45 (0.07)	(1.32, 1.58)	0.35 (0.09)	(0.17, 0.54)	<0.001 *
	Placebo	436	381 (87.4)	1.09 (0.07)	(0.96, 1.23)			
Week 36	Tezepelumab	446	399 (89.5)	1.51 (0.07)	(1.38, 1.64)	0.37 (0.10)	(0.18, 0.56)	<0.001 *
	Placebo	436	377 (86.5)	1.14 (0.07)	(1.01, 1.27)			
Week 52	Tezepelumab	446	360 (80.7)	1.57 (0.07)	(1.43, 1.70)	0.36 (0.10)	(0.17, 0.55)	<0.001 *
	Placebo	436	336 (77.1)	1.21 (0.07)	(1.07, 1.35)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 22FEB2022

Table NT1QGC\_ILMH0: Course of AQLQ+12 emotional function score  
 DITTTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 emotional function score	Baseline	Tezepelumab	395	394 (99.7)	3.62 (1.45)	1.0	2.40	3.60	4.60	7.0	
		Placebo	391	389 (99.5)	3.75 (1.41)	1.0	2.80	3.80	4.80	7.0	
	Week 4	Tezepelumab	395	382 (96.7)	4.70 (1.49)	1.0	3.60	4.80	6.00	7.0	
		Placebo	391	376 (96.2)	4.56 (1.54)	1.0	3.60	4.60	5.80	7.0	
	Week 12	Tezepelumab	395	377 (95.4)	5.00 (1.55)	1.0	4.00	5.20	6.20	7.0	
		Placebo	391	375 (95.9)	4.88 (1.56)	1.0	3.80	5.20	6.20	7.0	
	Week 24	Tezepelumab	395	365 (92.4)	5.20 (1.54)	1.0	4.20	5.60	6.40	7.0	
		Placebo	391	354 (90.5)	4.91 (1.56)	1.0	3.80	5.20	6.20	7.0	
	Week 36	Tezepelumab	395	363 (91.9)	5.25 (1.57)	1.0	4.20	5.80	6.60	7.0	
		Placebo	391	352 (90.0)	5.00 (1.53)	1.0	4.00	5.20	6.20	7.0	
	Week 52	Tezepelumab	395	354 (89.6)	5.29 (1.52)	1.0	4.20	5.60	6.60	7.0	
		Placebo	391	341 (87.2)	5.06 (1.45)	1.0	4.20	5.20	6.20	7.0	

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QGC\_ILMH0: Course of AQLQ+12 emotional function score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 emotional function score	Week 4	Tezepelumab	395	381 (96.5)	1.06 (1.39)	-2.8	0.00	0.80	2.00	5.2	0.18 [0.04, 0.32]
		Placebo	391	376 (96.2)	0.82 (1.25)	-3.0	0.00	0.80	1.60	4.8	
	Week 12	Tezepelumab	395	377 (95.4)	1.37 (1.53)	-3.4	0.20	1.20	2.40	5.2	0.17 [0.03, 0.31]
		Placebo	391	374 (95.7)	1.11 (1.48)	-2.6	0.00	1.00	2.00	6.0	
	Week 24	Tezepelumab	395	365 (92.4)	1.55 (1.66)	-5.2	0.40	1.40	2.60	5.6	0.26 [0.12, 0.41]
		Placebo	391	353 (90.3)	1.14 (1.45)	-2.6	0.20	1.20	2.00	6.0	
	Week 36	Tezepelumab	395	363 (91.9)	1.60 (1.66)	-3.4	0.40	1.40	2.80	5.4	0.25 [0.10, 0.40]
		Placebo	391	351 (89.8)	1.20 (1.50)	-5.0	0.20	1.00	2.00	6.0	
	Week 52	Tezepelumab	395	354 (89.6)	1.65 (1.63)	-3.0	0.40	1.60	2.80	5.6	0.25 [0.10, 0.40]
		Placebo	391	340 (87.0)	1.26 (1.51)	-2.8	0.20	1.00	2.10	6.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QGC\_ILMC0: Change from baseline in AQLQ+12 emotional function score - MMRM results  
 DITTTL

Change from baseline in AQLQ+12 emotional function score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	395	381 (96.5)	1.02 (0.06)	(0.90, 1.14)	0.17 (0.09)	(-0.00, 0.34)	0.052
	Placebo	391	376 (96.2)	0.85 (0.06)	(0.73, 0.97)			
Week 12	Tezepelumab	395	377 (95.4)	1.34 (0.07)	(1.20, 1.47)	0.21 (0.10)	(0.02, 0.41)	0.031 *
	Placebo	391	374 (95.7)	1.13 (0.07)	(0.99, 1.26)			
Week 24	Tezepelumab	395	365 (92.4)	1.51 (0.07)	(1.37, 1.65)	0.36 (0.10)	(0.16, 0.55)	<0.001 *
	Placebo	391	353 (90.3)	1.15 (0.07)	(1.01, 1.30)			
Week 36	Tezepelumab	395	363 (91.9)	1.55 (0.07)	(1.41, 1.69)	0.34 (0.10)	(0.13, 0.54)	0.001 *
	Placebo	391	351 (89.8)	1.21 (0.07)	(1.07, 1.36)			
Week 52	Tezepelumab	395	354 (89.6)	1.62 (0.07)	(1.48, 1.76)	0.34 (0.10)	(0.14, 0.53)	<0.001 *
	Placebo	391	340 (87.0)	1.28 (0.07)	(1.14, 1.42)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table PT3QGC\_ILMH0: Course of AQLQ+12 emotional function score  
 DITTTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 emotional function score	Baseline	Tezepelumab	66	58 (87.9)	4.26 (1.16)	1.4	3.60	4.20	5.00	6.4	
		Placebo	65	55 (84.6)	4.39 (1.16)	1.0	3.80	4.20	5.20	7.0	
	Week 4	Tezepelumab	66	60 (90.9)	4.88 (1.17)	1.2	4.00	4.80	5.90	7.0	
		Placebo	65	57 (87.7)	4.90 (1.29)	1.6	4.20	4.80	5.80	7.0	
	Week 8	Tezepelumab	66	62 (93.9)	5.16 (1.20)	2.8	4.20	5.10	6.20	7.0	
		Placebo	65	59 (90.8)	4.97 (1.15)	2.0	4.20	5.00	5.80	7.0	
	Week 12	Tezepelumab	66	62 (93.9)	5.37 (1.17)	2.8	4.40	5.40	6.40	7.0	
		Placebo	65	59 (90.8)	5.11 (1.22)	1.8	4.20	5.20	6.20	7.0	
	Week 16	Tezepelumab	66	62 (93.9)	5.31 (1.21)	2.6	4.40	5.60	6.20	7.0	
		Placebo	65	59 (90.8)	5.08 (1.29)	1.0	4.40	5.00	6.00	7.0	
	Week 20	Tezepelumab	66	63 (95.5)	5.38 (1.16)	2.4	4.40	5.60	6.40	7.0	
		Placebo	65	59 (90.8)	5.03 (1.25)	1.0	4.20	5.00	6.00	7.0	
	Week 24	Tezepelumab	66	63 (95.5)	5.28 (1.23)	2.0	4.20	5.40	6.40	7.0	
		Placebo	65	59 (90.8)	4.99 (1.29)	1.0	4.40	5.00	6.00	7.0	
	Week 28	Tezepelumab	66	65 (98.5)	5.37 (1.12)	2.8	4.40	5.40	6.40	7.0	
		Placebo	65	60 (92.3)	5.08 (1.33)	1.0	4.20	5.20	6.00	7.0	
	Week 32	Tezepelumab	66	65 (98.5)	5.35 (1.17)	2.6	4.40	5.60	6.40	7.0	
		Placebo	65	60 (92.3)	5.09 (1.33)	1.0	4.10	5.20	6.00	7.0	
	Week 36	Tezepelumab	66	65 (98.5)	5.49 (1.22)	2.8	4.60	5.60	6.60	7.0	
		Placebo	65	60 (92.3)	5.06 (1.28)	1.6	4.40	5.00	6.00	7.0	
	Week 40	Tezepelumab	66	65 (98.5)	5.29 (1.30)	1.8	4.20	5.40	6.40	7.0	
		Placebo	65	60 (92.3)	5.09 (1.30)	1.6	4.30	5.00	6.30	7.0	
	Week 44	Tezepelumab	66	65 (98.5)	5.41 (1.16)	2.8	4.40	5.40	6.40	7.0	
		Placebo	65	60 (92.3)	5.07 (1.32)	1.8	4.00	5.10	6.20	7.0	
	Week 48	Tezepelumab	66	65 (98.5)	5.40 (1.17)	2.6	4.60	5.40	6.40	7.0	
		Placebo	65	60 (92.3)	5.06 (1.32)	1.4	4.00	5.00	6.10	7.0	
	Week 52	Tezepelumab	66	65 (98.5)	5.42 (1.17)	2.6	4.60	5.40	6.40	7.0	
		Placebo	65	60 (92.3)	5.03 (1.35)	2.0	4.00	4.80	6.10	7.0	

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Last observation carried forward is applied in case of missing values.

Source Data: aqlq, created on: 22FEB2022



Table PT3QGC\_ILMH0: Course of AQLQ+12 emotional function score  
 DITTTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 emotional function score	Week 4	Tezepelumab	66	55 (83.3)	0.62 (1.34)	-4.2	-0.20	0.60	1.60	3.8	0.08 [-0.30, 0.45]
		Placebo	65	54 (83.1)	0.53 (1.04)	-2.2	0.00	0.40	1.20	3.0	
	Week 8	Tezepelumab	66	57 (86.4)	0.84 (1.31)	-2.2	-0.20	1.00	1.60	4.4	0.17 [-0.20, 0.55]
		Placebo	65	55 (84.6)	0.62 (1.17)	-1.6	0.00	0.60	1.20	4.0	
	Week 12	Tezepelumab	66	57 (86.4)	1.05 (1.24)	-2.4	0.20	1.00	1.80	3.8	0.25 [-0.12, 0.62]
		Placebo	65	55 (84.6)	0.74 (1.24)	-1.8	0.00	0.80	1.60	4.4	
	Week 16	Tezepelumab	66	57 (86.4)	0.99 (1.26)	-2.8	0.20	1.00	1.80	4.0	0.21 [-0.16, 0.58]
		Placebo	65	55 (84.6)	0.72 (1.31)	-3.4	0.20	0.60	1.40	4.4	
	Week 20	Tezepelumab	66	57 (86.4)	1.14 (1.19)	-1.4	0.40	1.20	2.00	4.6	0.38 [0.00, 0.75]
		Placebo	65	55 (84.6)	0.68 (1.25)	-3.4	0.00	0.80	1.60	4.2	
	Week 24	Tezepelumab	66	57 (86.4)	1.02 (1.29)	-1.4	0.00	1.00	1.80	4.6	0.29 [-0.08, 0.66]
		Placebo	65	55 (84.6)	0.64 (1.30)	-3.4	0.00	0.40	1.60	4.2	
	Week 28	Tezepelumab	66	57 (86.4)	1.07 (1.24)	-1.4	0.00	0.80	1.80	4.6	0.26 [-0.11, 0.64]
		Placebo	65	55 (84.6)	0.72 (1.42)	-3.4	0.00	0.80	1.60	4.4	
	Week 32	Tezepelumab	66	57 (86.4)	1.04 (1.29)	-1.6	0.20	1.00	2.00	4.6	0.24 [-0.13, 0.62]
		Placebo	65	55 (84.6)	0.73 (1.26)	-3.4	-0.20	0.80	1.40	4.2	
	Week 36	Tezepelumab	66	57 (86.4)	1.22 (1.39)	-1.6	0.40	1.20	2.00	4.6	0.44 [0.06, 0.81]
		Placebo	65	55 (84.6)	0.67 (1.11)	-2.0	0.00	0.60	1.40	3.8	
	Week 40	Tezepelumab	66	57 (86.4)	1.03 (1.37)	-2.4	0.00	1.00	2.00	4.6	0.22 [-0.15, 0.60]
		Placebo	65	55 (84.6)	0.73 (1.27)	-2.0	-0.40	0.80	1.60	3.6	
	Week 44	Tezepelumab	66	57 (86.4)	1.10 (1.30)	-1.4	0.00	1.20	1.60	4.6	0.32 [-0.05, 0.70]
		Placebo	65	55 (84.6)	0.68 (1.26)	-1.8	-0.40	0.60	1.20	4.2	
	Week 48	Tezepelumab	66	57 (86.4)	1.11 (1.29)	-1.4	0.20	1.20	1.80	4.6	0.33 [-0.05, 0.70]
		Placebo	65	55 (84.6)	0.70 (1.23)	-2.2	-0.20	0.60	1.40	4.2	
	Week 52	Tezepelumab	66	57 (86.4)	1.12 (1.31)	-1.6	0.20	1.20	1.80	4.6	0.34 [-0.03, 0.71]
		Placebo	65	55 (84.6)	0.67 (1.34)	-2.6	-0.20	0.60	1.40	4.4	

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.  
 Last observation carried forward is applied in case of missing values.

Source Data: aqlq, created on: 22FEB2022

Table PT3QGC\_ILMC0: Change from baseline in AQLQ+12 emotional function score - MMRM results  
 DITTTL

Change from baseline in AQLQ+12 emotional function score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 4	Tezepelumab	66	55 (83.3)	NE		NE			
	Placebo	65	54 (83.1)						
Week 8	Tezepelumab	66	55 (83.3)	NE		NE			
	Placebo	65	55 (84.6)						
Week 12	Tezepelumab	66	54 (81.8)	NE		NE			
	Placebo	65	52 (80.0)						
Week 16	Tezepelumab	66	53 (80.3)	NE		NE			
	Placebo	65	50 (76.9)						
Week 20	Tezepelumab	66	51 (77.3)	NE		NE			
	Placebo	65	47 (72.3)						
Week 24	Tezepelumab	66	50 (75.8)	NE		NE			
	Placebo	65	45 (69.2)						
Week 28	Tezepelumab	66	47 (71.2)	NE		NE			
	Placebo	65	44 (67.7)						
Week 32	Tezepelumab	66	48 (72.7)	NE		NE			
	Placebo	65	43 (66.2)						
Week 36	Tezepelumab	66	49 (74.2)	NE		NE			
	Placebo	65	44 (67.7)						
Week 40	Tezepelumab	66	48 (72.7)	NE		NE			
	Placebo	65	45 (69.2)						

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 22FEB2022

Table PT3QGC\_ILMC0: Change from baseline in AQLQ+12 emotional function score - MMRM results  
 DITTTL

Change from baseline in AQLQ+12 emotional function score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 44	Tezepelumab	66	47 (71.2)	NE		NE		
	Placebo	65	44 (67.7)					
Week 48	Tezepelumab	66	46 (69.7)	NE		NE		
	Placebo	65	44 (67.7)					
Week 52	Tezepelumab	66	18 (27.3)	NE		NE		
	Placebo	65	16 (24.6)					

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 22FEB2022

Table ST1QGC\_ILMH0: Course of AQLQ+12 emotional function score  
 DITTTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 emotional function score	Baseline	Tezepelumab	73	73 (100.0)	4.14 (1.55)	1.0	3.00	4.20	5.20	7.0	
		Placebo	76	74 (97.4)	4.04 (1.38)	1.0	3.20	4.20	4.80	6.6	
	Week 4	Tezepelumab	73	71 (97.3)	4.73 (1.63)	1.0	3.60	4.60	6.20	7.0	
		Placebo	76	76 (100.0)	4.59 (1.34)	1.0	3.70	4.80	5.40	7.0	
	Week 40	Tezepelumab	73	61 (83.6)	5.44 (1.62)	1.0	4.60	6.00	6.80	7.0	
		Placebo	76	68 (89.5)	4.88 (1.48)	1.6	3.80	5.00	6.10	7.0	
	Week 44	Tezepelumab	73	64 (87.7)	5.27 (1.45)	1.6	4.20	5.70	6.40	7.0	
		Placebo	76	72 (94.7)	4.86 (1.54)	1.0	3.90	5.00	6.00	7.0	
	Week 48	Tezepelumab	73	65 (89.0)	5.10 (1.70)	1.0	4.00	5.80	6.40	7.0	
		Placebo	76	68 (89.5)	4.79 (1.53)	1.0	3.90	5.00	6.00	7.0	

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 23FEB2022

Table ST1QGC\_ILMH0: Course of AQLQ+12 emotional function score  
 DITTTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 emotional function score	Week 4	Tezepelumab	73	71 (97.3)	0.61 (1.28)	-3.2	0.00	0.40	1.40	3.6	0.04 [-0.29, 0.36]
		Placebo	76	74 (97.4)	0.56 (1.04)	-2.2	0.00	0.30	1.00	3.2	
	Week 40	Tezepelumab	73	61 (83.6)	1.26 (1.45)	-1.0	0.00	1.00	2.20	4.6	0.28 [-0.07, 0.63]
		Placebo	76	66 (86.8)	0.85 (1.49)	-2.0	-0.40	0.60	1.60	5.2	
	Week 44	Tezepelumab	73	64 (87.7)	1.09 (1.40)	-2.0	0.20	1.10	2.00	3.8	0.24 [-0.10, 0.58]
		Placebo	76	70 (92.1)	0.74 (1.58)	-3.2	-0.20	0.60	1.60	5.2	
	Week 48	Tezepelumab	73	65 (89.0)	0.98 (1.34)	-2.0	0.00	0.80	2.00	3.8	0.19 [-0.15, 0.53]
		Placebo	76	67 (88.2)	0.73 (1.29)	-2.2	-0.20	0.60	1.40	4.4	

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 23FEB2022

Table ST1QGC\_ILMC0: Change from baseline in AQLQ+12 emotional function score - MMRM results  
 DITTLL

Change from baseline in AQLQ+12 emotional function score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	73	71 (97.3)	0.61 (0.13)	(0.36, 0.86)	0.07 (0.18)	(-0.28, 0.42)	0.698
	Placebo	76	74 (97.4)	0.54 (0.13)	(0.29, 0.79)			
Week 40	Tezepelumab	73	61 (83.6)	1.23 (0.16)	(0.91, 1.55)	0.38 (0.22)	(-0.06, 0.82)	0.092
	Placebo	76	66 (86.8)	0.85 (0.16)	(0.54, 1.16)			
Week 44	Tezepelumab	73	64 (87.7)	1.04 (0.16)	(0.72, 1.36)	0.27 (0.23)	(-0.17, 0.72)	0.229
	Placebo	76	70 (92.1)	0.77 (0.16)	(0.45, 1.08)			
Week 48	Tezepelumab	73	65 (89.0)	0.96 (0.15)	(0.67, 1.26)	0.29 (0.21)	(-0.13, 0.71)	0.178
	Placebo	76	67 (88.2)	0.68 (0.15)	(0.39, 0.97)			

Note: DITTLL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 23FEB2022

Table MT1QMC\_ILMH0: Course of AQLQ+12 symptom score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 symptom score	Baseline	Tezepelumab	446	437 (98.0)	3.67 (1.09)	1.0	2.92	3.75	4.42	6.7	
		Placebo	436	424 (97.2)	3.79 (1.05)	1.1	3.08	3.83	4.50	6.7	
	Week 4	Tezepelumab	446	428 (96.0)	4.75 (1.18)	1.2	3.92	4.75	5.75	7.0	
		Placebo	436	415 (95.2)	4.53 (1.19)	1.0	3.83	4.50	5.33	7.0	
	Week 12	Tezepelumab	446	426 (95.5)	5.08 (1.25)	1.2	4.25	5.33	6.00	7.0	
		Placebo	436	414 (95.0)	4.83 (1.22)	1.0	4.08	4.92	5.75	7.0	
	Week 24	Tezepelumab	446	415 (93.0)	5.21 (1.24)	1.1	4.25	5.42	6.17	7.0	
		Placebo	436	396 (90.8)	4.87 (1.29)	1.0	3.92	5.04	5.92	7.0	
	Week 36	Tezepelumab	446	415 (93.0)	5.25 (1.29)	1.6	4.25	5.50	6.25	7.0	
		Placebo	436	394 (90.4)	4.92 (1.27)	1.0	4.08	5.00	5.92	7.0	
	Week 52	Tezepelumab	446	407 (91.3)	5.35 (1.26)	1.4	4.42	5.50	6.42	7.0	
		Placebo	436	381 (87.4)	5.00 (1.27)	1.0	4.17	5.08	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Last observation carried forward is applied in case of missing values.

Source Data: aqlq, created on: 22FEB2022

Table MT1QMC\_ILMH0: Course of AQLQ+12 symptom score  
 DITTTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 symptom score	Week 4	Tezepelumab	446	422 (94.6)	1.07 (1.22)	-4.3	0.17	1.00	1.75	5.1	0.29 [0.15, 0.43]
		Placebo	436	412 (94.5)	0.74 (1.01)	-2.9	0.17	0.67	1.25	4.6	
	Week 12	Tezepelumab	446	421 (94.4)	1.39 (1.35)	-2.6	0.33	1.25	2.25	5.6	0.29 [0.15, 0.42]
		Placebo	436	409 (93.8)	1.03 (1.18)	-2.8	0.33	0.92	1.67	5.6	
	Week 24	Tezepelumab	446	409 (91.7)	1.52 (1.42)	-4.3	0.50	1.42	2.50	5.6	0.34 [0.20, 0.48]
		Placebo	436	391 (89.7)	1.06 (1.24)	-3.5	0.25	1.00	1.83	5.8	
	Week 36	Tezepelumab	446	407 (91.3)	1.55 (1.40)	-2.8	0.50	1.42	2.58	5.7	0.34 [0.20, 0.48]
		Placebo	436	388 (89.0)	1.09 (1.27)	-3.0	0.25	1.00	1.92	5.8	
	Week 52	Tezepelumab	446	399 (89.5)	1.65 (1.37)	-2.9	0.75	1.58	2.58	5.6	0.37 [0.22, 0.51]
		Placebo	436	375 (86.0)	1.16 (1.27)	-3.0	0.25	1.08	2.08	4.9	

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Last observation carried forward is applied in case of missing values.

Source Data: aqlq, created on: 22FEB2022



Table MT1QMC\_ILMC0: Change from baseline in AQLQ+12 symptom score - MMRM results  
 DITTTL

Change from baseline in AQLQ+12 symptom score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	446	422 (94.6)	1.04 (0.05)	(0.94, 1.14)	0.27 (0.07)	(0.13, 0.41)	<0.001 *
	Placebo	436	412 (94.5)	0.77 (0.05)	(0.67, 0.87)			
Week 12	Tezepelumab	446	418 (93.7)	1.37 (0.06)	(1.26, 1.48)	0.33 (0.08)	(0.17, 0.48)	<0.001 *
	Placebo	436	406 (93.1)	1.04 (0.06)	(0.93, 1.15)			
Week 24	Tezepelumab	446	402 (90.1)	1.48 (0.06)	(1.37, 1.60)	0.40 (0.08)	(0.23, 0.56)	<0.001 *
	Placebo	436	381 (87.4)	1.09 (0.06)	(0.97, 1.20)			
Week 36	Tezepelumab	446	399 (89.5)	1.52 (0.06)	(1.41, 1.64)	0.41 (0.09)	(0.24, 0.58)	<0.001 *
	Placebo	436	377 (86.5)	1.11 (0.06)	(0.99, 1.23)			
Week 52	Tezepelumab	446	360 (80.7)	1.64 (0.06)	(1.52, 1.76)	0.44 (0.09)	(0.27, 0.61)	<0.001 *
	Placebo	436	336 (77.1)	1.20 (0.06)	(1.07, 1.32)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 22FEB2022

Table NT1QMC\_ILMH0: Course of AQLQ+12 symptom score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 symptom score	Baseline	Tezepelumab	395	394 (99.7)	3.64 (1.09)	1.0	2.92	3.75	4.33	6.3	
		Placebo	391	389 (99.5)	3.76 (1.07)	1.1	3.00	3.83	4.50	6.7	
	Week 4	Tezepelumab	395	382 (96.7)	4.77 (1.19)	1.2	4.00	4.79	5.83	7.0	
		Placebo	391	376 (96.2)	4.54 (1.23)	1.0	3.83	4.54	5.42	7.0	
	Week 12	Tezepelumab	395	377 (95.4)	5.08 (1.27)	1.2	4.33	5.33	6.00	7.0	
		Placebo	391	375 (95.9)	4.86 (1.26)	1.0	4.08	4.92	5.83	7.0	
	Week 24	Tezepelumab	395	365 (92.4)	5.24 (1.25)	1.1	4.25	5.50	6.25	7.0	
		Placebo	391	354 (90.5)	4.90 (1.31)	1.0	4.00	5.08	5.92	7.0	
	Week 36	Tezepelumab	395	363 (91.9)	5.26 (1.31)	1.6	4.33	5.58	6.33	7.0	
		Placebo	391	352 (90.0)	4.96 (1.30)	1.0	4.08	5.00	6.00	7.0	
	Week 52	Tezepelumab	395	354 (89.6)	5.38 (1.28)	1.4	4.50	5.63	6.42	7.0	
		Placebo	391	341 (87.2)	5.03 (1.29)	1.0	4.17	5.17	6.08	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QMC\_ILMH0: Course of AQLQ+12 symptom score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 symptom score	Week 4	Tezepelumab	395	381 (96.5)	1.12 (1.21)	-2.2	0.25	1.00	1.75	5.1	0.28 [0.14, 0.43]
		Placebo	391	376 (96.2)	0.80 (1.03)	-2.9	0.17	0.75	1.33	4.6	
	Week 12	Tezepelumab	395	377 (95.4)	1.42 (1.37)	-2.3	0.33	1.25	2.33	5.6	0.26 [0.12, 0.41]
		Placebo	391	374 (95.7)	1.09 (1.18)	-2.5	0.33	1.00	1.75	5.6	
	Week 24	Tezepelumab	395	365 (92.4)	1.57 (1.45)	-4.3	0.58	1.50	2.58	5.6	0.34 [0.20, 0.49]
		Placebo	391	353 (90.3)	1.11 (1.22)	-2.8	0.33	1.00	1.83	5.8	
	Week 36	Tezepelumab	395	363 (91.9)	1.60 (1.43)	-2.8	0.58	1.50	2.58	5.7	0.32 [0.18, 0.47]
		Placebo	391	351 (89.8)	1.16 (1.31)	-3.6	0.25	1.00	2.00	5.8	
	Week 52	Tezepelumab	395	354 (89.6)	1.72 (1.39)	-2.9	0.83	1.67	2.67	5.6	0.36 [0.21, 0.51]
		Placebo	391	340 (87.0)	1.23 (1.29)	-1.7	0.33	1.08	2.08	4.9	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QMC\_ILMC0: Change from baseline in AQLQ+12 symptom score - MMRM results  
 DITTL

Change from baseline in AQLQ+12 symptom score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	395	381 (96.5)	1.09 (0.05)	(0.98, 1.19)	0.27 (0.07)	(0.12, 0.41)	<0.001 *
	Placebo	391	376 (96.2)	0.82 (0.05)	(0.71, 0.92)			
Week 12	Tezepelumab	395	377 (95.4)	1.40 (0.06)	(1.28, 1.51)	0.30 (0.08)	(0.14, 0.47)	<0.001 *
	Placebo	391	374 (95.7)	1.10 (0.06)	(0.98, 1.21)			
Week 24	Tezepelumab	395	365 (92.4)	1.52 (0.06)	(1.40, 1.64)	0.40 (0.09)	(0.23, 0.58)	<0.001 *
	Placebo	391	353 (90.3)	1.12 (0.06)	(1.00, 1.24)			
Week 36	Tezepelumab	395	363 (91.9)	1.56 (0.06)	(1.43, 1.69)	0.40 (0.09)	(0.22, 0.58)	<0.001 *
	Placebo	391	351 (89.8)	1.16 (0.06)	(1.03, 1.28)			
Week 52	Tezepelumab	395	354 (89.6)	1.68 (0.06)	(1.55, 1.80)	0.43 (0.09)	(0.26, 0.61)	<0.001 *
	Placebo	391	340 (87.0)	1.24 (0.06)	(1.12, 1.37)			

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table PT3QMC\_ILMH0: Course of AQLQ+12 symptom score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 symptom score	Baseline	Tezepelumab	66	58 (87.9)	3.98 (1.01)	1.4	3.42	4.04	4.67	6.7	
		Placebo	65	55 (84.6)	4.12 (0.88)	1.5	3.67	4.25	4.58	6.3	
	Week 4	Tezepelumab	66	60 (90.9)	4.74 (1.11)	1.3	3.92	4.75	5.58	6.8	
		Placebo	65	57 (87.7)	4.71 (0.92)	2.7	4.17	4.67	5.25	6.7	
	Week 8	Tezepelumab	66	62 (93.9)	5.00 (1.16)	2.0	4.08	4.96	5.83	6.8	
		Placebo	65	59 (90.8)	4.74 (1.08)	1.9	4.17	4.67	5.42	7.0	
	Week 12	Tezepelumab	66	62 (93.9)	5.21 (1.08)	3.0	4.33	5.21	6.17	7.0	
		Placebo	65	59 (90.8)	4.88 (1.06)	2.1	4.17	4.83	5.58	7.0	
	Week 16	Tezepelumab	66	62 (93.9)	5.22 (1.11)	2.7	4.33	5.29	6.08	7.0	
		Placebo	65	59 (90.8)	4.86 (1.23)	1.3	4.08	4.75	5.83	7.0	
	Week 20	Tezepelumab	66	63 (95.5)	5.16 (1.10)	2.3	4.25	5.00	6.00	7.0	
		Placebo	65	59 (90.8)	4.76 (1.22)	1.3	4.00	4.75	5.58	7.0	
	Week 24	Tezepelumab	66	63 (95.5)	5.19 (1.08)	3.1	4.33	5.17	6.08	7.0	
		Placebo	65	59 (90.8)	4.74 (1.23)	1.3	3.83	4.67	5.75	7.0	
	Week 28	Tezepelumab	66	65 (98.5)	5.14 (1.11)	3.2	4.17	5.00	6.08	7.0	
		Placebo	65	60 (92.3)	4.84 (1.30)	1.3	3.96	4.88	5.75	7.0	
	Week 32	Tezepelumab	66	65 (98.5)	5.22 (1.12)	2.8	4.33	5.08	6.08	7.0	
		Placebo	65	60 (92.3)	4.90 (1.17)	1.3	4.04	4.92	5.75	7.0	
	Week 36	Tezepelumab	66	65 (98.5)	5.27 (1.13)	2.9	4.33	5.25	6.17	7.0	
		Placebo	65	60 (92.3)	4.81 (1.18)	2.4	4.00	4.71	5.83	7.0	
	Week 40	Tezepelumab	66	65 (98.5)	5.21 (1.16)	2.3	4.33	5.08	6.08	7.0	
		Placebo	65	60 (92.3)	4.91 (1.19)	2.3	4.00	4.96	5.92	7.0	
	Week 44	Tezepelumab	66	65 (98.5)	5.22 (1.10)	3.0	4.33	5.08	6.08	7.0	
		Placebo	65	60 (92.3)	4.90 (1.15)	2.5	4.04	4.79	5.88	7.0	
	Week 48	Tezepelumab	66	65 (98.5)	5.25 (1.14)	2.8	4.33	5.17	6.17	7.0	
		Placebo	65	60 (92.3)	4.93 (1.15)	2.2	4.08	4.79	5.83	7.0	
	Week 52	Tezepelumab	66	65 (98.5)	5.25 (1.14)	2.8	4.33	5.17	6.17	7.0	
		Placebo	65	60 (92.3)	4.99 (1.12)	2.8	4.17	4.79	5.92	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Last observation carried forward is applied in case of missing values.

Source Data: aqlq, created on: 22FEB2022

Table PT3QMC\_ILMH0: Course of AQLQ+12 symptom score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 symptom score	Week 4	Tezepelumab	66	55 (83.3)	0.78 (1.10)	-4.3	0.08	0.92	1.50	3.1	0.17 [-0.21, 0.54]
		Placebo	65	54 (83.1)	0.61 (0.88)	-1.3	0.17	0.50	0.92	3.3	
	Week 8	Tezepelumab	66	57 (86.4)	0.95 (1.11)	-1.9	0.25	1.00	1.83	3.3	0.27 [-0.11, 0.64]
		Placebo	65	55 (84.6)	0.67 (1.03)	-1.8	0.08	0.67	1.17	3.6	
	Week 12	Tezepelumab	66	57 (86.4)	1.17 (1.13)	-2.6	0.42	1.08	1.92	3.7	0.33 [-0.04, 0.70]
		Placebo	65	55 (84.6)	0.78 (1.23)	-2.8	0.08	0.75	1.17	4.0	
	Week 16	Tezepelumab	66	57 (86.4)	1.19 (1.12)	-2.9	0.58	1.08	2.08	3.3	0.34 [-0.03, 0.72]
		Placebo	65	55 (84.6)	0.77 (1.32)	-3.5	0.17	0.83	1.33	4.2	
	Week 20	Tezepelumab	66	57 (86.4)	1.16 (1.08)	-1.8	0.42	1.08	2.08	3.3	0.41 [0.04, 0.78]
		Placebo	65	55 (84.6)	0.68 (1.26)	-3.5	0.08	0.83	1.33	3.8	
	Week 24	Tezepelumab	66	57 (86.4)	1.23 (1.08)	-1.6	0.50	1.17	2.00	3.3	0.47 [0.10, 0.85]
		Placebo	65	55 (84.6)	0.67 (1.31)	-3.5	0.00	0.83	1.25	3.9	
	Week 28	Tezepelumab	66	57 (86.4)	1.14 (1.10)	-1.7	0.42	1.00	2.00	3.3	0.33 [-0.04, 0.70]
		Placebo	65	55 (84.6)	0.73 (1.34)	-3.5	0.08	0.83	1.33	4.3	
	Week 32	Tezepelumab	66	57 (86.4)	1.23 (1.14)	-1.6	0.50	1.08	2.17	3.3	0.36 [-0.01, 0.73]
		Placebo	65	55 (84.6)	0.81 (1.19)	-3.5	0.33	0.92	1.25	3.5	
	Week 36	Tezepelumab	66	57 (86.4)	1.26 (1.20)	-1.7	0.33	1.08	2.17	3.4	0.47 [0.10, 0.85]
		Placebo	65	55 (84.6)	0.70 (1.14)	-3.0	0.08	0.83	1.25	3.8	
	Week 40	Tezepelumab	66	57 (86.4)	1.24 (1.19)	-1.7	0.50	1.08	2.25	3.4	0.35 [-0.02, 0.72]
		Placebo	65	55 (84.6)	0.82 (1.21)	-3.0	0.00	0.83	1.58	4.0	
	Week 44	Tezepelumab	66	57 (86.4)	1.23 (1.15)	-1.6	0.50	1.17	2.08	3.3	0.38 [0.00, 0.75]
		Placebo	65	55 (84.6)	0.79 (1.19)	-3.0	0.25	0.83	1.58	3.7	
	Week 48	Tezepelumab	66	57 (86.4)	1.28 (1.16)	-1.6	0.50	1.17	2.17	3.4	0.39 [0.01, 0.76]
		Placebo	65	55 (84.6)	0.83 (1.16)	-3.0	0.25	0.83	1.50	4.2	
	Week 52	Tezepelumab	66	57 (86.4)	1.28 (1.16)	-1.6	0.50	1.08	2.17	3.6	0.34 [-0.04, 0.71]
		Placebo	65	55 (84.6)	0.89 (1.16)	-3.0	0.25	0.83	1.67	4.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Last observation carried forward is applied in case of missing values.

Source Data: aqlq, created on: 22FEB2022

Table PT3QMC\_ILMC0: Change from baseline in AQLQ+12 symptom score - MMRM results  
 DITTTL

Change from baseline in AQLQ+12 symptom score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	66	55 (83.3)	NE		NE		
	Placebo	65	54 (83.1)					
Week 8	Tezepelumab	66	55 (83.3)	NE		NE		
	Placebo	65	55 (84.6)					
Week 12	Tezepelumab	66	54 (81.8)	NE		NE		
	Placebo	65	52 (80.0)					
Week 16	Tezepelumab	66	53 (80.3)	NE		NE		
	Placebo	65	50 (76.9)					
Week 20	Tezepelumab	66	51 (77.3)	NE		NE		
	Placebo	65	47 (72.3)					
Week 24	Tezepelumab	66	50 (75.8)	NE		NE		
	Placebo	65	45 (69.2)					
Week 28	Tezepelumab	66	47 (71.2)	NE		NE		
	Placebo	65	44 (67.7)					
Week 32	Tezepelumab	66	48 (72.7)	NE		NE		
	Placebo	65	43 (66.2)					
Week 36	Tezepelumab	66	49 (74.2)	NE		NE		
	Placebo	65	44 (67.7)					
Week 40	Tezepelumab	66	48 (72.7)	NE		NE		
	Placebo	65	45 (69.2)					

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 22FEB2022

Table PT3QMC\_ILMC0: Change from baseline in AQLQ+12 symptom score - MMRM results  
 DITTTL

Change from baseline in AQLQ+12 symptom score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 44	Tezepelumab	66	47 (71.2)	NE		NE		
	Placebo	65	44 (67.7)					
Week 48	Tezepelumab	66	46 (69.7)	NE		NE		
	Placebo	65	44 (67.7)					
Week 52	Tezepelumab	66	18 (27.3)	NE		NE		
	Placebo	65	16 (24.6)					

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 22FEB2022



Table ST1QMC\_ILMH0: Course of AQLQ+12 symptom score  
 DITTLL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 symptom score	Baseline	Tezepelumab	73	73 (100.0)	4.10 (1.15)	1.7	3.17	4.08	4.92	6.9	
		Placebo	76	74 (97.4)	4.08 (1.16)	1.8	3.17	4.00	4.92	6.3	
	Week 4	Tezepelumab	73	71 (97.3)	4.80 (1.32)	1.6	3.92	4.92	5.83	7.0	
		Placebo	76	76 (100.0)	4.52 (1.16)	2.3	3.42	4.50	5.50	7.0	
	Week 40	Tezepelumab	73	61 (83.6)	5.22 (1.40)	1.0	4.08	5.50	6.42	7.0	
		Placebo	76	68 (89.5)	4.77 (1.21)	2.2	3.88	4.83	5.75	7.0	
	Week 44	Tezepelumab	73	64 (87.7)	5.23 (1.37)	1.4	4.29	5.50	6.33	7.0	
		Placebo	76	72 (94.7)	4.74 (1.24)	1.7	3.92	4.75	5.71	7.0	
	Week 48	Tezepelumab	73	65 (89.0)	5.16 (1.42)	1.3	4.33	5.50	6.25	7.0	
		Placebo	76	68 (89.5)	4.73 (1.29)	1.8	3.63	4.92	5.67	7.0	

Note: DITTLL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 23FEB2022

Table ST1QMC\_ILMH0: Course of AQLQ+12 symptom score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 symptom score	Week 4	Tezepelumab	73	71 (97.3)	0.69 (1.27)	-3.4	0.00	0.50	1.33	3.4	0.23 [-0.10, 0.55]
		Placebo	76	74 (97.4)	0.43 (1.03)	-1.9	0.00	0.33	0.83	3.4	
	Week 40	Tezepelumab	73	61 (83.6)	1.01 (1.39)	-2.5	0.00	1.17	2.00	4.1	0.24 [-0.11, 0.59]
		Placebo	76	66 (86.8)	0.70 (1.21)	-1.8	-0.17	0.54	1.67	3.7	
	Week 44	Tezepelumab	73	64 (87.7)	1.06 (1.40)	-3.2	0.13	1.08	2.00	3.9	0.35 [0.01, 0.69]
		Placebo	76	70 (92.1)	0.59 (1.25)	-2.6	-0.17	0.54	1.33	4.3	
	Week 48	Tezepelumab	73	65 (89.0)	1.01 (1.37)	-2.2	0.00	1.17	1.83	3.7	0.31 [-0.04, 0.65]
		Placebo	76	67 (88.2)	0.63 (1.09)	-1.9	-0.17	0.50	1.33	3.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 23FEB2022

Table ST1QMC\_ILMC0: Change from baseline in AQLQ+12 symptom score - MMRM results  
 DITTTL

Change from baseline in AQLQ+12 symptom score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	73	71 (97.3)	0.68 (0.12)	(0.43, 0.92)	0.27 (0.17)	(-0.08, 0.62)	0.124
	Placebo	76	74 (97.4)	0.41 (0.12)	(0.17, 0.65)			
Week 40	Tezepelumab	73	61 (83.6)	0.98 (0.14)	(0.69, 1.26)	0.28 (0.20)	(-0.12, 0.67)	0.170
	Placebo	76	66 (86.8)	0.70 (0.14)	(0.43, 0.98)			
Week 44	Tezepelumab	73	64 (87.7)	1.01 (0.14)	(0.73, 1.30)	0.41 (0.20)	(0.01, 0.81)	0.045 *
	Placebo	76	70 (92.1)	0.60 (0.14)	(0.33, 0.88)			
Week 48	Tezepelumab	73	65 (89.0)	0.99 (0.14)	(0.72, 1.27)	0.39 (0.19)	(0.00, 0.77)	0.049 *
	Placebo	76	67 (88.2)	0.61 (0.14)	(0.34, 0.88)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 23FEB2022

Table NT1QTC\_KLMH0: Course of AQLQ+12 total score  
 DITTLL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 total score	Baseline	Tezepelumab	15	15 (100.0)	4.02 (0.85)	2.4	3.63	3.91	4.53	5.5	
		Placebo	20	20 (100.0)	4.18 (1.08)	2.1	3.81	4.19	4.89	6.0	
	Week 4	Tezepelumab	15	14 (93.3)	5.10 (0.96)	3.2	4.25	5.02	5.94	6.4	
		Placebo	20	18 (90.0)	5.34 (1.14)	3.0	4.69	5.70	6.28	6.8	
	Week 12	Tezepelumab	15	13 (86.7)	5.31 (1.01)	3.3	4.72	5.13	6.22	6.8	
		Placebo	20	20 (100.0)	5.45 (1.36)	2.0	4.92	5.61	6.45	7.0	
	Week 24	Tezepelumab	15	13 (86.7)	5.77 (0.70)	4.4	5.47	5.63	6.53	6.7	
		Placebo	20	17 (85.0)	5.20 (1.24)	2.9	4.41	5.13	6.25	7.0	
	Week 36	Tezepelumab	15	13 (86.7)	5.75 (1.02)	3.8	5.00	6.34	6.50	7.0	
		Placebo	20	18 (90.0)	5.45 (1.53)	1.5	4.72	5.81	6.56	7.0	
	Week 52	Tezepelumab	15	12 (80.0)	5.76 (1.02)	3.9	4.89	5.97	6.73	6.9	
		Placebo	20	20 (100.0)	5.67 (0.99)	3.3	5.14	5.75	6.39	7.0	

Note: DITTLL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QTC\_KLMH0: Course of AQLQ+12 total score  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 total score	Week 4	Tezepelumab	15	14 (93.3)	1.08 (0.83)	-0.7	0.44	1.11	1.81	2.3	-0.23 [-0.94, 0.47]
		Placebo	20	18 (90.0)	1.29 (0.96)	-0.4	0.78	0.97	1.91	3.7	
	Week 12	Tezepelumab	15	13 (86.7)	1.38 (1.18)	0.1	0.56	1.13	1.59	3.9	0.09 [-0.61, 0.79]
		Placebo	20	20 (100.0)	1.27 (1.25)	-0.4	0.61	0.98	1.52	4.4	
	Week 24	Tezepelumab	15	13 (86.7)	1.82 (1.03)	0.4	1.16	1.72	2.38	3.8	0.76 [0.01, 1.51]
		Placebo	20	17 (85.0)	0.99 (1.15)	-0.7	0.56	0.88	1.03	4.2	
	Week 36	Tezepelumab	15	13 (86.7)	1.81 (1.46)	-0.7	0.94	1.97	2.59	4.5	0.37 [-0.35, 1.09]
		Placebo	20	18 (90.0)	1.19 (1.75)	-3.5	0.72	1.02	1.94	4.4	
	Week 52	Tezepelumab	15	12 (80.0)	1.82 (1.38)	0.3	0.81	1.25	2.58	4.4	0.25 [-0.47, 0.97]
		Placebo	20	20 (100.0)	1.50 (1.19)	-0.5	0.86	1.25	1.75	4.5	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QTC\_KLMC0: Change from baseline in AQLQ+12 total score - MMRM results  
 DITTLL - adolescents

Change from baseline in AQLQ+12 total score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	15	14 (93.3)	1.04 (0.23)	(0.57, 1.51)	-0.22 (0.30)	(-0.84, 0.41)	0.483
	Placebo	20	18 (90.0)	1.26 (0.20)	(0.85, 1.66)			
Week 12	Tezepelumab	15	13 (86.7)	1.28 (0.30)	(0.67, 1.90)	-0.04 (0.39)	(-0.83, 0.76)	0.927
	Placebo	20	20 (100.0)	1.32 (0.25)	(0.81, 1.83)			
Week 24	Tezepelumab	15	13 (86.7)	1.75 (0.28)	(1.18, 2.32)	0.88 (0.36)	(0.13, 1.63)	0.023 *
	Placebo	20	17 (85.0)	0.87 (0.24)	(0.38, 1.35)			
Week 36	Tezepelumab	15	13 (86.7)	1.73 (0.39)	(0.94, 2.52)	0.51 (0.51)	(-0.52, 1.55)	0.320
	Placebo	20	18 (90.0)	1.22 (0.33)	(0.55, 1.88)			
Week 52	Tezepelumab	15	12 (80.0)	1.77 (0.28)	(1.20, 2.34)	0.23 (0.36)	(-0.51, 0.96)	0.535
	Placebo	20	20 (100.0)	1.54 (0.23)	(1.08, 2.00)			

Note: DITTLL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QAC\_KLMH0: Course of AQLQ+12 activity limitations score  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 activity limitations score	Baseline	Tezepelumab	15	15 (100.0)	3.96 (0.67)	2.7	3.45	3.82	4.64	5.1	
		Placebo	20	20 (100.0)	4.31 (1.14)	2.1	3.50	4.41	5.14	6.2	
	Week 4	Tezepelumab	15	14 (93.3)	5.10 (0.94)	3.4	4.55	5.05	5.73	6.5	
		Placebo	20	18 (90.0)	5.36 (1.11)	3.4	4.36	5.82	6.18	6.6	
	Week 12	Tezepelumab	15	13 (86.7)	5.42 (1.01)	3.5	4.82	5.55	6.36	6.7	
		Placebo	20	20 (100.0)	5.52 (1.32)	2.1	4.82	5.68	6.68	7.0	
	Week 24	Tezepelumab	15	13 (86.7)	5.90 (0.63)	4.7	5.55	5.82	6.36	6.8	
		Placebo	20	17 (85.0)	5.43 (1.20)	3.2	4.64	5.82	6.45	7.0	
	Week 36	Tezepelumab	15	13 (86.7)	5.80 (0.93)	4.1	5.27	5.73	6.55	7.0	
		Placebo	20	18 (90.0)	5.63 (1.43)	2.4	5.18	6.00	6.64	7.0	
	Week 52	Tezepelumab	15	12 (80.0)	5.89 (0.93)	4.1	5.18	5.95	6.64	7.0	
		Placebo	20	20 (100.0)	5.79 (1.01)	3.2	5.36	6.00	6.59	7.0	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.  
 Source Data: aqlq, created on: 21FEB2022

Table NT1QAC\_KLMH0: Course of AQLQ+12 activity limitations score  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 activity limitations score	Week 4	Tezepelumab	15	14 (93.3)	1.13 (1.06)	-0.5	0.27	1.27	1.45	3.5	-0.04 [-0.74, 0.66]
		Placebo	20	18 (90.0)	1.17 (0.87)	0.1	0.45	1.00	1.91	3.3	
	Week 12	Tezepelumab	15	13 (86.7)	1.53 (1.13)	0.1	0.82	1.09	2.64	3.5	0.28 [-0.42, 0.98]
		Placebo	20	20 (100.0)	1.21 (1.13)	-0.4	0.50	0.86	1.91	3.9	
	Week 24	Tezepelumab	15	13 (86.7)	2.00 (0.82)	0.6	1.45	2.00	2.82	3.2	1.01 [0.24, 1.77]
		Placebo	20	17 (85.0)	1.09 (0.96)	-0.5	0.64	0.91	1.18	3.5	
	Week 36	Tezepelumab	15	13 (86.7)	1.90 (1.27)	-0.5	1.36	2.09	2.64	3.7	0.46 [-0.27, 1.18]
		Placebo	20	18 (90.0)	1.24 (1.55)	-2.9	0.82	1.05	2.09	4.5	
	Week 52	Tezepelumab	15	12 (80.0)	1.98 (1.18)	0.3	0.95	2.18	2.77	3.7	0.40 [-0.32, 1.13]
		Placebo	20	20 (100.0)	1.48 (1.29)	-1.1	0.68	1.41	2.23	4.6	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022



Table NT1QAC\_KLMC0: Change from baseline in AQLQ+12 activity limitations score - MMRM results  
 DITTL - adolescents

Change from baseline in AQLQ+12 activity limitations score				Repeated measures analysis																																																								
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference																																																						
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value																																																				
Week 4	Tezepelumab	15	14 (93.3)	1.03 (0.24)	(0.55, 1.52)	-0.15 (0.31)	(-0.79, 0.48)	0.624																																																				
	Placebo	20	18 (90.0)	1.19 (0.20)	(0.77, 1.61)				Week 12	Tezepelumab	15	13 (86.7)	1.37 (0.29)	(0.78, 1.95)	0.06 (0.38)	(-0.70, 0.83)	0.868	Placebo	20	20 (100.0)	1.30 (0.24)	(0.82, 1.79)	Week 24	Tezepelumab	15	13 (86.7)	1.86 (0.25)	(1.35, 2.36)	0.85 (0.33)	(0.18, 1.52)	0.015 *	Placebo	20	17 (85.0)	1.01 (0.21)	(0.58, 1.44)	Week 36	Tezepelumab	15	13 (86.7)	1.76 (0.34)	(1.06, 2.47)	0.47 (0.45)	(-0.45, 1.39)	0.304	Placebo	20	18 (90.0)	1.29 (0.29)	(0.71, 1.88)	Week 52	Tezepelumab	15	12 (80.0)	1.89 (0.28)	(1.32, 2.45)	0.32 (0.36)	(-0.41, 1.05)	0.378	Placebo
Week 12	Tezepelumab	15	13 (86.7)	1.37 (0.29)	(0.78, 1.95)	0.06 (0.38)	(-0.70, 0.83)	0.868																																																				
	Placebo	20	20 (100.0)	1.30 (0.24)	(0.82, 1.79)				Week 24	Tezepelumab	15	13 (86.7)	1.86 (0.25)	(1.35, 2.36)	0.85 (0.33)	(0.18, 1.52)	0.015 *	Placebo	20	17 (85.0)	1.01 (0.21)	(0.58, 1.44)	Week 36	Tezepelumab	15	13 (86.7)	1.76 (0.34)	(1.06, 2.47)	0.47 (0.45)	(-0.45, 1.39)	0.304	Placebo	20	18 (90.0)	1.29 (0.29)	(0.71, 1.88)	Week 52	Tezepelumab	15	12 (80.0)	1.89 (0.28)	(1.32, 2.45)	0.32 (0.36)	(-0.41, 1.05)	0.378	Placebo	20	20 (100.0)	1.57 (0.22)	(1.11, 2.02)										
Week 24	Tezepelumab	15	13 (86.7)	1.86 (0.25)	(1.35, 2.36)	0.85 (0.33)	(0.18, 1.52)	0.015 *																																																				
	Placebo	20	17 (85.0)	1.01 (0.21)	(0.58, 1.44)				Week 36	Tezepelumab	15	13 (86.7)	1.76 (0.34)	(1.06, 2.47)	0.47 (0.45)	(-0.45, 1.39)	0.304	Placebo	20	18 (90.0)	1.29 (0.29)	(0.71, 1.88)	Week 52	Tezepelumab	15	12 (80.0)	1.89 (0.28)	(1.32, 2.45)	0.32 (0.36)	(-0.41, 1.05)	0.378	Placebo	20	20 (100.0)	1.57 (0.22)	(1.11, 2.02)																								
Week 36	Tezepelumab	15	13 (86.7)	1.76 (0.34)	(1.06, 2.47)	0.47 (0.45)	(-0.45, 1.39)	0.304																																																				
	Placebo	20	18 (90.0)	1.29 (0.29)	(0.71, 1.88)				Week 52	Tezepelumab	15	12 (80.0)	1.89 (0.28)	(1.32, 2.45)	0.32 (0.36)	(-0.41, 1.05)	0.378	Placebo	20	20 (100.0)	1.57 (0.22)	(1.11, 2.02)																																						
Week 52	Tezepelumab	15	12 (80.0)	1.89 (0.28)	(1.32, 2.45)	0.32 (0.36)	(-0.41, 1.05)	0.378																																																				
	Placebo	20	20 (100.0)	1.57 (0.22)	(1.11, 2.02)																																																							

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QEC\_KLMH0: Course of AQLQ+12 environmental stimuli score  
 DITTTL - adolescents

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 environmental stimuli Baseline score	Tezepelumab	15	15 (100.0)	3.83 (1.33)	1.3	3.25	3.75	4.50	6.0	
	Placebo	20	20 (100.0)	4.20 (1.47)	2.0	3.25	3.88	5.75	6.8	
Week 4	Tezepelumab	15	14 (93.3)	4.63 (1.32)	2.0	4.00	5.00	5.75	6.3	
	Placebo	20	18 (90.0)	5.11 (1.74)	1.0	3.75	5.75	6.25	7.0	
Week 12	Tezepelumab	15	13 (86.7)	4.94 (1.35)	2.3	4.00	5.00	6.25	6.5	
	Placebo	20	20 (100.0)	5.23 (1.76)	2.0	4.00	5.63	7.00	7.0	
Week 24	Tezepelumab	15	13 (86.7)	5.44 (1.00)	4.0	4.50	5.50	6.25	7.0	
	Placebo	20	17 (85.0)	5.09 (1.53)	2.0	4.00	5.50	6.25	7.0	
Week 36	Tezepelumab	15	13 (86.7)	5.44 (1.71)	1.0	4.50	5.75	6.75	7.0	
	Placebo	20	18 (90.0)	5.28 (1.96)	1.0	3.75	6.00	6.75	7.0	
Week 52	Tezepelumab	15	12 (80.0)	5.25 (1.40)	3.0	3.88	5.50	6.63	6.8	
	Placebo	20	20 (100.0)	5.59 (1.48)	2.0	4.88	6.00	6.75	7.0	

Note: DITTTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QEC\_KLMH0: Course of AQLQ+12 environmental stimuli score  
 DITTLL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 environmental stimuli score	Week 4	Tezepelumab	15	14 (93.3)	0.77 (0.98)	-0.8	0.25	0.63	1.50	2.3	-0.27 [-0.97, 0.43]
		Placebo	20	18 (90.0)	1.11 (1.45)	-2.8	0.50	1.00	2.00	3.5	
	Week 12	Tezepelumab	15	13 (86.7)	1.23 (1.87)	-1.5	0.25	1.00	1.75	5.0	0.13 [-0.57, 0.83]
		Placebo	20	20 (100.0)	1.03 (1.38)	-1.8	0.00	0.88	1.88	3.8	
	Week 24	Tezepelumab	15	13 (86.7)	1.62 (1.89)	-1.8	0.50	1.50	2.25	5.0	0.41 [-0.32, 1.14]
		Placebo	20	17 (85.0)	0.97 (1.26)	-1.0	0.25	0.50	1.75	3.8	
	Week 36	Tezepelumab	15	13 (86.7)	1.62 (2.73)	-4.8	0.25	2.00	3.50	5.5	0.24 [-0.48, 0.95]
		Placebo	20	18 (90.0)	1.06 (2.06)	-5.0	0.25	1.13	2.25	3.8	
	Week 52	Tezepelumab	15	12 (80.0)	1.40 (2.31)	-2.0	-0.13	0.38	3.13	5.5	0.00 [-0.71, 0.72]
		Placebo	20	20 (100.0)	1.39 (1.34)	-1.3	0.63	1.00	2.25	4.0	

Note: DITTLL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QEC\_KLMC0: Change from baseline in AQLQ+12 environmental stimuli score - MMRM results  
 DITTL - adolescents

Change from baseline in AQLQ+12 environmental stimuli score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 4	Tezepelumab	15	14 (93.3)	0.71 (0.33)	(0.04, 1.37)	-0.39 (0.43)	(-1.27, 0.50)	0.380
	Placebo	20	18 (90.0)	1.09 (0.28)	(0.51, 1.67)			
Week 12	Tezepelumab	15	13 (86.7)	1.01 (0.40)	(0.19, 1.82)	-0.09 (0.52)	(-1.15, 0.97)	0.862
	Placebo	20	20 (100.0)	1.10 (0.33)	(0.42, 1.77)			
Week 24	Tezepelumab	15	13 (86.7)	1.57 (0.36)	(0.84, 2.30)	0.69 (0.47)	(-0.27, 1.64)	0.153
	Placebo	20	17 (85.0)	0.89 (0.30)	(0.27, 1.50)			
Week 36	Tezepelumab	15	13 (86.7)	1.58 (0.56)	(0.43, 2.73)	0.44 (0.73)	(-1.05, 1.94)	0.549
	Placebo	20	18 (90.0)	1.13 (0.47)	(0.17, 2.09)			
Week 52	Tezepelumab	15	12 (80.0)	1.41 (0.41)	(0.57, 2.25)	-0.05 (0.53)	(-1.13, 1.03)	0.927
	Placebo	20	20 (100.0)	1.46 (0.33)	(0.78, 2.14)			

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QGC\_KLMH0: Course of AQLQ+12 emotional function score  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 emotional function score	Baseline	Tezepelumab	15	15 (100.0)	3.99 (1.37)	1.2	3.20	4.20	4.80	6.6	
		Placebo	20	20 (100.0)	4.22 (1.18)	2.2	3.10	4.40	4.90	6.2	
	Week 4	Tezepelumab	15	14 (93.3)	4.76 (1.80)	1.6	3.20	5.10	6.20	7.0	
		Placebo	20	18 (90.0)	5.37 (1.53)	2.2	5.00	5.80	6.80	7.0	
	Week 12	Tezepelumab	15	13 (86.7)	4.88 (1.53)	1.8	4.00	5.00	5.80	7.0	
		Placebo	20	20 (100.0)	5.30 (1.67)	1.8	4.60	5.60	6.70	7.0	
	Week 24	Tezepelumab	15	13 (86.7)	5.52 (0.96)	4.0	4.60	5.80	6.20	7.0	
		Placebo	20	17 (85.0)	5.45 (1.19)	3.2	4.80	5.60	6.40	7.0	
	Week 36	Tezepelumab	15	13 (86.7)	5.66 (1.27)	3.2	5.00	5.80	6.80	7.0	
		Placebo	20	18 (90.0)	5.61 (1.66)	1.2	5.00	6.00	7.00	7.0	
	Week 52	Tezepelumab	15	12 (80.0)	5.40 (1.52)	3.2	4.00	5.70	6.80	7.0	
		Placebo	20	20 (100.0)	5.68 (1.06)	3.6	5.00	5.80	6.50	7.0	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.  
 Source Data: aqlq, created on: 21FEB2022

Table NT1QGC\_KLMH0: Course of AQLQ+12 emotional function score  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 emotional function score	Week 4	Tezepelumab	15	14 (93.3)	0.83 (1.60)	-2.6	0.00	0.60	1.80	3.2	-0.27 [-0.98, 0.43]
		Placebo	20	18 (90.0)	1.28 (1.66)	-1.6	0.40	0.80	2.20	4.6	
	Week 12	Tezepelumab	15	13 (86.7)	1.08 (1.94)	-2.4	0.20	0.60	1.80	4.8	-0.00 [-0.70, 0.70]
		Placebo	20	20 (100.0)	1.08 (1.90)	-2.6	0.00	0.80	2.00	4.8	
	Week 24	Tezepelumab	15	13 (86.7)	1.68 (1.68)	-1.0	0.40	1.40	2.40	5.0	0.29 [-0.43, 1.02]
		Placebo	20	17 (85.0)	1.20 (1.58)	-1.0	0.40	0.80	1.40	4.8	
	Week 36	Tezepelumab	15	13 (86.7)	1.82 (1.95)	-1.0	0.20	2.40	2.80	5.0	0.23 [-0.48, 0.95]
		Placebo	20	18 (90.0)	1.34 (2.10)	-3.4	0.60	1.00	2.00	4.8	
	Week 52	Tezepelumab	15	12 (80.0)	1.60 (2.30)	-2.4	0.20	1.50	3.20	5.0	0.08 [-0.64, 0.79]
		Placebo	20	20 (100.0)	1.46 (1.49)	-1.0	0.60	1.20	1.60	4.8	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QGC\_KLMC0: Change from baseline in AQLQ+12 emotional function score - MMRM results  
 DITTL - adolescents

Change from baseline in AQLQ+12 emotional function score				Repeated measures analysis																																																								
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference																																																						
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value																																																				
Week 4	Tezepelumab	15	14 (93.3)	0.73 (0.41)	(-0.10, 1.57)	-0.57 (0.54)	(-1.67, 0.53)	0.297																																																				
	Placebo	20	18 (90.0)	1.30 (0.35)	(0.59, 2.02)				Week 12	Tezepelumab	15	13 (86.7)	0.83 (0.43)	(-0.06, 1.71)	-0.37 (0.56)	(-1.52, 0.78)	0.517	Placebo	20	20 (100.0)	1.20 (0.36)	(0.46, 1.93)	Week 24	Tezepelumab	15	13 (86.7)	1.53 (0.32)	(0.88, 2.19)	0.36 (0.42)	(-0.51, 1.22)	0.408	Placebo	20	17 (85.0)	1.18 (0.27)	(0.62, 1.74)	Week 36	Tezepelumab	15	13 (86.7)	1.66 (0.43)	(0.78, 2.55)	0.20 (0.57)	(-0.96, 1.35)	0.733	Placebo	20	18 (90.0)	1.47 (0.36)	(0.73, 2.21)	Week 52	Tezepelumab	15	12 (80.0)	1.47 (0.36)	(0.73, 2.21)	-0.11 (0.47)	(-1.06, 0.85)	0.819	Placebo
Week 12	Tezepelumab	15	13 (86.7)	0.83 (0.43)	(-0.06, 1.71)	-0.37 (0.56)	(-1.52, 0.78)	0.517																																																				
	Placebo	20	20 (100.0)	1.20 (0.36)	(0.46, 1.93)				Week 24	Tezepelumab	15	13 (86.7)	1.53 (0.32)	(0.88, 2.19)	0.36 (0.42)	(-0.51, 1.22)	0.408	Placebo	20	17 (85.0)	1.18 (0.27)	(0.62, 1.74)	Week 36	Tezepelumab	15	13 (86.7)	1.66 (0.43)	(0.78, 2.55)	0.20 (0.57)	(-0.96, 1.35)	0.733	Placebo	20	18 (90.0)	1.47 (0.36)	(0.73, 2.21)	Week 52	Tezepelumab	15	12 (80.0)	1.47 (0.36)	(0.73, 2.21)	-0.11 (0.47)	(-1.06, 0.85)	0.819	Placebo	20	20 (100.0)	1.58 (0.29)	(0.98, 2.17)										
Week 24	Tezepelumab	15	13 (86.7)	1.53 (0.32)	(0.88, 2.19)	0.36 (0.42)	(-0.51, 1.22)	0.408																																																				
	Placebo	20	17 (85.0)	1.18 (0.27)	(0.62, 1.74)				Week 36	Tezepelumab	15	13 (86.7)	1.66 (0.43)	(0.78, 2.55)	0.20 (0.57)	(-0.96, 1.35)	0.733	Placebo	20	18 (90.0)	1.47 (0.36)	(0.73, 2.21)	Week 52	Tezepelumab	15	12 (80.0)	1.47 (0.36)	(0.73, 2.21)	-0.11 (0.47)	(-1.06, 0.85)	0.819	Placebo	20	20 (100.0)	1.58 (0.29)	(0.98, 2.17)																								
Week 36	Tezepelumab	15	13 (86.7)	1.66 (0.43)	(0.78, 2.55)	0.20 (0.57)	(-0.96, 1.35)	0.733																																																				
	Placebo	20	18 (90.0)	1.47 (0.36)	(0.73, 2.21)				Week 52	Tezepelumab	15	12 (80.0)	1.47 (0.36)	(0.73, 2.21)	-0.11 (0.47)	(-1.06, 0.85)	0.819	Placebo	20	20 (100.0)	1.58 (0.29)	(0.98, 2.17)																																						
Week 52	Tezepelumab	15	12 (80.0)	1.47 (0.36)	(0.73, 2.21)	-0.11 (0.47)	(-1.06, 0.85)	0.819																																																				
	Placebo	20	20 (100.0)	1.58 (0.29)	(0.98, 2.17)																																																							

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QMC\_KLMH0: Course of AQLQ+12 symptom score  
 DITTLL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 symptom score	Baseline	Tezepelumab	15	15 (100.0)	4.16 (0.93)	2.1	3.33	4.17	4.92	5.4	
		Placebo	20	20 (100.0)	4.03 (1.16)	1.7	3.54	4.29	4.67	5.9	
	Week 4	Tezepelumab	15	14 (93.3)	5.39 (0.78)	4.0	4.67	5.83	6.00	6.3	
		Placebo	20	18 (90.0)	5.38 (1.17)	2.5	4.92	5.46	6.17	7.0	
	Week 12	Tezepelumab	15	13 (86.7)	5.52 (0.98)	3.3	5.00	5.83	6.17	6.8	
		Placebo	20	20 (100.0)	5.52 (1.41)	1.9	4.92	5.67	6.92	7.0	
	Week 24	Tezepelumab	15	13 (86.7)	5.85 (0.79)	4.2	5.50	5.92	6.58	6.8	
		Placebo	20	17 (85.0)	4.93 (1.44)	2.3	4.25	5.17	6.00	7.0	
	Week 36	Tezepelumab	15	13 (86.7)	5.84 (1.01)	3.7	5.42	6.00	6.58	7.0	
		Placebo	20	18 (90.0)	5.28 (1.65)	1.1	4.83	5.79	6.67	7.0	
	Week 52	Tezepelumab	15	12 (80.0)	5.96 (0.99)	4.3	4.92	6.50	6.79	6.9	
		Placebo	20	20 (100.0)	5.60 (1.14)	2.5	5.04	5.75	6.50	7.0	

Note: DITTLL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022



Table NT1QMC\_KLMH0: Course of AQLQ+12 symptom score  
 DITTTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 symptom score	Week 4	Tezepelumab	15	14 (93.3)	1.23 (0.80)	0.1	0.58	1.25	1.50	2.8	-0.26 [-0.96, 0.44]
		Placebo	20	18 (90.0)	1.46 (0.94)	-0.8	1.00	1.46	2.17	3.8	
	Week 12	Tezepelumab	15	13 (86.7)	1.42 (1.14)	-0.2	0.75	1.33	1.92	4.1	-0.05 [-0.75, 0.65]
		Placebo	20	20 (100.0)	1.48 (1.32)	-0.3	0.79	0.96	2.00	4.9	
	Week 24	Tezepelumab	15	13 (86.7)	1.79 (1.01)	0.5	1.08	1.50	2.67	3.4	0.81 [0.06, 1.56]
		Placebo	20	17 (85.0)	0.81 (1.34)	-1.0	0.08	0.58	1.00	4.8	
	Week 36	Tezepelumab	15	13 (86.7)	1.78 (1.32)	0.5	0.50	1.75	2.67	4.8	0.39 [-0.33, 1.11]
		Placebo	20	18 (90.0)	1.13 (1.84)	-3.6	0.50	1.08	1.75	4.8	
	Week 52	Tezepelumab	15	12 (80.0)	1.89 (1.25)	0.4	0.92	1.79	2.38	4.8	0.26 [-0.46, 0.98]
		Placebo	20	20 (100.0)	1.56 (1.24)	-0.5	0.79	1.21	2.08	4.8	

Note: DITTTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QMC\_KLMC0: Change from baseline in AQLQ+12 symptom score - MMRM results  
 DITTL - adolescents

Change from baseline in AQLQ+12 symptom score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 4	Tezepelumab	15	14 (93.3)	1.28 (0.21)	(0.85, 1.71)	-0.10 (0.28)	(-0.67, 0.47)	0.715
	Placebo	20	18 (90.0)	1.38 (0.18)	(1.01, 1.75)			
Week 12	Tezepelumab	15	13 (86.7)	1.47 (0.31)	(0.85, 2.09)	0.00 (0.40)	(-0.80, 0.81)	0.991
	Placebo	20	20 (100.0)	1.47 (0.25)	(0.95, 1.98)			
Week 24	Tezepelumab	15	13 (86.7)	1.78 (0.31)	(1.14, 2.41)	1.09 (0.41)	(0.25, 1.93)	0.013 *
	Placebo	20	17 (85.0)	0.68 (0.27)	(0.14, 1.23)			
Week 36	Tezepelumab	15	13 (86.7)	1.76 (0.41)	(0.93, 2.59)	0.69 (0.53)	(-0.39, 1.78)	0.202
	Placebo	20	18 (90.0)	1.06 (0.34)	(0.36, 1.77)			
Week 52	Tezepelumab	15	12 (80.0)	1.86 (0.28)	(1.29, 2.44)	0.32 (0.36)	(-0.42, 1.06)	0.388
	Placebo	20	20 (100.0)	1.55 (0.23)	(1.08, 2.01)			

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QTC\_ALMH0: Course of AQLQ+12 total score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 total score	Baseline	Tezepelumab	380	379 (99.7)	3.74 (1.06)	1.2	3.00	3.75	4.47	6.5	
		Placebo	371	369 (99.5)	3.83 (1.02)	1.2	3.13	3.88	4.53	6.6	
	Week 4	Tezepelumab	380	368 (96.8)	4.75 (1.17)	1.3	3.97	4.81	5.70	7.0	
		Placebo	371	358 (96.5)	4.55 (1.17)	1.0	3.75	4.66	5.34	7.0	
	Week 12	Tezepelumab	380	364 (95.8)	5.03 (1.22)	1.6	4.14	5.20	6.00	7.0	
		Placebo	371	355 (95.7)	4.84 (1.18)	1.0	4.03	4.91	5.75	7.0	
	Week 24	Tezepelumab	380	352 (92.6)	5.20 (1.25)	1.0	4.22	5.41	6.16	7.0	
		Placebo	371	337 (90.8)	4.90 (1.23)	1.0	4.13	5.03	5.84	7.0	
	Week 36	Tezepelumab	380	350 (92.1)	5.22 (1.26)	1.9	4.25	5.50	6.25	7.0	
		Placebo	371	334 (90.0)	4.94 (1.23)	1.2	4.06	4.94	5.91	7.0	
	Week 52	Tezepelumab	380	342 (90.0)	5.30 (1.24)	1.5	4.38	5.56	6.38	7.0	
		Placebo	371	321 (86.5)	4.99 (1.23)	1.3	4.16	5.03	5.94	7.0	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QTC\_ALMH0: Course of AQLQ+12 total score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 total score	Week 4	Tezepelumab	380	367 (96.6)	1.00 (1.09)	-1.7	0.19	0.81	1.59	4.6	0.27 [0.12, 0.41]
		Placebo	371	358 (96.5)	0.73 (0.92)	-2.8	0.16	0.69	1.25	4.8	
	Week 12	Tezepelumab	380	364 (95.8)	1.28 (1.22)	-1.7	0.41	1.16	2.14	4.6	0.24 [0.10, 0.39]
		Placebo	371	354 (95.4)	1.00 (1.08)	-2.0	0.28	0.89	1.66	5.4	
	Week 24	Tezepelumab	380	352 (92.6)	1.43 (1.33)	-4.7	0.50	1.28	2.41	4.8	0.31 [0.16, 0.46]
		Placebo	371	336 (90.6)	1.05 (1.12)	-1.8	0.28	0.97	1.75	5.5	
	Week 36	Tezepelumab	380	350 (92.1)	1.46 (1.29)	-2.2	0.56	1.34	2.34	4.8	0.30 [0.15, 0.45]
		Placebo	371	333 (89.8)	1.09 (1.15)	-2.2	0.28	0.94	1.75	5.5	
	Week 52	Tezepelumab	380	342 (90.0)	1.53 (1.27)	-2.7	0.56	1.53	2.38	5.0	0.32 [0.17, 0.48]
		Placebo	371	320 (86.3)	1.13 (1.18)	-2.0	0.28	1.00	1.92	5.1	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QTC\_ALMC0: Change from baseline in AQLQ+12 total score - MMRM results  
 DITTL - adult

Change from baseline in AQLQ+12 total score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	380	367 (96.6)	0.97 (0.05)	(0.88, 1.07)	0.23 (0.07)	(0.10, 0.37)	<0.001 *
	Placebo	371	358 (96.5)	0.74 (0.05)	(0.64, 0.84)			
Week 12	Tezepelumab	380	364 (95.8)	1.27 (0.06)	(1.16, 1.38)	0.27 (0.08)	(0.11, 0.42)	<0.001 *
	Placebo	371	354 (95.4)	1.00 (0.06)	(0.89, 1.11)			
Week 24	Tezepelumab	380	352 (92.6)	1.40 (0.06)	(1.28, 1.51)	0.34 (0.08)	(0.18, 0.51)	<0.001 *
	Placebo	371	336 (90.6)	1.05 (0.06)	(0.94, 1.17)			
Week 36	Tezepelumab	380	350 (92.1)	1.43 (0.06)	(1.31, 1.54)	0.35 (0.09)	(0.18, 0.52)	<0.001 *
	Placebo	371	333 (89.8)	1.08 (0.06)	(0.96, 1.20)			
Week 52	Tezepelumab	380	342 (90.0)	1.51 (0.06)	(1.39, 1.63)	0.37 (0.09)	(0.21, 0.54)	<0.001 *
	Placebo	371	320 (86.3)	1.14 (0.06)	(1.02, 1.26)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QAC\_ALMH0: Course of AQLQ+12 activity limitations score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 activity limitations score	Baseline	Tezepelumab	380	379 (99.7)	3.89 (1.07)	1.1	3.18	3.91	4.64	6.9	
		Placebo	371	369 (99.5)	3.95 (1.04)	1.2	3.18	4.00	4.64	6.7	
	Week 4	Tezepelumab	380	368 (96.8)	4.78 (1.23)	1.6	3.82	4.82	5.82	7.0	
		Placebo	371	358 (96.5)	4.62 (1.22)	1.0	3.73	4.64	5.55	7.0	
	Week 12	Tezepelumab	380	364 (95.8)	5.05 (1.26)	1.5	4.09	5.09	6.09	7.0	
		Placebo	371	355 (95.7)	4.87 (1.25)	1.1	4.00	4.91	5.91	7.0	
	Week 24	Tezepelumab	380	352 (92.6)	5.21 (1.28)	1.0	4.18	5.45	6.18	7.0	
		Placebo	371	337 (90.8)	4.92 (1.28)	1.0	4.00	5.00	5.91	7.0	
	Week 36	Tezepelumab	380	350 (92.1)	5.22 (1.29)	1.4	4.18	5.45	6.27	7.0	
		Placebo	371	334 (90.0)	4.94 (1.25)	1.3	4.00	5.00	5.91	7.0	
	Week 52	Tezepelumab	380	342 (90.0)	5.26 (1.27)	1.7	4.27	5.55	6.36	7.0	
		Placebo	371	321 (86.5)	5.00 (1.27)	1.5	4.00	5.09	6.00	7.0	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QAC\_ALMH0: Course of AQLQ+12 activity limitations score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 activity limitations score	Week 4	Tezepelumab	380	367 (96.6)	0.88 (1.08)	-2.3	0.09	0.73	1.55	4.3	0.20 [0.05, 0.34]
		Placebo	371	358 (96.5)	0.68 (0.95)	-2.8	0.09	0.64	1.18	5.4	
	Week 12	Tezepelumab	380	364 (95.8)	1.15 (1.21)	-1.9	0.27	1.05	1.95	4.3	0.20 [0.05, 0.34]
		Placebo	371	354 (95.4)	0.92 (1.11)	-2.2	0.18	0.82	1.55	5.3	
	Week 24	Tezepelumab	380	352 (92.6)	1.30 (1.28)	-5.1	0.45	1.18	2.27	4.4	0.27 [0.12, 0.42]
		Placebo	371	336 (90.6)	0.96 (1.14)	-2.5	0.18	0.91	1.64	5.2	
	Week 36	Tezepelumab	380	350 (92.1)	1.30 (1.24)	-2.3	0.36	1.27	2.18	4.9	0.27 [0.11, 0.42]
		Placebo	371	333 (89.8)	0.98 (1.14)	-2.1	0.18	0.91	1.64	5.3	
	Week 52	Tezepelumab	380	342 (90.0)	1.33 (1.24)	-2.9	0.45	1.36	2.09	4.6	0.25 [0.09, 0.40]
		Placebo	371	320 (86.3)	1.03 (1.20)	-2.5	0.18	0.95	1.86	4.9	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QAC\_ALMC0: Change from baseline in AQLQ+12 activity limitations score - MMRM results  
 DITTL - adult

Change from baseline in AQLQ+12 activity limitations score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 4	Tezepelumab	380	367 (96.6)	0.87 (0.05)	(0.77, 0.97)	0.18 (0.07)	(0.04, 0.32)	0.012 *
	Placebo	371	358 (96.5)	0.69 (0.05)	(0.59, 0.79)			
Week 12	Tezepelumab	380	364 (95.8)	1.14 (0.06)	(1.03, 1.25)	0.23 (0.08)	(0.08, 0.39)	0.004 *
	Placebo	371	354 (95.4)	0.91 (0.06)	(0.80, 1.02)			
Week 24	Tezepelumab	380	352 (92.6)	1.28 (0.06)	(1.16, 1.39)	0.32 (0.09)	(0.15, 0.49)	<0.001 *
	Placebo	371	336 (90.6)	0.96 (0.06)	(0.84, 1.07)			
Week 36	Tezepelumab	380	350 (92.1)	1.29 (0.06)	(1.17, 1.40)	0.32 (0.08)	(0.16, 0.49)	<0.001 *
	Placebo	371	333 (89.8)	0.97 (0.06)	(0.85, 1.08)			
Week 52	Tezepelumab	380	342 (90.0)	1.33 (0.06)	(1.22, 1.45)	0.31 (0.09)	(0.14, 0.48)	<0.001 *
	Placebo	371	320 (86.3)	1.02 (0.06)	(0.90, 1.14)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022



Table NT1QEC\_ALMH0: Course of AQLQ+12 environmental stimuli score  
 DITTl - adult

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 environmental stimuli Baseline score	Tezepelumab	380	379 (99.7)	3.85 (1.44)	1.0	2.75	4.00	5.00	7.0	
	Placebo	371	369 (99.5)	3.90 (1.42)	1.0	3.00	4.00	4.75	7.0	
Week 4	Tezepelumab	380	368 (96.8)	4.74 (1.52)	1.0	3.75	5.00	6.00	7.0	
	Placebo	371	358 (96.5)	4.53 (1.52)	1.0	3.50	4.75	5.75	7.0	
Week 12	Tezepelumab	380	364 (95.8)	4.96 (1.51)	1.0	4.00	5.25	6.25	7.0	
	Placebo	371	355 (95.7)	4.80 (1.45)	1.0	4.00	5.00	6.00	7.0	
Week 24	Tezepelumab	380	352 (92.6)	5.12 (1.52)	1.0	4.25	5.50	6.25	7.0	
	Placebo	371	337 (90.8)	4.86 (1.50)	1.0	4.00	5.00	6.00	7.0	
Week 36	Tezepelumab	380	350 (92.1)	5.16 (1.46)	1.0	4.25	5.50	6.25	7.0	
	Placebo	371	334 (90.0)	4.90 (1.58)	1.0	4.00	5.25	6.25	7.0	
Week 52	Tezepelumab	380	342 (90.0)	5.24 (1.45)	1.0	4.25	5.50	6.25	7.0	
	Placebo	371	321 (86.5)	4.91 (1.54)	1.0	4.00	5.25	6.00	7.0	

Note: DITTl - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QEC\_ALMH0: Course of AQLQ+12 environmental stimuli score  
 DITTl - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 environmental stimuli score	Week 4	Tezepelumab	380	367 (96.6)	0.87 (1.26)	-4.3	0.00	0.75	1.50	5.3	0.19 [0.04, 0.34]
		Placebo	371	358 (96.5)	0.64 (1.12)	-3.0	0.00	0.50	1.25	4.5	
	Week 12	Tezepelumab	380	364 (95.8)	1.10 (1.36)	-2.5	0.00	1.00	2.00	5.5	0.17 [0.02, 0.31]
		Placebo	371	354 (95.4)	0.88 (1.23)	-3.8	0.00	0.75	1.50	4.5	
	Week 24	Tezepelumab	380	352 (92.6)	1.26 (1.50)	-4.3	0.25	1.00	2.25	5.5	0.20 [0.05, 0.35]
		Placebo	371	336 (90.6)	0.98 (1.36)	-2.3	0.00	0.75	1.75	4.8	
	Week 36	Tezepelumab	380	350 (92.1)	1.29 (1.46)	-3.3	0.25	1.25	2.25	5.8	0.20 [0.05, 0.35]
		Placebo	371	333 (89.8)	1.01 (1.35)	-2.8	0.25	1.00	1.75	5.3	
	Week 52	Tezepelumab	380	342 (90.0)	1.37 (1.50)	-2.8	0.25	1.25	2.25	6.0	0.23 [0.08, 0.38]
		Placebo	371	320 (86.3)	1.04 (1.35)	-2.8	0.25	1.00	2.00	5.5	

Note: DITTl - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QEC\_ALMC0: Change from baseline in AQLQ+12 environmental stimuli score - MMRM results  
 DITTL - adult

Change from baseline in AQLQ+12 environmental stimuli score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 4	Tezepelumab	380	367 (96.6)	0.87 (0.06)	(0.75, 0.98)	0.21 (0.08)	(0.04, 0.37)	0.013	*
	Placebo	371	358 (96.5)	0.66 (0.06)	(0.54, 0.77)				
Week 12	Tezepelumab	380	364 (95.8)	1.10 (0.06)	(0.98, 1.22)	0.21 (0.09)	(0.04, 0.38)	0.017	*
	Placebo	371	354 (95.4)	0.89 (0.06)	(0.77, 1.01)				
Week 24	Tezepelumab	380	352 (92.6)	1.24 (0.07)	(1.11, 1.37)	0.26 (0.10)	(0.07, 0.45)	0.008	*
	Placebo	371	336 (90.6)	0.98 (0.07)	(0.85, 1.12)				
Week 36	Tezepelumab	380	350 (92.1)	1.28 (0.07)	(1.14, 1.41)	0.27 (0.10)	(0.08, 0.46)	0.006	*
	Placebo	371	333 (89.8)	1.01 (0.07)	(0.87, 1.15)				
Week 52	Tezepelumab	380	342 (90.0)	1.36 (0.07)	(1.22, 1.49)	0.31 (0.10)	(0.12, 0.51)	0.001	*
	Placebo	371	320 (86.3)	1.04 (0.07)	(0.90, 1.18)				

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QGC\_ALMH0: Course of AQLQ+12 emotional function score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 emotional function score	Baseline	Tezepelumab	380	379 (99.7)	3.61 (1.45)	1.0	2.40	3.60	4.60	7.0	
		Placebo	371	369 (99.5)	3.73 (1.41)	1.0	2.80	3.80	4.80	7.0	
	Week 4	Tezepelumab	380	368 (96.8)	4.70 (1.48)	1.0	3.60	4.80	5.80	7.0	
		Placebo	371	358 (96.5)	4.52 (1.54)	1.0	3.60	4.60	5.80	7.0	
	Week 12	Tezepelumab	380	364 (95.8)	5.00 (1.56)	1.0	4.00	5.30	6.20	7.0	
		Placebo	371	355 (95.7)	4.85 (1.56)	1.0	3.80	5.20	6.20	7.0	
	Week 24	Tezepelumab	380	352 (92.6)	5.19 (1.56)	1.0	4.20	5.60	6.50	7.0	
		Placebo	371	337 (90.8)	4.88 (1.58)	1.0	3.80	5.20	6.20	7.0	
	Week 36	Tezepelumab	380	350 (92.1)	5.24 (1.58)	1.0	4.20	5.80	6.60	7.0	
		Placebo	371	334 (90.0)	4.96 (1.52)	1.0	4.00	5.20	6.20	7.0	
	Week 52	Tezepelumab	380	342 (90.0)	5.29 (1.52)	1.0	4.20	5.60	6.60	7.0	
		Placebo	371	321 (86.5)	5.02 (1.47)	1.0	4.20	5.20	6.20	7.0	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QGC\_ALMH0: Course of AQLQ+12 emotional function score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 emotional function score	Week 4	Tezepelumab	380	367 (96.6)	1.07 (1.38)	-2.8	0.00	0.80	2.00	5.2	0.21 [0.06, 0.35]
		Placebo	371	358 (96.5)	0.80 (1.23)	-3.0	0.00	0.80	1.60	4.8	
	Week 12	Tezepelumab	380	364 (95.8)	1.38 (1.51)	-3.4	0.20	1.20	2.40	5.2	0.18 [0.03, 0.32]
		Placebo	371	354 (95.4)	1.11 (1.46)	-2.6	0.20	1.00	2.00	6.0	
	Week 24	Tezepelumab	380	352 (92.6)	1.55 (1.66)	-5.2	0.40	1.40	2.60	5.6	0.26 [0.11, 0.41]
		Placebo	371	336 (90.6)	1.14 (1.45)	-2.6	0.20	1.20	2.00	6.0	
	Week 36	Tezepelumab	380	350 (92.1)	1.59 (1.65)	-3.4	0.40	1.40	2.80	5.4	0.25 [0.10, 0.41]
		Placebo	371	333 (89.8)	1.19 (1.46)	-5.0	0.20	1.00	2.00	6.0	
	Week 52	Tezepelumab	380	342 (90.0)	1.65 (1.60)	-3.0	0.40	1.60	2.80	5.6	0.26 [0.10, 0.41]
		Placebo	371	320 (86.3)	1.25 (1.52)	-2.8	0.20	1.00	2.20	6.0	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QGC\_ALMC0: Change from baseline in AQLQ+12 emotional function score - MMRM results  
 DITTL - adult

Change from baseline in AQLQ+12 emotional function score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)
Week 4	Tezepelumab	380	367 (96.6)	1.03 (0.06)	(0.91, 1.16)	0.21 (0.09)	(0.03, 0.38)	0.020 *
	Placebo	371	358 (96.5)	0.83 (0.06)	(0.70, 0.95)			
Week 12	Tezepelumab	380	364 (95.8)	1.36 (0.07)	(1.22, 1.49)	0.23 (0.10)	(0.04, 0.43)	0.019 *
	Placebo	371	354 (95.4)	1.12 (0.07)	(0.98, 1.26)			
Week 24	Tezepelumab	380	352 (92.6)	1.51 (0.07)	(1.37, 1.65)	0.36 (0.10)	(0.15, 0.56)	<0.001 *
	Placebo	371	336 (90.6)	1.15 (0.07)	(1.00, 1.30)			
Week 36	Tezepelumab	380	350 (92.1)	1.55 (0.07)	(1.40, 1.69)	0.34 (0.10)	(0.14, 0.55)	0.001 *
	Placebo	371	333 (89.8)	1.20 (0.07)	(1.06, 1.35)			
Week 52	Tezepelumab	380	342 (90.0)	1.62 (0.07)	(1.48, 1.77)	0.36 (0.10)	(0.16, 0.56)	<0.001 *
	Placebo	371	320 (86.3)	1.27 (0.07)	(1.12, 1.41)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QMC\_ALMH0: Course of AQLQ+12 symptom score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 symptom score	Baseline	Tezepelumab	380	379 (99.7)	3.62 (1.10)	1.0	2.83	3.67	4.33	6.3	
		Placebo	371	369 (99.5)	3.74 (1.06)	1.1	3.00	3.75	4.50	6.7	
	Week 4	Tezepelumab	380	368 (96.8)	4.75 (1.19)	1.2	3.96	4.75	5.75	7.0	
		Placebo	371	358 (96.5)	4.50 (1.22)	1.0	3.75	4.50	5.42	7.0	
	Week 12	Tezepelumab	380	364 (95.8)	5.06 (1.28)	1.2	4.25	5.33	6.00	7.0	
		Placebo	371	355 (95.7)	4.83 (1.25)	1.0	4.08	4.92	5.75	7.0	
	Week 24	Tezepelumab	380	352 (92.6)	5.21 (1.26)	1.1	4.25	5.50	6.25	7.0	
		Placebo	371	337 (90.8)	4.89 (1.30)	1.0	4.00	5.08	5.92	7.0	
	Week 36	Tezepelumab	380	350 (92.1)	5.24 (1.32)	1.6	4.25	5.58	6.25	7.0	
		Placebo	371	334 (90.0)	4.94 (1.28)	1.0	4.08	5.00	5.92	7.0	
	Week 52	Tezepelumab	380	342 (90.0)	5.36 (1.28)	1.4	4.42	5.58	6.42	7.0	
		Placebo	371	321 (86.5)	5.00 (1.30)	1.0	4.17	5.08	6.00	7.0	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1QMC\_ALMH0: Course of AQLQ+12 symptom score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 symptom score	Week 4	Tezepelumab	380	367 (96.6)	1.11 (1.23)	-2.2	0.17	1.00	1.83	5.1	0.31 [0.16, 0.45]
		Placebo	371	358 (96.5)	0.76 (1.02)	-2.9	0.17	0.75	1.33	4.6	
	Week 12	Tezepelumab	380	364 (95.8)	1.42 (1.38)	-2.3	0.33	1.25	2.33	5.6	0.28 [0.13, 0.43]
		Placebo	371	354 (95.4)	1.07 (1.17)	-2.5	0.33	1.00	1.67	5.6	
	Week 24	Tezepelumab	380	352 (92.6)	1.56 (1.46)	-4.3	0.50	1.50	2.58	5.6	0.33 [0.18, 0.48]
		Placebo	371	336 (90.6)	1.13 (1.22)	-2.8	0.33	1.08	1.83	5.8	
	Week 36	Tezepelumab	380	350 (92.1)	1.59 (1.43)	-2.8	0.58	1.50	2.58	5.7	0.32 [0.17, 0.47]
		Placebo	371	333 (89.8)	1.16 (1.28)	-2.4	0.25	1.00	2.00	5.8	
	Week 52	Tezepelumab	380	342 (90.0)	1.71 (1.40)	-2.9	0.83	1.67	2.67	5.6	0.37 [0.22, 0.53]
		Placebo	371	320 (86.3)	1.21 (1.29)	-1.7	0.25	1.08	2.08	4.9	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022



Table NT1QMC\_ALMC0: Change from baseline in AQLQ+12 symptom score - MMRM results  
 DITTL - adult

Change from baseline in AQLQ+12 symptom score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	380	367 (96.6)	1.08 (0.05)	(0.97, 1.19)	0.29 (0.08)	(0.14, 0.44)	<0.001 *
	Placebo	371	358 (96.5)	0.79 (0.05)	(0.68, 0.89)			
Week 12	Tezepelumab	380	364 (95.8)	1.40 (0.06)	(1.28, 1.52)	0.32 (0.09)	(0.16, 0.49)	<0.001 *
	Placebo	371	354 (95.4)	1.07 (0.06)	(0.95, 1.19)			
Week 24	Tezepelumab	380	352 (92.6)	1.51 (0.06)	(1.39, 1.64)	0.38 (0.09)	(0.20, 0.56)	<0.001 *
	Placebo	371	336 (90.6)	1.14 (0.06)	(1.01, 1.26)			
Week 36	Tezepelumab	380	350 (92.1)	1.55 (0.06)	(1.43, 1.68)	0.39 (0.09)	(0.21, 0.58)	<0.001 *
	Placebo	371	333 (89.8)	1.16 (0.07)	(1.03, 1.29)			
Week 52	Tezepelumab	380	342 (90.0)	1.67 (0.06)	(1.54, 1.80)	0.45 (0.09)	(0.26, 0.63)	<0.001 *
	Placebo	371	320 (86.3)	1.22 (0.07)	(1.09, 1.35)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.

Source Data: aqlq, created on: 21FEB2022

Table NT1GTC\_ILMH0: Course of SGRQ total score  
 DITTL

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
SGRQ total score	Baseline	Tezepelumab	395	326 (82.5)	56.48 (19.55)	5.7	41.17	56.99	71.25	99.2
		Placebo	391	323 (82.6)	53.36 (19.08)	5.8	40.46	54.44	67.11	95.5
	Week 24	Tezepelumab	395	362 (91.6)	36.24 (23.39)	0.0	17.54	32.42	53.28	96.4
		Placebo	391	348 (89.0)	40.42 (21.68)	0.0	24.76	39.39	55.14	94.4
	Week 52	Tezepelumab	395	351 (88.9)	35.23 (23.86)	0.0	15.84	31.15	54.37	94.6
		Placebo	391	339 (86.7)	39.62 (22.72)	0.0	21.63	39.21	55.50	94.4

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.

Source Data: asgrq, created on: 20FEB2022

Table NT1GTC\_ILMH0: Course of SGRQ total score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ total score	Week 24	Tezepelumab	395	299 (75.7)	-20.87 (21.74)	-81.7	-34.29	-18.02	-6.80	56.5	-0.38 [-0.54, -0.21]
		Placebo	391	288 (73.7)	-13.29 (18.25)	-68.6	-25.00	-11.12	-1.41	47.5	
	Week 52	Tezepelumab	395	289 (73.2)	-22.69 (22.44)	-77.8	-37.18	-21.49	-8.21	46.3	-0.41 [-0.58, -0.25]
		Placebo	391	281 (71.9)	-14.08 (18.93)	-69.1	-26.61	-11.43	-2.24	53.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.

Source Data: asgrq, created on: 20FEB2022

Table NT1GTC\_ILMC0: Change from baseline in SGRQ total score - MMRM results  
 DITTTL

Change from baseline in SGRQ total score				Repeated measures analysis					
				Change from Baseline			Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 24	Tezepelumab	395	299 (75.7)	-20.36 (1.09)	(-22.49, -18.22)	-6.58 (1.55)	(-9.63, -3.54)	<0.001 *	
	Placebo	391	288 (73.7)	-13.77 (1.10)	(-15.93, -11.61)				
Week 52	Tezepelumab	395	289 (73.2)	-22.18 (1.14)	(-24.42, -19.94)	-7.61 (1.62)	(-10.79, -4.42)	<0.001 *	
	Placebo	391	281 (71.9)	-14.57 (1.15)	(-16.84, -12.31)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

SGRQ = St George s respiratory questionnaire.

Source Data: asgrq, created on: 20FEB2022

Table ST1GTC\_ILMH0: Course of SGRQ total score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
SGRQ total score	Baseline	Tezepelumab	73	73 (100.0)	56.42 (20.60)	3.2	43.56	57.34	71.84	97.5	
		Placebo	76	73 (96.1)	58.67 (18.50)	9.5	47.10	61.07	73.49	94.6	
	Week 48	Tezepelumab	73	65 (89.0)	41.08 (25.61)	0.0	22.39	37.33	60.34	87.9	
		Placebo	76	67 (88.2)	53.64 (24.24)	0.0	36.47	58.62	71.37	93.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20FEB2022

Table ST1GTC\_ILMH0: Course of SGRQ total score  
 DITTL

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ Week 48 total score	Tezepelumab	73	65 (89.0)	-14.35 (22.14)	-73.6	-26.24	-12.07	-3.62	36.4	-0.46 [-0.81, -0.11]
	Placebo	76	65 (85.5)	-4.89 (18.92)	-56.0	-15.83	-2.93	5.16	30.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20FEB2022

Table ST1GTC\_ILMC0: Change from baseline in SGRQ total score - MMRM results  
 DITTLL

Change from baseline in SGRQ total score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 48	Tezepelumab	73	65 (89.0)	-14.66 (2.49)	(-19.59, -9.73)	-10.08 (3.53)	(-17.06, -3.10)	0.005 *
	Placebo	76	65 (85.5)	-4.58 (2.49)	(-9.51, 0.35)			

Note: DITTLL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.  
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

SGRQ = St George s respiratory questionnaire.

Source Data: asgrq, created on: 20FEB2022

Table DT1GTC\_BLMH0: Course of SGRQ total score  
 DITTNL - LTE

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
SGRQ total score	Baseline	Teze+Teze	310	248 (80.0)	57.59 (19.19)	5.7	42.71	57.70	71.49	99.2
		Pbo+Pbo	149	117 (78.5)	53.15 (19.29)	10.1	40.26	53.58	66.81	95.5
	Week 24	Teze+Teze	310	301 (97.1)	37.34 (23.66)	0.0	18.37	33.28	53.96	96.4
		Pbo+Pbo	149	141 (94.6)	41.47 (23.05)	0.0	24.01	43.20	59.01	94.4
	Week 52	Teze+Teze	310	298 (96.1)	36.19 (23.80)	0.0	16.86	31.80	55.21	94.6
		Pbo+Pbo	149	143 (96.0)	40.22 (22.95)	0.0	22.46	42.30	55.42	92.8
	Week 76	Teze+Teze	310	304 (98.1)	32.38 (20.54)	0.0	16.07	29.58	48.75	86.0
		Pbo+Pbo	149	146 (98.0)	37.32 (21.98)	0.0	19.52	40.98	51.91	84.8
	Week 104	Teze+Teze	310	295 (95.2)	30.12 (21.04)	0.0	14.39	25.62	45.04	91.0
		Pbo+Pbo	149	143 (96.0)	35.41 (21.14)	0.0	17.41	36.39	50.46	86.8

Note: DITTNL - LTE = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20JUL2022



Table DT1GTC\_BLMH0: Course of SGRQ total score  
 DITTNL - LTE

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ total score	Week 24	Teze+Teze	310	243 (78.4)	-20.91 (21.60)	-81.7	-34.29	-18.02	-7.24	56.5	-0.41 [-0.63, -0.18]
		Pbo+Pbo	149	113 (75.8)	-12.70 (16.42)	-60.6	-24.58	-12.34	-3.17	29.4	
	Week 52	Teze+Teze	310	238 (76.8)	-22.94 (22.29)	-77.8	-36.84	-21.51	-8.40	46.3	-0.43 [-0.66, -0.21]
		Pbo+Pbo	149	112 (75.2)	-13.92 (17.13)	-61.0	-26.50	-11.37	-2.27	22.4	
	Week 76	Teze+Teze	310	242 (78.1)	-26.27 (20.97)	-89.2	-40.65	-23.92	-11.09	22.3	-0.46 [-0.69, -0.24]
		Pbo+Pbo	149	114 (76.5)	-16.88 (18.72)	-70.7	-27.47	-15.68	-7.46	27.4	
	Week 104	Teze+Teze	310	233 (75.2)	-28.46 (21.44)	-88.9	-43.88	-28.52	-12.76	37.9	-0.44 [-0.67, -0.22]
		Pbo+Pbo	149	113 (75.8)	-19.43 (17.91)	-70.6	-27.40	-15.91	-9.04	17.5	

Note: DITTNL - LTE = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20JUL2022

Table DT1GTC\_BLMC0: Change from baseline in SGRQ total score - MMRM results  
 DITTNL - LTE

Change from baseline in SGRQ total score				Repeated measures analysis					
				Change from Baseline			Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 24	Teze+Teze	310	243 (78.4)	-20.37 (1.24)	(-22.80, -17.94)	-6.61 (2.19)	(-10.92, -2.29)	0.003 *	
	Pbo+Pbo	149	113 (75.8)	-13.76 (1.81)	(-17.32, -10.21)				
Week 52	Teze+Teze	310	238 (76.8)	-22.78 (1.28)	(-25.29, -20.27)	-7.82 (2.26)	(-12.27, -3.37)	<0.001 *	
	Pbo+Pbo	149	112 (75.2)	-14.96 (1.86)	(-18.62, -11.30)				
Week 76	Teze+Teze	310	242 (78.1)	-25.59 (1.18)	(-27.91, -23.28)	-7.35 (2.09)	(-11.45, -3.24)	<0.001 *	
	Pbo+Pbo	149	114 (76.5)	-18.25 (1.72)	(-21.63, -14.87)				
Week 104	Teze+Teze	310	233 (75.2)	-27.19 (1.19)	(-29.53, -24.85)	-6.66 (2.10)	(-10.78, -2.53)	0.002 *	
	Pbo+Pbo	149	113 (75.8)	-20.54 (1.73)	(-23.93, -17.14)				

Note: DITTNL - LTE = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.  
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.  
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.  
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.  
 SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20JUL2022

Table NT1GMC\_ILMH0: Course of SGRQ symptom score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
SGRQ symptom score	Baseline	Tezepelumab	395	326 (82.5)	69.56 (19.02)	11.9	57.89	73.78	83.91	100.0	
		Placebo	391	323 (82.6)	66.76 (20.38)	0.0	53.69	69.42	83.44	100.0	
	Week 24	Tezepelumab	395	362 (91.6)	40.28 (26.72)	0.0	18.34	38.73	60.21	97.5	
		Placebo	391	348 (89.0)	49.88 (27.00)	0.0	28.20	51.99	73.03	100.0	
	Week 52	Tezepelumab	395	351 (88.9)	37.22 (27.11)	0.0	13.34	35.77	60.57	97.5	
		Placebo	391	339 (86.7)	48.03 (26.29)	0.0	27.77	48.27	69.45	100.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.

Source Data: asgrq, created on: 20FEB2022

Table NT1GMC\_ILMH0: Course of SGRQ symptom score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ symptom score	Week 24	Tezepelumab	395	299 (75.7)	-29.66 (27.89)	-96.0	-49.70	-27.09	-9.57	43.2	-0.49 [-0.66, -0.33]
		Placebo	391	288 (73.7)	-16.64 (24.65)	-82.0	-35.48	-14.88	0.00	69.4	
	Week 52	Tezepelumab	395	289 (73.2)	-33.22 (28.54)	-90.9	-55.39	-31.23	-11.23	36.3	-0.55 [-0.71, -0.38]
		Placebo	391	281 (71.9)	-18.35 (25.89)	-81.5	-36.18	-14.99	-1.99	56.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.

Source Data: asgrq, created on: 20FEB2022

Table NT1GMC\_ILMC0: Change from baseline in SGRQ symptom score - MMRM results  
 DITTTL

Change from baseline in SGRQ symptom score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 24	Tezepelumab	395	299 (75.7)	-28.73 (1.42)	(-31.51, -25.95)	-11.37 (2.02)	(-15.34, -7.41)	<0.001 *	
	Placebo	391	288 (73.7)	-17.36 (1.43)	(-20.18, -14.54)				
Week 52	Tezepelumab	395	289 (73.2)	-32.46 (1.47)	(-35.35, -29.58)	-13.57 (2.09)	(-17.68, -9.46)	<0.001 *	
	Placebo	391	281 (71.9)	-18.89 (1.48)	(-21.81, -15.98)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

SGRQ = St George s respiratory questionnaire.

Source Data: asgrq, created on: 20FEB2022

Table ST1GMC\_ILMH0: Course of SGRQ symptom score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
SGRQ symptom score	Baseline	Tezepelumab	73	73 (100.0)	69.15 (18.45)	17.5	59.15	70.08	80.89	100.0	
		Placebo	76	73 (96.1)	64.66 (19.88)	0.0	53.10	65.36	79.05	100.0	
	Week 48	Tezepelumab	73	65 (89.0)	45.41 (29.53)	0.0	23.76	38.58	72.21	100.0	
		Placebo	76	67 (88.2)	55.77 (28.05)	0.0	33.77	61.33	77.49	100.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.

Source Data: asgrq, created on: 20FEB2022

Table ST1GMC\_ILMH0: Course of SGRQ symptom score  
 DITTL

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ Week 48 symptom score	Tezepelumab	73	65 (89.0)	-23.94 (26.61)	-76.2	-42.37	-24.35	-4.18	40.0	-0.61 [-0.96, -0.26]
	Placebo	76	65 (85.5)	-8.58 (23.67)	-73.0	-22.53	-8.76	5.43	43.9	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.

Source Data: asgrq, created on: 20FEB2022

Table ST1GMC\_ILMC0: Change from baseline in SGRQ symptom score - MMRM results  
 DITTTL

Change from baseline in SGRQ symptom score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 48	Tezepelumab	73	65 (89.0)	-23.25 (3.09)	(-29.37, -17.13)	-13.98 (4.40)	(-22.68, -5.28)	0.002 *
	Placebo	76	65 (85.5)	-9.27 (3.09)	(-15.39, -3.15)			

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

SGRQ = St George s respiratory questionnaire.

Source Data: asgrq, created on: 20FEB2022



Table DT1GMC\_BLMH0: Course of SGRQ symptom score  
 DITTNL - LTE

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
SGRQ symptom score	Baseline	Teze+Teze	310	248 (80.0)	69.30 (19.48)	11.9	57.06	73.88	83.77	100.0	
		Pbo+Pbo	149	117 (78.5)	66.59 (20.78)	0.0	54.61	69.24	81.49	100.0	
	Week 24	Teze+Teze	310	301 (97.1)	39.96 (26.89)	0.0	16.69	37.86	61.58	97.5	
		Pbo+Pbo	149	141 (94.6)	50.35 (28.65)	0.0	27.29	52.69	75.00	100.0	
	Week 52	Teze+Teze	310	298 (96.1)	36.80 (27.03)	0.0	13.34	35.11	60.21	97.5	
		Pbo+Pbo	149	143 (96.0)	48.10 (26.91)	0.0	26.25	49.01	68.59	100.0	
	Week 76	Teze+Teze	310	304 (98.1)	34.94 (25.12)	0.0	13.56	31.80	54.20	95.5	
		Pbo+Pbo	149	146 (98.0)	45.84 (26.77)	0.0	25.10	45.90	66.40	100.0	
	Week 104	Teze+Teze	310	295 (95.2)	32.20 (25.36)	0.0	11.73	27.08	51.20	100.0	
		Pbo+Pbo	149	143 (96.0)	45.10 (26.94)	0.0	23.97	45.81	65.42	100.0	

Note: DITTNL - LTE = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20JUL2022

Table DT1GMC\_BLMH0: Course of SGRQ symptom score  
 DITTNL - LTE

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ symptom score	Week 24	Teze+Teze	310	243 (78.4)	-30.15 (28.07)	-96.0	-50.48	-27.43	-10.54	43.2	-0.49 [-0.72, -0.26]
		Pbo+Pbo	149	113 (75.8)	-17.19 (22.49)	-67.5	-34.04	-16.79	0.00	24.4	
	Week 52	Teze+Teze	310	238 (76.8)	-34.08 (28.06)	-90.9	-55.43	-33.48	-11.70	36.3	-0.57 [-0.80, -0.34]
		Pbo+Pbo	149	112 (75.2)	-18.97 (23.01)	-79.5	-35.27	-15.11	-3.10	40.0	
	Week 76	Teze+Teze	310	242 (78.1)	-35.09 (26.37)	-95.0	-53.44	-35.89	-18.42	36.2	-0.50 [-0.72, -0.27]
		Pbo+Pbo	149	114 (76.5)	-22.18 (24.75)	-79.5	-38.90	-19.80	-5.42	51.2	
	Week 104	Teze+Teze	310	233 (75.2)	-37.11 (27.36)	-100.0	-57.50	-35.86	-18.36	55.3	-0.51 [-0.74, -0.28]
		Pbo+Pbo	149	113 (75.8)	-23.61 (24.83)	-72.3	-42.73	-23.20	-6.05	39.1	

Note: DITTNL - LTE = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20JUL2022

Table DT1GMC\_BLMC0: Change from baseline in SGRQ symptom score - MMRM results  
 DITTNL - LTE

Change from baseline in SGRQ symptom score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 24	Teze+Teze	310	243 (78.4)	-29.46 (1.60)	(-32.60, -26.32)	-11.05 (2.83)	(-16.62, -5.49)	<0.001 *	
	Pbo+Pbo	149	113 (75.8)	-18.41 (2.33)	(-23.00, -13.81)				
Week 52	Teze+Teze	310	238 (76.8)	-34.01 (1.61)	(-37.17, -30.85)	-14.83 (2.84)	(-20.42, -9.24)	<0.001 *	
	Pbo+Pbo	149	112 (75.2)	-19.19 (2.34)	(-23.79, -14.58)				
Week 76	Teze+Teze	310	242 (78.1)	-34.54 (1.54)	(-37.57, -31.50)	-11.34 (2.73)	(-16.70, -5.97)	<0.001 *	
	Pbo+Pbo	149	114 (76.5)	-23.20 (2.25)	(-27.62, -18.78)				
Week 104	Teze+Teze	310	233 (75.2)	-36.34 (1.58)	(-39.44, -33.23)	-11.87 (2.78)	(-17.33, -6.41)	<0.001 *	
	Pbo+Pbo	149	113 (75.8)	-24.47 (2.28)	(-28.96, -19.98)				

Note: DITTNL - LTE = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.  
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.  
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.  
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.  
 SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20JUL2022

Table NT1GAC\_ILMH0: Course of SGRQ activities score  
 DITTLL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
SGRQ activities score	Baseline	Tezepelumab	395	326 (82.5)	65.08 (22.56)	0.0	53.53	66.89	80.32	100.0	
		Placebo	391	323 (82.6)	63.14 (22.94)	0.0	48.44	61.91	80.32	100.0	
	Week 24	Tezepelumab	395	362 (91.6)	47.29 (28.77)	0.0	25.07	47.70	66.98	100.0	
		Placebo	391	348 (89.0)	49.44 (26.95)	0.0	29.63	53.53	67.05	100.0	
	Week 52	Tezepelumab	395	351 (88.9)	46.37 (30.45)	0.0	18.47	47.69	72.33	100.0	
		Placebo	391	339 (86.7)	50.74 (28.38)	0.0	29.63	53.62	72.82	100.0	

Note: DITTLL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.

Source Data: asgrq, created on: 20FEB2022

Table NT1GAC\_ILMH0: Course of SGRQ activities score  
 DITTLL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ activities score	Week 24	Tezepelumab	395	299 (75.7)	-18.74 (26.16)	-92.5	-35.06	-14.34	0.00	70.0	-0.22 [-0.38, -0.06]
		Placebo	391	288 (73.7)	-13.50 (20.99)	-80.3	-24.42	-11.77	0.00	50.7	
	Week 52	Tezepelumab	395	289 (73.2)	-20.91 (27.57)	-92.5	-39.14	-19.07	0.00	70.0	-0.32 [-0.49, -0.16]
		Placebo	391	281 (71.9)	-12.81 (22.56)	-79.7	-25.02	-11.37	0.00	76.0	

Note: DITTLL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.

Source Data: asgrq, created on: 20FEB2022

Table NT1GAC\_ILMC0: Change from baseline in SGRQ activities score - MMRM results  
 DITTTL

Change from baseline in SGRQ activities score				Repeated measures analysis					
				Change from Baseline			Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 24	Tezepelumab	395	299 (75.7)	-18.44 (1.32)	(-21.03, -15.84)	-4.66 (1.88)	(-8.36, -0.97)	0.013 *	
	Placebo	391	288 (73.7)	-13.77 (1.34)	(-16.40, -11.14)				
Week 52	Tezepelumab	395	289 (73.2)	-20.52 (1.43)	(-23.32, -17.71)	-7.46 (2.03)	(-11.44, -3.47)	<0.001 *	
	Placebo	391	281 (71.9)	-13.06 (1.44)	(-15.89, -10.23)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

SGRQ = St George s respiratory questionnaire.

Source Data: asgrq, created on: 20FEB2022

Table ST1GAC\_ILMH0: Course of SGRQ activities score  
 DITTl

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
SGRQ activities score	Baseline	Tezepelumab	73	73 (100.0)	64.50 (23.75)	0.0	49.91	66.19	80.53	100.0	
		Placebo	76	73 (96.1)	69.56 (24.50)	0.0	59.46	72.33	86.67	100.0	
	Week 48	Tezepelumab	73	65 (89.0)	51.67 (29.02)	0.0	35.07	53.62	72.82	100.0	
		Placebo	76	67 (88.2)	67.66 (27.89)	0.0	51.41	73.68	92.51	100.0	

Note: DITTl = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.

Source Data: asgrq, created on: 20FEB2022

Table ST1GAC\_ILMH0: Course of SGRQ activities score  
 DITTL

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ Week 48 activities score	Tezepelumab	73	65 (89.0)	-10.88 (26.00)	-92.5	-24.40	-5.93	5.12	55.5	-0.40 [-0.74, -0.05]
	Placebo	76	65 (85.5)	-1.63 (20.19)	-61.1	-12.84	-0.06	13.33	41.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20FEB2022



Table ST1GAC\_ILMC0: Change from baseline in SGRQ activities score - MMRM results  
 DITTTL

Change from baseline in SGRQ activities score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 48	Tezepelumab	73	65 (89.0)	-11.73 (2.78)	(-17.23, -6.22)	-10.95 (3.95)	(-18.77, -3.13)	0.006	*
	Placebo	76	65 (85.5)	-0.78 (2.78)	(-6.29, 4.73)				

Note: DITTTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

SGRQ = St George s respiratory questionnaire.

Source Data: asgrq, created on: 20FEB2022

Table DT1GAC\_BLMH0: Course of SGRQ activities score  
 DITTNL - LTE

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
SGRQ activities score	Baseline	Teze+Teze	310	248 (80.0)	66.31 (21.12)	0.0	53.62	66.92	80.53	100.0	
		Pbo+Pbo	149	117 (78.5)	63.02 (23.33)	0.0	48.44	66.19	80.43	100.0	
	Week 24	Teze+Teze	310	301 (97.1)	49.05 (28.85)	0.0	29.49	49.20	72.29	100.0	
		Pbo+Pbo	149	141 (94.6)	50.18 (28.59)	0.0	29.49	53.62	68.70	100.0	
	Week 52	Teze+Teze	310	298 (96.1)	48.25 (29.95)	0.0	23.33	48.41	72.82	100.0	
		Pbo+Pbo	149	143 (96.0)	51.48 (29.60)	0.0	30.37	59.46	73.24	100.0	
	Week 76	Teze+Teze	310	304 (98.1)	44.69 (26.57)	0.0	23.33	47.69	66.19	100.0	
		Pbo+Pbo	149	146 (98.0)	47.65 (26.92)	0.0	29.31	53.62	66.19	100.0	
	Week 104	Teze+Teze	310	295 (95.2)	42.34 (27.11)	0.0	18.05	47.24	66.09	100.0	
		Pbo+Pbo	149	143 (96.0)	47.32 (27.18)	0.0	23.59	53.62	66.74	100.0	

Note: DITTNL - LTE = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20JUL2022

Table DT1GAC\_BLMH0: Course of SGRQ activities score  
 DITTNL - LTE

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ activities score	Week 24	Teze+Teze	310	243 (78.4)	-18.11 (25.71)	-92.5	-31.27	-14.16	0.00	70.0	-0.18 [-0.41, 0.04]
		Pbo+Pbo	149	113 (75.8)	-13.66 (21.06)	-79.7	-25.10	-11.31	0.00	39.0	
	Week 52	Teze+Teze	310	238 (76.8)	-20.11 (27.36)	-92.5	-38.23	-18.15	0.00	70.0	-0.29 [-0.51, -0.06]
		Pbo+Pbo	149	112 (75.2)	-12.74 (22.35)	-79.7	-25.07	-12.00	1.26	38.7	
	Week 76	Teze+Teze	310	242 (78.1)	-22.93 (25.17)	-93.3	-38.89	-19.56	-6.62	53.5	-0.29 [-0.51, -0.07]
		Pbo+Pbo	149	114 (76.5)	-15.82 (23.34)	-87.2	-30.30	-13.47	0.00	33.8	
	Week 104	Teze+Teze	310	233 (75.2)	-25.55 (25.76)	-94.8	-44.11	-20.86	-6.85	47.9	-0.31 [-0.53, -0.08]
		Pbo+Pbo	149	113 (75.8)	-17.83 (23.77)	-81.2	-30.11	-17.35	-4.37	30.6	

Note: DITTNL - LTE = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20JUL2022

Table DT1GAC\_BLMC0: Change from baseline in SGRQ activities score - MMRM results  
 DITTNL - LTE

Change from baseline in SGRQ activities score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 24	Teze+Teze	310	243 (78.4)	-17.69 (1.53)	(-20.69, -14.68)	-3.74 (2.71)	(-9.06, 1.59)	0.168	
	Pbo+Pbo	149	113 (75.8)	-13.95 (2.23)	(-18.34, -9.56)				
Week 52	Teze+Teze	310	238 (76.8)	-20.18 (1.63)	(-23.39, -16.98)	-6.82 (2.88)	(-12.50, -1.15)	0.019 *	
	Pbo+Pbo	149	112 (75.2)	-13.36 (2.38)	(-18.03, -8.69)				
Week 76	Teze+Teze	310	242 (78.1)	-22.36 (1.49)	(-25.28, -19.43)	-5.47 (2.63)	(-10.65, -0.30)	0.038 *	
	Pbo+Pbo	149	114 (76.5)	-16.88 (2.17)	(-21.15, -12.62)				
Week 104	Teze+Teze	310	233 (75.2)	-24.43 (1.54)	(-27.46, -21.41)	-6.00 (2.71)	(-11.32, -0.67)	0.027 *	
	Pbo+Pbo	149	113 (75.8)	-18.44 (2.23)	(-22.81, -14.06)				

Note: DITTNL - LTE = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.  
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.  
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.  
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.  
 SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20JUL2022

Table NT1GRC\_ILMH0: Course of SGRQ impact score  
 DITTLL

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]	
SGRQ impact score	Baseline	Tezepelumab	395	326 (82.5)	47.40 (22.51)	0.0	29.76	47.19	62.85	100.0	
		Placebo	391	323 (82.6)	43.50 (20.48)	1.6	28.27	44.19	56.69	92.1	
	Week 24	Tezepelumab	395	362 (91.6)	28.57 (23.88)	0.0	8.03	23.41	44.15	98.9	
		Placebo	391	348 (89.0)	32.24 (21.63)	0.0	15.30	29.23	47.67	91.8	
	Week 52	Tezepelumab	395	351 (88.9)	28.17 (23.53)	0.0	8.05	22.88	45.17	98.8	
		Placebo	391	339 (86.7)	30.55 (22.48)	0.0	12.59	27.13	44.06	96.9	

Note: DITTLL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.

Source Data: asgrq, created on: 20FEB2022

Table NT1GRC\_ILMH0: Course of SGRQ impact score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ impact score	Week 24	Tezepelumab	395	299 (75.7)	-19.36 (22.80)	-81.0	-35.33	-16.32	-4.62	73.6	-0.34 [-0.50, -0.18]
		Placebo	391	288 (73.7)	-12.10 (19.73)	-81.1	-25.12	-10.33	2.13	45.6	
	Week 52	Tezepelumab	395	289 (73.2)	-20.41 (23.13)	-84.3	-35.21	-17.72	-5.76	56.4	-0.32 [-0.49, -0.16]
		Placebo	391	281 (71.9)	-13.47 (19.66)	-80.9	-24.02	-12.61	-0.75	40.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.

Source Data: asgrq, created on: 20FEB2022

Table NT1GRC\_ILMC0: Change from baseline in SGRQ impact score - MMRM results  
 DITTLL

Change from baseline in SGRQ impact score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 24	Tezepelumab	395	299 (75.7)	-18.68 (1.10)	(-20.84, -16.51)	-5.90 (1.57)	(-8.98, -2.81)	<0.001 *	
	Placebo	391	288 (73.7)	-12.78 (1.12)	(-14.97, -10.59)				
Week 52	Tezepelumab	395	289 (73.2)	-19.70 (1.12)	(-21.91, -17.49)	-5.43 (1.60)	(-8.58, -2.29)	<0.001 *	
	Placebo	391	281 (71.9)	-14.27 (1.14)	(-16.50, -12.04)				

Note: DITTLL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

SGRQ = St George s respiratory questionnaire.

Source Data: asgrq, created on: 20FEB2022

Table ST1GRC\_ILMH0: Course of SGRQ impact score  
 DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
SGRQ impact score	Baseline	Tezepelumab	73	73 (100.0)	47.73 (23.57)	0.0	30.31	45.90	64.14	95.3	
		Placebo	76	73 (96.1)	50.52 (20.29)	3.5	35.88	53.78	65.24	94.4	
	Week 48	Tezepelumab	73	65 (89.0)	33.59 (26.03)	0.0	10.92	29.00	54.06	82.6	
		Placebo	76	67 (88.2)	44.90 (25.00)	0.0	24.30	48.46	65.24	94.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.

Source Data: asgrq, created on: 20FEB2022



Table ST1GRC\_ILMH0: Course of SGRQ impact score  
 DITTL

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ Week 48 impact score	Tezepelumab	73	65 (89.0)	-13.31 (23.87)	-76.5	-23.12	-10.80	1.03	38.1	-0.34 [-0.68, 0.01]
	Placebo	76	65 (85.5)	-5.61 (21.59)	-56.0	-18.52	-4.89	10.13	40.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20FEB2022

Table ST1GRC\_ILMC0: Change from baseline in SGRQ impact score - MMRM results  
 DITTLL

Change from baseline in SGRQ impact score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 48	Tezepelumab	73	65 (89.0)	-13.86 (2.65)	(-19.10, -8.61)	-8.79 (3.75)	(-16.21, -1.36)	0.021	*
	Placebo	76	65 (85.5)	-5.07 (2.65)	(-10.31, 0.18)				

Note: DITTLL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

SGRQ = St George s respiratory questionnaire.

Source Data: asgrq, created on: 20FEB2022

Table DT1GRC\_BLMH0: Course of SGRQ impact score  
 DITTNL - LTE

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
SGRQ impact score	Baseline	Teze+Teze	310	248 (80.0)	48.88 (22.62)	1.6	30.03	48.21	63.93	100.0	
		Pbo+Pbo	149	117 (78.5)	43.19 (20.51)	1.7	28.96	43.25	57.14	92.1	
	Week 24	Teze+Teze	310	301 (97.1)	29.74 (24.36)	0.0	8.73	24.35	45.61	98.9	
		Pbo+Pbo	149	141 (94.6)	33.64 (22.64)	0.0	15.08	30.05	51.54	91.8	
	Week 52	Teze+Teze	310	298 (96.1)	29.03 (23.79)	0.0	8.07	23.48	47.17	98.8	
		Pbo+Pbo	149	143 (96.0)	31.25 (22.32)	0.0	13.70	31.22	44.58	96.9	
	Week 76	Teze+Teze	310	304 (98.1)	24.53 (20.63)	0.0	6.94	19.07	39.88	85.0	
		Pbo+Pbo	149	146 (98.0)	28.74 (21.83)	0.0	8.87	25.93	43.62	83.6	
	Week 104	Teze+Teze	310	295 (95.2)	22.50 (20.50)	0.0	5.83	16.94	35.76	95.5	
		Pbo+Pbo	149	143 (96.0)	25.56 (20.28)	0.0	6.12	24.78	40.30	79.0	

Note: DITTNL - LTE = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20JUL2022

Table DT1GRC\_BLMH0: Course of SGRQ impact score  
 DITTNL - LTE

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ impact score	Week 24	Teze+Teze	310	243 (78.4)	-19.63 (22.80)	-81.0	-34.73	-17.04	-5.76	73.6	-0.42 [-0.64, -0.19]
		Pbo+Pbo	149	113 (75.8)	-10.70 (17.57)	-54.9	-22.37	-11.61	2.41	44.6	
	Week 52	Teze+Teze	310	238 (76.8)	-21.07 (23.32)	-84.3	-35.21	-19.25	-5.92	56.4	-0.37 [-0.60, -0.15]
		Pbo+Pbo	149	112 (75.2)	-12.97 (17.98)	-75.4	-23.48	-12.68	-0.85	25.6	
	Week 76	Teze+Teze	310	242 (78.1)	-25.37 (22.69)	-89.7	-39.42	-23.69	-9.34	24.9	-0.45 [-0.67, -0.22]
		Pbo+Pbo	149	114 (76.5)	-15.72 (19.36)	-59.2	-28.46	-14.68	-5.56	30.2	
	Week 104	Teze+Teze	310	233 (75.2)	-27.34 (23.23)	-88.8	-41.82	-26.43	-10.07	39.1	-0.39 [-0.61, -0.16]
		Pbo+Pbo	149	113 (75.8)	-18.93 (18.03)	-80.7	-27.78	-15.70	-8.00	25.2	

Note: DITTNL - LTE = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20JUL2022

Table DT1GRC\_BLMC0: Change from baseline in SGRQ impact score - MMRM results  
 DITTNL - LTE

Change from baseline in SGRQ impact score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 24	Teze+Teze	310	243 (78.4)	-18.93 (1.25)	(-21.39, -16.46)	-6.46 (2.23)	(-10.84, -2.08)	0.004 *	
	Pbo+Pbo	149	113 (75.8)	-12.47 (1.84)	(-16.08, -8.86)				
Week 52	Teze+Teze	310	238 (76.8)	-20.57 (1.27)	(-23.06, -18.08)	-5.72 (2.24)	(-10.13, -1.31)	0.011 *	
	Pbo+Pbo	149	112 (75.2)	-14.85 (1.85)	(-18.48, -11.22)				
Week 76	Teze+Teze	310	242 (78.1)	-24.41 (1.18)	(-26.73, -22.10)	-6.74 (2.09)	(-10.84, -2.64)	0.001 *	
	Pbo+Pbo	149	114 (76.5)	-17.67 (1.72)	(-21.05, -14.29)				
Week 104	Teze+Teze	310	233 (75.2)	-25.75 (1.16)	(-28.03, -23.47)	-5.03 (2.05)	(-9.06, -1.00)	0.015 *	
	Pbo+Pbo	149	113 (75.8)	-20.72 (1.68)	(-24.03, -17.41)				

Note: DITTNL - LTE = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension.  
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.  
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.  
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.  
 SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20JUL2022

Table NT1GTC\_KLMH0: Course of SGRQ total score  
 DITTLL - adolescents

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
SGRQ total score	Baseline	Tezepelumab	15	13 (86.7)	52.82 (10.35)	35.6	46.75	54.43	60.07	71.3
		Placebo	20	17 (85.0)	41.33 (18.16)	14.0	27.68	40.68	50.80	76.6
	Week 24	Tezepelumab	15	13 (86.7)	26.98 (12.22)	6.2	19.21	26.91	32.98	45.3
		Placebo	20	17 (85.0)	28.08 (20.38)	0.4	9.42	29.07	37.25	62.4
	Week 52	Tezepelumab	15	12 (80.0)	32.95 (16.56)	7.2	21.97	30.54	41.32	62.1
		Placebo	20	20 (100.0)	26.79 (18.97)	0.0	11.97	19.81	42.23	62.4

Note: DITTLL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20FEB2022

Table NT1GTC\_KLMH0: Course of SGRQ total score  
 DITTLL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ total score	Week 24	Tezepelumab	15	11 (73.3)	-24.52 (11.37)	-47.6	-29.41	-25.99	-14.00	-7.1	-0.90 [-1.73, -0.07]
		Placebo	20	14 (70.0)	-14.42 (11.18)	-41.0	-17.33	-14.96	-4.82	2.1	
	Week 52	Tezepelumab	15	10 (66.7)	-19.73 (11.35)	-36.8	-28.47	-18.06	-12.29	1.1	-0.29 [-1.08, 0.49]
		Placebo	20	17 (85.0)	-16.00 (13.38)	-54.2	-18.24	-11.72	-9.35	3.1	

Note: DITTLL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20FEB2022

Table NT1GTC\_KLMC0: Change from baseline in SGRQ total score - MMRM results  
 DITTTL - adolescents

Change from baseline in SGRQ total score				Repeated measures analysis					
				Change from Baseline			Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 24	Tezepelumab	15	11 (73.3)	-23.72 (3.57)	(-31.09, -16.34)	-8.54 (4.87)	(-18.56, 1.48)	0.091	
	Placebo	20	14 (70.0)	-15.17 (3.08)	(-21.51, -8.84)				
Week 52	Tezepelumab	15	10 (66.7)	-19.14 (4.08)	(-27.53, -10.75)	-2.68 (5.25)	(-13.47, 8.10)	0.613	
	Placebo	20	17 (85.0)	-16.46 (3.11)	(-22.87, -10.05)				

Note: DITTTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

SGRQ = St George s respiratory questionnaire.

Source Data: asgrq, created on: 20FEB2022



Table DT1GTC\_MLMH0: Course of SGRQ total score  
 DITTNL - LTE - adolescents

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
SGRQ total score	Baseline	Teze+Teze	14	12 (85.7)	52.21 (10.57)	35.6	44.14	54.15	58.90	71.3
		Pbo+Pbo	12	11 (91.7)	44.46 (16.37)	16.8	39.39	43.36	51.74	76.6
	Week 24	Teze+Teze	14	14 (100.0)	27.01 (11.74)	6.2	19.21	27.18	32.98	45.3
		Pbo+Pbo	12	12 (100.0)	27.73 (20.86)	0.9	9.71	26.54	42.42	62.4
	Week 52	Teze+Teze	14	13 (92.9)	33.28 (15.90)	7.2	23.46	31.05	41.06	62.1
		Pbo+Pbo	12	12 (100.0)	25.45 (16.02)	6.8	12.54	19.42	41.50	48.7
	Week 76	Teze+Teze	14	13 (92.9)	24.99 (17.16)	2.3	8.16	25.17	34.30	56.9
		Pbo+Pbo	12	12 (100.0)	16.23 (16.63)	1.6	4.37	8.87	27.90	50.7
	Week 104	Teze+Teze	14	14 (100.0)	19.63 (13.02)	0.9	10.89	19.04	27.62	51.2
		Pbo+Pbo	12	12 (100.0)	15.56 (14.49)	1.7	4.45	10.44	26.13	49.3

Note: DITTNL - LTE - adolescents = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20JUL2022

Table DT1GTC\_MLMH0: Course of SGRQ total score  
 DITTNL - LTE - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ total score	Week 24	Teze+Teze	14	12 (85.7)	-23.65 (11.25)	-47.6	-29.07	-24.26	-14.04	-7.1	-0.54 [-1.37, 0.30]
		Pbo+Pbo	12	11 (91.7)	-16.86 (13.94)	-41.0	-29.97	-15.42	-3.22	2.1	
	Week 52	Teze+Teze	14	11 (78.6)	-19.73 (10.77)	-36.8	-28.47	-19.39	-12.29	1.1	-0.12 [-0.96, 0.72]
		Pbo+Pbo	12	11 (91.7)	-18.05 (16.27)	-54.2	-28.57	-11.72	-9.35	3.1	
	Week 76	Teze+Teze	14	11 (78.6)	-31.15 (16.94)	-51.6	-46.08	-35.26	-16.14	-4.0	-0.22 [-1.06, 0.62]
		Pbo+Pbo	12	11 (91.7)	-27.12 (19.93)	-70.7	-41.14	-14.85	-11.06	-9.5	
	Week 104	Teze+Teze	14	12 (85.7)	-33.21 (13.77)	-53.5	-42.07	-37.20	-25.39	-9.5	-0.35 [-1.17, 0.48]
		Pbo+Pbo	12	11 (91.7)	-27.64 (18.20)	-70.6	-36.24	-25.12	-12.83	-10.3	

Note: DITTNL - LTE - adolescents = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20JUL2022

Table DT1GTC\_MLMC0: Change from baseline in SGRQ total score - MMRM results  
 DITTNL - LTE - adolescents

Change from baseline in SGRQ total score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 24	Teze+Teze	14	12 (85.7)	-22.66 (3.80)	(-30.59, -14.73)	-4.63 (5.61)	(-16.34, 7.08)	0.419	
	Pbo+Pbo	12	11 (91.7)	-18.03 (3.99)	(-26.35, -9.71)				
Week 52	Teze+Teze	14	11 (78.6)	-18.31 (4.02)	(-26.66, -9.97)	0.91 (5.86)	(-11.25, 13.07)	0.878	
	Pbo+Pbo	12	11 (91.7)	-19.22 (4.11)	(-27.78, -10.67)				
Week 76	Teze+Teze	14	11 (78.6)	-29.84 (4.93)	(-40.13, -19.54)	-1.54 (7.19)	(-16.56, 13.47)	0.832	
	Pbo+Pbo	12	11 (91.7)	-28.29 (5.13)	(-39.02, -17.56)				
Week 104	Teze+Teze	14	12 (85.7)	-32.22 (4.23)	(-41.14, -23.31)	-3.41 (6.23)	(-16.51, 9.68)	0.591	
	Pbo+Pbo	12	11 (91.7)	-28.81 (4.44)	(-38.15, -19.47)				

Note: DITTNL - LTE - adolescents = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adolescents.  
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.  
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.  
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.  
 SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20JUL2022

Table NT1GMC\_KLMH0: Course of SGRQ symptom score  
 DITTLL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
SGRQ symptom score	Baseline	Tezepelumab	15	13 (86.7)	58.86 (18.26)	29.6	47.56	58.28	64.62	92.7	
		Placebo	20	17 (85.0)	61.14 (18.51)	31.7	45.84	63.64	72.82	97.5	
	Week 24	Tezepelumab	15	13 (86.7)	30.22 (23.88)	0.0	7.71	30.48	51.55	69.1	
		Placebo	20	17 (85.0)	39.42 (30.51)	0.0	11.88	47.46	59.20	95.0	
	Week 52	Tezepelumab	15	12 (80.0)	31.56 (28.27)	0.0	4.54	35.68	44.76	85.3	
		Placebo	20	20 (100.0)	38.10 (21.48)	0.0	24.35	42.16	47.72	80.2	

Note: DITTLL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20FEB2022

Table NT1GMC\_KLMH0: Course of SGRQ symptom score  
 DITTLL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ symptom score	Week 24	Tezepelumab	15	11 (73.3)	-25.09 (18.73)	-50.5	-43.14	-29.60	-11.38	4.9	-0.05 [-0.84, 0.74]
		Placebo	20	14 (70.0)	-24.01 (24.60)	-67.5	-46.58	-19.42	-2.45	9.6	
	Week 52	Tezepelumab	15	10 (66.7)	-27.51 (21.24)	-56.8	-40.81	-31.00	-7.44	8.8	-0.15 [-0.93, 0.63]
		Placebo	20	17 (85.0)	-24.61 (18.20)	-54.1	-36.85	-25.03	-9.05	11.2	

Note: DITTLL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20FEB2022

Table NT1GMC\_KLMC0: Change from baseline in SGRQ symptom score - MMRM results  
 DITTLL - adolescents

Change from baseline in SGRQ symptom score				Repeated measures analysis					
				Change from Baseline			Treatment Difference		
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 24	Tezepelumab	15	11 (73.3)	-25.23 (6.84)	(-39.39, -11.08)	-1.82 (9.05)	(-20.54, 16.90)	0.842	
	Placebo	20	14 (70.0)	-23.41 (5.93)	(-35.64, -11.18)				
Week 52	Tezepelumab	15	10 (66.7)	-27.98 (6.07)	(-40.47, -15.49)	-3.57 (7.70)	(-19.43, 12.29)	0.647	
	Placebo	20	17 (85.0)	-24.41 (4.72)	(-34.14, -14.69)				

Note: DITTLL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

SGRQ = St George s respiratory questionnaire.

Source Data: asgrq, created on: 20FEB2022

Table DT1GMC\_MLMH0: Course of SGRQ symptom score  
 DITTNL - LTE - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
SGRQ symptom score	Baseline	Teze+Teze	14	12 (85.7)	58.06 (18.83)	29.6	46.56	57.52	64.17	92.7	
		Pbo+Pbo	12	11 (91.7)	64.10 (17.45)	40.4	51.77	69.86	73.48	97.5	
	Week 24	Teze+Teze	14	14 (100.0)	30.48 (22.96)	0.0	7.71	31.95	51.55	69.1	
		Pbo+Pbo	12	12 (100.0)	43.73 (31.78)	0.0	14.58	53.59	60.28	95.0	
	Week 52	Teze+Teze	14	13 (92.9)	31.30 (27.08)	0.0	6.75	35.28	43.95	85.3	
		Pbo+Pbo	12	12 (100.0)	36.99 (17.41)	5.1	24.35	42.16	47.66	63.2	
	Week 76	Teze+Teze	14	13 (92.9)	27.15 (15.32)	0.0	16.82	27.82	38.96	50.1	
		Pbo+Pbo	12	12 (100.0)	27.09 (19.01)	0.0	12.83	22.89	43.83	60.5	
	Week 104	Teze+Teze	14	14 (100.0)	21.26 (16.42)	0.0	9.36	19.56	27.08	58.5	
		Pbo+Pbo	12	12 (100.0)	26.50 (21.55)	0.0	9.36	23.96	36.05	76.2	

Note: DITTNL - LTE - adolescents = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20JUL2022

Table DT1GMC\_MLMH0: Course of SGRQ symptom score  
 DITTNL - LTE - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ symptom score	Week 24	Teze+Teze	14	12 (85.7)	-25.04 (17.86)	-50.5	-37.17	-27.06	-11.77	4.9	-0.16 [-0.98, 0.66]
		Pbo+Pbo	12	11 (91.7)	-21.49 (26.13)	-67.5	-46.58	-17.19	4.19	9.6	
	Week 52	Teze+Teze	14	11 (78.6)	-28.32 (20.33)	-56.8	-40.81	-32.39	-7.44	8.8	-0.12 [-0.96, 0.72]
		Pbo+Pbo	12	11 (91.7)	-26.02 (17.85)	-50.0	-36.85	-27.48	-13.57	11.2	
	Week 76	Teze+Teze	14	11 (78.6)	-32.92 (19.03)	-70.0	-47.56	-25.97	-17.57	-8.7	0.13 [-0.71, 0.97]
		Pbo+Pbo	12	11 (91.7)	-35.63 (22.69)	-76.2	-56.71	-40.42	-16.89	-7.0	
	Week 104	Teze+Teze	14	12 (85.7)	-37.20 (18.85)	-65.7	-48.33	-46.98	-20.71	-5.2	-0.08 [-0.89, 0.74]
		Pbo+Pbo	12	11 (91.7)	-35.66 (21.92)	-72.3	-50.12	-40.42	-22.19	-1.8	

Note: DITTNL - LTE - adolescents = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20JUL2022



Table DT1GMC\_MLMC0: Change from baseline in SGRQ symptom score - MMRM results  
 DITTNL - LTE - adolescents

Change from baseline in SGRQ symptom score				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 24	Teze+Teze	14	12 (85.7)	-26.51 (6.95)	(-41.09, -11.93)	-6.56 (10.09)	(-27.72, 14.60)	0.523
	Pbo+Pbo	12	11 (91.7)	-19.95 (7.26)	(-35.18, -4.72)			
Week 52	Teze+Teze	14	11 (78.6)	-30.01 (5.91)	(-42.40, -17.62)	-5.53 (8.48)	(-23.32, 12.26)	0.522
	Pbo+Pbo	12	11 (91.7)	-24.48 (6.01)	(-37.12, -11.84)			
Week 76	Teze+Teze	14	11 (78.6)	-35.05 (5.04)	(-45.61, -24.50)	-0.96 (7.28)	(-16.22, 14.30)	0.897
	Pbo+Pbo	12	11 (91.7)	-34.09 (5.17)	(-44.95, -23.23)			
Week 104	Teze+Teze	14	12 (85.7)	-38.67 (5.27)	(-49.65, -27.68)	-4.55 (7.68)	(-20.54, 11.45)	0.560
	Pbo+Pbo	12	11 (91.7)	-34.12 (5.51)	(-45.60, -22.65)			

Note: DITTNL - LTE - adolescents = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adolescents.  
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.  
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.  
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.  
 SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20JUL2022

Table NT1GAC\_KLMH0: Course of SGRQ activities score  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
SGRQ activities score	Baseline	Tezepelumab	15	13 (86.7)	61.19 (16.34)	17.1	55.13	66.09	66.95	80.3	
		Placebo	20	17 (85.0)	47.23 (24.48)	6.2	25.20	49.15	59.46	87.2	
	Week 24	Tezepelumab	15	13 (86.7)	34.28 (16.59)	6.0	25.07	35.48	41.77	72.3	
		Placebo	20	17 (85.0)	32.44 (25.88)	0.0	5.96	35.47	53.62	68.0	
	Week 52	Tezepelumab	15	12 (80.0)	41.36 (21.48)	6.0	23.89	42.36	54.77	79.1	
		Placebo	20	20 (100.0)	32.99 (28.90)	0.0	2.98	32.74	59.91	85.8	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20FEB2022

Table NT1GAC\_KLMH0: Course of SGRQ activities score  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ activities score	Week 24	Tezepelumab	15	11 (73.3)	-25.93 (13.75)	-53.8	-32.63	-25.18	-18.06	-0.6	-0.58 [-1.39, 0.23]
		Placebo	20	14 (70.0)	-17.18 (16.03)	-48.4	-23.99	-13.18	-7.36	6.0	
	Week 52	Tezepelumab	15	10 (66.7)	-16.93 (13.66)	-38.2	-23.88	-18.85	-11.16	6.3	-0.07 [-0.85, 0.72]
		Placebo	20	17 (85.0)	-15.58 (23.77)	-75.0	-19.47	-12.71	-2.36	17.7	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20FEB2022

Table NT1GAC\_KLMC0: Change from baseline in SGRQ activities score - MMRM results  
 DITTLL - adolescents

Change from baseline in SGRQ activities score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 24	Tezepelumab	15	11 (73.3)	-24.47 (4.72)	(-34.29, -14.66)	-5.51 (6.35)	(-18.66, 7.65)	0.395	
	Placebo	20	14 (70.0)	-18.96 (4.02)	(-27.27, -10.66)				
Week 52	Tezepelumab	15	10 (66.7)	-15.43 (6.42)	(-28.61, -2.26)	0.97 (8.21)	(-15.88, 17.81)	0.907	
	Placebo	20	17 (85.0)	-16.40 (4.96)	(-26.61, -6.19)				

Note: DITTLL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

SGRQ = St George s respiratory questionnaire.

Source Data: asgrq, created on: 20FEB2022

Table DT1GAC\_MLMH0: Course of SGRQ activities score  
 DITTNL - LTE - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
SGRQ activities score	Baseline	Teze+Teze	14	12 (85.7)	59.59 (15.98)	17.1	54.34	64.02	66.92	80.3	
		Pbo+Pbo	12	11 (91.7)	51.40 (22.74)	11.2	41.77	54.43	63.38	87.2	
	Week 24	Teze+Teze	14	14 (100.0)	35.34 (16.42)	6.0	25.07	35.64	43.83	72.3	
		Pbo+Pbo	12	12 (100.0)	28.32 (24.46)	0.0	6.06	24.19	45.53	67.0	
	Week 52	Teze+Teze	14	13 (92.9)	40.47 (20.82)	6.0	24.06	41.70	48.52	79.1	
		Pbo+Pbo	12	12 (100.0)	28.80 (26.47)	0.0	2.98	21.11	59.91	62.7	
	Week 76	Teze+Teze	14	13 (92.9)	33.73 (23.64)	0.0	11.16	30.55	47.71	73.6	
		Pbo+Pbo	12	12 (100.0)	21.47 (25.97)	0.0	0.00	5.96	45.35	66.2	
	Week 104	Teze+Teze	14	14 (100.0)	31.24 (20.39)	0.0	17.12	35.84	47.46	66.2	
		Pbo+Pbo	12	12 (100.0)	19.81 (23.57)	0.0	0.00	11.54	32.53	67.0	

Note: DITTNL - LTE - adolescents = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20JUL2022

Table DT1GAC\_MLMH0: Course of SGRQ activities score  
 DITTNL - LTE - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ activities score	Week 24	Teze+Teze	14	12 (85.7)	-24.27 (14.32)	-53.8	-32.48	-24.80	-14.61	-0.6	-0.10 [-0.92, 0.72]
		Pbo+Pbo	12	11 (91.7)	-22.64 (18.66)	-51.4	-41.67	-13.63	-11.21	3.6	
	Week 52	Teze+Teze	14	11 (78.6)	-18.76 (14.32)	-38.2	-30.57	-19.30	-11.16	6.3	0.06 [-0.78, 0.89]
		Pbo+Pbo	12	11 (91.7)	-19.99 (27.93)	-75.0	-31.38	-17.35	-2.36	17.7	
	Week 76	Teze+Teze	14	11 (78.6)	-29.50 (18.73)	-66.2	-36.53	-32.61	-13.33	-0.6	-0.06 [-0.90, 0.77]
		Pbo+Pbo	12	11 (91.7)	-27.99 (28.38)	-87.2	-52.35	-13.63	-5.97	5.8	
	Week 104	Teze+Teze	14	12 (85.7)	-27.53 (15.17)	-62.0	-32.05	-24.91	-18.95	-6.7	0.11 [-0.70, 0.93]
		Pbo+Pbo	12	11 (91.7)	-29.79 (24.03)	-81.2	-48.44	-25.12	-11.21	3.6	

Note: DITTNL - LTE - adolescents = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20JUL2022

Table DT1GAC\_MLMC0: Change from baseline in SGRQ activities score - MMRM results  
 DITTNL - LTE - adolescents

Change from baseline in SGRQ activities score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 24	Teze+Teze	14	12 (85.7)	-23.38 (4.75)	(-33.28, -13.48)	0.24 (6.97)	(-14.27, 14.75)	0.973	
	Pbo+Pbo	12	11 (91.7)	-23.61 (4.97)	(-33.97, -13.26)				
Week 52	Teze+Teze	14	11 (78.6)	-17.12 (6.27)	(-30.15, -4.09)	3.84 (9.03)	(-14.95, 22.63)	0.675	
	Pbo+Pbo	12	11 (91.7)	-20.96 (6.41)	(-34.33, -7.60)				
Week 76	Teze+Teze	14	11 (78.6)	-27.69 (6.69)	(-41.61, -13.77)	1.27 (9.65)	(-18.82, 21.36)	0.897	
	Pbo+Pbo	12	11 (91.7)	-28.96 (6.87)	(-43.29, -14.63)				
Week 104	Teze+Teze	14	12 (85.7)	-26.64 (5.58)	(-38.27, -15.01)	4.13 (8.15)	(-12.85, 21.10)	0.618	
	Pbo+Pbo	12	11 (91.7)	-30.77 (5.84)	(-42.92, -18.61)				

Note: DITTNL - LTE - adolescents = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adolescents.  
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.  
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.  
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.  
 SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20JUL2022

Table NT1GRC\_KLMH0: Course of SGRQ impact score  
 DITTLL - adolescents

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]	
SGRQ impact score	Baseline	Tezepelumab	15	13 (86.7)	46.01 (11.79)	24.0	39.95	48.25	53.31	60.7	
		Placebo	20	17 (85.0)	31.34 (16.53)	10.1	17.01	31.68	43.25	63.5	
	Week 24	Tezepelumab	15	13 (86.7)	21.66 (11.11)	7.7	8.42	21.50	26.99	38.4	
		Placebo	20	17 (85.0)	21.79 (18.37)	0.0	8.33	14.56	32.99	53.6	
	Week 52	Tezepelumab	15	12 (80.0)	28.47 (13.93)	10.3	17.98	23.30	38.90	54.1	
		Placebo	20	20 (100.0)	19.50 (16.18)	0.0	4.50	16.92	35.17	49.7	

Note: DITTLL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20FEB2022



Table NT1GRC\_KLMH0: Course of SGRQ impact score  
 DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ impact score	Week 24	Tezepelumab	15	11 (73.3)	-23.50 (15.66)	-43.1	-39.20	-27.97	-6.93	-1.6	-1.08 [-1.93, -0.23]
		Placebo	20	14 (70.0)	-9.64 (10.04)	-27.9	-16.04	-10.37	-2.45	10.7	
	Week 52	Tezepelumab	15	10 (66.7)	-18.91 (15.89)	-40.0	-38.32	-13.99	-4.75	-2.7	-0.45 [-1.24, 0.34]
		Placebo	20	17 (85.0)	-13.36 (9.83)	-43.0	-15.30	-11.54	-7.50	-3.1	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20FEB2022

Table NT1GRC\_KLMC0: Change from baseline in SGRQ impact score - MMRM results  
 DITTL - adolescents

Change from baseline in SGRQ impact score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 24	Tezepelumab	15	11 (73.3)	-20.51 (3.93)	(-28.60, -12.43)	-8.76 (5.43)	(-19.89, 2.37)	0.118	
	Placebo	20	14 (70.0)	-11.75 (3.34)	(-18.61, -4.89)				
Week 52	Tezepelumab	15	10 (66.7)	-16.19 (3.90)	(-24.19, -8.19)	-1.00 (5.13)	(-11.54, 9.54)	0.847	
	Placebo	20	17 (85.0)	-15.19 (2.94)	(-21.23, -9.15)				

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

SGRQ = St George s respiratory questionnaire.

Source Data: asgrq, created on: 20FEB2022

Table DT1GRC\_MLMH0: Course of SGRQ impact score  
 DITTNL - LTE - adolescents

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]	
SGRQ impact score	Baseline	Teze+Teze	14	12 (85.7)	46.03 (12.31)	24.0	36.94	48.45	56.07	60.7	
		Pbo+Pbo	12	11 (91.7)	33.92 (14.31)	12.4	25.91	31.88	43.25	63.5	
	Week 24	Teze+Teze	14	14 (100.0)	21.05 (10.92)	7.7	8.42	21.37	26.99	38.4	
		Pbo+Pbo	12	12 (100.0)	22.14 (19.29)	1.7	8.07	13.29	38.80	53.6	
	Week 52	Teze+Teze	14	13 (92.9)	29.70 (14.06)	10.3	19.18	25.18	39.56	54.1	
		Pbo+Pbo	12	12 (100.0)	19.78 (14.14)	1.7	7.53	20.00	31.88	42.4	
	Week 76	Teze+Teze	14	13 (92.9)	19.28 (16.49)	0.0	3.78	15.46	35.35	50.3	
		Pbo+Pbo	12	12 (100.0)	9.75 (12.47)	0.0	1.63	3.96	14.26	38.3	
	Week 104	Teze+Teze	14	14 (100.0)	12.42 (12.37)	0.0	1.63	8.67	19.54	40.3	
		Pbo+Pbo	12	12 (100.0)	9.66 (10.79)	0.0	2.60	4.77	14.32	34.4	

Note: DITTNL - LTE - adolescents = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20JUL2022

Table DT1GRC\_MLMH0: Course of SGRQ impact score  
 DITTNL - LTE - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ impact score	Week 24	Teze+Teze	14	12 (85.7)	-22.79 (15.13)	-43.1	-36.92	-25.39	-8.57	-1.6	-0.80 [-1.65, 0.05]
		Pbo+Pbo	12	11 (91.7)	-11.91 (11.65)	-27.9	-21.93	-13.20	-2.45	10.7	
	Week 52	Teze+Teze	14	11 (78.6)	-17.54 (15.74)	-40.0	-38.32	-7.20	-4.18	-2.7	-0.24 [-1.08, 0.60]
		Pbo+Pbo	12	11 (91.7)	-14.19 (12.19)	-43.0	-24.20	-12.14	-4.59	-3.1	
	Week 76	Teze+Teze	14	11 (78.6)	-31.46 (20.05)	-56.9	-45.74	-39.42	-4.46	-3.0	-0.43 [-1.28, 0.42]
		Pbo+Pbo	12	11 (91.7)	-23.63 (16.11)	-59.2	-30.25	-16.46	-12.87	-3.7	
	Week 104	Teze+Teze	14	12 (85.7)	-35.16 (17.27)	-59.0	-47.50	-39.79	-24.17	0.3	-0.69 [-1.54, 0.15]
		Pbo+Pbo	12	11 (91.7)	-23.53 (16.29)	-63.5	-30.25	-20.45	-8.46	-7.1	

Note: DITTNL - LTE - adolescents = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20JUL2022

Table DT1GRC\_MLMC0: Change from baseline in SGRQ impact score - MMRM results  
 DITTNL - LTE - adolescents

Change from baseline in SGRQ impact score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 24	Teze+Teze	14	12 (85.7)	-19.07 (4.13)	(-27.71, -10.42)	-2.72 (6.18)	(-15.61, 10.17)	0.665	
	Pbo+Pbo	12	11 (91.7)	-16.35 (4.35)	(-25.44, -7.25)				
Week 52	Teze+Teze	14	11 (78.6)	-12.97 (4.12)	(-21.52, -4.41)	5.66 (6.06)	(-6.91, 18.23)	0.360	
	Pbo+Pbo	12	11 (91.7)	-18.63 (4.16)	(-27.29, -9.96)				
Week 76	Teze+Teze	14	11 (78.6)	-27.15 (4.34)	(-36.15, -18.16)	0.91 (6.44)	(-12.43, 14.25)	0.889	
	Pbo+Pbo	12	11 (91.7)	-28.07 (4.54)	(-37.49, -18.64)				
Week 104	Teze+Teze	14	12 (85.7)	-31.44 (3.66)	(-39.09, -23.79)	-3.48 (5.53)	(-15.00, 8.05)	0.537	
	Pbo+Pbo	12	11 (91.7)	-27.97 (3.87)	(-36.04, -19.89)				

Note: DITTNL - LTE - adolescents = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adolescents.  
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.  
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.  
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.  
 SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20JUL2022

Table NT1GTC\_ALMH0: Course of SGRQ total score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
SGRQ total score	Baseline	Tezepelumab	380	313 (82.4)	56.63 (19.83)	5.7	41.09	57.66	71.43	99.2	
		Placebo	371	306 (82.5)	54.03 (18.93)	5.8	41.01	55.17	67.40	95.5	
	Week 24	Tezepelumab	380	349 (91.8)	36.58 (23.65)	0.0	17.54	32.80	54.21	96.4	
		Placebo	371	331 (89.2)	41.05 (21.58)	0.0	25.15	41.15	55.74	94.4	
	Week 52	Tezepelumab	380	339 (89.2)	35.31 (24.09)	0.0	15.56	31.21	54.82	94.6	
		Placebo	371	319 (86.0)	40.42 (22.72)	0.0	23.44	39.89	56.11	94.4	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.

Source Data: asgrq, created on: 20FEB2022

Table NT1GTC\_ALMH0: Course of SGRQ total score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ total score	Week 24	Tezepelumab	380	288 (75.8)	-20.73 (22.04)	-81.7	-34.29	-17.51	-6.46	56.5	-0.37 [-0.53, -0.20]
		Placebo	371	274 (73.9)	-13.23 (18.55)	-68.6	-25.16	-11.04	-1.06	47.5	
	Week 52	Tezepelumab	380	279 (73.4)	-22.80 (22.74)	-77.8	-38.23	-21.53	-7.93	46.3	-0.42 [-0.59, -0.25]
		Placebo	371	264 (71.2)	-13.96 (19.24)	-69.1	-26.65	-11.37	-2.09	53.7	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20FEB2022

Table NT1GTC\_ALMC0: Change from baseline in SGRQ total score - MMRM results  
 DITTL - adult

Change from baseline in SGRQ total score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 24	Tezepelumab	380	288 (75.8)	-20.31 (1.12)	(-22.51, -18.11)	-6.71 (1.60)	(-9.85, -3.56)	<0.001 *	
	Placebo	371	274 (73.9)	-13.60 (1.14)	(-15.85, -11.36)				
Week 52	Tezepelumab	380	279 (73.4)	-22.36 (1.18)	(-24.67, -20.05)	-8.00 (1.68)	(-11.30, -4.69)	<0.001 *	
	Placebo	371	264 (71.2)	-14.37 (1.20)	(-16.73, -12.01)				

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

SGRQ = St George s respiratory questionnaire.

Source Data: asgrq, created on: 20FEB2022



Table DT1GTC\_HLMH0: Course of SGRQ total score  
 DITTNL - LTE - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
SGRQ total score	Baseline	Teze+Teze	296	236 (79.7)	57.87 (19.51)	5.7	42.71	58.16	73.38	99.2	
		Pbo+Pbo	137	106 (77.4)	54.05 (19.42)	10.1	40.51	55.12	67.21	95.5	
	Week 24	Teze+Teze	296	287 (97.0)	37.84 (23.99)	0.0	18.14	34.06	55.50	96.4	
		Pbo+Pbo	137	129 (94.2)	42.74 (22.90)	0.0	25.61	44.17	60.06	94.4	
	Week 52	Teze+Teze	296	285 (96.3)	36.32 (24.11)	0.0	16.70	31.83	55.25	94.6	
		Pbo+Pbo	137	131 (95.6)	41.58 (23.05)	0.0	26.58	43.37	56.45	92.8	
	Week 76	Teze+Teze	296	291 (98.3)	32.71 (20.64)	0.0	16.29	29.87	49.23	86.0	
		Pbo+Pbo	137	134 (97.8)	39.20 (21.46)	0.0	22.60	42.51	52.52	84.8	
	Week 104	Teze+Teze	296	281 (94.9)	30.64 (21.24)	0.0	14.57	25.91	45.90	91.0	
		Pbo+Pbo	137	131 (95.6)	37.22 (20.75)	0.0	23.02	40.68	50.84	86.8	

Note: DITTNL - LTE - adult = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20JUL2022

Table DT1GTC\_HLMH0: Course of SGRQ total score  
 DITTNL - LTE - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ total score	Week 24	Teze+Teze	296	231 (78.0)	-20.76 (22.01)	-81.7	-34.29	-17.73	-7.16	56.5	-0.41 [-0.65, -0.18]
		Pbo+Pbo	137	102 (74.5)	-12.25 (16.67)	-60.6	-24.58	-11.77	-2.15	29.4	
	Week 52	Teze+Teze	296	227 (76.7)	-23.09 (22.71)	-77.8	-37.57	-22.19	-8.12	46.3	-0.45 [-0.69, -0.22]
		Pbo+Pbo	137	101 (73.7)	-13.47 (17.23)	-61.0	-24.81	-11.30	-2.17	22.4	
	Week 76	Teze+Teze	296	231 (78.0)	-26.04 (21.14)	-89.2	-40.37	-23.82	-10.80	22.3	-0.50 [-0.74, -0.27]
		Pbo+Pbo	137	103 (75.2)	-15.79 (18.35)	-64.8	-27.11	-15.69	-4.84	27.4	
	Week 104	Teze+Teze	296	221 (74.7)	-28.20 (21.77)	-88.9	-43.88	-27.90	-12.71	37.9	-0.47 [-0.71, -0.23]
		Pbo+Pbo	137	102 (74.5)	-18.55 (17.74)	-63.8	-27.12	-15.65	-7.83	17.5	

Note: DITTNL - LTE - adult = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20JUL2022

Table DT1GTC\_HLMC0: Change from baseline in SGRQ total score - MMRM results  
DITTNL - LTE - adult

Change from baseline in SGRQ total score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 24	Teze+Teze	296	231 (78.0)	-20.30 (1.29)	(-22.84, -17.77)	-7.10 (2.33)	(-11.67, -2.53)	0.002 *	
	Pbo+Pbo	137	102 (74.5)	-13.20 (1.93)	(-17.00, -9.40)				
Week 52	Teze+Teze	296	227 (76.7)	-23.06 (1.33)	(-25.68, -20.44)	-8.65 (2.40)	(-13.37, -3.93)	<0.001 *	
	Pbo+Pbo	137	101 (73.7)	-14.41 (1.99)	(-18.33, -10.49)				
Week 76	Teze+Teze	296	231 (78.0)	-25.44 (1.20)	(-27.80, -23.07)	-8.38 (2.17)	(-12.64, -4.12)	<0.001 *	
	Pbo+Pbo	137	103 (75.2)	-17.05 (1.80)	(-20.59, -13.52)				
Week 104	Teze+Teze	296	221 (74.7)	-26.99 (1.23)	(-29.40, -24.58)	-7.45 (2.20)	(-11.78, -3.13)	<0.001 *	
	Pbo+Pbo	137	102 (74.5)	-19.54 (1.82)	(-23.12, -15.95)				

Note: DITTNL - LTE - adult = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.  
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.  
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.  
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.  
SGRQ = St George s respiratory questionnaire.  
Source Data: asgrq, created on: 20JUL2022

Table NT1GMC\_ALMH0: Course of SGRQ symptom score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
SGRQ symptom score	Baseline	Tezepelumab	380	313 (82.4)	70.00 (18.95)	11.9	58.54	74.16	83.92	100.0	
		Placebo	371	306 (82.5)	67.07 (20.47)	0.0	54.57	69.53	83.46	100.0	
	Week 24	Tezepelumab	380	349 (91.8)	40.66 (26.78)	0.0	18.48	38.90	61.58	97.5	
		Placebo	371	331 (89.2)	50.42 (26.74)	0.0	29.52	52.26	73.48	100.0	
	Week 52	Tezepelumab	380	339 (89.2)	37.42 (27.09)	0.0	14.08	35.77	60.59	97.5	
		Placebo	371	319 (86.0)	48.65 (26.47)	0.0	29.04	49.69	69.66	100.0	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.

Source Data: asgrq, created on: 20FEB2022

Table NT1GMC\_ALMH0: Course of SGRQ symptom score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ symptom score	Week 24	Tezepelumab	380	288 (75.8)	-29.84 (28.19)	-96.0	-50.20	-27.02	-9.50	43.2	-0.51 [-0.68, -0.34]
		Placebo	371	274 (73.9)	-16.26 (24.64)	-82.0	-34.52	-14.27	0.00	69.4	
	Week 52	Tezepelumab	380	279 (73.4)	-33.42 (28.77)	-90.9	-57.21	-31.23	-11.23	36.3	-0.56 [-0.73, -0.39]
		Placebo	371	264 (71.2)	-17.95 (26.28)	-81.5	-36.17	-14.58	-1.32	56.3	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20FEB2022

Table NT1GMC\_ALMC0: Change from baseline in SGRQ symptom score - MMRM results  
 DITTL - adult

Change from baseline in SGRQ symptom score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 24	Tezepelumab	380	288 (75.8)	-28.85 (1.44)	(-31.69, -26.01)	-11.82 (2.07)	(-15.87, -7.76)	<0.001 *	
	Placebo	371	274 (73.9)	-17.03 (1.47)	(-19.93, -14.14)				
Week 52	Tezepelumab	380	279 (73.4)	-32.61 (1.51)	(-35.57, -29.65)	-14.04 (2.16)	(-18.28, -9.80)	<0.001 *	
	Placebo	371	264 (71.2)	-18.57 (1.54)	(-21.60, -15.54)				

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

SGRQ = St George s respiratory questionnaire.

Source Data: asgrq, created on: 20FEB2022

Table DT1GMC\_HLMH0: Course of SGRQ symptom score  
 DITTNL - LTE - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
SGRQ symptom score	Baseline	Teze+Teze	296	236 (79.7)	69.87 (19.38)	11.9	57.58	74.62	83.87	100.0	
		Pbo+Pbo	137	106 (77.4)	66.85 (21.15)	0.0	54.85	69.21	82.91	100.0	
	Week 24	Teze+Teze	296	287 (97.0)	40.43 (27.02)	0.0	17.90	38.54	62.38	97.5	
		Pbo+Pbo	137	129 (94.2)	50.96 (28.40)	0.0	28.15	52.69	75.26	100.0	
	Week 52	Teze+Teze	296	285 (96.3)	37.05 (27.05)	0.0	13.34	35.00	60.27	97.5	
		Pbo+Pbo	137	131 (95.6)	49.11 (27.44)	0.0	27.14	51.00	69.66	100.0	
	Week 76	Teze+Teze	296	291 (98.3)	35.29 (25.44)	0.0	13.48	32.12	55.73	95.5	
		Pbo+Pbo	137	134 (97.8)	47.52 (26.77)	0.0	26.90	47.74	67.34	100.0	
	Week 104	Teze+Teze	296	281 (94.9)	32.75 (25.63)	0.0	13.16	27.83	52.17	100.0	
		Pbo+Pbo	137	131 (95.6)	46.80 (26.81)	0.0	25.36	48.06	66.72	100.0	

Note: DITTNL - LTE - adult = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20JUL2022

Table DT1GMC\_HLMH0: Course of SGRQ symptom score  
 DITTNL - LTE - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ symptom score	Week 24	Teze+Teze	296	231 (78.0)	-30.41 (28.51)	-96.0	-53.77	-27.43	-10.53	43.2	-0.51 [-0.75, -0.28]
		Pbo+Pbo	137	102 (74.5)	-16.72 (22.16)	-67.1	-32.26	-16.76	0.00	24.4	
	Week 52	Teze+Teze	296	227 (76.7)	-34.36 (28.38)	-90.9	-57.27	-33.59	-11.70	36.3	-0.60 [-0.84, -0.36]
		Pbo+Pbo	137	101 (73.7)	-18.20 (23.44)	-79.5	-34.80	-14.14	-2.47	40.0	
	Week 76	Teze+Teze	296	231 (78.0)	-35.19 (26.70)	-95.0	-55.14	-35.89	-18.42	36.2	-0.55 [-0.79, -0.32]
		Pbo+Pbo	137	103 (75.2)	-20.75 (24.63)	-79.5	-34.80	-18.82	-3.98	51.2	
	Week 104	Teze+Teze	296	221 (74.7)	-37.11 (27.78)	-100.0	-57.75	-35.65	-18.36	55.3	-0.55 [-0.79, -0.31]
		Pbo+Pbo	137	102 (74.5)	-22.31 (24.87)	-67.3	-41.99	-22.12	-5.33	39.1	

Note: DITTNL - LTE - adult = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20JUL2022



Table DT1GMC\_HLMC0: Change from baseline in SGRQ symptom score - MMRM results  
 DITTNL - LTE - adult

Change from baseline in SGRQ symptom score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 24	Teze+Teze	296	231 (78.0)	-29.66 (1.65)	(-32.90, -26.42)	-11.52 (2.97)	(-17.36, -5.67)	<0.001 *	
	Pbo+Pbo	137	102 (74.5)	-18.15 (2.47)	(-23.00, -13.29)				
Week 52	Teze+Teze	296	227 (76.7)	-34.27 (1.67)	(-37.55, -30.98)	-15.75 (3.01)	(-21.66, -9.84)	<0.001 *	
	Pbo+Pbo	137	101 (73.7)	-18.52 (2.50)	(-23.43, -13.61)				
Week 76	Teze+Teze	296	231 (78.0)	-34.59 (1.60)	(-37.73, -31.44)	-12.66 (2.88)	(-18.32, -6.99)	<0.001 *	
	Pbo+Pbo	137	103 (75.2)	-21.93 (2.39)	(-26.63, -17.22)				
Week 104	Teze+Teze	296	221 (74.7)	-36.27 (1.64)	(-39.50, -33.05)	-12.95 (2.93)	(-18.72, -7.19)	<0.001 *	
	Pbo+Pbo	137	102 (74.5)	-23.32 (2.43)	(-28.09, -18.54)				

Note: DITTNL - LTE - adult = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.  
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.  
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.  
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.  
 SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20JUL2022

Table NT1GAC\_ALMH0: Course of SGRQ activities score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
SGRQ activities score	Baseline	Tezepelumab	380	313 (82.4)	65.24 (22.78)	0.0	53.49	66.98	80.53	100.0	
		Placebo	371	306 (82.5)	64.02 (22.57)	0.0	49.86	66.19	80.32	100.0	
	Week 24	Tezepelumab	380	349 (91.8)	47.78 (29.03)	0.0	25.10	49.20	67.12	100.0	
		Placebo	371	331 (89.2)	50.31 (26.75)	0.0	29.82	53.53	67.84	100.0	
	Week 52	Tezepelumab	380	339 (89.2)	46.54 (30.73)	0.0	18.47	47.69	72.82	100.0	
		Placebo	371	319 (86.0)	51.85 (28.02)	0.0	30.34	53.62	73.24	100.0	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20FEB2022

Table NT1GAC\_ALMH0: Course of SGRQ activities score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ activities score	Week 24	Tezepelumab	380	288 (75.8)	-18.46 (26.49)	-92.5	-35.11	-13.96	0.00	70.0	-0.21 [-0.38, -0.05]
		Placebo	371	274 (73.9)	-13.31 (21.22)	-80.3	-24.58	-11.77	0.00	50.7	
	Week 52	Tezepelumab	380	279 (73.4)	-21.06 (27.94)	-92.5	-42.34	-19.07	0.00	70.0	-0.33 [-0.50, -0.16]
		Placebo	371	264 (71.2)	-12.63 (22.52)	-79.7	-25.09	-11.06	0.08	76.0	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20FEB2022

Table NT1GAC\_ALMC0: Change from baseline in SGRQ activities score - MMRM results  
 DITTL - adult

Change from baseline in SGRQ activities score				Repeated measures analysis							
				N			Change from Baseline		Treatment Difference		
							LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Time	Treatment		n (%)								
Week 24	Tezepelumab	380	288 (75.8)	-18.25 (1.36)	(-20.92, -15.58)	-4.82 (1.94)	(-8.63, -1.00)	0.014 *			
	Placebo	371	274 (73.9)	-13.44 (1.39)	(-16.16, -10.71)						
Week 52	Tezepelumab	380	279 (73.4)	-20.74 (1.46)	(-23.62, -17.86)	-7.93 (2.09)	(-12.05, -3.82)	<0.001 *			
	Placebo	371	264 (71.2)	-12.81 (1.50)	(-15.75, -9.87)						

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

SGRQ = St George s respiratory questionnaire.

Source Data: asgrq, created on: 20FEB2022

Table DT1GAC\_HLMH0: Course of SGRQ activities score  
 DITTNL - LTE - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
SGRQ activities score	Baseline	Teze+Teze	296	236 (79.7)	66.65 (21.31)	0.0	53.62	67.20	81.57	100.0	
		Pbo+Pbo	137	106 (77.4)	64.22 (23.16)	0.0	48.50	66.92	85.77	100.0	
	Week 24	Teze+Teze	296	287 (97.0)	49.71 (29.17)	0.0	29.49	53.53	72.82	100.0	
		Pbo+Pbo	137	129 (94.2)	52.21 (28.17)	0.0	30.57	55.18	72.82	100.0	
	Week 52	Teze+Teze	296	285 (96.3)	48.60 (30.28)	0.0	23.33	53.16	72.82	100.0	
		Pbo+Pbo	137	131 (95.6)	53.56 (29.08)	0.0	38.68	59.46	73.68	100.0	
	Week 76	Teze+Teze	296	291 (98.3)	45.18 (26.63)	0.0	23.33	47.69	66.19	100.0	
		Pbo+Pbo	137	134 (97.8)	50.00 (25.82)	0.0	30.82	54.69	66.89	100.0	
	Week 104	Teze+Teze	296	281 (94.9)	42.89 (27.31)	0.0	18.15	47.55	66.16	100.0	
		Pbo+Pbo	137	131 (95.6)	49.84 (26.15)	0.0	35.47	54.42	66.86	100.0	

Note: DITTNL - LTE - adult = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20JUL2022

Table DT1GAC\_HLMH0: Course of SGRQ activities score  
 DITTNL - LTE - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ activities score	Week 24	Teze+Teze	296	231 (78.0)	-17.79 (26.15)	-92.5	-31.27	-13.55	0.00	70.0	-0.21 [-0.44, 0.03]
		Pbo+Pbo	137	102 (74.5)	-12.69 (21.16)	-79.7	-24.58	-7.85	0.00	39.0	
	Week 52	Teze+Teze	296	227 (76.7)	-20.18 (27.85)	-92.5	-39.14	-18.05	0.00	70.0	-0.32 [-0.55, -0.08]
		Pbo+Pbo	137	101 (73.7)	-11.95 (21.69)	-79.7	-24.80	-7.99	1.51	38.7	
	Week 76	Teze+Teze	296	231 (78.0)	-22.62 (25.42)	-93.3	-38.95	-19.50	-6.16	53.5	-0.33 [-0.56, -0.10]
		Pbo+Pbo	137	103 (75.2)	-14.52 (22.52)	-85.8	-29.70	-13.36	0.05	33.8	
	Week 104	Teze+Teze	296	221 (74.7)	-25.44 (26.23)	-94.8	-44.17	-20.28	-6.64	47.9	-0.35 [-0.59, -0.11]
		Pbo+Pbo	137	102 (74.5)	-16.54 (23.50)	-79.7	-29.29	-14.32	-0.90	30.6	

Note: DITTNL - LTE - adult = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20JUL2022

Table DT1GAC\_HLMC0: Change from baseline in SGRQ activities score - MMRM results  
 DITTNL - LTE - adult

Change from baseline in SGRQ activities score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 24	Teze+Teze	296	231 (78.0)	-17.45 (1.59)	(-20.57, -14.32)	-4.62 (2.86)	(-10.25, 1.01)	0.107	
	Pbo+Pbo	137	102 (74.5)	-12.82 (2.38)	(-17.50, -8.14)				
Week 52	Teze+Teze	296	227 (76.7)	-20.39 (1.69)	(-23.71, -17.07)	-7.93 (3.04)	(-13.91, -1.95)	0.010 *	
	Pbo+Pbo	137	101 (73.7)	-12.46 (2.53)	(-17.43, -7.50)				
Week 76	Teze+Teze	296	231 (78.0)	-22.14 (1.52)	(-25.12, -19.16)	-6.66 (2.73)	(-12.03, -1.29)	0.015 *	
	Pbo+Pbo	137	103 (75.2)	-15.48 (2.27)	(-19.94, -11.02)				
Week 104	Teze+Teze	296	221 (74.7)	-24.38 (1.59)	(-27.50, -21.26)	-7.37 (2.84)	(-12.95, -1.79)	0.010 *	
	Pbo+Pbo	137	102 (74.5)	-17.01 (2.35)	(-21.64, -12.38)				

Note: DITTNL - LTE - adult = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.  
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.  
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.  
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.  
 SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20JUL2022

Table NT1GRC\_ALMH0: Course of SGRQ impact score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
SGRQ impact score	Baseline	Tezepelumab	380	313 (82.4)	47.45 (22.86)	0.0	29.75	47.01	63.77	100.0	
		Placebo	371	306 (82.5)	44.18 (20.49)	1.6	29.24	45.67	57.14	92.1	
	Week 24	Tezepelumab	380	349 (91.8)	28.83 (24.19)	0.0	7.92	23.42	44.44	98.9	
		Placebo	371	331 (89.2)	32.77 (21.67)	0.0	15.76	29.80	48.30	91.8	
	Week 52	Tezepelumab	380	339 (89.2)	28.16 (23.81)	0.0	7.68	22.88	45.52	98.8	
		Placebo	371	319 (86.0)	31.24 (22.66)	0.0	13.14	27.78	44.77	96.9	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20FEB2022



Table NT1GRC\_ALMH0: Course of SGRQ impact score  
 DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ impact score	Week 24	Tezepelumab	380	288 (75.8)	-19.20 (23.03)	-81.0	-35.03	-16.06	-4.58	73.6	-0.32 [-0.49, -0.16]
		Placebo	371	274 (73.9)	-12.22 (20.11)	-81.1	-27.08	-10.33	2.41	45.6	
	Week 52	Tezepelumab	380	279 (73.4)	-20.46 (23.37)	-84.3	-35.21	-17.72	-5.76	56.4	-0.32 [-0.49, -0.15]
		Placebo	371	264 (71.2)	-13.48 (20.14)	-80.9	-24.78	-12.80	-0.30	40.2	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20FEB2022

Table NT1GRC\_ALMC0: Change from baseline in SGRQ impact score - MMRM results  
 DITTL - adult

Change from baseline in SGRQ impact score				Repeated measures analysis					
				Change from Baseline		Treatment Difference			
				Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI
Week 24	Tezepelumab	380	288 (75.8)	-18.69 (1.14)	(-20.92, -16.45)	-5.93 (1.63)	(-9.13, -2.74)	<0.001 *	
	Placebo	371	274 (73.9)	-12.75 (1.16)	(-15.03, -10.47)				
Week 52	Tezepelumab	380	279 (73.4)	-19.90 (1.16)	(-22.18, -17.62)	-5.79 (1.66)	(-9.06, -2.53)	<0.001 *	
	Placebo	371	264 (71.2)	-14.11 (1.19)	(-16.44, -11.78)				

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

SGRQ = St George s respiratory questionnaire.

Source Data: asgrq, created on: 20FEB2022

Table DT1GRC\_HLMH0: Course of SGRQ impact score  
 DITTNL - LTE - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
SGRQ impact score	Baseline	Teze+Teze	296	236 (79.7)	49.03 (23.03)	1.6	29.91	48.09	64.98	100.0	
		Pbo+Pbo	137	106 (77.4)	44.15 (20.86)	1.7	29.41	45.50	57.25	92.1	
	Week 24	Teze+Teze	296	287 (97.0)	30.16 (24.77)	0.0	8.73	24.54	47.57	98.9	
		Pbo+Pbo	137	129 (94.2)	34.71 (22.70)	0.0	15.76	32.13	52.24	91.8	
	Week 52	Teze+Teze	296	285 (96.3)	29.00 (24.15)	0.0	7.84	23.34	47.40	98.8	
		Pbo+Pbo	137	131 (95.6)	32.30 (22.67)	0.0	14.49	31.88	46.29	96.9	
	Week 76	Teze+Teze	296	291 (98.3)	24.76 (20.78)	0.0	7.20	19.10	40.44	85.0	
		Pbo+Pbo	137	134 (97.8)	30.44 (21.71)	0.0	12.81	29.57	45.50	83.6	
	Week 104	Teze+Teze	296	281 (94.9)	23.00 (20.71)	0.0	5.95	17.29	36.28	95.5	
		Pbo+Pbo	137	131 (95.6)	27.02 (20.34)	0.0	7.62	26.95	41.44	79.0	

Note: DITTNL - LTE - adult = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20JUL2022

Table DT1GRC\_HLMH0: Course of SGRQ impact score  
 DITTNL - LTE - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in SGRQ impact score	Week 24	Teze+Teze	296	231 (78.0)	-19.47 (23.14)	-81.0	-34.73	-16.61	-5.60	73.6	-0.41 [-0.64, -0.17]
		Pbo+Pbo	137	102 (74.5)	-10.57 (18.13)	-54.9	-23.19	-10.90	4.06	44.6	
	Week 52	Teze+Teze	296	227 (76.7)	-21.24 (23.63)	-84.3	-35.21	-19.37	-6.11	56.4	-0.38 [-0.61, -0.14]
		Pbo+Pbo	137	101 (73.7)	-12.84 (18.55)	-75.4	-23.20	-13.14	0.36	25.6	
	Week 76	Teze+Teze	296	231 (78.0)	-25.08 (22.80)	-89.7	-38.33	-22.56	-9.34	24.9	-0.47 [-0.70, -0.23]
		Pbo+Pbo	137	103 (75.2)	-14.88 (19.55)	-59.0	-28.31	-13.97	-5.40	30.2	
	Week 104	Teze+Teze	296	221 (74.7)	-26.91 (23.47)	-88.8	-41.24	-25.13	-9.65	39.1	-0.39 [-0.62, -0.15]
		Pbo+Pbo	137	102 (74.5)	-18.43 (18.21)	-80.7	-27.78	-15.20	-7.28	25.2	

Note: DITTNL - LTE - adult = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20JUL2022

Table DT1GRC\_HLMC0: Change from baseline in SGRQ impact score - MMRM results  
 DITTNL - LTE - adult

Change from baseline in SGRQ impact score				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 24	Teze+Teze	296	231 (78.0)	-18.91 (1.31)	(-21.49, -16.34)	-6.82 (2.36)	(-11.46, -2.17)	0.004 *	
	Pbo+Pbo	137	102 (74.5)	-12.10 (1.96)	(-15.96, -8.23)				
Week 52	Teze+Teze	296	227 (76.7)	-20.94 (1.32)	(-23.54, -18.34)	-6.45 (2.38)	(-11.13, -1.76)	0.007 *	
	Pbo+Pbo	137	101 (73.7)	-14.49 (1.98)	(-18.38, -10.60)				
Week 76	Teze+Teze	296	231 (78.0)	-24.27 (1.21)	(-26.64, -21.89)	-7.68 (2.18)	(-11.96, -3.40)	<0.001 *	
	Pbo+Pbo	137	103 (75.2)	-16.59 (1.81)	(-20.14, -13.04)				
Week 104	Teze+Teze	296	221 (74.7)	-25.44 (1.20)	(-27.80, -23.09)	-5.47 (2.15)	(-9.70, -1.25)	0.011 *	
	Pbo+Pbo	137	102 (74.5)	-19.97 (1.78)	(-23.47, -16.47)				

Note: DITTNL - LTE - adult = Dossier Label Intent-to-Treat Set - predecessor NAVIGATOR - Long term extension - adults.  
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.  
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.  
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.  
 SGRQ = St George s respiratory questionnaire.  
 Source Data: asgrq, created on: 20JUL2022

Table NT1PSC\_ILMH0: Course of PGI-S  
 DITTL

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]	
PGI-S	Baseline	Tezepelumab	395	394 (99.7)	2.8 (1.0)	0	2.0	3.0	3.0	5	
		Placebo	391	389 (99.5)	2.7 (0.9)	0	2.0	3.0	3.0	5	
	Week 2	Tezepelumab	395	380 (96.2)	2.1 (1.1)	0	1.0	2.0	3.0	5	
		Placebo	391	378 (96.7)	2.2 (1.1)	0	1.0	2.0	3.0	5	
	Week 4	Tezepelumab	395	390 (98.7)	1.9 (1.1)	0	1.0	2.0	3.0	5	
		Placebo	391	381 (97.4)	2.0 (1.1)	0	1.0	2.0	3.0	5	
	Week 8	Tezepelumab	395	389 (98.5)	1.8 (1.1)	0	1.0	2.0	3.0	5	
		Placebo	391	381 (97.4)	1.9 (1.1)	0	1.0	2.0	3.0	5	
	Week 12	Tezepelumab	395	387 (98.0)	1.6 (1.2)	0	1.0	2.0	2.0	5	
		Placebo	391	378 (96.7)	1.8 (1.2)	0	1.0	2.0	3.0	5	
	Week 52	Tezepelumab	395	353 (89.4)	1.6 (1.2)	0	1.0	1.0	3.0	4	
		Placebo	391	341 (87.2)	1.8 (1.2)	0	1.0	2.0	3.0	5	

Note: DITTL = Dossier Label Intent-to-Treat Set.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. PGI-S = Patient global impression of severity.  
 Source Data: apgi, created on: 23FEB2022

Table NT1PSC\_ILMH0: Course of PGI-S  
 DITTL

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in PGI-S Week 2	Tezepelumab	395	379 (95.9)	-0.8 (1.1)	-4	-1.0	-1.0	0.0	3	-0.26 [-0.40, -0.11]
	Placebo	391	378 (96.7)	-0.5 (1.1)	-4	-1.0	0.0	0.0	3	
Week 4	Tezepelumab	395	389 (98.5)	-1.0 (1.2)	-5	-2.0	-1.0	0.0	2	-0.20 [-0.34, -0.05]
	Placebo	391	381 (97.4)	-0.7 (1.2)	-5	-1.0	-1.0	0.0	3	
Week 8	Tezepelumab	395	388 (98.2)	-1.1 (1.3)	-5	-2.0	-1.0	0.0	2	-0.23 [-0.37, -0.08]
	Placebo	391	380 (97.2)	-0.8 (1.2)	-5	-2.0	-1.0	0.0	3	
Week 12	Tezepelumab	395	387 (98.0)	-1.2 (1.4)	-5	-2.0	-1.0	0.0	3	-0.24 [-0.38, -0.09]
	Placebo	391	377 (96.4)	-0.9 (1.2)	-5	-2.0	-1.0	0.0	3	
Week 52	Tezepelumab	395	353 (89.4)	-1.2 (1.4)	-5	-2.0	-1.0	0.0	3	-0.28 [-0.43, -0.13]
	Placebo	391	340 (87.0)	-0.9 (1.3)	-5	-2.0	-1.0	0.0	3	

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.

95% CI = 95% confidence interval for Hedges G. PGI-S = Patient global impression of severity.

Source Data: apgi, created on: 23FEB2022

Table NT1PSC\_ILMC0: Change from baseline in PGI-S - MMRM results  
 DITTL

Change from baseline in PGI-S				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 2	Tezepelumab	395	379 (95.9)	-0.7 (0.1)	(-0.8, -0.6)	-0.2 (0.1)	(-0.4, -0.1)	0.004 *
	Placebo	391	378 (96.7)	-0.5 (0.1)	(-0.6, -0.4)			
Week 4	Tezepelumab	395	389 (98.5)	-0.9 (0.1)	(-1.0, -0.8)	-0.1 (0.1)	(-0.3, -0.0)	0.046 *
	Placebo	391	381 (97.4)	-0.8 (0.1)	(-0.9, -0.7)			
Week 8	Tezepelumab	395	388 (98.2)	-1.0 (0.1)	(-1.1, -0.9)	-0.2 (0.1)	(-0.3, -0.0)	0.015 *
	Placebo	391	380 (97.2)	-0.9 (0.1)	(-1.0, -0.7)			
Week 12	Tezepelumab	395	387 (98.0)	-1.1 (0.1)	(-1.3, -1.0)	-0.2 (0.1)	(-0.4, -0.1)	0.005 *
	Placebo	391	377 (96.4)	-0.9 (0.1)	(-1.0, -0.8)			
Week 52	Tezepelumab	395	353 (89.4)	-1.2 (0.1)	(-1.3, -1.1)	-0.3 (0.1)	(-0.5, -0.1)	<0.001 *
	Placebo	391	340 (87.0)	-0.9 (0.1)	(-1.0, -0.8)			

Note: DITTL = Dossier Label Intent-to-Treat Set.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

PGI-S = Patient global impression of severity.

Source Data: apgi, created on: 23FEB2022



Table NT1PSC\_KLMH0: Course of PGI-S  
 DITTL - adolescents

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]	
PGI-S	Baseline										
		Tezepelumab	15	15 (100.0)	3.1 (0.7)	2	3.0	3.0	3.0	5	
		Placebo	20	20 (100.0)	2.8 (1.0)	1	2.0	3.0	3.0	5	
	Week 2										
		Tezepelumab	15	14 (93.3)	1.6 (1.3)	0	1.0	1.0	3.0	3	
		Placebo	20	20 (100.0)	1.6 (1.3)	0	0.5	1.0	3.0	4	
	Week 4										
		Tezepelumab	15	15 (100.0)	1.7 (1.3)	0	0.0	2.0	3.0	3	
		Placebo	20	18 (90.0)	1.4 (1.1)	0	1.0	1.0	2.0	3	
	Week 8										
		Tezepelumab	15	15 (100.0)	1.3 (1.0)	0	1.0	1.0	2.0	3	
		Placebo	20	18 (90.0)	1.8 (1.4)	0	1.0	1.0	3.0	5	
	Week 12										
		Tezepelumab	15	15 (100.0)	1.1 (0.8)	0	0.0	1.0	2.0	2	
		Placebo	20	20 (100.0)	1.5 (1.4)	0	0.0	1.0	3.0	4	
	Week 52										
	Tezepelumab	15	12 (80.0)	1.4 (1.1)	0	0.5	1.5	2.0	3		
	Placebo	20	20 (100.0)	1.4 (1.0)	0	1.0	1.0	2.0	3		

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. PGI-S = Patient global impression of severity.  
 Source Data: apgi, created on: 23FEB2022

Table NT1PSC\_KLMH0: Course of PGI-S  
 DITTLL - adolescents

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in PGI-S Week 2	Tezepelumab	15	14 (93.3)	-1.4 (1.5)	-4	-2.0	-2.0	0.0	1	-0.13 [-0.82, 0.55]
	Placebo	20	20 (100.0)	-1.3 (1.3)	-3	-2.0	-1.0	0.0	1	
Week 4	Tezepelumab	15	15 (100.0)	-1.3 (1.4)	-4	-2.0	-2.0	0.0	1	0.07 [-0.61, 0.76]
	Placebo	20	18 (90.0)	-1.4 (1.5)	-4	-3.0	-1.5	0.0	1	
Week 8	Tezepelumab	15	15 (100.0)	-1.7 (1.3)	-5	-3.0	-1.0	-1.0	0	-0.60 [-1.30, 0.11]
	Placebo	20	18 (90.0)	-1.0 (1.1)	-3	-2.0	-1.0	0.0	1	
Week 12	Tezepelumab	15	15 (100.0)	-1.9 (1.2)	-5	-2.0	-2.0	-1.0	-1	-0.55 [-1.24, 0.13]
	Placebo	20	20 (100.0)	-1.3 (1.1)	-3	-2.0	-1.0	0.0	0	
Week 52	Tezepelumab	15	12 (80.0)	-1.7 (1.1)	-4	-2.0	-1.5	-1.0	0	-0.25 [-0.96, 0.47]
	Placebo	20	20 (100.0)	-1.4 (1.1)	-3	-2.0	-1.5	-1.0	1	

Note: DITTLL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. PGI-S = Patient global impression of severity.  
 Source Data: apgi, created on: 23FEB2022

Table NT1PSC\_KLMC0: Change from baseline in PGI-S - MMRM results  
 DITTL - adolescents

Change from baseline in PGI-S				Repeated measures analysis				
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference		
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 2	Tezepelumab	15	14 (93.3)	-1.4 (0.3)	(-2.0, -0.7)	-0.0 (0.4)	(-0.9, 0.8)	0.914
	Placebo	20	20 (100.0)	-1.3 (0.3)	(-1.9, -0.8)			
Week 4	Tezepelumab	15	15 (100.0)	-1.3 (0.3)	(-1.9, -0.6)	0.3 (0.4)	(-0.7, 1.2)	0.573
	Placebo	20	18 (90.0)	-1.5 (0.3)	(-2.1, -0.9)			
Week 8	Tezepelumab	15	15 (100.0)	-1.7 (0.3)	(-2.3, -1.1)	-0.6 (0.4)	(-1.4, 0.2)	0.166
	Placebo	20	18 (90.0)	-1.1 (0.3)	(-1.6, -0.6)			
Week 12	Tezepelumab	15	15 (100.0)	-1.9 (0.3)	(-2.4, -1.3)	-0.5 (0.4)	(-1.2, 0.3)	0.219
	Placebo	20	20 (100.0)	-1.4 (0.2)	(-1.9, -0.9)			
Week 52	Tezepelumab	15	12 (80.0)	-1.6 (0.3)	(-2.1, -1.0)	-0.1 (0.4)	(-0.8, 0.6)	0.817
	Placebo	20	20 (100.0)	-1.5 (0.2)	(-1.9, -1.0)			

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.  
 N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.  
 LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.  
 A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.  
 PGI-S = Patient global impression of severity.  
 Source Data: apgi, created on: 23FEB2022

Table NT1PSC\_ALMH0: Course of PGI-S  
 DITTL - adult

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]	
PGI-S	Baseline	Tezepelumab	380	379 (99.7)	2.8 (1.0)	0	2.0	3.0	3.0	5	
		Placebo	371	369 (99.5)	2.7 (0.9)	0	2.0	3.0	3.0	5	
	Week 2	Tezepelumab	380	366 (96.3)	2.1 (1.1)	0	1.0	2.0	3.0	5	
		Placebo	371	358 (96.5)	2.2 (1.1)	0	1.0	2.0	3.0	5	
	Week 4	Tezepelumab	380	375 (98.7)	1.9 (1.1)	0	1.0	2.0	3.0	5	
		Placebo	371	363 (97.8)	2.0 (1.1)	0	1.0	2.0	3.0	5	
	Week 8	Tezepelumab	380	374 (98.4)	1.8 (1.1)	0	1.0	2.0	3.0	5	
		Placebo	371	363 (97.8)	1.9 (1.1)	0	1.0	2.0	3.0	5	
	Week 12	Tezepelumab	380	372 (97.9)	1.7 (1.2)	0	1.0	2.0	3.0	5	
		Placebo	371	358 (96.5)	1.8 (1.1)	0	1.0	2.0	3.0	5	
	Week 52	Tezepelumab	380	341 (89.7)	1.6 (1.2)	0	1.0	1.0	3.0	4	
		Placebo	371	321 (86.5)	1.8 (1.2)	0	1.0	2.0	3.0	5	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. PGI-S = Patient global impression of severity.  
 Source Data: apgi, created on: 23FEB2022

Table NT1PSC\_ALMH0: Course of PGI-S  
 DITTL - adult

	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in PGI-S Week 2	Tezepelumab	380	365 (96.1)	-0.8 (1.1)	-4	-1.0	-1.0	0.0	3	-0.28 [-0.42, -0.13]
	Placebo	371	358 (96.5)	-0.5 (1.1)	-4	-1.0	0.0	0.0	3	
Week 4	Tezepelumab	380	374 (98.4)	-0.9 (1.2)	-5	-2.0	-1.0	0.0	2	-0.22 [-0.36, -0.07]
	Placebo	371	363 (97.8)	-0.7 (1.1)	-5	-1.0	-1.0	0.0	3	
Week 8	Tezepelumab	380	373 (98.2)	-1.1 (1.3)	-5	-2.0	-1.0	0.0	2	-0.21 [-0.36, -0.07]
	Placebo	371	362 (97.6)	-0.8 (1.2)	-5	-2.0	-1.0	0.0	3	
Week 12	Tezepelumab	380	372 (97.9)	-1.2 (1.4)	-5	-2.0	-1.0	0.0	3	-0.23 [-0.38, -0.08]
	Placebo	371	357 (96.2)	-0.9 (1.2)	-5	-2.0	-1.0	0.0	3	
Week 52	Tezepelumab	380	341 (89.7)	-1.2 (1.4)	-5	-2.0	-1.0	0.0	3	-0.30 [-0.45, -0.14]
	Placebo	371	320 (86.3)	-0.8 (1.3)	-5	-2.0	-1.0	0.0	3	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.  
 N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.  
 95% CI = 95% confidence interval for Hedges G. PGI-S = Patient global impression of severity.  
 Source Data: apgi, created on: 23FEB2022

Table NT1PSC\_ALMC0: Change from baseline in PGI-S - MMRM results  
 DITTL - adult

Change from baseline in PGI-S				Repeated measures analysis					
Time	Treatment	N	n (%)	Change from Baseline		Treatment Difference			
				LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value	
Week 2	Tezepelumab	380	365 (96.1)	-0.7 (0.1)	(-0.8, -0.6)	-0.2 (0.1)	(-0.4, -0.1)	0.002 *	
	Placebo	371	358 (96.5)	-0.5 (0.1)	(-0.6, -0.4)				
Week 4	Tezepelumab	380	374 (98.4)	-0.9 (0.1)	(-1.0, -0.8)	-0.2 (0.1)	(-0.3, -0.0)	0.020 *	
	Placebo	371	363 (97.8)	-0.7 (0.1)	(-0.8, -0.6)				
Week 8	Tezepelumab	380	373 (98.2)	-1.0 (0.1)	(-1.1, -0.9)	-0.2 (0.1)	(-0.3, -0.0)	0.025 *	
	Placebo	371	362 (97.6)	-0.8 (0.1)	(-0.9, -0.7)				
Week 12	Tezepelumab	380	372 (97.9)	-1.1 (0.1)	(-1.2, -1.0)	-0.2 (0.1)	(-0.4, -0.1)	0.007 *	
	Placebo	371	357 (96.2)	-0.9 (0.1)	(-1.0, -0.8)				
Week 52	Tezepelumab	380	341 (89.7)	-1.2 (0.1)	(-1.3, -1.1)	-0.3 (0.1)	(-0.5, -0.2)	<0.001 *	
	Placebo	371	320 (86.3)	-0.9 (0.1)	(-1.0, -0.8)				

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.

N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.

LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. \* = significant treatment effect.

A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.

PGI-S = Patient global impression of severity.

Source Data: apgi, created on: 23FEB2022